PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	CARRERA, AC; PARADIS, H; BORLADO, LR; ROBERTS, TM; MARTINEZ, C				CARRERA, AC; PARADIS, H; BORLADO, LR; ROBERTS, TM; MARTINEZ, C			LCK UNIQUE DOMAIN INFLUENCES LCK SPECIFICITY AND BIOLOGICAL FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PROTEIN-KINASE; CELL ANTIGEN RECEPTOR; ACTIVATED T-CELLS; SIGNAL TRANSDUCTION; PHOSPHATIDYLINOSITOL 3-KINASE; NUCLEAR FACTOR; BETA-CHAIN; P56LCK; EXPRESSION; P56(LCK)	Src-family tyrosine kinases share structural and amino acid sequence homology, particularly in the catalytic domain as well as in the SH2 and SH3 domains of the regulatory region. However, each src-family member also contains a unique domain which is specific to and characteristic of each individual tyrosine kinase. These unique or specific domains may contribute to the functional specificity of each src-family kinase. To address this possibility, we analyzed the kinase activities and substrate specificities of the lymphoid src-kinase, pp56(lck), and a mutant of pp56(lck) lacking its specific domain. Our data show that both the wild type enzyme and the specific domain-deleted mutant displayed similar affinities for ATP and the non-physiological substrate denatured enolase. However, the specific domain-deleted mutant failed to phosphorylate a number of physiological substrates of pp56(lck). In addition, the ability of pp56(lck) to mediate induction of the interleukin-2 promoter was strongly impaired upon deletion of its specific domain. Thus, the unique domain is not required for the intrinsic kinase activity of pp56(lck), however, it influences substrate preference and contributes to the unique physiological function of this src-family tyrosine kinase.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DEPT BIOL CELLULAIRE & MOLEC, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	CARRERA, AC (corresponding author), UNIV AUTONOMA MADRID, CSIC, CTR NACL BIOTECNOL, CAMPUS CANTOBLANCO, E-28049 MADRID, SPAIN.			Carrera, Ana/0000-0002-3999-5434	NATIONAL CANCER INSTITUTE [R01CA043803] Funding Source: NIH RePORTER; NCI NIH HHS [CA 43803] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM KM, 1991, J EXP MED, V173, P1421, DOI 10.1084/jem.173.6.1421; AMREIN KE, 1992, P NATL ACAD SCI USA, V89, P3343, DOI 10.1073/pnas.89.8.3343; ANDERSON SJ, 1993, NATURE, V365, P552, DOI 10.1038/365552a0; BALDARI CT, 1993, J BIOL CHEM, V268, P8406; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BEVERLEY PCL, 1981, EUR J IMMUNOL, V11, P329, DOI 10.1002/eji.1830110412; CARRERA AC, 1992, J IMMUNOL, V149, P3142; CARRERA AC, 1993, P NATL ACAD SCI USA, V90, P442, DOI 10.1073/pnas.90.2.442; CARRERA AC, 1991, INT IMMUNOL, V3, P673, DOI 10.1093/intimm/3.7.673; CASNELLIE JE, 1991, METHOD ENZYMOL, V200, P115; CHENG HC, 1992, J BIOL CHEM, V267, P9248; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; DURAND DB, 1987, J EXP MED, V165, P395, DOI 10.1084/jem.165.2.395; ECK MJ, 1994, NATURE, V368, P764, DOI 10.1038/368764a0; EISENTHAL R, 1974, BIOCHEM J, V139, P715, DOI 10.1042/bj1390715; ETTEHADIEH E, 1992, SCIENCE, V255, P853, DOI 10.1126/science.1311128; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; KARNITZ L, 1992, MOL CELL BIOL, V12, P4521, DOI 10.1128/MCB.12.10.4521; KOYASU S, 1992, J BIOL CHEM, V267, P3375; LEVIN SD, 1993, EMBO J, V12, P1671, DOI 10.1002/j.1460-2075.1993.tb05812.x; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; MALEK SN, 1993, J BIOL CHEM, V268, P22557; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MERIDA I, 1993, J BIOL CHEM, V268, P6765; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; PLEIMAN CM, 1993, MOL CELL BIOL, V13, P5877, DOI 10.1128/MCB.13.9.5877; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; RAMER SE, 1991, P NATL ACAD SCI USA, V88, P6254, DOI 10.1073/pnas.88.14.6254; RIVEROLEZCANO OM, 1994, FEBS LETT, V338, P183, DOI 10.1016/0014-5793(94)80361-7; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; VEGA MA, 1990, EUR J IMMUNOL, V20, P453, DOI 10.1002/eji.1830200235; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VERWEIJ CL, 1990, J BIOL CHEM, V265, P15788; WATTS JD, 1993, J BIOL CHEM, V268, P23275; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; WOODROW MA, 1993, J IMMUNOL, V150, P3853; XU H, 1993, CELL, V74, P633, DOI 10.1016/0092-8674(93)90511-N; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	44	31	31	1	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	1995	270	7					3385	3391		10.1074/jbc.270.7.3385	http://dx.doi.org/10.1074/jbc.270.7.3385			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QG471	7531706	hybrid			2022-12-27	WOS:A1995QG47100074
J	OZCELEBI, F; MILLER, LJ				OZCELEBI, F; MILLER, LJ			PHOSPHOPEPTIDE MAPPING OF CHOLECYSTOKININ RECEPTORS ON AGONIST-STIMULATED NATIVE PANCREATIC ACINAR-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; DEPENDENT PROTEIN-KINASE; ENZYME-SECRETION; DESENSITIZATION; PHOSPHORYLATION; AFFINITY; CHROMATOGRAPHY; PURIFICATION; ARRESTIN; BINDING	The cholecystokinin (CCK) receptor on the rat pancreatic acinar cell is a G protein-coupled receptor that is phosphorylated in response to homologous and heterologous agonist stimulation. In this work we have studied the stoichiometry of receptor phosphorylation and have utilized one-dimensional phosphopeptide mapping after cyanogen bromide cleavage to demonstrate that the third intracellular loop is the predominant domain of phosphorylation of this receptor in response to these treatments. Of the average 5 mol of phosphate/mol of receptor, greater than 95% was on the third loop, with the remainder residing on the carboxyl-terminal tail. Serine residues were the site of greater than 95% of phosphorylation, with threonine representing the remainder, and no phosphotyrosine was detected. Further, we have utilized two dimensional phosphopeptide mapping after subtilisin cleavage to identify differing sites of CCK receptor phosphorylation which are dependent on the agonist utilized to stimulate this cell. Both qualitative and quantitative differences in phosphorylation sites were observed after acinar cell stimulation with different protein kinase C agonists. Further, distinct phosphopeptides on the map were identified as representing substrate(s) of a staurosporine-insensitive kinase activity stimulated only by receptor occupation with native CCK and were felt to represent site(s) of action of a member of the G protein-coupled receptor kinase family. This represents a sensitive and powerful approach that is applicable to sparse receptors residing in their native cellular environment to assess possible differences in patterns of phosphorylation which may be important in agonist-specific receptor regulation.	MAYO CLIN & MAYO FDN, CTR BASIC RES DIGEST DIS, ROCHESTER, MN 55905 USA	Mayo Clinic					NIDDK NIH HHS [DK32878] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK032878, R01DK032878] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABDELMOUMENE S, 1980, AM J PHYSIOL, V239, pG272, DOI 10.1152/ajpgi.1980.239.4.G272; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BENOVIC JL, 1987, P NATL ACAD SCI USA, V84, P8879, DOI 10.1073/pnas.84.24.8879; DOI R, 1993, J BIOL CHEM, V268, P22436; GAISANO HY, 1989, J CLIN INVEST, V83, P321, DOI 10.1172/JCI113877; GARDNER JD, 1994, PANCREAS BIOL PATHOB, P151; GATES LK, 1993, AM J PHYSIOL, V264, pG840, DOI 10.1152/ajpgi.1993.264.5.G840; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HONDA T, 1987, AM J PHYSIOL, V252, pG77, DOI 10.1152/ajpgi.1987.252.1.G77; HUGANIR RL, 1990, NEURON, V5, P555, DOI 10.1016/0896-6273(90)90211-W; INGLESE J, 1993, J BIOL CHEM, V268, P23735; KEMP BE, 1991, METHOD ENZYMOL, V200, P121; KLUEPPELBERG UG, 1991, J BIOL CHEM, V266, P2403; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEFKOWITZ RJ, 1990, TRENDS PHARMACOL SCI, V11, P190, DOI 10.1016/0165-6147(90)90113-M; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; LUTZ MP, 1993, J BIOL CHEM, V268, P11119; MILLER LJ, 1992, BIOCHEM BIOPH RES CO, V183, P396, DOI 10.1016/0006-291X(92)90494-6; MILLER LJ, 1981, J BIOL CHEM, V256, P2417; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NAIRN AC, 1987, J BIOL CHEM, V262, P7273; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PEARSON RK, 1987, J BIOL CHEM, V262, P13850; PEI G, 1994, P NATL ACAD SCI USA, V91, P3633, DOI 10.1073/pnas.91.9.3633; PITCHER J, 1992, BIOCHEMISTRY-US, V31, P3193, DOI 10.1021/bi00127a021; POLLO DA, 1993, GASTROENTEROLOGY, V104, pA329; SCHWEINSBERG PD, 1980, J CHROMATOGR, V181, P103, DOI 10.1016/S0378-4347(00)81276-1; SIBLEY DR, 1986, P NATL ACAD SCI USA, V83, P9408, DOI 10.1073/pnas.83.24.9408; SWANK RT, 1971, ANAL BIOCHEM, V39, P462, DOI 10.1016/0003-2697(71)90436-2; VINAYEK R, 1990, AM J PHYSIOL, V258, pG107, DOI 10.1152/ajpgi.1990.258.1.G107; WANK SA, 1992, P NATL ACAD SCI USA, V89, P3125, DOI 10.1073/pnas.89.7.3125; ZHU ZX, 1994, AM J PHYSIOL, V266, pC904, DOI 10.1152/ajpcell.1994.266.4.C904	34	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	1995	270	7					3435	3441		10.1074/jbc.270.7.3435	http://dx.doi.org/10.1074/jbc.270.7.3435			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QG471	7531708	hybrid			2022-12-27	WOS:A1995QG47100081
J	WANG, LL; RICHARD, S; SHAW, AS				WANG, LL; RICHARD, S; SHAW, AS			P62 ASSOCIATION WITH RNA IS REGULATED BY TYROSINE PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAP-ASSOCIATED PROTEINS; GTPASE-ACTIVATING PROTEIN; SIGNAL TRANSDUCTION; NUCLEIC-ACID; T-CELL; BINDING; TARGETS; INCLUDE; KINASE; DOMAIN	The ras-GAP associated protein, p62, is a major tyrosine phosphoprotein in transformed and growth factor treated cells, Although its exact function is not known, it can bind directly to src-family tyrosine kinases and has been implicated as a linker protein bridging activated src family tyrosine kinases with downstream effecters, One novel feature of p62, revealed by its predicted amino acid sequence, is the presence of an RNA-binding region, the KH domain. As p62 becomes tyrosine phosphorylated when src-kinases become activated, we compared the RNA binding ability of p62 in both its phosphorylated and unphosphorylated state, The ability of p62 to bind RNA was severely impaired when p62 was tyrosine phosphorylated. This suggests that the ability of p62 to bind RNA is regulated by tyrosine phosphorylation and implicates the regulation of RNA as a component of tyrosine kinase signaling pathways.	WASHINGTON UNIV,SCH MED,CTR IMMUNOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)				Shaw, Andrey/0000-0001-5685-0272				ASHLEY CT, 1993, SCIENCE, V262, P563, DOI 10.1126/science.7692601; BRAWERMAN G, 1989, CELL, V57, P9, DOI 10.1016/0092-8674(89)90166-9; BRAWERMAN G, 1987, CELL, V48, P5, DOI 10.1016/0092-8674(87)90346-1; CHANG JH, 1993, ONCOGENE, V8, P959; COREY S, 1993, EMBO J, V12, P2681, DOI 10.1002/j.1460-2075.1993.tb05929.x; DARBY C, 1994, J IMMUNOL, V152, P5429; DE BK, 1993, NAT GENET, V3, P31; DRUKER B, 1992, BLOOD, V79, P2215; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ELLIS C, 1991, ONCOGENE, V6, P895; EVAN GI, 1985, MOL CELL BIOL, V4, P2843; FILVAROFF E, 1992, MOL CELL BIOL, V12, P5319, DOI 10.1128/MCB.12.12.5319; FRACKELTON AJ, 1993, LEUK LYMPHOMA, V1, P125; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; GIBSON TJ, 1993, FEBS LETT, V324, P361, DOI 10.1016/0014-5793(93)80152-K; GOLD MR, 1993, J IMMUNOL, V150, P377; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; GOTTSCHALK AR, 1994, J IMMUNOL, V152, P2115; HEIDARAN MA, 1992, ONCOGENE, V7, P147; HUBERT P, 1993, J EXP MED, V178, P1587, DOI 10.1084/jem.178.5.1587; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; LAWRENCE JB, 1986, CELL, V45, P407, DOI 10.1016/0092-8674(86)90326-0; MORLEY SJ, 1991, PHARMACOL THERAPEUT, V50, P291, DOI 10.1016/0163-7258(91)90047-P; PLEIMAN CM, 1994, J IMMUNOL, V152, P2837; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; SIOMI H, 1994, CELL, V77, P33, DOI 10.1016/0092-8674(94)90232-1; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; WISNIEWSKI D, 1994, LEUKEMIA, V8, P688; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L	35	119	122	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 3	1995	270	5					2010	2013		10.1074/jbc.270.5.2010	http://dx.doi.org/10.1074/jbc.270.5.2010			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QE493	7530715	hybrid			2022-12-27	WOS:A1995QE49300007
J	YOSHIMURA, M; NISHIKAWA, A; NISHIURA, T; IHARA, Y; KANAYAMA, Y; MATSUZAWA, Y; TANIGUCHI, N				YOSHIMURA, M; NISHIKAWA, A; NISHIURA, T; IHARA, Y; KANAYAMA, Y; MATSUZAWA, Y; TANIGUCHI, N			CELL SPREADING IN COLO-201 BY STAUROSPORIN IS ALPHA-3-BETA-1-INTEGRIN MEDIATED WITH TYROSINE PHOSPHORYLATION OF SRC AND TENSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; EXTRACELLULAR-MATRIX; FOCAL ADHESIONS; RECEPTOR; FIBRONECTIN; COLLAGEN; LAMININ; EXPRESSION; PP60C-SRC; BINDING	Staurosporin, a broad-spectrum kinase inhibitor, induced cell spreading in a human colon cancer cell line, Colo 201. On collagen and laminin, cell spreading was induced in more than 90% of the cells and was dependent on very late activation antigen-3, as shown by an antibody inhibition assay, Cell spreading required divalent cations and showed the order of preference Mn2+ > Mg2+ > Ca2+. On fibronectin, only about 30% of the cells were observed to spread, and spreading occurred via a non-integrin, RGD-independent pathway. Staurosporin-induced spreading was inhibited by treatment with tyrosine kinase inhibitors herbimycin A and methyl 2,5-dihydroxycinnamate. Despite the presence of staurosporin, seven proteins (220, 175, 150, 98, 62, 58, and 45 kDa) showed increased levels of tyrosine phosphorylation in association with cell adhesion. Two of these (58 and 220 kDa) were identified by immunoprecipitation as Src product and tensin, respectively. Flow cytometric analysis showed that the Colo 201 cells expressed the alpha 2, alpha 3, alpha 6, and beta 1 chains of integrin, but expression of these chains was not influenced by staurosporin. Immunofluorescence microscopy revealed that the alpha 3 chain, diffusely expressed on the cell surface in the absence of staurosporin, was concentrated at focal adhesion plaques after staurosporin treatment. Neither alpha 2 nor alpha 6 was focalized by the treatment.	OSAKA UNIV,SCH MED,DEPT BIOCHEM,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,DEPT INTERNAL MED 2,SUITA,OSAKA 565,JAPAN	Osaka University; Osaka University			Taniguchi, Naoyuki/I-4182-2014; Nishikawa, Atsushi/E-6766-2013	Taniguchi, Naoyuki/0000-0001-5889-5968; Nishikawa, Atsushi/0000-0003-4325-1160				BENZEEV A, 1988, P NATL ACAD SCI USA, V85, P2161, DOI 10.1073/pnas.85.7.2161; BOCKHOLT SM, 1993, J BIOL CHEM, V268, P14565; BRUNS RF, 1991, BIOCHEM BIOPH RES CO, V176, P288, DOI 10.1016/0006-291X(91)90922-T; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CARTER WG, 1991, CELL, V65, P599, DOI 10.1016/0092-8674(91)90092-D; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; DAHL SC, 1989, J CELL BIOL, V108, P183, DOI 10.1083/jcb.108.1.183; DAVIS S, 1991, SCIENCE, V252, P712, DOI 10.1126/science.1708917; DEDHAR S, 1992, J BIOL CHEM, V267, P18908; ELICES MJ, 1991, J CELL BIOL, V112, P169, DOI 10.1083/jcb.112.1.169; ELICES MJ, 1989, P NATL ACAD SCI USA, V86, P9906, DOI 10.1073/pnas.86.24.9906; FUJITAYAMAGUCHI Y, 1988, BIOCHEM BIOPH RES CO, V157, P955, DOI 10.1016/S0006-291X(88)80967-7; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GOLDEN A, 1990, J CELL BIOL, V111, P3117, DOI 10.1083/jcb.111.6.3117; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; INGBER DE, 1990, J CELL BIOL, V110, P1803, DOI 10.1083/jcb.110.5.1803; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; KANAKURA Y, 1990, BLOOD, V76, P706; KMIECIK TE, 1988, MOL CELL BIOL, V8, P4541, DOI 10.1128/MCB.8.10.4541; MAHER PA, 1985, P NATL ACAD SCI USA, V82, P6576, DOI 10.1073/pnas.82.19.6576; MATSUYAMA T, 1988, J EXP MED, V170, P1133; MCCLAY DR, 1987, ANNU REV CELL BIOL, V3, P319, DOI 10.1146/annurev.cellbio.3.1.319; MIYAKE K, 1992, J CELL BIOL, V119, P653, DOI 10.1083/jcb.119.3.653; NAKANO H, 1987, J ANTIBIOT, V40, P706, DOI 10.7164/antibiotics.40.706; NATHAN C, 1989, J CELL BIOL, V109, P849; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SANES JR, 1989, ANNU REV NEUROSCI, V12, P491, DOI 10.1146/annurev.ne.12.030189.002423; SECRIST JP, 1990, J BIOL CHEM, V265, P20394; SEMPLE TU, 1978, CANCER RES, V38, P1345; SONNENBERG A, 1991, EXP CELL RES, V197, P234, DOI 10.1016/0014-4827(91)90428-W; STREULI CH, 1990, J CELL BIOL, V110, P1405; TAKADA Y, 1991, J CELL BIOL, V115, P257, DOI 10.1083/jcb.115.1.257; THOUVENIN VM, 1992, J CELL PHYSL, V153, P95; VUORI K, 1993, J BIOL CHEM, V268, P21459; WAYNER EA, 1988, J CELL BIOL, V107, P1881, DOI 10.1083/jcb.107.5.1881; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873; WEBER TK, 1992, J CLIN INVEST, V90, P815, DOI 10.1172/JCI115956; WEITZMAN JB, 1993, J BIOL CHEM, V268, P8651; WILKINS JA, 1986, J CELL BIOL, V103, P1483, DOI 10.1083/jcb.103.4.1483; WILKINS JA, 1987, J CELL BIOL, V105, pA103	44	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 3	1995	270	5					2298	2304		10.1074/jbc.270.5.2298	http://dx.doi.org/10.1074/jbc.270.5.2298			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QE493	7530722	hybrid			2022-12-27	WOS:A1995QE49300050
J	VONBONIN, A; WIENANDS, J; MANNING, U; ZUBER, JF; BAUMANN, G				VONBONIN, A; WIENANDS, J; MANNING, U; ZUBER, JF; BAUMANN, G			THE BETA-D-SHEET RESIDUES OF THE LCK-DERIVED SH2 DOMAIN DETERMINE SPECIFICITY OF THE INTERACTION WITH TYROSINE-PHOSPHORYLATED LIGANDS IN RAMOS B-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY PHOSPHOTYROSYL PEPTIDE; GTPASE-ACTIVATING PROTEIN; ANTIGEN RECEPTOR; SIGNAL TRANSDUCTION; LYMPHOCYTES-B; ZETA-CHAIN; BINDING; KINASES; ASSOCIATION; IMMUNOGLOBULIN	Src homology 2 (SH2) domains are noncatalytic regions that are conserved among a group of cellular signaling proteins, SH2 domains share the common property of binding phosphotyrosine-containing peptides, Previously, we showed that SH2 domains expressed as recombinant glutathione S-transferase-fusion proteins (GST-SH2) from GTPase-activating protein, She, zeta-chain-associated protein tyrosine kinase Zap-70, and Src-like tyrosine kinases precipitated distinct sets of phosphoproteins from activated B cells, To determine the intrinsic structural motifs responsible for the binding specificity within the different SH2 domains, we created chimeric SH2 domains especially focusing on crystal structure-defined contact residues, Recombinant SH2 domains of Lck, Zap-70, and She were tested in Ramos B cell lysates for phosphotyrosine-dependent protein binding, Biomolecular interaction analysis (BIAcore) was used to characterize the interaction between the various recombinant SH2 molecules and defined phosphorylated peptides, In agreement with the crystal structure data from the Src and the Lck SH2 domains, our results show that most of the ''specificity information'' of the Lck SH2 domain is provided by the beta D-sheet, located downstream of the SH2 conserved consensus motif GTFLVRES, In addition, the overall affinity is critically influenced by residues located at the N terminus of the SH2 domain.	SANDOZ PHARMA LTD, PRECLIN RES, CH-4002 BASEL, SWITZERLAND	Novartis; Sandoz								BAUMANN G, 1994, EUR J IMMUNOL, V24, P1799, DOI 10.1002/eji.1830240812; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHENG SH, 1988, MOL CELL BIOL, V8, P1736, DOI 10.1128/MCB.8.4.1736; COOPER JA, 1993, MOL CELL BIOL, V13, P1737, DOI 10.1128/MCB.13.3.1737; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FELDER S, 1993, MOL CELL BIOL, V13, P1449, DOI 10.1128/MCB.13.3.1449; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MALEK SN, 1993, J BIOL CHEM, V268, P22557; MARENGERE LEM, 1992, J BIOL CHEM, V267, P22779; MARENGERE LEM, 1994, NATURE, V369, P502, DOI 10.1038/369502a0; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MOELLER G, 1993, IMMUNOL REV, V132, P5; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; RETH M, 1992, ANNU REV IMMUNOL, V10, P97, DOI 10.1146/annurev.iy.10.040192.000525; RUSSELL RB, 1992, FEBS LETT, V304, P15, DOI 10.1016/0014-5793(92)80579-6; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; VANNOESEL CJM, 1992, J EXP MED, V175, P1511, DOI 10.1084/jem.175.6.1511; VONBONIN A, UNPUB; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WANGE RL, 1993, J BIOL CHEM, V268, P19797; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YAMANASHI Y, 1993, P NATL ACAD SCI USA, V90, P3631, DOI 10.1073/pnas.90.8.3631; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	32	7	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					33035	33041						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7528744				2022-12-27	WOS:A1994QA63800048
J	BAKKER, H; AGTERBERG, M; VANTETERING, A; KOELEMAN, CAM; VANDENEIJNDEN, DH; VANDIE, I				BAKKER, H; AGTERBERG, M; VANTETERING, A; KOELEMAN, CAM; VANDENEIJNDEN, DH; VANDIE, I			A LYMNAEA-STAGNALIS GENE, WITH SEQUENCE SIMILARITY TO THAT OF MAMMALIAN BETA-1-]4-GALACTOSYLTRANSFERASES, ENCODES A NOVEL UDP-GLCNAC-GLCNAC-BETA-R BETA-1-]4-N-ACETYLGLUCOSAMINYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED CARBOHYDRATE CHAINS; BOVINE BETA-1,4-GALACTOSYLTRANSFERASE; MURINE BETA-1,4-GALACTOSYLTRANSFERASE; HUMAN GALACTOSYLTRANSFERASE; HOMOLOGOUS SEQUENCES; MOLECULAR-CLONING; GENOMIC STRUCTURE; SIGNAL PEPTIDE; INSECT CELLS; EXPRESSION	A cDNA encoding a novel glycosyltransferase, that may be involved in a variant pathway for the synthesis of complex type oligosaccharide chains, was cloned from the pond snail Lymnaea stagnalis. By heterologous hybridization, using bovine beta 1 --> 4-galactosyltransferase cDNA as probe, a genomic clone from a snail library was isolated. This genomic clone was subsequently used to clone the corresponding cDNA from a prostate gland library. The isolated cDNA encodes a polypeptide of 490 amino acids with a type II membrane protein topology typical for glycosyltransferases. The carboxyl-terminal part, encoding the putative catalytic domain, reveals considerable sequence similarity with the corresponding region of mammalian beta 1 --> 4-galactosyltransferases, suggesting an evolutionary relationship. Expression of this cDNA in COS cells and insect cells revealed that the encoded enzyme transfers GlcNAc, rather than Gal or GalNAc, from the corresponding nucleotide sugars to several beta-N-acetylglucosaminides. Structural characterization by H-1 NMR spectroscopy of products formed in vitro demonstrated that the enzyme can be identified as a UDP-GlcNAc:GlcNAc beta-R beta 1 --> 4-N-acetylglucosaminyltransferase. A new family of glycosyltransferases has hereby been discovered, consisting of enzymes that act on acceptor substrates with a terminal beta-linked GlcNAc residue and establish a beta 1 --> 4-linkage, but have a different nucleotide sugar requirement.			BAKKER, H (corresponding author), VRIJE UNIV AMSTERDAM, DEPT MED CHEM, VAN DER BOECHORSTSTR 7, 1081 BT AMSTERDAM, NETHERLANDS.		Bakker, Hans/A-1787-2017; Bakker, Hans/AAA-1623-2020	Bakker, Hans/0000-0002-1364-9154; Bakker, Hans/0000-0002-1364-9154				ABEIJON C, 1992, TRENDS BIOCHEM SCI, V17, P32, DOI 10.1016/0968-0004(92)90424-8; AGTERBERG M, 1993, EUR J BIOCHEM, V217, P241, DOI 10.1111/j.1432-1033.1993.tb18239.x; AOKI D, 1990, EMBO J, V9, P3171, DOI 10.1002/j.1460-2075.1990.tb07515.x; BIERHUIZEN MFA, 1993, GENE DEV, V7, P468, DOI 10.1101/gad.7.3.468; BLANKEN WM, 1985, J BIOL CHEM, V260, P2927; BOGERD J, 1993, CELL MOL NEUROBIOL, V13, P123, DOI 10.1007/BF00735369; BULAWA CE, 1991, NATURE, V353, P710, DOI 10.1038/353710b0; CHEN WY, 1991, J BIOL CHEM, V266, P4081; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DAGOSTARO G, 1989, EUR J BIOCHEM, V183, P211, DOI 10.1111/j.1432-1033.1989.tb14915.x; DOHERTY PJ, 1989, ANAL BIOCHEM, V177, P7, DOI 10.1016/0003-2697(89)90003-1; EASTON EW, 1992, FEBS LETT, V308, P46, DOI 10.1016/0014-5793(92)81047-P; GEREMIA RA, 1994, P NATL ACAD SCI USA, V91, P2669, DOI 10.1073/pnas.91.7.2669; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; HOLLIS GF, 1989, BIOCHEM BIOPH RES CO, V162, P1069, DOI 10.1016/0006-291X(89)90782-1; HORST MN, 1981, J BIOL CHEM, V256, P1412; JOZIASSE DH, 1991, J BIOL CHEM, V266, P6991; JOZIASSE DH, 1992, GLYCOBIOLOGY, V2, P271, DOI 10.1093/glycob/2.4.271; JOZIASSE DH, 1989, J BIOL CHEM, V264, P14290; KAMERLING JP, 1991, GLYCOCONJUGATE J, V8, P259; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KEAN EL, 1992, BIOCHEM CELL BIOL, V70, P413, DOI 10.1139/o92-064; KUBELKA V, 1993, EUR J BIOCHEM, V213, P1193, DOI 10.1111/j.1432-1033.1993.tb17870.x; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIE JT, 1993, GLYCOCONJUGATE J, V10, P257, DOI 10.1007/BF01209920; MACHIDA S, 1993, J BIOL CHEM, V268, P1702; MANLEY JL, 1988, BIOCHIM BIOPHYS ACTA, V950, P1, DOI 10.1016/0167-4781(88)90067-X; MASIBAY AS, 1989, P NATL ACAD SCI USA, V86, P5733, DOI 10.1073/pnas.86.15.5733; MASRI KA, 1988, BIOCHEM BIOPH RES CO, V157, P657, DOI 10.1016/S0006-291X(88)80300-0; MENGLEGAW L, 1991, BIOCHEM BIOPH RES CO, V176, P1269, DOI 10.1016/0006-291X(91)90423-5; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NEELEMAN AP, 1994, GLYCOBIOLOGY, V4, P641, DOI 10.1093/glycob/4.5.641; OHTA M, 1991, ARCH BIOCHEM BIOPHYS, V290, P474, DOI 10.1016/0003-9861(91)90569-5; PALCIC MM, 1988, GLYCOCONJUGATE J, V5, P49, DOI 10.1007/BF01048331; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; RUSSO RN, 1990, J BIOL CHEM, V265, P3324; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAPER NL, 1988, J BIOL CHEM, V263, P10420; SHAPER NL, 1986, P NATL ACAD SCI USA, V83, P1573, DOI 10.1073/pnas.83.6.1573; SRIVATSAN J, 1992, GLYCOBIOLOGY, V2, P445, DOI 10.1093/glycob/2.5.445; TESSIER DC, 1991, GENE, V98, P177, DOI 10.1016/0378-1119(91)90171-7; VANDENEIJNDEN DH, 1993, CURR OPIN STRUC BIOL, V3, P711, DOI 10.1016/0959-440X(93)90054-O; VANDENEIJNDEN DH, 1995, IN PRESS BIOCH SOC T; VANKUIK JA, 1987, EUR J BIOCHEM, V169, P399; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; WEN DX, 1992, J BIOL CHEM, V267, P21011; WESTON BW, 1992, J BIOL CHEM, V267, P24575; YADAV S, 1990, J BIOL CHEM, V265, P14163; YADAV SP, 1991, J BIOL CHEM, V266, P698; YAMAMOTO F, 1990, NATURE, V345, P229, DOI 10.1038/345229a0; YAMAMOTO KR, 1970, VIROLOGY, V40, P734, DOI 10.1016/0042-6822(70)90218-7; ZERIAL M, 1986, EMBO J, V5, P1543, DOI 10.1002/j.1460-2075.1986.tb04395.x	55	58	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30326	30333						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7527028				2022-12-27	WOS:A1994PU52500046
J	GHERSA, P; VANHUIJSDUIJNEN, RH; WHELAN, J; CAMBET, Y; PESCINI, R; DELAMARTER, JF				GHERSA, P; VANHUIJSDUIJNEN, RH; WHELAN, J; CAMBET, Y; PESCINI, R; DELAMARTER, JF			INHIBITION OF E-SELECTIN GENE-TRANSCRIPTION THROUGH A CAMP-DEPENDENT PROTEIN-KINASE PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE ADHESION MOLECULE-1; NF-KAPPA-B; DIRECT EXPRESSION CLONING; CELL-SURFACE; BINDING PROTEINS; SIGNAL TRANSDUCTION; CYTOKINE INDUCTION; MAMMALIAN-CELLS; ACTIVATION; CREB	Cytokines induce the expression of E-selectin, VCAM-1, and ICAM-1 on human umbilical vein endothelial cells (HUVECs). We show that expression of these surface proteins is differently affected by cAMP. Increased cAMP levels decrease E-selectin and VCAM-1 but increase ICAM-1 expression. We demonstrate by mRNA half-life analysis and nuclear run-on assays that the cAMP repression of E-selectin occurs at the transcription level. This effect is abolished by protein kinase A inhibition, suggesting that repression is mediated by protein kinase A-driven phosphorylation. We found that a minimal E-selectin promoter sequence necessary to confer cytokine inducibility is also sufficient to mimic the cAMP effect in transfected HUVECs. Previously we characterized two regions (NF-kappa B and NF-ELAM1) of the minimal promoter that bind transcription factors necessary for E-selectin induction. Increased cAMP did not alter the binding of the complexes formed on either the NF-kappa B or NF-ELAM1 site. In contrast, in interleukin-1-treated HUVECs transactivity due to an NF-kappa B site is reduced by elevated cAMP. Increased cAMP in HUVECs appears to induce a protein kinase activity that reduces the cytokine signal for E-selectin and VCAM-1 expression. The reduction in signal may occur through an inhibitory phosphorylation of one or more of the factors responsible for regulating E-selectin expression.			GHERSA, P (corresponding author), GLAXO INST MOLEC BIOL SA,14 CHEMIN AULX,CH-1228 PLAN LES OUATES,SWITZERLAND.		van Huijsduijnen, Rob A.M. Hooft/B-3653-2009	van Huijsduijnen, Rob A.M. Hooft/0000-0002-2261-9424				Ausubel FM, 1988, MOL REPROD DEV; BAEUERLE PA, 1991, MOL ASPECTS CELL REG, V6, P409; BEVILACQUA MP, 1993, ANNU REV IMMUNOL, V11, P767, DOI 10.1146/annurev.iy.11.040193.004003; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLLINS T, 1991, J BIOL CHEM, V266, P2466; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; CULLEN BR, 1987, METHOD ENZYMOL, V152, P692; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; DUSTIN ML, 1986, J IMMUNOL, V137, P245; FLINT KJ, 1991, ONCOGENE, V6, P2019; GERRITSEN ME, 1993, FASEB J, V7, P523, DOI 10.1096/fasebj.7.6.8472891; GHERSA P, 1992, J BIOL CHEM, V267, P19226; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; HATTORI R, 1989, J BIOL CHEM, V264, P7768; HESSION C, 1990, P NATL ACAD SCI USA, V87, P1673, DOI 10.1073/pnas.87.5.1673; IWASAKI T, 1992, FEBS LETT, V298, P240, DOI 10.1016/0014-5793(92)80067-Q; KASZUBSKA W, 1993, MOL CELL BIOL, V13, P7180, DOI 10.1128/MCB.13.11.7180; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KUSHNER PJ, 1994, MOL ENDOCRINOL, V8, P405, DOI 10.1210/me.8.4.405; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; LEWIS H, 1994, MOL CELL BIOL, V14, P5701, DOI 10.1128/MCB.14.9.5701; MACCHIA G, 1990, MOL CELL BIOL, V10, P2731, DOI 10.1128/MCB.10.6.2731; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MONTGOMERY KF, 1991, P NATL ACAD SCI USA, V88, P6523, DOI 10.1073/pnas.88.15.6523; Muegge K, 1990, Cytokine, V2, P1, DOI 10.1016/1043-4666(90)90036-S; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; PESCINI R, 1994, J BIOL CHEM, V269, P1159; POBER JS, 1993, J IMMUNOL, V150, P5114; POBER JS, 1990, PHYSIOL REV, V70, P427, DOI 10.1152/physrev.1990.70.2.427; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; RITCHIE AJ, 1991, J IMMUNOL, V146, P3056; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P959, DOI 10.1128/MCB.9.3.959; VANHUIJSDUIJNEN RH, 1992, J BIOL CHEM, V267, P22385; VANHUIJSDUIJNEN RH, 1993, NUCLEIC ACIDS RES, V21, P3711, DOI 10.1093/nar/21.16.3711; VYAS S, 1990, EMBO J, V9, P3707, DOI 10.1002/j.1460-2075.1990.tb07583.x; WERTHEIMER S J, 1991, Journal of Cell Biology, V115, p453A; WHELAN J, 1991, NUCLEIC ACIDS RES, V19, P2645, DOI 10.1093/nar/19.10.2645; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; ZHANG Q, 1994, MOL CELL BIOL, V14, P3915, DOI 10.1128/MCB.14.6.3915	50	87	87	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					29129	29137						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7525580				2022-12-27	WOS:A1994PU16800090
J	BEARD, WA; STAHL, SJ; KIM, HR; BEBENEK, K; KUMAR, A; STRUB, MP; BECERRA, SP; KUNKEL, TA; WILSON, SH				BEARD, WA; STAHL, SJ; KIM, HR; BEBENEK, K; KUMAR, A; STRUB, MP; BECERRA, SP; KUNKEL, TA; WILSON, SH			STRUCTURE-FUNCTION STUDIES OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REVERSE-TRANSCRIPTASE - ALANINE SCANNING MUTAGENESIS OF AN ALPHA-HELIX IN THE THUMB SUBDOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEADY-STATE KINETICS; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; BINDING DOMAIN; DNA; MECHANISM; HIV-1; SITE; IDENTIFICATION	Human immunodeficiency virus type 1 reverse transcriptase has subunits of 66 and 51 kDa (p66 and p51, respectively). Structural studies indicate that each subunit consists of common subdomains. The polymerase domain of p66 forms a nucleic acid binding cleft, and, by analogy with a right hand, the subdomains are referred to as fingers, palm, and thumb (Kohlstaedt, L. A., Wang, J., Friedman, J. M., Rice, P. A., and Steitz, T. A. (1992) Science 256, 1783-1790). Residues 257-266 correspond to a highly conserved region of primary structure among retroviral pol genes. Crystallographic evidence indicates that these residues are in the thumb subdomain and form part of an alpha-helix (alpha H), which interacts with DNA (Jacobo-Molina, A., Ding, J., Nanni, R. G., Clark, A. D., Jr., Lu, X., Tantillo, C., Williams, R. L., Kamer, G., Ferris, A. L., Clark, P., Hizi, A., Hughes, S. H., and Arnold, E. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 6320-6324). To define the role of this region during catalytic cycling, we performed systematic site directed mutagenesis from position 253 through position 271 by changing each residue, one by one, to alanine. Each mutant protein was expressed and purified, and their substrate specific activities were surveyed. The results are consistent with alpha H (residues 255-268) of p66 interacting with the template and/or primer strand. The core of alpha H appears to play an important role in template-primer binding (residues Gln-258, Gly-262, and Trp-266), and in protein-protein interactions (residues Val-261 and Leu-264). The periodicity of the effects observed suggest that a segment of one face of alpha H interacts with the template-primer. The lower fidelity observed with alanine mutants of Gly-262 and Trp-266 correlated with an over 200-fold increase in the dissociation rate constant for template-primer relative to wild type enzyme and suggests that enzyme-DNA interactions in the template-primer stem are important fidelity determinants.	NCI, BIOCHEM LAB, BETHESDA, MD 20892 USA; UNIV TEXAS, SEALY CTR MOLEC SCI, MED BRANCH, GALVESTON, TX 77555 USA; NIEHS, MOLEC GENET LAB, RES TRIANGLE PK, NC 27709 USA; NIH, PROTEIN EXPRESS LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Texas System; University of Texas Medical Branch Galveston; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA			Kunkel, Thomas A./D-5088-2019; Wilson, Samuel H/E-6644-2019	Kunkel, Thomas A./0000-0002-9900-1788; Wilson, Samuel H/0000-0002-1702-5293				ABBOTTS J, 1993, J BIOL CHEM, V268, P10312; BASU A, 1989, J BIOL CHEM, V264, P8746; BASU A, 1992, BIOCHEMISTRY-US, V31, P616, DOI 10.1021/bi00117a045; BEARD WA, 1993, BIOCHEMISTRY-US, V32, P9745, DOI 10.1021/bi00088a029; BEBENEK K, 1993, J BIOL CHEM, V268, P10324; BEBENEK K, 1989, J BIOL CHEM, V264, P16948; BECERRA SP, 1993, PROTEIN EXPRES PURIF, V4, P187, DOI 10.1006/prep.1993.1025; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARL PL, 1980, J BACTERIOL, V144, P28, DOI 10.1128/JB.144.1.28-35.1980; CHANDRA A, 1986, FEBS LETT, V200, P327, DOI 10.1016/0014-5793(86)81162-0; GOEL R, 1993, BIOCHEMISTRY-US, V32, P13012, DOI 10.1021/bi00211a009; HSIEH JC, 1993, J BIOL CHEM, V268, P24607; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JACOBOMOLINA A, 1991, BIOCHEMISTRY-US, V30, P6351, DOI 10.1021/bi00240a001; KATI WM, 1992, J BIOL CHEM, V267, P25988; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KUNKEL TA, 1985, J BIOL CHEM, V260, P5787; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LARDER BA, 1987, NATURE, V327, P716, DOI 10.1038/327716a0; LIGHTFOOTE MM, 1986, J VIROL, V60, P771, DOI 10.1128/JVI.60.2.771-775.1986; MAJUMDAR C, 1988, J BIOL CHEM, V263, P15657; MITCHELL LLW, 1992, BIOCHEMISTRY-US, V31, P7707, DOI 10.1021/bi00148a035; MITSUYA H, 1990, SCIENCE, V249, P1533, DOI 10.1126/science.1699273; Nanni Raymond G., 1993, Perspectives in Drug Discovery and Design, V1, P129, DOI 10.1007/BF02171659; REARDON JE, 1990, J BIOL CHEM, V265, P20302; REARDON JE, 1992, BIOCHEMISTRY-US, V31, P4473, DOI 10.1021/bi00133a013; REARDON JE, 1993, J BIOL CHEM, V268, P8743; Richardson J.S., 1990, PREDICTION PROTEIN S, P1; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504	30	102	102	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28091	28097						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7525566				2022-12-27	WOS:A1994PV77200050
J	MILLER, KJ; HOFFMAN, BJ				MILLER, KJ; HOFFMAN, BJ			ADENOSINE A(3) RECEPTORS REGULATE SEROTONIN TRANSPORT VIA NITRIC-OXIDE AND CGMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; HIGH-AFFINITY UPTAKE; PROTEIN-KINASE-C; NEUROTRANSMITTER TRANSPORTERS; MEMBRANE-VESICLES; MOLECULAR-CLONING; CELL-CULTURES; GLUTAMATE; ACTIVATION; PHOSPHORYLATION	Many antidepressants inhibit 5-hydroxytryptamine (5HT) transport resulting in increased 5HT levels in the synapse. However, physiological regulation of neurotransmitter uptake has not been demonstrated. We have examined the effect of receptor-activated second messengers on the 5HT transporter in rat basophilic leukemia cells (RBL 2H3). Here, we show that activation of an A(3) adenosine receptor results in an increase of 5HT uptake in RBL cells, due to an increase in maximum velocity (V-max). The A(3) adenosine receptor-stimulated increase in transport is blocked by inhibitors of nitric oxide synthase and by a cGMP dependent kinase inhibitor. In fact, compounds that generate nitric oxide (NO) and the cGMP analog 8-bromo-cGMP mimicked the effect of A(3) receptor stimulation, suggesting that the elevation in transport occurs through the generation of the gaseous second messenger NO and a subsequent elevation in cGMP. Additionally, the 5HT transporter is differentially regulated by second messengers since direct activation of protein kinase C by phorbol esters decreases 5HT uptake by decreasing V-max. Our results suggest that the changes in transport are due to a direct modification of the 5HT transporter, possibly by phosphorylation, which appears to alter the rate at which transport occurs. As the 5HT transporter in RBL cells is identical to that in neurons, our results suggest that analogous mechanisms may operate in the brain.			MILLER, KJ (corresponding author), NIMH, CELL BIOL LAB, ROCKVILLE PIKE, BETHESDA, MD 20892 USA.							ALI H, 1990, J BIOL CHEM, V265, P745; AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; ANDERSON GM, 1992, BIOCHIM BIOPHYS ACTA, V1137, P331, DOI 10.1016/0167-4889(92)90154-4; AXELROD J, 1963, J PHARMACOL EXP THER, V141, P161; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BROWNSTEIN MJ, 1993, RECENT PROG HORM RES, V49, P27; CASADO M, 1991, J NEUROCHEM, V57, P1185, DOI 10.1111/j.1471-4159.1991.tb08278.x; CASADO M, 1993, J BIOL CHEM, V268, P27313; COOL DR, 1990, BIOCHEMISTRY-US, V29, P1818, DOI 10.1021/bi00459a022; COREY JL, 1994, J BIOL CHEM, V269, P14759; CUHNAMELO JR, 1989, J IMMUNOL, V143, P2617; DOUGLAS JG, 1982, PHARMACOL THERAPEUT, V18, P351, DOI 10.1016/0163-7258(82)90037-7; FULLER RW, 1990, NEUROPHARMACOLOGY SE, V600, P68; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; GLOWINSKI J, 1966, J PHARMACOL EXP THER, V164, P282; HANSSON E, 1989, LIFE SCI, V44, P27, DOI 10.1016/0024-3205(89)90214-2; HANSSON E, 1991, BRAIN RES, V548, P215, DOI 10.1016/0006-8993(91)91124-J; HOFFMAN BJ, 1991, SCIENCE, V254, P579, DOI 10.1126/science.1948036; HOFFMAN BJ, 1992, SOC NEUR ABSTR, V17, P1179; JAYANTHI LD, 1994, J BIOL CHEM, V269, P14424; KANNER BI, 1985, BIOCHIM BIOPHYS ACTA, V816, P403, DOI 10.1016/0005-2736(85)90508-5; KAUFMAN M, 1994, IN PRESS J NEUROCHEM; KUHAR MJ, 1972, J PHARMACOL-PARIS, V181, P36; KUHAR MJ, 1991, TRENDS NEUROSCI, V14, P299, DOI 10.1016/0166-2236(91)90141-G; MEYERS CL, 1989, AM J PHYSIOL, V257, pL253; MONCADA S, 1989, BIOCHEM PHARMACOL, V38, P1709, DOI 10.1016/0006-2952(89)90403-6; MULSCH A, 1989, N-S ARCH PHARMACOL, V340, P119; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PERRY KW, 1992, LIFE SCI, V50, P1683, DOI 10.1016/0024-3205(92)90423-M; PRISTUPA ZB, 1994, MOL PHARMACOL, V45, P125; RAMAMOORTHY S, 1993, P NATL ACAD SCI USA, V90, P2542, DOI 10.1073/pnas.90.6.2542; RAMAMOORTHY S, 1993, J BIOL CHEM, V268, P21626; RAMKUMAR V, 1993, J BIOL CHEM, V268, P16887; ROSS SB, 1982, BIOL SEROTONERGIC TR, P159; ROWLAND NE, 1986, PROG NEUROBIOL, V27, P13, DOI 10.1016/0301-0082(86)90011-0; RUDNICK G, 1992, P NATL ACAD SCI USA, V89, P1817, DOI 10.1073/pnas.89.5.1817; SHEARD MH, 1972, BRAIN RES, V43, P690, DOI 10.1016/0006-8993(72)90432-5; SNYDER SH, 1969, J PHARMACOL EXP THER, V165, P78; SOUTHAM E, 1991, NEUROSCI LETT, V130, P107, DOI 10.1016/0304-3940(91)90239-P; STEVENS CF, 1993, NATURE, V364, P147, DOI 10.1038/364147a0; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; UHL GR, 1992, TRENDS NEUROSCI, V15, P265, DOI 10.1016/0166-2236(92)90068-J; WOTHERSPOON G, 1994, NEUROSCI LETT, V173, P31, DOI 10.1016/0304-3940(94)90143-0; ZHOU M, 1993, SCIENCE, V260, P1946; ZHOU QY, 1992, P NATL ACAD SCI USA, V89, P7432, DOI 10.1073/pnas.89.16.7432	47	170	171	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27351	27356						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7525554				2022-12-27	WOS:A1994PV77100034
J	SIPPEL, CJ; FALLON, RJ; PERLMUTTER, DH				SIPPEL, CJ; FALLON, RJ; PERLMUTTER, DH			BILE-ACID EFFLUX MEDIATED BY THE RAT-LIVER CANALICULAR BILE-ACID TRANSPORT ECTO-ATPASE PROTEIN REQUIRES SERINE 503 PHOSPHORYLATION AND IS REGULATED BY TYROSINE-488 PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASIALOGLYCOPROTEIN RECEPTOR; DEPENDENT TRANSPORT; MOLECULAR-CLONING; INSULIN-RECEPTOR; BINDING PROTEIN; KINASE-C; MEMBRANE; EXPRESSION; GLYCOPROTEIN; DOMAIN	Transfection of cDNA for a hepatocyte canalicular phosphoprotein, the rat liver canalicular bile acid transporter/ecto-ATPase/cell CAM 105, confers bile acid efflux and ecto-ATPase activities on heterologous cells (Sippel, C. J., Suchy, F. J., Ananthanarayanan, M., and Perlmutter D. H. (1993) J. Biol. Chen. 268, 2083-2091). Our previous studies have also indicated that there is a positive correlation between the degree of phosphorylation of this transporter and its bile acid efflux activity. In this study, we introduced site-specific mutations of amino acid residues within a protein kinase C-dependent (T502A, S503A) and a tyrosine kinase-dependent (Y488F) phosphorylation consensus sequence in the cytoplasmic tail of this transporter in order to map the sites that are phosphorylated in vivo and to examine the functional significance of each. COS cells were transfected with mutant and wild type constructs using the pCDM8 expression vector. Metabolic labeling and cell surface labeling showed that the mutant proteins were synthesized and delivered to the cell surface as efficiently as the wild type. Phosphoamino acid analysis using lysates of transfected cells showed that the T502A, S503A mutant contained [P-32]phosphotyrosine, the Y488F mutant contained [P-32]phosphoserine, and the wild type contained both P-32-labeled amino acids, proving that Ser(503) and Tyr(488) are the only amino acids phosphorylated in this system under control conditions. Bile acid transport activity was completely abrogated in cells transfected with the T502A, S503A mutant cDNA and was retained but altered in kinetic characteristics in cells transfected with the Y488F mutant cDNA, even though both of these constructs conferred ecto-ATPase activity to the same extent as the wild type cDNA. Taken together, these data show that the bile acid efflux activity of this transporter requires site-specific phosphorylation of Ser(503) and is regulated by site specific phosphorylation of Tyr(488).	WASHINGTON UNIV,SCH MED,DEPT CELL BIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PHYSIOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)	SIPPEL, CJ (corresponding author), WASHINGTON UNIV,SCH MED,DEPT PEDIAT,1 CHILDRENS PL,ST LOUIS,MO 63110, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K08HD000954, T32HD007409] Funding Source: NIH RePORTER; NICHD NIH HHS [K08 HD00954-01, T32 HD07409] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADACHI Y, 1991, HEPATOLOGY, V14, P655, DOI 10.1016/0270-9139(91)90053-X; ANANTHANARAYANA.M, 1991, AM J PHYSIOL, V261, pG2810; ARIAS IM, 1993, HEPATOLOGY, V17, P318, DOI 10.1002/hep.1840170225; BARTLES JR, 1987, J CELL BIOL, V105, P1241, DOI 10.1083/jcb.105.3.1241; BECKER A, 1993, EUR J BIOCHEM, V214, P539, DOI 10.1111/j.1432-1033.1993.tb17952.x; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BLITZER B, 1982, AM J PHYSIOL, V6, pG48; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; CHEUNG PH, 1993, J BIOL CHEM, V268, P6139; CULIC O, 1992, BIOCHEM J, V285, P47, DOI 10.1042/bj2850047; CULLEN BR, 1987, METHOD ENZYMOL, V152, P562; FALLON RJ, 1990, J BIOL CHEM, V265, P3401; GONG YZ, 1993, HEPATOLOGY, V18, pA144; HAGENBUCH B, 1991, P NATL ACAD SCI USA, V88, P10629, DOI 10.1073/pnas.88.23.10629; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HARRISON BC, 1991, J NEUROCHEM, V56, P1723, DOI 10.1111/j.1471-4159.1991.tb02073.x; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; LEDERKREMER GZ, 1991, J BIOL CHEM, V266, P1237; LIN SH, 1989, J BIOL CHEM, V264, P14408; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARGOLIS RN, 1990, BIOCHEM BIOPH RES CO, V166, P562, DOI 10.1016/0006-291X(90)90845-E; MARGOLIS RN, 1988, P NATL ACAD SCI USA, V85, P7256, DOI 10.1073/pnas.85.19.7256; MULLER M, 1991, J BIOL CHEM, V266, P18920; NATHANSON MH, 1991, HEPATOLOGY, V14, P551, DOI 10.1002/hep.1840140324; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; ORR GA, 1993, J BIOL CHEM, V268, P25054; PERLMUTTER DH, 1988, J BIOL CHEM, V263, P16499; RUETZ S, 1987, J BIOL CHEM, V262, P11324; RUGOLO M, 1993, J BIOL CHEM, V268, P24779; SIPPEL CJ, 1993, J BIOL CHEM, V268, P2083; SIPPEL CJ, 1994, J BIOL CHEM, V269, P2820; SIPPEL CJ, 1990, AM J PHYSIOL, V258, pG728, DOI 10.1152/ajpgi.1990.258.5.G728; SWEETSER DA, 1986, J BIOL CHEM, V261, P5553; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; WONG MH, 1994, J BIOL CHEM, V269, P1340; YIH LH, 1991, CELL BIOL INT REP, V15, P253, DOI 10.1016/0309-1651(91)90157-E; ZIMNIAK P, 1993, HEPATOLOGY, V17, P330, DOI 10.1002/hep.1840170226	37	50	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19539	19545						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	7518458				2022-12-27	WOS:A1994NY33200053
J	GUINTO, ER; YE, J; LEBONNIEC, BF; ESMON, CT				GUINTO, ER; YE, J; LEBONNIEC, BF; ESMON, CT			GLU(192)-]GLN SUBSTITUTION IN THROMBIN YIELDS AN ENZYME THAT IS EFFECTIVELY INHIBITED BY BOVINE PANCREATIC TRYPSIN-INHIBITOR AND TISSUE FACTOR PATHWAY INHIBITOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRO-ARG CHLOROMETHYLKETONE; RAY CRYSTAL-STRUCTURE; HUMAN ALPHA-THROMBIN; PROTEIN-C; ACTIVE-SITE; KUNITZ INHIBITORS; ANTITHROMBIN-III; TRP INSERTION; THROMBOMODULIN; COAGULATION	Modeling studies have ascribed the remarkable resistance of thrombin to inhibition by the Kunitz type inhibitors, bovine pancreatic trypsin inhibitor (BPTI), and tissue factor pathway inhibitor (TFPI), to steric inhibition by the 60-loop insertion, especially Trp(60D) (in the chymotrypsin numbering system). Indeed, deletion of Pro(60B) Pro(60C), and Trp(60D) from this loop (des-PPW) enhances BPTI inhibition (K-i = 16 nM) (Le Bonniec, B. F., Guinto, E. R., MacGillivray, R. T. A., Stone, S. R., and Esmon, C. T. (1993) J. Biol. Chem. 268, 19055-19061). Activated protein C, however, lacks an equivalent insertion loop but is nevertheless resistant to inhibition by these Kunitz inhibitors. A unique feature of thrombin and activated protein C is the presence of Glu at position 192. Substitution of Glu(192) with Gin in activated protein C dramatically enhances inhibition by BPTI and TFPI (Rezaie, A and Esmon, C. T. (1993) J. Biol. Chem. 268, 19943-19948). We now demonstrate that thrombin E192Q (the Glu(192) --> Gln mutant) is inhibited by BPTI (K-i = 24 nM) or TFPI (K-i = 14 nM) much more effectively than wild type thrombin (K-i > 1 mu M for both inhibitors). A thrombin mutant having both the des-PPW deletion and E192Q substitution binds BPTI (K-i = 35 pM) and TFPI (K-i = 25 pM) even tighter. BPTI can displace dansylarginine N-(-3-ethyl-1,5-pentanediyl)-amide from the active site of thrombin E192Q (K-i = 19 nM), indicating that BPTI interacts directly with the S1 binding site in thrombin. The E192Q mutation and PPW deletion contribute comparably and additively to the binding energy of thrombin with the Kunitz inhibitors. We suggest that access to the active center of thrombin is less restricted than predicted from previous studies.	OKLAHOMA MED RES FDN, HOWARD HUGHES MED INST, OKLAHOMA CITY, OK 73104 USA; UNIV OKLAHOMA, HLTH SCI CTR, DEPT PATHOL, OKLAHOMA CITY, OK 73104 USA; UNIV OKLAHOMA, HLTH SCI CTR, DEPT BIOCHEM & MOLEC BIOL, OKLAHOMA CITY, OK 73104 USA; OKLAHOMA MED RES FDN, CARDIOVASC BIOL RES PROGRAM, OKLAHOMA CITY, OK 73104 USA; UNIV CAMBRIDGE, CTR MRC, DEPT HEMATOL, CAMBRIDGE CB2 2QH, ENGLAND	Howard Hughes Medical Institute; Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; Oklahoma Medical Research Foundation; University of Cambridge			Le Bonniec, Bernard/ABA-1366-2020; Le Bonniec, Bernard/S-5756-2016	Le Bonniec, Bernard/0000-0002-8432-7363; Le Bonniec, Bernard/0000-0002-8432-7363	NHLBI NIH HHS [R01-HL29807, R37-HL30340] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029807, R37HL030340] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANNER DW, 1991, J BIOL CHEM, V266, P20085; BERLINER LJ, 1986, ANN NY ACAD SCI, V485, P80, DOI 10.1111/j.1749-6632.1986.tb34570.x; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BODE W, 1992, PROTEIN SCI, V1, P426; BODE W, 1992, THROMBIN STRUCTURE F, P3; BRANDSTETTER H, 1992, J MOL BIOL, V226, P1085, DOI 10.1016/0022-2836(92)91054-S; BROZE GJ, 1990, BIOCHEMISTRY-US, V29, P7539, DOI 10.1021/bi00485a001; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; ESMON CT, 1989, J BIOL CHEM, V264, P4743; GIRARD TJ, 1989, NATURE, V338, P518, DOI 10.1038/338518a0; GREER J, 1990, PROTEINS, V7, P317, DOI 10.1002/prot.340070404; HUANG ZF, 1993, J BIOL CHEM, V268, P26950; HUBER R, 1974, BAYER S, V5, P497; LEBONNIEC BF, 1994, BIOCHEMISTRY-US, V33, P3959, DOI 10.1021/bi00179a023; LEBONNIEC BF, 1993, J BIOL CHEM, V268, P19055; LEBONNIEC BF, 1992, J BIOL CHEM, V267, P19341; LEBONNIEC BF, 1991, P NATL ACAD SCI USA, V88, P7371, DOI 10.1073/pnas.88.16.7371; NESHEIM ME, 1979, BIOCHEMISTRY-US, V18, P996, DOI 10.1021/bi00573a010; OWEN WG, 1974, J BIOL CHEM, V249, P594; PRATT CW, 1993, BLOOD COAGUL FIBRIN, V4, P479, DOI 10.1097/00001721-199306000-00013; REZAIE AR, 1993, J BIOL CHEM, V268, P19943; RUHLMANN A, 1973, J MOL BIOL, V77, P417, DOI 10.1016/0022-2836(73)90448-8; RYDEL TJ, 1991, J MOL BIOL, V221, P583, DOI 10.1016/0022-2836(91)80074-5; Segel I.H., 1975, ENZYME KINETICS; STEARNS DJ, 1988, J BIOL CHEM, V263, P826; STONE SR, 1986, BIOCHEMISTRY-US, V25, P4622, DOI 10.1021/bi00364a025; TULINSKY A, 1993, BLOOD COAGUL FIBRIN, V4, P305, DOI 10.1097/00001721-199304000-00012; VINCENT JP, 1972, BIOCHEMISTRY-US, V11, P2967, DOI 10.1021/bi00766a007; WELLS CM, 1992, BIOCHEMISTRY-US, V31, P11721, DOI 10.1021/bi00162a008	29	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18395	18400						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	7518431				2022-12-27	WOS:A1994NW79800028
J	GUTHER, MLS; MASTERSON, WJ; FERGUSON, MAJ				GUTHER, MLS; MASTERSON, WJ; FERGUSON, MAJ			THE EFFECTS OF PHENYLMETHYLSULFONYL FLUORIDE ON INOSITOL-ACYLATION AND FATTY-ACID REMODELING IN AFRICAN TRYPANOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIANT SURFACE GLYCOPROTEIN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHOR BIOSYNTHESIS; PHOSPHATIDYLINOSITOL MEMBRANE ANCHORS; CELL-FREE SYSTEM; GLYCOSYL-PHOSPHATIDYLINOSITOL; GLYCOLIPID PRECURSORS; MAMMALIAN-CELLS; DEVELOPMENTAL VARIATION; RESISTANT GLYCOLIPIDS; TOXOPLASMA-GONDII	Phenylmethylsulfonyl fluoride (PMSF) has been shown to inhibit the addition of ethanolamine phosphate to glycosylphosphatidylinositol (GPI) intermediates in Trypanosoma brucei (Masterson, W. J., and Ferguson, M. A. J. (1991) EMBO J. 10, 2041-2045). Here we show that the Man(3)-GlcN-PI intermediate that accumulates in the presence of PMSF can undergo fatty acid remodeling, suggesting that the fatty acid remodeling enzymes are not specific for ethanolamine phosphate-containing GPI intermediates. We also show that PMSF inhibits the acylation of the inositol residue of GPI intermediates in bloodstream form T. brucei. Pulse-chase experiments demonstrate that glycolipid C (ethanolamine-PO4-Man(3)-GlcN-(acyl)PI) is not an obligatory precursor cursor of glycolipid A (ethanolamine PO4-Man(3)-GlcN-PI) and that glycolipid C can be converted to glycolipid A. These data suggest a model where glycolipid C is the terminal product of the GPI biosynthetic pathway, in dynamic equilibrium with glycolipid A. The inhibition of ethanolamine phosphate addition and inositol acylation by PMSF was also observed for procyclic forms of T. brucei but not for mammalian HeLa cells. These results suggest differences between the relevant parasite and mammalian enzymes.	UNIV DUNDEE, DEPT BIOCHEM, DUNDEE DD1 4HN, SCOTLAND	University of Dundee			Ferguson, Michael A. J./F-7829-2010	Ferguson, Michael A. J./0000-0003-1321-8714	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BANGS JD, 1985, P NATL ACAD SCI USA, V82, P3207, DOI 10.1073/pnas.82.10.3207; BROWN D, 1993, CURR OPIN IMMUNOL, V5, P349, DOI 10.1016/0952-7915(93)90052-T; BRUN R, 1979, ACTA TROP, V36, P289; COSTELLO LC, 1992, J BIOL CHEM, V267, P8599; CROSS GAM, 1990, ANNU REV IMMUNOL, V8, P83, DOI 10.1146/annurev.iy.08.040190.000503; DOERING TL, 1989, J BIOL CHEM, V264, P11168; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; FERGUSON MAJ, 1991, CELL BIOL INT REP, V15, P991, DOI 10.1016/0309-1651(91)90052-K; FERGUSON MAJ, 1986, J BIOL CHEM, V261, P356; FIELD MC, 1991, J BIOL CHEM, V266, P8392; FIELD MC, 1992, J BIOL CHEM, V267, P5324; GEROLD P, 1994, J BIOL CHEM, V269, P2597; HIROSE S, 1991, P NATL ACAD SCI USA, V88, P3762, DOI 10.1073/pnas.88.9.3762; HIROSE S, 1992, J BIOL CHEM, V267, P16968; KAMITANI T, 1992, J BIOL CHEM, V267, P24611; KRAKOW JL, 1986, J BIOL CHEM, V261, P2147; KRAKOW JL, 1989, MOL BIOCHEM PARASIT, V36, P263, DOI 10.1016/0166-6851(89)90174-6; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MASTERSON WJ, 1991, EMBO J, V10, P2041, DOI 10.1002/j.1460-2075.1991.tb07734.x; MASTERSON WJ, 1990, CELL, V62, P73, DOI 10.1016/0092-8674(90)90241-6; MAYOR S, 1990, J BIOL CHEM, V265, P6164; MAYOR S, 1991, J CELL BIOL, V114, P61, DOI 10.1083/jcb.114.1.61; MAYOR S, 1990, J BIOL CHEM, V265, P6174; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MENON AK, 1992, J BIOL CHEM, V267, P15277; MENON AK, 1993, EMBO J, V12, P1907, DOI 10.1002/j.1460-2075.1993.tb05839.x; MENON AK, 1990, J BIOL CHEM, V265, P9033; MENON AK, 1990, EMBO J, V9, P4249, DOI 10.1002/j.1460-2075.1990.tb07873.x; MENON AK, 1991, CELL BIOL INT REP, V15, P1007; MILNE KG, 1992, EUR J BIOCHEM, V208, P309, DOI 10.1111/j.1432-1033.1992.tb17188.x; PUOTI A, 1993, J BIOL CHEM, V268, P7215; PUOTI A, 1991, J BIOL CHEM, V266, P21051; RALTON JE, 1993, J BIOL CHEM, V268, P24183; SUGIYAMA E, 1991, J BIOL CHEM, V266, P12119; TOMAVO S, 1992, J BIOL CHEM, V267, P21446; TOMAVO S, 1992, J BIOL CHEM, V267, P11721; URAKAZE M, 1992, J BIOL CHEM, V267, P6459; VIDUGIRIENE J, 1993, J CELL BIOL, V121, P987, DOI 10.1083/jcb.121.5.987	38	70	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18694	18701						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	7518442				2022-12-27	WOS:A1994NW79800073
J	IZUHARA, K; FELDMAN, RA; GREER, P; HARADA, N				IZUHARA, K; FELDMAN, RA; GREER, P; HARADA, N			INTERACTION OF THE C-FES PROTOONCOGENE PRODUCT WITH THE INTERLEUKIN-4 RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; TYROSINE KINASE; HEMATOPOIETIC-CELLS; SIGNAL TRANSDUCTION; PROTOONCOGENE PRODUCT; FPS/FES PROTOONCOGENE; ENCODED PROTEIN; MYELOID CELLS; B-CELLS; PHOSPHORYLATION	Interleukin-4 (IL-4) regulates proliferation and differentiation of a variety of hematopoietic cell lineages through binding to the IL-4 receptor (IL-4R). Recently, we have demonstrated that IL-4 induces tyrosine phosphorylation of several proteins including the IL-4R and also induces association of phosphatidylinositol-3 kinase with the IL-4R. Since IL-4 induces tyrosine phosphorylation, we speculated that some tyrosine kinase may associate with the IL-4R. In this study, we demonstrate that IL-4 induces tyrosine phosphorylation of a protein closely related to, or identical to the c-fes protooncogene-encoded protein tyrosine kinase (FES). Furthermore, tyrosine phosphorylated FES or the closely related protein is found associated with the IL-4R. We also demonstrate that FES associates with the IL-4R in COS7 cells transfected with cDNA expression plasmids encoding these two proteins and in transfected COS7 cells IL-4 augments association of FES with the IL-4R and tyrosine phosphorylation of both FES and the IL-4R. Through a deletion analysis of the IL-4R we have identified a putative FES-binding site in the cytoplasmic domain of the IL-4R.	DNAX RES INST MOLEC & CELLULAR BIOL INC,DEPT IMMUNOL,PALO ALTO,CA 94304; UNIV MARYLAND,SCH MED,DEPT MICROBIOL & IMMUNOL,BALTIMORE,MD 21201; UNIV MARYLAND,MARYLAND BIOTECHNOL INST,CTR MED BIOTECHNOL,BALTIMORE,MD 21201; QUEENS UNIV,DEPT PATHOL,CANC RES LABS,KINGSTON K7L 3N6,ON,CANADA; QUEENS UNIV,DEPT BIOCHEM,KINGSTON K7L 3N6,ON,CANADA	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Queens University - Canada; Queens University - Canada				Feldman, Ricardo A./0000-0001-6090-0439	NCI NIH HHS [R29 CA55293-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA055293] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; COOPER JA, 1984, J BIOL CHEM, V259, P7835; FELDMAN RA, 1990, ONCOGENE RES, V5, P187; FELDMAN RA, 1985, P NATL ACAD SCI USA, V82, P2379, DOI 10.1073/pnas.82.8.2379; FELDMAN RA, 1987, ONCOGENE RES, V1, P441; FELDMAN RA, 1986, MOL CELL BIOL, V6, P1065, DOI 10.1128/MCB.6.4.1065; GALIZZI JP, 1990, INT IMMUNOL, V2, P669, DOI 10.1093/intimm/2.7.669; GREER P, 1990, MOL CELL BIOL, V10, P2521, DOI 10.1128/MCB.10.6.2521; HANAZONO Y, 1993, BLOOD, V81, P3193; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; HARADA N, 1992, J BIOL CHEM, V267, P22752; HJERMSTAD SJ, 1993, ONCOGENE, V8, P2283; IZUHARA K, 1993, RES IMMUNOL, V144, P584, DOI 10.1016/S0923-2494(05)80007-0; IZUHARA K, 1993, J BIOL CHEM, V268, P13097; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MACDONALD I, 1985, MOL CELL BIOL, V5, P2543, DOI 10.1128/MCB.5.10.2543; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; PAUL WE, 1991, BLOOD, V77, P1859; PAWSON T, 1989, MOL CELL BIOL, V9, P5722, DOI 10.1128/MCB.9.12.5722; PLUZNIK DH, 1982, EXP HEMATOL, V10, P211; SAMARUT J, 1985, MOL CELL BIOL, V5, P1067, DOI 10.1128/MCB.5.5.1067; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; VELLENGA E, 1993, LEUKEMIA, V7, P1131; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YOKOTA T, 1988, IMMUNOL REV, V102, P137, DOI 10.1111/j.1600-065X.1988.tb00744.x; YU G, 1989, J BIOL CHEM, V264, P10276	32	85	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18623	18629						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	7518439				2022-12-27	WOS:A1994NW79800062
J	CHEN, BPC; LIANG, GS; WHELAN, J; HAI, TW				CHEN, BPC; LIANG, GS; WHELAN, J; HAI, TW			ATF3 AND ATF3-DELTA-ZIP - TRANSCRIPTIONAL REPRESSION VERSUS ACTIVATION BY ALTERNATIVELY SPLICED ISOFORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; LEUCINE ZIPPER STRUCTURE; AMP RESPONSE ELEMENT; DNA-BINDING PROTEIN; CYCLIC-AMP; GENE-TRANSCRIPTION; CDNA CLONES; CYTOKINE INDUCTION; FACTOR CREB; ENHANCER	ATF3 is a member of the mammalian activating transcription factor/cAMP responsive element binding protein (ATF/CREB) family of transcription factors. In this report, we demonstrate that, contrary to the implication of its name, ATF3 represses rather than activates transcription from promoters with ATF sites. We also present evidence suggesting that one possible mechanism by which ATF3 represses transcription is to stabilize inhibitory co-factors at the promoter. In addition, we describe a naturally occurring, alternatively spliced, form of ATF3: ATF3 Delta Zip. ATF3 Delta Zip lacks the leucine zipper domain and does not bind to DNA. In contrast to ATF3, ATF3 Delta Zip stimulates transcription, presumably by sequestering inhibitory co-factors away from the promoter. It is possible that ATF3 Delta Zip is a physiologically important regulator and that it, together with ATF3, regulates the expression of specific target genes.	OHIO STATE UNIV,DEPT MED BIOCHEM,COLUMBUS,OH 43210; OHIO STATE UNIV,OHIO STATE BIOCHEM PROGRAM,COLUMBUS,OH 43210; OHIO STATE UNIV,OHIO STATE BIOTECHNOL CTR,COLUMBUS,OH 43210; GLAXO INST MOLEC BIOL SA,GENEVA,SWITZERLAND	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; GlaxoSmithKline			Hai, Tsonwin/E-3185-2011; Hai, Tsonwin/H-4480-2011	Hai, Tsonwin/0000-0003-4510-0315; Hai, Tsonwin/0000-0003-4510-0315	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM046218] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46218] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDRISANI OM, 1989, P NATL ACAD SCI USA, V86, P2181, DOI 10.1073/pnas.86.7.2181; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BERK AJ, 1990, GENE DEV, V4, P151; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; COWELL IG, 1992, MOL CELL BIOL, V12, P3070, DOI 10.1128/MCB.12.7.3070; DU W, 1992, P NATL ACAD SCI USA, V89, P2150, DOI 10.1073/pnas.89.6.2150; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; DYNAN WS, 1989, CELL, V58, P1, DOI 10.1016/0092-8674(89)90393-0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; GAIRE M, 1990, NUCLEIC ACIDS RES, V18, P3467, DOI 10.1093/nar/18.12.3467; GARCIA J, 1987, NUCLEIC ACIDS RES, V15, P8367, DOI 10.1093/nar/15.20.8367; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HSU JC, 1991, P NATL ACAD SCI USA, V88, P3511, DOI 10.1073/pnas.88.9.3511; INOSTROZA JA, 1992, CELL, V70, P477; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KARA CJ, 1990, MOL CELL BIOL, V10, P1347, DOI 10.1128/MCB.10.4.1347; KASZUBSKA W, 1993, MOL CELL BIOL, V13, P7180, DOI 10.1128/MCB.13.11.7180; KEDAR PS, 1991, P NATL ACAD SCI USA, V88, P3729, DOI 10.1073/pnas.88.9.3729; KOUZARIDES T, 1989, CANCER CELL-MON REV, V1, P71; LEE KAW, 1987, P NATL ACAD SCI USA, V84, P8355, DOI 10.1073/pnas.84.23.8355; LEE KAW, 1987, EMBO J, V6, P1345, DOI 10.1002/j.1460-2075.1987.tb02374.x; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; LIU F, 1993, J BIOL CHEM, V268, P6714; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MERINO A, 1993, NATURE, V365, P227, DOI 10.1038/365227a0; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; NISHIZAWA M, 1992, FEBS LETT, V299, P36, DOI 10.1016/0014-5793(92)80094-W; PEI R, 1989, J VIROL, V63, P3499, DOI 10.1128/JVI.63.8.3499-3506.1989; QUINN PG, 1990, MOL CELL BIOL, V10, P3357, DOI 10.1128/MCB.10.7.3357; REHFUSS RP, 1991, J BIOL CHEM, V266, P18431; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; Sambrook J, 1989, MOL CLONING LABORATO; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; VANHUIJSDUIJNEN RH, 1992, J BIOL CHEM, V267, P22385; WHELAN J, 1991, NUCLEIC ACIDS RES, V19, P2645, DOI 10.1093/nar/19.10.2645; YOSHIMURA T, 1990, EMBO J, V9, P2537, DOI 10.1002/j.1460-2075.1990.tb07434.x	44	174	180	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15819	15826						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	7515060				2022-12-27	WOS:A1994NP51300066
J	SPIVAKKROIZMAN, T; MOHAMMADI, M; HU, P; JAYE, M; SCHLESSINGER, J; LAX, I				SPIVAKKROIZMAN, T; MOHAMMADI, M; HU, P; JAYE, M; SCHLESSINGER, J; LAX, I			POINT MUTATION IN THE FIBROBLAST GROWTH-FACTOR RECEPTOR ELIMINATES PHOSPHATIDYLINOSITOL HYDROLYSIS WITHOUT AFFECTING NEURONAL DIFFERENTIATION OF PC12 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C-GAMMA; TYROSINE PHOSPHORYLATION; MESODERM INDUCTION; SIGNAL TRANSDUCTION; MOLECULAR SWITCH; PROTEIN-KINASES; MAP KINASES; RAS PROTEIN; SH2 DOMAIN; MICROINJECTION	Fibroblast growth factors (FGF) stimulate growth arrest and differentiation in rat pheochromocytoma PC12 cells. We examined the role of phosphatidylinositol (PI) hydrolysis in FGF-induced differentiation of PC12 cells by exploring the biological and biochemical activity of a mutant FGF receptor 1 (flg) defective in stimulation of PI hydrolysis. We show that point mutation at Tyr-766 (Y766F) of the FGF receptor prevents tyrosine phosphorylation of phospholipase C gamma and eliminates acidic FGF (aFGF)-induced stimulation of PI hydrolysis in PC12 cells. Treatment of PC12 cells expressing either wildtype or the Y766F mutant with aFGF led to tyrosine phosphorylation of Shc, the association of Shc with GRB2, a shift in the electrophoretic mobility of the Ras guanine nucleotide-releasing factor, Sos (son of sevenless), and enhancement in mitogen-activated protein kinase phosphorylation. Moreover, stimulation with aFGF led to a typical neurite outgrowth of PC12 cells expressing either wild-type or the Y766F FGF receptor mutant. These experiments indicate that PI hydrolysis is not essential for FGF-induced neuronal differentiation of PC12 cells. Moreover, the aFGF-induced Ras signaling pathway, which is essential for PC12 cell differentiation, is not affected by elimination of PI hydrolysis.	RHONE POULENC RORER INC,CENT RES,COLLEGEVILLE,PA 19426		SPIVAKKROIZMAN, T (corresponding author), NYU,MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016, USA.		Mohammadi, Moosa/ABA-6745-2020; kasaei, fahime/T-7197-2018	Mohammadi, Moosa/0000-0003-2434-9437; Hu, Patrick/0000-0002-5611-8062				ALTIN JG, 1990, J NEUROCHEM, V54, P1666, DOI 10.1111/j.1471-4159.1990.tb01220.x; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BERRIDGE MJ, 1989, CELL, V59, P411, DOI 10.1016/0092-8674(89)90026-3; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURGESS WH, 1990, MOL CELL BIOL, V10, P4770, DOI 10.1128/MCB.10.9.4770; BUSA WB, 1989, DEV BIOL, V132, P315, DOI 10.1016/0012-1606(89)90228-5; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CONTRERAS ML, 1987, J NEUROCHEM, V48, P1466, DOI 10.1111/j.1471-4159.1987.tb05687.x; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HEASLEY LE, 1992, MOL BIOL CELL, V3, P545, DOI 10.1091/mbc.3.5.545; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JAYE M, 1988, EMBO J, V7, P963, DOI 10.1002/j.1460-2075.1988.tb02902.x; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; LI BQ, 1992, SCIENCE, V256, P1456, DOI 10.1126/science.1604323; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARGOLIS B, 1990, SCIENCE, V248, P607, DOI 10.1126/science.2333512; MASLANSKI JA, 1992, SCIENCE, V256, P243, DOI 10.1126/science.1314424; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; NAKAFUKU M, 1992, J BIOL CHEM, V267, P19448; NGUYEN TT, 1993, J BIOL CHEM, V268, P9803; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PESSIN MS, 1991, CELL REGUL, V2, P383, DOI 10.1091/mbc.2.5.383; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; QIU MS, 1991, NEURON, V7, P937, DOI 10.1016/0896-6273(91)90339-2; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; RUFFJAMISON S, 1993, J BIOL CHEM, V268, P7610; RYDEL RE, 1987, J NEUROSCI, V7, P3639; SATOH T, 1992, J BIOL CHEM, V267, P24149; SATOH T, 1987, MOL CELL BIOL, V7, P4553, DOI 10.1128/MCB.7.12.4553; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SEEDORF K, 1992, MOL CELL BIOL, V12, P4347, DOI 10.1128/MCB.12.10.4347; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TOGARI A, 1985, J NEUROSCI, V5, P307; TOGARI A, 1983, BIOCHEM BIOPH RES CO, V114, P1189, DOI 10.1016/0006-291X(83)90688-5; TRAYNOR AE, 1982, J NEUROCHEM, V39, P1677, DOI 10.1111/j.1471-4159.1982.tb08002.x; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VETTER ML, 1991, P NATL ACAD SCI USA, V88, P5650, DOI 10.1073/pnas.88.13.5650; WHITMAN M, 1992, NATURE, V357, P252, DOI 10.1038/357252a0; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; WITTINGHOFER A, 1991, TRENDS BIOCHEM SCI, V16, P382, DOI 10.1016/0968-0004(91)90156-P; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	67	74	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14419	14423						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	7514169				2022-12-27	WOS:A1994NM06500020
J	CULCASI, M; LAFONCAZAL, M; PIETRI, S; BOCKAERT, J				CULCASI, M; LAFONCAZAL, M; PIETRI, S; BOCKAERT, J			GLUTAMATE RECEPTORS INDUCE A BURST OF SUPEROXIDE VIA ACTIVATION OF NITRIC-OXIDE SYNTHASE IN ARGININE-DEPLETED NEURONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBELLAR GRANULE CELLS; BRAIN; RAT; CULTURES; HYDROXYL; NEUROTOXICITY; HEMOPROTEIN; CYCLASE; CGMP	We have previously shown in cultured cerebellar granule neurons (Lafon-Cazal, M., Pietri, S., Culcasi, M., and Bockaert, J. (1993) Nature 364, 535-537) that upon N-methyl-D-aspartate stimulation, a nitric oxide synthase (NOS)-independent, arachidonic acid-dependent generation of superoxide free radicals (O-2(radical anion)) is observed after a lag time of 10-15 min. Using the electron spin resonance spin trapping technique, we show that N-methyl-D-aspartate stimulation produced a more rapid burst of O-2(radical anion) in L-arginine (L-Arg)-depleted neurons, These O-2(radical anion) radicals are synthesized by NOS. KCl and kainate, which also stimulated NOS in these neurons, produced this rapid burst of O-2(radical anion), which was blocked as follows: (a) in the presence of L N-G-nitro-arginine (L-Narg), and (b) by L-Arg repletion. This burst of O-2(radical anion) was arachidonic acid-independent, and its time course was similar to that of nitric oxide production. It was also responsible for a weak but significant cell death that was suppressed by L-Narg and L-Arg.	CTR PHARMACOL ENDOCRINOL,CNRS,UR 9023,INSERM,F-34094 MONTPELLIER 5,FRANCE; UNIV AIX MARSEILLE 1,CNRS,URA 1412,F-13397 MARSEILLE 13,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite								BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BUETTNER GR, 1992, J BIOCHEM BIOPH METH, V24, P147, DOI 10.1016/0165-022X(92)90054-E; BUETTNER GR, 1988, J BIOCHEM BIOPH METH, V16, P27, DOI 10.1016/0165-022X(88)90100-5; CARMICHAEL J, 1987, CANCER RES, V47, P936; CHABARDES D, 1987, PFLUG ARCH EUR J PHY, V408, P366, DOI 10.1007/BF00581130; DAWSON VL, 1993, J NEUROSCI, V13, P2651; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; EIMERL S, 1991, BRAIN RES, V560, P282, DOI 10.1016/0006-8993(91)91244-U; FINKELSTEIN E, 1980, ARCH BIOCHEM BIOPHYS, V200, P1, DOI 10.1016/0003-9861(80)90323-9; GARTHWAITE J, 1989, EUR J PHARM-MOLEC PH, V172, P413, DOI 10.1016/0922-4106(89)90023-0; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; GIOVANELLI J, 1991, P NATL ACAD SCI USA, V88, P7091, DOI 10.1073/pnas.88.16.7091; HANNA PM, 1992, ARCH BIOCHEM BIOPHYS, V296, P640, DOI 10.1016/0003-9861(92)90620-C; HEINZEL B, 1992, BIOCHEM J, V281, P627, DOI 10.1042/bj2810627; JANZEN EG, 1971, ACCOUNTS CHEM RES, V4, P31, DOI 10.1021/ar50037a005; KLATT P, 1992, BIOCHEM J, V288, P15, DOI 10.1042/bj2880015; LAFONCAZAL M, 1993, NATURE, V364, P535, DOI 10.1038/364535a0; MACMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141; MARIN P, 1992, EUR J NEUROSCI, V4, P425, DOI 10.1111/j.1460-9568.1992.tb00892.x; MAYER B, 1991, FEBS LETT, V288, P187, DOI 10.1016/0014-5793(91)81031-3; MAYER B, 1993, SEMIN NEUROSCI, V5, P197, DOI 10.1016/S1044-5765(05)80053-3; MONCADA S, 1991, PHARMACOL REV, V43, P109; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NOVELLI A, 1987, J NEUROSCI, V7, P40; PAUWELS PJ, 1992, NEUROSCI LETT, V143, P27, DOI 10.1016/0304-3940(92)90225-V; POU S, 1992, J BIOL CHEM, V267, P24173; Rosen G.M., 1985, ADV FREE RADIC BIOL, V1, P345, DOI [10.1016/8755-9668(85)90012-2, DOI 10.1016/8755-9668(85)90012-2]; SCHMIDT HHHW, 1991, P NATL ACAD SCI USA, V88, P365, DOI 10.1073/pnas.88.2.365; SNYDER SH, 1991, TRENDS PHARMACOL SCI, V12, P125, DOI 10.1016/0165-6147(91)90526-X; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; VANVLIET BJ, 1989, J NEUROCHEM, V52, P1229; VIGE X, 1993, SEMIN NEUROSCI, V55, P893; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001	35	126	126	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12589	12593						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	7513691				2022-12-27	WOS:A1994NH71600036
J	ZHENG, MZ; FANG, H; HAKOMORI, SI				ZHENG, MZ; FANG, H; HAKOMORI, SI			FUNCTIONAL-ROLE OF N-GLYCOSYLATION IN ALPHA-5-BETA-1 INTEGRIN RECEPTOR - DE-N-GLYCOSYLATION INDUCES DISSOCIATION OR ALTERED ASSOCIATION OF ALPHA-5 AND BETA-1 SUBUNITS AND CONCOMITANT LOSS OF FIBRONECTIN-BINDING ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE RECEPTORS; PLASMA FIBRONECTIN; ADHESION RECEPTOR; MELANOMA-CELLS; IDENTIFICATION; PROTEINS; GLYCOPROTEIN; LAMININ; COMPLEX; FAMILY	Fibronectin (FN)-mediated cell adhesion is controlled mainly by alpha 5 beta 1 (recognizing the RGD sequence) and alpha 4 beta 1 (recognizing the CS-1 peptide sequence of FN) integrin receptors. Integrin-dependent cell adhesion to FN is greatly promoted by optimal G(M3) concentration at the surface membrane (Zheng, M., Fang, H., Tsuruoka, T., Tsuji, T., Sasaki, T., and Hakomori, S. (1993) J. Biol. Chem. 268, 2217-2222), and cell adhesion mediated by alpha 4 beta 1 (to FN) or alpha 6 beta 1 (to laminin) is inhibited by modifying N-glycosylation processing of the integrin receptor (e.g. Akiyama, S. K., Yamada, S. S., and Yamada, K. M. (1989) J. Biol. Chem. 264, 18011-18018). We therefore studied the specific role of N-glycosylation in alpha 5 beta 1 function. Key findings of the present study were as follows. (i) Adhesion of K562 cells to FN-coated plates, which is mediated solely by alpha 5 beta 1, was inhibited when cells were treated with a mixture of endo-N-acetylglucosaminidase F and peptide-N-4-(N-acetylglucosaminyl) asparagine amidase F (endo F/PNGase-F). (ii) The alpha 5 beta 1 receptor at the K562 cell surface tended to dissociate into alpha 5 and beta 1 subunits when an extract of cells treated with endo-F/PNGase-F was precipitated by integrin subunit-specific antibodies, i.e. the alpha 5 subunit was preferentially precipitated by anti-alpha 5 monoclonal antibody ZH5, and the beta 1 subunit was preferentially precipitated by anti-beta 1 monoclonal antibody ZH1. When intact cells were extracted and treated with either ZH5 or ZH1, both alpha 5 and beta 1 were coprecipitated, indicating that the two subunits are normally tightly associated with each other. (iii) Adhesion of alpha 5 beta 1-containing liposomes (phosphatidylcholine:cholesterol liposomes incorporating purified alpha 5 beta 1) to FN-coated plates was abolished by treatment of liposomes with endo-F/PNGase-F. Liposomes incorporating alpha 5 beta 1 pretreated with endo-F/PNGase-F also did not bind to FN. When purified alpha 5 beta 1 receptor was treated with endo-F/PNGase-F followed by ZH5 or ZH1, the alpha 5 or beta 1 subunit was precipitated separately, respectively. In contrast, both subunits were always coprecipitated when intact purified alpha 5 beta 1 receptor was directly treated with ZH5 or ZH1. These findings indicate that N-glycosylation of both the alpha and beta subunits of the alpha 5 beta 1 integrin receptor is essential for association of these subunits and for optimal binding to FN.	UNIV WASHINGTON,DEPT PATHOBIOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MICROBIOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	ZHENG, MZ (corresponding author), BIOMEMBRANE INST,SEATTLE,WA 98119, USA.				NCI NIH HHS [CA42505] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042505] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA SK, 1989, J BIOL CHEM, V264, P18011; BUCK CA, 1987, ANNU REV CELL BIOL, V3, P179, DOI 10.1146/annurev.cb.03.110187.001143; CHAMMAS R, 1991, J BIOL CHEM, V266, P3349; CHERESH DA, 1987, J CELL BIOL, V105, P1163, DOI 10.1083/jcb.105.3.1163; DEAN JW, 1990, J BIOL CHEM, V265, P12553; FAULL RJ, 1993, J CELL BIOL, V121, P155, DOI 10.1083/jcb.121.1.155; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GODING JW, 1980, J IMMUNOL METHODS, V39, P285, DOI 10.1016/0022-1759(80)90230-6; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HEUKESHOVEN J, 1985, ELECTROPHORESIS, V6, P103, DOI 10.1002/elps.1150060302; HUMPHRIES MJ, 1988, J CLIN INVEST, V81, P782, DOI 10.1172/JCI113384; HUMPHRIES MJ, 1987, J BIOL CHEM, V262, P6886; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; HYNES RO, 1973, P NATL ACAD SCI USA, V70, P3170, DOI 10.1073/pnas.70.11.3170; ISEMURA M, 1984, J BIOCHEM-TOKYO, V96, P163, DOI 10.1093/oxfordjournals.jbchem.a134808; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MATSUURA H, 1988, J BIOL CHEM, V263, P3314; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; MOULD AP, 1990, J BIOL CHEM, V265, P4020; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; PYTELA R, 1987, METHOD ENZYMOL, V144, P475; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; SHIH DT, 1993, J CELL BIOL, V122, P1361, DOI 10.1083/jcb.122.6.1361; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; SYMINGTON BE, 1989, J BIOL CHEM, V264, P13258; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; ZHENG MZ, 1992, BIOCHEM BIOPH RES CO, V186, P1397, DOI 10.1016/S0006-291X(05)81561-X; ZHENG MZ, 1993, J BIOL CHEM, V268, P2217	29	182	189	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12325	12331						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	7512965				2022-12-27	WOS:A1994NG37700098
J	DING, ZM; CRISTIANO, RJ; ROTH, JA; TAKACS, B; KUO, MT				DING, ZM; CRISTIANO, RJ; ROTH, JA; TAKACS, B; KUO, MT			MALARIAL CIRCUMSPOROZOITE PROTEIN IS A NOVEL GENE DELIVERY VEHICLE TO PRIMARY HEPATOCYTE CULTURES AND CULTURED-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ASIALOGLYCOPROTEIN RECEPTOR; POLYLYSINE DNA COMPLEXES; PLASMODIUM-FALCIPARUM; DESIALYLATED GLYCOPROTEINS; ADENOVIRUS ENHANCEMENT; RECOMBINANT ADENOVIRUS; MAMMALIAN-CELLS; EXPRESSION; SPOROZOITES; MEMBRANE	In this report we describe a novel gene delivery system using malaria circumsporozoite (CS) protein as a specific ligand, The CS protein covers the entire surface of sporozoites of malaria parasites, Previous studies have demonstrated that intravenously injected CS protein binds specifically to the basolateral surface of hepatocytes within minutes, indicating the high hepatocyte specificity of CS protein, This characteristic of CS protein prompted us to explore the possibility of using this protein as a liver-specific ligand for hepatic gene delivery vehicle, As an initial step, we investigated the efficacy of CS protein-mediated gene transfer into primary hepatocytes as well as established cell lines, Recombinant CS proteins were chemically conjugated to poly(L-lysine), The CS conjugates were complexed with recombinant plasmid DNA carrying a reporter gene, When the DNA complex was used to transfect primary hepatocytes, a very low level of expression of the reporter gene was observed, The level of expression was greatly enhanced when the cells were cotransfected with adenovirus, which presumably releases the internalized DNA from endosomal entrapment, The CS-mediated gene transfer into the cells required region II+, an evolutionarily conserved amino acid sequence conferring the binding of CS protein to its receptor, CS protein also efficiently mediated gene transfer into a number of cell lines, i,e, HepG(2), HeLa, NIH3T3, and K562, but not HL-60, which contains low levels of receptor, Thus, the CS conjugate can be used to deliver DNA into many different cultured cells, Most importantly, the CS conjugate has a potential to be further developed into a liver-specific gene delivery vehicle in vivo.	UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT MOLEC PATHOL, HOUSTON, TX 77030 USA; UNIV TEXAS, MD ANDERSON CANCER CTR, THORAC MOLEC ONCOL SECT, HOUSTON, TX 77030 USA; F HOFFMANN LA ROCHE & CO LTD, PHARMACEUT RES, PRECLIN DERMATOL, CH-4002 BASEL, SWITZERLAND	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Roche Holding					NATIONAL CANCER INSTITUTE [R01CA055813] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049091] Funding Source: NIH RePORTER; NCI NIH HHS [CA11672, CA 55813] Funding Source: Medline; NIDDK NIH HHS [DK49091] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arima T, 1977, Gastroenterol Jpn, V12, P39; BALLOU WR, 1985, SCIENCE, V228, P996, DOI 10.1126/science.2988126; CERAMI C, 1992, CELL, V70, P1021, DOI 10.1016/0092-8674(92)90251-7; CERAMI C, 1994, J EXP MED, V179, P695, DOI 10.1084/jem.179.2.695; COTTEN M, 1993, J VIROL, V67, P3777, DOI 10.1128/JVI.67.7.3777-3785.1993; COTTEN M, 1992, P NATL ACAD SCI USA, V89, P6094, DOI 10.1073/pnas.89.13.6094; COX FEG, 1992, NATURE, V359, P361, DOI 10.1038/359361a0; CRISTIANO RJ, 1993, P NATL ACAD SCI USA, V90, P2122, DOI 10.1073/pnas.90.6.2122; CRISTIANO RJ, 1993, P NATL ACAD SCI USA, V90, P11548, DOI 10.1073/pnas.90.24.11548; CRYSTAL RG, 1994, NAT GENET, V8, P42, DOI 10.1038/ng0994-42; CURIEL DT, 1992, HUM GENE THER, V3, P147, DOI 10.1089/hum.1992.3.2-147; CURIEL DT, 1991, P NATL ACAD SCI USA, V88, P8850, DOI 10.1073/pnas.88.19.8850; DODEUR M, 1982, EUR J BIOCHEM, V123, P383, DOI 10.1111/j.1432-1033.1982.tb19780.x; FERKOL T, 1993, FASEB J, V7, P1081, DOI 10.1096/fasebj.7.11.8370479; FREVERT U, 1993, J EXP MED, V177, P1287, DOI 10.1084/jem.177.5.1287; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GOUNDIS D, 1988, NATURE, V335, P82, DOI 10.1038/335082a0; HARBACH PR, 1989, MUTAT RES, V216, P101, DOI 10.1016/0165-1161(89)90010-1; JAFFE HA, 1992, NAT GENET, V1, P372, DOI 10.1038/ng0892-372; KIMURA O, 1994, HUM GENE THER, V5, P845, DOI 10.1089/hum.1994.5.7-845; KUO MT, 1992, CELL GROWTH DIFFER, V3, P531; Macgregor G R, 1991, Methods Mol Biol, V7, P217, DOI 10.1385/0-89603-178-0:217; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MARSHALL JS, 1978, J LAB CLIN MED, V92, P30; MARSHALL JS, 1974, J CLIN INVEST, V54, P555, DOI 10.1172/JCI107792; MASSIE B, 1986, MOL CELL BIOL, V6, P2872, DOI 10.1128/MCB.6.8.2872; MCKEE TD, 1994, BIOCONJUGATE CHEM, V5, P306, DOI 10.1021/bc00028a004; Means G E, 1977, Methods Enzymol, V47, P469; MILLER LH, 1994, SCIENCE, V264, P1878, DOI 10.1126/science.8009217; MORGAN RA, 1993, ANNU REV BIOCHEM, V62, P191; NUSSENZWEIG RS, 1994, SCIENCE, V265, P1381, DOI 10.1126/science.8073276; NUSSENZWEIG V, 1989, ADV IMMUNOL, V45, P283, DOI 10.1016/S0065-2776(08)60695-1; PANCAKE SJ, 1992, J CELL BIOL, V117, P1351, DOI 10.1083/jcb.117.6.1351; PERALES JC, 1994, P NATL ACAD SCI USA, V91, P4086, DOI 10.1073/pnas.91.9.4086; PLANK C, 1994, J BIOL CHEM, V269, P12918; RICH KA, 1990, SCIENCE, V249, P1574, DOI 10.1126/science.2120774; ROBSON KJH, 1988, NATURE, V335, P79, DOI 10.1038/335079a0; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SCHWARTZ AL, 1983, J BIOL CHEM, V258, P1249; SPIESS M, 1985, P NATL ACAD SCI USA, V82, P6465, DOI 10.1073/pnas.82.19.6465; STUBER D, 1990, EUR J IMMUNOL, V20, P819, DOI 10.1002/eji.1830200416; TAKACS BJ, 1991, J IMMUNOL METHODS, V143, P231, DOI 10.1016/0022-1759(91)90048-K; WAGNER E, 1992, P NATL ACAD SCI USA, V89, P7934, DOI 10.1073/pnas.89.17.7934; WAGNER E, 1992, P NATL ACAD SCI USA, V89, P6099, DOI 10.1073/pnas.89.13.6099; WAGNER E, 1990, P NATL ACAD SCI USA, V87, P3410, DOI 10.1073/pnas.87.9.3410; WILSON JM, 1992, J BIOL CHEM, V267, P963; WU GY, 1987, J BIOL CHEM, V262, P4429; WU GY, 1994, J BIOL CHEM, V269, P11542; WU GY, 1991, J BIOL CHEM, V266, P14338; WU GY, 1993, ADV DRUG DELIVER REV, V12, P159, DOI 10.1016/0169-409X(93)90057-B; ZHANG WW, 1993, BIOTECHNIQUES, V15, P868	51	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3667	3676		10.1074/jbc.270.8.3667	http://dx.doi.org/10.1074/jbc.270.8.3667			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7533154	hybrid			2022-12-27	WOS:A1995QH68800034
J	VELAZQUEZ, L; MOGENSEN, KE; BARBIERI, G; FELLOUS, M; UZE, G; PELLEGRINI, S				VELAZQUEZ, L; MOGENSEN, KE; BARBIERI, G; FELLOUS, M; UZE, G; PELLEGRINI, S			DISTINCT DOMAINS OF THE PROTEIN-TYROSINE KINASE TYK2 REQUIRED FOR BINDING OF INTERFERON-ALPHA/BETA AND FOR SIGNAL-TRANSDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC DOMAIN; RECEPTOR; CELLS; EXPRESSION; PATHWAY; JAK	tyk2 belongs to the JAK family of nonreceptor protein tyrosine kinases recently found implicated in signaling through a large number of cytokine receptors. These proteins are characterized by a large amino-terminal region and two tandemly arranged kinase domains, a kinase-like and a tyrosine kinase domain. Genetic and biochemical evidence supports the requirement for tyk2 in interferon-alpha/beta binding and signaling. To study the rob of the distinct domains of tyk2, constructs lacking one or both kinase domains were stably transfected in recipient cells lacking the endogenous protein. Removal of either or both kinase domains resulted in loss of the in vitro kinase activity. The mutant form truncated of the tyrosine kinase domain was found to reconstitute binding of interferon-alpha 8 and partial signaling. While no contribution of this protein toward interferon-beta binding was evident, increased signaling could be measured. The mutant form lacking both kinase domains did not exhibit any detectable activity. Altogether, these results show that a sequential deletion of domains engenders a sequential loss of function and that the different domains of tyk2 have distinct functions, all essential for full interferon-alpha and -beta binding and signaling.	INST PASTEUR, INSERM, U276, F-75724 PARIS 15, FRANCE; INST GENET MOLEC, CNRS, UMR 9942, MONTPELLIER, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS)			Barbieri, Giovanna/AAH-3645-2019; Pellegrini, Sandra/Y-6351-2019; Pellegrini, Sandra -/G-5546-2015; Uzé, Gilles/O-6383-2019	Pellegrini, Sandra/0000-0001-5837-7589; Pellegrini, Sandra -/0000-0001-5837-7589; Uze, Gilles/0000-0002-4150-5772; BARBIERI, GIOVANNA/0000-0002-5895-1795				ALLEN G, 1982, J GEN VIROL, V63, P207, DOI 10.1099/0022-1317-63-1-207; BARBIERI G, 1994, EUR J BIOCHEM, V223, P427, DOI 10.1111/j.1432-1033.1994.tb19010.x; CHANG CP, 1993, J BIOL CHEM, V268, P19132; CHINKERS M, 1989, SCIENCE, V245, P1392, DOI 10.1126/science.2571188; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DUSANTERFOURT I, 1994, EMBO J, V13, P2583, DOI 10.1002/j.1460-2075.1994.tb06548.x; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HONEGGER AM, 1990, J CELL BIOL, V110, P1541, DOI 10.1083/jcb.110.5.1541; IGARASHI K, 1994, J BIOL CHEM, V269, P14333; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; JOHN J, 1991, MOL CELL BIOL, V11, P4189, DOI 10.1128/MCB.11.8.4189; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; JONES SW, 1988, P NATL ACAD SCI USA, V85, P3377, DOI 10.1073/pnas.85.10.3377; KOLLER KJ, 1992, MOL CELL BIOL, V12, P2581, DOI 10.1128/MCB.12.6.2581; Maniatis T., 1982, MOL CLONING; MCKENDRY R, 1991, P NATL ACAD SCI USA, V88, P11455, DOI 10.1073/pnas.88.24.11455; MOGENSEN KE, 1986, METHOD ENZYMOL, V119, P267; MOGENSEN KE, 1983, EUR J BIOCHEM, V134, P355, DOI 10.1111/j.1432-1033.1983.tb07575.x; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; NICHOLSON SE, 1994, P NATL ACAD SCI USA, V91, P2985, DOI 10.1073/pnas.91.8.2985; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; PLATANIAS LC, 1994, J BIOL CHEM, V269, P3143; PLATANIAS LC, 1994, J BIOL CHEM, V269, P17761; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; RANE SG, 1994, ONCOGENE, V9, P2415; RUSSELL DS, 1987, J BIOL CHEM, V262, P11833; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; TAKAHASHI T, 1994, FEBS LETT, V342, P124, DOI 10.1016/0014-5793(94)80485-0; TANAKA N, 1994, P NATL ACAD SCI USA, V91, P7271, DOI 10.1073/pnas.91.15.7271; UZE G, 1992, P NATL ACAD SCI USA, V89, P4774, DOI 10.1073/pnas.89.10.4774; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; UZE G, 1994, J MOL BIOL, V243, P245, DOI 10.1006/jmbi.1994.1651; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WEISSMANN C, 1986, PROG NUCLEIC ACID RE, V33, P251, DOI 10.1016/S0079-6603(08)60026-4; WEK RC, 1989, P NATL ACAD SCI USA, V86, P4579, DOI 10.1073/pnas.86.12.4579; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; Ziemiecki Andrew, 1994, Trends in Cell Biology, V4, P207, DOI 10.1016/0962-8924(94)90143-0	43	121	126	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	1995	270	7					3327	3334		10.1074/jbc.270.7.3327	http://dx.doi.org/10.1074/jbc.270.7.3327			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QG471	7531704	Green Submitted, hybrid			2022-12-27	WOS:A1995QG47100066
J	SZABO, T; KADISH, JL; CZOP, JK				SZABO, T; KADISH, JL; CZOP, JK			BIOCHEMICAL-PROPERTIES OF THE LIGAND-BINDING 20-KDA SUBUNIT OF THE BETA-GLUCAN RECEPTORS ON HUMAN MONONUCLEAR PHAGOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-MONOCYTES; TYROSINE PHOSPHORYLATION; PARTICULATE ACTIVATORS; MONOCLONAL-ANTIBODIES; PHORBOL ESTERS; COMPLEMENT; PROTEIN; ZYMOSAN; PARTICLES; CELLS	beta-Glucan receptors are present on mammalian leukocytes and initiate phagocytosis of particulate yeast beta-glucans, such as zymosan particles, Human monocytes and U937 cells express two membrane proteins of 180 and 160 kDa, each of which binds particulate yeast glucan through a 20-kDa polypeptide constituent. In this report, the structural composition of the two beta-glucan receptors and the biochemical properties of their polypeptide constituents were examined, The 180-kDa receptor was composed of three disulfide-linked polypeptides of 95, 60, and 20 kDa, whereas the 160-kDa receptor was a multimer of two polypeptides of 27 and 20 kDa, Unlike other receptor constituents, the 20-kDa polypeptide was nonglycosylated and focused at two distinct isoelectric points. Immunoblots of the focused polypeptides showed the two 20-kDa variants and the 95-kDa subunit to be constitutively tyrosine-phosphorylated, a feature not previously reported for receptors on human mononuclear phagocytes, Dephosphorylation of the receptor proteins resulted in the loss of antigenic phosphotyrosine without affecting the antigenicity of either 20-kDa variant for the anti-idiotypic antibody to beta-glucan receptors, Separate analysis of the 160-kDa receptor showed it contained both variants of the 20-kDa polypeptide, Thus, the 20-kDa subunit constituent of the two beta-glucan receptors is a functionally and chemically unique polypeptide with apparent microheterogeneity in its primary structure.	HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT RHEUMATOL & IMMUNOL,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital					NIAID NIH HHS [AI23542] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023542] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABEL G, 1992, INT J IMMUNOPHARMACO, V14, P1363, DOI 10.1016/0192-0561(92)90007-8; ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; BABINEAU TJ, 1994, ANN SURG, V220, P601, DOI 10.1097/00000658-199411000-00002; BARTNICK.S, 1968, ANNU REV MICROBIOL, V22, P87, DOI 10.1146/annurev.mi.22.100168.000511; BENACH JL, 1982, INFECT IMMUN, V35, P947, DOI 10.1128/IAI.35.3.947-951.1982; CHAKRAVARTI B, 1988, CELL IMMUNOL, V113, P251, DOI 10.1016/0008-8749(88)90024-X; CHATILA TA, 1989, J CELL BIOL, V109, P3435, DOI 10.1083/jcb.109.6.3435; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; CZOP JK, 1985, J IMMUNOL, V134, P2588; CZOP JK, 1991, J EXP MED, V173, P1511, DOI 10.1084/jem.173.6.1511; CZOP JK, 1985, IMMUNOLOGY, V54, P407; CZOP JK, 1980, J IMMUNOL, V125, P124; CZOP JK, 1990, J IMMUNOL, V145, P995; DIAMOND MS, 1993, J CELL BIOL, V120, P1032; DICARLO FJ, 1958, SCIENCE, V120, P279; DIEMANN W, 1979, J EXP MED, V149, P883; DILUZIO NR, 1983, TRENDS PHARMACOL SCI, V4, P344, DOI 10.1016/0165-6147(83)90434-0; DILUZIO NR, 1979, J RETICULOENDOTHEL S, V7, P731; EHLENBERGER AG, 1977, J EXP MED, V145, P357, DOI 10.1084/jem.145.2.357; ELSTAD MR, 1994, J IMMUNOL, V152, P220; FERREIRA A, 1981, J IMMUNOL METHODS, V43, P291, DOI 10.1016/0022-1759(81)90177-0; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; HOYLE GW, 1988, J BIOL CHEM, V263, P7487; JANUSZ MJ, 1989, J IMMUNOL, V142, P959; JANUSZ MJ, 1986, J IMMUNOL, V137, P3270; JOHNSON E, 1984, SCAND J IMMUNOL, V19, P31, DOI 10.1111/j.1365-3083.1984.tb00897.x; KELLY BA, 1987, J BIOL CHEM, V262, P17404; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENNARTZ MR, 1987, BIOCHEM J, V245, P705, DOI 10.1042/bj2450705; LIAO F, 1992, P NATL ACAD SCI USA, V89, P3659, DOI 10.1073/pnas.89.8.3659; MANNERS DJ, 1974, J GEN MICROBIOL, V80, P411, DOI 10.1099/00221287-80-2-411; MARCH SC, 1974, ANAL BIOCHEM, V60, P149, DOI 10.1016/0003-2697(74)90139-0; MARKWELL MAK, 1978, BIOCHEMISTRY-US, V17, P4807, DOI 10.1021/bi00615a031; NEWMAN SL, 1985, J EXP MED, V161, P1414, DOI 10.1084/jem.161.6.1414; ONDERDONK AB, 1992, INFECT IMMUN, V60, P1642, DOI 10.1128/IAI.60.4.1642-1647.1992; RIGGI SJ, 1961, AM J PHYSIOL, V200, P297, DOI 10.1152/ajplegacy.1961.200.2.297; ROSS GD, 1985, J IMMUNOL, V134, P3307; SANGUEDOLCE MV, 1993, J IMMUNOL, V151, P405; SCHOLL PR, 1992, J IMMUNOL, V149, P1751; SEGE K, 1978, P NATL ACAD SCI USA, V75, P2443, DOI 10.1073/pnas.75.5.2443; SHARMA A, 1984, INT J IMMUNOPHARMACO, V6, P483, DOI 10.1016/0192-0561(84)90087-0; VANSTRIJP JAG, 1993, J IMMUNOL, V151, P3324; WRIGHT SD, 1982, J EXP MED, V156, P1149, DOI 10.1084/jem.156.4.1149	43	30	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 3	1995	270	5					2145	2151		10.1074/jbc.270.5.2145	http://dx.doi.org/10.1074/jbc.270.5.2145			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QE493	7530718	hybrid			2022-12-27	WOS:A1995QE49300027
J	WEERNINK, PAO; RIJKSEN, G				WEERNINK, PAO; RIJKSEN, G			ACTIVATION AND TRANSLOCATION OF C-SRC TO THE CYTOSKELETON BY BOTH PLATELET-DERIVED GROWTH-FACTOR AND EPIDERMAL GROWTH-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILY TYROSINE KINASES; ROUS-SARCOMA VIRUS; MORPHOLOGICAL TRANSFORMATION; SIGNAL-TRANSDUCTION; ASSOCIATION; PROTEIN; RECEPTOR; PP60(C-SRC); SUBSTRATE; P60SRC	We have examined the subcellular distribution and catalytic activity of C-Src tyrosine kinase after stimulation of A172 glioblastoma cells with peptide growth factors. Treatment of resting cells with platelet-derived growth factor resulted in an increase (3.5-fold) in the amount of c-Src protein associated with the cytoskeleton, In addition, an increase in specific c-Src kinase activity was observed in the cytoskeleton as well as in the cytosol and the membrane fraction. Similar effects on both c-Src redistribution and activity were seen after stimulation with epidermal growth factor. These data show that, like other signal transducing components, c-Src also becomes activated and associated to the cytoskeleton in response to growth factor stimulation.			WEERNINK, PAO (corresponding author), UNIV UTRECHT HOSP, DEPT HEMATOL, MED ENZYMOL LAB, POB 85500, 3508 GA UTRECHT, NETHERLANDS.							CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; DENHARTIGH JC, 1992, J CELL BIOL, V119, P349, DOI 10.1083/jcb.119.2.349; GOULD KL, 1986, J CELL BIOL, V102, P660, DOI 10.1083/jcb.102.2.660; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HAMAGUCHI M, 1993, ONCOGENE, V8, P559; HENEGOUWEN PMP, 1989, J CELL BIOCHEM, V39, P455; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KAPLAN KB, 1992, J CELL BIOL, V118, P321, DOI 10.1083/jcb.118.2.321; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LIEBENHOFF U, 1993, BIOCHEM J, V295, P41, DOI 10.1042/bj2950041; LIEBENHOFF U, 1993, INT CONGR SER, V1042, P171; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; MAA MC, 1992, ONCOGENE, V7, P2429; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; ODA A, 1992, J BIOL CHEM, V267, P20075; OKAMURA H, 1994, ONCOGENE, V9, P2293; PASQUALE EB, 1986, P NATL ACAD SCI USA, V83, P5507, DOI 10.1073/pnas.83.15.5507; PAYRASTRE B, 1991, J CELL BIOL, V115, P121, DOI 10.1083/jcb.115.1.121; PUMIGLIA KM, 1993, BIOCHEM J, V294, P253, DOI 10.1042/bj2940253; SEFTON BM, 1981, CELL, V24, P165, DOI 10.1016/0092-8674(81)90512-2; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; VASSBOTN FS, 1994, J CELL PHYSIOL, V158, P381, DOI 10.1002/jcp.1041580221; WALKER F, 1993, J BIOL CHEM, V268, P19552; WEERNINK PAO, 1994, FEBS LETT, V352, P296, DOI 10.1016/0014-5793(94)00977-5; WONG S, 1992, ONCOGENE, V7, P2407; YANG LJ, 1994, J BIOL CHEM, V269, P7156	30	84	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 3	1995	270	5					2264	2267		10.1074/jbc.270.5.2264	http://dx.doi.org/10.1074/jbc.270.5.2264			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QE493	7530720	hybrid			2022-12-27	WOS:A1995QE49300045
J	WU, WM; BLUMBERG, BM; FAY, PJ; BAMBARA, RA				WU, WM; BLUMBERG, BM; FAY, PJ; BAMBARA, RA			STRAND TRANSFER MEDIATED BY HUMAN-IMMUNODEFICIENCY-VIRUS REVERSE-TRANSCRIPTASE IN-VITRO IS PROMOTED BY PAUSING AND RESULTS IN MISINCORPORATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLONEY MURINE LEUKEMIA; RNASE-H ACTIVITY; RETROVIRAL RECOMBINATION; GENETIC-RECOMBINATION; PROCESSIVE SYNTHESIS; DNA-SYNTHESIS; TEMPLATE; POLYMERIZATION; TERMINATION; GENERATION	Human immunodeficiency virus (HIV-I) is able to recombine by transfer of the growing DNA strand from internal regions of one genome to another. The strand transfer reaction, catalyzed by HIV-1 reverse transcriptase (RT), was conducted in vitro between donor and acceptor RNA templates that were derived from natural HIV-1 nef genes. The donor and acceptor templates shared a nearly homologous region where strand transfer could occur, differing only in that the acceptor had a 36-nucleotide insertion and 6 widely spaced base substitutions compared with the donor. We sequenced elongated primers that underwent transfer, The position of transfer was revealed by the change of sequence from that of the donor to that of the acceptor. Results showed a positive correlation between positions where the RT paused during synthesis and enhancement of strand transfer. Elimination of a pause site, with a minimal change in sequence, decreased the frequency of strand transfer in the immediate area. Analysis of the sequence of DNA products resulting from transfer at a frequently used site showed that mutations had been introduced into the DNA at about the point of transfer. Remarkably, approximately 30% of the products contained mutations. Base substitutions, short additions and deletions were observed. Mutations did not appear in DNA products extended on the donor template without transfer. The identity of the mutations suggests that they were caused by a combination of slippage and non-template-directed nucleotide addition. These results indicated that the detected mutations were related to the process of strand transfer.	UNIV ROCHESTER,SCH MED & DENT,DEPT BIOCHEM,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,DEPT MED,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,DEPT NEUROL,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,DEPT MICROBIOL & IMMUNOL,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,CTR CANC,ROCHESTER,NY 14642	University of Rochester; University of Rochester; University of Rochester; University of Rochester; University of Rochester					NCI NIH HHS [CA11198] Funding Source: Medline; NIGMS NIH HHS [GM 49573] Funding Source: Medline; NINDS NIH HHS [NS28754] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA011198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049573] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028754] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABBOTTS J, 1993, J BIOL CHEM, V268, P10312; BEBENEK K, 1993, J BIOL CHEM, V268, P10324; BENDER W, 1978, J VIROL, V25, P888, DOI 10.1128/JVI.25.3.888-896.1978; BLUMBERG BM, 1992, J VIROL, V66, P5256, DOI 10.1128/JVI.66.9.5256-5264.1992; CLARK JM, 1987, J MOL BIOL, V198, P123, DOI 10.1016/0022-2836(87)90462-1; CLAVEL F, 1989, J VIROL, V63, P1455, DOI 10.1128/JVI.63.3.1455-1459.1989; Coffin J. M., 1990, VIROLOGY, P1437; COFFIN JM, 1979, J GEN VIROL, V42, P1, DOI 10.1099/0022-1317-42-1-1; COFFIN JM, 1990, APPLIED VIROLOGY RES, V2; DESROSIERS RC, 1992, AIDS RES HUM RETROV, V8, P411, DOI 10.1089/aid.1992.8.411; DESTEFANO JJ, 1994, J BIOL CHEM, V269, P161; DESTEFANO JJ, 1991, J BIOL CHEM, V266, P7423; DESTEFANO JJ, 1992, J VIROL, V66, P6370, DOI 10.1128/JVI.66.11.6370-6378.1992; DESTEFANO JJ, 1992, BIOCHIM BIOPHYS ACTA, V1131, P270, DOI 10.1016/0167-4781(92)90025-U; DESTEFANO JJ, 1991, J BIOL CHEM, V266, P24295; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; GOODRICH DW, 1990, P NATL ACAD SCI USA, V87, P2052, DOI 10.1073/pnas.87.6.2052; HANSEN J, 1987, J BIOL CHEM, V262, P12393; HOWELL RM, 1991, AIDS RES HUM RETROV, V7, P869, DOI 10.1089/aid.1991.7.869; HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865; HU WS, 1990, P NATL ACAD SCI USA, V87, P1556, DOI 10.1073/pnas.87.4.1556; KATZ RA, 1990, ANNU REV GENET, V24, P409, DOI 10.1146/annurev.ge.24.120190.002205; KLARMANN GJ, 1993, J BIOL CHEM, V268, P9793; LUO G, 1990, J VIROL, V64, P4321, DOI 10.1128/JVI.64.9.4321-4328.1990; MURTI KG, 1981, J VIROL, V37, P411, DOI 10.1128/JVI.37.1.411-419.1981; PATEL PH, 1994, P NATL ACAD SCI USA, V91, P549, DOI 10.1073/pnas.91.2.549; PELISKA JA, 1994, BIOCHEMISTRY-US, V33, P3890, DOI 10.1021/bi00179a014; PELISKA JA, 1992, SCIENCE, V258, P1112, DOI 10.1126/science.1279806; PERRINO FW, 1989, P NATL ACAD SCI USA, V86, P8343, DOI 10.1073/pnas.86.21.8343; SKALKA A, 1993, REVERSE TRANSCRIPTAS; SRINIVASAN A, 1989, P NATL ACAD SCI USA, V86, P6388, DOI 10.1073/pnas.86.16.6388; STARNES MC, 1989, J BIOL CHEM, V264, P7073; TEMIN HM, 1991, TRENDS GENET, V7, P71, DOI 10.1016/0168-9525(91)90048-U; Weiss R, 1985, RNA TUMOR VIRUSES; XU H, 1987, P NATL ACAD SCI USA, V84, P8553, DOI 10.1073/pnas.84.23.8553; ZHANG JY, 1994, J VIROL, V68, P2409, DOI 10.1128/JVI.68.4.2409-2414.1994	36	103	108	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					325	332		10.1074/jbc.270.1.325	http://dx.doi.org/10.1074/jbc.270.1.325			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7529228	hybrid			2022-12-27	WOS:A1995QA28700052
J	FLYNN, TR; HOLLENBERG, AN; COHEN, O; MENKE, JB; USALA, SJ; TOLLIN, S; HEGARTY, MK; WONDISFORD, FE				FLYNN, TR; HOLLENBERG, AN; COHEN, O; MENKE, JB; USALA, SJ; TOLLIN, S; HEGARTY, MK; WONDISFORD, FE			A NOVEL C-TERMINAL DOMAIN IN THE THYROID-HORMONE RECEPTOR SELECTIVELY MEDIATES THYROID-HORMONE INHIBITION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BETA-SUBUNIT GENE; DOMINANT-NEGATIVE INHIBITION; RETINOIC ACID RECEPTORS; LIGAND-BINDING DOMAIN; GLUCOCORTICOID RECEPTOR; GENERALIZED RESISTANCE; PITUITARY RESISTANCE; NUCLEAR RECEPTOR; BASE MUTATION; ERB-A	Resistance to thyroid hormone (RTH) action is due to mutations in the beta-isoform of the thyroid hormone receptor (TR-beta). RTH patients display inappropriate central secretion of thyrotropin-releasing hormone (TRH) from the hypothalamus and thyrotropin (TSH) from the anterior pituitary in association with abnormal peripheral tissue responses to thyroid hormone. Whether TR-beta mutations cause a selective form of RTH, which only leads to abnormal pituitary TSH secretion (PRTH), is unclear. In a patient with PRTH, a novel mutation of a conserved arginine residue adjacent to the ninth heptad of TR-beta selectively disrupts TR homodimer formation. The mutant TR displays normal or enhanced function on stimulatory thyroid hormone response elements found in peripheral tissues, but has defective function on inhibitory thyroid hormone response elements found in the TRH and TSH subunit genes and explains the PRTH phenotype. This is the first report of a mutation in a member of the nuclear receptor superfamily that selectively abolishes hormone dependent inhibition and localizes a novel C-terminal domain necessary for this property.	BETH ISRAEL HOSP,DEPT MED,THYROID UNIT,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA 02115; E CAROLINA UNIV,SCH MED,DEPT MED,GREENVILLE,NC 27858	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; University of North Carolina; East Carolina University				, Stephen/0000-0003-4068-6492	NIDDK NIH HHS [DK-42807, DK-43653] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK043653, R29DK042807] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS M, 1994, J CLIN INVEST, V94, P506, DOI 10.1172/JCI117362; ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; AUFLIEGNER M, 1993, MOL CELL BIOL, V13, P5725, DOI 10.1128/MCB.13.9.5725; BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; BODENNER DL, 1991, J BIOL CHEM, V266, P21666; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BREATHNACH R, 1983, NUCLEIC ACIDS RES, V11, P7119, DOI 10.1093/nar/11.20.7119; CHATTERJEE VKK, 1991, J CLIN INVEST, V87, P1977; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; GEFFNER ME, 1993, J CLIN INVEST, V91, P538, DOI 10.1172/JCI116233; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; HAYASHI Y, 1994, J CLIN INVEST, V94, P607, DOI 10.1172/JCI117376; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; INOUE A, 1983, ANAL BIOCHEM, V134, P176, DOI 10.1016/0003-2697(83)90280-4; ISHIKAWA T, 1990, MOL ENDOCRINOL, V4, P837, DOI 10.1210/mend-4-6-837; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MIXSON AJ, 1993, CLIN ENDOCRINOL, V38, P227, DOI 10.1111/j.1365-2265.1993.tb00999.x; NAGAYA T, 1993, J CLIN ENDOCR METAB, V77, P982, DOI 10.1210/jc.77.4.982; NAGAYA T, 1993, J BIOL CHEM, V268, P24278; NAGAYA T, 1993, J BIOL CHEM, V268, P15766; NAKAI A, 1988, P NATL ACAD SCI USA, V85, P2781, DOI 10.1073/pnas.85.8.2781; PARRILLA R, 1991, J CLIN INVEST, V88, P2123, DOI 10.1172/JCI115542; REFETOFF S, 1993, ENDOCR REV, V14, P348, DOI 10.1210/er.14.3.348; SAKURAI A, 1989, P NATL ACAD SCI USA, V86, P8977, DOI 10.1073/pnas.86.22.8977; SASAKI S, 1993, J CLIN ENDOCR METAB, V76, P1254, DOI 10.1210/jc.76.5.1254; USALA SJ, 1990, J CLIN INVEST, V85, P93, DOI 10.1172/JCI114438; VENNSTROM B, 1980, J VIROL, V36, P575; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WONDISFORD FE, 1988, J BIOL CHEM, V263, P12538; WONDISFORD FE, 1993, J BIOL CHEM, V268, P2749; YAMADA M, 1990, MOL ENDOCRINOL, V4, P551, DOI 10.1210/mend-4-4-551; YEN PM, 1992, J BIOL CHEM, V267, P3565; YEN PM, 1992, J CLIN INVEST, V90, P1825, DOI 10.1172/JCI116058; ZAVACKI AM, 1993, MOL ENDOCRINOL, V7, P1319, DOI 10.1210/me.7.10.1319	39	47	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32713	32716						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7528740				2022-12-27	WOS:A1994QA63800002
J	KUROKI, Y; MCCORMACK, FX; OGASAWARA, Y; MASON, RJ; VOELKER, DR				KUROKI, Y; MCCORMACK, FX; OGASAWARA, Y; MASON, RJ; VOELKER, DR			EPITOPE MAPPING FOR MONOCLONAL-ANTIBODIES IDENTIFIES FUNCTIONAL DOMAINS OF PULMONARY SURFACTANT PROTEIN-A THAT INTERACT WITH LIPIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE-RECOGNITION DOMAINS; II CELLS; SP-A; PHOSPHOLIPID SECRETION; HIGH-AFFINITY; BINDING PROTEIN; RAT; LUNG; APOPROTEIN; PHOSPHATIDYLCHOLINE	Pulmonary surfactant protein A (SP-A) contains 4 domains: a disulfide forming amino terminus, a collagen-like region, a neck region, and a carbohydrate recognition region. The protein binds the lipids dipalmitoylphosphatidylcholine and galactosylceramide and induces aggregation of phospholipid vesicles. SP-A also inhibits lipid secretion and enhances the uptake of phospholipid by alveolar type II cells. Previously described monoclonal antibody 1D6 blocks the inhibitory effect of SP-A on lipid secretion by type II cells, but antibody 6E3 has no effect. In the present study we mapped the epitopes for monoclonal antibodies 1D6 and 6E8 by enzyme-linked immunoassay of recombinant proteins expressed using the baculovirus system, and investigated the domain that is responsible for the SP-A interactions with lipid. Monoclonal antibody 1D6 bound to mutant SP-As in which the neck portion of the molecule was deleted or substituted with that of mannose-binding protein A, but 6E3 failed to bind to these mutants. In contrast, 1D6 did not bind to a chimera in which the carbohydrate recognition domain (CRD) was substituted with that of surfactant protein D (SP-D). In addition, 1D6 failed to recognize antigen in cells infected with the recombinant virus directing the synthesis of a Cys(204)-Cys(218) (small disulfide loop) deletion within the CRD. Antibody 1D6 completely blocked the binding of SP-A to dipalmitoylphosphatidylcholine and galactosylceramide and liposome aggregation. By comparison, 6E3 failed to completely attenuate the interactions of SP-A with lipids. However, both 6E3 and 1D6 blocked the up take of lipid by type II cells that is caused by SP-A From these data, we conclude that: I) the epitope for antibody 6E3 is located at the neck domain of SP-A and that for antibody 1D6 is at the small loop region in the CRD; 2) the CRD is essential for the SP-A functions of lipid binding, liposome aggregation, the inhibitory effect on lipid secretion, and the augmentation of lipid uptake by type II cells, and these activities are largely attributable to amino acid residues within the steric inhibitory footprint of 1D6 bound to the small disulfide loop region; and 3) the neck domain of SP-A may also be involved in the process of SP-A-mediated uptake of phospholipids by alveolar type II cells.	NATL JEWISH CTR IMMUNOL & RESP MED,DEPT MED,LORD & TAYLOR LAB LUNG BIOCHEM,DENVER,CO 80206; UNIV COLORADO,HLTH SCI CTR,DEPT MED,DIV PULM SCI & CRIT CARE MED,DENVER,CO 80262	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver			McCormack, Francis X./ABE-8398-2020	McCormack, Francis X./0000-0001-7168-9464	NHLBI NIH HHS [HL45286, HL29891, HL02423] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045286, R01HL029891, R37HL029891] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEZOUSKA K, 1991, J BIOL CHEM, V266, P11604; BOGGARAM V, 1988, J BIOL CHEM, V263, P293; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; CHILDS RA, 1992, J BIOL CHEM, V267, P9972; DETHLOFF LA, 1986, BIOCHEM J, V233, P111, DOI 10.1042/bj2330111; DOBBS LG, 1979, J CLIN INVEST, V63, P378, DOI 10.1172/JCI109313; DOBBS LG, 1987, P NATL ACAD SCI USA, V84, P1010, DOI 10.1073/pnas.84.4.1010; DRICKAMER K, 1986, J BIOL CHEM, V261, P6878; FLOROS J, 1985, J BIOL CHEM, V260, P495; HAWGOOD S, 1985, BIOCHEMISTRY-US, V24, P184, DOI 10.1021/bi00322a026; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLMSKOV U, 1993, J BIOL CHEM, V268, P10120; JACOBS HC, 1985, BIOCHIM BIOPHYS ACTA, V837, P77, DOI 10.1016/0005-2760(85)90087-6; KING RJ, 1983, J BIOL CHEM, V258, P672; KORFHAGEN TR, 1992, AM J PHYSIOL, V263, pL546, DOI 10.1152/ajplung.1992.263.5.L546; KUROKI Y, 1988, J BIOL CHEM, V263, P3388; KUROKI Y, 1988, J BIOL CHEM, V263, P17596; KUROKI Y, 1991, J BIOL CHEM, V266, P3068; KUROKI Y, 1992, ARCH BIOCHEM BIOPHYS, V299, P261, DOI 10.1016/0003-9861(92)90273-Y; KUROKI Y, 1988, P NATL ACAD SCI USA, V85, P5566, DOI 10.1073/pnas.85.15.5566; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALHOTRA R, 1992, EUR J IMMUNOL, V22, P1437, DOI 10.1002/eji.1830220616; MCCORMACK FX, 1994, J BIOL CHEM, V269, P5833; MCCORMACK FX, 1994, J BIOL CHEM, V269, P29801; MURATA Y, 1993, BIOCHEM J, V291, P71, DOI 10.1042/bj2910071; OGASAWARA Y, 1994, J BIOL CHEM, V269, P29785; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; QUESENBERRY M S, 1991, Glycobiology, V1, P615, DOI 10.1093/glycob/1.6.615; RICE WR, 1987, J APPL PHYSIOL, V63, P692, DOI 10.1152/jappl.1987.63.2.692; ROSS GF, 1991, BIOCHEMISTRY-US, V30, P858, DOI 10.1021/bi00217a040; ROSS GF, 1986, J BIOL CHEM, V261, P14283; RUST K, 1991, ARCH BIOCHEM BIOPHYS, V290, P116, DOI 10.1016/0003-9861(91)90597-C; RYAN RM, 1989, J HISTOCHEM CYTOCHEM, V37, P429, DOI 10.1177/37.4.2926121; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANO K, 1987, BIOCHEM BIOPH RES CO, V144, P367, DOI 10.1016/S0006-291X(87)80519-3; SHIMIZU H, 1992, J BIOL CHEM, V267, P1853; SPISSINGER T, 1991, EUR J BIOCHEM, V199, P65, DOI 10.1111/j.1432-1033.1991.tb16092.x; SUZUKI Y, 1989, AM REV RESPIR DIS, V140, P75, DOI 10.1164/ajrccm/140.1.75; TSUZUKI A, 1993, AM J PHYSIOL, V265, pL193, DOI 10.1152/ajplung.1993.265.2.L193; WEIS WI, 1991, J BIOL CHEM, V266, P20678; WHITE RT, 1985, NATURE, V317, P361, DOI 10.1038/317361a0; WRIGHT JR, 1986, J APPL PHYSIOL, V60, P817, DOI 10.1152/jappl.1986.60.3.817; WRIGHT JR, 1987, J BIOL CHEM, V262, P2888; WRIGHT JR, 1989, P NATL ACAD SCI USA, V86, P5410, DOI 10.1073/pnas.86.14.5410	44	65	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29793	29800						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7525589				2022-12-27	WOS:A1994PU28400075
J	SCHWARZ, M; GROSS, A; STEINKAMP, T; FLUGGE, UI; WAGNER, R				SCHWARZ, M; GROSS, A; STEINKAMP, T; FLUGGE, UI; WAGNER, R			ION-CHANNEL PROPERTIES OF THE RECONSTITUTED CHLOROPLAST TRIOSE PHOSPHATE/PHOSPHATE TRANSLOCATOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL ASPARTATE GLUTAMATE; PHOSPHATE TRANSLOCATOR; UNIDIRECTIONAL TRANSPORT; SPINACH-CHLOROPLASTS; SH-REAGENTS; MEMBRANE; ENVELOPE; CARRIER; PROTEIN; PURIFICATION	The chloroplast triose phosphate/phosphate translocator (cTPT) was isolated from envelope membranes or from transformed yeast cells and reconstituted into artificial membranes. Ionic currents mediated by the cTPT across these membranes were investigated by flux measurements and by the patch clamp technique. The results of the flux measurements indicate that inorganic phosphate (P-i) at saturating concentrations on both sides of the membrane and chloride (Cl-) at all applied concentrations are transported by the cTPT at rates about 20-fold higher than those measured in intact chloroplasts. After reconstitution of the protein into giant liposomes, single channel currents mediated by the cTPT were resolved with the patch-clamp technique. The protein was shown to be a voltage-dependent anion channel with complex gating revealing sublevels with conductances of 12, 54, 96, and 138 pS for Cl- and 6 pS and 18 pS for P-i, respectively. Recordings from patches compromising multiple channels show a synchronously appearing nonlinear current voltage (I/V) relationship in symmetrical buffers, and a different gating at positive and negative membrane potentials. This suggests that the cTPT is incorporated into the membrane in a unidirectional orientation. 3-Phosphoglycerate, a high affinity substrate of the transporter protein, induced a reversible flickering of open channel, and the channel open probability was decreased 60%. It is concluded that, besides its normal counter-exchange mode, the cTPT can also work as a voltage-dependent anion selective channel.	UNIV OSNABRUCK,FACHBEREICH BIOL CHEM,D-49069 OSNABRUCK,GERMANY; UNIV WURZBURG,JULIUS VON SACHS INST BIOWISSENSCH,D-97082 WURZBURG,GERMANY	University Osnabruck; University of Wurzburg								CORONADO R, 1980, J GEN PHYSIOL, V76, P425, DOI 10.1085/jgp.76.4.425; CRIADO M, 1987, FEBS LETT, V224, P172, DOI 10.1016/0014-5793(87)80442-8; DIERKS T, 1990, BIOCHIM BIOPHYS ACTA, V1028, P281, DOI 10.1016/0005-2736(90)90177-P; DIERKS T, 1990, BIOCHIM BIOPHYS ACTA, V1028, P268, DOI 10.1016/0005-2736(90)90176-O; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FISCHER K, 1994, PLANT MOL BIOL, V25, P167, DOI 10.1007/BF00023235; FLIEGE R, 1978, BIOCHIM BIOPHYS ACTA, V502, P232, DOI 10.1016/0005-2728(78)90045-2; FLUGGE UI, 1991, ANNU REV PLANT PHYS, V42, P129, DOI 10.1146/annurev.pp.42.060191.001021; FLUGGE UI, 1991, NATURE, V353, P364, DOI 10.1038/353364a0; FLUGGE UI, 1992, BIOCHIM BIOPHYS ACTA, V1110, P112, DOI 10.1016/0005-2736(92)90301-2; FLUGGE UI, 1985, BIOCHIM BIOPHYS ACTA, V815, P299, DOI 10.1016/0005-2736(85)90300-1; FRANCIOLINI F, 1992, BIOCHIM BIOPHYS ACTA, V1113, P1, DOI 10.1016/0304-4157(92)90031-5; Gennis R. B., 1989, BIOMEMBRANES MOL STR, DOI [10.1007/978-1-4757-2065-5, DOI 10.1007/978-1-4757-2065-5]; GROSS A, 1990, PLANTA, V180, P262, DOI 10.1007/BF00194006; GROSS A, 1990, THESIS FACHBEREICH B; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Heldt H. W., 1980, METHOD ENZYMOL, V69, P604; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hille B, 1984, IONIC CHANNELS EXCIT; INDIVERI C, 1991, BIOCHIM BIOPHYS ACTA, V1069, P110, DOI 10.1016/0005-2736(91)90110-T; JAN LY, 1992, CELL, V69, P715, DOI 10.1016/0092-8674(92)90280-P; KASAHARA M, 1977, J BIOL CHEM, V252, P7384; KELLER BU, 1988, PFLUG ARCH EUR J PHY, V411, P94, DOI 10.1007/BF00581652; KLINGENBERG M, 1981, NATURE, V290, P449, DOI 10.1038/290449a0; LAUGER P, 1987, PHYSIOL REV, V67, P1296, DOI 10.1152/physrev.1987.67.4.1296; LAUGER P, 1984, ION CHANNELS MOL PHY, P309; LODDENKOTTER B, 1993, P NATL ACAD SCI USA, V90, P2155, DOI 10.1073/pnas.90.6.2155; MALONEY PC, 1990, RES MICROBIOL, V141, P374, DOI 10.1016/0923-2508(90)90015-I; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; MARTEN I, 1993, EUR BIOPHYS J BIOPHY, V21, P403, DOI 10.1007/BF00185867; MENZLAFF E, 1993, BIOCHIM BIOPHYS ACTA, V1147, P13, DOI 10.1016/0005-2736(93)90310-V; MORAN O, 1992, J BIOENERG BIOMEMBR, V24, P91, DOI 10.1007/BF00769535; PATLAK BJ, 1988, J GEN PHYSIOL, V98, P413; PESKOFF A, 1988, BIOPHYS J, V53, P863, DOI 10.1016/S0006-3495(88)83167-9; RIORDAN JR, 1992, BIOCHIM BIOPHYS ACTA, V1101, P221, DOI 10.1016/0005-2728(92)90230-Y; SAIER MH, 1990, RES MICROBIOL, V141, P281, DOI 10.1016/0923-2508(90)90001-7; SCHULTZ JE, 1992, SCIENCE, V255, P600, DOI 10.1126/science.1371017; SPEER M, 1991, PLANT PHYSIOL, V97, P990, DOI 10.1104/pp.97.3.990; TABACHARINI JA, 1992, BIOPHYS J, V62, P1; TYERMAN SD, 1992, BIOPHYS J, V61, P736, DOI 10.1016/S0006-3495(92)81878-7; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; WAGNER R, 1989, EUR J BIOCHEM, V182, P165, DOI 10.1111/j.1432-1033.1989.tb14813.x; WALLMEIER H, 1992, TRANSPORT AND RECEPTOR PROTEINS OF PLANT MEMBRANES, P77; WILLEY DL, 1991, PLANTA, V183, P451, DOI 10.1007/BF00197745	44	51	51	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29481	29489						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7525584				2022-12-27	WOS:A1994PU28400029
J	FISCHER, K; WEBER, A; BRINK, S; ARBINGER, B; SCHUNEMANN, D; BORCHERT, S; HELDT, HW; POPP, B; BENZ, R; LINK, TA; ECKERSKORN, C; FLUGGE, UI				FISCHER, K; WEBER, A; BRINK, S; ARBINGER, B; SCHUNEMANN, D; BORCHERT, S; HELDT, HW; POPP, B; BENZ, R; LINK, TA; ECKERSKORN, C; FLUGGE, UI			PORINS FROM PLANTS - MOLECULAR-CLONING AND FUNCTIONAL-CHARACTERIZATION OF 2 NEW MEMBERS OF THE PORIN FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER MITOCHONDRIAL-MEMBRANE; DEPENDENT ANION CHANNEL; PEA ROOT PLASTIDS; SPINACH-CHLOROPLASTS; ENVELOPE MEMBRANES; PROTEIN; TRANSPORT; PURIFICATION; INVITRO; YEAST	Porins are voltage-gated diffusion pores found in all eukaryotic kingdoms. Here we describe, for the first time, the identification and characterization of two cDNAs encoding porins from plants. Peptide sequences obtained from a 30-kDa protein of envelope membranes from pea root plastids allowed the isolation of two cDNA clones from pea and maize. On the protein level, both proteins are homologous by 58%. Sequence comparison against the Swiss-Prot sequence data base revealed a homology of about 25% to mitochondrial porins from fungi and human. Computer-aided predictions of the secondary structure of the plant porins revealed the presence of 16 antiparallel beta-strands that are also found in mitochondrial porins. Porins from non-green plastids and from the outer mitochondrial membrane were reconstituted into planar lipid bilayers. The proteins showed high pore-forming activities and similar single-channel conductances. In vitro translated porin was preferentially imported only into non-green plastids but not into chloroplasts. To our knowledge, this is the first example of selective import of a plastidial protein into different types of plastids. This finding is in line with the observation that an immunoreactive 30-kDa band was only found in non-green plastids and mitochondria but not in chloroplasts, We conclude that mitochondria and non-green plastids possess homologous porin proteins, whereas chloroplasts are characterized by a different type of porin.	UNIV WURZBURG, JULIUS VON SACHS INST BIOWISSENSCH, D-97082 WURZBURG, GERMANY; UNIV GOTTINGEN, INST BIOCHEM PFLANZE, D-37073 GOTTINGEN, GERMANY; THEODOR BOVERI INST BIOWISSENSCH, D-97074 WURZBURG, GERMANY; UNIV FRANKFURT, GUSTAV EMBDEN ZENTRUM BIOL CHEM, D-60596 FRANKFURT, GERMANY; MAX PLANCK INST BIOCHEM, D-82152 MARTINSRIED, GERMANY	University of Wurzburg; University of Gottingen; Goethe University Frankfurt; Max Planck Society			Weber, Andreas PM/A-6250-2011; Weber, Andreas P.M./A-4121-2008; Weber, Andreas Paul Michael/O-3043-2019	Weber, Andreas PM/0000-0003-0970-4672; Weber, Andreas Paul Michael/0000-0003-0970-4672; Brink, Susanne C./0000-0002-3272-9707; Schuenemann, Danja/0000-0001-8894-7685; Benz, Roland/0000-0002-9510-9265				ALBAN C, 1988, PLANT PHYSIOL, V88, P709, DOI 10.1104/pp.88.3.709; ALJAMAL JA, 1993, PLANT PHYSIOL, V102, P615, DOI 10.1104/pp.102.2.615; ANDREWS J, 1983, PLANT PHYSIOL, V72, P735, DOI 10.1104/pp.72.3.735; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BENZ R, 1978, BIOCHIM BIOPHYS ACTA, V511, P305, DOI 10.1016/0005-2736(78)90269-9; BENZ R, 1994, BBA-REV BIOMEMBRANES, V1197, P167, DOI 10.1016/0304-4157(94)90004-3; BENZ R, 1985, CRC CR REV BIOCH MOL, V19, P145, DOI 10.3109/10409238509082542; BLACHLYDYSON E, 1993, J BIOL CHEM, V268, P1835; BORCHERT S, 1989, FEBS LETT, V253, P183, DOI 10.1016/0014-5793(89)80955-X; BORCHERT S, 1993, PLANT PHYSIOL, V101, P303, DOI 10.1104/pp.101.1.303; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; COLOMBINI M, 1979, NATURE, V279, P643, DOI 10.1038/279643a0; DEPINTO V, 1991, BIOCHEMISTRY-US, V30, P10191, DOI 10.1021/bi00106a017; DOUCE R, 1973, BIOCHIM BIOPHYS ACTA, V292, P105, DOI 10.1016/0005-2728(73)90255-7; ECKERSKORN C, 1989, CHROMATOGRAPHIA, V28, P92, DOI 10.1007/BF02290390; ECKERSKORN C, 1988, EUR J BIOCHEM, V176, P509, DOI 10.1111/j.1432-1033.1988.tb14308.x; FISCHER K, 1994, PLANT MOL BIOL, V25, P167, DOI 10.1007/BF00023235; FLUGGE UI, 1989, EMBO J, V8, P39, DOI 10.1002/j.1460-2075.1989.tb03346.x; FLUGGE UI, 1984, FEBS LETT, V169, P85, DOI 10.1016/0014-5793(84)80294-X; FORTE M, 1987, J MEMBRANE BIOL, V99, P65, DOI 10.1007/BF01870622; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; JOURNET EP, 1985, PLANT PHYSIOL, V79, P458, DOI 10.1104/pp.79.2.458; JOYARD J, 1980, PLANT PHYSIOL, V65, P1039, DOI 10.1104/pp.65.6.1039; JOYARD J, 1983, J BIOL CHEM, V258, P1; KAYSER H, 1989, BIOL CHEM H-S, V370, P1265; KEEGSTRA K, 1989, ANNU REV PLANT PHYS, V40, P471, DOI 10.1146/annurev.pp.40.060189.002351; KLEENE R, 1987, EMBO J, V6, P2627, DOI 10.1002/j.1460-2075.1987.tb02553.x; KLOSGEN RB, 1989, MOL GEN GENET, V217, P155, DOI 10.1007/BF00330955; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI HM, 1991, PLANT CELL, V3, P709, DOI 10.1105/tpc.3.7.709; LUBBEN TH, 1986, P NATL ACAD SCI USA, V83, P5502, DOI 10.1073/pnas.83.15.5502; LUCASLENARD J, 1971, ANNU REV BIOCHEM, V40, P409, DOI 10.1146/annurev.bi.40.070171.002205; LUDWIG O, 1988, EUR BIOPHYS J BIOPHY, V15, P269, DOI 10.1007/BF00256477; MIHARA K, 1985, EMBO J, V4, P769, DOI 10.1002/j.1460-2075.1985.tb03695.x; MOURIOUX G, 1981, PLANT PHYSIOL, V67, P470, DOI 10.1104/pp.67.3.470; SALOMON M, 1990, P NATL ACAD SCI USA, V87, P6778; SCHEIN SJ, 1976, J MEMBRANE BIOL, V30, P99, DOI 10.1007/BF01869662; SCHMID A, 1992, BIOCHIM BIOPHYS ACTA, V1112, P174, DOI 10.1016/0005-2736(92)90389-4; SCHUNEMANN D, 1993, PLANT PHYSIOL, V103, P131, DOI 10.1104/pp.103.1.131; SMACK DP, 1985, PLANT PHYSIOL, V79, P1094, DOI 10.1104/pp.79.4.1094; TROLL H, 1992, J BIOL CHEM, V267, P21072	42	71	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25754	25760						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7523392				2022-12-27	WOS:A1994PQ49100078
J	FOWLKES, JL; ENGHILD, JJ; SUZUKI, K; NAGASE, H				FOWLKES, JL; ENGHILD, JJ; SUZUKI, K; NAGASE, H			MATRIX METALLOPROTEINASES DEGRADE INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN-3 IN DERMAL FIBROBLAST-CULTURES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IGF-I; TISSUE INHIBITOR; NEUTROPHIL COLLAGENASES; CONDITIONED MEDIA; CLEAVAGE SITES; RAT PREGNANCY; ACTIVATION; CELLS; STROMELYSIN; POTENTIATION	Insulin-like growth factor binding protein-3 (IGFBP-3) is degraded by a Zn2+-dependent protease(s) produced by human dermal fibroblasts in vitro (Fowlkes, J. (1994) Endocrine J. 2, 63-68). Initial studies using IGFBP-3-substrate zymography identified several IGFBP-3-degrading proteases with M(r) 52,000-72,000, which were inhibitable by EDTA and were shifted to lower M, species after treatment of conditioned medium with an organomercurial, suggesting that they might represent one or more of the matrix metalloproteinases (MMPs). Immunoblotting of conditioned medium demonstrated the presence of proMMP-1 (52 and 55 kDa), proMMP-3 (58 and 60 kDa), and proMMP-2 (72 kDa) whose molecular masses corresponded identically to those of the IGFBP-3 degrading proteases. Degradation of recombinant human (rh) IGFBP-3 by conditioned media was blocked (>80% inhibition) by tissue inhibitor of metalloproteinases-l, a specific inhibitor of all MMPs, while removal of MMPs -1, -2, and -3 from conditioned medium by sequential immunoaffinity and gelatin-Sepharose chromatography resulted in the complete loss of IGFBP-3-degrading proteinase activity. Furthermore, human MMP-1, MMP-3, and to a lesser extent MMP-2 degraded rhIGFBP-3 in vitro. Sequence analysis of rhIGFBP-3 cleavage sites produced by MMP-1, -2, or -3 demonstrated that each cleaved within the mid-region of the binding protein, a domain with little or no homology with the other five cloned IGFBPs. These studies suggest that MMPs, beyond their previously described functions as extracellular degrading enzymes, may also exert effects on cellular growth and proliferation via degradation of IGFBP-3, thus enhancing IGF bioavailability.	DUKE UNIV,MED CTR,DEPT PATHOL,DURHAM,NC 27710; UNIV KANSAS,MED CTR,DEPT BIOCHEM & MOLEC BIOL,KANSAS CITY,KS 66160	Duke University; University of Kansas; University of Kansas Medical Center	FOWLKES, JL (corresponding author), DUKE UNIV,MED CTR,DEPT PEDIAT,DIV ENDOCRINOL,BOX 3080,DURHAM,NC 27710, USA.			Enghild, Jan Johannes/0000-0001-9292-9172	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039189] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49542] Funding Source: Medline; NIAMS NIH HHS [AR39189] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alexander CM, 1991, CELL BIOL EXTRACELLU; BAXTER RC, 1993, BIOCHEM BIOPH RES CO, V196, P1267, DOI 10.1006/bbrc.1993.2389; BINOUX M, 1992, MODERN CONCEPTS INSU, P329; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; CAMACHOHUBNER C, 1992, J BIOL CHEM, V267, P11949; CHEN JC, 1994, J CELL PHYSIOL, V158, P69, DOI 10.1002/jcp.1041580110; CLEMMONS DR, 1992, ENDOCRINOLOGY, V131, P890, DOI 10.1210/en.131.2.890; COHEN P, 1992, J CLIN ENDOCR METAB, V75, P1046, DOI 10.1210/jc.75.4.1046; COHICK WS, 1993, ANNU REV PHYSIOL, V55, P131, DOI 10.1146/annurev.ph.55.030193.001023; CONOVER CA, 1994, J BIOL CHEM, V269, P7076; CONOVER CA, 1993, J CLIN INVEST, V91, P1129, DOI 10.1172/JCI116272; CONOVER CA, 1992, ENDOCRINOLOGY, V130, P3191, DOI 10.1210/en.130.6.3191; CONOVER CA, 1990, ENDOCRINOLOGY, V127, P2795, DOI 10.1210/endo-127-6-2795; CONOVER CA, 1991, ENDOCRINOLOGY, V129, P3259, DOI 10.1210/endo-129-6-3259; DAVENPORT ML, 1992, J CLIN ENDOCR METAB, V75, P590, DOI 10.1210/jc.75.2.590; DAVENPORT ML, 1992, ENDOCRINOLOGY, V130, P2505, DOI 10.1210/en.130.5.2505; DAVENPORT ML, 1990, ENDOCRINOLOGY, V127, P1278, DOI 10.1210/endo-127-3-1278; DEMELLOW JSM, 1988, BIOCHEM BIOPH RES CO, V156, P199, DOI 10.1016/S0006-291X(88)80824-6; DESROCHERS PE, 1991, J CLIN INVEST, V87, P2258, DOI 10.1172/JCI115262; ENGHILD JJ, 1989, J BIOL CHEM, V264, P8779; FINI ME, 1990, J CELL SCI, V97, P373; Flaumenhaft R, 1991, CURR OPIN CELL BIOL, V3, P817, DOI 10.1016/0955-0674(91)90055-4; FOSANG AJ, 1993, BIOCHEM J, V295, P273, DOI 10.1042/bj2950273; FOWLKES J, 1992, ENDOCRINOLOGY, V131, P2071, DOI 10.1210/en.131.5.2071; FOWLKES JL, 1994, ENDOCRINE, V2, P63; FROST VJ, 1993, J ENDOCRINOL, V138, P545, DOI 10.1677/joe.0.1380545; GRIMES RW, 1994, ENDOCRINOLOGY, V134, P337, DOI 10.1210/en.134.1.337; ITO A, 1988, ARCH BIOCHEM BIOPHYS, V267, P211, DOI 10.1016/0003-9861(88)90025-2; JONES JI, 1993, J CELL BIOL, V121, P679, DOI 10.1083/jcb.121.3.679; KIEFER MC, 1992, J BIOL CHEM, V267, P12692; Kleiner DE, 1993, CURR OPIN CELL BIOL, V5, P891, DOI 10.1016/0955-0674(93)90040-W; KOKLITIS PA, 1991, BIOCHEM J, V276, P217, DOI 10.1042/bj2760217; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASSARRE C, 1994, ENDOCRINOLOGY, V134, P1254, DOI 10.1210/en.134.3.1254; MILLIS AJT, 1992, EXP CELL RES, V201, P373, DOI 10.1016/0014-4827(92)90286-H; MITCHELL TI, 1993, BIOCHIM BIOPHYS ACTA, V1156, P245, DOI 10.1016/0304-4165(93)90038-A; MORODOMI T, 1992, BIOCHEM J, V285, P603, DOI 10.1042/bj2850603; MURPHY G, 1992, AM J RESP CELL MOL, V7, P120, DOI 10.1165/ajrcmb/7.2.120; NAGASE H, 1991, BIOCHEM SOC T, V19, P715, DOI 10.1042/bst0190715; NETZELARNETT S, 1991, J BIOL CHEM, V266, P6747; NGUYEN Q, 1993, BIOCHEM J, V295, P595, DOI 10.1042/bj2950595; OH Y, 1993, ENDOCRINOLOGY, V132, P1337, DOI 10.1210/en.132.3.1337; OH Y, 1993, GROWTH REGULAT, V3, P84; OKADA Y, 1989, ANN RHEUM DIS, V48, P645, DOI 10.1136/ard.48.8.645; OKADA Y, 1990, VIRCHOWS ARCH B, V59, P305, DOI 10.1007/BF02899418; OKADA Y, 1990, EUR J BIOCHEM, V194, P721, DOI 10.1111/j.1432-1033.1990.tb19462.x; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; SCHMID C, 1991, BIOCHEM BIOPH RES CO, V179, P579, DOI 10.1016/0006-291X(91)91410-E; Shimasaki S, 1991, MODERN CONCEPTS INSU, P343; SIRES UI, 1993, J BIOL CHEM, V268, P2069; SOMMER A, 1991, MODERN CONCEPTS INSU, P715; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P393; SUZUKI K, 1990, BIOCHEMISTRY-US, V29, P10261, DOI 10.1021/bi00496a016; WARD RV, 1991, BIOCHIM BIOPHYS ACTA, V1079, P242, DOI 10.1016/0167-4838(91)90132-J	54	302	308	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25742	25746						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7523391				2022-12-27	WOS:A1994PQ49100076
J	UCHIDA, S; SASAKI, S; FUSHIMI, K; MARUMO, F				UCHIDA, S; SASAKI, S; FUSHIMI, K; MARUMO, F			ISOLATION OF HUMAN AQUAPORIN-CD GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; WATER-CHANNEL; DNA-BINDING; RAT-KIDNEY; PROTEIN; CLONING; EXPRESSION; LOCALIZATION; SEGMENTS; SEQUENCE	The human gene encoding aquaporin-CD (AQP-CD) was isolated, and its structural organization was characterized. The gene appeared to exist as a single copy in the human genome and comprises four exons distributing over 5 kilobases. The size range of exons is 81-761 base pairs, and that for introns is similar to 3000 to similar to 250 base pairs. The exon-intron boundaries of human AQP-CD gene are identified at identical positions in other related genes, the human AQP-CHIP gene and the human major intrinsic protein gene. The major transcription initiation sites were identified to positions 93 and 94 base pairs upstream of the ATG initiation codon by primer extension and ribonuclease protection assay. The 5'-flanking region of the hAQP-CD gene was characterized by a TATA box, two GATA consensus sequences, an AP-1 site, an AP-2 site, three E-boxes, and a cyclic AMP-responsive element. These structural features will lead to a better understanding of the mechanisms of tissue-specific expression and the regulation by dehydration in AQP-CD gene and will also be of help in search for possible genetic disorders in human AQP-CD gene.			SASAKI, S (corresponding author), TOKYO MED & DENT UNIV,SCH MED,DEPT INTERNAL MED 2,BUNKYO KU,1-5-45 YUSHIMA,TOKYO 113,JAPAN.		Uchida, Shinichi/D-1111-2013					BICHET DG, 1993, J CLIN INVEST, V92, P1262, DOI 10.1172/JCI116698; BONDY C, 1993, P NATL ACAD SCI USA, V90, P4500, DOI 10.1073/pnas.90.10.4500; DEEN PMT, 1994, SCIENCE, V264, P92, DOI 10.1126/science.8140421; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; KWON HM, 1992, J BIOL CHEM, V267, P6297; LEE ME, 1991, J BIOL CHEM, V266, P16188; MOON C, 1993, J BIOL CHEM, V268, P15772; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P11663, DOI 10.1073/pnas.90.24.11663; NIELSEN S, 1993, J CELL BIOL, V120, P371, DOI 10.1083/jcb.120.2.371; ORLOFF J, 1962, J CLIN INVEST, V41, P702, DOI 10.1172/JCI104528; PISANO MM, 1991, GENOMICS, V11, P981; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; SAITO F, 1994, IN PRESS CYTOGENET C; SASAKI S, 1994, J CLIN INVEST, V93, P1250, DOI 10.1172/JCI117079; SMARDO FL, 1992, AM J PHYSIOL, V262, pC776, DOI 10.1152/ajpcell.1992.262.3.C776; STRANGE K, 1987, J MEMBRANE BIOL, V96, P27, DOI 10.1007/BF01869332; TAMURA S, 1993, P NATL ACAD SCI USA, V90, P10876, DOI 10.1073/pnas.90.22.10876; TERADA Y, 1993, J CLIN INVEST, V92, P2339, DOI 10.1172/JCI116838; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; UCHIDA S, 1992, P NATL ACAD SCI USA, V89, P8230, DOI 10.1073/pnas.89.17.8230; Wade J B, 1981, Ann N Y Acad Sci, V372, P106, DOI 10.1111/j.1749-6632.1981.tb15464.x; WALKER MD, 1990, NUCLEIC ACIDS RES, V18, P1159, DOI 10.1093/nar/18.5.1159; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; YAMAUCHI A, 1992, J BIOL CHEM, V267, P649	27	112	113	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23451	23455						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	7522228				2022-12-27	WOS:A1994PQ34500014
J	BAJT, ML; LOFTUS, JC				BAJT, ML; LOFTUS, JC			MUTATION OF A LIGAND-BINDING DOMAIN OF BETA(3) INTEGRIN - INTEGRAL ROLE OF OXYGENATED RESIDUES IN ALPHA(IIB)BETA(3) (GPIIB-IIIA) RECEPTOR FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; LEUKOCYTE ADHESION GLYCOPROTEIN; AMINO-ACID-SEQUENCE; ALPHA-SUBUNIT; RECOGNITION SITE; PLATELET ACTIVATION; CLONING; MODULATION; AFFINITY; COMPLEX	A single amino acid substitution in beta(3) (Asp(119) --> Tyr) abrogates the Ligand binding function of beta(3) integrins and alters the divalent cation conformation of the platelet integrin alpha(IIb)beta(3) (GPIIb-IIIa). This aspartic acid residue resides within a conserved cluster of oxygenated residues that may provide ligands for the coordination of divalent cations. To assign function to the other oxygenated residues in this group (Ser(121), Ser(123), Asp(126), Asp(127), and Ser(130)), each of these amino acids in beta(3) was individually substituted by alanine. None of these amino acid substitutions altered heterodimer formation or surface expression. However, the substitutions had differential effects on receptor function. Substitution at positions Asp(119) or Ser(121) produced a complete loss of receptor function. Cells expressing these mutants failed to adhere to fibrinogen, failed to bind activation-independent ligand-mimetic peptides, and did not bind the ligand-mimetic mAb PAC1 following activation of the receptor. Similarly, cells expressing beta(3) with a substitution at Ser(123) also failed to adhere to fibrinogen and did not bind RGD peptide or mAb PAC1. These cells did retain the capacity to bind an alpha(IIb)beta(3)-specific, high affinity peptidomimetic, but occupancy did not induce the conformational change from resting to activated state observed following occupancy of the wild type receptor. Substitution at positions Asp(126), Asp(127), or Ser(130) had no effect on ligand binding function. These data indicate that Asp(119), along with Ser(121) and Ser(123), plays an integral role in the ligand binding function of alpha(IIb)beta(3).	Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048728, R01HL042977, R29HL042977] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR027214, R01AR027214] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 42977, HL 48728] Funding Source: Medline; NIAMS NIH HHS [AR 27214] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AGRAVES WS, 1987, J CELL BIOL, V105, P1183; BAJT ML, 1992, J BIOL CHEM, V267, P22211; BAJT ML, 1992, J BIOL CHEM, V267, P3789; CHARO IF, 1991, J BIOL CHEM, V266, P1415; CORBI AL, 1987, EMBO J, V6, P4023, DOI 10.1002/j.1460-2075.1987.tb02746.x; CORBI AL, 1988, J BIOL CHEM, V263, P12403; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; DSOUZA SE, 1991, NATURE, V350, P66, DOI 10.1038/350066a0; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; ERLE DJ, 1991, J BIOL CHEM, V266, P11009; FITZGERALD LA, 1987, J BIOL CHEM, V262, P3936; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; GINSBERG MH, 1992, COLD SPRING HARB SYM, V57, P221, DOI 10.1101/SQB.1992.057.01.027; GINSBERG MH, 1993, THROMB HAEMOSTASIS, V70, P87; HAAS TA, 1993, THROMB HAEMOSTASIS, V69, P786; HOGERVORST F, 1990, EMBO J, V9, P765, DOI 10.1002/j.1460-2075.1990.tb08171.x; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IGNATIUS MJ, 1990, J CELL BIOL, V111, P709, DOI 10.1083/jcb.111.2.709; KISHIMOTO TK, 1987, CELL, V48, P681, DOI 10.1016/0092-8674(87)90246-7; KOUNS WC, 1992, J BIOL CHEM, V267, P18844; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LARSON RS, 1989, J CELL BIOL, V108, P703, DOI 10.1083/jcb.108.2.703; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; MACKRELL AJ, 1988, P NATL ACAD SCI USA, V85, P2633, DOI 10.1073/pnas.85.8.2633; MARGUERIE GA, 1980, J BIOL CHEM, V255, P154; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; MOYLE M, 1991, J BIOL CHEM, V266, P19650; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NURDEN AT, 1974, BRIT J HAEMATOL, V28, P253, DOI 10.1111/j.1365-2141.1974.tb06660.x; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; OTOOLE TE, 1989, BLOOD, V74, P14; PHILLIPS DR, 1988, BLOOD, V71, P831; PLOW EF, 1989, PROG HEMOST THROMB, V9, P117; RAMASWAMY H, 1990, EMBO J, V9, P1561, DOI 10.1002/j.1460-2075.1990.tb08275.x; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SHEPPARD D, 1990, J BIOL CHEM, V265, P11502; SIMS PJ, 1991, J BIOL CHEM, V266, P7345; SMITH JW, 1988, J BIOL CHEM, V263, P18726; SUSUKI S, 1990, EMBO J, V9, P765; TAKADA Y, 1992, J CELL BIOL, V119, P913, DOI 10.1083/jcb.119.4.913; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; TOMIYAMA Y, 1992, BLOOD, V79, P2303; YLANNE J, 1993, J CELL BIOL, V122, P223, DOI 10.1083/jcb.122.1.223; YONG K, 1990, BLOOD REV, V4, P211, DOI 10.1016/0268-960X(90)90001-9; 1968, J BIOL CHEM, V243, P3557	50	147	148	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					20913	20919						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	7520434				2022-12-27	WOS:A1994PC40300018
J	MATSUOKA, A; STUEHR, DJ; OLSON, JS; CLARK, P; IKEDASAITO, M				MATSUOKA, A; STUEHR, DJ; OLSON, JS; CLARK, P; IKEDASAITO, M			L-ARGININE AND CALMODULIN REGULATION OF THE HEME IRON REACTIVITY IN NEURONAL NITRIC-OXIDE SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-PUTIDA CYTOCHROME-P-450; HYDROXY-L-ARGININE; LIGAND-BINDING; SPECTRAL CHARACTERIZATION; CRYSTAL-STRUCTURE; CARBON-MONOXIDE; BRAIN; SUBSTRATE; ENZYME; CHLOROPEROXIDASE	Neuronal nitric oxide synthase (NOS) is a calmodulin-dependent, flavin-containing hemoprotein that forms NO from L-arginine, NADPH, and molecular oxygen. Calmodulin binding to NOS triggers reduction of its heme groups (Abu-Soud, H., and Stuehr, D. J. (1993) Proc. Natl. Acad. Sci. U.S.A. 90, 10769-10762), leading to NADPH oxidation and NO synthesis. We have examined how L-arginine and calmodulin control the ligand binding and electron acceptor properties of the NOS heme iron. In the absence of bound calmodulin, ferric NOS exhibited a K-d of 0.6 mu M for L-arginine, as determined by the substrate-dependent shift in heme spin equilibrium toward a high spin state. L-Arginine binding reduced the affinity of the ferric NOS heme for cyanide by 8-fold. Carbon monoxide binding to substrate-free ferrous NOS occurred at a rate of 2 x 10(5) M(-1) s(-1); this rate was decreased 12-fold when L-arginine was bound. In contrast, bound calmodulin did not significantly affect cyanide or carbon monoxide binding to the NOS heme, nor did it alter NOS binding affinity for L-arginine. Anaerobic titration of a calmodulin-bound, L-arginine-free NOS with NADPH led to incomplete reduction of the heme iron; full reduction was achieved only in the presence of added L-arginine. Thus, our data suggest that L-arginine controls NOS heme iron reactivity in at least two ways: 1) it slows ligand interactions by binding in the distal pocket very near the heme and 2) it also appears to increase the reduction potential of the iron. In contrast, bound calmodulin does not alter the NOS affinity for L-arginine or heme ligands and may function solely as a switch that enables electrons to pass from the flavin domain onto the heme iron.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT PHYSIOL & BIOPHYS, CLEVELAND, OH 44106 USA; CLEVELAND CLIN FDN, DEPT IMMUNOL, CLEVELAND, OH 44195 USA; RICE UNIV, DEPT BIOCHEM & CELL BIOL, HOUSTON, TX 77251 USA; RICE UNIV, KECK CTR COMPUTAT BIOL, HOUSTON, TX 77251 USA	Case Western Reserve University; Cleveland Clinic Foundation; Rice University; Rice University			Ikeda-Saito, Masao/A-5992-2008; Ikeda-Saito, Masao/K-2703-2015	Olson, John/0000-0002-0760-5403	NCI NIH HHS [CA-53914] Funding Source: Medline; NHLBI NIH HHS [HL-47020] Funding Source: Medline; NIGMS NIH HHS [GM-35649] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053914, R29CA053914] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035649] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; DAWSON JH, 1992, NEW J CHEM, V16, P577; DAWSON JH, 1987, CHEM REV, V87, P1255, DOI 10.1021/cr00081a015; DAWSON JH, 1982, J BIOL CHEM, V257, P3606; FULCO AJ, 1991, ANNU REV PHARMACOL, V31, P177; HEVEL JM, 1992, BIOCHEMISTRY-US, V31, P7160, DOI 10.1021/bi00146a019; IGNARRO LJ, 1992, BIOCHEM SOC T, V20, P465, DOI 10.1042/bst0200465; IKEDASAITO M, 1985, J BIOL CHEM, V260, P1688; KLATT P, 1993, J BIOL CHEM, V268, P14781; KWON NS, 1990, J BIOL CHEM, V265, P13442; LOWENSTEIN CJ, 1992, CELL, V70, P705, DOI 10.1016/0092-8674(92)90301-R; MAYER B, 1991, FEBS LETT, V288, P187, DOI 10.1016/0014-5793(91)81031-3; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MCMILLAN K, 1993, BIOCHEMISTRY-US, V32, P9875, DOI 10.1021/bi00089a001; MIMS MP, 1983, J BIOL CHEM, V258, P4219; MONCADA S, 1992, J LAB CLIN MED, V120, P187; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; PETERSON JA, 1972, ARCH BIOCHEM BIOPHYS, V151, P427, DOI 10.1016/0003-9861(72)90518-8; POULOS TL, 1985, J BIOL CHEM, V260, P6122; POULOS TL, 1986, BIOCHEMISTRY-US, V25, P5314, DOI 10.1021/bi00366a049; PUFAHL RA, 1993, BIOCHEM BIOPH RES CO, V193, P963, DOI 10.1006/bbrc.1993.1719; REISBERG PI, 1980, J BIOL CHEM, V255, P4151; SCHMIDT HHHW, 1991, P NATL ACAD SCI USA, V88, P365, DOI 10.1073/pnas.88.2.365; SCHMIDT HHHW, 1992, BIOCHEMISTRY-US, V31, P3243, DOI 10.1021/bi00127a028; SLIGAR SG, 1976, BIOCHEMISTRY-US, V15, P5399, DOI 10.1021/bi00669a029; SLIGAR SG, 1987, CYTOCHROME P 450, P429; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; STUEHR DJ, 1992, ADV ENZYMOL RELAT AR, V65, P287; TOTANI K, 1983, ARCH BIOCHEM BIOPHYS, V222, P207, DOI 10.1016/0003-9861(83)90518-0; VERMILION JL, 1978, J BIOL CHEM, V253, P2694; WANG JL, 1993, J BIOL CHEM, V268, P22255; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001	38	112	114	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20335	20339						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	7519607				2022-12-27	WOS:A1994PB31700022
J	DZAMBA, BJ; BULTMANN, H; AKIYAMA, SK; PETERS, DM				DZAMBA, BJ; BULTMANN, H; AKIYAMA, SK; PETERS, DM			SUBSTRATE-SPECIFIC BINDING OF THE AMINO-TERMINUS OF FIBRONECTIN TO AN INTEGRIN COMPLEX IN FOCAL ADHESIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FIBROBLAST-CULTURES; MATRIX ASSEMBLY DOMAIN; CELL-ADHESION; PLASMA FIBRONECTIN; CONFORMATIONAL-CHANGES; MONOCLONAL-ANTIBODIES; BIOLOGICAL-ACTIVITY; ENDOTHELIAL-CELLS; RECEPTOR; ALPHA-5-BETA-1	The assembly of fibronectin fibrils involves the amino terminal and cell adhesion domains of fibronectin as well as alpha(5) beta(1) integrins. Efficient binding of biotinylated or radioiodinated 70-kDa amino-terminal fragments occurred only if fibroblasts were plated on fibronectin or on 180- or 85-kDa cell adhesion fragments of fibronectin. On an 11.5-kDa fragment of fibronectin that included the Arg-Gly-Asp (RGD) sequence, but not the synergy site, binding was reduced 50-fold. Conformation of the 180-kDa fragment was important for direct binding interactions with the amino terminus of fibronectin. No binding was seen if cells were plated on type I collagen, vitronectin, RGD peptides or antibodies to alpha(5) beta(1) inte grins. High affinity interactions between invasin and alpha(5) beta(1) integrin promoted low levels of binding. Monoclonal antibodies that blocked the function of either the RGD or the synergy site inhibited binding of I-125-labeled 70-kDa fragments to cells by similar to 60%. By fluorescence and interference reflection microscopy, biotinylated 70 kDa fragments were shown to co-localize with alpha(5) beta(1) integrins in focal adhesions. We propose that cell-mediated binding of the amino terminus of fibronectin involves interactions with both fibronectin and its alpha(5) beta(1) integrin receptor in an activated complex.	UNIV WISCONSIN, DEPT PATHOL & LAB MED, MADISON, WI 53706 USA; NIDR, DEV BIOL LAB, BETHESDA, MD 20892 USA	University of Wisconsin System; University of Wisconsin Madison; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)					NATIONAL EYE INSTITUTE [R01EY008540] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047221] Funding Source: NIH RePORTER; NCRR NIH HHS [RR570] Funding Source: Medline; NEI NIH HHS [EY08540] Funding Source: Medline; NIGMS NIH HHS [GM47221] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA SK, 1985, J BIOL CHEM, V260, P3256; AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; BLYSTONE SD, 1992, J BIOL CHEM, V267, P3968; CASTELLANI P, 1986, J CELL BIOL, V103, P1671, DOI 10.1083/jcb.103.5.1671; CHERNOUSOV MA, 1991, J BIOL CHEM, V266, P10851; DEJANA E, 1988, J CELL BIOL, V107, P1215, DOI 10.1083/jcb.107.3.1215; DZAMBA BJ, 1991, J CELL SCI, V100, P605; DZAMBA BJ, 1993, J CELL BIOL, V121, P1165, DOI 10.1083/jcb.121.5.1165; EHRISMANN R, 1982, J BIOL CHEM, V257, P7381; EHRISMANN R, 1981, J BIOL CHEM, V256, P4056; FAULL RJ, 1993, J CELL BIOL, V121, P155, DOI 10.1083/jcb.121.1.155; FOGERTY FJ, 1990, CELL DIFFER DEV, V32, P439, DOI 10.1016/0922-3371(90)90061-Z; FOGERTY FJ, 1990, J CELL BIOL, V111, P699, DOI 10.1083/jcb.111.2.699; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GIROUX TA, 1990, J COLLOID INTERF SCI, V139, P351, DOI 10.1016/0021-9797(90)90109-2; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; GRINNELL F, 1982, J BIOL CHEM, V257, P4888; GRINNELL F, 1981, J BIOMED MATER RES, V15, P363, DOI 10.1002/jbm.820150308; HOMANDBERG GA, 1986, BIOCHEMISTRY-US, V25, P6917, DOI 10.1021/bi00370a027; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; JOHANSSON S, 1985, J BIOL CHEM, V260, P1557; KOVACH NL, 1992, J CELL BIOL, V116, P499, DOI 10.1083/jcb.116.2.499; LAFLAMME SE, 1992, J CELL BIOL, V117, P437, DOI 10.1083/jcb.117.2.437; LIMPER AH, 1991, J BIOL CHEM, V266, P9697; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; MCDONALD JA, 1987, J BIOL CHEM, V262, P2957; MCKEOWNLONGO PJ, 1983, J CELL BIOL, V97, P466, DOI 10.1083/jcb.97.2.466; MCKEOWNLONGO PJ, 1985, J CELL BIOL, V100, P364, DOI 10.1083/jcb.100.2.364; MCKEOWNLONGO PJ, 1987, J CELL BIOL, V104, P601, DOI 10.1083/jcb.104.3.601; MOON KY, 1994, J BIOL CHEM, V269, P7651; MORLA A, 1992, CELL BIOL, V188, P421; Mosher Deane F., 1992, Current Opinion in Cell Biology, V4, P810, DOI 10.1016/0955-0674(92)90104-K; MOSHER DF, 1983, J BIOL CHEM, V258, P6595; NAGAI T, 1991, J CELL BIOL, V114, P1295, DOI 10.1083/jcb.114.6.1295; NARASIMHAN C, 1989, BIOCHEMISTRY-US, V28, P5041, DOI 10.1021/bi00438a021; NHIEU GTV, 1991, J BIOL CHEM, V266, P24367; PETERS DMP, 1987, J CELL BIOL, V104, P121, DOI 10.1083/jcb.104.1.121; PETERS DMP, 1990, J CELL BIOL, V111, P249, DOI 10.1083/jcb.111.1.249; PITT WG, 1987, PROTEINS INTERFACES, P324; QUADE BJ, 1988, J BIOL CHEM, V263, P19602; ROMAN J, 1989, J CELL BIOL, V108, P2529, DOI 10.1083/jcb.108.6.2529; SCHWARZ MA, 1984, EXP CELL RES, V153, P550, DOI 10.1016/0014-4827(84)90624-4; SCHWARZBAUER JE, 1991, J CELL BIOL, V113, P1463, DOI 10.1083/jcb.113.6.1463; SOTTILE J, 1991, J BIOL CHEM, V266, P12840; STANISLAWSKI L, 1993, J BIOMED MATER RES, V27, P619, DOI 10.1002/jbm.820270509; TAKADA Y, 1992, J CELL BIOL, V119, P913, DOI 10.1083/jcb.119.4.913; UNDERWOOD PA, 1993, J CELL SCI, V104, P793; WOLFF C, 1989, ARCH BIOCHEM BIOPHYS, V268, P536, DOI 10.1016/0003-9861(89)90320-2; WU CY, 1993, J BIOL CHEM, V268, P21883; YANG JT, 1993, DEVELOPMENT, V119, P1093; ZHANG ZH, 1993, J CELL BIOL, V122, P235, DOI 10.1083/jcb.122.1.235	52	60	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19646	19652						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	7518462				2022-12-27	WOS:A1994NY33200069
J	GUNDERSON, KL; KOPITO, RR				GUNDERSON, KL; KOPITO, RR			EFFECTS OF PYROPHOSPHATE AND NUCLEOTIDE ANALOGS SUGGEST A ROLE FOR ATP HYDROLYSIS IN CYSTIC-FIBROSIS TRANSMEMBRANE REGULATOR CHANNEL GATING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CFTR CHLORIDE CHANNELS; CONDUCTANCE REGULATOR; MULTIDRUG RESISTANCE; CL CHANNEL; CELLS; GENE; BINDING; EXPRESSION	Single channel analysis of artificial lipid planar bilayers reconstituted with wild-type human cystic fibrosis transmembrane regulator (CFTR) revealed a 10.3 pS Cl- selective channel that was activated upon phosphorylation with protein kinase A. Gating of this channel was described by a simple kinetic model consisting of a single open burst state and two closed states. The open probability of CFTR channels in bilayers increased as a function of increasing Mg-ATP concentration and exhibited negative cooperativity, suggesting the interaction of two or more ATP binding sites in channel gating. Mg-ATP increased channel open probability by decreasing the duration of the long-lived closed state but had no effect on either the mean open time or the fast closed state. ADP inhibited channel opening by precisely antagonizing the effect of ATP, suggesting that ADP inhibits the CFTR channel by competing with ATP for binding. Poorly hydrolyzable ATP analogs such as AMP-PNP and ATP gamma S, polyphosphates such as pyrophosphate (PPi) and tripolyphosphate (PPPi), and orthovanadate failed to support channel activity alone. When applied in the presence of ATP, these compounds all caused the CFTR channel to ''lock'' into a prolonged open burst state. These data support a model in which hydrolysis of ATP leads to closure of channels that have been opened by ATP.	STANFORD UNIV, DEPT BIOL SCI, STANFORD, CA 94305 USA	Stanford University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043994] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008294] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43994] Funding Source: Medline; NIGMS NIH HHS [GM08294] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMES GF, 1990, FEMS MICROBIOL LETT, V75, P429, DOI 10.1016/S0168-6445(05)80008-7; ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ASHCROFT FM, 1989, J PHYSIOL-LONDON, V416, P349, DOI 10.1113/jphysiol.1989.sp017765; BAUKROWITZ T, 1994, NEURON, V12, P473, DOI 10.1016/0896-6273(94)90206-2; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BELL CL, 1993, AM J PHYSIOL, V264, pC925, DOI 10.1152/ajpcell.1993.264.4.C925; CARSON MR, 1993, AM J PHYSIOL, V265, pL27, DOI 10.1152/ajplung.1993.265.1.L27; CHABRE M, 1990, TRENDS BIOCHEM SCI, V15, P6, DOI 10.1016/0968-0004(90)90117-T; GOODNO CC, 1982, METHOD ENZYMOL, V85, P116; HOROWITZ B, 1993, AM J PHYSIOL, V264, pH2214, DOI 10.1152/ajpheart.1993.264.6.H2214; HWANG TC, 1994, P NATL ACAD SCI USA, V91, P4698, DOI 10.1073/pnas.91.11.4698; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KANE SE, 1990, J BIOENERG BIOMEMBR, V22, P593, DOI 10.1007/BF00762963; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; LEE BS, 1991, J BIOL CHEM, V266, P11448; Miller C., 1986, ION CHANNEL RECONSTI; NAGEL G, 1992, NATURE, V360, P81, DOI 10.1038/360081a0; PENEFSKY HS, 1991, ADV ENZYMOL RELAT AR, V64, P173; QUINTON PM, 1992, NATURE, V360, P79, DOI 10.1038/360079a0; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RIORDAN JR, 1989, SCIENCE, V245, P1066; SMITH JS, 1985, NATURE, V316, P446, DOI 10.1038/316446a0; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; WARD CL, 1991, P NATL ACAD SCI USA, V88, P5277, DOI 10.1073/pnas.88.12.5277; WINTER MC, 1994, BIOPHYS J, V66, P1398, DOI 10.1016/S0006-3495(94)80930-0; WONDERLIN WF, 1990, BIOPHYS J, V58, P289, DOI 10.1016/S0006-3495(90)82376-6	27	149	153	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19349	19353						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	7518455				2022-12-27	WOS:A1994NY33200025
J	SU, J; BATZER, A; SAP, J				SU, J; BATZER, A; SAP, J			RECEPTOR TYROSINE PHOSPHATASE R-PTP-ALPHA IS TYROSINE-PHOSPHORYLATED AND ASSOCIATED WITH THE ADAPTER PROTEIN GRB2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SH3 DOMAINS; PHOSPHOTYROSINE PHOSPHATASE; CLONING; KINASES; IDENTIFICATION; ACTIVATION; EXPRESSION; TRANSFORMATION; PP60(C-SRC); FAMILY	Receptor tyrosine phosphatases (R-PTPases) have generated interest because of their suspected involvement in cellular signal transduction. The adaptor pro tein Grb2 has been implicated in coupling receptor tyrosine kinases to Ras. We report that a ubiquitous R-PTPase, R-PTP-alpha, is tyrosine-phosphorylated and associated in vivo with the Grb2 protein. This association can be reproduced in stably and transiently transfected cells, as well as in vitro using recombinant Grb2 protein. Association requires the presence of an intact SH2 domain in Grb2, as well as tyrosine phosphorylation of R-PTP-alpha. This observation links a receptor tyrosine phosphatase with a key component of a central cellular signaling pathway and provides a basis for addressing R-PTP-alpha function.	NYU, CTR MED, DEPT PHARMACOL, NEW YORK, NY 10016 USA	New York University								AUTERO M, 1994, MOL CELL BIOL, V14, P1308, DOI 10.1128/MCB.14.2.1308; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BIRGE RB, 1993, SCIENCE, V262, P1522, DOI 10.1126/science.7504323; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DAUM G, 1994, J BIOL CHEM, V269, P10524; DENHERTOG J, 1993, EMBO J, V12, P3789, DOI 10.1002/j.1460-2075.1993.tb06057.x; DENHERTOG J, 1994, IN PRESS EMBO J; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; JIRIK FR, 1990, FEBS LETT, V273, P239, DOI 10.1016/0014-5793(90)81094-5; KAMPS MP, 1988, ONCOGENE, V2, P305; KAPLAN R, 1990, P NATL ACAD SCI USA, V87, P7000, DOI 10.1073/pnas.87.18.7000; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATTHEWS RJ, 1990, P NATL ACAD SCI USA, V87, P4444, DOI 10.1073/pnas.87.12.4444; MIKI H, 1994, J BIOL CHEM, V269, P5489; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; SAP J, 1990, P NATL ACAD SCI USA, V87, P6112, DOI 10.1073/pnas.87.16.6112; SAP J, 1994, MOL CELL BIOL, V14, P1; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; STOVER DR, 1991, P NATL ACAD SCI USA, V88, P7704, DOI 10.1073/pnas.88.17.7704; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; YEUNG YG, 1992, J BIOL CHEM, V267, P23447; ZHANG ZY, 1992, J BIOL CHEM, V267, P23759; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	36	74	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					18731	18734						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	7518443				2022-12-27	WOS:A1994NX32700008
J	SANNA, MT; GIARDINA, B; SCATENA, R; PELLEGRINI, M; OLIANAS, A; MANCA, L; MASALA, B; CASTAGNOLA, M; CORDA, M				SANNA, MT; GIARDINA, B; SCATENA, R; PELLEGRINI, M; OLIANAS, A; MANCA, L; MASALA, B; CASTAGNOLA, M; CORDA, M			FUNCTIONAL ALTERATIONS IN ADULT AND FETAL HEMOGLOBIN SASSARI ASP-ALPHA-126(H9) -] HIS - THE ROLE OF ALPHA(1)ALPHA(2) CONTACT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HB-SASSARI; SARDINIA; BINDING	The effects of pH, organic phosphates (2,3-diphospho- glycerate), and temperature on the functional properties of both adult and fetal hemoglobin Sassari alpha (Asp-126 --> His) have been studied. The functional properties of the adult variant are characterized by the following: (i) an oxygen affinity higher than that of normal HbA in all the experimental conditions used; (ii) a dramatic reduction of homotropic interactions (n(50) very close to unity); and (iii) a significant decrease of the effect of 2,3-diphosphoglycerate, which is 35% lower than that observed on HbA. The fetal variant shows an increased oxygen affinity compared with normal HbF and an almost abolished heme-heme interaction. The molecular basis of these functional differences is discussed in terms of the possible role played by the substitution of alpha (Asp-26 --> His) on the stability of the R state of the molecule due to a decreased interaction at the level of alpha(1) alpha(2) contact.	UNIV CAGLIARI, INST BIOL CHEM, I-09126 CAGLIARI, ITALY; UNIV CATTOLICA SACRO CUORE, FAC MED & CHIRURG, IST CHIM & CHIM CLIN, I-00168 ROME, ITALY; UNIV CATTOLICA SACRO CUORE, CNR CHIM RECETTORI & MOLEC BIOL ATTIVE, I-00168 ROME, ITALY; UNIV SASSARI, INST GEN PHYSIOL & BIOCHEM, I-07100 SASSARI, ITALY; UNIV ROMA TOR VERGATA, DEPT EXPTL MED & BIOCHEM SCI, I-00173 ROME, ITALY	University of Cagliari; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; University of Sassari; University of Rome Tor Vergata			Castagnola, Massimo/AAM-6355-2021	Castagnola, Massimo/0000-0002-0959-7259				BALDWIN J, 1979, J MOL BIOL, V129, P175, DOI 10.1016/0022-2836(79)90277-8; BARDAKDJIANMICHAU J, 1990, BIOCHIM BIOPHYS ACTA, V1041, P250, DOI 10.1016/0167-4838(90)90279-O; FERMI G, 1975, J MOL BIOL, V97, P237, DOI 10.1016/S0022-2836(75)80037-4; GIARDINA B, 1993, J MOL BIOL, V229, P512, DOI 10.1006/jmbi.1993.1050; Giardina B, 1981, Methods Enzymol, V76, P417; MASALA B, 1987, HEMOGLOBIN, V11, P373, DOI 10.3109/03630268709042855; MASALA B, 1992, HEMOGLOBIN, V16, P331, DOI 10.3109/03630269208998879; MASALA B, 1991, CLIN CHIM ACTA, V198, P195, DOI 10.1016/0009-8981(91)90353-E; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; POYART C, 1976, FEBS LETT, V69, P103, DOI 10.1016/0014-5793(76)80663-1; YOSHIOKA M, 1968, J BIOCHEM-TOKYO, V63, P70, DOI 10.1093/oxfordjournals.jbchem.a128749	12	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18338	18342						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	7518430				2022-12-27	WOS:A1994NW79800019
J	HORUK, R; WANG, ZX; PEIPER, SC; HESSELGESSER, J				HORUK, R; WANG, ZX; PEIPER, SC; HESSELGESSER, J			IDENTIFICATION AND CHARACTERIZATION OF A PROMISCUOUS CHEMOKINE-BINDING PROTEIN IN A HUMAN ERYTHROLEUKEMIC CELL-LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-BLOOD-CELLS; PLASMODIUM-VIVAX; CYTOKINE FAMILY; RECEPTOR; PURIFICATION; PARASITE; FORMS	The erythrocyte chemokine receptor is a cell surface protein that binds a wide array of chemokines including interleukin-8 (IL-8), melanoma growth stimulating activity (MGSA), monocyte chemotactic protein-1 (MCP-1), and RANTES (Regulated on Activation, Normal T Expressed and Secreted). This protein has also been identified as the Duffy blood group antigen, a cell surface receptor for the malarial parasite Plasmodium vivax. In the present study, we have identified a chemokine receptor-like binding protein in a human erythroleukemic cell line (HEL), which, based on its molecular properties, may be related to the erythrocyte chemokine receptor. Saturation binding studies with I-125-IL-8 revealed a single class of IL-8 binding sites in HEL cells with a K-D of 7.4 +/- 1.9 nM and a receptor density of 12,818 +/- 965 binding sites/cell. In competition studies unlabeled IL-8, MGSA, MCP-1, and RANTES were fully able to inhibit the binding of I-125-IL-8 to HEL cells. Chemical cross-linking with radiolabeled IL-8 resulted in a crosslinked species of 60 kDa in membranes from HEL cells. The labeling was specific since it was inhibited by preincubation with 1 mu m unlabeled IL-8 or MGSA. A monoclonal antibody (Fy6) to the human erythrocyte Duffy blood group antigen/chemokine receptor blocked the binding of IL-8 and other chemokines to the HEL cell chemokine receptor like binding protein. Cell membranes from HEL cells and from erythrocyte ghosts were subjected to SDS-PAGE and analyzed by Western blotting with anti-Fy6. The antibody bound to a molecule with a molecular mass of 50 kDa in HEL cell membranes and 40 kDa in erythrocyte ghosts. Northern blot analysis of mRNA revealed that the HEL chemokine-binding protein hybridized to a cDNA probe to the Duffy antigen/chemokine receptor.	UNIV LOUISVILLE,SCH MED,JAMES GRAHAM BROWN CANC CTR,HENRY VOGT CANC RES INST,LOUISVILLE,KY 40292	University of Louisville	HORUK, R (corresponding author), GENENTECH INC,DEPT PROT CHEM,460 POINT SAN BRUNO BLVD,S SAN FRANCISCO,CA 94080, USA.							CHAUDHURI A, 1993, P NATL ACAD SCI USA, V90, P10793, DOI 10.1073/pnas.90.22.10793; CHAUDHURI A, 1994, J BIOL CHEM, V269, P7835; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DARBONNE WC, 1991, J CLIN INVEST, V88, P1362, DOI 10.1172/JCI115442; HEBERT CA, 1990, J IMMUNOL, V145, P3033; HORUK R, 1993, BIOCHEMISTRY-US, V32, P5733, DOI 10.1021/bi00073a002; HORUK R, 1991, BIOCHEM J, V273, P79, DOI 10.1042/bj2730079; HORUK R, 1993, SCIENCE, V261, P1182, DOI 10.1126/science.7689250; HORUK R, 1993, J BIOL CHEM, V268, P541; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MILLER LH, 1976, NEW ENGL J MED, V295, P302, DOI 10.1056/NEJM197608052950602; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NEOTE K, 1993, J BIOL CHEM, V268, P12247; NICHOLS ME, 1987, J EXP MED, V166, P776, DOI 10.1084/jem.166.3.776; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; ROBB RJ, 1984, J EXP MED, V160, P1126, DOI 10.1084/jem.160.4.1126; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; STECK TL, 1970, SCIENCE, V168, P255, DOI 10.1126/science.168.3928.255	18	54	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17730	17733						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	7517400				2022-12-27	WOS:A1994NU12800060
J	HATZ, P; WHALEN, G; KEHRL, JH				HATZ, P; WHALEN, G; KEHRL, JH			DIFFERENTIAL EXPRESSION OF A NOVEL PROTEIN-KINASE IN HUMAN B-LYMPHOCYTES - PREFERENTIAL LOCALIZATION IN THE GERMINAL CENTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOLLICULAR DENDRITIC CELLS; PRIMARY IMMUNE-RESPONSE; SACCHAROMYCES-CEREVISIAE; CONSERVED FEATURES; ANTIGEN; ENCODES; (4-HYDROXY-3-NITROPHENYL)ACETYL; IDENTIFICATION; ACTIVATION; GENERATION	B lymphocytes which reside in the germinal center region of lymphoid follicles are functionally and phenotypically distinct from the surrounding mantle zone B cells. We have isolated cDNA clones for several genes that are differentially expressed between these two populations of B lymphocytes. One such gene, BL44, is preferentially expressed in germinal center B cells. The nucleotide sequence of a 2,874-base pair EL44 cDNA was determined and a 2,451-bp open reading frame found that encodes for a 97-kDa serine/threonine protein kinase referred to as GC kinase. It has an NH2-terminal catalytic domain most similar to that of the Drosophila NinaC protein and the yeast STE20 protein. GC kinase mRNA transcripts are not unique to germinal center E cells and are found in several other tissues, including brain, lung, and placenta. The GC kinase protein was immunoprecipitated from transfected COS cells and from the Burkitt cell line RAMOS. GC kinase immunoprecipitated from transfected COS cells phosphorylated the substrates casein and myelin basic protein. In addition, a 97-kDa phosphoprotein likely to be GC kinase itself was detected. GC kinase may participate in an important signal transduction pathway in germinal center B cells.	NIAID, IMMUNOREGULAT LAB, BETHESDA, MD 20892 USA; GEORGETOWN UNIV, MED CTR, DEPT MED, DIV RHEUMATOL IMMUNOL & ALLERGY, WASHINGTON, DC 20007 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Georgetown University			Kehrl, John/AAE-6292-2019	Kehrl, John/0000-0002-6526-159X				AUSUBEL FM, 1991, CURRENT PROTOCOLS MO, V10; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; FALKOFF RJM, 1982, J IMMUNOL, V129, P97; FLIEDNER TM, 1964, ANN NY ACAD SCI, V113, P578, DOI 10.1111/j.1749-6632.1964.tb40692.x; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HAYNES BF, 1989, IMMUNOL TODAY, V10, P423, DOI 10.1016/0167-5699(89)90040-6; HAYNES BF, 1983, J IMMUNOL, V131, P1195; HEINEN E, 1984, EUR J IMMUNOL, V14, P267, DOI 10.1002/eji.1830140312; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; JACOB J, 1993, J EXP MED, V178, P1293, DOI 10.1084/jem.178.4.1293; JACOB J, 1991, NATURE, V354, P389, DOI 10.1038/354389a0; JACOB J, 1991, J EXP MED, V173, P1165, DOI 10.1084/jem.173.5.1165; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; KLAUS GGB, 1980, IMMUNOL REV, V53, P3, DOI 10.1111/j.1600-065X.1980.tb01038.x; KORSMEYER SJ, 1992, BLOOD, V80, P879; KROESE FGM, 1987, EUR J IMMUNOL, V17, P1069, DOI 10.1002/eji.1830170726; LANE HC, 1985, NEW ENGL J MED, V313, P79, DOI 10.1056/NEJM198507113130204; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; LIU YJ, 1991, EUR J IMMUNOL, V21, P2951, DOI 10.1002/eji.1830211209; LIU YJ, 1992, IMMUNOL TODAY, V13, P17, DOI 10.1016/0167-5699(92)90199-H; MONTELL C, 1988, CELL, V52, P757, DOI 10.1016/0092-8674(88)90413-8; NIEUWENHUIS P, 1976, CELL IMMUNOL, V23, P254, DOI 10.1016/0008-8749(76)90191-X; PARDUE ML, 1985, NUCLEIC ACID HYBRIDI, P179; RAMER SW, 1993, P NATL ACAD SCI USA, V90, P452, DOI 10.1073/pnas.90.2.452; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SCHNIZLEIN CT, 1984, IMMUNOBIOLOGY, V168, P391, DOI 10.1016/S0171-2985(84)80125-4; SCHWEITZER B, 1991, YEAST, V7, P265, DOI 10.1002/yea.320070308; Solomon MJ, 1993, CURR OPIN CELL BIOL, V5, P180, DOI 10.1016/0955-0674(93)90100-5; STYRKARSDOTTIR U, 1992, MOL GEN GENET, V235, P122, DOI 10.1007/BF00286189; SZAKAL AK, 1988, J IMMUNOL, V140, P341; THORBECKE GJ, 1962, J EXP MED, V116, P295, DOI 10.1084/jem.116.3.295; TOYOS J, 1989, BLOOD, V74, P751; WILSON GL, 1991, J EXP MED, V173, P137, DOI 10.1084/jem.173.1.137	35	112	115	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16802	16809						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	7515885				2022-12-27	WOS:A1994NR29600047
J	MURTHY, KS; MAKHLOUF, GM				MURTHY, KS; MAKHLOUF, GM			VASOACTIVE-INTESTINAL-PEPTIDE PITUITARY ADENYLATE CYCLASE-ACTIVATING PEPTIDE-DEPENDENT ACTIVATION OF MEMBRANE-BOUND NO SYNTHASE IN SMOOTH-MUSCLE MEDIATED BY PERTUSSIS-TOXIN-SENSITIVE G(I1-2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							NITRIC-OXIDE SYNTHASE; MOLECULAR-CLONING; ENTERIC NEURONS; CELLS; LOCALIZATION; VIP; PHOSPHORYLATION; CITRULLINE; RECEPTORS; RELEASE	Plasma membranes isolated from dispersed gastric muscle cells exhibited calmodulin dependent NOS activity that was stimulated by Ca2+ in the range 0.1-1 mM (maximum 10 mu M). Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating peptide (PACAP) (in the presence of GTP), and GTP gamma S (guanosine 5'-O-(gamma-thio)triphosphate) stimulated NOS activity in a concentration-dependent fashion above that maximally stimulated by Ca2+. The increase in NOS activity induced by VIP, PACAP, and GTP gamma S was abolished by GDP beta S (guanosine 5'-O-(beta-thio) diphosphate), which had no effect on NOS activity stimulated by Ca2+. The NOS inhibitor N-G-nitro-L arginine and the calmodulin antagonist calmidazolium abolished NOS activity stimulated by all agents including Ca2+. NOS activity stimulated by GTP gamma S, VIP, and PACAP was inhibited by G(i alpha 1-2) antibody but not by G(q alpha), G(s alpha), and G(i alpha 3) antibodies. NOS activity stimulated by VIP and PACAP was inhibited by 80-83% in membranes derived from pertussis toxin-treated cells, We conclude that a Ca2+/calmodulin-dependent NOS present in plasma membranes of gastric muscle cells is activated by two homologous peptide transmitters, VIP and PACAP, via a common receptor coupled to pertussis toxin (PTx)-sensitive G(i1-2). The study provides the first evidence of receptor-mediated G protein activation of NOS in smooth muscle cells.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PHYSIOL,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT MED,RICHMOND,VA 23298	Virginia Commonwealth University; Virginia Commonwealth University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028300] Funding Source: NIH RePORTER; NIDDK NIH HHS [NIDDK DK 28300] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHMAD S, 1988, AM J PHYSIOL, V255, pG462, DOI 10.1152/ajpgi.1988.255.4.G462; ARIMURA A, 1992, TRENDS ENDOCRIN MET, V3, P288, DOI 10.1016/1043-2760(92)90139-R; BITAR KN, 1982, SCIENCE, V216, P531, DOI 10.1126/science.6176025; BITAR KN, 1982, AM J PHYSIOL, V242, pG400, DOI 10.1152/ajpgi.1982.242.4.G400; BREDT DS, 1992, J BIOL CHEM, V267, P10976; BUSCONI L, 1993, J BIOL CHEM, V268, P8410; BUSH PA, 1992, BIOCHEM BIOPH RES CO, V186, P308, DOI 10.1016/S0006-291X(05)80808-3; FORSTERMANN U, 1991, P NATL ACAD SCI USA, V88, P1788, DOI 10.1073/pnas.88.5.1788; FORSTERMANN U, 1991, BIOCHEM PHARMACOL, V42, P1849, DOI 10.1016/0006-2952(91)90581-O; FURNESS JB, 1992, TRENDS NEUROSCI, V15, P66, DOI 10.1016/0166-2236(92)90029-8; GRIDER JR, 1993, NEUROSCIENCE, V54, P521, DOI 10.1016/0306-4522(93)90271-G; GRIDER JR, 1993, GASTROENTEROLOGY, V104, pA515; GRIDER JR, 1992, AM J PHYSIOL, V262, pG774, DOI 10.1152/ajpgi.1992.262.4.G774; JIN JG, 1993, AM J PHYSIOL, V264, pG470, DOI 10.1152/ajpgi.1993.264.3.G470; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; LLEWELLYNSMITH IJ, 1992, BRAIN RES, V577, P337, DOI 10.1016/0006-8993(92)90294-J; MAKHLOUF GM, 1993, NEWS PHYSIOL SCI, V8, P195; MARSDEN PA, 1992, FEBS LETT, V307, P287, DOI 10.1016/0014-5793(92)80697-F; MICHEL T, 1993, P NATL ACAD SCI USA, V90, P6252, DOI 10.1073/pnas.90.13.6252; MURTHY KS, 1991, AM J PHYSIOL, V261, pG945, DOI 10.1152/ajpgi.1991.261.6.G945; MURTHY KS, 1994, AM J PHYSIOL, V266, pG161, DOI 10.1152/ajpgi.1994.266.1.G161; MURTHY KS, 1991, AM J PHYSIOL, V261, pG937, DOI 10.1152/ajpgi.1991.261.6.G937; MURTHY KS, 1993, AM J PHYSIOL, V265, pG660, DOI 10.1152/ajpgi.1993.265.4.G660; MURTHY KS, 1994, GASTROENTEROLOGY, V106, pA545; POLLOCK JS, 1993, AM J PHYSIOL, V265, pC1379, DOI 10.1152/ajpcell.1993.265.5.C1379; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; WARD SM, 1992, AM J PHYSIOL, V263, pG277, DOI 10.1152/ajpgi.1992.263.2.G277	27	112	113	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					15977	15980						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	7515875				2022-12-27	WOS:A1994NQ72900006
J	JUNG, JS; PRESTON, GM; SMITH, BL; GUGGINO, WB; AGRE, P				JUNG, JS; PRESTON, GM; SMITH, BL; GUGGINO, WB; AGRE, P			MOLECULAR-STRUCTURE OF THE WATER CHANNEL THROUGH AQUAPORIN CHIP - THE HOURGLASS MODEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEIN; XENOPUS OOCYTES; RECONSTITUTION; CDNA	Aquaporin channel-forming integral protein (CHIP) is the first characterized water channel protein (genome symbol AQP1), but the molecular structure of the aqueous pathway through CHIP remains undefined. The two halves of CHIP are sequence-related, and each has three bilayer spanning domains with the motif asparagine-proline alanine (NPA) at residues 76-78 (in cytoplasmic loop B) and 192-194 (in extracellular loop E). The NPA motifs are oriented 180 degrees to each other, and the second NPA is near cysteine 189, the known site where mercurials inhibit osmotic water permeability (P-f). When expressed in Xenopus oocytes, the double mutant A73C/C189S exhibited high, mercurial-sensitive P-f similar to wild-type CHIP. Conservative substitutions of slightly greater mass in or near NPA motifs in loop B or loop E in CHIP caused reduced P-f and failure of the protein to localize at the plasma membrane. Certain nonfunctional loop E mutants complemented the truncation mutant D237Z. Formation of mixed oligomers was demonstrated by velocity sedimentation, immunoprecipitation, and analysis of dimeric-CHIP polypeptides. Cellular distributions of individual mutants or complementing pairs of mutants were verified by plasma membrane isolation and confocal microscopy. An hourglass structural model is proposed in which a cytoplasmic chamber (loop B) connects within the membrane to an extracellular chamber (loop E) forming a single, narrow aqueous pathway through each of the CHIP subunits; subunit oligomerization may provide the vertical symmetry necessary for residence within the lipid bilayer.	JOHNS HOPKINS UNIV, SCH MED, DEPT BIOL CHEM, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT MED, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PHYSIOL, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033991, R37HL048268, R01HL048268] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032753, R37DK032753] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL33991, HL48268] Funding Source: Medline; NIDDK NIH HHS [DK32753] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGRE P, 1993, AM J PHYSIOL, V265, pF463; AGRE P, 1993, AM J PHYSIOL, V265, pF461, DOI 10.1152/ajprenal.1993.265.3.F461; CATTERALL WA, 1993, TRENDS NEUROSCI, V16, P500, DOI 10.1016/0166-2236(93)90193-P; DENKER BM, 1988, J BIOL CHEM, V263, P15634; Finkelstein A., 1987, WATER MOVEMENT LIPID; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; GORIN MB, 1984, CELL, V39, P49, DOI 10.1016/0092-8674(84)90190-9; HORWITZ J, 1987, BIOCHEMISTRY-US, V26, P8092, DOI 10.1021/bi00399a012; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAUREL C, 1993, EMBO J, V12, P2241, DOI 10.1002/j.1460-2075.1993.tb05877.x; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P7275, DOI 10.1073/pnas.90.15.7275; NIELSEN S, 1993, J CELL BIOL, V120, P371, DOI 10.1083/jcb.120.2.371; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1994, J BIOL CHEM, V269, P1668; PRESTON GM, 1993, J BIOL CHEM, V268, P17; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; REIZER J, 1993, CRIT REV BIOCHEM MOL, V28, P235, DOI 10.3109/10409239309086796; SABOLIC I, 1992, AM J PHYSIOL, V263, pC1225, DOI 10.1152/ajpcell.1992.263.6.C1225; Sambrook J, 1989, MOL CLONING LABORATO; SMITH BL, 1991, J BIOL CHEM, V266, P6407; VANHOEK AN, 1991, J BIOL CHEM, V266, P16633; VANHOEK AN, 1993, BIOCHEMISTRY-US, V32, P11847, DOI 10.1021/bi00095a013; VANHOEK AN, 1992, J BIOL CHEM, V267, P18267; VERBAVATZ JM, 1993, J CELL BIOL, V123, P605, DOI 10.1083/jcb.123.3.605; WALL DA, 1989, J MEMBRANE BIOL, V107, P189, DOI 10.1007/BF01871724; WALZ T, 1994, J BIOL CHEM, V269, P1583; YISRAELI JK, 1989, METHOD ENZYMOL, V180, P42; ZEIDEL ML, 1994, BIOCHEMISTRY-US, V33, P1606, DOI 10.1021/bi00172a042; ZEIDEL ML, 1992, BIOCHEMISTRY-US, V31, P7436, DOI 10.1021/bi00148a002; ZHANG R, 1990, J BIOL CHEM, V265, P15375	31	501	527	1	48	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14648	14654						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	7514176				2022-12-27	WOS:A1994NM06500055
J	SHATTIL, SJ; HAIMOVICH, B; CUNNINGHAM, M; LIPFERT, L; PARSONS, JT; GINSBERG, MH; BRUGGE, JS				SHATTIL, SJ; HAIMOVICH, B; CUNNINGHAM, M; LIPFERT, L; PARSONS, JT; GINSBERG, MH; BRUGGE, JS			TYROSINE PHOSPHORYLATION OF PP125(FAK) IN PLATELETS REQUIRES COORDINATED SIGNALING THROUGH INTEGRIN AND AGONIST RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; PROTEIN-KINASE-C; CELL-ADHESION; MONOCLONAL-ANTIBODIES; ACTIVATED PLATELETS; FIBRINOGEN BINDING; BLOOD-PLATELETS; WHOLE-BLOOD; DUAL ROLE; EPINEPHRINE	FAK is a focal adhesion kinase that is phosphorylated on tyrosine in activated platelets. Induction of FAK phosphorylation requires both fibrinogen binding to integrin alpha(IIb)beta(3) and post-occupancy events during agonist-induced platelet aggregation or platelet spreading on a fibrinogen matrix. To identify the signaling pathways necessary for tyrosine phosphorylation of FAK, we have examined the conditions that stimulate or inhibit this phosphorylation in platelets in which fibrinogen binding to alpha(IIb)beta(3) and platelet aggregation were induced directly with an anti-beta(3), Fab fragment (anti-LIBS6). Apyrase was added to prevent effects of the endogenous platelet agonist, ADP. Under these conditions, neither fibrinogen binding nor primary platelet aggregation was sufficient to induce FAK phosphorylation, suggesting that a second ''costimulatory'' event was required. Indeed, when epinephrine was added with fibrinogen and anti-LIBS6, large platelet aggregates formed and FAK phosphorylation occurred. This response was prevented by blockade of cyclooxygenase with indomethacin or thromboxane A(2) receptors with SQ 30,741. A stable thromboxane A(2) analogue (U46619) could substitute for epinephrine as the costimulus. Epinephrine costimulation of FAK phosphorylation was also prevented by chelation of intracellular Ca2+ with BAPTA or selective inhibition of protein kinase C (PKC) with bisindolylmaleimide, indicating that Ca2+ and PKC are necessary for FAK phosphorylation under these conditions. Epinephrine also promoted FAK phosphorylation and adhesive spreading of apyrase-treated platelets on a fibrinogen matrix. Cytochalasin D, an inhibitor of actin polymerization, blocked FAK phosphorylation under all these conditions. Thus, tyrosine phosphorylation of FAK in platelets requires coordinated signaling through occupied integrin and agonist receptors. These separate pathways may converge to increase free Ca2+ and activate PKC and thus promote the cytoskeletal reorganization required for activation of FAK.	UNIV PENN, SCH MED, DEPT MED, DIV HEMATOL ONCOL, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT PATHOL & LAB MED, PHILADELPHIA, PA 19104 USA; UNIV MED & DENT NEW JERSEY, DEPT SURG, NEW BRUNSWICK, NJ 08903 USA; UNIV VIRGINIA, DEPT MICROBIOL, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, CTR CANC, SCH MED, CHARLOTTESVILLE, VA 22908 USA; SCRIPPS RES INST, COMM VASC BIOL, LA JOLLA, CA 92037 USA; ARIAD PHARMACEUT INC, CAMBRIDGE, MA 02138 USA	University of Pennsylvania; University of Pennsylvania; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Virginia; University of Virginia; Scripps Research Institute; Takeda Pharmaceutical Company Ltd; Takeda Oncology					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL040387, R01HL049845, P01HL048728] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-49845, HL-40387, HL-48728] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAMS CS, 1990, BLOOD, V75, P128; AGARWAL A, 1993, J BIOL CHEM, V268, P15900; ANDRE E, 1993, BIOCHEM BIOPH RES CO, V190, P140, DOI 10.1006/bbrc.1993.1022; BALDASSARE JJ, 1993, BIOCHEM J, V291, P235, DOI 10.1042/bj2910235; BANGA HS, 1986, P NATL ACAD SCI USA, V83, P9197, DOI 10.1073/pnas.83.23.9197; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; BLACHE D, 1986, THROMB HAEMOSTASIS, V55, P168; Burridge K., 1992, Current Biology, V2, P537, DOI 10.1016/0960-9822(92)90020-B; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; DAVIS PD, 1992, J MED CHEM, V35, P994, DOI 10.1021/jm00084a004; DRUCKER BJ, 1989, NEW ENGL J MED, V321, P1383; FOX JEB, 1987, THROMB DIATH HAEMO, P175; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; GOLDEN A, 1990, J CELL BIOL, V111, P3117, DOI 10.1083/jcb.111.6.3117; GROVER GJ, 1988, J CARDIOVASC PHARM, V12, P701, DOI 10.1097/00005344-198812000-00012; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HAIMOVICH B, 1993, J BIOL CHEM, V268, P15868; HAMAWY MM, 1993, J BIOL CHEM, V268, P6851; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HARTWIG JH, 1992, J CELL BIOL, V118, P1421, DOI 10.1083/jcb.118.6.1421; HORVATH AR, 1992, EMBO J, V11, P855, DOI 10.1002/j.1460-2075.1992.tb05123.x; HUANG MM, 1993, J CELL BIOL, V122, P473, DOI 10.1083/jcb.122.2.473; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LANZA F, 1988, AM J PHYSIOL, V255, pH1276, DOI 10.1152/ajpheart.1988.255.6.H1276; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MOHAMMADI M, 1993, BIOCHEMISTRY-US, V32, P8742, DOI 10.1021/bi00085a004; ODA A, 1992, BLOOD, V79, P920; Otey C. A., 1993, Molecular Biology of the Cell, V4, p347A; PLOW EF, 1989, PROG HEMOST THROMB, V9, P117; SAITOH M, 1989, BLOOD, V74, P2001; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; SAVAGE B, 1991, J BIOL CHEM, V266, P11227; SAVAGE B, 1992, J BIOL CHEM, V267, P11300; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schaller Michael D., 1993, Trends in Cell Biology, V3, P258, DOI 10.1016/0962-8924(93)90053-4; SCHWARTZ MA, 1993, CANCER RES, V53, P1503; SHATTIL SJ, 1993, THROMB HAEMOSTASIS, V70, P224; SHATTIL SJ, 1989, BLOOD, V73, P150; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SHATTIL SJ, 1987, BLOOD, V70, P307; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SIESS W, 1989, PHYSIOL REV, V69, P58, DOI 10.1152/physrev.1989.69.1.58; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; SMITH JB, 1992, BIOCHEM J, V288, P925, DOI 10.1042/bj2880925; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; SULDAN Z, 1991, BLOOD, V78, P2887; SWEATT JD, 1985, J BIOL CHEM, V260, P2910; TANGEN O, 1971, THROMB DIATH HAEMOST, V25, P268; TBULLEC D, 1991, J BIOL CHEM, V266, P15771; Turner CE, 1991, CURR OPIN CELL BIOL, V3, P849, DOI 10.1016/0955-0674(91)90059-8; VUORI K, 1993, J BIOL CHEM, V268, P21459; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WOODS A, 1992, J CELL SCI, V101, P277; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZACHARY I, 1993, J BIOL CHEM, V268, P22060; ZACHARY I, 1992, J BIOL CHEM, V267, P19031; ZHANG J, 1992, J BIOL CHEM, V267, P4686	66	229	231	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14738	14745						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	7514181				2022-12-27	WOS:A1994NM06500068
J	SLIWKOWSKI, MX; SCHAEFER, G; AKITA, RW; LOFGREN, JA; FITZPATRICK, VD; NUIJENS, A; FENDLY, BM; CERIONE, RA; VANDLEN, RL; CARRAWAY, KL				SLIWKOWSKI, MX; SCHAEFER, G; AKITA, RW; LOFGREN, JA; FITZPATRICK, VD; NUIJENS, A; FENDLY, BM; CERIONE, RA; VANDLEN, RL; CARRAWAY, KL			COEXPRESSION OF ERBB2 AND ERBB3 PROTEINS RECONSTITUTES A HIGH-AFFINITY RECEPTOR FOR HEREGULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; TYROSINE PHOSPHORYLATION; MOLECULAR-CLONING; NEU GENE; KINASE; CELLS; HETERODIMERIZATION; EXPRESSION; PRODUCT; BINDING	The heregulin/neu differentiation factor gene products were purified and cloned based on their ability to stimulate the phosphorylation of a 185-kDa protein in human breast carcinoma cell lines known to express erbB2. However, not all cells that express erbB2 respond to heregulin, indicating that other components besides erbB2 may be required for heregulin binding. Cells that are transfected with the closely related receptor, erbB3, display a single class of lower affinity heregulin binding sites than has been previously observed on breast carcinoma cell lines. Little or no stimulation of tyrosine phosphorylation in response to heregulin occurs in cells that are transfected with erbB3 alone. Transfection of cells with erbB3 and erbB2 reconstitutes a higher affinity binding receptor, which is also capable of generating a tyrosine phosphorylation signal in response to heregulin. A monoclonal antibody to erbB2 will inhibit heregulin activation of tyrosine phosphorylation and binding in cells transfected with both receptors but not with erbB3 alone. In cells expressing erbB2 and erbB3, both proteins become tyrosine-phosphorylated upon interaction with heregulin. Direct interaction between heregulin and the two proteins was demonstrated by chemical cross-linking experiments using I-125-heregulin followed by immunoprecipitation with antibodies specific for erbB2 or erbB3.	CORNELL UNIV,DEPT PHARMACOL,ITHACA,NY 14853; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DIV SIGNAL TRANSDUCT,BOSTON,MA 02115	Cornell University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	SLIWKOWSKI, MX (corresponding author), GENENTECH INC,390 POINT SAN BRUNO BLVD,MAIL STOP 63,S SAN FRANCISCO,CA 94080, USA.			Schaefer, Gabriele/0000-0001-9727-3555	NIGMS NIH HHS [GM40654] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040654] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CHOU YH, 1991, P NATL ACAD SCI USA, V88, P4897, DOI 10.1073/pnas.88.11.4897; CONNELLY PA, 1990, P NATL ACAD SCI USA, V87, P6054, DOI 10.1073/pnas.87.16.6054; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FENDLY BM, 1990, CANCER RES, V50, P1550; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KOSCHINSKY ML, 1991, BIOCHEMISTRY-US, V30, P5044, DOI 10.1021/bi00234a029; KRAUS MH, 1993, P NATL ACAD SCI USA, V90, P2900, DOI 10.1073/pnas.90.7.2900; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MORAN MF, 1988, ONCOGENE, V3, P665; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; PRIGENT SA, 1992, ONCOGENE, V7, P1279; QIAN XL, 1992, P NATL ACAD SCI USA, V89, P1330, DOI 10.1073/pnas.89.4.1330; ROBB RJ, 1984, J EXP MED, V160, P1126, DOI 10.1084/jem.160.4.1126; SPIVAKKROIZMAN T, 1992, J BIOL CHEM, V267, P8056; TAN JC, 1990, SCIENCE, V247, P209, DOI 10.1126/science.1688471; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M	28	600	709	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14661	14665						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	7514177				2022-12-27	WOS:A1994NM06500057
J	ROGLER, CE; YANG, DY; ROSSETTI, L; DONOHOE, J; ALT, E; CHANG, CJ; ROSENFELD, R; NEELY, K; HINTZ, R				ROGLER, CE; YANG, DY; ROSSETTI, L; DONOHOE, J; ALT, E; CHANG, CJ; ROSENFELD, R; NEELY, K; HINTZ, R			ALTERED BODY-COMPOSITION AND INCREASED FREQUENCY OF DIVERSE MALIGNANCIES IN INSULIN-LIKE GROWTH FACTOR-II TRANSGENIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BINDING-PROTEINS; LONGITUDINAL DATA-ANALYSIS; CHRONIC-RENAL-FAILURE; RAT-LIVER; IGF-II; CELL-PROLIFERATION; WILMS-TUMOR; HUMAN-SERUM; EXPRESSION; GENE	The physiological role of insulin-like growth factor (IGF) II (IGF-II) in adult humans is poorly understood. Rather high levels of IGF-II persist in adult human serum, whereas, in rodents, IGF-II levels are very low. To investigate the physiological and carcinogenic effects of persistently elevated IGF-II in adults, we have produced two lines of transgenic mice in which high levels of IGF-II (20- or 30 fold increase above normal) are persistently maintained in the blood. The transgene is driven by the major urinary protein promoter, and it is highly expressed in the liver and perputial glands in both lines. The adult transgenic mice are smaller than controls, and their body composition is altered. Their lean body mass is reduced by 5-8%, whereas fat mass is reduced between 44 and 77%. The mice expressing the highest level of IGF-II (30x) develop hypoglycemia and hypoinsulinemia and IGF-I levels are normal. Mice in the lower expression line (20-fold elevated IGF-II) develop hypoglycemia progressively over their lifetime. Mice from both lines also develop a diverse spectrum of tumors at a higher frequency than controls after 18 months of age, and the most frequent types of tumors are hepatocellular carcinomas and lymphomas. Squamous cell carcinoma, sar coma, and thyroid carcinomas also occurred in our test group. The long latent period before tumors arise and the wide spectrum of tumor types suggest that IGF-II may function primarily as a tumor progression factor in mice via autocrine and endocrine mechanisms of action.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,CTR DIABET RES & TRAINING,DEPT MED,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT PATHOL,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT EPIDEMIOL & SOCIAL MED,BRONX,NY 10461; STANFORD UNIV,STANFORD MED CTR,DEPT PEDIAT,PALO ALTO,CA 94305	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Stanford University	ROGLER, CE (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,MARION BESSIN LIVER RES CTR,1300 MORRIS PK AVE,BRONX,NY 10461, USA.				NATIONAL CANCER INSTITUTE [R01CA037232, R01CA056076] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK017702] Funding Source: NIH RePORTER; NCI NIH HHS [CA37232, CA56076] Funding Source: Medline; NIDDK NIH HHS [DK-17702] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AXELROD L, 1988, NEW ENGL J MED, V319, P1477, DOI 10.1056/NEJM198812013192209; BELL GI, 1984, NATURE, V310, P775, DOI 10.1038/310775a0; CAMPBELL PG, 1991, J CELL PHYSIOL, V149, P293, DOI 10.1002/jcp.1041490216; CARO JF, 1988, J CLIN INVEST, V81, P976, DOI 10.1172/JCI113451; COHEN P, 1993, MOL ENDOCRINOL, V7, P380, DOI 10.1210/me.7.3.380; CULLEN KJ, 1992, MOL ENDOCRINOL, V6, P91, DOI 10.1210/me.6.1.91; CZECH MP, 1989, CELL, V59, P235, DOI 10.1016/0092-8674(89)90281-X; DAINIAK N, 1985, J CLIN INVEST, V76, P1237, DOI 10.1172/JCI112079; DAUGHADAY WH, 1988, NEW ENGL J MED, V319, P1434, DOI 10.1056/NEJM198812013192202; DAUGHADAY WH, 1990, ENDOCRINOLOGY, V127, P1; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; DOUGLAS RG, 1991, J CLIN INVEST, V88, P614, DOI 10.1172/JCI115346; Drop S.L.S., 1991, MODERN CONCEPTS INSU, P311; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; DULAK NC, 1973, J CELL PHYSIOL, V81, P153, DOI 10.1002/jcp.1040810204; FOREJT J, 1992, CELL, V70, P443, DOI 10.1016/0092-8674(92)90168-C; FROESCH ER, 1985, ANNU REV PHYSIOL, V47, P443; FROESCH ER, 1966, BIOCHIM BIOPHYS ACTA, V121, P360, DOI 10.1016/0304-4165(66)90125-5; FU XX, 1988, J VIROL, V62, P3422, DOI 10.1128/JVI.62.9.3422-3430.1988; HAIG D, 1991, CELL, V64, P1045; HARTMANN H, 1992, DIABETOLOGIA, V35, P216, DOI 10.1007/BF00400920; HELD WA, 1987, MOL CELL BIOL, V7, P3705, DOI 10.1128/MCB.7.10.3705; HELD WA, 1989, EMBO J, V8, P183, DOI 10.1002/j.1460-2075.1989.tb03363.x; HOSSENLOPP P, 1986, ANAL BIOCHEM, V154, P138, DOI 10.1016/0003-2697(86)90507-5; HUDGINS WR, 1992, J BIOL CHEM, V267, P8153; KRATZ G, 1992, EXP CELL RES, V202, P381, DOI 10.1016/0014-4827(92)90089-Q; LAMSON G, 1989, J CLIN ENDOCR METAB, V69, P852, DOI 10.1210/jcem-69-4-852; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; LIU F, 1990, J CLIN ENDOCR METAB, V70, P620, DOI 10.1210/jcem-70-3-620; LOWELL BB, 1993, NATURE, V366, P740, DOI 10.1038/366740a0; MCCUSKER RH, 1991, ENDOCRINOLOGY, V129, P939, DOI 10.1210/endo-129-2-939; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; MOTTOLA C, 1984, J BIOL CHEM, V259, P2705; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; NISHIMOTO I, 1987, BIOCHEM BIOPH RES CO, V142, P275, DOI 10.1016/0006-291X(87)90481-5; NISHIMOTO I, 1987, J BIOL CHEM, V262, P12120; POWELL DR, 1986, J CLIN ENDOCR METAB, V63, P1186; RECHLER MM, 1986, HORM RES, V24, P152, DOI 10.1159/000180554; RECHLER MM, 1985, ANNU REV PHYSIOL, V47, P425; REEVE AE, 1985, NATURE, V317, P258, DOI 10.1038/317258a0; STUMPEL F, 1992, DIABETOLOGIA, V35, P932, DOI 10.1007/BF00401421; STYLIANOPOULOU F, 1988, P NATL ACAD SCI USA, V85, P141, DOI 10.1073/pnas.85.1.141; STYLIANOPOULOU F, 1988, DEVELOPMENT, V103, P497; Werther GA, 1990, GROWTH FACTORS, V3, P171, DOI 10.3109/08977199009043902; WOLFE RR, 1984, RADIOISOTOPE STABLE, P1; YANG DY, 1991, CARCINOGENESIS, V12, P1893, DOI 10.1093/carcin/12.10.1893; YANG YWH, 1985, J BIOL CHEM, V260, P2570; ZAPF J, 1978, EUR J BIOCHEM, V87, P285, DOI 10.1111/j.1432-1033.1978.tb12377.x; ZAPF J, 1986, J CLIN INVEST, V77, P1768, DOI 10.1172/JCI112500; ZAPF J, 1984, CLIN ENDOCRINOLOGY M, P3; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	52	239	249	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13779	13784						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	7514593				2022-12-27	WOS:A1994NL60600013
J	DIVITA, G; RESTLE, T; GOODY, RS; CHERMANN, JC; BAILLON, JG				DIVITA, G; RESTLE, T; GOODY, RS; CHERMANN, JC; BAILLON, JG			INHIBITION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REVERSE-TRANSCRIPTASE DIMERIZATION USING SYNTHETIC PEPTIDES DERIVED FROM THE CONNECTION DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HERPESVIRUS RIBONUCLEOTIDE REDUCTASE; MONOCLONAL-ANTIBODIES; ESCHERICHIA-COLI; RETROVIRUS; EXPRESSION; BINDING; AIDS	Based on presently available information on the structure of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase, peptides have been synthesized which correspond to the sequence of a particular region of the protein involved in formation of the active heterodimeric form of the enzyme. Several peptides that are 15-19 amino acids long and that are derived from the so called connection domain of the reverse transcriptase are able to inhibit dimerization of the enzyme and thus inhibit development of its enzymatic activities. In particular, a tryptophan-rich 19-mer corresponding to residues 389-407 was relatively efficient, showing an apparent dissociation constant in the micromolar range for one or both of the subunits. The sequence of this region is identical for both subunits, since one (molecular mass of 51 kDa) is the proteolytic product of the other (molecular mass of 66 kDa). Dissociation of the preformed heterodimer could not be induced by the peptides, but increasing concentrations reduced the rate of dimerization in a concentration dependent manner until it became immeasurable at high concentrations. The results suggest that inhibition of dimerization of reverse transcriptase is an attractive approach to chemotherapeutic intervention in HIV infection and that further development of peptide based inhibition strategies is worth pursuing.	MAX PLANCK INST MED RES,BIOPHYS ABT,D-69120 HEIDELBERG,GERMANY; MAX PLANCK INST MOLEK PHYSIOL,D-44139 DORTMUND,GERMANY; PARC SCI & TECHNOL LUMINY,INSERM,U322,F-13273 MARSEILLE 09,FRANCE	Max Planck Society; Max Planck Society; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite			DIVITA, GILLES/AAV-9214-2021; Goody, Roger S/J-8845-2014	Goody, Roger S/0000-0002-0772-0444				BAILLON JG, 1991, NEW BIOL, V3, P1015; BALTIMORE D, 1988, NATURE, V335, P396; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANDRA A, 1986, FEBS LETT, V200, P327, DOI 10.1016/0014-5793(86)81162-0; COHEN EA, 1986, NATURE, V321, P441, DOI 10.1038/321441a0; DECLERCQ E, 1992, AIDS RES HUM RETROV, V8, P119, DOI 10.1089/aid.1992.8.119; DIVITA G, 1993, FEBS LETT, V324, P153, DOI 10.1016/0014-5793(93)81383-B; DUTIA BM, 1986, NATURE, V321, P439, DOI 10.1038/321439a0; GROB PM, 1992, AIDS RES HUM RETROV, V8, P145, DOI 10.1089/aid.1992.8.145; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LIGHTFOOTE MM, 1986, J VIROL, V60, P771, DOI 10.1128/JVI.60.2.771-775.1986; MULLER B, 1989, J BIOL CHEM, V264, P13975; MULLER B, 1991, J BIOL CHEM, V266, P14709; Nanni Raymond G., 1993, Perspectives in Drug Discovery and Design, V1, P129, DOI 10.1007/BF02171659; RESTLE T, 1992, J BIOL CHEM, V267, P14654; RESTLE T, 1990, J BIOL CHEM, V265, P8986; REY F, 1987, J VIROL METHODS, V16, P239, DOI 10.1016/0166-0934(87)90008-5; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504; ZHANG ZY, 1991, J BIOL CHEM, V266, P15591	21	84	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13080	13083						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	7513698				2022-12-27	WOS:A1994NK18400007
J	PAVLOV, AR; KARAM, JD				PAVLOV, AR; KARAM, JD			BINDING-SPECIFICITY OF T4 DNA-POLYMERASE TO RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; BACTERIOPHAGE-T4; EXPRESSION; MUTATION; REPLICATION; ANTIMUTATOR; OPERATOR; PROTEIN	Bacteriophage T4 DNA polymerase, product of phage gene 43 (gp43), is a multifunctional DNA-binding protein and a key component of the phage DNA replicase. It is also an RNA-binding protein that selectively recognizes a site on its mRNA (the translational operator) and represses its own translation. We examined the ability of the protein to discriminate between DNA and RNA by using a gel mobility shift assay with defined RNA and DNA substrates. A higher affinity to RNA as compared with DNA (about 100-fold) was observed in assays that utilized synthetic DNA and in vitro transcribed RNA substrates bearing the T4 gene 43 translational operator sequence. The replacement of thymine with uracil in the synthetic DNA did not improve binding. The results suggest that the protein's selectivity for RNA is based in structure (intramolecular interactions) specific to the ribonucleotide sequence of the operator. Competition studies suggest that the protein determinants for RNA and DNA recognition are only partially overlapping.	TULANE UNIV,MED CTR,DEPT BIOCHEM,NEW ORLEANS,LA 70112	Tulane University			Pavlov, Andrey/HGB-3637-2022	Pavlov, Andrey/0000-0001-7891-269X	NIGMS NIH HHS [R01-GM18842] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018842] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDRAKE M, 1988, P NATL ACAD SCI USA, V85, P7942, DOI 10.1073/pnas.85.21.7942; ANDRAKE MD, 1991, GENETICS, V128, P203; ANTAO VP, 1992, NUCLEIC ACIDS RES, V20, P819, DOI 10.1093/nar/20.4.819; BLUMBERG DD, 1987, METHOD ENZYMOL, V152, P20; DEWAARD A, 1965, P NATL ACAD SCI USA, V54, P1241; DUGGLEBY RG, 1984, COMPUT BIOL MED, V14, P447, DOI 10.1016/0010-4825(84)90045-3; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; Fedorov V.V, 1972, THEORY OPTIMAL EXPT; FORMOSA T, 1983, P NATL ACAD SCI-BIOL, V80, P2442, DOI 10.1073/pnas.80.9.2442; FREY MW, 1993, P NATL ACAD SCI USA, V90, P2579, DOI 10.1073/pnas.90.7.2579; GILLIN FD, 1976, J BIOL CHEM, V251, P5225; GOULIAN M, 1968, J BIOL CHEM, V243, P627; HOCKENSMITH JW, 1993, J BIOL CHEM, V268, P15712; HSU T, 1990, J BIOL CHEM, V265, P5303; KARAM JD, 1974, J VIROL, V13, P428, DOI 10.1128/JVI.13.2.428-438.1974; LIN TC, 1987, P NATL ACAD SCI USA, V84, P7000, DOI 10.1073/pnas.84.20.7000; MCPHEETERS DS, 1988, J MOL BIOL, V201, P517, DOI 10.1016/0022-2836(88)90634-1; MILLER ES, 1994, IN PRESS MOL BIOL BA; MUZYCZKA N, 1972, J BIOL CHEM, V247, P7116; PRESS WH, 1986, NUMERICAL RECIPES AR; RUSSEL M, 1973, J MOL BIOL, V79, P83, DOI 10.1016/0022-2836(73)90271-4; RUSSEL M, 1976, J BIOL CHEM, V251, P7263; SHAMOO Y, 1993, J MOL BIOL, V232, P89, DOI 10.1006/jmbi.1993.1372; SPICER EK, 1988, J BIOL CHEM, V263, P7478; TUERK C, 1990, J MOL BIOL, V213, P749, DOI 10.1016/S0022-2836(05)80261-X; UNNITHAN S, 1990, NUCLEIC ACIDS RES, V18, P7083, DOI 10.1093/nar/18.23.7083; VONHIPPEL PH, 1982, J MOL BIOL, V162, P795, DOI 10.1016/0022-2836(82)90548-4; VONHIPPEL PH, 1983, BACTERIOPHAGE T4, P202; WARNER HR, 1966, VIROLOGY, V28, P100, DOI 10.1016/0042-6822(66)90310-2	29	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12968	12972						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	7513697				2022-12-27	WOS:A1994NH71600090
J	TARASEVICIENE, L; NAURECKIENE, S; UHLIN, BE				TARASEVICIENE, L; NAURECKIENE, S; UHLIN, BE			IMMUNOAFFINITY PURIFICATION OF THE ESCHERICHIA-COLI RNE GENE-PRODUCT - EVIDENCE THAT THE RNE GENE ENCODES THE PROCESSING ENDORIBONUCLEASE RNASE-E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STABILITY AMS GENE; MESSENGER-RNA; RIBONUCLEASE-E; RIBOSOMAL-RNA; PROTEIN; ENZYME; DECAY; INVITRO; INVIVO; ACID	The rne gene product was highly purified from Escherichia coli cells overproducing the protein by a procedure including immunoaffinity chromatography. Expression in vivo and in vitro of the cloned 6-kilobase pair DNA fragment containing the entire rne gene resulted in the synthesis of a protein migrating as a 180-kDa polypeptide in the SDS-polyacrylamide gel. The position of the protein on the two-dimensional polyacrylamide gel indicated that the protein is highly acidic. The enzymatic activity test which used as the substrate RNA I and 9 S RNA provided evidence that the rne gene is the structural gene for the RNA processing enzyme RNAse E. The Western blot analysis performed using a rabbit antiserum raised against a truncated 110-kDa protein fragment of RNase E (containing two-thirds of the sequence from the N terminus) revealed that the 180-kDa polypeptide is the only protein recognized by the antibodies in a wild type whole cell extract of E. coli. The antibodies cross-reacted with similar molecular weight proteins from a number of different bacteria, suggesting that the rne gene product is evolutionarily conserved in the bacterial world.	UMEA UNIV, DEPT MICROBIOL, S-90187 UMEA, SWEDEN	Umea University			Uhlin, Bernt Eric/AAO-6292-2021	Uhlin, Bernt Eric/0000-0002-2991-8072				APIRION D, 1978, GENETICS, V90, P659; APIRION D, 1993, BIOESSAYS, V15, P113, DOI 10.1002/bies.950150207; Ausubel FM, 1988, MOL REPROD DEV; BABITZKE P, 1991, P NATL ACAD SCI USA, V88, P1, DOI 10.1073/pnas.88.1.1; BOUVET P, 1992, NATURE, V360, P488, DOI 10.1038/360488a0; CASAREGOLA S, 1992, J MOL BIOL, V228, P30, DOI 10.1016/0022-2836(92)90489-7; CHAUHAN AK, 1991, NUCLEIC ACIDS RES, V19, P125, DOI 10.1093/nar/19.1.125; CLAVERIEMARTIN F, 1991, J BIOL CHEM, V266, P2843; CLAVERIEMARTIN F, 1989, J BACTERIOL, V171, P5479, DOI 10.1128/jb.171.10.5479-5486.1989; CORMACK RS, 1992, J MOL BIOL, V228, P1078, DOI 10.1016/0022-2836(92)90316-C; CORMACK RS, 1993, P NATL ACAD SCI USA, V90, P9006, DOI 10.1073/pnas.90.19.9006; DALLMANN G, 1987, MOL GEN LIFE SCI ADV, V6, P99; DEUTSCHER MP, 1993, J BIOL CHEM, V268, P13011; EHRETSMANN CP, 1992, GENE DEV, V6, P149, DOI 10.1101/gad.6.1.149; GAMPER M, 1993, GENE, V129, P119, DOI 10.1016/0378-1119(93)90706-9; GHORA BK, 1978, CELL, V15, P1055, DOI 10.1016/0092-8674(78)90289-1; GOLDBLUM K, 1981, J BACTERIOL, V146, P128, DOI 10.1128/JB.146.1.128-132.1981; HENRY MD, 1992, J BACTERIOL, V174, P743, DOI 10.1128/jb.174.3.743-748.1992; JOHNSTON KH, 1986, J EXP MED, V163, P697, DOI 10.1084/jem.163.3.697; KING TC, 1986, MICROBIOL REV, V50, P428, DOI 10.1128/MMBR.50.4.428-451.1986; KLUG G, 1992, GENE, V121, P95, DOI 10.1016/0378-1119(92)90166-M; LINCHAO S, 1991, CELL, V65, P1233, DOI 10.1016/0092-8674(91)90018-T; LUNDBERG U, 1990, EMBO J, V9, P2731, DOI 10.1002/j.1460-2075.1990.tb07460.x; MACKIE GA, 1991, J BACTERIOL, V173, P2488, DOI 10.1128/jb.173.8.2488-2497.1991; MCDOWALL KJ, 1993, J BACTERIOL, V175, P4245, DOI 10.1128/JB.175.13.4245-4249.1993; MELEFORS O, 1991, MOL MICROBIOL, V5, P857, DOI 10.1111/j.1365-2958.1991.tb00759.x; MISRA TK, 1979, J BIOL CHEM, V254, P1154; MUDD EA, 1988, EMBO J, V7, P3601, DOI 10.1002/j.1460-2075.1988.tb03238.x; MUDD EA, 1990, MOL MICROBIOL, V4, P2127, DOI 10.1111/j.1365-2958.1990.tb00574.x; MUDD EA, 1993, MOL MICROBIOL, V9, P557, DOI 10.1111/j.1365-2958.1993.tb01716.x; NILSSON P, 1991, MOL MICROBIOL, V5, P1791, DOI 10.1111/j.1365-2958.1991.tb01928.x; ONO M, 1979, J MOL BIOL, V129, P343, DOI 10.1016/0022-2836(79)90500-X; ROY MK, 1983, BIOCHIM BIOPHYS ACTA, V747, P200, DOI 10.1016/0167-4838(83)90098-5; SOHLBERG B, 1993, P NATL ACAD SCI USA, V90, P277, DOI 10.1073/pnas.90.1.277; SRIVASTAVA AK, 1990, ANNU REV MICROBIOL, V44, P105, DOI 10.1146/annurev.mi.44.100190.000541; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TARASEVICIENE L, 1991, MOL MICROBIOL, V5, P851, DOI 10.1111/j.1365-2958.1991.tb00758.x; TARASEVICIENE L, 1993, J CELL BIOL C S, V17, P178; TOMCSANYI T, 1985, J MOL BIOL, V185, P713, DOI 10.1016/0022-2836(85)90056-7; VANBOGELEN RA, 1990, P NATL ACAD SCI USA, V87, P5589, DOI 10.1073/pnas.87.15.5589	40	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12167	12172						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	7512961				2022-12-27	WOS:A1994NG37700075
J	ZHU, M; HIRAYAMA, K; KAPATOS, G				ZHU, M; HIRAYAMA, K; KAPATOS, G			REGULATION OF TETRAHYDROBIOPTERIN BIOSYNTHESIS IN CULTURED DOPAMINE NEURONS BY DEPOLARIZATION AND CAMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-HYDROXYLASE; RAT; BIOPTERIN; COFACTOR; CYCLOHYDROLASE; CELLS; INHIBITION; INCREASES; CLONING; ENZYME	Primary cultures containing embryonic rat brain mesencephalic or hypothalamic dopamine neurons were used to examine the effects of membrane depolarization and elevations of cAMP levels on tetrahydrobiopterin cofactor content. Initial studies showed that 24-h incubations with 8-bromo-cAMP or isobutyl methylxanthine increased cofactor levels in either culture system, whereas the stimulatory effects of forskolin or depolarization of membrane potential were only observed in cultures of hypothalamus. 8-Bromo-cAMP was found to increase cofactor content in a concentration-dependent manner, with increases observed up to 5 mM, The time course of the effect of 8-bromo-cAMP was biphasic. Over the short term, an increase of 50% in cofactor content at 2 and 5 h was detected. Over the long term, by 24-48 h, cofactor levels increased by between 100% and 300%. Studies of cofactor turnover indicated that the long-term increase was due to stimulation of tetrahydrobiopterin biosynthesis with no alteration in degradation rate. Inhibitors of gene transcription and translation prevented the long- but not short-term increase in cofactor content. Levels of GTP cyclohydrolase I mRNA were increased 7-10-fold following 5 h of incubation with 8-bromo-cAMP. Tetrahydrobiopterin biosynthesis within cultured dopamine neurons of the hypothalamus and mesencephalon thus appears to be regulated by a cAMP-dependent mechanism involving enhanced gene expression of enzyme(s) involved in cofactor biosynthesis.	WAYNE STATE UNIV,SCH MED,DEPT PSYCHIAT,CELLULAR & CLIN NEUROBIOL PROGRAM,DETROIT,MI 48201	Wayne State University					NINDS NIH HHS [NS26081] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026081] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABOUDONIA MM, 1986, J NEUROCHEM, V46, P1190, DOI 10.1111/j.1471-4159.1986.tb00637.x; ABOUDONIA MM, 1981, P NATL ACAD SCI-BIOL, V78, P2703, DOI 10.1073/pnas.78.5.2703; BARUCHIN A, 1990, J NEUROCHEM, V54, P1769, DOI 10.1111/j.1471-4159.1990.tb01232.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAHLSTROM A, 1964, ACTA PHYSIOL SCAND, V62, P1; DUCH DS, 1986, ENDOCRINOLOGY, V118, P1897, DOI 10.1210/endo-118-5-1897; FUKUSHIMA T, 1980, ANAL BIOCHEM, V102, P176, DOI 10.1016/0003-2697(80)90336-X; GRANNEMAN JG, 1990, J NEUROCHEM, V54, P1995, DOI 10.1111/j.1471-4159.1990.tb04903.x; HARADA T, 1993, SCIENCE, V260, P1507, DOI 10.1126/science.8502995; HATAKEYAMA K, 1991, J BIOL CHEM, V266, P765; HERVE D, 1993, J NEUROSCI, V13, P2237, DOI 10.1523/jneurosci.13-05-02237.1993; HIRAYAMA K, 1993, J NEUROCHEM, V61, P1006, DOI 10.1111/j.1471-4159.1993.tb03614.x; HOSSAIN MA, 1992, J NEUROCHEM, V59, P2237; INOUE Y, 1991, J BIOL CHEM, V266, P20791; KAPATOS G, 1981, SCIENCE, V213, P1129, DOI 10.1126/science.6168019; KAPATOS G, 1992, J NEUROCHEM, V59, P2048; KAPATOS G, 1990, J NEUROCHEM, V55, P1995; KAPATOS G, 1983, CHEM BIOL PTERIDINES, P171; KAPATOS G, 1989, PTERIDINES BIOGENIC, P243; KATOH S, 1982, BIOCHEM BIOPH RES CO, V105, P75, DOI 10.1016/S0006-291X(82)80012-0; KAUFMAN S, 1974, CIBA F S, V22, P85; KWON NS, 1989, J BIOL CHEM, V264, P20496; LENTZ SI, 1993, ADV EXP MED BIOL, V338, P171; SUZUKI H, 1988, BIOCHEM BIOPH RES CO, V153, P382, DOI 10.1016/S0006-291X(88)81235-X; TAYEH MA, 1989, J BIOL CHEM, V264, P19654	25	42	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11825	11829						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	7512954				2022-12-27	WOS:A1994NG37700026
J	WEGENER, AMK; HOU, XH; DIETRICH, J; GEISLER, C				WEGENER, AMK; HOU, XH; DIETRICH, J; GEISLER, C			DISTINCT DOMAINS OF THE CD3-GAMMA CHAIN ARE INVOLVED IN SURFACE EXPRESSION AND FUNCTION OF THE T-CELL ANTIGEN RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CHAIN; TCR/CD3 COMPLEX; ALPHA-CHAIN; SIGNAL TRANSDUCTION; LYMPHOCYTES-T; CD3 COMPLEX; SUBUNITS; PHOSPHORYLATION; CONSEQUENCES; GLYCOPROTEIN	The T cell antigen receptor (TcR) is a multisubunit complex that consists of at least six different polypeptides. We have recently demonstrated that the CD3-delta subunit cannot substitute for the CD3-gamma subunit in TcR cell surface expression, in spite of significant amino acid homology between these two subunits. To identify CD3-gamma-specific domains that are required for assembly of the complete TcR and for surface expression and function of the TcR, chimeric CD3-gamma/CD3-delta molecules were con structed and expressed in T cells devoid of endogenous CD3-gamma. Substitution of the extracellular domain of CD3-gamma with that of CD3-delta did not allow cell surface expression of the TcR, In contrast, substitution of the transmembrane and/or the intracellular domains of CD3-gamma with those of CD3-delta did allow TcR cell surface expression. These results conclusively demonstrate that the extracellular domain of CD3-gamma plays a unique role in TcR assembly. Functional analyses of the transfectants demonstrated that the intracellular domain of CD3-gamma is required for protein kinase C-mediated down-regulation of TcR but is dispensable for the pattern of tyrosine phosphorylation observed following activation through TcR.			WEGENER, AMK (corresponding author), UNIV COPENHAGEN, PANUM INST, INST MED MICROBIOL & IMMUNOL, BLDG 183, BLEGDAMSVEJ 3C, DK-2200 COPENHAGEN, DENMARK.		Geisler, Carsten/A-7056-2012	Geisler, Carsten/0000-0002-8472-0771				ALARCON B, 1991, EMBO J, V10, P903, DOI 10.1002/j.1460-2075.1991.tb08023.x; ALCOVER A, 1990, J BIOL CHEM, V265, P4131; ALEXANDER DR, 1992, BIOCHEM J, V288, P69, DOI 10.1042/bj2880069; BLUMBERG RS, 1990, P NATL ACAD SCI USA, V87, P7220, DOI 10.1073/pnas.87.18.7220; BUFERNE M, 1992, J IMMUNOL, V148, P657; CANTRELL D, 1987, NATURE, V325, P540, DOI 10.1038/325540a0; CANTRELL DA, 1985, P NATL ACAD SCI USA, V82, P8158, DOI 10.1073/pnas.82.23.8158; COSSON P, 1991, NATURE, V351, P414, DOI 10.1038/351414a0; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DELAHERA A, 1991, J EXP MED, V173, P7, DOI 10.1084/jem.173.1.7; DIETRICH J, 1994, EMBO J, V13, P2156, DOI 10.1002/j.1460-2075.1994.tb06492.x; GEISLER C, 1992, J IMMUNOL, V148, P2437; GEISLER C, 1988, SCAND J IMMUNOL, V27, P685, DOI 10.1111/j.1365-3083.1988.tb02402.x; GEISLER C, 1992, J IMMUNOL, V148, P3469; GROETTRUP M, 1993, CELL, V75, P283, DOI 10.1016/0092-8674(93)80070-U; HALL C, 1991, INT IMMUNOL, V3, P359, DOI 10.1093/intimm/3.4.359; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; JOHN S, 1989, EUR J IMMUNOL, V19, P335, DOI 10.1002/eji.1830190218; KAPPES DJ, 1991, P NATL ACAD SCI USA, V88, P10619, DOI 10.1073/pnas.88.23.10619; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; KONING F, 1990, EUR J IMMUNOL, V20, P299, DOI 10.1002/eji.1830200211; KRISSANSEN GW, 1986, EMBO J, V5, P1799, DOI 10.1002/j.1460-2075.1986.tb04429.x; LETOURNEUR F, 1989, EUR J IMMUNOL, V19, P2269, DOI 10.1002/eji.1830191214; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LOH C, 1994, J BIOL CHEM, V269, P8817; MANOLIOS N, 1990, SCIENCE, V249, P274, DOI 10.1126/science.2142801; MANOLIOS N, 1991, EMBO J, V10, P1643, DOI 10.1002/j.1460-2075.1991.tb07687.x; MANOLIOS N, 1994, EUR J IMMUNOL, V24, P84, DOI 10.1002/eji.1830240114; MORLEY BJ, 1988, J EXP MED, V168, P1971, DOI 10.1084/jem.168.6.1971; OHASHI PS, 1985, NATURE, V316, P606, DOI 10.1038/316606a0; PEREZACIEGO P, 1991, J EXP MED, V174, P319, DOI 10.1084/jem.174.2.319; PUNT JA, 1991, J EXP MED, V174, P775, DOI 10.1084/jem.174.4.775; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; SAITO T, 1987, J IMMUNOL, V139, P625; VANDENELSEN P, 1984, NATURE, V312, P413, DOI 10.1038/312413a0; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WEISS A, 1991, ANNU REV GENET, V25, P487, DOI 10.1146/annurev.ge.25.120191.002415; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WILLARDGALLO KE, 1990, P NATL ACAD SCI USA, V87, P6713, DOI 10.1073/pnas.87.17.6713	40	40	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4675	4680		10.1074/jbc.270.9.4675	http://dx.doi.org/10.1074/jbc.270.9.4675			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7533164	hybrid			2022-12-27	WOS:A1995QK08400073
J	HASEGAWA, G; HUNTER, AJ; CHARONIS, AS				HASEGAWA, G; HUNTER, AJ; CHARONIS, AS			MATRIX NONENZYMATIC GLYCOSYLATION LEADS TO ALTERED CELLULAR PHENOTYPE AND INTRACELLULAR TYROSINE PHOSPHORYLATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION; EXTRACELLULAR-MATRIX; GENE-EXPRESSION; FOCAL ADHESIONS; CROSS-LINKING; IV COLLAGEN; PROTEIN; FIBRONECTIN; LAMININ; GLUCOSYLATION	The effect of matrix nonenzymatic glycosylation on signal transduction and the cellular phenotype was examined, Human microvascular endothelial cells were plated on control or glycated basement membrane-like matrix. Cells exhibited a decrease in their ability to adhere and spread on modified matrix. The pattern of intracellular tyrosine phosphorylation was examined by Western Immunoblotting; a band with 65 kDa mobility exhibited a marked reduction of tyrosine phosphorylation in cells adherent to modified matrix. Immunoprecipitation experiments provided evidence that this band is paxillin, a member of focal adhesion proteins. Immunoprecipitation with antibodies against focal adhesion kinase (pp125(FAK)), the enzyme that is thought to regulate paxillin tyrosine phosphorylation, also demonstrated a reduction in tyrosine phosphorylation of pp125(FAK). To confirm these biochemical data, adherent cells were examined for the distribution of paxillin, using immunofluorescence microscopy; paxillin was seen in focal points peripherally located in cells on nor mal matrix, but lacked this pattern in cells on modified matrix. Actin filaments were also disorganized in cells plated on modified matrix. These data suggest that matrix nonenzymatic glycosylation can interfere with and potentially alter cellular phenotype and intracellular signaling.	UNIV MINNESOTA, SCH MED, DEPT LAB MED & PATHOL, MINNEAPOLIS, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities				Charonis, Aristidis/0000-0001-9956-732X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036007, R01DK043569] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-43569, DK-36007] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOCKHOLT SM, 1993, J BIOL CHEM, V268, P14565; BROWNLEE M, 1984, ANN INTERN MED, V101, P527, DOI 10.7326/0003-4819-101-4-527; BROWNLEE M, 1986, SCIENCE, V232, P1629, DOI 10.1126/science.3487117; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CHARONIS AS, 1990, DIABETES, V39, P807, DOI 10.2337/diabetes.39.7.807; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; EBLE AS, 1983, J BIOL CHEM, V258, P9406; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; HAITOGLOU CS, 1992, J BIOL CHEM, V267, P12404; HASEGAWA G, 1994, DIABETES RES CLIN PR, V23, P25, DOI 10.1016/0168-8227(94)90123-6; HASKILL S, 1988, J IMMUNOL, V140, P1690; HEDIN U, 1988, J CELL BIOL, V107, P307, DOI 10.1083/jcb.107.1.307; INGHER DE, 1990, J CELL BIOL, V110, P1803; IZZARD CS, 1976, J CELL SCI, V21, P129; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KIRSTEIN M, 1992, J CLIN INVEST, V90, P439, DOI 10.1172/JCI115879; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maillard LC, 1912, CR HEBD ACAD SCI, V154, P66; MCCANCE DR, 1993, J CLIN INVEST, V91, P2470, DOI 10.1172/JCI116482; MITSUHASHI T, 1993, DIABETES, V42, P826, DOI 10.2337/diabetes.42.6.826; MONNIER VM, 1981, SCIENCE, V211, P491, DOI 10.1126/science.6779377; MONNIER VM, 1990, J GERONTOL, V45, pB105, DOI 10.1093/geronj/45.4.B105; NEEPER M, 1992, J BIOL CHEM, V267, P14998; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SPORN SA, 1990, J IMMUNOL, V144, P4434; STREULI CH, 1991, J CELL BIOL, V115, P1383, DOI 10.1083/jcb.115.5.1383; TANAKA S, 1988, J BIOL CHEM, V263, P17650; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSILIBARY EC, 1988, J BIOL CHEM, V263, P4302; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; VLASSARA H, 1988, SCIENCE, V240, P1546, DOI 10.1126/science.3259727; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; YAN SD, 1994, J BIOL CHEM, V269, P9889; Zar JH, 1974, BIOSTATISTICAL ANAL; 1993, N ENG J, V329, P683	40	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	1995	270	7					3278	3283		10.1074/jbc.270.7.3278	http://dx.doi.org/10.1074/jbc.270.7.3278			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QG471	7531703	hybrid			2022-12-27	WOS:A1995QG47100059
J	CHAMPE, M; MCINTYRE, BW; BERMAN, PW				CHAMPE, M; MCINTYRE, BW; BERMAN, PW			MONOCLONAL-ANTIBODIES THAT BLOCK THE ACTIVITY OF LEUKOCYTE FUNCTION-ASSOCIATED ANTIGEN-1 RECOGNIZE 3 DISCRETE EPITOPES IN THE INSERTED DOMAIN OF CD11A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; COMPLEMENT RECEPTOR TYPE-3; CELL-ADHESION; ALPHA-SUBUNIT; VONWILLEBRAND-FACTOR; LYMPHOCYTE ADHESION; COUNTER-RECEPTOR; LFA-1; MAC-1; INTEGRINS	The epitopes recognized by eight independently isolated monoclonal antibodies to the alpha chain of human and murine leukocyte function-associated antigen 1 (LFA-1), all able to inhibit receptor function, were identified. Initial localization of epitopes was accomplished using chimeric proteins constructed by splicing fragments of cDNAs encoding the alpha subunit of LFA-1 (CD11a) and the alpha subunit of the closely related leukocyte integrin, Mac-1 (CD11b). Antibody binding to CD11a/CD11b chimeras, expressed in the 293 human kidney cell line, demonstrated that the epitopes recognized by six monoclonal antibodies to human CD11a were located in a similar to 200-amino acid sequence found in all beta(2)-integrin alpha subunits, termed the inserted (I) domain. Three distinct epitopes within the I domain (IdeA, IdeB, and IdeC) were identified using a series of mutants in which sequences from murine CD11a were substituted into human CD11a. A series of mutants incorporating single amino acid substitutions was used to identify individual amino acids essential for antibody binding. The location of these residues accounts for the binding specificity of LFA-1-blocking antibodies and identifies particular conserved sequences (residues 126-150) in the I domain of CD11a and homologous sequences in other beta(2)-integrin alpha subunits that may be important for ligand binding.	GENENTECH INC, DEPT IMMUNOL, San Francisco, CA 94080 USA; UNIV TEXAS, MD ANDERSON CANC CTR, DEPT IMMUNOL, HOUSTON, TX 77030 USA	Roche Holding; Genentech; University of Texas System; UTMD Anderson Cancer Center								ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; ALTIERI DC, 1990, J BIOL CHEM, V265, P12119; ALTIERI DC, 1988, J BIOL CHEM, V263, P7007; ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.med.38.1.175; ARNAOUT MA, 1990, BLOOD, V75, P1037; ARNAOUT MA, 1984, J CLIN INVEST, V74, P1291, DOI 10.1172/JCI111539; BERMAN PW, 1980, J BIOL CHEM, V255, P6133; BERMAN PW, 1993, J CELL BIOCHEM, V52, P183, DOI 10.1002/jcb.240520210; BILSLAND CAG, 1994, J IMMUNOL, V152, P4582; CORBI AL, 1987, EMBO J, V6, P4023, DOI 10.1002/j.1460-2075.1987.tb02746.x; CORBI AL, 1988, J BIOL CHEM, V263, P12403; DANA N, 1986, J IMMUNOL, V137, P3259; DEFOUGEROLLES AR, 1992, J EXP MED, V175, P185, DOI 10.1084/jem.175.1.185; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; DONGWORTH DW, 1985, EUR J IMMUNOL, V15, P888, DOI 10.1002/eji.1830150905; DRANSFIELD I, 1992, J CELL BIOL, V116, P1527, DOI 10.1083/jcb.116.6.1527; DUSTIN ML, 1989, COLD SPRING HARB SYM, V54, P753; DUSTIN ML, 1991, ANNU REV IMMUNOL, V9, P27, DOI 10.1146/annurev.iy.09.040191.000331; EATON DL, 1986, BIOCHEMISTRY-US, V25, P8343, DOI 10.1021/bi00374a001; FISCHER A, 1985, J CLIN INVEST, V76, P2385, DOI 10.1172/JCI112251; FISCHER A, 1986, J IMMUNOL, V136, P3198; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HILDRETH JEK, 1983, EUR J IMMUNOL, V13, P202, DOI 10.1002/eji.1830130305; HILDRETH JEK, 1985, J IMMUNOL, V134, P3272; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JOHNSTON SC, 1990, J IMMUNOL, V145, P1181; KISHIMOTO TK, 1989, ADV IMMUNOL, V46, P149, DOI 10.1016/S0065-2776(08)60653-7; KUIJPERS KC, 1990, J IMMUNOL, V144, P3281; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSON RS, 1989, J CELL BIOL, V108, P703, DOI 10.1083/jcb.108.2.703; LOLLO BA, 1993, J BIOL CHEM, V268, P21693; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; PYTELA R, 1988, EMBO J, V7, P1371, DOI 10.1002/j.1460-2075.1988.tb02953.x; RANDI AM, 1994, J BIOL CHEM, V269, P12395; ROTHLEIN R, 1986, J IMMUNOL, V137, P1270; RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X; SANCHEZMADRID F, 1982, P NATL ACAD SCI-BIOL, V79, P7489, DOI 10.1073/pnas.79.23.7489; SANCHEZMADRID F, 1982, CELL IMMUNOL, V73, P1, DOI 10.1016/0008-8749(82)90431-2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Scharf SJ, 1990, PCR PROTOCOLS GUIDE, P84; SIMMONS D, 1988, NATURE, V331, P624, DOI 10.1038/331624a0; SMITH CW, 1989, J CLIN INVEST, V83, P2008, DOI 10.1172/JCI114111; SPRINGER TA, 1984, J EXP MED, V160, P1901, DOI 10.1084/jem.160.6.1901; STANLEY P, 1994, EMBO J, V13, P1790, DOI 10.1002/j.1460-2075.1994.tb06447.x; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; STAUNTON DE, 1989, NATURE, V339, P61, DOI 10.1038/339061a0; TROWBRIDGE IS, 1981, J EXP MED, V154, P1517, DOI 10.1084/jem.154.5.1517; VANKOOYK Y, 1991, J CELL BIOL, V112, P345, DOI 10.1083/jcb.112.2.345; WAWRYK SO, 1989, IMMUNOL REV, V108, P135, DOI 10.1111/j.1600-065X.1989.tb00016.x; WRIGHT SD, 1983, P NATL ACAD SCI-BIOL, V80, P5699, DOI 10.1073/pnas.80.18.5699	55	57	112	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1388	1394		10.1074/jbc.270.3.1388	http://dx.doi.org/10.1074/jbc.270.3.1388			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7530713	hybrid			2022-12-27	WOS:A1995QB15600062
J	LIAO, JK; SHIN, WS; LEE, WY; CLARK, SL				LIAO, JK; SHIN, WS; LEE, WY; CLARK, SL			OXIDIZED LOW-DENSITY-LIPOPROTEIN DECREASES THE EXPRESSION OF ENDOTHELIAL NITRIC-OXIDE SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; RELAXING FACTOR; RABBIT AORTA; DEPENDENT RELAXATION; MESSENGER-RNA; CELLS; RECEPTOR; RELEASE; ATHEROSCLEROSIS; INTERLEUKIN-1	The atherogenic effects of low-density lipoprotein (LDL) may be mediated, in part, by its effect(s) on endothelial derived nitric oxide (NO). To determine whether LDL can modulate NO production by changing NO synthase expression, we treated human saphenous vein endothelial cells with increasing concentrations of native or oxidized LDL (0-100 mu g/ml) for various durations (0-72 h). Oxidized, but not native LDL caused a time-dependent decrease in steady state NO synthase mRNA levels. This coincided with a maximal 56% decrease in NOS activity as determined by [H-3]arginine to [SH]citrulline conversion. In the presence of actinomycin D, treatment with oxidized LDL reduced the half-life of NO synthase mRNA from 36 to 10 h, This decrease in NO synthase mRNA correlated with the degree of LDL oxidation and was attenuated by pretreatment with cycloheximide. Nuclear run-off studies showed a biphasic transcriptional pattern of NO synthase gene with an initial 25% decrease during the first 6 h followed by a maximal 2.2-fold increase over baseline during the subsequent 18 h. These results indicate that oxidized LDL regulates endothelial NOS expression through a combination of early transcriptional inhibition and post-transcriptional mRNA destabilization.	HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Harvard Medical School					NHLBI NIH HHS [HL02508] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDREWS HE, 1987, NATURE, V327, P237, DOI 10.1038/327237a0; BATH PMW, 1991, ARTERIOSCLER THROMB, V11, P254, DOI 10.1161/01.ATV.11.2.254; CHIN JH, 1992, J CLIN INVEST, V89, P10, DOI 10.1172/JCI115549; FLAVAHAN NA, 1992, CIRCULATION, V85, P1927, DOI 10.1161/01.CIR.85.5.1927; FORSTERMANN U, 1992, P NATL ACAD SCI USA, V88, P1788; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; GHIGO D, 1993, AM J PHYSIOL, V265, pC728, DOI 10.1152/ajpcell.1993.265.3.C728; Gimbrone M A Jr, 1976, Prog Hemost Thromb, V3, P1; GLOVER DM, 1988, DNA CLONING PRACTICA, V1, P49; HOGG N, 1993, FEBS LETT, V334, P170, DOI 10.1016/0014-5793(93)81706-6; INOUE N, 1992, CIRC RES, V71, P1410, DOI 10.1161/01.RES.71.6.1410; JACOBS M, 1990, BRIT J PHARMACOL, V100, P21, DOI 10.1111/j.1476-5381.1990.tb12045.x; JANSSENS SP, 1992, J BIOL CHEM, V267, P14519; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KAVANAUGH WM, 1988, J BIOL CHEM, V263, P8470; KUGIYAMA K, 1990, NATURE, V344, P160, DOI 10.1038/344160a0; LEONE AM, 1991, J BIOL CHEM, V266, P23790; LIAO JK, 1992, CIRC RES, V70, P1018, DOI 10.1161/01.RES.70.5.1018; LIAO JK, 1991, CIRC RES, V68, P1027, DOI 10.1161/01.RES.68.4.1027; LIAO JK, 1993, J CLIN INVEST, V92, P2168, DOI 10.1172/JCI116818; LIAO JK, 1993, J BIOL CHEM, V268, P19528; LIAO JK, 1994, J BIOL CHEM, V269, P12987; LIBBY P, 1986, AM J PATHOL, V124, P179; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MINOR RL, 1990, J CLIN INVEST, V86, P2109, DOI 10.1172/JCI114949; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; PARTHASARATHY S, 1990, P NATL ACAD SCI USA, V87, P9741, DOI 10.1073/pnas.87.24.9741; PLANE F, 1992, BRIT J PHARMACOL, V105, P216, DOI 10.1111/j.1476-5381.1992.tb14237.x; RADOMSKI MW, 1987, BRIT J PHARMACOL, V92, P639, DOI 10.1111/j.1476-5381.1987.tb11367.x; RASBAND W, 1993, NIH V149 IM PROGR; ROSENKRANZWEISS P, 1994, J CLIN INVEST, V93, P2236, DOI 10.1172/JCI117221; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SIMON BC, 1990, J CLIN INVEST, V86, P75, DOI 10.1172/JCI114718; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; SUNDELL CL, 1993, CIRCULATION S, V88, P473; TANNER FC, 1991, CIRCULATION, V83, P2012, DOI 10.1161/01.CIR.83.6.2012; TIPPING PG, 1993, AM J PATHOL, V142, P1721; WANG J, 1992, J BIOL CHEM, V268, P22255; YAGI K, 1976, BIOCHEM MED METAB B, V15, P212, DOI 10.1016/0006-2944(76)90049-1; YANG XC, 1994, CIRC RES, V74, P318, DOI 10.1161/01.RES.74.2.318; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271; YOSHIZUMI M, 1993, CIRC RES, V73, P205, DOI 10.1161/01.RES.73.1.205; [No title captured]	43	498	550	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					319	324		10.1074/jbc.270.1.319	http://dx.doi.org/10.1074/jbc.270.1.319			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7529227	hybrid			2022-12-27	WOS:A1995QA28700051
J	MALEK, SN; DESIDERIO, S				MALEK, SN; DESIDERIO, S			A CYCLIN-DEPENDENT KINASE HOMOLOG, P130(PITSLRE), IS A PHOSPHOTYROSINE-INDEPENDENT SH2 LIGAND	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHORYLATED PEPTIDES; MAMMALIAN PROTEIN-KINASE; HIGH-AFFINITY BINDING; SACCHAROMYCES-CEREVISIAE; CDC28 MUTATION; CELL-CYCLE; DOMAIN; GENE; ENCODES; FAMILY	Src-homology 2 (SH2) domains are conserved, globular protein modules that mediate assembly of multicomponent signaling complexes, Phosphoproteins from the B-lymphoid cell line A20 were isolated by SH2 affinity chromatography; the peptide sequence from one of these proteins was used to molecularly clone several related complementary DNAs whose predominant protein product, p130(PITSLRE), is abundant serine/threonine kinase with ubiquitous expression in murine tissues, The sequence of a previously described cyclin-dependent kinase homologue, p58(clk-1), is entirely contained within the p130(PITSLRE) sequence, Specific binding of p130(PITSLRE) to, SH2 domains is mediated by a serine- and glutamic acid-rich cluster of amino acids in the N-terminal region, This interaction is dependent on serine/threonine phosphorylation but independent of tyrosine phosphorylation, Binding is inhibited by free phosphotyrosine and by a phosphotyrosine-containing peptide from polyoma middle T antigen, suggesting that the p130(PITSLRE) binding site in the SH2 domain overlaps the region that binds phosphotyrosine containing peptides, Bacterially expressed p130(PITSLRE) fragments acquire the ability to bind an SH2 domain when phosphorylated in vitro with casein kinase II. A subset of casein kinase II phosphorylation sites may therefore constitute a phosphotyrosine-independent class of SH2 ligands.	JOHNS HOPKINS UNIV, SCH MED, DEPT MOLEC BIOL & GENET, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, HOWARD HUGHES MED INST, BALTIMORE, MD 21205 USA	Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University								BENDAVID Y, 1991, EMBO J, V10, P317, DOI 10.1002/j.1460-2075.1991.tb07952.x; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; BOOKER GW, 1992, NATURE, V358, P684, DOI 10.1038/358684a0; BUNNELL BA, 1990, P NATL ACAD SCI USA, V87, P7467, DOI 10.1073/pnas.87.19.7467; CLEGHON V, 1994, J BIOL CHEM, V269, P17749; COURCHESNE WE, 1989, CELL, V58, P1107, DOI 10.1016/0092-8674(89)90509-6; DYMECKI SM, 1992, J BIOL CHEM, V267, P4815; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; FELDER S, 1993, MOL CELL BIOL, V13, P1449, DOI 10.1128/MCB.13.3.1449; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HIRANO AA, 1988, J NEUROCHEM, V50, P1447, DOI 10.1111/j.1471-4159.1988.tb03029.x; IRIE K, 1991, CELL, V65, P785, DOI 10.1016/0092-8674(91)90386-D; JOHNSON KW, 1991, J BIOL CHEM, V266, P3402; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LEE CH, 1994, STRUCTURE, V2, P423, DOI 10.1016/S0969-2126(00)00044-7; MALEK SN, 1993, J BIOL CHEM, V268, P22557; MATSUSHIME H, 1990, MOL CELL BIOL, V10, P2261, DOI 10.1128/MCB.10.5.2261; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MORI K, 1993, CELL, V74, P743; MULLER AJ, 1992, MOL CELL BIOL, V12, P5087, DOI 10.1128/MCB.12.11.5087; NINOMIYATSUJI J, 1991, P NATL ACAD SCI USA, V88, P9006, DOI 10.1073/pnas.88.20.9006; OKUDA T, 1992, ONCOGENE, V7, P2249; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; PASCAL SM, 1994, CELL, V77, P461, DOI 10.1016/0092-8674(94)90160-0; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; XIANG JL, 1994, J BIOL CHEM, V269, P15786; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	41	37	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					33009	33020						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7528743				2022-12-27	WOS:A1994QA63800045
J	EVANS, DB; FAN, NS; SWANEY, SM; TARPLEY, WG; SHARMA, SK				EVANS, DB; FAN, NS; SWANEY, SM; TARPLEY, WG; SHARMA, SK			AN ACTIVE RECOMBINANT P15 RNASE-H DOMAIN IS FUNCTIONALLY DISTINCT FROM THE RNASE-H DOMAIN ASSOCIATED WITH HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REVERSE-TRANSCRIPTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT DNA-POLYMERASE; HIV-1 RIBONUCLEASE-H; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; ANGSTROM RESOLUTION; PRIMER BINDING; MUTAGENESIS; INHIBITION; IDENTIFICATION; PURIFICATION	An active p15 RNase H domain, consisting of amino acids 427-560 of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) and a genetically engineered penta-histidine N-terminal affinity tag, was expressed in Escherichia coli and purified to apparent homogeneity by immobilized metal affinity chromatography. The purified p15 RNase H domain exhibited no substrate preference far [H-3]poly(rG).poly(dC) compared to [H-3]poly(rA).poly(dT), in contrast with the HIV-1 RT-associated RNase H, which showed a 30-fold preference for the former substrate. Unlike the HIV-1 RT-associated RNase H, when challenged with unlabeled substrate, the recombinant p15 RNase H domain was relatively nonprocessive in RNA degradative activity of the [H-3]poly(rA).poly(dT) duplex. kinetic studies using p15 RNase H showed substrate inhibition with an apparent K-i value of 0.12 mu M for the [H-3]poly(rA).poly(dT) hybrid. Substrate inhibition was not observed for the HIV-1 RT-associated RNase H. The results show that the isolated p15 HIV-1 RNase H domain is functionally distinct from the recombinant HIV-1 RT-associated RNase H.	UPJOHN CO,UPJOHN LABS,CANC & INFECT DIS RES,KALAMAZOO,MI 49001; UPJOHN CO,UPJOHN LABS,BIOCHEM,KALAMAZOO,MI 49001	Pfizer; Pfizer					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI025696] Funding Source: NIH RePORTER; NIAID NIH HHS [U01 AI25696-7] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAVAND MR, 1993, BIOCHEMISTRY-US, V32, P10543, DOI 10.1021/bi00091a003; BOYER PL, 1992, J VIROL, V66, P1031, DOI 10.1128/JVI.66.2.1031-1039.1992; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHATTOPADHYAY D, 1993, ACTA CRYSTALLOGR D, V49, P423, DOI 10.1107/S0907444993002409; CHATTOPADHYAY D, 1992, J BIOL CHEM, V267, P14227; CIRINO NM, 1993, J BIOL CHEM, V268, P14743; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; EVANS DB, 1991, J BIOL CHEM, V266, P20583; EVANS DB, 1993, BIOTECHNOL APPL BIOC, V17, P91; GOFF SP, 1990, J ACQ IMMUN DEF SYND, V3, P817; HAFKEMEYER P, 1991, NUCLEIC ACIDS RES, V19, P4059, DOI 10.1093/nar/19.15.4059; HANSEN J, 1988, EMBO J, V7, P239, DOI 10.1002/j.1460-2075.1988.tb02805.x; HANSEN J, 1987, J BIOL CHEM, V262, P12393; HIZI A, 1989, VIROLOGY, V170, P326, DOI 10.1016/0042-6822(89)90389-9; HIZI A, 1990, VIROLOGY, V175, P575, DOI 10.1016/0042-6822(90)90444-V; HIZI A, 1988, P NATL ACAD SCI USA, V85, P1218, DOI 10.1073/pnas.85.4.1218; HIZI A, 1988, P NATL ACAD SCI USA, V267, P18255; HOSTOMSKY Z, 1991, P NATL ACAD SCI USA, V88, P1148, DOI 10.1073/pnas.88.4.1148; HOSTOMSKY Z, 1992, J VIROL, V66, P1218; HUGHES S H, 1991, Current Biology, V1, P323, DOI 10.1016/0960-9822(91)90100-B; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JOHNSON MS, 1986, P NATL ACAD SCI USA, V83, P7648, DOI 10.1073/pnas.83.20.7648; KANAYA S, 1990, J BIOL CHEM, V265, P4615; KATAYANAGI K, 1992, J MOL BIOL, V223, P1029, DOI 10.1016/0022-2836(92)90260-Q; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KRUG MS, 1991, BIOCHEMISTRY-US, V30, P10614, DOI 10.1021/bi00108a003; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOYA S, 1992, J BIOL CHEM, V267, P13879; LOYA SS, 1993, J BIOL CHEM, V268, P9323; MOELLING K, 1989, J VIROL, V63, P5489, DOI 10.1128/JVI.63.12.5489-5491.1989; PRASAD VR, 1989, P NATL ACAD SCI USA, V86, P3104, DOI 10.1073/pnas.86.9.3104; RESTLE T, 1990, J BIOL CHEM, V265, P8986; SCHATZ O, 1990, GENE REGULATION AIDS; SMITH JS, 1993, J VIROL, V67, P4037, DOI 10.1128/JVI.67.7.4037-4049.1993; SOBOL RW, 1991, BIOCHEMISTRY-US, V30, P10623, DOI 10.1021/bi00108a004; STARNES MC, 1989, J BIOL CHEM, V264, P7073; SZILVAY AM, 1993, ARCH VIROL, V131, P393, DOI 10.1007/BF01378640; TAN CK, 1991, BIOCHEMISTRY-US, V30, P4831, DOI 10.1021/bi00234a001; TAN CK, 1991, BIOCHEMISTRY-US, V30, P2651, DOI 10.1021/bi00224a013	39	10	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 26	1994	269	34					21741	21747						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PK973	7520442				2022-12-27	WOS:A1994PK97300055
J	CARDARELLI, PM; COBB, RR; NOWLIN, DM; SCHOLZ, W; GORCSAN, F; MOSCINSKI, M; YASUHARA, M; CHIANG, SL; LOBL, TJ				CARDARELLI, PM; COBB, RR; NOWLIN, DM; SCHOLZ, W; GORCSAN, F; MOSCINSKI, M; YASUHARA, M; CHIANG, SL; LOBL, TJ			CYCLIC RGD PEPTIDE INHIBITS ALPHA-4-BETA-1 INTERACTION WITH CONNECTING SEGMENT-1 AND VASCULAR CELL-ADHESION MOLECULE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARG-GLY-ASP; INTEGRIN VLA-4; MONOCLONAL-ANTIBODY; LATE ANTIGEN-4; T-CELLS; ALPHA-5-BETA-1 INTEGRIN; DROSOPHILA-MELANOGASTER; ANTI-ALPHA-4 INTEGRIN; SURFACE GLYCOPROTEIN; FIBRONECTIN RECEPTOR	The integrin supergene family includes receptors for a variety of extracellular matrix as well as cell surface proteins. Integrin alpha 4 has been shown to play an important role in leukocyte adhesion and extravasation during immune and inflammatory reactions. One recognition sequence known to interact with alpha 4 is the Leu-Asp-Val (LDV) site contained in the connecting segment 1 region of fibronectin. Here we present evidence that shows that a conformationally restricted RGD-containing peptide is a potent inhibitor of cell adhesion mediated by alpha 4 beta 1, a receptor not convincingly documented to interact with RGD peptides. This peptide, 1-adamantaneacetyl-Cys- Gly-Arg-Gly-Asp-Ser-Pro-Cys (disulfide bridge between residues 1-8), blocks Jurkat cell adhesion to connecting segment 1-containing peptides as well as cell adhesion to cytokine activated endothelial cells. Adhesion of Jurkat cells to either vascular cell adhesion molecule-expressing cells or recombinant vascular cell adhesion molecule-coated plates was likewise inhibited by this peptide. Furthermore, alpha 4 beta 1 can bind directly to a cyclic RGD peptide immobilized to Sepharose. Integrins, alpha 5 beta 1, alpha v beta 3, alpha IIb/beta IIIa, alpha 2 beta 1, alpha v beta 5, alpha v beta 6, and alpha 3 beta 1, have been shown to recognize the Arg-Gly-Asp (RGD) sequence present in a variety of extracellular matrix proteins, and our data support the addition of alpha 4 beta 1 to this group. Further studies using molecular modeling of such cyclic RGD peptides could help in the design of more potent peptides or nonpeptide mimetics that could effectively block alpha 4-mediated activity and have potential application in a number of inflammatory diseases.	TANABE SEIYAKU CO LTD,TOKYO,JAPAN	Mitsubishi Tanabe Pharma Corporation	CARDARELLI, PM (corresponding author), TANABE RES LABS,4540 TOWNE CTR CT,SAN DIEGO,CA 92121, USA.							AGER A, 1990, INT IMMUNOL, V2, P921, DOI 10.1093/intimm/2.10.921; BARON JL, 1993, J EXP MED, V177, P57, DOI 10.1084/jem.177.1.57; BELL RG, 1993, J IMMUNOL, V151, P4790; BEVILACQUA MP, 1985, J CLIN INVEST, V76, P2003, DOI 10.1172/JCI112200; BOCHNER BS, 1991, J EXP MED, V173, P1553, DOI 10.1084/jem.173.6.1553; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; BUSK M, 1992, J BIOL CHEM, V267, P5790; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CARDARELLI PM, 1992, J BIOL CHEM, V267, P23159; CARDARELLI PM, 1986, P NATL ACAD SCI USA, V83, P2647, DOI 10.1073/pnas.83.8.2647; CHERESH DA, 1989, CELL, V57, P59, DOI 10.1016/0092-8674(89)90172-4; CHISHOLM PL, 1993, EUR J IMMUNOL, V23, P682, DOI 10.1002/eji.1830230317; CYBULSKY MI, 1991, SCIENCE, V251, P788, DOI 10.1126/science.1990440; DSOUZA SE, 1991, TRENDS BIOCHEM SCI, V16, P246, DOI 10.1016/0968-0004(91)90096-E; ELICES MJ, 1994, J CLIN INVEST, V93, P405, DOI 10.1172/JCI116975; ELICES MJ, 1991, J CELL BIOL, V112, P169, DOI 10.1083/jcb.112.1.169; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; FERGUSON TA, 1993, J IMMUNOL, V150, P1172; FERGUSON TA, 1991, P NATL ACAD SCI USA, V88, P8072, DOI 10.1073/pnas.88.18.8072; Gimbrone M A Jr, 1976, Prog Hemost Thromb, V3, P1; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; HARLAN JM, 1985, BLOOD, V65, P513; HAYMAN EG, 1985, J CELL BIOL, V100, P1948, DOI 10.1083/jcb.100.6.1948; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HESSION C, 1991, J BIOL CHEM, V266, P6682; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; ISSEKUTZ TB, 1991, J IMMUNOL, V147, P4178; JOKERST RS, 1989, MOL GEN GENET, V215, P266, DOI 10.1007/BF00339727; KOIVUNEN E, 1993, J BIOL CHEM, V268, P20205; KOMORIYA A, 1991, J BIOL CHEM, V266, P15075; LAFFON A, 1991, J CLIN INVEST, V88, P546, DOI 10.1172/JCI115338; MASUMOTO A, 1993, J CELL BIOL, V123, P245, DOI 10.1083/jcb.123.1.245; MORALESDUCRET J, 1992, J IMMUNOL, V149, P1424; NOWLIN DM, 1993, J BIOL CHEM, V268, P20352; OSBORN L, 1990, CELL, V62, P3, DOI 10.1016/0092-8674(90)90230-C; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; PIERSCHBACHER M, 1983, P NATL ACAD SCI-BIOL, V80, P1224, DOI 10.1073/pnas.80.5.1224; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; PLOW EF, 1985, P NATL ACAD SCI USA, V82, P8057, DOI 10.1073/pnas.82.23.8057; PODOLSKY DK, 1993, J CLIN INVEST, V92, P372, DOI 10.1172/JCI116575; PYTELA R, 1985, P NATL ACAD SCI USA, V82, P5766, DOI 10.1073/pnas.82.17.5766; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; ROSEN GD, 1992, CELL, V69, P1107, DOI 10.1016/0092-8674(92)90633-N; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SHIMIZU Y, 1990, IMMUNOL REV, V114, P109, DOI 10.1111/j.1600-065X.1990.tb00563.x; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STEWART JM, 1984, SOLID PHASE PEPTIDE, P53; SZEKANECZ Z, 1992, J CELL SCI, V101, P885; VOGEL BE, 1990, J BIOL CHEM, V265, P5934; VONDERHEIDE RH, 1992, J EXP MED, V175, P1433, DOI 10.1084/jem.175.6.1433; VONKAMBER B, 1971, HELV CHIM ACTA, V94, P927; WALSH GM, 1991, J IMMUNOL, V146, P3419; WAYNER EA, 1992, J CELL BIOL, V116, P489, DOI 10.1083/jcb.116.2.489; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873; WEG VB, 1993, J EXP MED, V177, P561, DOI 10.1084/jem.177.2.561; WRIGHT SD, 1987, P NATL ACAD SCI USA, V84, P1965, DOI 10.1073/pnas.84.7.1965; YANG XD, 1993, P NATL ACAD SCI USA, V90, P10494, DOI 10.1073/pnas.90.22.10494; YEDNOCK TA, 1992, NATURE, V356, P63, DOI 10.1038/356063a0	62	56	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18668	18673						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	7518441				2022-12-27	WOS:A1994NW79800069
J	SUZUKI, H; PRADO, GN; WILKINSON, N; NAVARRO, J				SUZUKI, H; PRADO, GN; WILKINSON, N; NAVARRO, J			THE N-TERMINUS OF INTERLEUKIN-8 (IL-8) RECEPTOR CONFERS HIGH-AFFINITY FINDING TO HUMAN IL-8	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							AMINO TERMINUS; BINDING; NEUTROPHILS; RESIDUES; CLONING	Interleukin-8 (IL-8) is a potent inflammatory mediator that belongs to the family of C-X-C chemokines. IL-8 promotes the activation and the extravasation of circulating neutrophils to the site of inflammation. Two IL-8 receptor isotypes (type A and B) are identified in human and rabbit neutrophils. IL-8 receptors belongs to the superfamiIy of G-protein-coupled receptors. Both receptor subtypes A and B bind with high affinity to human IL-8, but they exhibit distinct binding affinity to two functional and structurally related IL-8 peptides, melanoma growth-stimulating activity peptide (MGSA) and neutrophil-activating peptide-2 (NAP-2). Human IL-8 receptor A binds with low affinity to MGSA or NAP-2. In contrast, human IL-8 receptor B binds MGSA with high affinity, and NAP-2 with lesser affinity. Using receptor subtype chimeras, we determined that the N-terminal domain of the receptor confers ligand binding specificity (LaRosa, G. J., Thomas, K. M., Kaufmann, M. E., Mark, R., White, M., Taylor, L., Gray, G., Witt, D., and Navarro, J. (1992) J. Biol. Chem. 267, 25402-25406). In this work, we characterized by molecular cloning and expression a mouse receptor structurally homologous to the IL-8 receptor. We isolated a clone by screening a mouse genomic library with a rabbit IL-8 receptor A cDNA fragment as a probe. The mouse clone exhibited an open reading frame encoding a 359-amino acid protein. Hydropathy plot analysis of the amino acid sequence reveals seven transmembrane domains characteristic of G-protein-coupled receptors. The N terminus and the second extracellular loop contain one and two putative N-glycosylation sites, respectively. The intracellular C-terminal tail contains Ser and Thr residues as potential phosphorylation sites. Northern blot analysis showed that the mouse receptor gene is expressed in mouse neutrophils. The mouse receptor shows 65, 74, 66, and 70% amino acid identity to the rabbit IL 8 receptor subtypes A and B and human IL-8 receptor subtypes A and B, respectively. However, neither mouse neutrophils nor CHO cells expressing the mouse receptor bind human IL-8 in the nanomolar range. To identify the domain(s) conferring high affinity binding to IL-8, we constructed rabbit/mouse receptor chimeras. A rabbit/mouse receptor chimera, in which the N terminus of the mouse receptor is replaced by the N terminus of the rabbit IL-8 receptor A, exhibited high affinity binding to human IL 8, as well as a pharmacological profile corresponding to the rabbit IL 8 receptor A. These data indicate that the N terminus of the IL-8 receptor plays a dual role, one in conferring high affinity to human IL-8 and another in determining the ligand binding specificity, This study also suggests the existence of a mouse IL-8 with distinct molecular determinants to the human IL-8, which could confer high affinity binding to the mouse IL-8 receptor.	UNIV TEXAS,SEALY CTR MOLEC SCI,MED BRANCH,DEPT PHYSIOL & BIOPHYS,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston				Navarro, Javier/0000-0001-7098-4373	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039602] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR 39602] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; CLARKLEWIS I, 1993, P NATL ACAD SCI USA, V90, P3574, DOI 10.1073/pnas.90.8.3574; GAYLE RB, 1993, J BIOL CHEM, V268, P7283; HEBERT CA, 1993, J BIOL CHEM, V268, P18549; HEBERT CA, 1991, J BIOL CHEM, V266, P18989; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; LAROSA GJ, 1992, J BIOL CHEM, V267, P25402; MOLDAY RS, 1983, BIOCHEMISTRY-US, V22, P55; MULLIGAN MS, 1993, J IMMUNOL, V150, P5585; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PRADO GN, 1994, J BIOL CHEM, V269, P12391; ROT A, 1991, CYTOKINE, V3, P21, DOI 10.1016/1043-4666(91)90006-Y; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; THOMAS KM, 1991, J BIOL CHEM, V266, P14839; THOMAS KM, 1990, J BIOL CHEM, V265, P20061	17	37	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18263	18266						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	7518426				2022-12-27	WOS:A1994NW79800002
J	CIACCIO, PJ; JAISWAL, AK; TEW, KD				CIACCIO, PJ; JAISWAL, AK; TEW, KD			REGULATION OF HUMAN DIHYDRODIOL DEHYDROGENASE BY MICHAEL ACCEPTOR XENOBIOTICS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YA-SUBUNIT GENE; ANTIOXIDANT RESPONSE ELEMENT; GLUTATHIONE S-TRANSFERASES; PROSTAGLANDIN-F SYNTHASE; RAT-LIVER CYTOSOL; INDUCIBLE EXPRESSION; ETHACRYNIC-ACID; 3-ALPHA-HYDROXYSTEROID DEHYDROGENASE; BOVINE LUNG; IDENTIFICATION	A human oxidoreductase (H-37) that is overexpressed in ethacrynic acid-resistant HT29 colon cells (Ciaccio, P. J., Stuart, J. E., and Tew, K. D. (1993) Mol. Pharmacol. 43, 845-853) has been identified as a dihydrodiol dehydro genase. Translated protein from a dihydrodiol dehydrogenase cDNA isolated from a library prepared from ethacrynic acid-resistant HT29 cell poly(A(+)) RNA was recognized by anti-H-37 IgG and was identical in molecular weight with H-37. The isolated cDNA was identical in both nucleotide and amino acid sequences with the recently cloned liver dihydrodiol dehydrogenase (Stolz, A, Hammond, L., Lou, H., Takikawa, H., Ronk, M., and Shivery, J. E. (1993) J. Biol. Chem. 268, 10448-10457). Using this cDNA as probe, we have examined its induction by Michael accepters. The steady state dihydrodiol dehydrogenase mRNA level in the ethacrynic acid-resistant line was increased 30-fold relative to that of wildtype cells. Twenty-four hour treatment of wild-type cells with ethacrynic acid or dimethyl maleate increased mRNA 10-fold and 5-fold, respectively. These changes are accompanied by both increased protein expression and increased NADP-dependent 1-acenaphthenol oxidative activity in cell cytosol. In gel shift assays, compared to wild type controls, increased binding of NAD(P)H quinone oxidoreductase human antioxidant response element (hARE) DNA to redox labile protein complexes present in treated and resistant cell nuclear extract was observed. Ethacrynic acid induced CAT activity 2-fold in Hepa1 cells stably transfected with NAD(P)H quinone oxidoreductase hARE-tk-CAT chimeric gene construct. Thus, dihydrodiol dehydrogenase protein is inducible by de novo synthesis from mRNA by structurally related monofunctional inducer Michael accepters. Altered in vitro binding of nuclear protein to the hARE is indirect evidence for the involvement of an element similar to hARE in the regulation of dihydrodiol dehydrogenase by these agents.			CIACCIO, PJ (corresponding author), FOX CHASE CANC CTR,DEPT PHARMACOL,7701 BURHOLME AVE,PHILADELPHIA,PA 19111, USA.				NCI NIH HHS [R35 CA53893] Funding Source: Medline; NCRR NIH HHS [RR05539] Funding Source: Medline; NIGMS NIH HHS [GM47466] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA053893] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM047466, R01GM047466] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; BELINSKY M, 1993, CANCER METAST REV, V12, P103, DOI 10.1007/BF00689804; BENSON AM, 1978, CANCER RES, V38, P4486; CABRAL JRP, 1983, CANCER LETT, V19, P125, DOI 10.1016/0304-3835(83)90146-5; CIACCIO PJ, 1991, BIOCHEM PHARMACOL, V42, P1504, DOI 10.1016/0006-2952(91)90468-K; CIACCIO PJ, 1993, MOL PHARMACOL, V43, P845; CLAPPER ML, 1990, CELL PHARM, V1, P7; DAVIES LG, 1980, BASIC METHODS MOL BI, P244; DIXON KH, 1989, BIOCHEM BIOPH RES CO, V163, P815, DOI 10.1016/0006-291X(89)92295-X; FLOWERSGEARY L, 1993, CHEM RES TOXICOL, V6, P252, DOI 10.1021/tx00033a002; FRILING RS, 1990, P NATL ACAD SCI USA, V87, P6258, DOI 10.1073/pnas.87.16.6258; GLATT HR, 1979, NATURE, V277, P319, DOI 10.1038/277319a0; GODWIN AK, 1992, P NATL ACAD SCI USA, V89, P3070, DOI 10.1073/pnas.89.7.3070; GRAVES PE, 1990, ARCH BIOCHEM BIOPHYS, V281, P106, DOI 10.1016/0003-9861(90)90419-Y; HARA A, 1990, J BIOCHEM-TOKYO, V108, P250, DOI 10.1093/oxfordjournals.jbchem.a123189; HAYES JD, 1993, CANCER RES, V53, P3887; JAISWAL AK, 1991, BIOCHEMISTRY-US, V30, P10647, DOI 10.1021/bi00108a007; KUZMICH S, 1992, BIOCHEM J, V281, P219, DOI 10.1042/bj2810219; LI Y, 1992, J BIOL CHEM, V267, P15097; LI Y, 1992, BIOCHEM BIOPH RES CO, V188, P992, DOI 10.1016/0006-291X(92)91329-O; LOTLIKAR PD, 1984, CARCINOGENESIS, V5, P269, DOI 10.1093/carcin/5.2.269; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; PAWLOWSKI JE, 1991, J BIOL CHEM, V266, P8820; PENNING TM, 1986, STEROIDS, V47, P221; PENNING TM, 1984, BIOCHEM J, V222, P601, DOI 10.1042/bj2220601; PENNING TM, 1990, CARCINOGENESIS, V11, P1203, DOI 10.1093/carcin/11.7.1203; PENNING TM, 1992, BIOCHEM PHARMACOL, V43, P1148, DOI 10.1016/0006-2952(92)90625-S; PENNING TM, 1993, CHEM-BIOL INTERACT, V89, P1, DOI 10.1016/0009-2797(93)03203-7; PRESTERA T, 1993, P NATL ACAD SCI USA, V90, P2965, DOI 10.1073/pnas.90.7.2965; PROCHASKA HJ, 1985, P NATL ACAD SCI USA, V82, P8232, DOI 10.1073/pnas.82.23.8232; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; RUSHMORE TH, 1990, P NATL ACAD SCI USA, V87, P3826, DOI 10.1073/pnas.87.10.3826; SAKAI M, 1988, P NATL ACAD SCI USA, V85, P9456, DOI 10.1073/pnas.85.24.9456; SCHISSELBAUER JC, 1992, PHARMACOGENETICS, V2, P63, DOI 10.1097/00008571-199204000-00003; SMITHGALL TE, 1986, J BIOL CHEM, V261, P6184; SPENCER SR, 1991, BIOCHEM J, V273, P711, DOI 10.1042/bj2730711; STOLZ A, 1993, J BIOL CHEM, V268, P10448; STOLZ A, 1989, ANNU REV PHYSIOL, V51, P161, DOI 10.1146/annurev.ph.51.030189.001113; TALALAY P, 1988, P NATL ACAD SCI USA, V85, P8261, DOI 10.1073/pnas.85.21.8261; TELAKOWSKIHOPKINS CA, 1988, P NATL ACAD SCI USA, V85, P1000, DOI 10.1073/pnas.85.4.1000; WATANABE K, 1985, J BIOL CHEM, V260, P7035; WATANABE K, 1988, P NATL ACAD SCI USA, V85, P11, DOI 10.1073/pnas.85.1.11; WILLIAMS GM, 1986, CARCINOGENESIS, V7, P1043, DOI 10.1093/carcin/7.7.1043; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x	44	60	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15558	15562						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	7515059				2022-12-27	WOS:A1994NP51300028
J	CAZALS, V; MOUHIEDDINE, B; MAITRE, B; LEBOUC, Y; CHADELAT, K; BRODY, JS; CLEMENT, A				CAZALS, V; MOUHIEDDINE, B; MAITRE, B; LEBOUC, Y; CHADELAT, K; BRODY, JS; CLEMENT, A			INSULIN-LIKE GROWTH-FACTORS, THEIR BINDING-PROTEINS, AND TRANSFORMING GROWTH-FACTOR-BETA-1 IN OXIDANT-ARRESTED LUNG ALVEOLAR EPITHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLIFERATION-RELATED GENES; PULMONARY OXYGEN-TOXICITY; POSTTRANSCRIPTIONAL REGULATION; HUMAN FIBROBLASTS; DNA DAMAGE; FACTOR-II; EXPRESSION; PHOSPHORYLATION; INHIBITION; ACTIVATION	The epithelium of the pulmonary alveolus is a major target for oxidant injury, and its proper repair following injury is dependent on the proliferative response of its stem cells, the type 2 cells. We have recently shown that hyperoxia arrests proliferation of an immortalized type 2 cell line (SV40T-T2) and that expression of several growth-related genes, normally induced near the G(1)/S and boundary was altered with a block of translation of their mRNA. In the present study we examined the possible role of the insulin-like growth factor (IGF) system and of transforming growth factor-beta 1 (TGF-beta 1) in the arrest of proliferation induced by hyperoxia. We show that IGF-binding protein 2 (IGFBP-2) accumulates to higher levels in culture medium of SV40T-T2 cells whose proliferation has been arrested by hyperoxia. This proliferation arrest is associated with increased expression of IGFBP-2 mRNA and with induction of type 2 IGF receptor and IGF-II mRNAs. When O-2-arrested cells were allowed to resume proliferation in normoxia, the level of expression of these genes rapidly decreased to control levels. We also, found that TGF-beta 1 was induced by O-2 exposure, that TGF-beta 1 inhibited SV40T-T2 proliferation, and that TGF-beta 1 itself was a potent stimulator of IGFBP-2 expression. These studies suggest a regulatory link between components of the IGF system and TGF-beta 1 in hyperoxic control of cell proliferation of alveolar epithelial cells.	UNIV PARIS, HOP TROUSSEAU, ST ANTOINE MED SCH, DEPT PHYSIOL, F-75012 PARIS, FRANCE; BOSTON UNIV, SCH MED, CTR PULM, BOSTON, MA 02118 USA; BOSTON UNIV, SCH MED, DEPT MED, BOSTON, MA 02118 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Armand-Trousseau - APHP; UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Boston University; Boston University				Maitre, Bernard/0000-0002-8061-1252; Brody, Jerome/0000-0002-2824-802X	NHLBI NIH HHS [P01-HL47049] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL047049] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMSON IYR, 1974, LAB INVEST, V30, P35; BABAJKO S, 1993, ENDOCRINOLOGY, V132, P2586, DOI 10.1210/en.132.6.2586; BARBU V, 1989, NUCLEIC ACIDS RES, V17, P7115, DOI 10.1093/nar/17.17.7115; CERUTTI PA, 1991, EUR J CLIN INVEST, V21, P1, DOI 10.1111/j.1365-2362.1991.tb01350.x; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; CHING G, 1988, P NATL ACAD SCI USA, V85, P151, DOI 10.1073/pnas.85.1.151; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLEMENT A, 1991, EXP CELL RES, V196, P198, DOI 10.1016/0014-4827(91)90251-O; CLEMENT A, 1990, P NATL ACAD SCI USA, V87, P318, DOI 10.1073/pnas.87.1.318; CLEMENT A, 1992, J CLIN INVEST, V90, P1812, DOI 10.1172/JCI116056; CLEMMONS DR, 1992, GROWTH REGULAT, V2, P80; CRAPO JD, 1986, ANNU REV PHYSIOL, V48, P721; DAVENPORT ML, 1988, EXP LUNG RES, V14, P607, DOI 10.3109/01902148809087832; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; DERCOLE AJ, 1987, J DEV PHYSIOL, V9, P481; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FURUKAWA Y, 1992, J BIOL CHEM, V267, P17121; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; GOLDSTEIN S, 1991, P NATL ACAD SCI USA, V88, P9680, DOI 10.1073/pnas.88.21.9680; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HAN VKM, 1988, J CLIN ENDOCR METAB, V66, P422, DOI 10.1210/jcem-66-2-422; HARRIS JB, 1991, AM J RESP CELL MOL, V4, P115, DOI 10.1165/ajrcmb/4.2.115; HILL DJ, 1989, J MOL ENDOCRINOL, V2, P31, DOI 10.1677/jme.0.0020031; HOENJE H, 1989, MUTAT RES, V219, P193; HOWE PH, 1991, MOL CELL BIOL, V11, P1185, DOI 10.1128/MCB.11.3.1185; HUMBEL RE, 1990, EUR J BIOCHEM, V190, P445, DOI 10.1111/j.1432-1033.1990.tb15595.x; IMLAY JA, 1988, SCIENCE, V240, P1302, DOI 10.1126/science.3287616; INAGAKI M, 1993, P NATL ACAD SCI USA, V90, P5359, DOI 10.1073/pnas.90.11.5359; JACKSON RM, 1985, CHEST, V88, P900, DOI 10.1378/chest.88.6.900; JACOBS T, 1992, DEV BIOL, V153, P1, DOI 10.1016/0012-1606(92)90087-W; JONES JI, 1993, P NATL ACAD SCI USA, V90, P10553, DOI 10.1073/pnas.90.22.10553; KAPANCI Y, 1969, LAB INVEST, V20, P101; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTIN JL, 1992, ENDOCRINOLOGY, V131, P1703, DOI 10.1210/en.131.4.1703; MATSUMOTO K, 1990, J CELL PHYSIOL, V145, P95, DOI 10.1002/jcp.1041450114; MILLER BE, 1990, ENVIRON HEALTH PERSP, V85, P15, DOI 10.2307/3430661; NEELY EK, 1991, ACTA PAEDIATR SCAND, P116; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARK JHY, 1992, ENDOCRINOLOGY, V131, P1359, DOI 10.1210/en.131.3.1359; PRICE WA, 1993, AM J RESP CELL MOL, V8, P425, DOI 10.1165/ajrcmb/8.4.425; RAPPOLEE DA, 1989, J CELL BIOCHEM, V39, P1, DOI 10.1002/jcb.240390102; RECHLER MM, 1992, GROWTH REGULAT, V2, P55; Rotwein P, 1991, Growth Factors, V5, P3, DOI 10.3109/08977199109000267; RUTANEN EM, 1990, ACTA ENDOCRINOL-COP, V123, P7, DOI 10.1530/acta.0.1230007; SPORN MB, 1992, J CELL BIOL, V119, P1017, DOI 10.1083/jcb.119.5.1017; STILES AD, 1990, AM J RESP CELL MOL, V3, P93, DOI 10.1165/ajrcmb/3.2.93; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; THET LA, 1986, EXP LUNG RES, V11, P209, DOI 10.3109/01902148609064297; UEDA K, 1985, ANNU REV BIOCHEM, V54, P73, DOI 10.1146/annurev.biochem.54.1.73; VUILLAUME M, 1987, MUTAT RES, V186, P43, DOI 10.1016/0165-1110(87)90014-5	55	55	58	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14111	14117						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	7514600				2022-12-27	WOS:A1994NL60600059
J	WENG, WK; JARVIS, L; LEBIEN, TW				WENG, WK; JARVIS, L; LEBIEN, TW			SIGNALING THROUGH CD19 ACTIVATES VAV MITOGEN-ACTIVATED PROTEIN-KINASE PATHWAY AND INDUCES FORMATION OF A CD19/VAV/PHOSPHATIDYLINOSITOL 3-KINASE COMPLEX IN HUMAN B-CELL PRECURSORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTES-B; VAV PROTOONCOGENE; PRE-B; MONOCLONAL-ANTIBODY; TYROSINE; ANTIGEN; EXPRESSION; RECEPTOR; DIFFERENTIATION; PROLIFERATION	The B cell-specific cell surface molecule CD19 plays a role in regulating immunoglobulin (Ig) receptor signaling, and cross-linking CD19 activates several signaling molecules in mature human B cells. In surface Ig-negative B cell precursors, a protein tyrosine kinase (PTK)-dependent homotypic aggregation response can be triggered by cross-linking CD19. In the current study, we examined the outcome of PTK-mediated signal transduction following CD19 cross-linking on surface Ig negative and surface Ig positive B cell lines, as well as freshly isolated surface Ig-negative B cell precursors. PIE activation resulted in the tyrosine phosphorylation of multiple protein substrates and peaked at 0.5-1 min following CD19 cross-linking in all B-lineage cells examined. One of the tyrosine-phosphorylated substrates was identified as the hematopoietic-specific protein Vav, a guanine nucleotide exchange factor that activates the Pas pathway. Evidence consistent with Pas pathway activation was also demonstrated by MEK activation and subsequent phosphorylation of a MAP kinase fusion protein. CD19 cross-linking, sequential immunoprecipitation, and Western blotting revealed that: (a) Vav becomes associated with CD19, (b) phosphatidylinositol 3-kinase (PI 3-kinase) becomes associated with CD19, and (c) PI 3-kinase becomes associated with Vav. No such physical interaction occurred following control IgG1 cross-linking or cross-linking of class I major histocompatability complex cell surface molecules. Coupled with a previous report (Tuveson, D. A, Carter, and H., Soltoff, S. P., and Fearon, D. T. (1993) Science 260, 986-988), our data support a model in which CD19 crosslinking induces the formation of a signaling complex that leads to the activation of two pathways involving Pas and PI 3-kinase.	UNIV MINNESOTA, SCH MED, DEPT PATHOL & LAB MED, MINNEAPOLIS, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities				LeBien, Tucker/0000-0001-5011-2199	NCI NIH HHS [R01 CA-31685] Funding Source: Medline; NIAID NIH HHS [T32 AI-07313] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA031685] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007313] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALESSANDRINI A, 1992, P NATL ACAD SCI USA, V89, P8200, DOI 10.1073/pnas.89.17.8200; BARRETT TB, 1990, EUR J IMMUNOL, V20, P1053, DOI 10.1002/eji.1830200516; BRADBURY LE, 1992, J IMMUNOL, V149, P2841; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; CALLARD RE, 1992, J IMMUNOL, V148, P2983; CARTER RH, 1992, SCIENCE, V256, P105, DOI 10.1126/science.1373518; CHALUPNY NJ, 1993, EMBO J, V12, P2691, DOI 10.1002/j.1460-2075.1993.tb05930.x; CHAREST DL, 1993, MOL CELL BIOL, V13, P4679, DOI 10.1128/MCB.13.8.4679; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; DERIE MA, 1989, CELL IMMUNOL, V118, P368, DOI 10.1016/0008-8749(89)90385-7; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; GODING JW, 1986, MONOCLONAL ANTIBODIE, P260; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; GULBINS E, 1994, J IMMUNOL, V152, P2123; HEBELL T, 1991, SCIENCE, V254, P102, DOI 10.1126/science.1718035; KANSAS GS, 1991, J IMMUNOL, V147, P4094; KARNITZ LM, 1994, J EXP MED, V179, P1799, DOI 10.1084/jem.179.6.1799; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; LASSOUED K, 1993, CELL, V73, P73, DOI 10.1016/0092-8674(93)90161-I; LAW CL, 1994, J BIOL CHEM, V269, P12310; LAZARUS AH, 1993, J EXP MED, V178, P1765, DOI 10.1084/jem.178.5.1765; LEBIEN TW, 1990, LEUKEMIA, V4, P354; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; MATSUMOTO AK, 1991, J EXP MED, V173, P55, DOI 10.1084/jem.173.1.55; MATSUMOTO AK, 1993, J EXP MED, V178, P1407, DOI 10.1084/jem.178.4.1407; NADLER LM, 1983, J IMMUNOL, V131, P244; PEZZUTTO A, 1987, J IMMUNOL, V138, P2793; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; REN CL, 1994, J EXP MED, V179, P673, DOI 10.1084/jem.179.2.673; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TEDDER TF, 1989, J IMMUNOL, V143, P712; TUVESON DA, 1993, SCIENCE, V260, P986, DOI 10.1126/science.7684160; UCKUN FM, 1988, P NATL ACAD SCI USA, V85, P8603, DOI 10.1073/pnas.85.22.8603; UCKUN FM, 1988, BLOOD, V71, P13; UCKUN FM, 1993, J BIOL CHEM, V268, P21172; VANNOESEL CJM, 1993, IMMUNOL TODAY, V14, P8, DOI 10.1016/0167-5699(93)90316-D; VANNOESEL CJM, 1993, INT IMMUNOL, V5, P699; WOLF ML, 1991, J IMMUNOL, V147, P3324; WOLF ML, 1993, J IMMUNOL, V151, P138; WORMANN B, 1989, J IMMUNOL, V142, P110; ZHOU LJ, 1991, J IMMUNOL, V147, P1424; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	47	144	145	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32514	32521						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7528218				2022-12-27	WOS:A1994PX30400074
J	HUANG, Y; RANE, SG				HUANG, Y; RANE, SG			POTASSIUM CHANNEL INDUCTION BY THE RAS/RAF SIGNAL-TRANSDUCTION CASCADE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAF-1 PROTEIN-KINASE; H-RAS ONCOGENE; GROWTH-FACTOR; TRANSCRIPTION FACTOR; SINGLE-CHANNEL; K+ CHANNELS; CELL-LINE; ACTIVATION; TRANSFORMATION; CONDUCTANCE	p21(ras) plays a critical role in cell growth, differentiation, and oncogenic transformation. However, the final physiological effecters of p21(ras)-mediated signal transduction remain to be determined. We have used patch clamp electrophysiology, pharmacological agents, and transfection with specific Ras or Raf plasmids, to demonstrate that induction of a unique Ca2+-activated K+ channel in murine fibroblast cell lines depends on p21(ras) and its immediate downstream target, the Raf kinase. The importance of this channel in mitogenic signaling is further indicated by its induction in nontransformed cells by epidermal growth factor and platelet-derived growth factor and the ability of K+ channel blockers to inhibit cell proliferation. We suggest that this Ca2+-activated K+ channel is one ultimate physiological target of p21(ras)-mediated signal transduction and that it may play a role in cell proliferation and ras transformation.	PURDUE UNIV,DEPT BIOL SCI,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus					NIGMS NIH HHS [R01GM43462] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043462] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AELST LV, 1993, P NATL ACAD SCI USA, V90, P6213; ASAI DJ, 1980, J CELL BIOL, V87, P114, DOI 10.1083/jcb.87.1.114; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CATARSI S, 1993, NATURE, V363, P353, DOI 10.1038/363353a0; CHEN CF, 1988, SCIENCE, V239, P1024, DOI 10.1126/science.2449730; COLLIN C, 1990, SCIENCE, V250, P1743, DOI 10.1126/science.2176747; COX AD, 1992, MOL CELL BIOL, V12, P2606, DOI 10.1128/MCB.12.6.2606; CROWELL PL, 1991, J BIOL CHEM, V266, P17679; DARCANGELO G, 1993, J CELL BIOL, V122, P915, DOI 10.1083/jcb.122.4.915; DAY ML, 1993, NATURE, V365, P560, DOI 10.1038/365560a0; DECOURSEY TE, 1987, J GEN PHYSIOL, V89, P405, DOI 10.1085/jgp.89.3.405; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DUBOIS JM, 1993, PROG BIOPHYS MOL BIO, V59, P1, DOI 10.1016/0079-6107(93)90005-5; ENOMOTO KI, 1991, J MEMBRANE BIOL, V119, P133, DOI 10.1007/BF01871412; FANGER GR, 1993, J NEUROCHEM, V61, P1977, DOI 10.1111/j.1471-4159.1993.tb09844.x; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; FLAMM RE, 1990, PFLUG ARCH EUR J PHY, V416, P120, DOI 10.1007/BF00370232; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; GRISSMER S, 1992, J GEN PHYSIOL, V99, P63, DOI 10.1085/jgp.99.1.63; HALL A, 1988, COLD SPRING HARB SYM, V53, P855, DOI 10.1101/SQB.1988.053.01.098; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HEMMICK LM, 1992, J NEUROSCI, V12, P2007; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HUANG XY, 1993, CELL, V75, P1145, DOI 10.1016/0092-8674(93)90324-J; HUANG Y, 1993, J PHYSIOL-LONDON, V461, P601, DOI 10.1113/jphysiol.1993.sp019531; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; KEYOMARSI K, 1991, CANCER RES, V51, P3602; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEE SC, 1986, J CELL BIOL, V102, P1200, DOI 10.1083/jcb.102.4.1200; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; MAGNI M, 1991, J BIOL CHEM, V266, P6329; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; PRICE M, 1989, P NATL ACAD SCI USA, V86, P10171, DOI 10.1073/pnas.86.24.10171; RANE SG, 1991, AM J PHYSIOL, V260, pC104, DOI 10.1152/ajpcell.1991.260.1.C104; REPP H, 1993, P NATL ACAD SCI USA, V90, P3403, DOI 10.1073/pnas.90.8.3403; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SAUVE R, 1986, J MEMBRANE BIOL, V92, P269, DOI 10.1007/BF01869395; SINENSKY M, 1990, J BIOL CHEM, V265, P19937; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STACEY DW, 1991, ONCOGENE, V6, P2297; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; VAIDYA TB, 1991, J CELL BIOL, V114, P809, DOI 10.1083/jcb.114.4.809; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	54	75	82	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					31183	31189						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7527041				2022-12-27	WOS:A1994PV51000069
J	ATFI, A; DROBETSKY, E; BOISSONNEAULT, M; CHAPDELAINE, A; CHEVALIER, S				ATFI, A; DROBETSKY, E; BOISSONNEAULT, M; CHAPDELAINE, A; CHEVALIER, S			TRANSFORMING GROWTH-FACTOR-BETA DOWN-REGULATES SRC FAMILY PROTEIN-TYROSINE KINASE SIGNALING PATHWAYS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; ADAPTER PROTEIN; II RECEPTOR; SH3 DOMAINS; RAS; PHOSPHORYLATION; ACTIVATION; GRB2; TRANSDUCTION; ASSOCIATION	Transforming growth factor beta (TGF beta) inhibits the proliferation of a wide range of cell types through interaction with its cell surface receptor (R-TGF beta). R-TGF beta possesses serine/threonine kinase activity rather than the tyrosine kinase activity normally associated with peptide growth factor receptors; nevertheless, TGF beta triggers a signaling pathway that leads to the repression of transcription factors, which appear to mediate the action of receptor tyrosine kinases within the nucleus. Accumulating evidence has also shown that the nonreceptor protein tyrosine kinases of the Src family play essential roles in the signal transduction pathways that regulate cell proliferation, differentiation, and function. Here, we investigate whether signals initiated by R-TGF beta are transduced, at least in part, through members of the Src family of tyrosine kinases. Treatment of the responsive human prostate carcinoma cell line PC3 with TGF beta induces a rapid and specific decrease in cellular levels of pp60(Src) and pp53/56(Lyn) and a corresponding decrease in their protein kinase activity when the assays were performed in vitro using the exogenous substrate enolase. Consistent with suppression of pp60(Src) and pp53/56(Lyn) kinase activity, TGF beta also caused a substantial intracellular accumulation of the unphosphorylated form of SH2-containing protein (SHC), a substrate of the Src family kinases. This was paralleled by de creased formation of a complex between the adaptor protein known as growth factor receptor-bound protein 2 and SHC. These results suggest, for the first time, that TGF beta induces down-regulation of Src family kinases, leading to disruption of the SHC-growth factor receptor-bound protein 2 complex. These events may play a crucial role in the negative regulation of Ras, as well as in the control of downstream effector molecules involved in the regulation of cell growth.	MONTREAL GEN HOSP,RES INST,MONTREAL H3G 1A4,PQ,CANADA; MCGILL UNIV,DEPT SURG,DIV UROL,MONTREAL H3G 1A4,PQ,CANADA; UNIV MONTREAL,DEPT MED,MONTREAL H1T 2M4,PQ,CANADA; UNIV MONTREAL,DEPT BIOCHEM,MONTREAL H1T 2M4,PQ,CANADA; MAISONNEUVE ROSEMONT HOSP,RES CTR,MONTREAL H1T 2M4,PQ,CANADA	McGill University; McGill University; Universite de Montreal; Universite de Montreal; Universite de Montreal								ATFI A, 1994, PROSTATE, V24, P149, DOI 10.1002/pros.2990240309; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EISEMAN E, 1990, CANCER CELL-MON REV, V2, P303; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MUSTELIN T, 1990, ONCOGENE, V5, P809; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; ROBERTS AB, 1981, P NATL ACAD SCI-BIOL, V78, P5339, DOI 10.1073/pnas.78.9.5339; ROBERTS AB, 1991, PEPTIDE GROWTH FACTO, P421; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; WANG XF, 1991, CELL, V67, P795; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S	50	49	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30688	30693						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7527036				2022-12-27	WOS:A1994PU52500098
J	CHRZANOWSKALIGHTOWLERS, ZMA; PREISS, T; LIGHTOWLERS, RN				CHRZANOWSKALIGHTOWLERS, ZMA; PREISS, T; LIGHTOWLERS, RN			INHIBITION OF MITOCHONDRIAL PROTEIN-SYNTHESIS PROMOTES INCREASED STABILITY OF NUCLEAR-ENCODED RESPIRATORY GENE TRANSCRIPTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; MESSENGER-RNA STABILITY; SKELETAL-MUSCLE; RAT-LIVER; THYROID-HORMONE; DIFFERENTIAL REGULATION; CONTRACTILE ACTIVITY; BINDING PROTEIN; BETA-SUBUNIT; EXPRESSION	To investigate the molecular basis of nuclear-mitochondrial communication, we have been studying the effect of mitochondrial stress (stimulated by inhibition of mitochondrial protein synthesis) on the homeostasis of transcripts encoding nuclear and mitochondrial gene products. We report that in cells treated with the inhibitor thiamphenicol, nuclear-encoded respiratory gene transcripts were dramatically stabilized. A concomitant up-regulation in the activity of the only known respiratory transcript binding protein, cytochrome c oxidase L-form transcript binding protein (COLBP), was also noted in thiamphenicol-treated cells, demonstrating a potential mechanism for the increased transcript protection. In contradistinction, stability of all mitochondrial RNAs was unaffected by the inhibitor, as were the nuclear encoded beta-actin, alpha-tubulin mRNAs and total cytosolic RNA. Steady state levels of all nuclear encoded transcripts tested remained constant after inhibition of mitochondrial protein synthesis, whereas a generalized increase in the levels of processed mitochondrial mRNA was noted. We conclude that thiamphenicol induces (i) an increase in steady state levels of mitochondrial mRNA, (ii) a selective protection of nuclear respiratory gene transcripts against degradation, and (iii) an up-regulation in activity of the respiratory transcript binding protein COLBP, consistent with this protein mediating increased transcript stability. Our results demonstrate a coordinated series of intracellular responses to thiamphenicol-induced mitochondrial stress, regulated at both the pre- and post-transcriptional levels.	UNIV NEWCASTLE UPON TYNE,SCH MED,DIV CLIN NEUROSCI,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND; UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT BIOCHEM & GENET,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND	Newcastle University - UK; Newcastle University - UK			Preiss, Thomas/F-7355-2010	Preiss, Thomas/0000-0001-6273-784X; Chrzanowska-Lightowlers, Zofia/0000-0002-0045-3152				ALTUS MS, 1991, J BIOL CHEM, V266, P21190; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; ATWATER JA, 1990, ANNU REV GENET, V24, P519; BINDOFF LA, 1993, J BIOL CHEM, V268, P19559; Brawerman G., 1993, CONTROL MESSENGER RN, P149; BROCK ML, 1983, CELL, V34, P207, DOI 10.1016/0092-8674(83)90151-4; CHRZANOWSKALIGHTOWLERS ZMA, 1993, BIOCHEM BIOPH RES CO, V196, P328, DOI 10.1006/bbrc.1993.2252; CHUNG AB, 1992, J BIOL CHEM, V267, P21154; FABRIZI GM, 1989, NUCLEIC ACIDS RES, V17, P7107, DOI 10.1093/nar/17.17.7107; GRIVELL LA, 1989, EUR J BIOCHEM, V182, P477, DOI 10.1111/j.1432-1033.1989.tb14854.x; HAMMANS SR, 1992, BRAIN, V115, P343, DOI 10.1093/brain/115.2.343; HEDDI A, 1993, J BIOL CHEM, V268, P12156; HENTZE MW, 1991, BIOCHIM BIOPHYS ACTA, V1090, P281, DOI 10.1016/0167-4781(91)90191-N; HESS JF, 1991, NATURE, V351, P236, DOI 10.1038/351236a0; HOLLOSZY JO, 1984, J APPL PHYSIOL, V56, P831, DOI 10.1152/jappl.1984.56.4.831; IZQUIERDO JM, 1990, J BIOL CHEM, V265, P9090; IZQUIERDO JM, 1993, FEBS LETT, V323, P109, DOI 10.1016/0014-5793(93)81459-D; JACKSON RJ, 1993, CELL, V74, P9, DOI 10.1016/0092-8674(93)90290-7; JOSTE V, 1989, EUR J BIOCHEM, V184, P255, DOI 10.1111/j.1432-1033.1989.tb15015.x; KADENBACH B, 1966, REGULATION METABOLIC, P508; KHALILI K, 1984, J MOL BIOL, V180, P1007, DOI 10.1016/0022-2836(84)90268-7; KOGA Y, 1993, NUCLEIC ACIDS RES, V21, P657, DOI 10.1093/nar/21.3.657; KUZELA S, 1988, BIOCHIM BIOPHYS ACTA, V936, P372, DOI 10.1016/0005-2728(88)90013-8; LANGECARTER CA, 1991, CANCER RES, V51, P6699; MCKNIGHT GS, 1979, J BIOL CHEM, V254, P9050; MURRAY MT, 1991, J CELL BIOL, V112, P1, DOI 10.1083/jcb.112.1.1; MUTVEI A, 1989, EUR J BIOCHEM, V180, P235, DOI 10.1111/j.1432-1033.1989.tb14638.x; OLSON W, 1972, ARCH NEUROL-CHICAGO, V26, P193, DOI 10.1001/archneur.1972.00490090019001; PARIKH VS, 1987, SCIENCE, V235, P576, DOI 10.1126/science.3027892; PASTORI RL, 1990, BIOCHEMISTRY-US, V29, P2599, DOI 10.1021/bi00462a024; PREISS T, 1994, BBA-MOL CELL RES, V1221, P286, DOI 10.1016/0167-4889(94)90252-6; PREISS T, 1993, J BIOL CHEM, V268, P10659; PREISS T, 1993, J BIOL CHEM, V268, P24523; RAIKHINSTEIN M, 1993, P NATL ACAD SCI USA, V90, P10509, DOI 10.1073/pnas.90.22.10509; SEMENKOVICH CF, 1993, J BIOL CHEM, V268, P6961; SUZUKI H, 1991, J BIOL CHEM, V266, P2333; VIRBASIUS CMA, 1993, GENE DEV, V7, P2431, DOI 10.1101/gad.7.12a.2431; VIRBASIUS JV, 1994, P NATL ACAD SCI USA, V91, P1309, DOI 10.1073/pnas.91.4.1309; WIESNER RJ, 1992, MOL ENDOCRINOL, V6, P1458, DOI 10.1210/me.6.9.1458; WIESNER RJ, 1992, TRENDS GENET, V8, P264, DOI 10.1016/0168-9525(92)90129-R; WILKINSON M, 1988, NUCLEIC ACIDS RES, V16, P10933, DOI 10.1093/nar/16.22.10933; WILLIAMS RS, 1986, J BIOL CHEM, V261, P376; WILLIAMS RS, 1987, J BIOL CHEM, V262, P2764; WISKOCIL R, 1980, P NATL ACAD SCI-BIOL, V77, P4474, DOI 10.1073/pnas.77.8.4474	45	73	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27322	27328						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7525553				2022-12-27	WOS:A1994PV77100030
J	MOULD, AP; ASKARI, JA; CRAIG, SE; GARRATT, AN; CLEMENTS, J; HUMPHRIES, MJ				MOULD, AP; ASKARI, JA; CRAIG, SE; GARRATT, AN; CLEMENTS, J; HUMPHRIES, MJ			INTEGRIN ALPHA(4)BETA(1)-MEDIATED MELANOMA CELL-ADHESION AND MIGRATION ON VASCULAR CELL-ADHESION MOLECULE-1 (VCAM-1) AND THE ALTERNATIVELY SPLICED IIICS REGION OF FIBRONECTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLASMA FIBRONECTIN; HEPARIN-BINDING; CONNECTING SEGMENT; ENDOTHELIAL-CELLS; ALPHA-4-BETA-1 INTEGRIN; EOSINOPHIL ADHERENCE; SULFATE PROTEOGLYCAN; COUNTER-RECEPTOR; LATE ANTIGEN-4; T-CELLS	The integrin receptor alpha(4) beta(1) (also known as VLA-4) binds two different ligands, the endothelial cell surface protein vascular cell adhesion molecule-1 (VCAM-1) and the extracellular matrix component fibronectin. Three distinct sites in fibronectin are recognized by alpha(4) beta(1). Two of these (represented by peptides CS1 and CS5) are present in the alternatively spliced IIICS region and lie in separate, independently spliced segments of this region. A third site resides in the adjacent constitutively expressed HepII domain. Recombinant proteins containing the HepII domain and different splice variants of the IIICS have been generated and compared for their ability to mediate cell attachment, spreading and migration. The activity of these proteins has also been compared with that of a recombinant soluble form of VCAM-1 (rsVCAM-1). All the recombinant proteins supported A375-SM human melanoma cell attachment and spreading in an alpha(4) beta(1)-dependent manner, but had varied adhesive activities with rsVCAM-1 > fibronectin variants containing the CS1 sequence >> other fibronectin variants. Low concentrations of rsVCAM-1 and CS1-containing fibronectin variants effectively supported cell migration in a trans-filter assay; however, cell motility was retarded at high concentrations of the same proteins. Fibronectin variants lacking CS1 supported little or no migration. To obtain further insight into the molecular basis of this varied adhesive activity apparent dissociation constants for each of the recombinant proteins were measured using a solid phase receptor-ligand binding assay. The results revealed a hierarchy of ligand affinities that mirrored their adhesive activity (rsVCAM-1 > fibronectin variants containing CS1 >> other fibronectin variants).	BRITISH BIOTECHNOL LTD, OXFORD OX4 5LY, ENGLAND		MOULD, AP (corresponding author), UNIV MANCHESTER, SCH BIOL SCI, MANCHESTER M13 9PT, LANCS, ENGLAND.		Garratt, Alistair/AAG-2715-2021; Garratt, Alistair N/D-9893-2013	Garratt, Alistair N/0000-0001-9631-3041; Humphries, Martin/0000-0002-4331-6967	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; ALBELDA SM, 1990, CANCER RES, V50, P6757; ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BAO L, 1993, DIFFERENTIATION, V52, P239, DOI 10.1111/j.1432-0436.1993.tb00636.x; BARON JL, 1993, J EXP MED, V177, P57, DOI 10.1084/jem.177.1.57; BAUER JS, 1992, J CELL BIOL, V116, P477, DOI 10.1083/jcb.116.2.477; BEDNARCZYK JL, 1992, CLIN EXP METASTAS, V10, P281; BERETA J, 1993, CELL IMMUNOL, V147, P313, DOI 10.1006/cimm.1993.1072; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CARLOS TM, 1990, BLOOD, V76, P965; CHAN BM, 1992, CELL, V68, P1051, DOI 10.1016/0092-8674(92)90077-P; CHARO IF, 1990, J CELL BIOL, V111, P2795, DOI 10.1083/jcb.111.6.2795; CLEMENTS JM, 1994, J CELL SCI, V107, P2127; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; DIMILLA PA, 1993, J CELL BIOL, V122, P729, DOI 10.1083/jcb.122.3.729; DIMILLA PA, 1991, BIOPHYS J, V60, P15, DOI 10.1016/S0006-3495(91)82027-6; DOBRINA A, 1991, J CLIN INVEST, V88, P20, DOI 10.1172/JCI115278; DRAKE SL, 1992, J CELL BIOL, V117, P1331, DOI 10.1083/jcb.117.6.1331; DUFOUR S, 1988, EMBO J, V7, P2661, DOI 10.1002/j.1460-2075.1988.tb03119.x; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; FERGUSON TA, 1991, P NATL ACAD SCI USA, V88, P8072, DOI 10.1073/pnas.88.18.8072; FREEDMAN AS, 1990, SCIENCE, V249, P1030, DOI 10.1126/science.1697696; GARCIAPARDO A, 1989, EXP CELL RES, V181, P420, DOI 10.1016/0014-4827(89)90099-2; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; HAUGEN PK, 1992, J NEUROSCI, V12, P2034; HEMLER ME, 1990, IMMUNOL REV, V114, P45, DOI 10.1111/j.1600-065X.1990.tb00561.x; HERSHBERGER RP, 1990, MOL CELL BIOL, V10, P662, DOI 10.1128/MCB.10.2.662; HESSION C, 1991, J BIOL CHEM, V266, P6682; HUMPHRIES MJ, 1986, J CELL BIOL, V103, P2637, DOI 10.1083/jcb.103.6.2637; HUMPHRIES MJ, 1987, J BIOL CHEM, V262, P6886; HUMPHRIES MJ, 1988, J CELL BIOL, V106, P1289, DOI 10.1083/jcb.106.4.1289; HUMPHRIES MJ, 1990, J CELL SCI, V97, P585; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IIDA J, 1992, J CELL BIOL, V118, P431, DOI 10.1083/jcb.118.2.431; KOMORIYA A, 1991, J BIOL CHEM, V266, P15075; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; KOZLOWSKI JM, 1984, J NATL CANCER I, V72, P913; KUENG W, 1989, ANAL BIOCHEM, V182, P16, DOI 10.1016/0003-2697(89)90710-0; KUIJPERS TW, 1993, J EXP MED, V178, P279, DOI 10.1084/jem.178.1.279; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LALLIER T, 1993, SCIENCE, V259, P692, DOI 10.1126/science.8430321; LAUFFENBURGER D, 1989, CHEM ENG SCI, V44, P1903, DOI 10.1016/0009-2509(89)85131-0; MAKAREM R, 1994, J BIOL CHEM, V269, P4005; MCCARTHY JB, 1988, BIOCHEMISTRY-US, V27, P1380, DOI 10.1021/bi00404a044; MCCARTHY JB, 1990, J CELL BIOL, V110, P777, DOI 10.1083/jcb.110.3.777; MIYAKE K, 1991, J CELL BIOL, V114, P557, DOI 10.1083/jcb.114.3.557; MOULD AP, 1990, J BIOL CHEM, V265, P4020; MOULD AP, 1991, J BIOL CHEM, V266, P3579; MOULD AP, 1991, EMBO J, V10, P4089, DOI 10.1002/j.1460-2075.1991.tb04985.x; MULLER B, 1993, J BIOL CHEM, V268, P6800; OSBORN L, 1994, J CELL BIOL, V124, P601, DOI 10.1083/jcb.124.4.601; OSBORN L, 1992, J EXP MED, V176, P99, DOI 10.1084/jem.176.1.99; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; PERRIS R, 1989, DEV BIOL, V136, P222, DOI 10.1016/0012-1606(89)90144-9; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; ROSEN GD, 1992, CELL, V69, P1107, DOI 10.1016/0092-8674(92)90633-N; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEKIGUCHI K, 1989, BIOCHEMISTRY-US, V28, P3293, DOI 10.1021/bi00434a026; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAMKUN JW, 1986, CELL, V46, P271, DOI 10.1016/0092-8674(86)90744-0; TENCHINI ML, 1993, CELL ADHES COMMUN, V1, P55, DOI 10.3109/15419069309095681; THORNHILL MH, 1991, J IMMUNOL, V146, P592; VONDERHEIDE RH, 1994, J CELL BIOL, V125, P215, DOI 10.1083/jcb.125.1.215; VONDERHEIDE RH, 1992, J EXP MED, V175, P1433, DOI 10.1084/jem.175.6.1433; WALSH GM, 1991, J IMMUNOL, V146, P3419; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; WELLER PF, 1991, P NATL ACAD SCI USA, V88, P7430, DOI 10.1073/pnas.88.16.7430; YAMADA KM, 1984, J CELL BIOL, V99, P29, DOI 10.1083/jcb.99.1.29; YEDNOCK TA, 1992, NATURE, V356, P63, DOI 10.1038/356063a0	71	115	116	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27224	27230						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7525548				2022-12-27	WOS:A1994PV77100014
J	GULLIVER, GA; VOSS, EW				GULLIVER, GA; VOSS, EW			EFFECT OF TRANSPLANTATION OF ANTIBODY HEAVY-CHAIN COMPLEMENTARITY-DETERMINING REGIONS ON LIGAND-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; MONOCLONAL-ANTIBODIES; IDIOTYPE FAMILY; FAB COMPLEX; AUTOANTIBODY	Active site structure-function analyses of anti-fluorescein single chain antibody 4-4-20 and anti-single-stranded DNA single chain antibody 04-01 were conducted studying the ligand binding properties of hybrid antibodies resulting from systematic transplantation of heavy chain complementarity regions (HCDRs) from monoclonal antibody 4-4-20 into 04-01. Two prototype monoclonal antibodies were chosen because the primary structures of their respective light chains were nearly identical but the specificities and shape of their active sites were distinctly different. Based on nearly identical light chains, the diverse active site conformations (i.e. 4-4-20 pocket and 04-01 cleft) and subsequent specificities of the two antibodies were likely dictated by heavy chain properties, As a result, specificities of each HCDR transplant were analyzed in terms of binding reactivity with either fluorescein or (dT)(8). Results of binding studies, together with idiotypic and secondary structure analyses, were used to determine the relative contribution of each HCDR to the active site conformations and ligand specificities of monoclonal antibodies 4-4-20 and 04-01. Collectively the various analyses led to the conclusion that the intradomain conformational dynamics and cooperativity necessary for the structural integrity of the low affinity cleft-shaped 04-01 anti-single-stranded DNA active site are probably less stringent than those of a high affinity pocket-shaped anti-fluorescein active site.	UNIV ILLINOIS,DEPT MICROBIOL,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign								BALLARD DW, 1984, J BIOL CHEM, V259, P3492; BATES RM, 1985, MOL IMMUNOL, V22, P871, DOI 10.1016/0161-5890(85)90072-0; BEDZYK WD, 1989, J BIOL CHEM, V264, P1565; BEDZYK WD, 1990, J BIOL CHEM, V265, P133; CHAMBERS SP, 1988, GENE, V68, P139, DOI 10.1016/0378-1119(88)90606-3; DENZIN LK, 1991, J BIOL CHEM, V266, P14095; GALFRE G, 1977, NATURE, V266, P550, DOI 10.1038/266550a0; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; GULLIVER GA, 1994, J BIOL CHEM, V269, P7934; HERRON JN, 1991, PROTEINS, V11, P159, DOI 10.1002/prot.340110302; HERRON JN, 1989, PROTEINS, V5, P271, DOI 10.1002/prot.340050404; KRANZ DM, 1981, MOL IMMUNOL, V18, P889, DOI 10.1016/0161-5890(81)90012-2; RUMBLEY CA, 1993, J BIOL CHEM, V268, P13667; SCANDELLA D, 1985, J CELL BIOCH B, V9, P203; SMITH R G, 1989, Journal of the Indian Institute of Science, V69, P25; SMITH RG, 1990, MOL IMMUNOL, V27, P463, DOI 10.1016/0161-5890(90)90171-U; TETIN SY, 1992, BIOCHEMISTRY-US, V31, P12029, DOI 10.1021/bi00163a010	18	6	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24040	24045						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7523365				2022-12-27	WOS:A1994PQ34600032
J	ZINNEN, S; HSIEH, JC; MODRICH, P				ZINNEN, S; HSIEH, JC; MODRICH, P			MISINCORPORATION AND MISPAIRED PRIMER EXTENSION BY HUMAN-IMMUNODEFICIENCY-VIRUS REVERSE-TRANSCRIPTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-I KLENOW; MURINE LEUKEMIA-VIRUS; KINETIC MECHANISM; DNA-REPLICATION; STEADY-STATE; FIDELITY; RNA; HIV-1; TYPE-1; THERMODYNAMICS	Pre-steady-state methods were used to study the fidelity of human immunodeficiency virus reverse transcriptase. Fidelity of DNA-directed DNA synthesis can be attributed to a 1-2 order of magnitude reduction in affinity for noncomplementary dNTPs, and a 1-4 order of magnitude reduction in the rate of the conformational change that limits the rate of nucleotide addition. Affinities of reverse transcriptase for paired or mispaired primer termini are similar. Discrimination against a mispaired primer is due to reduction in affinity for the next dNTP and reduction in rate of extension. Extension of mispaired termini proceeds 20-700-fold faster than the rate of dissociation of reverse transcriptase from the primer-template and is 2-3 orders of magnitude more frequent than nucleotide misincorporation. The rate-limiting step for extension of a mispaired terminus occurs at the conformational change or chemical step, depending on the nature of the mispair. Presence of a mismatch at the 3' penultimate position reduces pyrophosphorolysis of the primer by a factor of 10(3), indicating that mispairs 5' to the site of chemistry can also affect catalysis.	DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University				Modrich, Paul/0000-0001-8708-9885	NIGMS NIH HHS [GM23719] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023719, R37GM023719] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABBOTTS J, 1991, J BIOL CHEM, V266, P3937; BAKHANASHVILI M, 1992, FEBS LETT, V306, P151, DOI 10.1016/0014-5793(92)80988-S; BAKHANASHVILI M, 1992, BIOCHEMISTRY-US, V31, P9393, DOI 10.1021/bi00154a010; BAKHANASHVILI M, 1993, FEBS LETT, V319, P201, DOI 10.1016/0014-5793(93)80067-5; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; BEBENEK K, 1993, J BIOL CHEM, V268, P10324; BEBENEK K, 1992, J BIOL CHEM, V267, P3589; BEBENEK K, 1989, J BIOL CHEM, V264, P16948; BOYER JC, 1992, P NATL ACAD SCI USA, V89, P6919, DOI 10.1073/pnas.89.15.6919; DEUTSCHER MP, 1969, J BIOL CHEM, V244, P3019; EGER BT, 1992, BIOCHEMISTRY-US, V31, P9227, DOI 10.1021/bi00153a016; Fersht A., 1985, ENZYME STRUCTURE MEC; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V71, P4315; HSIEH JC, 1993, J BIOL CHEM, V268, P24607; HUBNER A, 1992, J MOL BIOL, V223, P595, DOI 10.1016/0022-2836(92)90975-P; JI JP, 1992, BIOCHEMISTRY-US, V31, P954, DOI 10.1021/bi00119a002; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; KATI WM, 1992, J BIOL CHEM, V267, P25988; KUCHTA RD, 1987, BIOCHEMISTRY-US, V26, P8410, DOI 10.1021/bi00399a057; KUCHTA RD, 1988, BIOCHEMISTRY-US, V27, P6716, DOI 10.1021/bi00418a012; KUNKEL TA, 1986, J BIOL CHEM, V261, P3610; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; PERRINO FW, 1989, P NATL ACAD SCI USA, V86, P8343, DOI 10.1073/pnas.86.21.8343; PETRUSKA J, 1988, P NATL ACAD SCI USA, V85, P6252, DOI 10.1073/pnas.85.17.6252; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; REARDON JE, 1992, BIOCHEMISTRY-US, V31, P4473, DOI 10.1021/bi00133a013; REARDON JE, 1993, J BIOL CHEM, V268, P8743; RICCHETTI M, 1990, EMBO J, V9, P1583, DOI 10.1002/j.1460-2075.1990.tb08278.x; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; TAKEUCHI Y, 1988, J VIROL, V62, P3900, DOI 10.1128/JVI.62.10.3900-3902.1988; VARMUS H, 1985, RNA TUMOR VIRUSES, P75; VARTANIAN JP, 1991, J VIROL, V65, P1779, DOI 10.1128/JVI.65.4.1779-1788.1991; WEBER J, 1989, NUCLEIC ACIDS RES, V17, P1379, DOI 10.1093/nar/17.4.1379; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030; YU H, 1992, J BIOL CHEM, V267, P10888	36	69	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24195	24202						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7523369				2022-12-27	WOS:A1994PQ34600056
J	WERGE, TM				WERGE, TM			IDENTIFICATION OF AN EPITOPE IN THE SUBSTANCE-P RECEPTOR IMPORTANT FOR RECOGNITION OF THE COMMON CARBOXYL-TERMINAL TACHYKININ SEQUENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; NEUROKININ-1 RECEPTOR; MONOCLONAL-ANTIBODY; BINDING; SPECIFICITY; EXPRESSION; DOMAINS; NK1; SELECTIVITY; ANTAGONIST	The substance P receptor and the anti-substance P antibody NC1 share the ability to bind to the COOH terminus of substance P. Sequence analysis identified a direct noninterrupted homology of 5 residues in the two molecules. Replacement of Gly(166) and Tyr(167) in this epitope of the substance P receptor by the corresponding substance K receptor amino acids (Cys and Phe) increases the affinity toward substance P 2-fold and toward substance K and neurokinin B 11- and 21-fold, respectively. A significantly larger effect of the mutation is observed for the hexapeptides of substance P and sub stance K which show a mutation-induced increase in binding energy of more than 2 kcal/mol. Hence, the NH2 terminus of substance P and, to a lesser extent, of substance K masks the effect of the mutation. I conclude that the epitope is important for recognition of the common COOH terminus of the tachykinins and for preservation of selectivity. The data furthermore suggest that formation of the peptide-receptor complex occurs through a composite set of interactions which are not adequately described by the two-site/no cooperativity ''address-message'' model.	CNR,INST NEUROBIOL,I-00137 ROME,ITALY	Consiglio Nazionale delle Ricerche (CNR)								CASCIERI MA, 1992, MOL PHARMACOL, V41, P1096; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; CUELLO AC, 1979, P NATL ACAD SCI USA, V76, P3532, DOI 10.1073/pnas.76.7.3532; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; FONG TM, 1992, J BIOL CHEM, V267, P25668; FONG TM, 1992, J BIOL CHEM, V267, P25664; FONG TM, 1992, BIOCHEMISTRY-US, V31, P11806, DOI 10.1021/bi00162a019; FONG TM, 1993, NATURE, V362, P350; GETHER U, 1993, NATURE, V362, P345, DOI 10.1038/362345a0; GETHER U, 1993, J BIOL CHEM, V268, P7893; GETHER U, 1993, P NATL ACAD SCI USA, V90, P6194, DOI 10.1073/pnas.90.13.6194; HUANG RRC, 1994, BIOCHEMISTRY-US, V33, P3007, DOI 10.1021/bi00176a033; INGI T, 1991, J PHARMACOL EXP THER, V259, P968; JONES PT, 1986, NATURE, V321, P522, DOI 10.1038/321522a0; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NAKANISHI S, 1987, PHYSIOL REV, V67, P1117, DOI 10.1152/physrev.1987.67.4.1117; NAKANISHI S, 1991, ANNU REV NEUROSCI, V14, P123, DOI 10.1146/annurev.ne.14.030191.001011; PICCIOLI P, 1991, P NATL ACAD SCI USA, V88, P5611, DOI 10.1073/pnas.88.13.5611; REGOLI D, 1988, TRENDS PHARMACOL SCI, V9, P290, DOI 10.1016/0165-6147(88)90013-2; SACHAIS BS, 1993, J BIOL CHEM, V268, P2319; Schwyzer R, 1977, Ann N Y Acad Sci, V297, P3, DOI 10.1111/j.1749-6632.1977.tb41843.x; SHIGEMOTO R, 1990, J BIOL CHEM, V265, P623; YOKOTA Y, 1992, EMBO J, V11, P3585, DOI 10.1002/j.1460-2075.1992.tb05442.x; YOKOTA Y, 1989, J BIOL CHEM, V264, P17649	24	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22054	22058						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	7520910				2022-12-27	WOS:A1994PE09800022
J	TSUKAHARA, H; ENDE, H; MAGAZINE, HI; BAHOU, WF; GOLIGORSKY, MS				TSUKAHARA, H; ENDE, H; MAGAZINE, HI; BAHOU, WF; GOLIGORSKY, MS			MOLECULAR AND FUNCTIONAL-CHARACTERIZATION OF THE NON-ISOPEPTIDE-SELECTIVE ET(B) RECEPTOR IN ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; HUMAN UMBILICAL VEIN; PROTEIN-KINASE-C; VASCULAR ENDOTHELIUM; SIGNAL TRANSDUCTION; MESANGIAL CELLS; SMOOTH-MUSCLE; CLONING; EXPRESSION; DNA	There is accumulating evidence that endothelial cells express a non-isopeptide-selective endothelin (ET) receptor, ET(B), which may be responsible for ET-1-induced transient vasorelaxation. The purpose of the present study was to seek direct evidence for ET(B) receptor expression in human umbilical vein endothelial cells (HUVEC) and to characterize its functional role in HUVEC and in Chinese hamster ovary cells stably transfected with ET(B) receptor cDNA (CHO-ET(B)). Reverse polymerase chain reaction using HUVEC total RNA and ET(B) receptor-specific oligonucleotide primers firmly demonstrated the presence of an endogenous transcript of the appropriate molecular size. Next, a biotinylated ligand specifically recognizing the ET(B) receptor, IRL-1620, was synthesized, and immunocytochemical mapping of binding sites was performed in CHO-ET(B) cells. Specific binding of biotinylated IRL-1620 was evident in CHO-ET(B) cells, confirming appropriate cell surface receptor expression. continuous nitric oxide (NO) monitoring with NO-selective electrode revealed a dose-dependent ET-1 stimulation of NO production by HUVEC. Stable transfection of CHO-ET(B) cells with endothelial nitric oxide synthase (NOS), but not mock-transfection, imparted responsiveness to ET-1 similar to that for HUVEC and was characterized by the immediate release of NO. Protein tyrosine kinase-dependent and calcium-calmodulin-dependent pathways were involved in ET-1-induced activation fo the constitutive NOS in CHO-ET(B)/NOS cells, but coupling of the receptor to the enzyme in HUVEC appeared to be predominantly protein tyrosine kinase-dependent. Although sufficient calcium/calmodulin system was not an obligatory prerequisite for the ET-1-induced activation of NOS in HUVEC. In conclusion, using two cell systems, we demonstrated that the ET(B) receptor is functionally coupled to NOS and coordinates the generation of NO via a tyrosine kinase-dependent and a calcium/calmodulin-dependent pathway.	SUNY STONY BROOK,DIV NEPHROL & HYPERTENS,STONY BROOK,NY 11794; SUNY STONY BROOK,DIV HEMATOL,STONY BROOK,NY 11794; SUNY STONY BROOK,DEPT MED,STONY BROOK,NY 11794; SUNY STONY BROOK,DEPT PHYSIOL & BIOPHYS,STONY BROOK,NY 11794; CUNY QUEENS COLL,DEPT BIOL,FLUSHING,NY 11367	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; City University of New York (CUNY) System; Queens College NY (CUNY)					NHLBI NIH HHS [HL-02431] Funding Source: Medline; NIDDK NIH HHS [DK-45695, DK-41573] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002431] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045695, R29DK041573] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; ARAMORI I, 1992, J BIOL CHEM, V267, P12468; BAHOU WF, 1992, J BIOL CHEM, V267, P13986; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DONG ZY, 1993, J IMMUNOL, V151, P2717; EMORI T, 1990, FEBS LETT, V263, P261, DOI 10.1016/0014-5793(90)81388-5; FORCE T, 1991, J BIOL CHEM, V266, P6650; FUJITANI Y, 1992, FEBS LETT, V298, P79, DOI 10.1016/0014-5793(92)80026-D; HAGIWARA H, 1993, AM J PHYSIOL, V264, pR777, DOI 10.1152/ajpregu.1993.264.4.R777; HIRATA Y, 1993, J CLIN INVEST, V91, P1367, DOI 10.1172/JCI116338; IIJIMA K, 1991, AM J PHYSIOL, V260, pF848, DOI 10.1152/ajprenal.1991.260.6.F848; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JANSSENS SP, 1992, J BIOL CHEM, V267, P14519; KAISER E, 1970, ANAL BIOCHEM, V34, P595, DOI 10.1016/0003-2697(70)90146-6; KAUFMAN RJ, 1982, J MOL BIOL, V159, P601, DOI 10.1016/0022-2836(82)90103-6; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LANDER HM, 1993, J IMMUNOL, V150, P1509; LEVITZKI A, 1992, FASEB J, V6, P3275, DOI 10.1096/fasebj.6.14.1426765; MAGAZINE HI, 1991, BIOCHEM BIOPH RES CO, V181, P1245, DOI 10.1016/0006-291X(91)92072-R; MARCZIN N, 1993, AM J PHYSIOL, V265, pH1014, DOI 10.1152/ajpheart.1993.265.3.H1014; OGAWA Y, 1991, BIOCHEM BIOPH RES CO, V178, P248, DOI 10.1016/0006-291X(91)91806-N; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHETTY SS, 1993, BIOCHEM BIOPH RES CO, V191, P459, DOI 10.1006/bbrc.1993.1240; SHIBUKI K, 1991, NATURE, V349, P326, DOI 10.1038/349326a0; SIMONSON MS, 1993, J BIOL CHEM, V268, P9347; SOKOLOVSKY M, 1992, J BIOL CHEM, V267, P20551; TAKAGI Y, 1990, BIOCHEM BIOPH RES CO, V168, P537, DOI 10.1016/0006-291X(90)92354-3; TAKAYANAGI R, 1991, FEBS LETT, V282, P103, DOI 10.1016/0014-5793(91)80454-B; TSUKAHARA H, 1993, BIOCHEM BIOPH RES CO, V193, P722, DOI 10.1006/bbrc.1993.1685; TSUKAHARA H, 1994, KIDNEY INT, V45, P598, DOI 10.1038/ki.1994.78; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	33	221	223	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 26	1994	269	34					21778	21785						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PK973	7520443				2022-12-27	WOS:A1994PK97300060
J	MAO, XH; MIESFELDT, S; YANG, HD; LEIDEN, JM; THOMPSON, CB				MAO, XH; MIESFELDT, S; YANG, HD; LEIDEN, JM; THOMPSON, CB			THE FLI-1 AND CHIMERIC EWS-FLI-1 ONCOPROTEINS DISPLAY SIMILAR DNA-BINDING SPECIFICITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ETS GENE FAMILY; TRANSCRIPTION FACTOR; PROTEIN; DOMAIN; SEQUENCE; ACTIVATION; EXPRESSION; ONCOGENE; ENHANCER; C-ETS-1	Although recent data have demonstrated that the chimeric EWS-FLI-1 cDNA isolated from cases of Ewing's sarcoma can transform NIH 3T3 cells, little is known about the basis for this transformation. Since FLI-1 and EWS-FLI-1 contain an Ets domain, both proteins may act as sequence-specific transcription factors. Here the DNA binding properties of FLI-1 and EWS-FLI-1 have been examined. An epitope-tagging strategy was developed to determine the optimum DNA-binding sequence of FLI-1. The alignment of cloned binding sequences showed a consensus DNA-binding site of ACCGGAAG/aT/c. This consensus sequence shows greater specificity for sequence 5' of the GGAA core site than those of other Ets proteins. Using several truncated forms of FLI-1, we show that the Ets domain is necessary and sufficient for the DNA binding specificity of FLI-1. The EWS-FLI-1 protein displayed the same DNA binding specificity and affinity as FLI-1 did. Despite their DNA binding similarities, the EWS-FLI-1 translocation product is likely to have a distinct pattern of expression from that of FLI-1 since the translocation results in the replacement of the 5' regulatory region of Fli-1 with that of EWS. Consistent with this we found that Fli-1 mRNA expression in lymphocytes was high in quiescent cells and disappeared upon activation while EWS mRNA expression was low in resting cells and increased in activated T cells. In summary, our data suggest that EWS-FLI-1 might act through the same target genes normally regulated by FLI-1, and EWS-FLI-1-induced transformation may result from dysregulation of FLI-1 target genes during cell proliferation and differentiation.	UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637; UNIV CHICAGO,DEPT PATHOL,CHICAGO,IL 60637; UNIV CHICAGO,DEPT MOLEC GENET & CELL BIOL,CHICAGO,IL 60637; UNIV CHICAGO,HOWARD HUGHES MED INST,CHICAGO,IL 60637; UNIV MICHIGAN,MED CTR,DEPT MICROBIOL IMMUNOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,MED CTR,DEPT INTERNAL MED,ANN ARBOR,MI 48109	University of Chicago; University of Chicago; University of Chicago; Howard Hughes Medical Institute; University of Chicago; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan								BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; FISHER RJ, 1991, ONCOGENE, V6, P2249; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; HAGMAN J, 1992, P NATL ACAD SCI USA, V89, P8889, DOI 10.1073/pnas.89.19.8889; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; JANKNECHT R, 1992, NUCLEIC ACIDS RES, V20, P3317, DOI 10.1093/nar/20.13.3317; JUNE CH, 1987, MOL CELL BIOL, V7, P4472, DOI 10.1128/MCB.7.12.4472; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KLEMSZ MJ, 1993, J BIOL CHEM, V268, P5769; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LEDBETTER JA, 1987, P NATL ACAD SCI USA, V84, P1384, DOI 10.1073/pnas.84.5.1384; LEIDEN JM, 1992, J VIROL, V66, P5890, DOI 10.1128/JVI.66.10.5890-5897.1992; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; MACARTHUR H, 1984, J VIROL, V52, P483, DOI 10.1128/JVI.52.2.483-491.1984; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; PRASAD DDK, 1992, CANCER RES, V52, P5833; REDDY ESP, 1991, ONCOGENE, V6, P2285; SOOD AK, 1981, P NATL ACAD SCI-BIOL, V78, P616, DOI 10.1073/pnas.78.1.616; THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WANG CY, 1992, J EXP MED, V175, P1391, DOI 10.1084/jem.175.5.1391; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; WEIGHT WE, 1991, MOL CELL BIOL, V11, P4104; WOODS DB, 1992, NUCLEIC ACIDS RES, V20, P699, DOI 10.1093/nar/20.4.699; ZHANG LQ, 1993, ONCOGENE, V8, P1621; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	41	117	118	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					18216	18222						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	7517940				2022-12-27	WOS:A1994NV42200068
J	KOMADA, M; KITAMURA, N				KOMADA, M; KITAMURA, N			REGULATORY ROLE OF MAJOR TYROSINE AUTOPHOSPHORYLATION SITE OF KINASE DOMAIN OF C-MET RECEPTOR (SCATTER FACTOR/HEPATOCYTE GROWTH-FACTOR RECEPTOR)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATING FACTOR-I; EPITHELIAL-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; HUMAN FIBROBLASTS; RAT HEPATOCYTES; DNA-SYNTHESIS; PROTOONCOGENE; IDENTIFICATION; MOTILITY; INSULIN	Ligand-induced tyrosine kinase activation of the scatter factor/hepatocyte growth factor receptor (c-Met) is thought to be essential for the biological responses of target cells. To assess the regulatory role of the major tyrosine autophosphorylation site (tyrosine 1233) of the mouse c-Met receptor in the tyrosine kinase activation of the receptor, we constructed a mutant receptor in which the tyrosine residue was replaced with phenylalanine. When the cells expressing the mutant receptor were incubated with the ligand, no biological responses were observed, and the level of tyrosine phosphorylation of the receptor was very low compared with that of the wild-type receptor. The in vitro kinase activity of the mutant receptor toward an exogenous substrate and the receptor itself was also low. Furthermore, tyrosine phosphorylation of the cellular proteins by ligand stimulation was not detected in intact cells expressing the mutant receptor. The low level of kinase activity and the lack of biological activity of the mutant receptor indicate that the major autophosphorylation site positively regulates the tyrosine kinase of the c-Met receptor and phosphorylation of cellular substrates in the scatter factor/hepatocyte growth factor signaling pathway.	KANSAI MED UNIV, INST LIVER RES, MORIGUCHI, OSAKA 570, JAPAN	Kansai Medical University								ARAKAKI N, 1992, BIOCHEM BIOPH RES CO, V185, P22, DOI 10.1016/S0006-291X(05)80949-0; BARDELLI A, 1992, ONCOGENE, V7, P1973; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CARPENTER G, 1976, J CELL BIOL, V71, P159, DOI 10.1083/jcb.71.1.159; CHAN AML, 1988, ONCOGENE, V2, P593; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; COURTNEIDGE SA, 1991, CELL GROWTH DIFFER, V2, P483; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FANTL WJ, 1989, MOL CELL BIOL, V9, P4473, DOI 10.1128/MCB.9.10.4473; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; GOTOH N, 1992, BIOCHEM BIOPH RES CO, V186, P768, DOI 10.1016/0006-291X(92)90812-Y; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GRONBORG M, 1993, J BIOL CHEM, V268, P23435; HIGASHIO K, 1990, BIOCHEM BIOPH RES CO, V170, P397, DOI 10.1016/0006-291X(90)91287-3; ISHIKI Y, 1992, HEPATOLOGY, V16, P1227, DOI 10.1016/0270-9139(92)90019-6; KAN M, 1991, BIOCHEM BIOPH RES CO, V174, P331, DOI 10.1016/0006-291X(91)90524-B; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KOMADA M, 1993, ONCOGENE, V8, P2381; KOMADA M, 1992, EUR J BIOCHEM, V204, P857, DOI 10.1111/j.1432-1033.1992.tb16705.x; KOMADA M, 1993, FEBS LETT, V328, P25, DOI 10.1016/0014-5793(93)80958-W; MARGOLIS BL, 1989, J BIOL CHEM, V264, P10667; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; MURAKAMI MS, 1991, J BIOL CHEM, V266, P22653; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; STERN CD, 1990, DEVELOPMENT, V110, P1271; STOKER M, 1989, J CELL PHYSIOL, V139, P565, DOI 10.1002/jcp.1041390316; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; STRAIN AJ, 1991, J CLIN INVEST, V87, P1853, DOI 10.1172/JCI115207; SUEMORI H, 1990, CELL DIFFER DEV, V29, P181, DOI 10.1016/0922-3371(90)90120-L; VANDERGEER P, 1991, MOL CELL BIOL, V11, P4698, DOI 10.1128/MCB.11.9.4698; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; WILDEN PA, 1992, J BIOL CHEM, V267, P13719	45	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16131	16136						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	7515877				2022-12-27	WOS:A1994NQ72900029
J	VANDEPUT, FHMM; DEPONT, JJHHM; WILLEMS, PHGM				VANDEPUT, FHMM; DEPONT, JJHHM; WILLEMS, PHGM			HETEROGENEITY BETWEEN INTRACELLULAR CA2+ STORES AS THE UNDERLYING PRINCIPLE OF QUANTAL CA2+ RELEASE BY INOSITOL 1,4,5-TRISPHOSPHATE IN PERMEABILIZED PANCREATIC ACINAR-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM RELEASE; LUMINAL CA2+; CA-2+ RELEASE; MOBILIZATION; HEPATOCYTES; SENSITIVITY; SIZE; POOL	Permeabilized rabbit pancreatic acinar cells were used to study the effects of Ca2+ pump inhibition and Ca2+ store depletion on the sensitivity of internal Ca2+ stores to emptying by inositol 1,4,5-trisphosphate (Ins-1,4,5-P-3). Complete inhibition of pump activity by thapsigargin resulted in the monoexponential loss of 92% of the actively stored Ca2+ with a half time of 6.2 min. Under these conditions, Ca2+ release evoked by a submaximal concentration of Ins-1,4,5-P, did not cease after 1.5 min, as was observed in the absence of thapsigargin, but continued for at least 5 min. This observation suggests that under normal conditions of Ca2+ pumping, a substantial part of the internal Ca2+ stores is not depleted by the action of Ins-1,4,5-P-3 due to compensatory Ca2+ uptake. Evidence in support of the idea of compensatory Ca2+ primping was obtained in exchange experiments performed in the absence of thapsigargin. The slow kinetics of sustained Ca2+ release in the absence of Ca2+ pump activity suggests that Ca2+ is released from stores containing either relatively few or less sensitive Ins-1,4,5-P-3-operated Ca2+ release channels. Gradual emptying of the internal Ca2+ stores by thapsigargin did not affect the potency with which Ins-1,4,5-P-3 released Ca2+, indicating that the intravesicular Ca2+ content does not control the sensitivity of the Ins-1,4,5-P-3-operated Ca2+ channel to activation by Ins-1,4,5-P-3. This was confirmed using ruthenium red, which preferentially depleted the Ins-1,4,5 P-3-releasable store without affecting the EC(50) for Ins-1,4,5 P-3-stimulated Ca2+ release. The data presented indicate that the quantal type of Ca2+ release observed with Ins 1,4,5 P-3 requires compensatory Ca2+ pumping. Moreover, they support the idea that internal Ca2+ stores display differential sensitivities toward Ins-1,4,5-P-3 rather than responding uniformly to this internal Ca2+-mobilizing messenger.	UNIV NIJMEGEN,DEPT BIOCHEM,6500 HB NIJMEGEN,NETHERLANDS	Radboud University Nijmegen			Willems, P.H.G.M./L-4759-2015	Willems, P.H.G.M./0000-0002-0915-1599				AMSTERDA.A, 1974, J CELL BIOL, V63, P1037, DOI 10.1083/jcb.63.3.1037; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BOOTMAN MD, 1992, J PHYSIOL-LONDON, V450, P163, DOI 10.1113/jphysiol.1992.sp019121; COMBETTES L, 1993, CELL CALCIUM, V14, P279, DOI 10.1016/0143-4160(93)90049-C; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; KASAI H, 1993, CELL, V74, P669, DOI 10.1016/0092-8674(93)90514-Q; LOOMISHUSSELBEE JW, 1993, BIOCHEM J, V289, P861, DOI 10.1042/bj2890861; MARSHALL ICB, 1993, J BIOL CHEM, V268, P13214; MEYER T, 1990, P NATL ACAD SCI USA, V87, P3841, DOI 10.1073/pnas.87.10.3841; MISSIAEN L, 1992, J BIOL CHEM, V267, P22961; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; MISSIAEN L, 1992, NATURE, V357, P599, DOI 10.1038/357599a0; MUALLEM S, 1989, J BIOL CHEM, V264, P205; NUNN DL, 1992, MOL PHARMACOL, V41, P115; OLDERSHAW KA, 1991, BIOCHEM J, V278, P705, DOI 10.1042/bj2780705; ROUXEL FP, 1992, J BIOL CHEM, V267, P20017; SCHOENMAKERS TJM, 1992, BIOTECHNIQUES, V12, P870; SHUTTLEWORTH TJ, 1992, J BIOL CHEM, V267, P3573; TAYLOR CW, 1985, BIOCHEM J, V232, P435, DOI 10.1042/bj2320435; TAYLOR CW, 1990, BIOCHEM J, V266, P189, DOI 10.1042/bj2660189; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; VANDEPUT FHMM, 1993, J MEMBRANE BIOL, V135, P153, DOI 10.1007/BF00231441; VANDEPUT FHMM, 1993, EUR J BIOCHEM, V218, P959; VANDEPUT FHMM, 1991, CELL CALCIUM, V12, P587, DOI 10.1016/0143-4160(91)90056-K; WILLEMS PHGM, 1989, J BIOL CHEM, V264, P9762; ZHANG BX, 1993, J BIOL CHEM, V268, P10997	27	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12438	12443						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	7513688				2022-12-27	WOS:A1994NH71600013
J	DUCHEMIN, AM; ERNST, LK; ANDERSON, CL				DUCHEMIN, AM; ERNST, LK; ANDERSON, CL			CLUSTERING OF THE HIGH-AFFINITY FC RECEPTOR FOR IMMUNOGLOBULIN-G (FC-GAMMA-RI) RESULTS IN PHOSPHORYLATION OF ITS ASSOCIATED GAMMA-CHAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; CELL ANTIGEN RECEPTOR; T-CELL; ZETA-CHAIN; SIGNAL TRANSDUCTION; CROSS-LINKING; ACTIVATION; IGG; REQUIREMENTS; ENGAGEMENT	We are investigating the role of gamma-chain in functions mediated by the high affinity Fc receptor for IgG (Fc gamma RI). In a previous study, we found that gamma-chain, which is a member of the family of zeta-chain proteins, associates with Fc gamma RI, Here we show that clustering of Fc gamma RI leads to a rapid and transient tyrosine phosphorylation of gamma-chain in U937 cells. The response was lim- ited to Fc gamma RI activation, and no phosphorylation of gamma-chain was observed after cross-linking of monoclonal antibodies to other surface receptors on these cells. The gamma-chain phosphorylated after Fc gamma RI clustering was the gamma-chain associated with the receptor. We also identified Syk as one of the kinases associated with the receptor complex. Upon Fc gamma RI activation, Syk, but not ZAP-70, was phosphorylated, and reimmunoadsorption experiments of phosphoproteins from immune complex in vitro kinase assays indicated that Syk is part of the activated gamma-chain-Fc gamma RI complex. These results suggest that gamma-chain links Fc gamma RI to intracellular transduction pathways.	OHIO STATE UNIV,COLL MED,DEPT INTERNAL MED,DAVIS MED RES CTR 2054,COLUMBUS,OH 43210	University System of Ohio; Ohio State University					NCI NIH HHS [R01-CA44983] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044983] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGARWAL A, 1993, J BIOL CHEM, V268, P15900; AKERLEY WL, 1991, BLOOD, V77, P607; ANDERSON CL, 1982, J EXP MED, V156, P1794, DOI 10.1084/jem.156.6.1794; AZZONI L, 1992, J EXP MED, V176, P1745, DOI 10.1084/jem.176.6.1745; BENHAMOU M, 1993, J BIOL CHEM, V268, P23318; BOLEN JB, 1993, ONCOGENE, V8, P2025; BONNEROT C, 1992, EMBO J, V11, P2747, DOI 10.1002/j.1460-2075.1992.tb05340.x; CENCIARELLI C, 1992, SCIENCE, V257, P795, DOI 10.1126/science.1323144; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; DEBETS JMH, 1990, J IMMUNOL, V144, P1304; EISEMAN E, 1992, NATURE, V355, P78; ENGELHARDT W, 1991, EUR J IMMUNOL, V21, P2227, DOI 10.1002/eji.1830210934; ERNST LK, 1992, J BIOL CHEM, V267, P15692; ERNST LK, 1993, P NATL ACAD SCI USA, V90, P6023, DOI 10.1073/pnas.90.13.6023; GREENBERG S, 1993, J EXP MED, V177, P529, DOI 10.1084/jem.177.2.529; GUYRE PM, 1989, J IMMUNOL, V143, P1650; HAMADA F, 1993, P NATL ACAD SCI USA, V90, P6305, DOI 10.1073/pnas.90.13.6305; HUANG MM, 1992, J BIOL CHEM, V267, P5467; HULETT MD, 1991, J IMMUNOL, V147, P1863; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; HUTCHCROFT JE, 1991, J BIOL CHEM, V266, P14846; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; LIAO F, 1992, P NATL ACAD SCI USA, V89, P3659, DOI 10.1073/pnas.89.8.3659; ODIN JA, 1991, SCIENCE, V254, P1785, DOI 10.1126/science.1837175; ORLOFF DG, 1990, NATURE, V347, P189, DOI 10.1038/347189a0; PAOLINI R, 1993, EMBO J, V12, P779, DOI 10.1002/j.1460-2075.1993.tb05712.x; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; RA C, 1989, NATURE, V341, P752, DOI 10.1038/341752a0; RANKIN BM, 1993, J IMMUNOL, V150, P605; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; SCHOLL PR, 1992, J IMMUNOL, V149, P1751; SCHOLL PR, 1993, P NATL ACAD SCI USA, V90, P8847, DOI 10.1073/pnas.90.19.8847; STRAUS DB, 1993, J EXP MED, V178, P1523, DOI 10.1084/jem.178.5.1523; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; WEINSTEIN SL, 1991, P NATL ACAD SCI USA, V88, P4148, DOI 10.1073/pnas.88.10.4148; WIRTHMUELLER U, 1992, J EXP MED, V175, P1381, DOI 10.1084/jem.175.5.1381	42	74	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12111	12117						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	7512959				2022-12-27	WOS:A1994NG37700067
J	LECABEC, V; MARIDONNEAUPARINI, I				LECABEC, V; MARIDONNEAUPARINI, I			COMPLETE AND REVERSIBLE INHIBITION OF NADPH OXIDASE IN HUMAN NEUTROPHILS BY PHENYLARSINE OXIDE AT A STEP DISTAL TO MEMBRANE TRANSLOCATION OF THE ENZYME SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY BURST OXIDASE; PROTEIN-KINASE-C; CHRONIC GRANULOMATOUS-DISEASE; CELL-FREE SYSTEM; TYROSINE PHOSPHORYLATION; 3T3-L1 ADIPOCYTES; PLASMA-MEMBRANE; SUPEROXIDE GENERATION; MICROBICIDAL OXIDASE; HEAT-SHOCK	The effects of the trivalent arsenical phenylarsine oxide (PAO) on the activity of NADPH oxidase in human neutrophils were studied. PAO caused a rapid dose-dependent inhibition of superoxide generation which was maximal at a concentration of 1 mu M, irrespective of the stimulating agent. This inhibitory effect was not due to impaired transduction of activation signals since neither degranulation nor phagocytosis were modified. When cytosolic and membrane fractions from resting neutrophils were combined to reconstitute the NADPH oxidase, O-2(radical anion) generation was inhibited by PAO while translocation of the NADPH oxidase components to the plasma membrane fraction was not affected. The inhibition was completely and specifically reversed by 2,3-dimercaptopropanol, not by dithiothreitol or beta-mercaptoethanol, indicating that PAO binds covalently to spatially vicinal thiol groups. PAO inhibited the plasma membrane's capacity to initiate O-2(radical anion) generation while it apparently did not affect the cytosol. When PAO was added subsequently to NADPH oxidase activation, no inhibition was observed, indicating that PAO cannot reach its target once the oxidase is functionally assembled. In conclusion, PAO is the first complete and reversible inhibitor of NADPH oxidase which could provide the basis for new therapeutical approaches in inflammatory diseases.	CNRS, UPR 8221, F-31077 TOULOUSE, FRANCE	Centre National de la Recherche Scientifique (CNRS)			Maridonneau-Parini, Isabelle/F-1985-2011; le cabec, veronique/U-2712-2019	Maridonneau-Parini, Isabelle/0000-0003-0189-0976				ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ABO A, 1994, BIOCHEM J, V298, P585, DOI 10.1042/bj2980585; AKARD LP, 1988, BLOOD, V72, P322; ANDERSON R, 1991, MOL PHARMACOL, V40, P427; ASAHI M, 1993, J BIOL CHEM, V268, P23334; BABIOR BM, 1992, ADV ENZYMOL RAMB, V65, P49; BALLOTTI R, 1991, EXP CELL RES, V197, P300, DOI 10.1016/0014-4827(91)90436-X; BELLAVITE P, 1992, J LEUKOCYTE BIOL, V51, P329, DOI 10.1002/jlb.51.4.329; BERNIER M, 1987, P NATL ACAD SCI USA, V84, P1844, DOI 10.1073/pnas.84.7.1844; BOKOCH GM, 1991, SCIENCE, V254, P1794, DOI 10.1126/science.1763330; BOLSCHER BGJM, 1989, J CLIN INVEST, V83, P757, DOI 10.1172/JCI113954; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; BOULET I, 1992, ONCOGENE, V7, P703; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; CONSEILLER EC, 1989, EUR J BIOCHEM, V187, P107; COX JA, 1987, J IMMUNOL, V138, P1884; CROSS AR, 1986, BIOCHEM J, V237, P111, DOI 10.1042/bj2370111; CROSS AR, 1990, FREE RADICAL BIO MED, V8, P71, DOI 10.1016/0891-5849(90)90147-B; CURNUTTE JT, 1987, J BIOL CHEM, V262, P5563; DUSI S, 1993, BIOCHEM J, V296, P367, DOI 10.1042/bj2960367; ELENNA J, 1994, J BIOL CHEM, V269, P6729; FROST SC, 1989, J CELL PHYSIOL, V141, P467, DOI 10.1002/jcp.1041410304; FROST SC, 1985, J BIOL CHEM, V260, P2646; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9255, DOI 10.1073/pnas.87.23.9255; HALLIWELL B, 1987, FASEB J, V1, P358, DOI 10.1096/fasebj.1.5.2824268; HETHERINGTON SV, 1983, J IMMUNOL METHODS, V65, P183, DOI 10.1016/0022-1759(83)90314-9; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; JHUN BH, 1991, J BIOL CHEM, V266, P22260; KATO Y, 1992, P NATL ACAD SCI USA, V89, P8507, DOI 10.1073/pnas.89.18.8507; KILPATRICK L, 1992, J IMMUNOL, V149, P3059; Klebanoff S. J., 1988, INFLAMMATION BASIC P; KLEINBERG ME, 1994, BIOCHEMISTRY-US, V33, P2490, DOI 10.1021/bi00175a018; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KOSHKIN V, 1994, FEBS LETT, V338, P285, DOI 10.1016/0014-5793(94)80285-8; KWONG CH, 1993, BIOCHEMISTRY-US, V32, P5711, DOI 10.1021/bi00072a029; LAMBETH JD, 1988, J BIOENERG BIOMEMBR, V20, P709, DOI 10.1007/BF00762549; LECABEC V, 1994, BIOCHEM BIOPH RES CO, V198, P1216, DOI 10.1006/bbrc.1994.1172; LEWIS CT, 1993, J BIOL CHEM, V268, P1628; LIAO K, 1991, J BIOL CHEM, V266, P6544; MADEMA RH, 1991, J BIOL CHEM, V266, P21186; MARIDONNEAUPARINI I, 1989, J CLIN INVEST, V83, P1936, DOI 10.1172/JCI114101; MARIDONNEAUPARINI I, 1986, J IMMUNOL, V137, P2925; MARIDONNEAUPARINI I, 1993, J CELL PHYSIOL, V156, P204, DOI 10.1002/jcp.1041560127; MARIDONNEAUPARINI I, 1991, J CLIN INVEST, V87, P901, DOI 10.1172/JCI115096; MARIDONNEAUPARINI I, 1992, J BIOL CHEM, V267, P6396; MARIDONNEAUPARINI I, 1988, BIOCHEM BIOPH RES CO, V154, P179, DOI 10.1016/0006-291X(88)90667-5; NAKANISHI A, 1992, J BIOL CHEM, V267, P19072; ODONNELL VB, 1993, BIOCHEM J, V290, P41, DOI 10.1042/bj2900041; OETKEN C, 1992, EUR J HAEMATOL, V49, P208; QUINN MT, 1993, J BIOL CHEM, V268, P20983; QUINN MT, 1989, NATURE, V342, P198, DOI 10.1038/342198a0; SCHUSTER MG, 1992, J BIOL CHEM, V267, P5056; SEGAL AW, 1993, TRENDS BIOCHEM SCI, V18, P43, DOI 10.1016/0968-0004(93)90051-N; SEGAL AW, 1989, J CLIN INVEST, V83, P1785, DOI 10.1172/JCI114083; SEIFERT R, 1987, BIOCHEM BIOPH RES CO, V146, P1296, DOI 10.1016/0006-291X(87)90790-X; SENGELOV H, 1992, J BIOL CHEM, V267, P14912; STOVER DR, 1991, P NATL ACAD SCI USA, V88, P7704, DOI 10.1073/pnas.88.17.7704; TAMURA M, 1992, J BIOL CHEM, V267, P7529; THELEN M, 1993, PHYSIOL REV, V73, P797, DOI 10.1152/physrev.1993.73.4.797; VERHOEVEN AJ, 1993, J BIOL CHEM, V268, P18593; WEBB JL, 1966, ENZYMES METABOL INH, V3, P595; WIENTJES FB, 1993, BIOCHEM J, V296, P557, DOI 10.1042/bj2960557; WILEY HS, 1982, J BIOL CHEM, V257, P4222; WILSON E, 1986, J BIOL CHEM, V261, P2616; YANG J, 1992, BIOCHEM J, V281, P809, DOI 10.1042/bj2810809; ZHANG ZY, 1992, BIOCHEMISTRY-US, V31, P1701, DOI 10.1021/bi00121a018	66	83	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	1995	270	5					2067	2073						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QE493	7530716				2022-12-27	WOS:A1995QE49300016
J	KATAGIRI, Y; HIROYAMA, T; AKAMATSU, N; SUZUKI, H; YAMAZAKI, H; TANOUE, K				KATAGIRI, Y; HIROYAMA, T; AKAMATSU, N; SUZUKI, H; YAMAZAKI, H; TANOUE, K			INVOLVEMENT OF ALPHA(V)BETA(3) INTEGRIN IN MEDIATING FIBRIN GEL RETRACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBUNIT CYTOPLASMIC DOMAINS; PLATELET GLYCOPROTEIN-IIB; MONOCLONAL-ANTIBODIES; FIBRONECTIN RECEPTOR; VITRONECTIN RECEPTOR; EXTRACELLULAR-MATRIX; SIGNAL TRANSDUCTION; ADHESION RECEPTORS; CELL-SURFACE; BETA-SUBUNIT	Platelet integrin alpha(IIb)beta(3) (GPIIb-IIIa) plays important roles in platelet-mediated clot retraction. However, little is known about the mechanisms of clot retraction mediated by nucleated cells, In this report, we demonstrate that another member of the beta(3) integrin family, alpha(v) beta(3), is involved in clot retraction mediated by nucleated cells. Retraction of fibrin clots was observed using a human melanoma cell line, C32TG, which contains no alpha(IIb)beta(3) complex. This retraction was inhibited by RGD-containing peptide, monoclonal anti-beta(3), and anti-alpha(v) beta(3) antibodies. Immunoelectron microscopic studies revealed a direct interaction between beta(3) integrin and fibrin fibers at an early stage of clot retraction. We found that another human embryonal cell line, 293, which is known to express alpha(v) beta(1), but no alpha(v) beta(3), lacks fibrin gel retractile activity. Upon transfection of beta(3) DNA into 293 cells, the beta(3) subunit formed a complex with an endogenous alpha(v) subunit. The beta(3)-bearing transfectants were found to retract fibrin gels, which was specifically inhibited by anti-beta(3) antibody. In addition, a point mutation at Asp(119) in the beta(3) ligand binding domain abolished the clot retractile activity of 293 transfectants, indicating the requirement of alpha(v) beta(3) ligand-binding activity, Our findings suggest that alpha(v) beta(3) is involved in mediating the interaction between the three dimensional fibrin network and nucleated cells and in promoting ''post-receptor occupancy'' events.			KATAGIRI, Y (corresponding author), TOKYO METROPOLITAN INST MED SCI, DEPT CARDIOVASC RES, BUNKYO KU, 3-18-22 HONKOMAGOME, TOKYO 113, JAPAN.							ADAMS JC, 1993, DEVELOPMENT, V117, P1183; ADAMS JC, 1990, CELL, V63, P425, DOI 10.1016/0092-8674(90)90175-E; BATES RC, 1991, J BIOL CHEM, V266, P18593; BODARY SC, 1990, J BIOL CHEM, V265, P5938; BRAATEN JV, 1994, BLOOD, V83, P982; BUSK M, 1992, J BIOL CHEM, V267, P5790; CARR ME, 1991, AM J MED SCI, V302, P13, DOI 10.1097/00000441-199107000-00004; CHAN BM, 1992, CELL, V68, P1051, DOI 10.1016/0092-8674(92)90077-P; CHARO IF, 1990, J CELL BIOL, V111, P2795, DOI 10.1083/jcb.111.6.2795; COHEN I, 1989, BLOOD, V73, P1880; COHEN I, 1982, J CELL BIOL, V93, P775, DOI 10.1083/jcb.93.3.775; COHEN I, 1985, PLATELET MEMBRANE GL, P299; DUSTIN ML, 1992, J IMMUNOL, V148, P2654; FOURNIER DJ, 1989, THROMB HAEMOSTASIS, V62, P977; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; GARTNER TK, 1988, THROMB RES, V49, P43; GARTNER TK, 1991, BIOCHEM BIOPH RES CO, V180, P1446; HANTGAN RR, 1985, BLOOD, V65, P1299, DOI 10.1182/blood.V65.6.1299.bloodjournal6561299; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; Horton MR, 1991, DIRECTED MUTAGENESIS, P217; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KATAGIRI Y, 1990, THROMB HAEMOSTASIS, V63, P122; KATAGIRI Y, 1991, CANCER RES, V51, P1286; KLEIN CE, 1991, J CELL BIOL, V115, P1427, DOI 10.1083/jcb.115.5.1427; KOUNS WC, 1992, BLOOD, V80, P2539; LAFLAMME SE, 1992, J CELL BIOL, V117, P437, DOI 10.1083/jcb.117.2.437; LAM SCT, 1989, J BIOL CHEM, V264, P3742; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; MACIEIRACOELHO A, 1990, J CELL PHYSIOL, V142, P610, DOI 10.1002/jcp.1041420322; MCGREGOR JL, 1983, EUR J BIOCHEM, V131, P427, DOI 10.1111/j.1432-1033.1983.tb07281.x; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NIEWIAROWSKI S, 1973, THROMB DIATH HAEMOST, P51; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PASQUALINI R, 1994, J CELL BIOL, V125, P447, DOI 10.1083/jcb.125.2.447; PHILLIPS DR, 1983, J BIOL CHEM, V258, P240; RAMASWAMY H, 1990, EMBO J, V9, P1561, DOI 10.1002/j.1460-2075.1990.tb08275.x; SCHWARTZ MA, 1993, CANCER RES, V53, P1503; SCHWARTZ MA, 1994, MOL BIOL CELL, V5, P389, DOI 10.1091/mbc.5.4.389; SHIMIZU Y, 1990, IMMUNOL REV, V114, P109, DOI 10.1111/j.1600-065X.1990.tb00563.x; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SUZUKI H, 1992, HISTOCHEMISTRY, V97, P381, DOI 10.1007/BF00270384; TAYLOR DB, 1994, P SOC EXP BIOL MED, V205, P35; TOKUYASU KT, 1989, HISTOCHEM J, V21, P163, DOI 10.1007/BF01007491; VOGEL BE, 1990, J BIOL CHEM, V265, P5934; WAYNER EA, 1991, J CELL BIOL, V113, P919, DOI 10.1083/jcb.113.4.919; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; Williams Michael J., 1994, Trends in Cell Biology, V4, P109, DOI 10.1016/0962-8924(94)90059-0; YAMAMOTO N, 1985, THROMB RES, V39, P751, DOI 10.1016/0049-3848(85)90259-2; YAMAMOTO N, 1989, BLOOD, V73, P1552; YLANNE J, 1993, J CELL BIOL, V122, P223, DOI 10.1083/jcb.122.1.223	52	55	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	1995	270	4					1785	1790		10.1074/jbc.270.4.1785	http://dx.doi.org/10.1074/jbc.270.4.1785			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QD204	7530248	hybrid			2022-12-27	WOS:A1995QD20400048
J	NASO, MF; ZIMMERMANN, DR; IOZZO, RV				NASO, MF; ZIMMERMANN, DR; IOZZO, RV			CHARACTERIZATION OF THE COMPLETE GENOMIC STRUCTURE OF THE HUMAN VERSICAN GENE AND FUNCTIONAL-ANALYSIS OF ITS PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; TRANSFORMING GROWTH FACTOR-BETA-1; TRANSCRIPTION FACTOR AP-2; MESSENGER-RNA LEVELS; SMOOTH-MUSCLE CELLS; EXTRACELLULAR-MATRIX; LINK PROTEIN; CORE PROTEIN; FIBROBLAST PROTEOGLYCAN; C4B-BINDING PROTEIN	Versican is a modular proteoglycan involved in the control of cellular growth and differentiation. To understand versican gene regulation and transcriptional control, we have isolated genomic clones spanning the entire gene locus including 5'- and 3'-flanking sequences, Versican was encoded by 15 exons encompassing over 90 kilobase pairs of continuous DNA, The exon organization corresponded to the protein subdomains encoded by homologous proteins, with a remarkable conservation of exon size and intron phase. We discovered an additional exon just proximal to the glycosaminoglycan-binding region that was identical to a recently identified splice variant of versican (Dours-Zimmermann, M, T., and Zimmermann, D. R. (1994) J. Biol. Chem. 269, 32992-32998). The versican promoter harbored a typical TATA box located approximately 16 base pairs upstream of the transcription start site and binding sites for a number of transcription factors involved in regulated gene expression, This promoter was shown to be highly functional in transiently transfected cells of both mesenchymal and epithelial origin. Stepwise 5' deletions identified a strong enhancer element between -209 and -445 base pairs and a strong negative element between -445 and -632 base pairs. This study provides the molecular basis for discerning the transcriptional control of the versican gene and offers the opportunity to investigate genetic disorders linked to this important human gene.	THOMAS JEFFERSON UNIV, DEPT PATHOL & CELL BIOL, PHILADELPHIA, PA 19107 USA; THOMAS JEFFERSON UNIV, JEFFERSON CANC INST, PHILADELPHIA, PA 19107 USA; UNIV ZURICH, INST CLIN PATHOL, DEPT PATHOL, CH-8091 ZURICH, SWITZERLAND	Jefferson University; Jefferson University; University of Zurich			Iozzo, Renato/AAS-1980-2020	Iozzo, Renato/0000-0002-5908-5112	NCI NIH HHS [CA-47282, CA-39481] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039481, R01CA047282] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADANY R, 1990, BIOCHEM BIOPH RES CO, V171, P1402, DOI 10.1016/0006-291X(90)90841-A; ALEXANDER F, 1984, J MOL BIOL, V173, P159, DOI 10.1016/0022-2836(84)90187-6; APPELLA E, 1988, FEBS LETT, V231, P1, DOI 10.1016/0014-5793(88)80690-2; AVRAHAM S, 1992, J BIOL CHEM, V267, P610; BALDWIN CT, 1989, J BIOL CHEM, V264, P15747; BARTA E, 1993, BIOCHEM J, V292, P947, DOI 10.1042/bj2920947; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; BEZOUSKA K, 1991, J BIOL CHEM, V266, P11604; BIGNAMI A, 1993, J NEUROSCI RES, V34, P97, DOI 10.1002/jnr.490340110; BOYD CD, 1993, MATRIX, V13, P457, DOI 10.1016/S0934-8832(11)80112-5; COHEN IR, 1993, P NATL ACAD SCI USA, V90, P10404, DOI 10.1073/pnas.90.21.10404; COLLINS T, 1991, J BIOL CHEM, V266, P2466; COMB M, 1990, NUCLEIC ACIDS RES, V18, P3975, DOI 10.1093/nar/18.13.3975; COSTA RH, 1988, P NATL ACAD SCI USA, V85, P3840, DOI 10.1073/pnas.85.11.3840; CRAWFORD TJ, 1993, DEV BRAIN RES, V76, P264, DOI 10.1016/0165-3806(93)90216-W; DECORDOBA SR, 1991, J EXP MED, V173, P1073, DOI 10.1084/jem.173.5.1073; DODGE GR, 1991, GENOMICS, V10, P673, DOI 10.1016/0888-7543(91)90451-J; DOEGE K, 1990, BIOCHEM SOC T, V18, P200, DOI 10.1042/bst0180200; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; DOURSZIMMERMANN MT, 1994, J BIOL CHEM, V269, P32992; Esko JD, 1991, CURR OPIN CELL BIOL, V3, P805, DOI 10.1016/0955-0674(91)90054-3; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FULOP C, 1993, J BIOL CHEM, V268, P17377; Gallagher JT, 1989, CURR OPIN CELL BIOL, V1, P1201, DOI 10.1016/S0955-0674(89)80072-9; GOETINCK PF, 1987, J CELL BIOL, V105, P2403, DOI 10.1083/jcb.105.5.2403; GRADIN K, 1993, J BIOL CHEM, V268, P4061; GROVER J, 1993, BIOCHEM J, V291, P361, DOI 10.1042/bj2910361; HALBERG DF, 1988, J BIOL CHEM, V263, P9486; HERDEGEN T, 1992, NEUROSCI LETT, V142, P57, DOI 10.1016/0304-3940(92)90619-I; HILLARP A, 1993, J BIOL CHEM, V268, P15017; IOZZO RV, 1992, GENOMICS, V14, P845, DOI 10.1016/S0888-7543(05)80103-X; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; JOHNSTON GI, 1990, J BIOL CHEM, V265, P21381; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; KAHARI VM, 1991, J BIOL CHEM, V266, P10608; KISS I, 1987, P NATL ACAD SCI USA, V84, P6399, DOI 10.1073/pnas.84.18.6399; KRUEGER RC, 1992, J BIOL CHEM, V267, P12149; KRUSIUS T, 1987, J BIOL CHEM, V262, P13120; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; LEBARON RG, 1992, J BIOL CHEM, V267, P10003; LEE TH, 1992, J CELL BIOL, V116, P545, DOI 10.1083/jcb.116.2.545; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MULLEREBERHARD HJ, 1988, ANNU REV BIOCHEM, V57, P321, DOI 10.1146/annurev.biochem.57.1.321; Peltz Stuart W., 1992, Current Opinion in Cell Biology, V4, P979, DOI 10.1016/0955-0674(92)90129-Z; POST TW, 1990, J IMMUNOL, V144, P740; QWARNSTROM EE, 1993, BIOCHEM J, V294, P613, DOI 10.1042/bj2940613; RAUCH U, 1992, J BIOL CHEM, V267, P19536; RHODES C, 1988, J BIOL CHEM, V263, P6063; RICCIO A, 1992, MOL CELL BIOL, V12, P1846, DOI 10.1128/MCB.12.4.1846; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SANTRA M, 1994, J BIOL CHEM, V269, P579; SATOBIGBEE C, 1993, J NEUROCHEM, V60, P2106, DOI 10.1111/j.1471-4159.1993.tb03495.x; SCHONHERR E, 1991, J BIOL CHEM, V266, P17640; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; SHINOMURA T, 1993, J BIOL CHEM, V268, P14461; STOOLMAN LM, 1989, CELL, V56, P907, DOI 10.1016/0092-8674(89)90620-X; TAN EML, 1991, LAB INVEST, V64, P474; TONA A, 1993, J HISTOCHEM CYTOCHEM, V41, P593, DOI 10.1177/41.4.8450198; UPHOLT WB, 1993, EXPERIENTIA, V49, P384, DOI 10.1007/BF01923583; YAMADA H, 1994, J BIOL CHEM, V269, P10119; YAO LY, 1994, MATRIX BIOL, V14, P213, DOI 10.1016/0945-053X(94)90185-6; YOSHITAKE S, 1985, BIOCHEMISTRY-US, V24, P3736, DOI 10.1021/bi00335a049; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x; ZIMMERMANN DR, 1994, J CELL BIOL, V124, P817, DOI 10.1083/jcb.124.5.817	65	142	148	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32999	33008						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7528742				2022-12-27	WOS:A1994QA63800044
J	PAN, Y; WILSON, P; GITSCHIER, J				PAN, Y; WILSON, P; GITSCHIER, J			THE EFFECT OF 8 V2 VASOPRESSIN RECEPTOR MUTATIONS ON STIMULATION OF ADENYLYL-CYCLASE AND BINDING TO VASOPRESSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEPHROGENIC DIABETES-INSIPIDUS; PROTEIN-COUPLED RECEPTORS; CLONING; GENE; MUTAGENESIS; EXPRESSION	We previously identified six V2 vasopressin receptor mutations in five unrelated nephrogenic diabetes insipidus (NDI) families. In order to elucidate the effect of these mutations on the function of the V2 vasopressin receptor, we introduced these six and two additional, naturally occurring mutations into the V2 vasopressin receptor gene by in vitro mutagenesis. Five of the mutants (two frameshift, one nonsense, and two missense) failed to stimulate adenylyl cyclase due to their inability to bind vasopressin under the experimental conditions. In contrast, ligand binding and cAMP accumulation were normal for two other mutations, a A61V missense mutation and an in-frame deletion of four amino acids (Arg-247 to Gly-250), suggesting that they are not the cause of NDI in these families. The deletion mutation was found in a family in conjunction with a second mutation, R181C, which yielded a much reduced ligand binding capacity. The K-D of R181C was at least 26 times higher than that of the wild type. Further characterization by an immunofluorescent assay showed that the R181C mutant receptor is expressed and distributed on the cell surface in a manner similar to that of the wild type. This finding indicates that the inability of this mutant to stimulate adenylyl cyclase is caused by the reduced capacity for vasopressin binding and that the R181C mutation is responsible for NDI in this family.	UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PSYCHIAT,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	PAN, Y (corresponding author), UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143, USA.							BICHET DG, 1993, J CLIN INVEST, V92, P1262, DOI 10.1172/JCI116698; BIRNBAUMER M, 1992, NATURE, V357, P333, DOI 10.1038/357333a0; BIRNBAUMER M, 1992, J BIOL CHEM, V267, P11783; BROWNSTEIN MJ, 1993, 4TH I8NT VAS C, P33; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; GODFREY P, 1993, NAT GENET, V4, P227, DOI 10.1038/ng0793-227; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; KNOERS N, 1993, 4TH INT VAS C, P571; KOJRA E, 1993, 4TH INT VAS C, P582; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LOLAIT SJ, 1992, NATURE, V357, P336, DOI 10.1038/357336a0; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MERENDINO JJ, 1993, NEW ENGL J MED, V328, P1538, DOI 10.1056/NEJM199305273282106; PAN Y, 1992, NAT GENET, V2, P103, DOI 10.1038/ng1092-103; ROBBINS LS, 1993, CELL, V72, P827, DOI 10.1016/0092-8674(93)90572-8; ROSENTHAL W, 1992, NATURE, V359, P233, DOI 10.1038/359233a0; ROSENTHAL W, 1993, J BIOL CHEM, V268, P13030; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P8840, DOI 10.1073/pnas.88.19.8840; VANDENOUWELAND AMW, 1992, NAT GENET, V2, P99, DOI 10.1038/ng1092-99; VONZASTROW M, 1993, J BIOL CHEM, V268, P763; WESS J, 1993, EMBO J, V12, P331, DOI 10.1002/j.1460-2075.1993.tb05661.x; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3	26	71	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31933	31937						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7527400				2022-12-27	WOS:A1994PX30300092
J	SHERMAN, M; GOLDBERG, AL				SHERMAN, M; GOLDBERG, AL			HEAT SHOCK-INDUCED PHOSPHORYLATION OF GROEL ALTERS ITS BINDING AND DISSOCIATION FROM UNFOLDED PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MOLECULAR CHAPERONES; DNAK; STABILITY; ATPASE; HSP70; HSP60	During heat shock of Escherichia coli, the expression of the major molecular chaperone, GroEL, increases; in addition, a small fraction of the GroEL becomes phosphorylated (Sherman, M. Yu., and Goldberg, A. L. (1992) Nature 367, 166-1692). This heat shock-induced phosphorylation was found to enhance 50-100-fold the capacity of GroEL to bind to several denatured proteins, including casein and fetuin, The phosphorylated species in the cell extract bound quantitatively to affinity columns containing these ligands, and treatment of the extract with alkaline phosphatase markedly reduced this binding, Like heat shock (42 degrees C), overproduction of GroEL (5-10-fold) from the multicopy plasmid at low temperature (25 degrees C) increased the phosphorylated fraction, which bound strongly to denatured fetuin, Heat shock of these cells further enhanced phosphorylation, and about 15% of the induced level of GroEL could bind tightly to the fetuin column, The predominant form of the GroEL that bound to the denatured protein columns appeared to contain at least one phosphate on each of its subunits, although multiple phosphorylated subunits were also observed, With fetuin and casein as affinity ligands, only the phosphorylated species bound, and this material dissociated quantitatively upon addition of ATP-Mg2+. With CRAG and histone as the ligands, some unphosphorylated GroEL also bound, but this species (unlike the phosphorylated form) was not released by ATP alone; its release required the addition of the cofactor GroES together with ATP. Thus, the phosphorylation of GroEL during heat shock greatly enhances its ability to bind to certain denatured proteins and stimulates its ATP-dependent dissociation in the absence of GroES, Presumably, these alterations in the properties of a fraction of GroEL aid in the refolding or the degradation of specific damaged polypeptides.			SHERMAN, M (corresponding author), HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115, USA.							BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; CRAIG E, 1990, TRENDS BIOCHEM SCI, V16, P135; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; GOFF SA, 1985, CELL, V41, P587, DOI 10.1016/S0092-8674(85)80031-3; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; GRAGEROV A, 1992, P NATL ACAD SCI USA, V89, P10341, DOI 10.1073/pnas.89.21.10341; Hartl F U, 1991, Semin Immunol, V3, P5; HARTL FU, 1992, ANNU REV BIOPH BIOM, V21, P293, DOI 10.1146/annurev.bb.21.060192.001453; HELLEBUST H, 1989, J BIOTECHNOL, V12, P275, DOI 10.1016/0168-1656(89)90047-3; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; KANDROR O, 1994, J BIOL CHEM, V269, P23575; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1992, SCIENCE, V258, P995, DOI 10.1126/science.1359644; MCCARTY JS, 1991, P NATL ACAD SCI USA, V88, P9513, DOI 10.1073/pnas.88.21.9513; MENDOZA JA, 1992, J BIOL CHEM, V267, P17631; SHERMAN M, 1991, J BACTERIOL, V173, P4249; SHERMAN MY, 1992, EMBO J, V11, P71; SHERMAN MY, 1993, P NATL ACAD SCI USA, V90, P8648, DOI 10.1073/pnas.90.18.8648; SHERMAN MY, 1992, NATURE, V367, P166; STRAUS D, 1990, GENE DEV, V4, P2202, DOI 10.1101/gad.4.12a.2202; STRAUS DB, 1988, GENE DEV, V2, P1851, DOI 10.1101/gad.2.12b.1851; ZYLICZ M, 1983, P NATL ACAD SCI-BIOL, V80, P6431, DOI 10.1073/pnas.80.21.6431; [No title captured]	25	30	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31479	31483						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7527389				2022-12-27	WOS:A1994PX30300026
J	BUELT, MK; GLIDDEN, BJ; STORM, DR				BUELT, MK; GLIDDEN, BJ; STORM, DR			REGULATION OF P68 RNA HELICASE BY CALMODULIN AND PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							AMINO-ACID-SEQUENCE; BINDING-PROTEIN; PHOSPHORYLATION SITE; IDENTIFICATION; NEUROMODULIN; PURIFICATION; BRAIN; MEMBRANES; CLONING; CALCIUM	Human p68 RNA helicase is a nuclear RNA-dependent ATPase that belongs to a family of putative helicases known as the DEAD box proteins. These proteins have been implicated in aspects of RNA function including translation initiation, splicing, and ribosome assembly in a variety of organisms ranging from Escherichia coli to humans. While members of this family are believed to function in the manipulation of RNA secondary structure, little is known about the regulation of these enzymes. By immunological methods and sequence comparison, we have found that p68 possesses a region of sequence similarity to the conserved protein kinase C phosphorylation site and calmodulin binding domain (also known as the IQ domain) of the neural-specific proteins neuromodulin (GAP-43) and neurogranin (RC3). We report that p68 is phosphorylated by protein kinase C in vitro and binds calmodulin in a Ca2+- dependent manner. Both phosphorylation and calmodulin binding inhibited p68 ATPase activity, suggesting that the RNA unwinding activity of p68 may be regulated by dual Ca2+ signal transduction pathways through its IQ domain.	UNIV WASHINGTON, DEPT PHARMACOL, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031496] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 31496, NS09174] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ALEXANDER KA, 1987, J BIOL CHEM, V262, P6108; ALEXANDER KA, 1988, J BIOL CHEM, V263, P7544; ANDREASEN TJ, 1983, BIOCHEMISTRY-US, V22, P4615, DOI 10.1021/bi00289a001; Apel E D, 1992, Perspect Dev Neurobiol, V1, P3; APEL ED, 1990, BIOCHEMISTRY-US, V29, P2330, DOI 10.1021/bi00461a017; BACHS O, 1987, J BIOL CHEM, V262, P10786; BAETGE EE, 1991, NEURON, V6, P21, DOI 10.1016/0896-6273(91)90118-J; BAUDIER J, 1991, J BIOL CHEM, V266, P229; BILLINGSLEY ML, 1985, P NATL ACAD SCI USA, V82, P7585, DOI 10.1073/pnas.82.22.7585; CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORNELIUSSEN D, 1994, NATURE, V368, P760; DALBADIEMCFARLAND G, 1990, P NATL ACAD SCI USA, V87, P4236, DOI 10.1073/pnas.87.11.4236; ESPREAFICO EM, 1992, J CELL BIOL, V119, P1541, DOI 10.1083/jcb.119.6.1541; FORD MJ, 1988, NATURE, V332, P736, DOI 10.1038/332736a0; HIRLING H, 1989, NATURE, V339, P562, DOI 10.1038/339562a0; HLOCH P, 1990, NUCLEIC ACIDS RES, V18, P3045, DOI 10.1093/nar/18.10.3045; IGGO RD, 1989, EMBO J, V8, P1827, DOI 10.1002/j.1460-2075.1989.tb03577.x; IGGO RD, 1991, MOL CELL BIOL, V11, P1326, DOI 10.1128/MCB.11.3.1326; LANE DP, 1980, NATURE, V288, P167, DOI 10.1038/288167a0; LASKO PF, 1988, NATURE, V335, P611, DOI 10.1038/335611a0; LIU YC, 1990, TRENDS PHARMACOL SCI, V11, P107; LU KP, 1993, ENDOCR REV, V14, P40, DOI 10.1210/er.14.1.40; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; PATTERSON LF, 1992, NUCLEIC ACIDS RES, V20, P3063, DOI 10.1093/nar/20.12.3063; PAUSE A, 1993, MOL CELL BIOL, V13, P6789, DOI 10.1128/MCB.13.11.6789; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAKAGI T, 1990, J BIOL CHEM, V265, P19721; TALLANT EA, 1983, METHOD ENZYMOL, V102, P244; VENDRELL M, 1991, J NEUROCHEM, V57, P622, DOI 10.1111/j.1471-4159.1991.tb03793.x; WAKIM BT, 1987, BIOCHEMISTRY-US, V26, P7466, DOI 10.1021/bi00397a040; WATSON JB, 1990, J NEUROSCI RES, V26, P397, DOI 10.1002/jnr.490260402	34	65	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29367	29370						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7525583				2022-12-27	WOS:A1994PU28400009
J	SHANG, J; CLAYTON, DA				SHANG, J; CLAYTON, DA			HUMAN MITOCHONDRIAL TRANSCRIPTION TERMINATION EXHIBITS RNA-POLYMERASE INDEPENDENCE AND BIASED BIPOLARITY IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEIN; TRANSFER RNALEU(UUR) GENE; STROKE-LIKE EPISODES; LACTIC-ACIDOSIS; POINT MUTATION; MELAS SUBGROUP; MYOPATHY; INVITRO; SITE; ENCEPHALOMYOPATHIES	Human mitochondrial 16 S rRNA 3'-end formation requires a tridecamer template sequence and a trans-acting protein of similar to 34 kDa. This protein binds tightly to its target sequence and further analysis of the protein-DNA complex revealed that the DNA is bent. Either T3, T7, Escherichia coli, or yeast mitochondrial RNA polymerase produced transcripts mapping at this termination site. With these heterologous RNA polymerases, RNA 3'-end formation was detected only in the transcription polarity opposite that of mitochondrial rRNA synthesis; the efficiency of termination in the homologous human RNA polymerase system is approximately a-fold greater in this same opposite polarity. These results suggested the possible importance of biased bipolar transcription termination in vivo. For wild-type mtDNA the apparent relative efficiency of termination in vivo reflected the values determined in vitro. Examination of a pathogenic human mtDNA mutation known to result in impaired termination in vitro showed no significant differences in relative transcript abundances in vivo, despite a loss of in vitro termination efficiency in both directions. Recently, six additional mitochondrial disease-associated point mutations have been reported that cluster at the human mitochondrial transcription termination site. None of these resulted in significantly impaired transcription termination in vitro.			SHANG, J (corresponding author), STANFORD UNIV,SCH MED,DEPT DEV BIOL,STANFORD,CA 94305, USA.				NIGMS NIH HHS [GM33088-24] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM033088, R01GM033088] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BATTEY J, 1980, J BIOL CHEM, V255, P1599; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221; CHRISTIANSON TW, 1988, MOL CELL BIOL, V8, P4502, DOI 10.1128/MCB.8.10.4502; CHRISTIANSON TW, 1986, P NATL ACAD SCI USA, V83, P6277, DOI 10.1073/pnas.83.17.6277; DAGA A, 1993, J BIOL CHEM, V268, P8123; FISHER RP, 1985, J BIOL CHEM, V260, P1330; FISHER RP, 1992, J BIOL CHEM, V267, P3358; FISHER RP, 1991, J BIOL CHEM, V266, P9153; GELFAND R, 1981, MOL CELL BIOL, V1, P497, DOI 10.1128/MCB.1.6.497; GOTO Y, 1992, ANN NEUROL, V31, P672, DOI 10.1002/ana.410310617; GOTO Y, 1991, BIOCHIM BIOPHYS ACTA, V1097, P238, DOI 10.1016/0925-4439(91)90042-8; GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0; GOTTLIEB E, 1989, EMBO J, V8, P851, DOI 10.1002/j.1460-2075.1989.tb03446.x; GRUMMT I, 1985, CELL, V43, P801, DOI 10.1016/0092-8674(85)90253-3; HAYASHI JI, 1993, BIOCHEM BIOPH RES CO, V197, P1049, DOI 10.1006/bbrc.1993.2584; HESS JF, 1991, NATURE, V351, P236, DOI 10.1038/351236a0; KERPPOLA TK, 1990, BIOCHEMISTRY-US, V29, P269, DOI 10.1021/bi00453a037; KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480; KRUSE B, 1989, CELL, V58, P391, DOI 10.1016/0092-8674(89)90853-2; KUHN A, 1990, NATURE, V344, P559, DOI 10.1038/344559a0; LIU B, 1993, NATURE, V366, P33, DOI 10.1038/366033a0; MORAES CT, 1993, J CLIN INVEST, V92, P2906, DOI 10.1172/JCI116913; MORTEN K, 1992, 2ND INT C HUM MIT PA, P39; OJALA D, 1981, NATURE, V290, P410; PAVCO PA, 1991, NUCLEIC ACIDS RES, V19, P4639, DOI 10.1093/nar/19.17.4639; PAVCO PA, 1990, J BIOL CHEM, V265, P9960; PRENTKI P, 1987, NUCLEIC ACIDS RES, V15, P10060, DOI 10.1093/nar/15.23.10060; SACCOMANNO CF, 1992, BIOTECHNIQUES, V13, P846; SCHON EA, 1992, BIOCHIM BIOPHYS ACTA, V1101, P206, DOI 10.1016/S0005-2728(05)80021-0; SMID A, 1992, J MOL BIOL, V227, P635, DOI 10.1016/0022-2836(92)90213-4; SWEENEY MG, 1993, Q J MED, V86, P709; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; ZEVIANI M, 1991, LANCET, V338, P143, DOI 10.1016/0140-6736(91)90136-D	34	42	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					29112	29120						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7525579				2022-12-27	WOS:A1994PU16800088
J	TAOUIS, M; LEVYTOLEDANO, R; ROACH, P; TAYLOR, SI; GORDEN, P				TAOUIS, M; LEVYTOLEDANO, R; ROACH, P; TAYLOR, SI; GORDEN, P			RESCUE AND ACTIVATION OF A BINDING DEFICIENT INSULIN-RECEPTOR - EVIDENCE FOR INTERMOLECULAR TRANSPHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; TYROSINE KINASE-ACTIVITY; STRUCTURAL BASIS; SIGNAL TRANSDUCTION; MUTATION; PHOSPHORYLATION; AUTOPHOSPHORYLATION; RESISTANCE; SUBSTRATE; PROTEIN	Binding of insulin to the a subunit of the insulin receptor (IR) leads to autophosphorylation of the beta subunit. The reaction proceeds as intramolecular transphosphorylation between alpha beta half-receptors of the heterotetrameric receptor dimer (alpha(2) beta(2)). Since IRs are mobile in the plane of the plasma membrane, it is also possible that transphosphorylation may occur between adjacent holoreceptors (alpha(2) beta(2)) by an intermolecular reaction. To address this question, we cotransfected NIH-3T3 cells with two IR cDNA constructs: a truncated but functionally normal IR lacking the C-terminal 43 amino acids (Delta 43) and a full-length Leu(323) mutant receptor that is expressed on the cell surface but that does not bind insulin. A clonal cell line was selected from cells cotransfected with a 1/5 ratio of Delta 43 cDNA/Leu(323) cDNA. The two homodimers (Leu(323) and Delta 43) were expressed without detectable formation of hybrid receptors. By using specific antibodies, we demonstrate that in cells coexpressing both homodimers, the Leu(323) mutant receptor was phosphorylated in vivo by the Delta 43 IR in an insulin-dependent manner. However, when the Leu(323) mutant receptor was expressed alone, no phosphorylation was detected. In addition, we demonstrate the association of the phosphorylated Leu(323) mutant receptor with insulin receptor substrate-1 and with phosphatidylinositol 3-kinase. These findings indicate that insulin binding is not required for phosphorylation of the Leu(323) mutant receptor, that the phosphorylation of the Leu(323) mutant receptor occurs by an intermolecular transphosphorylation mechanism, and, finally, that the Leu(323) mutant receptor, once phosphorylated, can associate with insulin receptor substrate-1 and phosphatidylinositol 3-kinase.	NIDDKD,DIABET BRANCH,BETHESDA,MD 20892; INRA,RECH AVICOLES STN,F-37380 NOUZILLY,FRANCE	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); INRAE			Taouis, Mohammed/CAA-1797-2022	Taouis, Mohammed/0000-0002-4101-691X				ACCILI D, 1991, J BIOL CHEM, V266, P434; BONISCHNETZLER M, 1987, J BIOL CHEM, V262, P8395; CAMA A, 1988, DIABETES, V37, P982, DOI 10.2337/diabetes.37.7.982; CAMA A, 1992, J BIOL CHEM, V267, P8383; CAMA A, 1991, J CLIN ENDOCR METAB, V73, P894, DOI 10.1210/jcem-73-4-894; DEMEYTS P, 1994, IN PRESS DIABETOLOGI; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; GORDEN P, 1978, P NATL ACAD SCI USA, V75, P5025, DOI 10.1073/pnas.75.10.5025; HONEGGER AM, 1989, P NATL ACAD SCI USA, V86, P925, DOI 10.1073/pnas.86.3.925; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; KADOWAKI T, 1988, SCIENCE, V240, P787, DOI 10.1126/science.2834824; KATO H, 1993, J BIOL CHEM, V268, P2655; LAMMERS R, 1990, J BIOL CHEM, V265, P16886; LEE JS, 1993, J BIOL CHEM, V268, P4092; LEVYTOLEDANO R, 1994, EMBO J, V13, P835, DOI 10.1002/j.1460-2075.1994.tb06326.x; MAEGAWA H, 1988, J BIOL CHEM, V263, P12629; MYERS MG, 1991, J BIOL CHEM, V266, P10616; ROACH P, 1994, DIABETES, V43, P1096, DOI 10.2337/diabetes.43.9.1096; SCHAFFER L, 1994, EUR J BIOCHEM, V221, P1127, DOI 10.1111/j.1432-1033.1994.tb18833.x; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SHOELSON SE, 1993, J BIOL CHEM, V268, P4085; SWEET LJ, 1987, J BIOL CHEM, V262, P6939; TAOUIS M, 1994, J BIOL CHEM, V269, P14912; TAOUIS M, 1993, MOL CELL ENDOCRINOL, V96, P113, DOI 10.1016/0303-7207(93)90101-O; TAYLOR SI, 1984, J CLIN ENDOCR METAB, V58, P182, DOI 10.1210/jcem-58-1-182; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VANHORN DJ, 1994, J BIOL CHEM, V269, P29; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034; ZANG B, 1991, P NATL ACAD SCI USA, V88, P9858	31	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27762	27766						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7525562				2022-12-27	WOS:A1994PV77100093
J	MCEWAN, IJ; ALMLOF, T; WIKSTROM, AC; DAHLMANWRIGHT, K; WRIGHT, APH; GUSTAFSSON, JA				MCEWAN, IJ; ALMLOF, T; WIKSTROM, AC; DAHLMANWRIGHT, K; WRIGHT, APH; GUSTAFSSON, JA			THE GLUCOCORTICOID RECEPTOR FUNCTIONS AT MULTIPLE STEPS DURING TRANSCRIPTION INITIATION BY RNA-POLYMERASE-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAINS; PREINITIATION COMPLEX; MONOCLONAL-ANTIBODIES; ACTIVATION DOMAIN; IMMUNOCYTOCHEMICAL LOCALIZATION; TRANSACTIVATION DOMAIN; DEOXYRIBONUCLEIC-ACID; PROGESTERONE-RECEPTOR; BASAL TRANSCRIPTION; GENE-EXPRESSION	We have used a panel of monoclonal antibodies and a cell-free transcription assay to study the function of the tau(1) transactivation domain of the human glucocorticoid receptor. Three antibodies (monoclonal antibodies 250, 275, and 286) specifically inhibited tau(1)-dependent transcription, but had little or no effect on either basal transcription or the activity of an unrelated yeast transcription factor. This inhibition was not due to interference of DNA binding activity, as all three antibodies super shifted tau(1)-containing protein-DNA complexes. Epitopes for all three antibodies were localized to a region between amino acids 190 and 200, which lies within the recently defined 41-amino acid core region of tau(1) that is required for transactivation (Dahlman-Wright, K., Almlof, T., McEwan, I.J., Gustafsson, J-A., and Wright, A. P. H. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 1619-1623). In contrast to the effect on tau(1)-dependent transcription none of the antibodies tested antagonized the squelching ability of the tau(1) domain, suggesting that tau(1)-mediated transactivation involves interactions in addition to those identified by the squelching assay. Consistent with this, a comparison of the kinetics of tau(1) squelching and inhibition of transactivation by monoclonal antibodies suggested a role for tau(1) mediated transcriptional induction at two or more steps during transcription initiation by RNA polymerase II.	KAROLINSKA INST,NOVUM,DEPT MED NUTR,S-14157 HUDDINGE,SWEDEN; KAROLINSKA INST,NOVUM,CTR STRUCT BIOCHEM,S-14157 HUDDINGE,SWEDEN	Karolinska Institutet; Karolinska Institutet	MCEWAN, IJ (corresponding author), KAROLINSKA INST,NOVUM,CTR BIOTECHNOL,S-14157 HUDDINGE,SWEDEN.		Wright, Anthony PH/J-8187-2015					AKNER G, 1990, EUR J CELL BIOL, V53, P390; ANTAKLY T, 1984, ENDOCRINOLOGY, V115, P1984, DOI 10.1210/endo-115-5-1984; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CARLSTEDTDUKE J, 1982, P NATL ACAD SCI-BIOL, V79, P4260, DOI 10.1073/pnas.79.14.4260; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; DAHLMANWRIGHT K, 1994, P NATL ACAD SCI USA, V91, P1619, DOI 10.1073/pnas.91.5.1619; DEJONG J, 1993, GENE DEV, V7, P2220, DOI 10.1101/gad.7.11.2220; EISEN HJ, 1980, P NATL ACAD SCI-BIOL, V77, P3893, DOI 10.1073/pnas.77.7.3893; EISEN LP, 1985, J BIOL CHEM, V260, P1805; FLANAGAN PM, 1991, NATURE, V350, P436, DOI 10.1038/350436a0; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; FREEDMAN LP, 1989, SCIENCE, V245, P298, DOI 10.1126/science.2473529; GAMETCHU B, 1984, ENDOCRINOLOGY, V114, P274, DOI 10.1210/endo-114-1-274; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GOVINDAN MV, 1984, J BIOL CHEM, V259, P2915; HAWLEY DK, 1985, J BIOL CHEM, V260, P8163; HOLLENBERG SM, 1987, CELL, V49, P39, DOI 10.1016/0092-8674(87)90753-7; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; ING NH, 1992, J BIOL CHEM, V267, P17617; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; LINDEMEYER RG, 1990, CANCER RES, V50, P7985; LUE NF, 1989, P NATL ACAD SCI USA, V86, P486, DOI 10.1073/pnas.86.2.486; MA DM, 1993, GENE DEV, V7, P2246, DOI 10.1101/gad.7.11.2246; MCEWAN IJ, 1993, MOL CELL BIOL, V13, P399, DOI 10.1128/MCB.13.1.399; MEYER ME, 1992, J BIOL CHEM, V267, P10882; OKRET S, 1984, P NATL ACAD SCI-BIOL, V81, P1609, DOI 10.1073/pnas.81.6.1609; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; ROBERTSON NM, 1987, BIOCHEM J, V246, P55, DOI 10.1042/bj2460055; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; RUSCONI S, 1987, EMBO J, V6, P1309, DOI 10.1002/j.1460-2075.1987.tb02369.x; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SHEMSHEDINI L, 1992, J BIOL CHEM, V267, P1834; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; TSAI SY, 1990, J BIOL CHEM, V265, P17055; WESTPHAL HM, 1982, EMBO J, V1, P1467, DOI 10.1002/j.1460-2075.1982.tb01339.x; WHITE J, 1992, EMBO J, V11, P2229, DOI 10.1002/j.1460-2075.1992.tb05282.x; WHITE JH, 1991, P NATL ACAD SCI USA, V88, P7674, DOI 10.1073/pnas.88.17.7674; WIKSTROM AC, 1987, ENDOCRINOLOGY, V120, P1232, DOI 10.1210/endo-120-4-1232; WILSON EM, 1988, MOL ENDOCRINOL, V2, P1018, DOI 10.1210/mend-2-11-1018; WRIGHT APH, 1993, J STEROID BIOCHEM, V47, P11, DOI 10.1016/0960-0760(93)90052-X; WRIGHT APH, 1991, P NATL ACAD SCI USA, V88, P8283, DOI 10.1073/pnas.88.19.8283; WRIGHT APH, 1990, J BIOL CHEM, V265, P14763; WRIGHT APH, 1991, MOL ENDOCRINOL, V5, P1366, DOI 10.1210/mend-5-10-1366; YOKOMORI K, 1993, GENE DEV, V7, P2235, DOI 10.1101/gad.7.11.2235; ZHU H, 1992, P NATL ACAD SCI USA, V89, P5291, DOI 10.1073/pnas.89.12.5291; ZILLIACUS J, 1991, J BIOL CHEM, V266, P3101	54	31	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25629	25636						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7523389				2022-12-27	WOS:A1994PQ49100062
J	MORRIS, CA; UNDERWOOD, PA; BEAN, PA; SHEEHAN, M; CHARLESWORTH, JA				MORRIS, CA; UNDERWOOD, PA; BEAN, PA; SHEEHAN, M; CHARLESWORTH, JA			RELATIVE TOPOGRAPHY OF BIOLOGICALLY-ACTIVE DOMAINS OF HUMAN VITRONECTIN - EVIDENCE FROM MONOCLONAL-ANTIBODY EPITOPE AND DENATURATION STUDIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM SPREADING FACTOR; S-PROTEIN VITRONECTIN; THROMBIN-ANTITHROMBIN-III; HEPARIN-BINDING PROPERTIES; PLASMINOGEN-ACTIVATOR; HUMAN-PLASMA; STAPHYLOCOCCUS-AUREUS; COMPLEX-FORMATION; COLLAGEN-BINDING; SC5B-9 COMPLEX	A panel of monoclonal antibodies to human vitronectin was used to define some epitopes for the multifunctions of this protein. Separate antibodies were identified which strongly inhibited cell spreading activity and which prevented binding to collagen. A third group interfered with the ability of vitronectin to inhibit complement-mediated guinea pig erythrocyte reactive lysis. None of the antibodies from these three groups prevented heparin binding, providing evidence that this reaction occurs at a fourth location; a different monoclonal antibody partially inhibited the binding of heparin, The relative accessibility of each biologically active epitope was assessed by the differential binding of the monoclonals to native and denatured vitronectin. Reactivity of the antibody which inhibited heparin binding greatly increased upon denaturation of vitronectin, implying that this region is normally inaccessible in the native form of the molecule. By contrast, epitopes for cell spreading, collagen binding, and inhibition of terminal complement complex lysis were destroyed by denaturation. On the basis of denaturation data and epitope mapping by competitive exclusion of monoclonal antibodies, a Venn diagram was constructed to represent overlap of monoclonal antibody epitopes in the tertiary structure. Linear epitopes for the antibodies were identified using cyanogen bromide and plasmin-derived peptides from vitronectin, The antibody which strongly inhibited cell binding reacted with a region containing the RGD site, whereas linear epitopes for collagen binding and complement inhibition appeared to reside in a 43-kDa peptide representing the internal region of the amino acid sequence, excluding the heparin-binding site. The latter two epitopes were differentiated from each other by reactivity of the antibody which inhibited collagen binding toward a smaller 20-kDa plasmin-derived peptide.	PRINCE HENRY HOSP,DEPT NEPHROL,LITTLE BAY,NSW 2036,AUSTRALIA; CSIRO,DIV BIOMOLEC ENGN,N RYDE,NSW 2113,AUSTRALIA	Commonwealth Scientific & Industrial Research Organisation (CSIRO)								BARNES DW, 1985, J BIOL CHEM, V260, P9117; BIESECKER G, 1990, J IMMUNOL, V145, P209; CHHATWAL GS, 1987, INFECT IMMUN, V55, P1878, DOI 10.1128/IAI.55.8.1878-1883.1987; DAHLBACK B, 1985, BIOCHEMISTRY-US, V24, P2368, DOI 10.1021/bi00330a036; DEBOER HC, 1992, J BIOL CHEM, V267, P2264; DECLERCK PJ, 1988, J BIOL CHEM, V263, P15454; FUQUAY JI, 1986, INFECT IMMUN, V52, P714, DOI 10.1128/IAI.52.3.714-717.1986; GEBB C, 1986, J BIOL CHEM, V261, P6698; GECHTMAN Z, 1993, FEBS LETT, V315, P293, DOI 10.1016/0014-5793(93)81181-X; HAYASHI M, 1985, J BIOCHEM-TOKYO, V98, P1135, DOI 10.1093/oxfordjournals.jbchem.a135363; HAYMAN EG, 1983, P NATL ACAD SCI-BIOL, V80, P4003, DOI 10.1073/pnas.80.13.4003; HETLAND G, 1989, SCAND J IMMUNOL, V29, P15, DOI 10.1111/j.1365-3083.1989.tb01094.x; HEUSSER C, 1973, J IMMUNOL, V110, P820; HILDEBRAND A, 1988, J BIOL CHEM, V263, P2436; HOGASEN K, 1992, J BIOL CHEM, V267, P23076; Hunt L T, 1987, Protein Seq Data Anal, V1, P21; ILL CR, 1985, J BIOL CHEM, V260, P5610; ISHIKAWA M, 1992, BIOCHIM BIOPHYS ACTA, V1121, P173, DOI 10.1016/0167-4838(92)90351-D; IZUMI M, 1988, CELL STRUCT FUNCT, V13, P217, DOI 10.1247/csf.13.217; JENNE D, 1985, THROMB RES, V38, P401, DOI 10.1016/0049-3848(85)90138-0; JENNE D, 1985, EMBO J, V4, P3153, DOI 10.1002/j.1460-2075.1985.tb04058.x; KANZ L, 1988, BLOOD S, V72, P327; KITAGAKIOGAWA H, 1990, BIOCHIM BIOPHYS ACTA, V1033, P49, DOI 10.1016/0304-4165(90)90193-Z; KOST C, 1992, J BIOL CHEM, V267, P12098; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MILIS L, 1993, CLIN EXP IMMUNOL, V92, P114; Murphy B F, 1989, Int Immunol, V1, P551, DOI 10.1093/intimm/1.5.551; PARKER CJ, 1989, BRIT J HAEMATOL, V71, P245, DOI 10.1111/j.1365-2141.1989.tb04262.x; PODACK ER, 1984, ACTA PATH MICRO IM C, V92, P89; PODACK ER, 1977, J IMMUNOL, V119, P2024; PREISSNER KT, 1990, BIOCHEM BIOPH RES CO, V168, P966, DOI 10.1016/0006-291X(90)91123-A; PREISSNER KT, 1990, J BIOL CHEM, V265, P18490; PREISSNER KT, 1991, ANNU REV CELL BIOL, V7, P275, DOI 10.1146/annurev.cellbio.7.1.275; PREISSNER KT, 1989, BLOOD, V74, P1989; PREISSNER KT, 1987, J BIOL CHEM, V262, P12247; PREISSNER KT, 1987, BIOCHEM J, V243, P105, DOI 10.1042/bj2430105; PYTELA R, 1985, P NATL ACAD SCI USA, V82, P5766, DOI 10.1073/pnas.82.17.5766; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; SANE DC, 1991, THROMB HAEMOSTASIS, V66, P310; SEIFFERT D, 1991, J BIOL CHEM, V266, P2824; SORENSEN K, 1986, EXPERIENTIA, V42, P161, DOI 10.1007/BF01952446; SUZUKI S, 1985, EMBO J, V4, P2519, DOI 10.1002/j.1460-2075.1985.tb03965.x; SUZUKI S, 1984, J BIOL CHEM, V259, P5307; TOMASINI BR, 1988, BLOOD, V72, P903; TOMASINI BR, 1990, PROG HEMOSTASIS THRO, V10, P269; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSCHOPP J, 1988, BIOCHEMISTRY-US, V27, P4103, DOI 10.1021/bi00411a029; TSCHOPP J, 1988, BIOCHEMISTRY-US, V27, P4109; UNDERWOOD PA, 1988, J IMMUNOL METHODS, V107, P119; UNDERWOOD PA, 1983, J IMMUNOL METHODS, V60, P33, DOI 10.1016/0022-1759(83)90332-0; UNDERWOOD PA, 1982, J GEN VIROL, V62, P153, DOI 10.1099/0022-1317-62-1-153; WIMAN B, 1988, FEBS LETT, V242, P125, DOI 10.1016/0014-5793(88)80999-2; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281	53	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23845	23852						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	7522235				2022-12-27	WOS:A1994PQ34500069
J	ACTON, SL; SCHERER, PE; LODISH, HF; KRIEGER, M				ACTON, SL; SCHERER, PE; LODISH, HF; KRIEGER, M			EXPRESSION CLONING OF SR-BI, A CD36-RELATED CLASS-B SCAVENGER RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; CONFORMATIONALLY MODIFIED ALBUMINS; GLYCOPROTEIN-IV CD36; MEDIATED ENDOCYTOSIS; ENDOTHELIAL-CELLS; MEMBRANE-PROTEIN; PERITONEAL-MACROPHAGES; CHOLESTEROL DEPOSITION; MALEYL-ALBUMIN; SERUM-ALBUMIN	Scavenger receptors are integral membrane proteins that mediate the endocytosis of modified lipoproteins. The first of these to be purified and cloned were the type I and II macrophage scavenger receptors (SR-AI and SR-AII; class A scavenger receptors). Subsequently, the cell surface protein CD36 was shown to bind oxidized low density lipoprotein (oxidized LDL). From a Chinese hamster ovary (CHO) cell variant we have cloned by expression the cDNA for a new member of the CD36 family of membrane proteins, SR-BI, whose predicted protein sequence of 509 amino acids is similar to 30% identical to those of the four previously identified family members. Both SR-BI and CD36 displayed high affinity binding for acetylated LDL with an apparent dissociation constant on the order of similar to 5 mu g of protein/ml. The ligand binding specificities of CD36 and SR-BI, determined by direct binding or competition assays, were similar, but not identical; both bind modified proteins (acetylated LDL, oxidized LBL, maleylated bovine serum albumin), but not the broad array of other polyanions (e.g. fucoidin, polyguanosinic acid, carrageenan) which are ligands of the class A receptors. Thus, SR-BI and CD36 define a second class of scavenger receptors, designated class B. Native LDL, which does not bind to either class A receptors or CD36, unexpectedly bound with high affinity to SR-BI. Northern blot analysis of murine tissues showed that SR-BI was most abundantly expressed in fat and was present at moderate levels in lung and liver. Furthermore, SR-BI mRNA expression was induced upon differentiation of 3T3-L1 cells into adipocytes. Thus, the tissue distribution of expression and ligand binding properties of SR-BI raise the possibility that this cell surface receptor may play an important role in lipid metabolism.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Whitehead Institute			Scherer, Philipp E/K-7819-2012	Scherer, Philipp E/0000-0003-0680-3392	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041484] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL41484] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; ACTON S, 1993, J BIOL CHEM, V268, P3530; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARAI H, 1989, BIOCHEM BIOPH RES CO, V159, P1375, DOI 10.1016/0006-291X(89)92262-6; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; ASCH AS, 1987, J CLIN INVEST, V79, P1054, DOI 10.1172/JCI112918; BALDINI G, 1992, P NATL ACAD SCI USA, V89, P5049, DOI 10.1073/pnas.89.11.5049; BICKEL PE, 1992, J CLIN INVEST, V90, P1450, DOI 10.1172/JCI116012; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; CALVO D, 1993, J BIOL CHEM, V268, P18929; CHARRON MJ, 1989, P NATL ACAD SCI USA, V86, P2535, DOI 10.1073/pnas.86.8.2535; CHARRON MJ, 1989, P NATL ACAD SCI USA, V86, P3123; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOI T, 1993, J BIOL CHEM, V268, P2126; ELSAADANI M, 1989, J LIPID RES, V30, P627; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; FRASER I, 1993, NATURE, V364, P343, DOI 10.1038/364343a0; FREEMAN M, 1990, P NATL ACAD SCI USA, V87, P8810, DOI 10.1073/pnas.87.22.8810; FREEMAN M, 1991, P NATL ACAD SCI USA, V88, P4931, DOI 10.1073/pnas.88.11.4931; GHITESCU L, 1992, J CELL BIOL, V117, P745, DOI 10.1083/jcb.117.4.745; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; GREENWALT DE, 1992, BLOOD, V80, P1105; HABERLAND ME, 1986, J CLIN INVEST, V77, P681, DOI 10.1172/JCI112362; HABERLAND ME, 1989, J IMMUNOL, V142, P855; HART K, 1993, J MOL BIOL, V234, P249, DOI 10.1006/jmbi.1993.1580; HORIUCHI S, 1985, J BIOL CHEM, V259, P53; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; HUNT C, 1990, GENE, V87, P199, DOI 10.1016/0378-1119(90)90302-8; KINGSLEY DM, 1986, MOL CELL BIOL, V6, P2734, DOI 10.1128/MCB.6.7.2734; KINGSLEY DM, 1984, P NATL ACAD SCI-BIOL, V81, P5454, DOI 10.1073/pnas.81.17.5454; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KRIEGER M, 1986, METHOD ENZYMOL, V128, P608; KRIEGER M, 1983, CELL, V33, P413, DOI 10.1016/0092-8674(83)90423-3; KRIEGER M, 1979, J SUPRAMOL STR CELL, V10, P467, DOI 10.1002/jss.400100409; KRIEGER M, 1992, TRENDS BIOCHEM SCI, V17, P141, DOI 10.1016/0968-0004(92)90322-Z; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; KRIEGER M, 1983, P NATL ACAD SCI-BIOL, V80, P5607, DOI 10.1073/pnas.80.18.5607; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NAGELKERKE JF, 1983, J BIOL CHEM, V258, P2221; NAITO M, 1991, AM J PATHOL, V139, P1411; OCKENHOUSE CF, 1989, J CLIN INVEST, V84, P468, DOI 10.1172/JCI114188; OQUENDO P, 1989, CELL, V58, P95, DOI 10.1016/0092-8674(89)90406-6; OTTNAD E, 1992, BIOCHEM J, V281, P745, DOI 10.1042/bj2810745; PITAS RE, 1985, J CELL BIOL, V100, P103, DOI 10.1083/jcb.100.1.103; PREDESCU D, 1988, J CELL BIOL, V107, P1729, DOI 10.1083/jcb.107.5.1729; ROHER L, 1990, NATURE, V343, P570; Sambrook J, 1989, MOL CLONING LABORATO; SAVILL J, 1991, CHEST S, V99, P7; SCHNITZER JE, 1993, J BIOL CHEM, V268, P7562; SCHNITZER JE, 1992, J BIOL CHEM, V267, P24544; SEGE RD, 1986, MOL CELL BIOL, V6, P3268, DOI 10.1128/MCB.6.9.3268; SPARROW CP, 1989, J BIOL CHEM, V264, P2599; STANTON LW, 1992, J BIOL CHEM, V267, P22446; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; TANDON NN, 1989, J BIOL CHEM, V264, P7576; VASILE E, 1985, GLOMERULAR DYSFUNCTI, P87; VEGA MA, 1991, J BIOL CHEM, V266, P16818; VIA D, 1992, FASEB J, V6, pA371; VILLASCHI S, 1986, MICROVASC RES, V32, P190, DOI 10.1016/0026-2862(86)90053-1	61	716	747	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					21003	21009						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	7520436				2022-12-27	WOS:A1994PC40300031
J	SHWORAK, NW; SHIRAKAWA, M; MULLIGAN, RC; ROSENBERG, RD				SHWORAK, NW; SHIRAKAWA, M; MULLIGAN, RC; ROSENBERG, RD			CHARACTERIZATION OF RYUDOCAN GLYCOSAMINOGLYCAN ACCEPTOR SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; CELL-SURFACE PROTEOGLYCAN; HUMAN-ENDOTHELIAL CELLS; HUMAN-LUNG FIBROBLASTS; HUMAN GROWTH-HORMONE; CHONDROITIN SULFATE; MOLECULAR-CLONING; CORE PROTEIN; MAST-CELLS; BIOSYNTHESIS	The specificity of the glycosaminoglycan (GAG) acceptor sites of ryudocan was examined by stably expressing epitope-tagged ryudocan cDNA constructs in mouse L cells, which normally produce this proteoglycan. Immunopurified ryudocan was glycanated with both heparan sulfate (HS) and chondroitin sulfate (CS). The attachment of GAGs to ryudocan was prevented by creating Ser --> Thr mutations in all possible combinations at positions 44, 65, and 67. The resulting ryudocan of exogenous origin was immunopurified and evaluated with regard to attached GAG chains. The data reveal that ryudocan possesses three functional GAG attachment sites, that the sites are always occupied with GAG chains, and that each site is capable of bearing either HS or CS. The sodium dodecyl sulfate-polyacrylamide gel electrophoresis patterns of GAG lyase digests of intact ryudocan reveal the production of the following multiple isoforms: pure HS-ryudocan, various HS/CS-hybrids, and pure CS-ryudocan. The data suggest that the occupancy bias of each site for HS or CS is slight and that each site functions in a relatively independent fashion. The GAG lyase analysis of partially purified L cell proteoglycans shows two pure CS-homoglycans with core proteins of M(r) = 130,000 and 52,000, respectively. A similar analysis of immunopurified L cell glypican demonstrates that this species only exists as a pure HS-homoglycan. The production of pure homoglycans by this clonal cell line strongly suggests that the functional promiscuity of GAG attachment sites of ryudocan must be encoded in the core protein structure. This property of ryudocan is not peculiar to L cells, as ryudocan synthesized by early passage human endothelial cells also bears both HS and CS. The production of multiple isoforms of ryudocan may serve to expand the functional versatility of this cell surface component and allow it to participate in many different biologic processes.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02215 USA; HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, DEPT MED, BOSTON, MA 02215 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School			Shworak, Nicholas/AAJ-6770-2020	Shworak, Nicholas/0000-0001-7783-4634	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041484, P01HL033014] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-41484, HL-33014, HL-437771] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDRES JL, 1989, J CELL BIOL, V109, P3137, DOI 10.1083/jcb.109.6.3137; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BOURDON MA, 1985, P NATL ACAD SCI USA, V82, P1321, DOI 10.1073/pnas.82.5.1321; BOURDON MA, 1986, J BIOL CHEM, V261, P2534; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAREW JA, 1990, BLOOD, V76, P2530; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; DAVID G, 1990, J CELL BIOL, V111, P3165, DOI 10.1083/jcb.111.6.3165; DAVIS LI, 1990, CELL, V61, P965, DOI 10.1016/0092-8674(90)90062-J; DEAGOSTINI AL, 1990, P NATL ACAD SCI USA, V87, P9784, DOI 10.1073/pnas.87.24.9784; DHAWAN J, 1991, SCIENCE, V254, P1509, DOI 10.1126/science.1962213; DIETRICH CP, 1984, BRAZ J MED BIOL RES, V17, P5; ENERBACK L, 1985, BIOCHEM J, V227, P661, DOI 10.1042/bj2270661; ESKO JD, 1987, J BIOL CHEM, V262, P12189; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; FARQUHAR MG, 1985, ANNU REV CELL BIOL, V1, P447, DOI 10.1146/annurev.cb.01.110185.002311; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FOXALL TL, 1986, J SURG RES, V41, P158, DOI 10.1016/0022-4804(86)90021-1; GIMBRONE MA, 1974, J CELL BIOL, V60, P673, DOI 10.1083/jcb.60.3.673; HARLOW E, 1988, ANTIBODIES LABORATOR, P421; HASLINGER A, 1985, P NATL ACAD SCI USA, V82, P8572, DOI 10.1073/pnas.82.24.8572; HORTIN G, 1986, BIOCHEM BIOPH RES CO, V141, P326, DOI 10.1016/S0006-291X(86)80372-2; HUTTNER WB, 1982, NATURE, V299, P273, DOI 10.1038/299273a0; ISHIHARA M, 1992, ANAL BIOCHEM, V206, P400, DOI 10.1016/0003-2697(92)90385-K; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; KARIN M, 1982, NATURE, V299, P797, DOI 10.1038/299797a0; KEARNS AE, 1991, BIOCHEMISTRY-US, V30, P7477, DOI 10.1021/bi00244a016; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KLINGER MM, 1985, J BIOL CHEM, V260, P4082; KOJIMA T, 1992, J BIOL CHEM, V267, P4859; KOJIMA T, 1992, J BIOL CHEM, V267, P4870; KOKENYESI R, 1994, J BIOL CHEM, V269, P12304; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KOLSET SO, 1990, BIOCHIM BIOPHYS ACTA, V1032, P191, DOI 10.1016/0304-419X(90)90004-K; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267; LIND T, 1993, J BIOL CHEM, V268, P20705; LITWACK ED, 1994, J NEUROSCI, V14, P3713; LORIES V, 1989, J BIOL CHEM, V264, P7009; MANN DM, 1990, J BIOL CHEM, V265, P5317; NADER HB, 1991, J BIOL CHEM, V266, P10518; OHANA B, 1993, P NATL ACAD SCI USA, V90, P138, DOI 10.1073/pnas.90.1.138; RAPRAEGER A, 1989, J CELL BIOL, V109, P2509, DOI 10.1083/jcb.109.5.2509; RAPRAEGER A, 1985, J BIOL CHEM, V260, P4103; ROBINSON HC, 1978, J BIOL CHEM, V253, P6687; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; ROHRMANN K, 1985, EUR J BIOCHEM, V148, P463, DOI 10.1111/j.1432-1033.1985.tb08862.x; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANDERSON RD, 1992, J INVEST DERMATOL, V99, P390, DOI 10.1111/1523-1747.ep12616103; SCHMIDTCHEN A, 1990, BIOCHEM J, V265, P289, DOI 10.1042/bj2650289; SEEBURG PH, 1982, DNA-J MOLEC CELL BIO, V1, P239, DOI 10.1089/dna.1.1982.1.239; SELDIN DC, 1985, J BIOL CHEM, V260, P1131; SHWORAK NW, 1993, J BIOL CHEM, V268, P24460; SIMONS M, 1993, J BIOL CHEM, V268, P627; SUGAHARA K, 1988, J BIOL CHEM, V263, P10168; THORNTON SC, 1983, SCIENCE, V222, P623, DOI 10.1126/science.6635659; TSUKADA T, 1987, AM J PATHOL, V126, P51; VERTEL BM, 1993, J BIOL CHEM, V268, P11105; VOYTA JC, 1984, J CELL BIOL, V99, P2034, DOI 10.1083/jcb.99.6.2034; WASTESON A, 1971, BIOCHEM J, V122, P477, DOI 10.1042/bj1220477; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451; YURT RW, 1977, J BIOL CHEM, V252, P518; ZUCKER M, 1981, NUCLEIC ACIDS RES, V9, P133	68	81	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					21204	21214						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	7520439				2022-12-27	WOS:A1994PC40300059
J	ANDERSSON, O; NORDLUNDMOLLER, L; BARNES, HJ; LUND, J				ANDERSSON, O; NORDLUNDMOLLER, L; BARNES, HJ; LUND, J			HETEROLOGOUS EXPRESSION OF HUMAN UTEROGLOBIN POLYCHLORINATED BIPHENYL-BINDING PROTEIN - DETERMINATION OF LIGAND-BINDING PARAMETERS AND MECHANISM OF PHOSPHOLIPASE A(2) INHIBITION IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL 10-KDA PROTEIN; C2221 CRYSTAL FORM; POLYCHLORINATED-BIPHENYLS; PROGESTERONE-BINDING; METABOLITE 4,4'-BIS(METHYLSULFONYL)-2,2',5,5'-TETRACHLOROBIPHENYL; AMINO-ACID; BRONCHOALVEOLAR LAVAGE; OXIDIZED UTEROGLOBIN; RABBIT UTEROGLOBIN; RUTHENIUM RED	High level expression of a human polychlorinated biphenyl-binding protein (hPCB-BP; also termed uteroglobin or CC10) was achieved in Escherichia coli. The recombinant protein (rhPCB-BP) constituted similar to 1% of total bacterial lysate proteins as judged from in vitro ligand binding assays using 4,4'-bis([H-3]methylsulfonyl)-2,2',5,5'-tetrachlorobiphenyl. rhPCB-BP was purified to homogeneity in its native dimeric form. Saturation analysis experiments indicated a K-d of similar to 69 nM for the binding of 4,4'-bis([H-3]methylsulfonyl)-2,2',5,5'-tetrachlorobiphenyl to rhPCB-BP. The average number of binding sites (B-max) calculated from such experiments on purified rhPCB-BP was 49 nmol/mg of protein and is close to the theoretical value of 1 mol of ligand associating with 1 mol of dimeric protein. Purified rhPCB-BP was also found to cause a dose-dependent inhibition of the enzyme orcine pancreatic phospholipase A(2) (PLA(2)) in vitro. Increasing the concentrations of calcium abolished the inhibition of PLA(2) by rhPCB-BP, suggesting that the protein functions in vitro by sequestering Ca2+ an essential PLA(2) cofactor. This notion was further supported by direct evidence that Ca-45(2+) binds to rhPCB-BP. 1 mol of dimeric protein was also found to bind 2 mol of ruthenium red, an organic dye that detects Ca2+-binding proteins, with a K-d of 3 mu M. This binding was inhibited by Ca2+, with an IC50 of 7 mM. Finally, it was demonstrated that the addition of a high affinity ligand for the protein had no effect on its ability to inhibit PLA(2) under conditions of limiting concentrations of calcium, and the addition of Ca2+ did not affect the binding characteristics of the PCB ligand, suggesting that these two properties of the protein are independent. Our results strongly support the notion that ligand binding is a conserved feature of the homologous uteroglobin/PCB-BP/CC10 proteins in different species, whereas our results question the suggested role of these proteins as specific inhibitors of PLA(2).	KAROLINSKA INST,HUDDINGE UNIV HOSP F60,NOVUM,DEPT LUNG MED,S-14186 HUDDINGE,SWEDEN; KAROLINSKA INST,HUDDINGE UNIV HOSP F60,NOVUM,DEPT MED NUTR,S-14186 HUDDINGE,SWEDEN	Karolinska Institutet; Karolinska Institutet								ACHARYA KR, 1991, J MOL BIOL, V221, P571; ANDERSSON O, 1991, AM J RESP CELL MOL, V5, P6, DOI 10.1165/ajrcmb/5.1.6; BALLY R, 1989, J MOL BIOL, V206, P153, DOI 10.1016/0022-2836(89)90530-5; BARTON GJ, 1991, EUR J BIOCHEM, V198, P749, DOI 10.1111/j.1432-1033.1991.tb16076.x; BEATO M, 1975, BIOCHIM BIOPHYS ACTA, V392, P346, DOI 10.1016/0304-4165(75)90016-1; BEIER HM, 1968, BIOCHIM BIOPHYS ACTA, V160, P289, DOI 10.1016/0005-2795(68)90108-6; BEIER HM, 1978, CELL TISSUE RES, V190, P15; BOCHSKANL R, 1988, CELL TISSUE RES, V252, P625, DOI 10.1007/BF00216650; BOCHSKANL R, 1984, HISTOCHEMISTRY, V80, P581, DOI 10.1007/BF00553721; BRANDT I, 1985, DRUG METAB DISPOS, V13, P490; BROERS JLV, 1992, LAB INVEST, V66, P337; CHARUK JHM, 1990, ANAL BIOCHEM, V188, P123, DOI 10.1016/0003-2697(90)90539-L; DAVIDSON FF, 1987, J BIOL CHEM, V262, P1698; DAVIDSON FF, 1990, J MOL EVOL, V31, P228, DOI 10.1007/BF02109500; DAVIDSON FF, 1989, BIOCHEM PHARMACOL, V38, P3645, DOI 10.1016/0006-2952(89)90567-4; FACCHIANO A, 1991, LIFE SCI, V48, P453, DOI 10.1016/0024-3205(91)90501-2; GARRIGOS M, 1991, ANAL BIOCHEM, V194, P82, DOI 10.1016/0003-2697(91)90154-L; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GILLNER M, 1988, J STEROID BIOCHEM, V31, P27, DOI 10.1016/0022-4731(88)90201-4; GLASER KB, 1993, TRENDS PHARMACOL SCI, V14, P92, DOI 10.1016/0165-6147(93)90071-Q; HAGEN G, 1990, NUCLEIC ACIDS RES, V18, P2939, DOI 10.1093/nar/18.10.2939; HALDANE JBS, 1957, NATURE, V179, P832, DOI 10.1038/179832b0; HARAGUCHI H, 1984, FOOD CHEM TOXICOL, V22, P283, DOI 10.1016/0278-6915(84)90007-3; KLASSONWEHLER E, 1983, J LABELLED COMPD RAD, V20, P1407, DOI 10.1002/jlcr.2580201212; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVIN SW, 1986, LIFE SCI, V38, P1813, DOI 10.1016/0024-3205(86)90135-9; LUND J, 1988, DRUG METAB DISPOS, V16, P590; LUND J, 1986, TOXICOL APPL PHARM, V83, P486, DOI 10.1016/0041-008X(86)90231-0; LUND J, 1985, MOL PHARMACOL, V27, P314; MANTILE G, 1993, J BIOL CHEM, V268, P20343; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MASUDA Y, 1985, ENVIRON HEALTH PERSP, V60, P321, DOI 10.2307/3429976; MAYER RJ, 1993, FASEB J, V7, P339, DOI 10.1096/fasebj.7.2.8440410; MIELE L, 1987, ENDOCR REV, V8, P474, DOI 10.1210/edrv-8-4-474; MIELE L, 1990, J BIOL CHEM, V265, P6427; MIELE L, 1988, NATURE, V335, P726, DOI 10.1038/335726a0; MORIZE I, 1987, J MOL BIOL, V194, P725, DOI 10.1016/0022-2836(87)90250-6; MORNON JP, 1980, J MOL BIOL, V137, P415, DOI 10.1016/0022-2836(80)90166-7; MUKHERJEE AB, 1992, DNA CELL BIOL, V11, P233, DOI 10.1089/dna.1992.11.233; NORDLUNDMOLLER L, 1990, J BIOL CHEM, V265, P12690; PETER W, 1992, PROTEIN ENG, V5, P351, DOI 10.1093/protein/5.4.351; PETER W, 1991, J STEROID BIOCHEM, V38, P27, DOI 10.1016/0960-0760(91)90397-N; POLLARD TD, 1984, NATURE, V312, P403, DOI 10.1038/312403a0; Sambrook J, 1989, MOL CLONING LABORATO; SASAKI T, 1992, J BIOL CHEM, V267, P21518; SHIGEMATSU N, 1978, ENVIRON RES, V16, P92, DOI 10.1016/0013-9351(78)90146-9; SINGH G, 1988, BIOCHIM BIOPHYS ACTA, V950, P329, DOI 10.1016/0167-4781(88)90129-7; SINGH G, 1988, J HISTOCHEM CYTOCHEM, V36, P73, DOI 10.1177/36.1.3275712; SINGH G, 1990, BIOCHIM BIOPHYS ACTA, V1039, P348, DOI 10.1016/0167-4838(90)90270-P; STRUM JM, 1990, ANAT REC, V227, P77, DOI 10.1002/ar.1092270109; TSIEN RY, 1989, ANNU REV NEUROSCI, V12, P227, DOI 10.1146/annurev.neuro.12.1.227; VANBINSBERGEN J, 1989, FEBS LETT, V247, P293, DOI 10.1016/0014-5793(89)81355-9; VANDYKE MW, 1992, GENE, V111, P99, DOI 10.1016/0378-1119(92)90608-R	53	55	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					19081	19087						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	7518449				2022-12-27	WOS:A1994NX32700058
J	WEAVER, CD; SHOMER, NH; LOUIS, CF; ROBERTS, DM				WEAVER, CD; SHOMER, NH; LOUIS, CF; ROBERTS, DM			NODULIN-26, A NODULE-SPECIFIC SYMBIOSOME MEMBRANE-PROTEIN FROM SOYBEAN, IS AN ION-CHANNEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR INTRINSIC PROTEIN; CELL CHIP28 PROTEIN; PERIBACTEROID MEMBRANE; XENOPUS-OOCYTES; WATER CHANNELS; MIP FAMILY; PHOSPHORYLATION; RECONSTITUTION; EVOLUTION	Nodulin 26 is an integral symbiosome membrane protein of nitrogen-fixing soybean nodules. Nodulin 26 is a member of a family of structurally homologous membrane proteins with diverse transport functions. Thus, it has been proposed to be involved in symbiosome membrane transport. Despite this claim, there has not been any evidence that nodulin 26 has a transport activity. In this study, nodulin 26 was purified from soybean nodules by a non-denaturing protocol and was reconstituted into liposomes for channel studies in planar lipid bilayers. Nodulin 26 readily incorporated into bilayers, forming single channels with a maximum unitary conductance of 3.1 nanosiemens (nS) in a recording buffer of 20 mM 3-(N-morpholino)propanesulfonate-NaOH, pH 7.4, 1 M KCl. Nodulin 26 also exhibited multiple, discreet lower conductance states ranging from 0.5 to 2.5 nS. Nodulin 26 channels were voltage-sensitive. The maximal 3.1-nS state was preferentially occupied at lower applied voltages, whereas the lower conductance states were more frequently occupied at higher voltage potentials. Nodulin 26 channels transported both cations and anions, but showed a weak selectivity for anions. These results represent the first purification and functional characterization of the nodulin 26 channel and support a role for this protein in symbiosome membrane transport.	UNIV TENNESSEE,DEPT BIOCHEM,KNOXVILLE,TN 37996; UNIV TENNESSEE,CTR LEGUME RES,KNOXVILLE,TN 37996; UNIV MINNESOTA,DEPT BIOCHEM,ST PAUL,MN 55108; UNIV MINNESOTA,DEPT VET PATHOBIOL,ST PAUL,MN 55108	University of Tennessee System; University of Tennessee Knoxville; University of Tennessee System; University of Tennessee Knoxville; UT Institute of Agriculture; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities				Shomer, Nirah/0000-0003-2520-0108	NATIONAL EYE INSTITUTE [R01EY005684] Funding Source: NIH RePORTER; NEI NIH HHS [EY 05684] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		DAY DA, 1993, SYMBIOSIS, V14, P175; EHRING GR, 1990, J GEN PHYSIOL, V96, P631, DOI 10.1085/jgp.96.3.631; EHRING GR, 1991, J MEMBRANE BIOL, V126, P75; FORTIN MG, 1987, NUCLEIC ACIDS RES, V15, P813, DOI 10.1093/nar/15.2.813; FRANSSEN HJ, 1992, BIOL NITROGEN FIXATI, P598; HAMILTON SL, 1989, ANAL BIOCHEM, V183, P31, DOI 10.1016/0003-2697(89)90167-X; HELLER KB, 1980, J BACTERIOL, V144, P274, DOI 10.1128/JB.144.1.274-278.1980; JOHNSON KR, 1986, J CELL BIOL, V102, P1334, DOI 10.1083/jcb.102.4.1334; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPE PD, 1990, EUR J BIOCHEM, V194, P541, DOI 10.1111/j.1432-1033.1990.tb15650.x; LEVITAN IB, 1985, J MEMBRANE BIOL, V87, P177, DOI 10.1007/BF01871217; LIN ECC, 1986, METHOD ENZYMOL, V125, P467; MAUREL C, 1993, EMBO J, V12, P2241, DOI 10.1002/j.1460-2075.1993.tb05877.x; OUYANG LJ, 1991, FEBS LETT, V293, P188, DOI 10.1016/0014-5793(91)81183-9; PAO GM, 1991, MOL MICROBIOL, V5, P33, DOI 10.1111/j.1365-2958.1991.tb01823.x; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRICE GD, 1987, J PLANT PHYSIOL, V130, P157, DOI 10.1016/S0176-1617(87)80219-5; REIZER J, 1993, CRIT REV BIOCHEM MOL, V28, P235, DOI 10.3109/10409239309086796; RONSON CW, 1981, P NATL ACAD SCI-BIOL, V78, P4284, DOI 10.1073/pnas.78.7.4284; Roth L.E., 1988, MOL GENETICS PLANT M, P220; SANDAL NN, 1988, NUCLEIC ACIDS RES, V16, P9347, DOI 10.1093/nar/16.19.9347; SHIELS A, 1988, NUCLEIC ACIDS RES, V16, P9348, DOI 10.1093/nar/16.19.9348; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SUSSMAN MR, 1989, PLANT CELL, V1, P953, DOI 10.1105/tpc.1.10.953; UDVARDI MK, 1988, FEBS LETT, V231, P36, DOI 10.1016/0014-5793(88)80697-5; UDVARDI MK, 1989, PLANT PHYSIOL, V90, P982, DOI 10.1104/pp.90.3.982; UDVARDI MK, 1992, ARCH MICROBIOL, V156, P362; VANDONGEN AMJ, 1992, BIOPHYS J, V61, pA256; VANHOEK AN, 1992, J BIOL CHEM, V267, P18267; VERMA DPS, 1992, TRANSPORT AND RECEPTOR PROTEINS OF PLANT MEMBRANES, P113; WEAVER CD, 1991, PLANT PHYSIOL, V95, P222, DOI 10.1104/pp.95.1.222; WEAVER CD, 1992, BIOCHEMISTRY-US, V31, P8954, DOI 10.1021/bi00152a035; YANG LJO, 1990, PLANTA, V182, P437, DOI 10.1007/BF02411397; ZEIDEL ML, 1992, BIOCHEMISTRY-US, V31, P7436, DOI 10.1021/bi00148a002	34	99	99	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					17858	17862						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	7517934				2022-12-27	WOS:A1994NV42200019
J	GUPTA, S; WEISS, A; KUMAR, G; WANG, S; NEL, A				GUPTA, S; WEISS, A; KUMAR, G; WANG, S; NEL, A			THE T-CELL ANTIGEN RECEPTOR UTILIZES LCK, RAF-1, AND MEK-1 FOR ACTIVATING MITOGEN-ACTIVATED PROTEIN-KINASE - EVIDENCE FOR THE EXISTENCE OF A 2ND PROTEIN-KINASE C-DEPENDENT PATHWAY IN AN LCK-NEGATIVE JURKAT CELL MUTANT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VAV PROTOONCOGENE PRODUCT; TYROSINE KINASE; MAP KINASE; SIGNAL TRANSDUCTION; GENE-PRODUCT; CROSS-LINKING; LYMPHOCYTES-T; CD4 RECEPTOR; ZETA-CHAIN; PHOSPHORYLATION	T cell antigen receptor (TCR) ligation of an Lck-deficient Jurkat mutant, J.CaM1, with anti-CD3 or anti-TCR beta monoclonal antibodies failed to induce tyrosine phosphorylation and activation of p42(MAPK). The same stimuli activated mitogen-activated protein (MAP) kinase in J.CaM1 cells transfected with Lck, demonstrating that Lck plays a critical role in MAP kinase activation. Utilizing immunocomplex kinase assays, we demonstrated that TCR/CD3 ligation activated a MAP kinase kinase kinase (Raf-1) as well as a MAP kinase kinase (MEK-1) in Jurkat but not in J.CaM1 cells. It was possible, however, to activate Raf-1, MEK-1, and p42(MAPK) in J.CaM1 cells during treatment with the phorbol ester phorbol 12-myristate 13-acetate, which activates protein kinase C (PKC). This demonstrates the presence of a PKC-dependent pathway which functions independently from Lck in MAP kinase activation. Stimulation of Jurkat cells with either anti-TCR beta or anti-CD3 monoclonal antibody failed to induce substantial tyrosine phosphorylation of She proteins or their association with Grb2 which forms a complex with the guanine nucleotide exchange factor hSOS. However, the same stimuli induced tyrosine phosphorylation of another putative guanine nucleotide exchange factor, p95(Vav), in Jurkat but not J.CaM1 cells. Moreover, Lck was reversibly co-immunoprecipitated with p95(Vav), and the stoichiometry of binding increased in anti-CD3-treated Jurkat cells. Phorbol 12-myristate 13-acetate did not induce tyrosine phosphorylation of p95(Vav). These data show that the TCR activates MAP kinase by way of a signaling cascade, which depends upon Lck, and may be mediated by downstream events involving PKC or p95(Vav) which act on Raf-1 and MEK-1.	UNIV CALIF LOS ANGELES,SCH MED,DEPT MED CIA,DIV CLIN IMMUNOL & ALLERGY,LOS ANGELES,CA 90024; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco			Nel, Andre E/J-2808-2012		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039553] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41576, GM39553] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHUNG J, 1991, P NATL ACAD SCI USA, V88, P4981, DOI 10.1073/pnas.88.11.4981; CREWS CM, 1992, P NATL ACAD SCI USA, V89, P8205, DOI 10.1073/pnas.89.17.8205; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAMEN JE, 1993, BLOOD, V82, P296; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DOWNWARD J, 1992, IMMUNOL TODAY, V13, P89, DOI 10.1016/0167-5699(92)90148-Z; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ETTEHADIEH E, 1992, SCIENCE, V255, P853, DOI 10.1126/science.1311128; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; GARDNER AM, 1994, METHOD ENZYMOL, V238, P258; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOLDSMITH MA, 1987, P NATL ACAD SCI USA, V84, P6879, DOI 10.1073/pnas.84.19.6879; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; IZQUIERDO M, 1993, J EXP MED, V178, P1199, DOI 10.1084/jem.178.4.1199; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MARTH JD, 1989, J IMMUNOL, V142, P2430; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NEL AE, 1991, J IMMUNOL, V147, P1933; NEL AE, 1987, J IMMUNOL, V138, P3519; NEL AE, 1990, J IMMUNOL, V145, P971; NEL AE, 1990, J IMMUNOL, V144, P2683; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; OWAKI H, 1993, EMBO J, V12, P4367, DOI 10.1002/j.1460-2075.1993.tb06121.x; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; ROBERTS TM, 1992, NATURE, V360, P534, DOI 10.1038/360534a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SEGER R, 1992, J BIOL CHEM, V267, P14373; SIEGEL JN, 1993, J IMMUNOL, V151, P4116; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TSYGANKOV AY, 1992, J BIOL CHEM, V267, P18259; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1989, MOL CELL BIOL, V9, P4441, DOI 10.1128/MCB.9.10.4441; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WEBER JR, 1992, J EXP MED, V176, P373, DOI 10.1084/jem.176.2.373; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WILLIAMS NG, 1993, P NATL ACAD SCI USA, V90, P5772, DOI 10.1073/pnas.90.12.5772; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	54	118	119	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 24	1994	269	25					17349	17357						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NT846	7516337				2022-12-27	WOS:A1994NT84600055
J	JIN, DJ				JIN, DJ			SLIPPAGE SYNTHESIS AT THE GALP2 PROMOTER OF ESCHERICHIA-COLI AND ITS REGULATION BY UTP CONCENTRATION AND CAMP-CENTER-DOT-CAMP RECEPTOR PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE; TRANSCRIPTION INITIATION; GALACTOSE OPERON; ACID; SEQUENCES; INVITRO; POOLS; GENE	An intriguing mechanism in regulating transcription initiation from the gal operon in Escherichia coli is described. Initiation from galP2, one of the two promoters of the E. coli galactose operon, is shown to be subject to promoter clearance control in responding to changes in UTP concentration. In vitro, RNA polymerase (RNAP) makes a large amount of nonproductive ''stuttering'' initiation products at the galP2 promoter at high concentrations of UTP and less of the stuttered products at low concentrations of UTP. Conversely, RNAP makes more productive initiation products at low UTP concentration than at high UTP concentration. The transcription factor cAMP CRP complex which normally inhibits transcription from galP2 also represses the stuttering synthesis from galP2. When galactose is used as a sole carbon source and the internal UTP pools are adjusted externally, a cya mutant (in which galP2 is mainly responsible for the expression of the gal operon and galP1 activity is minimal) has a slower growth rate and lower expression of the gal operon at high UTP pools than at low UTP pools. Such an apparent correlation between the in vitro and in vivo results allows one to speculate that changes in UTP concentration can modulate the expression of the gal operon. The implication of a gal promoter being controlled by UTP is discussed.			JIN, DJ (corresponding author), NCI,MOLEC BIOL LAB,9000 ROCKVILLE PIKE,BLDG 37,RM 2E14,BETHESDA,MD 20892, USA.							ADHYA S, 1979, NATURE, V279, P492, DOI 10.1038/279492a0; CARPOUSIS AJ, 1980, BIOCHEMISTRY-US, V19, P3245, DOI 10.1021/bi00555a023; CHAMBERLIN M, 1964, J MOL BIOL, V8, P708, DOI 10.1016/S0022-2836(64)80120-0; CHOY HE, 1992, P NATL ACAD SCI USA, V89, P11264, DOI 10.1073/pnas.89.23.11264; DONAHUE JP, 1990, J BIOL CHEM, V265, P19091; GOODRICH JA, 1992, J MOL BIOL, V224, P1; GUO HC, 1990, BIOCHEMISTRY-US, V29, P10702, DOI 10.1021/bi00499a019; HAGER DA, 1990, BIOCHEMISTRY-US, V29, P7890, DOI 10.1021/bi00486a016; HARLEY CB, 1990, NUCLEIC ACIDS RES, V18, P547, DOI 10.1093/nar/18.3.547; HARLEY CB, 1987, NUCLEIC ACIDS RES, V15, P2343, DOI 10.1093/nar/15.5.2343; HAWLEY DK, 1983, NUCLEIC ACIDS RES, V11, P2237, DOI 10.1093/nar/11.8.2237; JACQUES JP, 1990, GENE DEV, V4, P1801, DOI 10.1101/gad.4.10.1801; JIN DJ, 1994, J MOL BIOL, V236, P72, DOI 10.1006/jmbi.1994.1119; Johnston D. E., 1976, RNA POLYMERASE, P413; KAMMERER W, 1986, EMBO J, V5, P2995, DOI 10.1002/j.1460-2075.1986.tb04597.x; LEVIN JR, 1987, J MOL BIOL, V196, P85, DOI 10.1016/0022-2836(87)90512-2; MAJUMDAR A, 1987, J BIOL CHEM, V262, P2326; MATHEWS CK, 1972, J BIOL CHEM, V247, P7430; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; MULLIGAN ME, 1984, NUCLEIC ACIDS RES, V12, P789, DOI 10.1093/nar/12.1Part2.789; MUNSON LM, 1981, BIOCHEMISTRY-US, V20, P2081, DOI 10.1021/bi00511a003; MUSSO RE, 1977, CELL, V12, P847, DOI 10.1016/0092-8674(77)90283-5; POULSEN P, 1987, MOL GEN GENET, V208, P152, DOI 10.1007/BF00330436; QUEEN C, 1981, CELL, V25, P241, DOI 10.1016/0092-8674(81)90249-X; ROLAND KL, 1988, P NATL ACAD SCI USA, V85, P7149, DOI 10.1073/pnas.85.19.7149; RYU S, 1993, P NATL ACAD SCI USA, V90, P75, DOI 10.1073/pnas.90.1.75; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133; WILSON DB, 1966, METHOD ENZYMOL, V8, P229; XIONG XF, 1993, J MOL BIOL, V231, P569, DOI 10.1006/jmbi.1993.1310	29	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 24	1994	269	25					17221	17227						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NT846	7516334				2022-12-27	WOS:A1994NT84600038
J	BABITZKE, P; STULTS, JT; SHIRE, SJ; YANOFSKY, C				BABITZKE, P; STULTS, JT; SHIRE, SJ; YANOFSKY, C			TRAP, THE TRP RNA-BINDING ATTENUATION PROTEIN OF BACILLUS-SUBTILIS, IS A MULTISUBUNIT COMPLEX THAT APPEARS TO RECOGNIZE G/UAG REPEATS IN THE TRPEDCFBA AND TRPG TRANSCRIPTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINATION FACTOR-RHO; SECONDARY STRUCTURE; MASS-SPECTROMETRY; OPERON; EXPRESSION; SEQUENCE; FORM; ACID; MTRB; COM	A filter binding assay was developed to study interactions between purified TRAP, the trp RNA-binding attenuation protein of Bacillus subtilis, and trp specific transcripts. TRAP formed stable complexes with trpED-CFBA leader RNA; binding was L-tryptophan-dependent and was complete within 60 s. TRAP binds to a segment of the trp leader transcript that includes part of an RNA antiterminator structure. Binding to this segment allows formation of an RNA terminator structure, thereby promoting transcription termination. Using several trpEDCFBA leader deletion transcripts, we identified several closely spaced trinucleotide repeats (seven GAG and four UAG repeats) in the trp leader transcript that appeared to be required for TRAP binding. We also showed that TRAP binds to a segment of the trpG transcript that includes the trpG ribosome binding site; the nucleotide sequence of this segment contains several appropriately spaced trinucleotide repeats (seven GAG, one UAG, and one AAG). TRAP binding to the trpG transcript would block translation initiation. RNA footprint analysis confirmed interaction between TRAP and the trinucleotide repeats in the various transcripts. TRAP, in the presence or absence of L-tryptophan, appears to consist of 11 or 12 identical 8-kDa subunits. Our findings suggest that each tryptophan-activated TRAP subunit can bind one G/UAG repeat in a target transcript. Multiple protein-RNA interactions are required for stable association.	STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305; GENENTECH INC,DEPT PROT CHEM,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT PHARMACEUT RES & DEV,S SAN FRANCISCO,CA 94080	Stanford University; Roche Holding; Genentech; Roche Holding; Genentech			Babitzke, Paul/AAL-3048-2020	Babitzke, Paul/0000-0003-2481-1062	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM009738, R01GM009738] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM09738] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BABITZKE P, 1992, J BACTERIOL, V174, P2059, DOI 10.1128/JB.174.7.2059-2064.1992; BABITZKE P, 1993, P NATL ACAD SCI USA, V90, P133, DOI 10.1073/pnas.90.1.133; BEAVIS RC, 1990, P NATL ACAD SCI USA, V87, P6873, DOI 10.1073/pnas.87.17.6873; COHN EJ, 1965, PROTEINS AMINO ACIDS, P370; FARMER TB, 1991, BIOL MASS SPECTROM, V20, P796, DOI 10.1002/bms.1200201209; GEISELMANN J, 1993, P NATL ACAD SCI USA, V90, P7754, DOI 10.1073/pnas.90.16.7754; GOLLNICK P, 1990, P NATL ACAD SCI USA, V87, P8726, DOI 10.1073/pnas.87.22.8726; HATTMAN S, 1991, P NATL ACAD SCI USA, V88, P10027, DOI 10.1073/pnas.88.22.10027; HILLENKAMP F, 1991, ANAL CHEM, V63, pA1193; HOCH SO, 1971, J BACTERIOL, V105, P38, DOI 10.1128/JB.105.1.38-45.1971; INOUE T, 1985, P NATL ACAD SCI USA, V82, P648, DOI 10.1073/pnas.82.3.648; KANE JF, 1977, J BACTERIOL, V132, P419, DOI 10.1128/JB.132.2.419-425.1977; KURODA MI, 1988, J BACTERIOL, V170, P3080, DOI 10.1128/jb.170.7.3080-3088.1988; KURODA MI, 1986, J BACTERIOL, V167, P792, DOI 10.1128/jb.167.3.792-798.1986; MCSWIGGEN JA, 1988, J MOL BIOL, V199, P609, DOI 10.1016/0022-2836(88)90305-1; OTRIDGE J, 1993, P NATL ACAD SCI USA, V90, P128, DOI 10.1073/pnas.90.1.128; SEIFRIED SE, 1991, J MOL BIOL, V221, P1139; SHIMOTSU H, 1986, J BACTERIOL, V166, P461, DOI 10.1128/jb.166.2.461-471.1986; SLOCK J, 1990, J BACTERIOL, V172, P7211, DOI 10.1128/jb.172.12.7211-7226.1990; TINOCO I, 1973, NATURE-NEW BIOL, V246, P40, DOI 10.1038/newbio246040a0; WULCZYN FG, 1991, CELL, V65, P259, DOI 10.1016/0092-8674(91)90160-Z	21	110	111	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16597	16604						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	7515880				2022-12-27	WOS:A1994NR29600015
J	STRASSHEIM, D; MALBON, CC				STRASSHEIM, D; MALBON, CC			PHOSPHORYLATION OF G(I-ALPHA-2) ATTENUATES INHIBITORY ADENYLYL-CYCLASE IN NEUROBLASTOMA/GLIOMA HYBRID (NG-108-15) CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC RECEPTORS; PROTEIN-MEDIATED PATHWAYS; STEADY-STATE LEVELS; CYCLIC-AMP ACCUMULATION; CROSS-REGULATION; MESSENGER-RNA; BINDING-PROTEIN; BETA-2-ADRENERGIC RECEPTORS; INTACT HEPATOCYTES; HUMAN-PLATELETS	Cross-regulation from the stimulatory phospholipase C to the adenylyl cyclase pathways was explored in neuroblastoma-glioma NG-108-15 cells in culture. Activation of protein kinase C by phorbol myristic acid resulted in a markedly attenuated activation of the inhibitory adenylyl cyclase response to delta-opiate agonists and epinephrine but not to the muscarinic agonist carbachol. The ability of okadaic acid to mimic the effects of phorbol myristic acid on the inhibitory response suggested a role for protein phosphorylation. Adenylyl cyclase activity from cells in which protein kinase C had been activated demonstrated a loss in the inhibitory adenylyl cyclase response at the level of the G-protein. Activation of protein kinase C prompted a 2-4-fold increase in phosphorylation of G(i alpha 2) in cells metabolically labeled with [P-32]orthophosphate. The phosphate content of G(i alpha 2) was determined to be similar to-0.5 mol/mol subunit in the unstimulated cells and similar to-1.5 mol/mol subunit for cells in which protein kinase C was activated. The effects of okadaic acid, 4-alpha-phorbol, and calphostin C on inhibition of adenylyl cyclase in cells treated with phorbol myristic acid correlate with the effects of these agents on phosphorylation of G(i alpha 2). The time courses for attenuation of inhibitory adenylyl cyclase and that for phosphorylation of G(i alpha 2) were similar in cells challenged with phorbol myristic acid. These data argue for cross-regulation from the stimulatory protein kinase C to inhibitory adenylyl cyclase pathways at the level of G(i alpha 2) via protein phosphorylation.			STRASSHEIM, D (corresponding author), SUNY STONY BROOK,HLTH SCI CTR,SCH MED,DEPT MOLEC PHARMACOL,DIABET & METAB DIS RES PROGR,STONY BROOK,NY 11794, USA.		STRASSHEIM, DEREK/AHB-1158-2022; malbon, craig/ABF-3604-2020		NIDDK NIH HHS [DK30111] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030111] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BUSHFIELD M, 1991, BIOCHEM J, V274, P317, DOI 10.1042/bj2740317; BUSHFIELD M, 1990, BIOCHEM J, V271, P365, DOI 10.1042/bj2710365; BUSHFIELD M, 1990, BIOCHEM J, V268, P449, DOI 10.1042/bj2680449; BUSHFIELD M, 1990, EUR J BIOCHEM, V192, P537, DOI 10.1111/j.1432-1033.1990.tb19258.x; CARLSON KE, 1989, J BIOL CHEM, V264, P13298; CHEN JQ, 1993, J BIOL CHEM, V268, P12253; COLE GM, 1991, CELL, V64, P703, DOI 10.1016/0092-8674(91)90500-X; DANIELISSAKANI S, 1989, J BIOL CHEM, V264, P20240; ENGLAND PJ, 1976, ANAL BIOCHEM, V15, P429; EVANS CJ, 1992, SCIENCE, V258, P1882; GERHARDT MA, 1991, MOL PHARMACOL, V40, P707; GRAESER D, 1993, MOL PHARMACOL, V43, P434; GUNDERSEN RE, 1990, SCIENCE, V248, P591, DOI 10.1126/science.2110382; HADCOCK JR, 1991, J BIOL CHEM, V266, P11915; HADCOCK JR, 1992, J BIOL CHEM, V267, P26017; HADCOCK JR, 1988, P NATL ACAD SCI USA, V85, P8415, DOI 10.1073/pnas.85.22.8415; HADCOCK JR, 1990, J BIOL CHEM, V265, P14784; HADCOCK JR, 1989, J BIOL CHEM, V264, P13956; HADCOCK JR, 1989, AM J PHYSIOL, V256, pC457, DOI 10.1152/ajpcell.1989.256.3.C457; HADCOCK JR, 1988, BIOCHEM BIOPH RES CO, V154, P676; HAUSDORFF WP, 1992, P NATL ACAD SCI USA, V89, P5720, DOI 10.1073/pnas.89.13.5720; HERMOUET S, 1991, P NATL ACAD SCI USA, V88, P10455, DOI 10.1073/pnas.88.23.10455; JACOBOWITZ O, 1993, J BIOL CHEM, V268, P3829; JACOBS KH, 1985, EUR J BIOCHEM, V151, P425; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; LOUNSBURY KM, 1991, J BIOL CHEM, V266, P22051; LOUNSBURY KM, 1993, J BIOL CHEM, V268, P3494; LOWNDES JM, 1991, J BIOL CHEM, V266, P14193; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALBON CC, 1980, BIOCHEM J, V188, P593, DOI 10.1042/bj1880593; MALBON CC, 1993, HDB EXPT PHARM; MCKENZIE FR, 1990, BIOCHEM J, V267, P391, DOI 10.1042/bj2670391; MORRIS GM, 1991, J BIOL CHEM, V266, P2233; MOXHAM CM, 1993, SCIENCE, V260, P991, DOI 10.1126/science.8493537; PORT JD, 1992, J BIOL CHEM, V267, P8468; PORT JD, 1993, IN PRESS TRENDS CARD; PYNE NJ, 1992, BIOCHEM BIOPH RES CO, V186, P1081, DOI 10.1016/0006-291X(92)90857-H; PYNE NJ, 1989, FEBS LETT, V243, P77, DOI 10.1016/0014-5793(89)81221-9; PYNE NJ, 1992, BIOCHEM J, V285, P333, DOI 10.1042/bj2850333; ROS M, 1988, J BIOL CHEM, V263, P4362; SABOL SL, 1979, J BIOL CHEM, V254, P1913; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SCARPACE PJ, 1985, MOL PHARMACOL, V28, P495; SIBLEY DR, 1985, NATURE, V317, P124, DOI 10.1038/317124a0; SMITH DE, 1987, J CELL BIOL, V105, P771, DOI 10.1083/jcb.105.2.771; SPIEGEL AM, 1992, ENDOCR REV, V13, P536, DOI 10.1210/er.13.3.536; WANG HY, 1989, J BIOL CHEM, V264, P14424; WATKINS DC, 1992, SCIENCE, V258, P1373, DOI 10.1126/science.1455234; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957; ZACHARY I, 1991, NATURE, V321, P63	51	55	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14307	14313						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	7514603				2022-12-27	WOS:A1994NL60600088
J	CHELLAIAH, AT; MCEWEN, DG; WERNER, S; XU, JS; ORNITZ, DM				CHELLAIAH, AT; MCEWEN, DG; WERNER, S; XU, JS; ORNITZ, DM			FIBROBLAST GROWTH-FACTOR RECEPTOR (FGFR)-3 - ALTERNATIVE SPLICING IN IMMUNOGLOBULIN-LIKE DOMAIN-III CREATES A RECEPTOR HIGHLY SPECIFIC FOR ACIDIC FGF FGF-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING SPECIFICITY; PROTO-ONCOGENE INT-2; EXPRESSION PATTERN; CULTURED-CELLS; HEPARIN; MOUSE; CLONING; SURFACE; GENES; REQUIREMENT	Fibroblast growth factors (FGF) regulate the growth and differentiation of cells through complex combinatorial signaling pathways. There are nine ligands that interact with a family of four tyrosine kinase FGF receptors (FGFR). Diversity in FGF signaling is determined in part by the affinity of specific ligand-receptor pairs. Alternative splicing in the FGFR ligand binding domain generates additional receptor isoforms with novel ligand affinities. For example, splicing events in the ligand binding domain of FGFR2 dramatically increases its affinity for keratinocyte growth factor (KGF/FGF-7). We have identified an alternatively spliced form of the FGFR3 mRNA, corresponding to known splice variants of FGFRs 1 and 2. We demonstrate both by binding studies on genetically engineered soluble receptors and by the mitogenic response of growth factor-dependent cell lines that this splice variant of FGFR3 (FGFR3 IIIb), by binding only acidic FGF (aFGF/FGF-1), has the most restricted ligand binding properties of any FGFR thus far described. Furthermore, by constructing a chimeric receptor that contains the homologous exon from FGFR2, we demonstrate that this single domain from FGFR2 is sufficient to confer upon FGFR3 the ability to bind KGF/FGF-7. The uniquely limited repertoire of ligands that interact with this receptor suggests that a novel ligand for FGFR3 IIIb exists.	WASHINGTON UNIV, SCH MED, DEPT MOLEC BIOL & PHARMACOL, ST LOUIS, MO 63110 USA; MAX PLANCK INST BIOCHEM, D-82152 MARTINSRIED, GERMANY	Washington University (WUSTL); Max Planck Society				Ornitz, David/0000-0003-1592-7629; Werner, Sabine/0000-0001-7397-8710	NATIONAL CANCER INSTITUTE [R01CA060673] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA60673] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARUFFO A, 1987, EMBO J, V6, P3313, DOI 10.1002/j.1460-2075.1987.tb02651.x; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BURRUS LW, 1989, J BIOL CHEM, V264, P18647; BURRUS LW, 1992, MOL CELL BIOL, V12, P5600, DOI 10.1128/MCB.12.12.5600; CLEMENTS DA, 1993, ONCOGENE, V8, P1311; DELL KR, 1992, J BIOL CHEM, V267, P21225; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GHATTAS IR, 1991, MOL CELL BIOL, V11, P5848, DOI 10.1128/MCB.11.12.5848; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; Klagsbrun M, 1989, Prog Growth Factor Res, V1, P207, DOI 10.1016/0955-2235(89)90012-4; MANSUKHANI A, 1992, P NATL ACAD SCI USA, V89, P3305, DOI 10.1073/pnas.89.8.3305; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MATHEYPREVOT B, 1986, MOL CELL BIOL, V6, P4133, DOI 10.1128/MCB.6.11.4133; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; Nei M., 1987, MOL EVOLUT GENET, P293; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; ORRURTREGER A, 1993, DEV BIOL, V158, P475, DOI 10.1006/dbio.1993.1205; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PETERS K, 1993, DEV BIOL, V155, P423, DOI 10.1006/dbio.1993.1040; PIZETTE S, 1991, CELL GROWTH DIFFER, V2, P561; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; STARK KL, 1991, DEVELOPMENT, V113, P641; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; THOMAS KA, 1987, FASEB J, V1, P434, DOI 10.1096/fasebj.1.6.3315806; VAINIKKA S, 1992, EMBO J, V11, P4273, DOI 10.1002/j.1460-2075.1992.tb05526.x; WERNER S, 1993, EMBO J, V12, P2635, DOI 10.1002/j.1460-2075.1993.tb05924.x; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; WILKINSON DG, 1989, DEVELOPMENT, V105, P131; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x; YAYON A, 1992, EMBO J, V11, P1885, DOI 10.1002/j.1460-2075.1992.tb05240.x; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZIMMER Y, 1993, J BIOL CHEM, V268, P7899	42	282	292	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11620	11627						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	7512569				2022-12-27	WOS:A1994NF96600096
J	NAVON, A; SCHULZE, AJ; GUILLOU, Y; ZYLINSKI, CA; BALEUX, F; EXPERTBEZANCON, N; FRIGUET, B; DJAVADIOHANIANCE, L; GOLDBERG, ME				NAVON, A; SCHULZE, AJ; GUILLOU, Y; ZYLINSKI, CA; BALEUX, F; EXPERTBEZANCON, N; FRIGUET, B; DJAVADIOHANIANCE, L; GOLDBERG, ME			IMPORTANCE OF RESIDUES-2-9 IN THE IMMUNOREACTIVITY, SUBUNIT INTERACTIONS, AND ACTIVITY OF THE BETA(2)-SUBUNIT OF ESCHERICHIA-COLI TRYPTOPHAN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHASE BETA-2 SUBUNIT; MONOCLONAL-ANTIBODIES; TRUE AFFINITY; PROTEINS; ANTIGEN; CONFORMATION; SYNTHETASE; KINETICS; DOMAINS; CHAIN	The epitope recognized by a monoclonal antibody (mAb19) directed against the beta(2) subunit of Escherichia coli tryptophan synthase was found to be carried by residues 2-9 of the beta chain. The affinities of mAb19 for peptides of different lengths containing the 2-9 sequence were close to 0.6 x 10(9) M(-1), the affinity of mAb19 for native beta(2). In view of these results, a model is proposed to account for the kinetics of appearance of the epitope during in vitro renaturation of beta(2) (Murry-Brelier, A., and Goldberg, M. E. (1988) Biochemistry 27, 7633-7640). A mutant producing beta chains lacking residues 1-9 (beta(Delta 1-9)) was prepared. The beta(Delta 1-9) protein was able to fold into a heat stable homodimer resembling wild type beta(2). Isolated beta(Delta 1-9) had no detectable enzymatic activity. It could bind alpha chains extremely weakly and be slightly activated. In the presence of the 1-9 peptide, the beta(Delta 1-9) protein could bind alpha chains much more strongly and generate a 50% active enzyme, Thus, although having little role in the overall folding and stability of the protein, the 1-9 sequence of the beta chain appears strongly involved in the alpha-beta interactions and in the enzymatic activity.	INST PASTEUR, CNRS, URA 1129, UNITE BIOCHIM CELLULAIRE, F-75724 PARIS 15, FRANCE; BAR ILAN UNIV, DEPT LIFE SCI, RAMAT GAN, ISRAEL; INST PASTEUR, CNRS, URA 487, UNITE CHIM ORGAN, F-75724 PARIS 15, FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Bar Ilan University; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris				Friguet, Bertrand/0000-0001-8085-1961				BLONDELGUINDI S, 1990, BIOCHEMISTRY-US, V29, P2409, DOI 10.1021/bi00461a026; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHAFFOTTE AF, 1987, J MOL BIOL, V197, P131, DOI 10.1016/0022-2836(87)90615-2; CRAWFORD IP, 1978, BIOCHEM BIOPH RES CO, V85, P309, DOI 10.1016/S0006-291X(78)80044-8; CRAWFORD IP, 1964, P NATL ACAD SCI USA, V51, P391; DJAVADIOHANIANC.L, 1991, IMMUNOCHEMISTRY SOLI, P201; DJAVADIOHANIANCE L, 1984, BIOCHEMISTRY-US, V23, P97, DOI 10.1021/bi00296a016; FAEDER EJ, 1970, BIOCHEMISTRY-US, V9, P4043, DOI 10.1021/bi00823a003; FEDOROV AN, 1992, J MOL BIOL, V228, P351, DOI 10.1016/0022-2836(92)90825-5; FRIGUET B, 1993, ANAL BIOCHEM, V210, P344, DOI 10.1006/abio.1993.1206; FRIGUET B, 1989, RES IMMUNOL, V140, P355, DOI 10.1016/0923-2494(89)90142-9; FRIGUET B, 1984, MOL IMMUNOL, V21, P673, DOI 10.1016/0161-5890(84)90053-1; FRIGUET B, 1985, J IMMUNOL METHODS, V77, P305, DOI 10.1016/0022-1759(85)90044-4; FRIGUET B, 1993, J IMMUNOL METHODS, V158, P243, DOI 10.1016/0022-1759(93)90220-2; GOLDBERG ME, 1990, FEBS LETT, V263, P51, DOI 10.1016/0014-5793(90)80703-L; GOLDBERG ME, 1991, TRENDS BIOCHEM SCI, V16, P358, DOI 10.1016/0968-0004(91)90148-O; HOGBERGRAIBAUD A, 1977, BIOCHEMISTRY-US, V16, P4014, DOI 10.1021/bi00637a012; HYDE CC, 1988, J BIOL CHEM, V263, P17857; JACOBSON RH, 1994, NATURE, V369, P761, DOI 10.1038/369761a0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARVOR MP, 1991, MOL IMMUNOL, V28, P523, DOI 10.1016/0161-5890(91)90167-I; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; MILES EW, 1991, ADV ENZYMOL RAMB, V64, P93; MURRYBRELIER A, 1988, BIOCHEMISTRY-US, V27, P7633, DOI 10.1021/bi00420a010; Onoue K, 1965, Immunochemistry, V2, P401, DOI 10.1016/0019-2791(65)90039-X; Sambrook J, 1989, MOL CLONING LABORATO; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; ULLMANN A, 1967, J MOL BIOL, V24, P839; ZETINA CR, 1980, J BIOL CHEM, V255, P4381	31	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4255	4261		10.1074/jbc.270.9.4255	http://dx.doi.org/10.1074/jbc.270.9.4255			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7533160	hybrid			2022-12-27	WOS:A1995QK08400015
J	AVRAHAM, S; JIANG, SX; OTA, S; FU, YG; DENG, BJ; DOWLER, LL; WHITE, RA; AVRAHAM, H				AVRAHAM, S; JIANG, SX; OTA, S; FU, YG; DENG, BJ; DOWLER, LL; WHITE, RA; AVRAHAM, H			STRUCTURAL AND FUNCTIONAL-STUDIES OF THE INTRACELLULAR TYROSINE KINASE MATK GENE AND ITS TRANSLATED PRODUCT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-LINKED AGAMMAGLOBULINEMIA; CELL ANTIGEN RECEPTOR; SRC FAMILY KINASES; GROWTH-FACTOR; SIGNAL TRANSDUCTION; HUMAN HEMATOPOIESIS; PROTEIN; EXPRESSION; MOUSE; CSK	We recently cloned the cDNA which encodes a novel megakaryocyte-associated tyrosine kinase termed MATK. In this study, we have cloned and characterized the human MATK gene as well as the murine homolog of human MATK cDNA and performed functional studies of its translated product, Comparison of the deduced amino acid sequences of human and murine MATK cDNAs revealed 85% homology, indicating that MATK is highly conserved in mouse and human, The human gene consists of 13 exons interrupted by 12 introns, The genetic units which encode the SH3 and SH2 domains are located on separate exons, The putative ATP binding site (GXGXXG) is localized on exon 7, and the entire catalytic domain is subdivided into seven exons (7-13), Somatic cell hybrid analysis indicated that human MATK gene is located on chromosome 19 while the murine Math gene is located on chromosome 10, The immediate 5'-flanking region was highly rich in GC sequences, and potential cis-acting elements were identified including several SP1, GATA-1, APRE, and APRE1, Antisense oligonucleotides directed against MATK mRNA sequences significantly inhibited megakaryocyte progenitor proliferation, Functional studies indicated that MATK can phosphorylate the carboxyl-terminal conserved tyrosine of the Src protein, These results support the notion that MATK acts as a regulator of p60(c-src) in megakaryocytic cells and participates in the pathways regulating growth of cells of this lineage.	HARVARD UNIV,NEW ENGLAND DEACONESS HOSP,SCH MED,DIV HEMATOL ONCOL,BOSTON,MA 02215; UNIV MISSOURI,CHILDRENS MERCY HOSP,SCH MED,GENET SECT,KANSAS CITY,MO 64108	Harvard University; Harvard Medical School; Children's Mercy Hospital; University of Missouri System; University of Missouri Kansas City				Avraham, Hava/0000-0002-7545-3640	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046668, R01HL051456] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL46668, R01 HL51456] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AEGERTERSHAW M, 1987, J IMMUNOL, V138, P3488; ANDERSON SK, 1985, MOL CELL BIOL, V5, P1122, DOI 10.1128/MCB.5.5.1122; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; AVRAHAM H, 1992, INT J CELL CLONING, V10, P70, DOI 10.1002/stem.5530100203; AVRAHAM S, 1989, J BIOL CHEM, V264, P16719; BENNETT BD, 1994, J BIOL CHEM, V269, P1068; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; BRAUNINGER A, 1993, ONCOGENE, V8, P1365; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOW LML, 1993, NATURE, V365, P156, DOI 10.1038/365156a0; CHOW LML, 1994, P NATL ACAD SCI USA, V91, P4975, DOI 10.1073/pnas.91.11.4975; COOPER JA, 1990, PEPTIDES PROTEIN PHO; CRAIK CS, 1984, J BIOL CHEM, V259, P4255; DHAR A, 1990, MOL PHARMACOL, V37, P519; DHAR A, 1993, BRIT J HAEMATOL, V84, P1, DOI 10.1111/j.1365-2141.1993.tb03018.x; DHAR A, 1994, J BIOL CHEM, V269, P9123; FERRELL JE, 1988, MOL CELL BIOL, V8, P3603, DOI 10.1128/MCB.8.9.3603; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GREENBERG SM, 1988, BLOOD, V72, P1968; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KAPLAN JM, 1988, MOL CELL BIOL, V8, P2435, DOI 10.1128/MCB.8.6.2435; KLAGES S, 1994, P NATL ACAD SCI USA, V91, P2597, DOI 10.1073/pnas.91.7.2597; KOBAYASHI S, 1993, BLOOD, V81, P889; LEE JJ, 1986, J MOL BIOL, V188, P173, DOI 10.1016/0022-2836(86)90302-5; LEMARCHANDEL V, 1993, MOL CELL BIOL, V13, P668, DOI 10.1128/MCB.13.1.668; MATSUSHIME H, 1986, MOL CELL BIOL, V6, P3000, DOI 10.1128/MCB.6.8.3000; Maxam A M, 1980, Methods Enzymol, V65, P499; MCLEOD DL, 1976, NATURE, V261, P492, DOI 10.1038/261492a0; METHIA N, 1993, BLOOD, V82, P1395; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NADA S, 1991, NATURE, V35, P69; NAKAMURA S, 1989, J BIOL CHEM, V264, P7089; OKADA M, 1989, J BIOL CHEM, V264, P20886; OKADA M, 1991, J BIOL CHEM, V266, P24249; PARKER RC, 1985, MOL CELL BIOL, V5, P831, DOI 10.1128/MCB.5.4.831; PARTANEN J, 1991, ONCOGENE, V6, P2013; PATEL G, 1993, MOL CELL BIOL, V13, P2269, DOI 10.1128/MCB.13.4.2269; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RATAJCZAK MZ, 1992, P NATL ACAD SCI USA, V89, P1710, DOI 10.1073/pnas.89.5.1710; ROWE LB, 1994, MAMM GENOME, V5, P253, DOI 10.1007/BF00389540; SABE H, 1989, P NATL ACAD SCI USA, V89, P2190; SAKANO S, 1994, ONCOGENE, V19, P1155; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SATO T, 1987, EXP HEMATOL, V15, P495; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SMALL D, 1994, P NATL ACAD SCI USA, V91, P459, DOI 10.1073/pnas.91.2.459; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TANAKA A, 1987, MOL CELL BIOL, V7, P1978, DOI 10.1128/MCB.7.5.1978; TAYLOR BA, 1993, MAMM GENOME, V4, pS154, DOI 10.1007/BF00360836; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; ULLRICH A, 1990, CELL, V6, P203; VAINCHENKER W, 1979, BLOOD, V54, P940; VANDENBARK GR, 1992, ONCOGENE, V7, P1259; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; WHITE RA, 1992, NAT GENET, V2, P80, DOI 10.1038/ng0992-80; WINGENDER E, 1988, NUCLEIC ACIDS RES, V16, P1879, DOI 10.1093/nar/16.5.1879; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903	70	46	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 27	1995	270	4					1833	1842		10.1074/jbc.270.4.1833	http://dx.doi.org/10.1074/jbc.270.4.1833			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QD204	7530249	hybrid			2022-12-27	WOS:A1995QD20400054
J	HALL, AV; ANTONIOU, H; WANG, Y; CHEUNG, AH; ARBUS, AM; OLSON, SL; LU, WC; KAU, CL; MARSDEN, PA				HALL, AV; ANTONIOU, H; WANG, Y; CHEUNG, AH; ARBUS, AM; OLSON, SL; LU, WC; KAU, CL; MARSDEN, PA			STRUCTURAL ORGANIZATION OF THE HUMAN NEURONAL NITRIC-OXIDE SYNTHASE GENE (NOS1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; MESSENGER-RNA; NADPH-DIAPHORASE; Z-DNA; TRANSCRIPTION; BRAIN; PROMOTER; CELLS; EXPRESSION; SEQUENCES	Neuronal nitric oxide (NO) synthase, localized to human chromosome 12, uniquely participates in diverse biologic processes; neurotransmission, the regulation of body fluid homeostasis, neuroendocrine physiology, control of smooth muscle motility, sexual function, and myocyte/myoblast biology, among others. Restriction enzyme mapping, subcloning, and DNA sequence analysis of bacteriophage- and yeast artificial chromosome-derived human genomic DNA indicated that the mRNA for neuronal NO synthase is dispersed over a minimum of 160 kilobases of human genomic DNA. Analysis of intron-exon splice junctions predicted that the open reading frame is encoded by 28 exons, with translation initiation and termination in exon 2 and exon 29, respectively. Determination of transcription initiation sites in brain poly(A) RNA with primer extension analysis and RNase protection revealed a major start site 28 nucleotides downstream from a TATA box. Sequence inspection of 5'-flanking regions revealed potential cis-acting DNA elements: AP-2, TEF-1/MCBF, CREB/ATF/c-Fos, NRF-1, Ets, NF-1, and NF-kappa B-like sequences. Diversity appears to represent a major theme apparent upon analysis of human neuronal NO synthase mRNA transcripts. A microsatellite of the dinucleotide variety was detected within the S'-untranslated region of exon 29. Multiple alleles were evident in normal individuals indicating the existence of allelic mRNA sequence variation. Characterization of variant human neuronal NO synthase cDNAs indicated the existence of casette exon 9/10 and exon 10 deletions as examples of structural mRNA diversity due to alternative splicing. The latter deletion of a 175-nucleotide exon introduces a frameshift and premature stop codon indicating the potential existence of a novel NH2 terminus protein. In summary, analysis of the human neuronal NO synthase locus reveals a complex genomic organization and mRNA diversity that is both allelic and structural.	UNIV TORONTO,ST MICHAELS HOSP,DEPT MED,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,ST MICHAELS HOSP,DIV RENAL,TORONTO,ON M5S 1A8,CANADA	University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto			Marsden, Philip A/B-1441-2012					ABU SH, 1993, P NATL ACAD SCI USA, V90, P10769; AFEWORK M, 1992, NEUROREPORT, V3, P893, DOI 10.1097/00001756-199210000-00018; ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; BALLIGAND JL, 1993, P NATL ACAD SCI USA, V90, P347, DOI 10.1073/pnas.90.1.347; BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BOYES J, 1992, EMBO J, V11, P327, DOI 10.1002/j.1460-2075.1992.tb05055.x; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BREDT DS, 1991, J BIOL CHEM, V267, P10976; BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; BURNETT AL, 1992, SCIENCE, V257, P401, DOI 10.1126/science.1378650; CARANGO P, 1993, GENOMICS, V18, P340, DOI 10.1006/geno.1993.1474; CHARTRAIN NA, 1994, J BIOL CHEM, V269, P6765; DAWSON TM, 1992, ANN NEUROL, V32, P297, DOI 10.1002/ana.410320302; DINERMAN JL, 1994, P NATL ACAD SCI USA, V91, P4214, DOI 10.1073/pnas.91.10.4214; DUN NJ, 1993, NEUROSCI LETT, V158, P51, DOI 10.1016/0304-3940(93)90610-W; ELOFSSON R, 1993, NEUROREPORT, V4, P279, DOI 10.1097/00001756-199303000-00013; ELPHICK MR, 1993, BRAIN RES, V619, P344, DOI 10.1016/0006-8993(93)91632-3; FARRANCE IKG, 1992, J BIOL CHEM, V267, P17234; FUJISAWA H, 1994, J NEUROCHEM, V63, P140; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HAWKINS JD, 1988, NUCLEIC ACIDS RES, V16, P9893, DOI 10.1093/nar/16.21.9893; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; HYMAN SE, 1989, MOL CELL BIOL, V9, P321, DOI 10.1128/MCB.9.1.321; KOETSIER PA, 1993, BIOTECHNIQUES, V15, P260; LEE KH, 1994, J BIOL CHEM, V269, P14371; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LIN XH, 1993, J BIOL CHEM, V268, P17334; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MARSDEN PA, 1994, GENOMICS, V19, P183, DOI 10.1006/geno.1994.1039; MARSDEN PA, 1992, FEBS LETT, V307, P287, DOI 10.1016/0014-5793(92)80697-F; MARSDEN PA, 1993, J BIOL CHEM, V268, P17478; MCLAUCHLAN J, 1985, NUCLEIC ACIDS RES, V13, P1347, DOI 10.1093/nar/13.4.1347; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MORI N, 1992, NEURON, V9, P45, DOI 10.1016/0896-6273(92)90219-4; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MOYZIS RK, 1989, GENOMICS, V4, P273, DOI 10.1016/0888-7543(89)90331-5; MUNDEL P, 1992, KIDNEY INT, V42, P1017, DOI 10.1038/ki.1992.382; NADAUD S, 1994, BIOCHEM BIOPH RES CO, V198, P1027, DOI 10.1006/bbrc.1994.1146; NAKANE M, 1993, FEBS LETT, V316, P175, DOI 10.1016/0014-5793(93)81210-Q; NATHAN C, 1994, J BIOL CHEM, V269, P13725; NAYLOR LH, 1990, NUCLEIC ACIDS RES, V18, P1595, DOI 10.1093/nar/18.6.1595; OGURA T, 1993, BIOCHEM BIOPH RES CO, V193, P1014, DOI 10.1006/bbrc.1993.1726; OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063; PEUNOVA N, 1993, NATURE, V364, P450, DOI 10.1038/364450a0; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; RETTORI V, 1993, P NATL ACAD SCI USA, V90, P10130, DOI 10.1073/pnas.90.21.10130; RICH A, 1984, ANNU REV BIOCHEM, V53, P791, DOI 10.1146/annurev.bi.53.070184.004043; ROBINSON LJ, 1994, GENOMICS, V19, P350, DOI 10.1006/geno.1994.1068; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SCHMIDT HHHW, 1992, SCIENCE, V255, P721, DOI 10.1126/science.1371193; SHARP PA, 1981, CELL, V23, P643, DOI 10.1016/0092-8674(81)90425-6; SHIMOSEGAWA T, 1992, NEUROSCI LETT, V148, P67, DOI 10.1016/0304-3940(92)90806-I; SMITH MW, 1988, J MOL EVOL, V27, P45, DOI 10.1007/BF02099729; STAMM S, 1994, NUCLEIC ACIDS RES, V22, P1515, DOI 10.1093/nar/22.9.1515; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; VERGE VMK, 1992, P NATL ACAD SCI USA, V89, P11617, DOI 10.1073/pnas.89.23.11617; VINCENT SR, 1992, TRENDS NEUROSCI, V15, P108, DOI 10.1016/0166-2236(92)90021-Y; VIRBASIUS CMA, 1993, GENE DEV, V7, P2431, DOI 10.1101/gad.7.12a.2431; VODOVOTZ Y, 1993, J EXP MED, V178, P605, DOI 10.1084/jem.178.2.605; WEBER JL, 1989, AM J HUM GENET, V44, P388; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001; WILCOX CS, 1992, P NATL ACAD SCI USA, V89, P11993, DOI 10.1073/pnas.89.24.11993; XU WM, 1993, CYTOGENET CELL GENET, V64, P62, DOI 10.1159/000133562; YOSHIZUMI M, 1993, CIRC RES, V73, P205, DOI 10.1161/01.RES.73.1.205	68	266	284	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					33082	33090						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7528745				2022-12-27	WOS:A1994QA63800053
J	MEHINDATE, K; ALDACCAK, R; SCHALL, TJ; MOURAD, W				MEHINDATE, K; ALDACCAK, R; SCHALL, TJ; MOURAD, W			INDUCTION OF CHEMOKINE GENE-EXPRESSION BY MAJOR HISTOCOMPATIBILITY COMPLEX CLASS-II LIGANDS IN HUMAN FIBROBLAST-LIKE SYNOVIOCYTES - DIFFERENTIAL REGULATION BY INTERLEUKIN-4 AND DEXAMETHASONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; MONOCYTE CHEMOATTRACTANT PROTEIN-1; RHEUMATOID-ARTHRITIS; MESSENGER-RNA; FACTOR-ALPHA; MICROBIAL SUPERANTIGENS; GLUCOCORTICOID RECEPTOR; INFLAMMATORY CYTOKINES; SIGNAL TRANSDUCTION; T-CELLS	Chemokines play a key role in recruiting leukocytes into inflamed synovial environment, and the cells of the synovial membrane, which express high levels of major histocompatibility complex (MHC) class LI molecules, are a major source of these chemokines. Our data indicated that engagement of MHC class II molecules by staphylococcal enterotoxin A superantigen resulted in the induction of chemokine gene expression as well as protein synthesis. Pretreatment of the cells with cycloheximide potentiated the effect of superantigen on chemokine mRNA induction, suggesting that the expression of these genes may occur independently of prior protein synthesis. Ligation of MHC class II molecules in fibroblast-like synoviocytes by other ligands such as Mycoplasma arthritidis-derived superantigen and anti class II antibody could also trigger an increase in the mRNA level of RANTES, MCP-1, and interleukin (IL)-8. The addition of dexamethasone to superantigen-treated fibroblast-like synoviocytes inhibited the mRNA expression of all three chemokines. IL-4 treatment decreased only the stimulating effect of superantigen on RANTES messanger suggesting that different mechanisms are involved in regulating these genes. The inhibitory effect of dexamethasone did not require a de nova protein synthesis, whereas that of IL-4 was protein-dependent. This report demonstrates that MHC class II ligands (superantigens and anti-MHC class II antibodies) may represent an important agent by which inflammatory chemokines can be induced and shows that this response can be modulated by the anti-inflammatory agents dexamethasone and IL-4.	UNIV LAVAL,CHUL,CTR RECH RHUMATOL & IMMUNOL,ST FOY G1V 4G2,PQ,CANADA; GENENTECH INC,SAN FRANCISCO,CA 94080	Laval University; Roche Holding; Genentech			Al-Daccak, Reem/L-8804-2018	Mourad, Walid/0000-0002-1859-9387; Al-Daccak, Reem/0000-0002-6146-2845				ALDACCAK R, 1994, INFECT IMMUN, V62, P2409, DOI 10.1128/IAI.62.6.2409-2416.1994; ALDACCAK R, 1994, BIOCHEM BIOPH RES CO, V201, P855, DOI 10.1006/bbrc.1994.1779; ANTTILA HSI, 1992, CLIN EXP IMMUNOL, V89, P509; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; BAGGIOLILNI M, 1994, ADV IMMUNOL, V55, P98; BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; CALMAN AF, 1987, J IMMUNOL, V139, P2489; CHATILA T, 1993, IMMUNOL REV, V131, P43, DOI 10.1111/j.1600-065X.1993.tb01529.x; COLE BC, 1971, INFECT IMMUN, V4, P344, DOI 10.1128/IAI.4.4.344-355.1971; DAYER JM, 1976, P NATL ACAD SCI USA, V73, P945, DOI 10.1073/pnas.73.3.945; DONNELLY RP, 1993, J IMMUNOL, V151, P5603; DROUIN J, 1989, MOL CELL BIOL, V9, P5305, DOI 10.1128/MCB.9.12.5305; FRASER JD, 1989, NATURE, V339, P221, DOI 10.1038/339221a0; HACHICHA M, 1993, ARTHRITIS RHEUM, V36, P26, DOI 10.1002/art.1780360106; HARIGAI M, 1993, CLIN IMMUNOL IMMUNOP, V69, P83, DOI 10.1006/clin.1993.1153; HARRIS ED, 1990, NEW ENGL J MED, V322, P1277, DOI 10.1056/nejm199005033221805; HART PH, 1993, J IMMUNOL, V151, P3370; HART PH, 1989, P NATL ACAD SCI USA, V86, P3803, DOI 10.1073/pnas.86.10.3803; HOWARD M, 1982, J EXP MED, V155, P914, DOI 10.1084/jem.155.3.914; HOWELL MD, 1991, P NATL ACAD SCI USA, V88, P10921, DOI 10.1073/pnas.88.23.10921; KOTZIN BL, 1993, ADV IMMUNOL, V54, P99, DOI 10.1016/S0065-2776(08)60534-9; LANGER SJ, 1988, MOL CELL BIOL, V8, P3872, DOI 10.1128/MCB.8.9.3872; LEONARD EJ, 1990, IMMUNOL TODAY, V11, P97, DOI 10.1016/0167-5699(90)90035-8; LEW W, 1988, J IMMUNOL, V140, P1895; Matsushima K, 1989, Cytokine, V1, P2, DOI 10.1016/1043-4666(89)91043-0; MATSUSHIMA K, 1988, J EXP MED, V167, P1883, DOI 10.1084/jem.167.6.1883; MIOSSEC P, 1990, ARTHRITIS RHEUM, V33, P1180; MOURAD W, 1989, J EXP MED, V170, P2011, DOI 10.1084/jem.170.6.2011; MOURAD W, 1992, J EXP MED, V175, P613, DOI 10.1084/jem.175.2.613; Mourad W, 1993, Semin Immunol, V5, P47, DOI 10.1006/smim.1993.1007; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; MUKAIDA N, 1991, J IMMUNOL, V146, P1212; OHASHI PS, 1991, CELL, V65, P309; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PALIARD X, 1991, SCIENCE, V253, P325, DOI 10.1126/science.1857971; PHILLIPS PE, 1988, CLIN EXP RHEUMATOL, V6, P87; POON M, 1991, J BIOL CHEM, V266, P22375; Posnett D N, 1993, Semin Immunol, V5, P65, DOI 10.1006/smim.1993.1009; RATHANASWAMI P, 1993, J BIOL CHEM, V268, P5834; RINK L, 1994, INFECT IMMUN, V62, P462, DOI 10.1128/IAI.62.2.462-467.1994; ROLLINS BJ, 1989, MOL CELL BIOL, V9, P4687, DOI 10.1128/MCB.9.11.4687; Sambrook J, 1989, MOL CLONING LABORATO; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; SCHALL TJ, 1988, J IMMUNOL, V141, P1018; SCHMID J, 1987, J IMMUNOL, V139, P250; SCHOLL P, 1989, P NATL ACAD SCI USA, V86, P4210, DOI 10.1073/pnas.86.11.4210; SEARLES RP, 1988, ARTHRITIS RHEUM-US, V31, P834, DOI 10.1002/art.1780310703; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYY YJ, 1990, BIOCHEM BIOPH RES CO, V169, P346, DOI 10.1016/0006-291X(90)90338-N; STANDIFORD TJ, 1990, J IMMUNOL, V145, P1435; TOBLER A, 1992, BLOOD, V79, P45; TREDE NS, 1991, J IMMUNOL, V146, P2310; TREDE NS, 1993, EUR J IMMUNOL, V23, P2129, DOI 10.1002/eji.1830230913; TSUJI K, 1992, HLA 1991 DISEASE COM, V1, P693; TUMANG JR, 1990, J EXP MED, V171, P2153, DOI 10.1084/jem.171.6.2153; VILLIGER PM, 1992, J IMMUNOL, V149, P722; WONG HL, 1992, J IMMUNOL, V148, P2118; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	59	37	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32063	32069						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7528208				2022-12-27	WOS:A1994PX30400011
J	NAKANISHI, S; UEDA, T; HORI, H; YAMAZAKI, N; OKADA, N; WATANABE, K				NAKANISHI, S; UEDA, T; HORI, H; YAMAZAKI, N; OKADA, N; WATANABE, K			A UGU SEQUENCE IN THE ANTICODON LOOP IS A MINIMUM REQUIREMENT FOR RECOGNITION BY ESCHERICHIA-COLI TRANSFER-RNA-GUANINE TRANSGLYCOSYLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER RIBONUCLEIC-ACID; TRANSFER-RNA TRANSGLYCOSYLASE; MODIFIED NUCLEOSIDE-Q; BIOSYNTHESIS; INSERTION; QUEUINE; LIVER; GENES	Escherichia coli tRNA-guanine transglycosylase is an enzyme which catalyzes replacement of guanine (G(34)) Of tRNA(Asp), tRNA(Asn), tRNA(His) and tRNA(Tyr) by free guanine or free preQ(1) base by a base exchange reaction in the biosynthesis of queuosine (Q) (Okada, N., and Nishimura, S. (1979) J. Biol. Chem. 254, 3061-3066). The gene encoding for this enzyme was amplified from the E. coli genome by polymerase chain reaction and inserted into an overexpression vector, pJLA503, The enzyme was overexpressed by heat induction in E. coli transformed by this recombinant plasmid and purified to homogeneity by two column chromatographies. The sequence requirement in tRNA for recognition by this enzyme was investigated using minihelices corresponding to the anticodon arm of E. coli tRNA(His). Two uridine residues (U-33, U-35) were found to be prerequisite for such recognition by this enzyme, Position 32 required pyrimidines, because the enzyme activity toward the minihelices was markedly reduced or entirely lost when this residue was replaced by purines or was deleted, Adenosine at position 37 and the G(30)-C-40 base pair were not essential despite their conservation. Our results suggest that the enzyme recognizes the U-33-G(34)-U-35 sequence in the anticodon loop and not the tertiary structure of tRNA itself.	UNIV TOKYO,FAC ENGN,DEPT CHEM & BIOTECHNOL,BUNKYO KU,TOKYO 113,JAPAN; TOKYO INST TECHNOL,FAC BIOSCI & BIOTECHNOL,DEPT BIOL SCI,MIDORI KU,YOKOHAMA,KANAGAWA 227,JAPAN	University of Tokyo; Tokyo Institute of Technology			Ueda, Takuya/K-5217-2014; Hori, Hiroyuki/AAB-3911-2021	Ueda, Takuya/0000-0002-7760-8271; 				BIENZ M, 1981, NATURE, V294, P188, DOI 10.1038/294188a0; CARBON P, 1988, EMBO J, V2, P1093; CURNOW AW, 1993, BIOCHEMISTRY-US, V32, P5239, DOI 10.1021/bi00070a036; FREY B, 1989, J BACTERIOL, V171, P1524, DOI 10.1128/jb.171.3.1524-1530.1989; GARCIA GA, 1993, J MOL BIOL, V231, P489, DOI 10.1006/jmbi.1993.1296; HARADA F, 1972, BIOCHEMISTRY-US, V11, P301, DOI 10.1021/bi00752a024; HIMENO H, 1989, NUCLEIC ACIDS RES, V17, P7855, DOI 10.1093/nar/17.19.7855; KASAI H, 1975, NUCLEIC ACIDS RES, V2, P1931, DOI 10.1093/nar/2.10.1931; KASAI H, 1976, J AM CHEM SOC, V98, P5044, DOI 10.1021/ja00432a071; KASAI H, 1975, BIOCHEMISTRY-US, V14, P4198, DOI 10.1021/bi00690a008; LIMBACH PA, 1994, NUCLEIC ACIDS RES, V22, P2183, DOI 10.1093/nar/22.12.2183; NISHIMURA S, 1983, PROG NUCLEIC ACID RE, V28, P49, DOI 10.1016/S0079-6603(08)60082-3; NISHIMURA S, 1979, TRANSFER RNA STRUCTU, P59; OKADA N, 1977, NUCLEIC ACIDS RES, V4, P415, DOI 10.1093/nar/4.2.415; OKADA N, 1976, NUCLEIC ACIDS RES, V3, P2593, DOI 10.1093/nar/3.10.2593; OKADA N, 1979, J BIOL CHEM, V254, P3067; OKADA N, 1979, J BIOL CHEM, V254, P3061; REUTER K, 1991, J BACTERIOL, V173, P2256, DOI 10.1128/JB.173.7.2256-2264.1991; SCARINGE SA, 1990, NUCLEIC ACIDS RES, V18, P5433, DOI 10.1093/nar/18.18.5433; SHINDOOKADA N, 1980, BIOCHEMISTRY-US, V19, P395, DOI 10.1021/bi00543a023; SLANY RK, 1993, BIOCHEMISTRY-US, V32, P7811, DOI 10.1021/bi00081a028	21	56	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32221	32225						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7528209				2022-12-27	WOS:A1994PX30400034
J	VANDERGOOT, FG; HARDIE, KR; PARKER, MW; BUCKLEY, JT				VANDERGOOT, FG; HARDIE, KR; PARKER, MW; BUCKLEY, JT			THE C-TERMINAL PEPTIDE PRODUCED UPON PROTEOLYTIC ACTIVATION OF THE CYTOLYTIC TOXIN AEROLYSIN IS NOT INVOLVED IN CHANNEL FORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENCE; AEROMONAS; SITE	The channel-forming toxin aerolysin is secreted by Aeromonas hydrophila as a protoxin that can be activated by nicking with endoproteinase Lys-C after Lys-427 near the C terminus of the protein. The fate of the 43-amino acid peptide distal to the activation site was investigated. A cysteine was introduced into the C-terminal region by replacing Ile-445, and another replaced Gly-202, which is on the proximal side of the activation site. In a double mutant, the two new cysteines were close enough in the folded molecule to form an intrachain 202-445 disulfide bond. Tryptophan fluorescence measurements on wild type and the 2 single cysteine mutants indicated that activation results in exposure of at least 1 tryptophan residue, leading to the conclusion that the peptide moves with respect to the protein when it is produced. This was supported by the observation that upon activation there was a decrease in energy transfer between a tryptophan in the bulk of the protein and a probe attached to Cys-445. The peptide could be separated from active toxin by several methods, indicating that it leaves the protein when it is produced, and that it plays no further role in the process of channel formation.	UNIV VICTORIA,DEPT BIOCHEM & MICROBIOL,VICTORIA V8W 3P6,BC,CANADA; UNIV GENEVA,DEPT BIOCHIM,CH-1211 GENEVA,SWITZERLAND; ST VINCENTS INST MED RES,FITZROY,VIC 3065,AUSTRALIA	University of Victoria; University of Geneva; St. Vincent's Institute of Medical Research			van der Goot, Gisou G/B-2279-2012; Parker, Michael W/F-9069-2013	van der Goot, Gisou G/0000-0002-8522-274X; Parker, Michael W/0000-0002-3101-1138; Hardie, Kim/0000-0002-4892-2739	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALTWEGG M, 1989, CRC CR REV MICROBIOL, V16, P253, DOI 10.3109/10408418909105478; BUCKLEY JT, 1990, BIOCHEM CELL BIOL, V68, P221, DOI 10.1139/o90-029; BUCKLEY JT, 1992, FEBS LETT, V307, P30, DOI 10.1016/0014-5793(92)80896-O; GARLAND WJ, 1988, INFECT IMMUN, V56, P1249, DOI 10.1128/IAI.56.5.1249-1253.1988; HOWARD SP, 1985, J BACTERIOL, V163, P336, DOI 10.1128/JB.163.1.336-340.1985; HOWARD SP, 1982, BIOCHEMISTRY-US, V21, P1662, DOI 10.1021/bi00536a029; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAKEY J, 1992, BACTERIOCINS MICROCI, P127; LAKEY JH, 1991, J MOL BIOL, V218, P639, DOI 10.1016/0022-2836(91)90707-D; LEHRER SS, 1971, BIOCHEMISTRY-US, V10, P3254, DOI 10.1021/bi00793a015; NEVILLE DM, 1971, J BIOL CHEM, V246, P6328; PARKER MW, 1994, NATURE, V367, P292, DOI 10.1038/367292a0; Stern O, 1919, PHYS Z, V20, P183; VANDERGOOT FG, 1992, BIOCHEMISTRY-US, V31, P8566, DOI 10.1021/bi00151a026; VANDERGOOT FG, 1993, J BIOL CHEM, V268, P18272	15	38	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30496	30501						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7527031				2022-12-27	WOS:A1994PU52500071
J	WU, RL; CHEN, TT; SUN, TT				WU, RL; CHEN, TT; SUN, TT			FUNCTIONAL IMPORTANCE OF AN SP1-RELATED AND AN NFKB-RELATED NUCLEAR-PROTEIN IN A KERATINOCYTE-SPECIFIC PROMOTER OF RABBIT K3 KERATIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIATION-SPECIFIC EXPRESSION; B TRANSCRIPTION FACTOR; BOX-BINDING-PROTEINS; KAPPA-B; CELL-TYPE; TRANSGENIC MICE; INTERMEDIATE FILAMENTS; BASEMENT-MEMBRANE; EPITHELIAL-CELLS; ACTIVATION	We have shown previously that a 300-base pair (bp) 5' upstream sequence of rabbit keratin K3 gene (RK3) can function as a keratinocyte-specific promoter in transient transfection assays. Electrophoretic mobility shift assays using various overlapping and mutated oligonucleotides established that corneal keratinocyte nuclear proteins bound in vitro to two sites (B and E). Immuno-supershift and UV cross-linking established that the keratinocyte nuclear binding protein of site B (5'-GGGGCTTTCC-3', -262 to -253 bp) was NFkB consisting of the p65 and p50 subunits. The E site contained an unusual GC-rich motif (5'-CCGCCCCCTG-3', -203 to -194 bp) whose sequence deviated from the Spl consensus in 4 out of 10 positions; this site bound an Sp1-related keratinocyte nuclear protein. Mutagenesis of the NFkB, GC motif, and both sites abolished 20, 50, and 75%, respectively, of the promoter activity in transfected keratinocytes. The NFkB-like keratinocyte nuclear protein was barely detectable in kidney epithelial cells, HeLa, and fibroblasts. The Sp1-related nuclear protein was abundant in keratinocytes and simple epithelial cells, but was much less abundant in fibroblasts. These results indicate that NFkB is present in significant quantities in keratinocyte nuclei and that the tissue restriction of the NFkB- and Sp1-related proteins, in combination with other factors, may contribute to the keratinocyte specificity of RK3 promoter.	NYU, SCH MED, RONALD O PERELMAN DEPT DERMATOL, EPITHELIAL BIOL UNIT, NEW YORK, NY 10016 USA; NYU, SCH MED, KAPLAN COMPREHENS CANC CTR, DEPT PHARMACOL, NEW YORK, NY 10016 USA	New York University; New York University			Sun, Tung-Tien/J-4425-2015	Sun, Tung-Tien/0000-0002-6841-1063	NEI NIH HHS [EY04722] Funding Source: Medline; NIAMS NIH HHS [AR7190-20] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY004722] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007190] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ACKERMAN SL, 1991, P NATL ACAD SCI USA, V88, P7523, DOI 10.1073/pnas.88.17.7523; ADAMS BS, 1991, NEW BIOL, V3, P1063; ALBERS K, 1992, INT REV CYTOL, V134, P243, DOI 10.1016/S0074-7696(08)62030-6; ANDERSEN B, 1993, SCIENCE, V260, P78, DOI 10.1126/science.7682011; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALDWIN AS, 1988, P NATL ACAD SCI USA, V85, P723, DOI 10.1073/pnas.85.3.723; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; BESSEREAU JL, 1993, EMBO J, V12, P443, DOI 10.1002/j.1460-2075.1993.tb05676.x; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BLESSING M, 1989, EMBO J, V8, P117, DOI 10.1002/j.1460-2075.1989.tb03355.x; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BUCHER P, 1992, MOL CELL BIOL, V13, P3176; BYRNE C, 1993, MOL CELL BIOL, V13, P3176, DOI 10.1128/MCB.13.6.3176; CHAVRIER P, 1990, EMBO J, V9, P1209, DOI 10.1002/j.1460-2075.1990.tb08228.x; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; CHODOSH LA, 1989, CURRENT PROTOCOLS MO; COUREY AJ, 1992, TRANSCRIPTIONAL REGU, P743; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DORAN TI, 1980, CELL, V22, P17, DOI 10.1016/0092-8674(80)90150-6; EICHNER R, 1984, J CELL BIOL, V98, P1388, DOI 10.1083/jcb.98.4.1388; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRILLI M, 1993, INT REV CYTOL, V143, P1; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HUFF CA, 1993, J BIOL CHEM, V268, P377; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JAMIESON C, 1989, J EXP MED, V170, P1737, DOI 10.1084/jem.170.5.1737; JIANG CK, 1990, NUCLEIC ACIDS RES, V18, P247, DOI 10.1093/nar/18.2.247; JIANG CK, 1993, P NATL ACAD SCI USA, V90, P6786, DOI 10.1073/pnas.90.14.6786; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; KAWAKAMI K, 1988, P NATL ACAD SCI USA, V85, P4700, DOI 10.1073/pnas.85.13.4700; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KOLEGA J, 1989, DIFFERENTIATION, V42, P54, DOI 10.1111/j.1432-0436.1989.tb00607.x; KURPAKUS MA, 1992, DEV BIOL, V150, P243, DOI 10.1016/0012-1606(92)90239-D; LATTION AL, 1992, MOL CELL BIOL, V12, P5217, DOI 10.1128/MCB.12.11.5217; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; LEASK A, 1990, GENE DEV, V4, P1985, DOI 10.1101/gad.4.11.1985; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; MACCHI M, 1989, EMBO J, V8, P4215, DOI 10.1002/j.1460-2075.1989.tb08607.x; MASTRANGELO IA, 1991, P NATL ACAD SCI USA, V88, P5670, DOI 10.1073/pnas.88.13.5670; MCKNIGTH S, 1992, TRANSCRIPTIONAL REGU; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; NEHLS MC, 1992, DNA CELL BIOL, V11, P443, DOI 10.1089/dna.1992.11.443; NEZNANOV NS, 1993, MOL CELL BIOL, V13, P1815, DOI 10.1128/MCB.13.3.1815; OGUIN WM, 1990, CELLULAR MOL BIOL IN, P301; OSHIMA R G, 1992, Current Opinion in Cell Biology, V4, P110, DOI 10.1016/0955-0674(92)90067-M; PECORINO LT, 1991, MOL CELL BIOL, V11, P3139, DOI 10.1128/MCB.11.6.3139; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; QUINLAN RA, 1985, ANN NY ACAD SCI, V455, P282, DOI 10.1111/j.1749-6632.1985.tb50418.x; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; ROBIDOUX S, 1992, MOL CELL BIOL, V12, P3796, DOI 10.1128/MCB.12.9.3796; ROMAN D, 1990, New Biologist, V2, P642; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAUFELE F, 1990, J BIOL CHEM, V265, P17189; SCHERMER A, 1989, DIFFERENTIATION, V42, P103, DOI 10.1111/j.1432-0436.1989.tb00611.x; SCHERMER A, 1986, J CELL BIOL, V103, P49, DOI 10.1083/jcb.103.1.49; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SNAPE AM, 1991, DEVELOPMENT, V113, P283; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; STUN TT, 1984, TRANSFORMED PHENOTYP, P169; TSENG H, 1992, P NATL ACAD SCI USA, V89, P10311, DOI 10.1073/pnas.89.21.10311; VALLETTE F, 1989, NUCLEIC ACIDS RES, V17, P723, DOI 10.1093/nar/17.2.723; VASSAR R, 1989, P NATL ACAD SCI USA, V86, P1563, DOI 10.1073/pnas.86.5.1563; WEISS RA, 1984, J CELL BIOL, V98, P1397, DOI 10.1083/jcb.98.4.1397; WU RL, 1993, J CELL SCI, V105, P303; YU CY, 1990, MOL CELL BIOL, V10, P282, DOI 10.1128/MCB.10.1.282	75	52	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28450	28459						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7525574				2022-12-27	WOS:A1994PV77200099
J	SCHWINDINGER, WF; MIRIC, A; ZIMMERMAN, D; LEVINE, MA				SCHWINDINGER, WF; MIRIC, A; ZIMMERMAN, D; LEVINE, MA			A NOVEL G(S)ALPHA MUTANT IN A PATIENT WITH ALBRIGHT HEREDITARY OSTEODYSTROPHY UNCOUPLES CELL-SURFACE RECEPTORS FROM ADENYLYL-CYCLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE REGULATORY PROTEIN; STIMULATORY G-PROTEIN; GTP-BINDING PROTEIN; ALPHA-SUBUNIT; DEFICIENT ACTIVITY; S49 LYMPHOMA; GENE; PSEUDOHYPOPARATHYROIDISM; IDENTIFICATION; MUTATIONS	Albright hereditary osteodystrophy (AHO) is an autosomal-dominant disorder characterized by decreased expression of G(s) alpha and widespread tissue resistance to hormones that activate adenylyl cyclase. We identified a single mutation, R385H, in the G(s) alpha gene of a subject with AHO who had evidence for a dysfunctional G(s) alpha protein. The R385H substitution is near the carboxyl terminus of the G(s) alpha protein and is located five amino acids upstream of the R389P mutation that uncouples G(s) alpha from cell surface receptors in the une clone of S49 murine lymphoma. To test the biological activity of the R385H mutant, we transiently expressed wild type, R385H, and R389P G(s) alpha cDNAs in COS-1 cells. Neither of the mutant G(s) alpha proteins stimulated adenylyl cyclase in response to l-isoproterenol (1 to 30 mu M). By contrast, both mutant G(s) alpha proteins showed activation of adenylyl cyclase in response to forskolin (10 mu M) and fluoroaluminate (10 mM). We propose that the R385H mutation produces a G(s) alpha molecule that is unable to interact with hormone receptors and results in uncoupling of adenylyl cyclase from cell surface receptors. This uncoupling mutation represents a new type of molecular defect that can result in AHO.	JOHNS HOPKINS UNIV,SCH MED,DIV ENDOCRINOL & METAB,BALTIMORE,MD 21205; MAYO CLIN & MAYO FDN,DIV PEDIAT ENDOCRINOL & METAB,ROCHESTER,MN 55905	Johns Hopkins University; Mayo Clinic				Levine, Michael/0000-0003-0036-7809	NCRR NIH HHS [RR0035] Funding Source: Medline; NIDDK NIH HHS [DK-08725, DK34281] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK008725, R01DK034281] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBRIGHT F, 1952, T ASSOC AM PHYSICIAN, V65, P337; BOURNE HR, 1982, MOL PHARMACOL, V22, P204; CARTER A, 1987, P NATL ACAD SCI USA, V84, P7266, DOI 10.1073/pnas.84.20.7266; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; HIGICHI R, 1988, NATURE, V332, P543; INOUE Y, 1990, J BIOL CHEM, V265, P10645; JONES DT, 1987, J BIOL CHEM, V262, P14241; KOZASA T, 1988, P NATL ACAD SCI USA, V85, P2081, DOI 10.1073/pnas.85.7.2081; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEVINE MA, 1983, J CLIN INVEST, V72, P316, DOI 10.1172/JCI110971; LEVINE MA, 1980, BIOCHEM BIOPH RES CO, V94, P1319, DOI 10.1016/0006-291X(80)90563-X; LEVINE MA, 1983, AM J MED, V74, P545, DOI 10.1016/0002-9343(83)91008-2; LEVINE MA, 1988, P NATL ACAD SCI USA, V85, P617, DOI 10.1073/pnas.85.2.617; LEVINE MA, 1989, ENDOCRINOLOGY, P1065; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; MASTERS SB, 1988, SCIENCE, V241, P448, DOI 10.1126/science.2899356; MIRIC A, 1993, J CLIN ENDOCR METAB, V76, P1560, DOI 10.1210/jc.76.6.1560; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; PATTEN JL, 1990, NEW ENGL J MED, V322, P1412, DOI 10.1056/NEJM199005173222002; PATTEN JL, 1990, J CLIN ENDOCR METAB, V71, P1208, DOI 10.1210/jcem-71-5-1208; RALL T, 1987, FEBS LETT, V224, P365, DOI 10.1016/0014-5793(87)80486-6; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEAMON K, 1981, J BIOL CHEM, V256, P9799; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; SIMONDS WF, 1989, FEBS LETT, V249, P189, DOI 10.1016/0014-5793(89)80622-2; SPIEGEL AM, 1992, ENDOCR REV, V13, P536, DOI 10.1210/er.13.3.536; SULLIVAN KA, 1987, NATURE, V330, P758, DOI 10.1038/330758a0; WEINSTEIN LS, 1990, P NATL ACAD SCI USA, V87, P8287, DOI 10.1073/pnas.87.21.8287; WEINSTEIN LS, 1992, GENOMICS, V13, P1319, DOI 10.1016/0888-7543(92)90056-X; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; WEST RE, 1985, J BIOL CHEM, V260, P4428	32	78	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25387	25391						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7523385				2022-12-27	WOS:A1994PQ49100027
J	OKUDA, K; ERNST, TJ; GRIFFIN, JD				OKUDA, K; ERNST, TJ; GRIFFIN, JD			INHIBITION OF P21(RAS) ACTIVATION BLOCKS PROLIFERATION BUT NOT DIFFERENTIATION OF INTERLEUKIN-3-DEPENDENT MYELOID CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; NERVE GROWTH-FACTOR; TYROSINE KINASE-ACTIVITY; RECEPTOR GENE FAMILY; SIGNAL-TRANSDUCTION; BETA-SUBUNIT; T-CELLS; RAS; PROTEIN; PHOSPHORYLATION	Interleukin-5 (IL-3) induces proliferation of immature myeloid cells and mast cells and prevents programmed cell death (apoptosis) in vitro. These activities are exerted through binding of IL-3 to specific, high affinity receptors that then initiate a series of intracellular signaling events. Among the earliest of these signaling events in an IL-3-dependent cell line such as 32Dc13 are activation of one or more receptor-associated tyrosine kinases followed by activation of p21(ras). In an effort to define the functional role of p21(ras) activation in mediating the effects of IL-3, we constructed a series of sublines of 32Dc13 in which a dominant inhibitory mutant of Ha-ras (c-Ha-ras(Asn-17)) was expressed under the control of a steroid-inducible promoter. Steroid treatment (dexamethasone, 1 mu M) specifically induced c-Ha-ras(Asn-17) protein and mRNA and blocked IL-3-induced accumulation of p21(ras)-GTP in 32Dc13/p21(ras)N17 cell lines, but not in control cells. Dexamethasone slightly inhibited IL-3-dependent proliferation of control 32Dc13 cell lines (to 80% of maximum), but it completely blocked proliferation of 32Dc13/p21(ras)N17 cell lines and induced cell cycle arrest in G(0)/G(1). This proliferative block could be overcome by cotransfection with v-ras, and was reversible if dexamethasone was washed out. Cells arrested by c-Ha-ras(Asn-17) were viable in culture for >2 weeks, despite their inability to proliferate. Notably, however, these cells remained dependent on IL-3 for viability and initiated apoptosis within 18 h of IL-3 deprivation. Finally, granulocyte colony-stimulating factor-induced differentiation of 32Dc13/p21(ras)N17 cells to neutrophils was not affected by steroid-induced expression of c-Ha-ras(Asn-17) and did not require removal of IL-3. These results suggest that IL-3-induced proliferation and maintenance of cell viability are either initiated through separate signal transduction pathways or require different degrees of p21(ras) activation. Similarly, granulocyte colony-stimulating factor-induced neutrophil differentiation is not blocked by expression of c-Ha-ras(Asn-17).	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV HEMATOL MALIGNANCIES, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School					NATIONAL CANCER INSTITUTE [R01CA047843, R37CA036167, P01CA034183, R01CA036167] Funding Source: NIH RePORTER; NCI NIH HHS [CA47843, CA34183, CA36167] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BUDEL LM, 1990, BLOOD, V75, P1439; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DOWNWARD J, 1992, IMMUNOL TODAY, V13, P89, DOI 10.1016/0167-5699(92)90148-Z; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FEIG LA, 1986, P NATL ACAD SCI USA, V83, P4607, DOI 10.1073/pnas.83.13.4607; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; FURUKAWA Y, 1990, P NATL ACAD SCI USA, V87, P2770, DOI 10.1073/pnas.87.7.2770; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GORMAN DM, 1990, P NATL ACAD SCI USA, V87, P5459, DOI 10.1073/pnas.87.14.5459; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; HARA T, 1992, EMBO J, V11, P1875, DOI 10.1002/j.1460-2075.1992.tb05239.x; Ihle J N, 1989, Year Immunol, V5, P59; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; KANAKURA Y, 1990, BLOOD, V76, P706; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; LOPEZ AF, 1990, J ALLERGY CLIN IMMUN, V85, P99, DOI 10.1016/0091-6749(90)90229-W; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; PARK LS, 1989, J BIOL CHEM, V264, P5420; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SATOH T, 1992, J BIOL CHEM, V267, P25423; SATOH T, 1992, J BIOL CHEM, V267, P24149; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SORENSEN P, 1986, J BIOL CHEM, V261, P9094; STACEY DW, 1991, ONCOGENE, V6, P2297; SZEBERENYI J, 1992, ONCOGENE, V7, P2105; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TORIGOE T, 1992, BLOOD, V80, P617; VALTIERI M, 1987, J IMMUNOL, V138, P3829; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WOODROW MA, 1993, J IMMUNOL, V150, P3853	43	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24602	24607						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7523375				2022-12-27	WOS:A1994PQ49000017
J	ISHIWATA, N; TAKIO, K; KATAYAMA, M; WATANABE, K; TITANI, K; IKEDA, Y; HANDA, M				ISHIWATA, N; TAKIO, K; KATAYAMA, M; WATANABE, K; TITANI, K; IKEDA, Y; HANDA, M			ALTERNATIVELY SPLICED ISOFORM OF P-SELECTIN IS PRESENT IN-VIVO AS A SOLUBLE MOLECULE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRANULE MEMBRANE-PROTEIN; ENDOTHELIAL VONWILLEBRAND-FACTOR; SYSTEMIC LUPUS-ERYTHEMATOSUS; FACTOR-BINDING DOMAIN; WEIBEL-PALADE BODIES; AMINO-ACID SEQUENCE; MONOCLONAL-ANTIBODY; CELL-SURFACE; ACTIVATED PLATELETS; ADHESION RECEPTORS	To demonstrate the presence of a soluble isoform of P-selectin predicted from cDNA sequencing (Johnston, G. I., Bliss, G. A., Newman, P. J., and McEver, R. P. (1990) J. Biol. Chem. 265, 21381-21885), we immunoisolated and compared structurally P-selectin from fresh frozen human plasma with that from washed intact platelets. Plasma P-selectin was reactive with rabbit antiserum to a synthesized peptide (residues 762-774 of mature P-selectin) but was significantly less reactive with antibody to a peptide (residues 747-760). In contrast, platelet P-selectin reacted with both antibodies. S-Pyridylethylated plasma P-selectin was fractionated by reversed phase-high performance liquid chromatography into two major species. From platelets, two virtually identical species were separated. Sequential digestion with Achromobacter protease I and then Staphylococcus V8 protease produced peptides assigned to the tail region of the protein including the putative spliced site. From the more hydrophilic species in both plasma and platelets, a peptide completely lacking the sequence of the putative spliced site was identified. In contrast, the more hydrophobic species yielded a peptide with an intact transmembrane sequence. Hence, these results provide direct evidence that the previously predicted soluble isoform of P-selectin is actually synthesized in vivo and is present as a circulating molecule.	KEIO UNIV,CTR BLOOD,SCH MED,DEPT INTERNAL MED,SHINJUKU KU,TOKYO 160,JAPAN; KEIO UNIV,SCH MED,DEPT LAB MED,TOKYO 160,JAPAN; INST PHYS & CHEM RES,DIV BIOMOLEC CHARACTERIZAT,WAKO,SAITAMA 35101,JAPAN; TAKARA SHUZO CO LTD,BIOTECHNOL RES LABS,OTSU,SHIGA 52021,JAPAN; FUJITA HLTH UNIV,SCH MED,INST COMPREHENS MED SCI,DIV BIOMED POLYMER SCI,TOYOAKE,AICHI 47011,JAPAN	Keio University; Keio University; RIKEN; Takara Holdings Inc.; Fujita Health University			Handa, Makoto/B-1121-2014					ARVAN P, 1987, J CELL BIOL, V104, P243, DOI 10.1083/jcb.104.2.243; BERMAN CL, 1986, J CLIN INVEST, V78, P130, DOI 10.1172/JCI112542; BEVILACQUA M, 1991, CELL, V67, P233, DOI 10.1016/0092-8674(91)90174-W; BONFANTI R, 1989, BLOOD, V73, P1109; Bornstein P, 1977, Methods Enzymol, V47, P132; CARSON CW, 1993, J RHEUMATOL, V20, P809; DELISSER HM, 1994, J CELL BIOL, V124, P195, DOI 10.1083/jcb.124.1.195; DISDIER M, 1992, MOL BIOL CELL, V3, P309, DOI 10.1091/mbc.3.3.309; DORE M, 1993, BLOOD, V82, P1308; Drapeau G R, 1977, Methods Enzymol, V47, P189; DUNLOP LC, 1992, J EXP MED, V175, P1147, DOI 10.1084/jem.175.4.1147; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; FERNANDEZBOTRAN R, 1991, FASEB J, V5, P2567, DOI 10.1096/fasebj.5.11.1868981; FRIEDMAN M, 1970, J BIOL CHEM, V245, P3868; GAMBLE JR, 1990, SCIENCE, V249, P414; GEARING AJH, 1993, IMMUNOL TODAY, V14, P506, DOI 10.1016/0167-5699(93)90267-O; GENG JG, 1992, J BIOL CHEM, V267, P19846; GOLDBERGER A, 1992, BLOOD, V80, pA266; GUNNING P, 1991, FASEB J, V5, P3064, DOI 10.1096/fasebj.5.15.1835946; HANDA M, 1986, J BIOL CHEM, V261, P2579; HANDAGAMA PJ, 1989, J CLIN INVEST, V84, P73, DOI 10.1172/JCI114173; HANDAGAMA PJ, 1987, P NATL ACAD SCI USA, V84, P851; HARLOW E, 1988, ANTIBODIES LABORATOR; HATTORI R, 1989, J BIOL CHEM, V264, P9053; HATTORI R, 1989, J BIOL CHEM, V264, P7768; HSULIN SC, 1984, J BIOL CHEM, V259, P9121; ISHIWATA N, 1993, THROMB HAEMOSTASIS, V69, pA2860; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; JOHNSTON GI, 1990, J BIOL CHEM, V265, P21381; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; JYONOUCHI H, 1991, J ALLERGY CLIN IMMUN, V87, P965, DOI 10.1016/0091-6749(91)90418-N; KATAYAMA M, 1993, BRIT J HAEMATOL, V84, P702, DOI 10.1111/j.1365-2141.1993.tb03149.x; KATAYAMA M, 1992, J IMMUNOL METHODS, V153, P41, DOI 10.1016/0022-1759(92)90303-B; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LEROITH D, 1993, ANN NY ACAD SCI, V692, P1; MASAKI T, 1981, BIOCHIM BIOPHYS ACTA, V660, P51, DOI 10.1016/0005-2744(81)90107-8; MATSUI M, 1993, FEBS LETT, V335, P51, DOI 10.1016/0014-5793(93)80437-Y; MAYADAS TN, 1993, CELL, V74, P541, DOI 10.1016/0092-8674(93)80055-J; MCEVER RP, 1984, J BIOL CHEM, V259, P9799; MCEVER RP, 1989, J CLIN INVEST, V84, P92, DOI 10.1172/JCI114175; MOORE HPH, 1985, J CELL BIOL, V101, P1773, DOI 10.1083/jcb.101.5.1773; MOORE KL, 1991, J CELL BIOL, V112, P491, DOI 10.1083/jcb.112.3.491; MULLIGAN MS, 1992, J CLIN INVEST, V90, P1600, DOI 10.1172/JCI116029; NEWMAN W, 1993, J IMMUNOL, V150, P644; NORMENT AM, 1988, EMBO J, V7, P3433, DOI 10.1002/j.1460-2075.1988.tb03217.x; RHODES CJ, 1987, J CELL BIOL, V105, P145, DOI 10.1083/jcb.105.1.145; Ruegg U T, 1977, Methods Enzymol, V47, P111; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SAWADA S, 1992, AM J MED, V92, P134, DOI 10.1016/0002-9343(92)90103-I; SCHLEIFFENBAUM B, 1992, J CELL BIOL, V119, P229, DOI 10.1083/jcb.119.1.229; SETH R, 1991, LANCET, V338, P83, DOI 10.1016/0140-6736(91)90077-3; SKINNER MP, 1991, J BIOL CHEM, V266, P5371; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; SPERTINI O, 1992, J IMMUNOL METHODS, V156, P115, DOI 10.1016/0022-1759(92)90017-N; STENBERG PE, 1985, J CELL BIOL, V101, P880, DOI 10.1083/jcb.101.3.880; TAYLOR P, 1993, CHEM-BIOL INTERACT, V87, P199, DOI 10.1016/0009-2797(93)90043-X; TITANI K, 1987, P NATL ACAD SCI USA, V84, P5610, DOI 10.1073/pnas.84.16.5610; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; USHIYAMA S, 1993, J BIOL CHEM, V268, P15229; WELLICOME SM, 1993, CLIN EXP IMMUNOL, V92, P412; WONG CS, 1991, P NATL ACAD SCI USA, V88, P2397, DOI 10.1073/pnas.88.6.2397; ZHOU Q, 1991, J CELL BIOL, V115, P557, DOI 10.1083/jcb.115.2.557	62	117	124	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23708	23715						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	7522232				2022-12-27	WOS:A1994PQ34500050
J	KAO, PN; CHEN, L; BROCK, G; NG, J; KENNY, J; SMITH, AJ; CORTHESY, B				KAO, PN; CHEN, L; BROCK, G; NG, J; KENNY, J; SMITH, AJ; CORTHESY, B			CLONING AND EXPRESSION OF CYCLOSPORINE-A-SENSITIVE AND FK506-SENSITIVE NUCLEAR FACTOR OF ACTIVATED T-CELLS - NF45 AND NF90	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTE-SPECIFIC FACTORS; DOUBLE-STRANDED-RNA; HUMAN IL-2 GENE; INTERLEUKIN-2 GENE; ANTIGEN RECEPTOR; VACCINIA VIRUS; BINDING; TRANSCRIPTION; PROMOTER; PROTEINS	Nuclear Factor of Activated T-cells (NF-AT) is a crucial transcription factor required for T-cell expression of interleukin 2. Purified NF-AT contains 45-kDa and 90-kDa subunits (Corthesy, B., and Kao, P. N. (1994) J. Biol. Chem. 269, 20682-20690). Partial internal amino acid sequences derived from each subunit indicate that these proteins are novel, The amino acid sequences were used to clone the cDNAs encoding each subunit. The cDNAs predict proteins of novel structures: NF45 has limited similarity to prokaryotic transcription factor sigma-54 and to human DNA topoisomerase II; NF90 has limited similarity to Drosophila Staufen in a domain predicted to bind double-stranded RNA. RNA encoding NF45 and NF90 exists in nonstimulated Jurkat T-cells and in all other cell types examined (HeLa, HepG2, K562). Immunofluorescence microscopy was used to demonstrate that both proteins are located in the nucleus of Jurkat T-cells. Clones NF45 and NF90 with a polyhistidine fusion tag were transiently expressed and processed in the native environment of Jurkat T-cells. Histidine-tagged NF45 and NF90 proteins, affinity-purified on nickel chelate columns, encode a NF-AT DNA-binding activity that is enhanced following T-cell stimulation, and this enhancement is blocked when T-cells are stimulated in the presence of cyclosporin A or FK506.	STANFORD UNIV, MED CTR, SCH MED, DEPT PATHOL, STANFORD, CA 94305 USA; STANFORD UNIV, MED CTR, SCH MED, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA; STANFORD UNIV, MED CTR, SCH MED, PROT & NUCLE ACID FACIL, STANFORD, CA 94305 USA; UNIV LAUSANNE, INST BIOL ANIM, CH-1015 LAUSANNE, SWITZERLAND	Stanford University; Howard Hughes Medical Institute; Stanford University; Stanford University; University of Lausanne	KAO, PN (corresponding author), STANFORD UNIV, MED CTR, SCH MED, DIV PULM & CRIT CARE MED, STANFORD, CA 94305 USA.				NIAID NIH HHS [1-K04-AI01147-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K04AI001147] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BANERJI SS, 1991, MOL CELL BIOL, V11, P4074, DOI 10.1128/MCB.11.8.4074; BICKEL M, 1987, P NATL ACAD SCI USA, V84, P3274, DOI 10.1073/pnas.84.10.3274; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; BRUNVAND MW, 1988, J BIOL CHEM, V263, P18904; BRUTLAG DL, 1993, COMPUT CHEM, V17, P203, DOI 10.1016/0097-8485(93)85011-Z; CHANG HW, 1993, VIROLOGY, V194, P537, DOI 10.1006/viro.1993.1292; CORTHESY B, 1994, J BIOL CHEM, V269, P20682; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DIGNAM JD, 1990, METHOD ENZYMOL, V182, P194; DURAND DB, 1987, J EXP MED, V165, P395, DOI 10.1084/jem.165.2.395; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; ELLIOTT JF, 1984, SCIENCE, V226, P1439, DOI 10.1126/science.6334364; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FUJITA T, 1986, CELL, V46, P401, DOI 10.1016/0092-8674(86)90660-4; GATIGNOL A, 1993, MOL CELL BIOL, V13, P2193, DOI 10.1128/MCB.13.4.2193; GRALLA JD, 1991, CELL, V66, P415, DOI 10.1016/0092-8674(81)90001-5; GRANELLIPIPERNO A, 1990, J EXP MED, V172, P1869, DOI 10.1084/jem.172.6.1869; GRANELLIPIPERNO A, 1991, P NATL ACAD SCI USA, V88, P11431, DOI 10.1073/pnas.88.24.11431; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JANKNECHT R, 1991, P NATL ACAD SCI USA, V88, P8972, DOI 10.1073/pnas.88.20.8972; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KRONKE M, 1984, P NATL ACAD SCI-BIOL, V81, P5214, DOI 10.1073/pnas.81.16.5214; LATHE R, 1985, J MOL BIOL, V183, P1, DOI 10.1016/0022-2836(85)90276-1; LI C, 1991, P NATL ACAD SCI USA, V88, P7739, DOI 10.1073/pnas.88.17.7739; MACDONALD RJ, 1987, METHOD ENZYMOL, V152, P219; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; MERINO A, 1993, NATURE, V365, P227, DOI 10.1038/365227a0; MOUZAKI A, 1991, EMBO J, V10, P1399, DOI 10.1002/j.1460-2075.1991.tb07660.x; NABEL GJ, 1988, P NATL ACAD SCI USA, V85, P2934, DOI 10.1073/pnas.85.9.2934; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; ONEILL EA, 1993, TRANSPLANT SCI, V3, P77; RANDAK C, 1990, EMBO J, V9, P2529, DOI 10.1002/j.1460-2075.1990.tb07433.x; RIEGEL JS, 1992, CHEM IMMUNOL, V51, P266; Sambrook J, 1989, MOL CLONING LABORATO; SAWADA S, 1987, J IMMUNOL, V139, P1797; SERFLING E, 1989, EMBO J, V8, P465, DOI 10.1002/j.1460-2075.1989.tb03399.x; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; SHAW PE, 1989, EMBO J, V8, P2567, DOI 10.1002/j.1460-2075.1989.tb08395.x; SHIBUYA H, 1989, NUCLEIC ACIDS RES, V17, P9173, DOI 10.1093/nar/17.22.9173; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; TOCCI MJ, 1989, J IMMUNOL, V143, P718; UETSUKI T, 1989, J BIOL CHEM, V264, P5791; WILLIAMS TM, 1988, J IMMUNOL, V141, P662; YASEEN NR, 1993, J BIOL CHEM, V268, P14285	51	165	172	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20691	20699						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	7519613				2022-12-27	WOS:A1994PB31700074
J	THOMAS, PE; WHARRAM, BL; GOYAL, M; WIGGINS, JE; HOLZMAN, LB; WIGGINS, RC				THOMAS, PE; WHARRAM, BL; GOYAL, M; WIGGINS, JE; HOLZMAN, LB; WIGGINS, RC			GLEPP1, A RENAL GLOMERULAR EPITHELIAL-CELL (PODOCYTE) MEMBRANE PROTEIN-TYROSINE-PHOSPHATASE - IDENTIFICATION, MOLECULAR-CLONING, AND CHARACTERIZATION IN RABBIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-S-TRANSFERASE; LEUKOCYTE-COMMON ANTIGEN; CENTRAL-NERVOUS-SYSTEM; AMINONUCLEOSIDE NEPHROSIS; ESCHERICHIA-COLI; MESSENGER-RNA; HPTP-BETA; RECEPTOR; CD45; PURIFICATION	Podocytes are specialized epithelial cells with delicate interdigitating foot processes which cover the exterior basement membrane surface of the glomerular capillary. They are in part responsible for the extraor dinary charge and size filtration characteristics of the glomerulus. To better understand disease processes affecting the glomerular filter, we searched for proteins with relative specificity to the podocyte using a monoclonal antibody strategy. The first such protein characterized (designated glomerular epithelial protein 1 (GLEPP1)) is a membrane protein-tyrosine phosphatase (PTPase) with a large extracellular domain containing eight fibronectin type III-like repeats, a hydrophobic transmembrane segment, and a single PTPase domain. The GLEPP1 PTPase domain shows homology with two other single domain transmembrane PTPases,(PTP beta and Drosophila central nervous system PTP10D). This homology includes 2 cysteines in the PTPase domain not present in intracellular or tandem domain membrane PTPases. GLEPP1 PTPase protein is distributed to the podocyte foot processes themselves. RNase protection assay shows that GLEPP1 mRNA is also present in brain. By analogy with the CD45 PTPase of T cells, we expect that this receptor might play a role in maintaining foot process structure and/or function by regulating tyrosine phosphorylation of podocyte proteins.	UNIV MICHIGAN,DEPT INTERNAL MED,DIV NEPHROL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan				Wiggins, Roger/0000-0002-1166-2849; Holzman, Lawrence/0000-0002-8961-234X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038149, P50DK039255] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK39255, DK38149] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARIMURA Y, 1992, TUMOR BIOL, V13, P180, DOI 10.1159/000217763; Austen BM, 1981, BIOCH SOC S, V46, P235; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BOYD D, 1990, CELL, V62, P1031, DOI 10.1016/0092-8674(90)90378-R; BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DOWNER G, 1988, J CLIN INVEST, V82, P998, DOI 10.1172/JCI113710; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GEBBINK MFBG, 1993, J BIOL CHEM, V268, P16101; GOYAL M, 1991, J AM SOC NEPHROL, V1, P1334; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; HEBERT S, 1993, DIS KIDNEY, P1; ITOH M, 1992, J BIOL CHEM, V267, P12356; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JANEWAY CA, 1992, ANNU REV IMMUNOL, V10, P645, DOI 10.1146/annurev.immunol.10.1.645; KERJASCHKI D, 1985, AM J PATHOL, V118, P343; KORETZKY GA, 1993, FASEB J, V7, P420, DOI 10.1096/fasebj.7.5.8462784; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KREUGER NX, 1990, EMBO J, V9, P3241; KURIHARA H, 1992, AM J PATHOL, V141, P805; LEVY JB, 1993, J BIOL CHEM, V268, P10573; LOGIN GR, 1987, LAB INVEST, V57, P585; MERRITT SE, 1990, LAB INVEST, V63, P762; NADASDY T, 1989, RENAL PATHOLOGY, P330; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHRAVEN B, 1991, EUR J IMMUNOL, V21, P2469, DOI 10.1002/eji.1830211025; SECRIST JP, 1991, J BIOL CHEM, V266, P12135; SIBLEY RK, 1989, RENAL PATHOLOGY, P1291; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STOW JL, 1989, AM J PATHOL, V135, P637; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; TIAN SS, 1991, CELL, V67, P675, DOI 10.1016/0092-8674(91)90063-5; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TROWBRIDGE IS, 1991, J BIOL CHEM, V266, P23517; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; WANG Y, 1992, J BIOL CHEM, V267, P16696; WIGGINS R, 1987, LAB INVEST, V56, P264; YANG XH, 1991, CELL, V67, P661, DOI 10.1016/0092-8674(91)90062-4; YOUNG RA, 1985, GENETIC ENG, P29; ZANKE B, 1992, EUR J IMMUNOL, V22, P235, DOI 10.1002/eji.1830220134	47	141	156	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					19953	19961						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	7519601				2022-12-27	WOS:A1994PA12600047
J	MINOGUCHI, K; BENHAMOU, M; SWAIM, WD; KAWAKAMI, Y; KAWAKAMI, T; SIRAGANIAN, RP				MINOGUCHI, K; BENHAMOU, M; SWAIM, WD; KAWAKAMI, Y; KAWAKAMI, T; SIRAGANIAN, RP			ACTIVATION OF PROTEIN-TYROSINE KINASE P72(SYK) BY FC-EPSILON-RI AGGREGATION IN RAT BASOPHILIC LEUKEMIA-CELLS P72(SYK) IS A MINOR COMPONENT BUT THE MAJOR PROTEIN-TYROSINE KINASE OF PP72	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY; ANTIGEN RECEPTOR; IMMUNOGLOBULIN-E; PHOSPHOLIPASE C-GAMMA-1; SIGNAL TRANSDUCTION; MAST-CELLS; ZETA-CHAIN; MONOCLONAL-ANTIBODIES; CROSS-LINKING; RBL-2H3 CELLS	Aggregation of the high affinity IgE receptors (Fc epsilon RI) on rat basophilic leukemia RBL-2H3 cells results in protein tyrosine phosphorylations. Previously we reported that there is prominent tyrosine phosphorylation of similar to 72-kDa proteins (pp72) and that the tyrosine kinase p72(syk) is one component of pp72. Here we studied further the relationship of p72(syk) to pp72. The aggregation of Fc epsilon RI induced the activation of p72(syk) which was parallel to its tyrosine phosphorylation. By in vitro kinase assay of immune complexes purified with anti-phosphotyrosine antibodies, p72(syk) was the major pp72 tyrosine kinase. However, by immunoblotting with anti-phosphotyrosine antibodies, p72(syk) was a minor component of pp72. The heterogeneous nature of pp72 was indicated by different studies. Under optimum conditions of one-dimensional sodium dodecyl sulfate-polyacrylamide gel electrophoresis, pp72 consisted of a heterogeneous group of 69-, 71-, and 72-kDa tyrosine-phosphorylated proteins. There were differences in the tyrosine phosphorylation of these proteins in cells activated in the absence of extracellular calcium or when stimulation was with the calcium ionophore A23187 or with phorbol myristate acetate. One of the proteins migrating at 69 kDa was p72(syk). By two-dimensional gel electrophoresis pp72 was found to consist of multiple tyrosine-phosphorylated proteins including 71-80-kDa proteins that associate with p53/56(lyn). A 75-kDa tyrosine-phosphorylated protein, different from pp72, was identified as p75(HS1) (SPY75). These results demonstrate the heterogeneous nature of the pp72 and that p72(syk) is activated after Fc epsilon RI aggregation.	LA JOLLA INST ALLERGY & IMMUNOL, DIV IMMUNOBIOL, LA JOLLA, CA 92037 USA	La Jolla Institute for Immunology	MINOGUCHI, K (corresponding author), NIDR, IMMUNOL LAB, BLDG 10, RM 1N106, BETHESDA, MD 20892 USA.		Kawakami, Toshiaki/O-1616-2015	Benhamou, Marc/0000-0001-7763-3795				AGARWAL A, 1993, J BIOL CHEM, V268, P15900; BASCIANO LK, 1986, J BIOL CHEM, V261, P1823; BEAVEN MA, 1988, PROG ALLERGY, V42, P123; BENHAMOU M, 1992, J BIOL CHEM, V267, P7310; BENHAMOU M, 1992, IMMUNOL TODAY, V13, P195, DOI 10.1016/0167-5699(92)90152-W; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BENHAMOU M, 1993, J BIOL CHEM, V268, P23318; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CICHOWSKI K, 1992, J BIOL CHEM, V267, P5025; DASILVA AJ, 1993, J BIOL CHEM, V268, P16537; DRABEROVA L, 1993, P NATL ACAD SCI USA, V90, P3611, DOI 10.1073/pnas.90.8.3611; EISEMAN E, 1992, NATURE, V355, P78; FUKAMACHI H, 1992, P NATL ACAD SCI USA, V89, P9524, DOI 10.1073/pnas.89.20.9524; FUKAMACHI H, 1994, J IMMUNOL, V152, P642; FUKAMACHI H, 1993, INT ARCH ALLERGY IMM, V102, P15, DOI 10.1159/000236546; HAMAWY MM, 1993, J BIOL CHEM, V268, P6851; HAMAWY MM, 1993, J BIOL CHEM, V268, P5227; HEYECK SD, 1993, P NATL ACAD SCI USA, V90, P669, DOI 10.1073/pnas.90.2.669; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; HUTCHCROFT JE, 1991, J BIOL CHEM, V266, P14846; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; KAMPS MP, 1988, ONCOGENE, V2, P305; KAWAKAMI T, 1992, J IMMUNOL, V148, P3513; KITAMURA D, 1989, NUCLEIC ACIDS RES, V17, P9367; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; LI W, 1992, MOL CELL BIOL, V12, P3176, DOI 10.1128/MCB.12.7.3176; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; METZGER H, 1986, ANNU REV IMMUNOL, V4, P419, DOI 10.1146/annurev.iy.04.040186.002223; MINOGUCHI K, 1994, J BIOL CHEM, V269, P5249; MINOGUCHI K, 1994, IN PRESS MOL IMMUNOL, V31; PAOLINI R, 1992, P NATL ACAD SCI USA, V89, P10733, DOI 10.1073/pnas.89.22.10733; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; PARK DJ, 1991, J BIOL CHEM, V266, P24237; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; SANTINI F, 1993, J BIOL CHEM, V268, P22716; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; SIRAGANIAN RP, 1988, INFLAMMATION BASIC P, P513; STEPHAN V, 1992, J BIOL CHEM, V267, P5434; STRACKE ML, 1987, MOL IMMUNOL, V24, P347, DOI 10.1016/0161-5890(87)90176-3; TANIGUCHI T, 1993, J BIOL CHEM, V268, P2277; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; TORIGOE T, 1992, P NATL ACAD SCI USA, V89, P2674, DOI 10.1073/pnas.89.7.2674; WANGE RL, 1992, J BIOL CHEM, V267, P11685; YAMADA N, 1993, BIOCHEM BIOPH RES CO, V192, P231, DOI 10.1006/bbrc.1993.1404; YAMADA T, 1993, EUR J BIOCHEM, V213, P455, DOI 10.1111/j.1432-1033.1993.tb17781.x; YAMANASHI Y, 1993, P NATL ACAD SCI USA, V90, P3631, DOI 10.1073/pnas.90.8.3631; YU KT, 1991, J BIOL CHEM, V266, P22564	49	72	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16902	16908						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	7515887				2022-12-27	WOS:A1994NR29600059
J	LAVAGNA, C; MARCHETTO, S; BIRNBAUM, D; ROSNET, O				LAVAGNA, C; MARCHETTO, S; BIRNBAUM, D; ROSNET, O			IDENTIFICATION AND CHARACTERIZATION OF A FUNCTIONAL MURINE FLT3 ISOFORM PRODUCED BY EXON SKIPPING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; C-KIT GENE; GROWTH-FACTOR RECEPTOR; STEM-CELL FACTOR; HEMATOPOIETIC-CELLS; PROTO-ONCOGENE; BINDING-SITE; LIGAND; DIMERIZATION; ACTIVATION	The FLT3 gene encodes an hematopoietic receptor related to the receptors for colony-stimulating factor 1, FMS, and for Steel factor, KIT. The extracellular part of these molecules is exclusively composed of five immunoglobulin (Ig)-like domains, designated 1 to 5, from the amino terminus to the carboxyl terminus of the extracellular region. We have isolated a unique murine FLT3 cDNA that codes for a variant isoform of FLT3, devoid of the fifth Ig-like domain, by comparison with the prototypic form. The corresponding mRNA is the result of a splicing event that leads to the elimination of two coding exons, mRNA coding for this variant was detected in almost all the tissues expressing the mRNA coding for the prototypic molecule, although at a lower level. Ligand-induced tyrosine phosphorylation of the two isoforms was equivalent in COS-1 transfected cells, indicating that the fifth Ig-like domain is not strictly necessary for either ligand-binding or kinase activation.			LAVAGNA, C (corresponding author), INSERM, U119, MOLEC ONCOL LAB, 27 BD LEI ROURE, F-13009 MARSEILLE, FRANCE.		Rosnet, Olivier/G-3536-2013	Rosnet, Olivier/0000-0002-3020-910X				AGNES F, 1994, GENE, V145, P283, DOI 10.1016/0378-1119(94)90021-3; ANDRE C, 1992, ONCOGENE, V7, P685; BLECHMAN JM, 1993, STEM CELLS, V11, P12; BLECHMAN JM, 1993, J BIOL CHEM, V268, P4399; BLUMEJENSEN P, 1991, EMBO J, V10, P4121, DOI 10.1002/j.1460-2075.1991.tb04989.x; BORDEREAUX D, 1987, J VIROL, V61, P4043, DOI 10.1128/JVI.61.12.4043-4045.1987; BROXMEYER HE, 1991, CANCER CELL-MON REV, V3, P480; CASTERAN N, 1994, CELL MOL BIOL, V40, P443; CHEON HG, 1994, P NATL ACAD SCI USA, V91, P989, DOI 10.1073/pnas.91.3.989; CHIBA T, 1993, NATURE, V362, P646, DOI 10.1038/362646a0; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; CROSIER PS, 1993, BLOOD, V82, P1151; DOSIL M, 1993, MOL CELL BIOL, V13, P6572, DOI 10.1128/MCB.13.10.6572; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; GALLAND F, 1993, ONCOGENE, V8, P1233; GIEBEL LB, 1992, ONCOGENE, V7, P2207; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; GOKKEL E, 1992, ONCOGENE, V7, P1423; HAMPE A, 1989, ONCOGENE RES, V4, P9; HANNUM C, 1994, NATURE, V368, P643, DOI 10.1038/368643a0; HAYASHI SI, 1991, NUCLEIC ACIDS RES, V19, P1267, DOI 10.1093/nar/19.6.1267; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; INOBE M, 1994, BIOCHEM BIOPH RES CO, V200, P443, DOI 10.1006/bbrc.1994.1469; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KELLY JD, 1991, J BIOL CHEM, V266, P8987; LEE KH, 1990, MOL CELL BIOL, V10, P2237, DOI 10.1128/MCB.10.5.2237; LEV S, 1993, MOL CELL BIOL, V13, P2224, DOI 10.1128/MCB.13.4.2224; LI W, 1991, EMBO J, V10, P277, DOI 10.1002/j.1460-2075.1991.tb07948.x; LYMAN SD, 1993, CELL, V75, P1157, DOI 10.1016/0092-8674(93)90325-K; MAROC N, 1993, ONCOGENE, V8, P909; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; MORRISONGRAHAM K, 1993, BIOESSAYS, V15, P77, DOI 10.1002/bies.950150202; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; OHTSUKA M, 1990, MOL CELL BIOL, V10, P1664, DOI 10.1128/MCB.10.4.1664; Pawson T, 1992, CURR OPIN GENET DEV, V2, P4, DOI 10.1016/S0959-437X(05)80314-4; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; ROSNET O, 1991, ONCOGENE, V6, P1641; ROSNET O, 1993, BLOOD, V82, P1110, DOI 10.1182/blood.V82.4.1110.bloodjournal8241110; ROTTAPEL R, 1994, ONCOGENE, V9, P1755; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SHERR CJ, 1988, COLD SPRING HARB SYM, V53, P521, DOI 10.1101/SQB.1988.053.01.060; SMALL D, 1994, P NATL ACAD SCI USA, V91, P459, DOI 10.1073/pnas.91.2.459; VANDENBARK GR, 1992, ONCOGENE, V7, P1259; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WILLIAMS DE, 1992, DEV BIOL, V151, P368, DOI 10.1016/0012-1606(92)90176-H; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; ZE W, 1993, MOL CELL BIOL, V13, P5348, DOI 10.1128/MCB.13.9.5348	49	15	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	1995	270	7					3165	3171		10.1074/jbc.270.7.3165	http://dx.doi.org/10.1074/jbc.270.7.3165			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QG471	7531700	hybrid			2022-12-27	WOS:A1995QG47100043
J	MUNDSCHAU, LJ; FALLER, DV				MUNDSCHAU, LJ; FALLER, DV			PLATELET-DERIVED GROWTH-FACTOR SIGNAL-TRANSDUCTION THROUGH THE INTERFERON-INDUCIBLE KINASE PKR - IMMEDIATE-EARLY GENE INDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; DEPENDENT EIF-2-ALPHA KINASE; INITIATION FACTOR-II; GCN2 PROTEIN-KINASE; EJ-RAS ONCOGENE; C-FOS; NIH-3T3 CELLS; RECEPTOR AUTOPHOSPHORYLATION; GLUCOCORTICOID RECEPTOR; SELECTIVE-INHIBITION	The interferon-inducible, double-stranded RNA (dsRNA)-dependent eukaryotic initiation factor-2 alpha kinase PKR has primarily been characterized as a component of the interferon-mediated cellular antiviral response. Several lines of evidence now exist that suggest that PKR plays a role in the regulation of growth in uninfected cells. The most direct examples are the finding of an oncogenic variant of PKR and the effects of activators and inhibitors of PKR phosphorylation on the expression of platelet-derived growth factor (PDGF)-inducible genes. Previous reports have shown that 1) dsRNA, a direct activator of PKR, induces the genes c-myc, c-fos, and JE; 2) 2-aminopurine, a chemical inhibitor of PKR, blocks the induction of these genes by serum; and 3) activated p21(ras) induces a cellular inhibitor of PKR. We report here that activation of PKR was correlated with the induction of the immediate early genes c-fos, c-myc, and JE by PDGF in the following situations: 1) PDGF induction of these genes, also inducible by dsRNA, was blocked by two inhibitors of PKR activation: 2-aminopurine and v-ras; 2) PDGF induction of another immediate early gene, egr-1, which could not be induced by dsRNA, was not blocked by 2-aminopurine or v-ras; 3) agents that reverse v-ras inhibition of PKR activation also reversed the v-ras block of PDGF induction of c-myc, c-fos, and JE; 4) down-regulation of PKR protein levels by antisense inhibition of translation blocked the induction of c-myc, c-fos, and JE by PDGF, but had no effect on egr-1 induction; and finally, 5) PHR was autophosphorylated in vivo in response to PDGF. These results provide direct evidence that PKR activation functions as a second messenger in a growth factor signal transduction pathway. Thus, PKR may serve as a common mediator of growth-promoting and growth inhibitory signals.	BOSTON UNIV,SCH MED,CTR CANC RES,BOSTON,MA 02118	Boston University			Kasman, Laura/AAF-3536-2021	Kasman, Laura/0000-0002-8661-2918				BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BARBER GN, 1993, P NATL ACAD SCI USA, V90, P4621, DOI 10.1073/pnas.90.10.4621; BARBER GN, 1994, P NATL ACAD SCI USA, V91, P4278, DOI 10.1073/pnas.91.10.4278; BENJAMIN CW, 1988, P NATL ACAD SCI USA, V85, P4345, DOI 10.1073/pnas.85.12.4345; BENJAMIN CW, 1987, P NATL ACAD SCI USA, V84, P546, DOI 10.1073/pnas.84.2.546; CARCHMAN RA, 1974, CELL, V1, P59, DOI 10.1016/0092-8674(74)90156-1; CHEN JJ, 1991, P NATL ACAD SCI USA, V88, P7729, DOI 10.1073/pnas.88.17.7729; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEMENS MJ, 1993, J INTERFERON RES, V13, P241, DOI 10.1089/jir.1993.13.241; CLEMENS MJ, 1994, BIOCHIMIE PARIS, V8, P770; DENIS M, 1988, NATURE, V333, P686, DOI 10.1038/333686a0; DEVER TE, 1993, P NATL ACAD SCI USA, V90, P4616, DOI 10.1073/pnas.90.10.4616; ERUSALIMSKY JD, 1988, J BIOL CHEM, V263, P19188; EXTON JH, 1990, J BIOL CHEM, V265, P1; FALLER DV, 1994, J BIOL CHEM, V269, P5022; FARRELL PJ, 1977, CELL, V11, P187, DOI 10.1016/0092-8674(77)90330-0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FENG GS, 1992, P NATL ACAD SCI USA, V89, P5447, DOI 10.1073/pnas.89.12.5447; GIANTINI M, 1989, J VIROL, V63, P2415, DOI 10.1128/JVI.63.6.2415-2421.1989; HALL DJ, 1987, J BIOL CHEM, V262, P15302; HALL DJ, 1989, MOL CELL BIOL, V9, P1705, DOI 10.1128/MCB.9.4.1705; JUDWARE R, 1991, MOL CELL BIOL, V11, P3259, DOI 10.1128/MCB.11.6.3259; KALVAKOLANU DVR, 1991, J BIOL CHEM, V266, P873; KATZE MG, 1991, MOL CELL BIOL, V11, P5497, DOI 10.1128/MCB.11.11.5497; KAUFMAN RJ, 1987, MOL CELL BIOL, V7, P1568, DOI 10.1128/MCB.7.4.1568; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; KOSTURA M, 1989, MOL CELL BIOL, V9, P1576, DOI 10.1128/MCB.9.4.1576; LEE TG, 1990, P NATL ACAD SCI USA, V87, P6208, DOI 10.1073/pnas.87.16.6208; LI JH, 1991, EUR J BIOCHEM, V195, P41, DOI 10.1111/j.1432-1033.1991.tb15673.x; MAHADEVAN LC, 1990, ONCOGENE, V5, P327; MATTS RL, 1989, J BIOL CHEM, V264, P15542; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; MUNDSCHAU LJ, 1991, MOL CELL BIOL, V11, P3148, DOI 10.1128/MCB.11.6.3148; MUNDSCHAU LJ, 1992, J BIOL CHEM, V267, P23092; MUNDSCHAU LJ, 1994, BIOCHIMIE PARIS, V8, P792; MURTHARIEL P, 1993, J BIOL CHEM, V268, P12946; OLINGER PL, 1989, J CELL PHYSIOL, V139, P335, DOI 10.1002/jcp.1041390216; OMALLEY RP, 1986, CELL, V44, P391, DOI 10.1016/0092-8674(86)90460-5; PETRYSHYN R, 1983, METHOD ENZYMOL, V99, P346; PETRYSHYN R, 1984, J BIOL CHEM, V259, P4736; PRATT WB, 1988, J BIOL CHEM, V263, P267; QUINONES MA, 1991, J BIOL CHEM, V266, P14055; RAKE JB, 1991, J BIOL CHEM, V266, P5348; RICE AP, 1989, J BIOL CHEM, V264, P20632; ROLLINS BJ, 1988, P NATL ACAD SCI USA, V85, P3738, DOI 10.1073/pnas.85.11.3738; SAMUEL CE, 1991, VIROLOGY, V183, P1, DOI 10.1016/0042-6822(91)90112-O; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; SULTZMAN L, 1991, MOL CELL BIOL, V11, P2018, DOI 10.1128/MCB.11.4.2018; TIWARI RK, 1988, MOL CELL BIOL, V8, P4289, DOI 10.1128/MCB.8.10.4289; WATHELET MG, 1989, EUR J BIOCHEM, V184, P503, DOI 10.1111/j.1432-1033.1989.tb15043.x; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; WRIGHT TC, 1989, P NATL ACAD SCI USA, V86, P3199, DOI 10.1073/pnas.86.9.3199; ZINN K, 1988, SCIENCE, V240, P210, DOI 10.1126/science.3281258; ZULLO JN, 1985, CELL, V43, P793, DOI 10.1016/0092-8674(85)90252-1; ZULLO JN, 1988, MOL CELL BIOL, V8, P5080, DOI 10.1128/MCB.8.12.5080	59	81	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 17	1995	270	7					3100	3106		10.1074/jbc.270.7.3100	http://dx.doi.org/10.1074/jbc.270.7.3100			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QG471	7531699	hybrid			2022-12-27	WOS:A1995QG47100034
J	PLUSKEY, S; WANDLESS, TJ; WALSH, CT; SHOELSON, SE				PLUSKEY, S; WANDLESS, TJ; WALSH, CT; SHOELSON, SE			POTENT STIMULATION OF SH-PTP2 PHOSPHATASE-ACTIVITY BY SIMULTANEOUS OCCUPANCY OF BOTH SH2 DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; PROTEIN-TYROSINE-PHOSPHATASE; PHOSPHORYLATION; BINDING; ASSOCIATION; ACTIVATION; 3-KINASE	Src homology 2 (SH2) domains are phosphotyrosine binding modules found within many cytoplasmic proteins. A major function of SR2 domains is to bring about the physical assembly of signaling complexes, We now show that, in addition, simultaneous occupancy of both SH2 domains of the phosphotyrosine phosphatase SH-PTP2 (Syp, PTP 1D, PTP-2C) by a tethered peptide with two IRS-1-derived phosphorylation sites potently stimulates phosphatase activity. The concentration required for activation by the tethered peptide is 80-160-fold lower than either corresponding monophosphorylated peptide. Moreover, the diphosphorylated peptide stimulates catalytic activity 37-fold, compared with 9-16-fold for the monophosphorylated peptides. Mutational analyses of the SH2 domains of SH-PTP2 confirm that both SH2 domains participate in this effect. Binding studies with a tandem construct comprising the N- plus C-terminal SH2 domains show that the diphosphorylated peptide binds with 60-90-fold higher affinity than either monophosphorylated sequence. These results demonstrate that SH-PTP2 activity can be potently regulated by interacting via both of its SH2 domains with phosphoproteins having two cognate phosphorylation sites.	JOSLIN DIABET CTR,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK036836] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM020011, R01GM020011] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK36836] Funding Source: Medline; NIGMS NIH HHS [GM 20011] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CASE RD, 1994, J BIOL CHEM, V269, P10467; DOMCHEK SM, 1992, BIOCHEMISTRY-US, V31, P9865, DOI 10.1021/bi00156a002; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; Morrison M, 1980, Methods Enzymol, V70, P214; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; PERALDI P, 1994, P NATL ACAD SCI USA, V91, P5002, DOI 10.1073/pnas.91.11.5002; PICCIONE E, 1993, BIOCHEMISTRY-US, V32, P3197, DOI 10.1021/bi00064a001; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; SUGIMOTO S, 1993, J BIOL CHEM, V268, P22771; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; TONKS NK, 1988, J BIOL CHEM, V263, P6731; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; XIAO S, 1994, J BIOL CHEM, V269, P21244; ZHAO ZZ, 1994, J BIOL CHEM, V269, P8780	25	227	229	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 17	1995	270	7					2897	2900		10.1074/jbc.270.7.2897	http://dx.doi.org/10.1074/jbc.270.7.2897			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QG471	7531695	hybrid			2022-12-27	WOS:A1995QG47100005
J	PERRONE, CE; FENWICKSMITH, D; VANDENBURGH, HH				PERRONE, CE; FENWICKSMITH, D; VANDENBURGH, HH			COLLAGEN AND STRETCH MODULATE AUTOCRINE SECRETION OF INSULIN-LIKE GROWTH-FACTOR-I AND INSULIN-LIKE GROWTH-FACTOR BINDING-PROTEINS FROM DIFFERENTIATED SKELETAL-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLICATION-STIMULATING ACTIVITY; LIVER TRANSCRIPTION FACTORS; RAT MYOBLASTS RELEASE; I IGF-I; GENE-EXPRESSION; SATELLITE CELLS; TISSUE-CULTURE; SOMATOMEDIN; RECEPTOR; INVITRO	Stretch-induced skeletal muscle growth may involve increased autocrine secretion of insulin-like growth factor-1 (IGF-1) since IGF-1 is a potent growth factor for skeletal muscle hypertrophy, and stretch elevates IGF-1 mRNA levels in vivo, In tissue cultures of differentiated avian pectoralis skeletal muscle cells, nanomolar concentrations of exogenous IGF-1 stimulated growth in mechanically stretched but not static cultures, These cultures released up to 100 pg of endogenously produced IGF-1/mu g of protein/day, as well as three major IGF binding proteins of 31, 36, and 43 kilodaltons (kDa), IGF-1 was secreted from both myofibers and fibroblasts coexisting in the muscle cultures, Repetitive stretch/relaxation of the differentiated skeletal muscle cells stimulated the acute release of IGF-1 during the first 4 h after initiating mechanical activity, but caused no increase in the long-term secretion over 24-72 h of IGF-1, or its binding proteins, Varying the intensity and frequency of stretch had no effect on the long-term efflux of IGF-1, In contrast to stretch, embedding the differentiated muscle cells in a three-dimensional collagen (Type I) matrix resulted in a 2-5-fold increase in long-term IGF-1 efflux over 24-72 h, Collagen also caused a 2-5-fold increase in the release of the IGF binding proteins, Thus, both the extracellular matrix protein type I collagen and stretch stimulate the autocrine secretion of IGF-1, but with different time kinetics, This endogenously produced growth factor may be important for the growth response of skeletal myofibers to both types of external stimuli.	BROWN UNIV, SCH MED, DEPT PATHOL, PROVIDENCE, RI 02906 USA	Brown University	PERRONE, CE (corresponding author), MIRIAM HOSP, DEPT LAB MED, 164 SUMMIT AVE, PROVIDENCE, RI 02906 USA.				NIAMS NIH HHS [R0I AR 39998] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039998] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AGREZ MV, 1991, CELL REGUL, V2, P1035, DOI 10.1091/mbc.2.12.1035; ALLEN RE, 1990, P SOC EXP BIOL MED, V194, P81; ARMSTRONG DG, 1989, J ENDOCRINOL, V120, P373, DOI 10.1677/joe.0.1200373; BREIER BH, 1991, J ENDOCRINOL, V128, P347, DOI 10.1677/joe.0.1280347; CLEMMONS DR, 1991, ADV EXP MED BIOL, V293, P113; DEVOL DL, 1990, AM J PHYSIOL, V259, pE89, DOI 10.1152/ajpendo.1990.259.1.E89; DIPERSIO CM, 1991, MOL CELL BIOL, V11, P4405, DOI 10.1128/MCB.11.9.4405; DODSON MV, 1985, ENDOCRINOLOGY, V117, P2357, DOI 10.1210/endo-117-6-2357; DUCLOS MJ, 1991, J ENDOCRINOL, V128, P35, DOI 10.1677/joe.0.1280035; EDWALL D, 1989, ENDOCRINOLOGY, V124, P820, DOI 10.1210/endo-124-2-820; ERNST CW, 1992, ENDOCRINOLOGY, V130, P607, DOI 10.1210/en.130.2.607; EWTON DZ, 1990, P SOC EXP BIOL MED, V194, P76; FLORINI JR, 1991, ANNU REV PHYSIOL, V53, P201, DOI 10.1146/annurev.ph.53.030191.001221; FLORINI JR, 1991, J BIOL CHEM, V266, P15917; FURLANETTO RW, 1977, J CLIN INVEST, V60, P648, DOI 10.1172/JCI108816; GILLERY P, 1992, J CELL PHYSIOL, V152, P389, DOI 10.1002/jcp.1041520221; HILL DJ, 1985, ENDOCRINOLOGY, V117, P2061, DOI 10.1210/endo-117-5-2061; HILL DJ, 1984, J CELL PHYSIOL, V119, P349, DOI 10.1002/jcp.1041190314; HOPPELER H, 1992, INT J SPORTS MED, V13, pS166, DOI 10.1055/s-2007-1024628; HOSSENLOPP P, 1986, ANAL BIOCHEM, V154, P138, DOI 10.1016/0003-2697(86)90507-5; HUMBEL RE, 1990, EUR J BIOCHEM, V190, P445, DOI 10.1111/j.1432-1033.1990.tb15595.x; INGBER DE, 1989, CELL, V58, P803, DOI 10.1016/0092-8674(89)90928-8; JANECZKO RA, 1984, J BIOL CHEM, V259, P6292; JENNISCHE E, 1989, ACTA ENDOCRINOL-COP, V121, P733, DOI 10.1530/acta.0.1210733; JENNISCHE E, 1987, ACTA PHYSIOL SCAND, V130, P327, DOI 10.1111/j.1748-1716.1987.tb08144.x; JENNISCHE E, 1992, ACTA PHYSIOL SCAND, V146, P79, DOI 10.1111/j.1748-1716.1992.tb09395.x; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINOVITZ A, 1992, MOL ENDOCRINOL, V6, P1227, DOI 10.1210/me.6.8.1227; LIU JK, 1991, MOL CELL BIOL, V11, P773, DOI 10.1128/MCB.11.2.773; LOWE WL, 1992, MOL ENDOCRINOL, V6, P741, DOI 10.1210/me.6.5.741; MAGRI KA, 1991, ADV EXP MED BIOL, V293, P57; MANGAT H, 1993, ENDOCRINOLOGY, V133, P1398, DOI 10.1210/en.133.3.1398; MCCUSKER RH, 1988, J CELL PHYSIOL, V137, P505, DOI 10.1002/jcp.1041370316; RUTANEN EM, 1990, ACTA ENDOCRINOL-COP, V123, P7, DOI 10.1530/acta.0.1230007; Sambrook J, 1989, MOL CLONING LABORATO; SARA VR, 1990, PHYSIOL REV, V70, P591, DOI 10.1152/physrev.1990.70.3.591; STAATZ WD, 1991, J BIOL CHEM, V266, P7363; SWADISON S, 1992, J CELL SCI, V102, P643; TOLLEFSEN SE, 1989, J BIOL CHEM, V264, P13810; VANDENBURGH H, 1980, J BIOL CHEM, V255, P5826; VANDENBURGH HH, 1990, AM J PHYSIOL, V259, pC232, DOI 10.1152/ajpcell.1990.259.2.C232; VANDENBURGH HH, 1989, AM J PHYSIOL, V256, pC674, DOI 10.1152/ajpcell.1989.256.3.C674; VANDENBURGH HH, 1988, IN VITRO CELL DEV B, V24, P166, DOI 10.1007/BF02623542; VANDENBURGH HH, 1991, AM J PHYSIOL, V260, pC475, DOI 10.1152/ajpcell.1991.260.3.C475	45	125	127	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	1995	270	5					2099	2106		10.1074/jbc.270.5.2099	http://dx.doi.org/10.1074/jbc.270.5.2099			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QE493	7530717	Green Submitted, hybrid			2022-12-27	WOS:A1995QE49300020
J	CARSON, MR; TRAVIS, SM; WELSH, MJ				CARSON, MR; TRAVIS, SM; WELSH, MJ			THE 2 NUCLEOTIDE-BINDING DOMAINS OF CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) HAVE DISTINCT FUNCTIONS IN CONTROLLING CHANNEL ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLORIDE CHANNELS; ADENYLATE KINASE; MULTIDRUG RESISTANCE; STRUCTURAL MODEL; ATP-BINDING; CL CHANNEL; G-PROTEINS; MEMBRANE; PURIFICATION; EXPRESSION	The cystic fibrosis transmembrane conductance regulator (CFTR) Cl- channel contains two cytoplasmic nucleotide-binding domains (NBDs), After phosphorylation of the R domain, ATP interacts with the NBDs to regulate channel activity, To learn how the NBDs regulate channel function, we used the patch-clamp technique to study CFTR and variants which contained site-directed mutations in the conserved Walker A motif lysine residues in either NBD1 (K464A), NBD2 (K1250A and K1250M), or both NBDs simultaneously (K464A/K1250A), Studies in related proteins suggest that such mutations slow the rate of ATP hydrolysis, These mutations did not alter the conductive properties of the channel or the requirement for phosphorylation and ATP to open the channel, However, all mutations decreased open state probability, Mutations in NBD1 decreased the frequency of bursts of activity, whereas mutations in NBD2 and mutations in both NBDs simultaneously prolonged bursts of activity, as well as decreased the frequency of bursts, These results could not be attributed to altered binding of nucleotide because none of the mutants studied had reduced 8-N(3)ATP binding. These data suggest that the two NBDs have distinct functions in channel gating; ATP hydrolysis at NBD1 initiates a burst of activity, and hydrolysis at NBD2 terminates a burst.	UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT INTERNAL MED,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	Howard Hughes Medical Institute; University of Iowa; University of Iowa; University of Iowa				Welsh, Michael/0000-0002-1646-6206				ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; ANDERSON MP, 1992, AM J PHYSIOL, V263, pL1, DOI 10.1152/ajplung.1992.263.1.L1; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; BAUKROWITZ T, 1994, NEURON, V12, P473, DOI 10.1016/0896-6273(94)90206-2; BELL CL, 1993, AM J PHYSIOL, V264, pC925, DOI 10.1152/ajpcell.1993.264.4.C925; CARSON MR, 1993, AM J PHYSIOL, V265, pL27, DOI 10.1152/ajplung.1993.265.1.L27; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; COLQUHOUN D, 1985, J PHYSIOL-LONDON, V369, P501, DOI 10.1113/jphysiol.1985.sp015912; FERGUSON KM, 1986, J BIOL CHEM, V261, P7393; FRY DC, 1988, BIOCHEMISTRY-US, V27, P3588, DOI 10.1021/bi00410a009; FUERST TR, 1987, MOL CELL BIOL, V7, P2538, DOI 10.1128/MCB.7.7.2538; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARTMAN J, 1992, J BIOL CHEM, V267, P6455; HORN R, 1987, BIOPHYS J, V51, P255, DOI 10.1016/S0006-3495(87)83331-3; HWANG TC, 1994, P NATL ACAD SCI USA, V91, P4698, DOI 10.1073/pnas.91.11.4698; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KO YH, 1994, J BIOL CHEM, V269, P14584; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MIMURA CS, 1991, P NATL ACAD SCI USA, V88, P84, DOI 10.1073/pnas.88.1.84; NAGEL G, 1992, NATURE, V360, P81, DOI 10.1038/360081a0; OSTEDGAARD LS, 1992, J BIOL CHEM, V267, P26142; PAI EF, 1977, J MOL BIOL, V114, P37, DOI 10.1016/0022-2836(77)90281-9; QUINTON PM, 1992, NATURE, V360, P79, DOI 10.1038/360079a0; RICH DP, 1993, RECEPTOR CHANNEL, V1, P221; RICH DP, 1993, J BIOL CHEM, V268, P20259; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SHEPPARD DN, 1994, CELL, V76, P1091, DOI 10.1016/0092-8674(94)90385-9; SHYAMALA V, 1991, J BIOL CHEM, V266, P18714; SIGURDSON WJ, 1987, J EXP BIOL, V127, P191; SMIT LS, 1993, P NATL ACAD SCI USA, V90, P9963, DOI 10.1073/pnas.90.21.9963; THOMAS PJ, 1991, SCIENCE, V251, P555, DOI 10.1126/science.1703660; TIAN G, 1990, BIOCHEMISTRY-US, V29, P4296, DOI 10.1021/bi00470a006; TRAVIS SM, 1993, J BIOL CHEM, V268, P15336; WELSH MJ, 1992, NEURON, V8, P821, DOI 10.1016/0896-6273(92)90196-K; WINTER MC, 1994, BIOPHYS J, V66, P1398, DOI 10.1016/S0006-3495(94)80930-0	39	229	231	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 27	1995	270	4					1711	1717		10.1074/jbc.270.4.1711	http://dx.doi.org/10.1074/jbc.270.4.1711			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QD204	7530246	hybrid			2022-12-27	WOS:A1995QD20400037
J	BOLDIN, MP; METT, IL; VARFOLOMEEV, EE; CHUMAKOV, I; SHEMERAVNI, Y; CAMONIS, JH; WALLACH, D				BOLDIN, MP; METT, IL; VARFOLOMEEV, EE; CHUMAKOV, I; SHEMERAVNI, Y; CAMONIS, JH; WALLACH, D			SELF-ASSOCIATION OF THE DEATH DOMAINS OF THE P55 TUMOR-NECROSIS-FACTOR (TNF) RECEPTOR AND FAS/APO1 PROMPTS SIGNALING FOR TNF AND FAS/APO1 EFFECTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; MONOCLONAL-ANTIBODY; FAS ANTIGEN; EXPRESSION; INDUCTION; APOPTOSIS; INTERLEUKIN-1; PROMOTERS; PROTEINS; FAMILY	Signaling by the p55 tumor necrosis factor (TNF) receptor and by the structurally related receptor Fas/APO1 is initiated by receptor clustering. Data presented here and in other recent studies (Wallach, D., Boldin, M., Varfolomeev, E. E., Bigda, Y., Camonis, H. J. and Mett, I. (1994) Cytokine 6, 556; Song, H. Y., Dunbar, J. D., and Bonner, D. B. (1994) J. Biol. Chem. 269, 22492-22495) indicate that part of that region within the intracellular domains of the two receptors that is involved in signaling for cell, death, as well as for some other effects (the ''death domain'', specifically self-associates. We demonstrate also the expected functional consequence of this association; a mere increase in p55 TNF receptor expression, or the expression just of its intracellular domain, is shown to trigger signaling for cytotoxicity as well as for interleukin 8 gene induction, while expression of the intracellular domain of Fas/APO1 potentiates the cytotoxicity of co-expressed p55 TNF receptor. These findings indicate that the p55 TNF and Fas/APO1 receptors play active roles in their own clustering and suggest the existence of cellular mechanisms that restrict the self-association of these receptors, thus preventing constitutive signaling.	WEIZMANN INST SCI,DEPT MEMBRANE RES & BIOPHYS,IL-76100 REHOVOT,ISRAEL; DENIS DIDEROT UNIV,INSERM,U248,F-75010 PARIS,FRANCE	Weizmann Institute of Science; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			AVNI, YONAT SHEMER/F-1772-2012	Boldin, Mark/0000-0003-4593-0669				ADERKA D, 1991, CANCER RES, V51, P5602; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BARTEL P, 1993, BIOTECHNIQUES, V14, P920; BIGDA J, 1994, J EXP MED, V180, P445, DOI 10.1084/jem.180.2.445; BRAKEBUSCH C, 1992, EMBO J, V11, P943, DOI 10.1002/j.1460-2075.1992.tb05133.x; DHEIN J, 1992, J IMMUNOL, V149, P3166; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; ECK MJ, 1989, J BIOL CHEM, V264, P17595; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GOODWIN RG, 1991, MOL CELL BIOL, V11, P3020, DOI 10.1128/MCB.11.6.3020; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HALEY JD, 1989, ONCOGENE, V4, P273; HELLER RA, 1992, CELL, V70, P47; HOLTMANN H, 1987, J IMMUNOL, V139, P1161; ITOH N, 1993, J BIOL CHEM, V268, P10932; JONES EY, 1989, NATURE, V338, P225, DOI 10.1038/338225a0; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; LONARDO F, 1990, New Biologist, V2, P992; MATSUSHIMA K, 1988, J EXP MED, V167, P1883, DOI 10.1084/jem.167.6.1883; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SONG HY, 1994, J BIOL CHEM, V268, P22492; STAMENKOVIC I, 1989, EMBO J, V8, P1408; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; WALLACH D, 1984, J IMMUNOL, V132, P2464; WALLACH D, 1994, CYTOKINE, V6, P558; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	33	348	375	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					387	391		10.1074/jbc.270.1.387	http://dx.doi.org/10.1074/jbc.270.1.387			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7529234	hybrid			2022-12-27	WOS:A1995QA28700061
J	ORTEN, DJ; STRAWHECKER, JM; SANDERSON, SD; HUANG, DY; PRYSTOWSKY, MB; HINRICHS, SH				ORTEN, DJ; STRAWHECKER, JM; SANDERSON, SD; HUANG, DY; PRYSTOWSKY, MB; HINRICHS, SH			DIFFERENTIAL-EFFECTS OF MONOCLONAL-ANTIBODIES ON ACTIVATING TRANSCRIPTION FACTOR-I AND CAMP RESPONSE ELEMENT-BINDING PROTEIN INTERACTIONS WITH DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; RNA-POLYMERASE; CREB BINDING; TAX PROTEIN; FACTOR ATF; PROMOTER; GENE; EXPRESSION; COMPLEX; PHOSPHORYLATION	Activating transcription factor-1 (ATF1) and cAMP response element binding protein (CREB) have been implicated in cAMP-, calcium-, and virus-induced transcriptional alterations. Although CREB and ATF1 share extensive homology, they appear to mediate distinct cellular functions. We investigated the effect on DNA binding and in vitro transcription of four monoclonal antibodies (mAb) that bound to domains in either the regulatory region (mAb 1 and 3) or unique regions near the DNA-binding domains (mAb 4 and 5) of ATF1. mAb 1 and 3 supershifted both ATF1 and CREB in a DNA binding assay but did not affect in vitro transcription. mAb 4 prevented ATF1-DNA binding while supershifting CREB.DNA complexes and inhibited in vitro transcription by 95% from the CRE-containing murine proliferating cell nuclear antigen promoter. mAb 5 reacted specifically with ATF1 and did not prevent DNA binding or affect in vitro transcription. The mAb 4 epitope was located within ATF1 amino acid residues 205-219, including the first 3 basic residues in the putative DNA-binding domain. Secondary structural analysis predicted that this region comprises a transition site from alpha-helix to a turn-like conformation in ATF1. The transition to turn-like motifs is predicted to occur in CREB after 5 additional residues, with a correspondingly longer Ly-helical domain. Although regulatory domains distinct from DNA binding regions are thought to account for most of the differences in activity of members of the CREB subfamily, our results suggest that small structural variations adjacent to DNA binding regions may also contribute to the distinct functional activities of ATF1 and CREB.	UNIV NEBRASKA,MED CTR,DEPT PATHOL,OMAHA,NE 68198; UNIV NEBRASKA,MED CTR,DEPT MICROBIOL,OMAHA,NE 68198; UNIV NEBRASKA,MED CTR,EPPLEY INST RES CANC & ALLIED DIS,OMAHA,NE 68198; MONTEFIORE MED CTR,ALBERT EINSTEIN COLL MED,DEPT PATHOL,BRONX,NY 10467	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine					NCI NIH HHS [CA49624] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA049624] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADYA N, 1994, P NATL ACAD SCI USA, V91, P5642, DOI 10.1073/pnas.91.12.5642; ARMSTRONG AP, 1993, P NATL ACAD SCI USA, V90, P7303, DOI 10.1073/pnas.90.15.7303; CHEN D, 1993, MOL CELL BIOL, V13, P228, DOI 10.1128/MCB.13.1.228; DASH PK, 1993, CELL MOL BIOL, V39, P35; DEUTSCH PJ, 1988, J BIOL CHEM, V263, P18466; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EMBER JA, 1992, J IMMUNOL, V148, P3165; FARNHAM PJ, 1986, MOL CELL BIOL, V6, P2392, DOI 10.1128/MCB.6.7.2392; FRIGUET B, 1985, J IMMUNOL METHODS, V77, P305, DOI 10.1016/0022-1759(85)90044-4; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; HAI T, 1988, CELL, V54, P1043, DOI 10.1016/0092-8674(88)90119-5; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HAWLEY DK, 1987, J BIOL CHEM, V262, P3452; HUANG DY, 1994, MOL CELL BIOL, V14, P4233, DOI 10.1128/MCB.14.6.4233; HUMMLER E, 1994, P NATL ACAD SCI USA, V91, P5647, DOI 10.1073/pnas.91.12.5647; HURST HC, 1991, NUCLEIC ACIDS RES, V19, P4601, DOI 10.1093/nar/19.17.4601; HURST HC, 1990, MOL CELL BIOL, V10, P6192, DOI 10.1128/MCB.10.12.6192; JAMESON BA, 1988, COMPUT APPL BIOSCI, V4, P181; KELLY D, 1994, IN PRESS MOL REPROD; KLIEWER S, 1990, J VIROL, V64, P4507, DOI 10.1128/JVI.64.9.4507-4515.1990; KONIG P, 1993, J MOL BIOL, V233, P139, DOI 10.1006/jmbi.1993.1490; LABRIE C, 1993, MOL CELL BIOL, V13, P1697, DOI 10.1128/MCB.13.3.1697; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; LEMAIGRE FP, 1993, NUCLEIC ACIDS RES, V21, P2907, DOI 10.1093/nar/21.12.2907; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; MANTOVANI R, 1992, EMBO J, V11, P3316; MASSON N, 1993, NUCLEIC ACIDS RES, V21, P4166, DOI 10.1093/nar/21.18.4166; MASSON N, 1993, NUCLEIC ACIDS RES, V21, P1163, DOI 10.1093/nar/21.5.1163; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MORRIS GF, 1990, J BIOL CHEM, V265, P16116; NICHOLS M, 1992, EMBO J, V11, P3337, DOI 10.1002/j.1460-2075.1992.tb05412.x; PRUZAN R, 1992, NUCLEIC ACIDS RES, V20, P5705, DOI 10.1093/nar/20.21.5705; QUINN PG, 1993, J BIOL CHEM, V268, P16999; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SETH A, 1993, ONCOGENE, V8, P1783; Shipman-Appasamy P M, 1991, DNA Seq, V2, P181, DOI 10.3109/10425179109039688; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; SZILVAY AM, 1993, ARCH VIROL, V131, P393, DOI 10.1007/BF01378640; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAEBER G, 1991, MOL ENDOCRINOL, V5, P1418, DOI 10.1210/mend-5-10-1418; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; WALZ DA, 1974, THROMB RES, V4, P713, DOI 10.1016/0049-3848(74)90226-6; YAMAGUCHI M, 1991, NUCLEIC ACIDS RES, V19, P2403, DOI 10.1093/nar/19.9.2403; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070	48	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32254	32263						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7528210				2022-12-27	WOS:A1994PX30400039
J	MEACOCK, S; PESCINIGOBERT, R; DELAMARTER, JF; VANHUIJSDUIJNEN, RH				MEACOCK, S; PESCINIGOBERT, R; DELAMARTER, JF; VANHUIJSDUIJNEN, RH			TRANSCRIPTION FACTOR-INDUCED, PHASED BENDING OF THE E-SELECTIN PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; LEUKOCYTE-ADHESION MOLECULE-1; CURVED DNA; REGULATORY PROTEINS; CYTOKINE INDUCTION; GENE-TRANSCRIPTION; ESCHERICHIA-COLI; BINDING; FAMILY; ELAM-1	E-selectin is an endothelial adhesion molecule that is critically involved in neutrophil adhesion and recruitment. All DNA elements required for interleukin-l inducibility have been located in the proximal promoter: an NF-ELAM1/ATF site, two NF-kappa B sites (I and II), the NF-ELAM2 element and a TATA box We show here that interleukin-1 induced promoter activity is exquisitely sensitive to the spatial arrangements of these elements. Phasing of the ATF and NF-kappa B II elements indicates that their relative helix orientation is more important than distance per se. This sensitivity is partly due to a requirement for correctly oriented, transcription factor-induced DNA-bending. (i) Band shift analyses with permuted ATF- and NF-kappa B elements show that their associated factors all bend DNA (ii) One can functionally replace the NF-ELAM1/ATF element by a subset of a panel of DNA fragments that contain defined bends in various planes, We conclude that the main role of the factors binding at the NF-ELAM1/ATF element is to alter the conformation of the E-selectin promoter, presumably looping distant enhancer elements into each other's proximity,	GLAXO,INST MOLEC BIOL,CH-1228 PLAN LES OUATES,SWITZERLAND	GlaxoSmithKline			van Huijsduijnen, Rob A.M. Hooft/B-3653-2009	van Huijsduijnen, Rob A.M. Hooft/0000-0002-2261-9424; Pescini Gobert, Rosanna/0000-0002-2434-7530				Ausubel FM, 1988, MOL REPROD DEV; BECKERANDRE M, 1992, EUR J BIOCHEM, V206, P401, DOI 10.1111/j.1432-1033.1992.tb16940.x; BEVILACQUA M, 1991, CELL, V67, P233, DOI 10.1016/0092-8674(91)90174-W; BEVILACQUA MP, 1985, J CLIN INVEST, V76, P2003, DOI 10.1172/JCI112200; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BOLSHOY A, 1991, P NATL ACAD SCI USA, V88, P2312, DOI 10.1073/pnas.88.6.2312; BRACCO L, 1989, EMBO J, V8, P4289, DOI 10.1002/j.1460-2075.1989.tb08615.x; COLLIS CM, 1989, NUCLEIC ACIDS RES, V17, P9447, DOI 10.1093/nar/17.22.9447; DELUCA LG, 1994, J BIOL CHEM, V269, P19193; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; ECKERT KA, 1990, NUCLEIC ACIDS RES, V18, P3739, DOI 10.1093/nar/18.13.3739; GASTON K, 1992, NUCLEIC ACIDS RES, V20, P3391, DOI 10.1093/nar/20.13.3391; GHERSA P, 1992, J BIOL CHEM, V267, P19226; GHERSA P, 1994, J BIOL CHEM, V269, P29129; GHERSA P, GENE AMST, V151, P331; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; HORIKOSHI M, 1992, P NATL ACAD SCI USA, V89, P1060, DOI 10.1073/pnas.89.3.1060; HUBER HE, 1994, J BIOL CHEM, V269, P6999; KASZUBSKA W, 1993, MOL CELL BIOL, V13, P7180, DOI 10.1128/MCB.13.11.7180; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P5479, DOI 10.1128/MCB.13.9.5479; KERR LD, 1993, NATURE, V365, P412, DOI 10.1038/365412a0; KIM J, 1989, GENE, V85, P15, DOI 10.1016/0378-1119(89)90459-9; LARIGAN JD, 1992, DNA CELL BIOL, V11, P149, DOI 10.1089/dna.1992.11.149; LEWIS H, 1994, MOL CELL BIOL, V14, P5701, DOI 10.1128/MCB.14.9.5701; MARTIN JP, 1993, SCIENCE, V260, P805; MATTHEWS KS, 1992, MICROBIOL REV, V56, P123, DOI 10.1128/MMBR.56.1.123-136.1992; MUROI M, 1993, J BIOL CHEM, V268, P19534; NABEL GJ, 1993, GENE DEV, V7, P2063, DOI 10.1101/gad.7.11.2063; NATESAN S, 1993, GENE DEV, V7, P2497, DOI 10.1101/gad.7.12b.2497; OSBORN L, 1990, CELL, V62, P3, DOI 10.1016/0092-8674(90)90230-C; PESCINI R, 1994, J BIOL CHEM, V269, P1159; PESCINI R, 1994, BIOCHEM BIOPH RES CO, V202, P1664, DOI 10.1006/bbrc.1994.2125; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; SCHLEIF R, 1992, ANNU REV BIOCHEM, V61, P199, DOI 10.1146/annurev.bi.61.070192.001215; SCHRECK R, 1990, NUCLEIC ACIDS RES, V18, P6497, DOI 10.1093/nar/18.22.6497; SHPIGELMAN ES, 1993, COMPUT APPL BIOSCI, V9, P435; SMITH GM, 1993, BIOCHEM BIOPH RES CO, V194, P215, DOI 10.1006/bbrc.1993.1806; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; VANDERVLIET PC, 1993, BIOESSAYS, V15, P25, DOI 10.1002/bies.950150105; VANHUIJSDUIJNEN RAMH, 1992, BIOTECHNIQUES, V12, P830; VANHUIJSDUIJNEN RH, 1992, J BIOL CHEM, V267, P22385; VANHUIJSDUIJNEN RH, 1993, NUCLEIC ACIDS RES, V21, P3711, DOI 10.1093/nar/21.16.3711; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; WHELAN J, 1991, NUCLEIC ACIDS RES, V19, P2645, DOI 10.1093/nar/19.10.2645	47	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31756	31762						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7527395				2022-12-27	WOS:A1994PX30300067
J	VILALTA, A; KICKHOEFER, VA; ROME, LH; JOHNSON, DL				VILALTA, A; KICKHOEFER, VA; ROME, LH; JOHNSON, DL			THE RAT VAULT RNA GENE CONTAINS A UNIQUE RNA-POLYMERASE-III PROMOTER COMPOSED OF BOTH EXTERNAL AND INTERNAL ELEMENTS THAT FUNCTION SYNERGISTICALLY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER RNA(SER)SEC GENE; TRANSCRIPTION FACTOR-TAU; HUMAN U6 GENE; RIBONUCLEOPROTEIN-PARTICLES; SACCHAROMYCES-CEREVISIAE; COMPLEX-FORMATION; CONTROL REGIONS; INVITRO; BINDING; UPSTREAM	A novel gene transcribed by RNA polymerase (pol) III has been recently identified that produces an RNA component of a large cytoplasmic ribonucleoprotein complex (Kickhoefer, V. A., Searles, R. P., Kedersha, N. L., Garber, M. E., Johnson, D. L., and Rome, L. H. (1993) J. Biol. Chem. 268, 7868-7873). Since sequence analysis revealed that this gene contains promoter elements from two different classes of RNA pol III gene promoters, we examined the function of the 5'-flanking type-3 and internal type-2 sequences on transcription activity and the production of stable transcription complexes. We find that the vRNA gene contains a novel RNA pol III promoter, where both the external and internal sequences are essential for template activity and for the productive interaction of TFIIIC with the internal elements. Thus, the vRNA gene represents the first example of a template that requires both type-2 and type-3 promoter elements that appear to function synergistically in the formation of productive transcription complexes. We have further examined the function of the unique arrangement of an internal A box and two B box elements. We find that at least one B element is required for template activity. In the absence of the 5'-flanking sequence the presence of both B elements inhibits transcription and the binding of TFIIIC. The formation of active complexes is restored when either the B2 element is inactivated or the distance separating the two B elements is increased. Therefore, the B2 element appears to negatively regulate template activity in the absence of the upstream sequences. This unique RNA pol III promoter arrangement may provide a novel mechanism for the regulation of vRNA gene activity.	UNIV SO CALIF,SCH PHARM,DEPT MOLEC PHARMACOL,LOS ANGELES,CA 90024; UNIV SO CALIF,SCH PHARM,DEPT BIOCHEM,LOS ANGELES,CA 90024; UNIV SO CALIF,SCH MED,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,MENTAL RETARDAT RES CTR,LOS ANGELES,CA 90024	University of Southern California; University of Southern California; University of Southern California; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA			Rome, Leonard H/E-8786-2016	Rome, Leonard H/0000-0002-1236-2063	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038097, R01GM045299] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-45299, GM-38097] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKUSJARVI G, 1980, P NATL ACAD SCI-BIOL, V77, P2424, DOI 10.1073/pnas.77.5.2424; ARNOLD GJ, 1987, GENE, V51, P237, DOI 10.1016/0378-1119(87)90312-X; BAKER RE, 1986, J BIOL CHEM, V261, P5275; BAKER RE, 1987, P NATL ACAD SCI USA, V84, P8768, DOI 10.1073/pnas.84.24.8768; BARTHOLOMEW B, 1991, MOL CELL BIOL, V11, P5181, DOI 10.1128/MCB.11.10.5181; BOULANGER PA, 1987, J BIOL CHEM, V262, P15098; BREDOW S, 1990, NUCLEIC ACIDS RES, V18, P6779, DOI 10.1093/nar/18.23.6779; CAMIER S, 1985, EMBO J, V4, P491, DOI 10.1002/j.1460-2075.1985.tb03655.x; CARBON P, 1991, EMBO J, V10, P599, DOI 10.1002/j.1460-2075.1991.tb07987.x; CHUGANI DC, 1993, J CELL SCI, V106, P23; DINGERMANN T, 1983, J BIOL CHEM, V258, P395; DINGERMANN T, 1981, NUCLEIC ACIDS RES, V9, P3907, DOI 10.1093/nar/9.16.3907; GABRIELSEN OS, 1991, TRENDS BIOCHEM SCI, V16, P412, DOI 10.1016/0968-0004(91)90166-S; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; HERNANDEZ N, 1988, EMBO J, V7, P3125, DOI 10.1002/j.1460-2075.1988.tb03179.x; HOEFFLER WK, 1988, CELL, V53, P907, DOI 10.1016/S0092-8674(88)90409-6; HOWE JG, 1989, CELL, V57, P825, DOI 10.1016/0092-8674(89)90797-6; JOHNSONBURKE DJ, 1985, J BIOL CHEM, V260, P816; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KEDERSHA NL, 1991, J CELL BIOL, V112, P225, DOI 10.1083/jcb.112.2.225; KEDERSHA NL, 1990, J CELL BIOL, V110, P895, DOI 10.1083/jcb.110.4.895; KEDERSHA NL, 1986, J CELL BIOL, V103, P699, DOI 10.1083/jcb.103.3.699; KICKHOEFER VA, 1993, J BIOL CHEM, V268, P7868; KUNKEL GR, 1991, BIOCHIM BIOPHYS ACTA, V1088, P1, DOI 10.1016/0167-4781(91)90146-D; LEE JY, 1991, P NATL ACAD SCI USA, V88, P6986, DOI 10.1073/pnas.88.16.6986; LOBO SM, 1991, GENE DEV, V5, P1477, DOI 10.1101/gad.5.8.1477; MCCLARY JA, 1989, BIOTECHNIQUES, V7, P282; MORRY MJ, 1986, MOL CELL BIOL, V6, P105, DOI 10.1128/MCB.6.1.105; MYSLINSKI E, 1992, NUCLEIC ACIDS RES, V20, P203, DOI 10.1093/nar/20.2.203; PARRY HD, 1990, EMBO J, V9, P1097, DOI 10.1002/j.1460-2075.1990.tb08215.x; Rome L, 1991, Trends Cell Biol, V1, P47, DOI 10.1016/0962-8924(91)90088-Q; SADOWSKI CL, 1993, GENE DEV, V7, P1535, DOI 10.1101/gad.7.8.1535; SIMMEN KA, 1991, EMBO J, V10, P1853, DOI 10.1002/j.1460-2075.1991.tb07711.x; WALDSCHMIDT R, 1991, EMBO J, V10, P2595, DOI 10.1002/j.1460-2075.1991.tb07801.x; WILLIS IM, 1993, EUR J BIOCHEM, V212, P1, DOI 10.1111/j.1432-1033.1993.tb17626.x; WINGENDER E, 1986, J BIOL CHEM, V261, P1409; YOSHINAGA S, 1986, EMBO J, V5, P343, DOI 10.1002/j.1460-2075.1986.tb04218.x; YOSHINAGA SK, 1987, P NATL ACAD SCI USA, V84, P3585, DOI 10.1073/pnas.84.11.3585	38	32	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29752	29759						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7525587				2022-12-27	WOS:A1994PU28400069
J	NGUYEN, TTM; HINTON, DA; SHUR, BD				NGUYEN, TTM; HINTON, DA; SHUR, BD			EXPRESSING MURINE BETA-1,4-GALACTOSYLTRANSFERASE IN HELA-CELLS PRODUCES A CELL-SURFACE GALACTOSYLTRANSFERASE-DEPENDENT PHENOTYPE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GOLGI RETENTION; TRANSMEMBRANE DOMAIN; LOCALIZATION; ANTIBODIES; SIGNAL	beta 1,4-Galactosyltransferase is traditionally viewed as a biosynthetic component of the Golgi complex, but a portion of galactosyltransferase is also expressed on the cell surface, where it has been suggested to function as a receptor for extracellular oligosaccharide Ligands. Although results from a variety of studies are consistent with a cell adhesion function for galactosyltransferase, the most rigorous test of surface galactosyltransferase function is to produce a surface galactosyltransferase-dependent phenotype in cells that normally express negligible levels of surface galactosyltransferase. In agreement with previous reports, human HeLa cells were found to express low levels of galactosyltransferase on their surface and, therefore, were stably transfected with cDNAs encoding murine galactosyltransferase. Murine galactosyltransferase was expressed both within the presumed Golgi complex and on the cell surface, as assayed by enzyme activity and with antiserum raised against the bacterially expressed murine enzyme. HeLa cell transfectants adhered more strongly to their extracellular substrates than did control transfectants, as evidenced by a natter morphology in culture and a more rapid spreading upon plating. In contrast, cell spreading was low and similar among all cell types when plated on extracellular substrates that did not contain binding sites for galactosyltransferase. Antibodies and Fab fragments against recombinant murine galactosyltransferase inhibited the increased cell spreading characteristic of galactosyltransferase transfectants, as did soluble recombinant galactosyltransferase and a variety of galactosyltransferase perturbants. Thus, expression of heterologous galactosyltransferase produces a surface galactosyltransferase-dependent phenotype, confirming its function as a cell adhesion molecule.	UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT BIOCHEM & MOLEC BIOL, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center					NICHD NIH HHS [HD07699, HD22590] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022590, F32HD007699] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		APPEDDU PA, 1994, J CELL SCI, V107, P2535; APPEDDU PA, 1994, P NATL ACAD SCI USA, V91, P2095, DOI 10.1073/pnas.91.6.2095; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ECKSTEIN DJ, 1989, J CELL BIOL, V108, P2507, DOI 10.1083/jcb.108.6.2507; EVANS SC, 1993, J CELL BIOL, V120, P1045, DOI 10.1083/jcb.120.4.1045; GAYAGONZALEZ L, 1991, J NEUROSCI RES, V29, P474, DOI 10.1002/jnr.490290407; HAGOPIAN A, 1968, ARCH BIOCHEM BIOPHYS, V128, P387, DOI 10.1016/0003-9861(68)90045-3; HATHAWAY JH, 1991, GLYCOBIOLOGY, V1, P211; LOPEZ LC, 1991, J BIOL CHEM, V266, P15984; LOPEZ LC, 1989, MOL CELL BIOL, V9, P2370, DOI 10.1128/MCB.9.6.2370; MASIBAY AS, 1993, J BIOL CHEM, V268, P9908; MASRI KA, 1988, BIOCHEM BIOPH RES CO, V157, P657, DOI 10.1016/S0006-291X(88)80300-0; MENGLEGAW L, 1991, BIOCHEM BIOPH RES CO, V176, P1269, DOI 10.1016/0006-291X(91)90423-5; NILSSON T, 1991, EMBO J, V10, P3567, DOI 10.1002/j.1460-2075.1991.tb04923.x; ROSEMAN S, 1970, CHEM PHYS LIPIDS, V5, P270, DOI 10.1016/0009-3084(70)90024-1; ROTH J, 1982, J CELL BIOL, V93, P223, DOI 10.1083/jcb.93.1.223; ROTH S, 1971, J CELL BIOL, V51, P536, DOI 10.1083/jcb.51.2.536; RUNYAN RB, 1988, J CELL BIOL, V107, P1863, DOI 10.1083/jcb.107.5.1863; RUSSO RN, 1992, J BIOL CHEM, V267, P9241; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAPER NL, 1988, J BIOL CHEM, V263, P10420; Shur BD, 1993, CURR OPIN CELL BIOL, V5, P854, DOI 10.1016/0955-0674(93)90035-O; SHUR BD, 1977, DEV BIOL, V58, P40, DOI 10.1016/0012-1606(77)90073-2; STROUS GJAM, 1982, J BIOL CHEM, V257, P7623; TEASDALE RD, 1992, J BIOL CHEM, V267, P4084; WATZELE G, 1991, EUR J CELL BIOL, V56, P451; WILLINGHAM MC, 1985, ATLAS IMMUNOFLUORESC; YOUAKIM A, 1993, GLYCOBIOLOGY, V3, P155, DOI 10.1093/glycob/3.2.155; YOUAKIM A, 1994, IN PRESS P NATL ACAD	31	27	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28000	28009						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7525565				2022-12-27	WOS:A1994PV77200038
J	XIE, QW; CHO, H; KASHIWABARA, Y; BAUM, M; WEIDNER, JR; ELLISTON, K; MUMFORD, R; NATHAN, C				XIE, QW; CHO, H; KASHIWABARA, Y; BAUM, M; WEIDNER, JR; ELLISTON, K; MUMFORD, R; NATHAN, C			CARBOXYL-TERMINUS OF INDUCIBLE NITRIC-OXIDE SYNTHASE - CONTRIBUTION TO NADPH BINDING AND ENZYMATIC-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLS; PURIFICATION; MACROPHAGES; CALMODULIN; REDUCTASE; CLONING; FAMILY	Cloning of a nitric oxide synthase (NOS) fi om RAW 264.7 mouse macrophages (Xie, Q.-w., Cho, H. J., Calaycay, J., Mumford, R. A., Swiderek, K. M., Lee, T. D., Ding, A., Troso, T., and Nathan, C. (1992) Science 256, 225-228) yielded two sets of cDNA: one with a longer coding region of 1144 amino acids, whose sequence matched that of the purified protein, and another with a shorter coding region of 1122 amino acids, in which the last 10 carboxyl-terminal amino acids differed completely from those of the long form. me have now found that the short form lacks NOS activity. To determine the basis of this defect, we prepared recombinant chimeric, deletional, and point mutants of the long and short NOS variants, monitored their expression by immunoblot, and tested their enzymatic activity. By itself, lack of the 22-carboxyl-terminal residues of the long form NOS was scarcely consequential. Mutation of Phe(1122), the only aromatic residue within one of the longest conserved regions shared by all NOSs of reported sequence, reduced enzymatic activity by 41%. Deletion of 23 carboxyl-terminal amino acids (including Phe(1122)) reduced activity by 71%. Further loss of Ile(1121), another completely conserved residue, reduced activity by 95%, and with the deletion of the rest of the conserved region, NOS activity was undetectable. Normal dimerization and binding of heme and calmodulin by the short variants militated against distortions of tertiary structure affecting the amino-terminal half or middle portion of the protein. In contrast, the short variants were deficient in binding to NADPH, as predicted by a model of tertiary structure based on that of spinach ferredoxin-NADP(+) reductase. This is the first demonstration that the carboxyl terminus of NOS is a functionally critical region.	MERCK & CO INC,MERCK SHARP & DOHME RES LABS,RAHWAY,NJ 07065	Merck & Company	XIE, QW (corresponding author), CORNELL UNIV,COLL MED,DEPT MED,BEATRICE & SAMUEL A SEAVER LAB,BOX 57,1300 YORK AVE,NEW YORK,NY, USA.			Elliston, Keith/0000-0002-9110-9233	NIAID NIH HHS [AI34543] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034543, R21AI034543] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; HARLOW E, 1988, ANTIBODIES LABORATOR, P421; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; LIU JW, 1994, J BIOL CHEM, V269, P11691; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MICHEL T, 1992, J CARDIOVASC PHARM, V20, pS45, DOI 10.1097/00005344-199204002-00014; MICHEL T, 1994, METHODS NITRIC OXIDE; MILLER DK, 1993, J BIOL CHEM, V268, P18062; MONCADA S, 1991, PHARMACOL REV, V43, P109; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NATHAN C, 1994, J BIOL CHEM, V269, P13725; POLLOCK JS, 1992, FEBS LETT, V309, P402, DOI 10.1016/0014-5793(92)80816-Y; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; SASSA S, 1976, J EXP MED, V143, P305, DOI 10.1084/jem.143.2.305; SHETA EA, 1994, J BIOL CHEM, V269, P15147; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; VORRHERR T, 1993, BIOCHEMISTRY-US, V32, P6081; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; ZHANG MJ, 1994, J BIOL CHEM, V269, P981	23	77	77	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28500	28505						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7525576				2022-12-27	WOS:A1994PV77200106
J	ANDO, K; KIKUGAWA, K; BEPPU, M				ANDO, K; KIKUGAWA, K; BEPPU, M			INVOLVEMENT OF SIALYLATED POLY-N-ACETYLLACTOSAMINYL SUGAR CHAINS OF BAND 3 GLYCOPROTEIN ON SENESCENT ERYTHROCYTES IN ANTI-BAND-3 AUTOANTIBODY BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-BLOOD-CELLS; OCCURRING ANTI-BAND-3 ANTIBODIES; ALPHA-GALACTOSYL IGG; CARBOHYDRATE MOIETY; MEMBRANE; REMOVAL; LACTOSAMINOGLYCAN; PHAGOCYTOSIS; LOCALIZATION; MACROPHAGES	When young and senescent erythrocytes, separated from freshly collected human blood, were incubated with I-125-goat anti-human IgG, binding of the IgG to the senescent cells was three times as high as that to the young cells. The release of the radioactivity from the anti-human IgG-bound senescent cells was enhanced by incubation with band 3 oligosaccharides but not by those digested with endo-beta-galactosidase or neuraminidase. The senescent cells whose surface band 3 saccharide chains were cleaved by endo-beta-galactosidase or totally removed by N-glycosidase F showed decreased binding of the anti-human IgG. The radioactivity was effectively released from the anti-human IgG-bound senescent cells by digestion with endo-beta-galactosidase. The results suggest that senescent erythrocytes bind anti-band 3 autoantibody, and the antigenic sites on the cell surface are sialylated poly-N-acetyllactosaminyl sugar chains of band 3 glycoprotein.	TOKYO COLL PHARM,HACHIOJI,TOKYO 19203,JAPAN	Tokyo University of Pharmacy & Life Sciences								ALDERMAN EM, 1981, BLOOD, V58, P341; ALDERMAN EM, 1980, BLOOD, V55, P817; BENNETT GD, 1981, EXP HEMATOL, V9, P297; BEPPU M, 1992, J BIOL CHEM, V267, P14691; BEPPU M, 1990, J BIOL CHEM, V265, P3226; BEPPU M, 1992, J PHARMACOBIO-DYNAM, V15, P353, DOI 10.1248/bpb1978.15.353; COOPER RA, 1986, HEMATOLOGY, P377; DODGE JT, 1963, ARCH BIOCHEM BIOPHYS, V100, P119, DOI 10.1016/0003-9861(63)90042-0; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; FUKUDA M, 1985, Biochimica et Biophysica Acta, V780, P119; FUKUDA M, 1984, J BIOL CHEM, V259, P8260; FUKUDA M, 1979, J BIOL CHEM, V254, P3700; FUKUDA M, 1984, J BIOL CHEM, V259, P925; GALILI U, 1986, BRIT J HAEMATOL, V62, P317, DOI 10.1111/j.1365-2141.1986.tb02935.x; GALILI U, 1984, J EXP MED, V160, P1519, DOI 10.1084/jem.160.5.1519; GALILI U, 1985, J EXP MED, V162, P573, DOI 10.1084/jem.162.2.573; GALILI U, 1987, J BIOL CHEM, V262, P4683; GOLDBERG B, 1983, HISTOLOGY CELL TISSU, P139; JOURDIAN GW, 1971, J BIOL CHEM, V246, P430; KANNAN R, 1991, BIOCHEM J, V278, P57, DOI 10.1042/bj2780057; KANNAN R, 1988, J BIOL CHEM, V263, P13766; KAY MMB, 1993, CELL MOL BIOL, V39, P131; KAY MMB, 1983, P NATL ACAD SCI-BIOL, V80, P1631, DOI 10.1073/pnas.80.6.1631; KAY MMB, 1984, P NATL ACAD SCI-BIOL, V81, P5753, DOI 10.1073/pnas.81.18.5753; KAY MMB, 1978, J SUPRAMOL STR CELL, V9, P555, DOI 10.1002/jss.400090409; KAY MMB, 1975, P NATL ACAD SCI USA, V72, P3521, DOI 10.1073/pnas.72.9.3521; KAY MMB, 1990, P NATL ACAD SCI USA, V87, P5734, DOI 10.1073/pnas.87.15.5734; KHANSARI N, 1983, CELL IMMUNOL, V78, P114, DOI 10.1016/0008-8749(83)90264-2; KHANSARI N, 1983, MECH AGEING DEV, V21, P49, DOI 10.1016/0047-6374(83)90015-5; LOW PS, 1985, SCIENCE, V227, P531, DOI 10.1126/science.2578228; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUTZ HU, 1987, P NATL ACAD SCI USA, V84, P7368, DOI 10.1073/pnas.84.21.7368; LUTZ HU, 1993, J BIOL CHEM, V268, P23562; PRUZANSKI W, 1977, NEW ENGL J MED, V297, P583, DOI 10.1056/NEJM197709152971105; SCHLUTER K, 1986, P NATL ACAD SCI USA, V83, P6137, DOI 10.1073/pnas.83.16.6137; THOMAS DB, 1974, EUR J IMMUNOL, V4, P819, DOI 10.1002/eji.1830041210; TSUJI T, 1980, BIOCHEM J, V187, P677, DOI 10.1042/bj1870677; WATANABE K, 1979, J BIOL CHEM, V254, P8223; WAUGH SM, 1985, BIOCHEMISTRY-US, V24, P34, DOI 10.1021/bi00322a006; WAUGH SM, 1987, BIOCHEMISTRY-US, V26, P1777, DOI 10.1021/bi00380a041	40	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19394	19398						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	7518456				2022-12-27	WOS:A1994NY33200032
J	WALTZ, DA; CHAPMAN, HA				WALTZ, DA; CHAPMAN, HA			REVERSIBLE CELLULAR ADHESION TO VITRONECTIN LINKED TO UROKINASE RECEPTOR OCCUPANCY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR; BOUND UROKINASE; HUMAN-MONOCYTES; BINDING-SITE; TYPE-1; CELLS; DIFFERENTIATION; INTERNALIZATION; IDENTIFICATION; PURIFICATION	Urokinase receptors are distributed on surfaces of many cell types where they are thought to focus plasminogen-dependent proteolysis important to migration and tissue remodeling to the immediate pericellular space. in addition to its well characterized role in proteolysis, urokinase receptor binding per se promotes the adhesiveness of leukemic cell Lines exposed to differentiating cytokines in vitro. We sought to determine if a serum or matrix component is involved in urokinase-dependent adhesion. We now report that cytokine-stimulated human myelomonocytic cells express a divalent cation- and Arg-Gly-Asp-independent high affinity receptor for urea-purified vitronectin (K-d < 10 nM). Soluble native vitronectin does not effectively bind to the receptor, while cellular adhesion was noted to both urea-purified and native vitronectin when adsorbed to plastic. The activity of this receptor is tightly coupled to urokinase receptor occupancy. Urokinase receptor binding thus induces selective and reversible cellular adhesion to the matrix form of vitronectin. Because transfer of vitronectin-bound plasminogen activator inhibitor type 1 to urokinase promotes rapid turnover of receptor-bound enzyme, these results illuminate a novel binding cycle by which urokinase receptor occupancy coordinately regulates cellular adhesiveness and pericellular proteolysis.	HARVARD UNIV,CHILDRENS HOSP,SCH MED,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV RESP,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044712] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-44712] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BITTORF SV, 1993, J BIOL CHEM, V268, P24838; BLASI F, 1987, J CELL BIOL, V104, P801, DOI 10.1083/jcb.104.4.801; CHAPMAN HA, 1990, J IMMUNOL, V145, P3398; CHAPMAN HA, 1982, CELL, V28, P653, DOI 10.1016/0092-8674(82)90220-3; Colton T., 1974, STAT MED, V1; CROWLEY CW, 1993, P NATL ACAD SCI USA, V90, P5021, DOI 10.1073/pnas.90.11.5021; CUBELLIS MV, 1990, EMBO J, V9, P1079, DOI 10.1002/j.1460-2075.1990.tb08213.x; CUBELLIS MV, 1989, P NATL ACAD SCI USA, V86, P4828, DOI 10.1073/pnas.86.13.4828; DEBOER HC, 1992, J BIOL CHEM, V267, P2264; ELLIS V, 1990, J BIOL CHEM, V265, P9904; ESTREICHER A, 1990, J CELL BIOL, V111, P783, DOI 10.1083/jcb.111.2.783; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KIRCHHEIMER JC, 1989, BLOOD, V74, P1396; KIRCHHEIMER JC, 1989, J IMMUNOL, V143, P2634; MANCHANDA N, 1991, J BIOL CHEM, V266, P14580; MANCHANDA N, 1990, J IMMUNOL, V145, P4174; MIGNATTI P, 1986, CELL, V47, P487, DOI 10.1016/0092-8674(86)90613-6; NIELSEN LS, 1988, J BIOL CHEM, V263, P2358; NUSRAT AR, 1991, J CLIN INVEST, V87, P1091, DOI 10.1172/JCI115070; OLSON D, 1992, J BIOL CHEM, V267, P9129; PANETTI TS, 1993, J BIOL CHEM, V268, P11988; PREISSNER KT, 1991, ANNU REV CELL BIOL, V7, P275, DOI 10.1146/annurev.cellbio.7.1.275; RABBANI SA, 1992, J BIOL CHEM, V267, P14151; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SALONEN EM, 1989, J BIOL CHEM, V264, P6339; Scopes RK., 1987, PROTEIN PURIFICATION, V2nd ed; STOPPELLI MP, 1985, P NATL ACAD SCI USA, V82, P4939, DOI 10.1073/pnas.82.15.4939; STOPPELLI MP, 1986, CELL, V45, P675, DOI 10.1016/0092-8674(86)90782-8; VASSALLI JD, 1985, J CELL BIOL, V100, P86, DOI 10.1083/jcb.100.1.86; VOGEL BE, 1993, J CELL BIOL, V121, P461, DOI 10.1083/jcb.121.2.461; WALTZ DA, 1993, J CLIN INVEST, V91, P1541, DOI 10.1172/JCI116360; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281	33	215	220	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14746	14750						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	7514182				2022-12-27	WOS:A1994NM06500069
J	MEERZAMAN, D; CHARLES, P; DASKAL, E; POLYMEROPOULOS, MH; MARTIN, BM; ROSE, MC				MEERZAMAN, D; CHARLES, P; DASKAL, E; POLYMEROPOULOS, MH; MARTIN, BM; ROSE, MC			CLONING AND ANALYSIS OF CDNA-ENCODING A MAJOR AIRWAY GLYCOPROTEIN, HUMAN TRACHEOBRONCHIAL MUCIN (MUC5)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								Two unique nucleotide probes for human tracheobronchial mucin glycoprotein (TBM) were generated via polymerase chain reaction with degenerate primers deduced from the TBM:TR-3A tryptic peptide sequence and were used to isolate a 3.6 kilobase cDNA, clone NP3a, from a human nasal polyp cDNA library. Clone NP3a was localized to chromosome 11 and contained a 3168 nucleotide open reading frame which encoded three TBM peptide fragments, thus confirming that clone NP3a partially encodes TBM. TBM also contains five tandem repeats of TTVGP/S and an octapeptide GQCGTCTN, which is conserved in human intestinal mucin MUC2 and rat intestinal mucin-like protein (MLP) suggesting that this sequence has a functional significance for secreted mucins. TBM has amino acid similarity to the cysteine-rich domains at the carboxyl termini of MUC2, rat MLP, bovine and porcine submaxillary mucins, and human von Willebrand factor. Strikingly, a large percentage of the cysteine residues in the overlaps are highly conserved: 90% in MUC2 and von Willebrand factor, 80% in bovine submaxillary mucin, 70% in porcine submaxillary mucin, and 64% in rat MLP, suggesting that conserved cysteines may be important for the tertiary structure of secreted glycoproteins. These studies demonstrate that clone NP3a is a candidate for MUC5, making it the only human mucin gene reported to date whose gene product has been isolated from airway secretions.	GEORGE WASHINGTON UNIV, CHILDRENS NATL MED CTR, CHILDRENS RES INST, CTR MOLEC MECHANISMS DIS, WASHINGTON, DC 20010 USA; GEORGE WASHINGTON UNIV, DEPT PEDIAT, WASHINGTON, DC 20010 USA; GEORGE WASHINGTON UNIV, DEPT BIOCHEM & MOLEC BIOL, WASHINGTON, DC 20010 USA; ST ELIZABETH HOSP, NIMH, CTR NEUROSCI, BIOCHIM GENET LAB, WASHINGTON, DC 20032 USA; NIMH, CLIN NEUROSCI BRANCH, BETHESDA, MD 20892 USA	Children's National Health System; George Washington University; George Washington University; George Washington University; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)					NHLBI NIH HHS [HL 33152] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033152] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLEN A, 1983, TRENDS BIOCHEM SCI, V8, P169, DOI 10.1016/0968-0004(83)90166-4; AUBERT JP, 1991, AM J RESP CELL MOL, V5, P178, DOI 10.1165/ajrcmb/5.2.178; BHARGAVA AK, 1990, P NATL ACAD SCI USA, V87, P6798, DOI 10.1073/pnas.87.17.6798; BOBEK LA, 1993, J BIOL CHEM, V268, P20563; CARLSTEDT I, 1983, BIOCHEM J, V213, P427, DOI 10.1042/bj2130427; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONG NV, 1990, HUM GENET, V86, P167; DONALD ASR, 1973, BIOCHIM BIOPHYS ACTA, V317, P420, DOI 10.1016/0005-2795(73)90235-3; DUFOSSE J, 1993, BIOCHEM J, V293, P329, DOI 10.1042/bj2930329; DUNSTONE JR, 1965, BIOCHIM BIOPHYS ACTA, V101, P300, DOI 10.1016/0926-6534(65)90009-6; ECKHARDT AE, 1991, J BIOL CHEM, V266, P9678; FELDHOFF PA, 1979, BIOCHEMISTRY-US, V18, P2430, DOI 10.1021/bi00578a044; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; GERARD C, 1990, J CLIN INVEST, V86, P1921, DOI 10.1172/JCI114925; GRIFFITHS B, 1990, ANN HUM GENET, V54, P277, DOI 10.1111/j.1469-1809.1990.tb00383.x; GUM JR, 1990, BIOCHEM BIOPH RES CO, V171, P407, DOI 10.1016/0006-291X(90)91408-K; GUM JR, 1989, J BIOL CHEM, V264, P6480; GUM JR, 1992, AM J RESP CELL MOL, V7, P557, DOI 10.1165/ajrcmb/7.6.557; GUM JR, 1992, J BIOL CHEM, V267, P21375; GUPTA R, 1989, BIOCHEMISTRY-US, V28, P6114, DOI 10.1021/bi00440a058; HILL HD, 1977, J BIOL CHEM, V252, P3791; HOLLINGSWORTH MA, 1992, AM J RESP CELL MOL, V6, P516, DOI 10.1165/ajrcmb/6.5.516; LAN MS, 1990, J BIOL CHEM, V265, P15294; LI M, 1993, FOCUS, V15, P19; Maniatis T., 1982, MOL CLONING; MANTLE M, 1984, BIOCHEM J, V224, P345, DOI 10.1042/bj2240345; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; Neutra M.R., 1987, PHYSL GASTROINTESTIN, V2, P975; POLYMEROPOULOS MH, 1991, GENOMICS, V11, P777, DOI 10.1016/0888-7543(91)90091-R; POLYMEROPOULOS MH, 1992, GENOMICS, V12, P492, DOI 10.1016/0888-7543(92)90439-Y; PORCHET N, 1991, BIOCHEM BIOPH RES CO, V175, P414, DOI 10.1016/0006-291X(91)91580-6; PROBST JC, 1990, BIOCHEMISTRY-US, V29, P6240, DOI 10.1021/bi00478a018; RAO KSPB, 1977, J BIOL CHEM, V252, P7788; REDDY MS, 1992, BIOCHEM J, V287, P639, DOI 10.1042/bj2870639; ROBERTS GP, 1976, ARCH BIOCHEM BIOPHYS, V173, P528, DOI 10.1016/0003-9861(76)90289-7; ROSE MC, 1984, J BIOL CHEM, V259, P3167; ROSE MC, 1989, METHOD ENZYMOL, V179, P3; ROSE MC, 1992, AM J PHYSIOL, V263, pL413, DOI 10.1152/ajplung.1992.263.4.L413; ROSE MC, 1984, BIOCHEM J, V222, P371, DOI 10.1042/bj2220371; ROSE MC, 1987, PEDIATR RES, V22, P545, DOI 10.1203/00006450-198711000-00015; ROSE MC, 1979, BIOCHEMISTRY-US, V18, P4030, DOI 10.1021/bi00585a029; ROSE MC, 1989, J BIOL CHEM, V264, P8193; RUGGERI ZM, 1993, FASEB J, V7, P308, DOI 10.1096/fasebj.7.2.8440408; SADLER JE, 1985, P NATL ACAD SCI USA, V82, P6394, DOI 10.1073/pnas.82.19.6394; TIMPTE CS, 1988, J BIOL CHEM, V263, P1081; TORIBARA NW, 1991, J CLIN INVEST, V88, P1005, DOI 10.1172/JCI115360; TORIBARA NW, 1993, J BIOL CHEM, V268, P5879; TOSI M, 1981, NUCLEIC ACIDS RES, V9, P2313, DOI 10.1093/nar/9.10.2313; VERMA M, 1993, P NATL ACAD SCI USA, V90, P7144, DOI 10.1073/pnas.90.15.7144; VOORBERG J, 1991, J CELL BIOL, V113, P195, DOI 10.1083/jcb.113.1.195; XU G, 1992, BIOCHEM BIOPH RES CO, V183, P821, DOI 10.1016/0006-291X(92)90557-2; XU GQ, 1992, J BIOL CHEM, V267, P5401	53	209	215	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12932	12939						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	7513696				2022-12-27	WOS:A1994NH71600085
J	CACERESCORTES, J; RAJOTTE, D; DUMOUCHEL, J; HADDAD, P; HOANG, T				CACERESCORTES, J; RAJOTTE, D; DUMOUCHEL, J; HADDAD, P; HOANG, T			PRODUCT OF THE STEEL LOCUS SUPPRESSES APOPTOSIS IN HEMATOPOIETIC-CELLS - COMPARISON WITH PATHWAYS ACTIVATED BY GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GM-CSF; MOLECULAR-CLONING; PROGENITOR CELLS; PROTEIN-KINASE; GROWTH-FACTOR; DEATH; SURVIVAL; ASSAY; ERYTHROPOIETIN; INTERLEUKIN-3	Steel factor (SF), also referred to as Kit ligand, stem cell factor, or mast cell growth factor, is essential for the development of hematopoietic stem cells in vivo. It is shown here that SF is mainly a survival factor for hemopoietic cells with little if any proliferative effect. In contrast, granulocyte macrophage colony-stimulating factor (GM-CSF) acts both as a survival factor and as a potent growth factor. We have probed the pathways activated by SF and GM-CSF in suppression of active cell death (apoptosis) using two classes of inhibitors: Tyrphostins that are specific inhibitors of protein tyrosine kinase, and amiloride derivatives (5-(N-ethyl-n-isopropyl)amiloride and 5-(N,N-hexamethylene)amiloride) that have been designed as specific inhibitors of the Na+/H+ antiporter. Both SF-dependent and GM-CSF-dependent pathways are sensitive to inhibition by Tyrphostins with, nonetheless, a quantitative difference. All Tyrphostins tested are more potent inhibitors of c-Kit than of GM-CSF receptor triggered pathways, the most striking being Tyrphostin B42 that is 10 times more potent. In contrast to the discrepancy in Tyrphostin dose-response curves, titration curves for 5-(N-ethyl-n-isopropyl)amiloride and 5-(N,N-hexamethylene)amiloride are comparable in SF or GM-CSF-stimulated cells. Furthermore, SF induces a rapid and sustained alkalinization of the intracellular pH, as assessed with the pH-sensitive probe 2',7'-bis(2-carboxyethyl)-5-carboxyfluorescein. Taken together, our data indicate that input from two distinct pathways with discrepancy in immediate early events, that of c-Kit and GM-CSF receptor, results in a common output, activation of the Na+/H+ antiporter and suppression of apoptosis by the two ligands.	CLIN RES INST MONTREAL,HEMOPOIESIS & LEUKEMIA LAB,MONTREAL H2W 1R7,PQ,CANADA; UNIV MONTREAL,DEPT PHARMACOL,MONTREAL H2W 1R7,PQ,CANADA	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal								AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; AVANZI GC, 1990, J CELL PHYSIOL, V145, P458, DOI 10.1002/jcp.1041450310; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; CACERESCORTES JR, 1992, CANCER RES, V52, P5208; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; DOLEI S, 1991, NATURE, V352, P809; FLEISHMAN RA, 1993, TRENDS GENET, V9, P259; GAZIT A, 1989, J MED CHEM, V32, P2344, DOI 10.1021/jm00130a020; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GODIN I, 1991, NATURE, V352, P807, DOI 10.1038/352807a0; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; KLEYMAN TR, 1988, J MEMBRANE BIOL, V105, P1, DOI 10.1007/BF01871102; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; LOTEM J, 1991, BLOOD, V78, P953; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; MASU J, 1993, NATURE, V365, P27; MATZINGER P, 1991, J IMMUNOL METHODS, V145, P185, DOI 10.1016/0022-1759(91)90325-A; MCCOLL SR, 1991, BLOOD, V78, P1842; MCCONKEY DJ, 1990, IMMUNOL TODAY, V11, P120, DOI 10.1016/0167-5699(90)90048-E; MCNIECE IK, 1991, EXP HEMATOL, V19, P226; MEKORI YA, 1993, J IMMUNOL, V151, P3775; METCALF D, 1991, P NATL ACAD SCI USA, V88, P6239, DOI 10.1073/pnas.88.14.6239; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; RAJOTTE D, 1992, J BIOL CHEM, V267, P9980; RODRIGUEZTARDUCHY G, 1990, EMBO J, V9, P2997, DOI 10.1002/j.1460-2075.1990.tb07492.x; SIRARD C, 1994, IN PRESS BLOOD; STANLEY JB, 1990, J IMMUNOL, V145, P2189; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0	32	85	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12084	12091						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	7512958				2022-12-27	WOS:A1994NG37700063
J	THOMPSON, NE; STRASHEIM, LA; NOLAN, KM; BURGESS, RR				THOMPSON, NE; STRASHEIM, LA; NOLAN, KM; BURGESS, RR			ACCESSIBILITY OF EPITOPES ON HUMAN TRANSCRIPTION FACTOR IIB IN THE NATIVE PROTEIN AND IN A COMPLEX WITH DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; BOX-BINDING-PROTEIN; FACTOR-TFIIB; CRYSTAL-STRUCTURE; FUNCTIONAL DOMAINS; INITIATION-FACTORS; MINIMAL SET; GENE; IDENTIFICATION; ACTIVATOR	Transcription factor IIB (TFIIB) plays a central role in the assembly of the RNA polymerase If initiation complex. Monoclonal antibodies (mAbs) that react with human TFIIB were prepared and used as probes to identify portions of TFIIB that are accessible when the factor is in solution and when it is contained in a complex with DNA. Seven mAbs were examined and were mapped to three regions of the TFIIB molecule. Only the mAbs that mapped to residues 52-105 inhibited transcription, immunoprecipitated recombinant TFIIB and TFIIB from HeLa cell nuclear extract (NE), and supershifted a complex containing TFIIB, the TATA-binding protein and DNA. The mAbs that mapped to residues 1-51 and the mAb that mapped to residues 106-316 did not show activity in the functional assays, with the exception of the far N-terminal mAbs (residues 151), which immunoprecipitated recombinant TFIIB, but not TFIIB from HeLa cell NE. These data indicate that the region containing residues 52-105 is exposed in solution and when TFIIB is part of the preinitiation complex and that some far N-terminal epitopes are accessible on the purified protein, but become blocked when TFIIB is in HeLa cell NE or in the preinitiation complex.			THOMPSON, NE (corresponding author), UNIV WISCONSIN,MCARDLE LAB CANC RES,1400 UNIV AVE,MADISON,WI 53706, USA.			Burgess, Richard/0000-0001-9545-3165	NATIONAL CANCER INSTITUTE [R01CA060896, P01CA023076, P30CA007175] Funding Source: NIH RePORTER; NCI NIH HHS [CA60896, CA23076, CA07175] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BARBERIS A, 1993, P NATL ACAD SCI USA, V90, P5628, DOI 10.1073/pnas.90.12.5628; BURATOWSKI S, 1993, P NATL ACAD SCI USA, V90, P5633, DOI 10.1073/pnas.90.12.5633; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; COLGAN J, 1993, NATURE, V362, P549, DOI 10.1038/362549a0; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; DARST SA, 1991, CELL, V66, P121, DOI 10.1016/0092-8674(91)90144-N; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HA I, 1993, GENE DEV, V7, P1021, DOI 10.1101/gad.7.6.1021; HISATAKE K, 1993, NATURE, V363, P744, DOI 10.1038/363744a0; ING NH, 1992, J BIOL CHEM, V267, P17617; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM TK, 1994, P NATL ACAD SCI USA, V91, P4170, DOI 10.1073/pnas.91.10.4170; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; MALIK S, 1991, P NATL ACAD SCI USA, V88, P9553, DOI 10.1073/pnas.88.21.9553; MALIK S, 1993, MOL CELL BIOL, V13, P6253, DOI 10.1128/MCB.13.10.6253; MAXON ME, 1994, GENE DEV, V8, P515, DOI 10.1101/gad.8.5.515; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; PARVIN JD, 1991, J BIOL CHEM, V266, P22878; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; STRICKLAND MS, 1988, BIOCHEMISTRY-US, V27, P5755, DOI 10.1021/bi00415a054; STUDIER WF, 1990, METHOD ENZYMOL, V185, P60, DOI DOI 10.1016/0076-6879(90)85008-C; THOMPSON NE, 1992, BIOCHEMISTRY-US, V31, P7003, DOI 10.1021/bi00145a019; THOMPSON NE, 1994, PROTEIN EXPRES PURIF, V5, P468, DOI 10.1006/prep.1994.1066; THOMPSON NE, 1989, J BIOL CHEM, V264, P11511; TYREE CM, 1993, GENE DEV, V7, P1254, DOI 10.1101/gad.7.7a.1254; WILEY SR, 1992, P NATL ACAD SCI USA, V89, P5814, DOI 10.1073/pnas.89.13.5814; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2; ZHOU Q, 1993, GENE DEV, V7, P180, DOI 10.1101/gad.7.2.180	33	12	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4735	4740		10.1074/jbc.270.9.4735	http://dx.doi.org/10.1074/jbc.270.9.4735			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7533165	hybrid			2022-12-27	WOS:A1995QK08400081
J	JAMESPEDERSON, M; YOST, S; SHEWCHUK, B; ZEIGLER, T; MILLER, R; HARDISON, R				JAMESPEDERSON, M; YOST, S; SHEWCHUK, B; ZEIGLER, T; MILLER, R; HARDISON, R			FLANKING AND INTRAGENIC SEQUENCES REGULATING THE EXPRESSION OF THE RABBIT ALPHA-GLOBIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE ERYTHROLEUKEMIA-CELLS; HUMAN BETA-GLOBIN; NUCLEOTIDE-SEQUENCE; TRANSCRIPTION UNIT; DNA METHYLATION; CONTROL REGION; BINDING-SITES; ENHANCER; ELEMENT; EVOLUTION	Despite their descent from a common ancestral gene and the requirement for coordinated, tissue-specific regulation, the alpha- and beta-globin genes in many mammals are regulated in distinctly different ways. Unlike the beta-globin gene, the rabbit alpha-globin gene is transiently expressed at a high level without an added enhancer in transfected erythroid and non-erythroid cells. By examining a series of alpha/beta fusion genes, we show that internal sequences of the rabbit alpha-globin gene (within the first two exons and introns) are required along with the 5' flank for this enhancer-independent expression. Furthermore, deletion of the introns of the alpha-globin gene, or replacement by introns of the beta-globin gene, results in severely decreased expression of the transfecting genes, Hybrid constructs between segments of the alpha-globin gene and a luciferase gene confirm that internal alpha-globin sequences are needed for high level production of RNA in transfected cells, The flanking and internal sequences implicated in regulation of the rabbit alpha-globin gene coincide with a prominent CpG-rich island and may comprise an extended promoter (including both flanking and intragenic sequences) that is active in transfected cells without an enhancer,	PENN STATE UNIV,CTR GENE REGULAT,DEPT BIOCHEM & MOLEC BIOL,UNIVERSITY PK,PA 16802	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park			Hardison, Ross C/G-1142-2010; Shewchuk, Brian/AAA-3388-2021	Hardison, Ross C/0000-0003-4084-7516; Yost, Susan/0000-0002-9422-0316	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044491] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K04DK001589, R01DK027635] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-44491] Funding Source: Medline; NIDDK NIH HHS [DK-01589, DK-27635] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ATCHISON ML, 1989, MOL CELL BIOL, V9, P2067, DOI 10.1128/MCB.9.5.2067; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BANERJI J, 1981, CELL, V27, P299, DOI 10.1016/0092-8674(81)90413-X; BANERJI J, 1983, CELL, V33, P729, DOI 10.1016/0092-8674(83)90015-6; BENTLEY DL, 1984, NATURE, V307, P77, DOI 10.1038/307077a0; BERNARDI G, 1985, SCIENCE, V228, P953, DOI 10.1126/science.4001930; BIRD AP, 1987, EMBO J, V6, P999, DOI 10.1002/j.1460-2075.1987.tb04851.x; BRICKNER HE, 1991, J BIOL CHEM, V266, P15363; CHAO MV, 1983, CELL, V32, P483, DOI 10.1016/0092-8674(83)90468-3; CHARNAY P, 1984, CELL, V38, P251, DOI 10.1016/0092-8674(84)90547-6; CHENG JF, 1988, J BIOL CHEM, V263, P9981; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUNG S, 1989, MOL CELL BIOL, V9, P2075, DOI 10.1128/MCB.9.5.2075; DEISSEROTH A, 1978, CELL, V15, P55, DOI 10.1016/0092-8674(78)90082-X; Favaloro J, 1980, Methods Enzymol, V65, P718; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HARDISON R, 1991, J MOL BIOL, V222, P233, DOI 10.1016/0022-2836(91)90209-O; HARDISON R, 1993, MOL BIOL EVOL, V10, P73; HIGGS DR, 1990, GENE DEV, V4, P1588, DOI 10.1101/gad.4.9.1588; HUMPHRIES RK, 1982, CELL, V30, P173; LAKER C, 1987, P NATL ACAD SCI USA, V84, P8458, DOI 10.1073/pnas.84.23.8458; MARGOT JB, 1989, J MOL BIOL, V205, P15, DOI 10.1016/0022-2836(89)90362-8; MELLON P, 1981, CELL, V27, P279, DOI 10.1016/0092-8674(81)90411-6; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NEUMANN E, 1982, EMBO J, V1, P841, DOI 10.1002/j.1460-2075.1982.tb01257.x; PHILIPSEN S, 1990, EMBO J, V9, P2159, DOI 10.1002/j.1460-2075.1990.tb07385.x; PONDEL MD, 1992, NUCLEIC ACIDS RES, V20, P237, DOI 10.1093/nar/20.2.237; POTTER H, 1984, P NATL ACAD SCI-BIOL, V81, P7161, DOI 10.1073/pnas.81.22.7161; PYATI J, 1980, P NATL ACAD SCI USA, V79, P4337; REN SC, 1993, BLOOD, V81, P1058; ROHRBAUGH ML, 1985, MOL CELL BIOL, V5, P147, DOI 10.1128/MCB.5.1.147; Sambrook J, 1989, MOL CLONING LABORATO; SHEN CKJ, 1980, P NATL ACAD SCI-BIOL, V77, P6634, DOI 10.1073/pnas.77.11.6634; TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G; TREISMAN R, 1983, P NATL ACAD SCI-BIOL, V80, P7428, DOI 10.1073/pnas.80.24.7428; Tuan D, 1987, DEV CONTROL GLOBIN G, P211; VANDENBERGH DJ, 1991, J MOL BIOL, V220, P255, DOI 10.1016/0022-2836(91)90011-T; VANDERPLOEG LHT, 1980, CELL, V19, P947, DOI 10.1016/0092-8674(80)90086-0; WHITELAW E, 1989, MOL CELL BIOL, V9, P241, DOI 10.1128/MCB.9.1.241; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; WILLING MC, 1979, NATURE, V277, P534, DOI 10.1038/277534a0; WRIGHT S, 1983, NATURE, V305, P333, DOI 10.1038/305333a0; YANG JQ, 1986, EMBO J, V5, P3553, DOI 10.1002/j.1460-2075.1986.tb04682.x; YOST SE, 1993, MOL CELL BIOL, V13, P5439, DOI 10.1128/MCB.13.9.5439	45	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3965	3973		10.1074/jbc.270.8.3965	http://dx.doi.org/10.1074/jbc.270.8.3965			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7533158	hybrid			2022-12-27	WOS:A1995QH68800076
J	COLE, PA; BURN, P; TAKACS, B; WALSH, CT				COLE, PA; BURN, P; TAKACS, B; WALSH, CT			EVALUATION OF THE CATALYTIC MECHANISM OF RECOMBINANT HUMAN CSK (C-TERMINAL SRC KINASE) USING NUCLEOTIDE ANALOGS AND VISCOSITY EFFECTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; FAMILY TYROSINE KINASES; GROWTH-FACTOR RECEPTOR; KINETIC MECHANISM; ESCHERICHIA-COLI; SUBUNIT; PHOSPHORYLATION; PHOSPHOTRANSFER; HYDROLYSIS; SUBSTRATE	Tyrosine kinases catalyze phosphoryl transfers from ATP to tyrosine residues in proteins. Despite their growing importance, their kinetic mechanism has remained largely unexplored. In this study we have investigated the tyrosine kinase reaction catalyzed by purified human recombinant Csk (C-terminal Src kinase). Poly(Glu,Tyr) 4:1 was used as the tyrosine containing substrate. Both ATP and poly(Glu,Tyr) were shown to be well behaved saturable substrates for recombinant Csk, with K-m values that were in reasonable agreement with Literature values reported for the non-recombinant enzyme and with k(cat) about 40 min(-1). A sequential kinetic mechanism is suggested by a steady state kinetic analysis. Inhibitor studies with ADP and beta,gamma-imidoadenosine 5'-triphosphate were performed, and these results provided evidence against the possibility that ordered binding of peptide prior to ATP occurs. While a suitable competitive inhibitor of poly(Glu,Tyr) has not yet been identified, other evidence pointed to a rapid equilibrium random mechanism. Csk utilized adenosine 5'-O-(3-thiotriphosphate) in place of ATP. The phosphorothioyl transfer occurred with a k(cat) about 15-20-fold lower than the ATP reaction but with similar K-m values. Deuterium solvent isotope effects on k(cat) were small for both reactions in a pH-independent range, consistent with the possibility that proton transfer is asymmetric in the reaction transition state. Using viscosity effects, ADP product release was suggested to be partially rate determining for catalysis in the standard ATP reaction. A comparison of the Csk kinetic mechanism with that of protein kinase A is discussed.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115; HOFFMANN LA ROCHE INC,NUTLEY,NJ 07110; F HOFFMANN LA ROCHE & CO LTD,CH-4002 BASEL,SWITZERLAND	Harvard University; Harvard Medical School; Roche Holding; Roche Holding								ADAMS JA, 1992, BIOCHEMISTRY-US, V31, P8516, DOI 10.1021/bi00151a019; AMREIN KE, 1994, IN PRESS P NATL ACAD, V91; AUTERO M, 1994, MOL CELL BIOL, V14, P1308, DOI 10.1128/MCB.14.2.1308; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BLACKLOW SC, 1988, BIOCHEMISTRY-US, V27, P1158, DOI 10.1021/bi00404a013; BOUGERET C, 1993, ONCOGENE, V8, P1241; BRAUN S, 1984, J BIOL CHEM, V259, P2051; BRUNATI AM, 1992, FEBS LETT, V313, P291, DOI 10.1016/0014-5793(92)81212-5; BUDDE RJA, 1993, J BIOL CHEM, V268, P24868; CALDWELL SR, 1991, BIOCHEMISTRY-US, V30, P7438, DOI 10.1021/bi00244a010; CAREY J, 1991, METHOD ENZYMOL, V208, P103; CARRERA AC, 1993, P NATL ACAD SCI USA, V90, P442, DOI 10.1073/pnas.90.2.442; CASPERS P, 1994, CELL MOL BIOL, V40, P635; CHLEBOWSKI JF, 1974, J BIOL CHEM, V249, P7192; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; ECKSTEIN F, 1983, ANGEW CHEM INT EDIT, V22, P423, DOI 10.1002/anie.198304233; ERNEUX C, 1983, J BIOL CHEM, V258, P4137; Fersht A, 1985, ENZYME STRUCTURE MEC, P105; GIBBS CS, 1992, J BIOL CHEM, V267, P4806; GRATECOS D, 1974, BIOCHEM BIOPH RES CO, V58, P960, DOI 10.1016/S0006-291X(74)80237-8; HEATH DF, 1956, J CHEM SOC, P3796, DOI 10.1039/jr9560003796; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; Kemp BE, 1990, PEPTIDES PROTEIN PHO; KLAGES S, 1994, P NATL ACAD SCI USA, V91, P2597, DOI 10.1073/pnas.91.7.2597; KNIGHTON DR, 1993, P NATL ACAD SCI USA, V90, P5001, DOI 10.1073/pnas.90.11.5001; KONG CT, 1988, BIOCHEMISTRY-US, V27, P4795, DOI 10.1021/bi00413a032; LEE TR, 1994, BIOCHEMISTRY-US, V33, P4245, DOI 10.1021/bi00180a019; MUSTELIN T, 1993, TRENDS BIOCHEM SCI, V18, P215, DOI 10.1016/0968-0004(93)90192-P; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OKADA M, 1988, J BIOCHEM-TOKYO, V104, P297, DOI 10.1093/oxfordjournals.jbchem.a122461; OKADA M, 1989, J BIOL CHEM, V264, P20886; QAMAR R, 1993, BIOCHEMISTRY-US, V32, P6802, DOI 10.1021/bi00077a035; Schowen R. L., 1977, ISOTOPE EFFECTS ENZY, P64; Segel I.H., 1975, ENZYME KINETICS; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; WALKER DH, 1987, BIOCHEMISTRY-US, V26, P1428, DOI 10.1021/bi00379a033; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3693; WONG TW, 1984, J BIOL CHEM, V259, P3127; YOON MY, 1987, BIOCHEMISTRY-US, V26, P4118, DOI 10.1021/bi00387a056; YUAN CJ, 1990, J BIOL CHEM, V265, P16205; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	42	87	88	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					30880	30887						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7527038				2022-12-27	WOS:A1994PV51000025
J	CHEN, YH; POUYSSEGUR, J; COURTNEIDGE, SA; VANOBBERGHENSCHILLING, E				CHEN, YH; POUYSSEGUR, J; COURTNEIDGE, SA; VANOBBERGHENSCHILLING, E			ACTIVATION OF SRC FAMILY KINASE-ACTIVITY BY THE G-PROTEIN-COUPLED THROMBIN RECEPTOR IN GROWTH RESPONSIVE FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; TYROSINE PHOSPHORYLATION; ALPHA-THROMBIN; HUMAN PLATELETS; SIGNAL-TRANSDUCTION; NEURITE RETRACTION; PERTUSSIS TOXIN; ASSOCIATION; PP60C-SRC; PATHWAY	Thrombin stimulates G protein-coupled signaling pathways in target cells by proteolytic cleavage of its seven transmembrane domain receptor. Protein tyrosine phosphorylation is also stimulated by the protease via poorly defined mechanisms. In human platelets, thrombin has been shown to activate the nonreceptor tyrosine kinase Src. To elucidate the signal transduction pathways involved in transmission of thrombin's cellular effects, we have examined the ability of thrombin to activate Src family tyrosine kinases in a growth-responsive line of lung fibroblasts (CCL39 cells). We report here that thrombin induces a rapid (less than or equal to 30 s) and transient increase in the kinase activity of Src and Fyn as determined by autophosphorylation in immune complex kinase assays. Activation is mediated by the G protein-coupled thrombin receptor since a synthetic peptide agonist of the receptor mimics thrombin action. The involvement of one or more G proteins in this response was confirmed by the observation that thrombin's effect is partially sensitive to pertussis toxin. Furthermore, both alpha(2)-adrenegic and muscarinic m(1) receptors are able to increase Src kinase activity via pertussis toxin-sensitive and insensitive G proteins, respectively. These findings suggest that nonreceptor tyrosine kinases of the Src family may represent a novel effector system linking G protein-coupled receptors to downstream activation of Ras and the mitogen-activated protein kinase cascade.	CTR BIOCHIM,CNRS,UMR 134,F-06108 NICE 2,FRANCE; EUROPEAN MOLEC BIOL LAB,D-69012 HEIDELBERG,GERMANY	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; European Molecular Biology Laboratory (EMBL)			Van Obberghen-Schilling, Ellen/O-1581-2016; Van Obberghen-Schilling, Ellen/Q-4372-2019	Van Obberghen-Schilling, Ellen/0000-0003-2961-0059; Van Obberghen-Schilling, Ellen/0000-0003-2961-0059				ALBLAS J, 1993, J BIOL CHEM, V268, P22235; CARNEY DH, 1992, THROMBIN STRUCTURE F, P351; CHAMBARD JC, 1987, NATURE, V326, P800, DOI 10.1038/326800a0; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COUGHLIN SR, 1992, J CLIN INVEST, V89, P351, DOI 10.1172/JCI115592; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; COURTNEIDGE SA, 1984, EMBO J, V3, P585, DOI 10.1002/j.1460-2075.1984.tb01852.x; FERRELL JE, 1988, MOL CELL BIOL, V8, P3603, DOI 10.1128/MCB.8.9.3603; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; GUTKIND JS, 1990, MOL CELL BIOL, V10, P3806, DOI 10.1128/MCB.10.7.3806; HAUSDORFF WP, 1992, P NATL ACAD SCI USA, V89, P5720, DOI 10.1073/pnas.89.13.5720; HORAK ID, 1990, ONCOGENE, V5, P597; HOWE LR, 1993, J BIOL CHEM, V268, P20717; JALINK K, 1992, J CELL BIOL, V118, P411, DOI 10.1083/jcb.118.2.411; JALINK K, 1993, CELL GROWTH DIFFER, V4, P247; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; KOHNO M, 1986, BIOCHEM J, V238, P451, DOI 10.1042/bj2380451; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; LAMORTE VJ, 1993, J BIOL CHEM, V268, P19411; LIEBENHOFF U, 1993, BIOCHEM J, V295, P41, DOI 10.1042/bj2950041; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; MARI B, 1994, J BIOL CHEM, V269, P8517; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; OFFERMANNS S, 1993, BIOCHEM J, V290, P27, DOI 10.1042/bj2900027; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; POUYSSEGUR J, 1992, ANNU REV PHYSIOL, V54, P195, DOI 10.1146/annurev.ph.54.030192.001211; POUYSSEGUR J, 1990, G PROTEINS, P555; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; RASMUSSEN UB, 1991, FEBS LETT, V288, P123, DOI 10.1016/0014-5793(91)81017-3; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SEUWEN K, 1990, J BIOL CHEM, V265, P22292; SEUWEN K, 1990, CELL REGUL, V1, P445, DOI 10.1091/mbc.1.6.445; SUIDAN HS, 1992, NEURON, V8, P363, DOI 10.1016/0896-6273(92)90302-T; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VOURETCRAVIARI V, 1993, BIOCHEM J, V289, P209, DOI 10.1042/bj2890209; VOURETCRAVIARI V, 1992, MOL BIOL CELL, V3, P95, DOI 10.1091/mbc.3.1.95; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WEISS RH, 1993, J BIOL CHEM, V268, P5724; WEISS RH, 1992, J BIOL CHEM, V267, P5608; WINITZ S, 1993, J BIOL CHEM, V268, P19196	48	176	177	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27372	27377						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7525555				2022-12-27	WOS:A1994PV77100037
J	EYTAN, GD; BORGNIA, MJ; REGEV, R; ASSARAF, YG				EYTAN, GD; BORGNIA, MJ; REGEV, R; ASSARAF, YG			TRANSPORT OF POLYPEPTIDE IONOPHORES INTO PROTEOLIPOSOMES RECONSTITUTED WITH RAT-LIVER P-GLYCOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANALICULAR MEMBRANE-VESICLES; MULTIDRUG-RESISTANCE PUMP; CLASS-II REGION; GENE-PRODUCT; PLASMA-MEMBRANE; DRUG TRANSPORT; CELL-LINES; MDR-GENE; EXPRESSION; PROTEIN	The aim of this study was to examine the peptide transport activity of a naturally occurring P-glycoprotein such as that present in rat liver canalicular membrane vesicles. The peptide ionophores valinomycin and gramicidin D, which are known substrates of P-glycoprotein, served to monitor the P-glycoprotein activity indirectly as the ATP-dependent uptake of Rb-86(+) mediated by these ionophores. Canalicular membrane vesicles proved inherently permeable to K+ ions, which prevented assay of transport ionophore activity. Therefore, P-glycoprotein was extracted from canalicular membrane vesicles and reconstituted into proteoliposomes that are relatively impermeable to cations. P-glycoprotein activity in the proteoliposomes was dependent on ATP hydrolysis since it was not observed with non-hydrolyzable analogs of ATP. Maximal ATP-dependent Rb-86(+) uptake occurred at 50 nM gramicidin D and at 500 nM valinomycin thus possibly reflecting higher affinity of P-glycoprotein for gramicidin D. Nigericin, which does not participate in the multidrug resistance phenomenon, did not support an ATP-depend ent uptake of Rb-86(+). ATP hydrolysis increased the amount of Rb-86(+) transported into the proteoliposomes. Furthermore, preincubation of the proteoliposomes in the presence of gramicidin D and Rb-86(+), allowing for maximal ATP-independent Rb-86(+) uptake to occur, did not interfere with subsequent ATP-dependent uptake, indicating the latter to constitute an active transport mechanism, The ATP-dependent component of Rb-86(+) uptake occurred neither with liposomes nor with proteoliposomes reconstituted with proteins extracted from sinusoidal vesicles that lack P-glycoprotein. The ATP-dependent uptake was blocked by the known inhibitors of the ATPase activity associated with P-glycoprotein, oligomycin and vanadate, as well as by its established substrates, daunorubicin, doxorubicin, vinblastine, and the tripeptide N-acetyl-leucyl-leucyl-norleucinal. Thus, the reconstituted P-glycoprotein catalyzes the ATP-dependent Rb-86(+) uptake that appears to occur by an energy-dependent translocation of the Rb-86(+)-ionophore complex. In this case, the actual substrate of P-glycoprotein is the ionophore cation complex, which is both hydrophobic and positively charged as are most of the substrates of P-glycoprotein. This is the first demonstration of transport of a naturally occurring polypeptide by proteoliposomes reconstituted with physiologically expressed P-glycoprotein.			EYTAN, GD (corresponding author), TECHNION ISRAEL INST TECHNOL, DEPT BIOL, IL-32000 HAIFA, ISRAEL.							ABRAHAM EH, 1993, P NATL ACAD SCI USA, V90, P312, DOI 10.1073/pnas.90.1.312; ALTUVIA S, 1993, J BIOL CHEM, V268, P27127; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; ARCECI RJ, 1988, P NATL ACAD SCI USA, V85, P4350, DOI 10.1073/pnas.85.12.4350; ASSARAF YG, 1994, EUR J BIOCHEM, V222, P813, DOI 10.1111/j.1432-1033.1994.tb18928.x; CHABNER BA, 1990, CANCER CHEMOTHERAPY; CORDONCARDO C, 1990, J HISTOCHEM CYTOCHEM, V38, P1277, DOI 10.1177/38.9.1974900; CURRIER SJ, 1992, J BIOL CHEM, V267, P25153; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; DOIGE CA, 1992, BIOCHIM BIOPHYS ACTA, V1109, P161, DOI 10.1016/0005-2736(92)90079-2; ESEN A, 1978, ANAL BIOCHEM, V89, P264, DOI 10.1016/0003-2697(78)90749-2; FREI E, 1985, CANCER RES, V45, P6523; GARTY H, 1989, METHOD ENZYMOL, V172, P155; GASKO OD, 1976, ANAL BIOCHEM, V72, P57, DOI 10.1016/0003-2697(76)90506-6; GERLACH JH, 1986, NATURE, V324, P485, DOI 10.1038/324485a0; GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HIGGINS CF, 1992, TRENDS BIOCHEM SCI, V17, P18, DOI 10.1016/0968-0004(92)90419-A; HORIO M, 1988, P NATL ACAD SCI USA, V85, P3580, DOI 10.1073/pnas.85.10.3580; INOUE M, 1982, HEPATOLOGY, V2, P572; KAGAWA Y, 1971, J BIOL CHEM, V246, P5477; KAMIMOTO Y, 1989, J BIOL CHEM, V264, P11693; LINCKE CR, 1990, CANCER RES, V50, P1779; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; MUKHOPADHYAY T, 1988, J NATL CANCER I, V80, P269, DOI 10.1093/jnci/80.4.269; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; RAYMOND M, 1992, SCIENCE, V256, P232, DOI 10.1126/science.1348873; RIORDAN JR, 1985, NATURE, V316, P817, DOI 10.1038/316817a0; ROMAN LM, 1983, J CELL BIOL, V96, P1548, DOI 10.1083/jcb.96.6.1548; SHAPIRO AB, 1994, J BIOL CHEM, V269, P3745; SHARMA RC, 1992, J BIOL CHEM, V267, P5731; SHAROM FJ, 1993, J BIOL CHEM, V268, P24197; SINICROPE FA, 1992, J BIOL CHEM, V267, P24995; SLOVAK ML, 1988, CANCER RES, V48, P2793; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SUGAWARA I, 1988, CANCER RES, V48, P1926; THIEBAUT F, 1989, J HISTOCHEM CYTOCHEM, V37, P159, DOI 10.1177/37.2.2463300; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0	40	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26058	26065						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7523400				2022-12-27	WOS:A1994PQ93000022
J	HARROCH, S; REVEL, M; CHEBATH, J				HARROCH, S; REVEL, M; CHEBATH, J			INTERLEUKIN-6 SIGNALING VIA 4 TRANSCRIPTION FACTORS BINDING PALINDROMIC ENHANCERS OF DIFFERENT GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON REGULATORY FACTOR; PROTEIN-TYROSINE KINASE; GAMMA-INTERFERON; ALPHA-INTERFERON; TRANSDUCTION PATHWAYS; NUCLEAR FACTOR; IFN-GAMMA; M1 CELLS; FACTOR-I; ACTIVATION	Interferons (IFNs), as well as some interleukins, growth factors, and hormones, all induce tyrosine phosphorylation of STAT1 and additional transcription factors of similar sizes. These factors are activated to translocate to nucleus and bind to enhancers of consensus sequence TTnCnnnAA (gamma-IFN activated sequence like enhancers). In mammary cells or hybridoma B9 cells, four distinct tyrosine phosphorylated transcription complexes activated by interleukin-6 (IL-6) and IFN-beta were observed: pIRFA and complexes I, II, and III (of increasing electrophoretic mobility). The factors have unequal affinities for enhancers of different genes; they are activated with distinct kinetics and to different extents by IL-6 and IFNs. The pIRFA band isolated from IL-6-stimulated B9 hybridoma cells revealed three DNA-interacting components: two large subunits of 91 and 98 kDa, as well as a small component of 46 kDa not seen in other complexes analyzed. One of the large pIRFA subunits may be APRF/STAT3, since pIRFA reacted with anti-APRF antibodies as do complexes I and II. However, pIRFA did not react with antibodies to STAT1, indicating STAT1 is not the other large component of pIRFA. Complex II, which reacted to anti-acute phase response factor antibodies also reacted to anti-STAT1 antibodies, whereas complex III reacted only to anti-STAT1 and was the only complex resistant to N-ethylmaleimide. By its multimeric subunit structure and its cytokine and enhancer sequence specificities, the slowly migrating pIRFA band appears as a novel tyrosine-phosphorylated transcription complex acting on a subset of gamma-IFN activated sequence-like enhancers.			HARROCH, S (corresponding author), WEIZMANN INST SCI,DEPT MOLEC GENET,IL-76100 REHOVOT,ISRAEL.			Chebath, Judith/0000-0002-8151-7428				ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; AKYIAMA T, 1987, J BIOL CHEM, V262, P5592; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BONNI A, 1993, SCIENCE, V262, P1575, DOI 10.1126/science.7504325; DECKER T, 1991, MOL CELL BIOL, V11, P5147, DOI 10.1128/MCB.11.10.5147; GOTHELF Y, 1991, LYMPHOKINE CYTOK RES, V10, P369; HARROCH S, 1994, EMBO J, V13, P1942, DOI 10.1002/j.1460-2075.1994.tb06463.x; HARROCH S, 1993, J BIOL CHEM, V268, P9092; IGARASHI K, 1993, MOL CELL BIOL, V13, P1634, DOI 10.1128/MCB.13.3.1634; KANNO Y, 1993, MOL CELL BIOL, V13, P3951, DOI 10.1128/MCB.13.7.3951; KHAN KD, 1993, P NATL ACAD SCI USA, V90, P6806, DOI 10.1073/pnas.90.14.6806; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LEW DJ, 1989, MOL CELL BIOL, V9, P5404, DOI 10.1128/MCB.9.12.5404; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; PEARSE RN, 1993, P NATL ACAD SCI USA, V90, P4314, DOI 10.1073/pnas.90.9.4314; PEREZ C, 1993, MOL CELL BIOL, V13, P2182, DOI 10.1128/MCB.13.4.2182; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	36	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26191	26195						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7523403				2022-12-27	WOS:A1994PQ93000040
J	WARD, CL; KOPITO, RR				WARD, CL; KOPITO, RR			INTRACELLULAR TURNOVER OF CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR - INEFFICIENT PROCESSING AND RAPID DEGRADATION OF WILD-TYPE AND MUTANT PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CFTR CHLORIDE CHANNEL; ENDOPLASMIC-RETICULUM; NUCLEOTIDE-BINDING; MOLECULAR-BASIS; TRANSPORT; COMPARTMENT; DELTA-F508; MUTATIONS; CELL; GENE	Mutant (Delta F508) and wild-type cystic fibrosis transmembrane conductance regulator (CFTR) were synthesized initially as an similar to 140-kDa core-glycosylated precursor, which, in the case of wild-type CFTR, was chased to an similar to 160 kDa form bearing complex oligosaccharides. Mutant CFTR disappeared from the detergent-soluble cell extract with rapid (t(1/2) = 27 min) kinetics. Only similar to 25% of the initially synthesized wild-type 140-kDa CFTR precursor was detected as mature protein; the remaining similar to 75% decayed with kinetics (t(1/2) = 33 min) indistinguishable from those of the mutant. Rapid degradation kinetics and inefficient processing of wild-type CFTR were also observed in the colonic carcinoma lines HT29 and T84 and in stably transfected C127 cells, which express 5-50 times lower levels of CFTR. These results suggest that inefficient processing and rapid degradation of wild-type CFTR precursor are an intrinsic property of CFTR in these diverse cell types and are not an artifact of overexpression. Degradation of wild-type and mutant 140-kDa CFTR began without significant lag following synthesis. These data suggest that wild-type and Delta F508 CFTR differ in the efficiency of folding of the core glycosylated primary translation product.	STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305	Stanford University					NIDDK NIH HHS [DK43994] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043994] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; BAUKROWITZ T, 1994, NEURON, V12, P473, DOI 10.1016/0896-6273(94)90206-2; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DOOLITTLE RF, 1987, URFS ORFS PRIMER ANA; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUNDERSON MS, 1994, VIROLOGY, V269, P19349; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KEREM BS, 1990, P NATL ACAD SCI USA, V87, P8447, DOI 10.1073/pnas.87.21.8447; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE BS, 1991, J BIOL CHEM, V266, P11448; LODISH HF, 1971, BIOCHEMISTRY-US, V10, P2348, DOI 10.1021/bi00788a027; MARSHALL J, 1994, J BIOL CHEM, V269, P2987; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PIND S, 1994, J BIOL CHEM, V269, P12784; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; RUETZ S, 1993, J CELL BIOL, V121, P37, DOI 10.1083/jcb.121.1.37; SHEPPARD DN, 1994, CELL, V76, P1091, DOI 10.1016/0092-8674(94)90385-9; THOMAS PJ, 1991, SCIENCE, V251, P555, DOI 10.1126/science.1703660; THOMAS PJ, 1992, FEBS LETT, V312, P7, DOI 10.1016/0014-5793(92)81399-7; TSUI LC, 1992, TRENDS GENET, V8, P392, DOI 10.1016/0168-9525(92)90301-J; WARD CL, 1991, P NATL ACAD SCI USA, V88, P5277, DOI 10.1073/pnas.88.12.5277; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; YANG YP, 1993, P NATL ACAD SCI USA, V90, P9480, DOI 10.1073/pnas.90.20.9480; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139	34	401	406	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25710	25718						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7523390				2022-12-27	WOS:A1994PQ49100072
J	GUO, B; YU, Y; LEIBOLD, EA				GUO, B; YU, Y; LEIBOLD, EA			IRON REGULATES CYTOPLASMIC LEVELS OF A NOVEL IRON-RESPONSIVE ELEMENT-BINDING PROTEIN WITHOUT ACONITASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FERRITIN MESSENGER-RNA; TRANSFERRIN RECEPTOR; UNTRANSLATED REGION; CYTOSOLIC ACONITASE; REPRESSOR PROTEIN; HEART ACONITASE; SULFUR CLUSTER; RAT-LIVER; TRANSLATION; PURIFICATION	Iron-responsive element-binding proteins (IRE-BPs) are cytosolic proteins that bind to a conserved RNA stem-loop, termed the iron-responsive element (IRE), that is located in the 5'- or 3'-untranslated regions of mRNAs involved in iron metabolism. Binding of the IRE-BP to 5'-IREs represses translation, whereas binding to 3'-IREs stabilizes the mRNA. The previously identified IRE-BP (BP1) contains a 4Fe-4S cluster and has sequence homology to mitochondrial aconitase. The 4Fe-4S cluster is important for iron-dependent regulation: BP1 containing iron has low affinity for the IRE and contains aconitase activity, whereas BP1 lacking iron has high affinity for the IRE, but lacks aconitase activity. A second IRE-BP (BP2) has been identified in rat tissues and cells and exhibits many of the hallmarks of an IRE BP, including binding to the IRE and functioning as a translational repressor of IRE-containing RNAs, BP1 and BP2 RNA binding activities are decreased in extracts from cells treated with iron, indicating that BP1 and BP2 are negatively regulated by iron. Although BP1 and BP2 share similar characteristics, they differ in two significant ways. Unlike BP1 levels, which do not change when RNA binding activity decreases in response to iron, BP2 decreases to undetectable levels in extracts from cells treated with iron; and unlike BP1, BP2 does not have aconitase activity. These data indicate that BP1 and BP2 are distinct proteins that have similar specificity for IRE binding and that function similarly in translation, but are regulated by iron via different mechanisms.	UNIV UTAH, DEPT MED, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, ECCLES PROGRAM HUMAN MOLEC BIOL & GENET, SALT LAKE CITY, UT 84112 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah					NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045201] Funding Source: NIH RePORTER; NCI NIH HHS [CA42014] Funding Source: Medline; NIGMS NIH HHS [GM45201] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AZIZ N, 1986, NUCLEIC ACIDS RES, V14, P915, DOI 10.1093/nar/14.2.915; AZIZ N, 1987, P NATL ACAD SCI USA, V84, P8478, DOI 10.1073/pnas.84.23.8478; BASILION JP, 1994, P NATL ACAD SCI USA, V91, P574, DOI 10.1073/pnas.91.2.574; CASEY JL, 1989, EMBO J, V8, P3693, DOI 10.1002/j.1460-2075.1989.tb08544.x; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; CONSTABLE A, 1992, P NATL ACAD SCI USA, V89, P4554, DOI 10.1073/pnas.89.10.4554; COX TC, 1991, EMBO J, V10, P1891, DOI 10.1002/j.1460-2075.1991.tb07715.x; DANDEKAR T, 1991, EMBO J, V10, P1903, DOI 10.1002/j.1460-2075.1991.tb07716.x; DRAPIER JC, 1986, J CLIN INVEST, V78, P790, DOI 10.1172/JCI112642; GOESSLING LS, 1992, SCIENCE, V256, P670, DOI 10.1126/science.1316633; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P7536, DOI 10.1073/pnas.89.16.7536; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P11735, DOI 10.1073/pnas.89.24.11735; HENDERSON BR, 1993, J BIOL CHEM, V268, P27327; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; HENTZE MW, 1987, SCIENCE, V238, P1570, DOI 10.1126/science.3685996; KENNEDY MC, 1988, J BIOL CHEM, V263, P8194; KENNEDY MC, 1992, P NATL ACAD SCI USA, V89, P11730, DOI 10.1073/pnas.89.24.11730; KLAUSNER RD, 1993, MOL BIOL CELL, V4, P1; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KOELLER DM, 1991, P NATL ACAD SCI USA, V88, P7778, DOI 10.1073/pnas.88.17.7778; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; LEIBOLD EA, 1992, ANNU REV NUTR, V12, P345, DOI 10.1146/annurev.nu.12.070192.002021; LEIBOLD EA, 1990, NUCLEIC ACIDS RES, V18, P1819, DOI 10.1093/nar/18.7.1819; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; NEUPERT B, 1990, NUCLEIC ACIDS RES, V18, P51, DOI 10.1093/nar/18.1.51; OWEN D, 1987, EMBO J, V6, P1287, DOI 10.1002/j.1460-2075.1987.tb02366.x; PATINO MM, 1992, J BIOL CHEM, V267, P19011; PHILPOTT CC, 1991, NUCLEIC ACIDS RES, V19, P6333, DOI 10.1093/nar/19.22.6333; POLSON A, 1980, IMMUNOL COMMUN, V9, P475, DOI 10.3109/08820138009066010; ROUAULT TA, 1988, SCIENCE, V241, P1207, DOI 10.1126/science.3413484; ROUAULT TA, 1991, CELL, V64, P881, DOI 10.1016/0092-8674(91)90312-M; ROUAULT TA, 1990, P NATL ACAD SCI USA, V87, P7958, DOI 10.1073/pnas.87.20.7958; TANG CK, 1992, J BIOL CHEM, V267, P24466; WALDEN WE, 1989, J BIOL CHEM, V264, P13765; YU Y, 1992, J BIOL CHEM, V267, P19005; ZAHRINGER J, 1976, P NATL ACAD SCI USA, V73, P857, DOI 10.1073/pnas.73.3.857; ZHENG L, 1992, J BIOL CHEM, V267, P7895; ZHENG LM, 1990, J BIOL CHEM, V265, P2814	39	234	238	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24252	24260						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7523370				2022-12-27	WOS:A1994PQ34600063
J	MOORE, KL; EATON, SF; LYONS, DE; LICHENSTEIN, HS; CUMMINGS, RD; MCEVER, RP				MOORE, KL; EATON, SF; LYONS, DE; LICHENSTEIN, HS; CUMMINGS, RD; MCEVER, RP			THE P-SELECTIN GLYCOPROTEIN LIGAND FROM HUMAN NEUTROPHILS DISPLAYS SIALYLATED, FUCOSYLATED, O-LINKED POLY-N-ACETYLLACTOSAMINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADHESION MOLECULE-1 ELAM-1; MYELOID CELLS; BACTEROIDES-FRAGILIS; CARBOHYDRATE LIGAND; ENDOTHELIAL-CELLS; GMP-140 BINDS; OLIGOSACCHARIDES; IDENTIFICATION; RECOGNITION; EXPRESSION	We previously demonstrated that P-selectin binds with high affinity to a trace, homodimeric glycoprotein ligand on human myeloid cells. The ligand carries the sialyl Lewis x (sLe(x)) epitope, a limited number of N-linked glycans, and clustered, sialylated O-linked glycans. In this study we demonstrate that the polypeptide component of this ligand is identical to that of P-selectin glycoprotein ligand-1 (PSGL-1), a molecule recently identified by expression cloning from a human myeloid cell cDNA library. We have examined the effects of glycosidases on purified, radioiodinated PSGL-1 from human neutrophils to further characterize the structure and function of the attached oligosaccharides. We found that PSGL-1 had poly-N-acetyllactosamine, only some of which could be removed with endo-beta-galactosidase. The majority of the Le(x) and sLe(x) structures were on endo-beta-galactosidase-sensitive chains. Peptide:N-glycosidase F (PNGaseF) treatment removed at least two of the three possible N-linked oligosaccharides from PSGL-1. Expression of Le(x) and sLe(x) was not detectably altered by PNGaseF digestion, indicating that these structures were primarily on O-linked poly-N-acetyllactosamine. Endo-beta-galactosidase-treated PSGL-1 retained the ability to bind to P-selectin, suggesting that some of the oligosaccharides recognized by P-selectin were either on enzyme-resistant poly-N-acetyllactosamine or on chains which lack poly-N-acetyllactosamine. PNGaseF treatment did not affect the ability of PSGL-1 to bind to P-selectin, demonstrating that the oligosaccharides required for P-selectin recognition are O-linked. PSGL-1 also bound to E-selectin, but with at least 50-fold lower affinity than to P-selectin. These data suggest that PSGL-1 from human neutrophils displays complex, sialylated, and fucosylated O-linked poly-N-acetyllactosamine that promote high affinity binding to P-selectin, but not to E-selectin.	UNIV OKLAHOMA,HLTH SCI CTR,DEPT BIOCHEM,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA,HLTH SCI CTR,WK WARREN MED RES INST,OKLAHOMA CITY,OK 73104; OKLAHOMA MED RES FDN,CARDIOVASC BIOL RES PROGRAM,OKLAHOMA CITY,OK 73104; UNIV NEW HAMPSHIRE,DEPT BIOCHEM,DURHAM,NH 03824; AMGEN INC,THOUSAND OAKS,CA 91320	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; Oklahoma Medical Research Foundation; University System Of New Hampshire; University of New Hampshire; Amgen	MOORE, KL (corresponding author), UNIV OKLAHOMA,HLTH SCI CTR,DEPT MED,825 NE 13TH ST,OKLAHOMA CITY,OK 73104, USA.				NATIONAL CANCER INSTITUTE [R01CA037626] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045510] Funding Source: NIH RePORTER; NCI NIH HHS [CA 37626] Funding Source: Medline; NHLBI NIH HHS [HL 45510] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600; BERG EL, 1993, NATURE, V366, P695, DOI 10.1038/366695a0; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; BOURDREL L, 1993, PROTEIN EXPRES PURIF, V4, P130, DOI 10.1006/prep.1993.1019; CUMMINGS RD, 1994, METHOD ENZYMOL, V230, P66; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; FUKUDA M, 1986, J BIOL CHEM, V261, P2796; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; HANISCH FG, 1989, J BIOL CHEM, V264, P872; JOHNSON ML, 1985, METHOD ENZYMOL, V117, P301; KOZAK M, 1981, NUCLEIC ACIDS RES, V9, P5233, DOI 10.1093/nar/9.20.5233; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN GR, 1992, J BIOL CHEM, V267, P11104; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; Laue T. M, 1981, THESIS U CONNECTICUT; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LENTER M, 1994, J CELL BIOL, V125, P471, DOI 10.1083/jcb.125.2.471; LEVINOVITZ A, 1993, J CELL BIOL, V121, P449, DOI 10.1083/jcb.121.2.449; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MAEMURA K, 1992, J BIOL CHEM, V267, P24379; MCEVER RP, 1994, CURR OPIN IMMUNOL, V6, P75, DOI 10.1016/0952-7915(94)90037-X; MCEVER RP, 1984, J BIOL CHEM, V259, P9799; MERKLE RK, 1987, J BIOL CHEM, V262, P8179; MOORE KL, 1991, J CELL BIOL, V112, P491, DOI 10.1083/jcb.112.3.491; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; MULLIGAN MS, 1991, J CLIN INVEST, V88, P1396, DOI 10.1172/JCI115446; NELSON RM, 1993, J CLIN INVEST, V91, P1157, DOI 10.1172/JCI116275; NORGARD KE, 1993, J BIOL CHEM, V268, P12764; NORGARDSUMNICHT KE, 1993, SCIENCE, V261, P480, DOI 10.1126/science.7687382; OGATA S, 1975, J BIOCHEM, V78, P687, DOI 10.1093/oxfordjournals.jbchem.a130956; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SANO M, 1992, J BIOL CHEM, V267, P1522; SASAKI K, 1994, J BIOL CHEM, V269, P14730; SCUDDER P, 1984, J BIOL CHEM, V259, P6586; SCUDDER P, 1983, BIOCHEM J, V213, P485, DOI 10.1042/bj2130485; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SPOONCER E, 1984, J BIOL CHEM, V259, P4792; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; STEININGER CN, 1992, BIOCHEM BIOPH RES CO, V188, P760, DOI 10.1016/0006-291X(92)91121-6; TURNER AM, 1992, BLOOD, V80, P374; UMEMOTO J, 1977, J BIOL CHEM, V252, P8609; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216; USHIYAMA S, 1993, J BIOL CHEM, V268, P15229; VARKI A, 1992, Current Opinion in Cell Biology, V4, P257, DOI 10.1016/0955-0674(92)90041-A; WALCHECK B, 1993, J EXP MED, V178, P853, DOI 10.1084/jem.178.3.853; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; YPHANTIS DA, 1964, BIOCHEMISTRY-US, V3, P297, DOI 10.1021/bi00891a003; ZHOU Q, 1991, J CELL BIOL, V115, P557, DOI 10.1083/jcb.115.2.557; ZIMMERMAN GA, 1985, J CLIN INVEST, V76, P2235, DOI 10.1172/JCI112232	55	258	271	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					23318	23327						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	7521878				2022-12-27	WOS:A1994PQ16400064
J	WOLF, A; SHAW, EW; NIKAIDO, K; AMES, GFL				WOLF, A; SHAW, EW; NIKAIDO, K; AMES, GFL			THE HISTIDINE-BINDING PROTEIN UNDERGOES CONFORMATIONAL-CHANGES IN THE ABSENCE OF LIGAND AS ANALYZED WITH CONFORMATION-SPECIFIC MONOCLONAL-ANTIBODIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY STRUCTURE; SALMONELLA-TYPHIMURIUM; ACTIVE-TRANSPORT; PERIPLASMIC TRANSPORT; ESCHERICHIA-COLI; RHODOBACTER-CAPSULATUS; RESOLUTION STRUCTURE; ARGININE-BINDING; LYSINE-BINDING; RECEPTOR	The periplasmic histidine-binding protein, HisJ, and the lysine-, arginine-, ornithine-binding protein (LAO) are receptors for histidine transport via the histidine permease of Salmonella typhimurium. The receptors have similar structures, being composed of two lobes held together by two peptide segments, with the ligand-binding site located in a cleft between the lobes. The two lobes are far apart in the unliganded structure (open conformation) and are drawn close together in the liganded structure (closed conformation). The tight binding of the ligand via protein side chains as well as the peptide backbone from both lobes stabilizes the closed conformation (Oh, B.-H., Pandit, J., Kang, C.-H., Nikaido, K., Gokcen, S., Ames, G. F.-L., and Kim, S.-H. (1993) J. Biol. Chem. 268, 11348-11353; Oh, B.-H., hang C.-H., De Bondt, H., Kim, S.-H., Nikaido, K., Joshi, A., and Ames, G. F.-L. (1994) J. Biol. Chem. 269, 4135-4143). In this study two conformation-specific monoclonal antibodies (mAbs) that trap the protein in the closed empty form have been characterized and used to provide evidence that HisJ can assume the closed empty form in the absence of ligand. Several pieces of evidence were provided to demonstrate that these mAbs are specific for HisJ in the closed form. Histidine improves the interaction of these mAbs with immobilized HisJ. The mAbs inhibit both the exchange and the dissociation of histidine from HisJ, indicating that they are able to trap the protein in the closed liganded form. The characterization of the epitopes of the conformation-specific mAbs shows that they include residues that are located in both lobes and that are far apart in the open form but close to each other in the closed form, so that the mAbs must be sensitive to their spatial orientation. Two mAbs that are not conformation-specific according to these criteria were also identified.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,DIV BIOCHEM & MOLEC BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley					NIDDK NIH HHS [DK12121] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK012121, R01DK012121] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMES BN, 1952, J AM CHEM SOC, V74, P252; AMES GF, 1989, J BIOL CHEM, V264, P3998; AMES GFL, 1986, ANNU REV BIOCHEM, V55, P397, DOI 10.1146/annurev.biochem.55.1.397; ANDERSON BF, 1990, NATURE, V344, P784, DOI 10.1038/344784a0; BENNETT WS, 1984, CRIT REV BIOCH, V15, P290; BISHOP L, 1989, P NATL ACAD SCI USA, V86, P6953, DOI 10.1073/pnas.86.18.6953; CARREY EA, 1990, PROTEIN STRUCTURE PR, P117; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; FLOCCO MM, 1994, J BIOL CHEM, V269, P8931; FRIGUET B, 1990, IMMUNOCHEMICAL ANAL, P287; GILLILAND GL, 1981, J MOL BIOL, V146, P341, DOI 10.1016/0022-2836(81)90392-2; GOLDBERG ME, 1991, TRENDS BIOCHEM SCI, V16, P358, DOI 10.1016/0968-0004(91)90148-O; HIGGINS CF, 1981, P NATL ACAD SCI-BIOL, V78, P6038, DOI 10.1073/pnas.78.10.6038; KANG CH, 1991, J BIOL CHEM, V266, P23893; KATCHALSKIKATZIR E, 1988, B CHEM SOC JPN, V61, P133, DOI 10.1246/bcsj.61.133; KERPPOLA RE, 1991, J BIOL CHEM, V266, P9857; LEVER JE, 1972, J BIOL CHEM, V247, P4317; LEVER JE, 1972, ANAL BIOCHEM, V50, P73, DOI 10.1016/0003-2697(72)90487-3; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUCK LA, 1991, BIOCHEMISTRY-US, V30, P4248, DOI 10.1021/bi00231a021; MAO B, 1982, J BIOL CHEM, V257, P1131; MILLER DM, 1983, J BIOL CHEM, V258, P3665; MOWBRAY SL, 1992, J MOL BIOL, V225, P155, DOI 10.1016/0022-2836(92)91033-L; NIKAIDO K, 1992, J BIOL CHEM, V267, P20706; NOEL D, 1979, BIOCHEMISTRY-US, V18, P4159, DOI 10.1021/bi00586a017; OH BH, 1993, J BIOL CHEM, V268, P11348; OH BH, 1994, J BIOL CHEM, V269, P4135; PFLUGRATH JW, 1988, J MOL BIOL, V200, P163, DOI 10.1016/0022-2836(88)90341-5; PROSSNITZ E, 1988, J BIOL CHEM, V263, P17917; PROSSNITZ E, 1989, J BIOL CHEM, V265, P5006; PROSSNITZ E, 1989, THESIS U CALIFORNIA; QUIOCHO FA, 1990, PHILOS T R SOC B, V326, P341, DOI 10.1098/rstb.1990.0016; SACK JS, 1989, J MOL BIOL, V206, P171, DOI 10.1016/0022-2836(89)90531-7; SACK JS, 1989, J MOL BIOL, V206, P193, DOI 10.1016/0022-2836(89)90532-9; SHARFF AJ, 1992, BIOCHEMISTRY-US, V31, P10657, DOI 10.1021/bi00159a003; SHARMA S, 1991, P NATL ACAD SCI USA, V88, P4877, DOI 10.1073/pnas.88.11.4877; SPEISER DM, 1989, THESIS U CALIFORNIA; SPURLINO JC, 1991, J BIOL CHEM, V266, P5202; VYAS NK, 1988, SCIENCE, V242, P1290, DOI 10.1126/science.3057628; WALMSLEY AR, 1992, BIOCHEMISTRY-US, V31, P11175, DOI 10.1021/bi00160a031; WALMSLEY AR, 1992, J BIOL CHEM, V267, P8064; ZOU JY, 1993, J MOL BIOL, V233, P739, DOI 10.1006/jmbi.1993.1549	42	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					23051	23058						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	7521874				2022-12-27	WOS:A1994PQ16400026
J	GROUPP, ER; CRAWFORD, N; LOCKER, J				GROUPP, ER; CRAWFORD, N; LOCKER, J			CHARACTERIZATION OF THE DISTAL ALPHA-FETOPROTEIN ENHANCER, A STRONG, LONG-DISTANCE, LIVER-SPECIFIC ACTIVATOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR FACTOR-I; TISSUE-SPECIFIC EXPRESSION; DNA-BINDING SPECIFICITY; HEPATITIS-B VIRUS; TRANSCRIPTION FACTORS; ALPHA-1-FETOPROTEIN GENE; FUNCTIONAL-ANALYSIS; RESPONSE ELEMENT; ALBUMIN GENE; PROMOTER	High level expression of the alpha-fetoprotein (AFP) gene is controlled by three upstream enhancers which function even in hepatic cell lines that repress the AFP gene promoter. The most distal (''Complex 3,'' at -6 kilobases) is the strongest in HepG2 cells. We mapped the main activity of Complex 3 to a 170-base pair (BP) region from -6069 to -5900; progressive deletion of the 5'- and 3'-ends identified an 84-bp segment which accounted for 90% of enhancer activity. Expression studies, which combined the deleted Complex 3 with an AFP or tk promoter chloramphenicol acetyltransferase gene fusion, resolved five regions in the enhancer (Ia, Ib, II, III, and IV). Deletion of Regions Ia or II strongly reduced stimulation of the AFP promoter, while Regions Ia and Ib were essential for stimulation of the tk promoter. Footprinting indicated multiple binding sites in regions Ia, Ib, and II. Gel shift and oligonucleotide competition demonstrated that Regions Ia and II had high affinity HNF3- and C/EBP-binding sites, respectively, while additional unidentified factors bound throughout Regions I-III. Complex 3 is a powerful liver-specific transcriptional regulator and an important model of long distance gene activation.	UNIV PITTSBURGH, SCH MED, DEPT PATHOL, PITTSBURGH, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NCI NIH HHS [CA43909] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043909] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGRE P, 1989, SCIENCE, V246, P922, DOI 10.1126/science.2530632; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERNIER D, 1993, MOL CELL BIOL, V13, P1619, DOI 10.1128/MCB.13.3.1619; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; Buzard G, 1990, DNA Seq, V1, P33, DOI 10.3109/10425179009041345; CEREGHINI S, 1987, CELL, V50, P627, DOI 10.1016/0092-8674(87)90036-5; CHEVRETTE M, 1987, NUCLEIC ACIDS RES, V15, P1338, DOI 10.1093/nar/15.3.1338; CHILES TC, 1991, J IMMUNOL, V146, P1730; COSTA RH, 1988, MOL CELL BIOL, V8, P81, DOI 10.1128/MCB.8.1.81; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; COSTA RH, 1988, P NATL ACAD SCI USA, V85, P3840, DOI 10.1073/pnas.85.11.3840; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GODHOUT R, 1988, MOL CELL BIOL, V8, P1169; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HAMMER RE, 1987, SCIENCE, V235, P53, DOI 10.1126/science.2432657; HARRINGTON MA, 1988, P NATL ACAD SCI USA, V85, P2066, DOI 10.1073/pnas.85.7.2066; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; INGRAM RS, 1981, P NATL ACAD SCI-BIOL, V78, P4694, DOI 10.1073/pnas.78.8.4694; JACKSON DA, 1993, MOL CELL BIOL, V13, P2401, DOI 10.1128/MCB.13.4.2401; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; KAKKIS E, 1989, NATURE, V339, P718, DOI 10.1038/339718a0; KELLER AD, 1991, GENE DEV, V5, P868, DOI 10.1101/gad.5.5.868; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LIU JK, 1991, MOL CELL BIOL, V11, P773, DOI 10.1128/MCB.11.2.773; LOCKER J, 1993, TRANSCRIPTIONAL CONT, P321; MASTRANGELO IA, 1991, P NATL ACAD SCI USA, V88, P5670, DOI 10.1073/pnas.88.13.5670; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; Miller J. H, 1972, EXPT MOL GENETICS; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; NAKABAYASHI H, 1991, MOL CELL BIOL, V11, P5885, DOI 10.1128/MCB.11.12.5885; NEHLS MC, 1991, MOL CELL BIOL, V11, P4065, DOI 10.1128/MCB.11.8.4065; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; Sambrook J, 1989, MOL CLONING; SHAUL Y, 1987, EMBO J, V6, P1913, DOI 10.1002/j.1460-2075.1987.tb02451.x; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; SU W, 1991, GENE DEV, V5, P820, DOI 10.1101/gad.5.5.820; TAM SP, 1985, J BIOL CHEM, V260, P1670; TIAN JM, 1991, GENE DEV, V5, P2225, DOI 10.1101/gad.5.12a.2225; TILGHMAN SM, 1982, P NATL ACAD SCI-BIOL, V79, P5254, DOI 10.1073/pnas.79.17.5254; TREISMAN R, 1987, EMBO J, V6, P2711, DOI 10.1002/j.1460-2075.1987.tb02564.x; TRONCHE F, 1990, MOL BIOL MED, V7, P173; TRUJILLO MA, 1991, P NATL ACAD SCI USA, V88, P3797, DOI 10.1073/pnas.88.9.3797; VACHER J, 1990, SCIENCE, V250, P1732, DOI 10.1126/science.1702902; WANG WD, 1991, MOL CELL BIOL, V11, P4561, DOI 10.1128/MCB.11.9.4561; WEN P, 1993, NUCLEIC ACIDS RES, V21, P1911, DOI 10.1093/nar/21.8.1911; WEN P, 1991, DNA CELL BIOL, V10, P525, DOI 10.1089/dna.1991.10.525; XANTHOPOULOS KG, 1991, P NATL ACAD SCI USA, V88, P3807, DOI 10.1073/pnas.88.9.3807; ZARET KS, 1990, P NATL ACAD SCI USA, V87, P5469, DOI 10.1073/pnas.87.14.5469; ZHANG DE, 1990, J BIOL CHEM, V265, P3382	56	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22178	22187						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	7520913				2022-12-27	WOS:A1994PE09800041
J	ADEMA, GJ; DEBOER, AJ; VOGEL, AM; LOENEN, WAM; FIGDOR, CG				ADEMA, GJ; DEBOER, AJ; VOGEL, AM; LOENEN, WAM; FIGDOR, CG			MOLECULAR CHARACTERIZATION OF THE MELANOCYTE LINEAGE-SPECIFIC ANTIGEN GP100	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINASE-RELATED PROTEIN; PRE-MESSENGER-RNA; MONOCLONAL-ANTIBODY; GENE; EXPRESSION; SEQUENCE; CDNA; LYMPHOCYTES; LOCUS; PIGMENTATION	The glycoproteins recognized by monoclonal antibody (mAb) NKI-beteb are among the best diagnostic markers for human melanoma because their expression is restricted to melanocytic cells. Recently, we isolated a cDNA clone, termed gp100-c1, which confers immunoreactivity not only to mAb NKI-beteb, but also to two other mAbs used to diagnose malignant melanoma, HMB-50 and HRIB-45. In this report, we demonstrate that gp100-c1 cDNA encodes glycoproteins of 100 kDa (gp100) and 10 kDa (gp10) which are recognized by these mAbs in human melanoma cells. The translation product deduced from the open reading frame present in gp100-c1 cDNA is highly homologous to another melanocyte-specific protein, Pmel17. Nucleotide sequence analysis of genomic DNA indicates that the transcripts corresponding to gp100 and Pmel17 cDNAs originate from a single gene via alternative splicing. In all normal and malignant melanocytic cells analyzed, gp100 and Pmel17 RNAs are simultaneously expressed.	NETHERLANDS CANC INST, DIV IMMUNOL, 1066 CX AMSTERDAM, NETHERLANDS; ST LOUIS UNIV, DEPT PATHOL, ST LOUIS, MO 63104 USA	Netherlands Cancer Institute; Saint Louis University			Figdor, Carl G/A-4232-2010; Adema, G.J./H-8007-2014	Figdor, Carl G/0000-0002-2366-9212; 				ADEMA GJ, 1993, AM J PATHOL, V143, P1579; ADEMA GJ, 1991, BIOCHEM BIOPH RES CO, V178, P985, DOI 10.1016/0006-291X(91)90989-K; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANICHINI A, 1993, J EXP MED, V177, P989, DOI 10.1084/jem.177.4.989; BAKKER ABH, 1994, J EXP MED, V179, P1005, DOI 10.1084/jem.179.3.1005; BRICHARD V, 1993, J EXP MED, V178, P489, DOI 10.1084/jem.178.2.489; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EISINGER M, 1982, P NATL ACAD SCI-BIOL, V79, P2018, DOI 10.1073/pnas.79.6.2018; ESCLAMADO RM, 1986, AM J SURG, V152, P376, DOI 10.1016/0002-9610(86)90308-9; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GOWN AM, 1986, AM J PATHOL, V123, P195; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; HEARING VJ, 1991, FASEB J, V5, P2902, DOI 10.1096/fasebj.5.14.1752358; JACKSON IJ, 1992, EMBO J, V11, P527, DOI 10.1002/j.1460-2075.1992.tb05083.x; KAPUR RP, 1992, J HISTOCHEM CYTOCHEM, V40, P207, DOI 10.1177/40.2.1552165; KIM RY, 1992, EXP EYE RES, V55, P657, DOI 10.1016/0014-4835(92)90170-W; KISHIMOTO TK, 1989, ADV IMMUNOL, V46, P149, DOI 10.1016/S0065-2776(08)60653-7; KNUTH A, 1992, CANCER SURV, V13, P39; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KSANDER BR, 1991, INVEST OPHTH VIS SCI, V32, P3198; KWON BS, 1991, P NATL ACAD SCI USA, V88, P9228, DOI 10.1073/pnas.88.20.9228; KWON BS, 1987, MOL BIOL MED, V4, P339; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MALLETT S, 1991, IMMUNOL TODAY, V12, P220, DOI 10.1016/0167-5699(91)90033-P; MATTES MJ, 1983, INT J CANCER, V32, P717, DOI 10.1002/ijc.2910320610; MOCHII M, 1991, PIGM CELL RES, V4, P41, DOI 10.1111/j.1600-0749.1991.tb00312.x; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; RUITER D J, 1990, Current Opinion in Oncology, V2, P377; RUSKIN B, 1984, CELL, V38, P317, DOI 10.1016/0092-8674(84)90553-1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIBAHARA S, 1986, NUCLEIC ACIDS RES, V14, P2413, DOI 10.1093/nar/14.6.2413; SMIT N, 1993, ARCH DERMATOL RES, V285, P356, DOI 10.1007/BF00371837; TSUKAMOTO K, 1992, EMBO J, V11, P519, DOI 10.1002/j.1460-2075.1992.tb05082.x; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; VENNEGOOR C, 1988, AM J PATHOL, V130, P179; VIJAYASARADHI S, 1990, J EXP MED, V171, P1375, DOI 10.1084/jem.171.4.1375; VOGEL AM, 1988, CANCER RES, V48, P1286; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683	42	161	176	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					20126	20133						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	7519602				2022-12-27	WOS:A1994PA12600070
J	KIRKEN, RA; RUI, H; MALABARBA, MG; FARRAR, WL				KIRKEN, RA; RUI, H; MALABARBA, MG; FARRAR, WL			IDENTIFICATION OF INTERLEUKIN-2 RECEPTOR-ASSOCIATED TYROSINE KINASE P116 AS NOVEL LEUKOCYTE-SPECIFIC JANUS KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE RECEPTOR; IL-2 RECEPTOR; GAMMA-CHAIN; FUNCTIONAL COMPONENT; BETA-SUBUNIT; SUPERFAMILY; JAK2; PHOSPHORYLATION; DOMAIN; FAMILY	Janus tyrosine kinase (JAK) has recently been linked to signal transduction by cytokine receptors of the hematopoietin family. We have recently described a 116-kDa tyrosine kinase (p116) present in interleukin-2 (IL-2) receptor complexes in human YT cells that showed functional characteristics of a JAK kinase. These included receptor association, rapid and transient tyrosine phosphorylation kinetics in response to ligand, and in vitro autophosphorylating tyrosine kinase activity (Kirken, R. A., Rui, H., Evans, G. A., and Farrar, W. L. (1993) J. Biol. Chem. 268, 22765-22770). Here we extend these observations by demonstrating structural homologies between IL-2-modulated p116 and prolactin-modulated JAK2 in the rat T cell line Nb2. These include similar net charge as determined by nonequilibrium pH gradient electrofocusing and related primary structure based upon phosphopeptide mapping of V8 protease-digested hyperphosphorylated proteins. This putative JAK kinase underwent marked tyrosine phosphorylation in response to IL-2, IL-4, and IL-7, lymphoid growth factors that use the common IL-2 receptor gamma-chain, but not in response to prolactin. Furthermore, polyclonal antisera to JAK1, JAK2, or tyrosine kinase 2 did not recognize either rat or human p116. However, we identified the IL-2-modulated p116 as the recently cloned novel leukocyte Janus kinase, L-JAK, using an antiserum to a peptide corresponding to the COOH terminus of human L-JAK.	NCI,FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES INC DYNCORP,BIOL CARCINOGENESIS & DEV PROGRAM,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	KIRKEN, RA (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,BIOL RESPONSE MODIFIERS PROGRAM,MOLEC IMMUNOREGULAT LAB,FREDERICK,MD 21702, USA.		Malabarba, Maria Grazia/L-4805-2015	Malabarba, Maria Grazia/0000-0002-9457-2047				ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COLOSI P, 1993, J BIOL CHEM, V268, P12617; COSMAN D, 1993, CYTOKINE, V5, P95, DOI 10.1016/1043-4666(93)90047-9; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FARRAR WL, 1989, J BIOL CHEM, V264, P12562; FERRIS DK, 1989, LYMPHOKINE RES, V8, P215; FOXWELL BMJ, 1992, CLIN EXP IMMUNOL, V90, P61; GRIMM EA, 1982, J EXP MED, V155, P1823, DOI 10.1084/jem.155.6.1823; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HENNEY CS, 1981, NATURE, V291, P335, DOI 10.1038/291335a0; JUNG LKL, 1984, J EXP MED, V160, P1597, DOI 10.1084/jem.160.5.1597; KAWAMURA M, 1994, IN PRESS P NATL ACAD; KIRKEN RA, 1993, J BIOL CHEM, V268, P22765; Kirken Robert A., 1994, Progress in Growth Factor Research, V5, P195, DOI 10.1016/0955-2235(94)90005-1; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; LINNEKIN D, 1992, J BIOL CHEM, V267, P23993; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; ONEAL KD, 1993, LYMPHOKINE CYTOK RES, V12, P309; RAYHEL EJ, 1988, BIOCHEM J, V249, P333, DOI 10.1042/bj2490333; RUI H, 1994, J BIOL CHEM, V269, P5364; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; TAKAHASHI T, 1994, FEBS LETT, V342, P124, DOI 10.1016/0014-5793(94)80485-0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L	32	65	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					19136	19141						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	7518451				2022-12-27	WOS:A1994NX32700066
J	HOWELL, S; LANCTOT, C; BOILEAU, G; CRINE, P				HOWELL, S; LANCTOT, C; BOILEAU, G; CRINE, P			A CLEAVABLE N-TERMINAL SIGNAL PEPTIDE IS NOT A PREREQUISITE FOR THE BIOSYNTHESIS OF GLYCOSYLPHOSPHATIDYLINOSITOL-ANCHORED PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GLYCOPHOSPHOLIPID MEMBRANE ANCHOR; ENDOPEPTIDASE 24.11 ENKEPHALINASE; KIDNEY BRUSH-BORDER; NEUTRAL ENDOPEPTIDASE; CELLS; ATTACHMENT; EXPRESSION; SECRETION; DOMAINS; DNA	During the biosynthesis of glycosylphosphatidylinositol (GPI)-anchored proteins, an N-terminal signal peptide is used to direct biosynthesis to the endoplasmic reticulum. It was previously unknown whether or not this signal must be removed during the biosynthesis of GPI-anchored proteins. Using neutral endopeptidase (EC 3.4.24.11), a well characterized type II membrane protein that is attached to the membrane via an uncleaved N-terminal signal peptide, we extended its C terminus with 33 of the 37 amino acids of the GPI anchor signal sequence of decay-accelerating factor. When expressed in COS-1 and Chinese hamster fibroblast (CHW) cells, the protein was shown to possess both transmembrane and GPI anchors, indicating that a cleavable N-terminal signal peptide is not a prerequisite for the biosynthesis of GPI-anchored proteins.	UNIV MONTREAL,FAC MED,DEPT BIOCHIM,MONTREAL H3C 3J7,PQ,CANADA	Universite de Montreal				Lanctot, Christian/0000-0003-3211-3061				AUBRY M, 1988, BIOCHIM BIOPHYS ACTA, V967, P56, DOI 10.1016/0304-4165(88)90188-2; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; CARAS IW, 1991, J CELL BIOL, V113, P77, DOI 10.1083/jcb.113.1.77; CARAS IW, 1989, SCIENCE, V243, P1196, DOI 10.1126/science.2466338; CORBEIL D, 1992, J BIOL CHEM, V267, P2798; CRINE P, 1985, BIOCHEM BIOPH RES CO, V131, P255, DOI 10.1016/0006-291X(85)91796-6; DEVAULT A, 1987, EMBO J, V6, P1317, DOI 10.1002/j.1460-2075.1987.tb02370.x; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; FERGUSON MAJ, 1992, BIOCHEM SOC T, V20, P243, DOI 10.1042/bst0200243; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HOOPER NM, 1988, BIOCHEM J, V250, P865, DOI 10.1042/bj2500865; HOOPER NM, 1990, MOL CELL BIOL MEMBRA, P129; HOWELL S, 1993, FEBS LETT, V317, P109, DOI 10.1016/0014-5793(93)81502-Q; HOWELL S, 1994, BIOCHEM J, V299, P171, DOI 10.1042/bj2990171; KERR MA, 1974, BIOCHEM J, V137, P477, DOI 10.1042/bj1370477; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LOW MG, 1989, BIOCHIM BIOPHYS ACTA, V988, P427, DOI 10.1016/0304-4157(89)90014-2; Maniatis T., 1982, MOL CLONING; MATTER K, 1991, BIOCHEMISTRY-US, V30, P1916, DOI 10.1021/bi00221a026; SARGIACOMO M, 1989, J MEMBRANE BIOL, V107, P277, DOI 10.1007/BF01871942; TARTAKOFF AM, 1992, TRENDS BIOCHEM SCI, V17, P470, DOI 10.1016/0968-0004(92)90491-Q; TURNER AJ, 1990, MOL CELL BIOL MEMBRA	23	19	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 24	1994	269	25					16993	16996						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NT846	7516327				2022-12-27	WOS:A1994NT84600003
J	KUHNE, MR; ZHAO, ZH; ROWLES, J; LAVAN, BE; SHEN, SH; FISCHER, EH; LIENHARD, GE				KUHNE, MR; ZHAO, ZH; ROWLES, J; LAVAN, BE; SHEN, SH; FISCHER, EH; LIENHARD, GE			DEPHOSPHORYLATION OF INSULIN-RECEPTOR SUBSTRATE-1 BY THE TYROSINE PHOSPHATASE PTP2C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; GROWTH-FACTOR RECEPTOR; INTACT-CELLS; PROTEIN; PHOSPHORYLATION; BINDING; KINASE; PURIFICATION; ACTIVATION; EXPRESSION	The phosphotyrosine (Tyr(P)) form of insulin receptor substrate 1 (IRS-1) is a key component in insulin signaling. Our previous study revealed that Tyr(P) IRS-1 binds to the widely distributed tyrosine phosphatase PTP2C through the src homology 2 (SH2) domains of the latter. In the present study, we examined the activity of this enzyme and of a truncated form lacking the SH2 domains (Delta PTP2C) toward IRS-1 and also toward the cytoplasmic domain of the insulin receptor. Tyr(P) IRS-1 was prepared by phosphorylation of recombinant IRS-1 with recombinant cytoplasmic insulin receptor kinase (CIRK). PTP2C rapidly dephosphorylated Tyr(P) IRS-1; dephosphorylation by Delta PTP2C was approximately one-third as fast, Other substrates, including Tyr(P) CIRK, were not dephosphorylated as rapidly by PTP2C; moreover, Delta PTP2C was at least 10 times more active than PTP2C toward CIRK and other substrates. These results indicate that the binding of Tyr(P) residues on IRS-1 to the SH2 domain(s) of PTP2C enhances its activity toward IRS-1 and suggest that PTP2C is the phosphatase responsible for the dephosphorylation of IRS-1 in vivo. In addition, with the expectation that a PTP2C-resistant form of IRS-1 will be useful in investigations of IRS-1 function, we determined that IRS-1 can be thiophosphorylated with adenosine 5'-O-(3-thiotriphosphate) and CIRK and that this form of IRS-1 is resistant to PTP2C.	DARTMOUTH COLL, SCH MED, DEPT BIOCHEM, HANOVER, NH 03755 USA; UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA; NIDDKD, CLIN DIABET & NUTR SECT, PHOENIX, AZ 85016 USA; NATL RES COUNCIL CANADA, BIOTECHNOL RES INST, MONTREAL H4P 2R2, PQ, CANADA	Dartmouth College; University of Washington; University of Washington Seattle; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Research Council Canada					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042816, T32DK007508] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 07902, DK 42816, DK 07508] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; GIORGINO F, 1992, ENDOCRINOLOGY, V130, P1433, DOI 10.1210/en.130.3.1433; KELLER SR, 1991, J BIOL CHEM, V266, P12817; Keller Susanne R., 1994, Trends in Cell Biology, V4, P115, DOI 10.1016/0962-8924(94)90065-5; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LAMMERS R, 1993, J BIOL CHEM, V268, P22456; LAMPHERE L, 1992, ENDOCRINOLOGY, V131, P2196, DOI 10.1210/en.131.5.2196; LAMPHERE L, 1994, AM J PHYSIOL, V266, pE486, DOI 10.1152/ajpendo.1994.266.3.E486; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; SUN XJ, 1992, J BIOL CHEM, V267, P22662; TAVARE JM, 1991, J BIOL CHEM, V266, P1390; TAVARE JM, 1993, BIOCHIM BIOPHYS ACTA, V1178, P21, DOI 10.1016/0167-4889(93)90106-Y; TONKS NK, 1988, J BIOL CHEM, V263, P6722; VILLALBA M, 1989, P NATL ACAD SCI USA, V86, P7848, DOI 10.1073/pnas.86.20.7848; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; ZHAO ZZ, 1994, J BIOL CHEM, V269, P8780; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	23	71	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15833	15837						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	7515062				2022-12-27	WOS:A1994NP51300068
J	ORTEL, TL; QUINNALLEN, MA; KELLER, FG; PETERSON, JA; LAROCCA, D; KANE, WH				ORTEL, TL; QUINNALLEN, MA; KELLER, FG; PETERSON, JA; LAROCCA, D; KANE, WH			LOCALIZATION OF FUNCTIONALLY IMPORTANT EPITOPES WITHIN THE 2ND C-TYPE DOMAIN OF COAGULATION-FACTOR V USING RECOMBINANT CHIMERAS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FACTOR-VIII; MURINE MONOCLONAL-ANTIBODIES; BREAST-CARCINOMA CELLS; MILK FAT GLOBULE; PROCOAGULANT ACTIVITY; LIGHT-CHAIN; FACTOR-XA; PHOSPHATIDYLSERINE; THROMBIN; SURFACE	Coagulation factor V, an integral component of the prothrombinase complex, possesses two C-type domains at the carboxyl-terminal end of the molecule. Homologous C-type domains are present in factor WI as well as several non-coagulation proteins. Deletion of the second C-type domain of factor V results in the loss of procoagulant activity and the ability to bind phosphatidylserine. We now report the effect of substitution of all or a portion of the C2 domain of factor V with the corresponding regions of factor VIII or the human breast carcinoma protein BA46. Substitution of the entire domain with a heterologous C2 domain does not restore significant procoagulant activity, although smaller, exon-size substitutions do result in chimeras with partial activity (similar to 10% of factor Va). Using chimeras with partial substitutions, we determined that the amino-terminal region of the domain is involved in binding to phosphatidylserine. In contrast, the central region of the domain is not involved in phosphatidylserine binding, but an antibody binding at or near this site inhibits procoagulant activity, suggesting that this region is involved in a separate function. Lastly, the molecular basis for the light chain doublet, which is important in the expression of full procoagulant activity, is located within the carboxyl-terminal region of the C2 domain.	DUKE UNIV,MED CTR,DEPT MED,DIV HEMATOL ONCOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT PEDIAT,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT PATHOL,DURHAM,NC 27710; CANC RES FUND CONTRA COSTA,DEPT CANC RES,WALNUT CREEK,CA 94596	Duke University; Duke University; Duke University				Larocca, Dana/0000-0001-5863-9833	NCI NIH HHS [CA39932] Funding Source: Medline; NHLBI NIH HHS [HL43106] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039932] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043106] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANNAMALAI AE, 1987, BLOOD, V70, P139; ARAI M, 1989, J CLIN INVEST, V83, P1978, DOI 10.1172/JCI114107; COOTS MC, 1978, AM J HEMATOL, V4, P193, DOI 10.1002/ajh.2830040212; CRIPE LD, 1992, BIOCHEMISTRY-US, V31, P3777, DOI 10.1021/bi00130a007; CUNNINGHAM BC, 1989, SCIENCE, V243, P1330, DOI 10.1126/science.2466339; DAHLBACK B, 1980, J CLIN INVEST, V66, P583, DOI 10.1172/JCI109890; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; EATON DL, 1987, J BIOL CHEM, V262, P3285; ESMON CT, 1979, J BIOL CHEM, V254, P964; FOSTER PA, 1990, BLOOD, V75, P1999; GITSCHIER J, 1984, NATURE, V312, P326, DOI 10.1038/312326a0; GRIFFIN BD, 1986, THROMB HAEMOSTASIS, V55, P40; HARLOW E, 1988, ANTIBODIES LABORATOR; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; JOHNSON JD, 1993, P NATL ACAD SCI USA, V90, P5677, DOI 10.1073/pnas.90.12.5677; KANE WH, 1988, BLOOD, V71, P539; KANE WH, 1990, BIOCHEMISTRY-US, V29, P6762, DOI 10.1021/bi00481a003; KANE WH, 1981, J BIOL CHEM, V256, P1002; KISIEL W, 1979, J BIOL CHEM, V254, P2230; LAROCCA D, 1991, CANCER RES, V51, P4994; MANN KG, 1990, BLOOD, V76, P1; MONKOVIC DD, 1990, BIOCHEMISTRY-US, V29, P1118, DOI 10.1021/bi00457a004; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; ORTEL TL, 1992, J BIOL CHEM, V267, P4189; ORTEL TL, 1992, J CLIN INVEST, V90, P2340, DOI 10.1172/JCI116123; ORTEL TL, 1992, CIRCULATION, V86, P686; ORTEL TL, 1994, MOL BIOL THROMBOSIS; PETERSON JA, 1990, HYBRIDOMA, V9, P221, DOI 10.1089/hyb.1990.9.221; ROSING J, 1993, J BIOL CHEM, V268, P21130; SCANDELLA D, 1991, BLOOD S1, V78, P56; STUBBS JD, 1990, P NATL ACAD SCI USA, V87, P8417, DOI 10.1073/pnas.87.21.8417; TAKAGI S, 1991, NEURON, V7, P295, DOI 10.1016/0896-6273(91)90268-5; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; XUE JC, 1993, BIOCHEMISTRY-US, V32, P5917, DOI 10.1021/bi00073a026	34	58	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15898	15905						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	7515064				2022-12-27	WOS:A1994NP51300077
J	RUZZENE, M; JAMES, P; BRUNATI, AM; DONELLADEANA, A; PINNA, LA				RUZZENE, M; JAMES, P; BRUNATI, AM; DONELLADEANA, A; PINNA, LA			REGULATION OF C-FGR PROTEIN-KINASE BY C-SRC KINASE (CSK) AND BY POLYCATIONIC EFFECTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; GENE-PRODUCT; RAT SPLEEN; TPK-IIB; PP60C-SRC; PHOSPHORYLATION; PEPTIDES; POLYLYSINE; ONCOGENE; AUTOPHOSPHORYLATION	The protein tyrosine kinase expressed by the protooncogene c-fgr is phosphorylated and down-regulated in vitro by the c-Src kinase (CSK). CSK catalyzed phosphorylation affects Tyr-511 of c-Fgr, homologous to Tyr-527 of c-Src and it prevents the autophosphorylation normally occurring at c-Fgr Tyr-800, homologous to c-Src Tyr-416. Polylysine, histones H1 and H2A and other polycationic proteins on the other hand stimulate c-Fgr activity while promoting enhanced autophosphorylation of both Tyr-400 and Tyr-511. Once phosphorylated at Tyr-511 and down-regulated by CSK, c-Fgr is no more susceptible to polylysine stimulation. Previous autophosphorylation (at Tyr-400) reduces c-Fgr susceptibility to down-regulation by CSK, although Tyr-511 can be still phosphorylated by it. If a more exhaustive autophosphorylation (of both Tyr-4OO and Tyr-811) is performed in the presence of polylysine, c-Fgr becomes totally insensitive to CSK down-regulation. These data support the concept that down-regulation of c-Fgr by Tyr-511 phosphorylation is prevented if Tyr-400 is also phosphorylated and they are consistent with an outcompetition of phospho Tyr-511 from the Src homology 2 domain by phospho-Tyr-400, which, in c-Fgr, is surrounded by an amino acid sequence divergent from that of the other Src-related protein tyrosine kinases.	UNIV PADUA, DIPARTIMENTO CHIM BIOL, I-35121 PADUA, ITALY; CNR, CTR STUDIO FISIOL MITOCONDRIALE, I-35121 PADUA, ITALY; ETH ZENTRUM, PROT CHEM LAB, ZURICH, SWITZERLAND	University of Padua; Consiglio Nazionale delle Ricerche (CNR); ETH Zurich			Brunati, Anna Maria/I-8136-2018	Brunati, Anna Maria/0000-0002-3481-9503; Ruzzene, Maria/0000-0001-8712-8151				ABDELGHANY M, 1990, P NATL ACAD SCI USA, V87, P7061, DOI 10.1073/pnas.87.18.7061; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BRUNATI AM, 1988, EUR J BIOCHEM, V172, P451, DOI 10.1111/j.1432-1033.1988.tb13909.x; BRUNATI AM, 1992, FEBS LETT, V313, P291, DOI 10.1016/0014-5793(92)81212-5; BRUNATI AM, 1993, EUR J BIOCHEM, V216, P323, DOI 10.1111/j.1432-1033.1993.tb18149.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CHEAH MSC, 1986, NATURE, V319, P238, DOI 10.1038/319238a0; COLA C, 1989, BIOCHIM BIOPHYS ACTA, V1012, P191, DOI 10.1016/0167-4889(89)90095-5; COLLETT MS, 1978, P NATL ACAD SCI USA, V75, P2021, DOI 10.1073/pnas.75.4.2021; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; DONELLADEANA A, 1992, EUR J BIOCHEM, V204, P1159, DOI 10.1111/j.1432-1033.1992.tb16742.x; FUJITAYAMAGUCHI Y, 1989, P NATL ACAD SCI USA, V86, P7306, DOI 10.1073/pnas.86.19.7306; GATICA M, 1987, P NATL ACAD SCI USA, V84, P324, DOI 10.1073/pnas.84.2.324; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; KATAMINE S, 1988, MOL CELL BIOL, V8, P259, DOI 10.1128/MCB.8.1.259; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEY TJ, 1989, MOL CELL BIOL, V9, P92, DOI 10.1128/MCB.9.1.92; LUO KX, 1991, METHOD ENZYMOL, V201, P149; MACAULEY A, 1993, ONCOGENE, V8, P117; MARIN O, 1991, J BIOL CHEM, V266, P17798; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OKADA M, 1988, J BIOCHEM-TOKYO, V104, P297, DOI 10.1093/oxfordjournals.jbchem.a122461; OKADA M, 1989, J BIOL CHEM, V264, P20886; OKADA M, 1991, J BIOL CHEM, V266, P24249; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; SARNO S, 1993, BIOCHEM BIOPH RES CO, V194, P83, DOI 10.1006/bbrc.1993.1788; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; TURCK C W, 1991, Peptide Research, V4, P36; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	36	30	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15885	15891						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	7515063				2022-12-27	WOS:A1994NP51300075
J	DUBOIS, MF; NGUYEN, VT; BELLIER, S; BENSAUDE, O				DUBOIS, MF; NGUYEN, VT; BELLIER, S; BENSAUDE, O			INHIBITORS OF TRANSCRIPTION SUCH AS 5,6-DICHLORO-1-BETA-D-RIBOFURANOSYLBENZIMIDAZOLE AND ISOQUINOLINE SULFONAMIDE DERIVATIVES (H-8 AND H-7-ASTERISK) PROMOTE DEPHOSPHORYLATION OF THE CARBOXYL-TERMINAL DOMAIN OF RNA-POLYMERASE-II LARGEST SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; HEAT-SHOCK; MAMMALIAN-CELLS; CALF THYMUS; PHOSPHORYLATION; INITIATION; INVITRO; REPEAT; ELONGATION; EXPRESSION	The RNA polymerases IIO and IIA differ by the extent of phosphorylation in the carboxyl-terminal domain (CTD) of the largest subunit. It has been proposed that the IIA form of RNA polymerase II interacts with the promoter to form a stable preinitiation complex whereas the IIO form would be generated upon entry into initiation of transcription. Phosphorylation of the CTD might be required to release the interaction between the polymerase and the promoter binding factors. In this paper, we show that in the presence of actinomycin D, the phosphorylated IIO form accumulates. In contrast, the dephosphorylated IIA form accumulates while the amount of phosphorylated IIo form decreases in cells treated with CTD-kinase inhibitors such as the nucleoside analog, 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole or the isoquinoline sulfonamide derivatives H-7* or H-8. These changes are fast and suggest a very rapid phosphate turnover on the CTD. Transcription is inhibited in intact cells by drug concentrations that are effective in altering CTD phosphorylation, although no causal relationship is established yet. These effects do not concern other cellular functions such as protein synthesis, Thus isoquinoline sulfonamide derivatives might be helpful to further dissect the role of CTD phosphorylation in transcription.			DUBOIS, MF (corresponding author), ECOLE NORMALE SUPER, GENET MOLEC LAB, CNRS, URA 1302, 46 RUE ULM, F-75230 PARIS 05, FRANCE.			Bensaude, Olivier/0000-0002-0259-6608; Bellier, Sylvain/0000-0002-7590-4907				ALLISON LA, 1989, P NATL ACAD SCI USA, V86, P2794, DOI 10.1073/pnas.86.8.2794; CHODOSH LA, 1989, J BIOL CHEM, V264, P2250; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; CISEK LJ, 1991, METHOD ENZYMOL, V200, P301; CORDEN JL, 1993, CURR OPIN GENET DEV, V3, P213, DOI 10.1016/0959-437X(93)90025-K; CORDEN JL, 1990, TRENDS BIOCHEM SCI, V15, P383, DOI 10.1016/0968-0004(90)90236-5; DAHMUS ME, 1981, J BIOL CHEM, V256, P3332; DAHMUS ME, 1994, IN PRESS PROG NUCLEI; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DUBOIS MF, 1994, J CELL PHYSIOL, V158, P417, DOI 10.1002/jcp.1041580305; DUBOIS MF, 1991, CR ACAD SCI III-VIE, V313, P165; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FOECKING MK, 1986, GENE, V45, P101, DOI 10.1016/0378-1119(86)90137-X; FRASER NW, 1978, NATURE, V272, P590, DOI 10.1038/272590a0; GIARDINA C, 1993, J BIOL CHEM, V268, P23806; HIDAKA H, 1991, METHOD ENZYMOL, V201, P328; KELLY WG, 1993, J BIOL CHEM, V268, P10416; KIM WY, 1986, J BIOL CHEM, V261, P14219; KIM WY, 1988, J BIOL CHEM, V263, P18880; KOLESKE AJ, 1992, CELL, V69, P883, DOI 10.1016/0092-8674(92)90298-Q; KRAMER A, 1980, MOL GEN GENET, V180, P193, DOI 10.1007/BF00267369; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; LEE JM, 1991, GENE EXPRESSION, V1, P149; LEE JM, 1989, P NATL ACAD SCI USA, V86, P3624, DOI 10.1073/pnas.86.10.3624; LEGAGNEUX V, 1990, EUR J BIOCHEM, V193, P121, DOI 10.1111/j.1432-1033.1990.tb19312.x; LIAO SM, 1991, GENE DEV, V5, P2431, DOI 10.1101/gad.5.12b.2431; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; MEULIA T, 1993, MOL CELL BIOL, V13, P5647, DOI 10.1128/MCB.13.9.5647; MORIMOTO RI, 1992, J BIOL CHEM, V267, P21987; NGUYEN VT, 1988, ANAL BIOCHEM, V171, P404, DOI 10.1016/0003-2697(88)90505-2; NOVER L., 1991, HEAT SHOCK RESPONSE; PAYNE JM, 1989, J BIOL CHEM, V264, P19621; PAYNE JM, 1993, J BIOL CHEM, V268, P80; PERRY RP, 1970, J CELL PHYSIOL, V76, P127, DOI 10.1002/jcp.1040760202; PETERSON CL, 1991, CELL, V64, P1135, DOI 10.1016/0092-8674(91)90268-4; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SCAFE C, 1990, NATURE, V347, P491, DOI 10.1038/347491a0; SERIZAWA H, 1993, J BIOL CHEM, V268, P17300; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; SERIZAWA H, 1993, NATURE, V363, P371, DOI 10.1038/363371a0; SOBELL HM, 1985, P NATL ACAD SCI USA, V82, P5328, DOI 10.1073/pnas.82.16.5328; STEVENS A, 1989, BIOCHEM BIOPH RES CO, V159, P508, DOI 10.1016/0006-291X(89)90022-3; STONE N, 1992, J BIOL CHEM, V267, P6353; SUZUKI M, 1990, NATURE, V344, P562, DOI 10.1038/344562a0; TAMM I, 1976, J CELL BIOL, V69, P229, DOI 10.1083/jcb.69.2.229; THOMPSON NE, 1989, J BIOL CHEM, V264, P11511; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; WIBORG O, 1985, EMBO J, V4, P755, DOI 10.1002/j.1460-2075.1985.tb03693.x; WU B, 1985, MOL CELL BIOL, V5, P330, DOI 10.1128/MCB.5.2.330; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.biochem.60.1.689; ZANDOMENI R, 1984, J BIOL CHEM, V259, P4804; ZANDOMENI R, 1986, J BIOL CHEM, V261, P3414; ZANDOMENI R, 1983, J MOL BIOL, V167, P561, DOI 10.1016/S0022-2836(83)80098-9; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6; ZHANG J, 1991, J BIOL CHEM, V266, P2297	58	112	114	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13331	13336						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	7513701				2022-12-27	WOS:A1994NK18400044
J	TIMERMAN, AP; WIEDERRECHT, G; MARCY, A; FLEISCHER, S				TIMERMAN, AP; WIEDERRECHT, G; MARCY, A; FLEISCHER, S			CHARACTERIZATION OF AN EXCHANGE-REACTION BETWEEN SOLUBLE FKBP-12 AND THE FKBP RYANODINE RECEPTOR COMPLEX - MODULATION BY FKBP MUTANTS DEFICIENT IN PEPTIDYL-PROLYL ISOMERASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTIONAL TERMINAL CISTERNAE; MUSCLE SARCOPLASMIC-RETICULUM; CYTOSOLIC BINDING-PROTEIN; CALCIUM-RELEASE CHANNEL; RABBIT SKELETAL-MUSCLE; CYCLOSPORINE-A; IMMUNOSUPPRESSANT FK506; FK-506-BINDING PROTEIN; MOLECULAR-CLONING; CYCLOPHILIN	FKBP-12 (FKBP), the soluble receptor for the immunosuppresant drug FK-506, is tightly bound to the calcium release channel (CRC)/ryanodine receptor (RyR) of skeletal muscle terminal cisternae (TC) of sarcoplasmic reticulum with a stoichiometry of 4 mol of FKBP per tetrameric RyR complex. FKBP displays cis/trans-peptidyl-prolyl isomerase (PPIase) activity which is inhibited by FK-590 or rapamycin. In skeletal muscle TC, FK-590 or rapamycin binds to and dissociates FKBP from the RyR in a time- and temperature-dependent manner which increases the open probability of the channel. Therefore, the net energized Ca2+ uptake rate of TC vesicles devoid of FKBP is reduced due to the increased leak of Ca2+ from the TC specifically via the RyR, which is reversed upon rebinding of FKBP. Thus, the RyR is modulated by FKBP (Timerman, A. P., Ogunbumni, E., Freund, E. A., Wiederrecht, G., Marks, A. R., and Fleischer, S., (1993) J. Biol. Chem. 268, 22922-22999; Mayrleitner, M., Timerman, A. P., Wiederrecht, G., and Fleischer S. (1994) Cell Calcium 15, 99-108). We now find that FKBP can be displaced from the FKBP RyR complex by exchange with FKBP in solution. The EC(50) for exchange is 0.30 mu M for wild type FKBP versus 0.6 to 2.4 mu M for three different site-directed mutants that are practically devoid of any measurable PPIase activity. Substitution of wild-type FKBP on the RyR complex with these PPIase-deficient mutants did not alter the Ca2+ flux of TC vesicles, whereas dissociation of FKBP from TC with FK-590 increased the Ca2+ leak rate. Our studies show that, in vivo, the FKBP.RyR complex is in equilibrium with the cytosolic pool of FKBP (similar to 3 mu M) and suggest that modulation of the CRC by FKBP is independent of PPIase activity.	VANDERBILT UNIV, DEPT MOLEC BIOL, NASHVILLE, TN 37235 USA; MERCK & CO INC, MERCK SHARP & DOHME RES LABS, DEPT IMMUNOL, RAHWAY, NJ 07065 USA; MERCK & CO INC, MERCK SHARP & DOHME RES LABS, DEPT BIOPHYS CHEM, RAHWAY, NJ 07065 USA	Vanderbilt University; Merck & Company; Merck & Company					NHLBI NIH HHS [HL32711] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032711] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; CHU A, 1988, METHOD ENZYMOL, V157, P36; COLLINS JH, 1991, BIOCHEM BIOPH RES CO, V178, P1288, DOI 10.1016/0006-291X(91)91033-9; CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; Eisenberg B. R., 2010, COMPREHENSIVE PHYSL, P73; FLEISCHER S, 1985, P NATL ACAD SCI USA, V82, P7256, DOI 10.1073/pnas.82.21.7256; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; INUI M, 1987, J BIOL CHEM, V262, P1740; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; KUNZ J, 1993, TRENDS BIOCHEM SCI, V18, P334, DOI 10.1016/0968-0004(93)90069-Y; LIMBIRD LE, 1986, CELL SURFACE RECEPTO, P105; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACK MM, 1994, J BIOL CHEM, V269, P23236; MARKS AR, 1990, J BIOL CHEM, V265, P13143; MARKS AR, 1989, P NATL ACAD SCI USA, V86, P8683, DOI 10.1073/pnas.86.22.8683; MAYRLEITNER M, 1994, CELL CALCIUM, V15, P99, DOI 10.1016/0143-4160(94)90048-5; MCPHERSON PS, 1993, J BIOL CHEM, V268, P13765; SAITO A, 1989, Biophysical Journal, V55, p206A; SAITO A, 1984, J CELL BIOL, V99, P875, DOI 10.1083/jcb.99.3.875; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SEWELL TJ, 1994, J BIOL CHEM, V269, P21094; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TIMERMAN AP, 1993, J BIOL CHEM, V268, P22992; WAGENKNECHT T, 1989, NATURE, V338, P167, DOI 10.1038/338167a0; WANG TW, 1994, SCIENCE, V265, P674, DOI 10.1126/science.7518616; WIEDERRECHT G, 1992, J BIOL CHEM, V267, P21753; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	32	129	133	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2451	2459		10.1074/jbc.270.6.2451	http://dx.doi.org/10.1074/jbc.270.6.2451			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7531689	hybrid			2022-12-27	WOS:A1995QF53500011
J	SEIBERT, FS; TABCHARANI, JA; CHANG, XB; DULHANTY, AM; MATHEWS, C; HANRAHAN, JW; RIORDAN, JR				SEIBERT, FS; TABCHARANI, JA; CHANG, XB; DULHANTY, AM; MATHEWS, C; HANRAHAN, JW; RIORDAN, JR			CAMP-DEPENDENT PROTEIN KINASE-MEDIATED PHOSPHORYLATION OF CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR RESIDUE SER-753 AND ITS ROLE IN CHANNEL ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CFTR CHLORIDE CHANNEL; CL CHANNEL; R-DOMAIN; BINDING; PHOSPHATASES; DELTA-F508; MODULATION; SEQUENCES; GENE; SITE	Hormonal regulation of the cystic fibrosis transmembrane conductance regulator (CFTR) Cl- channel is largely mediated via cAMP-dependent protein kinase (PKA), CFTR contains 10 dibasic consensus sites for potential PKA phosphorylation ((R/K)(R/K)X(S*/T*)). Previous studies (Chang, X-B., Tabcharani, J. A., Hou, Y.-X., Jensen, T. J., Kartner, N., Alon, N., Hanrahan, J.W., and Riordan, J.R (1993) J. Biol. Chem. 268, 11304-11311) showed that approximately 25% of the CFTR wild-type response to PKA activation remained upon inhibition of most detectable phosphorylation by in vitro mutagenesis of all 10 dibasic consensus sites (10SA CFTR), To identify potential additional sites responsible for the residual activity, large amounts of this mutant CFTR were phosphorylated with PKA using high specific activity [gamma-P-32]ATP. Cyanogen bromide cleavage indicated that a large portion of the observed PKA phosphorylation occurred within a 5.8-kDa fragment of the R domain between residues 722-773. Removal of serines at potential PKA sites in this fragment showed that Ser-753 accounted for all of the gamma-P-32 labeling of the 5.8-kDa peptide. Replacement of Ser-753 with alanine reduced the level of residual CFTR activity by a further 40%, indicating that phosphorylation at this previously unidentified site contributes to the activation of 10SA CFTR.	MAYO CLIN SCOTTSDALE, SC JOHNSON MED RES CTR, SCOTTSDALE, AZ 85259 USA; HOSP SICK CHILDREN, RES INST, TORONTO, ON M5G 1X8, CANADA; UNIV TORONTO, TORONTO, ON M5G 1X8, CANADA; MCGILL UNIV, DEPT PHYSIOL, MONTREAL, PQ H3G 1Y6, CANADA	Mayo Clinic; Mayo Clinic Phoenix; SC Johnson & Son; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; McGill University			Hanrahan, John/AGG-1926-2022	Hanrahan, John/0000-0001-9080-2039				ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; BAUKROWITZ T, 1994, NEURON, V12, P473, DOI 10.1016/0896-6273(94)90206-2; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BECQ F, 1994, IN PRESS P NATL ACAD; BELL CL, 1993, AM J PHYSIOL, V264, pC925, DOI 10.1152/ajpcell.1993.264.4.C925; BERGER HA, 1993, J BIOL CHEM, V268, P2037; CHANG XB, 1993, J BIOL CHEM, V268, P11304; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; DULHANTY AM, 1994, BIOCHEMISTRY-US, V33, P4072, DOI 10.1021/bi00179a036; GUNDERSON KL, 1994, J BIOL CHEM, V269, P19349; HANRAHAN JW, 1994, ADV COMP ENV PHYSL, V19, P193; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HWANG TC, 1994, P NATL ACAD SCI USA, V91, P4698, DOI 10.1073/pnas.91.11.4698; KARTNER N, 1992, NAT GENET, V1, P321, DOI 10.1038/ng0892-321; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; LIEBERMAN DN, 1994, NATURE, V369, P235, DOI 10.1038/369235a0; NUMANN R, 1991, SCIENCE, V254, P115, DOI 10.1126/science.1656525; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; QUINTON PM, 1992, NATURE, V360, P79, DOI 10.1038/360079a0; RAYMOND LA, 1993, TRENDS NEUROSCI, V16, P147, DOI 10.1016/0166-2236(93)90123-4; RICH DP, 1993, J BIOL CHEM, V268, P20259; Riordan J. R., 1993, CYSTIC FIBROSIS CURR, VI, P157; RIORDAN JR, 1989, SCIENCE, V245, P1066; RIORDAN JR, 1994, IN PRESS J EXP BIOL; RIORDAN JR, 1992, CURRENT OPINION NEPH, P34; SMIT LS, 1993, P NATL ACAD SCI USA, V90, P9963, DOI 10.1073/pnas.90.21.9963; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALAAS SI, 1991, PHARMACOL REV, V43, P299; WELSH MJ, 1992, NEURON, V8, P821, DOI 10.1016/0896-6273(92)90196-K; WEST JW, 1991, SCIENCE, V254, P866, DOI 10.1126/science.1658937	34	77	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	1995	270	5					2158	2162		10.1074/jbc.270.5.2158	http://dx.doi.org/10.1074/jbc.270.5.2158			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QE493	7530719	hybrid			2022-12-27	WOS:A1995QE49300029
J	CAMPOS, KL; GIOVANELLI, J; KAUFMAN, S				CAMPOS, KL; GIOVANELLI, J; KAUFMAN, S			CHARACTERISTICS OF THE NITRIC-OXIDE SYNTHASE-CATALYZED CONVERSION OF ARGININE TO N-HYDROXYARGININE, THE FIRST OXYGENATION STEP IN THE ENZYMATIC-SYNTHESIS OF NITRIC-OXIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROXY-L-ARGININE; BRAIN; HEME; INTERMEDIATE; OXIDATION; REDUCTION; CYTOCHROME-P-450; BIOSYNTHESIS; HEMOPROTEIN; COFACTOR	The nitric oxide synthase-catalyzed conversion of L-arginine to L-citrulline and nitric oxide is known to be the sum of two partial reactions: oxygenation of arginine to N-hydroxyarginine, followed by oxygenation of N-hydroxyarginine to citrulline and nitric oxide, Whereas the conversion of N-hydroxyarginine to citrulline and nitric oxide has been the subject of a number of studies, the oxygenation of arginine to N-hydroxyarginine has received little attention, Here we show that substrate amounts of rat cerebellar nitric oxide synthase, in the absence of added NADPH, catalyze the conversion of arginine to N-hydroxyarginine as the dominant product, The product appears not to be tightly bound to the enzyme. A maximum of 0.16 mol of N-hydroxyarginine/mol of nitric oxide synthase subunit was formed. The reaction requires oxygen and the addition of Ca2+/calmodulin and is stimulated 3-fold by tetrahydrobiopterin. Upon addition of NADPH, citrulline is formed exclusively, Conversion of N-hydroxyarginine to citrulline, like the first partial reaction, requires Ca2+/calmodulin and is stimulated by tetrahydrobiopterin but differs from the first partial reaction in being completely dependent upon addition of NADPH, These results indicate that brain nitric oxide synthase contains an endogenous reductant that can support oxygenation of arginine but not of N-hydroxyarginine, The reductant is not NADPH, since the amount of nitric oxide synthase-bound NADPH is appreciably less than the amount required for N-hydroxyarginine synthesis. Possible candidates for this role are discussed in relation to proposed mechanisms of action of nitric oxide synthase.	NIMH, NEUROCHEM LAB, BETHESDA, MD 20895 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)								ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; ARCHER MC, 1972, CAN J BIOCHEM CELL B, V50, P1174, DOI 10.1139/o72-160; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; CHENAIS B, 1993, BIOCHEM BIOPH RES CO, V196, P1558, DOI 10.1006/bbrc.1993.2429; CHENAIS B, 1991, J CHROMATOGR, V539, P433, DOI 10.1016/S0021-9673(01)83952-2; DAWSON JH, 1988, SCIENCE, V240, P433, DOI 10.1126/science.3358128; ESTABROOK RW, 1970, ANN NY ACAD SCI, V174, P218, DOI 10.1111/j.1749-6632.1970.tb49788.x; GIOVANELLI J, 1991, P NATL ACAD SCI USA, V88, P7091, DOI 10.1073/pnas.88.16.7091; GUENGERICH FP, 1984, ACCOUNTS CHEM RES, V17, P9, DOI 10.1021/ar00097a002; Gunsalus I C, 1972, Biochem Soc Symp, V34, P135; HEINZEL B, 1992, BIOCHEM J, V281, P627, DOI 10.1042/bj2810627; KLATT P, 1993, J BIOL CHEM, V268, P14781; KLATT P, 1992, BIOCHEM J, V288, P15, DOI 10.1042/bj2880015; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; KRAAK JC, 1977, J CHROMATOGR, V142, P671, DOI 10.1016/S0021-9673(01)92076-X; Lai C Y, 1977, Methods Enzymol, V47, P236; LOWRY OH, 1961, J BIOL CHEM, V236, P2746; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; MASTERS BSS, 1994, ANNU REV NUTR, V14, P131, DOI 10.1146/annurev.nu.14.070194.001023; MATSCHINSKY FM, 1968, J NEUROCHEM, V15, P643, DOI 10.1111/j.1471-4159.1968.tb08963.x; MATSUOKA A, 1994, J BIOL CHEM, V269, P20335; MAYUZUMI H, 1994, ARCH BIOCHEM BIOPHYS, V310, P367, DOI 10.1006/abbi.1994.1180; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MCMILLAN K, 1993, BIOCHEMISTRY-US, V32, P9875, DOI 10.1021/bi00089a001; OPRIAN DD, 1979, J BIOL CHEM, V254, P8895; PIERRE J, 1982, EUR J BIOCHEM, V124, P533; PUFAHL RA, 1993, BIOCHEM BIOPH RES CO, V193, P963, DOI 10.1006/bbrc.1993.1719; PUFAHL RA, 1992, BIOCHEMISTRY-US, V31, P6822, DOI 10.1021/bi00144a024; PUFAHL RA, 1994, FASEB J, V8, pA1382; SALET C, 1981, PHOTOCHEM PHOTOBIOL, V33, P753, DOI 10.1111/j.1751-1097.1981.tb05485.x; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; STUEHR DJ, 1992, ADV ENZYMOL RELAT AR, V65, P287; VERMILION JL, 1981, J BIOL CHEM, V256, P266; WANG JL, 1993, J BIOL CHEM, V268, P22255; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001	36	40	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	1995	270	4					1721	1728		10.1074/jbc.270.4.1721	http://dx.doi.org/10.1074/jbc.270.4.1721			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QD204	7530247	hybrid			2022-12-27	WOS:A1995QD20400039
J	ABUSOUD, HM; FELDMAN, PL; CLARK, P; STUEHR, DJ				ABUSOUD, HM; FELDMAN, PL; CLARK, P; STUEHR, DJ			ELECTRON-TRANSFER IN THE NITRIC-OXIDE SYNTHASES - CHARACTERIZATION OF L-ARGININE ANALOGS THAT BLOCK HEME IRON REDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYL-L-ARGININE; PERITONEAL-MACROPHAGES; MOLECULAR-CLONING; BRAIN; CALMODULIN; ENZYME; FLAVOPROTEIN; INHIBITION; MECHANISM; COMPLEXES	Heme iron reduction in the nitric-oxide syntheses (NOSs) requires calmodulin binding and is associated with increased NO synthesis and NADPH oxidation (Abu-Soud, H. M., and Stuehr, D. J. (1993) Proc. Natl. Acad. Sci., U. S. A. 90, 10769-10772). Here, we examined how L-arginine and the analogs N-w-methyl-L-arginine (NMA), N-w-nitro-L-arginine methyl ester (NAME), and d-(thioureido)-L-norvaline (thiocitrulline) affect electron flux through neuronal and macrophage NOS. L-Arginine and NMA increased or decreased NOS NADPH consumption depending on the isoform, while thiocitrulline and NAME decreased NADPH oxidation in both NOS by 73-86% relative to their ligand-free rates. Kinetic studies showed that thiocitrulline and NAME inhibited NOS NADPH consumption through binding within the substrate binding site. Thiocitrulline and NAME did not affect the NADPH-dependent reduction of NOS flavins nor NOS cytochrome c reduction, indicating that they blocked electron flux at a point beyond the flavins in the electron transfer sequence. Thiocitrulline and NAME inhibited both NADPH-dependent and dithionite-mediated heme iron reduction in the NOS isoforms relative to the substrate-free NOS, whereas L-arginine and NMA did not. Thus, L-arginine and NMA increase or decrease electron flux through the NOS by coupling NADPH oxidation to NO synthesis (L-arginine), or by occupying the substrate binding site with minimal catalytic coupling (NMA). In contrast, thiocitrulline and NAME decrease electron nux through both NOS isoforms by decreasing the reduction potential of the heme iron. Inhibition of heme iron reduction by substrate analogs is unusual and represents a new means to modulate electron now through the NOS.	CLEVELAND CLIN, DEPT IMMUNOL, CLEVELAND, OH 44195 USA; CASE WESTERN RESERVE UNIV, DEPT PHYSIOL & BIOPHYS, CLEVELAND, OH 44106 USA; GLAXO INC, RES INST, DEPT CHEM, RES TRIANGLE PK, NC 27709 USA	Cleveland Clinic Foundation; Case Western Reserve University; GlaxoSmithKline					NCI NIH HHS [CA53914] Funding Source: Medline; NIGMS NIH HHS [GM51491] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053914, R29CA053914] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051491] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; BREDT DS, 1992, J BIOL CHEM, V267, P10976; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; DAWSON JH, 1983, J BIOL CHEM, V258, P3637; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; DENG WL, 1993, J IMMUNOL, V151, P322; DING AH, 1988, J IMMUNOL, V141, P2407; FELDMAN PL, 1991, TETRAHEDRON LETT, V32, P875, DOI 10.1016/S0040-4039(00)92109-9; FISHER MT, 1985, J AM CHEM SOC, V107, P5018, DOI 10.1021/ja00303a045; GROSS SS, 1990, BIOCHEM BIOPH RES CO, V170, P96, DOI 10.1016/0006-291X(90)91245-N; HEINZEL B, 1992, BIOCHEM J, V281, P627, DOI 10.1042/bj2810627; HEVEL JM, 1992, BIOCHEMISTRY-US, V31, P7160, DOI 10.1021/bi00146a019; HINTZ MJ, 1980, J BIOL CHEM, V255, P7317; KELM M, 1988, BIOCHEM BIOPH RES CO, V154, P236, DOI 10.1016/0006-291X(88)90675-4; KLATT P, 1994, J BIOL CHEM, V269, P1674; KLATT P, 1993, J BIOL CHEM, V268, P14781; KLATT P, 1992, J BIOL CHEM, V267, P11374; KNOWLES RG, 1990, BIOCHEM J, V269, P207, DOI 10.1042/bj2690207; KWON NS, 1990, J BIOL CHEM, V265, P13442; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; LAMBERT LE, 1991, LIFE SCI, V48, P69, DOI 10.1016/0024-3205(91)90426-C; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MANSUY D, 1978, EUR J BIOCHEM, V86, P573, DOI 10.1111/j.1432-1033.1978.tb12341.x; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MATHEIS G, 1992, AM J PHYSIOL, V262, pH616, DOI 10.1152/ajpheart.1992.262.2.H616; MATSUOKA A, 1994, J BIOL CHEM, V269, P20335; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MORIKAWA E, 1992, AM J PHYSIOL, V263, pH1632, DOI 10.1152/ajpheart.1992.263.5.H1632; NARAYANAN K, 1994, J MED CHEM, V37, P885, DOI 10.1021/jm00033a004; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; OLKEN NM, 1993, BIOCHEMISTRY-US, V32, P9677, DOI 10.1021/bi00088a020; OLKEN NM, 1991, BIOCHEM BIOPH RES CO, V177, P828, DOI 10.1016/0006-291X(91)91864-9; OPRIAN DD, 1979, J BIOL CHEM, V254, P8895; OSTROWSKI J, 1989, J BIOL CHEM, V264, P15796; PETERSON JA, 1992, ARCH BIOCHEM BIOPHYS, V294, P654, DOI 10.1016/0003-9861(92)90738-I; PORTER TD, 1991, TRENDS BIOCHEM SCI, V16, P154, DOI 10.1016/0968-0004(91)90059-5; POU S, 1992, J BIOL CHEM, V267, P24173; SCHMIDT HHHW, 1992, BIOCHEMISTRY-US, V31, P3243, DOI 10.1021/bi00127a028; SLIGAR SG, 1976, P NATL ACAD SCI USA, V73, P1078, DOI 10.1073/pnas.73.4.1078; SLIGAR SG, 1986, CYTOCHROME P450 STRU, P429; SONO M, 1982, J BIOL CHEM, V257, P8308; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; STUEHR DJ, 1992, ADV ENZYMOL RELAT AR, V65, P287; WANG JL, 1993, J BIOL CHEM, V268, P22255; WINK DA, 1993, P NATL ACAD SCI USA, V90, P9813, DOI 10.1073/pnas.90.21.9813; WOLFF DJ, 1993, J BIOL CHEM, V268, P9425; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522	51	125	130	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32318	32326						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7528212				2022-12-27	WOS:A1994PX30400048
J	BRIZZI, MF; ZINI, MG; ARONICA, MG; BLECHMAN, JM; YARDEN, Y; PEGORARO, L				BRIZZI, MF; ZINI, MG; ARONICA, MG; BLECHMAN, JM; YARDEN, Y; PEGORARO, L			CONVERGENCE OF SIGNALING BY INTERLEUKIN-3, GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR, AND MAST-CELL GROWTH-FACTOR ON JAK2 TYROSINE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; C-KIT; GM-CSF; TRANSCRIPTION FACTOR; FACTOR RECEPTOR; HEMATOPOIETIC-CELLS; EXPRESSION CLONING; INTERFERON-GAMMA; STEEL FACTOR; PHOSPHORYLATION	Mast cell growth factor (MGF) (also called stem cell factor) synergizes with several lymphokines, including interleukin-3 (IL-3) and granulocyte-macrophage colony-stimulating factor (GM CSF), to promote proliferation and differentiation of certain hemopoietic progenitor cells. Although similar patterns of tyrosine-phosphorylated proteins characterize cells stimulated by MGF, IL-3, and GM-CSF, only the MGF receptor is a tyrosine kinase, and the heterodimeric receptors for IL-3 and GM-CSF share a common beta subunit that is devoid of enzymatic activity. Here we show that signaling pathways utilized by all three cytokines include the cytoplasmic tyrosine kinase JAK2. Analysis of several factor-dependent myeloid cell lines indicated that JAK2 is physically associated with the common beta subunit and with MGF receptor (c-Kit) even prior to ligand binding. However, each of the ligands induced elevated tyrosine phosphorylation of JAK2 and a consequent increase in its catalytic activity. These results demonstrate for the first time the convergence within the same myeloid cells of signaling pathways originating in two distinct lymphokine receptors and a tyrosine kinase receptor on activation of a cytoplasmic tyrosine kinase.	UNIV TURIN,DIPARTIMENTO SCI BIOMED & ONCOL UMANA,SEZ CLIN,I-10126 TURIN,ITALY; WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL	University of Turin; Weizmann Institute of Science			Brizzi, Maria Felice/J-7882-2016; YARDEN, YOSEF/K-1467-2012					ALAI M, 1992, J BIOL CHEM, V267, P18021; AVANZI GC, 1990, J CELL PHYSIOL, V145, P458, DOI 10.1002/jcp.1041450310; AVANZI GC, 1991, CANCER RES, V51, P1741; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BLECHMAN JM, 1993, J BIOL CHEM, V268, P4399; CARROLL MP, 1991, J BIOL CHEM, V266, P14964; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; HARPUR AG, 1992, ONCOGENE, V7, P1347; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HORIE M, 1993, J BIOL CHEM, V268, P968; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; KANAKURA Y, 1990, BLOOD, V76, P706; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; LANGE B, 1987, BLOOD, V70, P192; LEV S, 1992, J BIOL CHEM, V267, P10866; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MIYAJIMA A, 1993, BLOOD, V82, P1960; MIYAZAWA K, 1991, EXP HEMATOL, V19, P1110; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; NICHOLSON SE, 1994, P NATL ACAD SCI USA, V91, P2985, DOI 10.1073/pnas.91.8.2985; OKUDA K, 1991, BLOOD, V78, P1928; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; TORTI M, 1992, J BIOL CHEM, V267, P8293; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P433; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4	54	95	96	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31680	31684						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7527392				2022-12-27	WOS:A1994PX30300056
J	NANDA, A; ROMANEK, R; CURNUTTE, JT; GRINSTEIN, S				NANDA, A; ROMANEK, R; CURNUTTE, JT; GRINSTEIN, S			ASSESSMENT OF THE CONTRIBUTION OF THE CYTOCHROME-B MOIETY OF THE NADPH OXIDASE TO THE TRANSMEMBRANE H+ CONDUCTANCE OF LEUKOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; RESPIRATORY BURST OXIDASE; HUMAN-NEUTROPHILS; INTRACELLULAR PH; ACTIVATION; MEMBRANE; CELLS; CURRENTS; CHANNEL	Phagocytic cells can kill microorganisms by synthesizing superoxide. Activation of the NADPH oxidase that generates superoxide is accompanied by a large intracellular burst of metabolic acid production. Despite the excess acid generation, cytosolic pH (pH(i)) remains near neutrality due to the concomitant stimulation of several homeostatic H+ extrusion mechanisms including a recently described H+-conductive pathway. Activation of the conductance by phorbol esters is defective in neutrophils of chronic granulomatous disease (CGD) patients lacking the transmembrane cytochrome b subunits of the NADPH oxidase. This finding suggests that the oxidase itself undertakes H+ translocation or that, alternatively, assembly of the oxidase is required to activate a separate H+ conducting entity. To distinguish between these possibilities, the presence of the conductive pathway was assessed in unstimulated normal and CGD cells by manipulating pH(i) and the transmembrane potential. Using fluorimetric determinations of pH(i), a conductive, Zn2+-sensitive alkalinization was observed in neutrophils from both normal and cytochrome b deficient CGD donors. The electrophysiological properties of the conductance were defined in purified blood monocytes using the whole cell configuration of the patch clamp. Depolarizing pulses induced slowly activating outward currents in cells from both normal and cytochrome b deficient individuals. The elicited currents were potentiated by cytosolic acidification and did not inactivate within the times tested. As in control leukocytes, the reversal potential of tail currents in the CGD cells closely approximated the H+ equilibrium potential and was unaffected by substitution of the major ionic components of the external bathing medium. At all voltages tested, the magnitude of the evoked currents was comparable in normal and CGD cells. The results indicate that, like macrophages and granulocytes, human monocytes display a voltage-gated highly H+-selective conductance. More importantly, our findings imply that the conductive pathway is present in cells devoid of cytochrome b. Therefore, the defective activation of the conductive pathway by protein kinase C agonists in CGD cells is not due to the physical absence of the transporter. Instead we propose that the oxidase functions in a regulatory capacity, facilitating the opening of a distinct H+ conductance during cellular stimulation.	HOSP SICK CHILDREN, RES INST, DIV CELL BIOL, TORONTO M5G 1X8, ON, CANADA; UNIV TORONTO, DEPT BIOCHEM, TORONTO, ON, CANADA; SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; Scripps Research Institute					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024838] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00833] Funding Source: Medline; NIAID NIH HHS [AI24838] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BABIOR BM, 1992, ADV ENZYMOL RAMB, V65, P49; BORREGAARD N, 1984, J CLIN INVEST, V74, P455, DOI 10.1172/JCI111442; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; CLARK RA, 1990, J INFECT DIS, V161, P1140, DOI 10.1093/infdis/161.6.1140; COLLETTE J, 1956, J AM CHEM SOC, V78, P3819, DOI 10.1021/ja01596a070; CROSS AR, 1991, BIOCHIM BIOPHYS ACTA, V1057, P281, DOI 10.1016/S0005-2728(05)80140-9; CURNUTTE J T, 1992, Immunodeficiency Reviews, V3, P149; CURNUTTE JT, 1988, J CLIN INVEST, V81, P606, DOI 10.1172/JCI113360; DECOURSEY TE, 1993, BIOPHYS J, V65, P1590, DOI 10.1016/S0006-3495(93)81198-6; DEMAUREX N, 1993, J PHYSIOL-LONDON, V466, P329; GRINSTEIN S, 1986, AM J PHYSIOL, V250, pC283, DOI 10.1152/ajpcell.1986.250.2.C283; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HENDERSON LM, 1987, BIOCHEM J, V246, P325, DOI 10.1042/bj2460325; HENDERSON LM, 1988, BIOCHEM J, V255, P285; HENDERSON LM, 1988, BIOCHEM J, V251, P563, DOI 10.1042/bj2510563; Henderson Lydia M., 1994, European Journal of Clinical Investigation, V24, pA32; HOPKINS PJ, 1992, AM J HUM GENET, V51, P37; KAPUS A, 1994, J BIOL CHEM, V269, P4736; KAPUS A, 1993, J GEN PHYSIOL, V102, P729, DOI 10.1085/jgp.102.4.729; KAPUS A, 1992, BIOCHEM J, V281, P697, DOI 10.1042/bj2810697; LEBANOFF SJ, 1995, INFLAMMATION BASIC P, P541; MOREL F, 1991, EUR J BIOCHEM, V201, P523, DOI 10.1111/j.1432-1033.1991.tb16312.x; NANDA A, 1993, P NATL ACAD SCI USA, V90, P760, DOI 10.1073/pnas.90.2.760; NANDA A, 1994, J CLIN INVEST, V93, P1770, DOI 10.1172/JCI117162; NANDA A, 1992, J BIOL CHEM, V267, P22740; NANDA A, 1991, P NATL ACAD SCI USA, V88, P10816, DOI 10.1073/pnas.88.23.10816; QU AY, 1994, AM J PHYSIOL, V35, pC1263; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; SIMCHOWITZ L, 1985, J BIOL CHEM, V260, P3248; SMITH RM, 1991, BLOOD, V77, P673; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012	31	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27280	27285						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7525551				2022-12-27	WOS:A1994PV77100023
J	STAUBS, PA; REICHART, DR; SALTIEL, AR; MILARSKI, KL; MAEGAWA, H; BERHANU, P; OLEFSKY, JM; SEELY, BL				STAUBS, PA; REICHART, DR; SALTIEL, AR; MILARSKI, KL; MAEGAWA, H; BERHANU, P; OLEFSKY, JM; SEELY, BL			LOCALIZATION OF THE INSULIN-RECEPTOR BINDING-SITES FOR THE SH2 DOMAIN PROTEINS P85, SYP, AND GAP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; GTPASE-ACTIVATING PROTEIN; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE-PHOSPHATASE; INTACT-CELLS; SIGNAL TRANSDUCTION; BETA-SUBUNIT; IRS-1; ENDOCYTOSIS; KINASE	The insulin receptor is known to interact with the SH2 domain proteins p85 (the regulatory subunit of phosphatidylinositol 3-kinase), Syp (a tyrosine phosphatase), and GAP (GTPase-activating protein). In this study, we mapped the insulin receptor binding sites for each of these proteins by examining the ability of phosphopeptides, corresponding to insulin receptor phosphorylation sites, and mutant insulin receptors to inhibit an insulin receptor-SH2 domain interaction. Precipitation of partially purified insulin receptors by glutathione S-transferase fusion proteins containing the N-terminal SH2 domains of p85 and GAP and both SH2 domains of Syp was demonstrated. The effect of the addition of each phosphopeptide on insulin receptor precipitation was tested. pY1322, the C-terminal insulin receptor peptide, inhibited insulin receptor precipitation by both p85- and Syp GST. The NPXY internalization domain peptide inhibited insulin receptor precipitation by GAP GST. These data were confirmed by mutant insulin receptor experiments. The insulin receptor C-terminal mutants, Delta CT and Y/F2, were not precipitated by p85 or Syp GST and the NPXY mutant insulin receptors, Delta Ex16 and HI Delta NPEY, were not precipitated by GAP-GST. Therefore, we conclude that p85 and Syp bind to the insulin receptor C terminus at tyrosine 1322 and GAP binds to the insulin receptor NPXY domain at tyrosine 960.	UNIV CALIF SAN DIEGO, DEPT BIOMED SCI, DIVEND, LA JOLLA, CA USA; VET ADM MED CTR, SAN DIEGO, CA 92161 USA	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA)	STAUBS, PA (corresponding author), UNIV CALIF SAN DIEGO, DEPT MED 0673, DIV ENDOCRINOL & METAB, 9500 GILMAN DR, LA JOLLA, CA 92093 USA.		Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828; Maegawa, Hiroshi/0000-0002-4611-8149	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK033651, K08DK002162, R01DK033651, R01DK032880] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 02162-02, DK 32880, DK 33651] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BACKER JM, 1990, J BIOL CHEM, V265, P16450; BACKER JM, 1993, J BIOL CHEM, V268, P8204; BERHANU P, 1991, MOL ENDOCRINOL, V5, P1827, DOI 10.1210/mend-5-12-1827; BIRGE RB, 1993, SCIENCE, V262, P1522, DOI 10.1126/science.7504323; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COOPER JA, 1993, MOL CELL BIOL, V13, P1737, DOI 10.1128/MCB.13.3.1737; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; GIORGETTI S, 1993, J BIOL CHEM, V268, P7358; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KELLY KL, 1993, J BIOL CHEM, V268, P4391; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; MAEGAWA H, 1993, BIOCHEM BIOPH RES CO, V194, P208, DOI 10.1006/bbrc.1993.1805; MAEGAWA H, 1994, BIOCHEM BIOPH RES CO, V199, P780, DOI 10.1006/bbrc.1994.1297; MCCLAIN DA, 1990, J BIOL CHEM, V265, P21363; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MCCLAIN DA, 1988, J BIOL CHEM, V263, P8904; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; MYERS MG, 1994, DIABETES, V43, pA1; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PICCIONE E, 1993, BIOCHEMISTRY-US, V32, P3197, DOI 10.1021/bi00064a001; PRONK GJ, 1992, J BIOL CHEM, V267, P24058; RIEDEL H, 1987, SCIENCE, V236, P197, DOI 10.1126/science.3494307; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUGIMOTO S, 1993, J BIOL CHEM, V268, P22771; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; SUN XJ, 1992, J BIOL CHEM, V267, P22662; TAKATA Y, 1992, J BIOL CHEM, V267, P9065; TAMEMOTO H, 1994, J CELL BIOCHEM, P148; TAVARE JM, 1988, BIOCHEM J, V253, P783, DOI 10.1042/bj2530783; THIES RS, 1990, J BIOL CHEM, V265, P10132; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VANHORN DJ, 1994, J BIOL CHEM, V269, P29; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	45	84	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27186	27192						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7525547				2022-12-27	WOS:A1994PV77100009
J	GARVEY, EP; OPLINGER, JA; TANOURY, GJ; SHERMAN, PA; FOWLER, M; MARSHALL, S; HARMON, MF; PAITH, JE; FURFINE, ES				GARVEY, EP; OPLINGER, JA; TANOURY, GJ; SHERMAN, PA; FOWLER, M; MARSHALL, S; HARMON, MF; PAITH, JE; FURFINE, ES			POTENT AND SELECTIVE-INHIBITION OF HUMAN NITRIC-OXIDE SYNTHASES - INHIBITION BY NON-AMINO ACID ISOTHIOUREAS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYL-L-ARGININE; PURIFICATION; AMINOGUANIDINE; EXPRESSION; MACROPHAGE; SUBSTRATE; REVERSAL; CLONING; SHOCK; CELLS	S-Ethylisothiourea was a potent competitive inhibitor of human nitric oxide synthase (NOS), with K-i, values of 17, 36, and 29 nM for the inducible (i), endothelial (e), and neuronal (n) isozymes, respectively. Unlike some potent inhibitors of NOS, no time dependence was observed. S-Ethylisothiourea was not a detectable substrate for eNOS. S-Ethylisothiourea was also a potent inhibitor of mouse iNOS (K-i value of 5.2 nM), and its binding perturbed the spectrum of iNOS consistent with its altering the environment of the bound heme. The optimum binding of S-ethyl- and S-isopropylisothiourea relative to 70 other analogs suggested that these alkyl substitutions fit into a small hydrophobic pocket. Most isothioureas were 2-6-fold selective for the human iNOS (K-i for iNOS versus K-i for eNOS), with one being 19-fold selective. The cyclized mimics of S-ethylisothiourea, 2-NH2-thiazoline, and 2-NH2-thiazole, were also competitive inhibitors of human NOS. A third structural class of inhibitors, bisisothioureas, were, in general, the most selective in their inhibition of human iNOS. S,S'-(1,3-Phenylenebis(1,2-ethanediyl))bisisothiourea was 190-fold selective (K-i value of 0.047 mu M against iNOS versus 9.0 mu M against eNOS). These results demonstrate that potent and selective inhibition of human NOS isozymes is achievable.	BURROUGHS WELLCOME CO, WELLCOME RES LABS, DIV ORGAN CHEM, RES TRIANGLE PK, NC 27709 USA	Burroughs Wellcome Fund; Wellcome Research Laboratories	GARVEY, EP (corresponding author), BURROUGHS WELLCOME CO, WELLCOME RES LABS, DIV EXPTL THERAPY, RES TRIANGLE PK, NC 27709 USA.							BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHARLES IG, 1993, P NATL ACAD SCI USA, V90, P11419, DOI 10.1073/pnas.90.23.11419; CORBETT JA, 1993, P NATL ACAD SCI USA, V90, P8992, DOI 10.1073/pnas.90.19.8992; DAWSON TM, 1992, ANN NEUROL, V32, P297, DOI 10.1002/ana.410320302; DUZHAK VG, 1968, FARMAKOL TOKSIKOL, V4, P62; FASTIER FN, 1950, BRIT J PHARMACOL, V7, P417; FORSTERMANN U, 1991, BIOCHEM PHARMACOL, V42, P1849, DOI 10.1016/0006-2952(91)90581-O; FURFINE ES, 1994, J BIOL CHEM, V269, P26677; FURFINE ES, 1993, BIOCHEMISTRY-US, V32, P8512, DOI 10.1021/bi00084a017; GARVEY EP, 1994, ARCH BIOCHEM BIOPHYS, V311, P235, DOI 10.1006/abbi.1994.1232; GROSS SS, 1990, BIOCHEM BIOPH RES CO, V170, P96, DOI 10.1016/0006-291X(90)91245-N; HASAN K, 1993, EUR J PHARMACOL, V249, P101, DOI 10.1016/0014-2999(93)90667-7; HENDERSHOT LC, 1958, J PHARMACOL EXP THER, V123, P1; HIBBS JB, 1992, J CLIN INVEST, V89, P867, DOI 10.1172/JCI115666; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; JANSSENS SP, 1992, J BIOL CHEM, V267, P14519; KILBOURN RG, 1990, BIOCHEM BIOPH RES CO, V172, P1132, DOI 10.1016/0006-291X(90)91565-A; LAMBERT LE, 1992, EUR J PHARMACOL, V216, P131, DOI 10.1016/0014-2999(92)90221-O; MAYER B, 1993, FEBS LETT, V333, P203, DOI 10.1016/0014-5793(93)80405-J; MCCALL TB, 1991, BRIT J PHARMACOL, V102, P234, DOI 10.1111/j.1476-5381.1991.tb12159.x; MCCARTNEYFRANCIS N, 1993, J EXP MED, V178, P749, DOI 10.1084/jem.178.2.749; MCMILLAN K, 1993, BIOCHEMISTRY-US, V32, P9875, DOI 10.1021/bi00089a001; MEYER J, 1992, J APPL PHYSIOL, V73, P324, DOI 10.1152/jappl.1992.73.1.324; MISKO TP, 1993, EUR J PHARMACOL, V233, P119, DOI 10.1016/0014-2999(93)90357-N; MONCADA S, 1991, PHARMACOL REV, V43, P109; NAKANE M, 1993, FEBS LETT, V316, P175, DOI 10.1016/0014-5793(93)81210-Q; NARAYANAN K, 1994, J MED CHEM, V37, P885, DOI 10.1021/jm00033a004; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; OLKEN NM, 1993, BIOCHEMISTRY-US, V32, P9677, DOI 10.1021/bi00088a020; OLKEN NM, 1992, J MED CHEM, V35, P1137, DOI 10.1021/jm00084a020; PETROS A, 1994, CARDIOVASC RES, V28, P34, DOI 10.1093/cvr/28.1.34; SCHENKMAN JB, 1967, MOL PHARMACOL, V3, P113; SCHMIDT HHHW, 1991, P NATL ACAD SCI USA, V88, P365, DOI 10.1073/pnas.88.2.365; SHERMAN PA, 1993, BIOCHEMISTRY-US, V32, P11600, DOI 10.1021/bi00094a017; Smirk FH, 1941, BRIT MED J, V1941, P510, DOI 10.1136/bmj.2.4214.510; Smirk FR, 1942, LANCET, V2, P301; STUEHR DJ, 1992, ADV ENZYMOL RAMB, V65, P287; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001; WRIGHT CE, 1992, CARDIOVASC RES, V26, P48, DOI 10.1093/cvr/26.1.48	39	321	340	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26669	26676						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7523409				2022-12-27	WOS:A1994PQ93100017
J	TECTOR, M; ZHANG, Q; SALTER, RD				TECTOR, M; ZHANG, Q; SALTER, RD			PHOSPHATASE INHIBITORS BLOCK IA VIVO BINDING OF PEPTIDES TO CLASS-I MAJOR HISTOCOMPATIBILITY COMPLEX-MOLECULES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-GOLGI COMPARTMENT; HLA-B ANTIGENS; ENDOPLASMIC-RETICULUM; BREFELDIN-A; INTRACELLULAR-TRANSPORT; MONOCLONAL-ANTIBODY; POST-ER; RMA-S; MHC; PROTEINS	Class I major histocompatibility complex (MHC) molecules are heterotrimers of heavy chains, beta(2)-microglobulin, and 8-10 amino acid-long peptides. Assembly of class I MHC molecules into complexes which are stable and can be transported to the cell surface occurs soon after insertion of individual subunits into the endoplasmic reticulum (ER). To identify subcellular compartments required for class I MHC assembly, we studied class I biosynthesis in human cell lines treated with several inhibitors of intracellular transport. We found that HLA-B701 molecules do not assemble in CIR transfectants in which a block in protein transport from the ER is established by treatment with phosphatase inhibitors. In contrast, stable HLA-B701 complexes form in cells in which the ER becomes mixed with the Golgi after treatment with brefeldin A. Neither treatment impaired binding of HLA-B701 to the ER-resident protein calnexin, and unassembled heavy chains in phosphatase-inhibited cells showed prolonged association with calnexin. In addition, the mouse class I molecule H-2D(b), which binds beta(2)-microglobulin in human T2 cells in the absence of transporter of antigenic peptides, formed complexes in CIR cell transfectants treated with phosphatase inhibitors. Taken together, these data demonstrate that phosphatase inhibitors do not prevent assembly of class I heavy chain-beta(2)-microglobulin dimers, but instead interfere with peptide loading. These results are consistent with the possibility that class I MHC molecules are transported from their initial site of insertion into the rough ER before binding peptides, or alternatively that peptide loading mediated by transporter of antigenic peptides is blocked by phosphatase inhibitors.	UNIV PITTSBURGH,SCH MED,DEPT PATHOL,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh				Salter, Russell/0000-0003-4553-2986				ALEXANDER J, 1989, IMMUNOGENETICS, V29, P380, DOI 10.1007/BF00375866; ANDERSON KS, 1994, EMBO J, V13, P675, DOI 10.1002/j.1460-2075.1994.tb06306.x; ANDERSON KS, 1993, J IMMUNOL, V151, P3407; ANDROLEWICZ MJ, 1993, P NATL ACAD SCI USA, V90, P9130, DOI 10.1073/pnas.90.19.9130; ARNOLD D, 1992, NATURE, V360, P171, DOI 10.1038/360171a0; ATTAYA M, 1992, NATURE, V355, P647, DOI 10.1038/355647a0; BAAS EJ, 1992, J EXP MED, V176, P147, DOI 10.1084/jem.176.1.147; BONATTI S, 1989, J BIOL CHEM, V264, P12590; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; DAVIDSON HW, 1992, J CELL BIOL, V116, P1343, DOI 10.1083/jcb.116.6.1343; DAVIS JE, 1990, J IMMUNOL, V144, P990; DEGEN E, 1992, J EXP MED, V175, P1653, DOI 10.1084/jem.175.6.1653; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; DEMARS R, 1985, P NATL ACAD SCI USA, V82, P8183, DOI 10.1073/pnas.82.23.8183; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; HAMADA H, 1987, CANCER RES, V47, P2860; HOBMAN TC, 1992, J CELL BIOL, V118, P795, DOI 10.1083/jcb.118.4.795; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; HSU VW, 1991, NATURE, V352, P441, DOI 10.1038/352441a0; HUOVILA APJ, 1992, J CELL BIOL, V118, P1305, DOI 10.1083/jcb.118.6.1305; JACKSON MR, 1994, SCIENCE, V263, P384, DOI 10.1126/science.8278813; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; KELLY A, 1992, NATURE, V355, P641, DOI 10.1038/355641a0; KLEIJMEER MJ, 1992, NATURE, V357, P342, DOI 10.1038/357342a0; LAPHAM CK, 1993, J EXP MED, V177, P1633, DOI 10.1084/jem.177.6.1633; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; LUCOCQ J, 1991, J CELL SCI, V100, P753; MELLADO W, 1987, BIOCHEMISTRY-US, V26, P6900, DOI 10.1021/bi00396a005; MOMBURG F, 1994, NATURE, V367, P648, DOI 10.1038/367648a0; MONACO JJ, 1992, IMMUNOL TODAY, V13, P173, DOI 10.1016/0167-5699(92)90122-N; NEEFJES JJ, 1988, EUR J IMMUNOL, V18, P801, DOI 10.1002/eji.1830180522; NEEFJES JJ, 1986, IMMUNOGENETICS, V23, P164, DOI 10.1007/BF00373817; NISHIWAKI S, 1990, CARCINOGENESIS, V11, P1837, DOI 10.1093/carcin/11.10.1837; ORTMANN B, 1994, NATURE, V368, P864, DOI 10.1038/368864a0; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PARHAM P, 1981, HUM IMMUNOL, V3, P277, DOI 10.1016/0198-8859(81)90065-3; PARHAM P, 1979, J IMMUNOL, V123, P342; POWIS SJ, 1991, NATURE, V354, P528, DOI 10.1038/354528a0; SALTER RD, 1986, EMBO J, V5, P943, DOI 10.1002/j.1460-2075.1986.tb04307.x; SALTER RD, 1992, HUM IMMUNOL, V35, P40, DOI 10.1016/0198-8859(92)90093-3; SHEPHERD JC, 1993, CELL, V74, P577, DOI 10.1016/0092-8674(93)80058-M; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SUH WK, 1994, SCIENCE, V264, P1322, DOI 10.1126/science.8191286	45	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25816	25822						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7523393				2022-12-27	WOS:A1994PQ49100086
J	KNAUS, HG; EBERHART, A; KACZOROWSKI, GJ; GARCIA, ML				KNAUS, HG; EBERHART, A; KACZOROWSKI, GJ; GARCIA, ML			COVALENT ATTACHMENT OF CHARYBDOTOXIN TO THE BETA-SUBUNIT OF THE HIGH-CONDUCTANCE CA2+-ACTIVATED K+ CHANNEL - IDENTIFICATION OF THE SITE OF INCORPORATION AND IMPLICATIONS FOR CHANNEL TOPOLOGY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED POTASSIUM CHANNELS; AORTIC SMOOTH-MUSCLE; ALPHA-1 SUBUNIT; CA2+ CHANNELS; BINDING; RECEPTOR; INHIBITOR; PORE; PHOSPHORYLATION; MECHANISM	Purified high conductance Ca2+ activated K+ (maxi-K) channels hom bovine tracheal smooth muscle have been covalently labeled employing monoiodotyrosine charybdotoxin ([I-125]ChTX), and different bifunctional crosslinking reagents. [I-125]ChTX was specifically incorpo rated into the beta-subunit, which was thereafter isolated by size exclusion high performance liquid chromatography. Proteolytic fragments of the [I-125]ChTX-labeled beta-subunit were generated by digestion with various endoproteinases. Glu-C or Asp-N cleavage yielded a glycosylated [I-125]ChTX-labeled fragment of 13-14 kDa. A site-directed antiserum raised against residues 62-75 of the cloned beta-subunit of the maxi-K channel specifically recognizes the beta-subunit in immunostaining experiments and was capable of immunoprecipitating these ChTX-labeled peptides. Lys-C cleavage resulted in two fragments of 16 and 28 kDa, respectively, which were both precipitated by anti-beta((62-75)). However, only the 28-kDa fragment was recognized by anti-beta((118-132)) and shown to carry double the amount of N-linked carbohydrates. Taken together, these data restrict the site of covalent incorporation of ChTX into the beta-subunit exclusively at Lys(69), confirm the predicted topology of this subunit, and indicate that both canonical N-linked glycosylation sites are occupied with complex carbohydrates of 5-6 kDa each. We propose that an extracellularly located portion of the beta-subunit is located within 7.7 Angstrom of the ChTX receptor site and could even participate in the formation of this receptor by close apposition of its extracellular domain with structural elements provided by the alpha-subunit.	MERCK & CO INC, MERCK SHARP & DOHME RES LABS, DEPT MEMBRANE BIOCHEM & BIOPHYS, RAHWAY, NJ 07065 USA	Merck & Company	KNAUS, HG (corresponding author), UNIV INNSBRUCK, INST BIOCHEM PHARMACOL, PETER MAYR STR 1, A-6020 INNSBRUCK, AUSTRIA.							BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; DOHLMAN HG, 1987, J BIOL CHEM, V262, P14282; GARCIACALVO M, 1991, BIOCHEMISTRY-US, V30, P11157, DOI 10.1021/bi00110a020; GARCIACALVO M, 1994, J BIOL CHEM, V269, P676; GIMENEZGALLEGO G, 1988, P NATL ACAD SCI USA, V85, P3329, DOI 10.1073/pnas.85.10.3329; GOLDSTEIN SAN, 1993, BIOPHYS J, V65, P1613, DOI 10.1016/S0006-3495(93)81200-1; KNAUS HG, 1994, J BIOL CHEM, V269, P3921; KNAUS HG, 1994, BIOCHEMISTRY-US, V33, P5819, DOI 10.1021/bi00185a021; KNAUS HG, 1994, J BIOL CHEM, V269, P17274; KUME H, 1989, NATURE, V341, P152, DOI 10.1038/341152a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATORRE R, 1989, ANNU REV PHYSIOL, V51, P385, DOI 10.1146/annurev.ph.51.030189.002125; MACKINNON R, 1988, J GEN PHYSIOL, V91, P335, DOI 10.1085/jgp.91.3.335; MACKINNON R, 1989, BIOCHEMISTRY-US, V28, P8092, DOI 10.1021/bi00446a020; MACKINNON R, 1990, NEURON, V5, P767, DOI 10.1016/0896-6273(90)90335-D; MACKINNON R, 1989, SCIENCE, V245, P1383; NAKAYAMA H, 1991, P NATL ACAD SCI USA, V88, P9203, DOI 10.1073/pnas.88.20.9203; PARK CS, 1992, BIOCHEMISTRY-US, V31, P7749, DOI 10.1021/bi00149a002; PARK CS, 1992, NEURON, V9, P307, DOI 10.1016/0896-6273(92)90169-E; STAMPE P, 1994, BIOCHEMISTRY-US, V33, P443, DOI 10.1021/bi00168a008; STRIESSNIG J, 1991, P NATL ACAD SCI USA, V88, P10769, DOI 10.1073/pnas.88.23.10769; STRIESSNIG J, 1990, P NATL ACAD SCI USA, V87, P9108, DOI 10.1073/pnas.87.23.9108; SUGG EE, 1990, J BIOL CHEM, V265, P18745; TEJEDOR FJ, 1988, P NATL ACAD SCI USA, V85, P8742, DOI 10.1073/pnas.85.22.8742; VAZQUEZ J, 1989, J BIOL CHEM, V264, P20902; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494	26	59	59	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					23336	23341						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	7521879				2022-12-27	WOS:A1994PQ16400066
J	LEE, CC; YAMADA, KM				LEE, CC; YAMADA, KM			IDENTIFICATION OF A NOVEL TYPE OF ALTERNATIVE SPLICING OF A TYROSINE KINASE RECEPTOR - JUXTAMEMBRANE DELETION OF THE C-MET PROTEIN-KINASE-C SERINE PHOSPHORYLATION REGULATORY SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE GROWTH-FACTOR; EGF RECEPTOR; ONCOGENE	We have detected a novel type of structural variant of the tyrosine kinase receptor for c-met, also known as the hepatocyte growth factor receptor, in mouse tissues. The cDNA of the variant transcript of c-met lacks 141 base pairs, which predicts an in-frame deletion of 47 amino acids in the juxtamembrane region of the cytoplasmic domain. Sequence analysis of genomic DNA containing the c-net locus revealed that the absence of a discrete exon is responsible for this 141-base pair deletion and that alternative splicing leads to production of two forms of transcript. These two forms of transcript are designated as c-met(sm) (for small) and c-met(lg) (for large) to distinguish the absence or presence of the 141-base pair segment, respectively. The c-met(sm) variant is present in adult mouse tissues including kidney, liver, and brain as well as in 9-10-day-old embryos. In all cases, expression of c-met(sm) was lower than that of the normal transcript, c-met(lg). An antiserum against mouse c-Met protein immunoprecipitated corresponding protein forms of similar to 152 and similar to 145 kDa from whole kidney lysate under reducing conditions. The size difference of similar to 7 kDa between these isoforms corresponds to the predicted difference of 47 amino acids, The presence of this shorter variant transcript and its corresponding protein isoform in a variety of normal tissues suggests a physiological role. The deleted region in the cytoplasmic domain of c-met(sm) contains a sequence motif ((S) under bar(985)A (R) under bar S) for protein kinase C phosphorylation that has recently been shown to play a key role in the down-regulation of hepatocyte growth factor receptor kinase activity. The identification of this novel isoform, c-met(sm), demonstrates that a tyrosine kinase receptor can achieve additional diversity by alternative splicing at a key regulatory site in its cytoplasmic domain.	NIDR,DEV BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)				Yamada, Kenneth/0000-0003-1512-6805				BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CHAN AML, 1988, ONCOGENE, V2, P593; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; CREPALDI T, 1994, J BIOL CHEM, V269, P1750; GANDINO L, 1994, J BIOL CHEM, V269, P1815; GANDINO L, 1990, ONCOGENE, V5, P721; GIORDANO S, 1989, ONCOGENE, V4, P1383; LIN CR, 1986, CELL, V44, P839, DOI 10.1016/0092-8674(86)90006-1; MONTESANO R, 1991, CELL, V66, P697, DOI 10.1016/0092-8674(91)90115-F; MOSTHAF L, 1990, EMBO J, V9, P2409, DOI 10.1002/j.1460-2075.1990.tb07416.x; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PRAT M, 1991, MOL CELL BIOL, V11, P5954, DOI 10.1128/MCB.11.12.5954; RODRIGUES GA, 1991, MOL CELL BIOL, V11, P2962, DOI 10.1128/MCB.11.6.2962; SAMBROOK J, 1989, MOL CLONING LABORATO, V1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; WHITELEY B, 1986, J CELL BIOL, V103, P1355, DOI 10.1083/jcb.103.4.1355	18	52	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19457	19461						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	7518457				2022-12-27	WOS:A1994NY33200041
J	FONG, AM; SANTORO, SA				FONG, AM; SANTORO, SA			TRANSCRIPTIONAL REGULATION OF ALPHA(IIB) INTEGRIN GENE-EXPRESSION DURING MEGAKARYOCYTIC DIFFERENTIATION OF K562 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE RECEPTORS; BINDING; ENHANCER; PROMOTER; LINE; FIBRONECTIN; INHIBITION; ADHESION; ELEMENTS; DOMAIN	A portion of the 5'-flanking region of the glycoprotein IIb (alpha(IIb)) integrin gene extending from -598 to +32 base pairs was isolated. This DNA segment is capable of driving low level base-line transcription in undifferentiated K562 cells. It also contains elements which direct the markedly increased expression observed following megakaryocytic differentiation of K562 cells with phorbol dibutyrate. Analysis of hybrid alpha(IIb)-chloramphenicol acetyltransferase reporter gene constructs indicates that at least three regions within the -598 to +32 region control differentiation dependent alpha(IIb) transcription. Two enhancer elements as well as a silencer domain all regulate chloramphenicol acetyltransferase transcriptional activity in K562 cells. Gel mobility shift experiments revealed that nuclear binding proteins are able to interact with all three DNA regions. A small region lying between -124 and -99 bases is able to bind to nuclear proteins in undifferentiated cells but not in differentiated cells as evidenced by gel mobility shift and footprinting studies and corresponds to the silencer element identified in the functional studies. Therefore, the tissue-specific expression of (alpha(IIb) may be controlled transcriptionally by both positive and negative factors with the silencer element playing a major role in regulating differentiation-dependent expression.	WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110	Washington University (WUSTL)	FONG, AM (corresponding author), WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110, USA.				NHLBI NIH HHS [F32 HL08686] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL008686] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ausubel FM., 2006, ENZYMATIC MANIPULATI; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BIGGIN MD, 1989, CELL, V58, P433, DOI 10.1016/0092-8674(89)90424-8; BUCK CA, 1987, ANNU REV CELL BIOL, V3, P179, DOI 10.1146/annurev.cb.03.110187.001143; BURGER SR, 1992, EXP CELL RES, V202, P28, DOI 10.1016/0014-4827(92)90400-3; CAEN JP, 1966, AM J MED, V41, P4, DOI 10.1016/0002-9343(66)90003-9; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; GINSBERG M, 1985, J BIOL CHEM, V260, P3931; HAVERSTICK DM, 1985, BLOOD, V66, P946; HERSCHBACH BM, 1993, ANNU REV CELL BIOL, V9, P479, DOI 10.1146/annurev.cellbio.9.1.479; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; INOSTROZA JA, 1992, CELL, V70, P477; LEARY JF, 1987, LEUKEMIA RES, V11, P807, DOI 10.1016/0145-2126(87)90065-8; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LOPEZCABRERA M, 1993, J BIOL CHEM, V268, P1187; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; PHILLIPS DR, 1988, BLOOD, V71, P831; PRANDINI MH, 1988, BIOCHEM BIOPH RES CO, V156, P595, DOI 10.1016/S0006-291X(88)80884-2; PRANDINI MH, 1992, J BIOL CHEM, V267, P10370; RAVID K, 1991, MOL CELL BIOL, V11, P6116, DOI 10.1128/MCB.11.12.6116; ROSEN GD, 1991, P NATL ACAD SCI USA, V88, P4094, DOI 10.1073/pnas.88.10.4094; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; Sambrook J, 1989, MOL CLONING LABORATO; SANTORO SA, 1987, CELL, V48, P867, DOI 10.1016/0092-8674(87)90083-3; TABILIO A, 1983, CANCER RES, V43, P4569; TETTEROO PAT, 1984, LEUKEMIA RES, V8, P197, DOI 10.1016/0145-2126(84)90143-7; ULRICH MJ, 1990, BLOOD, V75, P990; UZAN G, 1991, J BIOL CHEM, V266, P8932; ZUTTER MM, 1994, J BIOL CHEM, V269, P463; ZUTTER MM, 1992, J BIOL CHEM, V267, P20233	31	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18441	18447						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	7518432				2022-12-27	WOS:A1994NW79800035
J	CECCONI, O; NELSON, RM; ROBERTS, WG; HANASAKI, K; MANNORI, G; SCHULTZ, C; ULICH, TR; ARUFFO, A; BEVILACQUA, MP				CECCONI, O; NELSON, RM; ROBERTS, WG; HANASAKI, K; MANNORI, G; SCHULTZ, C; ULICH, TR; ARUFFO, A; BEVILACQUA, MP			INOSITOL POLYANIONS - NONCARBOHYDRATE INHIBITORS OF L-SELECTIN AND P-SELECTIN THAT BLOCK INFLAMMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE ADHESION MOLECULES; HIGH ENDOTHELIAL VENULES; FIBROBLAST GROWTH-FACTOR; CARBOHYDRATE LIGAND; SULFATED POLYSACCHARIDES; GLYCOPROTEIN LIGAND; NATURAL ANTIOXIDANT; MYELOID CELLS; LUNG INJURY; TUMOR-CELLS	Selectins are cell adhesion molecules known to support the initial attachment of leukocytes to inflamed vascular endothelium through their recognition of carbohydrate ligands such as the tetrasaccharide sialyl Lewis(x) (NeuSAc alpha 2-3Gal beta 1-4(Fuc alpha 1-3)GlcNAc-). In the present study, we describe the inhibition of L- and P-selectin function by inositol polyanions, simple 6-carbon ring structures that have multiple ester-linked phosphate or sulfate groups. In a purified component competition assay, binding of L- and P-selectin-Ig fusion proteins to immobilized bovine serum albumin-sialyl Lewis(x) neoglycoprotein was inhibited by inositol hexakisphosphate (InsP(6) IC50 = 2.1 +/- 1.4 mu M and 160 +/- 40 mu M), by inositol pentakisphosphate (InsP(5), IC50 = 1.4 +/- 0.2 and 260 +/- 40 mu M), and by inositol hexakissulfate (InsS(6),, IC50 = 210 +/- 80 mu M and 2.8 +/- 0.9 mM); E-selectin-Ig binding was unaffected. Inositol polyanions diminished the adhesion of LS180 colon carcinoma cells to plates coated with L- and P-selectin-Ig but not with E-selectin-Ig. Inositol polyanions blocked polymorphonuclear leukocyte (PMN) adhesion to COS cells expressing recombinant transmembrane P-selectin but not to those expressing E-selectin. In addition, inositol polyanions diminished PMN adhesion to activated endothelial cells under rotation-induced shear stress, a process known to require L-selectin function. In vivo, the effects of inositol polyanions were studied in two murine models of acute inflammation. Intravenously administered InsP(6), (two doses of 40 mu mol/kg) inhibited PMN accumulation in thioglycolate-induced inflammation (55 +/- 10% inhibition) and in zymosan-induced inflammation (61 L 4% inhibition), InsP(5) and Ins(6), also inhibited inflammation in these models, although higher doses were required for InsS(6). In conclusion, inositol polyanions are noncarbohydrate small molecules that inhibit L- and P-selectin function in vitro and inflammation in vivo.	UNIV CALIF SAN DIEGO, HOWARD HUGHES MED INST, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT PATHOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT PHARMACOL, LA JOLLA, CA 92093 USA; BRISTOL MYERS SQUIBB PHARMACEUT RES INST, SEATTLE, WA 98121 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Bristol-Myers Squibb				Schultz, Carsten/0000-0002-5824-2171				ARNONE A, 1974, NATURE, V249, P34, DOI 10.1038/249034a0; ARUFFO A, 1992, P NATL ACAD SCI USA, V89, P2292, DOI 10.1073/pnas.89.6.2292; ARUFFO A, 1991, CELL, V67, P35, DOI 10.1016/0092-8674(91)90570-O; ARUFFO A, 1992, CURRENT PROTOCOLS MO; BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600; BENESCH R, 1976, BIOCHEMISTRY-US, V15, P3396, DOI 10.1021/bi00660a035; BENOVIC JL, 1989, J BIOL CHEM, V264, P6707; BEVILACQUA MP, 1993, ANNU REV IMMUNOL, V11, P767, DOI 10.1146/annurev.iy.11.040193.004003; BEVILACQUA MP, 1994, ANNU REV MED, V45, P361, DOI 10.1146/annurev.med.45.1.361; BEVILACQUA MP, 1993, THROMB HAEMOSTASIS, V70, P152; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; BURKE CJ, 1993, BIOCHEMISTRY-US, V32, P6419, DOI 10.1021/bi00076a015; Cosgrove D., 1980, INOSITOL PHOSPHATES; DABORA JM, 1991, J BIOL CHEM, V266, P23637; ERBE DV, 1992, J CELL BIOL, V119, P215, DOI 10.1083/jcb.119.1.215; ERBE DV, 1993, J CELL BIOL, V120, P1227, DOI 10.1083/jcb.120.5.1227; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; GEOFFROY JS, 1989, J CELL BIOL, V109, P2463, DOI 10.1083/jcb.109.5.2463; GERSONDE K, 1981, TOXICOLOGY, V22, P279, DOI 10.1016/0300-483X(81)90022-6; GRAF E, 1987, J BIOL CHEM, V262, P11647; GREEN PJ, 1992, BIOCHEM BIOPH RES CO, V188, P244, DOI 10.1016/0006-291X(92)92376-9; GUSE AH, 1992, J IMMUNOL, V149, P2452; GUSE AH, 1991, J BIOL CHEM, V266, P24498; HESLOP JP, 1985, J EXP BIOL, V119, P395; HOLLENBAUGH D, 1993, BIOCHEMISTRY-US, V32, P2960, DOI 10.1021/bi00063a006; IMAI Y, 1992, GLYCOBIOLOGY, V2, P373, DOI 10.1093/glycob/2.4.373; IMAI Y, 1990, J CELL BIOL, V111, P1225, DOI 10.1083/jcb.111.3.1225; KOTOVUORI P, 1993, GLYCOBIOLOGY, V3, P131, DOI 10.1093/glycob/3.2.131; KUIJPERS TW, 1992, J CELL BIOL, V118, P457, DOI 10.1083/jcb.118.2.457; LARKIN M, 1992, J BIOL CHEM, V267, P13661; LARSEN GR, 1992, J BIOL CHEM, V267, P11104; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LEVINOVITZ A, 1993, J CELL BIOL, V121, P449, DOI 10.1083/jcb.121.2.449; LEWINSOHN DM, 1987, J IMMUNOL, V138, P4313; LEY K, 1991, AM J PHYSIOL, V260, pH1667, DOI 10.1152/ajpheart.1991.260.5.H1667; LEY K, 1993, BLOOD, V81, P177; MAYADAS TN, 1993, CELL, V74, P541, DOI 10.1016/0092-8674(93)80055-J; MENNITI FS, 1993, TRENDS BIOCHEM SCI, V18, P53, DOI 10.1016/0968-0004(93)90053-P; MENNITI FS, 1993, J BIOL CHEM, V268, P3850; MOORE KL, 1991, J CELL BIOL, V112, P491, DOI 10.1083/jcb.112.3.491; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; MULLIGAN MS, 1993, J EXP MED, V178, P623, DOI 10.1084/jem.178.2.623; MULLIGAN MS, 1993, NATURE, V364, P149, DOI 10.1038/364149a0; NELSON RM, 1993, BLOOD, V82, P3253; NELSON RM, 1993, J CLIN INVEST, V91, P1157, DOI 10.1172/JCI116275; NELSON RM, 1992, S QUANT BIOL, V57, P271; NICKOLOFF BJ, 1990, J INVEST DERMATOL, V94, pS151, DOI 10.1111/1523-1747.ep12876134; NORGARDSUMNICHT KE, 1993, SCIENCE, V261, P480, DOI 10.1126/science.7687382; PALMITER RD, 1987, CELL, V50, P435, DOI 10.1016/0092-8674(87)90497-1; PERICH JW, 1987, TETRAHEDRON LETT, V28, P101, DOI 10.1016/S0040-4039(00)95660-0; PICKER LJ, 1991, CELL, V66, P921, DOI 10.1016/0092-8674(91)90438-5; PITTET D, 1989, J BIOL CHEM, V264, P18489; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; RAO PS, 1991, ANN THORAC SURG, V52, P908, DOI 10.1016/0003-4975(91)91254-S; SIREN M, 1991, ACS SYM SER, V463, P103; SKINNER MP, 1991, J BIOL CHEM, V266, P5371; SLODKI ME, 1987, IND POLYSACCHARIDES, P109; SPERTINI O, 1991, J IMMUNOL, V147, P2565; SPERTINI O, 1991, J IMMUNOL, V147, P942; STEPHENS L, 1993, J BIOL CHEM, V268, P4009; STOOLMAN LM, 1984, J CELL BIOL, V99, P1535, DOI 10.1083/jcb.99.4.1535; SZWERGOLD BS, 1987, BIOCHEM BIOPH RES CO, V149, P874, DOI 10.1016/0006-291X(87)90489-X; TANGELDER GJ, 1991, BLOOD, V77, P1565; TYRRELL D, 1991, P NATL ACAD SCI USA, V88, P10372, DOI 10.1073/pnas.88.22.10372; ULICH TR, 1991, AM J PATHOL, V138, P1485; VALLEJO M, 1987, NATURE, V330, P656, DOI 10.1038/330656a0; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WATSON SR, 1991, NATURE, V349, P164, DOI 10.1038/349164a0; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; WONG NS, 1992, BIOCHEM J, V286, P459, DOI 10.1042/bj2860459; YEDNOCK TA, 1987, J CELL BIOL, V104, P713, DOI 10.1083/jcb.104.3.713	73	63	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15060	15066						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	7515048				2022-12-27	WOS:A1994NP73800035
J	YU, JS; YANG, SD				YU, JS; YANG, SD			OKADAIC ACID, A SERINE/THREONINE PHOSPHATASE INHIBITOR, INDUCES TYROSINE DEPHOSPHORYLATION INACTIVATION OF PROTEIN-KINASE F-A/GSK-3-ALPHA IN A431 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GLYCOGEN-SYNTHASE KINASE-3; RABBIT SKELETAL-MUSCLE; BRAIN MICROTUBULES; ACTIVATING FACTOR; CROSS-LINKING; SYNAPSIN-I; PIG BRAIN; PHOSPHORYLATION; FA; IDENTIFICATION	The signal transduction mechanism of protein kinase F-A/GSK-3 alpha by tyrosine phosphorylation in A431 cells was investigated. Kinase F(A)GSK-3 alpha was found to exist in a highly tyrosine-phosphorylated/activated state in resting cells but could be tyrosine-dephosphorylated and inactivated down to less than 15% of control values in a concentration-dependent manner by 50-400 nM okadaic acid (a specific inhibitor of protein phosphatase types 1 and 2A), as demonstrated by metabolic P-32 labeling the cells, followed by immunoprecipitation and two dimensional phosphoamino acid analysis and by immunodetection in an anti-kinase F-A/GSK-3 alpha immunoprecipitate kinase assay. Taken together, the results provide initial evidence that serine/threonine phosphatase(s) may play a role involved in the modulation of kinase F-A/GSK-3 alpha activity in cells, suggesting an involvement of serine/ threonine dephosphorylation in the modulation of tyrosine phosphorylation and activation of protein kinase F-A/GSK-3 alpha, representing a new mode of signal transduction pathway for the regulation of this multisubstrate protein kinase in cells.	NATL TSING HUA UNIV, INST BIOMED SCI, HSINCHU, TAIWAN; CHANG GUNG MED COLL, INST BASIC MED, TAYUAN, TAIWAN	National Tsing Hua University; Chang Gung University				Yu, Jau-Song/0000-0002-4295-983X				BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DENT P, 1989, FEBS LETT, V248, P67, DOI 10.1016/0014-5793(89)80433-8; FIOL CJ, 1988, ARCH BIOCHEM BIOPHYS, V267, P797, DOI 10.1016/0003-9861(88)90089-6; GUAN RJ, 1991, J BIOL CHEM, V266, P8262; HANGER DP, 1992, NEUROSCI LETT, V147, P58, DOI 10.1016/0304-3940(92)90774-2; HARLOW E, 1988, ANTIBODIES LABORATOR; HEMMINGS BA, 1981, EUR J BIOCHEM, V119, P443, DOI 10.1111/j.1432-1033.1981.tb05628.x; HEMMINGS BA, 1982, EUR J BIOCHEM, V127, P473; HUGHES K, 1993, EMBO J, V12, P803, DOI 10.1002/j.1460-2075.1993.tb05715.x; HUGHES K, 1992, BIOCHEM J, V288, P309, DOI 10.1042/bj2880309; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACKIE K, 1989, J NEUROSCI, V9, P1883; MANDELKOW EM, 1992, FEBS LETT, V314, P315, DOI 10.1016/0014-5793(92)81496-9; Reichlin M, 1980, Methods Enzymol, V70, P159; TAMAOKI T, 1991, METHOD ENZYMOL, V201, P340; TANIUCHI M, 1986, J BIOL CHEM, V261, P3342; VANDENHEEDE JR, 1980, J BIOL CHEM, V255, P1768; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; WOODGETT JR, 1991, TRENDS BIOCHEM SCI, V16, P177, DOI 10.1016/0968-0004(91)90071-3; YANG SD, 1987, J NEUROCHEM, V48, P160, DOI 10.1111/j.1471-4159.1987.tb13141.x; YANG SD, 1986, J BIOL CHEM, V261, P5590; YANG SD, 1993, J NEUROCHEM, V61, P1742, DOI 10.1111/j.1471-4159.1993.tb09811.x; YANG SD, 1986, J BIOL CHEM, V261, P1786; YANG SD, 1992, BIOCHEM BIOPH RES CO, V184, P973, DOI 10.1016/0006-291X(92)90686-F; YANG SD, 1992, J PROTEIN CHEM, V11, P539, DOI 10.1007/BF01025031; YANG SD, 1980, J BIOL CHEM, V255, P1759; YANG SD, 1991, J PROTEIN CHEM, V10, P171, DOI 10.1007/BF01024781; YANG SD, 1993, BIOCHEM BIOPH RES CO, V193, P1202, DOI 10.1006/bbrc.1993.1753; YANG SD, 1993, J PROTEIN CHEM, V12, P393, DOI 10.1007/BF01025039; YANG SD, 1992, DIABETES, V41, P68, DOI 10.2337/diabetes.41.1.68; YANG SD, 1991, ADV PROT PHOSPHATASE, V6, P133; YU JS, 1993, J PROTEIN CHEM, V12, P667, DOI 10.1007/BF01024925; YU JS, 1989, J PROTEIN CHEM, V8, P499, DOI 10.1007/BF01026435	37	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14341	14344						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	7514166				2022-12-27	WOS:A1994NM06500004
J	MISRA, UK; CHU, TC; GAWDI, G; PIZZO, SV				MISRA, UK; CHU, TC; GAWDI, G; PIZZO, SV			EVIDENCE FOR A 2ND ALPHA(2)-MACROGLOBULIN RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN ALPHA-2-MACROGLOBULIN RECEPTOR; LIPOPROTEIN RECEPTOR; ALPHA-MACROGLOBULIN; BINDING DOMAIN; FAST FORMS; INOSITOL TRISPHOSPHATE; PLASMINOGEN-ACTIVATOR; CHYLOMICRON REMNANTS; MURINE MACROPHAGES; APOLIPOPROTEIN-E	alpha(2)-Macroglobulin (alpha(2)M)-methylamine binds to purified low density lipoprotein receptor-related protein (LRP), and it is assumed that LRP functions as the alpha(2)M receptor in vivo. Binding of alpha(2)M-methylamine to macrophage receptors elevates intracellular calcium ([Ca2+](i)), inositol phosphates, and cyclic AMP. We have employed human alpha(2)M-methylamine and recombinant receptor binding fragment (RBF) to study transduction mechanisms. Macrophages exposed to either ligand demonstrated a rapid rise in [Ca2+](i). Since the 39-kDa LRP/alpha(2)M receptor-associated protein (RAP) blocks alpha(2)M binding to LRP, we explored the effects of RAP upon signaling. Pretreatment of macrophages with RAP did not block the increase in [Ca2+], elicited by alpha(2)M-methylamine or RBF, suggesting a distinct binding site. RBF also elicited a transient 1.5-2.0 fold increase in inositol 1,4,B-triphosphate. In permeabilized macrophages, GTP gamma S and Gpp(NH)p potentiated and sustained this inositol 1,4,5-triphosphate increase. Preincubation of permeabilized macrophages with GDP beta S abrogated the effects of GTP gamma S. Our results suggest that the signaling alpha(2)M receptor is coupled to a pertussis toxin-insensitive G protein and possibly to a cholera toxin-sensitive G protein. We conclude that macrophages contain a second alpha(2)M receptor that is G protein-coupled.	DUKE UNIV,MED CTR,DEPT PATHOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University; Duke University			Chu, Charleen/B-1601-2008	Chu, Charleen/0000-0002-5052-8271	NCI NIH HHS [CA-29589] Funding Source: Medline; NHLBI NIH HHS [HL-24066] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA029589] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024066, R37HL024066] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1983, BIOCHEM J, V212, P709; BLANK JL, 1991, J BIOL CHEM, V266, P18206; BORTH W, 1992, FASEB J, V6, P3345, DOI 10.1096/fasebj.6.15.1281457; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; CHOI SY, 1993, J BIOL CHEM, V268, P15804; CHU CT, 1993, J IMMUNOL, V150, P48; ENGHILD JJ, 1989, BIOCHEMISTRY-US, V28, P1400; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GLIEMANN J, 1989, BIOCHIM BIOPHYS ACTA, V980, P326, DOI 10.1016/0005-2736(89)90320-9; GOMPERTS BD, 1990, ANNU REV PHYSIOL, V52, P591; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAACK BM, 1993, J IMMUNOL, V150, P2599; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; HERZ J, 1990, J BIOL CHEM, V265, P21355; HOFFMAN M, 1983, BIOCHIM BIOPHYS ACTA, V760, P421, DOI 10.1016/0304-4165(83)90384-7; HUETTINGER M, 1992, J BIOL CHEM, V267, P18551; IMBER MJ, 1981, J BIOL CHEM, V256, P8134; JACKLE S, 1993, J LIPID RES, V34, P309; JENSEN PEH, 1989, BIOCHEM ARCH, V5, P171; JOHNSON WJ, 1982, SCIENCE, V218, P574, DOI 10.1126/science.6289443; JONES LG, 1988, CIRC RES, V62, P299, DOI 10.1161/01.RES.62.2.299; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; LAMARRE J, 1991, LAB INVEST, V65, P3; MILLIGAN G, 1991, TRENDS PHARMACOL SCI, V12, P207, DOI 10.1016/0165-6147(91)90551-3; MISRA UK, 1993, BIOCHEM J, V290, P885, DOI 10.1042/bj2900885; MITCHELL FM, 1993, BIOCHEM J, V293, P495, DOI 10.1042/bj2930495; MOESTRUP SK, 1989, J BIOL CHEM, V264, P15574; MOESTRUP SK, 1993, J BIOL CHEM, V268, P13691; NYKJAER A, 1993, J BIOL CHEM, V268, P15048; OKONOGI K, 1991, J BIOL CHEM, V266, P10305; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; PIZZO SV, 1988, ISI ATLAS-BIOCHEM, V1, P242; RHEE SG, 1992, J BIOL CHEM, V267, P12393; SALVESEN G, 1992, FEBS LETT, V313, P198, DOI 10.1016/0014-5793(92)81443-P; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SOTTRUPJENSEN L, 1986, FEBS LETT, V205, P20, DOI 10.1016/0014-5793(86)80857-2; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; UHING RJ, 1991, BIOCHIM BIOPHYS ACTA, V1093, P115, DOI 10.1016/0167-4889(91)90111-A; VANDIJK MCM, 1992, J BIOL CHEM, V267, P17732; VANDIJK MCM, 1991, BIOCHEM J, V279, P863, DOI 10.1042/bj2790863; VANDIJK MCM, 1992, BIOCHEM J, V287, P447, DOI 10.1042/bj2870447; VANLEUVEN F, 1986, J BIOL CHEM, V261, P1369; VANLEUVEN F, 1992, J BIOL CHEM, V267, P17732; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172	56	100	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12541	12547						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	7513689				2022-12-27	WOS:A1994NH71600029
J	NAKAYAMA, I; KAWAHARA, Y; TSUDA, T; OKUDA, M; YOKOYAMA, M				NAKAYAMA, I; KAWAHARA, Y; TSUDA, T; OKUDA, M; YOKOYAMA, M			ANGIOTENSIN-II INHIBITS CYTOKINE-STIMULATED INDUCIBLE NITRIC-OXIDE SYNTHASE EXPRESSION IN VASCULAR SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCTION; LIPOPOLYSACCHARIDE; PROLIFERATION; MACROPHAGES; ACTIVATION; RECEPTORS; CLONING; BINDING; INJURY	In cultured vascular smooth muscle cells (VSMC), inflammatory cytokines such as interleukin 1beta (IL-1beta) and tumor necrosis factor a stimulated nitric oxide (NO) production via the expression of an inducible type of NO synthase (iNOS). A potent vasoconstrictor, angiotensin II (Ang II), which causes a rapid phospholipase C-mediated phosphoinositide hydrolysis via the Ang II type 1 (AT1) receptor in VSMC, by itself did not stimulate the production of nitrite, a stable metabolite of NO, but dose dependently inhibited the IL-1beta-induced nitrite production. This inhibitory effect of Ang II was blocked by an AT1 receptor antagonist, CV-11974, but not by an Ang II type 2 receptor antagonist, PD 123319. The presence of Ang II during the early induction phase of iNOS was required for this inhibition. Consistently, Ang II suppressed IL-1beta-induced increases in iNOS mRNA and protein levels. Ang II also inhibited increases in nitrite production and iNOS mRNA and protein levels caused by tumor necrosis factor alpha. A protein kinase C-activating phorbol ester, phorbol 12-myristate 13-acetate, and a membrane-permeable diacylglycerol, 1,2-dioctanoyl-glycerol, similarly inhibited the IL-1beta-induced nitrite production and iNOS mRNA and protein expression, although repetitive additions were needed in the case of diacylglycerol. These results indicate that Ang II negatively modulates cytokine-induced NO production by blocking iNOS expression via the AT1 receptor in VSMC and suggest that protein kinase C could be involved in this process.	KOBE UNIV,SCH MED,DEPT INTERNAL MED,DIV 1,7-5-1 KUSUNOKI CHO,CHUO KU,KOBE 650,JAPAN	Kobe University								ASAOKA Y, 1991, P NATL ACAD SCI USA, V88, P8681, DOI 10.1073/pnas.88.19.8681; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUMPUS FM, 1991, HYPERTENSION, V17, P720, DOI 10.1161/01.HYP.17.5.720; BUSSE R, 1990, FEBS LETT, V275, P87, DOI 10.1016/0014-5793(90)81445-T; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAEMEN MJAP, 1991, CIRC RES, V68, P450, DOI 10.1161/01.RES.68.2.450; DINERMAN JL, 1993, CIRC RES, V73, P217, DOI 10.1161/01.RES.73.2.217; DUDLEY DT, 1990, MOL PHARMACOL, V38, P370; FLEMING I, 1990, BIOCHEM BIOPH RES CO, V171, P562, DOI 10.1016/0006-291X(90)91183-S; GUNTHER S, 1982, J CELL BIOL, V92, P289, DOI 10.1083/jcb.92.2.289; HAUSCHILDT S, 1990, BIOCHEM J, V270, P351, DOI 10.1042/bj2700351; HORTELANO S, 1992, J BIOL CHEM, V267, P24937; JOLY GA, 1992, CIRC RES, V71, P331, DOI 10.1161/01.RES.71.2.331; KAIBUCHI K, 1983, J BIOL CHEM, V258, P6701; KOIDE M, 1993, J BIOL CHEM, V268, P24959; KOIDE M, 1993, FEBS LETT, V318, P213, DOI 10.1016/0014-5793(93)80514-U; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIBBY P, 1991, LAB INVEST, V64, P5; LOWENSTEIN CJ, 1992, CELL, V70, P705, DOI 10.1016/0092-8674(92)90301-R; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MONCADA S, 1991, PHARMACOL REV, V43, P109; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NODA M, 1993, BIOCHEM PHARMACOL, V46, P311; OHSHIMA H, 1992, BIOCHEM BIOPH RES CO, V187, P1291, DOI 10.1016/0006-291X(92)90443-O; POWELL JS, 1989, SCIENCE, V245, P186, DOI 10.1126/science.2526370; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522	26	119	119	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11628	11633						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	7512570				2022-12-27	WOS:A1994NF96600097
J	WEBER, P; ZIMMERMANN, DR; WINTERHALTER, KH; VAUGHAN, L				WEBER, P; ZIMMERMANN, DR; WINTERHALTER, KH; VAUGHAN, L			TENASCIN-C BINDS HEPARIN BY ITS FIBRONECTIN TYPE-III DOMAIN-5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; CYTOTACTIN; SEQUENCES; RNA	Two sites on tenascin mediate interactions with glycosaminoglycan chains of proteoglycans. One is situated on the fibrinogen-like domain, whereas the other lies within the fibronectin type III homology region (Aukhil, I., Joshi, P., Yan, Y.Z., and Erickson, H.P. (1993) J. Biol. Chem. 268, 2542-2553.). We now characterize the latter binding site more closely by means of recombinant protein fragments derived from the type III homology region of tenascin, Using a heparin-Sepharose column we localize the second heparin binding site to the fifth fibronectin type III domain, This is confirmed in solid phase assays by incubation of fusion proteins with biotin-labeled heparin. In addition, we demonstrate the binding of heparan sulfate and dermatan sulfate to domain five, Molecular modelling of this domain reveals a conserved heparin-binding motif that we propose as the putative binding site, The fact, that different glycosaminoglycans may bind to this domain, implies that different classes of proteoglycans may in vivo compete for the same site.	ETH ZENTRUM, BIOCHEM LAB 1, CH-8092 ZURICH, SWITZERLAND; UNIV ZURICH, INST KLIN PATHOL, DEPT PATHOL, CH-8091 ZURICH, SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich			Vaughan, Lloyd/GNP-4888-2022; Vaughan, L/E-6528-2011	Vaughan, L/0000-0003-3474-9426				AUKHIL I, 1993, J BIOL CHEM, V268, P2542; BARNEA G, 1994, J BIOL CHEM, V269, P14349; CARDIN AD, 1991, METHOD ENZYMOL, V203, P556; CHUNG CY, 1994, J CELL BIOL, V126, P539, DOI 10.1083/jcb.126.2.539; DEBBAGE PL, 1988, J HISTOCHEM CYTOCHEM, V36, P1097, DOI 10.1177/36.9.2900263; ERICKSON HP, 1994, PERSPECT DEV NEUROBI, V2, P9; ERICKSON HP, 1984, NATURE, V311, P267, DOI 10.1038/311267a0; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; HOFFMAN S, 1987, P NATL ACAD SCI USA, V84, P2523, DOI 10.1073/pnas.84.8.2523; JONES FS, 1989, P NATL ACAD SCI USA, V86, P1905, DOI 10.1073/pnas.86.6.1905; KAPLONY A, 1991, DEVELOPMENT, V112, P605; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; LOLLOUCH AC, 1992, BIOCHEMISTRY-US, V31, P2279; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MARGALIT H, 1993, J BIOL CHEM, V268, P19228; MARTON LS, 1989, J BIOL CHEM, V264, P13145; SALMIVIRTA M, 1991, J BIOL CHEM, V266, P7733; SINAY P, 1984, CARBOHYD RES, V132, pC5, DOI 10.1016/0008-6215(84)85236-2; SPRING J, 1989, CELL, V59, P325, DOI 10.1016/0092-8674(89)90294-8; STUBER D, 1990, IMMUNOLOGICAL METHOD, V4, P121; TUCKER RP, 1993, DEVELOPMENT, V117, P347; VAUGHAN L, 1994, PERSPECT DEV NEUROBI, V2, P43; VAUGHAN L, 1994, CONTRIB NEPHROL, V107, P80; VAUGHAN L, 1987, EMBO J, V6, P349, DOI 10.1002/j.1460-2075.1987.tb04761.x; ZIMMERMANN DR, 1994, J CELL BIOL, V124, P817, DOI 10.1083/jcb.124.5.817; ZISCH AH, 1992, J CELL BIOL, V119, P203, DOI 10.1083/jcb.119.1.203	27	38	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4619	4623		10.1074/jbc.270.9.4619	http://dx.doi.org/10.1074/jbc.270.9.4619			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7533163	hybrid			2022-12-27	WOS:A1995QK08400066
J	NAKAMURA, K; SUZUKI, H; HIRABAYASHI, Y; SUZUKI, A				NAKAMURA, K; SUZUKI, H; HIRABAYASHI, Y; SUZUKI, A			IV3 ALPHA(NEUGC-ALPHA-2-8NEUGC)-GG(4)CER IS RESTRICTED TO CD4(+) T-CELLS PRODUCING INTERLEUKIN-2 AND A SMALL POPULATION OF MATURE THYMOCYTES IN MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE LYMPHOCYTE SUBPOPULATIONS; MONOCLONAL-ANTIBODIES; STRUCTURAL CHARACTERIZATION; DIFFERENTIATION ANTIGEN; MOUSE SPLEEN; ASIALO GM1; NK-CELLS; B-CELLS; GANGLIOSIDES; SURFACE	Monoclonal antibody YK-3 was established by immunization with IV3 alpha(NeuGc alpha 2-8NeuGc)-Gg(4)Cer (GD(D1c) (NeuGc-NeuGc-)), and its epitope was determined to be NeuGc alpha 2-8NeuGc alpha 23Gal beta 1. Thin layer chromatography immunostaining with YK-3 detected only G(D1c) (NeuGc-NeuGc-) among the gangliosides of mouse thymocytes and splenocytes. Immunohistochemical staining with YK-3 visualized the medulla of mouse thymus and T cell-dependent areas of mouse spleen and mesenteric lymph nodes. Two-color flow cytometry demonstrated that G(D1c)(NeuGc-NeuGc-) was expressed on a quarter of CD3(+) mature thymocytes and strongly expressed on three quarters of CD4(+) T cells in the spleen, lymph nodes, and peripheral blood but not on CD8(+) T cells or B cells. G(D1c)(NeuGc-NeuGc-)-positive cells and negative cells were separated by panning with YK-3 on Petri dishes into adherent and nonadherent fractions. Following stimulation with concanavalin A, adherent cells, predominantly G(D1c)(NeuGc-NeuGc-)(+), produced more interleukin-2 (IL-2) and markedly less interleukin-4 (IL-4) than nonadherent cells. This conclusion is supported by data obtained by lysis of cells by YK-3 and complement. These data indicate that the cell surface expression of G(D1c)(NeuGc-NeuGc-) is restricted to a small number of mature thymocytes and a subset of CD4(+) T cells, which produce abundant IL-2 and very little IL-4, suggesting that G(D1c)(NeuGc-NeuGc-) is an excellent marker for mouse naive T or T helper 1-like cells in vivo.	TOKYO METROPOLITAN INST MED SCI,DEPT MEMBRANE BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN; TOKYO METROPOLITAN INST MED SCI,DEPT CARDIOVASC RES,BUNKYO KU,TOKYO 113,JAPAN; INST PHYS & CHEM RES,GLYCO CELL BIOL LAB,FRONTIER RES PROGRAM,WAKO,SAITAMA 35101,JAPAN	Tokyo Metropolitan Institute of Medical Science; Tokyo Metropolitan Institute of Medical Science; RIKEN				Hirabayashi, Yoshio/0000-0002-5774-7354				ABO T, 1981, J IMMUNOL, V127, P1024; ARIGA T, 1987, J BIOL CHEM, V262, P848; BARTHEL LK, 1990, J HISTOCHEM CYTOCHEM, V38, P1383, DOI 10.1177/38.9.2201738; CERNY A, 1990, J EXP MED, V171, P315, DOI 10.1084/jem.171.1.315; CHOU DKH, 1986, J BIOL CHEM, V261, P1717; COMMISSION II, 1978, J LIPID RES, V19, P114; DITTRICH F, 1994, BIOCHEM BIOPH RES CO, V200, P1557, DOI 10.1006/bbrc.1994.1628; DORKEN B, 1989, LEUCOCYTE TYPING, V4, P118; EBEL F, 1992, BIOCHEMISTRY-US, V31, P12190, DOI 10.1021/bi00163a031; FITCH FW, 1993, ANNU REV IMMUNOL, V11, P29, DOI 10.1146/annurev.immunol.11.1.29; GILLESPIE W, 1993, J BIOL CHEM, V268, P3801; GREER JM, 1993, GLYCOBIOLOGY, V3, P391, DOI 10.1093/glycob/3.4.391; HABU S, 1980, J IMMUNOL, V125, P2284; HANDA S, 1964, JPN J EXP MED, V34, P293; HANSSON GC, 1983, J BIOL CHEM, V258, P4091; HASHIMOTO Y, 1986, SEIKAGAKU, V58, P862; HAYAKAWA K, 1988, J EXP MED, V168, P1825, DOI 10.1084/jem.168.5.1825; HAYAKAWA K, 1991, IMMUNOL REV, V123, P145, DOI 10.1111/j.1600-065X.1991.tb00609.x; HEINZEL FP, 1989, J EXP MED, V169, P59, DOI 10.1084/jem.169.1.59; HERSEY P, 1986, CANCER RES, V46, P6083; HOLMGREN J, 1973, INFECT IMMUN, V8, P851, DOI 10.1128/IAI.8.6.851-859.1973; KASAI M, 1980, EUR J IMMUNOL, V10, P175, DOI 10.1002/eji.1830100304; KITAGAWA H, 1994, J BIOL CHEM, V269, P1394; KNIEP B, 1992, BIOCHEM BIOPH RES CO, V187, P1343, DOI 10.1016/0006-291X(92)90450-Y; KNIEP B, 1990, LEUCOCYTE TYPING, V4, P362; LEE YC, 1993, EUR J BIOCHEM, V216, P377, DOI 10.1111/j.1432-1033.1993.tb18155.x; MADASSERY J V, 1991, Journal of Immunology, V147, P823; MAKITA A, 1963, JPN J EXP MED, V33, P361; MERCURIO AM, 1984, J EXP MED, V160, P1114, DOI 10.1084/jem.160.4.1114; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MUTHING J, 1989, BIOCHEMISTRY-US, V28, P2923; NAKAMURA K, 1987, J BIOCHEM-TOKYO, V101, P825, DOI 10.1093/oxfordjournals.jbchem.a121949; NAKAMURA K, 1984, J BIOCHEM-TOKYO, V96, P949, DOI 10.1093/oxfordjournals.jbchem.a134954; NAKAMURA K, 1991, J BIOCHEM-TOKYO, V110, P832, DOI 10.1093/oxfordjournals.jbchem.a123667; NOHARA K, 1994, BIOCHEMISTRY-US, V33, P4661, DOI 10.1021/bi00181a601; NOHARA K, 1991, J BIOCHEM-TOKYO, V110, P274, DOI 10.1093/oxfordjournals.jbchem.a123570; NORIHISA Y, 1994, J IMMUNOL, V152, P485; NUDELMAN E, 1983, SCIENCE, V220, P509, DOI 10.1126/science.6836295; OHASHI M, 1981, GLYCOCONJUGATES, P33; OSHANNESSY DJ, 1984, IMMUNOL LETT, V8, P273, DOI 10.1016/0165-2478(84)90008-7; OZAWA H, 1992, BIOCHIM BIOPHYS ACTA, V1123, P184, DOI 10.1016/0005-2760(92)90110-H; PORTNER A, 1993, BIOCHEMISTRY-US, V32, P12685; RIEBER EP, 1990, LEUCOCYTE TYPING, V4, P361; ROSSIBERGMANN B, 1993, INFECT IMMUN, V61, P2266, DOI 10.1128/IAI.61.5.2266-2269.1993; SCHWARTING GA, 1983, J BIOL CHEM, V258, P5893; SEKINE M, 1988, J BIOCHEM-TOKYO, V103, P722, DOI 10.1093/oxfordjournals.jbchem.a122335; SHARON N, 1983, ADV IMMUNOL, V34, P213, DOI 10.1016/S0065-2776(08)60380-6; STEINDOUGLAS KE, 1976, J EXP MED, V143, P822, DOI 10.1084/jem.143.4.822; SUTTLES J, 1986, J IMMUNOL, V136, P1586; SUZUKI M, 1986, CARBOHYD RES, V151, P213, DOI 10.1016/S0008-6215(00)90342-2; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P613, DOI 10.1111/j.1471-4159.1963.tb08933.x; WELTE K, 1987, J IMMUNOL, V139, P1763; YOSHINO H, 1993, J NEUROCHEM, V61, P658; YOUNG WW, 1980, J IMMUNOL, V124, P199	54	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3876	3881		10.1074/jbc.270.8.3876	http://dx.doi.org/10.1074/jbc.270.8.3876			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7533156	hybrid			2022-12-27	WOS:A1995QH68800063
J	MURAKAMI, M; MATSUMOTO, R; URADE, Y; AUSTEN, KF; ARM, JP				MURAKAMI, M; MATSUMOTO, R; URADE, Y; AUSTEN, KF; ARM, JP			C-KIT LIGAND MEDIATES INCREASED EXPRESSION OF CYTOSOLIC PHOSPHOLIPASE A(2), PROSTAGLANDIN ENDOPEROXIDE SYNTHASE-1, AND HEMATOPOIETIC PROSTAGLANDIN D-2 SYNTHASE AND INCREASED IGE-DEPENDENT PROSTAGLANDIN D-2 GENERATION IN IMMATURE MOUSE MAST-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; D SYNTHETASE; 5-LIPOXYGENASE-ACTIVATING PROTEIN; MOLECULAR-CLONING; LEUKOTRIENE C-4; MESSENGER-RNA; G/H SYNTHASE; SI-LOCUS; RAT; RELEASE	We have examined the cytokine regulation of IgE-dependent prostaglandin (PG) D-2 generation in mouse mast cells by assessing the changes in the levels of the transcript, translated protein, and activity of the enzymes involved in the synthesis of PGD(2) from endogenous arachidonic acid. When mouse mast cells, derived by culture of bone marrow cells with WEHI-3 cell-conditioned medium as a source of interleukin (IL)-3 (BMMC) were cultured in recombinant c-kit ligand (KL), sensitized with IgE, and stimulated with antigen, PGD(2) generation increased 3-fold; when KL was combined with IL-3, IL-9, or IL-10, PGD(2) generation increased 6-8-fold above that produced by the cells cultured in IL -3 alone. The increased IgE-dependent PGD(2) generation by BMMC was apparent after 1 day of culture, reached a maximum after 2-4 days of culture, and was dose-dependent for KL and for each of the accessory cytokines. IgE-dependent generation of leukotriene C-4 increased 2-fold after the cells were cultured with KL and was not increased by the addition of IL-3, IL-9, or IL-10. Assays for steady-state transcripts by RNA blotting, for protein by SDS-PAGE/immunoblotting, and for function by enzymatic activities revealed that KL alone stimulated the increased expression of cytosolic phospholipase A(2) (cPLA(2)), prostaglandin endoperoxide synthase (PGHS)-1, and the terminal enzyme, hematopoietic PGD(2) synthase, without a change in expression of 5-lipoxygenase. IL-3, IL-9, and IL-10 each enhanced the KL-induced expression of PGHS-1. In contrast, transcripts for PGHS-2, which were detected transiently after the cells had been cultured for 5 h in KL + IL-3, were not expressed during the period of subsequent increase in IgE-dependent PGD(2) generation. These findings demonstrate that KL up-regulates expression of cPLA(2), PGHS-1, and hematopoietic PGD, synthase, leading to a relatively selective increase in IgE-dependent production of PGD(2) from endogenously released arachidonic acid in BMMC, and they provide the first example of cytokine regulation of hematopoietic PGD(2) synthase.	HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DEPT RHEUMATOL & IMMUNOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA USA; OSAKA BIOSCI INST, SUITA, OSAKA 565, JAPAN	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI031599, R01AI022531, U19AI031599, R37AI022531] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36110] Funding Source: Medline; NIAID NIH HHS [AI22531, AI31599] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; BISCHOFF SC, 1992, J EXP MED, V175, P237, DOI 10.1084/jem.175.1.237; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; COLEMAN JW, 1993, J IMMUNOL, V150, P556; COLUMBO M, 1992, J IMMUNOL, V149, P599; DASTYCH J, 1994, J IMMUNOL, V152, P213; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; DIXON RAF, 1988, P NATL ACAD SCI USA, V85, P416, DOI 10.1073/pnas.85.2.416; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; DOVER GA, 1991, CELL, V65, P9, DOI 10.1016/0092-8674(91)90401-J; EKLUND KK, 1993, J IMMUNOL, V151, P4266; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; FLETCHER BS, 1992, J BIOL CHEM, V267, P4338; FUNK CD, 1991, FASEB J, V5, P2304, DOI 10.1096/fasebj.5.9.1907252; GALLI SJ, 1993, J CLIN INVEST, V91, P148, DOI 10.1172/JCI116164; GALLI SJ, 1994, ADV IMMUNOL, V55, P11; GHILDYAL N, 1992, J IMMUNOL, V149, P2123; GHILDYAL N, 1992, J BIOL CHEM, V267, P8473; GHILDYAL N, 1993, J IMMUNOL, V151, P3206; GURISH MF, 1992, J EXP MED, V175, P1003, DOI 10.1084/jem.175.4.1003; HEAVEY DJ, 1988, J IMMUNOL, V140, P1953; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; HOECK WG, 1993, P NATL ACAD SCI USA, V90, P4475, DOI 10.1073/pnas.90.10.4475; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; HULTNER L, 1990, EUR J IMMUNOL, V20, P1413, DOI 10.1002/eji.1830200632; JONES DA, 1993, J BIOL CHEM, V268, P9049; KATZ HR, 1992, J IMMUNOL, V148, P868; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V1170, P217, DOI 10.1016/0005-2760(93)90003-R; LAM BK, 1994, P NATL ACAD SCI USA, V91, P7663, DOI 10.1073/pnas.91.16.7663; LEVISCHAFFER F, 1987, J IMMUNOL, V139, P3431; LEVISCHAFFER F, 1986, P NATL ACAD SCI USA, V83, P6485, DOI 10.1073/pnas.83.17.6485; LEWIS RA, 1982, J IMMUNOL, V129, P1627; LIN LL, 1992, J BIOL CHEM, V267, P23451; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MANCINI JA, 1993, FEBS LETT, V318, P277, DOI 10.1016/0014-5793(93)80528-3; MEKORI YA, 1993, J IMMUNOL, V151, P3775; MENCIAHUERTA JM, 1983, J IMMUNOL, V131, P2958; MOORE KW, 1990, SCIENCE, V248, P1230, DOI 10.1126/science.2161559; MURAKAMI M, 1992, J BIOCHEM-TOKYO, V111, P175, DOI 10.1093/oxfordjournals.jbchem.a123733; MURAKAMI M, 1992, EUR J BIOCHEM, V209, P257, DOI 10.1111/j.1432-1033.1992.tb17284.x; MURAKAMI M, 1994, J BIOL CHEM, V269, P22269; NAGATA A, 1991, P NATL ACAD SCI USA, V88, P4020, DOI 10.1073/pnas.88.9.4020; NAKAMURA T, 1992, EMBO J, V11, P4917, DOI 10.1002/j.1460-2075.1992.tb05598.x; NAKANO T, 1985, J EXP MED, V162, P1025, DOI 10.1084/jem.162.3.1025; NAKATANI Y, 1994, J IMMUNOL, V153, P796; OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PENROSE JF, 1992, P NATL ACAD SCI USA, V89, P11603, DOI 10.1073/pnas.89.23.11603; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; PRITCHARD KA, 1994, J BIOL CHEM, V269, P8504; RAZIN E, 1983, J EXP MED, V157, P189, DOI 10.1084/jem.157.1.189; REDDY ST, 1994, J BIOL CHEM, V269, P15473; ROBINSON D, 1968, BIOCHEM J, V107, P321, DOI 10.1042/bj1070321; ROTTEM M, 1993, J IMMUNOL, V151, P4950; ROUZER CA, 1988, J BIOL CHEM, V263, P10135; SCHALKWIJK CG, 1992, EUR J BIOCHEM, V210, P169, DOI 10.1111/j.1432-1033.1992.tb17405.x; STEVENS RL, 1989, IMMUNOL TODAY, V10, P381, DOI 10.1016/0167-5699(89)90272-7; THOMPSONSNIPES LA, 1991, J EXP MED, V173, P507, DOI 10.1084/jem.173.2.507; TSAI M, 1991, P NATL ACAD SCI USA, V88, P6382, DOI 10.1073/pnas.88.14.6382; URADE Y, 1989, J IMMUNOL, V143, P2982; URADE Y, 1987, J BIOL CHEM, V262, P3820; URADE Y, 1990, J BIOL CHEM, V265, P371; VANE J, 1994, NATURE, V367, P215, DOI 10.1038/367215a0; VANSNICK J, 1989, J EXP MED, V169, P363, DOI 10.1084/jem.169.1.363; WERSHIL BK, 1992, J EXP MED, V175, P245, DOI 10.1084/jem.175.1.245; WOODS JW, 1993, J EXP MED, V178, P1935, DOI 10.1084/jem.178.6.1935; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; YEE NS, 1994, J EXP MED, V179, P1777, DOI 10.1084/jem.179.6.1777; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	72	137	139	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	1995	270	7					3239	3246		10.1074/jbc.270.7.3239	http://dx.doi.org/10.1074/jbc.270.7.3239			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QG471	7531701	hybrid			2022-12-27	WOS:A1995QG47100054
J	PHILIPPE, J; MOREL, C; CORDIERBUSSAT, M				PHILIPPE, J; MOREL, C; CORDIERBUSSAT, M			ISLET-SPECIFIC PROTEINS INTERACT WITH THE INSULIN-RESPONSE ELEMENT OF THE GLUCAGON GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEINS; TRANSCRIPTION FACTORS; CELL-LINES; PATHO-PHYSIOLOGY; SIMIAN VIRUS-40; EXPRESSION; ENHANCER; SOMATOSTATIN; PROMOTER; SEQUENCES	Glucagon gene expression is negatively regulated by insulin at the transcriptional level. G3, a DNA control element located in the 5'-flanking sequence of the rat glucagon gene mediates the inhibition of transcription, which occurs in response to insulin. We show here that two islet-specific protein complexes C1A and C1B, bind to the A domain of G3, which is critical for the insulin response. These two complexes bind to overlapping sequences of the A domain and display Very similar binding specificities. Point mutations in the A domain that affect binding of C1A and C1B result in both decreased G3 enhancer activity and insulin-mediated inhibitory effects with a close correlation between diminution of binding and function. One of the two complexes, C1A, is similar or identical to B1, a protein complex interacting with the upstream promoter element of the glucagon gene, G(1), implicated in the A cell-specific expression of the glucagon gene. Our data indicate that islet-specific proteins are involved in glucagon gene regulation by insulin.	UNIV GENEVA,SCH MED,CTR MED UNIV,DEPT MED,CH-1211 GENEVA 4,SWITZERLAND	University of Geneva	PHILIPPE, J (corresponding author), UNIV GENEVA,SCH MED,CTR MED UNIV,DEPT GENET & MICROBIOL,9 AVE CHAMPEL,CH-1211 GENEVA 4,SWITZERLAND.		Cordier-Bussat, Martine/G-4019-2014					BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; CHEN L, 1989, J CLIN INVEST, V84, P711, DOI 10.1172/JCI114219; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; DAVIDSON I, 1986, NATURE, V323, P544, DOI 10.1038/323544a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; DRUCKER DJ, 1987, J BIOL CHEM, V262, P15659; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; GANSS R, 1994, MOL ENDOCRINOL, V8, P895, DOI 10.1210/me.8.7.895; GOODBOURN S, 1988, P NATL ACAD SCI USA, V85, P1447, DOI 10.1073/pnas.85.5.1447; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; HENTHORN P, 1988, P NATL ACAD SCI USA, V85, P6342, DOI 10.1073/pnas.85.17.6342; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KELLER SA, 1990, GENE DEV, V4, P1316, DOI 10.1101/gad.4.8.1316; KENNEDY GC, 1990, J BIOL CHEM, V265, P6279; KNEPEL W, 1990, J BIOL CHEM, V265, P8725; KNEPEL W, 1991, MOL ENDOCRINOL, V5, P1457, DOI 10.1210/mend-5-10-1457; KOBR M, 1990, MOL CELL BIOL, V10, P965, DOI 10.1128/MCB.10.3.965; KORANYI L, 1992, J CLIN INVEST, V89, P432, DOI 10.1172/JCI115602; Maxam A M, 1980, Methods Enzymol, V65, P499; MERCURIO F, 1989, EMBO J, V8, P1455, DOI 10.1002/j.1460-2075.1989.tb03528.x; MOREL C, 1995, J BIOL CHEM, V269, P3046; NOMIYAMA H, 1987, P NATL ACAD SCI USA, V84, P7881, DOI 10.1073/pnas.84.22.7881; OBRIEN RM, 1991, BIOCHEM J, V278, P609, DOI 10.1042/bj2780609; PAPACHRISTOU DN, 1989, DIABETES, V38, P752, DOI 10.2337/diabetes.38.6.752; PHILIPPE J, 1988, MOL CELL BIOL, V8, P4877, DOI 10.1128/MCB.8.11.4877; PHILIPPE J, 1989, J CLIN INVEST, V84, P672, DOI 10.1172/JCI114214; PHILIPPE J, 1987, J CLIN INVEST, V79, P351, DOI 10.1172/JCI112819; PHILIPPE J, 1991, P NATL ACAD SCI USA, V88, P7224, DOI 10.1073/pnas.88.16.7224; PHILIPPE J, 1994, MOL CELL BIOL, V14, P3514, DOI 10.1128/MCB.14.5.3514; POWERS AC, 1990, DIABETES, V39, P406, DOI 10.2337/diabetes.39.4.406; SANTISTEBAN P, 1992, MOL ENDOCRINOL, P1310; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; TAKAKI R, 1986, IN VITRO CELL DEV B, V22, P120; UNGER RH, 1981, NEW ENGL J MED, V304, P1575, DOI 10.1056/NEJM198106253042604; UNGER RH, 1981, NEW ENGL J MED, V304, P1518, DOI 10.1056/NEJM198106183042504; VALLEJO M, 1992, J BIOL CHEM, V267, P12876; WHELAN J, 1989, MOL CELL BIOL, V9, P3253, DOI 10.1128/MCB.9.8.3253	38	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 17	1995	270	7					3039	3045		10.1074/jbc.270.7.3039	http://dx.doi.org/10.1074/jbc.270.7.3039			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QG471	7531697	hybrid			2022-12-27	WOS:A1995QG47100025
J	STAN, R; MCLAUGHLIN, MM; CAFFERKEY, R; JOHNSON, RK; ROSENBERG, M; LIVI, GP				STAN, R; MCLAUGHLIN, MM; CAFFERKEY, R; JOHNSON, RK; ROSENBERG, M; LIVI, GP			INTERACTION BETWEEN FKBP12-RAPAMYCIN AND TOR INVOLVES A CONSERVED SERINE RESIDUE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PEPTIDYL-PROLYL ISOMERASE; SACCHAROMYCES-CEREVISIAE; CYCLOSPORINE-A; PHOSPHATIDYLINOSITOL 3-KINASE; IMMUNOSUPPRESSANT FK506; SIGNAL TRANSDUCTION; PROTEIN; RAPAMYCIN; YEAST; CYCLOPHILIN	The yeast TOR1 and TOR2 proteins were previously discovered as putative targets of the immunosuppressive drug rapamycin, Although their cellular function is unknown, they are predicted to be at least 215 kDa in size and possess a C-terminal phosphatidylinositol (PI) kinase-related domain. We previously identified a conserved Ser residue, within the PI kinase-related domain of both yeast TOR proteins (Ser(1972) in TOR1; Ser(1975) in TOR2), as being the site of missense mutations conferring dominant rapamycin resistance. The Ser(1972/1975) res. residue of yeast TOR is conserved in mammalian TOR homologs. One possibility is that this residue is critical for a direct interaction between TOR and the FKBP12-rapamycin complex. There is very recent biochemical evidence for an interaction between mammalian TOR and FKBP12-rapamycin (Brown, E. J., Albers, M. W., Shin, T. B., Ichikawa, K., Keith, C. T., Lane, W. S., and Schreiber, S. L. (1994) Nature 369, 756-758; Sabatini, D. M., Erdjument-Bromage, H., Lui, M., Tempst, P., and Snyder, S. H. (1994) Cell 78, 35-43). Using the yeast two-hybrid system, we now have obtained genetic proof of a physical interaction between FKBP12-rapamycin and TOR and have demonstrated that this interaction requires the conserved Ser residue. We have found that a small fragment of wild-type yeast TOR2 spanning Ser(1975) is capable of interacting with human FKBP12 in the presence of rapamycin, whereas an Arg(1975) mutant fails to interact, This effect is dependent upon rapamycin and is antagonized by FK506.	SMITHKLINE BEECHAM PHARMACEUT,DEPT GENE EXPRESS SCI,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT BIOMOLEC DISCOVERY,KING OF PRUSSIA,PA 19406; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854	GlaxoSmithKline; GlaxoSmithKline; Rutgers State University New Brunswick; Rutgers State University Medical Center								Bartel P. L., 1993, CELLULAR INTERACTION, P153; BIERER BE, 1990, SCIENCE, V250, P556, DOI 10.1126/science.1700475; BOSSARD MJ, 1994, BIOCHEM J, V297, P365, DOI 10.1042/bj2970365; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CAFFERKEY R, 1994, GENE, V141, P133, DOI 10.1016/0378-1119(94)90141-4; CAFFERKEY R, 1993, MOL CELL BIOL, V13, P6012, DOI 10.1128/MCB.13.10.6012; Cardenas Maria E., 1994, Perspectives in Drug Discovery and Design, V2, P103, DOI 10.1007/BF02171739; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; DUMONT FJ, 1990, J IMMUNOL, V144, P251; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HEITMAN J, 1991, P NATL ACAD SCI USA, V88, P1948, DOI 10.1073/pnas.88.5.1948; HEITMAN J, 1992, NEW BIOL, V4, P448; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; HELLIWELL SB, 1994, MOL BIOL CELL, V5, P105, DOI 10.1091/mbc.5.1.105; KOLTIN Y, 1991, MOL CELL BIOL, V11, P1718, DOI 10.1128/MCB.11.3.1718; KOSER PL, 1993, GENE, V129, P159, DOI 10.1016/0378-1119(93)90264-4; KUNZ J, 1993, TRENDS BIOCHEM SCI, V18, P334, DOI 10.1016/0968-0004(93)90069-Y; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; Miller J.H., 1972, EXPT MOL GENETICS; Morris R.E., 1992, TRANSPLANT REV-ORLAN, P39; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SCHREIBER SL, 1992, CELL, V70, P365, DOI 10.1016/0092-8674(92)90158-9; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P139; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; STEARNS T, 1988, GENETICS, V119, P249; WALSH CT, 1992, J BIOL CHEM, V267, P13115; WEIDERRECHT G, 1991, P NATL ACAD SCI USA, V88, P1029	34	114	120	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32027	32030						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7528205				2022-12-27	WOS:A1994PX30400002
J	NAGATA, K; TSUJI, T; HANAI, N; IRIMURA, T				NAGATA, K; TSUJI, T; HANAI, N; IRIMURA, T			ROLE OF O-LINKED CARBOHYDRATE CHAINS ON LEUKOCYTE CELL-MEMBRANES IN PLATELET-INDUCED LEUKOCYTE ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-SELECTIN CD62; GLYCOPROTEIN LIGAND; T-CELLS; OLIGOSACCHARIDES; NEUTROPHILS; MONOCYTES; ADHESION; IDENTIFICATION; GLYCOSYLATION; BIOSYNTHESIS	We previously reported that activated platelets stimulated neutrophils and monocytes to produce superoxide anion (O-2(-)) through the interaction between P-selectin and its carbohydrate ligand, sialyl Lewis X (sLe(X)) (Nagata, K., Tsuji, T., Todoroki, N., Katagiri, Y., Tanoue, K., Yamazaki, H., Hanai N., and Irimura, T. (1993) J. Immunol. 151, 3267-3273). In the present study, we investigated the role of cell surface carbohydrate chains of leukocytes in this process. Glycoconjugate-specific hydrolytic enzymes and inhibitors of glycosylation processing were applied. Granulocyte-like differentiated HL-60 (gHL-60) cells released an increased amount of O-2(-) in response to activated platelets in a beta-selectin-dependent manner. When HL-60 cells were differentiated in the presence of benzyl-alpha-N-acetylgalactosaminide (Bzl-alpha-GalNAc), an inhibitor of chain elongation of O-linked carbohydrates, the enhanced generation of O-2(-) was abrogated in parallel with decrease in the expression of sLe(X) structure and in the adhesion capacity to activated platelets, In contrast, treatment with swainsonine or 1-deoxymannojirimycin, inhibitors of processing of N-linked carbohydrate chains, did not show such effects. O-Sialoglycoprotease treatment of gHL-60 cells decreased the activated platelet-induced O-2(-) production with concomitant reduction of cell surface sLe(X) expression. Treatment of these cells with N-glycanase did not affect the O-2(-) production. These results strongly suggested that serine/threonine-linked carbohydrate chains containing sLe(X) played an essential role in the P-selectin-mediated leukocyte activation. By Western blotting analysis of gHL-60 cell lysates, we identified two glycoproteins which carried sLe(X) structures and were sensitive to Bzl-alpha-GalNAc treatment.	UNIV TOKYO,FAC PHARMACEUT SCI,DIV CHEM TOXICOL & IMMUNOCHEM,BUNKYO KU,TOKYO 113,JAPAN; KYOWA HAKKO KOGYO CO LTD,TOKYO RES LABS,MACHIDA 194,TOKYO,JAPAN	University of Tokyo; Kyowa Kirin Ltd								BRISKIN MJ, 1993, NATURE, V363, P461, DOI 10.1038/363461a0; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; FUKUDA MN, 1979, J BIOL CHEM, V254, P5458; GALLAGHER JT, 1985, BIOCHEM J, V231, P115, DOI 10.1042/bj2310115; IMAI Y, 1988, MOL IMMUNOL, V25, P419; KOJIMA N, 1992, BIOCHEM BIOPH RES CO, V182, P1288, DOI 10.1016/0006-291X(92)91872-N; KUAN SF, 1989, J BIOL CHEM, V264, P19271; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN E, 1989, CELL, V59, P305, DOI 10.1016/0092-8674(89)90292-4; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; MAEMURA K, 1992, J BIOL CHEM, V267, P24379; MCEVER RP, 1991, J CELL BIOCHEM, V45, P156, DOI 10.1002/jcb.240450206; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; MULLIGAN MS, 1993, NATURE, V364, P149, DOI 10.1038/364149a0; NAGATA K, 1993, J IMMUNOL, V151, P3267; OSAWA T, 1987, ANNU REV BIOCHEM, V56, P21, DOI 10.1146/annurev.biochem.56.1.21; PICK E, 1981, J IMMUNOL METHODS, V46, P211, DOI 10.1016/0022-1759(81)90138-1; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; RINDER HM, 1991, BLOOD, V78, P1760; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SHITARA K, 1987, CANCER RES, V47, P1267; SUTHERLAND DR, 1992, J IMMUNOL, V148, P1458; TANOUE K, 1993, PLATELETS, V4, P31, DOI 10.3109/09537109309013193; TSUNEHISA S, 1984, BIOCHIM BIOPHYS ACTA, V797, P10; YAMASHITA Y, 1989, J BIOCHEM-TOKYO, V106, P961, DOI 10.1093/oxfordjournals.jbchem.a122982	27	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					23290	23295						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	7521876				2022-12-27	WOS:A1994PQ16400060
J	TAKEUCHI, M; LILLIS, R; DEMPLE, B; TAKESHITA, M				TAKEUCHI, M; LILLIS, R; DEMPLE, B; TAKESHITA, M			INTERACTIONS OF ESCHERICHIA-COLI ENDONUCLEASE-IV AND EXONUCLEASE-III WITH ABASIC SITES IN DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APURINIC APYRIMIDINIC ENDONUCLEASES; IONIZING-RADIATION; REPAIR; PROTEIN; DAMAGE; ENZYME; CDNA; GLYCOSYLASES; MUTAGENESIS; HOMOLOGY	Duplex oligodeoxynucleotides with synthetic analogs of abasic sites were used to study the specificity of the abasic endonucleases of Escherichia coli. The apparent K-m values of exonuclease III for the tetrahydrofuranyl, propanyl, and deoxyribosyl substrates varied only somewhat (20-140 nM) in either Mg2+ or Ca2+ and were similar to those for endonuclease IV. In Mg2+, exonuclease III had a turnover number 4-13-fold higher than measured for endonuclease IV (ranging 5.6-18 min(-1)), but was lowered in Ca2+ to values similar to those for endonuclease IV. The rate of cleavage of tetrahydrofuranyl (F) substrate by both enzymes was unaffected by the base in the opposite strand or its replacement by a tetrahydrofuranyl moiety. A C:C mismatch on the 5' but not the 3' side of F strongly inhibited cleavage by exonuclease III in Ca2+ while mismatches on both sides were required to diminish endonuclease IV cleavage significantly. A phosphorothioate ester linked 5' to the tetrahydrofuranyl moiety inhibited both enzymes, with the R(p) stereoisomer most effective. Endonuclease IV bound stably to duplex substrates containing the R(p) phosphorothioate in the presence of poly(dI-dC). Although the apurinic/apyrimidinic-cleaving activities of endonuclease IV and exonuclease III have some common features they also differ in their specific interactions with DNA containing abasic sites.	SUNY STONY BROOK, DEPT PHARMACOL SCI, STONY BROOK, NY 11794 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT MOLEC & CELLULAR TOXICOL, BOSTON, MA 02115 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Harvard University; Harvard T.H. Chan School of Public Health					NATIONAL CANCER INSTITUTE [R37CA017395, R01CA017395, R01CA037831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES003926] Funding Source: NIH RePORTER; NCI NIH HHS [CA 37831, CA17395] Funding Source: Medline; NIEHS NIH HHS [ES03926] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BERNELOTMOENS C, 1989, NUCLEIC ACIDS RES, V17, P587, DOI 10.1093/nar/17.2.587; CAREY J, 1991, METHOD ENZYMOL, V208, P103; CHAN E, 1987, P NATL ACAD SCI USA, V84, P3189, DOI 10.1073/pnas.84.10.3189; CHIN DH, 1987, P NATL ACAD SCI USA, V84, P7070, DOI 10.1073/pnas.84.20.7070; CUNNINGHAM RP, 1986, J BACTERIOL, V168, P1120, DOI 10.1128/jb.168.3.1120-1127.1986; DEMPLE B, 1983, J BACTERIOL, V153, P1079, DOI 10.1128/JB.153.2.1079-1082.1983; DEMPLE B, 1986, P NATL ACAD SCI USA, V83, P7731, DOI 10.1073/pnas.83.20.7731; DEMPLE B, 1991, P NATL ACAD SCI USA, V88, P11450, DOI 10.1073/pnas.88.24.11450; DOETSCH PW, 1990, MUTAT RES, V236, P173, DOI 10.1016/0921-8777(90)90004-O; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; GILONI L, 1981, J BIOL CHEM, V256, P8608; HENNER WD, 1983, J BIOL CHEM, V258, P5198; HUTCHINSON F, 1985, PROG NUCLEIC ACID RE, V32, P115, DOI 10.1016/S0079-6603(08)60347-5; KOW YW, 1985, P NATL ACAD SCI USA, V82, P8354, DOI 10.1073/pnas.82.24.8354; LEVIN JD, 1991, J BIOL CHEM, V266, P22893; LEVIN JD, 1988, J BIOL CHEM, V263, P8066; Lindahl T, 1979, Prog Nucleic Acid Res Mol Biol, V22, P135; LINDAHL T, 1972, BIOCHEMISTRY-US, V11, P3610, DOI 10.1021/bi00769a018; LJUNGQUIST S, 1976, J BACTERIOL, V126, P646, DOI 10.1128/JB.126.2.646-653.1976; LOEB LA, 1986, ANNU REV GENET, V20, P201, DOI 10.1146/annurev.ge.20.120186.001221; POPOFF SC, 1990, P NATL ACAD SCI USA, V87, P4193, DOI 10.1073/pnas.87.11.4193; POVIRK LF, 1989, MUTAT RES, V214, P13, DOI 10.1016/0027-5107(89)90193-0; ROBSON CN, 1991, NUCLEIC ACIDS RES, V19, P5519, DOI 10.1093/nar/19.20.5519; Rogers S G, 1980, Methods Enzymol, V65, P201; RYDBERG B, 1991, P NATL ACAD SCI USA, V88, P6839, DOI 10.1073/pnas.88.15.6839; SANDER M, 1991, P NATL ACAD SCI USA, V88, P6780, DOI 10.1073/pnas.88.15.6780; SEKI S, 1991, J BIOL CHEM, V266, P20797; SPITZER S, 1988, NUCLEIC ACIDS RES, V16, P11691, DOI 10.1093/nar/16.24.11691; TAKESHITA M, 1987, J BIOL CHEM, V262, P10171; TCHOU J, 1993, J BIOL CHEM, V268, P26738; TULLIUS TD, 1987, METHOD ENZYMOL, V155, P537; VONSONNTAG C, 1981, ADV RADIAT BIOL, V9, P109; WALLACE SS, 1988, ENVIRON MOL MUTAGEN, V12, P431, DOI 10.1002/em.2860120411; WEISS B, 1976, J BIOL CHEM, V251, P1896; WEISS B, 1981, ENZYMES, V14, P203	35	59	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	1994	269	34					21907	21914						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PK973	7520446				2022-12-27	WOS:A1994PK97300076
J	LAFLEUR, DW; FAGIN, JA; FORRESTER, JS; RUBIN, SA; SHARIFI, BG				LAFLEUR, DW; FAGIN, JA; FORRESTER, JS; RUBIN, SA; SHARIFI, BG			CLONING AND CHARACTERIZATION OF ALTERNATIVELY SPLICED ISOFORMS OF RAT TENASCIN - PLATELET-DERIVED GROWTH FACTOR-BB MARKEDLY STIMULATES EXPRESSION OF SPLICED VARIANTS OF TENASCIN MESSENGER-RNA IN ARTERIAL SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; HEXABRACHION TENASCIN; FIBRONECTIN; MIGRATION; FRAGMENTS; PHENOTYPE; ADHESION; SEQUENCE; LAMININ; BINDING	To understand the alteration of extracellular matrix composition evoked by chemotactic factors, we have studied the expression of adhesive (fibronectin) and anti-adhesive (tenascin) proteins in response to platelet-derived growth factor-BB (PDGF-BB), a potent chemoattractant for rat aortic smooth muscle cells (ASMC). PDGF-BB markedly induced two major tenascin mRNA transcripts, whereas fibronectin mRNA levels did not change. The results of immunoprecipitation studies paralleled Northern blot data. Since alternative splicing is responsible for the generation of multiple tenascin mRNAs in other cell types, we studied the effect of chemotactic factors on the relative abundance of tenascin isoforms. The alternatively spliced region of ASMC-derived rat tenascin was amplified and the identity of the products confirmed by sequencing. Three major polymerase chain reaction products were detected: a 1727-base pair unspliced form which was maximal at 2 h and 635- and 362-base pair products which were more abundant at 8 h after treatment with PDGF-BB or angiotensin II, Functional studies showed that the unspliced isoform of human tenascin inhibited attachment of both human and rat ASMC to fibronectin. These results suggest that PDGF-BB markedly up-regulates the expression of tenascin variants, which may bad to destabilization of cell matrix interactions and promotion of cell migration.	UNIV CALIF LOS ANGELES,CEDARS SINAI MED CTR,SCH MED,DIV CARDIOL,LOS ANGELES,CA 90048	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043802] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL43802] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUKHIL I, 1990, MATRIX, V10, P98, DOI 10.1016/S0934-8832(11)80176-9; BOWENPOPE DF, 1989, J BIOL CHEM, V264, P2502; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chiquet-Ehrismann R, 1991, CURR OPIN CELL BIOL, V3, P800, DOI 10.1016/0955-0674(91)90053-2; CHIQUETEHRISMANN R, 1986, CELL, V47, P131, DOI 10.1016/0092-8674(86)90374-0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLOWES AW, 1985, CIRC RES, V56, P139, DOI 10.1161/01.RES.56.1.139; DIMILLA PA, 1993, J CELL BIOL, V122, P729, DOI 10.1083/jcb.122.3.729; DURNAM DM, 1983, ANAL BIOCHEM, V131, P385, DOI 10.1016/0003-2697(83)90188-4; ERICKSON HP, 1989, ANNU REV CELL BIOL, V5, P71, DOI 10.1146/annurev.cb.05.110189.000443; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; GLUKHOVA MA, 1989, J CELL BIOL, V109, P357, DOI 10.1083/jcb.109.1.357; GOODMAN SL, 1989, J CELL BIOL, V109, P799, DOI 10.1083/jcb.109.2.799; GULCHER JR, 1989, P NATL ACAD SCI USA, V86, P1588, DOI 10.1073/pnas.86.5.1588; HEDIN U, 1991, AM J PATHOL, V139, P649; HEDIN U, 1988, J CELL BIOL, V107, P307, DOI 10.1083/jcb.107.1.307; HUSMANN K, 1992, J CELL BIOL, V116, P1475, DOI 10.1083/jcb.116.6.1475; Hynes RO, 1990, FIBRONECTIN; INGBER DE, 1990, P NATL ACAD SCI USA, V87, P3579, DOI 10.1073/pnas.87.9.3579; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; LIGHTNER VA, 1990, J CELL SCI, V95, P263; MERRIL CR, 1980, ANAL BIOCHEM, V105, P361; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; SAGA Y, 1991, GENE, V104, P177, DOI 10.1016/0378-1119(91)90248-A; SHARIFI BG, 1992, J BIOL CHEM, V267, P23910; SPRING J, 1989, CELL, V59, P325, DOI 10.1016/0092-8674(89)90294-8; STEIN WD, 1989, CELL SHAPE; WELLER A, 1991, J CELL BIOL, V112, P355, DOI 10.1083/jcb.112.2.355; WOODS A, 1988, COLLAGEN REL RES, V8, P155	29	57	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20757	20763						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	7519614				2022-12-27	WOS:A1994PB31700083
J	WADDELL, TK; FIALKOW, L; CHAN, CK; KISHIMOTO, TK; DOWNEY, GP				WADDELL, TK; FIALKOW, L; CHAN, CK; KISHIMOTO, TK; DOWNEY, GP			POTENTIATION OF THE OXIDATIVE BURST OF HUMAN NEUTROPHILS - A SIGNALING ROLE FOR L-SELECTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; FACTOR-INDUCED DEGRANULATION; INTEGRIN-ASSOCIATED PROTEIN; ADHERENT HUMAN NEUTROPHILS; CYTOSOLIC FREE CA-2+; HYDROGEN-PEROXIDE; RESPIRATORY BURST; ENDOTHELIAL-CELLS; CD11B CD18; P-SELECTIN	Production of reactive oxygen intermediates (ROI) by the NADPH oxidase of neutrophils is a major mechanism of bacterial killing and, in pathologic circumstances, tissue damage. Integrins and selectins participate in neutrophil adhesion but may also play a role in intracellular signaling. The role of L-selectin in ROI production and Ca2+ signaling in suspended neutrophils was examined using the DREG series of anti-L-selectin antibodies. NADPH oxidase activation was assessed in three ways: H2O2 production using either scopoletin or dihydrorhodamine and O-2(-) production using cytochrome c. Alterations in [Ca2+](i) were measured using Fura 2-AM and fluorescence spectrophotometry, Cross-linking of L-selectin with DREG and 2 degrees antibody did not trigger production of H2O2 by itself but significantly enhanced the subsequent response to two soluble activating agents; the formyl peptide formyl-Met-Leu-Phe (fMLP) and tumor necrosis factor (TNF). Potentiation of the oxidative burst was observed using F(ab')(2) fragments but not with irrelevant antibodies and was observed whether 2 degrees antibody was added before or after fMLP. Cross linking of L-selectin also triggered a rise in [Ca2+](i), due, in part, to release from intracellular stores. The intracellular Ca2+ chelator BAPTA blocked both the rise in [Ca2+](i) and the potentiation of the oxidative burst in response to fMLP or TNF. We conclude that cross linking of L-selectin induces intracellular signals, including release of Ca2+, which may contribute to potentiation of the oxidative burst.	UNIV TORONTO,DEPT MED,TORONTO M5S 1A8,ON,CANADA; BOEHRINGER INGELHEIM PHARMACEUT INC,DEPT IMMUNOL,RIDGEFIELD,CT 06877	University of Toronto; Boehringer Ingelheim				Downey, Gregory P/0000-0003-3253-5862				BERTON G, 1992, J CELL BIOL, V116, P1007, DOI 10.1083/jcb.116.4.1007; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; ENTMAN ML, 1990, J CLIN INVEST, V85, P1497, DOI 10.1172/JCI114596; FUORTES M, 1993, J CELL BIOL, V120, P777, DOI 10.1083/jcb.120.3.777; GALLATIN WM, 1983, NATURE, V304, P30, DOI 10.1038/304030a0; HASLETT C, 1985, AM J PATHOL, V119, P101; ISHII Y, 1992, J CELL PHYSIOL, V153, P187, DOI 10.1002/jcp.1041530123; JACONI MEE, 1991, J CELL BIOL, V112, P1249, DOI 10.1083/jcb.112.6.1249; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LINDBERG FP, 1993, J CELL BIOL, V123, P485, DOI 10.1083/jcb.123.2.485; LO SK, 1993, AM J PHYSIOL, V264, pL406; LO SK, 1991, J EXP MED, V173, P1493, DOI 10.1084/jem.173.6.1493; LORANT DE, 1993, J CLIN INVEST, V92, P559, DOI 10.1172/JCI116623; LUNDJOHANSEN F, 1992, J IMMUNOL, V148, P3221; MOREL F, 1991, EUR J BIOCHEM, V201, P523, DOI 10.1111/j.1432-1033.1991.tb16312.x; MURAKAWA Y, 1992, J IMMUNOL, V148, P1771; NAGATA K, 1993, J IMMUNOL, V151, P3267; NASMITH PE, 1987, J BIOL CHEM, V262, P13558; NATHAN C, 1989, J CELL BIOL, V109, P1341, DOI 10.1083/jcb.109.3.1341; NATHAN CF, 1977, J EXP MED, V146, P1648, DOI 10.1084/jem.146.6.1648; NATHAN CF, 1987, J CLIN INVEST, V80, P1550, DOI 10.1172/JCI113241; NAUSEEF WM, 1991, J BIOL CHEM, V266, P5911; NGSIKORSKI J, 1991, EXP CELL RES, V195, P504, DOI 10.1016/0014-4827(91)90402-G; OBRIEN PJ, 1984, METHOD ENZYMOL, V105, P370; PATEL KD, 1991, J CELL BIOL, V112, P749, DOI 10.1083/jcb.112.4.749; RICHTER J, 1990, P NATL ACAD SCI USA, V87, P9472, DOI 10.1073/pnas.87.23.9472; RICHTER J, 1990, J BIOL CHEM, V265, P14358; ROTHE G, 1988, NATURWISSENSCHAFTEN, V75, P354, DOI 10.1007/BF00368326; ROTHLEIN R, 1994, J IMMUNOL, V152, P2488; SCHWARTZ MA, 1991, P NATL ACAD SCI USA, V88, P7849, DOI 10.1073/pnas.88.17.7849; SCHWARTZ MA, 1993, J BIOL CHEM, V268, P19931; SETH A, 1991, P NATL ACAD SCI USA, V88, P7877, DOI 10.1073/pnas.88.17.7877; SHAPPELL SB, 1990, J IMMUNOL, V144, P2702; SNYDERMAN R, 1993, INFLAMMATION BASIC P; STRAUCH UG, 1993, INT IMMUNOL, V5, P393, DOI 10.1093/intimm/5.4.393; VONANDRIAN UH, 1991, P NATL ACAD SCI USA, V88, P7538, DOI 10.1073/pnas.88.17.7538	38	159	161	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18485	18491						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	7518434				2022-12-27	WOS:A1994NW79800042
J	MEI, L; DOHERTY, CA; HUGANIR, RL				MEI, L; DOHERTY, CA; HUGANIR, RL			RNA SPLICING REGULATES THE ACTIVITY OF A SH2 DOMAIN-CONTAINING PROTEIN-TYROSINE-PHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE SIMILARITY; HEMATOPOIETIC-CELLS; MESSENGER-RNAS; RECEPTOR; CLONING; EXPRESSION; FAMILY; PURIFICATION; HOMOLOGY; KINASES	A cDNA which encodes a protein tyrosine phosphatase with two src homology 2 (SH2) domains was isolated from a rat brain cDNA library. This phosphatase appears to be a rat homologue of PTP1D based on its amino acid sequence. The gene is expressed in a variety of tissues, and its mRNA is enriched in the brain, skeletal muscle, and lung. An RNA splice variant (PTP1Di) was also isolated which has four additional amino acid residues (Ala-Leu-Leu-Gln) in the catalytic domain. The catalytic domains of PTP1D and PTP1Di were expressed in Escherichia coli as glutathione S-transferase fusion proteins and purified to near homogeneity. Whereas both PTP1D and PTP1Di had catalytic activity, the V-max of PTP1Di relative to that of PTP1D was 8-fold lower for para-nitrophenylphosphate, 20-fold lower for nicotinic acetylcholine receptor, and 14-fold lower for myelin basic protein. The K-m values of PTP1Di were lower than those of PTP1D for both nicotinic acetylcholine receptor and myelin basic protein, suggesting a higher affinity of PTP1Di for a protein substrate. These two forms also differed in optimum pH for para-nitrophenylphosphate and sensitivity to the inhibitory effects of vanadate, molybdate, and spermidine, In order to see if this insert would affect the catalytic activity of other related phosphatases, the 4-amino acids were inserted in the corresponding region of the catalytic domain of PTP1C. Whereas both the wild type and PTP1Ci which contained the 4-amino acid insert dephosphorylated para-nitrophenylphosphate, nicotinic receptor, and myelin basic protein, the enzyme activity of PTP1Ci was only 11-24% of that of PTP1C wild type. These results demonstrate that the 4-amino acid insert in the catalytic do mains of PTP1D down-regulates its phosphatase activity and suggests that RNA splicing may serve as a regulatory mechanism of protein tyrosine phosphatase activity.	JOHNS HOPKINS UNIV, SCH MED, HOWARD HUGHES MED INST, DEPT NEUROSCI, BALTIMORE, MD 21205 USA	Howard Hughes Medical Institute; Johns Hopkins University			Mei, Lin/G-8755-2012					AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUTIGAN DL, 1992, BIOCHIM BIOPHYS ACTA, V1114, P63, DOI 10.1016/0304-419X(92)90007-L; BROWNSHIMER S, 1990, P NATL ACAD SCI USA, V87, P5148, DOI 10.1073/pnas.87.13.5148; CHARBONNEAU H, 1989, P NATL ACAD SCI USA, V86, P5252, DOI 10.1073/pnas.86.14.5252; CHERNOFF J, 1990, P NATL ACAD SCI USA, V87, P2735, DOI 10.1073/pnas.87.7.2735; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; GU MX, 1991, P NATL ACAD SCI USA, V88, P5867, DOI 10.1073/pnas.88.13.5867; GUAN KL, 1990, P NATL ACAD SCI USA, V87, P1501, DOI 10.1073/pnas.87.4.1501; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; HIRAGA A, 1992, EUR J BIOCHEM, V209, P195, DOI 10.1111/j.1432-1033.1992.tb17277.x; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; JIRIK FR, 1990, FEBS LETT, V273, P239, DOI 10.1016/0014-5793(90)81094-5; KAPLAN R, 1990, P NATL ACAD SCI USA, V87, P7000, DOI 10.1073/pnas.87.18.7000; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KOZLOWSKI M, 1993, J EXP MED, V178, P2157, DOI 10.1084/jem.178.6.2157; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LEVY JB, 1993, J BIOL CHEM, V268, P10573; LOMBROSO PJ, 1991, P NATL ACAD SCI USA, V88, P7242, DOI 10.1073/pnas.88.16.7242; MATTHEWS RJ, 1990, P NATL ACAD SCI USA, V87, P4444, DOI 10.1073/pnas.87.12.4444; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MCLAUGHLIN S, 1993, J BIOL CHEM, V268, P6839; MEI L, 1991, J BIOL CHEM, V266, P16063; OON SH, 1993, J BIOL CHEM, V268, P23964; PAN MG, 1993, J BIOL CHEM, V268, P19284; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; PLUTZKY J, 1992, GENOMICS, V13, P869, DOI 10.1016/0888-7543(92)90172-O; POT DA, 1991, J BIOL CHEM, V266, P19688; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SAHIN M, 1993, J NEUROSCI, V13, P4968; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAP J, 1990, P NATL ACAD SCI USA, V87, P6112, DOI 10.1073/pnas.87.16.6112; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STREULI M, 1987, J EXP MED, V166, P1548, DOI 10.1084/jem.166.5.1548; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; SUGIMOTO S, 1993, J BIOL CHEM, V268, P22771; TIAN SS, 1991, CELL, V67, P675, DOI 10.1016/0092-8674(91)90063-5; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; Wagner K R, 1991, Curr Opin Neurobiol, V1, P65, DOI 10.1016/0959-4388(91)90011-U; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; WALTON KM, 1993, NEURON, V11, P387, DOI 10.1016/0896-6273(93)90193-U; WANG Y, 1991, EMBO J, V10, P3231, DOI 10.1002/j.1460-2075.1991.tb04886.x; YAN H, 1993, J BIOL CHEM, V268, P24880; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949; YANG XH, 1991, CELL, V67, P661, DOI 10.1016/0092-8674(91)90062-4; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; YI TL, 1991, BLOOD, V78, P2222; YU Q, 1992, ONCOGENE, V7, P1051	57	27	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12254	12262						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	7512964				2022-12-27	WOS:A1994NG37700088
J	BOULTON, TG; STAHL, N; YANCOPOULOS, GD				BOULTON, TG; STAHL, N; YANCOPOULOS, GD			CILIARY NEUROTROPHIC FACTOR LEUKEMIA INHIBITORY FACTOR INTERLEUKIN-6 ONCOSTATIN-M FAMILY OF CYTOKINES INDUCES TYROSINE PHOSPHORYLATION OF A COMMON SET OF PROTEINS OVERLAPPING THOSE INDUCED BY OTHER CYTOKINES AND GROWTH-FACTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; SIGNAL TRANSDUCTION; SH3 DOMAINS; TRANSCRIPTION FACTOR; INTERFERON-ALPHA; FACTOR RECEPTOR; KINASE-ACTIVITY; CELLS; GP130; DIFFERENTIATION	Ciliary neurotrophic factor (CNTF), leukemia inhibitory factor (LIF), oncostatin M (OSM), and interleukin-6 (IL6) compose a family of distantly related cytokines that initiate signaling by inducing either homodimerization of the ''beta'' signal transducing receptor component gp130 (in the case of IL6) or heterodimerization between gp130 and the gp130-related LIFRbeta (in the case of CNTF, LIF, and OSM); dimerization of beta receptor components in turn activates members of the Jak/Tyk family of receptor-associated tyrosine kinases. Here we report that CNTF, LIF, OSM, and IL6 induce most of the same protein tyrosine phosphorylations, regardless of the cell type assayed or whether they initiate signaling by inducing homo- or heterodimerization of beta components. Although several of the protein tyrosine phosphorylations induced by the CNTF/LIF/OSM/IL6 family of factors may correspond to novel tyrosine kinase targets, we have been able to demonstrate the involvement of known signaling molecules, such as phospholipase Cgamma, phosphoinositol 3-kinase, phosphotyrosine phosphatase (PTP1D), pp120, SHC, GRB2, STAT91, Paf-1, and the mitogen-activated protein kinases ERK1 and ERK2, revealing substantial convergence not only between the pathways activated by this cytokine family and other cytokines, but with pathways previously known to be activated only by factors that utilize receptor tyrosine kinases. Our data suggest the beta receptor components can form complexes with some of the signaling proteins identified and may play some role in their recruitment.	REGENERON PHARMACEUT INC, TARRYTOWN, NY 10591 USA	Regeneron								ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BONNI A, 1993, SCIENCE, V262, P1575, DOI 10.1126/science.7504325; BOULTON TG, 1991, BIOCHEMISTRY-US, V30, P278, DOI 10.1021/bi00215a038; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; CARTERSU C, 1989, J BIOL CHEM, V264, P18654; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COREY S, 1993, EMBO J, V12, P2681, DOI 10.1002/j.1460-2075.1993.tb05929.x; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DAEIPOUR M, 1993, J IMMUNOL, V150, P4743; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; FLYNN DC, 1992, ONCOGENE, V7, P579; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GOMEZCAMBRONERO J, 1992, P NATL ACAD SCI USA, V89, P7551, DOI 10.1073/pnas.89.16.7551; HALLEK M, 1992, J CELL PHYSIOL, V153, P176, DOI 10.1002/jcp.1041530122; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; IP NY, 1993, NEURON, V10, P89, DOI 10.1016/0896-6273(93)90245-M; KANNER SB, 1991, MOL CELL BIOL, V11, P713, DOI 10.1128/MCB.11.2.713; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; NAKAFUKU M, 1992, J BIOL CHEM, V267, P19448; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; REMILLARD B, 1991, J BIOL CHEM, V266, P14167; ROSE TM, 1991, P NATL ACAD SCI USA, V88, P8641, DOI 10.1073/pnas.88.19.8641; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SATOH T, 1992, J BIOL CHEM, V267, P24149; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; STAHL N, 1993, J BIOL CHEM, V268, P7628; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; TURNER BC, 1993, P NATL ACAD SCI USA, V90, P5544, DOI 10.1073/pnas.90.12.5544; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; VENKITARAMAN AR, 1992, P NATL ACAD SCI USA, V89, P12083, DOI 10.1073/pnas.89.24.12083; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WELHAM MJ, 1992, J IMMUNOL, V149, P2772; WINSTON LA, 1992, J BIOL CHEM, V267, P4747; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	58	321	324	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11648	11655						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	7512571				2022-12-27	WOS:A1994NF96600100
J	HUSLER, T; LOCKERT, DH; KAUFMAN, KM; SODETZ, JM; SIMS, PJ				HUSLER, T; LOCKERT, DH; KAUFMAN, KM; SODETZ, JM; SIMS, PJ			CHIMERAS OF HUMAN-COMPLEMENT C9 REVEAL THE SITE RECOGNIZED BY COMPLEMENT REGULATORY PROTEIN CD59	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MEMBRANE ATTACK COMPLEX; INHIBITORY ACTIVITY; C5B-9; DOMAIN; LYSIS; INSERTION; C8	CD59 antigen is a membrane glycoprotein that inhibits the activity of the C9 component of the C5b-9 membrane attack complex, thereby protecting human cells from lysis by human complement. The complement-inhibitory activity of CD59 is species-selective and is most effective toward C9 derived from human or other primate plasma. By contrast, rabbit C9, which can substitute for human C9 in the membrane attack complex, mediates unrestricted lysis of human cells. To identify the peptide segment of human C9 that is recognized by CD59, rabbit C9 cDNA clones were isolated, characterized, and used to construct hybrid cDNAs for expression of full-length human/rabbit C9 chimeras in COS-7 cells. Ah resulting chimeras were hemolytically active, when tested against chicken erythrocytes bearing C5b-8 complexes. Assays performed in the presence or absence of CD59 revealed that this inhibitor reduced the hemolytic activity of those chimeras containing human C9 sequence between residues 334-415, irrespective of whether the remainder of the protein contained human or rabbit sequence. By contrast, when this segment of C9 contained rabbit sequence, lytic activity was unaffected by CD59. These data establish that human C9 residues 334-415 contain the site recognized by CD59, and they suggest that sequence variability within this segment of C9 is responsible for the observed species-selective inhibitory activity of CD59.	BLOOD CTR SE WISCONSIN INC, BLOOD RES INST, MILWAUKEE, WI 53201 USA; UNIV S CAROLINA, SCH MED, COLUMBIA, SC 29208 USA; UNIV S CAROLINA, DEPT CHEM & BIOCHEM, COLUMBIA, SC 29208 USA	Versiti Blood Center of Wisconsin; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of South Carolina; University of South Carolina System; University of South Carolina Columbia					NHLBI NIH HHS [HL36061] Funding Source: Medline; NIGMS NIH HHS [GM42898] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036061, R37HL036061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042898] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRAGA LL, 1992, J CLIN INVEST, V90, P1131, DOI 10.1172/JCI115931; CHANG CP, 1994, J BIOL CHEM, V269, P26424; DALMASSO AP, 1992, IMMUNOPHARMACOLOGY, V24, P149, DOI 10.1016/0162-3109(92)90020-D; DAVIES A, 1993, IMMUNOL RES, V12, P258, DOI 10.1007/BF02918257; DUPUIS M, 1993, MOL IMMUNOL, V30, P95, DOI 10.1016/0161-5890(93)90430-J; ESSER AF, 1994, TOXICOLOGY, V87, P229, DOI 10.1016/0300-483X(94)90253-4; HUGHES TR, 1992, BIOCHEM J, V284, P169, DOI 10.1042/bj2840169; MERI S, 1990, IMMUNOLOGY, V71, P1; NINOMIYA H, 1992, J BIOL CHEM, V267, P13675; Okada N, 1989, Int Immunol, V1, P205, DOI 10.1093/intimm/1.2.205; PARIZADE M, 1994, J EXP MED, V179, P1625, DOI 10.1084/jem.179.5.1625; PEITSCH MC, 1990, MOL IMMUNOL, V27, P589, DOI 10.1016/0161-5890(90)90001-G; ROLLINS SA, 1990, J IMMUNOL, V144, P3478; ROLLINS SA, 1991, J IMMUNOL, V146, P2345; ROSSE WF, 1992, CURR TOP MICROBIOL, V178, P163; ROTHER RP, 1994, J VIROL, V68, P730, DOI 10.1128/JVI.68.2.730-737.1994; STANLEY KK, 1989, CURR TOP MICROBIOL, V140, P49; TOMLINSON S, 1994, J IMMUNOL, V152, P1927; VANDENBERG CW, 1993, IMMUNOLOGY, V78, P349; WHITE RV, 1994, J IMMUNOL, V152, P2501; WIEDMER T, 1985, J MEMBRANE BIOL, V84, P249, DOI 10.1007/BF01871388; WIEDMER T, 1985, J BIOL CHEM, V260, P8014; ZHAO J, 1991, J BIOL CHEM, V266, P13418	23	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3483	3486						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7533152				2022-12-27	WOS:A1995QH68800006
J	ASHMARINA, LI; RUSNAK, N; MIZIORKO, HM; MITCHELL, GA				ASHMARINA, LI; RUSNAK, N; MIZIORKO, HM; MITCHELL, GA			3-HYDROXY-3-METHYLGLUTARYL-COA LYASE IS PRESENT IN MOUSE AND HUMAN LIVER PEROXISOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMARY HYPEROXALURIA TYPE-1; RAT-LIVER; GLYOXYLATE AMINOTRANSFERASE; COENZYME; CHOLESTEROL; LOCALIZATION; BIOSYNTHESIS; FIBROBLASTS; METABOLISM; MICROSOMES	3-Hydroxy-3-methylglutaryl (HMG)-CoA metabolism is compartmentalized in mitochondria, endoplasmic reticulum, and peroxisomes. We investigated the subcellular distribution of HMG-CoA lyase (HL), which is found principally in mitochondria but in which we observed the potential peroxisomal targeting motif cysteine-lysine/arginine-leucine at the carboxyl terminus. We used differential and density gradient centrifugation to separate peroxisomes and mitochondria in liver homogenates of outbred CD-1 mice. Peroxisomal fractions contained 6.4% of total HL activity in mouse liver and 5.6% in human liver. Liver peroxisomal HL activity increased 2.3-2.5 times following induction of peroxisomal proliferation by clofibrate administration. Western blotting with anti-human HL antibodies confirmed the presence of immunoreactive HL in peroxisomal fractions, Mouse liver peroxisomal HL is distinct from mitochondrial HL, measuring similar to 2.5 kDa more by sodium dodecyl sulfate polyacrylamide gel electrophoresis. By fast protein liquid chromatofocusing analysis, the pi of peroxisomal. HL is 7.3, in contrast to 6.2 for mitochondrial HL. These results are consistent with noncleavage of the mitochondrial leader peptide in peroxisomal HL. A distinct species of enzymatically active HL exists in peroxisomes and may play a role in HMG-CoA metabolism in that organelle.	HOP ST JUSTINE, SERV GENET MED, MONTREAL H3T 1C5, PQ, CANADA; UNIV MONTREAL, FAC MED, DEPT PEDIAT, MONTREAL H3T 1C5, PQ, CANADA; MED COLL WISCONSIN, DEPT BIOCHEM, MILWAUKEE, WI 53226 USA	Universite de Montreal; Universite de Montreal; Medical College of Wisconsin					NIDDK NIH HHS [DK 21491] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK021491, R01DK021491] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEAUFAY H, 1974, J CELL BIOL, V61, P188, DOI 10.1083/jcb.61.1.188; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLINKENBEARD KD, 1975, J BIOL CHEM, V250, P3108; DANPURE CJ, 1993, BIOCHIMIE, V75, P309, DOI 10.1016/0300-9084(93)90091-6; DANPURE CJ, 1989, J CELL BIOL, V108, P1345, DOI 10.1083/jcb.108.4.1345; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DUVE CD, 1955, BIOCHEM J, V60, P604, DOI 10.1042/bj0600604; ENDO A, 1989, ADV ENZYME REGUL, V28, P53; ERICSSON J, 1993, BIOCHIMIE, V75, P167, DOI 10.1016/0300-9084(93)90074-3; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; KELLER GA, 1986, J CELL BIOL, V103, P875, DOI 10.1083/jcb.103.3.875; KRAMER PR, 1983, BIOCHEMISTRY-US, V22, P2353, DOI 10.1021/bi00279a008; KRISANS SK, 1992, AM J RESP CELL MOL, V7, P358, DOI 10.1165/ajrcmb/7.4.358; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZAROW PB, 1987, J INHERIT METAB DIS, V10, P11, DOI 10.1007/BF01812843; LEIGHTON F, 1968, J CELL BIOL, V37, P482, DOI 10.1083/jcb.37.2.482; MITCHELL GA, 1993, J BIOL CHEM, V268, P4376; MIURA S, 1984, J BIOL CHEM, V259, P6397; NOLTMANN EA, 1966, METHOD ENZYMOL, V9, P557; ROBERTS JR, 1994, J BIOL CHEM, V269, P17841; ROME LH, 1979, CELL, V17, P143, DOI 10.1016/0092-8674(79)90302-7; SHMIDT E, 1974, METHOD ENZYMAT AN, P650; STAMELLOS KD, 1992, J BIOL CHEM, V267, P5560; SWEETMAN L, 1989, METABOLIC BASIS INHE, P791; THOMPSON SL, 1990, J BIOL CHEM, V265, P5731; VANDENBOSCH H, 1992, ANNU REV BIOCHEM, V61, P157, DOI 10.1146/annurev.bi.61.070192.001105; WANDERS RJA, 1988, CLIN CHIM ACTA, V171, P95, DOI 10.1016/0009-8981(88)90294-X; Wang S., 1994, American Journal of Human Genetics, V55, pA248; WANG SP, 1993, MAMM GENOME, V4, P382, DOI 10.1007/BF00360589; WYSYNSKI AM, 1993, HUM EXP TOXICOL, V12, P337, DOI 10.1177/096032719301200413	31	34	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31929	31932						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7527399				2022-12-27	WOS:A1994PX30300091
J	TERADA, Y; TOMITA, K; HOMMA, MK; NONOGUCHI, H; YANG, TX; YAMADA, T; YUASA, Y; KREBS, EG; SASAKI, S; MARUMO, F				TERADA, Y; TOMITA, K; HOMMA, MK; NONOGUCHI, H; YANG, TX; YAMADA, T; YUASA, Y; KREBS, EG; SASAKI, S; MARUMO, F			SEQUENTIAL ACTIVATION OF RAF-1 KINASE, MITOGEN-ACTIVATED PROTEIN (MAP) KINASE KINASE, MAP KINASE, AND S6 KINASE BY HYPEROSMOLALITY IN RENAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; DIRECT PHOSPHORYLATION; SIGNAL; OSMOREGULATION; EXPRESSION; PATHWAY; VOLUME; YEAST; NACL; GENE	In the renal medulla during antidiuresis, the extracellular fluid becomes hyperosmotic. Madin-Darby canine kidney (MDCK) epithelial cells adapt in hyperosmotic conditions and serve as a useful tissue culture model for cellular responses to hyperosmolality, We demonstrate that hyperosmolality stimulates phospholipase C, Raf-1 kinase mitogen-activated protein (MAP) kinase kinase, MAP kinase, and S6 kinase activities and that it increases phosphorylation of Raf-1 kinase, and p42 MAP kinase in MDCK cells. Stimulation of these kinases is osmolality-dependent (from 300 to 600 mosm/kg H2O). The time course of activation is sequential; the peak stimulation for Raf-1 kinase is at 5 min, at 10 min for MAP kinase kinase and MAP kinase, and at 20 min for S6 kinase. The activation of Raf-1 kinase and MAP kinase is inhibited by phorbol 12-myristate 13-acetate pretreatment in the presence of calphostin C or H-7. Tyrosine kinase inhibitors (genistein, herbimycin) do not significantly suppress hyperosmolality-induced MAP kinase activity. The increase of Ins-1,4,5-P-s levels by hyperosmolality suggests that activation of these kinases is mediated at least partially via activation of phospholipase C. Thus, hyperosmolality stimulates the serine/threonine kinases, Raf-1 kinase, MAP kinase kinase, MAP kinase, and S6 kinase, via predominantly protein kinase C-dependent, tyrosine kinase-independent pathways in MDCK cells.	TOKYO MED & DENT UNIV,DEPT HYG & ONCOL,BUNKYO KU,TOKYO 113,JAPAN; UNIV WASHINGTON,HOWARD HUGHES MED INST,DEPT PHARMACOL,SEATTLE,WA 98195	Tokyo Medical & Dental University (TMDU); Howard Hughes Medical Institute; University of Washington; University of Washington Seattle	TERADA, Y (corresponding author), TOKYO MED & DENT UNIV,DEPT INTERNAL MED 2,BUNKYO KU,5-45 YUSHIMA 1-CHOME,TOKYO 113,JAPAN.			Nonoguchi, Hiroshi/0000-0001-7831-7380				AHN NG, 1990, J BIOL CHEM, V265, P11495; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BECK F, 1985, PFLUG ARCH EUR J PHY, V405, pS28, DOI 10.1007/BF00581776; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; BURG MB, 1992, J AM SOC NEPHROL, V3, P121; CARDONE MH, 1994, J CELL BIOL, V124, P717, DOI 10.1083/jcb.124.5.717; COHEN DM, 1991, AM J PHYSIOL, V261, pC594, DOI 10.1152/ajpcell.1991.261.4.C594; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; FUKAMI K, 1989, J BIOL CHEM, V264, P14985; GARCIAPEREZ A, 1991, J MEMBRANE BIOL, V119, P1, DOI 10.1007/BF01868535; GRINSTEIN S, 1986, J BIOL CHEM, V261, P8009; HATGUELDEMOUZON S, 1992, J CELL PHYSL, V150, P180; HUGHES DA, 1993, NATURE, V364, P349, DOI 10.1038/364349a0; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LONGECARTER CA, 1993, SCIENCE, V260, P315; LYTLE C, 1992, J BIOL CHEM, V267, P25438; NAKANISHI T, 1989, AM J PHYSIOL, V257, pC795, DOI 10.1152/ajpcell.1989.257.4.C795; NGUYEN TT, 1993, J BIOL CHEM, V268, P9803; PARKER JC, 1993, AM J PHYSIOL, V265, pC1191, DOI 10.1152/ajpcell.1993.265.5.C1191; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; ROBERTS TM, 1992, NATURE, V360, P534, DOI 10.1038/360534a0; SEGER R, 1992, J BIOL CHEM, V267, P14373; SELDIN DW, 1992, KIDNEY PHYSL PATHOPH; SIEGEL JN, 1990, J BIOL CHEM, V265, P18472; THOMAS G, 1982, CELL, V30, P235, DOI 10.1016/0092-8674(82)90029-0; TILLY BC, 1993, J BIOL CHEM, V268, P19919; UCHIDA S, 1989, AM J PHYSIOL, V256, pC614, DOI 10.1152/ajpcell.1989.256.3.C614; UCHIDA S, 1987, AM J PHYSIOL, V253, pC230, DOI 10.1152/ajpcell.1987.253.2.C230; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WANG YZ, 1992, BIOCHEM J, V287, P589, DOI 10.1042/bj2870589; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U	31	115	115	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					31296	31301						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7527042				2022-12-27	WOS:A1994PV51000084
J	HSU, YT; MOLDAY, RS				HSU, YT; MOLDAY, RS			INTERACTION OF CALMODULIN WITH THE CYCLIC GMP-GATED CHANNEL OF ROD PHOTORECEPTOR CELLS - MODULATION OF ACTIVITY, AFFINITY PURIFICATION, AND LOCALIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER SEGMENTS; GUANYLATE-CYCLASE; FUNCTIONAL EXPRESSION; BINDING-PROTEINS; PLASMA-MEMBRANE; CONDUCTANCE; PHOSPHODIESTERASE; SPECTRIN	The cGMP-gated cation channel of rod photoreceptor cells plays a central role in the phototransduction process by controlling the influx of cations into the rod outer segment in response to changes in cGMP levels. Previous studies have shown that the cGMP-gated channel in native rod outer segment membrane vesicles is modulated by calmodulin in a calcium-dependent manner. In this study we report that the immunoaffinity-purified channel consisting of the 63-kDa alpha-subunit and a 240-kDa protein is also modulated by calmodulin when reconstituted into lipid vesicles. In the absence of calmodulin, the purified channel had an apparent k(m) of 33 mu M and a Hill coefficient of 33 for cGMP-dependent efflux of Ca2+ from reconstituted lipid vesicles. In the presence of calmodulin, the K-m increased to 44 mu M without affecting the Hill coefficient or maximum velocity of ion efflux. CalModulin modulation of the channel is inhibited by the calmodulin antagonist, mastoparan. In the absence of mastoparan, the half-maximum inhibition of channel activity (IC50) occurred at 1.85 +/- 0.25 nM calmodulin at a cGMP concentration of 12.5 mu M in the presence of mastoparan, the IC50 value increased to 20.3 +/- 3.8 mu M calmodulin. Based on the strong, selective interaction of calmodulin with the channel, an efficient, general method has been developed to isolate functionally active cGMP-gated channels from mammalian and amphibian photoreceptor membranes. Calmodulin extraction studies, Western blotting, and channel activity measurements indicate that endogenous rod outer segment calmodulin modulates the activity of the channel through its binding to the 240-kDa protein. From these studies we conclude that the 240-kDa protein of the cGMP-gated channel is a major calmodulin target protein of rod outer segment membranes.	UNIV BRITISH COLUMBIA,DEPT BIOCHEM & MOLEC BIOL,VANCOUVER V6T 1Z3,BC,CANADA	University of British Columbia					NATIONAL EYE INSTITUTE [R01EY002422] Funding Source: NIH RePORTER; NEI NIH HHS [EY 02422] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BIEL M, 1993, FEBS LETT, V329, P134, DOI 10.1016/0014-5793(93)80209-D; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BONIGK W, 1993, NEURON, V10, P865, DOI 10.1016/0896-6273(93)90202-3; CHEN TY, 1994, NATURE, V368, P545, DOI 10.1038/368545a0; CHEN TY, 1993, NATURE, V362, P764, DOI 10.1038/362764a0; CHEN TY, 1994, INVEST OPHTH VIS SCI, V35, P1474; COOK NJ, 1987, P NATL ACAD SCI USA, V84, P585, DOI 10.1073/pnas.84.2.585; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; FESENKO EE, 1985, NATURE, V313, P310, DOI 10.1038/313310a0; FLANAGAN SD, 1984, ANAL BIOCHEM, V140, P510, DOI 10.1016/0003-2697(84)90202-1; GORCZYCA WA, 1994, P NATL ACAD SCI USA, V91, P4014, DOI 10.1073/pnas.91.9.4014; GORDON SE, 1994, BIOPHYS J, V66, pA355; HSU YT, 1993, NATURE, V361, P76, DOI 10.1038/361076a0; JOHNSON LV, 1984, CURR EYE RES, V3, P969, DOI 10.3109/02713688409167215; KAUPP UB, 1992, ANNU REV PHYSIOL, V54, P153; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; KAWAMURA S, 1991, NATURE, V349, P420, DOI 10.1038/349420a0; KAWAMURA S, 1993, NATURE, V362, P855, DOI 10.1038/362855a0; KLEE CB, 1988, MOL ASPECTS CELLULAR, V5, P35; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; KOHNKEN RE, 1981, J BIOL CHEM, V256, P2517; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAGNADO L, 1992, NEURON, V8, P995, DOI 10.1016/0896-6273(92)90122-T; LAMBRECHT HG, 1991, EMBO J, V10, P793, DOI 10.1002/j.1460-2075.1991.tb08011.x; MOLDAY LL, 1990, J BIOL CHEM, V265, P18690; MOLDAY RS, 1991, J BIOL CHEM, V266, P21917; MOLDAY RS, 1987, J CELL BIOL, V105, P2589, DOI 10.1083/jcb.105.6.2589; NAGAO S, 1987, BIOCHEMISTRY-US, V26, P1659, DOI 10.1021/bi00380a026; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; STRYER L, 1991, J BIOL CHEM, V266, P10711; WEYAND I, 1994, NATURE, V368, P859, DOI 10.1038/368859a0; WONG S, 1986, BIOCHEMISTRY-US, V25, P6294, DOI 10.1021/bi00368a069; WYLIE DC, 1988, MOL ASPECTS CELLULAR, V5, P1; YAU KW, 1989, ANNU REV NEUROSCI, V12, P289, DOI 10.1146/annurev.ne.12.030189.001445; YAU KW, 1985, NATURE, V317, P252, DOI 10.1038/317252a0	35	66	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29765	29770						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7525588				2022-12-27	WOS:A1994PU28400071
J	GU, ZX; FLETCHER, RS; ARTS, EJ; WAINBERG, MA; PARNIAK, MA				GU, ZX; FLETCHER, RS; ARTS, EJ; WAINBERG, MA; PARNIAK, MA			THE K65R MUTANT REVERSE-TRANSCRIPTASE OF HIV-1 CROSS-RESISTANT TO 2',3'-DIDEOXYCYTIDINE, 2',3'-DIDEOXY-3'-THIACYTIDINE, AND 2',3'-DIDEOXYINOSINE SHOWS REDUCED SENSITIVITY TO SPECIFIC DIDEOXYNUCLEOSIDE TRIPHOSPHATE INHIBITORS IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; DEPENDENT DNA-POLYMERASE; ESCHERICHIA-COLI; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; HTLV-III; TYPE-1; AZT; 3'-AZIDO-3'-DEOXYTHYMIDINE; SUSCEPTIBILITY	The K65R mutation in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) encodes cross-resistance to 2',3'-dideoxycytidine (ddC), 2',3'-dideoxy-3'-thiacytidine (3TC), and 2',3'-dideoxyinosine (ddI). We characterized the in vitro sensitivities of recombinant wild type (wt) and K65R mutant RT to dideoxynucleoside triphosphate (ddNTP) inhibitors, using a variety of primer-templates, With poly(rA)-oligo(dT), the K65R mutant showed slight increases in K-i for ddTTP and 3'-azido, 3'-deoxythymidine triphosphate (AZTTP) compared to wt RT, but neither wt nor K65R RT was inhibited by ddCTP or ddATP. With poly(rI)-oligo(dC), the K65R mutant showed a 2-fold increase in Ii;, for dCTP and a 20-fold increase in K-i for ddCTP compared to wt, whereas ddATP, ddTTP, and AZTTP failed to inhibit either enzyme. With a heteropolymeric primer-template, the K65R mutant showed 10-fold reduced sensitivities to ddCTP, 3TCTP, and ddATP, and 4-fold reduced sensitivity to AZTTP, compared to wt. In contrast, both enzymes were equally inhibited by ddTTP and ddGTP. HIV-1 cross-resistance to ddC/3TC/ddI resulting from the K65R mutation may therefore involve selective alterations in substrate/inhibitor recognition. Additionally, competitive inhibition by ddNTPs noncomplementary to the template base appears to be unimportant in the mechanism of inhibition of HIV-1 RT by dideoxynucleoside analogs.	SIR MORTIMER B DAVIS JEWISH HOSP,LADY DAVIS INST MED RES,MONTREAL H3T 1E2,PQ,CANADA; MCGILL UNIV,MCGILL AIDS CTR,MONTREAL H3T 1E2,PQ,CANADA	Lady Davis Institute; McGill University; McGill University				Arts, Eric/0000-0002-4880-7968				ARTS EJ, 1994, J BIOL CHEM, V269, P14672; BOYER PL, 1992, J VIROL, V66, P1031, DOI 10.1128/JVI.66.2.1031-1039.1992; CLARK PK, 1990, AIDS RES HUM RETROV, V6, P753, DOI 10.1089/aid.1990.6.753; DEIBEL MR, 1990, AIDS RES HUM RETROV, V6, P329, DOI 10.1089/aid.1990.6.329; FITZGIBBON JE, 1992, ANTIMICROB AGENTS CH, V36, P153, DOI 10.1128/AAC.36.1.153; GOODY RS, 1991, FEBS LETT, V291, P1, DOI 10.1016/0014-5793(91)81089-Q; GU ZX, 1992, J VIROL, V66, P7128, DOI 10.1128/JVI.66.12.7128-7135.1992; GU ZX, 1994, ANTIMICROB AGENTS CH, V38, P275, DOI 10.1128/AAC.38.2.275; HIZI A, 1989, VIROLOGY, V170, P326, DOI 10.1016/0042-6822(89)90389-9; HOFFMAN AD, 1985, VIROLOGY, V147, P326, DOI 10.1016/0042-6822(85)90135-7; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LACEY SF, 1992, J BIOL CHEM, V267, P15789; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; MARTIN JL, 1993, P NATL ACAD SCI USA, V90, P6135, DOI 10.1073/pnas.90.13.6135; MULLER B, 1989, J BIOL CHEM, V264, P13975; MULLER B, 1991, J BIOL CHEM, V266, P14709; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; REARDON JE, 1990, J BIOL CHEM, V265, P20302; REY MA, 1984, BIOCHEM BIOPH RES CO, V121, P126, DOI 10.1016/0006-291X(84)90696-X; RICHMAN DD, 1993, ANTIMICROB AGENTS CH, V37, P1207, DOI 10.1128/AAC.37.6.1207; Sambrook J, 1989, MOL CLONING LABORATO; Segel I.H., 1975, ENZYME KINETICS; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504; WAINBERG MA, 1990, ANN NY ACAD SCI, V616, P346; WU J, 1993, J BIOL CHEM, V268, P9980; ZHANG D, 1994, ANTIMICROB AGENTS CH, V38, P282, DOI 10.1128/AAC.38.2.282	28	89	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28118	28122						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7525567				2022-12-27	WOS:A1994PV77200053
J	BRDICZKA, D; KALDIS, P; WALLIMANN, T				BRDICZKA, D; KALDIS, P; WALLIMANN, T			IN-VITRO COMPLEX-FORMATION BETWEEN THE OCTAMER OF MITOCHONDRIAL CREATINE-KINASE AND PORIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; OUTER-MEMBRANE PORE; SARCOPLASMIC-RETICULUM; CONTACT SITES; PURIFICATION; METABOLISM; TISSUES; PROTEIN; FORMS	An interaction of mitochondrial creatine kinase with purified outer mitochondrial porin (voltage-dependent anion channel) was shown by co sedimentation assays as well as by gel permeation chromatography. Porin formed high M(r) complexes with wild-type mitochondrial creatine kinase as well as with an N-terminal deletion mutant, lacking the first five N-terminal amino acids. The complexes were identified by creatine kinase activity in parallel with immunoblotting using specific antibodies against the two proteins. In addition, porin induced octamerization of the N-terminal creatine kinase mutant, which under the same conditions without porin, did not polymerize but remained more than 90% dimeric. Furthermore, binding of mitochondrial creatine kinase to porin affected the conductance of porin when reconstituted in ''black membranes.'' At 10 mV the pore in the complex adopted a low conductance (1.5-2 nanosiemens) state, compared to the high conductance state (3-4 nanosiemens) of the free incorporated pores. The former state of the pore is known to be cationically selective. Thus, besides a specific structural interaction, a defined physiological function is assumed of the mitochondrial creatine kinase porin complexes that are discussed here.	ETH HONGGERBERG, INST CELL BIOL, CH-8093 ZURICH, SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich	BRDICZKA, D (corresponding author), UNIV KONSTANZ, FAC BIOL, D-78434 CONSTANCE, GERMANY.		Kaldis, Philipp/G-2714-2010; Wallimann, Theo/C-6047-2008	Kaldis, Philipp/0000-0002-7247-7591; Wallimann, Theo/0000-0003-4957-5836				BENZ R, 1990, BIOCHIM BIOPHYS ACTA, V1022, P311, DOI 10.1016/0005-2736(90)90279-W; BENZ R, 1992, J BIOENERG BIOMEMBR, V24, P33, DOI 10.1007/BF00769528; BESSMAN SP, 1985, ANNU REV BIOCHEM, V54, P831, DOI 10.1146/annurev.bi.54.070185.004151; BRDICZKA D, 1991, BIOCHIM BIOPHYS ACTA, V1071, P291, DOI 10.1016/0304-4157(91)90018-R; BROOKS SPJ, 1987, ARCH BIOCHEM BIOPHYS, V257, P144, DOI 10.1016/0003-9861(87)90553-4; Bucher T, 1964, HOPPESEYLER THIERFEL, P293; COLOMBINI M, 1979, NATURE, V279, P643, DOI 10.1038/279643a0; DEPINTO V, 1987, BIOCHIM BIOPHYS ACTA, V905, P499, DOI 10.1016/0005-2736(87)90480-9; DEPINTO V, 1991, BIOCHEMISTRY-US, V30, P10191, DOI 10.1021/bi00106a017; ERICKSONVIITANEN S, 1982, J BIOL CHEM, V257, P4395; GELLERICH FN, 1994, NATO ASI SER H, V83, P337; JACOBS H, 1964, BIOCHEM BIOPH RES CO, V16, P516, DOI 10.1016/0006-291X(64)90185-8; JACOBUS WE, 1985, ANNU REV PHYSIOL, V47, P707; KALDIS P, 1994, BIOCHEMISTRY-US, V33, P952, DOI 10.1021/bi00170a014; KALDIS P, 1994, THESIS ETH ZURICH; KORGE P, 1993, EUR J BIOCHEM, V213, P973, DOI 10.1111/j.1432-1033.1993.tb17842.x; KOTTKE M, 1994, BIOCHEM MED METAB B, V51, P105, DOI 10.1006/bmmb.1994.1015; KOTTKE M, 1991, BIOCHIM BIOPHYS ACTA, V1061, P215, DOI 10.1016/0005-2736(91)90287-I; KRAUSE SM, 1992, J BIOL CHEM, V267, P2480; LINDEN M, 1983, BIOCHIM BIOPHYS ACTA, V736, P125, DOI 10.1016/0005-2736(83)90177-3; MULLER M, 1985, J BIOL CHEM, V260, P3839; ROJO M, 1991, J BIOL CHEM, V266, P20290; ROOS N, 1982, BIOCHIM BIOPHYS ACTA, V686, P204, DOI 10.1016/0005-2736(82)90114-6; ROSSI AM, 1990, J BIOL CHEM, V265, P5258; SAKS VA, 1978, CAN J PHYSIOL PHARM, V56, P691, DOI 10.1139/y78-113; SAKS VA, 1993, BIOCHIM BIOPHYS ACTA, V1144, P134, DOI 10.1016/0005-2728(93)90166-D; SCHEIN SJ, 1976, J MEMBRANE BIOL, V30, P99, DOI 10.1007/BF01869662; SCHLEGEL J, 1988, J BIOL CHEM, V263, P16942; SCHNYDER T, 1988, J BIOL CHEM, V263, P16954; THINNES FP, 1989, BIOL CHEM H-S, V370, P1253; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; Wallimann T, 1985, Cell Muscle Motil, V6, P239; WYSS M, 1992, BIOCHIM BIOPHYS ACTA, V1102, P119, DOI 10.1016/0167-4838(92)90506-9	33	84	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27640	27644						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7525559				2022-12-27	WOS:A1994PV77100075
J	DELUDE, RL; FENTON, MJ; SAVEDRA, R; PERERA, PY; VOGEL, SN; THIERINGER, R; GOLENBOCK, DT				DELUDE, RL; FENTON, MJ; SAVEDRA, R; PERERA, PY; VOGEL, SN; THIERINGER, R; GOLENBOCK, DT			CD14-MEDIATED TRANSLOCATION OF NUCLEAR FACTOR-KAPPA-B INDUCED BY LIPOPOLYSACCHARIDE DOES NOT REQUIRE TYROSINE KINASE-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LPS BINDING-PROTEIN; TRANSCRIPTION FACTOR; SOLUBLE CD14; BACTERIAL LIPOPOLYSACCHARIDE; INTERLEUKIN-6 GENE; BEARING PARTICLES; ENDOTHELIAL-CELLS; CNTF RECEPTOR; ACTIVATION; MACROPHAGES	During the course of serious bacterial infections, lipopolysaccharide (LPS) is believed to interact with macrophage receptors, resulting in the generation of inflammatory mediators and systemic symptoms including hemodynamic instability and shock. CD14, a glycosylphosphatidylinositol-linked antigen, functions as an LPS signaling receptor. A critical issue concerns the mechanism by which CD14, which has no transmembrane domain, transduces its signal following LPS binding. Recently, investigators have hypothesized that CD14-mediated signaling is effected through a receptor-associated tyrosine kinase (TK), suggesting a multicomponent receptor model of LPS signaling. Wild-type Chinese hamster ovary (CHO)-K1 cells can be activated by endotoxin to release arachidonate following transfection with human CD14 (CHO/CD14). Nuclear translocation of cytosolic NF-kappa B is correlated with a number of LPS-inducible responses. We sought to determine if this pathway were present in CHO/CD14 cells and to elucidate the relationship of NF-kappa B activation to the CD14 receptor system. LPS-stimulated translocation of NF-kappa B in CHO/CD14 cells resembled the same response in the murine macrophage-like cell line RAW 264.7. Protein synthesis inhibitors and corticosteroids, which suppress arachidonate release and the synthesis of proinflammatory cytokines, had no effect on translocation of NF-kappa B in CHO/CD14 or RAW 264.7 cells, demonstrating that NF-kappa B translocation is an early event. Although TK activity was consistently observed by immunoblotting extracts from activated RAW 264.7 cells, LPS-induced phosphotyrosine residues were not observed from similarly treated CHO/CD14 cells. Furthermore, the TK inhibitors herbimycin A and genistein failed to inhibit translocation of NF-kappa B in CHO/CD14 or RAW 264.7 cells, although both of these agents inhibited LPS-induced TK activity in RAW 264.7 cells. These results imply that TK activity is not obligatory for CD14-mediated signal transduction to occur in response to LPS.	BOSTON CITY HOSP,MAXWELL FINLAND LAB INFECT DIS,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT MED,BOSTON,MA 02118; BOSTON UNIV,SCH MED,RES IMMUNOL SECT,BOSTON,MA 02118; UNIFORMED SERV UNIV HLTH SCI,DEPT MICROBIOL & IMMUNOL,BETHESDA,MD 20814; MERCK & CO INC,MERCK SHARP & DOHME RES LABS,DEPT BIOCHEM,RAHWAY,NJ 07065	Boston Medical Center; Boston University; Boston University; Uniformed Services University of the Health Sciences - USA; Merck & Company					NIAID NIH HHS [AI18797, AI33087] Funding Source: Medline; NIGMS NIH HHS [GM47127] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI018797, R56AI018797, R01AI018797, P01AI033087] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM047127] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARDITI M, 1993, INFECT IMMUN, V61, P3149, DOI 10.1128/IAI.61.8.3149-3156.1993; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FREY EA, 1992, J EXP MED, V176, P1665, DOI 10.1084/jem.176.6.1665; GOLDBLUM SE, 1994, J CLIN INVEST, V93, P692, DOI 10.1172/JCI117022; GOLENBOCK DT, 1993, J BIOL CHEM, V268, P22055; HAILMANE, 1994, J EXP MED, V179, P269; HAN JH, 1993, J BIOL CHEM, V268, P25009; HAZIOT A, 1988, J IMMUNOL, V141, P547; HAZIOT A, 1993, J IMMUNOL, V151, P1500; HEUMANND, 1992, J IMMUNOL, V148, P35056; HUNNINGHAKE GW, 1992, MOL CELL BIOL, V12, P3439, DOI 10.1128/MCB.12.8.3439; KITCHENS RL, 1992, J EXP MED, V176, P485, DOI 10.1084/jem.176.2.485; LEE JD, 1993, P NATL ACAD SCI USA, V90, P9930, DOI 10.1073/pnas.90.21.9930; LEE JD, 1992, J EXP MED, V175, P1697, DOI 10.1084/jem.175.6.1697; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; LYNN WA, 1993, INFECT IMMUN, V61, P4452, DOI 10.1128/IAI.61.10.4452-4461.1993; LYNN WA, 1991, J IMMUNOL, V147, P3072; MANTHEY CL, 1993, J EXP MED, V178, P695, DOI 10.1084/jem.178.2.695; MULLER JM, 1993, IMMUNOBIOLOGY, V187, P233; PUGIN J, 1993, P NATL ACAD SCI USA, V90, P2744, DOI 10.1073/pnas.90.7.2744; READ MA, 1993, P NATL ACAD SCI USA, V90, P9887, DOI 10.1073/pnas.90.21.9887; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; SHIMIZU H, 1990, MOL CELL BIOL, V10, P561, DOI 10.1128/MCB.10.2.561; STEFANOVA I, 1993, J BIOL CHEM, V268, P20725; TAMURA GS, 1984, ANAL BIOCHEM, V136, P458, DOI 10.1016/0003-2697(84)90244-6; TOBIAS PS, 1986, J EXP MED, V164, P777, DOI 10.1084/jem.164.3.777; WEINSTEIN SL, 1991, P NATL ACAD SCI USA, V88, P4148, DOI 10.1073/pnas.88.10.4148; WEINSTEIN SL, 1993, J IMMUNOL, V151, P3829; WEINSTEINSL, 1992, J BIOL CHEM, V267, P14955; WRIGHT SD, 1992, J EXP MED, V176, P719, DOI 10.1084/jem.176.3.719; WRIGHT SD, 1989, J EXP MED, V170, P1231, DOI 10.1084/jem.170.4.1231; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311	38	111	111	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22253	22260						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	7520914				2022-12-27	WOS:A1994PE09800052
J	LEPOIVRE, M; FLAMAN, JM; BOBE, P; LEMAIRE, G; HENRY, Y				LEPOIVRE, M; FLAMAN, JM; BOBE, P; LEMAIRE, G; HENRY, Y			QUENCHING OF THE TYROSYL FREE-RADICAL OF RIBONUCLEOTIDE REDUCTASE BY NITRIC-OXIDE - RELATIONSHIP TO CYTOSTASIS INDUCED IN TUMOR-CELLS BY CYTOTOXIC MACROPHAGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED MACROPHAGES; MOLECULAR-CLONING; SMALL-SUBUNIT; PLASMODIUM-FALCIPARUM; ADENOCARCINOMA CELLS; MAMMALIAN-CELLS; IRON COMPLEXES; TARGET-CELLS; SYNTHASE; INHIBITION	Nitric oxide (NO) synthesized by macrophages inhibits tumor cell replication. NO also inhibits ribonucleotide reductase, an enzyme essential for DNA synthesis, probably by quenching the catalytically active tyrosyl free radical of its R2 subunit. The role of this inhibition in NO-mediated cytostasis was thus evaluated. After a 4-h coculture with macrophages, quenching of the radical was demonstrated by electron paramagnetic resonance spectroscopy in transfected L1210-R2 cells overexpressing the R2 protein. Pronounced cytostasis was simultaneously observed. A NO synthase inhibitor greatly reduced both phenomena. Target cells withdrawn from macrophages partially recovered from cytostasis and radical loss within 90 min. Deoxyribonucleosides added to by-pass ribonucleotide reductase inhibition efficiently reversed cytostasis of K-562 cells. After a 24-h coculture, the quenched tyrosyl radical still reappeared in L1210-R2 cells withdrawn from macrophages, but DNA synthesis did not resume. Moreover, deoxyribonucleosides marginally reversed overnight cytostasis of K-562 cells mediated by macrophages but were efficient against cytostasis induced by hydroxyurea, a ribonucleotide reductase inhibitor. Autocrine cytostasis observed early in TA3-H2 cells committed to produce NO was closely correlated with quenching of the tyrosyl radical but not with formation of dinitrosyl-iron complexes. We thus propose that NO-dependent cytostasis begins with a rapid and reversible inhibition of ribonucleotide reductase, progressively reinforced by other, long-lasting antiproliferative effects.	INST CURIE, INSERM, U350, F-91405 ORSAY, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	LEPOIVRE, M (corresponding author), UNIV PARIS 11, INST BIOCHIM, CNRS, URA 1116, F-91405 ORSAY, FRANCE.		Flaman, Jean-Michel/K-8415-2018; Lepoivre, Michel/J-8578-2013	Flaman, Jean-Michel/0000-0003-3544-0199; Bobe, Pierre/0000-0002-8835-6786				BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CAVANAUGH PF, 1985, CANCER RES, V45, P4754; DRAPIER JC, 1993, EMBO J, V12, P3643, DOI 10.1002/j.1460-2075.1993.tb06038.x; DRAPIER JC, 1991, J BIOL CHEM, V266, P10162; DRAPIER JC, 1986, J CLIN INVEST, V78, P790, DOI 10.1172/JCI112642; ENGSTROM Y, 1988, EMBO J, V7, P1615, DOI 10.1002/j.1460-2075.1988.tb02987.x; ERIKSSON S, 1979, BIOCHEMISTRY-US, V18, P2948, DOI 10.1021/bi00581a005; ERIKSSON S, 1984, J BIOL CHEM, V259, P1695; FILATOV D, 1992, J BIOL CHEM, V267, P15816; GIRARD P, 1993, FEBS LETT, V320, P7, DOI 10.1016/0014-5793(93)81645-G; HENRY Y, 1993, FASEB J, V7, P1124, DOI 10.1096/fasebj.7.12.8397130; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; HIBBS JB, 1990, INT CONGR SER, V897, P189; HOWELL ML, 1992, J BIOL CHEM, V267, P1705; HURTA RAR, 1992, J BIOL CHEM, V267, P7066; KARUPIAH G, 1993, SCIENCE, V261, P1445, DOI 10.1126/science.7690156; KELLER R, 1990, CANCER RES, V50, P1421; KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P834, DOI 10.1021/tx00030a017; KWON NS, 1991, J EXP MED, V174, P761, DOI 10.1084/jem.174.4.761; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; LEPOIVRE M, 1990, J BIOL CHEM, V265, P14143; LEPOIVRE M, 1992, J BIOL CHEM, V267, P22994; LEPOIVRE M, 1991, BIOCHEM BIOPH RES CO, V179, P442, DOI 10.1016/0006-291X(91)91390-X; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MAYER J, 1993, INFECT IMMUN, V61, P491, DOI 10.1128/IAI.61.2.491-497.1993; MCCLARTY GA, 1987, BIOCHEMISTRY-US, V26, P8004, DOI 10.1021/bi00398a068; MONCADA S, 1991, PHARMACOL REV, V43, P109; MULSCH A, 1993, BIOCHEM BIOPH RES CO, V196, P1303, DOI 10.1006/bbrc.1993.2394; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; NUSSLER AK, 1993, BIOCHEM BIOPH RES CO, V194, P826, DOI 10.1006/bbrc.1993.1896; NYHOLM S, 1993, BIOCHEMISTRY-US, V32, P11569, DOI 10.1021/bi00094a013; NYHOLM S, 1993, J BIOL CHEM, V268, P26200; PADMAJA S, 1993, BIOCHEM BIOPH RES CO, V195, P539, DOI 10.1006/bbrc.1993.2079; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; ROCKETT KA, 1991, INFECT IMMUN, V59, P3280, DOI 10.1128/IAI.59.9.3280-3283.1991; RUBIN H, 1993, P NATL ACAD SCI USA, V90, P9280, DOI 10.1073/pnas.90.20.9280; SAHLIN M, 1987, BIOCHEMISTRY-US, V26, P5541, DOI 10.1021/bi00391a049; STUBBE JA, 1990, J BIOL CHEM, V265, P5329; STUEHR DJ, 1989, J EXP MED, V169, P1543, DOI 10.1084/jem.169.5.1543; THELANDER M, 1989, EMBO J, V8, P2475, DOI 10.1002/j.1460-2075.1989.tb08383.x; TIPPLES G, 1991, J BACTERIOL, V173, P4932, DOI 10.1128/jb.173.16.4932-4940.1991; VANIN AF, 1993, BIOCHIM BIOPHYS ACTA, V1177, P37, DOI 10.1016/0167-4889(93)90154-H; WEISS G, 1993, EMBO J, V12, P3651, DOI 10.1002/j.1460-2075.1993.tb06039.x; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; YIM CY, 1993, CANCER RES, V53, P5507	50	168	174	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 26	1994	269	34					21891	21897						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PK973	7520445				2022-12-27	WOS:A1994PK97300074
J	KORTH, HG; SUSTMANN, R; THATER, C; BUTLER, AR; INGOLD, KU				KORTH, HG; SUSTMANN, R; THATER, C; BUTLER, AR; INGOLD, KU			ON THE MECHANISM OF THE NITRIC-OXIDE SYNTHASE-CATALYZED CONVERSION OF N-OMEGA-HYDROXY-L-ARGININE TO CITRULLINE AND NITRIC-OXIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BOND-DISSOCIATION ENERGIES; OLEFIN FORMATION; CYTOCHROME-P-450; RADICALS; DEFORMYLATION; INVOLVEMENT; POTENTIALS; AROMATASE; OXIDATION	The mechanism of oxidation of N-omega-hydroxy-L-arginine (NHA) by the iron-dioxygen complex in nitric oxide synthase (NOS) is still uncertain. The uncertainty has not been helped by a lack of precision in the notation used to describe the oxidation states and electrical charges on the iron and oxygen in some of the suggested mechanisms. These problems of notation are addressed, and, in addition, a cyclic voltammetric measurement of the oxidation potential of NHA, namely +0.10 +/- 0.04 V versus normal hydrogen electrode, is used to argue that the sometimes postulated oxidation of NHA by the iron-dioxygen complex to form an intermediate radical cation, NHA(.+), is very unlikely for thermodynamic reasons. Instead, it is suggested that this oxidation occurs by a thermodynamically favored abstraction of the hydrogen atom from the >C=NOH moiety of NHA to form an intermediate iminoxyl radical, 2C=NO.. A subsequent nucleophilic attack by the iron hydroperoxide species formed by this H-atom abstraction on the carbon atom of the iminoxyl radical moiety leads to the production of nitric oxide (NO) and citrulline.	UNIV ST ANDREWS,DEPT CHEM,ST ANDREWS KY16 9ST,FIFE,SCOTLAND; NATL RES COUNCIL CANADA,STEACIE INST MOLEC SCI,OTTAWA K1A 0R6,ON,CANADA	University of St Andrews; National Research Council Canada	KORTH, HG (corresponding author), UNIV ESSEN GESAMTHSCH,INST ORGAN CHEM,UNIV STR 5,D-45117 ESSEN,GERMANY.							AKHTAR M, 1993, J STEROID BIOCHEM, V44, P375, DOI 10.1016/0960-0760(93)90241-N; AKHTAR M, 1982, BIOCHEM J, V201, P569, DOI 10.1042/bj2010569; AKHTAR M, 1991, NAT PROD REP, P527; ATKINSON JK, 1993, BIOCHEMISTRY-US, V32, P9209, DOI 10.1021/bi00086a028; CLEMENT B, 1993, ENDOTHELIUM S, V1, pS18; COLE PA, 1991, J AM CHEM SOC, V113, P8130, DOI 10.1021/ja00021a044; FELDMAN PL, 1993, CHEM ENG NEWS, V71, P26; FUKUZUMI S, 1987, J AM CHEM SOC, V109, P305, DOI 10.1021/ja00236a003; FUKUZUMI S, 1983, B CHEM SOC JPN, V56, P2220, DOI 10.1246/bcsj.56.2220; GERSONDE K, 1983, BIOCH OXIDATIONS, P170; GOLDEN DM, 1990, J PHYS CHEM-US, V94, P5413, DOI 10.1021/j100376a046; GRIVA AP, 1973, INT J CHEM KINET, V5, P869; GROVES JT, 1978, BIOCHEM BIOPH RES CO, V81, P154, DOI 10.1016/0006-291X(78)91643-1; GROVES JT, 1985, J CHEM EDUC, V62, P928, DOI 10.1021/ed062p928; HAWKER PN, 1987, COMPREHENSIVE COORDI, V4, P1185; HILL HAO, 1978, COMPREHENSIVE COORDI, V2, P315; Jefcoate C.R., 1986, CYTOCHROME P 450 STR, P387; KAIM W, 1991, BIOANORGANISCHE CHEM, P87; MAHONEY LR, 1975, J AM CHEM SOC, V97, P4722, DOI 10.1021/ja00849a039; MAHONEY LR, 1973, J AM CHEM SOC, V95, P8610, DOI 10.1021/ja00807a018; MAHONEY LR, 1970, J AM CHEM SOC, V92, P4063, DOI 10.1021/ja00716a039; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MERENYI G, 1990, J PHYS CHEM-US, V94, P5412, DOI 10.1021/j100376a044; MILLER LL, 1988, J AM CHEM SOC, V110, P3982, DOI 10.1021/ja00220a042; PUFAHL RA, 1993, BIOCHEM BIOPH RES CO, V193, P963, DOI 10.1006/bbrc.1993.1719; ROBERTS ES, 1991, P NATL ACAD SCI USA, V88, P8963, DOI 10.1073/pnas.88.20.8963; VAZ ADN, 1991, J AM CHEM SOC, V113, P5886, DOI 10.1021/ja00015a066; WELBORN CH, 1981, J AM CHEM SOC, V103, P2869, DOI 10.1021/ja00400a067; WHITE RE, 1991, PHARMACOL THERAPEUT, V49, P21, DOI 10.1016/0163-7258(91)90020-M	29	115	117	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					17776	17779						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	7517932				2022-12-27	WOS:A1994NV42200006
J	GRUMET, M; MILEV, P; SAKURAI, T; KARTHIKEYAN, L; BOURDON, M; MARGOLIS, RK; MARGOLIS, RU				GRUMET, M; MILEV, P; SAKURAI, T; KARTHIKEYAN, L; BOURDON, M; MARGOLIS, RK; MARGOLIS, RU			INTERACTIONS WITH TENASCIN AND DIFFERENTIAL-EFFECTS ON CELL-ADHESION OF NEUROCAN AND PHOSPHACAN, 2 MAJOR CHONDROITIN SULFATE PROTEOGLYCANS OF NERVOUS-TISSUE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX PROTEIN; CYTOTACTIN; BRAIN; EXPRESSION; RECEPTOR; DOMAINS; LIGAND	We have studied interactions of tenascin with two chondroitin sulfate proteoglycans, neurocan and phosphacan. Neurocan is a multi-domain proteoglycan with a 136-kDa core protein that is synthesized by neurons and binds to hyaluronic acid, whereas the 173-kDa core protein of phosphacan, which is synthesized by glia, represents an extracellular variant of the receptor-type protein tyrosine phosphatase RPTP zeta/beta. Keratan sulfate-containing glycoforms of phosphacan (designated phosphacan-KS) are also present in brain. Immunocytochemical studies of early postnatal rat cerebellum demonstrated that the localization of neurocan, phosphacan, and phosphacan-KS all overlap extensively with that of tenascin, an extracellular matrix protein that modulates cell adhesion and migration. Binding studies using purified proteins covalently attached to fluorescent microbeads demonstrated that proteoglycan-coated beads co-aggregated with differently fluorescing beads coated with tenascin. The co-aggregation was specifically inhibited by Fab' fragments of antibodies against tenascin or the proteoglycans and by soluble neurocan, phosphacan, and tenascin. A solid phase radioligand binding assay confirmed that neurocan, phosphacan, and phosphacan-KS bind to tenascin but not to laminin and fibronectin. Chondroitinase treatment of the proteoglycans or addition of free chondroitin sulfate had no significant effect, indicating that the binding activity is mediated largely via the core glycoproteins. Scatchard analysis demonstrated high affinity binding of I-125-phosphacan, phosphacan-KS, and neurocan to a single site in tenascin, and neurocan and various glycoforms of phosphacan all inhibited binding of I-125-phosphacan to tenascin. In studies of cell adhesion to proteins adsorbed to Petri dishes, phosphacan inhibited adhesion of C6 glioma cells to tenascin whereas neurocan had no effect. Our results suggest that tenascin binds phosphacan and neurocan in vivo and that interactions between chondroitin sulfate proteoglycans and tenascin may play important roles in nervous tissue histogenesis, possibly by modulating signal transduction across the plasma membrane.	NYU,MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016; LA JOLLA INST EXPTL MED,LA JOLLA,CA 92037; SUNY HLTH SCI CTR,DEPT PHARMACOL,BROOKLYN,NY 11203	New York University; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center			grumet, martin/ABC-6462-2020		NIMH NIH HHS [MH-00129] Funding Source: Medline; NINDS NIH HHS [NS-13876, NS-09348] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS009348, R01NS013876] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AUKHIL I, 1993, J BIOL CHEM, V268, P2542; BARNEA G, 1994, IN PRESS J BIOL CHEM; BARTSCH S, 1992, J NEUROSCI, V12, P736; BOURDON MA, 1989, J CELL BIOL, V108, P1149, DOI 10.1083/jcb.108.3.1149; BOURDON MA, 1983, CANCER RES, V43, P2796; CANOLL PD, 1993, DEV BRAIN RES, V75, P293, DOI 10.1016/0165-3806(93)90035-9; Caterson B, 1987, BIOL PROTEOGLYCANS, P1; CROSSIN KL, 1986, J CELL BIOL, V102, P1917, DOI 10.1083/jcb.102.5.1917; ERICKSON HP, 1989, ANNU REV CELL BIOL, V5, P71, DOI 10.1146/annurev.cb.05.110189.000443; FALTZ LL, 1979, J BIOL CHEM, V254, P1375; FRIEDLANDER DR, 1988, J CELL BIOL, V107, P2329, DOI 10.1083/jcb.107.6.2329; FRIEDLANDER DR, 1994, IN PRESS J CELL BIOL; GRUMET M, 1985, P NATL ACAD SCI USA, V82, P8075, DOI 10.1073/pnas.82.23.8075; GRUMET M, 1993, J CELL BIOL, V120, P815, DOI 10.1083/jcb.120.3.815; HIGUCHI M, 1993, ACTA NEUROPATHOL, V85, P481; HOFFMAN S, 1987, P NATL ACAD SCI USA, V84, P2523, DOI 10.1073/pnas.84.8.2523; HOFFMAN S, 1988, J CELL BIOL, V106, P519, DOI 10.1083/jcb.106.2.519; KIANG WL, 1981, J BIOL CHEM, V256, P529; KRUEGER NX, 1992, P NATL ACAD SCI USA, V89, P7417, DOI 10.1073/pnas.89.16.7417; LEVY JB, 1993, J BIOL CHEM, V268, P10573; MAUREL P, 1994, P NATL ACAD SCI USA, V91, P2512, DOI 10.1073/pnas.91.7.2512; Milev P., 1993, Glycobiology, V3, P535; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PRIETO AL, 1992, J CELL BIOL, V119, P663, DOI 10.1083/jcb.119.3.663; PRIETO AL, 1993, P NATL ACAD SCI USA, V90, P10154, DOI 10.1073/pnas.90.21.10154; RAUCH U, 1992, J BIOL CHEM, V267, P19536; RAUCH U, 1991, J BIOL CHEM, V266, P14785; SNOW DM, 1990, DEV BIOL, V138, P359, DOI 10.1016/0012-1606(90)90203-U; SRIRAMARAO P, 1993, J CELL SCI, V105, P1001; WEHRLEHALLER B, 1993, J CELL SCI, V106, P597; ZISCH AH, 1992, J CELL BIOL, V119, P203, DOI 10.1083/jcb.119.1.203	31	235	242	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12142	12146						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	7512960				2022-12-27	WOS:A1994NG37700071
J	JOSEPH, SK; RYAN, SV; PIERSON, S; RENARDROONEY, D; THOMAS, AP				JOSEPH, SK; RYAN, SV; PIERSON, S; RENARDROONEY, D; THOMAS, AP			THE EFFECT OF MERSALYL OIL INOSITOL TRISPHOSPHATE RECEPTOR-BINDING AND ION-CHANNEL FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1,4,5-TRISPHOSPHATE RECEPTOR; CALCIUM RELEASE; CA2+ RELEASE; PERMEABILIZED HEPATOCYTES; THIOL REAGENTS; HAMSTER EGGS; RAT-LIVER; THIMEROSAL; CEREBELLUM; MEMBRANES	A number of thiol-reactive agents induce repetitive Ca2+ spiking in cells by a mechanism thought to involve sensitization of the inositol 1,4,5-trisphosphate receptor (IP(3)R). To further define the basis of this interaction, we have studied the effect of several thiol-reactive agents on [H-3]IP3 binding, IP3-gated channel activity, and conformation of the IP(3)R in membranes from hepatocytes, cultured WR rat liver epithelial cells, and cerebellum microsomes, At 4 degrees C, the organomercurial thiol-reactive agent mersalyl markedly stimulates (3-4-fold) [H-3]IP3 binding to permeabilized hepatocytes. The closely related molecule, thimerosal, has only a small stimulatory effect under these conditions, and GSSG or N-ethylmaleimide are without effect. The stimulatory effect of mersalyl was associated with a decrease in K-d of the IP(3)R with no change in B-max. Mersalyl was without effect on detergent-solubilized hepatocyte binding sites or on the [H-3]IP3 binding activity of cerebellum microsomes. In contrast to thimerosal, which potentiates IP3-mediated Ca2+ release, mersalyl blocked IP3-gated Ca2+ channels. Mersalyl pretreatment of WB membranes altered the pattern of immunoreactive receptor fragments generated upon subsequent cleavage of the receptor with proteinase K. This effect was not reproduced py thimerosal and was also not observed in experiments on cerebellum microsomes. We conclude that the WB cell and brain IP3 receptors are differently regulated by modification of thiol groups. Reaction of the WB cell IP3 receptor with mersalyl alters its conformation and modifies the accessibility of sites on the protein that are cleaved by proteinase K. In the presence of mersalyl, the receptor has high affinity for IP3 but is inactive as a Ca2+ channel, This contrasts with the high affinity receptor/active Ca2+ channel induced by thimerosal, suggesting that even closely related thiol agents may interact at different thiol groups.			JOSEPH, SK (corresponding author), THOMAS JEFFERSON UNIV,SCH MED,DEPT PATHOL & CELL BIOL,RM 230A JAH,1020 LOCUST ST,PHILADELPHIA,PA 19107, USA.		Thomas, Andrew/C-6755-2013	Thomas, Andrew/0000-0002-9026-7467	NIAAA NIH HHS [AA-07186] Funding Source: Medline; NIDDK NIH HHS [DK-38422, DK-34804] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK038422, R01DK038422, R01DK034804] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P50AA007186] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BIRD GS, 1993, J BIOL CHEM, V268, P17917; BLONDEL O, 1993, J BIOL CHEM, V268, P11356; BOOTMAN MD, 1992, J BIOL CHEM, V267, P25113; DANOFF SK, 1991, P NATL ACAD SCI USA, V88, P2951, DOI 10.1073/pnas.88.7.2951; DESMEDT H, 1994, J BIOL CHEM, V269, P21691; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FONYO A, 1978, J BIOENERG BIOMEMBR, V10, P171, DOI 10.1007/BF00743106; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; HILLY M, 1993, J BIOL CHEM, V268, P16488; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; JOSEPH SK, 1985, J BIOL CHEM, V260, P2508; JOSEPH SK, 1993, J BIOL CHEM, V268, P6477; JOSEPH SK, 1989, BIOCHEM J, V258, P261, DOI 10.1042/bj2580261; JOSEPH SK, 1994, J BIOL CHEM, V269, P5673; JOSEPH SK, 1993, J BIOL CHEM, V268, P23059; MAEDA N, 1991, J BIOL CHEM, V266, P1109; MARANTO AR, 1994, J BIOL CHEM, V269, P1222; MARSHALL ICB, 1993, J BIOL CHEM, V268, P13214; MAUGER JP, 1989, J BIOL CHEM, V264, P8821; MICHIKAWA T, 1994, J BIOL CHEM, V269, P9184; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; MIKOSHIBA K, 1993, TRENDS PHARMACOL SCI, V14, P86, DOI 10.1016/0165-6147(93)90069-V; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; MIYAZAKI S, 1992, FEBS LETT, V309, P180, DOI 10.1016/0014-5793(92)81090-9; MIYAZAKI S, 1992, SCIENCE, V257, P251, DOI 10.1126/science.1321497; NAKAGAWA T, 1991, P NATL ACAD SCI USA, V88, P6244, DOI 10.1073/pnas.88.14.6244; PARYS JB, 1993, PFLUG ARCH EUR J PHY, V424, P516, DOI 10.1007/BF00374916; PIETRI F, 1990, J BIOL CHEM, V265, P17478; POITRAS M, 1993, J BIOL CHEM, V268, P24078; PRUIJN FB, 1990, BIOCHEM PHARMACOL, V40, P1947, DOI 10.1016/0006-2952(90)90223-8; RENARD DC, 1992, BIOCHEM J, V284, P507, DOI 10.1042/bj2840507; RENARDROONEY DC, 1993, J BIOL CHEM, V268, P23601; ROONEY TA, 1993, CELL CALCIUM, V14, P674, DOI 10.1016/0143-4160(93)90094-M; ROONEY TA, 1991, J BIOL CHEM, V266, P12272; ROSS CA, 1992, P NATL ACAD SCI USA, V89, P4265, DOI 10.1073/pnas.89.10.4265; ROUXEL FP, 1992, J BIOL CHEM, V267, P20017; SAYERS LG, 1993, BIOCHEM J, V289, P883, DOI 10.1042/bj2890883; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; TAKETERA K, 1993, ANAL CHEM, V65, P3644; TANAKA Y, 1994, J BIOL CHEM, V269, P11247; TSAO MS, 1984, EXP CELL RES, V154, P38, DOI 10.1016/0014-4827(84)90666-9; VANIWAARDEN PR, 1992, BIOCHIM BIOPHYS ACTA, V1113, P161, DOI 10.1016/0304-4157(92)90037-B	46	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3588	3593		10.1074/jbc.270.8.3588	http://dx.doi.org/10.1074/jbc.270.8.3588			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7533153	hybrid			2022-12-27	WOS:A1995QH68800022
J	TEWARI, M; DIXIT, VM				TEWARI, M; DIXIT, VM			FAS-INDUCED AND TUMOR NECROSIS FACTOR-INDUCED APOPTOSIS IS INHIBITED BY THE POXVIRUS CRMA GENE-PRODUCT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-1-BETA CONVERTING ENZYME; PROGRAMMED CELL-DEATH; MONOCLONAL-ANTIBODY; CYTO-TOXICITY; C-ELEGANS; PROTEASE; ANTIGEN; PROTECTION; INDUCTION; RECEPTOR	crmA is a cowpox virus gene that encodes a protease inhibitor of the serpin family, The only reported target for the CrmA protein is the cysteine protease interleukin-1 beta converting enzyme (ICE). ICE, by virtue of its homology to the Caenorhabditis elegans cell death protein Ced-3, has been suggested to play a fundamentally important role in mammalian apoptosis. We hypothe sized that a function of crmA may be to inhibit cell death, since a major mechanism of viral clearance is the immune system-mediated induction of apoptosis of infected cells. The tumor necrosis factor receptor and the Fas antigen are two cytokine receptors which, by engaging and activating the death pathway, can eliminate virus-infected cells. Remarkably, crmA was found to be an exceptionally potent inhibitor of apoptosis induced by both these receptors, capable of blocking the cell death program even at pharmacological doses of the death stimulus. Therefore, an important new function for crmA is the inhibition of cytokine-induced apoptosis. Further, the data suggest that a protease, either ICE or a related crmA-inhibitable protein, is a component of the Fas- and tumor necrosis factor-induced cell death pathways.	UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,GRAD PROGRAM CELLULAR & MOLEC BIOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326	NATIONAL CANCER INSTITUTE [R01CA061348] Funding Source: NIH RePORTER; NCI NIH HHS [CA61348] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAGLIONI C, 1992, TUMOR NECROSIS FACTO, P425; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; DIXIT VM, 1990, J BIOL CHEM, V265, P2973; DUKE RC, 1991, APOPTOSIS MOL BASIS, P209; DUVALL E, 1986, IMMUNOL TODAY, V7, P115, DOI 10.1016/0167-5699(86)90152-0; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; GOODING LR, 1992, CELL, V71, P5; HANABUCHI S, 1994, P NATL ACAD SCI USA, V91, P4930, DOI 10.1073/pnas.91.11.4930; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JU ST, 1994, P NATL ACAD SCI USA, V91, P4185, DOI 10.1073/pnas.91.10.4185; KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; KUMAR S, 1991, J BIOL CHEM, V266, P20960; MARTIN DP, 1992, J NEUROBIOL, V23, P1205, DOI 10.1002/neu.480230911; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; RUGGIERO V, 1987, CELL IMMUNOL, V107, P317, DOI 10.1016/0008-8749(87)90240-1; SPRIGGS DR, 1988, J CLIN INVEST, V81, P455, DOI 10.1172/JCI113341; STALDER T, 1994, J IMMUNOL, V152, P1127; SUFFYS P, 1988, EUR J BIOCHEM, V178, P257, DOI 10.1111/j.1432-1033.1988.tb14451.x; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WANG GHW, 1992, TUMOR NECROSIS FACTO, P371; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	34	597	631	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 17	1995	270	7					3255	3260		10.1074/jbc.270.7.3255	http://dx.doi.org/10.1074/jbc.270.7.3255			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QG471	7531702	hybrid			2022-12-27	WOS:A1995QG47100056
J	POULIN, R; LESSARD, M; ZHAO, CQ				POULIN, R; LESSARD, M; ZHAO, CQ			INORGANIC CATION DEPENDENCE OF PUTRESCINE AND SPERMIDINE TRANSPORT IN HUMAN BREAST-CANCER CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI CHROMOSOME; VACUOLAR MEMBRANE-VESICLES; ISOLATED RAT ENTEROCYTES; BRUSH-BORDER MEMBRANE; PROTON MOTIVE FORCE; POLYAMINE TRANSPORT; ORNITHINE DECARBOXYLASE; LEUKEMIA-CELLS; SACCHAROMYCES-CEREVISIAE; INTRACELLULAR CALCIUM	The mechanism of polyamine uptake in mammalian cells is still poorly understood, The role of inorganic cations in polyamine transport was investigated in ZR-75-1 human breast cancer cells, Although strongly temperature dependent, neither putrescine nor spermidine uptake was mediated by a Na+ cotransport mechanism, In fact, Na+ and cholinium competitively inhibited putrescine uptake relative to that measured in a sucrose based medium, On the other hand, ouabain, H+, Na+, and Ca2+ ionophores, as well as dissipation of the K+ diffusion potential, strongly inhibited polyamine uptake in keeping with a major role of membrane potential in that process, Polyamine transport was inversely de pendent on ambient osmolality at near physiological values, Putrescine transport was inhibited by 70% by decreasing extracellular pH from 7.2 to 6.2, whereas spermidine uptake had a more acidic optimum, Deletion of extracellular Ca2+ inhibited putrescine uptake more strongly than chelation of intracellular Ca2+. In fact, bound divalent cations were absolutely required for polyamine transport, as shown after brief chelation of the cell monolayers with EDTA, Either Mn2+, Ca2+, or Mg2+ sustained putrescine uptake activity with high potency (K-m = 50-300 mu M). Mn2+ was a much stronger activator of spermidine than putrescine uptake, suggesting a specific role for this metal in polyamine transport, Other transition metals (Co2+, Ni2+, Cu2+, and Zn2+) were mixed activators/antagonists of carrier activity, while Sr2+ and Ba2+ were very weak agonists, while not interfering with Ca2+/Mg2+-dependent trans port, Thus, polyamine uptake in human breast tumor cells is negatively affected by ionic strength and osmolality, and is driven, at least in part, by the membrane potential, but not by the Na+ electrochemical gradient, Moreover, the polyamine carrier, or a tightly coupled accessory component, appears to have a high-affinity binding site for divalent cations, which is essential for the uptake mechanism.			POULIN, R (corresponding author), UNIV LAVAL,MED RES CTR,DEPT PHYSIOL,MOLEC ENDOCRINOL LAB,ST FOY,PQ G1V 4G2,CANADA.							ADAMS DJ, 1989, FASEB J, V3, P2389, DOI 10.1096/fasebj.3.12.2477294; AMES GF, 1992, FASEB J, V6, P2660, DOI 10.1096/fasebj.6.9.1377140; BAGNI N, 1985, PLANT PHYSIOL, V77, P398, DOI 10.1104/pp.77.2.398; BALANAFOUCE R, 1989, MOL BIOCHEM PARASIT, V35, P43, DOI 10.1016/0166-6851(89)90140-0; BOGLE RG, 1994, AM J PHYSIOL, V266, pC776, DOI 10.1152/ajpcell.1994.266.3.C776; BYERS TL, 1989, AM J PHYSIOL, V257, pC545, DOI 10.1152/ajpcell.1989.257.3.C545; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.bi.56.070187.002143; CHANG BK, 1988, BIOCHEM BIOPH RES CO, V157, P264, DOI 10.1016/S0006-291X(88)80042-1; DAVIS RH, 1991, ARCH BIOCHEM BIOPHYS, V285, P297, DOI 10.1016/0003-9861(91)90363-N; DAVIS S, 1985, J BIOL CHEM, V260, P3844; DESMEDT H, 1989, BIOCHIM BIOPHYS ACTA, V1012, P171, DOI 10.1016/0167-4889(89)90092-X; FURUCHI T, 1991, J BIOL CHEM, V166, P20928; GALSTON AW, 1989, PHYSL POLYAMINES, V2, P99; GAWELTHOMPSON K, 1988, J CELL PHYSIOL, V136, P237, DOI 10.1002/jcp.1041360205; GORDONSMITH RH, 1983, BIOCHEM PHARMACOL, V32, P3701, DOI 10.1016/0006-2952(83)90138-7; GROBLEWSKI GE, 1992, AM J PHYSIOL, V262, pC1356, DOI 10.1152/ajpcell.1992.262.6.C1356; HANDEL TM, 1993, SCIENCE, V261, P879, DOI 10.1126/science.8346440; HAUSER MR, 1990, AM J PHYSIOL, V259, pC84, DOI 10.1152/ajpcell.1990.259.1.C84; HESTON WDW, 1988, BIOCHEM PHARMACOL, V37, P2511, DOI 10.1016/0006-2952(88)90239-0; KAKINUMA Y, 1988, EUR J BIOCHEM, V176, P409, DOI 10.1111/j.1432-1033.1988.tb14297.x; KAKINUMA Y, 1992, BIOCHIM BIOPHYS ACTA, V1107, P126, DOI 10.1016/0005-2736(92)90337-L; KAPYAHO K, 1982, BIOCHIM BIOPHYS ACTA, V714, P93, DOI 10.1016/0304-4165(82)90130-1; KASHIWAGI K, 1990, J BIOL CHEM, V265, P20893; KASHIWAGI K, 1993, J BIOL CHEM, V268, P19358; KASHIWAGI K, 1991, J BIOL CHEM, V266, P20922; KASHIWAGI K, 1986, J BACTERIOL, V165, P972, DOI 10.1128/jb.165.3.972-977.1986; KHAN NA, 1991, CELL BIOL INT REP, V15, P9, DOI 10.1016/0309-1651(91)90078-W; KHAN NA, 1992, EXP CELL RES, V199, P378, DOI 10.1016/0014-4827(92)90448-H; KHAN NA, 1993, J CELL PHYSIOL, V157, P493, DOI 10.1002/jcp.1041570308; KOBAYASHI M, 1993, BIOCHIM BIOPHYS ACTA, V1151, P161, DOI 10.1016/0005-2736(93)90100-E; KOBAYASHI M, 1992, BIOCHIM BIOPHYS ACTA, V1105, P177, DOI 10.1016/0005-2736(92)90177-N; KUMAGAI J, 1989, AM J PHYSIOL, V256, pG905, DOI 10.1152/ajpgi.1989.256.5.G905; KUMAGAI J, 1988, AM J PHYSIOL, V254, pG81, DOI 10.1152/ajpgi.1988.254.1.G81; LESSARD M, 1995, J BIOL CHEM, V270, P1685, DOI 10.1074/jbc.270.4.1685; Marton LJ, 1987, INHIB POLYAM METABOL, P79; MCCORMACK SA, 1989, AM J PHYSIOL, V256, pG868, DOI 10.1152/ajpgi.1989.256.5.G868; MITCHELL JLA, 1992, BIOCHEM BIOPH RES CO, V186, P81, DOI 10.1016/S0006-291X(05)80778-8; MORGAN MLD, 1991, BIOCHEM SOC T, V18, P1223; MUNRO GF, 1972, J BIOL CHEM, V247, P1272; MUNRO GF, 1973, J BACTERIOL, V116, P488, DOI 10.1128/JB.116.1.488-490.1973; NEWELL KJ, 1989, CANCER RES, V49, P4477; OHSUMI Y, 1981, J BIOL CHEM, V256, P2079; OSBORNE DL, 1990, AM J PHYSIOL, V258, pG576, DOI 10.1152/ajpgi.1990.258.4.G576; PECKER F, 1985, J BIOL CHEM, V260, P731; PEGG AE, 1988, CANCER RES, V48, P759; PERRY JW, 1980, BIOCHIM BIOPHYS ACTA, V629, P24, DOI 10.1016/0304-4165(80)90261-5; PERSSON L, 1988, CANCER RES, V48, P4807; PISTOCCHI R, 1993, J BIOL CHEM, V268, P146; PISTOCCHI R, 1988, J PLANT PHYSL, V136, P728; POHJANPELTO P, 1976, J CELL BIOL, V68, P512, DOI 10.1083/jcb.68.3.512; POULIN R, 1991, J BIOL CHEM, V266, P6142; POULIN R, 1990, J BIOL CHEM, V265, P4025; POULIN R, 1993, J BIOL CHEM, V268, P4690; RANNELS DE, 1989, AM J PHYSIOL, V257, pL346, DOI 10.1152/ajplung.1989.257.6.L346; RINEHART CA, 1984, J BIOL CHEM, V259, P4750; SCALABRINO G, 1991, MOL CELL ENDOCRINOL, V77, P1, DOI 10.1016/0303-7207(91)90056-X; SCALABRINO G, 1991, MOL CELL ENDOCRINOL, V77, P37, DOI 10.1016/0303-7207(91)90057-Y; SEILER N, 1990, CANCER RES, V50, P5077; SEILER N, 1990, INT J BIOCHEM, V22, P211, DOI 10.1016/0020-711X(90)90332-W; SIMARD J, 1990, ENDOCRINOLOGY, V126, P3223, DOI 10.1210/endo-126-6-3223; TABOR CW, 1966, J BIOL CHEM, V241, P3714; TONINELLO A, 1992, J BIOL CHEM, V267, P18393; WATANABE S, 1991, J BIOL CHEM, V266, P20803; WILLIAMS JA, 1970, J THEOR BIOL, V28, P287, DOI 10.1016/0022-5193(70)90056-1	64	37	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 27	1995	270	4					1695	1704		10.1074/jbc.270.4.1695	http://dx.doi.org/10.1074/jbc.270.4.1695			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QD204	7530245	hybrid			2022-12-27	WOS:A1995QD20400035
J	JACKSON, A; TARANTINI, F; GAMBLE, S; FRIEDMAN, S; MACIAG, T				JACKSON, A; TARANTINI, F; GAMBLE, S; FRIEDMAN, S; MACIAG, T			THE RELEASE OF FIBROBLAST GROWTH-FACTOR-I FROM NIH 3T3 CELLS IN RESPONSE TO TEMPERATURE INVOLVES THE FUNCTION OF CYSTEINE RESIDUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							FACTOR-I; GOLGI-COMPLEX; PROTEINS; SEQUENCE	Fibroblast growth factor (FGF)-1 is released from NIH 3T3 cells in response to heat shock as a biologically inactive protein that is unable to bind heparin and requires activation by (NH4)(2)SO4 to generate a biologically active extracellular heparin-binding growth factor (Jackson, A., Friedman, S., Zhan, X., Engleka, K. A., Forough, R., and Maciag, T. (1992) Proc. Natl. Acad. Sci. USA 89, 10691-10695). To further study the mechanism of FGF-1 release in response to heat shock (42 degrees C), we examined the kinetics of FGF-1 release from FGF-1-transfected NIH 3T3 cells and observed that the cells require at least 1 h of exposure to heat shock conditions for the release of FGF-1, Interestingly, agents that interfere with the function of the endoplasmic reticulum-Golgi apparatus, exocytosis, and the multidrug resistance pathway (brefelden A, methylamine, and verapamil, respectively) do not inhibit the release of FGF-1 in response to temperature; rather, they exaggerate the release of FGF-1. Because immunoblot analysis of FGF-1 in the conditioned medium of heat-shocked NM 3T3 cells revealed the presence of a minor band with an apparent molecular weight of a FGF-1 homodimer and because we have previously shown that FGF-1, but not FGF-2, is able to form a homodimer in response to chemical oxidation by CuCl2 (Engleka, K. A., and Maciag, T. (1992) J. Biol. Chem. 267, 11307-11315), we examined whether reducing agents would substitute for (NH4)(2)SO4 and activate extracellular FGF-1. Indeed, dithiothreitol and reduced glutathione are able to individually generate a FGF-1 monomer as a heparin-binding protein from the conditioned medium of heat-shocked NM 3T3 cell transfectants. To confirm that cysteine residues are involved in the release of FGF-1 in response to temperature, we used mutagenesis to prepare a human FGF-1 Cys-free mutant in which Cys(30), Cys(97), and Cys(131) were converted to serine. Analysis of the release of the FGF-1 Cys-free mutant in NM 3T3 cells transfected with the FGF-1 Cys-free mutant demonstrated that the FGF-1 Cys-free mutant is not released into the conditioned medium in response to temperature. Interestingly, exposure of the NM 3T3 cell FGF-1 Cys-free transfectants to brefelden A followed by heat shock also demonstrated the absence of the extracellular FGF-1 Cys-free mutant, Finally, ion-exchange and reverse-phase chromatographies of heat-shocked conditioned medium analyzed by FGF-1 immunoblot analysis were able to resolve FGF-1 as a homodimer under nonreducing conditions and as a monomer under reducing conditions. These data demonstrate that FGF-1 utilizes cysteine residues as an important component of its release from NM 3T3 cells in vitro in response to temperature and exits the cell as a biologically inactive homodimer with reduced heparin affinity that requires activation by reducing agents to generate heparin binding and biological activities.	AMER RED CROSS,HOLLAND LAB,DEPT BIOL MOLEC,ROCKVILLE,MD 20855	American Red Cross			Tarantini, Francesca/I-6332-2012	TARANTINI, FRANCESCA/0000-0002-1390-2965	NHLBI NIH HHS [HL44336, T32-HL07698, HL32348] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032348, T32HL007698, P50HL044336] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; DORVAL G, 1975, J IMMUNOL METHODS, V7, P237, DOI 10.1016/0022-1759(75)90021-6; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; ENGLEKA KA, 1992, J BIOL CHEM, V267, P11307; FOROUGH R, 1993, J BIOL CHEM, V268, P2960; FRIEDMAN S, 1994, BIOCHEM BIOPH RES CO, V198, P1203, DOI 10.1006/bbrc.1994.1170; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; JACKSON A, 1992, P NATL ACAD SCI USA, V89, P10691, DOI 10.1073/pnas.89.22.10691; LIPPINCOTTSCHWARTZ, 1989, CELL, V56, P801; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MIGNATTI P, 1992, J CELL PHYSIOL, V151, P81, DOI 10.1002/jcp.1041510113; ORTEGA S, 1991, J BIOL CHEM, V266, P5842; SARASTE J, 1986, P NATL ACAD SCI USA, V83, P6425, DOI 10.1073/pnas.83.17.6425	14	88	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					33	36		10.1074/jbc.270.1.33	http://dx.doi.org/10.1074/jbc.270.1.33			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7529229	Green Submitted, hybrid			2022-12-27	WOS:A1995QA28700009
J	WEI, Y; WALTZ, DA; RAO, N; DRUMMOND, RJ; ROSENBERG, S; CHAPMAN, HA				WEI, Y; WALTZ, DA; RAO, N; DRUMMOND, RJ; ROSENBERG, S; CHAPMAN, HA			IDENTIFICATION OF THE UROKINASE RECEPTOR AS ALL ADHESION RECEPTOR FOR VITRONECTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR; CELL-ADHESION; GROWTH-FACTOR; HUMAN-BREAST; LIGAND-BINDING; EXPRESSION; MEMBRANE; LOCALIZATION; INTEGRIN; SURFACE	Urokinase receptors, expressed on surfaces of many cell types, focus to the pericellular space plasminogen-dependent proteolysis important in matrix remodeling and cell movement. We now report that the urokinase receptor (uPAR) is also a high affinity (K-d < 30 nar) receptor for vitronectin. Recombinant uPAR binds vitronectin in the absence of urokinase, but vitronectin binding is promoted by concurrent receptor binding of either urokinase or fragments thereof containing its uPAR binding domain. Stable epithelial cell transfectants expressing membrane-anchored uPAR, but not cells expressing soluble uPAR,become strongly adhesive with altered morphology in the absence of urokinase. These observations identify a new class of vitronectin receptor and imply a duality in function for the receptor that intrinsically links matrix adhesion to regulation of protease activity. Increases in urokinase receptor expression known to be associated with cellular activation and malignant transformation could modulate cellular trafficking and function by promoting attachment to vitronectin.	BRIGHAM & WOMENS HOSP, DEPT MED, DIV RESP, BOSTON, MA 02115 USA; HARVARD UNIV, CHILDRENS HOSP, SCH MED, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DIV BIOL SCI, PHYSIOL PROGRAM, BOSTON, MA 02115 USA; CHIRON CORP, EMERYVILLE, CA 94608 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Novartis					NHLBI NIH HHS [HL44712] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044712] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTIERI DC, 1988, J BIOL CHEM, V263, P7007; BACHARACH E, 1992, P NATL ACAD SCI USA, V89, P10686, DOI 10.1073/pnas.89.22.10686; BEHRENDT N, 1991, J BIOL CHEM, V266, P7842; BERTOZZI P, 1990, NEW ENGL J MED, V322, P890, DOI 10.1056/NEJM199003293221304; BITTORF SV, 1993, J BIOL CHEM, V268, P24838; BLASI F, 1987, J CELL BIOL, V104, P801, DOI 10.1083/jcb.104.4.801; BODARY SC, 1990, J BIOL CHEM, V265, P5938; BORDIER C, 1981, J BIOL CHEM, V256, P1604; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; CHAPMAN HA, 1982, CELL, V28, P653, DOI 10.1016/0092-8674(82)90220-3; CHAPMAN HA, 1990, AM J PHYSIOL, V259, pL432, DOI 10.1152/ajplung.1990.259.6.L432; CIAMBRONE GJ, 1992, J BIOL CHEM, V267, P13617; CUBELLIS MV, 1990, EMBO J, V9, P1079, DOI 10.1002/j.1460-2075.1990.tb08213.x; DUSTIN ML, 1987, NATURE, V329, P846, DOI 10.1038/329846a0; ESTREICHER A, 1990, J CELL BIOL, V111, P783, DOI 10.1083/jcb.111.2.783; FALCONE DJ, 1993, J CELL PHYSIOL, V155, P595, DOI 10.1002/jcp.1041550317; FAULL RJ, 1993, J CELL BIOL, V121, P155, DOI 10.1083/jcb.121.1.155; GLADSON CL, 1991, J CLIN INVEST, V88, P1924, DOI 10.1172/JCI115516; GOODSON RJ, 1994, P NATL ACAD SCI USA, V91, P7129, DOI 10.1073/pnas.91.15.7129; Habermann BF, 1993, CURR OPIN CELL BIOL, V5, P864, DOI 10.1016/0955-0674(93)90036-P; HEMPERLY JJ, 1986, P NATL ACAD SCI USA, V83, P9822, DOI 10.1073/pnas.83.24.9822; HORTSCH M, 1990, J BIOL CHEM, V265, P15104; ISHIHARA A, 1987, P NATL ACAD SCI USA, V84, P1290, DOI 10.1073/pnas.84.5.1290; JANKUN J, 1993, J CELL BIOCHEM, V53, P135, DOI 10.1002/jcb.240530206; KAUFMAN SE, 1993, ANAL BIOCHEM, V211, P261, DOI 10.1006/abio.1993.1267; KORETZ K, 1993, EUR J CANCER, V29A, P1184; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P21862; LISANTI MP, 1991, EMBO J, V10, P1969, DOI 10.1002/j.1460-2075.1991.tb07726.x; LORIDONROSA B, 1988, AM J CLIN PATHOL, V90, P7, DOI 10.1093/ajcp/90.1.7; LOSKUTOFF DJ, 1989, PROG HEMOST THROMB, V9, P87; MASUMOTO A, 1993, J BIOL CHEM, V268, P228; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; NICULESCU F, 1989, ATHEROSCLEROSIS, V78, P197, DOI 10.1016/0021-9150(89)90223-2; NUSRAT AR, 1991, J CLIN INVEST, V87, P1091, DOI 10.1172/JCI115070; PARANJPE M, 1980, LIFE SCI, V26, P1223, DOI 10.1016/0024-3205(80)90067-3; PEDERSEN H, 1994, CANCER RES, V54, P120; PEPPER MS, 1993, J CELL BIOL, V122, P673, DOI 10.1083/jcb.122.3.673; PLOUG M, 1992, EUR J BIOCHEM, V208, P397, DOI 10.1111/j.1432-1033.1992.tb17200.x; POLLANEN J, 1987, J CELL BIOL, V104, P1085, DOI 10.1083/jcb.104.4.1085; PREISSNER KT, 1991, THROMB HAEMOSTASIS, V66, P189; PYKE C, 1991, AM J PATHOL, V138, P1059; RABBANI SA, 1992, J BIOL CHEM, V267, P14151; REICH E, 1978, BIOL MARKERS NEOPLAS, P491; REILLY JT, 1988, J CLIN PATHOL, V41, P1269, DOI 10.1136/jcp.41.12.1269; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; RONNE E, 1991, FEBS LETT, V288, P233, DOI 10.1016/0014-5793(91)81042-7; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SALONEN EM, 1989, J BIOL CHEM, V264, P6339; SCHLECHTE W, 1989, CANCER RES, V49, P6064; SHI GP, 1992, J BIOL CHEM, V267, P7258; SIER CFM, 1992, CANCER RES, V33, pA386; STOCKMANN A, 1993, J BIOL CHEM, V268, P22874; SUMIYOSHI K, 1991, THROMB RES, V63, P59, DOI 10.1016/0049-3848(91)90270-7; Tomasini B R, 1991, Prog Hemost Thromb, V10, P269; VASSALLI JD, 1987, FEBS LETT, V214, P187, DOI 10.1016/0014-5793(87)80039-X; VASSALLI JD, 1985, J CELL BIOL, V100, P86, DOI 10.1083/jcb.100.1.86; VOGEL BE, 1993, J CELL BIOL, V121, P461, DOI 10.1083/jcb.121.2.461; WALTZ DA, 1994, J BIOL CHEM, V269, P14746; WALTZ DA, 1993, J CLIN INVEST, V91, P1541, DOI 10.1172/JCI116360; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281	60	548	565	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32380	32388						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7528215				2022-12-27	WOS:A1994PX30400056
J	BALL, T; VRTALA, S; SPERR, WR; VALENT, P; SUSANI, M; KRAFT, D; VALENTA, R				BALL, T; VRTALA, S; SPERR, WR; VALENT, P; SUSANI, M; KRAFT, D; VALENTA, R			ISOLATION OF AN IMMUNODOMINANT IGE HAPTEN FROM AN EPITOPE EXPRESSION CDNA LIBRARY - DISSECTION OF THE ALLERGIC EFFECTOR REACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHLEUM-PRATENSE POLLEN; LOL-P-I; BIRCH POLLEN; GRASS-POLLEN; ANTIGENIC DETERMINANTS; CLONING; PROTEIN; BASOPHILS	An epitope expression cDNA library was constructed from the randomly fragmented cDNA coding for Phl p I, the major grass pollen allergen. Using IgE from allergic patients, epitope clones were isolated and immunodominant fragments were selected. Among three epitope clones coding for a similar region of Phl p I, one clone expressed a 15-amino-acid epitope which was target for IgE antibodies from approximately 30% of grass pollen allergic patients. According to the prevalence of grass pollen allergy, 22% of all allergic patients are expected to display IgE reactivity with this epitope. Although the purified recombinant epitope specifically bound IgE, it did not release histamine from basophiles of most grass pollen allergic patients and thus represents an IgE hapten, Immunodominant IgE haptens may be useful as therapeutic agents to saturate mast cell-bound IgE prior to allergen exposure and may represent candidates for a safe immunotherapy of allergic diseases by reducing anaphylactic side effects.	UNIV VIENNA, AKH, INST GEN & EXPTL PATHOL, A-1090 VIENNA, AUSTRIA; UNIV VIENNA, AKH, DEPT HEMATOL & HEMOSTASEOL, A-1090 VIENNA, AUSTRIA; AUSTRIAN ACAD SCI, ABS, A-5020 SALZBURG, AUSTRIA	University of Vienna; University of Vienna; Austrian Academy of Sciences			Gamperl, Susi/V-2715-2019; Sperr, Mast/V-4767-2019; Test, Test/Y-7921-2019; Valent, Peter/B-8533-2016	Gamperl, Susi/0000-0003-0456-5095; Sperr, Mast/0000-0002-7778-5219; Valent, Peter/0000-0003-0456-5095; Sperr, Wolfgang/0000-0003-3288-8027; Vrtala, Susanne/0000-0003-4250-8243; Valenta, Rudolf/0000-0001-5944-3365				Ausubel FA, 1990, CURRENT PROTOCOLS MO; BERZOFSKY JA, 1985, SCIENCE, V229, P932, DOI 10.1126/science.2410982; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; Chothia C, 1991, CURR OPIN STRUC BIOL, V1, P53, DOI 10.1016/0959-440X(91)90011-H; DRESKIN S C, 1988, Journal of the American Medical Association, V260, P1265, DOI 10.1001/jama.260.9.1265; FERREIRA FD, 1993, J BIOL CHEM, V268, P19574; FREIDHOFF LR, 1986, J ALLERGY CLIN IMMUN, V78, P1190, DOI 10.1016/0091-6749(86)90271-X; GEYSEN HM, 1987, J IMMUNOL METHODS, V102, P259, DOI 10.1016/0022-1759(87)90085-8; GRIFFITH IJ, 1991, FEBS LETT, V279, P210, DOI 10.1016/0014-5793(91)80151-R; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; JAMESON BA, 1988, COMPUT APPL BIOSCI, V4, P181; JAROLIM E, 1989, ALLERGY, V44, P385, DOI 10.1111/j.1398-9995.1989.tb04169.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFFER S, 1993, IN PRESS J ALLERGY C; LAVER WG, 1990, CELL, V61, P553, DOI 10.1016/0092-8674(90)90464-P; MEHRA V, 1986, P NATL ACAD SCI USA, V83, P7013, DOI 10.1073/pnas.83.18.7013; MIYAMOTO T, 1992, ADVANCES IN ALLERGOLOGY AND CLINICAL IMMUNOLOGY, P343; Noon L, 1911, LANCET, V1, P1572; PEREZ M, 1990, J BIOL CHEM, V265, P16210; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEINER O, 1992, ADVANCES IN ALLERGOLOGY AND CLINICAL IMMUNOLOGY, P115; SEGAL DM, 1977, P NATL ACAD SCI USA, V41, P457; SPITZAUER S, 1994, J ALLERGY CLIN IMMUN, V93, P614, DOI 10.1016/S0091-6749(94)70073-7; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALENT P, 1989, P NATL ACAD SCI USA, V86, P5542, DOI 10.1073/pnas.86.14.5542; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; VALENTA R, 1993, J ALLERGY CLIN IMMUN, V91, P88, DOI 10.1016/0091-6749(93)90300-5; VALENTA R, 1992, INT ARCH ALLERGY IMM, V97, P287, DOI 10.1159/000236135; VALENTA R, 1993, VACCINES93 : MODERN APPROACHES TO NEW VACCINES INCLUDING PREVENTION OF AIDS, P37; VRTALA S, 1993, J IMMUNOL, V151, P4773; VRTALA S, 1993, INT ARCH ALLERGY IMM, V102, P160, DOI 10.1159/000236567	33	79	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28323	28328						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7525573				2022-12-27	WOS:A1994PV77200082
J	FABBRI, M; BANNYKH, S; BALCH, WE				FABBRI, M; BANNYKH, S; BALCH, WE			EXPORT OF PROTEIN FROM THE ENDOPLASMIC-RETICULUM IS REGULATED BY A DIACYLGLYCEROL PHORBOL ESTER BINDING-PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							VESICULAR STOMATITIS-VIRUS; SUCCESSIVE GOLGI COMPARTMENTS; PHOSPHOLIPID TRANSFER PROTEIN; INTEGRAL MEMBRANE-PROTEIN; ADP-RIBOSYLATION FACTOR; SEMI-INTACT CELLS; KINASE-C; BETA-COP; PHORBOL ESTERS; CAENORHABDITIS-ELEGANS	The export of vesicular stomatitis virus glycoprotein (VSV-G) from the endoplasmic reticulum (ER) involves sorting and concentration, and has been proposed to require the function of heterotrimeric G proteins. To begin to identify the basic elements of a potential signaling pathway involved in vesicle assembly, we have examined whether protein kinase C (PKC) is required for ER to Golgi transport. Calphostin C, a specific inhibitor of the highly conserved cysteine-rich C6H2 motif present in the regulatory domain of PKC was found to be a potent inhibitor of export of VSV-G and vesicle budding from the ER in vivo and in vitro (IC50 similar to 60 nM). In contrast, the diacylglycerol analog phorbol 12-myristate 13-acetate, which activates PKC, enhanced the migration of VSV-G from the ER to pre-Golgi intermediates. Neither reagent had detectable effects on the oligomerization of VSV-G prior to export nor perturbed transport of protein between compartments of the Golgi stack. In contrast to the striking effects of calphostin C, reagents that inhibit the function of the catalytic domain of PKC (including the general kinase inhibitor staurosporine, as well as the more specific inhibitors H-7, H-8, pseudosubstrate inhibitor, or chelerythrine) did not inhibit export from the ER. Export was also insensitive to down-regulation of various PKC isoforms. These results suggest that a novel protein containing the conserved C6H2 motif may serve as a potential link in a signaling pathway regulating vesicle budding from the ER.	Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute					NCRR NIH HHS [RR07273, RR08176] Funding Source: Medline; NIGMS NIH HHS [GM42336] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR007273] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042336] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMED S, 1992, BIOCHEM J, V287, P995, DOI 10.1042/bj2870995; AHMED S, 1990, BIOCHEM J, V272, P767, DOI 10.1042/bj2720767; AHMED S, 1993, J BIOL CHEM, V268, P10709; AHMED S, 1991, BIOCHEM J, V280, P233, DOI 10.1042/bj2800233; AKITA Y, 1994, J BIOL CHEM, V269, P4653; ALEXANDER DR, 1989, BIOCHEM J, V260, P893, DOI 10.1042/bj2600893; BACKER JM, 1991, BIOCHEM PHARMACOL, V41, P1267, DOI 10.1016/0006-2952(91)90097-O; BALCH W E, 1992, Current Biology, V2, P157, DOI 10.1016/0960-9822(92)90276-G; Balch W. E., 1993, Methods (Orlando), V5, P258, DOI 10.1006/meth.1993.1032; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; BALCH WE, 1992, J BIOL CHEM, V267, P13053; BANKAITIS VA, 1990, NATURE, V347, P561, DOI 10.1038/347561a0; BARLOWE C, 1993, J BIOL CHEM, V268, P873; Barr F A, 1992, Trends Cell Biol, V2, P91, DOI 10.1016/0962-8924(92)90001-4; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BENSHLOMO H, 1991, BIOCHEM J, V280, P65, DOI 10.1042/bj2800065; BERGMANN JE, 1981, P NATL ACAD SCI-BIOL, V78, P1746, DOI 10.1073/pnas.78.3.1746; BOMSEL M, 1992, MOL BIOL CELL, V3, P1317, DOI 10.1091/mbc.3.12.1317; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; BRUNS RF, 1991, BIOCHEM BIOPH RES CO, V176, P288, DOI 10.1016/0006-291X(91)90922-T; BUCCIONE R, 1994, BIOCHEM J, V298, P149, DOI 10.1042/bj2980149; CARDONE MH, 1994, J CELL BIOL, V124, P717, DOI 10.1083/jcb.124.5.717; CHOI OH, 1994, J BIOL CHEM, V269, P536; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; COFFEY ET, 1993, J BIOL CHEM, V268, P21060; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; DASCHER C, 1994, J BIOL CHEM, V269, P1437; DAVIDSON HW, 1992, J CELL BIOL, V116, P1343, DOI 10.1083/jcb.116.6.1343; DAVIDSON HW, 1993, J BIOL CHEM, V268, P4216; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DEKKER LV, 1991, J NEUROCHEM, V54, P205; DEMATTEIS MA, 1993, NATURE, V364, P818, DOI 10.1038/364818a0; DESILVA AM, 1990, J CELL BIOL, V111, P857, DOI 10.1083/jcb.111.3.857; DOMS RW, 1987, J CELL BIOL, V105, P1957, DOI 10.1083/jcb.105.5.1957; DOMS RW, 1988, J CELL BIOL, V107, P89, DOI 10.1083/jcb.107.1.89; EICHHOLTZ T, 1990, FEBS LETT, V261, P147, DOI 10.1016/0014-5793(90)80657-5; FERRONOVICK S, 1993, ANNU REV CELL BIOL, V9, P575; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; GSCHWENDT M, 1991, TRENDS BIOCHEM SCI, V16, P167, DOI 10.1016/0968-0004(91)90064-3; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; HAY JC, 1993, NATURE, V366, P572, DOI 10.1038/366572a0; HENDRICKS LC, 1993, MOL BIOL CELL, V4, P413, DOI 10.1091/mbc.4.4.413; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; HOSOBUCHI M, 1992, NATURE, V360, P603, DOI 10.1038/360603a0; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; KAHN RA, 1993, CELL, V75, P1045, DOI 10.1016/0092-8674(93)90314-G; KAZANIETZ MG, 1994, J BIOL CHEM, V269, P11590; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; KIKKAWA U, 1982, J BIOL CHEM, V257, P13341; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KOCHS G, 1993, EUR J BIOCHEM, V216, P597, DOI 10.1111/j.1432-1033.1993.tb18179.x; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; KUGE O, 1994, J CELL BIOL, V125, P51, DOI 10.1083/jcb.125.1.51; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFAY F, 1974, J VIROL, V14, P1220, DOI 10.1128/JVI.14.5.1220-1228.1974; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; LUINI A, 1993, TRENDS CELL BIOL, V3, P291; MACHAMER CE, 1990, J BIOL CHEM, V265, P6879; MARUYAMA IN, 1991, P NATL ACAD SCI USA, V88, P5729, DOI 10.1073/pnas.88.13.5729; MCGEE TP, 1994, J CELL BIOL, V124, P273, DOI 10.1083/jcb.124.3.273; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MIZUNO M, 1993, P NATL ACAD SCI USA, V90, P5732, DOI 10.1073/pnas.90.12.5732; NAKANO A, 1989, J CELL BIOL, V109, P2677, DOI 10.1083/jcb.109.6.2677; NEWTON AC, 1993, ANNU REV BIOPH BIOM, V22, P1, DOI 10.1146/annurev.bb.22.060193.000245; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NUOFFER C, 1994, J CELL BIOL, V125, P225, DOI 10.1083/jcb.125.2.225; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; OKA T, 1994, J CELL BIOL, V124, P425, DOI 10.1083/jcb.124.4.425; OPRINS A, 1993, J CELL BIOL, V121, P49, DOI 10.1083/jcb.121.1.49; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; ORCI L, 1993, NATURE, V364, P732, DOI 10.1038/364732a0; OZAWA K, 1993, J BIOL CHEM, V268, P1749; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; PETER F, 1993, J CELL BIOL, V122, P1155, DOI 10.1083/jcb.122.6.1155; PIND SN, 1994, J CELL BIOL, V125, P239, DOI 10.1083/jcb.125.2.239; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; PLUTNER H, 1990, EMBO J, V9, P2375, DOI 10.1002/j.1460-2075.1990.tb07412.x; PLUTNER H, 1992, J CELL BIOL, V119, P1097, DOI 10.1083/jcb.119.5.1097; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; QUINN P, 1984, J CELL BIOL, V98, P2142, DOI 10.1083/jcb.98.6.2142; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SALAMA NR, 1993, EMBO J, V12, P4073, DOI 10.1002/j.1460-2075.1993.tb06091.x; Saraste J, 1992, Semin Cell Biol, V3, P343, DOI 10.1016/1043-4682(92)90020-V; SCHWANINGER R, 1991, J BIOL CHEM, V266, P13055; SCHWANINGER R, 1992, J CELL BIOL, V119, P1077, DOI 10.1083/jcb.119.5.1077; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; TABAS I, 1979, J BIOL CHEM, V254, P1655; TAKIZAWA PA, 1993, CELL, V75, P593, DOI 10.1016/0092-8674(93)90477-8; TERBUSH DR, 1990, J BIOL CHEM, V265, P21179; TING AT, 1992, J BIOL CHEM, V267, P23957; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39; VITALE N, 1993, J BIOL CHEM, V268, P14715; WHITTERS EA, 1993, J CELL BIOL, V122, P79, DOI 10.1083/jcb.122.1.79	101	77	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26848	26857						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7523413				2022-12-27	WOS:A1994PQ93100043
J	SOM, S; FRIEDMAN, S				SOM, S; FRIEDMAN, S			INHIBITION OF TRANSCRIPTION IN-VITRO BY BINDING OF DNA(CYTOSINE-5)-METHYLASES TO DNA TEMPLATES CONTAINING CYTOSINE ANALOGS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AZACYTOSINE-CONTAINING DNA; ESCHERICHIA-COLI; ECORII METHYLTRANSFERASE; RNA-POLYMERASE; LAC REPRESSOR; 5-AZACYTIDINE; METHYLASE; MECHANISM; CLONING; GENE	DNA(cytosine-5)-methylases form tight complexes at their methylation sites when the target cytosine residue is substituted by analogs such as 5-azacytosine or 5-fluorocytosine. To test whether such complexes can block RNA transcription in vitro, template DNA-containing methylation sites were prepared, in which cytosine residues in either the (+)- or (-)-strand were substituted by the analogs. Such templates, irrespective of the strand in which substitution was made, could effectively block the elongation of RNA at specific sites when complexed with EcoRII methylase. The protein-DNA complex probably prevents the unwinding of the template strands or might directly present itself as a steric block to the advancing RNA polymerase. RNA synthesis was also inhibited at specific sites due to complex formation between azacytosine-containing DNA and two other methylases, HhaI and HpaII. The 3' ends of the interrupted transcripts were mapped and were found to lie within 13-14, 13, and 23 nucleotides of the binding sites on the (-)-strand for HhaI, HpaII, and EcoRII methylases, respectively. Exonuclease III footprinting revealed that the boundaries of the complexed methylases, HhaI, HpaII, and EcoRII, on the (-)-strand were within 2-3, 1-2, and 9-10 nucleotides, respectively, of the last nucleotide copied by the RNA polymerase.	SUNY HLTH SCI CTR,DEPT PHARMACOL,BROOKLYN,NY 11203	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center								BHAGWAT AS, 1987, J BACTERIOL, V169, P1537, DOI 10.1128/jb.169.4.1537-1546.1987; CARD CO, 1990, NUCLEIC ACIDS RES, V18, P1377, DOI 10.1093/nar/18.6.1377; CASERTA M, 1987, J BIOL CHEM, V262, P4770; DEUSCHLE U, 1990, SCIENCE, V248, P480, DOI 10.1126/science.2158670; DEUSCHLE U, 1986, P NATL ACAD SCI USA, V83, P4134, DOI 10.1073/pnas.83.12.4134; DOSKOCIL J, 1967, BIOCHIM BIOPHYS ACTA, V145, P771, DOI 10.1016/0005-2787(67)90136-0; FRIEDMAN S, 1992, NUCLEIC ACIDS RES, V20, P3241, DOI 10.1093/nar/20.12.3241; FRIEDMAN S, 1982, J BACTERIOL, V151, P262, DOI 10.1128/JB.151.1.262-268.1982; FRIEDMAN S, 1986, NUCLEIC ACIDS RES, V14, P4543, DOI 10.1093/nar/14.11.4543; FRIEDMAN S, 1981, MOL PHARMACOL, V19, P314; FRIEDMAN S, 1993, J BACTERIOL, V175, P6293, DOI 10.1128/JB.175.19.6293-6298.1993; FRIEDMAN S, 1985, J BIOL CHEM, V260, P5698; GIORDANO TJ, 1989, GENE, V84, P209, DOI 10.1016/0378-1119(89)90494-0; HUANG Y, 1991, J BIOL CHEM, V266, P17424; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; LAL D, 1988, MUTAT RES, V193, P229, DOI 10.1016/0167-8817(88)90033-8; OSTERMAN DG, 1988, BIOCHEMISTRY-US, V27, P5204, DOI 10.1021/bi00414a039; PAVCO PA, 1991, NUCLEIC ACIDS RES, V19, P4639, DOI 10.1093/nar/19.17.4639; PAVCO PA, 1990, J BIOL CHEM, V265, P9960; Sambrook J, 1989, MOL CLONING LABORATO; SANTI DV, 1984, P NATL ACAD SCI-BIOL, V81, P6993, DOI 10.1073/pnas.81.22.6993; SANTI DV, 1983, CELL, V33, P9, DOI 10.1016/0092-8674(83)90327-6; SCHENBORN ET, 1985, NUCLEIC ACIDS RES, V13, P6223, DOI 10.1093/nar/13.17.6223; SOM S, 1987, NUCLEIC ACIDS RES, V15, P313, DOI 10.1093/nar/15.1.313; SOM S, 1990, J BIOL CHEM, V265, P4278; WU JC, 1985, BIOCH BIOL DNA METHY, P115	26	8	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					25986	25991						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7523398				2022-12-27	WOS:A1994PQ93000011
J	MELOTTI, P; CALABRETTA, B				MELOTTI, P; CALABRETTA, B			ETS-2 AND C-MYB ACT INDEPENDENTLY IN REGULATING EXPRESSION OF THE HEMATOPOIETIC STEM-CELL ANTIGEN CD34	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-1; MARROW-CELLS; GENE; PROMOTER; PROTEINS; BINDING; DIFFERENTIATION; INVITRO; FAMILY; DNA	CD34 is currently the only well defined human hematopoietic stem cell marker and is expressed on 1-4% of normal bone marrow cells. Putative binding sites for Ets proteins, a family of transcription factors involved in the regulation of cell differentiation and proliferation in many cell systems, are present in the 5'-flanking region of the CD34 gene. Some of these sites are in close proximity to binding sequences of the encoded product of the proto oncogene c-myb, which regulates CD34 expression by interacting with the Myb binding sites. Here we demonstrate that Ets-2 (i) transactivates the CD34 promoter in rodent fibroblasts upon interaction with Ets binding sites and (ii) induces expression of CD34 mRNA and pro protein in the CD34(-) human glioblastoma T98G cells. Ets-2 and c-Myb transactivate the CD34 promoter independently because specific transactivation is abrogated by site specific mutations of the binding sites or by competition with oligomers that include wild type but not mutated Myb or Ets binding sites. Ets-2 and c-Myb appear to have addictive effects on transactivation of the CD34 promoter and on induction of CD34 mRNA. Instead, CD34 surface protein levels might be induced synergistically, raising the possibility of a posttranslational mechanism of CD34 expression in cells constitutively expressing c-Myb and Ets-2.			MELOTTI, P (corresponding author), THOMAS JEFFERSON UNIV, JEFFERSON CANC INST, DEPT MICROBIOL & IMMUNOL, PHILADELPHIA, PA 19107 USA.		Melotti, Paola/J-6205-2018	Melotti, Paola/0000-0002-5276-1595				AURIGEMMA RE, 1992, J VIROL, V66, P3056, DOI 10.1128/JVI.66.5.3056-3061.1992; BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600; BERENSON RJ, 1988, J CLIN INVEST, V81, P951, DOI 10.1172/JCI113409; BERENSON RJ, 1991, BLOOD, V77, P1717; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN J, 1991, INT IMMUNOL, V3, P175, DOI 10.1093/intimm/3.2.175; BURN TC, 1992, BLOOD, V80, P3051; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIVIN CI, 1984, J IMMUNOL, V133, P157; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; DELIA D, 1993, BLOOD, V81, P1001; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; FACKLER MJ, 1990, J BIOL CHEM, V265, P11056; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GRITZ L, 1983, GENE, V25, P179, DOI 10.1016/0378-1119(83)90223-8; HAGMAN J, 1992, P NATL ACAD SCI USA, V89, P8889, DOI 10.1073/pnas.89.19.8889; HE XY, 1992, BLOOD, V79, P2296; HUTTNER KM, 1981, J CELL BIOL, V91, P153, DOI 10.1083/jcb.91.1.153; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KATZ FE, 1985, LEUKEMIA RES, V9, P191, DOI 10.1016/0145-2126(85)90082-7; LEMARCHANDEL V, 1993, MOL CELL BIOL, V13, P668, DOI 10.1128/MCB.13.1.668; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; MELOTTI P, 1994, J EXP MED, V179, P1023, DOI 10.1084/jem.179.3.1023; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; METZ T, 1991, CELL, V66, P95, DOI 10.1016/0092-8674(91)90142-L; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; SALMON P, 1993, P NATL ACAD SCI USA, V90, P7739, DOI 10.1073/pnas.90.16.7739; SATTERTHWAITE AB, 1990, BLOOD, V75, P2299; SIMMONS PJ, 1991, BLOOD, V78, P2848; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x	34	49	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25303	25309						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7523384				2022-12-27	WOS:A1994PQ49100013
J	BONNER, G; LAFER, EM; SOUSA, R				BONNER, G; LAFER, EM; SOUSA, R			THE THUMB SUBDOMAIN OF T7 RNA-POLYMERASE FUNCTIONS TO STABILIZE THE TERNARY COMPLEX DURING PROCESSIVE TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; ACTIVE-SITE; 3-DIMENSIONAL STRUCTURE; ANGSTROM RESOLUTION; KLENOW FRAGMENT; BACTERIOPHAGE-T7; DNA; INITIATION; TERMINATION	To examine the function of the thumb subdomain in bacteriophage T7 RNA polymerase we constructed a set of deletion mutants within this subdomain. These mutants exhibited reduced processivity during the processive, but not the abortive, stage of transcription. Reduced processivity was found to be due primarily to an increase in the processive ternary complex dissociation rate (destabilization of the processive ternary complex). The destabilization of the ternary complex does not appear to be due to a decrease in the affinity of the polymerase for the nascent RNA. These observations support the proposal that the thumb subdomain functions to stabilize the processive ternary complex during the processive (but not the abortive) stage of transcription, probably by wrapping around the template to prevent polymerase dissociation.	UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,SAN ANTONIO,TX 78284; UNIV TEXAS,HLTH SCI CTR,INST BIOTECHNOL,PROGRAM MOLEC MED,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio				Sousa, Rui/0000-0003-4314-121X; Lafer, Eileen/0000-0002-0493-6522				ARNOLD E, 1992, NATURE, V357, P85, DOI 10.1038/357085a0; AUSUBEL MF, 1987, CURRENT PROTOCOLS MO, V1; BASU S, 1986, J MOL BIOL, V190, P425, DOI 10.1016/0022-2836(86)90013-6; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; BONNER G, 1994, J BIOL CHEM, V269, P25120; BONNER G, 1992, EMBO J, V11, P3767, DOI 10.1002/j.1460-2075.1992.tb05462.x; DARST SA, 1989, NATURE, V340, P730, DOI 10.1038/340730a0; DARST SA, 1991, CELL, V66, P121, DOI 10.1016/0092-8674(91)90144-N; DAVANLOO P, 1984, P NATL ACAD SCI-BIOL, V81, P2035, DOI 10.1073/pnas.81.7.2035; GOLOMB M, 1974, J BIOL CHEM, V249, P2858; GROSS L, 1992, J MOL BIOL, V228, P488, DOI 10.1016/0022-2836(92)90837-A; IKEDA RA, 1987, J BIOL CHEM, V262, P3790; IKEDA RA, 1986, P NATL ACAD SCI USA, V83, P3614, DOI 10.1073/pnas.83.11.3614; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LING ML, 1989, NUCLEIC ACIDS RES, V17, P1605, DOI 10.1093/nar/17.4.1605; MACDONALD LE, 1993, J MOL BIOL, V232, P1030, DOI 10.1006/jmbi.1993.1458; MARTIN CT, 1988, BIOCHEMISTRY-US, V27, P3966, DOI 10.1021/bi00411a012; McClure W R, 1980, Methods Enzymol, V64, P277; MOOKHTIAR KA, 1991, BIOCHEMISTRY-US, V30, P6305, DOI 10.1021/bi00239a032; MULLER DK, 1988, BIOCHEMISTRY-US, V27, P5763, DOI 10.1021/bi00415a055; OLLIS DL, 1985, NATURE, V313, P765; OSUMIDAVIS PA, 1992, J MOL BIOL, V226, P37, DOI 10.1016/0022-2836(92)90122-Z; PATRA D, 1992, J MOL BIOL, V224, P307, DOI 10.1016/0022-2836(92)90996-W; POLESKY AH, 1992, J BIOL CHEM, V267, P8417; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; SANKAR S, 1992, J BIOL CHEM, V267, P10168; SHI YB, 1988, J BIOL CHEM, V263, P527; SOUSA R, 1992, J MOL BIOL, V224, P319, DOI 10.1016/0022-2836(92)90997-X; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; YON J, 1989, NUCLEIC ACIDS RES, V17, P4895, DOI 10.1093/nar/17.12.4895	32	33	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					25129	25136						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7523379				2022-12-27	WOS:A1994PQ49000090
J	BUSCONI, L; MICHEL, T				BUSCONI, L; MICHEL, T			ENDOTHELIAL NITRIC-OXIDE SYNTHASE MEMBRANE TARGETING - EVIDENCE AGAINST INVOLVEMENT OF A SPECIFIC MYRISTATE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C SUBSTRATE; PLASMA-MEMBRANE; N-MYRISTOYLATION; PROTEIN; PHOSPHORYLATION; TRANSLOCATION; ASSOCIATION; BINDING; MARCKS; DOMAIN	The endothelial isoform of nitric oxide synthase (ecNOS) is targeted to the particulate subcellular fraction by means of N-terminal myristoylation. However, the association of ecNOS with the particulate subcellular fraction appears to be dynamically regulated, in that agonist treatment of endothelial cells induces translocation of the enzyme from membrane to cytosol (Michel, T., Li, G., and Busconi, L. (1993) Proc. Natl, Acad. Sci. U. S. A. 90, 6252-6255). cDNA encoding wild-type and myristoylation-deficient mutant (myr-()) ecNOS was transcribed and translated in vitro, and we found that the recombinant wild-type but not the myr(-) mutant protein undergoes myristoylation and is able to associate with biological membranes prepared from diverse cell sources. Treatment of these cell membranes with heat or with trypsin did not affect their ability subsequently to serve as acceptor membranes for the wild-type recombinant enzyme. The wild-type ecNOS, but not the myr(-) mutant, is able to form stable associations with phospholipid liposomes. We also explored the possibility that a polybasic domain within the ecNOS protein might serve as a secondary structural determinant for ecNOS membrane association and constructed truncation mutants that flank a polybasic domain present in the ecNOS. These truncation mutants, transcribed and translated in vitro or transfected into COS-7 cells, undergo myristoylation and are able to associate with biological membranes in a fashion indistinguishable from the wild type ecNOS. Taken together, these results indicate that ecNOS binding to biological membranes is dependent upon interactions of the N-terminal myristoyl moiety of ecNOS with lipid components of the membrane, and this association does not require a specific membrane protein functioning as a myristate receptor nor the presence of a polybasic domain within the ecNOS.	HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DIV CARDIOVASC, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School					NHLBI NIH HHS [HL46457] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046457, R29HL046457] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARBOGAST LY, 1976, P NATL ACAD SCI USA, V73, P3680, DOI 10.1073/pnas.73.10.3680; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BAUDIER J, 1991, J BIOL CHEM, V266, P229; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BUSCONI L, 1993, J BIOL CHEM, V268, P8410; GEORGE DJ, 1992, J BIOL CHEM, V267, P24879; GORDON JI, 1991, J BIOL CHEM, V266, P8647; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; KOTKOW KJ, 1993, J BIOL CHEM, V268, P15633; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MICHEL T, 1993, P NATL ACAD SCI USA, V90, P6252, DOI 10.1073/pnas.90.13.6252; MONCADA S, 1991, PHARMACOL REV, V43, P109; MUMBY SM, 1994, P NATL ACAD SCI USA, V91, P2800, DOI 10.1073/pnas.91.7.2800; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NATHAN C, 1994, J BIOL CHEM, V269, P13725; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; RESH MD, 1989, CELL, V58, P281, DOI 10.1016/0092-8674(89)90842-8; SCHERERSINGLER U, 1983, J NEUROSCI METH, V9, P229, DOI 10.1016/0165-0270(83)90085-7; SESSA WC, 1993, CIRC RES, V72, P921, DOI 10.1161/01.RES.72.4.921; SILVERMAN L, 1992, J CELL BIOL, V119, P415, DOI 10.1083/jcb.119.2.415; TANIGUCHI H, 1993, J BIOL CHEM, V268, P9960; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; WALKER F, 1993, J BIOL CHEM, V268, P19552; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	26	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					25016	25020						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7523377				2022-12-27	WOS:A1994PQ49000075
J	HIRAOKA, O; ANAGUCHI, H; YAMASAKI, G; FUKUNAGA, R; NAGATA, S; OTA, Y				HIRAOKA, O; ANAGUCHI, H; YAMASAKI, G; FUKUNAGA, R; NAGATA, S; OTA, Y			LIGAND-BINDING DOMAIN OF GRANULOCYTE-COLONY-STIMULATING FACTOR-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GROWTH-HORMONE; ESCHERICHIA-COLI; EXTRACELLULAR DOMAIN; MUTATIONAL ANALYSIS; DRUG-THERAPY; PURIFICATION; SECRETION; DESIGN	The amino-terminal domain of the cytokine receptor homologous region (BN domain; roughly 100 amino acid residues) in the receptor for murine granulocyte colony-stimulating factor (G-CSF) was secreted as a maltose-binding protein fusion into the Escherichia coli periplasm. The murine BN domain (mBN) was prepared from the fusion protein by restriction protease Factor Xa digestion and purified to homogeneity. The purified BN domain specifically and stoichiometrically bound G-CSF, with an apparent dissociation constant (K-d) of 3-8 x 10-(8) M. The CD spectrum of the mBN domain was similar to that of the extracellular region of the human growth hormone (GH) receptor, which is composed of turns and beta-sheets held together by disulfide bonds, Tertiary folding and the beta-sheet of this small domain was confirmed by NMR spectroscopy. Disulfide bonds determined by peptide mapping were in the following locations: Cys(107)-Cys(118), Cys(153)-Cys(162), and Cys(143)-Cys(194). Among them, the first and the second produce small loops (roughly 10 amino acid residues) as found in the human GH receptor. These results suggested that the mBN domain of the G-CSF receptor expressed by E. coli has a GH receptorlike structure. However, the third disulfide bond varied considerably between the G-CSF and GH receptors. Disruption of these disulfide bonds in the BN domain of the G-CSP receptor suggested that all of them are critical for maintaining a stably folded protein. Our results will facilitate understanding of the biophysical and structural properties of this receptor.	PROT ENGN RES INST,SUITA,OSAKA 565,JAPAN; OSAKA BIOSCI INST,SUITA,OSAKA 565,JAPAN				Nagata, Shigekazu/AAG-3203-2019; Yamasaki, Kazuhiko/L-7108-2018; Fukunaga, Rikiro/CAG-2891-2022	Nagata, Shigekazu/0000-0001-9758-8426; Yamasaki, Kazuhiko/0000-0003-0320-9697; 				BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; CLEARY S, 1989, BIOCHEMISTRY-US, V28, P1884, DOI 10.1021/bi00430a068; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DEMETRI GD, 1991, BLOOD, V78, P2791; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FOUNTOULAKIS M, 1990, J BIOL CHEM, V265, P13268; FUH G, 1990, J BIOL CHEM, V265, P3111; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; FUKUNAGA R, 1990, P NATL ACAD SCI USA, V87, P8702, DOI 10.1073/pnas.87.22.8702; GOLDENBERG DP, 1992, TRENDS BIOCHEM SCI, V17, P257, DOI 10.1016/0968-0004(92)90405-X; Goodwin T. W., 1946, BIOCHEM JOUR, V40, P628; HARRIS KW, 1992, J BIOL CHEM, V267, P15205; IZHIZAKAIKEDA E, 1993, P NATL ACAD SCI USA, V90, P123; LIESCHKE GJ, 1992, NEW ENGL J MED, V327, P99; LIESCHKE GJ, 1992, NEW ENGL J MED, V327, P28; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; MARTI T, 1987, BIOCHEMISTRY-US, V26, P8099, DOI 10.1021/bi00399a013; NAGATA S, 1991, Progress in Growth Factor Research, V3, P131, DOI 10.1016/S0955-2235(05)80004-3; NAGATA S, 1990, HDB EXPT PHARM, V95, P699; NICOLA NA, 1989, ANNU REV BIOCHEM, V58, P45; OTA Y, 1991, GENE, V106, P159, DOI 10.1016/0378-1119(91)90195-H; ROZAKISADCOCK M, 1991, J BIOL CHEM, V266, P16472; SETO Y, 1992, J IMMUNOL, V148, P259; STRAUCH KL, 1989, J BACTERIOL, V171, P2689, DOI 10.1128/jb.171.5.2689-2696.1989; Wuthrich K., 1986, NMR PROTEINS NUCL AC	28	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22412	22419						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	7520915				2022-12-27	WOS:A1994PE09800073
J	GRISCAVAGE, JM; FUKUTO, JM; KOMORI, Y; IGNARRO, LJ				GRISCAVAGE, JM; FUKUTO, JM; KOMORI, Y; IGNARRO, LJ			NITRIC-OXIDE INHIBITS NEURONAL NITRIC-OXIDE SYNTHASE BY INTERACTING WITH THE HEME PROSTHETIC GROUP - ROLE OF TETRAHYDROBIOPTERIN IN MODULATING THE INHIBITORY-ACTION OF NITRIC-OXIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-ARGININE; AQUEOUS-SOLUTION; RELAXING FACTOR; METHYLENE-BLUE; BRAIN; CYTOCHROME-P-450; SUPEROXIDE; PROTEINS; CALMODULIN; HEMOGLOBIN	The objective of this study was to elucidate the mechanism by which nitric oxide (NO) inhibits NO synthase. Previous studies revealed that NO inhibits unpurified preparations of NO synthase. In the present study, the mechanism by which NO inhibits purified neuronal NO synthase from rat cerebellum was examined. The rate of L-citrulline formation from L-arginine was non-linear despite the presence of excess substrate adn cofactors and was further inhibited by 30% by 200 units/ml superoxide dismutase. In contrast, 30 mu M oxyhemoglobin increased NO synthase activity by 2-fold and made the reaction rate linear. These observations were consistent with the hypothesis that enzymatically generated NO inhibits NO synthase activity. Exogenous NO (0.1-10 mu M) (but not NO2, nitrite, or nitrate) also inhibited NO synthase, and enzyme inhibition was not competitive with L-arginine. NO synthase inhibition by NO and other heme ligands supports the view that heme is involved in the catalytic activity of NO synthase. Oxyhemoglobin prevented but could not reverse enzyme inhibition by NO. NO synthase inhibition by NO was markedly diminished and reversed, however, by tetrahydrobiopterin (50 mu M) or a tetrahydrobiopterin-regenerating system, and the latter made the reaction rate linear. In contrast, NO synthase inhibition by NO was markedly enhanced by heme oxidants (10 mu M methylene blue; 3 mu M ferricynanide), and these oxidants directly inhibited NO synthase activity. In support of this view, NO inhibited enzyme activity in the absence of turnover, when the heme iron is in the ferric state, and this inhibition was reversed by tetrahydrobiopterin. Therefore, the oxidation state of heme iron appears to be one important determinant for the inhibitory action of NO, and tetrahydrobiopterin may increase NO synthase activity by diminishing the inhibitory action of NO.	UNIV CALIF LOS ANGELES,CTR HLTH SCI,SCH MED,DEPT MOLEC PHARMACOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NHLBI NIH HHS [HL-43688, HL-35014, HL-40922] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035014, R01HL040922] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASSREUY J, 1993, BRIT J PHARMACOL, V108, P833, DOI 10.1111/j.1476-5381.1993.tb12886.x; BLOUGH NV, 1985, INORG CHEM, V24, P3502, DOI 10.1021/ic00216a003; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BUGA GM, 1993, CIRC RES, V73, P808, DOI 10.1161/01.RES.73.5.808; BUSH PA, 1992, BIOCHEM BIOPH RES CO, V185, P960, DOI 10.1016/0006-291X(92)91720-B; CASSOLY R, 1975, J MOL BIOL, V91, P301, DOI 10.1016/0022-2836(75)90382-4; Drabkin DL, 1935, J BIOL CHEM, V112, P51; EBEL RE, 1975, FEBS LETT, V55, P198, DOI 10.1016/0014-5793(75)80991-4; FORSTERMANN U, 1990, MOL PHARMACOL, V38, P7; GIBSON QH, 1957, J PHYSIOL-LONDON, V136, P507, DOI 10.1113/jphysiol.1957.sp005777; GIOVANELLI J, 1991, P NATL ACAD SCI USA, V88, P7091, DOI 10.1073/pnas.88.16.7091; GRISCAVAGE JM, 1993, J IMMUNOL, V151, P6329; HEINZEL B, 1992, BIOCHEM J, V281, P627, DOI 10.1042/bj2810627; IGNARRO LJ, 1993, P NATL ACAD SCI USA, V90, P8103, DOI 10.1073/pnas.90.17.8103; IGNARRO LJ, 1981, J PHARMACOL EXP THER, V218, P739; IGNARRO LJ, 1987, CIRC RES, V61, P866, DOI 10.1161/01.RES.61.6.866; KANNER J, 1992, LIPIDS, V27, P46, DOI 10.1007/BF02537058; KELNER MJ, 1988, ARCH BIOCHEM BIOPHYS, V262, P422, DOI 10.1016/0003-9861(88)90393-1; KHATSENKO OG, 1993, P NATL ACAD SCI USA, V90, P11147, DOI 10.1073/pnas.90.23.11147; KLATT P, 1993, J BIOL CHEM, V268, P14781; KLATT P, 1992, BIOCHEM J, V288, P15, DOI 10.1042/bj2880015; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAYER B, 1993, BIOCHEM PHARMACOL, V45, P367, DOI 10.1016/0006-2952(93)90072-5; MAYER B, 1991, FEBS LETT, V288, P187, DOI 10.1016/0014-5793(91)81031-3; MCCORD JM, 1970, J BIOL CHEM, V245, P1374; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MONCADA S, 1991, PHARMACOL REV, V43, P109; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; OKEEFFE DH, 1978, J BIOL CHEM, V253, P3509; POU S, 1992, J BIOL CHEM, V267, P24173; POULOS TL, 1985, J BIOL CHEM, V260, P6122; RENGASAMY A, 1993, MOL PHARMACOL, V44, P124; ROGERS NE, 1992, BIOCHEM BIOPH RES CO, V189, P242, DOI 10.1016/0006-291X(92)91550-A; SHARMA VS, 1983, BIOCHEMISTRY-US, V22, P3897, DOI 10.1021/bi00285a026; SHARMA VS, 1987, BIOCHEMISTRY-US, V26, P3837, DOI 10.1021/bi00387a015; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; TSUBAKI M, 1987, BIOCHEMISTRY-US, V26, P4527, DOI 10.1021/bi00388a054; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001; WINK DA, 1993, ARCH BIOCHEM BIOPHYS, V300, P115, DOI 10.1006/abbi.1993.1016; WOLFF DJ, 1993, J BIOL CHEM, V268, P9425; WOLIN MS, 1982, J BIOL CHEM, V257, P13312	42	173	174	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 26	1994	269	34					21644	21649						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PK973	7520440				2022-12-27	WOS:A1994PK97300042
J	MISRA, UK; CHU, CTC; GAWDI, G; PIZZO, SV				MISRA, UK; CHU, CTC; GAWDI, G; PIZZO, SV			THE RELATIONSHIP BETWEEN LOW-DENSITY LIPOPROTEIN-RELATED PROTEIN ALPHA(2)-MACROGLOBULIN (ALPHA(2)M) RECEPTORS AND THE NEWLY DESCRIBED ALPHA(2)M SIGNALING RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SMOOTH-MUSCLE CELLS; ALPHA-2-MACROGLOBULIN RECEPTOR; GROWTH-FACTOR; BINDING-PROTEIN; MULTIFUNCTIONAL RECEPTOR; INOSITOL TRISPHOSPHATE; PLASMINOGEN-ACTIVATOR; PHOSPHOLIPASE-C; PERTUSSIS TOXIN; GI-PROTEIN	alpha(2)-Macroglobulin (alpha(2)M)-methylamine binding to macrophages appears to involve two receptors. Binding of alpha(2)M-methylamine to low density lipoprotein-related protein (LRP) results in cellular uptake and degradation, while binding to a newly described alpha(2)M signaling receptor elevates intracellular calcium ([Ca2+](i)) and inositol phosphates. We now demonstrate that binding of lactoferrin, Pseudomonas exotoxin A, and lipoprotein lipase to LRP on macrophages results in increased [Ca2+](i) and inositol 1,4,5-triphosphate. Receptor-associated protein, which binds to LRP but not the alpha(2)M signaling receptor, blocks the lactoferrin signal but has no effect on alpha(2)M-methylamine signaling. The latter observation supports our hypothesis that a distinct signaling receptor binds alpha(2)M-methylamine. We further demonstrate that the signaling events induced by lactoferrin may involve a pertussis toxin-sensitive G protein, while the alpha(2)M signaling receptor appears to be coupled to a pertussis toxin-insensitive G protein.	DUKE UNIV,MED CTR,DEPT PATHOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University; Duke University			Chu, Charleen/B-1601-2008	Chu, Charleen/0000-0002-5052-8271	NCI NIH HHS [NCI CA-29589] Funding Source: Medline; NHLBI NIH HHS [NHLBI HL-24066] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA029589] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL024066, R01HL024066] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALDWIN JM, 1994, CURR OPIN CELL BIOL, V6, P180, DOI 10.1016/0955-0674(94)90134-1; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1983, BIOCHEM J, V212, P709; BORTH W, 1992, FASEB J, V6, P3345, DOI 10.1096/fasebj.6.15.1281457; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; BYER S, 1993, BIOCHEM BIOPH RES CO, V196, P99; CHAPPELL DA, 1993, J BIOL CHEM, V268, P14168; CHOUDHURY GG, 1991, J BIOL CHEM, V266, P23147; DELAIN E, 1992, ELECTRON MICROSC REV, V5, P231, DOI 10.1016/0892-0354(92)90012-F; GARFINKEL AS, 1983, J LIPID RES, V24, P775; Herz Joachim, 1993, Current Opinion in Lipidology, V4, P107, DOI 10.1097/00041433-199304000-00006; HUANG CL, 1989, J BIOL CHEM, V264, P4391; HUETTINGER M, 1992, J BIOL CHEM, V267, P18551; IVERIUS PH, 1976, J BIOL CHEM, V251, P7791; KATAOKA R, 1993, J BIOL CHEM, V268, P19851; KONDO T, 1993, J BIOL CHEM, V268, P4458; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; MISRA UK, 1993, BIOCHEM J, V290, P885, DOI 10.1042/bj2900885; MISRA UK, 1994, J BIOL CHEM, V269, P12541; NYKJAER A, 1993, J BIOL CHEM, V268, P15048; OKAMOTO T, 1993, FEBS LETT, V334, P143, DOI 10.1016/0014-5793(93)81700-A; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; PIZZO SV, 1988, ISI ATLAS-BIOCHEM, V1, P242; PONZONI M, 1993, BIOCHEM J, V294, P893, DOI 10.1042/bj2940893; Sottrup-Jensen L., 1987, PLASMA PROTEINS, V5, P191; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; YANG LJ, 1991, J BIOL CHEM, V266, P22451; YANG LJ, 1993, J BIOL CHEM, V268, P3739	32	74	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18303	18306						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	7518427				2022-12-27	WOS:A1994NW79800012
J	DONAHUE, JP; TURNBOUGH, CL				DONAHUE, JP; TURNBOUGH, CL			NUCLEOTIDE-SPECIFIC TRANSCRIPTIONAL PAUSING IN THE PYRBI LEADER REGION OF ESCHERICHIA-COLI K-12	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE; SALMONELLA-TYPHIMURIUM; OPERON EXPRESSION; GUANOSINE TETRAPHOSPHATE; TERMINATION; ATTENUATION; INVITRO; HAIRPIN; PROTEIN; GENES	Expression of the pyrBI operon, which encodes the subunits of the pyrimidine biosynthetic enzyme aspartate transcarbamylase, is regulated primarily through a UTP-sensitive transcriptional attenuation control mechanism in Escherichia coli. In this mechanism, the extent of coupling between transcription and translation within the pyrBI leader region determines the level of rho-independent transcriptional termination at an attenuator preceding the pyrB gene. A key feature in this mechanism is transcriptional pausing that occurs before the attenuator in the pyrBI leader region when UTP concentrations are low. In this study, we characterized in detail this UTP-sensitive transcriptional pausing in vitro. Our results show that pausing occurs, to different extents, before the addition of every uridine residue in the leader transcript. This pausing occurred only at low UTP concentrations (20-200 mu M) that cause high levels of pyrBI expression in vivo. Transcriptional pausing did not occur in the pyrBI leader region at 20 mu M CTP or ATP and only occurred strongly at one site at 20 mu M GTP. We also demonstrated that NusA functions as a general enhancer of UTP-sensitive transcriptional pausing in the pyrBI leader region. Finally, we identified at the 3' end of the pyrBI attenuator a 3-base region at which termination occurs. Selection of termination sites within this region was shifted by varying the UTP concentration or including NusA in the transcription reaction mixture.	UNIV ALABAMA, DEPT MICROBIOL, BIRMINGHAM, AL 35294 USA	University of Alabama System; University of Alabama Birmingham					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029466] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM29466] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSEN JT, 1991, MOL MICROBIOL, V5, P327, DOI 10.1111/j.1365-2958.1991.tb02113.x; CHAN CL, 1989, J BIOL CHEM, V264, P20796; CHAN CL, 1993, J MOL BIOL, V233, P25, DOI 10.1006/jmbi.1993.1482; DONAHUE JP, 1990, J BIOL CHEM, V265, P19091; GREENBLATT J, 1981, NATURE, V292, P215, DOI 10.1038/292215a0; JENSEN KF, 1979, J BACTERIOL, V138, P731, DOI 10.1128/JB.138.3.731-738.1979; JENSEN KF, 1986, J BACTERIOL, V166, P857, DOI 10.1128/jb.166.3.857-865.1986; KASSAVETIS GA, 1981, J BIOL CHEM, V256, P2777; KINGSTON RE, 1981, J BIOL CHEM, V256, P2787; KNAPP G, 1989, METHOD ENZYMOL, V180, P192; LAU LF, 1983, J BIOL CHEM, V258, P9391; LEE DN, 1990, J BIOL CHEM, V265, P15145; LEVIN HL, 1989, J BIOL CHEM, V264, P14638; LIU C, 1990, THESIS U ALABAMA BIR; LIU CG, 1989, J BACTERIOL, V171, P3337, DOI 10.1128/jb.171.6.3337-3342.1989; LIU CG, 1993, J BACTERIOL, V175, P2363, DOI 10.1128/JB.175.8.2363-2369.1993; Maxam A M, 1980, Methods Enzymol, V65, P499; Neuhard J, 1987, ESCHERICHIA COLI SAL, P445; Nishimura S, 1972, Prog Nucleic Acid Res Mol Biol, V12, P49; POULSEN P, 1987, MOL GEN GENET, V208, P152, DOI 10.1007/BF00330436; ROLAND KL, 1988, P NATL ACAD SCI USA, V85, P7149, DOI 10.1073/pnas.85.19.7149; ROLAND KL, 1985, J BACTERIOL, V163, P991, DOI 10.1128/JB.163.3.991-999.1985; SIGMUND CD, 1988, BIOCHEMISTRY-US, V27, P5622, DOI 10.1021/bi00415a034; TURNBOUGH CL, 1983, J BACTERIOL, V153, P998, DOI 10.1128/JB.153.2.998-1007.1983; TURNBOUGH CL, 1983, P NATL ACAD SCI-BIOL, V80, P368, DOI 10.1073/pnas.80.2.368; YAGER TD, 1987, ESCHERICHIA COLI SAL, P1241	26	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					18185	18191						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	7517939				2022-12-27	WOS:A1994NV42200064
J	BROWN, VK; OGLE, EW; BURKHARDT, AL; ROWLEY, RB; BOLEN, JB; JUSTEMENT, LB				BROWN, VK; OGLE, EW; BURKHARDT, AL; ROWLEY, RB; BOLEN, JB; JUSTEMENT, LB			MULTIPLE COMPONENTS OF THE B-CELL ANTIGEN RECEPTOR COMPLEX ASSOCIATE WITH THE PROTEIN-TYROSINE-PHOSPHATASE, CD45	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTES-B; CROSS-LINKING; MEMBRANE IMMUNOGLOBULIN; SIGNAL TRANSDUCTION; SRC FAMILY; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOTYROSINE PHOSPHATASE; PHOSPHOLIPASE C-GAMMA-2; KINASE PP56LCK; IG-ALPHA	Signal transduction via the B cell antigen receptor complex is regulated by changes in tyrosine phosphorylation of several proteins. The equilibrium between tyrosine phosphorylation and dephosphorylation is regulated by the combined action of protein tyrosine kinase and protein tyrosine phosphatase enzymes. In particular, the protein tyrosine phosphatase, CD45, has been shown to play an essential role in signal transduction via the B cell antigen receptor. Therefore, experiments were performed to examine the intermolecular associations between CD45 and phosphotyrosine containing proteins in the B cell to identify potential substrates for CD45. Based on coprecipitation experiments, CD45 was found to be physically associated with multiple components of the B cell antigen receptor complex including the MB-1/B29 heterodimer. Additionally, CD45 was selectively associated with the src family protein tyrosine kinase, lyn. Neither blk nor fyn, were observed to interact with CD45 even though they have been implicated in antigen receptor signal transduction. This finding suggests that CD45 may preferentially regulate the phosphorylation of lyn and thus, its activity. In summary, these studies provide evidence to support the hypothesis that CD45 regulates antigen receptor-mediated signal transduction by controlling the tyrosine phosphorylation of multiple components of the antigen receptor complex.	UNIV TEXAS,MED BRANCH,DEPT MICROBIOL & IMMUNOL,GALVESTON,TX 77555; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOLEC BIOL,PRINCETON,NJ 08543	University of Texas System; University of Texas Medical Branch Galveston; Bristol-Myers Squibb				Justement, Louis/0000-0001-7058-867X	NIGMS NIH HHS [GM-46524] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM046524, R01GM046524] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMBIER JC, 1991, J IMMUNOL, V146, P2075; CAMPBELL KS, 1990, EMBO J, V9, P441, DOI 10.1002/j.1460-2075.1990.tb08129.x; CAMPBELL KS, 1991, J IMMUNOL, V147, P1575; CAMPBELL KS, 1991, P NATL ACAD SCI USA, V88, P3982, DOI 10.1073/pnas.88.9.3982; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P2745, DOI 10.1073/pnas.88.7.2745; CARTER RH, 1991, J IMMUNOL, V147, P3663; CASILLAS A, 1991, J BIOL CHEM, V266, P19088; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; COGGESHALL KM, 1992, P NATL ACAD SCI USA, V89, P5660, DOI 10.1073/pnas.89.12.5660; GOLD MR, 1991, P NATL ACAD SCI USA, V88, P3436, DOI 10.1073/pnas.88.8.3436; GOLD MR, 1993, J IMMUNOL, V150, P377; GOLD MR, 1992, J IMMUNOL, V148, P2012; HEMPEL WM, 1992, J IMMUNOL, V148, P3021; HURLEY TR, 1993, MOL CELL BIOL, V13, P1651, DOI 10.1128/MCB.13.3.1651; JULIUS MH, 1984, EUR J IMMUNOL, V14, P753, DOI 10.1002/eji.1830140816; JUSTEMENT LB, 1990, J IMMUNOL, V144, P3272; JUSTEMENT LB, 1991, SCIENCE, V252, P1839, DOI 10.1126/science.1648262; KIM KM, 1993, EUR J IMMUNOL, V23, P911, DOI 10.1002/eji.1830230422; KISHIHARA K, 1993, CELL, V74, P143, DOI 10.1016/0092-8674(93)90302-7; KORETZKY GA, 1993, J BIOL CHEM, V268, P8958; LANE PJL, 1991, J IMMUNOL, V146, P715; LI ZH, 1992, BIOCHEM BIOPH RES CO, V187, P1536, DOI 10.1016/0006-291X(92)90477-3; LIN JJ, 1992, J IMMUNOL, V149, P3182; LIN JJ, 1992, J IMMUNOL, V149, P1548; MCFARLAND EDC, 1993, P NATL ACAD SCI USA, V90, P1402, DOI 10.1073/pnas.90.4.1402; MIZUGUCHI J, 1992, J IMMUNOL, V148, P689; Morrison M, 1974, Methods Enzymol, V32, P103; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; MUSTELIN T, 1992, EUR J IMMUNOL, V22, P1173, DOI 10.1002/eji.1830220510; MUSTELIN T, 1990, ONCOGENE, V5, P809; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; RETH M, 1991, IMMUNOL TODAY, V12, P196, DOI 10.1016/0167-5699(91)90053-V; ROIFMAN CM, 1992, BIOCHEM BIOPH RES CO, V183, P411, DOI 10.1016/0006-291X(92)90496-8; RUFFJAMISON S, 1991, J BIOL CHEM, V266, P6607; SAKAGUCHI N, 1988, EMBO J, V7, P3457, DOI 10.1002/j.1460-2075.1988.tb03220.x; SCHRAVEN B, 1991, EUR J IMMUNOL, V21, P2469, DOI 10.1002/eji.1830211025; SCHRAVEN B, 1992, EUR J IMMUNOL, V22, P1857, DOI 10.1002/eji.1830220727; SCHULTE RJ, 1992, SCIENCE, V258, P1001, DOI 10.1126/science.1279802; SIEH M, 1993, EMBO J, V12, P315, DOI 10.1002/j.1460-2075.1993.tb05659.x; SPANA C, 1993, PROTEIN EXPRES PURIF, V4, P390, DOI 10.1006/prep.1993.1051; STOVER DR, 1991, P NATL ACAD SCI USA, V88, P7704, DOI 10.1073/pnas.88.17.7704; TROWBRIDGE IS, 1978, J EXP MED, V148, P313, DOI 10.1084/jem.148.1.313; TUVESON DA, 1993, SCIENCE, V260, P986, DOI 10.1126/science.7684160; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YI TL, 1991, MOL CELL BIOL, V11, P2391, DOI 10.1128/MCB.11.5.2391; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	49	52	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 24	1994	269	25					17238	17244						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NT846	7516335				2022-12-27	WOS:A1994NT84600040
J	GAISANO, HY; SHEU, L; FOSKETT, JK; TRIMBLE, WS				GAISANO, HY; SHEU, L; FOSKETT, JK; TRIMBLE, WS			TETANUS TOXIN LIGHT-CHAIN CLEAVES A VESICLE-ASSOCIATED MEMBRANE-PROTEIN (VAMP) ISOFORM-2 IN RAT PANCREATIC ZYMOGEN GRANULES AND INHIBITS ENZYME-SECRETION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLES; NEUROTRANSMITTER RELEASE; REGULATED EXOCYTOSIS; SYNTHETIC PEPTIDES; CHROMAFFIN CELLS; EFFECTOR DOMAIN; FUSION; SYNAPTOBREVIN; BINDING; FAMILY	Pancreatic acinar cells, a model cell type for the study of exocytosis in non-excitable cells, were used here to test the hypothesis that molecular mechanisms regulating exocytosis from neuronal and neuroendocrine cells may also be utilized in exocrine cells. Using specific antisera raised against vesicle-associated membrane protein (VAMP) isoforms 1 and 2, we have identified VAMP-2, but not VAMP-1, immunoreactive proteins on rat pancreatic acinar cell secretory (zymogen) granules. This 18-kDa protein co-migrated with rat brain synaptic vesicle VAMP-2. Tetanus toxin (TeTx) light chain caused complete cleavage of this protein, which was prevented by the addition of EDTA. This toxin also inhibited in a dose-dependent manner Ca2+-stimulated enzyme secretion by up to similar to 30% in streptolysin O-permeabilized acini. This effect of TeTx on secretion was prevented by the zinc endopeptidase inhibitor captopril or by boiling the toxin. Incomplete inhibition of secretion by TeTx may suggest that TeTx-insensitive or VAMP-2-independent mechanisms also regulate exocytosis. In support, TeTx light chain was without effect on Rab3AL, (effector domain peptide of Rab3)-mediated potentiation of Ca2+-stimulated secretion. These results indicate that a TeTx-sensitive VAMP-2-like protein on zymogen granules participates in Ca2+-regulated pancreatic enzyme secretion and that undefined Rab3AL-activated mechanisms may act independently to regulate exocytosis.	TORONTO HOSP,TORONTO M5S 1A8,ON,CANADA; HOSP SICK CHILDREN,RES INST,DIV CELL BIOL,TORONTO M5G 1X8,ON,CANADA; UNIV TORONTO,DEPT PHYSIOL,TORONTO M5S 1A8,ON,CANADA; UNIV TORONTO,CTR RES NEURODEGENERAT DIS,TORONTO M5S 1A8,ON,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto	GAISANO, HY (corresponding author), UNIV TORONTO,DEPT MED,RM 7226,MED SCI BLDG,TORONTO M5S 1A8,ON,CANADA.		Foskett, Kevin/R-2549-2019	Foskett, J. Kevin/0000-0002-8854-0268				AHNERTHILGER G, 1989, FEBS LETT, V242, P245, DOI 10.1016/0014-5793(89)80478-8; AHNERTHILGER G, 1989, J NEUROCHEM, V52, P1751, DOI 10.1111/j.1471-4159.1989.tb07253.x; BALDINI G, 1992, P NATL ACAD SCI USA, V89, P5049, DOI 10.1073/pnas.89.11.5049; BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; BEAUDOIN AR, 1992, INT REV CYTOL, V132, P177, DOI 10.1016/S0074-7696(08)62456-0; BENNETT MK, 1992, J CELL BIOL, V116, P761, DOI 10.1083/jcb.116.3.761; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUN JEA, 1994, J BIOL CHEM, V269, P5328; CAIN CC, 1992, J BIOL CHEM, V267, P11681; CAMERON RS, 1986, J CELL BIOL, V103, P1299, DOI 10.1083/jcb.103.4.1299; CARLSON SS, 1978, BIOCHEMISTRY-US, V17, P1188, DOI 10.1021/bi00600a009; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; DAYANITHI G, 1994, NEUROSCIENCE, V58, P423, DOI 10.1016/0306-4522(94)90048-5; EDWARDSON JM, 1993, FEBS LETT, V320, P52, DOI 10.1016/0014-5793(93)81656-K; ELFERINK LA, 1989, J BIOL CHEM, V264, P11061; GAISANO HY, 1989, J CLIN INVEST, V83, P321, DOI 10.1172/JCI113877; HORIKAWA HPM, 1993, FEBS LETT, V330, P236, DOI 10.1016/0014-5793(93)80281-X; JENA BP, 1994, J CELL BIOL, V124, P43, DOI 10.1083/jcb.124.1.43; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAW GJ, 1993, FEBS LETT, V333, P56, DOI 10.1016/0014-5793(93)80374-4; LINK E, 1992, BIOCHEM BIOPH RES CO, V189, P1017, DOI 10.1016/0006-291X(92)92305-H; MACLEAN CM, 1993, BIOCHEM J, V294, P325, DOI 10.1042/bj2940325; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; OBERHAUSER AF, 1992, NATURE, V360, P270, DOI 10.1038/360270a0; PADFIELD PJ, 1992, P NATL ACAD SCI USA, V89, P1656, DOI 10.1073/pnas.89.5.1656; PAQUET MR, 1982, EUR J CELL BIOL, V28, P20; PENNER R, 1986, NATURE, V324, P719; SCHIAVO G, 1990, INFECT IMMUN, V58, P4136, DOI 10.1128/IAI.58.12.4136-4141.1990; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SENYSHYN J, 1992, FEBS LETT, V309, P41, DOI 10.1016/0014-5793(92)80735-Y; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STETCHER B, 1992, BIOCHEM J, V283, P899; SUDHOF TC, 1989, NEURON, V2, P1475, DOI 10.1016/0896-6273(89)90193-1; TRIMBLE WS, 1990, J NEUROSCI, V10, P1380; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; TRIMBLE WS, 1993, J PHYSIOLOGY-PARIS, V87, P107, DOI 10.1016/0928-4257(93)90004-D; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; WELLER U, 1989, EUR J BIOCHEM, V182, P649, DOI 10.1111/j.1432-1033.1989.tb14874.x; [No title captured]	41	131	132	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 24	1994	269	25					17062	17066						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NT846	7516331				2022-12-27	WOS:A1994NT84600015
J	SRINIVASAN, M; BEGUM, N				SRINIVASAN, M; BEGUM, N			STIMULATION OF PROTEIN PHOSPHATASE-1 ACTIVITY BY PHORBOL ESTERS - EVALUATION OF THE REGULATORY ROLE OF PROTEIN-KINASE-C IN INSULIN ACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; GLUCOSE-TRANSPORT; SKELETAL-MUSCLE; RAT ADIPOCYTES; RIBOSOMAL PROTEIN-S6; GLYCOGEN-SYNTHESIS; BC3H-1 MYOCYTES; PHOSPHORYLATION; ACTIVATION; CELLS	In this study, we examined the role of insulin, protein kinase C (PKC) and mitogen-activated protein kinase (MAPK) cascade in activation of protein phosphatase-1 (PP-1) by using three complementary approaches. First, differentiated L6 cells were acutely exposed to 12-O-tetradecanoylphorbol-13-acetate (TPA, 400 nM) to activate PKC. In these cells, TPA caused 32% stimulation of PP-1 activity. The PP-1 stimulation by TPA was comparable to stimulation by insulin (t(1/2) = 1 min and EC(50) = 5 nM) with a maximum effect in 5 min. The effects of insulin and TPA were not additive. Insulin and TPA also stimulated MAPK (>2-fold increase over basal, with myelin basic protein as a substrate). ML-9, a myosin light chain kinase inhibitor, blocked the effects of insulin and TPA on both MAPK and PP-1 activation. In the second approach, PKC was down-regulated by chronic treatment with TPA. In these cells subsequent effects of insulin on MAPK and PP-1 activation were blocked, without an effect on basal enzyme levels. In the third approach, two selective inhibitors of PKC, calphostin and chelerythrine chloride, were used to inhibit PKC. These inhibitors completely prevented insulin and TPA stimulation of MAPK and PP-1 and blocked insulin induced translocation of PKC to the plasma membranes. We conclude that PKC plays an important role in insulin stimulation of PP-1 via the activation of MAPK cascade.	WINTHROP UNIV HOSP, DIABET RES LAB, MINEOLA, NY 11501 USA; SUNY STONY BROOK, DEPT MED, STONY BROOK, NY 11790 USA	Winthrop University Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook								ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BEGUM N, 1993, J BIOL CHEM, V268, P7917; BLENIS J, 1984, P NATL ACAD SCI-BIOL, V81, P6408, DOI 10.1073/pnas.81.20.6408; CARO JF, 1992, MOL CELL BIOCHEM, V109, P115; CHAN CP, 1988, P NATL ACAD SCI USA, V85, P6257, DOI 10.1073/pnas.85.17.6257; CLARKE PR, 1993, FEBS LETT, V336, P37, DOI 10.1016/0014-5793(93)81604-X; COHEN P, 1991, METHOD ENZYMOL, V201, P389; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; COHEN P, 1983, METHOD ENZYMOL, V99, P243; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; FARESE RV, 1992, CELL SIGNAL, V4, P133, DOI 10.1016/0898-6568(92)90077-L; GRANOT Y, 1993, J BIOL CHEM, V268, P9564; HEIDECKER G, 1992, ADV CANCER RES, V58, P53, DOI 10.1016/S0065-230X(08)60290-0; HEIDENREICH KA, 1993, J BIOL CHEM, V268, P14663; HENRIKSEN EJ, 1989, J BIOL CHEM, V264, P21536; HOFFMAN JM, 1991, ENDOCRINOLOGY, V128, P2937, DOI 10.1210/endo-128-6-2937; INOUE G, 1993, J BIOL CHEM, V268, P5272; KLIP A, 1987, BIOCHEM J, V242, P131, DOI 10.1042/bj2420131; KLIP A, 1984, AM J PHYSIOL, V247, pE291, DOI 10.1152/ajpendo.1984.247.3.E291; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KYRIAKIS JM, 1993, J BIOL CHEM, V268, P16009; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARNER J, 1990, ADV ENZYMOL RAMB, V63, P173; MEIER KE, 1991, J BIOL CHEM, V266, P1914; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; RAPP UR, 1991, ONCOGENE, V6, P495; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SRINIVASAN M, 1994, J BIOL CHEM, V269, P12514; STANDAERT ML, 1990, METABOLISM, V39, P1170, DOI 10.1016/0026-0495(90)90090-Y; STANDAERT ML, 1993, ENDOCRINOLOGY, V132, P689, DOI 10.1210/en.132.2.689; TANG PM, 1991, J BIOL CHEM, V266, P15782; TREVILLYAN JM, 1984, J BIOL CHEM, V259, P897; VILLAMORUZZI E, 1989, FEBS LETT, V258, P208, DOI 10.1016/0014-5793(89)81654-0; WELSH GI, 1993, FEBS LETT, V316, P241, DOI 10.1016/0014-5793(93)81300-O; YU BZ, 1992, ENDOCRINOLOGY, V130, P3345, DOI 10.1210/en.130.6.3345	36	56	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16662	16667						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	7515882				2022-12-27	WOS:A1994NR29600025
J	PERSECHINI, A; MCMILLAN, K; LEAKEY, P				PERSECHINI, A; MCMILLAN, K; LEAKEY, P			ACTIVATION OF MYOSIN LIGHT-CHAIN KINASE AND NITRIC-OXIDE SYNTHASE ACTIVITIES BY CALMODULIN FRAGMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL HELIX; PEPTIDE COMPLEX; BASIC RESIDUES; BINDING; PROTEINS; ENZYME; IDENTIFICATION; CHROMATOGRAPHY; PURIFICATION; DELETIONS	We have investigated the abilities of calmodulin (CaM) tryptic fragments 1-75 (TRCI) or 78-148 (TRCII) to activate gizzard smooth muscle myosin light chain kinase (gMLCK), rabbit skeletal muscle myosin light chain kinase (skMLCK), and neural nitric oxide synthase (nNOS) activities. Our results indicate for all three enzymes that binding of CaM follows an ordered mechanism wherein the C-terminal lobe, represented by TRCII, binds specifically to a site we designated as A, followed by binding of the N-terminal lobe, represented by TRCI, to a site designated as B. With TRCII and TRCI bound to their respective sites, skMLCK and gMLCK activities are both activated to about 80% of their maximum levels. Occupancy of both sites in the MLCK enzymes by TRCI results in only low levels of enzyme activation; occupancy of both sites by TRCII also results in low levels of gMLCK activity, but activates skMLCK activity to 65% of the maximum level. With TRCI bound at site B and either TRCII or TRCI bound at site A, nNOS activity is 50% of the maximum level. Apparent dissociation constants for TRCII binding to site A and TRCI binding to site B are, respectively; 0.3 and 3 mu M (skMLCK); 1.2 and 0.8 mu M (gMLCK); 10 nM and 150 mu M (nNOS). Our results demonstrate that the CaM lobes can make distinct contributions to binding and/or activation of different CaM-dependent enzymes and that the tethering function of the central helix can be mimicked by sufficiently high concentrations of the CaM fragments. We have modeled tethering as if it stabilizes the CaM-enzyme complex by creating a high effective concentration of the N-terminal lobe. Calculated values for this concentration term indicate essentially identical contributions by the central helix to the observed nanomolar dissociation constants of the three CaM-enzyme complexes examined.	UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio	PERSECHINI, A (corresponding author), UNIV ROCHESTER,MED CTR,DEPT PHYSIOL,ROCHESTER,NY 14642, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030050, R37HL030050] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK044322] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30050] Funding Source: Medline; NIDDK NIH HHS [DK44322] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; Colbran R J, 1990, Curr Top Cell Regul, V31, P181; CROTHERS DM, 1972, IMMUNOCHEMISTRY, V9, P341, DOI 10.1016/0019-2791(72)90097-3; FITZSIMONS DP, 1992, J BIOL CHEM, V267, P23903; GUERINI D, 1985, ANAL BIOCHEM, V150, P178, DOI 10.1016/0003-2697(85)90458-0; HEIDORN DB, 1988, BIOCHEMISTRY-US, V27, P909, DOI 10.1021/bi00403a011; HERRING BP, 1991, J BIOL CHEM, V266, P11838; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; KUZNICKI J, 1981, FEBS LETT, V130, P141, DOI 10.1016/0014-5793(81)80683-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANALAN AS, 1984, ADV CYCLIC NUCL PROT, V18, P227; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MONCRIEF ND, 1990, J MOL EVOL, V30, P522, DOI 10.1007/BF02101108; NAIRN AC, 1987, J BIOL CHEM, V262, P7273; NAIRN AC, 1985, P NATL ACAD SCI USA, V82, P7939, DOI 10.1073/pnas.82.23.7939; NEWTON D, 1985, BIOCHIM BIOPHYS ACTA, V845, P533, DOI 10.1016/0167-4889(85)90222-8; NEWTON DL, 1984, J BIOL CHEM, V259, P4419; NI WC, 1985, J BIOL CHEM, V260, P6974; PERSECHINI A, 1989, J BIOL CHEM, V264, P8052; PERSECHINI A, 1988, J BIOL CHEM, V263, P12175; PERSECHINI A, 1988, J CARDIOVASC PHARM, V12, pS1; PERSECHINI A, 1993, FASEB J, V7, pA1141; POLLOCK JS, 1991, P NATL ACAD SCI USA, V88, P10480, DOI 10.1073/pnas.88.23.10480; PUTKEY JA, 1988, J BIOL CHEM, V263, P11242; SANYAL G, 1988, BIOCHEMISTRY-US, V27, P6229, DOI 10.1021/bi00417a006; THULIN E, 1984, BIOCHEMISTRY-US, V23, P1862, DOI 10.1021/bi00303a043; VANBERKUM MFA, 1990, J BIOL CHEM, V265, P3750	31	85	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16148	16154						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	7515878				2022-12-27	WOS:A1994NQ72900032
J	IGARASHI, K; GAROTTA, G; OZMEN, L; ZIEMIECKI, A; WILKS, AF; HARPUR, AG; LARNER, AC; FINBLOOM, DS				IGARASHI, K; GAROTTA, G; OZMEN, L; ZIEMIECKI, A; WILKS, AF; HARPUR, AG; LARNER, AC; FINBLOOM, DS			INTERFERON-GAMMA INDUCES TYROSINE PHOSPHORYLATION OF INTERFERON-GAMMA RECEPTOR AND REGULATED ASSOCIATION OF PROTEIN-TYROSINE KINASES, JAK1 AND JAK2, WITH ITS RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SIGNAL TRANSDUCER; DOMAIN	Interferon-gamma (IFN-gamma) induces the expression of a set of early response genes by tyrosine phosphorylation of latent transcription factors such as p91. Although the tyrosine kinases, Jak1 and Jak2, have recently been shown to be critical for signal transduction by IFN-gamma, evidence is lacking for both tyrosine phosphorylation of the IFN-gamma receptor (IFN-gamma R) and the interaction between Jak1, Jak2, and the IFN-gamma R. In this report, we show that binding of IFN-gamma to HeLa cells initiated a series of events that resulted in the extremely rapid (15 s) tyrosine phosphorylation of not only Jak1, Jak2, and p91 but also the IFN-gamma R. Coimmunoprecipitation experiments revealed that Jak1 was associated with the IFN-gamma R prior to ligand binding, whereas Jak2 became part of the IFN-gamma R Jak1 complex immediately after ligand binding. H2O2/vanadate treatment of cells for 15 min resulted in only the tyrosine phosphorylation of Jak1 and IFN-gamma R. Only after 60 min of this treatment did we observe tyrosine phosphorylation of Jak2 and p91 and assembly of the transcription factor complex FcRF gamma that binds to the promoter of the fcgr1 gene. These data suggest that JAK1 associates with the IFN-gamma R prior to ligand binding. IFN-gamma treatment of cells results in recruitment of JAK2 into the IFN-gamma R-Jak1 complex followed by assembly of the transcription factor FcRF gamma complex.	US FDA,CTR BIOL EVALUAT & RES,DIV CYTOKINE BIOL,BETHESDA,MD 20892; HOFFMANN LA ROCHE AG,PHARMACEUT RES NEW TECHNOL,CH-4002 BASEL,SWITZERLAND; UNIV BERN,INST CLIN & EXPTL CANC RES,CH-3004 BERN,SWITZERLAND; LUDWIG INST CANC RES,MELBOURNE TUMOUR BIOL BRANCH,MELBOURNE,VIC 3050,AUSTRALIA	US Food & Drug Administration (FDA); Roche Holding; University of Bern; Ludwig Institute for Cancer Research			Wilks, Andrew F/R-5542-2019	Wilks, Andrew F/0000-0002-8554-2399				AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; FARRAR MA, 1992, P NATL ACAD SCI USA, V89, P11706, DOI 10.1073/pnas.89.24.11706; FINBLOOM DS, 1994, MOL CELL BIOL, V14, P2113, DOI 10.1128/MCB.14.3.2113; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; GAROTTA G, 1990, J BIOL CHEM, V265, P6908; GIBBS VC, 1991, MOL CELL BIOL, V11, P5860, DOI 10.1128/MCB.11.12.5860; HARPUR AG, 1992, ONCOGENE, V7, P1347; HEMMI S, 1992, P NATL ACAD SCI USA, V89, P2737, DOI 10.1073/pnas.89.7.2737; HOWARD OMZ, 1992, ONCOGENE, V7, P895; IGARASHI K, 1993, MOL CELL BIOL, V13, P3984, DOI 10.1128/MCB.13.7.3984; JUNG V, 1987, P NATL ACAD SCI USA, V84, P6934; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WILSON KC, 1992, P NATL ACAD SCI USA, V89, P11964, DOI 10.1073/pnas.89.24.11964	22	211	216	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14333	14336						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	7514165				2022-12-27	WOS:A1994NM06500002
J	SASAOKA, T; ROSE, DW; JHUN, BH; SALTIEL, AR; DRAZNIN, B; OLEFSKY, JM				SASAOKA, T; ROSE, DW; JHUN, BH; SALTIEL, AR; DRAZNIN, B; OLEFSKY, JM			EVIDENCE FOR A FUNCTIONAL-ROLE OF SHE PROTEINS IN MITOGENIC SIGNALING INDUCED BY INSULIN, INSULIN-LIKE GROWTH-FACTOR-I, AND EPIDERMAL GROWTH-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASES; RAS; TRANSDUCTION; DOMAINS; CELLS; MICROINJECTION; REQUIREMENT; ASSOCIATION; PI3-KINASE; CLONING	Shc proteins contain a single SH2 domain, lack catalytic activity, and are substrates for activated receptors for insulin, insulin-like growth factor-1 (IGF-1), and epidermal growth factor (EGF). Treatment with these growth factors induced rapid tyrosine phosphorylation of Shc. We investigated the potential role of Shc in mitogenic signaling. Affinity-purified antibodies were microinjected into living Rat1 fibroblasts overexpressing human insulin receptors. Bromodeoxyuridine incorporation into newly synthesized DNA was subsequently studied to assess the importance of Shc. Cellular microinjection of anti-Shc antibody inhibited BrdU incorporation induced by insulin, IGF-1, and EGF, but did not affect cells stimulated by fetal calf serum. Microinjection of an oncogenic p21(ras) protein (T24) into quiescent cells produced constitutively active mitogenic signaling, and comicroinjection of T24 with the anti-Shc antibody restored insulin and EGF stimulation of DNA synthesis. Immunoprecipitates of Shc from lysates of insulin-stimulated cells removed 70-80% of guanine nucleotide-releasing factor activity. These results indicate that Shc is an important component in a mitogenic signal transduction pathway that is shared by insulin, IGF-1, and EGF. The functional locus of Shc is either upstream of p21(ras) or lies on a distinct branch of the pathway leading to cell cycle progression.	VET ADM MED CTR,MED RES SERV 111G,SAN DIEGO,CA 92161; UNIV CALIF SAN DIEGO,DEPT MED,DIV ENDOCRINOL & METAB,LA JOLLA,CA 92093; WARNER LAMBERT PARKE DAVIS,PARKE DAVIS PHARMACEUT RES DIV,DEPT SIGNAL TRANSDUCT,ANN ARBOR,MI 48105; VET AFFAIRS MED CTR,MED RES SERV,DENVER,CO 80220; VET AFFAIRS MED CTR,DEPT MED,DENVER,CO 80220; UNIV COLORADO,HLTH SCI CTR,DENVER,CO 80220	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Diego; Pfizer; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver			Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK033651, R01DK033651] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK33651] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; COCHET C, 1991, J BIOL CHEM, V266, P637; DRAZNIN B, 1993, J BIOL CHEM, V268, P19998; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; OHMICHI M, 1993, ENDOCRINOLOGY, V133, P46, DOI 10.1210/en.133.1.46; OHMICHI M, 1994, J BIOL CHEM, V269, P1143; OLEFSKY JM, 1990, DIABETES, V39, P1009, DOI 10.2337/diabetes.39.9.1009; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; RUFFJAMISON S, 1993, J BIOL CHEM, V268, P7610; SATOH T, 1992, J BIOL CHEM, V267, P24149; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; THIES RS, 1989, J BIOL CHEM, V264, P12820; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; YAMAUCHI K, 1993, J BIOL CHEM, V268, P14597; YONEZAWA K, 1992, J BIOL CHEM, V267, P25958; ZHU GC, 1993, J BIOL CHEM, V268, P1775	43	258	266	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13689	13694						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	7513704				2022-12-27	WOS:A1994NK18400092
J	KOEPPE, RE; GREATHOUSE, DV; JUDE, A; SABERWAL, G; PROVIDENCE, LL; ANDERSEN, OS				KOEPPE, RE; GREATHOUSE, DV; JUDE, A; SABERWAL, G; PROVIDENCE, LL; ANDERSEN, OS			HELIX SENSE OF GRAMICIDIN CHANNELS AS A NONLOCAL FUNCTION OF THE PRIMARY SEQUENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								Gramicidin A (gA) channels are dimers formed by right-handed beta(6.3)-helical monomers. The stereochemical basis for the preference of a right-handed conformation remains obscure, but it has earlier been demonstrated that the handedness can be shifted by changing the chirality of each residue in the LD-sequence and therefore is determined by the peptide itself and not by channel-membrane interactions, We now examine the contributions of Trp(15), the central Val residues 6-8, and residues 1-5. None of these alone are sufficient to specify the helix sense. To examine the D-Va(6)-L-Val(7)-D-Val(8) sequence, the register of the 3 valines was shifted by one to L-Val(5)-D-Val(6)-Val(7). The resulting analogue, [Val(5),D-AlA(8)]gA, forms channels with a conductance and duration that are both somewhat less than those of gA channels. The reduced channel duration can be attributed to a steric conflict between the side chains of Val(1) in one monomer and Val(5) in the other monomer. The helix handedness is not altered by this modification, as shown by circular dichroism and two-dimensional nuclear magnetic resonance spectroscopy and by hybrid channel experiments. [Val(5),D-Ala(8)]gA forms hybrid channels with gA (which forms right-handed channels), but not with des-Val(1)-gA(-) (which forms left-handed channels). Similar hybrid channel analysis shows that des-Trp(15)-gA and [L-Ala(1),D-Ala(2),L-Ala(3),D-Ala(4)]gA also form right-handed channels. We conclude that the helix handedness most probably is a complex function of the arrangement of both the D-Val-L-Val-D-Val and the L-Trp-(D-Leu-L-Trp)(3) segments.	CORNELL UNIV, COLL MED, DEPT PHYSIOL & BIOPHYS, NEW YORK, NY 10021 USA	Cornell University	KOEPPE, RE (corresponding author), UNIV ARKANSAS, DEPT CHEM & BIOCHEM, FAYETTEVILLE, AR 72701 USA.			Koeppe, Roger/0000-0003-0676-6413	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021342, R01GM034968] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM021342, GM34968, GM21342] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSEN O S, 1992, Biophysical Journal, V61, pA526; ANDERSEN OS, 1992, PHYSIOL REV, V72, pS89, DOI 10.1152/physrev.1992.72.suppl_4.S89; ANDERSEN OS, 1983, BIOPHYS J, V41, P119, DOI 10.1016/S0006-3495(83)84414-2; ARSENIEV AS, 1986, BIOL MEMBRANY, V3, P1077; ARSENIEV AS, 1985, FEBS LETT, V186, P168, DOI 10.1016/0014-5793(85)80702-X; BANO MC, 1992, BIOPHYS J, V63, P70, DOI 10.1016/S0006-3495(92)81590-4; BANO MC, 1991, BIOCHEMISTRY-US, V30, P886, DOI 10.1021/bi00218a002; BARANY G, 1987, INT J PEPT PROT RES, V30, P707; BARSUKOV IL, 1987, BIOORG KHIM+, V13, P1501; BECKER MD, 1991, BIOCHEMISTRY-US, V30, P8830, DOI 10.1021/bi00100a015; BUSATH DD, 1993, ANNU REV PHYSIOL, V55, P473; BYSTROV VF, 1988, TETRAHEDRON, V44, P925, DOI 10.1016/S0040-4020(01)86126-3; CIFU AS, 1992, BIOPHYS J, V61, P189, DOI 10.1016/S0006-3495(92)81826-X; COX DR, 1966, STATISTICAL ANAL SER; DURKIN JT, 1992, BIOPHYS J, V62, P145, DOI 10.1016/S0006-3495(92)81801-5; DURKIN JT, 1993, J MOL BIOL, V231, P1102, DOI 10.1006/jmbi.1993.1355; DURKIN JT, 1990, J MOL BIOL, V211, P221, DOI 10.1016/0022-2836(90)90022-E; ETCHEBEST C, 1988, JERUS SYM Q, V21, P167; ETCHEBEST C, 1985, BIOCHIM BIOPHYS ACTA, V818, P23, DOI 10.1016/0005-2736(85)90133-6; FONSECA V, 1992, BIOCHEMISTRY-US, V31, P5340, DOI 10.1021/bi00138a014; HALL P, 1981, J PHYS CHEM-US, V85, P2941, DOI 10.1021/j150620a019; HEITZ F, 1982, BIOPHYS J, V40, P87, DOI 10.1016/S0006-3495(82)84462-7; HLADKY SB, 1972, BIOCHIM BIOPHYS ACTA, V274, P294, DOI 10.1016/0005-2736(72)90178-2; KETCHEM RR, 1993, SCIENCE, V261, P1457, DOI 10.1126/science.7690158; KILLIAN JA, 1992, BIOCHEMISTRY-US, V31, P11283, DOI 10.1021/bi00161a004; KILLIAN JA, 1988, BIOCHEMISTRY-US, V27, P4848, DOI 10.1021/bi00413a040; KILLIAN JA, 1992, BIOCHIM BIOPHYS ACTA, V1113, P391; KOEPPE R E II, 1991, Biophysical Journal, V59, p319A; KOEPPE RE, 1984, BIOPOLYMERS, V23, P23, DOI 10.1002/bip.360230104; KOEPPE RE, 1992, PROTEINS, V12, P49, DOI 10.1002/prot.340120107; KOEPPE RE, 1994, BIOPHYS J, V66, pA219; LANGS DA, 1988, SCIENCE, V241, P188, DOI 10.1126/science.2455345; MASOTTI L, 1980, CELL BIOPHYS, V2, P241, DOI 10.1007/BF02790452; MATTICE GL, 1993, BIOPHYS J, V64, pA300; MAZET JL, 1984, BIOPHYS J, V45, P263, DOI 10.1016/S0006-3495(84)84153-3; MONOI H, 1993, BIOPHYS J, V64, P36, DOI 10.1016/S0006-3495(93)81338-9; MYERS VB, 1972, BIOCHIM BIOPHYS ACTA, V274, P313, DOI 10.1016/0005-2736(72)90179-4; NICHOLSON LK, 1989, BIOCHEMISTRY-US, V28, P9379, DOI 10.1021/bi00450a019; OCONNELL AM, 1990, SCIENCE, V250, P1256, DOI 10.1126/science.1700867; RUSSELL EWB, 1986, BIOPHYS J, V49, P673, DOI 10.1016/S0006-3495(86)83694-3; SABERWAL G, 1994, BIOPHYS J, V66, pA219; SARGES R, 1965, BIOCHEMISTRY-US, V4, P2491, DOI 10.1021/bi00887a031; SAWYER DB, 1990, BIOPHYS J, V57, P515, DOI 10.1016/S0006-3495(90)82567-4; SAWYER DB, 1990, BIOPHYS J, V58, P1207, DOI 10.1016/S0006-3495(90)82461-9; SOEH SA, 1993, BIOPHYS J, V65, P1817; TURNER GL, 1983, BIOCHIM BIOPHYS ACTA, V756, P133, DOI 10.1016/0304-4165(83)90083-1; URRY DW, 1971, P NATL ACAD SCI USA, V68, P672, DOI 10.1073/pnas.68.3.672; VEATCH WR, 1974, BIOCHEMISTRY-US, V13, P5249, DOI 10.1021/bi00723a001; VEATCH WR, 1974, BIOCHEMISTRY-US, V13, P5257, DOI 10.1021/bi00723a002; VENKATACHALAM CM, 1983, J COMPUT CHEM, V4, P461, DOI 10.1002/jcc.540040403; WALLACE BA, 1981, BIOCHEMISTRY-US, V20, P5754, DOI 10.1021/bi00523a018; WALLACE BA, 1990, ANNU REV BIOPHYS BIO, V19, P127, DOI 10.1146/annurev.bb.19.060190.001015; WALLACE BA, 1988, SCIENCE, V241, P182, DOI 10.1126/science.2455344; WEISS LB, 1985, INT J PEPT PROT RES, V26, P305; WILLIAMS LP, 1992, BIOCHEMISTRY-US, V31, P7311, DOI 10.1021/bi00147a015; Wuthrich K., 1986, NMR PROTEINS NUCL AC; 1984, EUR J BIOCHEM, V188, P9	57	11	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12567	12576						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	7513690				2022-12-27	WOS:A1994NH71600033
J	PIND, S; RIORDAN, JR; WILLIAMS, DB				PIND, S; RIORDAN, JR; WILLIAMS, DB			PARTICIPATION OF THE ENDOPLASMIC-RETICULUM CHAPERONE CALNEXIN (P88, IP90) IN THE BIOGENESIS OF THE CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CFTR EXPRESSION; GENE; PROTEIN; IDENTIFICATION; PURIFICATION; DELTA-F508; MOLECULES; PRODUCT; PEPTIDE; CELLS	Deletion of phenylalanine at position 508 (Delta F508) in the first nucleotide binding fold of the cystic fibrosis transmembrane conductance regulator (CFTR) is the most common mutation in patients with cystic fibrosis. Although retaining functional Cl- channel activity, this mutant is recognized as abnormal by the cellular ''quality control'' machinery and is retained within the endoplasmic reticulum (ER). We have used human epithelial cells and recombinant Chinese hamster ovary cells to identify molecular interactions that may contribute to this intracellular retention. Based upon coimmunoprecipitation and cosedimentation through glycerol density gradients, newly synthesized wild-type and Delta F508 mutant CFTRs associated specifically with calnexin, the calcium-binding transmembrane chaperone of the ER. This association was restricted to the immature (or ER-associated) forms of the CFTR proteins. Although the bulk of wild-type and Delta F508 CFTRs were present initially in complexes containing calnexin, only wild-type CFTR was able to escape from this association and exit the ER. Calnexin retains misfolded or incompletely assembled proteins in the ER and thus is likely to contribute to the mislocalization of mutant CFTR.	UNIV TORONTO,DEPT BIOCHEM,TORONTO M5S 1A8,ON,CANADA; UNIV TORONTO,DEPT CLIN BIOCHEM,TORONTO M5S 1A8,ON,CANADA; HOSP SICK CHILDREN,RES INST,TORONTO M5G 1X8,ON,CANADA	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)								AHLUWALIA N, 1992, J BIOL CHEM, V267, P10914; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BIRREN BW, 1986, NUCLEIC ACIDS RES, V14, P853, DOI 10.1093/nar/14.2.853; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHANG XB, 1993, J BIOL CHEM, V268, P11304; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; DAVID V, 1993, J BIOL CHEM, V268, P9585; DEGEN E, 1992, J EXP MED, V175, P1653, DOI 10.1084/jem.175.6.1653; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DENNING GM, 1992, J CELL BIOL, V118, P551, DOI 10.1083/jcb.118.3.551; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; ENGELHARDT JF, 1992, NAT GENET, V2, P240, DOI 10.1038/ng1192-240; GALVIN K, 1992, P NATL ACAD SCI USA, V89, P8452, DOI 10.1073/pnas.89.18.8452; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; HARTMAN J, 1992, J BIOL CHEM, V267, P6455; Helenius Ari, 1992, Trends in Cell Biology, V2, P227, DOI 10.1016/0962-8924(92)90309-B; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; HYDE SC, 1993, NATURE, V362, P250, DOI 10.1038/362250a0; JACKSON MR, 1994, SCIENCE, V263, P384, DOI 10.1126/science.8278813; KARTNER N, 1992, NAT GENET, V1, P321, DOI 10.1038/ng0892-321; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI CH, 1993, NAT GENET, V3, P311, DOI 10.1038/ng0493-311; LUKACS GL, 1993, J BIOL CHEM, V268, P21592; MARGOLESE L, 1993, J BIOL CHEM, V268, P17959; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; RAJAGOPALAN S, 1994, SCIENCE, V263, P387, DOI 10.1126/science.8278814; RIORDAN JR, 1989, SCIENCE, V245, P1066; RIORDAN JR, 1993, ANNU REV PHYSIOL, V55, P609, DOI 10.1146/annurev.ph.55.030193.003141; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SFERRA TJ, 1993, ANNU REV MED, V44, P133, DOI 10.1146/annurev.med.44.1.133; SMALL GM, 1988, ANAL BIOCHEM, V169, P405, DOI 10.1016/0003-2697(88)90304-1; SOOD R, 1992, EMBO J, V11, P2487, DOI 10.1002/j.1460-2075.1992.tb05313.x; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; TEEM JL, 1993, CELL, V73, P335, DOI 10.1016/0092-8674(93)90233-G; THOMAS PJ, 1992, J BIOL CHEM, V267, P5727; WADA I, 1991, J BIOL CHEM, V266, P19559; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; YANG YP, 1993, P NATL ACAD SCI USA, V90, P9480, DOI 10.1073/pnas.90.20.9480; ZABNER J, 1993, CELL, V75, P207, DOI 10.1016/0092-8674(93)80063-K	45	305	314	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12784	12788						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	7513695				2022-12-27	WOS:A1994NH71600064
J	CONRAD, R; KERANEN, LM; ELLINGTON, AD; NEWTON, AC				CONRAD, R; KERANEN, LM; ELLINGTON, AD; NEWTON, AC			ISOZYME-SPECIFIC INHIBITION OF PROTEIN-KINASE-C BY RNA APTAMERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ACTIVATION	In vitro selection technology has been used to purify RNA aptamers from a random sequence pool that can bind to, and specifically inhibit, protein kinase C beta IL. Two of the selected RNA aptamers bind to this isozyme of protein kinase C with nanomolar affinities and inhibit activation with unprecedented selectivity; the highly related, alternatively spliced beta I isozyme, which differs by 23 residues, is inhibited with 1 order of magnitude lower potency; the next most similar isozyme, alpha, shows no detectable inhibition. The production of isozyme-specific inhibitors of protein kinase C opens the possibilities for dissecting the roles of specific protein kinase Cs in the myriad of intracellular signaling pathways.	INDIANA UNIV,DEPT CHEM,BLOOMINGTON,IN 47405	Indiana University System; Indiana University Bloomington					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043154, R37GM043154] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 43154] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0; CHAKRAVARTHY BR, 1991, ANAL BIOCHEM, V196, P144, DOI 10.1016/0003-2697(91)90130-L; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; ELLINGTON AD, 1992, NATURE, V355, P850, DOI 10.1038/355850a0; GIVER L, 1993, NUCLEIC ACIDS RES, V21, P5509, DOI 10.1093/nar/21.23.5509; JAEGER JA, 1989, METHOD ENZYMOL, V183, P281; KISHIMOTO A, 1983, J BIOL CHEM, V258, P1156; NEWTON AC, 1993, ANNU REV BIOPH BIOM, V22, P1, DOI 10.1146/annurev.bb.22.060193.000245; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; ONO Y, 1986, FEBS LETT, V206, P347, DOI 10.1016/0014-5793(86)81010-9; ORR JW, 1994, J BIOL CHEM, V269, P8383; ORR JW, 1992, J BIOL CHEM, V267, P15263; TUERK C, 1992, P NATL ACAD SCI USA, V89, P6988, DOI 10.1073/pnas.89.15.6988; WALKER JM, 1988, J BIOL CHEM, V263, P4537; WILKINSON SE, 1994, TRENDS PHARMACOL SCI, V15, P53, DOI 10.1016/0165-6147(94)90110-4; WILKINSON SE, 1993, BIOCHEM J, V294, P335, DOI 10.1042/bj2940335	16	86	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32051	32054						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7528207				2022-12-27	WOS:A1994PX30400008
J	BIRD, TA; KYRIAKIS, JM; TYSHLER, L; GAYLE, M; MILNE, A; VIRCA, GD				BIRD, TA; KYRIAKIS, JM; TYSHLER, L; GAYLE, M; MILNE, A; VIRCA, GD			INTERLEUKIN-1 ACTIVATES P54 MITOGEN-ACTIVATED PROTEIN (MAP) KINASE KINASE STRESS-ACTIVATED PROTEIN-KINASE BY A PATHWAY THAT IS INDEPENDENT OF P21(RAS), RAF-1, AND MAP KINASE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; GROWTH-FACTOR RECEPTOR; MYELIN BASIC-PROTEIN; SMOOTH-MUSCLE CELLS; SUBSTRATE RECOGNITION; HUMAN-FIBROBLASTS; SIGNAL TRANSDUCTION; FACTOR-ALPHA; C-MYC; PHOSPHORYLATION	In KB epidermoid cells, we previously showed that interleukin-1 alpha (IL-1) and various mitogens activate the mitogen-activated protein (MAP) kinases ERK1 and ERK2, which phosphorylate both myelin basic protein (MBP) and a peptide containing Thr(669) of the epidermal growth factor receptor. In cell-free extracts made from gingival fibroblasts treated with platelet-derived growth factor or HepG2 hepatoma cells stimulated with phorbol myristate acetate, MBP and Thr(669) kinase were both elevated 4-fold, and ERK1 and ERK2 were tyrosine-phosphorylated. In these cells IL-1 activated a kinase(s) that phosphorylated Thr(669) peptide but not MBP and failed to cause tyrosine phosphorylation of ERK1/ERK2. Ceramide has been proposed as an intracellular mediator of IL-1 action, but C-2-ceramide or sphingosine stimulated predominantly MBP-specific kinase activity in fibroblasts and had no effect in HepG2 cells, p54 MAP kinase (also called stress-activated protein kinase) is a c-Jun kinase first isolated from livers of cycloheximide-treated rats. After IL-1 stimulation, immunoprecipitates of lysates made from all three cell types with specific anti-p54 MAP kinase serum contained Thr(669) and c-Jun phosphorylating activity, whereas precipitates from unstimulated cells contained no detectable p54 kinase activity. The major peak of IL-1 stimulated HepG2 Thr(669) kinase activity co chromatographed on Mono Q and phenyl-Superose with immunodetectable p54 MAP kinase. IL-1 did not cause p21(ras) activation in any cell type. Induction of Thr(669) kinase activity was not abrogated by elevation of cAMP levels, which has been shown to interfere with the activation of Raf-1. We could not detect MAP kinase kinase phosphorylating activity in unfractionated lysates made from IL-1-stimulated fibroblasts or HepG2 cells. KB cells contained a small amount of this activity, but it was not precipitated with an anti-Raf-1 antibody. We conclude that most of the IL-1-activated Thr(669) kinase activity in fibroblasts and HepG2 cells, and a portion in KB cells, is due to p54 MAP kinase and that its activation is Ras-, Raf-, and MAP kinase kinase-independent.	IMMUNEX CORP,DEPT BIOCHEM,SEATTLE,WA 98101; IMMUNEX RES & DEV CORP,DEPT MOLEC BIOL,SEATTLE,WA 98101; IMMUNEX RES & DEV CORP,DEPT PROT CHEM,SEATTLE,WA 98101; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DIABET UNIT,BOSTON,MA 02129	Immunex Corporation; Harvard University; Harvard Medical School; Massachusetts General Hospital								AHN NG, 1991, J BIOL CHEM, V266, P4220; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BALLOU LR, 1992, J BIOL CHEM, V267, P20044; BIRD TA, 1990, J BIOL CHEM, V265, P235; BIRD TA, 1992, CYTOKINE, V4, P429, DOI 10.1016/1043-4666(92)90003-A; BIRD TA, 1991, J BIOL CHEM, V266, P22661; BIRD TA, 1994, FEBS LETT, V338, P31, DOI 10.1016/0014-5793(94)80111-8; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CHAO TSO, 1994, J BIOL CHEM, V269, P7337; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; CONCA W, 1991, J BIOL CHEM, V266, P16265; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; COOPER JA, 1984, MOL CELL BIOL, V4, P30, DOI 10.1128/MCB.4.1.30; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DOWER SK, 1985, J EXP MED, V162, P501, DOI 10.1084/jem.162.2.501; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; ERICKSON AK, 1990, J BIOL CHEM, V265, P19728; GOLDKORN T, 1991, J BIOL CHEM, V266, P16092; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; GUY GR, 1991, J BIOL CHEM, V266, P14343; HORDIJK PL, 1994, J BIOL CHEM, V269, P3534; JOSEPH CK, 1993, J BIOL CHEM, V268, P20002; KIM MY, 1991, J BIOL CHEM, V266, P484; KISHIMOTO A, 1985, J BIOL CHEM, V260, P2492; KIZAKAKONDOH S, 1993, FEBS LETT, V336, P255, DOI 10.1016/0014-5793(93)80814-B; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; KYRIAKIS JM, 1991, J BIOL CHEM, V266, P10043; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LIN JX, 1987, J BIOL CHEM, V262, P11908; LIN LL, 1992, J BIOL CHEM, V267, P23451; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LIU J, 1994, J BIOL CHEM, V269, P3047; LOWENTHAL JW, 1986, J IMMUNOL, V137, P1226; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NAKIELNY S, 1992, FEBS LETT, V308, P183, DOI 10.1016/0014-5793(92)81271-M; NORTHWOOD IC, 1991, J BIOL CHEM, V266, P15266; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; PORRAS A, 1994, J BIOL CHEM, V269, P12741; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; PULVERER BJ, 1993, ONCOGENE, V8, P407; RAINES EW, 1989, SCIENCE, V243, P393, DOI 10.1126/science.2783498; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; RAY LB, 1988, J BIOL CHEM, V263, P12721; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; SAKLATVALA J, 1993, FEBS LETT, V334, P189, DOI 10.1016/0014-5793(93)81709-9; SEGER R, 1992, J BIOL CHEM, V267, P25628; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; WILLIAMS NG, 1993, P NATL ACAD SCI USA, V90, P5772, DOI 10.1073/pnas.90.12.5772; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	64	105	106	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31836	31844						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7527398				2022-12-27	WOS:A1994PX30300078
J	GAO, AG; FRAZIER, WA				GAO, AG; FRAZIER, WA			IDENTIFICATION OF A RECEPTOR CANDIDATE FOR THE CARBOXYL-TERMINAL CELL-BINDING DOMAIN OF THROMBOSPONDINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEINS; DIFFERENTIAL EXPRESSION; TRITON X-114; PLATELET; CD36; SPECIFICITY; REQUIREMENT; CARCINOMA; PEPTIDES; MATRIX	The carboxyl-terminal cell binding domain (CBD) of thrombospondin-1 (TS1) contains two cell attachment peptides, 4N1s (RFYVVMWK) and 7N3 (FIRVVMYGKK), which share the sequence VVM. These peptides, and more soluble derivatives have been radiolabeled with I-125 and used in conjunction with a variety of membrane impermeant cross-linking reagents to identify and characterize receptor candidates on several cell types. All of the VVM containing peptides tested with five different cross-linking reagents specifically labeled a 52-kDa protein, which was also affinity labeled by the recombinant TS1 CBD. After cross-linking peptide to K562 cells to block the 52-kDa protein, both cell adhesion to and affinity labeling by VVM peptides were inhibited in a concentration-dependent manner. Peptide labeling, like cell adhesion, was partially inhibited by heparin and stimulated by EDTA The 52-kDa protein did not appear to contain sulfated glycan chains and was trypsin sensitive. It was recovered in a membrane fraction and was readily solubilized with Triton X-100 and X-114. Upon phase separation of the Triton X-114, the 52-kDa protein partitioned into the hydrophobic detergent phase. The detergent-solubilized receptor candidate bound selectively to wheat germ agglutinin-Sepharose, and after cell surface labeling with a membrane impermeant biotinylating reagent, bound 60 streptavidin-Sepharose. Furthermore, fluorescent beads covalently derivatized with peptide specifically decorated intact K562 cells. Thus the properties of the 52-kDa protein are consistent with those of a receptor for the CBD of TS1 and other TS isoforms.	WASHINGTON UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOPHYS, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)					NHLBI NIH HHS [HL14147] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014147] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS J, 1993, CURR BIOL, V3, P188, DOI 10.1016/0960-9822(93)90270-X; ASCH AS, 1993, SCIENCE, V262, P1436, DOI 10.1126/science.7504322; BORDIER C, 1981, J BIOL CHEM, V256, P1604; CASTLE V, 1991, J CLIN INVEST, V87, P1883, DOI 10.1172/JCI115212; FRAZIER WA, 1993, THROMBOSPONDIN, P91; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; GREENWALT DE, 1990, BIOCHEMISTRY-US, V29, P7054, DOI 10.1021/bi00482a015; IMAI Y, 1993, NATURE, V361, P555; INGALLS HM, 1986, P NATL ACAD SCI USA, V83, P4779, DOI 10.1073/pnas.83.13.4779; IRUELAARISPE ML, 1993, DEV DYNAM, V197, P40, DOI 10.1002/aja.1001970105; IRUELAARISPE ML, 1991, P NATL ACAD SCI USA, V88, P5026, DOI 10.1073/pnas.88.11.5026; JANSSEN K, 1993, CURR PROT MOL BIOL, V2; KIRCHHOFER D, 1990, J BIOL CHEM, V265, P18525; KOSFELD MD, 1993, J BIOL CHEM, V268, P8808; KOSFELD MD, 1992, J BIOL CHEM, V267, P16230; KOSFELD MD, 1991, J BIOL CHEM, V266, P24257; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWLER J, 1989, BLOOD, V74, P2022; LI WX, 1993, J BIOL CHEM, V268, P16179; MCGREGOR JL, 1989, J BIOL CHEM, V264, P501; MURPHYULLRICH JE, 1988, J BIOL CHEM, V263, P6400; NEWMAN PJ, 1982, THROMB RES, V27, P221, DOI 10.1016/0049-3848(82)90202-X; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RAUGI GJ, 1987, J INVEST DERMATOL, V89, P551, DOI 10.1111/1523-1747.ep12461198; REED MJ, 1993, J HISTOCHEM CYTOCHEM, V41, P1467, DOI 10.1177/41.10.8245406; ROBERTS DD, 1985, J BIOL CHEM, V260, P9405; SHEPHARD EG, 1988, ANAL BIOCHEM, V168, P306, DOI 10.1016/0003-2697(88)90323-5; SORENSEN P, 1986, J BIOL CHEM, V261, P9094; STAROS JV, 1982, BIOCHEMISTRY-US, V21, P3950, DOI 10.1021/bi00260a008; SUN XJ, 1989, J BIOL CHEM, V264, P11288; SUNDBLAD G, 1988, J BIOL CHEM, V263, P8890; TANDON NN, 1989, J BIOL CHEM, V264, P7570; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; TUSZYNSKI GP, 1993, J CELL BIOL, V120, P513, DOI 10.1083/jcb.120.2.513; YABKOWITZ R, 1991, CANCER RES, V51, P3648	36	65	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29650	29657						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7525586				2022-12-27	WOS:A1994PU28400054
J	MA, L; RAYCROFT, L; ASA, D; ANDERSON, DC; GENG, JG				MA, L; RAYCROFT, L; ASA, D; ANDERSON, DC; GENG, JG			A SIALOGLYCOPROTEIN FROM HUMAN-LEUKOCYTES FUNCTIONS AS A LIGAND FOR P-SELECTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRANULE MEMBRANE-PROTEIN; CARBOHYDRATE LIGAND; GLYCOPROTEIN LIGAND; MYELOID CELLS; ADHESION MOLECULE-1; ENDOTHELIAL-CELLS; MEDIATES ADHESION; GMP-140 BINDS; LECTIN DOMAIN; SIALYL-LEX	P-selectin (CD62P), a Ca2+-dependent lectin expressed on activated platelets and endothelial cells, functions as a receptor for myeloid and monocytoid cells. Previous reports have described a homodimeric sialoglycoprotein from human leukocytes and HL-60 cells specifically recognized by P-selectin. We describe here a panel of monoclonal antibodies prepared against high molecular weight fractions of HL-60 cell membranes. These antibodies are of IgM isotype, bind to a similar to 240-kDa protein from human leukocyte membranes which is also reactive with P-selectin. They recognize a Ca2+-dependent, sialidase-sensitive determinant on myeloid and monocytoid cell lines. Each antibody specifically inhibits adhesion of neutrophils or HL-60 cells to: 1) purified P-selectin, 2) thrombin-stimulated platelets, and 3) phorbol 12-myristate 13-acetate-activated endothelial cells. These results suggest that the sialoglycoprotein recognized by this panel of monoclonal antibodies may function as a cell surface ligand for P-selectin.	UPJOHN CO,UPJOHN LABS,CELL BIOL & INFLAMMAT RES,KALAMAZOO,MI 49001	Pfizer								ARUFFO A, 1992, P NATL ACAD SCI USA, V89, P2292, DOI 10.1073/pnas.89.6.2292; ARUFFO A, 1991, CELL, V67, P35, DOI 10.1016/0092-8674(91)90570-O; ASA D, 1992, GLYCOBIOLOGY, V2, P395, DOI 10.1093/glycob/2.5.395; BAJORATH J, 1994, BIOCHEMISTRY-US, V33, P1332, DOI 10.1021/bi00172a007; BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600; BERG EL, 1991, J BIOL CHEM, V266, P14869; BERG EL, 1993, NATURE, V366, P695, DOI 10.1038/366695a0; BRANDLEY BK, 1993, GLYCOBIOLOGY, V3, P633, DOI 10.1093/glycob/3.6.633; BRISKIN MJ, 1993, NATURE, V363, P461, DOI 10.1038/363461a0; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; GENG JG, 1991, J BIOL CHEM, V266, P22313; GENG JG, 1992, J BIOL CHEM, V267, P19846; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; HAMBURGER SA, 1990, BLOOD, V75, P550; HANDA K, 1991, BIOCHEM BIOPH RES CO, V181, P1223, DOI 10.1016/0006-291X(91)92069-V; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; JOHNSTON GI, 1989, J BIOL CHEM, V264, P1816; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; LARKIN M, 1992, J BIOL CHEM, V267, P13661; LARSEN E, 1989, CELL, V59, P305, DOI 10.1016/0092-8674(89)90292-4; LARSEN E, 1990, CELL, V63, P467, DOI 10.1016/0092-8674(90)90443-I; LARSEN GR, 1992, J BIOL CHEM, V267, P11104; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LEVINOVITZ A, 1993, J CELL BIOL, V121, P449, DOI 10.1083/jcb.121.2.449; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; McEver Rodger P., 1992, Current Opinion in Cell Biology, V4, P840, DOI 10.1016/0955-0674(92)90109-P; MOORE KL, 1991, J CELL BIOL, V112, P491, DOI 10.1083/jcb.112.3.491; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; MULLIGAN MS, 1993, NATURE, V364, P149, DOI 10.1038/364149a0; MYADAS TN, 1993, CELL, V74, P541; NORGARD KE, 1993, J BIOL CHEM, V268, P12764; NORGARDSUMNICHT KE, 1993, SCIENCE, V261, P480, DOI 10.1126/science.7687382; PALABRICA T, 1992, NATURE, V359, P848, DOI 10.1038/359848a0; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; PICKER LJ, 1991, CELL, V66, P921, DOI 10.1016/0092-8674(91)90438-5; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SAWADA R, 1994, J BIOL CHEM, V269, P1425; SKINNER MP, 1989, BIOCHEM BIOPH RES CO, V164, P1373, DOI 10.1016/0006-291X(89)91821-4; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STONE JP, 1993, J CLIN INVEST, V92, P804, DOI 10.1172/JCI116654; TIEMEYER M, 1991, P NATL ACAD SCI USA, V88, P1138, DOI 10.1073/pnas.88.4.1138; TYRRELL D, 1991, P NATL ACAD SCI USA, V88, P10372, DOI 10.1073/pnas.88.22.10372; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; Watkins W M, 1980, Adv Hum Genet, V10, P1; WEYRICH AS, 1993, J CLIN INVEST, V91, P2620, DOI 10.1172/JCI116501; ZHOU Q, 1991, J CELL BIOL, V115, P557, DOI 10.1083/jcb.115.2.557	50	95	98	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27739	27746						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7525560				2022-12-27	WOS:A1994PV77100090
J	CLARK, EA; TRIKHA, M; MARKLAND, FS; BRUGGE, JS				CLARK, EA; TRIKHA, M; MARKLAND, FS; BRUGGE, JS			STRUCTURALLY DISTINCT DISINTEGRINS CONTORTROSTATIN AND MULTISQUAMATIN DIFFERENTIALLY REGULATE PLATELET TYROSINE PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GLYCOPROTEIN-IIB-IIIA; ACTIVATOR-INDUCED THROMBOLYSIS; PLASMINOGEN-ACTIVATOR; AGGREGATION INHIBITOR; CORONARY-THROMBOSIS; INTEGRIN RECEPTORS; CONTAINING PEPTIDE; VIPER VENOMS; CANINE MODEL; GPIIB-IIIA	Tyrosine phosphorylation of multiple platelet proteins is regulated by the integrin alpha(IIb)beta(3). In order to further examine integrin-regulated tyrosine phosphorylation, we have used small Arg-Gly-Asp-containing snake venom proteins (termed disintegrins) that inhibit platelet aggregation to competitively block the agonist-induced binding of fibrinogen to alpha(IIb)beta(3). One structurally unique disintegrin, contortrostatin (which appears to be a disulfide-linked dimer of 13.5 kDa with two Arg-Gly-Asp sites), was found to trigger signaling events typically mediated by fibrinogen cross-linking of alpha(IIb)beta(3), as demonstrated by tyrosine phosphorylation of the tyrosine kinase pp72(syk) and a 140-kDa protein. Contortrostatin and another disintegrin, multisquamatin (a monomer of 5.7 kDa with a single Arg-Gly-Asp site), did not affect thrombin-induced platelet shape change, secretion, or integrin-independent tyrosine phosphorylation; however, they inhibited aggregation and aggregation-dependent tyrosine phosphorylation of numerous proteins, including the focal adhesion kinase pp125(FAK). Our results suggest that structurally distinct disintegrins have varying effects on tyrosine phosphorylation; while monomeric multisquamatin and dimeric contortrostatin both inhibit aggregation-dependent tyrosine phosphorylation, contortrostatin also possesses a unique functional activity that allows it to activate an intracellular signaling pathway leading to tyrosine phosphorylation. This activity may be involved in the function of this snake venom protein on hemostasis.	ARIAD PHARMACEUT INC,CAMBRIDGE,MA 02139; UNIV PENN,SCH MED,GRAD GRP CELL BIOL,PHILADELPHIA,PA 19104; UNIV SO CALIF,SCH MED,DEPT BIOCHEM & MOLEC BIOL,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,KENNETH NORRIS JR COMPREHENS CANC CTR,LOS ANGELES,CA 90033	Takeda Pharmaceutical Company Ltd; Takeda Oncology; University of Pennsylvania; University of Southern California; University of Southern California			Clark, Edward/K-3462-2012		NATIONAL CANCER INSTITUTE [R01CA047527] Funding Source: NIH RePORTER; NCI NIH HHS [NCI CA47527] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER M, 1991, SCIENCE, V253, P445, DOI 10.1126/science.1862345; Blobel Carl P., 1992, Current Opinion in Cell Biology, V4, P760; CHAO BH, 1989, P NATL ACAD SCI USA, V86, P8050, DOI 10.1073/pnas.86.20.8050; CICHOWSKI K, 1992, J BIOL CHEM, V267, P5025; CLARK EA, 1993, TRENDS CARDIOVAS MED, V3, P218, DOI 10.1016/1050-1738(93)90043-6; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; COLLER BS, 1989, CIRCULATION, V80, P1766, DOI 10.1161/01.CIR.80.6.1766; COOK JJ, 1989, AM J PHYSIOL, V256, pH1038, DOI 10.1152/ajpheart.1989.256.4.H1038; DENNIS MS, 1990, P NATL ACAD SCI USA, V87, P2471, DOI 10.1073/pnas.87.7.2471; FERRELL JE, 1989, P NATL ACAD SCI USA, V86, P2234, DOI 10.1073/pnas.86.7.2234; FOX JEB, 1993, J BIOL CHEM, V268, P25973; GAN ZR, 1988, J BIOL CHEM, V263, P19827; GOLDEN A, 1990, J CELL BIOL, V111, P3117, DOI 10.1083/jcb.111.6.3117; GOULD RJ, 1990, P SOC EXP BIOL MED, V195, P168, DOI 10.3181/00379727-195-43129B; HAIMOVICH B, 1993, J BIOL CHEM, V268, P15868; HOLAHAN MA, 1991, PHARMACOLOGY, V42, P340, DOI 10.1159/000138817; Huang E. M., 1986, BIOCH PLATELETS, P1; HUANG MM, 1993, J CELL BIOL, V122, P473, DOI 10.1083/jcb.122.2.473; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; PHILLIPS DR, 1991, CELL, V65, P359, DOI 10.1016/0092-8674(91)90451-4; SAUDEK V, 1991, BIOCHEMISTRY-US, V30, P7369, DOI 10.1021/bi00244a003; SAUDEK V, 1991, EUR J BIOCHEM, V202, P329, DOI 10.1111/j.1432-1033.1991.tb16380.x; SCARBOROUGH RM, 1993, J BIOL CHEM, V268, P1058; SHATTIL SJ, 1994, J BIOL CHEM, V269, P14733; SHEBUSKI RJ, 1990, CIRCULATION, V82, P169, DOI 10.1161/01.CIR.82.1.169; TENG CM, 1991, THROMB HAEMOSTASIS, V65, P624; TRIKHA M, 1994, THROMB RES, V73, P39, DOI 10.1016/0049-3848(94)90052-3; TRIKHA M, 1994, IN PRESS CANCER RES; WENCELDRAKE JD, 1993, BLOOD, V81, P62; WILLIAMS JA, 1992, PATHOL BIOL, V40, P813; WONG S, 1992, ONCOGENE, V7, P2407; YASUDA T, 1991, CIRCULATION, V83, P1038, DOI 10.1161/01.CIR.83.3.1038	32	57	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					21940	21943						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	7520909				2022-12-27	WOS:A1994PE09800005
J	KOLEV, K; LERANT, I; TENEKEJIEV, K; MACHOVICH, R				KOLEV, K; LERANT, I; TENEKEJIEV, K; MACHOVICH, R			REGULATION OF FIBRINOLYTIC-ACTIVITY OF NEUTROPHIL LEUKOCYTE ELASTASE, PLASMIN, AND MINIPLASMIN BY PLASMA PROTEASE INHIBITORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-1-PROTEINASE INHIBITOR; ALPHA-2-MACROGLOBULIN; ALPHA-2-ANTIPLASMIN; STREPTOKINASE; ACTIVATION; KINETICS; HEPARIN	The effect of solid-phase fibrin on the inactivation of plasmin, miniplasmin, and neutrophil leukocyte elastase (PMN elastase) by plasma protease inhibitors (alpha(2)-antiplasmin, alpha(1)-protease inhibitor, alpha(2)-macroglobulin) was studied. In Hanks' balanced salt solution, fibrin reduces the second order rate constant for the inhibition of PMN elastase by alpha(1)-protease inhibitor from 8,760 x 10(4) to 4 x 10(4) M(-1).S-1 and by alpha(2)-macroglobulin from 121 x 10(4) to 1.8 x 10(4) M(-1) S-1. The rate constant for miniplasmin inactivation by alpha(2)-antiplasmin decreases from 99 x 10(4) to 1 x 10(4) M(-1).S-1, by alpha(2)-macroglobulin from 78 x 10(4) to 1.8 x 10(4) M(-1).S-1, and by alpha(1)-protease inhibitor from 0.11 x 10(4) M(-1).S-1 to 0. Plasmin bound to fibrin is completely protected against alpha(2)-macroglobulin and alpha(1)-protease inhibitor, whereas the rate constant for the inactivation by its primary plasma inhibitor alpha(2)-antiplasmin is reduced from 430 x 10(4) to 1.08 x 10(4) M(-1).S-1. The competition of substrate and inhibitor for the enzyme was also studied, using fibrin preincubated with inhibitor. Under our pseudo-first-order experimental conditions, fibrin completely eliminates those interactions, the second-order rate constant of which is 1.1 x 10(5) M(-1).S-1 or less in a system without fibrin surface.	SEMMELWEIS UNIV MED,DEPT BIOCHEM 2,H-1444 BUDAPEST,HUNGARY	Semmelweis University			Kolev, Krasimir/A-3517-2008; Tenekedjiev, Kiril/D-8141-2012; Kolev, Krasimir/J-7648-2019	Kolev, Krasimir/0000-0002-5612-004X; Tenekedjiev, Kiril/0000-0003-3549-0671; Kolev, Krasimir/0000-0002-5612-004X				ANONICK PK, 1990, THROMB RES, V59, P449, DOI 10.1016/0049-3848(90)90406-3; BACHMANN F, 1987, THROMB DIATH HAEMO, P227; BEATTY K, 1980, J BIOL CHEM, V255, P3931; CEDERHOLMWILLIAMS SA, 1979, EUR J BIOCHEM, V100, P125, DOI 10.1111/j.1432-1033.1979.tb02040.x; FROMMHERZ KJ, 1991, J BIOL CHEM, V266, P15356; GONIAS SL, 1988, BIOCHEM J, V255, P725; GUREWICH V, 1992, ANN NY ACAD SCI, V667, P224, DOI 10.1111/j.1749-6632.1992.tb51619.x; HEKMAN CM, 1987, SEMIN THROMB HEMOST, V13, P514, DOI 10.1055/s-2007-1003527; MACHOVICH R, 1989, BIOCHEMISTRY-US, V28, P4517, DOI 10.1021/bi00436a059; Machovich R, 1990, Blood Coagul Fibrinolysis, V1, P79, DOI 10.1097/00001721-199003000-00011; NIEWIAROWSKI S, 1972, ANN NY ACAD SCI, V201, P72, DOI 10.1111/j.1749-6632.1972.tb16288.x; PETERSEN LC, 1981, BIOCHEM J, V199, P121, DOI 10.1042/bj1990121; PLOW EF, 1980, BIOCHIM BIOPHYS ACTA, V630, P47, DOI 10.1016/0304-4165(80)90136-1; STEINER JP, 1987, BIOCHEMISTRY-US, V26, P8487, DOI 10.1021/bi00399a068; THORSEN S, 1992, ANN NY ACAD SCI, V667, P52, DOI 10.1111/j.1749-6632.1992.tb51597.x; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255	16	69	74	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 24	1994	269	25					17030	17034						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NT846	7516329				2022-12-27	WOS:A1994NT84600010
J	AKHOUNDI, C; AMIOT, M; AUBERGER, P; LECAM, A; ROSSI, B				AKHOUNDI, C; AMIOT, M; AUBERGER, P; LECAM, A; ROSSI, B			INSULIN AND INTERLEUKIN-1 DIFFERENTIALLY REGULATE PP63, AN ACUTE-PHASE PHOSPHOPROTEIN IN HEPATOMA-CELL LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE INHIBITOR; HUMAN ALPHA-2-HS GLYCOPROTEIN; PLASMA-PROTEIN GENES; STIMULATING FACTOR; RAT HEPATOCYTES; FETUIN; GLYCOSYLATION; EXPRESSION; RECEPTOR; PURIFICATION	We have reported previously that the phosphoprotein pp63, an acute phase protein, which has been recently identified as the rat fetuin, was capable of blocking the mitogenic effect of insulin on the rat Fao hepatoma cell line, without affecting metabolic effects of the hormone. Only the phosphorylated form of the protein has been shown to exhibit both anti-tyrosine kinase and growth inhibitory properties. In this study, we used the FTO-2B rat hepatoma cell line to analyze the mechanisms involved in the control of synthesis and/or phosphorylation of pp63. For this purpose, we investigated the action of effectors known to modulate hepatic functions, such as cytokines (interleukin (IL)-1 beta and IL-6), which regulate the production of acute phase proteins, and insulin, which elicits profound effects on hepatocyte metabolism. Here, we demonstrate that IL-1 beta diminished markedly the pp63 production by affecting its m;RNA transcription and that the cytokine was able to modify the N-glycosylation process of the protein. In contrast, insulin did not affect the biosynthesis of pp63 but dramatically decreased its extent of phosphorylation.	FAC MED NICE, INSERM, U364, F-06107 NICE 02, FRANCE; CNRS, INSERM, CTR PHARMACOL ENDOCRINOL, F-34094 MONTPELLIER, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier			AUBERGER, Patrick/G-1491-2013	AUBERGER, Patrick/0000-0002-2481-8275				AUBERGER P, 1989, CELL, V58, P631, DOI 10.1016/0092-8674(89)90098-6; BAUMANN H, 1989, J IMMUNOL, V143, P1163; BAUMANN H, 1990, MOL BIOL MED, V7, P147; BAUMANN H, 1991, J BIOL CHEM, V266, P20424; BROWN WM, 1992, CELL, V68, P7, DOI 10.1016/0092-8674(92)90200-V; CZECH MP, 1988, J BIOL CHEM, V263, P11017; DAVEAU M, 1990, FEBS LETT, V273, P79, DOI 10.1016/0014-5793(90)81055-S; DESCHATRETTE J, 1974, BIOCHIMIE, V56, P1603; DOGLIO A, 1986, BIOCHEM J, V238, P123, DOI 10.1042/bj2380123; Dziegielewska KM, 1988, HDB HUMAN GROWTH DEV, P169; HAASEMANN M, 1991, BIOCHEM J, V274, P899, DOI 10.1042/bj2740899; HAYASE T, 1992, BIOCHEMISTRY-US, V31, P4915, DOI 10.1021/bi00135a024; ISHIKAWA Y, 1991, J CELL PHYSIOL, V149, P222, DOI 10.1002/jcp.1041490208; JOHNSON WV, 1986, BIOCHEMISTRY-US, V25, P5518, DOI 10.1021/bi00367a026; KILLARY AM, 1984, CELL, V38, P523, DOI 10.1016/0092-8674(84)90507-5; KOJ A, 1974, STRUCTURE FUNCTION P, V1, P73; LE J, 1987, LAB INVEST, V52, P232; LEBRETON JP, 1979, J CLIN INVEST, V64, P1118, DOI 10.1172/JCI109551; LECAM A, 1985, J BIOL CHEM, V260, P5965; LECAM A, 1976, EXP CELL RES, V98, P382, DOI 10.1016/0014-4827(76)90448-1; LECAM A, 1992, CELL, V68, P8, DOI 10.1016/0092-8674(92)90201-M; LECAM A, 1985, BIOCHEM J, V230, P603, DOI 10.1042/bj2300603; MACKIEWICZ A, 1989, SCAND J IMMUNOL, V29, P265, DOI 10.1111/j.1365-3083.1989.tb01124.x; MACKIEWICZ A, 1991, J IMMUNOL, V146, P3032; MACKIEWICZ A, 1987, J EXP MED, V166, P253, DOI 10.1084/jem.166.1.253; OHNISHI T, 1991, J BIOL CHEM, V266, P14636; POUS C, 1992, INFLAMMATION, V16, P197, DOI 10.1007/BF00918809; PUCK TT, 1968, P NATL ACAD SCI USA, V59, P192, DOI 10.1073/pnas.59.1.192; RAUTH G, 1992, EUR J BIOCHEM, V204, P523, DOI 10.1111/j.1432-1033.1992.tb16663.x; RICHARDS C, 1991, NEW TR CYT, P29; RICHARDS CD, 1992, J IMMUNOL, V148, P1731; WOLOSKI BM, 1985, BIOCHEM BIOPH RES CO, V130, P234; WOLOSKI BMRNJ, 1986, BIOCHIM BIOPHYS ACTA, V885, P185, DOI 10.1016/0167-4889(86)90087-X; ZAITSU H, 1990, J CELL PHYSIOL, V144, P485, DOI 10.1002/jcp.1041440316	34	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15925	15930						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	7515065				2022-12-27	WOS:A1994NP51300081
J	WILLNOW, TE; ORTH, K; HERZ, J				WILLNOW, TE; ORTH, K; HERZ, J			MOLECULAR DISSECTION OF LIGAND-BINDING SITES ON THE LOW-DENSITY-LIPOPROTEIN RECEPTOR-RELATED PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATOR INHIBITOR TYPE-1; ALPHA-2-MACROGLOBULIN RECEPTOR; PLASMINOGEN-ACTIVATOR; LDL-RECEPTOR; APOLIPOPROTEIN-E; CHYLOMICRON REMNANTS; MEDIATED ENDOCYTOSIS; HEYMANN NEPHRITIS; CULTURED-CELLS; RAT-LIVER	The low density lipoprotein receptor-related protein (LRP) is a large multifunctional receptor that is involved in the cellular uptake of a number of functionally diverse ligands including apoE-rich remnant lipoproteins, lipoprotein lipase, alpha(2)-macroglobulin-protease complexes, plasminogen activator-inhibitor complexes, and the active protease tissue-type plasminogen activator. Ligand binding and competition experiments suggest that most LRP ligands bind to specific, independent sites on the large 515-kDa subunit of the receptor. In a previous study (Moestrup, S. K., Holtet, T. L., Etzerodt, M., Thogersen, H. C., Nykjaer, A., Andreasen, P. A., Rasmussen, H. H., Sottrup-Jensen, L., and Gliemann, J. (1993) J. Biol. Chem. 268, 13691-13696), ligand blotting was used to localize the binding sites for urokinase-type plasminogen activator-plasminogen activator inhibitor-1 (PAI-1) complexes and for alpha(1)-macroglobulin to a proteolytic fragment of LRP containing the second cluster of complement-type cysteine-rich repeats. Here, we have used a recombinant DNA approach to express functionally restricted chimeric ''LRP-minireceptors'' containing two different regions of the extracellular domain of the receptor in cultured cells. Receptor-associated protein, a negative modulator of LRP activity, is bound and internalized by cells transfected with either construct. A minireceptor containing the cluster of eight complement-type cysteine-rich repeats followed by four epidermal growth factor precursor homologous domains binds and internalizes I-125-labeled plasminogen activator-PAI-1 complexes. It also mediates the cellular uptake of the uncomplexed protease tissue-type plasminogen activator (tPA), suggesting that the tPA and PAI-1 binding sites on LRP are in close vicinity and might promote cooperative binding of tPA PAI-1 complexes. However, alpha(2)-macroglobulin is not internalized by this minireceptor suggesting that this ligand requires the presence of a single epidermal growth factor-repeat which is contained in the previously studied proteolytic fragment but is absent from the minireceptor.	UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	WILLNOW, TE (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235, USA.		Orth, Kim/AAV-4421-2021	Orth, Kim/0000-0002-0678-7620; Willnow, Thomas/0000-0001-9515-7921	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 20948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BASSELDUBY R, 1992, J BIOL CHEM, V267, P9668; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BROWN MS, 1991, CURR OPIN LIPIDOL, V2, P65; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; CAMANI C, 1994, J BIOL CHEM, V269, P5770; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; CHAPPELL DA, 1993, J BIOL CHEM, V268, P14168; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HERZ J, 1993, CELL, V73, P428, DOI 10.1016/0092-8674(93)90130-I; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; HERZ J, 1990, J BIOL CHEM, V265, P21355; HUETTINGER M, 1992, J BIOL CHEM, V267, P18551; HUETTINGER M, 1988, CLIN BIOCHEM, V21, P87, DOI 10.1016/S0009-9120(88)80093-6; HUSSAIN MM, 1991, J BIOL CHEM, V266, P13936; IADONATO SP, 1993, BIOCHEM J, V296, P867, DOI 10.1042/bj2960867; KINGSLEY DM, 1984, P NATL ACAD SCI-BIOL, V81, P5454, DOI 10.1073/pnas.81.17.5454; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; Mahley R. W., 1991, CURR OPIN LIPIDOL, V2, P170; MOESTRUP SK, 1993, J BIOL CHEM, V268, P13691; NGUYEN G, 1992, BIOCHEM J, V287, P911, DOI 10.1042/bj2870911; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; RAYCHOWDHURY R, 1989, SCIENCE, V244, P1163, DOI 10.1126/science.2786251; Sambrook J, 1989, MOL CLONING LABORATO; STIFANI S, 1991, J BIOL CHEM, V266, P19079; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; VANDIJK MCM, 1992, EUR J BIOCHEM, V205, P775, DOI 10.1111/j.1432-1033.1992.tb16842.x; WEISGRABER KH, 1990, J BIOL CHEM, V265, P22453; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172	42	121	124	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15827	15832						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	7515061				2022-12-27	WOS:A1994NP51300067
J	VALLETTE, FM; JUIN, P; PELLESCHI, M; HENRY, JP				VALLETTE, FM; JUIN, P; PELLESCHI, M; HENRY, JP			BASIC PEPTIDES CAN BE IMPORTED INTO YEAST MITOCHONDRIA BY 2 DISTINCT TARGETING PATHWAYS - INVOLVEMENT OF THE PEPTIDE-SENSITIVE CHANNEL OF THE OUTER-MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN IMPORT; CATIONIC CHANNEL; SYNTHETIC PRESEQUENCE; INTERMEMBRANE SPACE; LARGE CONDUCTANCE; SIGNAL PEPTIDES; BILAYERS; CYTOCHROME-B2; PRECURSORS; TRANSPORT	The interaction of several basic peptides with yeast mitochondria has been analyzed. The peptides were selected for their ability to block a cationic channel of the outer membrane, the peptide-sensitive channel. These peptides possess common characteristics, such as a net positive charge superior to 2 and the capacity to form amphiphilic structures. They can be divided into two classes as follows: peptides of class I derived from mitochondrial signal peptides, such as the presequence of cytochrome c oxidase subunit IV, e.g. pCyt OX IV (1-12) Y; and peptides of class II unrelated to the mitochondria, such as dynorphin B (1-13). Class I peptides inhibited the translocation of a chimeric protein, cytochrome b(2)- DHFR, into the mitochondrial matrix, whereas peptides of class II failed to inhibit-this import. Experiments with iodinated pCyt OX TV (1-12) Y and dynorphin B (1-13) showed, however, that both types of peptides were imported into yeast mitochondria in vitro and subsequently degraded. At 30 degrees C, two import mechanisms could be distinguished; the mitochondrial presequences (class I) were translocated into the matrix in a temperature- and potential-sensitive manner, probably along the general import pathway, while class II dynorphin B (1-13) was imported into the intermembrane space by a process that was neither temperature- nor potential-sensitive. At 0 degrees C, both peptides were imported in a class II manner. The class II characteristics suggested the existence of a direct pathway into the intermembrane space, which may be associated with the peptide-sensitive channel. This hypothesis is substantiated by the competition for the import into the mitochondria between peptides of the two classes. The import of pCyt OX (1-12) Y was inhibited at 30 degrees C only by peptides of class I, IV whereas, at 0 degrees C, this import was also inhibited by peptides of class II. Import of peptides of the latter class was inhibited by peptides of the two classes both at 0 degrees C and 30 degrees C.			VALLETTE, FM (corresponding author), INST BIOL PHYSICOCHIM, SERV NEUROBIOL PHYSICOCHIM, CNRS, UNITE RECH ASSOCIEE 1112, F-75005 PARIS, FRANCE.		Vallette, Francois/N-2361-2018; JUIN, Philippe P/H-3636-2014; JUIN, Philippe/Q-1338-2019; Vallette, Francois M/K-9047-2015	JUIN, Philippe P/0000-0002-4997-3888; JUIN, Philippe/0000-0002-4997-3888; Vallette, Francois M/0000-0002-3296-8572; Vallette, Francois/0000-0003-0802-0519				ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BAKER KP, 1991, NATURE, V349, P205, DOI 10.1038/349205a0; CHICH JF, 1991, EUR J BIOCHEM, V196, P29, DOI 10.1111/j.1432-1033.1991.tb15781.x; CYR DM, 1991, J BIOL CHEM, V266, P21700; DAUM G, 1982, J BIOL CHEM, V257, P3028; FEVRE F, 1990, FEBS LETT, V262, P201, DOI 10.1016/0014-5793(90)80189-P; FURUYA S, 1987, J BIOCHEM, V102, P821, DOI 10.1093/oxfordjournals.jbchem.a122121; FURUYA S, 1991, EMBO J, V10, P1759, DOI 10.1002/j.1460-2075.1991.tb07700.x; GILLESPIE LL, 1985, J BIOL CHEM, V260, P6045; GLASER SM, 1990, J BIOL CHEM, V265, P8817; GLASER SM, 1990, J BIOL CHEM, V265, P8808; GLICK B, 1991, ANNU REV GENET, V25, P21; GLICK BS, 1992, TRENDS BIOCHEM SCI, V17, P453, DOI 10.1016/0968-0004(92)90487-T; GRAZIA I, 1993, P NATL ACAD SCI USA, V82, P8317; GUIARD B, 1985, EMBO J, V4, P3265, DOI 10.1002/j.1460-2075.1985.tb04076.x; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HENRY JP, 1989, J MEMBRANE BIOL, V112, P139, DOI 10.1007/BF01871275; LILL R, 1992, EMBO J, V11, P449, DOI 10.1002/j.1460-2075.1992.tb05074.x; MADUKE M, 1993, SCIENCE, V260, P364, DOI 10.1126/science.8385804; MAYER A, 1993, J CELL BIOL, V121, P1233, DOI 10.1083/jcb.121.6.1233; MICHEJDA J, 1989, ANION CARRIERS OF MITOCHONDRIAL MEMBRANES, P225; ONO H, 1988, J BIOL CHEM, V263, P3188; PAK YK, 1990, J BIOL CHEM, V265, P14298; PFANNER N, 1990, ANNU REV BIOCHEM, V59, P331, DOI 10.1146/annurev.bi.59.070190.001555; PFANNER N, 1988, EUR J BIOCHEM, V175, P205, DOI 10.1111/j.1432-1033.1988.tb14185.x; RASSOW J, 1989, J CELL BIOL, V109, P1421, DOI 10.1083/jcb.109.4.1421; ROISE D, 1992, P NATL ACAD SCI USA, V89, P608, DOI 10.1073/pnas.89.2.608; ROISE D, 1986, EMBO J, V5, P1327, DOI 10.1002/j.1460-2075.1986.tb04363.x; SCHWARZ E, 1993, EMBO J, V12, P2295, DOI 10.1002/j.1460-2075.1993.tb05883.x; SEGUIREAL B, 1992, FEBS LETT, V313, P2, DOI 10.1016/0014-5793(92)81171-H; SEQUIREAL B, 1993, EMBO J, V12, P2211, DOI 10.1002/j.1460-2075.1993.tb05869.x; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SWANSON ST, 1992, BIOCHEMISTRY-US, V31, P5746, DOI 10.1021/bi00140a009; THIEFFRY M, 1988, EMBO J, V7, P1449, DOI 10.1002/j.1460-2075.1988.tb02962.x; THIEFFRY M, 1992, BIOPHYS J, V63, P333, DOI 10.1016/S0006-3495(92)81626-0	36	33	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13367	13374						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	7513702				2022-12-27	WOS:A1994NK18400049
J	BOIE, Y; RUSHMORE, TH; DARMONGOODWIN, A; GRYGORCZYK, R; SLIPETZ, DM; METTERS, KM; ABRAMOVITZ, M				BOIE, Y; RUSHMORE, TH; DARMONGOODWIN, A; GRYGORCZYK, R; SLIPETZ, DM; METTERS, KM; ABRAMOVITZ, M			CLONING AND EXPRESSION OF A CDNA FOR THE HUMAN PROSTANOID IP RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROLOGOUS DESENSITIZATION; THROMBOXANE-A2 RECEPTOR; XENOPUS OOCYTES; PROSTAGLANDIN; PROSTACYCLIN; RESPONSES; PROTEIN	A cDNA clone coding for a functional human prostanoid IP receptor has been isolated from a lung cDNA library. The human IP receptor consists of 386 amino acid residues with a predicted molecular mass of 40,961, and has the seven putative transmembrane domains characteristic of G-protein-coupled receptors. Challenge of Xenopus oocytes co-expressing the IP receptor and the cystic fibrosis transmembrane conductance regulator (cAMP-activated Cl- channel) with the stable prostacyclin analog iloprost resulted in specific inward Cl- currents, demonstrating that the cDNA encoded a functional IP prostanoid receptor coupled to elevation in cAMP. Radioreceptor binding studies using membranes prepared from mammalian COS cells transfected with the IP receptor cDNA showed that the rank order of potency for prostaglandins and prostaglandin analogs in competition for [H-3]iloprost specific binding sites was as predicted for the IP receptor, with iloprost >> carbacyclin >> prostaglandin (PG) E(2) > PGF(2 alpha) = PGD(2) = U46619. Northern blot analysis showed that IP mRNA was most abundantly expressed in kidney, with lesser amounts detected in lung and liver. In summary, we have cloned and expressed a cDNA for the human prostanoid IP receptor that is functionally coupled to a signaling pathway involving stimulation of intracellular cARIP production.	MERCK FROSST CANADA INC,MERCK FROSST CTR THERAPEUT RES,DEPT BIOCHEM & MOLEC BIOL,POINTE CLAIRE H9R 4P8,PQ,CANADA	Merck & Company				Grygorczyk, Ryszard/0000-0002-9798-7651				ABRAMOVITZ M, 1994, J BIOL CHEM, V269, P2632; ATWOOD TK, 1991, GENE, V98, P153; BLAIR IA, 1981, BRIT J PHARMACOL, V72, P435, DOI 10.1111/j.1476-5381.1981.tb10994.x; CAMPBELL WB, 1990, GOODMAN GILMANS PHAR; COLEMAN RA, 1989, COMPREHENSIVE MED CH, V3, P643; COLLINS PW, 1993, CHEM REV, V93, P1533, DOI 10.1021/cr00020a007; Colman A., 1984, TRANSCRIPTION TRANSL, P49; DAVIES P, 1992, INFLAMMATION BASIC P, P123; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; FREY EA, 1993, EUR J PHARM-MOLEC PH, V244, P239, DOI 10.1016/0922-4106(93)90149-4; FUNK CD, 1993, J BIOL CHEM, V268, P26767; HALUSHKA PV, 1989, ANN REV PHARM TOXICO, V10, P213; HANRAHAN JW, 1993, CYSTIC FIBROSIS CURR, V1, P93; HASIMOTO H, 1990, PROSTAGLANDINS, V40, P491; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; HONDA A, 1993, J BIOL CHEM, V268, P7759; JASCHONEK K, 1988, EUR J PHARMACOL, V147, P187, DOI 10.1016/0014-2999(88)90777-7; JEREMY JY, 1986, PROSTAG LEUKOTR ESS, V23, P211, DOI 10.1016/0262-1746(86)90188-5; KELLY E, 1990, BRIT J PHARMACOL, V99, P309, DOI 10.1111/j.1476-5381.1990.tb14700.x; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Moncada S, 1980, Adv Prostaglandin Thromboxane Res, V6, P43; NAMBA T, 1992, BIOCHEM BIOPH RES CO, V184, P1197, DOI 10.1016/S0006-291X(05)80009-9; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; SADLER SE, 1987, J BIOL CHEM, V262, P10644; Sambrook J, 1989, MOL CLONING LABORATO; SELSEN RF, 1987, CURRENT PROTOCOLS MO; SENIOR J, 1992, BRIT J PHARMACOL, V107, P215, DOI 10.1111/j.1476-5381.1992.tb14489.x; SKUBALLA W, 1987, PROSTACYCLIN ITS STA, P17; SUGIMOTO Y, 1992, J BIOL CHEM, V267, P6463; SUGIMOTO Y, 1993, J BIOL CHEM, V268, P2712; UEDA N, 1985, BRAIN RES, V337, P347, DOI 10.1016/0006-8993(85)90073-3; WATABE A, 1993, J BIOL CHEM, V268, P20175; WATSON S, 1993, TRENDS PHARM SCI S, P31; WENNMALM M, 1987, PROSTAG OTH LIPID M, V33, P675, DOI 10.1016/0090-6980(87)90034-7	35	186	198	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12173	12178						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	7512962				2022-12-27	WOS:A1994NG37700076
J	RANDALL, WR				RANDALL, WR			CELLULAR EXPRESSION OF A CLONED, HYDROPHILIC, MURINE ACETYLCHOLINESTERASE - EVIDENCE OF PALMITOYLATED MEMBRANE-BOUND FORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT HUMAN ACETYLCHOLINESTERASE; CHICK-EMBRYO MUSCLE; MOLECULAR-FORMS; MESSENGER-RNA; TORPEDO ACETYLCHOLINESTERASE; DISULFIDE BONDS; PALMITIC ACID; SINGLE GENE; CELLS; ACYLATION	The expression and cellular targeting of murine acetylcholinesterase (AChE) was examined after transient transfection of a human 293 cell line with a cDNA encoding the hydrophilic T-subunit. Expression of the recombinant clone produced catalytically active AChE either bound to the cell membranes, in an intracellular pool, or secreted into the medium. About 22% of the cell-associated AChE was membrane-linked as dimers and tetramers, required Triton X-100 for extraction, and bound to Triton X-100 as assessed by sucrose gradients. Immunocytochemical staining of live and permeabilized cells showed reactive epitopes at the plasma membrane. Assays of cell surface AChE activity indicated about 18% of the cellular enzyme was oriented on the external surface of the plasma membrane. Isotopic labeling of cultures with precursors of fatty acylation showed incorporation of [H-3]palmitate into the membrane-bound fraction of AChE only. The label was sensitive to cleavage by mild alkaline methanol treatment, and the cleaved lipid was identified as methyl palmitate by thin layer chromatography, indicating covalent linkage of the fatty acid through an ester or thioester residue. Thus the membrane-bound AChE is palmitoylated, suggesting that fatty acylation may serve as an alternative mechanism for anchoring the hydrophilic polypeptide subunit of AChE to the external face of the plasma membrane.	UNIV MARYLAND, SCH MED, CTR MED BIOTECHNOL, BALTIMORE, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	RANDALL, WR (corresponding author), UNIV MARYLAND, SCH MED, DEPT PHARMACOL & EXPTL THERAPEUT, BALTIMORE, MD 21201 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS026885] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 26885] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMSON ED, 1977, J NEUROCHEM, V28, P605, DOI 10.1111/j.1471-4159.1977.tb10432.x; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BAZAN NG, 1985, J BIOL CHEM, V260, P3677; BIZZOZERO OA, 1987, J BIOL CHEM, V262, P13550; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BULGER JE, 1982, DEV NEUROSCI-BASEL, V5, P474, DOI 10.1159/000112708; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Dittmer J, 1969, METHOD ENZYMOL, V14, P482, DOI [DOI 10.1016/S0076-6879(69)14055-0, 10.1016/S0076-6879(69)14055-0]; DUVAL N, 1992, J CELL BIOL, V118, P641, DOI 10.1083/jcb.118.3.641; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FERRAND C, 1986, J NEUROCHEM, V46, P349, DOI 10.1111/j.1471-4159.1986.tb12975.x; FUTERMAN AH, 1985, J NEUROCHEM, V45, P1487, DOI 10.1111/j.1471-4159.1985.tb07217.x; GIBNEY G, 1990, J BIOL CHEM, V265, P12576; GNAGEY AL, 1987, J BIOL CHEM, V262, P13290; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HAAS R, 1986, BIOCHEMISTRY-US, V25, P3098, DOI 10.1021/bi00359a005; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HOEG JM, 1986, J BIOL CHEM, V261, P3911; HUANG G, 1988, BIOCHEMISTRY-US, V27, P1395, DOI 10.1021/bi00405a001; INESTROSA NC, 1987, J BIOL CHEM, V262, P4441; JING SQ, 1990, J BIOL CHEM, V265, P11555; JOHNSON CD, 1975, ANAL BIOCHEM, V64, P229, DOI 10.1016/0003-2697(75)90423-6; KITA T, 1980, J CLIN INVEST, V66, P1094, DOI 10.1172/JCI109938; KREJCI E, 1991, EMBO J, V10, P1285, DOI 10.1002/j.1460-2075.1991.tb08070.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZAR M, 1984, J BIOL CHEM, V259, P3703; LEE SL, 1982, J BIOL CHEM, V257, P2283; LEGAY C, 1993, J NEUROCHEM, V60, P337, DOI 10.1111/j.1471-4159.1993.tb05856.x; LI Y, 1991, J BIOL CHEM, V266, P23083; MACPHEEQUIGLEY K, 1986, J BIOL CHEM, V261, P3565; MARSH D, 1984, J NEUROCHEM, V43, P204, DOI 10.1111/j.1471-4159.1984.tb06698.x; MASSOULIE J, 1982, ANNU REV NEUROSCI, V5, P57, DOI 10.1146/annurev.ne.05.030182.000421; MASSOULIE J, 1993, PROG NEUROBIOL, V41, P31, DOI 10.1016/0301-0082(93)90040-Y; MAULET Y, 1990, NEURON, V4, P289, DOI 10.1016/0896-6273(90)90103-M; OBRIEN PJ, 1987, J BIOL CHEM, V262, P5210; OMARY MB, 1981, J BIOL CHEM, V256, P4715; PEARCE EJ, 1991, EMBO J, V10, P2741, DOI 10.1002/j.1460-2075.1991.tb07822.x; RACHINSKY TL, 1990, NEURON, V5, P317, DOI 10.1016/0896-6273(90)90168-F; ROBERTS WL, 1991, J BIOL CHEM, V266, P7481; ROTUNDO RL, 1988, P NATL ACAD SCI USA, V85, P7805, DOI 10.1073/pnas.85.20.7805; ROTUNDO RL, 1980, CELL, V22, P595, DOI 10.1016/0092-8674(80)90369-4; ROTUNDO RL, 1980, CELL, V22, P583, DOI 10.1016/0092-8674(80)90368-2; ROTUNDO RL, 1979, J BIOL CHEM, V254, P4790; RUBIN LL, 1985, J NEUROCHEM, V45, P1932, DOI 10.1111/j.1471-4159.1985.tb10553.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT MFG, 1989, BIOCHIM BIOPHYS ACTA, V988, P411, DOI 10.1016/0304-4157(89)90013-0; SCHUMACHER M, 1986, NATURE, V319, P407, DOI 10.1038/319407a0; SCHUMACHER M, 1988, J BIOL CHEM, V263, P18979; SIKORAV JL, 1988, EMBO J, V7, P2983, DOI 10.1002/j.1460-2075.1988.tb03161.x; SLOMIANY BL, 1984, J BIOL CHEM, V259, P1997; STAUFENBIEL M, 1986, P NATL ACAD SCI USA, V83, P318, DOI 10.1073/pnas.83.2.318; STOFFEL W, 1983, H-S Z PHYSIOL CHEM, V364, P1455, DOI 10.1515/bchm2.1983.364.2.1455; TOWLER DA, 1987, J BIOL CHEM, V262, P1030; VELAN B, 1991, J BIOL CHEM, V266, P23977; VELAN B, 1991, CELL MOL NEUROBIOL, V11, P143, DOI 10.1007/BF00712806; VIGNY M, 1978, EUR J BIOCHEM, V85, P317, DOI 10.1111/j.1432-1033.1978.tb12241.x; WATSON CJ, 1985, DNA CLONING PRACTICA, V1, P79; WILSON BW, 1973, DEV BIOL, V33, P285, DOI 10.1016/0012-1606(73)90138-3	58	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12367	12374						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	7512968				2022-12-27	WOS:A1994NG37700104
J	FALCONE, DJ; BORTH, W; MCCAFFREY, TA; MATHEW, J; MCADAM, K				FALCONE, DJ; BORTH, W; MCCAFFREY, TA; MATHEW, J; MCADAM, K			REGULATION OF MACROPHAGE RECEPTOR-BOUND PLASMIN BY AUTOPROTEOLYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; PHORBOL-MYRISTATE ACETATE; HUMAN-ENDOTHELIAL-CELLS; UROKINASE RECEPTOR; EXTRACELLULAR-MATRIX; CATALYTIC EFFICIENCY; LYS-PLASMINOGEN; HUMAN-MONOCYTES; U937 CELLS; ACTIVATOR	The activation of plasminogen by macrophage is regulated by their expression of receptors for urokinase and plasmin(ogen). In these studies we have examined plasmin(ogen) binding to adherent human THP-1 macrophage. Plasmin bound to the THP-1 cells in a time- and dose-dependent manner (K-d 15.8 +/- 6.2 nM; B-max 1.4 +/- 0.3 x 10(6)/cell). The lysine analog epsilon-aminocaproic acid competitively inhibited plasmin binding. The fraction of membrane-bound plasmin, however, became increasingly resistant to displacement with E-aminocaproic acid. Over a 24-h period, membrane-bound plasmin activity fell 80% despite the presence of catalytically active plasmin in the incubation media. The loss of receptor-bound plasmin activity was not due to proteolytic alterations of its receptor since I-125-Lys-plasminogen bound to THP-1 cells pretreated with plasmin with similar affinity as to untreated cells. Following a 24-h incubation of I-125-Lys-plasminogen or I-125-plasmin with THP-1 cells, several degradative fragments were apparent in their conditioned media. The smaller degradative fragments (28 and 36 kDa) lacked cell binding activity and were demonstrated to be active by casein-zymography. A 48-kDa fragment bound to cells in a lysine-dependent manner but was not active. In contrast, phenylmethylsulfonyl fluoride-inactivated I-125-plasmin retained its binding activity over 24 h, and degradative fragments were not present in the conditioned media. The binding of I-125-Lys-plasmin(ogen) to THP-1 cells was also examined in the presence of excess alpha 2 plasmin inhibitor. Despite the absence of fluid-phase plasmin activity, membrane-bound I-125-Lys-plasmin(ogen) decreased over 24 h. At 24 h a radiolabeled 48-kDa fragment was observed in the conditioned media and together with I-125-Lys-plasmin(ogen) was bound to cells. Unlike I-125-Lys-plasmin, the 48-kDa fragment did not form a complex with alpha 2 plasmin inhibitor. Thus, autoproteolysis of receptor-bound plasmin results in fragments with truncated physiologic properties that possess either cell binding or catalytic activities. We propose that autoproteolysis is a mechanism for regulating membrane-bound plasmin activity.	CORNELL UNIV,COLL MED,DEPT CELL BIOL & ANAT,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,DEPT MED,NEW YORK,NY 10021; CUNY MT SINAI SCH MED,DIV HEMATOL,NEW YORK,NY 10021	Cornell University; Cornell University; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	FALCONE, DJ (corresponding author), CORNELL UNIV,COLL MED,DEPT PATHOL,1300 YORK AVE,NEW YORK,NY 10021, USA.				NHLBI NIH HHS [P01 HL46403, R29 HL42606, R01-HL40819] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046403, R01HL040819, R29HL042606] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENDIXEN E, 1993, J BIOL CHEM, V268, P21962; BURGE SM, 1992, BRIT J DERMATOL, V126, P35, DOI 10.1111/j.1365-2133.1992.tb08400.x; CASTELLINO FJ, 1981, J BIOL CHEM, V256, P4778; DENT MAR, 1993, EUR J NEUROSCI, V5, P633, DOI 10.1111/j.1460-9568.1993.tb00529.x; ELLIS V, 1991, J BIOL CHEM, V266, P12752; ESTREICHER A, 1990, J CELL BIOL, V111, P783, DOI 10.1083/jcb.111.2.783; FALCONE DJ, 1993, J BIOL CHEM, V268, P11951; FALCONE DJ, 1993, J CELL PHYSIOL, V155, P595, DOI 10.1002/jcp.1041550317; FELEZ J, 1990, J CELL BIOL, V111, P1673, DOI 10.1083/jcb.111.4.1673; GONZALEZGRONOW M, 1991, ARCH BIOCHEM BIOPHYS, V286, P625, DOI 10.1016/0003-9861(91)90090-6; HAJJAR KA, 1986, J BIOL CHEM, V261, P1656; HAJJAR KA, 1988, J CLIN INVEST, V82, P1769, DOI 10.1172/JCI113790; HAJJAR KA, 1994, J BIOL CHEM, V269, P21191; HALL SW, 1991, J BIOL CHEM, V266, P12329; HUARTE J, 1993, DEV BIOL, V157, P539, DOI 10.1006/dbio.1993.1156; KIRCHHEIMER JC, 1989, BLOOD, V74, P1396; KIRCHHEIMER JC, 1989, J IMMUNOL, V143, P2634; KONNO H, 1993, EUR SURG RES, V25, P239, DOI 10.1159/000129283; LUND LR, 1991, J BIOL CHEM, V266, P5177; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; MCNEILL H, 1990, CELL REGUL, V1, P843, DOI 10.1091/mbc.1.11.843; MIGNATTI P, 1991, J CELL BIOL, V113, P1193, DOI 10.1083/jcb.113.5.1193; MILES LA, 1989, BIOCHEMISTRY-US, V28, P9337, DOI 10.1021/bi00450a014; MILES LA, 1991, BIOCHEMISTRY-US, V30, P1682, DOI 10.1021/bi00220a034; MOHANAM S, 1993, CANCER RES, V53, P4143; MOSER TL, 1993, J BIOL CHEM, V268, P18917; MURPHY G, 1992, ANN NY ACAD SCI, V667, P1, DOI 10.1111/j.1749-6632.1992.tb51590.x; PICONE R, 1989, J CELL BIOL, V108, P693, DOI 10.1083/jcb.108.2.693; PLOUG M, 1991, J BIOL CHEM, V266, P1926; PLOW EF, 1986, J CELL BIOL, V103, P2411, DOI 10.1083/jcb.103.6.2411; RICHARDSON M, 1988, CLIN INVEST MED, V11, P139; SAKSELA O, 1990, J CELL BIOL, V110, P767, DOI 10.1083/jcb.110.3.767; SCHLECHTE W, 1990, CANCER COMMUN, V2, P173; SILVERSTEIN RL, 1988, J CLIN INVEST, V82, P1948, DOI 10.1172/JCI113814; SOTTRUPJENSEN L, 1978, PROGR CHEM FIBRINOLY, V3, P191; TAIPALE J, 1992, J BIOL CHEM, V267, P25378; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; TSUCHIYA S, 1980, INT J CANCER, V26, P171, DOI 10.1002/ijc.2910260208; WANG L, 1994, J BIOL CHEM, V269, P4332; WU HL, 1992, BIOCHEM BIOPH RES CO, V188, P703, DOI 10.1016/0006-291X(92)91113-5; WU HL, 1990, J BIOL CHEM, V265, P19658; WU LH, 1987, P NATL ACAD SCI USA, V84, P8292	42	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32660	32666						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7528219				2022-12-27	WOS:A1994PX30400095
J	TIBERI, M; CARON, MG				TIBERI, M; CARON, MG			HIGH AGONIST-INDEPENDENT ACTIVITY IS A DISTINGUISHING FEATURE OF THE DOPAMINE D1B RECEPTOR SUBTYPE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONSTITUTIVELY ACTIVATING MUTATION; PROTEIN-COUPLED RECEPTORS; MOLECULAR-CLONING; ALPHA-1B-ADRENERGIC RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; INTRINSIC ACTIVITY; LIGAND-BINDING; RAT-BRAIN; EXPRESSION; GENE	Dopamine D1A and D1B receptor subtypes belong to the superfamily of G protein-coupled receptors. Both receptors are coupled to the activation of adenylyl cyclase and exhibit distinct brain distribution. To identify functional differences, binding and stimulation of adenylyl cyclase were assessed in 293 cells expressing transiently either dopamine D1A or D1B receptors. Membranes expressing DIB receptors displayed higher affinities for agonists than those expressing D1A receptors, whereas antagonist affinities were lower at the D1B than at the D1A receptor. Basal activity of adenylyl cyclase in whole 293 cells expressing various levels of D1B receptors was significantly higher than the basal activity measured in cells expressing D1A receptors. Maximal activation of adenylyl cyclase resulting from stimulation of the D1B receptor was less than that obtained following agonist activation of the D1A receptor. In cells expressing D1B receptors, agonists displayed an increased potency for stimulating adenylyl cyclase in comparison with the potencies determined for the D1A receptor. On the other hand, certain antagonists displayed ''negative efficacy'' at both receptor subtypes but had a more profound inhibition on the agonist-independent signaling activity of the D1B receptor. The properties described here are reminiscent of those of constitutively active G protein-coupled receptors obtained by site-directed mutations. Thus, the D1B receptor may represent a naturally occurring receptor subtype with properties akin to those of constitutively active G protein-coupled receptors. The different anatomical distribution and biochemical properties of these D1 receptors strengthen the functional distinctions between the two subtypes and could account for the basis of heterogeneity within a given class of neurotransmitter or hormone receptors. In addition, if these properties are recapitulated in cells expressing the D1B receptors, they may underlie important role in the regulation of physiological effects by dopamine. Finally, these results raise the interesting possibility that psychotropic antagonist drugs used in the management of certain brain disorders may have their beneficial actions as negative efficacy compounds.	DUKE UNIV, MED CTR, DEPT CELL BIOL, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, HOWARD HUGHES MED INST LABS, DURHAM, NC 27710 USA	Duke University; Duke University					NIMH NIH HHS [MH-44221, MH-40159] Funding Source: Medline; NINDS NIH HHS [NS-15976] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH040159, P30MH040159] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BARKER EL, 1994, J BIOL CHEM, V269, P11687; BOONE C, 1993, P NATL ACAD SCI USA, V90, P9921, DOI 10.1073/pnas.90.21.9921; CARLSSON A, 1991, EXCERPTA MED INT C S, V968, P687; CHABRE O, 1994, J BIOL CHEM, V269, P5730; CHIDIAC P, 1994, MOL PHARMACOL, V45, P490; CLAPHAM DE, 1993, CELL, V75, P1237, DOI 10.1016/0092-8674(93)90609-T; CLARK D, 1987, SYNAPSE, V1, P347, DOI 10.1002/syn.890010408; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; COSTA T, 1989, P NATL ACAD SCI USA, V86, P7321, DOI 10.1073/pnas.86.19.7321; COSTA T, 1992, MOL PHARMACOL, V41, P549; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DEARRY A, 1990, NATURE, V347, P72, DOI 10.1038/347072a0; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; DUPREZ L, 1994, NAT GENET, V7, P396, DOI 10.1038/ng0794-396; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; GOVARDHAN CP, 1994, J BIOL CHEM, V269, P6524; GRANDY DK, 1991, P NATL ACAD SCI USA, V88, P9175, DOI 10.1073/pnas.88.20.9175; GREEN SA, 1993, J BIOL CHEM, V268, P23116; JARVIE KR, 1993, J RECEPTOR RES, V13, P573, DOI 10.3109/10799899309073680; JARVIE KR, 1994, DOPAMINE RECEPTORS T, P133; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; LEFKOWITZ RJ, 1993, NATURE, V365, P603, DOI 10.1038/365603a0; LIGGETT SB, 1993, P NATL ACAD SCI USA, V90, P3665, DOI 10.1073/pnas.90.8.3665; MEADORWOODRUFF JH, 1992, NEUROSCI LETT, V145, P209, DOI 10.1016/0304-3940(92)90024-2; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NILSSON CL, 1993, J NEURAL TRANSM-GEN, V92, P213, DOI 10.1007/BF01244880; PARKER EM, 1991, J BIOL CHEM, V266, P9987; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; PEI G, 1994, P NATL ACAD SCI USA, V91, P2699, DOI 10.1073/pnas.91.7.2699; RAO VR, 1994, NATURE, V367, P639, DOI 10.1038/367639a0; REN Q, 1993, J BIOL CHEM, V268, P16483; ROBBINS LS, 1993, CELL, V72, P827, DOI 10.1016/0092-8674(93)90572-8; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; SALOMON Y, 1991, METHOD ENZYMOL, V195, P22; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SAMAMA P, 1994, MOL PHARMACOL, V45, P390; SCHUTZ W, 1992, TRENDS PHARMACOL SCI, V13, P376, DOI 10.1016/0165-6147(92)90116-N; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; SIBLEY DR, 1992, TRENDS PHARMACOL SCI, V13, P61, DOI 10.1016/0165-6147(92)90025-2; SUNAHARA RK, 1991, NATURE, V350, P614, DOI 10.1038/350614a0; SUZUKI T, 1992, MOL PHARMACOL, V41, P542; TIBERI M, 1991, P NATL ACAD SCI USA, V88, P7491, DOI 10.1073/pnas.88.17.7491; WEINSHANK RL, 1991, J BIOL CHEM, V266, P22427	47	209	218	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					27925	27931						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7525564				2022-12-27	WOS:A1994PV77200027
J	BURGER, RM; DRLICA, K; BIRDSALL, B				BURGER, RM; DRLICA, K; BIRDSALL, B			THE DNA CLEAVAGE PATHWAY OF IRON BLEOMYCIN - STRAND SCISSION PRECEDES DEOXYRIBOSE 3-PHOSPHATE BOND-CLEAVAGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE PROPENAL FORMATION; ACTIVATED BLEOMYCIN; MECHANISM; DEGRADATION; SITE; ABSTRACTION; RESOLUTION; RELEASE; OXYGEN; ORIGIN	DNA strand scission initiated by bleomycin is a multistep process. Three C-C or C-O bonds are broken, releasing base propenal, a nucleic base derivative with deoxyribose carbons 1-3. Either C-3'-(phosphate-O) cleavage or C-3'-C-4' plus C-1'-(ring-O) bond cleavages could cause strand cleavage. To determine the sequence of bond breakage, d(CAAGCTTG) duplex was examined for rates of 1) strand scission, monitored by the hyperchromicity of cleavage-induced denaturation; 2) base propenal formation, monitored by H-1 NMR spectroscopy; 3) 5'-terminal phosphomonoester formation, monitored by P-31 NMR spectroscopy. Strand scission occurred with t(1/2) = 4.1 +/- 0.5 min at 4 degrees C, faster than base propenal formation (t(1/2) = 6.7 +/- 0.3 min). Thus newly cleaved DNA includes a base propenal precursor (t(1/2) = 2-3 min). The 5'-phosphate terminus forms (t(1/2) = 7.4 +/- 0.8 min) concurrently with base propenal. Since strand scission precedes phosphomonoester formation, strand scission cannot arise from C-3'-(phosphate-O) cleavage. Instead, the base propenal precursor must be linked to the future 5'-phosphate terminus, with strand scission arising from a combination of C-3'-C-4' and C-1'-(ring-O) bond cleavages. These results provide experimental support for a recently proposed mechanism that accommodates an early oxygen attack at C-4' and 2'-deprotonation without requiring simultaneous strand scission and 5'-phosphate terminus formation.	NATL INST MED RES,MOLEC STRUCT LAB,LONDON NW7 1AA,ENGLAND	MRC National Institute for Medical Research	BURGER, RM (corresponding author), PUBL HLTH RES INST CITY NEW YORK INC,455 1ST AVE,NEW YORK,NY 10016, USA.				NIAID NIH HHS [AI 35257, AI 23337] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023337, R01AI035257] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AJMERA S, 1986, BIOCHEMISTRY-US, V25, P6586, DOI 10.1021/bi00369a037; BERTINI I, 1993, CHEM REV, V93, P2833, DOI 10.1021/cr00024a009; Borer P. N., 1975, CRC HDB BIOCH MOL BI, V1, P589; BURGER RM, 1981, J BIOL CHEM, V256, P1636; BURGER RM, 1982, J BIOL CHEM, V257, P3372; BURGER RM, 1979, J BIOL CHEM, V254, P906; BURGER RM, 1985, J BIOL CHEM, V260, P5406; BURGER RM, 1980, J BIOL CHEM, V255, P1832; BURGER RM, 1982, J BIOL CHEM, V257, P8612; BURGER RM, 1985, BIOCHEMISTRY-US, V24, P3623, DOI 10.1021/bi00335a034; BURGER RM, 1986, J BIOL CHEM, V261, P5955; CRAIG ME, 1971, J MOL BIOL, V62, P383, DOI 10.1016/0022-2836(71)90434-7; GILONI L, 1981, J BIOL CHEM, V256, P8608; Gorenstein DG, 1984, PHOSPHORUS 31 NMR PR; GROLLMAN AP, 1985, CANCER RES, V45, P1127; Hecht S. M., 1979, BLEOMYCIN CHEM BIOCH; HECHT SM, 1986, FASEB J, V45, P2784; ILES RA, 1982, PROG NUCL MAG RES SP, V15, P49, DOI 10.1016/0079-6565(82)80008-3; KOZARICH JW, 1989, SCIENCE, V245, P1396, DOI 10.1126/science.2476851; KURAMOCHI H, 1981, J ANTIBIOT TOKYO, V34, P578; LEVITT MH, 1983, ADV MAGN RESON, V11, P47; MCGALL GH, 1992, J AM CHEM SOC, V114, P4958, DOI 10.1021/ja00039a002; PORCHKE D, 1971, J MOL BIOL, V62, P361; SAITO I, 1987, J ORG CHEM, V52, P1008, DOI 10.1021/jo00382a007; SHIPLEY JB, 1988, CHEM RES TOXICOL, V1, P25, DOI 10.1021/tx00001a004; STUBBE J, 1987, CHEM REV, V87, P1107, DOI 10.1021/cr00081a011; SUGIYAMA H, 1985, J AM CHEM SOC, V107, P7765, DOI 10.1021/ja00311a092; SUZUKI H, 1969, J ANTIBIOT, V22, P446, DOI 10.7164/antibiotics.22.446; SUZUKI H, 1968, J ANTIBIOT, V21, P379, DOI 10.7164/antibiotics.21.379; TAKESHITA M, 1979, BLEOMYCIN CHEM BIOCH, P207; TAYLOR P, 1975, BIOCHEMISTRY-US, V14, P1989, DOI 10.1021/bi00680a029; UMEZAWA H, 1966, J ANTIBIOT, V19, P200; UMEZAWA H, 1966, J ANTIBIOT, V19, P210; WU JC, 1983, J BIOL CHEM, V258, P4694; WU JC, 1985, BIOCHEMISTRY-US, V24, P7562, DOI 10.1021/bi00347a009	35	39	39	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					25978	25985						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7523397				2022-12-27	WOS:A1994PQ93000010
J	TAKAHARA, K; KESSLER, E; BINIAMINOV, L; BRUSEL, M; EDDY, RL; JANISAIT, S; SHOWS, TB; GREENSPAN, DS				TAKAHARA, K; KESSLER, E; BINIAMINOV, L; BRUSEL, M; EDDY, RL; JANISAIT, S; SHOWS, TB; GREENSPAN, DS			TYPE-I PROCOLLAGEN COOH-TERMINAL PROTEINASE ENHANCER PROTEIN - IDENTIFICATION, PRIMARY STRUCTURE, AND CHROMOSOMAL LOCALIZATION OF THE COGNATE HUMAN GENE (PCOLCE)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; C-PROTEINASE; MOUSE FIBROBLASTS; HUMAN GENOME; PURIFICATION; COLLAGEN; DNA; GLYCOPROTEIN; QUANTITIES; EXPRESSION	Type I procollagen COOH-terminal proteinase (C-proteinase) enhancer, a glycoprotein that binds to the COOH-terminal propeptide of type I procollagen and enhances procollagen C-proteinase activity, was purified from mouse fibroblast culture media. Partial amino acid sequences obtained from proteolytic fragments were found to have identity with the deduced amino acid sequence of a cDNA clone of unknown function, previously isolated from a mouse astrocyte library. Sequences of mouse enhancer cDNA, obtained in the present study, predict a similar to 50-kDa, 468-amino acid protein that differs from the 43-kDa, 402-amino acid protein predicted by the previously reported astrocyte-derived clone. Human cDNAs encode an enhancer of 449 amino acids. Previous biochemical studies have found the mouse enhancer as a 55-kDa form, which is readily processed to 36- and 34-kDa forms, retaining full C-proteinase enhancing activity and the ability to bind the COOH-terminal propeptide. Data presented here show the 36-kDa form to correspond to the amino-terminal portion of the 55-kDa protein. This is the most conserved region between mouse and human enhancers, comprising two domains with homology to domains found in a number of proteases and proteins with developmental functions. Such domains are thought to mediate interactions between proteins. Mouse enhancer RNA is shown to be at highest levels in collagen-rich tissues, especially tendon. The human enhancer gene, PCOLCE, is localized to 7q21.3-->q22, the same chromosomal region containing the type I collagen alpha 2 chain gene, COL1A2.	UNIV WISCONSIN,DEPT PATHOL & LAB MED,MADISON,WI 53706; UNIV WISCONSIN,CELL & MOLEC BIOL PROGRAM,MADISON,WI 53706; TEL AVIV UNIV,FAC MED,SHEBA MED CTR,MAURICE & GABRIELA GOLDSCHLEGER EYE RES INST,IL-52621 TEL HASHOMER,ISRAEL; NEW YORK STATE DEPT HLTH,ROSWELL PK MEM INST,DEPT HUMAN GENET,BUFFALO,NY 14263	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Chaim Sheba Medical Center; Tel Aviv University; Roswell Park Cancer Institute				Greenspan, Daniel/0000-0001-8096-7446	NIGMS NIH HHS [GM46846] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAR R, 1986, COLLAGEN REL RES, V6, P267; ARLAUD GJ, 1987, IMMUNOL TODAY, V8, P106, DOI 10.1016/0167-5699(87)90860-7; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P9383; DUMERMUTH E, 1991, J BIOL CHEM, V266, P21381; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GREENSPAN DS, 1991, GENE EXPRESSION, V1, P29; HOJIMA Y, 1985, J BIOL CHEM, V260, P5996; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; KESSLER E, 1989, EUR J BIOCHEM, V186, P115, DOI 10.1111/j.1432-1033.1989.tb15184.x; KESSLER E, 1990, BIOCHEM BIOPH RES CO, V173, P81, DOI 10.1016/S0006-291X(05)81024-1; KESSLER E, 1986, COLLAGEN REL RES, V6, P249; KIVIRIKKO KI, 1984, EXTRACELLULAR MATRIX, P83; KUHN K, 1987, STRUCTURE FUNCTION C, P1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECAIN E, 1991, J NEUROCHEM, V56, P2133, DOI 10.1111/j.1471-4159.1991.tb03476.x; LEE ST, 1988, J BIOL CHEM, V263, P13414; LEPAGE T, 1992, DEVELOPMENT, V114, P147; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; PERETZ M, 1989, BIOCHEMISTRY-US, V28, P6549, DOI 10.1021/bi00442a004; PESCIOTTA DM, 1982, IMMUNOCHEMISTRY EXTR, V1, P91; PROCKOP DJ, 1984, NEW ENGL J MED, V311, P376, DOI 10.1056/NEJM198408093110606; REYNOLDS SD, 1992, DEVELOPMENT, V114, P769; RHYNER TA, 1990, J NEUROSCI RES, V27, P144, DOI 10.1002/jnr.490270204; SATO SM, 1990, DEV BIOL, V137, P135, DOI 10.1016/0012-1606(90)90014-A; SHIMELL MJ, 1991, CELL, V67, P469, DOI 10.1016/0092-8674(91)90522-Z; SHOWS T, 1984, SOMAT CELL MOLEC GEN, V10, P315, DOI 10.1007/BF01535253; SHOWS TB, 1983, ISOZYMES-CURR T BIOL, V10, P323; SHOWS TB, 1982, ADV HUM GENET, V12, P341; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; TRASK B, 1991, METHOD CELL BIOL, V35, P1; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241	35	87	97	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26280	26285						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7523404				2022-12-27	WOS:A1994PQ93000054
J	KUO, SR; LIU, JS; BROKER, TR; CHOW, LT				KUO, SR; LIU, JS; BROKER, TR; CHOW, LT			CELL-FREE REPLICATION OF THE HUMAN PAPILLOMAVIRUS DNA WITH HOMOLOGOUS VIRAL E1 AND E2 PROTEINS AND HUMAN CELL-EXTRACTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN VIRUS-40 DNA; BOVINE PAPILLOMAVIRUS; TRANSCRIPTIONAL ACTIVATION; BINDING-SITE; TRANSIENT REPLICATION; REGULATORY PROTEINS; TYPE-11 ORIGIN; MESSENGER-RNAS; INVITRO; INITIATION	We have established the first homologous cell-free DNA replication system for a papillomavirus. The replication of the human papillomavirus type 11 (HPV-11) origin was achieved by using human 293 cell extracts supplemented with the HPV-11 E1 and E2 proteins purified from insect cells infected with recombinant baculoviruses. Efficient replication depends on the HPV-11 origin, the HPV-11 E1 and E2 proteins, as well as human DNA polymerase alpha, delta, replication protein A, topoisomerase I, and topoisomerase II. High concentrations of E1 protein also promoted a low level of origin-independent replication which was suppressed by the addition of the E2 protein, whereas E2 protein stimulated origin-dependent replication. We also show that an intact E2 protein binding site was absolutely necessary for origin activity, as a strong HPV-11 origin was rendered inactive when one half-site of each of the three E2 binding sites was mutated. In contrast, there was only a relatively small reduction in this mutant origin activity when the cell extracts were supplemented with the bovine papillomavirus type 1 (BPV-1) proteins. These results suggest that the HPV-11 E2 protein plays a primary role in HPV origin recognition. Furthermore, unlike transient replication in which HPV-11 and BPV-1 viral proteins promote efficient replication of homologous and heterologous origins, efficient cell-free replication took place only with the homologous combinations.	UNIV ALABAMA, SCH MED & DENT, DEPT BIOCHEM & MOLEC GENET, BIRMINGHAM, AL 35294 USA; UNIV ROCHESTER, SCH MED & DENT, DEPT BIOCHEM, ROCHESTER, NY 14642 USA	University of Alabama System; University of Alabama Birmingham; University of Rochester					NATIONAL CANCER INSTITUTE [R01CA036200] Funding Source: NIH RePORTER; NCI NIH HHS [CA36200] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEDROSIAN CL, 1990, VIROLOGY, V174, P557, DOI 10.1016/0042-6822(90)90109-5; BLITZ IL, 1991, J VIROL, V65, P649, DOI 10.1128/JVI.65.2.649-656.1991; BREAM GL, 1993, J VIROL, V67, P2655, DOI 10.1128/JVI.67.5.2655-2663.1993; BROKER TR, 1989, CANCER CEL, V7, P197; CHENG LH, 1989, CELL, V59, P541, DOI 10.1016/0092-8674(89)90037-8; CHENG LZ, 1992, P NATL ACAD SCI USA, V89, P589, DOI 10.1073/pnas.89.2.589; CHIANG CM, 1992, P NATL ACAD SCI USA, V89, P5799, DOI 10.1073/pnas.89.13.5799; CHIANG CM, 1992, J VIROL, V66, P5224, DOI 10.1128/JVI.66.9.5224-5231.1992; CHIANG CM, 1991, J VIROL, V65, P3317, DOI 10.1128/JVI.65.6.3317-3329.1991; DELVECCHIO AM, 1992, J VIROL, V66, P5949, DOI 10.1128/JVI.66.10.5949-5958.1992; DEPAMPHILIS ML, 1993, ANNU REV BIOCHEM, V62, P29; DEPAMPHILIS ML, 1986, PAPOVAVIRIDAE, P99; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOLLARD SC, 1992, GENE DEV, V6, P1131, DOI 10.1101/gad.6.7.1131; DONG G, 1994, J VIROL, V68, P1115, DOI 10.1128/JVI.68.2.1115-1127.1994; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; HAM J, 1991, TRENDS BIOCHEM SCI, V16, P440, DOI 10.1016/0968-0004(91)90172-R; Harlow E., 1988, ANTIBODIES LABORATOR, P511; HOLT SE, 1994, J VIROL, V68, P1094, DOI 10.1128/JVI.68.2.1094-1102.1994; HUGHES FJ, 1993, NUCLEIC ACIDS RES, V21, P5817, DOI 10.1093/nar/21.25.5817; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; LI R, 1994, P NATL ACAD SCI USA, V91, P7051, DOI 10.1073/pnas.91.15.7051; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LIU LF, 1990, DNA TOPOLOGY ITS BIO, P371; LU JZJ, 1993, J VIROL, V67, P7131, DOI 10.1128/JVI.67.12.7131-7139.1993; LUSKY M, 1991, P NATL ACAD SCI USA, V88, P6363, DOI 10.1073/pnas.88.14.6363; LUSKY M, 1993, J BIOL CHEM, V268, P15795; MCBRIDE AA, 1991, J BIOL CHEM, V266, P18411; MEYERS C, 1992, SCIENCE, V257, P971, DOI 10.1126/science.1323879; MOHR IJ, 1990, SCIENCE, V250, P1694, DOI 10.1126/science.2176744; MUNGAL S, 1992, J VIROL, V66, P3220, DOI 10.1128/JVI.66.5.3220-3224.1992; REMM M, 1992, NUCLEIC ACIDS RES, V20, P6015, DOI 10.1093/nar/20.22.6015; ROTENBERG MO, 1989, VIROLOGY, V172, P468, DOI 10.1016/0042-6822(89)90189-X; SALAHUDDIN, 1990, GENE DEV, V4, P968, DOI 10.1101/gad.4.6.968; SCHIRMBECK R, 1991, J VIROL, V65, P2578, DOI 10.1128/JVI.65.5.2578-2588.1991; SEO YS, 1993, P NATL ACAD SCI USA, V90, P2865, DOI 10.1073/pnas.90.7.2865; SEO YS, 1993, P NATL ACAD SCI USA, V90, P702, DOI 10.1073/pnas.90.2.702; SPALHOLZ BA, 1993, VIROLOGY, V193, P201, DOI 10.1006/viro.1993.1116; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; STOLER MH, 1989, VIROLOGY, V172, P331, DOI 10.1016/0042-6822(89)90135-9; STOLER MH, 1990, J VIROL, V64, P3310, DOI 10.1128/JVI.64.7.3310-3318.1990; SVERDRUP F, 1994, J VIROL, V68, P505, DOI 10.1128/JVI.68.1.505-509.1994; THORNER LK, 1993, J VIROL, V67, P6000, DOI 10.1128/JVI.67.10.6000-6014.1993; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1961; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; USTAV E, 1993, P NATL ACAD SCI USA, V90, P898, DOI 10.1073/pnas.90.3.898; USTAV M, 1991, EMBO J, V10, P4321, DOI 10.1002/j.1460-2075.1991.tb05010.x; USTAV M, 1991, EMBO J, V10, P449, DOI 10.1002/j.1460-2075.1991.tb07967.x; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WEBB N R, 1990, Technique (Philadelphia), V2, P173; WILSON VG, 1991, J VIROL, V65, P5314, DOI 10.1128/JVI.65.10.5314-5322.1991; WINOKUR PL, 1992, EMBO J, V11, P4111, DOI 10.1002/j.1460-2075.1992.tb05504.x; YANG L, 1991, COLD SPRING HARB SYM, V56, P335; YANG L, 1993, P NATL ACAD SCI USA, V90, P5086, DOI 10.1073/pnas.90.11.5086; YANG L, 1991, NATURE, V353, P628, DOI 10.1038/353628a0	60	102	108	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24058	24065						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7523366				2022-12-27	WOS:A1994PQ34600035
J	COCCIA, EM; KRUST, B; HOVANESSIAN, AG				COCCIA, EM; KRUST, B; HOVANESSIAN, AG			SPECIFIC-INHIBITION OF VIRAL PROTEIN-SYNTHESIS IN HIV-INFECTED CELLS IN RESPONSE TO INTERFERON TREATMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; GENE-EXPRESSION; ENVELOPE GLYCOPROTEINS; 2-5A SYNTHETASE; MESSENGER-RNA; REPLICATION; TYPE-1; ALPHA; TRANSLATION; KINASE	The mechanism of action of different types of interferons (IFN-alpha, -beta, and -gamma) against human immunodeficiency virus (HIV)-1 infection was investigated in chronically infected monocytoid U937 cells and during an acute infection of the T lymphoblastoid CEM cells. Two chronically infected U937 cell populations, obtained independently (referred to as type A and B cells), were analyzed for their response to IFNs. In type A cells, IFNs mainly inhibited virus particle release, whereas in type B cells, the anti-HIV effect of IFNs cells was found to be largely due to a specific inhibition of viral protein synthesis without any apparent effect on total cellular protein synthesis. Interestingly, such a differential inhibition of HIV protein synthesis could also be demonstrated in acutely infected CEM cells in response to treatment with IFN-a. Both in chronically infected U937 type B and acutely infected CEM cells, equivalent amounts of nuclear and cytoplasmic HIV-1 mRNA were detected in control and IFN-treated cells in spite of at least 80% inhibition of HIV protein synthesis. Analysis of the distribution of cellular and viral mRNAs on polysomes in HIV-1-infected cells demonstrated that IFN treatment induces a specific block on viral mRNA translation. These results indicate that the antiviral mechanism of IFN on later stages of HIV replication cycle may be partly due to the inhibition of HIV mRNA translation, besides an effect on virus budding or release.	INST PASTEUR,CNRS,UNITE VIROL & IMMUNOL CELLULAIRE 1157,F-75724 PARIS 15,FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			Coccia, Eliana M/B-4752-2013	Coccia, Eliana M/0000-0002-1606-2949				AGY MB, 1990, VIROLOGY, V177, P251, DOI 10.1016/0042-6822(90)90478-A; ARRIGO SJ, 1991, GENE DEV, V5, P808, DOI 10.1101/gad.5.5.808; BISWAS P, 1992, J EXP MED, V176, P739, DOI 10.1084/jem.176.3.739; BOULERICE F, 1990, J VIROL, V64, P1745, DOI 10.1128/JVI.64.4.1745-1755.1990; CULLEN BR, 1991, ANNU REV MICROBIOL, V45, P19; DAGOSTINO DM, 1992, MOL CELL BIOL, V12, P1375, DOI 10.1128/MCB.12.3.1375; FRANCIS ML, 1992, AIDS RES HUM RETROV, V8, P199, DOI 10.1089/aid.1992.8.199; FRIEDMAN RL, 1984, CELL, V38, P745, DOI 10.1016/0092-8674(84)90270-8; GENDELMAN HE, 1990, J IMMUNOL, V145, P2669; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; HAMMER SM, 1986, P NATL ACAD SCI USA, V83, P8734, DOI 10.1073/pnas.83.22.8734; HANSEN BD, 1992, J VIROL, V66, P7543, DOI 10.1128/JVI.66.12.7543-7548.1992; HO DD, 1985, LANCET, V1, P602; HOVANESSIAN AG, 1987, EMBO J, V6, P1273, DOI 10.1002/j.1460-2075.1987.tb02364.x; HOVANESSIAN AG, 1993, SEMIN VIROL, V4, P237, DOI 10.1006/smvy.1993.1020; HOVANESSIAN AG, 1991, J INTERFERON RES, V11, P199, DOI 10.1089/jir.1991.11.199; Hovanessian Ara G., 1993, P41; KATZE MG, 1990, ENZYME, V44, P332, DOI 10.1159/000468769; KIM SY, 1989, J VIROL, V63, P3708, DOI 10.1128/JVI.63.9.3708-3713.1989; KORNBLUTH RS, 1990, CLIN IMMUNOL IMMUNOP, V54, P200, DOI 10.1016/0090-1229(90)90082-2; KRUST B, 1993, AIDS RES HUM RETROV, V9, P1081; LAURENT AG, 1989, J VIROL, V63, P4074, DOI 10.1128/JVI.63.9.4074-4078.1989; LAURENTCRAWFORD AG, 1993, J GEN VIROL, V74, P2619, DOI 10.1099/0022-1317-74-12-2619; LAURENTCRAWFORD AG, 1991, VIROLOGY, V185, P829, DOI 10.1016/0042-6822(91)90554-O; LAURENTCRAWFORD AG, 1993, AIDS RES HUM RETROV, V9, P761, DOI 10.1089/aid.1993.9.761; LODISH HF, 1977, J BIOL CHEM, V252, P8804; LODISH HF, 1976, ANNU REV BIOCHEM, V45, P39, DOI 10.1146/annurev.bi.45.070176.000351; Maniatis T., 1982, MOL CLONING; MARIE I, 1989, BIOCHEM BIOPH RES CO, V160, P580, DOI 10.1016/0006-291X(89)92472-8; MARTON MJ, 1993, MOL CELL BIOL, V13, P3541, DOI 10.1128/MCB.13.6.3541; MASSARI FE, 1990, J IMMUNOL, V144, P4628; MCELRATH MJ, 1989, P NATL ACAD SCI USA, V86, P675, DOI 10.1073/pnas.86.2.675; MELTZER MS, 1990, IMMUNOL TODAY, V11, P217, DOI 10.1016/0167-5699(90)90086-O; MICHAELIS B, 1989, AIDS, V3, P27, DOI 10.1097/00002030-198903010-00006; PEDEN K, 1991, VIROLOGY, V185, P661, DOI 10.1016/0042-6822(91)90537-L; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PITHA PM, 1979, J GEN VIROL, V42, P467, DOI 10.1099/0022-1317-42-3-467; PITHA PM, 1991, J INTERFERON RES, V11, P313, DOI 10.1089/jir.1991.11.313; POLI G, 1989, SCIENCE, V244, P575, DOI 10.1126/science.2470148; REY MA, 1989, VIROLOGY, V173, P258, DOI 10.1016/0042-6822(89)90242-0; REY MA, 1989, J VIROL, V63, P647, DOI 10.1128/JVI.63.2.647-658.1989; ROSENBERG ZF, 1991, FASEB J, V5, P2382, DOI 10.1096/fasebj.5.10.1676689; SHIRAZI Y, 1992, J VIROL, V66, P1321, DOI 10.1128/JVI.66.3.1321-1328.1992; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; WAINHOBSON S, 1991, SCIENCE, V252, P961, DOI 10.1126/science.2035026	45	67	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					23087	23094						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	7521875				2022-12-27	WOS:A1994PQ16400031
J	CHITTENDEN, K; BLACK, SD; ZWIEB, C				CHITTENDEN, K; BLACK, SD; ZWIEB, C			SYSTEMATIC SITE-DIRECTED MUTAGENESIS OF PROTEIN SRP19 - IDENTIFICATION OF THE RESIDUES ESSENTIAL FOR BINDING TO SIGNAL RECOGNITION PARTICLE RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; SYNTHESIZING SECRETORY PROTEIN; RICIN-A-CHAIN; MICROSOMAL-MEMBRANES; TETRANUCLEOTIDE LOOP; RIBOSOMAL-RNA; TRANSLOCATION; SEQUENCE; CATALYSIS; DOMAIN	Protein SRP19 is an important structural and functional constituent of the signal recognition particle (SRP) and belongs to a group of RNA binding proteins that specifically recognize certain tetranucleotide loops. Systematic site-directed mutagenesis was used to identify the amino acid residues in human SRP19 essential for interaction with SRP RNA. In our studies, three different groups of mutants were constructed, and each group covered essentially the entire sequence of the SRP19 protein in a consecutive nonoverlapping fashion. Results from 10 deletion mutants followed by the analysis of 24 mutants in which adjacent five residues were changed to pentaglycine suggested that a large portion of the protein may be required for RNA binding. Further examination of 53 mutant polypeptides in which adjacent dipeptide segments were altered showed, however, that 84 of the 144 SRP19 amino acids (58%) were not important for binding to the SRP RNA. The essential amino acids cluster in five regions which encompass most of the SRP19 sequence, with the exception of residues located at the N and C termini and a predicted internal loop. The results from the systematic site-directed mutagenesis study, when combined with protein secondary structure calculations, demonstrate that SRP19 is a precisely tooled protein which associates intimately with the SRP RNA.	UNIV TEXAS, HLTH SCI CTR, DEPT MOLEC BIOL, TYLER, TX 75710 USA; UNIV TEXAS, HLTH SCI CTR, DEPT BIOCHEM, TYLER, TX 75710 USA	University of Texas System; University of Texas at Tyler; University of Texas-Health Sciences Center at Tyler (UTHSCT); University of Texas System; University of Texas at Tyler; University of Texas-Health Sciences Center at Tyler (UTHSCT)								AERNE BL, 1993, NUCLEIC ACIDS RES, V21, P3575, DOI 10.1093/nar/21.15.3575; BENNER SA, 1992, CURR OPIN STRUC BIOL, V2, P402; BLACK SD, 1986, BIOTECHNIQUES, V4, P448; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; CUNNINGHAM BC, 1990, SCIENCE, V247, P1461, DOI 10.1126/science.2321008; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GATIGNOL A, 1993, MOL CELL BIOL, V13, P2193, DOI 10.1128/MCB.13.4.2193; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; GLUCK A, 1992, J MOL BIOL, V226, P411, DOI 10.1016/0022-2836(92)90956-K; HAMMES SR, 1993, VIROLOGY, V193, P41, DOI 10.1006/viro.1993.1101; Held W.A., 1974, RIBOSOMES, P193; HSIAO KC, 1991, NUCLEIC ACIDS RES, V19, P2787, DOI 10.1093/nar/19.10.2787; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LARSEN N, 1993, NUCLEIC ACIDS RES, V21, P3019, DOI 10.1093/nar/21.13.3019; LARSEN N, 1991, NUCLEIC ACIDS RES, V19, P209, DOI 10.1093/nar/19.2.209; LINGELBACH K, 1988, NUCLEIC ACIDS RES, V16, P9431, DOI 10.1093/nar/16.20.9431; Maniatis T., 1982, MOL CLONING; Maxam A M, 1980, Methods Enzymol, V65, P499; MORRIS KN, 1992, P NATL ACAD SCI USA, V89, P4869, DOI 10.1073/pnas.89.11.4869; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; PREHN S, 1987, EMBO J, V6, P2093, DOI 10.1002/j.1460-2075.1987.tb02475.x; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; RENNELL D, 1991, J MOL BIOL, V222, P67, DOI 10.1016/0022-2836(91)90738-R; ROMISCH K, 1990, J CELL BIOL, V111, P1793, DOI 10.1083/jcb.111.5.1793; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; ROST B, 1993, TRENDS BIOCHEM SCI, V18, P120, DOI 10.1016/0968-0004(93)90017-H; SABATINI DD, 1982, J CELL BIOL, V92, P1, DOI 10.1083/jcb.92.1.1; STIRLING CJ, 1992, NATURE, V356, P534, DOI 10.1038/356534a0; STRUB K, 1991, MOL CELL BIOL, V11, P3949, DOI 10.1128/MCB.11.8.3949; TAO JS, 1992, P NATL ACAD SCI USA, V89, P2723, DOI 10.1073/pnas.89.7.2723; TREICH I, 1992, NUCLEIC ACIDS RES, V20, P4721, DOI 10.1093/nar/20.18.4721; WALTER P, 1981, J CELL BIOL, V91, P551, DOI 10.1083/jcb.91.2.551; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; WALTER P, 1983, CELL, V34, P525, DOI 10.1016/0092-8674(83)90385-9; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P8467, DOI 10.1073/pnas.87.21.8467; ZWIEB C, 1992, NUCLEIC ACIDS RES, V20, P4397, DOI 10.1093/nar/20.17.4397; ZWIEB C, 1989, PROG NUCLEIC ACID RE, V37, P207; ZWIEB C, 1991, NUCLEIC ACIDS RES, V19, P2955, DOI 10.1093/nar/19.11.2955; ZWIEB C, 1992, J BIOL CHEM, V267, P15650; ZWIEB C, 1991, BIOCHEM CELL BIOL, V69, P649, DOI 10.1139/o91-096; ZWIEB C, 1994, IN PRESS EUR J BIOCH	43	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20497	20502						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	7519610				2022-12-27	WOS:A1994PB31700046
J	RAO, BNN; ANDERSON, MB; MUSSER, JH; GILBERT, JH; SCHAEFER, ME; FOXALL, C; BRANDLEY, BK				RAO, BNN; ANDERSON, MB; MUSSER, JH; GILBERT, JH; SCHAEFER, ME; FOXALL, C; BRANDLEY, BK			SIALYL-LEWIS-X MIMICS DERIVED FROM A PHARMACOPHORE SEARCH ARE SELECTIN INHIBITORS WITH ANTIINFLAMMATORY ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							LEUKOCYTE ADHESION MOLECULE-1; ACUTE LUNG INJURY; H-1-NMR SPECTRA; OLIGOSACCHARIDES; SPECTROSCOPY; LIGANDS; BINDING; ELAM-1; NMR	The selectins, a family of adhesion receptors involved in leukocyte extravasation, recognize sialyl Lewis X (sLe(x); NeuAc alpha 2-3Gal beta 1-4(Fuc alpha 1-3)GlcNAc) and related oligosaccharides. We used conformational energy computations, high field NMR, and structure-function studies to define distance parameters of critical functional groups of sLe(x). This sLe(x) pharmacophore was used to search a three dimensional data base of chemical structures. Compounds that had a similar spatial relationship of functional groups were tested as inhibitors of selectin binding. Glycyrrhizin, a triterpene glycoside, was identified and found to block selectin binding to sLe(x) in vitro. We substituted different sugars for the glucuronic acids of glycyrrhizin and found the L-fucose derivative to be the most active in vitro and in vivo. A C-fucoside derivative, synthesized on a linker designed for stability and to more closely approximate the original sLe(x) pharmacophore, resulted in an easily synthesized, effective selectin blocker with anti-inflammatory activity,			RAO, BNN (corresponding author), GLYCOMED INC,860 ATLANTIC AVE,ALAMEDA,CA 94501, USA.							BALL GE, 1992, J AM CHEM SOC, V114, P5449, DOI 10.1021/ja00039a080; BERG EL, 1992, BIOCHEM BIOPH RES CO, V184, P1048, DOI 10.1016/0006-291X(92)90697-J; BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462; BRANDLEY BK, 1993, GLYCOBIOLOGY, V3, P633, DOI 10.1093/glycob/3.6.633; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; DAVIS DG, 1985, J AM CHEM SOC, V107, P2820, DOI 10.1021/ja00295a052; DAVIS EA, 1991, MOL CELL ENDOCRINOL, V1, P5; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; GREEN PJ, 1992, BIOCHEM BIOPH RES CO, V188, P244, DOI 10.1016/0006-291X(92)92376-9; GUNDEL RH, 1991, J CLIN INVEST, V88, P1407, DOI 10.1172/JCI115447; HARRIS R R, 1990, Skin Pharmacology, V3, P29; HEAVNER GA, 1993, INT J PEPT PROT RES, V42, P484; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LIN YC, 1992, J AM CHEM SOC, V114, P5452, DOI 10.1021/ja00039a082; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MILLER KE, 1992, BIOCHEMISTRY-US, V31, P6703, DOI 10.1021/bi00144a009; MULLIGAN MS, 1991, J CLIN INVEST, V88, P1396, DOI 10.1172/JCI115446; MULLIGAN MS, 1993, J EXP MED, V178, P623, DOI 10.1084/jem.178.2.623; MULLIGAN MS, 1992, J CLIN INVEST, V90, P1600, DOI 10.1172/JCI116029; MUSSER JH, 1993, TRENDS DRUG RES, V20, P33; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; RAO BNN, 1991, MED CHEM RES, V1, P1; TIEMEYER M, 1991, P NATL ACAD SCI USA, V88, P1138, DOI 10.1073/pnas.88.4.1138; TYRRELL D, 1991, P NATL ACAD SCI USA, V88, P10372, DOI 10.1073/pnas.88.22.10372; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; YUEN CT, 1994, J BIOL CHEM, V269, P1595; YUENCT, 1992, BIOCHEMISTRY-US, V31, P9126	28	108	119	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					19663	19666						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	7519598				2022-12-27	WOS:A1994PA12600002
J	CHANG, XB; HOU, YX; JENSEN, TJ; RIORDAN, JR				CHANG, XB; HOU, YX; JENSEN, TJ; RIORDAN, JR			MAPPING OF CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEMBRANE TOPOLOGY BY GLYCOSYLATION SITE INSERTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CFTR CHLORIDE CHANNEL; PROTEIN EXPORT SIGNALS; BETA-LACTAMASE; PROTEOLIPID PROTEIN; GENETIC-ANALYSIS; PLASMA-MEMBRANE; MYELIN; ORGANIZATION; ARRANGEMENT; ANTIBODIES	Technical difficulties in obtaining three-dimensional structures of intrinsic membrane proteins continues to limit understanding of their function. However, considerable insight can be gained from their two-dimensional topological arrangement in the lipid bilayer. Efficient molecular genetic approaches are available to discern the topology of prokaryotic but not of eukaryotic membrane proteins. The absolute asymmetry of the sidedness of their N-glycosylation was employed here to develop such a method using the cystic fibrosis transmembrane conductance regulator (CFTR). Insertion by in vitro mutagenesis of N-glycosylation consensus sequences (NXS/T) in predicted cytoplasmic and extracytoplasmic loops between hydrophobic sequences capable of traversing the membrane established the membrane topology of CFTR. This provides the first experimental evaluation of the original topological model of CFTR based solely on hydropathy algorithms and a method which may be generally applicable for the in vivo evaluation of the topology of other mammalian membrane proteins.	HOSP SICK CHILDREN,RES INST,TORONTO M5G 1X8,ON,CANADA; UNIV TORONTO,TORONTO M5G 1X8,ON,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto								ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; BOYD D, 1987, P NATL ACAD SCI USA, V84, P8525, DOI 10.1073/pnas.84.23.8525; BROOMESMITH JK, 1986, GENE, V49, P341, DOI 10.1016/0378-1119(86)90370-7; BROOMESMITH JK, 1990, MOL MICROBIOL, V4, P1637, DOI 10.1111/j.1365-2958.1990.tb00540.x; CHANG XB, 1993, J BIOL CHEM, V268, P11304; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; EDELMAN A, 1987, MOL MICROBIOL, V1, P101, DOI 10.1111/j.1365-2958.1987.tb00533.x; EHRMANN M, 1990, P NATL ACAD SCI USA, V87, P7574, DOI 10.1073/pnas.87.19.7574; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; GREGORY RJ, 1991, MOL CELL BIOL, V11, P3886, DOI 10.1128/MCB.11.8.3886; HUDSON LD, 1989, J CELL BIOL, V109, P717, DOI 10.1083/jcb.109.2.717; HUGHES EN, 1981, J BIOL CHEM, V256, P664; KAHANE I, 1978, SCIENCE, V201, P351, DOI 10.1126/science.663661; KARTNER N, 1992, NAT GENET, V1, P321, DOI 10.1038/ng0892-321; KEELING P, 1983, J MEMBRANE BIOL, V74, P217, DOI 10.1007/BF02332125; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANDOLTMARTICOR.C, 1994, IN PRESS BIOCH J; LAURSEN RA, 1984, P NATL ACAD SCI-BIOL, V81, P2912, DOI 10.1073/pnas.81.9.2912; MANOIL C, 1986, SCIENCE, V233, P1403, DOI 10.1126/science.3529391; MANOIL C, 1985, P NATL ACAD SCI USA, V82, P8129, DOI 10.1073/pnas.82.23.8129; OLENDER EH, 1992, J BIOL CHEM, V267, P4223; PHILLIPS DR, 1980, THROMB HAEMOSTASIS, V42, P1638; RIORDAN JR, 1989, SCIENCE, V245, P1066; RIORDAN JR, 1993, ANNU REV PHYSIOL, V55, P609, DOI 10.1146/annurev.ph.55.030193.003141; SKATCH WR, 1993, J BIOL CHEM, V268, P6903; STOFFEL W, 1984, P NATL ACAD SCI-BIOL, V81, P5012, DOI 10.1073/pnas.81.16.5012; TABCHARANI JA, 1993, NATURE, V366, P79, DOI 10.1038/366079a0; Tsui Lap-Chee, 1992, Human Mutation, V1, P197, DOI 10.1002/humu.1380010304; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; ZHANG JT, 1993, J BIOL CHEM, V268, P15101	31	108	109	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18572	18575						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	7518437				2022-12-27	WOS:A1994NW79800054
J	LICHENSTEIN, HS; LYONS, DE; WURFEL, MM; JOHNSON, DA; MCGINLEY, MD; LEIDLI, JC; TROLLINGER, DB; MAYER, JP; WRIGHT, SD; ZUKOWSKI, MM				LICHENSTEIN, HS; LYONS, DE; WURFEL, MM; JOHNSON, DA; MCGINLEY, MD; LEIDLI, JC; TROLLINGER, DB; MAYER, JP; WRIGHT, SD; ZUKOWSKI, MM			AFAMIN IS A NEW MEMBER OF THE ALBUMIN, ALPHA-FETOPROTEIN, AND VITAMIN-D-BINDING PROTEIN GENE FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-SPECIFIC COMPONENT; HUMAN-SERUM-ALBUMIN; FULMINANT HEPATIC-NECROSIS; C5A DES ARG; FATTY-ACIDS; GC-GLOBULIN; ANTENATAL DIAGNOSIS; NUCLEOTIDE-SEQUENCE; MESSENGER-RNA; SPINA-BIFIDA	A novel human serum protein with a molecular mass of 87,000 daltons was purified to homogeneity and subjected to amino acid sequence analyses. These sequences were used to design oligonucleotide primers and to isolate a full-length cDNA. The amino acid sequence encoded by the cDNA shares strong similarity to albumin family members and shares the characteristic pattern of Cys residues observed in this family. In addition, the gene maps to chromosome 4 as do other members of the albumin gene family. Based upon these observations, we conclude that the 87,000-dalton protein, which we designate afamin (AFM), is the fourth member of the albumin family of proteins. Afamin cDNA was stably transfected into Chinese hamster ovary cells and recombinant protein (rAFM) was purified from conditioned medium. Both rAFM and AFM purified from human serum react with a polyclonal antibody that was raised against a synthetic peptide derived from the deduced amino acid sequence of AFM.	ROCKEFELLER UNIV,CELLULAR PHYSIOL & IMMUNOL LAB,NEW YORK,NY 10021	Rockefeller University	LICHENSTEIN, HS (corresponding author), AMGEN INC,THOUSAND OAKS,CA 91320, USA.							ALLAN LD, 1973, LANCET, V2, P522; ALPERT E, 1978, IMMUNOL COMMUN, V7, P163, DOI 10.3109/08820137809033882; Atherton E., 1990, SOLID PHASE PEPTIDE; AUER IO, 1977, CELL IMMUNOL, V30, P173, DOI 10.1016/0008-8749(77)90058-2; Ausubel FM., 2006, ENZYMATIC MANIPULATI; BELANGER L, 1973, PATHOL BIOL, V21, P449; BELANGER L, 1973, PATHOL BIOL, V21, P457; BERDE CB, 1979, J BIOL CHEM, V254, P2609; BOURDREL L, 1993, PROTEIN EXPRES PURIF, V4, P130, DOI 10.1006/prep.1993.1019; BROCK DJH, 1972, LANCET, V2, P197; BROWN JR, 1976, FED PROC, V35, P2141; CHAKRABORTY M, 1993, IMMUNOL INVEST, V22, P329, DOI 10.3109/08820139309063412; COOKE NE, 1985, J CLIN INVEST, V76, P2420, DOI 10.1172/JCI112256; DAIGER SP, 1975, P NATL ACAD SCI USA, V72, P2076, DOI 10.1073/pnas.72.6.2076; DUGAICZYK A, 1982, P NATL ACAD SCI-BIOL, V79, P71, DOI 10.1073/pnas.79.1.71; GIBBS PEM, 1987, BIOCHEMISTRY-US, V26, P1332, DOI 10.1021/bi00379a020; GOLDSCHMIDTCLERMONT PJ, 1988, GASTROENTEROLOGY, V94, P1454, DOI 10.1016/0016-5085(88)90686-5; GUTTERIDGE JMC, 1986, BIOCHIM BIOPHYS ACTA, V869, P119, DOI 10.1016/0167-4838(86)90286-4; HADDAD JG, 1992, BIOCHEMISTRY-US, V31, P7174, DOI 10.1021/bi00146a021; HARPER ME, 1983, AM J HUM GENET, V35, P565; HE XM, 1992, NATURE, V358, P209, DOI 10.1038/358209a0; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HOLT ME, 1984, BRIT J EXP PATHOL, V65, P231; KEW RR, 1988, J CLIN INVEST, V82, P364, DOI 10.1172/JCI113596; KOJ A, 1985, ACUTE PHASE RESPONSE, P45; KOZAK M, 1981, NUCLEIC ACIDS RES, V9, P5233, DOI 10.1093/nar/9.20.5233; LAWN RM, 1981, NUCLEIC ACIDS RES, V9, P6103, DOI 10.1093/nar/9.22.6103; LEE WM, 1989, CIRC SHOCK, V28, P249; MIKKELSEN M, 1977, HUM HERED, V27, P105, DOI 10.1159/000152857; MINGHETTI PP, 1986, J BIOL CHEM, V261, P6747; MORINAGA T, 1983, P NATL ACAD SCI-BIOL, V80, P4604, DOI 10.1073/pnas.80.15.4604; NATHAN C, 1993, J CELL BIOL, V122, P243, DOI 10.1083/jcb.122.1.243; PARMELEE DC, 1978, J BIOL CHEM, V253, P2114; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PEREZ HD, 1988, J CLIN INVEST, V82, P360, DOI 10.1172/JCI113595; PETERS T, 1985, ADV PROTEIN CHEM, V37, P161, DOI 10.1016/S0065-3233(08)60065-0; RUOSLAHTI E, 1974, TRANSPLANT REV-DENMA, V20, P38; SAKAI M, 1985, J BIOL CHEM, V260, P5055; SARKAR B, 1983, LIFE CHEM REPORTS, V1, P165; SHAW CF, 1979, INORG PERSPECT BIOL, V2, P287; TAMAOKI T, 1984, RECOMBINANT DNA CELL, P145; TURNER AM, 1992, BLOOD, V80, P374; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216; VANBAELEN H, 1980, J BIOL CHEM, V255, P2270; WALDMANN TA, 1972, LANCET, V2, P1112; WILLIAMS MH, 1988, BIOCHEM BIOPH RES CO, V153, P1019, DOI 10.1016/S0006-291X(88)81330-5; WITKE WF, 1993, GENOMICS, V16, P751, DOI 10.1006/geno.1993.1258; YACHNIN S, 1976, P NATL ACAD SCI USA, V73, P2857, DOI 10.1073/pnas.73.8.2857; YAMAMOTO N, 1991, P NATL ACAD SCI USA, V88, P8539, DOI 10.1073/pnas.88.19.8539; YANG F, 1985, P NATL ACAD SCI USA, V82, P7994, DOI 10.1073/pnas.82.23.7994; YOUNG WO, 1987, J LAB CLIN MED, V110, P83	51	116	143	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					18149	18154						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	7517938				2022-12-27	WOS:A1994NV42200060
J	BAUMANN, H; GEARING, D; ZIEGLER, SF				BAUMANN, H; GEARING, D; ZIEGLER, SF			SIGNALING BY THE CYTOPLASMIC DOMAIN OF HEMATOPOIETIN RECEPTORS INVOLVES 2 DISTINGUISHABLE MECHANISMS IN HEPATIC CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; GROWTH-HORMONE RECEPTOR; PLASMA-PROTEIN GENES; RAT ALPHA-1-ACID GLYCOPROTEIN; ACUTE-PHASE RESPONSE; ERYTHROPOIETIN RECEPTOR; CYTOKINE RECEPTORS; INTERLEUKIN-4 RECEPTOR; MOLECULAR-CLONING; TYROSINE KINASE	The receptor for granulocyte colony stimulating factor (G-CSFR) and chimeric receptors consisting of the extracellular domain of G-CSFR and the transmembrane and cytoplasmic domain of the leukemia inhibitory factor receptor, gp130, or c-mpl function as homodimeric complexes. These receptors mediate a similar stimulation of gene transcription via separate regulatory elements of acute phase plasma protein genes. To identify the receptor regions within the cytoplasmic domains necessary for transcriptional regulation, the receptors were transiently expressed in rat hepatoma cells. Each receptor form reconstituted G-CSF-induced expression of a chloramphenicol acetyltransferase gene construct containing the cytokine response element of the rat cu,acid glycoprotein gene. This regulation required the presence of two conserved sequence motifs (referred to as box 1 and box 2) in the cytoplasmic domains of each receptor. With the exception of G-CSFR-MPL chimera, the receptors also mediated a similarly high stimulation via the IL-6 response element of the rat beta-fibrinogen and hemopexin genes. Regulation of the IL-6 response element required, however, in addition to boxes 1 and 2, a third sequence motif (box 3). This motif is absent in the cytoplasmic domain of c-mpl, possibly explaining its inability to activate the IL-6 response element. When cells which express receptor forms with prominent box 3 function were treated with suramin, a ligand-independent gene stimulation via the IL-6 response element was observed. The suramin effect probably involves a receptor dimerization mediated by the extracellular G-CSFR domain and by the intracellular regions that include box 3.	IMMUNEX CORP,SEATTLE,WA 98101	Immunex Corporation	BAUMANN, H (corresponding author), ROSWELL PK CANC INST,DEPT MOLEC & CELLULAR BIOL,BUFFALO,NY 14263, USA.				NATIONAL CANCER INSTITUTE [R01CA026122] Funding Source: NIH RePORTER; NCI NIH HHS [CA26122] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BAUMANN H, 1993, J IMMUNOL, V151, P1456; BAUMANN H, 1992, J BIOL CHEM, V267, P19744; BAUMANN H, 1994, MOL CELL BIOL, V14, P138, DOI 10.1128/MCB.14.1.138; BAUMANN H, 1993, J BIOL CHEM, V268, P8414; BAUMANN H, 1990, J BIOL CHEM, V265, P22275; BAUMANN H, 1988, J BIOL CHEM, V263, P17390; BAUMANN H, 1989, ANN NY ACAD SCI, V557, P280; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; CAMPOS SP, 1993, J IMMUNOL, V151, P7128; CHENG J, 1990, NUCLEIC ACIDS RES, V18, P4261, DOI 10.1093/nar/18.14.4261; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLOSI P, 1993, J BIOL CHEM, V268, P12617; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; DANDREA AD, 1991, MOL CELL BIOL, V11, P1980, DOI 10.1128/MCB.11.4.1980; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; FUKUNAGA R, 1993, CELL, V74, P1079, DOI 10.1016/0092-8674(93)90729-A; GEARING DP, 1994, IN PRESS P NATL ACAD; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; HARADA N, 1992, J BIOL CHEM, V267, P22752; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATTORI M, 1990, P NATL ACAD SCI USA, V87, P2364, DOI 10.1073/pnas.87.6.2364; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LARSEN A, 1990, J EXP MED, V172, P1559, DOI 10.1084/jem.172.6.1559; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MIURA O, 1993, MOL CELL BIOL, V13, P1788, DOI 10.1128/MCB.13.3.1788; MIYAJIMA A, 1992, TRENDS BIOCHEM SCI, V17, P378, DOI 10.1016/0968-0004(92)90004-S; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; NAGAE Y, 1992, BIOCHEM BIOPH RES CO, V185, P420, DOI 10.1016/S0006-291X(05)81002-2; QUELLE DE, 1991, P NATL ACAD SCI USA, V88, P4801, DOI 10.1073/pnas.88.11.4801; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SADOWSKI HB, 1993, SCIENCE, V262, P1019; SKODA RC, 1993, EMBO J, V12, P2645, DOI 10.1002/j.1460-2075.1993.tb05925.x; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STRASSMANN G, 1993, J CLIN INVEST, V92, P2152, DOI 10.1172/JCI116816; VIGON I, 1993, ONCOGENE, V8, P2607; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; WON KA, 1990, MOL CELL BIOL, V10, P3965, DOI 10.1128/MCB.10.8.3965; WON KA, 1991, MOL CELL BIOL, V11, P3001, DOI 10.1128/MCB.11.6.3001; ZIEGLER SF, 1993, MOL CELL BIOL, V13, P2384, DOI 10.1128/MCB.13.4.2384	48	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16297	16304						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	7515879				2022-12-27	WOS:A1994NQ72900054
J	KLATT, P; SCHMID, M; LEOPOLD, E; SCHMIDT, K; WERNER, ER; MAYER, B				KLATT, P; SCHMID, M; LEOPOLD, E; SCHMIDT, K; WERNER, ER; MAYER, B			THE PTERIDINE BINDING-SITE OF BRAIN NITRIC-OXIDE SYNTHASE - TETRAHYDROBIOPTERIN BINDING-KINETICS, SPECIFICITY, AND ALLOSTERIC INTERACTION WITH THE SUBSTRATE DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AORTIC ENDOTHELIAL-CELLS; PORCINE CEREBELLUM; L-ARGININE; PURIFICATION; COFACTOR; REDUCTASE; FLAVIN; ENZYME; IDENTIFICATION; FLAVOPROTEIN	Nitric oxide (NO) synthases contain FAD, FMN, heme, and (6R)-5,6,7,8-tetrahydro-L-biopterin as prosthetic groups. We have characterized the pteridine-binding site of purified brain NO synthase, using H-3-labeled (6R)-5,6,7,8-tetrahydro-L-biopterin as radioligand. Asso ciation of [H-3]tetrahydrobiopterin followed second order kinetics (k(on) = 1.3 x 10(6) M(-1) min(-1)), the dissociation reaction was reversible and first-order (k(off) = 3.2 x 10(-1) min(-1)), yielding a kinetic K-D of 0.25 mu M. Binding of the radioligand was competitively antagonized by several pteridine derivatives with the following order of potency (K-I): 7,8-dihydro-L-biopterin (2.2 mu M), (6S)-5,6,7,8-tetrahydro- L-biopterin (19 mu M), (6R,S)-6-methyl-5,6,7,8-tetrahydropterin (240 mu M), and 6,7-dimethyl-5,6,7,8-tetrahydropterin (> 1 mM). The affinity of NO synthase for tetrahydrobiopterin was increased 6-fold in the pres ence of 0.1 mM L-argnine (K-D = 37 nM), and, conversely, tetrahydrobiopterin enhanced the affinity of the enzyme for H-3-labeled N-G-nitro-L-arginine about 2-fold. 7-Nitroindazole, which presumably binds to the heme group of NO synthase, competitively inhibited binding of [H-3]tetrahydrobiopterin and [H-3]N-G-nitro-L-arginine with similar K-I values (0.1 mu M). Functional as well as binding studies revealed that 7-nitroindazole was competitive with both L-arginine and tetrahydrobiopterin. Our data indicate that brain NO synthase exhibits a highly specific binding site for (6R)-5,6,7,8-tetrahydro-L-biopterin, which allosterically interacts with the substrate domain and may be located proximal to the prosthetic heme group of NO synthase.	GRAZ UNIV, INST PHARMAKOL & TOXICOL, A-8010 GRAZ, AUSTRIA; UNIV INNSBRUCK, INST MED CHEM & BIOCHEM, A-6020 INNSBRUCK, AUSTRIA	University of Graz; University of Innsbruck			Mayer, Bernd/B-9391-2008	Mayer, Bernd/0000-0002-2921-3494; Werner, Ernst R./0000-0003-1948-3391				ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; BABBEDGE RC, 1993, BRIT J PHARMACOL, V110, P225, DOI 10.1111/j.1476-5381.1993.tb13796.x; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; BAILEY SW, 1978, J BIOL CHEM, V253, P1598; BREDT DS, 1992, J BIOL CHEM, V267, P10976; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BRUNNER F, 1991, BRIT J PHARMACOL, V102, P373, DOI 10.1111/j.1476-5381.1991.tb12181.x; EVANS T, 1992, P NATL ACAD SCI USA, V89, P5361, DOI 10.1073/pnas.89.12.5361; GIOVANELLI J, 1991, P NATL ACAD SCI USA, V88, P7091, DOI 10.1073/pnas.88.16.7091; HEINZEL B, 1992, BIOCHEM J, V281, P627, DOI 10.1042/bj2810627; HEVEL JM, 1992, BIOCHEMISTRY-US, V31, P7160, DOI 10.1021/bi00146a019; HEVEL JM, 1991, J BIOL CHEM, V266, P22789; KATOH S, 1971, ARCH BIOCHEM BIOPHYS, V146, P202, DOI 10.1016/S0003-9861(71)80057-7; KATZENMEIER G, 1990, FEMS MICROBIOL LETT, V66, P231; KLATT P, 1994, J BIOL CHEM, V269, P1674; KLATT P, 1993, J BIOL CHEM, V268, P14781; KLATT P, 1992, BIOCHEM J, V288, P15, DOI 10.1042/bj2880015; KLATT P, 1992, J BIOL CHEM, V267, P11374; KWON NS, 1989, J BIOL CHEM, V264, P20496; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MAYER B, 1991, J CARDIOVASC PHARM, V17, pS46, DOI 10.1097/00005344-199117003-00009; MAYER B, 1990, FEBS LETT, V277, P215, DOI 10.1016/0014-5793(90)80848-D; MAYER B, 1991, FEBS LETT, V288, P187, DOI 10.1016/0014-5793(91)81031-3; MAYER B, 1993, SEMIN NEUROSCI, V5, P197, DOI 10.1016/S1044-5765(05)80053-3; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MCMILLAN K, 1993, BIOCHEMISTRY-US, V32, P9875, DOI 10.1021/bi00089a001; MICHEL AD, 1993, BRIT J PHARMACOL, V109, P287, DOI 10.1111/j.1476-5381.1993.tb13566.x; MOORE PK, 1993, BRIT J PHARMACOL, V108, P296, DOI 10.1111/j.1476-5381.1993.tb12798.x; MOORE PK, 1993, BRIT J PHARMACOL, V110, P219, DOI 10.1111/j.1476-5381.1993.tb13795.x; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NICHOL CA, 1985, ANNU REV BIOCHEM, V54, P729, DOI 10.1146/annurev.biochem.54.1.729; PARK YS, 1990, BIOCHIM BIOPHYS ACTA, V1038, P186, DOI 10.1016/0167-4838(90)90203-R; POLLOCK JS, 1991, P NATL ACAD SCI USA, V88, P10480, DOI 10.1073/pnas.88.23.10480; POU S, 1992, J BIOL CHEM, V267, P24173; PUFAHL RA, 1993, BIOCHEM BIOPH RES CO, V193, P963, DOI 10.1006/bbrc.1993.1719; SCHMIDT HHHW, 1992, BIOCHEMISTRY-US, V31, P3243, DOI 10.1021/bi00127a028; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; TAYEH MA, 1989, J BIOL CHEM, V264, P19654; WATANABE Y, 1993, CHEM BIOL PTERIDINES, P301; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001; WOLFF DJ, 1993, J BIOL CHEM, V268, P9425	43	218	219	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13861	13866						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	7514595				2022-12-27	WOS:A1994NL60600024
J	RAINA, S; PRESTON, GM; GUGGINO, WB; AGRE, P				RAINA, S; PRESTON, GM; GUGGINO, WB; AGRE, P			MOLECULAR-CLONING AND CHARACTERIZATION OF AN AQUAPORIN CDNA FROM SALIVARY, LACRIMAL, AND RESPIRATORY TISSUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHIP28 WATER CHANNEL; INTEGRAL MEMBRANE-PROTEIN; RAT-KIDNEY; LOCALIZATION; EXPRESSION; SEQUENCES; FAMILY; RECONSTITUTION; APPEARANCE; SECRETION	The Aquaporin family of water channels plays a fundamental role in transmembrane water movements in numerous plant and animal tissues. Since the molecular pathway by which water is secreted by salivary glands is unknown, a cDNA was isolated from rat submandibular gland by homology cloning. Similar to other Aquaporins, the salivary cDNA encodes a 265-residue polypeptide with six putative transmembrane domains separated by five connecting loops (A-E); the NH2- and COOH-terminal halves of the polypeptide are sequence-related, and each contains the motif Asn-Pro Ala. A mercurial-inhibition site is present in extracellular loop E, and cytoplasmic loop D contains a cAMP-protein kinase phosphorylation consensus. In vitro translation yielded a 27-kDa polypeptide, and expression of the cRNA in Xenopus oocytes conferred a 20- fold increase in osmotic water permeability (P-f) which was reversibly inhibited by 1 mM HgCl2. Northern analysis demonstrated a 1.6-kilobase mRNA in submandibular, parotid, and sublingual salivary glands, lacrimal gland, eye, trachea, and lung. In situ hybridization revealed a strong hybridization over the corneal epithelium in eye and over the secretory lobules in salivary glands. These studies have identified a new mammalian member of the Aquaporin water channel family (gene symbol AQP5) which is implicated in the generation of saliva, tears, and pulmonary secretions.	JOHNS HOPKINS UNIV, SCH MED, DEPT BIOL CHEM, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT MED, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PHYSIOL, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University			wei, chi/H-5730-2011		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048268, R01HL033991, R37HL048268] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK032753, R01DK032753] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL33991, HL48268] Funding Source: Medline; NIDDK NIH HHS [DK32753] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGRE P, 1994, J CLIN INVEST, V94, P1050, DOI 10.1172/JCI117419; AGRE P, 1993, AM J PHYSIOL, V265, pF463; AGRE P, 1993, AM J PHYSIOL, V265, pF461, DOI 10.1152/ajprenal.1993.265.3.F461; BAUM BJ, 1987, J DENT RES, V66, P628, DOI 10.1177/00220345870660S204; BHAT RV, 1994, J NEUROSCI, V14, P3059; BONDY C, 1993, P NATL ACAD SCI USA, V90, P450; BROWN D, 1993, EUR J CELL BIOL, V61, P264; CANDIA OA, 1995, IN PRESS J MEMBR BIO; CHRISPEELS MJ, 1994, TRENDS BIOCHEM SCI, V19, P421, DOI 10.1016/0968-0004(94)90091-4; DEEN PMT, 1994, SCIENCE, V264, P92, DOI 10.1126/science.8140421; DENKER BM, 1988, J BIOL CHEM, V263, P15634; DIGIOVANNI SR, 1994, P NATL ACAD SCI USA, V91, P8984, DOI 10.1073/pnas.91.19.8984; ECHEVARRIA M, 1993, J GEN PHYSIOL, V101, P827, DOI 10.1085/jgp.101.6.827; ECHEVARRIA M, 1993, AM J PHYSIOL, V265, pC1349, DOI 10.1152/ajpcell.1993.265.5.C1349; FENG DF, 1990, METHOD ENZYMOL, V183, P375; FOLKESSON HG, 1994, P NATL ACAD SCI USA, V91, P4970, DOI 10.1073/pnas.91.11.4970; FOX RI, 1994, ARTHRITIS RHEUM, V37, P771, DOI 10.1002/art.1780370523; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; GIRARD LR, 1993, J BIOL CHEM, V268, P26592; GORIN MB, 1984, CELL, V39, P49, DOI 10.1016/0092-8674(84)90190-9; GREINER JV, 1994, PRINCIPLES PRACTICE, pCH52; HASEGAWA H, 1994, J BIOL CHEM, V269, P5497; HELENIUS A, 1975, BIOCHIM BIOPHYS ACTA, V415, P29, DOI 10.1016/0304-4157(75)90016-7; ISHIBASHI K, 1994, P NATL ACAD SCI USA, V91, P6269, DOI 10.1073/pnas.91.14.6269; JUNG JS, 1994, J BIOL CHEM, V269, P14648; JUNG JS, 1994, P NATL ACAD SCI USA, V91, P13052, DOI 10.1073/pnas.91.26.13052; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KNEPPER MA, 1994, P NATL ACAD SCI USA, V91, P6255, DOI 10.1073/pnas.91.14.6255; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LI J, 1994, PFLUG ARCH EUR J PHY, V428, P455, DOI 10.1007/BF00374565; MCFADDEN ER, 1994, NEW ENGL J MED, V330, P1362, DOI 10.1056/NEJM199405123301907; MOON C, 1993, J BIOL CHEM, V268, P15772; NAUNTOFTE B, 1992, AM J PHYSIOL, V263, pG823, DOI 10.1152/ajpgi.1992.263.6.G823; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P7275, DOI 10.1073/pnas.90.15.7275; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P11663, DOI 10.1073/pnas.90.24.11663; NIELSEN S, 1993, J CELL BIOL, V120, P371, DOI 10.1083/jcb.120.2.371; NIELSEN S, 1995, IN PRESS KIDNEY INT; Preston G M, 1993, Methods Mol Biol, V15, P317, DOI 10.1385/0-89603-244-2:317; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1994, J BIOL CHEM, V269, P1668; PRESTON GM, 1994, SCIENCE, V265, P1585, DOI 10.1126/science.7521540; PRESTON GM, 1993, J BIOL CHEM, V268, P17; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; REIZER J, 1993, CRIT REV BIOCHEM MOL, V28, P235, DOI 10.3109/10409239309086796; ROBERTS SK, 1994, P NATL ACAD SCI USA, V91, P13009, DOI 10.1073/pnas.91.26.13009; SABOLIC I, 1992, AM J PHYSIOL, V263, pC1225, DOI 10.1152/ajpcell.1992.263.6.C1225; SASAKI S, 1994, J CLIN INVEST, V93, P1250, DOI 10.1172/JCI117079; SMITH BL, 1993, J CLIN INVEST, V92, P2035, DOI 10.1172/JCI116798; SMITH BL, 1991, J BIOL CHEM, V266, P6407; VANHOEK AN, 1992, J BIOL CHEM, V267, P18267; VOKES EE, 1993, NEW ENGL J MED, V328, P184, DOI 10.1056/NEJM199301213280306; ZEIDEL ML, 1992, BIOCHEMISTRY-US, V31, P7436, DOI 10.1021/bi00148a002; ZHANG RB, 1993, J CELL BIOL, V120, P359, DOI 10.1083/jcb.120.2.359	54	354	372	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	1995	270	4					1908	1912		10.1074/jbc.270.4.1908	http://dx.doi.org/10.1074/jbc.270.4.1908			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QD204	7530250	hybrid			2022-12-27	WOS:A1995QD20400064
J	ALNEMRI, ES; FERNANDESALNEMRI, T; POMERENKE, K; ROBERTSON, NM; DUDLEY, K; DUBOIS, GC; LITWACK, G				ALNEMRI, ES; FERNANDESALNEMRI, T; POMERENKE, K; ROBERTSON, NM; DUDLEY, K; DUBOIS, GC; LITWACK, G			FKBP46, A NOVEL SF9 INSECT-CELL NUCLEAR IMMUNOPHILIN THAT FORMS A PROTEIN-KINASE COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIS-TRANS ISOMERASE; HUMAN FK506-BINDING PROTEIN; CYCLOSPORINE-A; SIGNAL TRANSDUCTION; BINDING-PROTEIN; CYCLOPHILIN; RAPAMYCIN; SEQUENCE; FK-506; OVEREXPRESSION	Recently, we identified a 59-kDa nuclear phosphoprotein that is associated with a recombinant mouse FKBP-52 (Alnemri, E. S., Fernandes-Alnemri, T., Nelki, D. S., Dudley, K., DuBois, G. C., and Litwack, G. (1993) Proc. Natl. Acad. Sci. U.S.A. 90, 6839-6843). Here we describe the cloning, overexpression, and characterization of this protein from Spodoptera frugiperda insect cells (Sf9 cells). The cloned cDNA codes for an acidic protein of 412 amino acids with distinct structural domains. Starting with the N terminus, the first 218 amino acids contain two highly acidic domains separated by a short basic domain. Following the second large acidic domain is another basic domain of 87 amino acids with significant sequence and structural homology to HMG1 and HMG2 DNA binding proteins. The two basic domains contain several nuclear targeting signals. The last 108 C-terminal amino acids contain a binding domain for immunosuppressive drugs FK506 and rapamycin, which makes this protein a new member of the immunophilin family. We provide evidence that the new immunophilin (FKBP46) is a DNA binding protein that can bind immunosuppressive drug FK506 and possesses peptidylprolyl isomerase activity. FKBP46 is localized in the nucleus and is associated with a nuclear kinase that specifically phosphorylates it in the presence of Mg2+ and ATP. Upon subsequent sequence analysis of the mouse FKBP52 cDNA used in our previous study, it was observed that a spermatid nuclear transition protein 2 (TP2) sequence is fused in frame with the C terminus of the recombinant FKBP52 probably as a result of a cloning artifact. We demonstrate that the FKBP46 does not form a complex with the FKBP52 but rather with the highly basic nuclear protein TP2. Our data suggest that interaction of FKBP46 with TP2 is mediated by the N-terminal acidic domains of FKBP46. This implies that the acidic domains of FKBP46 are involved in protein-protein interaction between nuclear FKBP46 and other basic chromatin proteins.	THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT PHARMACOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19107; UNIV LONDON KINGS COLL,DIV BIOMOLEC SCI,LONDON WC2B 5RL,ENGLAND	Jefferson University; Jefferson University; University of London; King's College London					NIAID NIH HHS [AI 35035-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035035] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALNEMRI ES, 1993, P NATL ACAD SCI USA, V90, P6839, DOI 10.1073/pnas.90.14.6839; ALNEMRI ES, 1993, BIOCHEMISTRY-US, V32, P5387, DOI 10.1021/bi00071a014; ALNEMRI ES, 1992, P NATL ACAD SCI USA, V89, P7295, DOI 10.1073/pnas.89.16.7295; ALNEMRI ES, 1991, J BIOL CHEM, V266, P3925; BASKARAN R, 1991, BIOCHEM BIOPH RES CO, V179, P1491, DOI 10.1016/0006-291X(91)91741-T; COLE KD, 1987, BIOCHEM BIOPH RES CO, V147, P437, DOI 10.1016/S0006-291X(87)80140-7; GALAT A, 1992, BIOCHEMISTRY-US, V31, P2427, DOI 10.1021/bi00123a031; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HARRISON RK, 1990, BIOCHEMISTRY-US, V29, P3813, DOI 10.1021/bi00468a001; HEITMAN J, 1992, NEW BIOL, V4, P448; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; JIN YJ, 1993, P NATL ACAD SCI USA, V90, P7769, DOI 10.1073/pnas.90.16.7769; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KOLTIN Y, 1991, MOL CELL BIOL, V11, P1718, DOI 10.1128/MCB.11.3.1718; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; MAKI N, 1990, P NATL ACAD SCI USA, V87, P5440, DOI 10.1073/pnas.87.14.5440; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; PARK ST, 1992, J BIOL CHEM, V267, P3316; PEATTIE DA, 1992, P NATL ACAD SCI USA, V89, P10974, DOI 10.1073/pnas.89.22.10974; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SCHREIBER SL, 1992, CELL, V70, P365, DOI 10.1016/0092-8674(92)90158-9; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SHIRAKAWA H, 1990, BIOCHEMISTRY-US, V29, P4419, DOI 10.1021/bi00470a022; SIEKIERKA JJ, 1990, J BIOL CHEM, V265, P21011; SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511; STAMNES MA, 1991, CELL, V65, P219, DOI 10.1016/0092-8674(91)90156-S; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555; TAI PKK, 1993, BIOCHEMISTRY-US, V32, P8842, DOI 10.1021/bi00085a015; TAI PKK, 1992, SCIENCE, V256, P1315, DOI 10.1126/science.1376003; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302	34	41	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					30828	30834						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7527037				2022-12-27	WOS:A1994PV51000018
J	BUDDE, P; BEWARDER, N; WEINRICH, V; SCHULZECK, O; FREY, J				BUDDE, P; BEWARDER, N; WEINRICH, V; SCHULZECK, O; FREY, J			TYROSINE-CONTAINING SEQUENCE MOTIFS OF THE HUMAN-IMMUNOGLOBULIN-G RECEPTORS FCRIIB1 AND FCRIIB2 ESSENTIAL FOR ENDOCYTOSIS AND REGULATION OF CALCIUM FLUX IN B-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FC-GAMMA RECEPTOR; CROSS-LINKING; LYMPHOCYTES-B; HUMAN-IGG; PHOSPHORYLATION; ANTIGEN; ACTIVATION; EXPRESSION; PROLIFERATION; HETEROGENEITY	Human B cells express two closely related immunoglobulin G receptors, FcRIIb1 and FcRIIb2, which differ by a 19 amino acid insertion in the cytoplasmic tail of FcRIIb1. The cytoplasmic tails of both isoforms contain a conserved sequence motif (AENTITYSLL) essential for mediating endocytosis via FcRIIb2. Truncation of this motif abolished endocytosis, while replacement of tyrosine (Tyr-(273)) in FcRIIba by phenylalanine had no effect on the amount and kinetics of ligand uptake. Co-crosslinking of FcRIIb1 or FcRIIb2 with the antigen receptor on B cells led to an abortive calcium signal. Neither isoform interfered with the early intracellular calcium mobilization, but both prevented the opening of a plasma membrane calcium channel essential for a sustained elevated intracellular calcium level. Modulation of calcium channel activity is mediated by the same sequence motif essential for endocytosis but requires the pres- ence of Tyr(292) in FcRIIb1 and Tyr(273) in, FcRIIb2. Co-crosslinking of FcRIIb1 with surface IgG is associated with tyrosine phosphorylation of Tyr(292), whereas Tyr(272) in FcRIIb2 was not phosphorylated. Thus, FcRIIb phosphorylation is probably not directly involved in the modulation of the calcium signal but may be essential for further diversification of signals transduced via the coexpressed isoforms FcRIIb1 and FcRIIb2.	UNIV BIELEFELD,FAK CHEM,D-33615 BIELEFELD,GERMANY	University of Bielefeld								AMIGORENA S, 1992, SCIENCE, V256, P1808, DOI 10.1126/science.1535455; ARTELT P, 1988, GENE, V68, P213, DOI 10.1016/0378-1119(88)90023-6; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BUDDE P, 1994, EUR J CELL BIOL, V64, P45; CAMBIER JC, 1994, CURR OPIN GENET DEV, V4, P55, DOI 10.1016/0959-437X(94)90091-4; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P2745, DOI 10.1073/pnas.88.7.2745; CASSEL DL, 1993, MOL IMMUNOL, V30, P451, DOI 10.1016/0161-5890(93)90113-P; CHOQUET D, 1993, J CELL BIOL, V121, P355, DOI 10.1083/jcb.121.2.355; CHOQUET D, 1994, J BIOL CHEM, V269, P6491; ENENKEL B, 1991, EUR J IMMUNOL, V21, P659, DOI 10.1002/eji.1830210318; ENGELHARDT W, 1991, EUR J IMMUNOL, V21, P2227, DOI 10.1002/eji.1830210934; ENGELHARDT W, 1990, EUR J IMMUNOL, V20, P1367, DOI 10.1002/eji.1830200624; FRIDMAN WH, 1992, IMMUNOL REV, V125, P49, DOI 10.1111/j.1600-065X.1992.tb00625.x; GOLD MR, 1991, P NATL ACAD SCI USA, V88, P3436, DOI 10.1073/pnas.88.8.3436; GREENMAN J, 1991, MOL IMMUNOL, V28, P1243, DOI 10.1016/0161-5890(91)90011-8; HONING S, 1991, EUR J CELL BIOL, V55, P48; HUNZIKER W, 1990, NATURE, V345, P628, DOI 10.1038/345628a0; JENKINS MK, 1990, J IMMUNOL, V144, P1585; JONES B, 1986, J IMMUNOL, V136, P348; KEIJ JF, 1989, CYTOMETRY, V10, P814, DOI 10.1002/cyto.990100623; KLAUS GGB, 1985, IMMUNOLOGY, V56, P321; KOLANUS W, 1992, EMBO J, V11, P4861, DOI 10.1002/j.1460-2075.1992.tb05592.x; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE PJL, 1991, J IMMUNOL, V146, P715; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LIU Y, 1992, P NATL ACAD SCI USA, V89, P3845, DOI 10.1073/pnas.89.9.3845; MIETTINEN HM, 1992, J CELL BIOL, V116, P875, DOI 10.1083/jcb.116.4.875; MUTA T, 1994, NATURE, V368, P70, DOI 10.1038/368070a0; PHILLIPS NE, 1984, J IMMUNOL, V132, P627; PULFORD K, 1986, IMMUNOLOGY, V57, P71; RIJKERS GT, 1990, CYTOMETRY, V11, P923, DOI 10.1002/cyto.990110813; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARMAY G, 1990, INT IMMUNOL, V2, P1235, DOI 10.1093/intimm/2.12.1235; SARMAY G, 1994, P NATL ACAD SCI USA, V91, P4140, DOI 10.1073/pnas.91.10.4140; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; VANDENHERIKOUDIJK IE, 1994, J IMMUNOL, V152, P574; VANDEWINKEL JGJ, 1993, IMMUNOL TODAY, V14, P215, DOI 10.1016/0167-5699(93)90166-I; VARIN N, 1989, EUR J IMMUNOL, V19, P2263, DOI 10.1002/eji.1830191213; WARMERDAM PAM, 1991, J IMMUNOL, V147, P13338	40	46	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30636	30644						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7527034				2022-12-27	WOS:A1994PU52500091
J	GARCIA, P; SHOELSON, SE; DREW, JS; MILLER, WT				GARCIA, P; SHOELSON, SE; DREW, JS; MILLER, WT			PHOSPHOPEPTIDE OCCUPANCY AND PHOTOAFFINITY CROSS-LINKING OF THE V-SRC SH2 DOMAIN ATTENUATES TYROSINE KINASE-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; PHOSPHORYLATED PEPTIDES; BINDING-SITE; PI 3-KINASE; PP60C-SRC; ACTIVATION; VIRUS; PHOSPHOTYROSINE; GENE; ASSOCIATION	Phosphorylation of c-Src at carboxyl-terminal Tyr-527 suppresses tyrosine kinase activity and transforming potential, presumably by facilitating the intramolecular interaction of the C terminus of Src with its SH2 domain. In addition, it has been shown previously that occupancy of the c-Src SH2 domain with a phosphopeptide stimulates c-Src kinase catalytic activity. We have performed analogous studies with v-Src, the transforming protein from Rous sarcoma virus, which has extensive homology with c-Src. v-Src lacks an autoregulatory phosphorylation site, and its kinase domain is constitutively active. Phosphopeptides corresponding to the sequences surrounding c-Src Tyr-527 and a Tyr-Glu-Glu-Ile motif from the hamster polyoma virus middle T antigen inhibit tyrosine kinase activity of baculovirus-expressed v-Src 2- and 4-fold, respectively. To determine the mechanism of this regulation, the Tyr-527 phosphopeptide was substituted with the photoactive amino acid p-benzoylphenylalanine at the adjacent positions (N- and C-terminal) to phosphotyrosine. These peptides photoinactivate the v-Src tyrosine kinase 5-fold in a time and concentration-dependent manner. Furthermore, the peptides cross-link an isolated Src SH2 domain with similar rates and specificity. These data indicate that occupancy of the v-Src SH2 domain induces a conformational change that is transmitted to the kinase domain and attenuates tyrosine kinase activity.	SUNY STONY BROOK, SCH MED, DEPT PHYSIOL & BIOPHYS, STONY BROOK, NY 11794 USA; BRIGHAM & WOMENS HOSP, DEPT MED, JOSLIN DIABET CTR, DIV RES, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02215 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Harvard University; Brigham & Women's Hospital; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School					NCI NIH HHS [CA5853001] Funding Source: Medline; NIDDK NIH HHS [T32DK07521] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058530, R29CA058530] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007521] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUGER KR, 1992, J BIOL CHEM, V267, P5408; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BRUGGE JS, 1993, SCIENCE, V260, P918, DOI 10.1126/science.8388123; BURKE TR, 1994, BIOCHEMISTRY-US, V33, P6490, DOI 10.1021/bi00187a015; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CASE RD, 1994, J BIOL CHEM, V269, P10467; CASNELLIE JE, 1991, METHOD ENZYMOL, V200, P115; COLLETT MS, 1979, P NATL ACAD SCI USA, V76, P3159, DOI 10.1073/pnas.76.7.3159; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; DOMCHEK SM, 1992, BIOCHEMISTRY-US, V31, P9865, DOI 10.1021/bi00156a002; ECK MJ, 1994, NATURE, V368, P764, DOI 10.1038/368764a0; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FELDER S, 1993, MOL CELL BIOL, V13, P1449, DOI 10.1128/MCB.13.3.1449; GARCIA P, 1993, J BIOL CHEM, V268, P25146; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KAUER JC, 1986, J BIOL CHEM, V261, P695; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOCH CA, 1989, MOL CELL BIOL, V9, P4131, DOI 10.1128/MCB.9.10.4131; LAUDANO AP, 1986, P NATL ACAD SCI USA, V83, P892, DOI 10.1073/pnas.83.4.892; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LIU XQ, 1993, ONCOGENE, V8, P1119; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MILLER WT, 1991, METHOD ENZYMOL, V200, P500; MILLER WT, 1988, P NATL ACAD SCI USA, V85, P5429, DOI 10.1073/pnas.85.15.5429; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MURPHY SM, 1993, MOL CELL BIOL, V13, P5290, DOI 10.1128/MCB.13.9.5290; OKADA M, 1993, J BIOL CHEM, V268, P18070; OPPERMANN H, 1979, P NATL ACAD SCI USA, V76, P1804, DOI 10.1073/pnas.76.4.1804; PANAYOTOU G, 1992, EMBO J, V11, P4261, DOI 10.1002/j.1460-2075.1992.tb05524.x; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAYNE G, 1993, P NATL ACAD SCI USA, V90, P4902, DOI 10.1073/pnas.90.11.4902; PICCIONE E, 1993, BIOCHEMISTRY-US, V32, P3197, DOI 10.1021/bi00064a001; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; SHOELSON SE, 1993, EMBO J, V12, P795, DOI 10.1002/j.1460-2075.1993.tb05714.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; VERON M, 1993, P NATL ACAD SCI USA, V90, P10618, DOI 10.1073/pnas.90.22.10618; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WILLIAMS KP, 1993, J BIOL CHEM, V268, P5361; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	51	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30574	30579						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7527032				2022-12-27	WOS:A1994PU52500082
J	KERN, A; BRIESEWITZ, R; BANK, I; MARCANTONIO, EE				KERN, A; BRIESEWITZ, R; BANK, I; MARCANTONIO, EE			THE ROLE OF THE I-DOMAIN IN LIGAND-BINDING OF THE HUMAN INTEGRIN-ALPHA(1)BETA(1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VONWILLEBRAND-FACTOR; CYTOPLASMIC DOMAIN; RECOGNITION SITE; CELL ATTACHMENT; ADHESION; COLLAGEN; RECEPTOR; SUBUNIT; FIBRONECTIN; MUTATION	We report here the analysis of potential ligand binding domains within the human integrin alpha(1) subunit, a known collagen/laminin receptor. This integrin is effectively blocked by the mouse monoclonal antibody 1B3.1. A truncated version of the alpha 1 subunit lacking the NH2-terminal half of the extracellular domain is not recognized by monoclonal antibody 1B3.1. Furthermore, we have isolated a cDNA containing the I domain from chicken alpha(1) bearing significant homology to the human and rat alpha(1) sequences. Replacing the human I domain with its chicken counterpart led to the surface expression of a functional heterodimer with endogenous mouse beta(1) on NIH 3T3 cells. However, 1B3.1 does mot bind to the chicken/human chimera, demonstrating that the human alpha(1) I domain is required for epitope recognition. Mutation of Asp(253) within the I domain to alanine resulted in surface expression of an alpha beta heterodimer recognized by 1B3.1 but with markedly reduced binding to collagen TV or laminin. Since a previously reported mutation of a homologous Asp in the Mac-1 I domain has similar consequences, these results suggest a central role for the I domain in ligand recognition for all integrin alpha subunits containing this domain.	COLUMBIA UNIV,COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032; COLUMBIA UNIV,COLL PHYS & SURG,DEPT ANAT & CELL BIOL,NEW YORK,NY 10032; CHAIM SHEBA MED CTR,DEPT MED,IL-52621 TEL HASHOMER,ISRAEL	Columbia University; Columbia University; Chaim Sheba Medical Center			Bank, I./I-7153-2012		NIGMS NIH HHS [GM44585] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044585] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUMAILLEY M, 1989, EXP CELL RES, V181, P463, DOI 10.1016/0014-4827(89)90103-1; Ausubel FM, 1988, MOL REPROD DEV; BANK I, 1989, CELL IMMUNOL, V122, P416, DOI 10.1016/0008-8749(89)90088-9; BRIESEWITZ R, 1993, J BIOL CHEM, V268, P2989; BRIESEWITZ R, 1993, MOL BIOL CELL, V4, P593, DOI 10.1091/mbc.4.6.593; BUSK M, 1992, J BIOL CHEM, V267, P5790; CHAN BMC, 1993, J CELL BIOL, V120, P537, DOI 10.1083/jcb.120.2.537; CHARO IF, 1991, J BIOL CHEM, V266, P1415; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORBI AL, 1988, J BIOL CHEM, V263, P12403; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; DSOUZA SE, 1991, NATURE, V350, P66, DOI 10.1038/350066a0; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; Ginsberg Mark H., 1992, Current Opinion in Cell Biology, V4, P766, DOI 10.1016/0955-0674(92)90099-X; GRZESIAK JJ, 1992, J CELL BIOL, V117, P1109, DOI 10.1083/jcb.117.5.1109; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HALL DE, 1990, J CELL BIOL, V110, P2175, DOI 10.1083/jcb.110.6.2175; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; HYNES RO, 1973, P NATL ACAD SCI USA, V70, P3170, DOI 10.1073/pnas.70.11.3170; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IGNATIUS MJ, 1990, J CELL BIOL, V111, P709, DOI 10.1083/jcb.111.2.709; KAMATA T, 1994, J BIOL CHEM, V269, P9659; KERN A, 1993, EUR J BIOCHEM, V215, P151, DOI 10.1111/j.1432-1033.1993.tb18017.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDIS RC, 1993, J CELL BIOL, V120, P1519, DOI 10.1083/jcb.120.6.1519; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; MARCANTONIO EE, 1988, J CELL BIOL, V106, P1765, DOI 10.1083/jcb.106.5.1765; MASUMOTO A, 1993, J CELL BIOL, V123, P245, DOI 10.1083/jcb.123.1.245; MASUMOTO A, 1993, J BIOL CHEM, V268, P228; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; PYTELA R, 1988, EMBO J, V7, P1371, DOI 10.1002/j.1460-2075.1988.tb02953.x; ROTHLEIN R, 1986, J EXP MED, V163, P1132, DOI 10.1084/jem.163.5.1132; SHIH DT, 1993, J CELL BIOL, V122, P1361, DOI 10.1083/jcb.122.6.1361; SMITH JW, 1988, J BIOL CHEM, V263, P18726; SMITH JW, 1991, J BIOL CHEM, V266, P11429; SOLOWSKA J, 1989, J CELL BIOL, V109, P853, DOI 10.1083/jcb.109.2.853; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; TAKADA Y, 1992, J CELL BIOL, V119, P913, DOI 10.1083/jcb.119.4.913; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; VANDENBERG P, 1991, J CELL BIOL, V113, P1475, DOI 10.1083/jcb.113.6.1475; VOGEL BE, 1990, J BIOL CHEM, V265, P5934	42	118	128	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 9	1994	269	36					22811	22816						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ163	7521332				2022-12-27	WOS:A1994PQ16300054
J	KEW, Y; SONG, QB; PRASAD, VR				KEW, Y; SONG, QB; PRASAD, VR			SUBUNIT-SELECTIVE MUTAGENESIS OF GLU-89 RESIDUE IN HUMAN-IMMUNODEFICIENCY-VIRUS REVERSE-TRANSCRIPTASE - CONTRIBUTION OF P66 AND P51 SUBUNITS TO NUCLEOSIDE ANALOG SENSITIVITY, DIVALENT-CATION PREFERENCE, AND STEADY-STATE KINETIC-PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; ZIDOVUDINE AZT; HIV-1; RESISTANCE	The E89G alteration in the human immunodeficiency virus type 1 reverse transcriptase has been shown to confer resistance to nucleoside analogs and a loss of magnesium cation preference (Prasad, V. R., Lowy, I., De Los Santos, T., Chiang, L., and Goff, S. P. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 11363-11367. The wild type reverse transcriptase heterodimer, chimeric reverse transcriptases that contain the E89G alteration in one of the subunits (p66(wt)/p51(m) and p66(m)/p51(wt)), and the mutant enzyme (p66(m)/p51(m)) were prepared. Analysis of steady state kinetic parameters showed that the mutant enzyme (p66(m)/p5l(m)) displayed a higher V-max a higher K-m for 2'-deoxythymidine triphosphate, and a higher K-i for 2',3'-dideoxythymidine triphosphate than the wild type enzyme. The increased K-m and K-i values were observed only when a heterodimer contained the alteration in the p66 subunit. Tests for divalent cation requirement showed that only the dimers containing the wild type p66 (p66(wt)/p51(wt) and p66(wt)/p51(m)) displayed a preference for magnesium. Our results indicate that p66 plays a dominant role in deoxynucleotide triphosphate substrate recognition (K-m), nucleoside analog sensitivity (K-i), and magnesium preference. However, the increased V-max displayed by the mutant enzyme (p66(m)/p51(m)) appeared to be determined by both of the subunits.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MICROBIOL & IMMUNOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine			Prasad, Vinayaka R./A-1029-2011	Prasad, Vinayaka/0000-0002-9461-0189	NIAID NIH HHS [AI-30861] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI030861, R37AI030861, R01AI030861] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARGOS P, 1988, NUCLEIC ACIDS RES, V16, P9908; Cleland W W, 1979, Methods Enzymol, V63, P103; HOSTOMSKY Z, 1992, J VIROL, V66, P3197; HOWARD KJ, 1991, J BIOL CHEM, V266, P23003; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LARDER BA, 1987, NATURE, V327, P716, DOI 10.1038/327716a0; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; LEGRICE SFJ, 1991, EMBO J, V10, P3905, DOI 10.1002/j.1460-2075.1991.tb04960.x; LEGRICE SFJ, 1990, EUR J BIOCHEM, V187, P307, DOI 10.1111/j.1432-1033.1990.tb15306.x; MAJUMDAR C, 1988, J BIOL CHEM, V263, P15657; POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x; PRASAD VR, 1991, P NATL ACAD SCI USA, V88, P11363, DOI 10.1073/pnas.88.24.11363; RICHMAN DD, 1990, J ACQ IMMUN DEF SYND, V3, P743; SCHATZ O, 1990, EMBO J, V9, P1171, DOI 10.1002/j.1460-2075.1990.tb08224.x; SONG QG, 1992, J VIROL, V66, P7568, DOI 10.1128/JVI.66.12.7568-7571.1992; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; TANESE N, 1988, DNA-J MOLEC CELL BIO, V7, P407, DOI 10.1089/dna.1.1988.7.407; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x	20	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15331	15336						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	7515055				2022-12-27	WOS:A1994NP73800071
J	MALHERBE, P; KOHLER, C; DAPRADA, M; LANG, G; KIEFER, V; SCHWARCZ, R; LAHM, HW; CESURA, AM				MALHERBE, P; KOHLER, C; DAPRADA, M; LANG, G; KIEFER, V; SCHWARCZ, R; LAHM, HW; CESURA, AM			MOLECULAR-CLONING AND FUNCTIONAL EXPRESSION OF HUMAN 3-HYDROXYANTHRANILIC-ACID DIOXYGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUINOLINIC ACID; RAT-BRAIN; KYNURENIC ACID; INDOLEAMINE 2,3-DIOXYGENASE; TRYPTOPHAN DEGRADATION; OXYGENASE ACTIVITY; DISEASE; LOCALIZATION; PROTEINS; INVITRO	Increased cerebral levels of the endogenous excitotoxin quinolinic acid (QUIN) have been speculatively linked to neuronal damage following neurological and inflammatory disorders. 3-Hydroxyanthranilic-acid dioxygenase (3-HAO; 3-hydroxyanthranilate 3,4-dioxygenase, EC 1.13.11.6) is the enzyme that catalyzes the synthesis of QUIN from 3-hydroxyanthranilic acid, and evidence suggests that it could play a role in disorders associated with altered tissue levels of QUIN. In this report, we describe the isolation of a full-length cDNA clone encoding human 3-HAO (h3-HAO). Degenerate oligonucleotides were designed from the amino acid se quences of tryptic peptides of rat liver 3-HAO, and they were used as primers for reverse transcription-polymerase chain reaction of rat liver RNA. The resulting rat cDNA product was used to screen a human hepatoma cell line (HepG(2)) cDNA library and to isolate a human 3-HAO cDNA clone. This clone was found to have an insert of 1276 nucleotides. The deduced primary structure of h3-HAO is composed of 286 amino acid residues with a predicted molecular mass of similar to 32.6 kDa. The human sequence exhibits high similarity (94%) to the rat partial amino acid sequence deduced from the rat reverse transcription-polymerase chain reaction fragment. Insertion of the h3-HAO coding sequence into a eukaryotic expression vector yielded relatively high amounts of the active enzyme in human embryonic kidney HEK-293 cells. The K-m value of 3-HANA for recombinant h3-HAO (similar to 2 mu M) was in good agreement with that reported for the native enzyme. Immunoblot analysis of recombinant h3-HAO revealed a polypeptide with an apparent molecular mass of 32 kDa, as predicted from the deduced amino acid sequence. RNA blot analysis of human liver and HepG(2) cells revealed one major species of h3-HAO mRNA of similar to 1.3 kilobases.	F HOFFMANN LA ROCHE & CO LTD,DIV PHARMA,PRECLIN RES,NERVOUS SYST,CH-4002 BASEL,SWITZERLAND; F HOFFMANN LA ROCHE & CO LTD,NEW TECHNOL,CH-4002 BASEL,SWITZERLAND; UNIV MARYLAND,SCH MED,MARYLAND PSYCHIAT RES CTR,CATONSVILLE,MD 21228	Roche Holding; Roche Holding								BAUW G, 1989, P NATL ACAD SCI USA, V86, P7701, DOI 10.1073/pnas.86.20.7701; BEAL MF, 1990, J NEUROCHEM, V55, P1327, DOI 10.1111/j.1471-4159.1990.tb03143.x; BERTOCCI B, 1991, P NATL ACAD SCI USA, V88, P1416, DOI 10.1073/pnas.88.4.1416; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DU F, 1993, NEUROSCIENCE, V55, P975, DOI 10.1016/0306-4522(93)90312-4; FOSTER AC, 1986, J NEUROCHEM, V47, P23; HALPERIN JJ, 1992, NEUROLOGY, V42, P43, DOI 10.1212/WNL.42.1.43; HEYES MP, 1992, BRAIN, V115, P1249, DOI 10.1093/brain/115.5.1249; HEYES MP, 1992, FASEB J, V6, P2977, DOI 10.1096/fasebj.6.11.1322853; HEYES MP, 1993, BIOCHEM SOC T, V21, P83, DOI 10.1042/bst0210083; HUYNH TV, 1984, PRACTICAL APPROACHES, P49; KOHLER C, 1988, NEUROSCIENCE, V27, P49, DOI 10.1016/0306-4522(88)90219-9; KOONTZ WA, 1976, J BIOL CHEM, V251, P368; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOEFFLER JP, 1990, J NEUROCHEM, V54, P1812, DOI 10.1111/j.1471-4159.1990.tb01240.x; MARSHALL RD, 1972, ANNU REV BIOCHEM, V41, P673, DOI 10.1146/annurev.bi.41.070172.003325; MORONI F, 1984, BRAIN RES, V295, P352, DOI 10.1016/0006-8993(84)90984-3; MORONI F, 1991, J NEUROCHEM, V57, P1630, DOI 10.1111/j.1471-4159.1991.tb06361.x; NAKANO K, 1991, AGR BIOL CHEM TOKYO, V55, P1195, DOI 10.1080/00021369.1991.10870719; OKUNO E, 1987, J NEUROCHEM, V49, P771, DOI 10.1111/j.1471-4159.1987.tb00960.x; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PERKINS MN, 1983, J PHARMACOL EXP THER, V226, P551; SAITO K, 1993, BIOCHEM J, V291, P11, DOI 10.1042/bj2910011; SAITO K, 1993, J NEUROCHEM, V60, P180, DOI 10.1111/j.1471-4159.1993.tb05836.x; SAITO K, 1993, J BIOL CHEM, V268, P15496; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SCHWARCZ R, 1992, ANN NY ACAD SCI, V648, P140; SCHWARCZ R, 1983, SCIENCE, V219, P316, DOI 10.1126/science.6849138; SCHWARCZ R, 1988, P NATL ACAD SCI USA, V85, P4079, DOI 10.1073/pnas.85.11.4079; SCHWARCZ R, 1993, BIOCHEM SOC T, V21, P77, DOI 10.1042/bst0210077; SCHWARCZ R, 1992, DRUG RES RELATED NEU, P287; TAKIKAWA O, 1988, J BIOL CHEM, V263, P2041; TAKIKAWA O, 1986, J BIOL CHEM, V261, P3648; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VESCIA A, 1962, J BIOL CHEM, V237, P2318; WALSH JL, 1991, BIOCHEM PHARMACOL, V42, P985, DOI 10.1016/0006-2952(91)90279-E	38	60	62	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13792	13797						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	7514594				2022-12-27	WOS:A1994NL60600015
J	ZHENG, B; CHAMBERS, TC; RAYNOR, RL; MARKHAM, PN; GEBEL, HM; VOGLER, WR; KUO, JF				ZHENG, B; CHAMBERS, TC; RAYNOR, RL; MARKHAM, PN; GEBEL, HM; VOGLER, WR; KUO, JF			HUMAN LEUKEMIA K562 CELL MUTANT (K562/OA200) SELECTED FOR RESISTANCE TO OKADAIC ACID (PROTEIN PHOSPHATASE INHIBITOR) LACKS PROTEIN-KINASE C-EPSILON, EXHIBITS MULTIDRUG-RESISTANCE PHENOTYPE, AND EXPRESSES DRUG PUMP P-GLYCOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST CANCER-CELLS; BLACK SPONGE TOXIN; KB CARCINOMA-CELLS; TUMOR PROMOTER; SMOOTH-MUSCLE; HL60 CELLS; GLUCOSE-TRANSPORT; GENE-EXPRESSION; PHOSPHORYLATION; ADRIAMYCIN	A human leukemia K562 cell mutant (K562/OA200) selected for resistance to okadaic acid (OA), an inhibitor of protein phosphatases 1 and 2A (PP1/PP2A), has been established. In wild type cells, the cytotoxicity of OA was associated with mitotic arrest and concentration- and time dependent DNA fragmentation, a hallmark of apoptosis. The mutant was 100-fold more resistant to OA in terms of effects on these parameters. Although the synthesis of several proteins was altered, enzyme assay and immunoblot analysis indicated that the levels of PP1 and PP2A were unchanged in the mutant. Protein kinase C (PKC) assays and immunoblot analysis of calcium-dependent (cPKC) and calcium-independent (nPKC) isoforms revealed that nPKC-epsilon was strikingly absent in the mutant, which otherwise expressed in comparable amounts all other isotypes (cPKC-alpha, cPKC-beta, and nPKC-zeta) also present in the wild type. Northern blot analysis confirmed an absence of PKC-epsilon mRNA in the mutant cells. The OA200 cells were cross-resistant not only to another PP1/PP2A inhibitor, calyculin A, but also to structurally unrelated anticancer drugs (such as vinblastine and taxol) and furthermore, overexpressed the verapamil-sensitive drug pump P-glycoprotein at both the protein and mRNA levels. The mutant, however, was not cross-resistant to several PKC inhibitors tested including cardiotoxin, mastoparan, staurosporine, and an alkylphospholipid. Cardiotoxin, at a subtoxic concentration, enhanced by 6-fold vinblastine cytotoxicity in OA200 cells. These findings indicate that the multidrug resistance phenotype can be induced by cytotoxic agents other than conventional anticancer drugs, show that the development of multidrug resistance is not necessarily associated with increased cPKC activity, and identify certain PKC inhibitors that have potential as resistance modulators.	EMORY UNIV,SCH MED,DEPT PHARMACOL,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DEPT MED HEMATOL ONCOL,ATLANTA,GA 30322; RUSH PRESBYTERIAN ST LUKES MED CTR,DEPT IMMUNOL,CHICAGO,IL 60612; RUSH PRESBYTERIAN ST LUKES MED CTR,DEPT GEN SURG,CHICAGO,IL 60612	Emory University; Emory University; Rush University; Rush University					NATIONAL CANCER INSTITUTE [R01CA036777, R01CA029850, R01CA057470] Funding Source: NIH RePORTER; NCI NIH HHS [CA-57470, CA-36777, CA-29850] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AQUINO A, 1988, CANCER RES, V48, P3324; AQUINO A, 1990, BIOCHEM BIOPH RES CO, V166, P723, DOI 10.1016/0006-291X(90)90869-O; ASHIZAWA N, 1989, BIOCHEM BIOPH RES CO, V162, P971, DOI 10.1016/0006-291X(89)90768-7; AXTON JM, 1990, CELL, V63, P33, DOI 10.1016/0092-8674(90)90286-N; BARRY MA, 1990, BIOCHEM PHARMACOL, V40, P2353, DOI 10.1016/0006-2952(90)90733-2; BATES SE, 1993, BIOCHEMISTRY-US, V32, P9156, DOI 10.1021/bi00086a022; BATIST G, 1986, J BIOL CHEM, V261, P5544; BHALLA K, 1985, CANCER RES, V45, P3657; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BLOBE GC, 1993, J BIOL CHEM, V268, P658; BRUGGEMANN EP, 1989, J BIOL CHEM, V264, P15483; CHAMBERS TC, 1990, J BIOL CHEM, V265, P7679; CHAMBERS TC, 1993, INT J CANCER, V53, P323, DOI 10.1002/ijc.2910530225; CHAMBERS TC, 1993, J BIOL CHEM, V268, P4592; CHAMBERS TC, 1992, MOL PHARMACOL, V41, P1008; CHAUDHARY PM, 1992, ONCOL RES, V4, P281; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COHEN P, 1989, J BIOL CHEM, V264, P21435; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FINE RL, 1988, P NATL ACAD SCI USA, V85, P582, DOI 10.1073/pnas.85.2.582; FOJO A, 1985, CANCER RES, V45, P3002; GIRARD PR, 1986, J BIOL CHEM, V261, P370; GOLLAPUDI S, 1992, CANCER LETT, V62, P69, DOI 10.1016/0304-3835(92)90200-F; GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HESCHELER J, 1988, PFLUG ARCH EUR J PHY, V412, P248, DOI 10.1007/BF00582504; HIMMELMANN AW, 1990, CANCER CHEMOTH PHARM, V26, P437, DOI 10.1007/BF02994095; JAKES S, 1988, BIOCHIM BIOPHYS ACTA, V967, P11, DOI 10.1016/0304-4165(88)90182-1; KARAKI H, 1989, BRIT J PHARMACOL, V98, P590, DOI 10.1111/j.1476-5381.1989.tb12633.x; KINOSHITA N, 1990, CELL, V63, P405, DOI 10.1016/0092-8674(90)90173-C; LAWRENCE JC, 1990, J BIOL CHEM, V265, P19768; MA LD, 1991, J BIOL CHEM, V266, P5593; MCGRATH T, 1988, CANCER RES, V48, P3959; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; NISHIZUKA Y, 1992, NATURE, V258, P607; NOONAN KE, 1990, P NATL ACAD SCI USA, V87, P7160, DOI 10.1073/pnas.87.18.7160; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OBRIAN CA, 1989, FEBS LETT, V246, P78, DOI 10.1016/0014-5793(89)80257-1; OBRIAN CA, 1991, BIOCHEM PHARMACOL, V41, P797, DOI 10.1016/0006-2952(91)90083-H; PALAYOOR ST, 1987, BIOCHEM BIOPH RES CO, V148, P718, DOI 10.1016/0006-291X(87)90935-1; PASTAN I, 1991, ANNU REV MED, V42, P277, DOI 10.1146/annurev.med.42.1.277; PASTAN I, 1991, FASEB J, V5, P2523, DOI 10.1096/fasebj.5.11.1868977; PEARCE HL, 1989, P NATL ACAD SCI USA, V86, P5128, DOI 10.1073/pnas.86.13.5128; POSADA J, 1989, CANCER RES, V49, P6634; Posada J A, 1989, Cancer Commun, V1, P285; RAYNOR RL, 1991, J BIOL CHEM, V266, P2753; SAKURADA K, 1992, BIOCHEM BIOPH RES CO, V187, P488, DOI 10.1016/S0006-291X(05)81520-7; Sambrook J, 1989, MOL CLONING LABORATO; SAMPSON KE, 1993, CANCER LETT, V68, P7, DOI 10.1016/0304-3835(93)90213-S; SCHWARTZ GK, 1991, CANCER RES, V51, P55; SHARMA RC, 1992, J BIOL CHEM, V267, P5731; SHEN DW, 1986, J BIOL CHEM, V261, P7762; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; TACHIBANA K, 1981, J AM CHEM SOC, V103, P2469, DOI 10.1021/ja00399a082; TAKAI A, 1987, FEBS LETT, V217, P81, DOI 10.1016/0014-5793(87)81247-4; TANTI JF, 1991, J BIOL CHEM, V266, P2099; TSURUO T, 1981, CANCER RES, V41, P1967; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; YOUNG WS, 1991, FOCUS, V13, P46; YU G, 1991, CANCER COMMUN, V3, P181, DOI 10.3727/095535491820873263; ZAMORA JM, 1988, MOL PHARMACOL, V33, P454; ZHENG B, 1991, J BIOL CHEM, V266, P10031	63	30	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12332	12338						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	7512966				2022-12-27	WOS:A1994NG37700099
J	PEARCE, SFA; WU, J; SILVERSTEIN, RL				PEARCE, SFA; WU, J; SILVERSTEIN, RL			RECOMBINANT GST/CD36 FUSION PROTEINS DEFINE A THROMBOSPONDIN BINDING DOMAIN - EVIDENCE FOR A SINGLE CALCIUM-DEPENDENT BINDING-SITE ON CD36	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; MEMBRANE-PROTEIN; GLYCOPROTEIN-IV; PLATELET THROMBOSPONDIN; SECRETE THROMBOSPONDIN; COMPLEX-FORMATION; TISSUE ACTIVATOR; EPITHELIAL-CELLS; RECEPTOR; ADHESION	CD36 is a multifunctional cell surface glycoprotein that acts as a surface receptor for thrombospondin (TSP), and thereby may mediate adhesive interactions between cells and substrata, platelets and other cells, and macrophages and apoptotic neutrophils. The identity of the TSP binding site on CD36 is controversial and may involve more than one structural domain. We have constructed a series of recombinant bacterial GST/CD36 fusion proteins that span nearly all of the CD36 molecule and have demonstrated that fusion proteins containing the region extending from amino acid 93 to 120 formed specific, saturable, and reversible complexes with TSP. As with intact CD36, binding was calcium-dependent, was independent of which ligand was immobilized, and was blocked by monoclonal antibodies to both CD36 and TSP. Stoichiometry and affinity of the fusion proteins for TSP were consistent with that of the intact protein. We also demonstrated that these fusion proteins competitively inhibited binding of TSP to puri fied platelet CD36 and to cell surface CD36 on peripheral blood monocytes and CD36 cDNA-transfected melanoma cells. These data demonstrate that the region between amino acids 93 and 120 has all of the characteristics required of the TSP binding domain.	CORNELL UNIV,COLL MED,DEPT MED HEMATOL ONCOL,NEW YORK,NY 10021	Cornell University					NHLBI NIH HHS [T32 HL-07029, R01-HL42540, P5O-HL46403] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007029, P01HL046403, R01HL042540] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; ASCH AS, 1992, BIOCHEM BIOPH RES CO, V182, P1208, DOI 10.1016/0006-291X(92)91860-S; ASCH AS, 1991, J BIOL CHEM, V266, P1740; ASCH AS, 1987, J CLIN INVEST, V79, P1054, DOI 10.1172/JCI112918; ASCH AS, 1993, SCIENCE, V262, P1436, DOI 10.1126/science.7504322; BORNSTEIN P, 1992, FASEB J, V6, P3290, DOI 10.1096/fasebj.6.14.1426766; CATIMEL B, 1992, BIOCHEM J, V284, P21; CLEMETSON KJ, 1977, BIOCHIM BIOPHYS ACTA, V464, P493, DOI 10.1016/0005-2736(77)90025-6; CLEMETSON KJ, 1985, PLATELET MEMBRANE GL, P51; DAVIES J, 1987, SEMIN THROMB HEMOST, V13, P378; EDELMAN P, 1986, BLOOD, V67, P56; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; FRAZIER WA, 1987, J CELL BIOL, V105, P625, DOI 10.1083/jcb.105.2.625; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; GREENWALT DE, 1990, BIOCHEMISTRY-US, V29, P7054, DOI 10.1021/bi00482a015; HANDUNNETTI SM, 1992, BLOOD, V80, P2097; JAFFE EA, 1985, BLOOD, V65, P79; JAFFE EA, 1983, P NATL ACAD SCI-BIOL, V80, P998, DOI 10.1073/pnas.80.4.998; KNOWLES DM, 1984, J IMMUNOL, V132, P2170; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; LEUNG LLK, 1992, J BIOL CHEM, V267, P18244; LEUNG LLK, 1984, J CLIN INVEST, V74, P1764, DOI 10.1172/JCI111595; MAJACK RA, 1985, J CELL BIOL, V101, P1059, DOI 10.1083/jcb.101.3.1059; MAJACK RA, 1986, P NATL ACAD SCI USA, V83, P9050, DOI 10.1073/pnas.83.23.9050; MAJACK RA, 1988, J CELL BIOL, V106, P415, DOI 10.1083/jcb.106.2.415; MCGREGOR JL, 1989, J BIOL CHEM, V264, P501; MOSHER DF, 1982, J CELL BIOL, V93, P343, DOI 10.1083/jcb.93.2.343; MURPHYULLRICH JE, 1992, MOL BIOL CELL, V3, P181, DOI 10.1091/mbc.3.2.181; OQUENDO P, 1989, CELL, V58, P95, DOI 10.1016/0092-8674(89)90406-6; OSHEA KS, 1990, J CELL BIOL, V111, P2713, DOI 10.1083/jcb.111.6.2713; OSHEA KS, 1990, J CELL BIOL, V110, P1275, DOI 10.1083/jcb.110.4.1275; PEARCE SFA, 1994, BLOOD, V84, P384; RISER BL, 1989, CANCER RES, V49, P6123; ROBERTS DD, 1985, J BIOL CHEM, V260, P9405; RYEOM SW, 1994, CLIN RES, V42, pA113; SAVILL J, 1992, J CLIN INVEST, V90, P1513, DOI 10.1172/JCI116019; SILVERSTEIN RL, 1985, J BIOL CHEM, V260, P346; SILVERSTEIN RL, 1984, J CLIN INVEST, V74, P1625, DOI 10.1172/JCI111578; SILVERSTEIN RL, 1989, J CLIN INVEST, V84, P546, DOI 10.1172/JCI114197; SILVERSTEIN RL, 1992, J BIOL CHEM, V267, P16607; SILVERSTEIN RL, 1986, J CLIN INVEST, V79, P867; TANDON NN, 1989, J BIOL CHEM, V264, P7576; TARABOLETTI G, 1990, J CELL BIOL, V111, P765, DOI 10.1083/jcb.111.2.765; TUSZYNSKI GP, 1993, J CELL BIOL, V120, P513, DOI 10.1083/jcb.120.2.513; VEGA MA, 1991, J BIOL CHEM, V266, P16818; WRIGHT SD, 1982, J EXP MED, V156, P1149, DOI 10.1084/jem.156.4.1149	46	73	77	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 17	1995	270	7					2981	2986		10.1074/jbc.270.7.2981	http://dx.doi.org/10.1074/jbc.270.7.2981			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QG471	7531696	hybrid			2022-12-27	WOS:A1995QG47100017
J	BENJAMIN, CW; LINSEMAN, DA; JONES, DA				BENJAMIN, CW; LINSEMAN, DA; JONES, DA			PLATELET-DERIVED GROWTH-FACTOR STIMULATES PHOSPHORYLATION OF GROWTH-FACTOR RECEPTOR-BINDING PROTEIN-2 IN VASCULAR SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GUANINE-NUCLEOTIDE EXCHANGE; SIGNAL TRANSDUCTION; TYROSINE KINASES; PHOSPHOAMINO ACIDS; GRB2; RAS; SH2; ASSOCIATION; SEVENLESS; DOMAIN	Growth factor receptor binding protein-2 (GRB2) couples growth factor receptor activation to the p21(ras) nucleotide exchange factor son-of-sevenless (SOS). Son-of-sevenless can serve as a substrate for mitogen-activated protein kinases and may be subject to feed back regulation in mitogen-stimulated cells. Herein, we demonstrate phosphorylation on GRB2 in rat A10 Vascular smooth muscle cells exposed to platelet-derived growth factor (PDGF). Lysates from smooth cells stimulated with PDGF revealed a shift in the electrophoretic mobility of GRB2. Further investigation confirmed that phosphorylation on GRB2 accompanied this mobility shift. Phosphorylation on GRB2 was time dependent and correlated with PDGF receptor activation. The time-course for phosphorylation of GRB2 and subsequent decay corresponded with other events characteristic of platelet-derived growth factor signaling. GRB2 was not phosphorylated in cells treated with phorbol 12-myristate 13-acetate, and down-regulation of protein kinase C failed to attenuate phosphorylation on GRB2 in response to growth factor. Analysis of GRB2 immune complexes revealed a kinase activity capable of phosphorylating GRB2 in vitro and demonstrated that the kinase activated in response to PDGF may physically associate with GRB2 signaling complexes.	UPJOHN CO,UPJOHN LABS,KALAMAZOO,MI 49001	Pfizer			Linseman, Daniel/L-3846-2019					BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BENJAMIN CW, 1994, J BIOL CHEM, V269, P30911; BOBIK A, 1993, PHARMACOL REV, V45, P1; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MCCROSKEY MC, 1988, J CHROMATOGR, V442, P307, DOI 10.1016/S0021-9673(00)94478-9; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SAMPSON KE, 1993, J CELL BIOCHEM, V52, P384, DOI 10.1002/jcb.240520403; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254; YOKOTE K, 1994, J BIOL CHEM, V269, P15337	22	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31346	31349						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7527385				2022-12-27	WOS:A1994PX30300007
J	LEMMON, MA; LADBURY, JE; MANDIYAN, V; ZHOU, M; SCHLESSINGER, J				LEMMON, MA; LADBURY, JE; MANDIYAN, V; ZHOU, M; SCHLESSINGER, J			INDEPENDENT BINDING OF PEPTIDE LIGANDS TO THE SH2 AND SH3 DOMAINS OF GRB2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHORYLATED PEPTIDES; GUANINE-NUCLEOTIDE EXCHANGE; SURFACE-PLASMON RESONANCE; SIGNALING GENE SEM-5; ADAPTER PROTEIN; VIRAL ONCOGENE; RAS; RECEPTOR; ASSOCIATION; KINASES	Grb2, composed entirely of SH2 and SH3 domains, serves as an adaptor protein in signaling from growth factor-activated tyrosine kinase receptors. It interacts via its SH2 domain with the autophosphorylated carboxyl-terminal tail of activated epidermal growth factor (EGF) receptor and via its SH3 domains with proline-rich sequences in the Ras guanine nucleotide releasing factor, Son of sevenless (Sos). Recruitment of the Grb2.Sos complex to the receptor upon its stimulation leads to Ras activation. A major question remains as to whether SH2-mediated binding of Grb2 to the activated receptor results in conformational changes that influence its SH3-mediated association with Sos, thereby affecting Sos activity, This question is addressed through studies of the binding to intact Grb2 of an EGF receptor-derived phosphotyrosine-containing peptide and a Sos-derived proline-rich peptide using isothermal titration calorimetry and surface plasmon resonance measurements. The phosphopeptide binds to Grb2 in a 1:1 complex, with a K-D of 0.4 mu M. The Sos proline-rich peptide binds to Grb2 in a 2:1 complex, with a K-D of 22 mu M. Saturation of the SH2 domain of Grb2 with the EGFR phosphopeptide was found not to affect its subsequent binding to the Sos peptide. Thus we detected no influence of SH2 binding upon SH3-mediated interactions, suggesting that the domains do not communicate, and that recruitment itself of Sos to the cell surface is sufficient for Ras signaling.	NYU, MED CTR, DEPT PHARMACOL, NEW YORK, NY 10016 USA	New York University				Lemmon, Mark/0000-0002-3379-5319; Ladbury, John/0000-0002-6328-7200	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM004725] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM04725] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; CUSSAC D, 1994, EMBO J, V13, P4011, DOI 10.1002/j.1460-2075.1994.tb06717.x; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; ECK MJ, 1994, NATURE, V368, P764, DOI 10.1038/368764a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FELDER S, 1993, MOL CELL BIOL, V13, P1449, DOI 10.1128/MCB.13.3.1449; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; JI XH, 1992, BIOCHEMISTRY-US, V31, P10169, DOI 10.1021/bi00157a004; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LEMMON MA, 1994, BIOCHEMISTRY-US, V33, P5070, DOI 10.1021/bi00183a010; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIM WA, 1994, PROTEIN SCI, V3, P1261, DOI 10.1002/pro.5560030812; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; PANAYOTOU G, 1993, MOL CELL BIOL, V13, P3567, DOI 10.1128/MCB.13.6.3567; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAYNE G, 1993, P NATL ACAD SCI USA, V90, P4902, DOI 10.1073/pnas.90.11.4902; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STERN MJ, 1993, MOL BIOL CELL, V4, P1175, DOI 10.1091/mbc.4.11.1175; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	41	64	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31653	31658						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7527391				2022-12-27	WOS:A1994PX30300052
J	WANG, DR; BAUMANN, A; SZEBENI, A; OLSON, MOJ				WANG, DR; BAUMANN, A; SZEBENI, A; OLSON, MOJ			THE NUCLEIC-ACID BINDING-ACTIVITY OF NUCLEOLAR PROTEIN B23.1 RESIDES IN ITS CARBOXYL-TERMINAL END	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOPROTEIN B23; 2 FORMS; GENE; LOCALIZATION; C23	Protein B23 is a major nucleolar phosphoprotein proposed to be a ribosome assembly factor. Protein B23 exists as two isoforms, B23.1 and B23.2, differing only in their carboxyl-terminal sequences. The interaction of recombinantly produced B23 isoforms with double-stranded DNA was studied using gel retardation and nitrocellulose filter disk assays. Protein B23.1 bound saturably to radiolabeled plasmid DNA. By competition assays protein B23.1 was also capable of binding RNA and single-stranded DNA. On the other hand, protein B23.2, the shorter of the two isoforms, was not capable of binding double-stranded DNA. The latter result suggested that the carboxyl-terminal end of B23.1 is essential for DNA binding activity. This was confirmed by partial digestion experiments using staphylococcal V8 protease which showed that a 5-kDa fragment, containing the carboxyl-terminal end of protein B23.1 retained DNA binding activity similar to that of the parent molecule. In contrast, a 19-kDa fragment from the aminoterminal half of B23.1 did not bind DNA. The sequence of the carboxyl-terminal 68 amino acids comprising the 5-kDa fragment showed little, if any, similarity to other proteins, suggesting that this segment contains a previously undiscovered nucleic acid binding motif.	UNIV MISSISSIPPI,MED CTR,DEPT BIOCHEM,JACKSON,MS 39216	University of Mississippi; University of Mississippi Medical Center					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028349] Funding Source: NIH RePORTER; NIGMS NIH HHS [5 RO1 GM28349] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIGGIOGERA M, 1989, J HISTOCHEM CYTOCHEM, V37, P1371, DOI 10.1177/37.9.2768807; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; CHAN PK, 1986, J BIOL CHEM, V261, P14335; CHAN WY, 1989, BIOCHEMISTRY-US, V28, P1033, DOI 10.1021/bi00429a017; CHANG JH, 1989, J BIOL CHEM, V264, P11732; CHANG JH, 1990, J BIOL CHEM, V265, P18227; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; DUMBAR TS, 1989, BIOCHEMISTRY-US, V28, P9495, DOI 10.1021/bi00450a037; ENGLE DB, 1990, J BIOL CHEM, V265, P16132; FANKHAUSER C, 1991, MOL CELL BIOL, V11, P2567, DOI 10.1128/MCB.11.5.2567; FEUERSTEIN N, 1990, BIOCHIM BIOPHYS ACTA, V1087, P127, DOI 10.1016/0167-4781(90)90196-9; FLORES C, 1990, NUCLEIC ACIDS RES, V18, P901, DOI 10.1093/nar/18.4.901; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GOLDFARB DS, 1988, CELL BIOL INT REP, V12, P809, DOI 10.1016/0309-1651(88)90090-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARIDOR G, 1990, NUCLEIC ACIDS RES, V18, P1286, DOI 10.1093/nar/18.5.1286; MARKS GL, 1993, GENE, V123, P121, DOI 10.1016/0378-1119(93)90550-M; OLSON MOJ, 1983, BIOCHEMISTRY-US, V22, P3345, DOI 10.1021/bi00283a007; OLSON MOJ, 1990, EUKARYOTIC NUCLEUS M, V2, P541; PECULIS BA, 1992, J CELL BIOL, V116, P1, DOI 10.1083/jcb.116.1.1; Raska I., 1993, CHROMOSOME TODAY, V11, P101, DOI [DOI 10.1007/978-94-011-1510-0_8, 10.1007/978-94-011-1510-0_8]; RIGGS AD, 1970, J MOL BIOL, V48, P67, DOI 10.1016/0022-2836(70)90219-6; SCHMIDTZACHMANN MS, 1988, CHROMOSOMA, V96, P417, DOI 10.1007/BF00303035; SCHMIDTZACHMANN MS, 1987, EMBO J, V6, P1881, DOI 10.1002/j.1460-2075.1987.tb02447.x; SPECTOR DL, 1984, CHROMOSOMA, V90, P139, DOI 10.1007/BF00292451; TAKEMURA M, 1994, BIOCHEM BIOPH RES CO, V199, P461; UMEKAWA H, 1993, CELL MOL BIOL RES, V39, P635; WANG DR, 1993, CELL MOL BIOL RES, V39, P33; YUNG BYM, 1985, BIOCHIM BIOPHYS ACTA, V826, P167, DOI 10.1016/0167-4781(85)90002-8; YUNG BYM, 1987, BIOCHIM BIOPHYS ACTA, V925, P74, DOI 10.1016/0304-4165(87)90149-8	30	102	105	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					30994	30998						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7527039				2022-12-27	WOS:A1994PV51000042
J	WEBB, DJ; ATKINS, TL; CROOKSTON, KP; BURMESTER, JK; QIAN, SW; GONIAS, SL				WEBB, DJ; ATKINS, TL; CROOKSTON, KP; BURMESTER, JK; QIAN, SW; GONIAS, SL			TRANSFORMING GROWTH-FACTOR-BETA ISOFORM 2-SPECIFIC HIGH-AFFINITY BINDING TO NATIVE ALPHA(2)-MACROGLOBULIN - CHIMERAS IDENTIFY A SEQUENCE THAT DETERMINES AFFINITY FOR NATIVE BUT NOT ACTIVATED ALPHA(2)-MACROGLOBULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-2-MACROGLOBULIN RECEPTOR; ALPHA-MACROGLOBULIN; ENDOTHELIAL-CELLS; CRYSTAL-STRUCTURE; PRIMARY AMINES; FAST FORMS; FACTOR-BETA-1; METHYLAMINE; COMPLEX; GROWTH-FACTOR-BETA-2	Transforming growth factor beta 2 (TGF-beta 2) is less potent than TGF-beta 1 in some endothelial cell proliferation as says due to the greater tendency of TGF-beta 2 to bind alpha(2)-macroglobulin (alpha(2)M). Substitution of TGF-beta 1 residues 40-47 into the TGF-beta 2 sequence yields a chimeric molecule that, like TGF-beta 1, expresses activity that is not substantially affected by serum alpha(2)M (Burmester, J. K., Qian, S. W., Roberts, A. B., Huang, A., Amatayakul-Chantler, S., Suardet, L., Odartchenko, N., Madri, J. A., and Sporn, M. B. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 8628-8632). In this investigation, we studied the binding of TGF-beta chimeras, which contain TGF-beta 1 residues 40-47, to both major conformations of human alpha(2)M under apparent equilibrium conditions. Native alpha(2)M, the primary form of this protein in serum, bound TGF-beta(2)/beta(1)(40-82) and TGF-beta(2)/beta(1)(40-47) with low affinity. The apparent K-D values for the two chimeras and native alpha(2)M were 310 and 330 nM, respectively. These values were much higher than the K-D determined for TGF-beta 2 and native alpha(2)M (11 nM) and equivalent to the K-D determined for TGF-beta 1 and native alpha(2)M. By contrast, both TGF-beta chimeras bound alpha(2)M-methylamine, an altered conformation of alpha(2)M, with high affinity (16 and 19 nM), which is characteristic of TGF-beta 2 and not TGF-beta 1. Fetal bovine heart endothelial cell DNA synthesis was inhibited to a similar degree by TGF-beta 1, TGF-beta 2, TGF-beta(2)/beta(1)(40-82), and TGF-beta(2)/beta(1)(40-47) in the presence of dilute (0.2%) fetal bovine serum. When 0.07 mu M alpha 2M-methylamine was added, the activities of TGF-beta 2, TGF-beta(2)/beta(1)(40-82), and TGF-beta(2)/beta(1)(40-47) were significantly counteracted while the activity of TGF-beta 1 was unchanged, as would be predicted by the equilibrium binding analyses. These studies indicate that the TGF-beta structural elements, which mediate binding to native alpha(2)M and conformationally transformed alpha(2)M, are not equivalent. Residues 40-47 are critical in determining affinity for native alpha(2)M but are less important in determining affinity for alpha(2)MM methylamine.	UNIV VIRGINIA,HLTH SCI CTR,DEPT BIOCHEM,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,HLTH SCI CTR,DEPT PATHOL,CHARLOTTESVILLE,VA 22908; MARSHFIELD CLIN FDN MED RES & EDUC,MARSHFIELD,WI 54449; NIH,CHEMOPREVENT LAB,BETHESDA,MD 20892	University of Virginia; University of Virginia; Marshfield Clinic; National Institutes of Health (NIH) - USA					NATIONAL CANCER INSTITUTE [R01CA053462] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K04HL002272] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007267] Funding Source: NIH RePORTER; NCI NIH HHS [CA-53462] Funding Source: Medline; NHLBI NIH HHS [HL-02272] Funding Source: Medline; NIGMS NIH HHS [GM 07267] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARCHER SJ, 1993, BIOCHEMISTRY-US, V32, P1164, DOI 10.1021/bi00055a022; BARRETT AJ, 1979, BIOCHEM J, V181, P401, DOI 10.1042/bj1810401; BJORK I, 1982, BIOCHEM J, V207, P347; BURMESTER JK, 1993, P NATL ACAD SCI USA, V90, P8628, DOI 10.1073/pnas.90.18.8628; CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533; CROOKSTON KP, 1993, BIOCHEM J, V293, P443, DOI 10.1042/bj2930443; CROOKSTON KP, 1994, BIOCHEM BIOPH RES CO, V200, P1578, DOI 10.1006/bbrc.1994.1631; CROOKSTON KP, 1994, J BIOL CHEM, V269, P1533; DANIELPOUR D, 1990, J BIOL CHEM, V265, P6973; DAOPIN S, 1992, SCIENCE, V257, P369, DOI 10.1126/science.1631557; GANROT PO, 1967, CLIN CHIM ACTA, V16, P328, DOI 10.1016/0009-8981(67)90201-X; GONIAS SL, 1994, ANN NY ACAD SCI, V737, P273, DOI 10.1111/j.1749-6632.1994.tb44318.x; GONIAS SL, 1982, BIOCHIM BIOPHYS ACTA, V705, P306, DOI 10.1016/0167-4838(82)90252-7; HALL PK, 1978, BIOCHEM J, V173, P27, DOI 10.1042/bj1730027; HALL SW, 1992, BIOCHEM J, V281, P569, DOI 10.1042/bj2810569; HOWARD JB, 1981, P NATL ACAD SCI-BIOL, V78, P2235, DOI 10.1073/pnas.78.4.2235; HUANG SS, 1988, J BIOL CHEM, V263, P1535; IMBER MJ, 1981, J BIOL CHEM, V256, P8134; JENNINGS JC, 1988, J CELL PHYSIOL, V137, P167, DOI 10.1002/jcp.1041370120; LAMARRE J, 1990, LAB INVEST, V62, P545; LAMARRE J, 1991, J CLIN INVEST, V87, P39, DOI 10.1172/JCI114998; MERWIN JR, 1991, AM J PATHOL, V138, P37; MOESTRUP SK, 1989, J BIOL CHEM, V264, P15574; OCONNORMCCOURT MD, 1987, J BIOL CHEM, V262, P14090; PIZZO SV, 1984, RECEPTORS, V1, P177; QIAN SW, 1992, P NATL ACAD SCI USA, V89, P6290, DOI 10.1073/pnas.89.14.6290; Roberts AB, 1990, PEPTIDE GROWTH FACTO, P419; RUFF E, 1986, BIOCHEM BIOPH RES CO, V138, P714, DOI 10.1016/S0006-291X(86)80555-1; SCHLUNEGGER MP, 1992, NATURE, V358, P430, DOI 10.1038/358430a0; Sottrup-Jensen L., 1987, PLASMA PROTEINS, V5, P191; SOTTRUPJENSEN L, 1980, FEBS LETT, V121, P275, DOI 10.1016/0014-5793(80)80361-9; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; VANLEUVEN F, 1981, J BIOL CHEM, V256, P9016; WOLF BB, 1994, BIOCHEMISTRY-US, V33, P11270, DOI 10.1021/bi00203a024	34	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30402	30406						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7527030				2022-12-27	WOS:A1994PU52500057
J	BURG, DL; FURLONG, MT; HARRISON, ML; GEAHLEN, RL				BURG, DL; FURLONG, MT; HARRISON, ML; GEAHLEN, RL			INTERACTIONS OF LYN WITH THE ANTIGEN RECEPTOR DURING B-CELL ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; SIGNAL TRANSDUCTION; LYMPHOCYTES-B; ZETA-CHAIN; PHOSPHATIDYLINOSITOL 3-KINASE; IG-BETA; PHOSPHORYLATION; COMPLEX; ASSOCIATION; COMPONENTS	Signaling through the B cell antigen receptor requires a complex set of interactions involving transmembrane components of the IgM receptor complex and cytosolic protein-tyrosine kinases. We have focused on the nature of these protein-protein interactions, the requirements for their occurrence, as well as the temporal sequence of events during the activation process. me found that cross-linking B cell antigen receptors at 0 degrees C resulted in the rapid association of the Src-family protein-tyrosine kinase, Lyn, with the antigen receptor complex as judged by the presence of Lyn in anti-IgM and anti-phosphotyrosine immune complexes and the presence of MB-1 in anti-Lyn immune complexes. Receptor engagement also resulted in the rapid association of Lyn with the phosphotyrosine phosphatase, CD45. This association of Lyn with receptor components was stable in the detergent Brij 96, but was readily disrupted by Nonidet P-40, suggesting the involvement of hydrophobic interactions in stabilizing formation of the Lyn-receptor complex. The protein-tyrosine kinase, Syk, was also found associated with activated receptor complexes. This association of Syk with components of the antigen receptor complex was stable to Nonidet P-40. Antibodies directed against the carboxyl teminus of Syk, but not against the amino-terminal SH2 domain, co-immunoprecipitated MB-1 from activated cells, consistent with the binding of Syk through an SH2 domain-phosphotyrosine interaction.	PURDUE UNIV, DEPT MED CHEM & PHARMACOGNOSY, W LAFAYETTE, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus				Geahlen, Robert/0000-0001-8400-2924	NATIONAL CANCER INSTITUTE [R01CA037372] Funding Source: NIH RePORTER; NCI NIH HHS [CA37372] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEYERS AD, 1992, P NATL ACAD SCI USA, V89, P2945, DOI 10.1073/pnas.89.7.2945; BRAUN J, 1982, J IMMUNOL, V128, P1198; BROWN VK, 1994, J BIOL CHEM, V269, P17238; BURG DL, 1993, J BIOL CHEM, V268, P2304; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMPBELL KS, 1990, EMBO J, V9, P441, DOI 10.1002/j.1460-2075.1990.tb08129.x; CAMPBELL KS, 1991, P NATL ACAD SCI USA, V88, P3982, DOI 10.1073/pnas.88.9.3982; CAMPBELL MA, 1990, EMBO J, V9, P2125, DOI 10.1002/j.1460-2075.1990.tb07381.x; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; GOLD MR, 1991, P NATL ACAD SCI USA, V88, P3436, DOI 10.1073/pnas.88.8.3436; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; GORDON JI, 1991, J BIOL CHEM, V266, P8647; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HOMBACH J, 1990, NATURE, V343, P760, DOI 10.1038/343760a0; HOMBACH J, 1990, EUR J IMMUNOL, V20, P2795, DOI 10.1002/eji.1830201239; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; HUTCHCROFT JE, 1991, J BIOL CHEM, V266, P14846; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; JUSTEMENT LB, 1991, SCIENCE, V252, P1839, DOI 10.1126/science.1648262; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; LANE PJL, 1991, J IMMUNOL, V146, P715; LAW DA, 1993, CURR BIOL, V3, P645, DOI 10.1016/0960-9822(93)90062-S; LAW DA, 1992, MOL IMMUNOL, V29, P917, DOI 10.1016/0161-5890(92)90130-P; LEPRINCE C, 1993, P NATL ACAD SCI USA, V90, P3236, DOI 10.1073/pnas.90.8.3236; LIN JJ, 1992, J IMMUNOL, V149, P1548; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MATSUMOTO AK, 1991, J EXP MED, V173, P55, DOI 10.1084/jem.173.1.55; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MUSTELIN T, 1993, TRENDS BIOCHEM SCI, V18, P215, DOI 10.1016/0968-0004(93)90192-P; ROIFMAN CM, 1993, BIOCHEM BIOPH RES CO, V194, P222, DOI 10.1006/bbrc.1993.1807; SCHULTE RJ, 1992, SCIENCE, V258, P1001, DOI 10.1126/science.1279802; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; TUVESON DA, 1993, SCIENCE, V260, P986, DOI 10.1126/science.7684160; WANGE RL, 1992, J BIOL CHEM, V267, P11685; WANGE RL, 1993, J BIOL CHEM, V268, P19797; YAMADA T, 1993, EUR J BIOCHEM, V213, P455, DOI 10.1111/j.1432-1033.1993.tb17781.x; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118; YI TL, 1991, MOL CELL BIOL, V11, P2391, DOI 10.1128/MCB.11.5.2391	43	57	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28136	28142						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7525568				2022-12-27	WOS:A1994PV77200056
J	CZUBAYKO, F; SMITH, RV; CHUNG, HC; WELLSTEIN, A				CZUBAYKO, F; SMITH, RV; CHUNG, HC; WELLSTEIN, A			TUMOR-GROWTH AND ANGIOGENESIS INDUCED BY A SECRETED BINDING-PROTEIN FOR FIBROBLAST GROWTH-FACTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBENDOTHELIAL EXTRACELLULAR-MATRIX; HEPARIN AFFINITY; BREAST-CANCER; BOVINE BRAIN; CELLS; PROLIFERATION; PURIFICATION; ANTIBODIES; EXPRESSION; CLONING	Basic fibroblast growth factor (bFGF) is a strong inducer of angiogenesis and thus may play an important role in the growth of solid tumors. However, bFGF is usually found immobilized on the extracellular matrix, and it is only partly understood how it is solubilized to reach and activate its extracellular receptors. We studied the potential contribution to this process by a secreted binding protein (BP) with high affinity for FGFs. An expression vector for BP was transfected into a human cell line (SW-13) that contains constitutively high levels of bFGF. The BP-expressing cells began to grow colonies in soft agar due to their autocrine stimulation by bFGF and released biologically active bFGF into their media. Furthermore, they grew into well vascularized tumors in athymic nude mice. In addition, we found the BP mRNA expressed at high levels in squamous cell carcinoma (SCC) tissues from patients and in SCC cell lines of different origin as well as in immortalized keratinocytes. However, we failed to detect EP mRNA in normal adult tissues or in a number of non-SCC tumor cell lines. Expression of the secreted EP appears to be a mechanism through which immobilized FGF can be activated to support tumor growth and angiogenesis.	GEORGETOWN UNIV,VT LOMBARDI CANC CTR,DEPT PHARMACOL,WASHINGTON,DC 20007; GEORGETOWN UNIV,DEPT OTOLARYNGOL HEAD & NECK SURG,WASHINGTON,DC 20007	Georgetown University; Georgetown University				Wellstein, Anton/0000-0002-0570-4950	NATIONAL CANCER INSTITUTE [U01CA051908, P50CA058185] Funding Source: NIH RePORTER; NCI NIH HHS [CA51908, CA58185] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAIRD A, 1990, HDB EXPT PHARM, V95, P369; BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; ESCH F, 1985, P NATL ACAD SCI USA, V82, P6507, DOI 10.1073/pnas.82.19.6507; FANG WJ, 1992, J BIOL CHEM, V267, P25889; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; HORAK ER, 1992, LANCET, V340, P1120, DOI 10.1016/0140-6736(92)93150-L; HUANG YQ, 1993, J CLIN INVEST, V91, P1191, DOI 10.1172/JCI116279; KIEFER MC, 1990, P NATL ACAD SCI USA, V87, P6985, DOI 10.1073/pnas.87.18.6985; LOBB RR, 1984, BIOCHEMISTRY-US, V23, P6295, DOI 10.1021/bi00321a001; MACIAG T, 1984, SCIENCE, V225, P932, DOI 10.1126/science.6382607; MATSUZAKI K, 1989, P NATL ACAD SCI USA, V86, P9911, DOI 10.1073/pnas.86.24.9911; MERLO GR, 1990, CELL GROWTH DIFFER, V1, P463; MOSCATELLI D, 1986, J CELL PHYSIOL, V129, P273, DOI 10.1002/jcp.1041290220; MOSCATELLI D, 1992, J BIOL CHEM, V267, P25803; PARUMS DV, 1990, J CLIN PATHOL, V43, P752, DOI 10.1136/jcp.43.9.752; PATTERSON SL, 1993, BRAIN RES, V605, P43, DOI 10.1016/0006-8993(93)91354-U; RISAU W, 1986, P NATL ACAD SCI USA, V83, P3855, DOI 10.1073/pnas.83.11.3855; RISAU W, 1988, EMBO J, V7, P959, DOI 10.1002/j.1460-2075.1988.tb02901.x; ROBERTSON PL, 1985, DEV BRAIN RES, V23, P219, DOI 10.1016/0165-3806(85)90044-6; ROGELJ S, 1989, J CELL BIOL, V109, P823, DOI 10.1083/jcb.109.2.823; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULTZHECTOR S, 1993, CANCER RES, V53, P1444; SHING Y, 1984, SCIENCE, V223, P1296, DOI 10.1126/science.6199844; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; VLODAVSKY I, 1991, ANN NY ACAD SCI, V638, P207; Vlodavsky I, 1988, Adv Exp Med Biol, V233, P201; WELLSTEIN A, 1990, CELL GROWTH DIFFER, V1, P63; WELLSTEIN A, 1991, JNCI-J NATL CANCER I, V83, P716, DOI 10.1093/jnci/83.10.716; WELLSTEIN A, 1992, J BIOL CHEM, V267, P2582; WU DQ, 1991, J BIOL CHEM, V266, P16778	32	113	120	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28243	28248						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7525570				2022-12-27	WOS:A1994PV77200071
J	QUON, MJ; BUTTE, AJ; ZARNOWSKI, MJ; SESTI, G; CUSHMAN, SW; TAYLOR, SI				QUON, MJ; BUTTE, AJ; ZARNOWSKI, MJ; SESTI, G; CUSHMAN, SW; TAYLOR, SI			INSULIN-RECEPTOR SUBSTRATE-1 MEDIATES THE STIMULATORY EFFECT OF INSULIN ON GLUT4 TRANSLOCATION IN TRANSFECTED RAT ADIPOSE-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-TRANSPORT ACTIVITY; SIGNAL TRANSDUCTION; PLASMA-MEMBRANE; SH2 DOMAINS; IRS-1; SYSTEMS; GENE; SITE	Insulin signaling is initiated at least in part by activation of the insulin receptor tyrosine kinase and subsequent phosphorylation of cellular substrates such as insulin receptor substrate 1 (IRS-l). Previous studies have focused on the role of IRS-1 in the mitogenic actions of insulin. We have now investigated the possible role of IRS 1 in mediating the effect of insulin to stimulate glucose transport in a physiologically relevant insulin target tissue. In this study, we transfected rat adipose cells in primary culture with an antisense ribozyme directed against rat IRS-l. Expression of the ribozyme in these cells caused a 4.4-fold increase in the concentration of insulin required to achieve half-maximal stimulation of the translocation of cotransfected epitope-tagged GLUT4 without changing the maximal insulin response. Overexpression of human IRS-1 increased the basal cell surface GLUT4 to nearly the maximal level in the absence of insulin. When the ribozyme (specific to rat IRS-1) was cotransfected along with human IRS-1, the insulin dose-response curve was shifted to the left when compared with cells transfected with the ribozyme alone. These data provide strong support for the hypothesis that IRS-1 plays a role in insulin-stimulated glucose transport in insulin-responsive cells.	NIDDK, DIABET BRANCH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Sesti, Giorgio/B-1509-2012; Quon, Michael/B-1970-2008	QUON, MICHAEL/0000-0002-5289-3707; Quon, Michael/0000-0002-9601-9915; Sesti, Giorgio/0000-0002-1618-7688				ALMIND K, 1993, LANCET, V342, P828, DOI 10.1016/0140-6736(93)92694-O; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHOI T, 1991, MOL CELL BIOL, V11, P3070, DOI 10.1128/MCB.11.6.3070; CHUANG LM, 1993, MOL CELL BIOL, V13, P6653, DOI 10.1128/MCB.13.11.6653; CUSHMAN SW, 1978, J LIPID RES, V19, P269; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; IMAI Y, 1994, IN PRESS J CLIN ENDO; KAHN CR, 1993, RECENT PROG HORM RES, V48, P291; KARNIELI E, 1981, J BIOL CHEM, V256, P4772; MYERS MG, 1993, DIABETES, V42, P643, DOI 10.2337/diabetes.42.5.643; OKADA T, 1994, J BIOL CHEM, V269, P3568; PESSIN JE, 1992, ANNU REV PHYSIOL, V54, P911, DOI 10.1146/annurev.ph.54.030192.004403; QUON MJ, 1993, BIOCHEM BIOPH RES CO, V194, P338, DOI 10.1006/bbrc.1993.1825; QUON MJ, 1994, P NATL ACAD SCI USA, V91, P5587, DOI 10.1073/pnas.91.12.5587; QUON MJ, 1994, AM J PHYSIOL, V266, pE144, DOI 10.1152/ajpendo.1994.266.1.E144; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SATOH S, 1993, J BIOL CHEM, V268, P17820; SIMPSON IA, 1986, ANNU REV BIOCHEM, V55, P1059, DOI 10.1146/annurev.biochem.55.1.1059; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; TAMEMOTO H, 1994, DIABETES, V43, pA144; TAYLOR SI, 1992, ENDOCR REV, V13, P566, DOI 10.1210/er.13.3.566; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANHORN DJ, 1994, J BIOL CHEM, V269, P29; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; ZAIA JA, 1992, ANN NY ACAD SCI, V660, P95, DOI 10.1111/j.1749-6632.1992.tb21062.x	28	123	124	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					27920	27924						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7525563				2022-12-27	WOS:A1994PV77200026
J	SILVA, CM; LU, HW; WEBER, MJ; THORNER, MO				SILVA, CM; LU, HW; WEBER, MJ; THORNER, MO			DIFFERENTIAL TYROSINE PHOSPHORYLATION OF JAK1, JAK2, AND STAT1 BY GROWTH-HORMONE AND INTERFERON-GAMMA IN IM-9 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; DNA-BINDING PROTEINS; ERYTHROPOIETIN RECEPTOR; EXTRACELLULAR DOMAIN; CYTOKINE RECEPTORS; ACTIVATION; KINASE; TRANSCRIPTION; ALPHA; GENE	Both the growth hormone (GH) and interferon gamma (IFN gamma) receptors are members of the cytokine receptor family that activate tyrosine phosphorylation despite the lack of a tyrosine kinase domain. Recently, the Janus kinase (JAK) family of tyrosine kinases have been shown to play an integral role in intracellular signaling by the cytokine receptors. We demonstrate that, in the human IM-9 lymphocyte, both JAK1 and JAK2 are tyrosine-phosphorylated in response to IFN gamma, whereas only JAK2 is tyrosine-phosphorylated in response to GH. Furthermore, dimerization of the GH receptor appears to be necessary for GH stimulated tyrosine phosphorylation of JAK2. We provide two lines of evidence that the JAK2 kinases can be regulated independently by GH and IFN gamma in IM-9 cells: 1) desensitization of JAK2 to GH stimulation does not affect the IFN gamma stimulated tyrosine phosphorylation of JAK2; and 2) JAK2 tyrosine phosphorylation by GH and IFN gamma is additive to that seen with either hormone alone. Furthermore, we demonstrate that although IFN gamma activates the tyrosine phosphorylation of the p91 signal transducer and activator of transcription (STAT1) in IM-9 cells, GH does not. GH does activate the tyrosine phosphorylation of a 93-kDa protein that appears to be distinct from STAT1.	UNIV VIRGINIA, HLTH SCI CTR, DEPT MED, DIV ENDOCRINOL & METAB, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, HLTH SCI CTR, DEPT MICROBIOL, CHARLOTTESVILLE, VA 22908 USA	University of Virginia; University of Virginia					NCI NIH HHS [CA39076] Funding Source: Medline; NIDDK NIH HHS [DK-32632, DK-08942] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA039076, R01CA039076] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032632, F33DK008942] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BAZAN JF, 1989, BIOCHEM BIOPH RES CO, V164, P788, DOI 10.1016/0006-291X(89)91528-3; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DALE TC, 1989, P NATL ACAD SCI USA, V86, P1203, DOI 10.1073/pnas.86.4.1203; DAVID M, 1992, SCIENCE, V257, P813, DOI 10.1126/science.1496402; FELDMAN GM, 1994, J BIOL CHEM, V269, P10747; FINBLOOM DS, 1994, MOL CELL BIOL, V14, P2113, DOI 10.1128/MCB.14.3.2113; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; GREENLUND AC, 1993, J BIOL CHEM, V268, P18103; GRONOWSKI AM, 1994, J BIOL CHEM, V269, P7874; ISHIZAKAIKEDA E, 1993, P NATL ACAD SCI USA, V90, P123, DOI 10.1073/pnas.90.1.123; KITAMURA T, 1994, TRENDS ENDOCRIN MET, V5, P8, DOI 10.1016/1043-2760(94)90115-5; KOZMA LM, 1991, METHOD ENZYMOL, V201, P28; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MEYER DJ, 1994, J BIOL CHEM, V269, P4701; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; PEARSE RN, 1993, P NATL ACAD SCI USA, V90, P4314, DOI 10.1073/pnas.90.9.4314; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; RUI H, 1994, J BIOL CHEM, V269, P5364; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVA CM, 1993, ENDOCRINOLOGY, V133, P2307, DOI 10.1210/en.133.5.2307; SILVA CM, 1993, ENDOCRINOLOGY, V132, P101, DOI 10.1210/en.132.1.101; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; THOREAU E, 1991, FEBS LETT, V282, P26, DOI 10.1016/0014-5793(91)80437-8; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WILSON KC, 1992, P NATL ACAD SCI USA, V89, P11964, DOI 10.1073/pnas.89.24.11964; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YUAN JP, 1994, MOL CELL BIOL, V14, P1657, DOI 10.1128/MCB.14.3.1657; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	50	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27532	27539						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7525556				2022-12-27	WOS:A1994PV77100059
J	LANIADOSCHWARTZMAN, M; LAVROVSKY, Y; STOLTZ, RA; CONNERS, MS; FALCK, JR; CHAUHAN, K; ABRAHAM, NG				LANIADOSCHWARTZMAN, M; LAVROVSKY, Y; STOLTZ, RA; CONNERS, MS; FALCK, JR; CHAUHAN, K; ABRAHAM, NG			ACTIVATION OF NUCLEAR FACTOR KAPPA-B AND ONCOGENE EXPRESSION BY 12(R)-HYDROXYEICOSATRIENOIC ACID, AN ANGIOGENIC FACTOR IN MICROVESSEL ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTACT-LENS WEAR; ARACHIDONIC-ACID; 12-HYDROXYEICOSATRIENOIC ACID; CORNEAL EPITHELIUM; PROTEIN SUBUNITS; GENE-EXPRESSION; METABOLISM; TISSUES; INITIATION; INDUCTION	12(R)-Hydroxy-5,8,14(Z,Z,Z)-eicosatrienoic acid (12(R)-HETrE) is an arachidonic acid metabolite formed by the corneal epithelium of several species, porcine leukocytes, and human and rat epidermal cells. It is a potent, stereospecific proinflammatory and angiogenic factor and its synthesis is increased manyfold in inflamed tissues, e.g. cornea and skin. It is possible that the angiogenic activity of 12(R)-HETrE is due to a direct mitogenic effect on microvessel endothelial cells via yet to be elucidated cellular and molecular mechanisms. In the present study, we demonstrated the ability of 12(R)-HETrE to stimulate the growth of quiescent endothelial cells in a time- and concentration-dependent manner with a maximal effect at 0.1 nM. This effect was highly stereospecific since its enantiomer, 12(S)-HETrE, had no effect within the same concentration range. Northern blot analysis and transient transfection experiments with chloramphenicol acetyltransferase constructs of oncogene promoter regions demonstrated significant increases over control (0.5% fetal calf serum) in c-myc, c-jun, and c-fos mRNA levels and expression in cells treated with 0.1 nM 12(R)-HETrE. Electrophoretic mobility shift assay of nuclear protein extracts from cells treated with 12(R)-HETrE with specific radiolabeled oligonucleotides corresponding to known transcriptional binding sites, including AP-1, AP-2, SP1, TRE, NF kappa B, TFIID, OKT1, CREB, CTF/NF1, and GRE demonstrated a markedly rapid and specific increase in the binding activity of NF kappa B and to a lesser extent, AP-1. No significant increase was observed in the binding of other transcription factors assayed as compared to control (untreated) cells. Since the protooncogenes (c-fos, c-jun, and c-myc) are immediate early response genes that are implicated in the process of cell proliferation and differentiation, and activation of certain transcription factors, in particular NF kappa B, is associated with the immediate response of the cell to an injury, we propose that 12(R)HETrE's mitogenic and angiogenic activities are mediated, in part, via the activation of NF kappa B and expression of these protooncogenes,	ROCKEFELLER UNIV HOSP, DEPT PHARMACOL, NEW YORK, NY 10021 USA; UNIV TEXAS, SW MED CTR, DEPT MOLEC GENET, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA	Rockefeller University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	LANIADOSCHWARTZMAN, M (corresponding author), NEW YORK MED COLL, DEPT PHARMACOL, VALHALLA, NY 10595 USA.			Falck, John/0000-0002-9219-7845	NEI NIH HHS [EY05613] Funding Source: Medline; NIGMS NIH HHS [GM31278] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031278] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1991, MOL ASPECTS CELL REG, V6, P409; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COLLINS T, 1993, LAB INVEST, V68, P499; CONNERS MS, 1993, INVEST OPHTH VIS SCI, V34, P1406; CONNERS MS, 1992, INVEST OPHTH VIS SCI, V33, P780; CONNERS MS, 1994, IN PRESS J INVEST DE; Cotran RS, 1989, ROBBINS PATHOLOGIC B; DAVIS KL, 1992, INVEST OPHTH VIS SCI, V33, P291; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Folkman J., 1992, INFLAMMATION BASIC P, P821; GERRITSEN ME, 1993, FASEB J, V7, P523, DOI 10.1096/fasebj.7.6.8472891; GERRITSEN ME, 1988, ADV CELL CULT, V6, P35; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAEBER JE, 1990, PROSTAGLANDINS, V39, P665, DOI 10.1016/0090-6980(90)90026-R; GRIFFIN M O, 1990, Investigative Ophthalmology and Visual Science, V31, P505; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; HOLTZMAN MJ, 1989, J CLIN INVEST, V84, P1446, DOI 10.1172/JCI114319; HURST JS, 1991, J BIOL CHEM, V266, P6726; IADEMARCO MF, 1992, J BIOL CHEM, V267, P16323; LAVROVSKY Y, 1994, GENE, V142, P285, DOI 10.1016/0378-1119(94)90276-3; LAVROVSKY YV, 1993, FEBS LETT, V316, P161, DOI 10.1016/0014-5793(93)81207-G; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LIN MT, 1993, BIOCHEM BIOPH RES CO, V190, P1122, DOI 10.1006/bbrc.1993.1166; MASFERRER JL, 1991, EXP EYE RES, V52, P417, DOI 10.1016/0014-4835(91)90037-F; MASFERRER JL, 1989, INVEST OPHTH VIS SCI, V30, P454; MURPHY RC, 1988, J BIOL CHEM, V263, P17197; NISHIMURA M, 1991, ARCH BIOCHEM BIOPHYS, V290, P326, DOI 10.1016/0003-9861(91)90548-W; PEPPER MS, 1993, J CELL BIOL, V122, P673, DOI 10.1083/jcb.122.3.673; SCHWARTZMAN ML, 1987, P NATL ACAD SCI USA, V84, P8125, DOI 10.1073/pnas.84.22.8125; SCHWARTZMAN ML, 1990, METHOD ENZYMOL, V187, P372; SCHWARTZMAN ML, 1987, CURR EYE RES, V6, P623, DOI 10.3109/02713688709025223; SCHWARTZMAN ML, 1993, INVEST OPHTH VIS SCI, V34, P1405; SETTY BNY, 1987, J BIOL CHEM, V262, P17613; SHIN DS, 1989, TETRAHEDRON LETT, V30, P3923, DOI 10.1016/S0040-4039(00)99285-2; SINKOVICS JG, 1988, CRC CR REV IMMUNOL, V8, P217; TRAVALI S, 1990, FASEB J, V4, P3209, DOI 10.1096/fasebj.4.14.2227212; VANWAUWE J, 1991, EICOSANOIDS, V4, P155; WAINWRIGHT S, 1990, BIOCHEMISTRY-US, V29, P10126, DOI 10.1021/bi00495a017; WILLIAMS RN, 1985, EXP EYE RES, V41, P733, DOI 10.1016/0014-4835(85)90181-2; YAMAMOTO S, 1993, BIOCHIM BIOPHYS ACTA, V1210, P217	44	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24321	24327						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7523372				2022-12-27	WOS:A1994PQ34600073
J	GRUBE, BJ; COCHRANE, CG				GRUBE, BJ; COCHRANE, CG			IDENTIFICATION OF A REGULATORY DOMAIN OF THE INTERLEUKIN-6 RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE-PHASE RESPONSE; STIMULATORY FACTOR-II; HUMAN GROWTH-HORMONE; HUMAN IL-6 RECEPTOR; B-CELL HYBRIDOMA; HEPATOMA-CELLS; EXTRACELLULAR DOMAIN; SIGNAL TRANSDUCTION; CRYSTAL-STRUCTURE; HUMAN CD4	IL-6 signal transduction occurs when the liganded interleukin-6 receptor (IL-6R) interacts with glycoprotein (gp) 130. We hypothesized that synthetic peptides modeled from the extramembranous domain of the IL-6R may interfere with the IL-6-induced reaction between IL-6R and gp130 and may serve to elucidate the initial steps in IL-6 signal transduction. The capacity of such peptides to modulate two different IL-6 functions was evaluated: 1) IL-6-dependent B9 cell mitogenesis, and 2) IL-6-induced acute phase protein synthesis in HepG2 cells. A synthetic peptide, (249)Y16T(264), corresponding to residues 249-264, inhibited IL-6-dependent B9 proliferation and IL-6-induced acute phase protein up-regulation in HepG2 cells. Other peptides modeled from different regions of the IL-6R were not inhibitory. (249)Y16T(264) did not inhibit IL-6-independent HepG2 cell proliferation or total cellular protein synthesis. The inhibitory effect was reversible, indicating that the peptide was not cytotoxic. (249)Y16T(264) did not inhibit I-125-IL-6 binding in U266 cells. Delineation of this domain identified (249)Y10R(258) as the minimum effective sequence capable of inhibiting fibrinogen synthesis. Amino acid substitutions in (249)Y10R(258) obliterated the inhibitory effect on fibrinogen synthesis. In conclusion, a region of the extramembranous domain of the IL-6R has been identified that is involved in the regulation of IL-6 signal transmission. A synthetic peptide representing this region inhibits IL-6-dependent B9 cell mitogenesis and IL-6-stimulated acute phase response in HepG2 cells without affecting ligand binding.			GRUBE, BJ (corresponding author), SCRIPSS RES INST, DEPT IMMUNOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.				NIGMS NIH HHS [GM-37696] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM037696] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AARDEN LA, 1987, EUR J IMMUNOL, V17, P1411, DOI 10.1002/eji.1830171004; BAUMANN H, 1990, MOL BIOL MED, V7, P147; BAUMANN H, 1988, J BIOL CHEM, V263, P17390; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BAZAN JF, 1989, BIOCHEM BIOPH RES CO, V164, P788, DOI 10.1016/0006-291X(89)91528-3; COULIE PG, 1987, EUR J IMMUNOL, V17, P1435, DOI 10.1002/eji.1830171008; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DALESSANDRO F, 1993, J BIOL CHEM, V268, P2149; DARLINGTON GJ, 1987, IN VITRO CELL DEV B, V23, P349; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DUKOVICH M, 1987, NATURE, V327, P518, DOI 10.1038/327518a0; FIORILLO MT, 1992, EUR J IMMUNOL, V22, P799, DOI 10.1002/eji.1830220325; GRUBE BJ, 1994, J BIOL CHEM, V269, P8477; GRUBE BJ, 1993, J IMMUNOL, V150, pA217; GRUBE BJ, 1993, CIRC SHOCK S2, V39, P47; HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANSDORP PM, 1986, CURR TOP MICROBIOL, V132, P105; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MACKIEWICZ A, 1992, J IMMUNOL, V149, P2021; MACKIEWICZ A, 1992, FEBS LETT, V306, P257, DOI 10.1016/0014-5793(92)81012-B; MARKWELL MAK, 1982, ANAL BIOCHEM, V125, P427, DOI 10.1016/0003-2697(82)90025-2; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; MYRSET AH, 1993, EUR J CELL BIOL, V60, P108; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; NAKAJIMA T, 1992, JPN J CANCER RES, V83, P373, DOI 10.1111/j.1349-7006.1992.tb00117.x; PIETZKO D, 1993, J BIOL CHEM, V268, P4250; ROSEJOHN S, 1991, J BIOL CHEM, V266, P3841; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SABOURIN LA, 1990, J CELL PHYSIOL, V145, P564, DOI 10.1002/jcp.1041450325; SAVINO R, 1994, EMBO J, V13, P1357, DOI 10.1002/j.1460-2075.1994.tb06389.x; SAVINO R, 1993, P NATL ACAD SCI USA, V90, P4067, DOI 10.1073/pnas.90.9.4067; SCHRAUFSTATTER IU, 1986, J CLIN INVEST, V77, P1312, DOI 10.1172/JCI112436; SCHREIBER G, 1982, J BIOL CHEM, V257, P271; STANLEY ER, 1981, J IMMUNOL METHODS, V42, P253, DOI 10.1016/0022-1759(81)90156-3; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAGA T, 1987, J EXP MED, V166, P967, DOI 10.1084/jem.166.4.967; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TESHIGAWARA K, 1987, J EXP MED, V165, P223, DOI 10.1084/jem.165.1.223; VANDAM M, 1993, J BIOL CHEM, V268, P15285; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.immunol.8.1.253; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YASUKAWA K, 1990, J BIOCHEM-TOKYO, V108, P673, DOI 10.1093/oxfordjournals.jbchem.a123261; YAWATA H, 1993, EMBO J, V12, P1705, DOI 10.1002/j.1460-2075.1993.tb05815.x; ZOHLNHOFER D, 1992, FEBS LETT, V306, P219, DOI 10.1016/0014-5793(92)81004-6	49	12	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20791	20797						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	7519615				2022-12-27	WOS:A1994PB31700088
J	ZHAN, X; PLOURDE, C; KU, XG; FRIESEL, R; MACIAG, T				ZHAN, X; PLOURDE, C; KU, XG; FRIESEL, R; MACIAG, T			ASSOCIATION OF FIBROBLAST GROWTH-FACTOR RECEPTOR-1 WITH C-SRC CORRELATES WITH ASSOCIATION BETWEEN C-SRC AND CORTACTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ROUS-SARCOMA VIRUS; TRANSFORMED CELLS; FACTOR-I; TYROSINE PHOSPHORYLATION; NUCLEAR TRANSLOCATION; PP60(SRC) SUBSTRATE; PP60SRC SUBSTRATE; HUMAN CARCINOMAS; FOCAL ADHESIONS; 3T3 CELLS	The initiation of maximal DNA synthesis by fibroblast growth factor (FGF)-1 requires the presence of the growth factor during the entire G(0) to G(1) transition period of the cell cycle (Zhan, X., Hu, X., Friesel, R., and Maciag, T. (1993) J. Biol. Chem. 268, 9611-9620). During this time, the phosphorylation of several novel proteins on tyrosine residues occurs, and one of these phosphotyrosyl-containing proteins has been characterized as the murine homolog of the chicken cortactin gene (Zhan, X., Hu, X., Hampton, B., Burgess, W. H., Friesel, R., and Maciag, T. (1993) J. Biol. Chem. 268, 24427-24431), a putative substrate for v-Src. We have examined the possibility that FGF-1 employs c-Src or Src-like kinases as signaling intermediates during the mid and late G(1) phase of the NIH 3T3 cell cycle using immunoprecipitation and immunoblot analysis. We have demonstrated that c-Src can associate with cortactin in a FGF-1-dependent manner. We have also demonstrated that a monoclonal antibody prepared against FGF receptor (R)-1 is able to co-precipitate Src-related proteins in lysates from FGF-1-treated NIH 3T3 cells. Furthermore, a kinase-active form of FGFR-1 expressed in a bacterial system was also able to associate with Src kinases in a manner dependent on the phosphorylation status of the FGFR-1 protein. Lastly, the Src homology (SH)-2 domain of v-Src was able to recognize a recombinant form of FGFR-1. Because (i) the association between FGFR-1 and Src-like kinases exhibits kinetics similar to those observed between the Src kinases and cortactin and (ii) the Src-SH2 domain is likely to be involved in the association with FGFR-1, we propose that the association of c-Src with activated FGF receptors may be responsible for the tyrosine phosphorylation of cortactin during the mid to late G(1) phase of the cell cycle.	AMER RED CROSS,HOLLAND LAB,DEPT MOLEC BIOL,ROCKVILLE,MD 20855; ST FRANCIS HOSP & MED CTR,HOFFMAN HEART INST,RES DEPT,HARTFORD,CT 06105; UNIV CONNECTICUT,SCH MED,DEPT MED,FARMINGTON,CT 06030	American Red Cross; Saint Francis Hospital & Medical Center; University of Connecticut					NHLBI NIH HHS [HL44336, HL32348] Funding Source: Medline; NICHD NIH HHS [HD29561] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD029561] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL044336, R01HL032348] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRICKELL P M, 1992, Critical Reviews in Oncogenesis, V3, P401; BROWN SAN, 1993, BIOCHEM BIOPH RES CO, V193, P1116, DOI 10.1006/bbrc.1993.1741; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; DAVIS S, 1991, SCIENCE, V252, P712, DOI 10.1126/science.1708917; DECLUE JE, 1987, MOL CELL BIOL, V7, P371, DOI 10.1128/MCB.7.1.371; FLYNN DC, 1993, MOL CELL BIOL, V13, P7892, DOI 10.1128/MCB.13.12.7892; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; KANNER SB, 1991, MOL CELL BIOL, V11, P713, DOI 10.1128/MCB.11.2.713; KITAMURA D, 1989, NUCLEIC ACIDS RES, V17, P9367; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LIEBL EC, 1992, ONCOGENE, V7, P2417; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; REYNOLDS AB, 1992, ONCOGENE, V7, P2439; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHUURING E, 1993, MOL CELL BIOL, V13, P2891, DOI 10.1128/MCB.13.5.2891; SCHUURING E, 1992, ONCOGENE, V7, P355; SEFTON BM, 1981, CELL, V24, P165, DOI 10.1016/0092-8674(81)90512-2; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; YAMANASHI Y, 1993, P NATL ACAD SCI USA, V90, P3631, DOI 10.1073/pnas.90.8.3631; ZHAN X, 1993, J BIOL CHEM, V268, P24427; ZHAN X, 1992, BIOCHEM BIOPH RES CO, V188, P982, DOI 10.1016/0006-291X(92)91328-N; ZHAN X, 1993, J BIOL CHEM, V268, P9611; ZHAN X, 1986, MOL CELL BIOL, V6, P3541, DOI 10.1128/MCB.6.10.3541	30	159	159	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20221	20224						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	7519605				2022-12-27	WOS:A1994PB31700004
J	SEIFFERT, D; CRAIN, K; WAGNER, NV; LOSKUTOFF, DJ				SEIFFERT, D; CRAIN, K; WAGNER, NV; LOSKUTOFF, DJ			VITRONECTIN GENE-EXPRESSION IN-VIVO - EVIDENCE FOR EXTRAHEPATIC SYNTHESIS AND ACUTE-PHASE REGULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR; POLYMERASE CHAIN-REACTION; S-PROTEIN VITRONECTIN; NECROSIS-FACTOR-ALPHA; GROWTH-FACTOR-BETA; MESSENGER-RNA; ANTITHROMBIN-III; BINDING-PROTEIN; TYPE-1; SPECIFICITY	A competitive polymerase chain reaction (PCR) assay was developed to quantitate vitronectin (Vn) mRNA in murine tissues using a synthetic RNA as an external standard. Although the liver contained the highest concentration of Vn mRNA, significant levels were also detected in the brain (25-fold less) and in adipose tissue, heart, and skeletal muscle (100-fold less than liver). Lower concentrations also were detected in the lung, uterus, testis, and thymus, and little or no Vn mRNA could be detected in kidney, spleen, and blood. These results indicate that significant amounts of Vn mRNA are produced in extrahepatic organs. The regulation of Vn gene expression in vivo was studied in a murine model system in which acute systemic inflammation was induced by endotoxin administration. Plasma Vn levels increased 2- to 3-fold within 16 h after endotoxin administration and remained elevated for up to 72 h. This increase appeared to result from increased synthesis in the liver since the steady-state level of hepatic Vn mRNA increased 4-fold after endotoxin administration. Moreover, Vn mRNA levels in heart, lung, and brain were not significantly increased by endotoxin. These results suggest that Vn gene expression in vivo is regulated in a tissue-specific manner and identify Vn as a novel acute phase reactant.			SEIFFERT, D (corresponding author), SCRIPPS RES INST, DEPT VASC BIOL VB3, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.				NHLBI NIH HHS [HL48728, HL31950] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048728, P01HL031950] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x; CHELLY J, 1989, P NATL ACAD SCI USA, V86, P2617, DOI 10.1073/pnas.86.8.2617; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER S, 1993, INT CONGR SER, V1042, P83; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DECLERCK PJ, 1988, J BIOL CHEM, V263, P15454; EHRLICH HJ, 1990, J BIOL CHEM, V265, P13029; Gauldie J, 1991, CYTOKINES INFLAMMATI, P275; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; HARLOW E, 1988, ANTIBODIES LABORATOR; ILL CR, 1985, J BIOL CHEM, V260, P5610; JENNE D, 1985, EMBO J, V4, P3153, DOI 10.1002/j.1460-2075.1985.tb04058.x; KOLI K, 1991, EUR J BIOCHEM, V199, P337, DOI 10.1111/j.1432-1033.1991.tb16129.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOSKUTOFF DJ, 1989, PROG HEMOST THROMB, V9, P87; MIMURO J, 1989, J BIOL CHEM, V264, P936; MULLEREBERHARD HJ, 1988, ANNU REV BIOCHEM, V57, P321, DOI 10.1146/annurev.biochem.57.1.321; NASKI MC, 1993, J BIOL CHEM, V268, P12367; PODOR TJ, 1993, THROMB HAEMOSTASIS, V69, P1026; PREISSNER KT, 1991, ANNU REV CELL BIOL, V7, P275, DOI 10.1146/annurev.cellbio.7.1.275; PREISSNER KT, 1987, J BIOL CHEM, V262, P12247; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SARKAR G, 1989, SCIENCE, V244, P331, DOI 10.1126/science.2565599; SAWA H, 1993, CIRC RES, V73, P671, DOI 10.1161/01.RES.73.4.671; SAWDEY M, 1989, J BIOL CHEM, V264, P10396; SAWDEY MS, 1991, J CLIN INVEST, V88, P1346, DOI 10.1172/JCI115440; SEIFFERT D, 1990, J CELL BIOL, V111, P1283, DOI 10.1083/jcb.111.3.1283; SEIFFERT D, 1991, P NATL ACAD SCI USA, V88, P9402, DOI 10.1073/pnas.88.21.9402; SEIFFERT D, 1993, GENE, V134, P303, DOI 10.1016/0378-1119(93)90113-H; SEIFFERT D, 1993, INT CONGR SER, V1042, P75; SOLEM M, 1991, MOL CELL BIOCHEM, V100, P141; SUZUKI S, 1985, EMBO J, V4, P2519, DOI 10.1002/j.1460-2075.1985.tb03965.x; TOMASINI BR, 1990, PROGR HEMOSTASIS THR, P269; VANDENHEUVEL JP, 1993, BIOTECHNIQUES, V14, P395; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717; WIMAN B, 1988, THROMB HAEMOSTASIS, V59, P392	36	70	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					19836	19842						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	7519600				2022-12-27	WOS:A1994PA12600030
J	PETRONILLI, V; COSTANTINI, P; SCORRANO, L; COLONNA, R; PASSAMONTI, S; BERNARDI, P				PETRONILLI, V; COSTANTINI, P; SCORRANO, L; COLONNA, R; PASSAMONTI, S; BERNARDI, P			THE VOLTAGE SENSOR OF THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE IS TUNED BY THE OXIDATION-REDUCTION STATE OF VICINAL THIOLS - INCREASE OF THE GATING POTENTIAL BY OXIDANTS AND ITS REVERSAL BY REDUCING AGENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; CA-2+-INDUCED MEMBRANE TRANSITION; PARA-BENZOQUINONE IMINE; CYCLOSPORINE-A; HEART-MITOCHONDRIA; DIVALENT-CATIONS; CA-2+-DEPENDENT PORE; PROTECTS HEPATOCYTES; RECEPTOR-CHANNEL; INNER MEMBRANE	Reaction of isolated mitochondria with a variety of agents that lead to oxidation or cross-linking of sulfhydryl groups leads to an increased ''open'' probability of the permeability transition pore, a cyclosporin A-sensitive channel. We have investigated the mechanism by which the pore is induced by menadione, diamide, arsenite, and tert-butylhydroperoxide. We find that these inducers increase the probability of pore opening by shifting its gating potential to higher values. Furthermore, the induced shift was prevented by treatment with N-ethylmaleimide or dithiothreitol. At moderate levels of depolarization an apparent I-50 for N-ethylmaleimide of about 5 mu M can be defined, while the N-ethylmaleimide or dithiothreitol effects are overcome by maximal depolarization. We conclude that the oxidation-reduction state of vicinal thiols in cysteinyl residues plays a critical role in tuning the voltage sensor of the transition pore, with an increase of gating potential (i.e. an increase in the probability of pore opening despite a high transmembrane potential difference) as the couple is poised to a more oxidized state. These findings may have implications for the mechanism of cell damage under oxidative stress.	UNIV PADUA,SCH MED,CNR,STUDY PHYSIOL MITOCHONDRIA UNIT,I-35121 PADUA,ITALY; UNIV PADUA,SCH MED,DEPT BIOMED SCI,BIOPHYS & MEMBRANE BIOL LAB,I-35121 PADUA,ITALY; UNIV TRIESTE,DEPT BIOCHEM BIOPHYS & CHEM MACROMOLECULES,I-34127 TRIESTE,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Padua; University of Padua; University of Trieste			Petronilli, Valeria/C-3558-2015; Scorrano, Luca/A-6652-2008; Sabina Passamonti, Medical degree/G-4299-2012; Bernardi, Paolo/C-3656-2008	Petronilli, Valeria/0000-0003-4026-6404; Scorrano, Luca/0000-0002-8515-8928; Sabina Passamonti, Medical degree/0000-0001-7876-4666; Bernardi, Paolo/0000-0001-9187-3736				AIZENMAN E, 1989, NEURON, V2, P1257, DOI 10.1016/0896-6273(89)90310-3; ALNASSER I, 1986, BIOCHEM J, V239, P19, DOI 10.1042/bj2390019; ASMUS KD, 1990, METHOD ENZYMOL, V186, P168; BEATRICE MC, 1984, J BIOL CHEM, V259, P1279; BELLOMO G, 1984, EUR J BIOCHEM, V140, P1, DOI 10.1111/j.1432-1033.1984.tb08058.x; BELLOMO G, 1982, J BIOL CHEM, V257, P1558; BELLOMO G, 1980, METHOD ENZYMOL, V186, P627; BERNARDI P, 1992, J BIOL CHEM, V267, P2934; BERNARDI P, 1993, J BIOL CHEM, V268, P1005; BERNARDI P, 1992, J BIOL CHEM, V267, P8834; BERNARDI P, 1984, EUR J BIOCHEM, V134, P377; BROEKEMEIER KM, 1992, FEBS LETT, V304, P192, DOI 10.1016/0014-5793(92)80616-O; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; CROMPTON M, 1987, BIOCHEM J, V245, P915, DOI 10.1042/bj2450915; CROMPTON M, 1988, BIOCHEM J, V255, P357; CROMPTON M, 1988, EUR J BIOCHEM, V178, P488; DALTON LA, 1993, BIOCHEM J, V269, P563; DIMONTE D, 1984, ARCH BIOCHEM BIOPHYS, V235, P343, DOI 10.1016/0003-9861(84)90207-8; FLIER EAM, 1984, BIOCHEMISTRY-US, V23, P5142; FOURNIER N, 1987, J BIOENERG BIOMEMBR, V19, P297, DOI 10.1007/BF00762419; GRIFFITHS EJ, 1993, J MOL CELL CARDIOL, V25, P1461, DOI 10.1006/jmcc.1993.1162; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; HALESTRAP AP, 1990, BIOCHEM J, V268, P153, DOI 10.1042/bj2680153; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HAWORTH RA, 1979, ARCH BIOCHEM BIOPHYS, V195, P460, DOI 10.1016/0003-9861(79)90372-2; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P453, DOI 10.1016/0003-9861(79)90371-0; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P468, DOI 10.1016/0003-9861(79)90373-4; IGBAVBOA U, 1988, J BIOL CHEM, V263, P1405; IGBAVBOA U, 1991, J BIOL CHEM, V266, P4283; IMBERTI R, 1993, J PHARMACOL EXP THER, V265, P392; JEWELL SA, 1982, SCIENCE, V217, P1257, DOI 10.1126/science.7112127; JIMENEZ JS, 1982, BIOCHEMISTRY-US, V21, P1623, DOI 10.1021/bi00536a024; KASS GEN, 1992, BIOCHEM PHARMACOL, V44, P1995, DOI 10.1016/0006-2952(92)90102-O; KINNALLY KW, 1989, J BIOENERG BIOMEMBR, V21, P497, DOI 10.1007/BF00762521; KOSOWER NS, 1969, BIOCHEM BIOPH RES CO, V37, P593, DOI 10.1016/0006-291X(69)90850-X; KOSOWER NS, 1987, METHOD ENZYMOL, V143, P264; LEI SZ, 1992, NEURON, V8, P1087, DOI 10.1016/0896-6273(92)90130-6; LOTSCHER HR, 1979, P NATL ACAD SCI USA, V76, P4340, DOI 10.1073/pnas.76.9.4340; MOORE M, 1985, J BIOL CHEM, V260, P3035; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; NAZARETH W, 1991, J MOL CELL CARDIOL, V23, P1351, DOI 10.1016/0022-2828(91)90181-K; NICOLLI A, 1993, BIOCHEMISTRY-US, V32, P4461, DOI 10.1021/bi00067a039; NOVGORODOV SA, 1987, J BIOENERG BIOMEMBR, V19, P191, DOI 10.1007/BF00762412; PASSAMONTI S, 1989, BIOCHIM BIOPHYS ACTA, V979, P294, DOI 10.1016/0005-2736(89)90247-2; PASTORINO JG, 1993, J BIOL CHEM, V268, P13791; PETRONILLI V, 1993, J BIOL CHEM, V268, P1011; PETRONILLI V, 1989, FEBS LETT, V259, P137, DOI 10.1016/0014-5793(89)81513-3; PETRONILLI V, 1993, J BIOL CHEM, V268, P21939; ROBILLARD GT, 1982, EUR J BIOCHEM, V127, P597; SILIPRANDI D, 1978, Journal of Bioenergetics and Biomembranes, V10, P1, DOI 10.1007/BF00743223; SZABO I, 1992, J BIOL CHEM, V267, P2940; SZABO I, 1991, J BIOL CHEM, V266, P3376; SZABO I, 1992, J BIOENERG BIOMEMBR, V24, P111, DOI 10.1007/BF00769537; TANG LH, 1993, MOL PHARMACOL, V44, P473; THOR H, 1982, J BIOL CHEM, V257, P2419; WEIS M, 1992, J BIOL CHEM, V267, P804; ZAHLER WL, 1968, J BIOL CHEM, V243, P716; ZORATTI M, 1986, BIOCHEMISTRY-US, V25, P760, DOI 10.1021/bi00352a004	59	486	491	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16638	16642						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	7515881				2022-12-27	WOS:A1994NR29600021
J	HUSI, H; LUYTEN, MA; ZURINI, MGM				HUSI, H; LUYTEN, MA; ZURINI, MGM			MAPPING OF THE IMMUNOPHILIN-IMMUNOSUPPRESSANT SITE OF INTERACTION ON CALCINEURIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDYL-PROLYL ISOMERASE; CYCLOSPORINE-A; MOLECULAR-CLONING; HUMAN CYCLOPHILIN; PROTEIN; ACTIVATION; RAPAMYCIN; RECEPTOR; COMPLEX; IDENTIFICATION	The interaction of the immunosuppressive complexes cyclosporin A-cyclophilin A and FK506 binding protein-FK506 with the Ca2+- and calmodulin-dependent protein phosphatase calcineurin has been investigated by means of photoaffinity labeling and chemical cross-linking. Photolabeling of purified bovine brain calcineurin with the affinity label [O-[4-[4-(1-diazo-2,2,2-trifluoroethyl)benzoyl] aminobutanoyl]-D-serine(8)]cyclosporin in the presence of cyclophilin A results, in addition to the labeling of cyclophilin itself, in the transfer of some of the chemical probe to both the catalytic subunit A and the regulatory subunit B of calcineurin. Chemical cross-linking studies with disuccinimidyl suberate in the presence of either cyclophilin A, B, or C in complex with cyclosporin A or FK506 binding protein-FK506 result on the other hand in the apparently exclusive and strictly immunosuppressant-dependent formation of covalent immunophilin-calcineurin B subunit products. Cross-linking of immunophilins to calcineurin B subunit requires the presence of subunit A. In the present study, using a set of recombinant maltose-binding protein fusion products representing different stretches of the catalytic subunit A, we were able to map the minimal calcineurin A sequence necessary for immunophilin-ligand-calcineurin B interaction to occur.	SANDOZ PHARMA LTD,PRECLIN RES,MOLEC BIOL LAB,DRUG DESIGN GRP,CH-4002 BASEL,SWITZERLAND	Novartis; Sandoz	HUSI, H (corresponding author), SANDOZ PHARMA LTD,PRECLIN RES,BIOCHEM LAB,DRUG DESIGN GRP,CH-4002 BASEL,SWITZERLAND.							ALDAPE RA, 1992, J BIOL CHEM, V267, P16029; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COHEN DJ, 1984, ANN INTERN MED, V101, P667, DOI 10.7326/0003-4819-101-5-667; DEDMAN JR, 1983, METHOD ENZYMOL, V102, P1; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FOXWELL BMJ, 1992, BIOCHIM BIOPHYS ACTA, V1138, P1115; FRANSSON C, 1992, FEBS LETT, V296, P90, DOI 10.1016/0014-5793(92)80410-I; FRIEDMAN J, 1991, CELL, V66, P799, DOI 10.1016/0092-8674(91)90123-G; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; GUERINI D, 1992, J BIOL CHEM, V267, P22542; HADDY A, 1992, FEBS LETT, V314, P37, DOI 10.1016/0014-5793(92)81456-V; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HASHIMOTO Y, 1990, J BIOL CHEM, V265, P1924; JIN YJ, 1991, P NATL ACAD SCI USA, V88, P6677, DOI 10.1073/pnas.88.15.6677; KAHAN BD, 1991, TRANSPLANTATION, V52, P185, DOI 10.1097/00007890-199108000-00001; KALLEN J, 1991, NATURE, V353, P276, DOI 10.1038/353276a0; KIEFFER LJ, 1992, J BIOL CHEM, V267, P5503; KINCAID RL, 1990, J BIOL CHEM, V265, P11312; KINCAID RL, 1988, P NATL ACAD SCI USA, V85, P8983, DOI 10.1073/pnas.85.23.8983; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CY, 1982, ANAL BIOCHEM, V111, P385; LI W, 1993, J BIOL CHEM, V268, P14040; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1990, P NATL ACAD SCI USA, V87, P2304, DOI 10.1073/pnas.87.6.2304; MANALAN AS, 1983, P NATL ACAD SCI-BIOL, V80, P4291, DOI 10.1073/pnas.80.14.4291; MICHNICK SW, 1991, SCIENCE, V252, P836, DOI 10.1126/science.1709301; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; PALLEN CJ, 1988, CALCIUM BINDING PROT, V1, P51; PFLUGL G, 1993, NATURE, V361, P91, DOI 10.1038/361091a0; PRICE ER, 1991, P NATL ACAD SCI USA, V88, P1903, DOI 10.1073/pnas.88.5.1903; RATAJCZAK T, 1993, J BIOL CHEM, V268, P13187; SCHONBRUNNER ER, 1991, J BIOL CHEM, V266, P3630; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SIGAL NH, 1991, J EXP MED, V173, P619, DOI 10.1084/jem.173.3.619; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0; SWANSON SKH, 1992, P NATL ACAD SCI USA, V89, P3741, DOI 10.1073/pnas.89.9.3741; TAI PKK, 1992, SCIENCE, V256, P1315, DOI 10.1126/science.1376003; THOMSON AW, 1989, IMMUNOL TODAY, V10, P6, DOI 10.1016/0167-5699(89)90057-1; UEKI K, 1993, J BIOL CHEM, V268, P6554; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; YANG D, 1993, J AM CHEM SOC, V115, P819, DOI 10.1021/ja00055a081	41	45	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14199	14204						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	7514602				2022-12-27	WOS:A1994NL60600072
J	NODA, K; SAAD, Y; KINOSHITA, A; BOYLE, TP; GRAHAM, RM; HUSAIN, A; KARNIK, SS				NODA, K; SAAD, Y; KINOSHITA, A; BOYLE, TP; GRAHAM, RM; HUSAIN, A; KARNIK, SS			TETRAZOLE AND CARBOXYLATE GROUPS OF ANGIOTENSIN RECEPTOR ANTAGONISTS BIND TO THE SAME SUBSITE BY DIFFERENT MECHANISMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II RECEPTOR; ANTIHYPERTENSIVES; DISCOVERY; POTENT	To identify specific interactions between either the tetrazole or carboxylate pharmacophores of non-peptide antagonists and the rat AT(1) receptor, 6 basic residues were examined by site-directed mutagenesis. Three of the mutants (H183Q, H256Q, and H272Q) appeared to be like wild type. Lys(102) and Arg(167) mutants displayed reduced binding of the non-peptide antagonist losartan. Examination of their properties employing group-specific angiotensin II analogues indicated that their effects on binding were indirect. Interestingly, the affinity of losartan was not altered by a K199Q mutation, but the same mutation reduced the affinity of angiotensin II, the antagonist [Sar(1),Ile(8)]angiotensin II, and several carboxylate analogues of losartan. An Ala(199) substitution reduced the affinity of peptide analogues to a larger extent as compared to the affinity of losartan, Thus, the crucial acidic pharmacophores of angiotensin and losartan appear to occupy the same space within the receptor pocket, but the protonated amino group of Lys(199) is not essential for binding the tetrazole anion. The binding of the tetrazole moiety with the AT(1) receptor involves multiple contacts with residues such as Lys(199) and His(256) that constitute the same subsite of the ligand binding pocket, However, this interaction does not involve a conventional salt bridge, but rather an unusual lysine-aromatic interaction.	CLEVELAND CLIN FDN,DEPT MOLEC CARDIOL,RES INST,CLEVELAND,OH 44195	Cleveland Clinic Foundation			Karnik, Sadashiva/Y-2477-2019; Husain, Ahsan/J-6861-2012	Karnik, Sadashiva/0000-0003-0746-2753; Husain, Ahsan/0000-0003-3426-3469	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL033713] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL33713, R01 HL057470] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BIHAREAU C, 1993, P NATL ACAD SCI USA, V90, P5133; BUMPUS FM, 1977, HYPERTENSION PHYSIOP, P183; CARINI DJ, 1991, J MED CHEM, V34, P2525, DOI 10.1021/jm00112a031; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Creighton T. E., 1984, PROTEINS STRUCTURES, V2nd; DUNCIA JV, 1990, J MED CHEM, V33, P1312, DOI 10.1021/jm00167a007; ERIKSSON AE, 1992, SCIENCE, V255, P179; FERRETTI L, 1986, P NATL ACAD SCI USA, V83, P599, DOI 10.1073/pnas.83.3.599; FONG TM, 1994, NATURE, V362, P350; Furakawa Y, 1982, U. S. Patent, Patent No. [4340 598, 4355 040, 4340598]; FURUKAWA Y, 1982, Patent No. 4355040; HENDSCH ZS, 1994, PROTEIN SCI, V3, P211; HSIEH KH, 1986, J MED CHEM, V29, P1968, DOI 10.1021/jm00160a028; HUSAIN A, 1986, J PHARMACOL EXP THER, V2339, P71; JI H, 1994, J BIOL CHEM, V269, P16533; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P537, DOI 10.1016/0076-6879(90)85044-O; MARIE J, 1994, J BIOL CHEM, V269, P20815; MARSHALL GR, 1974, RECENT ADV RENAL PHY, P215; MITCHELL JBO, 1994, J MOL BIOL, V239, P315, DOI 10.1006/jmbi.1994.1370; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; NODA K, 1994, J BIOL CHEM, V269, P6743; PRENDERGAST K, 1994, J COMPUT AID MOL DES, V8, P491, DOI 10.1007/BF00123662; PUCELL AG, 1987, J BIOL CHEM, V262, P7076; RAO VR, 1994, NATURE, V367, P639, DOI 10.1038/367639a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAMBYE HT, 1994, P NATL ACAD SCI USA, V91, P7046, DOI 10.1073/pnas.91.15.7046; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205; YAMANO Y, 1992, BIOCHEM BIOPH RES CO, V187, P1426, DOI 10.1016/0006-291X(92)90461-S	29	168	169	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 3	1995	270	5					2284	2289		10.1074/jbc.270.5.2284	http://dx.doi.org/10.1074/jbc.270.5.2284			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QE493	7530721	hybrid			2022-12-27	WOS:A1995QE49300048
J	FURUYA, S; IRIE, F; HASHIKAWA, T; NAKAZAWA, K; KOZAKAI, A; HASEGAWA, A; SUDO, K; HIRABAYASHI, Y				FURUYA, S; IRIE, F; HASHIKAWA, T; NAKAZAWA, K; KOZAKAI, A; HASEGAWA, A; SUDO, K; HIRABAYASHI, Y			GANGLIOSIDE GD1-ALPHA IN CEREBELLAR PURKINJE-CELLS - ITS SPECIFIC ABSENCE IN MOUSE MUTANTS WITH PURKINJE-CELL ABNORMALITY AND ALTERED IMMUNOREACTIVITY IN RESPONSE TO CONJUNCTIVE STIMULI CAUSING LONG-TERM DESENSITIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-CONTAINING GLYCOSPHINGOLIPIDS; HANGANUTZIU-DEICHER ANTIGENS; RAT ASCITES HEPATOMA; ADULT BOVINE BRAINS; MONOCLONAL-ANTIBODY; IMMUNOHISTOCHEMICAL LOCALIZATION; STAGGERER MUTANT; MURINE MUTANTS; WEAVER MUTANT; MICE	The alpha-series ganglioside, IV(3)NeuAc,III(6)NeuAcGgOse(4)-Cer (G(D1 alpha)), was previously identified as a minor constituent in bovine brain gangliosides (Hirabayashi, Y., Hyogo, A., Nakao, T., Tsuchiya, K., Suzuki, Y., Matsumoto, M., Kon, K, and Ando, S. (1990) J. Biol. Chem. 265, 8144-8151). In the present study, we have generated a specific mouse monoclonal antibody against G(D1 alpha) and explored the distribution of G(D1 alpha) in murine central nervous system. In adult rat brain, G(D1 alpha) occurred as a minor constituent, and its expression was exclusively detected in the mouse cerebellum, the content of G(D1 alpha) was reduced significantly in the Purkinje cell-deficient mutants, lurcher (Lc/+), staggerer (sg/sg), and Purkinje cell degeneration (pcd/pcd), but were not reduced in the weaver (wv/wv) mutant, which loses mostly granule cells. The G(D1 alpha) synthase, assayed in cerebellar microsomes, was also reduced in Purkinje cell-deficient mutants. Immunohistochemistry showed that the staining for G(D1 alpha) in rat and mouse cerebella was mostly found in the proximal dendrites and cell bodies of Purkinje cells. Also, it appeared slightly in the processes of Bergmann glial cells. The immunoreactivity of G(D1 alpha) disappeared specifically from the Purkinje cell dendrites and the Bergmann glial processes after co-application of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and 8-bromo-guanosine 3':5'-cyclic monophosphate, which induced long-term desensitization of the AMPA-selective glutamate receptors in Purkinje cells. The present data provide suggestive evidence that G(d1 alpha) ganglioside is enriched in Purkinje cells and may have a role in Purkinje cell functions in the cerebellum.	INST PHYS & CHEM RES,GLYCOCELL BIOL LAB,WAKO,SAITAMA 35101,JAPAN; INST PHYS & CHEM RES,NEURAL SYST LAB,WAKO,SAITAMA 35101,JAPAN; INST PHYS & CHEM RES,NEURAL NETWORKS LAB,FRONTIER RES PROGRAM,WAKO,SAITAMA 35101,JAPAN; GIFU UNIV,FAC AGR,DEPT APPL BIOORGAN CHEM,GIFU 50111,JAPAN; UNIV TOKYO,INST MED SCI,ANIM RES CTR,TOKYO 108,JAPAN; UNIV TOKYO,FAC MED,DEPT PHYSIOL CHEM & NUTR,TOKYO 113,JAPAN	RIKEN; RIKEN; RIKEN; Gifu University; University of Tokyo; University of Tokyo			Nakazawa, Kazutoshi/J-6195-2015	Nakazawa, Kazutoshi/0000-0001-5699-9093; Furuya, Shigeki/0000-0001-9020-3597; Hirabayashi, Yoshio/0000-0002-5774-7354				ANDO S, 1992, J BIOCHEM, V111, P287, DOI 10.1093/oxfordjournals.jbchem.a123751; ARIGA T, 1987, J LIPID RES, V28, P285; CADDY KWT, 1979, PHILOS T ROY SOC B, V287, P167, DOI 10.1098/rstb.1979.0055; CADDY KWT, 1976, BRAIN RES, V111, P396, DOI 10.1016/0006-8993(76)90783-6; CHOU DKH, 1990, J NEUROCHEM, V54, P1598, DOI 10.1111/j.1471-4159.1990.tb01210.x; CHOU DKH, 1988, J NEUROCHEM, V50, P1655, DOI 10.1111/j.1471-4159.1988.tb03056.x; CHOU DKH, 1990, J NEUROCHEM, V54, P1589, DOI 10.1111/j.1471-4159.1990.tb01209.x; CONYERS SM, 1991, ANAL BIOCHEM, V192, P207, DOI 10.1016/0003-2697(91)90208-B; FOLCH J, 1957, J BIOL CHEM, V226, P497; FURUYA S, 1993, GLYCOCONJUGATE J, V10, P293, DOI 10.1007/BF01210029; HAKOMORI S, 1993, ADV LIPID RES, V25, P235; HIDARI KIPJ, 1994, EUR J BIOCHEM, V221, P603, DOI 10.1111/j.1432-1033.1994.tb18772.x; HIGASHI H, 1984, J BIOCHEM, V95, P785, DOI 10.1093/oxfordjournals.jbchem.a134670; HIGASHI H, 1984, J BIOCHEM-TOKYO, V95, P1517, DOI 10.1093/oxfordjournals.jbchem.a134760; HIRABAYASHI Y, 1988, J CHROMATOGR, V445, P377, DOI 10.1016/S0021-9673(01)84550-7; HIRABAYASHI Y, 1992, J BIOL CHEM, V267, P12973; HIRABAYASHI Y, 1979, FEBS LETT, V100, P253, DOI 10.1016/0014-5793(79)80345-2; HIRABAYASHI Y, 1985, J BIOL CHEM, V260, P3328; HIRABAYASHI Y, 1990, J BIOL CHEM, V265, P8144; IRIE F, 1994, FEBS LETT, V351, P291, DOI 10.1016/0014-5793(94)00883-3; IRIE F, 1993, GLYCOCONJUGATE J, V10, P292, DOI 10.1007/BF01210027; Ito M, 1990, Neuroreport, V1, P129; Ito M, 1984, CEREBELLUM NEURAL CO; JOHNSTONE SR, 1988, J NEUROCHEM, V51, P1655, DOI 10.1111/j.1471-4159.1988.tb01138.x; KOTANI M, 1992, P JPN ACAD B-PHYS, V68, P109, DOI 10.2183/pjab.68.109; KUSUNOKI S, 1993, BRAIN RES, V623, P83, DOI 10.1016/0006-8993(93)90013-D; LANDIS DMD, 1978, J COMP NEUROL, V179, P831, DOI 10.1002/cne.901790408; LEDEEN RW, 1989, NEUROBIOLOGY GLYCOCO, P43; LEDEEN RW, 1992, TRENDS GLYCOSCI GLYC, V4, P174; MALLET J, 1976, BRAIN RES, V103, P291, DOI 10.1016/0006-8993(76)90800-3; MATSUMOTO M, 1981, J BIOL CHEM, V256, P9737; MIYAZAWA A, 1992, J NEUROCHEM, V59, P1547, DOI 10.1111/j.1471-4159.1992.tb08472.x; MULLEN RJ, 1976, P NATL ACAD SCI USA, V73, P208, DOI 10.1073/pnas.73.1.208; NAGAI Y, 1989, GANGLIOSIDES CANCER, P33; NAKAZAWA K, 1993, NEUROREPORT, V4, P1275, DOI 10.1097/00001756-199309000-00017; OBROCKI J, 1988, EXP BRAIN RES, V72, P71, DOI 10.1007/BF00248502; OHASHI M, 1981, GLYCOCONJUGATES, P33; PRABHANJAN H, 1992, CARBOHYD RES, V233, P87, DOI 10.1016/S0008-6215(00)90922-4; PRASADARAO N, 1990, J HISTOCHEM CYTOCHEM, V38, P1193, DOI 10.1177/38.8.1694876; RAKIC P, 1973, P NATL ACAD SCI USA, V70, P240, DOI 10.1073/pnas.70.1.240; ROSNER H, 1993, POLYSIALIC ACID, P279; SEYFRIED TN, 1984, J NEUROCHEM, V43, P1152, DOI 10.1111/j.1471-4159.1984.tb12856.x; SEYFRIED TN, 1990, J NEUROSCI RES, V26, P105, DOI 10.1002/jnr.490260113; SEYFRIED TN, 1982, J NEUROCHEM, V38, P551, DOI 10.1111/j.1471-4159.1982.tb08662.x; SEYFRIED TN, 1983, J NEUROCHEM, V41, P491, DOI 10.1111/j.1471-4159.1983.tb04767.x; SEYFRIED TN, 1994, J LIPID RES, V35, P993; SIDMAN RL, 1962, SCIENCE, V137, P610, DOI 10.1126/science.137.3530.610; SUZUKI Y, 1986, J BIOL CHEM, V261, P7057; SUZUKI Y, 1985, J BIOCHEM-TOKYO, V97, P1189, DOI 10.1093/oxfordjournals.jbchem.a135164; SVENNERHOLM L, 1964, J LIPID RES, V5, P145; SVENNERHOLM L, 1973, J BIOL CHEM, V248, P740; TAKI T, 1986, J BIOL CHEM, V261, P3075; TETTAMANTI G, 1993, ADV LIPID RES, V25, P235; TODD AJ, 1991, NEUROSCIENCE, V44, P741, DOI 10.1016/0306-4522(91)90093-4; YAMAMOTO M, 1992, CELL SURFACE CARBOHY, P195	55	47	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32418	32425						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7528216				2022-12-27	WOS:A1994PX30400061
J	SUEYOSHI, S; TSUBOI, S; SAWADAHIRAI, R; DANG, UN; LOWE, JB; FUKUDA, M				SUEYOSHI, S; TSUBOI, S; SAWADAHIRAI, R; DANG, UN; LOWE, JB; FUKUDA, M			EXPRESSION OF DISTINCT FUCOSYLATED OLIGOSACCHARIDES AND CARBOHYDRATE-MEDIATED ADHESION EFFICIENCY DIRECTED BY 2 DIFFERENT ALPHA-1,3-FUCOSYL-TRANSFERASES - COMPARISON OF E-SELECTIN-MEDIATED AND L-SELECTIN-MEDIATED ADHESION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA(1,3)FUCOSYLTRANSFERASE GENE; LYSOSOMAL MEMBRANE-GLYCOPROTEINS; ELAM-1-DEPENDENT CELL-ADHESION; MYELOGENOUS LEUKEMIA-CELLS; POLY-N-ACETYLLACTOSAMINE; SIALYL-LEWIS-X; LINKED OLIGOSACCHARIDES; DETERMINES EXPRESSION; ENDOTHELIAL LIGAND; EMBRYONIC ANTIGEN	Among five different human alpha 1-->3 fucosyltransferases cloned, fucosyltransferases III (Fuc-TIII) and IV (Fuc-TIV) differ significantly from each other. Fuc-TIII transfers a fucose to both sialylated and nonsialylated N-acetyllactosamine, but Fuc-TIV apparently transfers a fucose only to neutral N-acetyllactosamine, In this study, Chinese hamster ovary (CHO) cells were stably transfected with Fuc-TIII or Fuc-TIV, and the resultant cell lines, CHO-FTIII and CHO-FTIV, were compared for the carbohydrate structures and for their binding to E-selectin or L-selectin. CHO-FTIII and CHO-FTIV cells were labeled metabolically with [H-3]galactose, and glycopeptides obtained from these cells were fractionated by serial lectin affinity chromatography. The fractionated glycopeptides were then subjected to various combinations of exoglycosidase treatment or endo-beta-galactosidase digestion. The results obtained can be summarized as follows. CHO-FTIII cells express sialyl Lewis(x), Lewis(x), and VIM-2 structures, whereas CHO-FTIV cells express only an Le(x) structure with a small amount of VIM-2 structure. When CHO-FTIII and CHO-FTIV cells were tested for adhesion to E-selectin expressed by tumor necrosis factor-activated endothelial cells and to an E-selectin chimeric protein, only CHO-FTIII cells were found to adhere well to E-selectin. Moreover, both CHO-FTIII and CHO-FTIV cells failed to adhere to an L-selectin chimeric protein. T hese results clearly indicate that FT-III and FT-IV direct distinctly different fucosylated oligosaccharides. This difference in oligosaccharide structures results in an entirely different efficiency in adhesion to E-selectin. The results also demonstrate that expression of sialyl Le(x) itself is not sufficient for L-selectin binding.	LA JOLLA CANC RES FDN,GLYCOBIOL PROGRAM,LA JOLLA,CA 92037; UNIV MICHIGAN,MED CTR,HOWARD HUGHES MED INST,ANN ARBOR,MI 48109	Sanford Burnham Prebys Medical Discovery Institute; Howard Hughes Medical Institute; University of Michigan System; University of Michigan					NATIONAL CANCER INSTITUTE [R01CA033000] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI033189] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA33000] Funding Source: Medline; NIAID NIH HHS [AI33189] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BERG EL, 1991, J BIOL CHEM, V266, P14869; BIERHUIZEN MFA, 1994, J BIOL CHEM, V269, P4473; BIRD JM, 1984, DEV BIOL, V104, P449, DOI 10.1016/0012-1606(84)90101-5; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; FENDERSON BA, 1984, J EXP MED, V160, P1591, DOI 10.1084/jem.160.5.1591; FINNE J, 1982, J CELL BIOL, V92, P277, DOI 10.1083/jcb.92.2.277; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; FUKUDA M, 1984, J BIOL CHEM, V259, P925; FUKUDA M, 1985, J BIOL CHEM, V260, P2957; Fukuda M., 1994, MOL GLYCOBIOLOGY, P1; FUKUDA MN, 1981, J BIOL CHEM, V256, P3900; FUKUDA MN, 1986, J BIOL CHEM, V261, P2376; GLASGOW LR, 1977, J BIOL CHEM, V252, P8615; GOELZ S, 1994, J BIOL CHEM, V269, P1033; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; GOOI HC, 1981, NATURE, V292, P156, DOI 10.1038/292156a0; HANSSON GC, 1985, J BIOL CHEM, V260, P9388; HEMMERICH S, 1994, BIOCHEMISTRY-US, V33, P4830, DOI 10.1021/bi00182a011; HOWARD DR, 1987, J BIOL CHEM, V262, P16830; IMAI Y, 1992, GLYCOBIOLOGY, V2, P373, DOI 10.1093/glycob/2.4.373; IMAI Y, 1993, NATURE, V361, P555; KANSAS GS, 1994, J CELL BIOL, V124, P609, DOI 10.1083/jcb.124.4.609; KAWASHIMA H, 1993, J BIOL CHEM, V268, P27118; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LEE N, 1990, J BIOL CHEM, V265, P20476; Lowe J B, 1991, Semin Cell Biol, V2, P289; LOWE JB, 1991, J BIOL CHEM, V266, P17467; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MACHER BA, 1988, J BIOL CHEM, V263, P10186; MAEMURA K, 1992, J BIOL CHEM, V267, P24379; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; NEEDHAM LK, 1993, P NATL ACAD SCI USA, V90, P1359, DOI 10.1073/pnas.90.4.1359; PAULSON JC, 1982, J BIOL CHEM, V257, P2734; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; PRIEELS JP, 1981, J BIOL CHEM, V256, P456; ROSEN SD, 1985, SCIENCE, V228, P1005, DOI 10.1126/science.4001928; SAITOH O, 1992, J BIOL CHEM, V267, P5700; SANO M, 1992, J BIOL CHEM, V267, P1522; SASAKI K, 1994, J BIOL CHEM, V269, P14730; SAWADA R, 1993, J BIOL CHEM, V268, P12675; SAWADA R, 1994, J BIOL CHEM, V269, P1425; SUEYOSHI S, 1992, GLYCOCONJUGATE J, V9, P99, DOI 10.1007/BF00731706; SUGDEN B, 1985, MOL CELL BIOL, V5, P410, DOI 10.1128/MCB.5.2.410; TAKADA A, 1991, BIOCHEM BIOPH RES CO, V179, P713, DOI 10.1016/0006-291X(91)91875-D; TEDDER TF, 1989, J EXP MED, V170, P123, DOI 10.1084/jem.170.1.123; TIEMEYER M, 1991, P NATL ACAD SCI USA, V88, P1138, DOI 10.1073/pnas.88.4.1138; TOYAMASORIMACHI N, 1993, EUR J IMMUNOL, V23, P439, DOI 10.1002/eji.1830230221; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; Watkins W M, 1980, Adv Hum Genet, V10, P1; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WESTON BW, 1992, J BIOL CHEM, V267, P24575; YAMASHITA K, 1987, J BIOL CHEM, V262, P1602; YOSHIDA T, 1994, BIOCHEM BIOPH RES CO, V204, P969, DOI 10.1006/bbrc.1994.2555	56	48	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32342	32350						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7528213				2022-12-27	WOS:A1994PX30400051
J	MATSUMOTO, K; MATSUMOTO, K; NAKAMURA, T; KRAMER, RH				MATSUMOTO, K; MATSUMOTO, K; NAKAMURA, T; KRAMER, RH			HEPATOCYTE GROWTH-FACTOR SCATTER FACTOR INDUCES TYROSINE PHOSPHORYLATION OF FOCAL ADHESION KINASE (P125(FAK)) AND PROMOTES MIGRATION AND INVASION BY ORAL SQUAMOUS-CELL CARCINOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAMININ-BINDING INTEGRIN; SCATTER FACTOR; EXTRACELLULAR-MATRIX; FACTOR RECEPTOR; PROTEIN; EXPRESSION; IDENTIFICATION; PP125(FAK); FIBRONECTIN; INVITRO	Fibroblasts or their conditioned medium stimulated invasion by squamous cell carcinoma cells. The fibroblast-derived activity responsible for increased invasion is the hepatocyte growth factor/scatter factor (HGF/SF), a ligand for the c-Met receptor, HGF/SF stimulated migration of the cells on various extracellular matrix substrates but did not alter their adhesion efficiency nor integrin expression, HGF/SF stimulated motility in a two step process: initially cells spread rapidly and formed focal adhesions, and then they disassembled these condensations, which was followed by increased cell locomotion, The focal adhesions contained vinculin, p125(FAK), beta 1 integrin, and phosphotyrosine, Within minutes after exposure of cells to HGF/SF, proteins of 125 and 145 kDa showed elevated tyrosine phosphorylation and were identified as p125(FAK) and c-Met, respectively, Gradual loss of tyrosine phosphorylation coincided with disruption of focal adhesions and conversion to a motile phenotype, HGF/SF-mediated tyrosine phosphorylation of p125(FAK) was inhibited by the tyrosine kinase inhibitor, herbimycin A, which also blocked spreading and the migratory response, These results indicate that fibroblast-derived HGF/SF triggers migration through the initial recruiting of integrins, cytoskeletal proteins, and p125(FAK) into focal adhesions that is dependent on tyrosine kinase activity.	UNIV CALIF SAN FRANCISCO, DEPT STOMATOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT ANAT, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, SAN FRANCISCO, CA 94143 USA; OSAKA UNIV, SCH MED, BIOMED RES CTR, DEPT BIOCHEM, SUITA, OSAKA 565, JAPAN	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Osaka University					NCI NIH HHS [CA51884] Funding Source: Medline; NIDCR NIH HHS [DE10356, DE10306] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051884] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE010306] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AZNAVOORIAN S, 1993, CANCER-AM CANCER SOC, V71, P1368, DOI 10.1002/1097-0142(19930215)71:4<1368::AID-CNCR2820710432>3.0.CO;2-L; BARDELLI A, 1992, ONCOGENE, V7, P1973; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHAN AM, 1988, ONCOGENE, V2, P599; CHEN BMC, 1991, SCIENCE, V251, P1600; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; ENENSTEIN J, 1992, EXP CELL RES, V203, P499, DOI 10.1016/0014-4827(92)90028-7; FIDLER IJ, 1987, CANCER B, V39, P129; FURLONG RA, 1991, J CELL SCI, V100, P173; GHERARDI E, 1990, NATURE, V346, P228, DOI 10.1038/346228b0; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HAMAWY MM, 1993, J BIOL CHEM, V268, P6851; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KRAMER RH, 1991, CELL REGUL, V2, P805, DOI 10.1091/mbc.2.10.805; KRAMER RH, 1991, CANCER METAST REV, V10, P49, DOI 10.1007/BF00046843; LANDEGREN U, 1984, J IMMUNOL METHODS, V67, P379, DOI 10.1016/0022-1759(84)90477-0; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; MATSUMOTO K, 1989, J ORAL PATHOL MED, V18, P498, DOI 10.1111/j.1600-0714.1989.tb01350.x; MIZOGUCHI H, 1991, INT J CANCER, V49, P738, DOI 10.1002/ijc.2910490518; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; MOORADIAN DL, 1992, J NATL CANCER I, V84, P523, DOI 10.1093/jnci/84.7.523; NAKAJIMA M, 1990, J NATL CANCER I, V82, P1890, DOI 10.1093/jnci/82.24.1890; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; OTEY CA, 1993, MOL BIOL CELL S, V4, P2011; PICARD O, 1986, CANCER RES, V46, P3290; RAMOS DM, 1991, INVAS METAST, V11, P125; RANKIN S, 1994, J BIOL CHEM, V269, P704; REGEN CM, 1992, J CELL BIOL, V119, P1347, DOI 10.1083/jcb.119.5.1347; RENZO MFD, 1991, ONCOGENE, V6, P1997; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; SANTALA P, 1991, J BIOL CHEM, V266, P23505; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; STOKER M, 1987, NATURE, V327, P238; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; WARM RM, 1989, NATURE, V340, P186; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	47	336	336	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31807	31813						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7527397				2022-12-27	WOS:A1994PX30300074
J	MITRA, S; BECHHOFER, DH				MITRA, S; BECHHOFER, DH			SUBSTRATE-SPECIFICITY OF AN RNASE III-LIKE ACTIVITY FROM BACILLUS-SUBTILIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; EARLY MESSENGER-RNA; PROCESSING SIGNALS; CLEAVAGE SITES; DNA; MECHANISM; SEQUENCE; LAMBDA; GENE	Bacillus subtilis bacteriophage SP82 codes for several early RNAs that were shown previously to be cleaved by an RNase III-like enzyme called ''Bs-RNase III.'' Cloning of DNA fragments that encode these RNA sequences downstream of a T7 RNA polymerase promoter allowed the synthesis of substrates that were used to test the cleavage specificity of Bs-RNase III, which was purified from a protease-deficient strain of B. subtilis. Single nucleotide changes at or near the cleavage site and deletions upstream and downstream of the cleavage site were constructed. The effects of these changes on the rate of Bs-RNase III cleavage were measured. The activity of Bs-RNase III and Escherichia coli RNase III on heterologous substrates was also tested. Although the local environment of the site of Bs-RNase III cleavage appears very similar to that of E. coli RNase III, there are important differences in their substrate specificity.	CUNY MT SINAI SCH MED, DEPT BIOCHEM, NEW YORK, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai					NIGMS NIH HHS [GM-48804, GM-39516] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048804, R29GM039516] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTA JA, 1994, J BIOL CHEM, V269, P4532; ALTUVIA S, 1987, P NATL ACAD SCI USA, V84, P6511, DOI 10.1073/pnas.84.18.6511; BECHHOFER DH, 1989, J BACTERIOL, V171, P5803, DOI 10.1128/jb.171.11.5803-5811.1989; CHELLADURAI B, 1993, BIOCHEMISTRY-US, V32, P7549, DOI 10.1021/bi00080a029; CHELLADURAI BS, 1991, NUCLEIC ACIDS RES, V19, P1759, DOI 10.1093/nar/19.8.1759; Court D. L., 1993, CONTROL MESSENGER RN, P71; DIMARI JF, 1993, MOL MICROBIOL, V7, P705; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; KRINKE L, 1987, GENE DEV, V1, P1005, DOI 10.1101/gad.1.9.1005; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI DS, 1993, NUCLEIC ACIDS RES, V21, P3977, DOI 10.1093/nar/21.17.3977; LI HL, 1993, NUCLEIC ACIDS RES, V21, P1919, DOI 10.1093/nar/21.8.1919; MERRIL CR, 1984, METHOD ENZYMOL, V104, P441; NICHOLSON AW, 1988, NUCLEIC ACIDS RES, V16, P1577, DOI 10.1093/nar/16.4.1577; PANGANIBAN AT, 1983, CELL, V33, P907, DOI 10.1016/0092-8674(83)90033-8; PANGANIBAN AT, 1983, J BIOL CHEM, V258, P2487; ROBERTSON HD, 1982, CELL, V30, P669, DOI 10.1016/0092-8674(82)90270-7; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	19	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31450	31456						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7527387				2022-12-27	WOS:A1994PX30300022
J	STAPPENBECK, TS; LAMB, JA; CORCORAN, CM; GREEN, KJ				STAPPENBECK, TS; LAMB, JA; CORCORAN, CM; GREEN, KJ			PHOSPHORYLATION OF THE DESMOPLAKIN COOH TERMINUS NEGATIVELY REGULATES ITS INTERACTION WITH KERATIN INTERMEDIATE FILAMENT NETWORKS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CULTURED-CELLS; DESMOSOME; DOMAINS; PROTEIN; PLAQUE; FORM	Desmoplakins (DPs) are the most abundant proteins in the innermost portion of the desmosomal plaque and have been proposed to play a role in the attachment of intermediate filaments (IF) to cell-cell contact sites. Our previous results suggest that the globular end domains of DP perform dual functions: first, to target DP to the desmosome via the NH2 terminus and second, to attach IF to the desmosomal plaque via the COOH terminus. When ectopically expressed in most cultured cells, the COOH terminus plus the rod domain (DP.Delta N.SerC23) exhibits striking coalignment with keratin IF networks. However, in certain cell types (e.g. PtK2) or in cells treated with forskolin to activate protein kinase A, DP.Delta N.SerC23 exhibits a diffuse cytoplasmic distribution. A Variant molecule (DP.Delta N.GlyC23) in which a serine located 23 amino acids from the COOH terminus is altered to a glycine, thereby disrupting a protein kinase A consensus phosphorylation site, co-localizes with keratin IF networks regardless of cell type or forskolin treatment. Analysis of the phosphopeptide maps of these DP variants and endogenous DP is consistent with the phosphorylation of the serine 23 residues from the COOH terminus. These results suggest that phosphorylation of a specific residue in the DP COOH terminus may negatively regulate its interaction with keratin IF networks.	NORTHWESTERN UNIV, SCH MED, DEPT PATHOL, CHICAGO, IL 60611 USA; NORTHWESTERN UNIV, SCH MED, DEPT DERMATOL, CHICAGO, IL 60611 USA; NORTHWESTERN UNIV, SCH MED, ROBERT H LURIE CANC CTR, CHICAGO, IL 60611 USA	Northwestern University; Northwestern University; Northwestern University; Robert H. Lurie Comprehensive Cancer Center								ALLEN TD, 1975, J ULTRA MOL STRUCT R, V51, P94, DOI 10.1016/S0022-5320(75)80011-6; BARIBAULT H, 1991, J CELL BIOL, V115, P1675, DOI 10.1083/jcb.115.6.1675; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Buxton R S, 1992, Semin Cell Biol, V3, P157; FRANKE WW, 1989, P NATL ACAD SCI USA, V86, P4027, DOI 10.1073/pnas.86.11.4027; FRANKE WW, 1982, CELL, V30, P103, DOI 10.1016/0092-8674(82)90016-2; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; Garrod DR, 1993, CURR OPIN CELL BIOL, V5, P30, DOI 10.1016/S0955-0674(05)80005-5; Green Kathleen J., 1994, P157; GREEN KJ, 1990, J BIOL CHEM, V265, P2603; GREEN KJ, 1990, CELLULAR MOL BIOL IN, P147; JONES JCR, 1985, J CELL BIOL, V101, P506, DOI 10.1083/jcb.101.2.506; Juliano RL, 1993, CURR OPIN CELL BIOL, V5, P812, DOI 10.1016/0955-0674(93)90030-T; LOWEY S, 1969, J MOL BIOL, V42, P1, DOI 10.1016/0022-2836(69)90483-5; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; OKEEFE EJ, 1989, J BIOL CHEM, V264, P8310; OUYANG P, 1992, J CELL BIOL, V118, P1477, DOI 10.1083/jcb.118.6.1477; PASDAR M, 1988, J CELL BIOL, V106, P677, DOI 10.1083/jcb.106.3.677; SKALLI O, 1994, J CELL BIOL, V125, P159, DOI 10.1083/jcb.125.1.159; SKERROW CJ, 1974, J CELL BIOL, V63, P515, DOI 10.1083/jcb.63.2.515; STANLEY JR, 1993, ADV IMMUNOL, V53, P291, DOI 10.1016/S0065-2776(08)60503-9; STAPPENBECK TS, 1992, J CELL BIOL, V116, P1197, DOI 10.1083/jcb.116.5.1197; STAPPENBECK TS, 1993, J CELL BIOL, V123, P691, DOI 10.1083/jcb.123.3.691; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; TROYANOVSKY SM, 1993, CELL, V72, P561, DOI 10.1016/0092-8674(93)90075-2; WICHE G, 1993, J CELL BIOL, V121, P607, DOI 10.1083/jcb.121.3.607	26	106	106	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29351	29354						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7525582				2022-12-27	WOS:A1994PU28400005
J	NISHIMURA, SL; SHEPPARD, D; PYTELA, R				NISHIMURA, SL; SHEPPARD, D; PYTELA, R			INTEGRIN ALPHA-V-BETA-8 - INTERACTION WITH VITRONECTIN AND FUNCTIONAL, DIVERGENCE OF THE BETA-8 CYTOPLASMIC DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-MELANOMA CELLS; ALPHA-V; BIOLOGICAL PROPERTIES; FIBRONECTIN RECEPTOR; GLYCOPROTEIN-IIIA; SURFACE-ANTIGENS; ADHESION; SUBUNIT; BINDING; PROTEIN	The integrin beta 8 subunit was identified by cloning and sequencing of the cDNA and has been shown to associate with the alpha v subunit (Moyle, M., Napier, M. A., and McLean, J. W. (1991) J. Biol. Chem. 266, 19650-19658). We now present initial data on its functional properties. We produced a recombinant secreted form of alpha v beta 8 and used it to raise monoclonal antibodies that recognize the alpha v beta 8 complex or the beta 8 subunit alone on the surface of melanoma cells and on beta 8-transfected human embryonic kidney (293) cells. Affinity chromatography experiments showed that secreted alpha v beta 8 bound to vitronectin but not to fibronectin, collagen, or fibrinogen. Supporting evidence that intact full-length alpha v beta 8 could also bind to vitronectin-Sepharose was provided by performing affinity chromatography with the melanoma cell line MeWo, which normally expresses the intact beta 8 subunit. By studying the adhesive properties of melanoma cells and beta 8-transfected 293 cells, we found that alpha v beta 8 by itself does not promote cell adhesion on a vitronectin-coated substrate. To test the respective functional activities of the beta 8 extracellular and cytoplasmic domains, we analyzed chimeric beta 8/beta 3 subunit constructs. The beta 3 subunit was chosen because full-length beta 3, when transfected into 293 cells, strongly supports cell adhesion. We found that a chimeric integrin containing the beta 3 extracellular domain combined with the beta 8 transmembrane and cytoplasmic domains did not promote 293 cell adhesion. Conversely, a chimeric integrin construct combining the beta 8 extracellular domain with the beta 3 transmembrane and cytoplasmic domains did promote adhesion of transfected 293 cells. This suggests that the ps cytoplasmic domain does not interact with the cytoskeleton and with cytoplasmic signaling pathways in an adhesion-promoting fashion. We conclude that the beta 8 cytoplasmic domain, which is structurally unrelated to the conserved cytoplasmic domains of other beta subunits, is functionally distinct.	UNIV CALIF SAN FRANCISCO, DEPT PATHOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PHARMACOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	NISHIMURA, SL (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT MED, CTR LUNG BIOL, BOX 0854, SAN FRANCISCO, CA 94143 USA.				NCI NIH HHS [CA53259] Funding Source: Medline; NHLBI NIH HHS [HLA133259, HL191551] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS JC, 1993, J CELL SCI, V104, P1061; ALBELDA SM, 1990, CANCER RES, V50, P6757; BODARY SC, 1989, J BIOL CHEM, V264, P18859; BODARY SC, 1990, J BIOL CHEM, V265, P5938; BUSK M, 1992, J BIOL CHEM, V267, P5790; CHEN YP, 1992, P NATL ACAD SCI USA, V89, P10169, DOI 10.1073/pnas.89.21.10169; CHENG YF, 1991, EXP CELL RES, V194, P69, DOI 10.1016/0014-4827(91)90131-D; CHERESH DA, 1991, CANCER METAST REV, V10, P3, DOI 10.1007/BF00046839; CHERESH DA, 1989, CELL, V57, P59, DOI 10.1016/0092-8674(89)90172-4; CHUNTHARAPAI A, 1993, EXP CELL RES, V205, P345, DOI 10.1006/excr.1993.1096; CREASEY AA, 1979, IN VITRO CELL DEV B, V15, P342; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; DEJANA E, 1989, J CELL BIOL, V109, P367, DOI 10.1083/jcb.109.1.367; DEJANA E, 1990, BLOOD, V75, P1509; DITTEL BN, 1993, BLOOD, V81, P2272; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; FELDINGHABERMANN B, 1992, J CLIN INVEST, V89, P2018, DOI 10.1172/JCI115811; FITZGERALD LA, 1987, J BIOL CHEM, V262, P3936; FREED E, 1989, EMBO J, V8, P2955, DOI 10.1002/j.1460-2075.1989.tb08445.x; HARLOW E, 1988, ANTIBODIES LABORATOR, P311; HIBBS ML, 1991, J EXP MED, V174, P1227, DOI 10.1084/jem.174.5.1227; HOUGHTON AN, 1982, J EXP MED, V156, P1755, DOI 10.1084/jem.156.6.1755; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JONES JCR, 1991, CELL REGUL, V2, P427, DOI 10.1091/mbc.2.6.427; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KAWAGUCHI S, 1993, J BIOL CHEM, V268, P16279; KIRCHHOFER D, 1991, J BIOL CHEM, V266, P4471; KORHONEN M, 1992, KIDNEY INT, V41, P641, DOI 10.1038/ki.1992.98; LANDEGREN U, 1984, J IMMUNOL METHODS, V67, P379, DOI 10.1016/0022-1759(84)90477-0; MIYAUCHI A, 1991, J BIOL CHEM, V266, P20369; MOYLE M, 1991, J BIOL CHEM, V266, P19650; NEWMAN PJ, 1985, BLOOD, V65, P227; NIP J, 1992, J CLIN INVEST, V90, P1406, DOI 10.1172/JCI116007; OLDBERG A, 1988, J BIOL CHEM, V263, P19433; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PASQUALINI R, 1994, J CELL BIOL, V125, P447, DOI 10.1083/jcb.125.2.447; PRIETO AL, 1993, P NATL ACAD SCI USA, V90, P10154, DOI 10.1073/pnas.90.21.10154; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; SMITH JW, 1990, J BIOL CHEM, V265, P11008; SOLOWSKA J, 1991, J CELL BIOL, V114, P1079, DOI 10.1083/jcb.114.5.1079; SONNENBERG A, 1991, J CELL BIOL, V113, P907, DOI 10.1083/jcb.113.4.907; SRIRAMARAO P, 1993, J CELL SCI, V105, P1001; Tomasini B R, 1991, Prog Hemost Thromb, V10, P269; VOGEL BE, 1990, J BIOL CHEM, V265, P5934; WEINACKER A, 1994, J BIOL CHEM, V269, P6940; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281	48	117	119	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28708	28715						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7525578				2022-12-27	WOS:A1994PU16800032
J	BENZ, R; MAIER, E; LADANT, D; ULLMANN, A; SEBO, P				BENZ, R; MAIER, E; LADANT, D; ULLMANN, A; SEBO, P			ADENYLATE-CYCLASE TOXIN (CYAA) OF BORDETELLA-PERTUSSIS - EVIDENCE FOR THE FORMATION OF SMALL ION-PERMEABLE CHANNELS AND COMPARISON WITH HLYA OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE BACTERIA; TARGET-CELL MEMBRANES; MATRIX PROTEIN PORIN; NUCLEOTIDE-SEQUENCE; HEMOLYSIN HLYA; ACTINOBACILLUS-PLEUROPNEUMONIAE; ERYTHROCYTE-MEMBRANES; CHROMOSOMAL HEMOLYSIN; ELECTRICAL-PROPERTIES; LIPID-MEMBRANES	The interaction between the adenylate cyclase toxin (CyaA) of Bordetella pertussis and lipid was studied using the lipid bilayer assay. The addition of CyaA to the aqueous phase bathing lipid bilayer membranes composed of different lipids resulted in the increase of the membrane conductance. This increase was rather small for membranes formed of pure lipids as compared with lipid mixtures such as asolectin. The toxin formed in asolectin membranes small transient ion-permeable channels with a single-channel conductance of 27 pS in 1 M KCl, which is considerably smaller than that of the alpha-hemeolysin (HlyA) of Escherichia coli (1500 pS). Experiments with different salts suggested that the CyaA-induced channels were exclusively cation-selective because of negative charges localized at the channel mouth. The single-channel conductance of channels initiated by CyaA was independent of whether the toxin was purified from B. pertussis or from recombinant E. coli. However, the channel-forming activity of the CyaA expressed in B. pertussis was substantially higher than that of the recombinant toxin. Experiments with mutant forms of CyaA suggested that both the activation of CyaA. by CyaC and the hemeolytic part of the toxin, but not the repeats and the cyclase activity are required for channel formation in lipid bilayer membranes.	INST PASTEUR, UNITE BIOCHIM REGULAT CELLULAIRES, F-75724 PARIS 15, FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	BENZ, R (corresponding author), UNIV WURZBURG, BIOZENTRUM, THEODOR BOVERI INST, LEHRSTUHL BIOTECHNOL, HUBLAND, D-97074 WURZBURG, GERMANY.		SEBO, Peter/N-2043-2019; SEBO, Peter/F-7423-2011	SEBO, Peter/0000-0002-9755-7715; SEBO, Peter/0000-0002-9755-7715; LADANT, Daniel/0000-0003-1955-548X; Benz, Roland/0000-0002-9510-9265				BARRY EM, 1991, J BACTERIOL, V173, P720, DOI 10.1128/jb.173.2.720-726.1991; BAUMANN U, 1993, EMBO J, V12, P3357, DOI 10.1002/j.1460-2075.1993.tb06009.x; BELLALOU J, 1990, INFECT IMMUN, V58, P1195, DOI 10.1128/IAI.58.5.1195-1200.1990; BELLALOU J, 1990, INFECT IMMUN, V58, P3242, DOI 10.1128/IAI.58.10.3242-3247.1990; BENZ R, 1979, BIOCHIM BIOPHYS ACTA, V551, P238, DOI 10.1016/0005-2736(89)90002-3; BENZ R, 1978, BIOCHIM BIOPHYS ACTA, V511, P305, DOI 10.1016/0005-2736(78)90269-9; BENZ R, 1988, ANNU REV MICROBIOL, V42, P359, DOI 10.1146/annurev.mi.42.100188.002043; BENZ R, 1989, INFECT IMMUN, V57, P887, DOI 10.1128/IAI.57.3.887-895.1989; BENZ R, 1994, EUR J BIOCHEM, V220, P339, DOI 10.1111/j.1432-1033.1994.tb18630.x; Benz R., 1994, BACTERIAL CELL WALL, P397; BETSOU F, 1993, INFECT IMMUN, V61, P3583, DOI 10.1128/IAI.61.9.3583-3589.1993; BHAKDI S, 1989, J EXP MED, V169, P737, DOI 10.1084/jem.169.3.737; BHAKDI S, 1986, INFECT IMMUN, V52, P63, DOI 10.1128/IAI.52.1.63-69.1986; BOEHM DF, 1990, INFECT IMMUN, V58, P1959, DOI 10.1128/IAI.58.6.1959-1964.1990; BOEHM DF, 1990, INFECT IMMUN, V58, P1951, DOI 10.1128/IAI.58.6.1951-1958.1990; CONFER DL, 1982, SCIENCE, V217, P948, DOI 10.1126/science.6287574; COOTE JG, 1992, FEMS MICROBIOL LETT, V88, P137, DOI 10.1016/0378-1097(92)90688-K; DEVENISH J, 1989, INFECT IMMUN, V57, P3210, DOI 10.1128/IAI.57.10.3210-3213.1989; EHRMANN IE, 1991, FEBS LETT, V278, P79, DOI 10.1016/0014-5793(91)80088-K; FELMLEE T, 1985, J BACTERIOL, V163, P94, DOI 10.1128/JB.163.1.94-105.1985; FREY J, 1991, INFECT IMMUN, V59, P3026, DOI 10.1128/IAI.59.9.3026-3032.1991; GENTILE F, 1990, J BIOL CHEM, V265, P10686; GLASER P, 1989, EMBO J, V8, P967, DOI 10.1002/j.1460-2075.1989.tb03459.x; GORDON VM, 1989, J BIOL CHEM, V264, P14792; HANSKI E, 1989, TRENDS BIOCHEM SCI, V14, P459, DOI 10.1016/0968-0004(89)90106-0; HANSKI E, 1985, J BIOL CHEM, V260, P5526; Hanski E, 1991, SOURCEBOOK BACTERIAL, P349; HESS J, 1986, FEMS MICROBIOL LETT, V34, P1, DOI 10.1016/0378-1097(86)90261-2; HEWLETT EL, 1991, J BIOL CHEM, V266, P17503; HEWLETT EL, 1989, J BIOL CHEM, V264, P19379; ISSARTEL JP, 1991, NATURE, V351, P759, DOI 10.1038/351759a0; LADANT D, 1992, J BIOL CHEM, V267, P2244; LADANT D, 1989, J BIOL CHEM, V264, P4015; LALONDE G, 1989, J BIOL CHEM, V264, P13559; LO RYC, 1987, INFECT IMMUN, V55, P1987, DOI 10.1128/IAI.55.9.1987-1996.1987; LUDWIG A, 1988, MOL GEN GENET, V214, P553, DOI 10.1007/BF00330494; LUDWIG A, 1993, MOL GEN GENET, V241, P89, DOI 10.1007/BF00280205; LUDWIG A, 1987, MOL GEN GENET, V206, P238, DOI 10.1007/BF00333579; LUDWIG A, 1991, MOL GEN GENET, V226, P198, DOI 10.1007/BF00273604; LUDWIG A, 1992, BACTERIAL PROTEIN TO, P450; MASURE HR, 1989, BIOCHEMISTRY-US, V28, P438, DOI 10.1021/bi00428a005; MENESTRINA G, 1987, BIOCHIM BIOPHYS ACTA, V905, P109, DOI 10.1016/0005-2736(87)90014-9; NELSON AP, 1975, J THEOR BIOL, V55, P13, DOI 10.1016/S0022-5193(75)80106-8; OROPEZAWEKERLE RL, 1992, MOL MICROBIOL, V6, P115, DOI 10.1111/j.1365-2958.1992.tb00843.x; PEARSON RD, 1987, J IMMUNOL, V139, P2749; ROGEL A, 1989, EMBO J, V8, P2755, DOI 10.1002/j.1460-2075.1989.tb08417.x; ROGEL A, 1992, J BIOL CHEM, V267, P22599; ROPELE M, 1989, BIOCHIM BIOPHYS ACTA, V985, P9, DOI 10.1016/0005-2736(89)90096-5; SAKAMOTO H, 1992, J BIOL CHEM, V267, P13598; Sambrook J, 1989, MOL CLONING LABORATO; SEBO P, 1993, MOL MICROBIOL, V9, P999, DOI 10.1111/j.1365-2958.1993.tb01229.x; SEBO P, 1991, GENE, V104, P19, DOI 10.1016/0378-1119(91)90459-O; WELCH RA, 1991, MOL MICROBIOL, V5, P521, DOI 10.1111/j.1365-2958.1991.tb00723.x; WOLFF J, 1980, P NATL ACAD SCI-BIOL, V77, P3841, DOI 10.1073/pnas.77.7.3841	54	130	134	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27231	27239						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7525549				2022-12-27	WOS:A1994PV77100015
J	LEINONEN, A; MARIYAMA, M; MOCHIZUKI, T; TRYGGVASON, K; REEDERS, ST				LEINONEN, A; MARIYAMA, M; MOCHIZUKI, T; TRYGGVASON, K; REEDERS, ST			COMPLETE PRIMARY STRUCTURE OF THE HUMAN TYPE-IV COLLAGEN ALPHA-4(IV) CHAIN - COMPARISON WITH STRUCTURE AND EXPRESSION OF THE OTHER ALPHA(IV) CHAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANE COLLAGEN; DISTAL LONG ARM; ALPORT SYNDROME; GOODPASTURE ANTIGEN; DIFFUSE LEIOMYOMATOSIS; BIDIRECTIONAL PROMOTER; ALPHA-2(IV) CHAINS; GENE; IDENTIFICATION; ALPHA-1(IV)	The entire sequence of the human alpha 4(IV) collagen chain was determined from cDNA clones and polymerase chain reaction-amplified DNAs. The complete translation product has 1,690 amino acid residues and the processed alpha 4(IV) chain proper 1,652 residues. There is a 38-residue putative signal peptide, a 1,421-residue collagenous domain starting with a 23-residue noncollagenous sequence, and a 231-residue NC1 domain. The Gly-Xaa-Yaa-repeat sequence of the collagenous domain is interrupted at 26 locations by noncollagenous sequences of 1-12 residues in length. The alpha 4(IV) chain contains 31 cysteine residues of which 18 are conserved in the other type IV collagen alpha chains. The calculated molecular weight of the mature alpha 4(IV) chain is 164,123. Analysis of the primary structure showed that the alpha 4(IV) chain belongs to the alpha 2-like type IV collagen chains together with alpha 2(IV) and alpha 6(IV). Northern analyses with RNA from several human fetal tissues revealed quite similar expression patterns for the alpha 4(IV) and alpha 3(IV) chains, but there were also distinct differences in some tissues. The expression patterns of alpha 5(IV) and alpha 6(IV) differed extensively between each other and they also differed from those of alpha 3(IV) and alpha 4(IV).	YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06536; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06536; UNIV OULU,BIOCTR OULU,SF-90570 OULU,FINLAND; UNIV OULU,DEPT BIOCHEM,SF-90570 OULU,FINLAND	Yale University; Howard Hughes Medical Institute; Yale University; University of Oulu; Finland National Institute for Health & Welfare; University of Oulu	LEINONEN, A (corresponding author), YALE UNIV,SCH MED,DEPT INTERNAL MED,NEW HAVEN,CT 06536, USA.							ANTIGNAC C, 1992, KIDNEY INT, V42, P1178, DOI 10.1038/ki.1992.402; BARKER DF, 1990, SCIENCE, V248, P1224, DOI 10.1126/science.2349482; BERNAL D, 1993, J BIOL CHEM, V268, P12090; BURBELO PD, 1988, P NATL ACAD SCI USA, V85, P9679, DOI 10.1073/pnas.85.24.9679; BUTKOWSKI RJ, 1987, J BIOL CHEM, V262, P7874; BUTKOWSKI RJ, 1989, KIDNEY INT, V35, P1195, DOI 10.1038/ki.1989.110; GRIFFIN CA, 1987, P NATL ACAD SCI USA, V84, P512, DOI 10.1073/pnas.84.2.512; GUO XD, 1989, J BIOL CHEM, V264, P17574; HEIKKILA P, 1993, J BIOL CHEM, V268, P24677; HOSTIKKA SL, 1988, J BIOL CHEM, V263, P19488; HOSTIKKA SL, 1990, P NATL ACAD SCI USA, V87, P1606, DOI 10.1073/pnas.87.4.1606; HUDSON BG, 1993, J BIOL CHEM, V268, P26033; JOHANSSON C, 1992, J BIOL CHEM, V267, P24533; KAMAGATA Y, 1992, J BIOL CHEM, V267, P23753; KLEPPEL MM, 1989, AM J PATHOL, V134, P813; KLEPPEL MM, 1989, LAB INVEST, V61, P278; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; MARIYAMA M, 1992, GENOMICS, V13, P809, DOI 10.1016/0888-7543(92)90157-N; MARIYAMA M, 1994, J BIOL CHEM, V269, P23013; MARIYAMA M, 1992, J BIOL CHEM, V267, P1253; MOCHIZUKI T, 1994, NAT GENET, V8, P77, DOI 10.1038/ng0994-77; MORRISON KE, 1991, AM J HUM GENET, V49, P545; NEILSON EG, 1993, J BIOL CHEM, V268, P8402; OOHASHI T, 1994, J BIOL CHEM, V269, P7520; PIHLAJANIEMI T, 1985, J BIOL CHEM, V260, P7681; POSCHL E, 1988, EMBO J, V7, P2687, DOI 10.1002/j.1460-2075.1988.tb03122.x; Sambrook J, 1989, MOL CLONING LABORATO; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUS J, 1988, J BIOL CHEM, V263, P13374; SOININEN R, 1988, J BIOL CHEM, V263, P17217; SOININEN R, 1987, FEBS LETT, V225, P188; SUGIMOTO M, 1993, FEBS LETT, V330, P122, DOI 10.1016/0014-5793(93)80256-T; TRYGGVASON K, 1993, KIDNEY INT, V43, P38, DOI 10.1038/ki.1993.8; TURNER N, 1992, J CLIN INVEST, V89, P592, DOI 10.1172/JCI115625; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; ZHOU J, 1994, J BIOL CHEM, V269, P13193; ZHOU J, 1993, SCIENCE, V261, P1167, DOI 10.1126/science.8356449; ZHOU J, 1991, GENOMICS, V9, P10, DOI 10.1016/0888-7543(91)90215-Z; ZHOU J, 1992, J BIOL CHEM, V267, P12475	41	90	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26172	26177						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7523402				2022-12-27	WOS:A1994PQ93000037
J	SHARIF, KA; FUJITA, N; JIN, RH; IGARASHI, K; ISHIHAMA, A; KRAKOW, JS				SHARIF, KA; FUJITA, N; JIN, RH; IGARASHI, K; ISHIHAMA, A; KRAKOW, JS			EPITOPE MAPPING AND FUNCTIONAL-CHARACTERIZATION OF MONOCLONAL-ANTIBODIES SPECIFIC FOR THE ALPHA-SUBUNIT OF ESCHERICHIA-COLI RNA-POLYMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TEMPERATURE-SENSITIVE MUTATIONS; TRANSCRIPTION ACTIVATION; RPOA MUTATION; GENE; EXPRESSION; BIOSYNTHESIS; PROTEINS; IMPAIRS; ENVZ; OMPR	The epitopes have been localized for a set of monoclonal antibodies specific for the alpha subunit of the Escherichia coli RNA polymerase. The antibodies are classified into three groups based on their epitopic assignments. Group 1, mAb 123C2, maps in the N terminus of cu between amino acids 1 and 23; Group 2 antibodies (mAb 129C4, mAb 124D1 and mAb 121C5) map in the central region between amino acids 190 and 210; Group 3 antibodies (mAb 130B1 and mAb 125C6) map in the C terminus between amino acids 310 and 320, mAb 130C2 is anomalous since it maps to the N terminus between amino acids 1 and 23 as well as to the C terminus between amino acids 320 and 329. The antibodies were used to investigate the role of cu in transcription activation with cAMP receptor protein dependent promoters. Three antibodies (130C2, 121C5, and 125C6) inhibited cAMP receptor protein-dependent initiation with lac P+ but not with lac UV5 or gal P+. Inhibition was observed with free RNA polymerase and the closed promoter complex; the preformed open promoter complex was insensitive. Only lac P+ was sensitive to these anti-alpha antibodies supporting the concept that the mode of interaction of RNA polymerase with cAMP receptor protein differs between lac P+ and gal PC.	CUNY HUNTER COLL, DEPT BIOL SCI, NEW YORK, NY 10021 USA; NATL INST GENET, DEPT MOLEC GENET, MISHIMA, SHIZUOKA 411, JAPAN	City University of New York (CUNY) System; Hunter College (CUNY); Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan				Igarashi, Kazuhiko/0000-0002-2470-2475	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022619] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM22619] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Battey, 1986, BASIC METHODS MOL BI; BENJAMIN DC, 1992, BIOCHEMISTRY-US, V31, P9539, DOI 10.1021/bi00155a005; DALE EC, 1986, J MOL BIOL, V192, P793, DOI 10.1016/0022-2836(86)90029-X; DALLAVENEZIA N, 1990, J BIOL CHEM, V265, P8122; FUJITA N, 1987, J BIOL CHEM, V262, P1855; GARRETT S, 1987, J BACTERIOL, V169, P1379, DOI 10.1128/jb.169.4.1379-1385.1987; GIFFARD PM, 1988, MOL GEN GENET, V214, P148, DOI 10.1007/BF00340193; HAYWARD RS, 1991, J MOL BIOL, V221, P23, DOI 10.1016/0022-2836(91)80197-3; IGARASHI K, 1990, NUCLEIC ACIDS RES, V18, P5945, DOI 10.1093/nar/18.20.5945; IGARASHI K, 1991, P NATL ACAD SCI USA, V88, P8958, DOI 10.1073/pnas.88.20.8958; IGARASHI K, 1991, CELL, V65, P1015, DOI 10.1016/0092-8674(91)90553-B; ISHIHAMA A, 1993, J BACTERIOL, V175, P2483, DOI 10.1128/JB.175.9.2483-2489.1993; ISHIHAMA A, 1987, PROTEINS, V2, P42, DOI 10.1002/prot.340020106; ISHIHAMA A, 1980, J MOL BIOL, V137, P137, DOI 10.1016/0022-2836(80)90321-6; IWAKURA Y, 1974, MOL GEN GENET, V133, P1, DOI 10.1007/BF00268673; KAWAKAMI K, 1980, BIOCHEMISTRY-US, V19, P3491, DOI 10.1021/bi00556a013; KUMAR A, 1994, J MOL BIOL, V235, P405, DOI 10.1006/jmbi.1994.1001; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVER WG, 1990, CELL, V61, P553, DOI 10.1016/0092-8674(90)90464-P; LESLEY SA, 1991, J BIOL CHEM, V266, P2632; LOMBARDO MJ, 1991, J BACTERIOL, V173, P7511, DOI 10.1128/jb.173.23.7511-7518.1991; LUO JY, 1992, J BIOL CHEM, V267, P18175; MATSUYAMA S, 1987, J MOL BIOL, V195, P847, DOI 10.1016/0022-2836(87)90489-X; NIELSEN DA, 1986, NUCLEIC ACIDS RES, V14, P5936, DOI 10.1093/nar/14.14.5936; RIFTINA F, 1989, BIOCHEMISTRY-US, V28, P3299, DOI 10.1021/bi00434a027; ROCKWELL P, 1985, BIOCHEMISTRY-US, V24, P3240, DOI 10.1021/bi00334a025; SALAHUDDIN, 1990, GENE DEV, V4, P968, DOI 10.1101/gad.4.6.968; SLAUCH JM, 1991, J BACTERIOL, V173, P7501, DOI 10.1128/jb.173.23.7501-7510.1991; SUNSHINE MG, 1975, P NATL ACAD SCI USA, V72, P2770, DOI 10.1073/pnas.72.7.2770; THOMAS MS, 1991, MOL MICROBIOL, V5, P2719, DOI 10.1111/j.1365-2958.1991.tb01980.x; YAN C, 1994, SCIENCE, V265, P90; ZOU C, 1992, MOL MICROBIOL, V6, P2599, DOI 10.1111/j.1365-2958.1992.tb01437.x	32	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23655	23660						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	7522231				2022-12-27	WOS:A1994PQ34500042
J	CHEN, RH; DERYNCK, R				CHEN, RH; DERYNCK, R			HOMOMERIC INTERACTIONS BETWEEN TYPE-II TRANSFORMING GROWTH-FACTOR-BETA RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE THREONINE KINASE; TGF-BETA; SIGNAL TRANSDUCTION; ACTIVIN RECEPTOR; XENOPUS EMBRYOS; EXPRESSION CLONING; EGF RECEPTOR; BINDING; LIGAND; CELLS	Transforming growth factor-beta (TGF-beta) binds with high affinity to three cell-surface receptors. Both type I and II receptors are transmembrane serine/threonine kinases and thought to mediate TGF-beta responses by forming a heteromeric complex in the presence of TGF-beta. We investigated whether the type II receptors form a homomeric complex in the presence or absence of ligand. Double immunoprecipitation analyses were performed using lysates from metabolically labeled cells cotransfected with differentially epitope-tagged type II receptors. We demonstrate that the type II receptors can form a homomeric complex even in the absence of their ligand, TGF-beta. This pre-existing type II receptor complex has the ability to bind TGF-beta. Moreover, in addition to the extracellular and transmembrane domains, the cytoplasmic portions of the receptors are also able to interact with each other, indicating that multiple contact points are involved in the formation of the homemeric type II receptor complex. Our results suggest a novel mechanism of complex formation and receptor activation of the serine/threonine kinase receptor family	UNIV CALIF SAN FRANCISCO, DEPT GROWTH & DEV, CELL BIOL PROGRAMME, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT ANAT, CELL BIOL PROGRAMME, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, PROGRAM DEV BIOL, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Chen, Ruey-Hwa/G-6121-2019	Chen, Ruey-Hwa/0000-0001-8124-5832				AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; BOYD FT, 1989, J BIOL CHEM, V264, P2272; BRAND T, 1993, J BIOL CHEM, V268, P11500; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; EBNER R, 1993, SCIENCE, V262, P900, DOI 10.1126/science.8235612; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; ESTEVEZ M, 1993, NATURE, V365, P644, DOI 10.1038/365644a0; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GARBERS DL, 1994, MOL BIOL CELL, V5, P1; GAZIT D, 1993, MOL ENDOCRINOL, V7, P189, DOI 10.1210/me.7.2.189; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GRAYCAR JL, 1989, MOL ENDOCRINOL, V3, P1977, DOI 10.1210/mend-3-12-1977; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; HERREN B, 1993, J BIOL CHEM, V268, P15088; HURWITZ DR, 1991, J BIOL CHEM, V266, P22035; INAGAKI M, 1993, P NATL ACAD SCI USA, V90, P5359, DOI 10.1073/pnas.90.11.5359; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAIHO M, 1991, J BIOL CHEM, V266, P9108; LAX I, 1991, J BIOL CHEM, V266, P13828; Lin Herbert Y., 1993, Trends in Cell Biology, V3, P14, DOI 10.1016/0962-8924(93)90195-7; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LOPEZ AR, 1992, MOL CELL BIOL, V12, P1674, DOI 10.1128/MCB.12.4.1674; LUCAS C, 1991, METHOD ENZYMOL, V198, P303; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MATHEWS LS, 1993, J BIOL CHEM, V268, P19013; MATHEWS LS, 1992, SCIENCE, V255, P1702, DOI 10.1126/science.1313188; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MOUSTAKAS A, 1993, J BIOL CHEM, V268, P22215; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SHUM L, 1994, J CELL BIOL, V125, P903, DOI 10.1083/jcb.125.4.903; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WHITE MF, 1994, J BIOL CHEM, V269, P1; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S	41	124	128	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	1994	269	36					22868	22874						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ163	7521335				2022-12-27	WOS:A1994PQ16300062
J	CASATORRES, J; NAVARRO, JM; BLESSING, M; JORCANO, JL				CASATORRES, J; NAVARRO, JM; BLESSING, M; JORCANO, JL			ANALYSIS OF THE CONTROL OF EXPRESSION AND TISSUE-SPECIFICITY OF THE KERATIN-5 GENE, CHARACTERISTIC OF BASAL KERATINOCYTES - FUNDAMENTAL ROLE OF AN AP-1 ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PAPILLOMAVIRUS TYPE-18; EPIDERMOLYSIS-BULLOSA SIMPLEX; TRANSCRIPTION FACTOR AP-1; MOUSE EPIDERMAL-CELLS; C-JUN; RETINOIC ACID; INTERMEDIATE FILAMENTS; NEGATIVE REGULATOR; CYTOKERATIN GENES; ENHANCER ELEMENTS	The keratin 5 gene presents a complex regulation, since it is expressed at different rates in the basal cells of most, if not all, stratified epithelia. We have analyzed the 5'-upstream region of the bovine keratin 5 (BK5) gene and found that the 5.2 kilobases preceding the gene mimic in vitro the cell type-specific expression of BK5. Most of the transcriptional activity maps to an enhancer located between positions -762 and -1009. The only regulatory element found in this enhancer by electrophoretic mobility shift, competition, and footprinting experiments is a consensus AP-1 site. Mutation of this site abolishes the activity of tire enhancer and reduces to 25% the activity of the 5.2-kilobase upstream promoter region. Surprisingly, although the AP-1 presents indistinguishable footprints in all cell types tested, the enhancer is active only in some of them. Even an oligonucleotide containing the AP-1 region protected from DNase I is active in epithelial cell lines but not in NIH 3T3 fibroblasts, suggesting that this region could constitute an epithelium-specific AP-1 element. We also show that BK5 does not respond to phorbol ester induction, which suggests that the regulation of this gene by AP-1 must be complex and probably different from several other suprabasal, AP-1-regulated cellular and viral genes.	CIEMAT, DEPT CELL & MOLEC BIOL, E-28040 MADRID, SPAIN; VANDERBILT UNIV, SCH MED, DEPT CELL BIOL, NASHVILLE, TN 37232 USA	Centro de Investigaciones Energeticas, Medioambientales Tecnologicas; Vanderbilt University				Navarro, Manuel/0000-0003-1118-8531				ALBERS K, 1992, INT REV CYTOL, V134, P243, DOI 10.1016/S0074-7696(08)62030-6; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Ausubel FA, 1990, CURRENT PROTOCOLS MO; BAICHWAL VR, 1992, GENE DEV, V6, P1493, DOI 10.1101/gad.6.8.1493; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; Bernerd Francoise, 1993, Gene Expression, V3, P187; BLESSING M, 1989, EMBO J, V8, P117, DOI 10.1002/j.1460-2075.1989.tb03355.x; BLESSING M, 1987, EMBO J, V6, P567, DOI 10.1002/j.1460-2075.1987.tb04792.x; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BONIFAS JM, 1991, SCIENCE, V254, P1202, DOI 10.1126/science.1720261; BYRNE C, 1993, MOL CELL BIOL, V13, P3176, DOI 10.1128/MCB.13.6.3176; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; CHAN YM, 1993, P NATL ACAD SCI USA, V90, P7414, DOI 10.1073/pnas.90.15.7414; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHONG T, 1991, J VIROL, V65, P5933, DOI 10.1128/JVI.65.11.5933-5943.1991; CHUVPILO SA, 1985, FEBS LETT, V179, P34, DOI 10.1016/0014-5793(85)80185-X; COOPER D, 1985, LAB INVEST, V52, P243; COULOMBE PA, 1990, J CELL BIOL, V111, P153, DOI 10.1083/jcb.111.1.153; COULOMBE PA, 1991, CELL, V66, P1301, DOI 10.1016/0092-8674(91)90051-Y; CRIPE T P, 1990, New Biologist, V2, P450; FISHER C, 1991, DEVELOPMENT, V111, P253; FUCHS E, 1988, TRENDS GENET, V4, P277, DOI 10.1016/0168-9525(88)90169-2; FUCHS EV, 1981, CELL, V27, P75, DOI 10.1016/0092-8674(81)90362-7; GARCIACARRANCA A, 1988, J VIROL, V62, P4321, DOI 10.1128/JVI.62.11.4321-4330.1988; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAGMEYER BM, 1993, EMBO J, V12, P3559, DOI 10.1002/j.1460-2075.1993.tb06030.x; HATZFELD M, 1991, J CELL SCI, V99, P351; HEID HW, 1986, DIFFERENTIATION, V32, P101, DOI 10.1111/j.1432-0436.1986.tb00562.x; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HUFF CA, 1993, J BIOL CHEM, V268, P377; ISHIJI T, 1992, EMBO J, V11, P2271, DOI 10.1002/j.1460-2075.1992.tb05286.x; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; JORCANO JL, 1984, DIFFERENTIATION, V28, P155, DOI 10.1111/j.1432-0436.1984.tb00278.x; KLEINSZANTO AJP, 1984, MECHANISMS TUMOR PRO, V2, P41; KULESZMARTIN M, 1983, CARCINOGENESIS, V4, P1367, DOI 10.1093/carcin/4.11.1367; KUWABARA MD, 1987, BIOCHEMISTRY-US, V26, P7234, DOI 10.1021/bi00397a006; LANE EB, 1992, NATURE, V356, P244, DOI 10.1038/356244a0; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; LEASK A, 1990, GENE DEV, V4, P1985, DOI 10.1101/gad.4.11.1985; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEE WY, 1993, MOL CARCINOGEN, V7, P26, DOI 10.1002/mc.2940070106; LERSCH R, 1989, MOL CELL BIOL, V9, P3685, DOI 10.1128/MCB.9.9.3685; LICHTI U, 1988, CANCER RES, V48, P74; LIEW FM, 1992, EXP CELL RES, V202, P310, DOI 10.1016/0014-4827(92)90080-R; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LYNCH MH, 1986, J CELL BIOL, V103, P2593, DOI 10.1083/jcb.103.6.2593; MACK DH, 1991, P NATL ACAD SCI USA, V88, P9102, DOI 10.1073/pnas.88.20.9102; MIGNOTTE V, 1989, P NATL ACAD SCI USA, V86, P6548, DOI 10.1073/pnas.86.17.6548; MIKSICEK R, 1986, CELL, V46, P283, DOI 10.1016/0092-8674(86)90745-2; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MOLLOY CJ, 1987, CANCER RES, V47, P4674; NELSON WG, 1983, J CELL BIOL, V97, P244, DOI 10.1083/jcb.97.1.244; OFFORD EA, 1990, J VIROL, V64, P4792, DOI 10.1128/JVI.64.10.4792-4798.1990; OHTSUKI M, 1992, J INVEST DERMATOL, V99, P206, DOI 10.1111/1523-1747.ep12650436; Ohtsuki Mamitaro, 1993, Gene Expression, V3, P201; QUINLAN RA, 1984, J MOL BIOL, V178, P365, DOI 10.1016/0022-2836(84)90149-9; QUINTANILLA M, 1991, CARCINOGENESIS, V12, P1875, DOI 10.1093/carcin/12.10.1875; ROTHNAGEL JA, 1993, J INVEST DERMATOL, V101, P506, DOI 10.1111/1523-1747.ep12365886; RYSECK RP, 1991, ONCOGENE, V6, P533; Sambrook J, 1989, MOL CLONING LABORATO; SCHMID E, 1983, J CELL BIOL, V96, P37, DOI 10.1083/jcb.96.1.37; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SCHWEIZER J, 1987, J INVEST DERMATOL, V89, P125, DOI 10.1111/1523-1747.ep12470544; Schweizer Juergen, 1993, P33; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SLAGA T J, 1989, P1; STEINERT PM, 1990, J BIOL CHEM, V265, P8766; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; Sun TT, 1984, CANCER CELLS, V1, P169; TAKAHASHI H, 1993, J INVEST DERMATOL, V100, P10, DOI 10.1111/1523-1747.ep12349867; THIERRY F, 1992, J VIROL, V66, P3740, DOI 10.1128/JVI.66.6.3740-3748.1992; TOFTGARD R, 1985, CANCER RES, V45, P5845; WILKINSON DG, 1989, DEVELOPMENT, V106, P465; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	79	87	90	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20489	20496						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	7519609				2022-12-27	WOS:A1994PB31700045
J	FEARON, K; MCCLENDON, V; BONETTI, B; BEDWELL, DM				FEARON, K; MCCLENDON, V; BONETTI, B; BEDWELL, DM			PREMATURE TRANSLATION TERMINATION MUTATIONS ARE EFFICIENTLY SUPPRESSED IN A HIGHLY CONSERVED REGION OF YEAST STE6P, A MEMBER OF THE ATP-BINDING CASSETTE (ABC) TRANSPORTER FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE LEUKEMIA-VIRUS; CYSTIC-FIBROSIS GENE; GLUTAMINE TRANSFER-RNA; PROTEIN-SYNTHESIS; MESSENGER-RNA; IMPORT SIGNAL; READ-THROUGH; STOP CODON; IDENTIFICATION; SEQUENCE	The requirements for efficient translation termination are incompletely understood. Since the local context surrounding stop codons can influence the efficiency of translation termination, premature termination codons introduced by random mutation may not always terminate at the optimal efficiencies expected of naturally occurring stop codons. To investigate whether this could result in physiologically significant levels of read through, we examined the suppression of premature translation termination mutations within a sequence motif of the yeast Ste6 protein (Ste6p) that is highly conserved among members of the ATP-binding cassette (ABC) transporter family. The human cystic fibrosis transmembrane conductance regulator (CFTR), which is defective in individuals with the disease cystic fibrosis, is also a member of this protein family. The mutations examined in Ste6p were chosen because a premature termination codon at the corresponding residue of CFTR has previously been reported to cause less severe pulmonary involvement than some missense mutations, suggesting that low level suppression of this stop codon could be occurring. Our results indicate that these premature stop codons in Ste6p can be suppressed at frequencies as high as 10%. Characterization of this phenomenon using a beta-galactosidase read through assay system showed that a limited sequence context surrounding this site contained information that was sufficient to cause suppression of translation termination. Amino acid sequence analysis of the full length translation products produced by read through of an amber codon demonstrated that termination suppression was mediated by near-cognate tRNA mispairing that resulted in the insertion of tyrosine, lysine, or tryptophan.	UNIV ALABAMA,DEPT MICROBIOL,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham				Bedwell, David/0000-0002-6605-818X; BONETTI, Bruno/0000-0002-3944-4165	NIAID NIH HHS [P30 AI27767] Funding Source: Medline; NIDDK NIH HHS [DK38518] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027767] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038518] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ATKINS JF, 1990, CELL, V62, P413, DOI 10.1016/0092-8674(90)90007-2; BEDWELL DM, 1989, MOL CELL BIOL, V9, P1014, DOI 10.1128/MCB.9.3.1014; BEIER H, 1984, EMBO J, V3, P351, DOI 10.1002/j.1460-2075.1984.tb01810.x; BELCOURT MF, 1990, CELL, V62, P339, DOI 10.1016/0092-8674(90)90371-K; BERKOWER C, 1991, EMBO J, V10, P3777, DOI 10.1002/j.1460-2075.1991.tb04947.x; BERRY MJ, 1991, NATURE, V353, P273, DOI 10.1038/353273a0; BOCK A, 1991, MOL MICROBIOL, V5, P515, DOI 10.1111/j.1365-2958.1991.tb00722.x; BROWN CM, 1990, NUCLEIC ACIDS RES, V18, P6339, DOI 10.1093/nar/18.21.6339; CHAMORRO M, 1992, P NATL ACAD SCI USA, V89, P713, DOI 10.1073/pnas.89.2.713; CUTTING GR, 1990, NATURE, V346, P366, DOI 10.1038/346366a0; CUTTING GR, 1990, NEW ENGL J MED, V323, P1685, DOI 10.1056/NEJM199012133232407; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EMR SD, 1986, J CELL BIOL, V102, P523, DOI 10.1083/jcb.102.2.523; FARABAUGH PJ, 1993, CELL, V74, P93, DOI 10.1016/0092-8674(93)90297-4; FENG YX, 1989, J VIROL, V63, P2870, DOI 10.1128/JVI.63.6.2870-2873.1989; FENG YX, 1992, J VIROL, V66, P5127, DOI 10.1128/JVI.66.8.5127-5132.1992; FENG YX, 1990, P NATL ACAD SCI USA, V87, P8860, DOI 10.1073/pnas.87.22.8860; GESTELAND RF, 1992, SCIENCE, V257, P1640, DOI 10.1126/science.1529352; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; KEREM BS, 1990, P NATL ACAD SCI USA, V87, P8447, DOI 10.1073/pnas.87.21.8447; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KUCHINO Y, 1987, P NATL ACAD SCI USA, V84, P2668, DOI 10.1073/pnas.84.9.2668; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIN JP, 1986, GENE, V49, P383, DOI 10.1016/0378-1119(86)90375-6; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SKUZESKI JM, 1991, J MOL BIOL, V218, P365, DOI 10.1016/0022-2836(91)90718-L; SMITH D, 1989, P NATL ACAD SCI USA, V86, P4397, DOI 10.1073/pnas.86.12.4397; TATE WP, 1992, BIOCHEMISTRY-US, V31, P2443, DOI 10.1021/bi00124a001; TSUI LC, 1992, TRENDS GENET, V8, P392, DOI 10.1016/0168-9525(92)90301-J; VALLE RPC, 1987, EMBO J, V6, P3049, DOI 10.1002/j.1460-2075.1987.tb02611.x; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WEISS R, 1988, J MOL BIOL, V203, P403, DOI 10.1016/0022-2836(88)90008-3; WEISS RB, 1987, COLD SPRING HARB SYM, V52, P687, DOI 10.1101/SQB.1987.052.01.078; WEISS WA, 1986, J MOL BIOL, V192, P725, DOI 10.1016/0022-2836(86)90024-0; WILLS NM, 1991, P NATL ACAD SCI USA, V88, P6991, DOI 10.1073/pnas.88.16.6991; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YOSHINAKA Y, 1985, P NATL ACAD SCI USA, V82, P1618, DOI 10.1073/pnas.82.6.1618	38	72	73	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					17802	17808						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	7517933				2022-12-27	WOS:A1994NV42200010
J	REX, G; SURIN, B; BESSE, G; SCHNEPPE, B; MCCARTHY, JEG				REX, G; SURIN, B; BESSE, G; SCHNEPPE, B; MCCARTHY, JEG			THE MECHANISM OF TRANSLATIONAL COUPLING IN ESCHERICHIA-COLI - HIGHER-ORDER STRUCTURE IN THE ATPHA MESSENGER-RNA ACTS AS A CONFORMATIONAL SWITCH REGULATING THE ACCESS OF DE-NOVO INITIATING RIBOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING ATPASE; RNA SECONDARY STRUCTURE; REPRESSOR MESSENGER-RNA; SP STRAIN PCC-7120; NUCLEOTIDE-SEQUENCE; BINDING SITE; BETA-SUBUNIT; LYSIS GENE; UNC OPERON; H+-ATPASE	Bacterial genes are commonly transcribed to form polycistronic mRNAs bearing reading frames whose respective translational efficiencies are not independently determined. As in many bacterial operons, expression of the atp genes of Escherichia coli is strongly influenced by translational coupling. The gene pair atpHA is tightly coupled, whereby atpA is translated at least three times more efficiently than atpH. However, there is no fixed stoichiometry of coupling: mutations in atpH lead to increases in the translation ratio (atpA/ atpH) of up to approximately 40-fold. We have demonstrated that secondary structure sequestering the atpA translational initiation region (TIR) is important to the coupling mechanism in that it inhibits de novo translational initiation at the atpA start codon. Genetic and structural analyses indicate that this inhibitory structure can be induced to refold into a less inhibitory con formation either by introducing two single-base substitutions or as a result of ribosomes translating atpH. We propose a model in which the secondary structure of the atpA TIR acts analogously to a ''gating device'' in that it restricts de novo ribosomal initiation until it is ''switched'' into a more open conformation. This contrasts with the function of a stem-loop structure located immediately downstream of atpA and upstream of the Shine-Dalgarno region of atpG, which was found to inhibit translation, but not to mediate tight coupling. Results obtained using the ''specialized'' ribosome system of Hui and de Boer ((1987) Proc. Natl. Acad. Sci. U. S. A. 84, 4762-4766) indicate that primarily ribosomes reinitiating after termination on atpH are responsible for inducing refolding of the atpA TIR. The principle of alternative mRNA conformations with different functional properties embodied in the model presented here can only be fulfilled by certain types of structure. It is likely to operate in several steps of prokaryotic gene expression, underlying a range of regulatory events including transcriptional attenuation and translational activation.	GESELL BIOTECHNOL FORSCH MBH, DEPT GENE EXPRESS SCI, D-38124 BRAUNSCHWEIG, GERMANY	Gesellschaft fur Biotechnologische Forschung mbH				Surin, Prayoon/0000-0002-9529-6427				ADHIN MR, 1989, MOL GEN GENET, V218, P137, DOI 10.1007/BF00330576; ALTUVIA S, 1987, P NATL ACAD SCI USA, V84, P6511, DOI 10.1073/pnas.84.18.6511; ARIS JP, 1985, J BIOL CHEM, V260, P1207; BAUGHMAN G, 1983, CELL, V34, P979, DOI 10.1016/0092-8674(83)90555-X; BERKHOUT B, 1987, J MOL BIOL, V195, P517, DOI 10.1016/0022-2836(87)90180-X; BRUSILOW WSA, 1989, J BIOL CHEM, V264, P1528; BRUSILOW WSA, 1987, J BACTERIOL, V169, P4984, DOI 10.1128/jb.169.11.4984-4990.1987; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; COZENS AL, 1987, J MOL BIOL, V194, P359, DOI 10.1016/0022-2836(87)90667-X; CURTIS SE, 1987, J BACTERIOL, V169, P80, DOI 10.1128/jb.169.1.80-86.1987; DEBOER H, 1985, SEQUENCE SPECIFICITY, P419; DESMIT MH, 1990, PROG NUCLEIC ACID RE, V38, P1; DUBNAU D, 1984, CRC CR REV BIOCH MOL, V16, P103, DOI 10.3109/10409238409102300; DUNN SD, 1990, J BACTERIOL, V172, P2782, DOI 10.1128/jb.172.5.2782-2784.1990; DUNN SD, 1980, J BIOL CHEM, V255, P113; ENGELBRECHT S, 1990, BIOCHIM BIOPHYS ACTA, V1015, P379, DOI 10.1016/0005-2728(90)90072-C; FALK G, 1985, BIOCHEM J, V228, P391, DOI 10.1042/bj2280391; FILLINGAME RH, 1986, J BACTERIOL, V165, P244, DOI 10.1128/jb.165.1.244-251.1986; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; GATENBY AA, 1989, P NATL ACAD SCI USA, V86, P4066, DOI 10.1073/pnas.86.11.4066; GERSTEL B, 1989, MOL MICROBIOL, V3, P851, DOI 10.1111/j.1365-2958.1989.tb00234.x; GOLD L, 1988, ANNU REV BIOCHEM, V57, P199, DOI 10.1146/annurev.bi.57.070188.001215; GUALERZI CO, 1988, GENETICS TRANSLATION, P317; HATFIELD GW, 1987, TRANSLATIONAL REGULA, P447; HELLMUTH K, 1991, MOL MICROBIOL, V5, P813, DOI 10.1111/j.1365-2958.1991.tb00754.x; HUI A, 1987, P NATL ACAD SCI USA, V84, P4762, DOI 10.1073/pnas.84.14.4762; IVEYHOYLE M, 1989, J MOL BIOL, V208, P233, DOI 10.1016/0022-2836(89)90385-9; KASTELEIN RA, 1983, NATURE, V305, P741, DOI 10.1038/305741a0; KLIONSKY DJ, 1986, J BIOL CHEM, V261, P8096; KNAPP G, 1989, METHOD ENZYMOL, V180, P192; KOZAK M, 1992, CRIT REV BIOCHEM MOL, V27, P385, DOI 10.3109/10409239209082567; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KRUMHOLZ LR, 1989, NUCLEIC ACIDS RES, V17, P7993, DOI 10.1093/nar/17.19.7993; LANG V, 1989, J MOL BIOL, V210, P659, DOI 10.1016/0022-2836(89)90140-X; LASO MRV, 1993, J BIOL CHEM, V268, P6453; LINDAHL L, 1986, ANNU REV GENET, V20, P297; Lindahl L, 1992, CURR OPIN GENET DEV, V2, P720, DOI 10.1016/S0959-437X(05)80132-7; LITTLE S, 1989, J BACTERIOL, V171, P3518, DOI 10.1128/jb.171.6.3518-3522.1989; MARSH S, 1990, POST TRANSCRIPTIONAL, P249; MATTESON RJ, 1991, NUCLEIC ACIDS RES, V19, P3499, DOI 10.1093/nar/19.13.3499; MCCARN DF, 1988, J BACTERIOL, V170, P3448, DOI 10.1128/jb.170.8.3448-3458.1988; MCCARTHY JEG, 1988, MOL MICROBIOL, V2, P455, DOI 10.1111/j.1365-2958.1988.tb00051.x; MCCARTHY JEG, 1990, TRENDS GENET, V6, P78, DOI 10.1016/0168-9525(90)90098-Q; MCCARTHY JEG, 1990, MOL MICROBIOL, V4, P1233, DOI 10.1111/j.1365-2958.1990.tb00702.x; MCCARTHY JEG, 1985, EMBO J, V4, P519, DOI 10.1002/j.1460-2075.1985.tb03659.x; MCCARTHY JEG, 1990, POSTTRANSCRIPTIONAL, P157; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; OHTA S, 1988, BIOCHIM BIOPHYS ACTA, V933, P141, DOI 10.1016/0005-2728(88)90064-3; PATI S, 1992, MOL MICROBIOL, V6, P3559, DOI 10.1111/j.1365-2958.1992.tb01791.x; PETERSEN C, 1989, J MOL BIOL, V206, P323, DOI 10.1016/0022-2836(89)90482-8; PHILIPPE C, 1993, P NATL ACAD SCI USA, V90, P4394, DOI 10.1073/pnas.90.10.4394; PRASZKIER J, 1992, J BACTERIOL, V174, P2376, DOI 10.1128/JB.174.7.2376-2383.1992; RINGQUIST S, 1992, MOL MICROBIOL, V6, P1219, DOI 10.1111/j.1365-2958.1992.tb01561.x; SCHUMPERLI D, 1982, CELL, V30, P865, DOI 10.1016/0092-8674(82)90291-4; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; SPANJAARD RA, 1989, NUCLEIC ACIDS RES, V17, P5501, DOI 10.1093/nar/17.14.5501; STEEGE DA, 1977, P NATL ACAD SCI USA, V74, P4163, DOI 10.1073/pnas.74.10.4163; TYBULEWICZ VLJ, 1984, J MOL BIOL, V179, P185, DOI 10.1016/0022-2836(84)90465-0; VONMEYENBURG K, 1985, EMBO J, V4, P2357, DOI 10.1002/j.1460-2075.1985.tb03939.x; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; WALKER JE, 1982, FEBS LETT, V146, P393, DOI 10.1016/0014-5793(82)80960-5; WU RP, 1992, J BACTERIOL, V174, P7620, DOI 10.1128/JB.174.23.7620-7628.1992; YATES JL, 1981, NATURE, V294, P190, DOI 10.1038/294190a0; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	64	47	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					18118	18127						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	7517937				2022-12-27	WOS:A1994NV42200056
J	SUGAWARA, E; NIKAIDO, H				SUGAWARA, E; NIKAIDO, H			OMPA PROTEIN OF ESCHERICHIA-COLI OUTER-MEMBRANE OCCURS IN OPEN AND CLOSED CHANNEL FORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ENVELOPE MEMBRANE; TRANSPORT SPECIFICITY FRACTIONATION; PSEUDOMONAS-AERUGINOSA; MAJOR PROTEINS; LIPID BILAYER; PORIN; RECONSTITUTION; PERMEABILITY; PURIFICATION; K-12	OmpA protein of Escherichia coli outer membrane can produce diffusion channels when reconstituted into proteoliposomes (Sugawara, E., and Nikaido, H. (1992) J. Biol. Chem. 267, 2507-2511). The pore size is similar to that of the classical E. coli porins OmpF and OmpC, but the penetration rates of small solutes through the OmpA channel are about 50 times slower than that through the OmpF channel. Here we examined the possibility that only a small fraction of the OmpA molecules produces open channels. Unilamellar proteoliposomes were made so that each vesicle contained only a small number of OmpA molecules. These vesicles, containing 0.3 M urea within, were fractionated on a linear iso-osmolar density gradient made of urea and sucrose. This resulted in the clear separation of vesicles not containing any open channel, staying on top of the gradient, from those containing at least one open channel, sedimenting close to the bottom. Calculation using Poisson distribution indicated that only between 2 and 3% of the OmpA molecules contained open channel. The open form is estimated to allow the diffusion of L-arabinose at a rate comparable with that through the OmpF porin channel. The open and closed states were relatively stable properties of the protein. Denaturation of open form OmpA and its subsequent renaturation converted it into a nonfunctional or closed form, suggesting that the open and closed forms represent two alternative conformers of this protein.			SUGAWARA, E (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,229 STANLEY HALL,BERKELEY,CA 94720, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI009644, R37AI009644] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-09644] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMBUDKAR SV, 1986, METHOD ENZYMOL, V125, P558; Ames B.N., 1966, METHOD ENZYMOL, V8, P115, DOI [10.1016/0076-6879(66)08014-5, DOI 10.1016/0076-6879(66)08014-5]; ANGUS BL, 1982, ANTIMICROB AGENTS CH, V21, P299, DOI 10.1128/AAC.21.2.299; BAVOIL P, 1977, MOL GEN GENET, V158, P23, DOI 10.1007/BF00455116; BENZ R, 1978, BIOCHIM BIOPHYS ACTA, V511, P305, DOI 10.1016/0005-2736(78)90269-9; BENZ R, 1981, BIOCHIM BIOPHYS ACTA, V646, P298, DOI 10.1016/0005-2736(81)90336-9; BREMER E, 1982, EUR J BIOCHEM, V122, P223, DOI 10.1111/j.1432-1033.1982.tb05870.x; CHAI T, 1978, J BACTERIOL, V135, P164, DOI 10.1128/JB.135.1.164-170.1978; CHEN CC, 1984, J BIOL CHEM, V259, P150; CHEN R, 1980, P NATL ACAD SCI-BIOL, V77, P4592, DOI 10.1073/pnas.77.8.4592; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; DATTA DB, 1977, J BACTERIOL, V131, P821, DOI 10.1128/JB.131.3.821-829.1977; DORNMAIR K, 1990, J BIOL CHEM, V265, P18907; FINNEN RL, 1992, J BACTERIOL, V174, P4977, DOI 10.1128/JB.174.15.4977-4985.1992; GALANOS C, 1969, EUR J BIOCHEM, V9, P245, DOI 10.1111/j.1432-1033.1969.tb00601.x; GOLDIN SM, 1980, P NATL ACAD SCI-BIOL, V77, P6884, DOI 10.1073/pnas.77.11.6884; GOLDIN SM, 1978, J BIOL CHEM, V253, P2575; HARRIS AL, 1989, J MEMBRANE BIOL, V109, P243, DOI 10.1007/BF01870281; HESS GP, 1977, P NATL ACAD SCI USA, V74, P482, DOI 10.1073/pnas.74.2.482; HEUKESHOVEN J, 1988, ELECTROPHORESIS, V9, P28, DOI 10.1002/elps.1150090106; LUGTENBERG B, 1975, FEBS LETT, V58, P254, DOI 10.1016/0014-5793(75)80272-9; MORONA R, 1984, J BACTERIOL, V159, P570, DOI 10.1128/JB.159.2.570-578.1984; NIKAIDO H, 1985, MICROBIOL REV, V49, P1; NIKAIDO H, 1981, J GEN PHYSIOL, V77, P121, DOI 10.1085/jgp.77.2.121; NIKAIDO H, 1983, J BACTERIOL, V153, P241, DOI 10.1128/JB.153.1.241-252.1983; NIKAIDO H, 1991, J BIOL CHEM, V266, P770; Nikaido H., 1986, BACTERIA, V10, P145; PAPAZIAN D, 1979, P NATL ACAD SCI USA, V76, P3708, DOI 10.1073/pnas.76.8.3708; ROBINSON RA, 1955, ELECTROLYTE SOLUTION, P247; SCHIRMER T, 1993, PROTEIN SCI, V2, P1361, DOI 10.1002/pro.5560020820; SCHWEIZER M, 1977, J BACTERIOL, V129, P1651, DOI 10.1128/JB.129.3.1651-1652.1977; SCHWEIZER M, 1978, EUR J BIOCHEM, V82, P211, DOI 10.1111/j.1432-1033.1978.tb12013.x; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SONNTAG I, 1978, J BACTERIOL, V136, P280, DOI 10.1128/JB.136.1.280-285.1978; SUGAWARA E, 1992, J BIOL CHEM, V267, P2507; SURREY T, 1992, P NATL ACAD SCI USA, V89, P7457, DOI 10.1073/pnas.89.16.7457; VANALPHEN L, 1977, FEBS LETT, V75, P285, DOI 10.1016/0014-5793(77)80104-X; VOGEL H, 1986, J MOL BIOL, V190, P191, DOI 10.1016/0022-2836(86)90292-5; WOODRUFF WA, 1989, J BACTERIOL, V171, P3304, DOI 10.1128/jb.171.6.3304-3309.1989; WOODRUFF WA, 1986, J BACTERIOL, V167, P473, DOI 10.1128/jb.167.2.473-479.1986; YOSHIMURA F, 1983, J BIOL CHEM, V258, P2308	42	103	104	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					17981	17987						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	7517935				2022-12-27	WOS:A1994NV42200037
J	WILDE, CG; SEILHAMER, JJ; MCGROGAN, M; ASHTON, N; SNABLE, JL; LANE, JC; LEONG, SR; THORNTON, MB; MILLER, KL; SCOTT, RW; MARRA, MN				WILDE, CG; SEILHAMER, JJ; MCGROGAN, M; ASHTON, N; SNABLE, JL; LANE, JC; LEONG, SR; THORNTON, MB; MILLER, KL; SCOTT, RW; MARRA, MN			BACTERICIDAL PERMEABILITY-INCREASING PROTEIN AND LIPOPOLYSACCHARIDE (LPS)-BINDING PROTEIN - LPS BINDING-PROPERTIES AND EFFECTS ON LPS-MEDIATED CELL ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTOXIN; CD14; CLONING; CDNA	We have previously shown that human bactericidal/ permeability-increasing protein (BPI) is able to inhibit serum-dependent lipopolysaccharide (LPS)-mediated activation of human monocytes and neutrophils in vitro, and to counteract the lethal effects of LPS challenge in vivo. Lipopolysaccharide-binding protein (LBP) is a serum protein which participates in LPS-mediated activation of cells (Tobias, P. S., Mathison, J., Mintz, D., Lee, J. D., Kravchenko, V., Kato, K., Pugin, J., and Ulevitch, R. J. (1992) Am. J. Respir: Cell. Mel. Biol. 7, 239-245). We have proposed that BPI functions in a negative feedback loop which opposes this activation (Marra, M. N., Wilde, C. G., Collins, M. S., Snable, J. L., Thornton, M. E., and Scott, R. W. (1992) J. Immunol. 148, 532-537). We have now cloned and expressed recombinant forms of human BPI and LBP. Here we demonstrate that purified recombinant human LBP can replace the serum requirement for both LPS binding to human monocytes and LPS-mediated secretion of tumor necrosis factor alpha from these cells. These activities of LBP are inhibited by a neutralizing anti-CD14 monoclonal antibody. We further demonstrate that purified recombinant human BPI can inhibit LBP-mediated LPS binding to cells and their subsequent activation. Comparison of the LPS binding properties of BPI and LBP in enzyme-linked immunosorbent type assays and in the Limulus amebocyte lysate assay suggest that BPI has a stronger affinity for LPS than does LBP. Direct competition between BPI and LBP for LPS may ex plain the inhibition by EPI of the proinflammatory effects of LBP in the presence of LPS.	INCYTE PHARMACEUT,PALO ALTO,CA 94304; GENENTECH INC,S SAN FRANCISCO,CA 94080	Incyte; Roche Holding; Genentech								BAZIL V, 1986, EUR J IMMUNOL, V16, P1583, DOI 10.1002/eji.1830161218; BONE RC, 1991, ANN INTERN MED, V115, P457, DOI 10.7326/0003-4819-115-6-457; DRAYNA D, 1987, NATURE, V327, P632, DOI 10.1038/327632a0; Elsbach P, 1992, INFLAMMATION BASIC P, P603; GRAY PW, 1989, J BIOL CHEM, V264, P9505; HEUMANN D, 1993, J INFECT DIS, V167, P1351, DOI 10.1093/infdis/167.6.1351; LYNN WA, 1992, IMMUNOL TODAY, V13, P271, DOI 10.1016/0167-5699(92)90009-V; MARRA MN, 1990, J IMMUNOL, V144, P662; MARRA MN, 1992, J IMMUNOL, V148, P532; MORRISON DC, 1987, ANNU REV MED, V38, P417, DOI 10.1146/annurev.me.38.020187.002221; MORRISON DC, 1978, AM J PATHOL, V93, P527; PUGIN J, 1993, P NATL ACAD SCI USA, V90, P2744, DOI 10.1073/pnas.90.7.2744; RAETZ CRH, 1991, FASEB J, V5, P2652, DOI 10.1096/fasebj.5.12.1916089; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; TOBIAS PS, 1992, AM J RESP CELL MOL, V7, P239, DOI 10.1165/ajrcmb/7.3.239; TOBIAS PS, 1989, J BIOL CHEM, V264, P10867; TSUCHIYA S, 1980, INT J CANCER, V26, P171, DOI 10.1002/ijc.2910260208; WRIGHT SD, 1992, J EXP MED, V176, P719, DOI 10.1084/jem.176.3.719; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311	19	69	73	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17411	17416						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	7517398				2022-12-27	WOS:A1994NU12800013
J	LUO, YQ; LU, SJ; CHEN, P; WANG, D; HALPERN, M				LUO, YQ; LU, SJ; CHEN, P; WANG, D; HALPERN, M			IDENTIFICATION OF CHEMOATTRACTANT RECEPTORS AND G-PROTEINS IN THE VOMERONASAL SYSTEM OF GARTER SNAKES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING-PROTEINS; SENSITIVE ADENYLATE-CYCLASE; OLFACTORY RECEPTOR; ADP-RIBOSYLATION; PHOSPHOINOSITIDE TURNOVER; INOSITOL TRISPHOSPHATE; ADRENERGIC-RECEPTORS; SIGNAL TRANSDUCTION; VAGINAL DISCHARGE; HUMAN FIBROBLASTS	Garter snakes respond to purified chemoattractants derived from prey. The specific binding sites for one of these chemoattractants, ES20, in the vomeronasal organ was saturable and reversible. Binding sites for ES20 were abolished by heating or greatly reduced by Pronase digestion. ES20 chemoattractant activity and receptor binding required Ca2+. Binding of ES20 to sensory epithelium derived from animals with bipolar neurons depleted by denervation was reduced 22-43% as compared to control animals. However, there was an up-regulation of the ES20 receptor population in the nonsensory cells following nerve cuts. Three G-proteins (G(s), G(i), and G(o)) were tentatively identified using immunoreactivity and ADP-ribosylation techniques. G(i) and G(o) proteins were shown to be coupled with ES20-receptor and effecters as evidenced by: 1) the affinity of ES20-receptor was decreased by GTP gamma S; 2) ES20-receptor binding caused a reduction in ADP-ribosylation of pertussis toxin-susceptible G-proteins, and the inhibitory effect of ES20-receptor on ADP-ribosylation was attenuated by GDP beta S; 3) the effect of ES20-receptor on ADP-ribosylation of the pertussis toxin-susceptible G-proteins could be mimicked by G-protein activators, such as GTP gamma S or AIF(3); 4) ES20-receptor binding resulted in a decrease of the basal level of cAMP; 5) the binding of ES20 to its receptors caused an increase in the level of D-myo-inositol 1,4,5-trisphosphate.	SUNY HLTH SCI CTR, DEPT BIOCHEM, BROOKLYN, NY 11203 USA; SUNY HLTH SCI CTR, DEPT ANAT & CELL BIOL, BROOKLYN, NY 11203 USA	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center					NIDCD NIH HHS [DC 00104] Funding Source: Medline	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		BASU SK, 1978, J BIOL CHEM, V253, P3852; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BORISY FF, 1992, J NEUROSCI, V12, P915; BOSCH F, 1986, BIOCHEM J, V239, P523, DOI 10.1042/bj2390523; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOYD ND, 1991, BIOCHEMISTRY-US, V30, P336, DOI 10.1021/bi00216a005; BRAND JG, 1987, BRAIN RES, V416, P119, DOI 10.1016/0006-8993(87)91503-4; BRANDT DR, 1986, J BIOL CHEM, V261, P1656; BRUCH RC, 1988, COMP BIOCHEM PHYS B, V91, P535, DOI 10.1016/0305-0491(88)90018-1; CALDWELL PC, 1970, CALCIUM CELLULAR FUN, P11; Caprio J, 1982, CHEMORECEPTION FISHE, P109; CUATRECASAS P, 1971, J BIOL CHEM, V246, P7265; DEMOLIOUMASON CD, 1986, J NEUROCHEM, V46, P1118, DOI 10.1111/j.1471-4159.1986.tb00626.x; FRANCES B, 1985, EUR J PHARMACOL, V117, P223, DOI 10.1016/0014-2999(85)90607-7; GILL DM, 1991, METHOD ENZYMOL, V195, P267; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOEDERT M, 1989, METHOD ENZYMOL, V168, P462; GOLDSTEIN JL, 1974, J BIOL CHEM, V249, P5153; GRAF R, 1992, EUR J BIOCHEM, V210, P609, DOI 10.1111/j.1432-1033.1992.tb17461.x; HOMBURGER V, 1987, MOL PHARMACOL, V31, P313; HUQUE T, 1986, BIOCHEM BIOPH RES CO, V137, P36, DOI 10.1016/0006-291X(86)91172-1; INOUCHI J, 1993, BRAIN BEHAV EVOLUT, V41, P171, DOI 10.1159/000113835; JIANG XC, 1990, J BIOL CHEM, V265, P8736; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KRUEGER JM, 1976, J BIOL CHEM, V251, P88; LEFF SE, 1985, MOL PHARMACOL, V27, P184; LEFKOWITZ RJ, 1988, J BIOL CHEM, V263, P4993; LEFKOWITZ RJ, 1983, ANNU REV BIOCHEM, V52, P159, DOI 10.1146/annurev.bi.52.070183.001111; LI CS, 1993, SOC NEUROSCI, V23, P122; LINDER ME, 1990, J BIOL CHEM, V265, P8243; MAEHAMA T, 1991, J BIOL CHEM, V266, P10062; Means G E, 1977, Methods Enzymol, V47, P469; MILLIGAN G, 1987, BIOCHIM BIOPHYS ACTA, V929, P197, DOI 10.1016/0167-4889(87)90176-5; MILLIGAN G, 1988, BIOCHEM J, V255, P1; MOODY TW, 1989, METHOD ENZYMOL, V168, P481; MUMBY SM, 1991, METHOD ENZYMOL, V195, P215; NEER EJ, 1984, J BIOL CHEM, V259, P4222; NISHIMOTO I, 1989, J BIOL CHEM, V264, P14029; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OCONNELL RJ, 1978, BEHAV BIOL, V24, P244, DOI 10.1016/S0091-6773(78)93110-3; OLSON KS, 1992, BRAIN RES, V583, P262, DOI 10.1016/S0006-8993(10)80032-0; OPPENHEIMER NJ, 1978, J BIOL CHEM, V253, P4907; PACE U, 1985, NATURE, V316, P255, DOI 10.1038/316255a0; REED RR, 1992, NEURON, V8, P205, DOI 10.1016/0896-6273(92)90287-N; RENSDOMIANO S, 1992, J NEUROCHEM, V58, P1987, DOI 10.1111/j.1471-4159.1992.tb10938.x; RONNETT GV, 1993, J NEUROSCI, V13, P1751; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; Salomon Y, 1979, Adv Cyclic Nucleotide Res, V10, P35; SCHMIDT A, 1991, J BIOL CHEM, V266, P18025; SHEPHERD GM, 1991, CELL, V67, P845, DOI 10.1016/0092-8674(91)90358-6; SHINOHARA H, 1992, J NEUROSCI, V12, P1275; SINGER AG, 1984, PHYSIOL BEHAV, V33, P639, DOI 10.1016/0031-9384(84)90384-6; SINGER AG, 1986, J BIOL CHEM, V261, P3323; SKLAR PB, 1986, J BIOL CHEM, V261, P5538; STEPHENS L, 1993, J BIOL CHEM, V268, P17162; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; VANDOP C, 1984, J BIOL CHEM, V259, P23; WANG D, 1993, BRAIN BEHAV EVOLUT, V41, P246, DOI 10.1159/000113846; WANG D, 1988, ARCH BIOCHEM BIOPHYS, V267, P459, DOI 10.1016/0003-9861(88)90051-3; WANG D, 1992, CHEM SIGNALS VERTEBR, V6, P107; WANG RT, 1980, AM J ANAT, V157, P399, DOI 10.1002/aja.1001570408; WANG RT, 1980, J MORPHOL, V164, P47, DOI 10.1002/jmor.1051640105; WEISS ER, 1990, J MOL ENDOCRINOL, V4, P71, DOI 10.1677/jme.0.0040071	68	69	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16867	16877						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	7515886				2022-12-27	WOS:A1994NR29600055
J	AKABAS, MH; KAUFMANN, C; COOK, TA; ARCHDEACON, P				AKABAS, MH; KAUFMANN, C; COOK, TA; ARCHDEACON, P			AMINO-ACID-RESIDUES LINING THE CHLORIDE CHANNEL OF THE CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SITE-DIRECTED MUTAGENESIS; XENOPUS OOCYTES; CYSTEINE-SUBSTITUTION; MILD-DISEASE; CL CHANNELS; CFTR GENE; R-DOMAIN; RECEPTOR; SELECTIVITY; MUTATIONS	The cystic fibrosis transmembrane conductance regulator forms a chloride channel that is regulated by phosphorylation and intracellular ATP levels. The structure of the channel-forming domains is undetermined. To identify the residues lining this channel we substituted cysteine, one at a time, for 9 consecutive residues (91-99) in the M1 membrane spanning segment. The cysteine substitution mutants were expressed in Xenopus oocytes. We determined the accessibility of the engineered cysteine to charged, sulfhydryl-specific methanethiosulfonate reagents added extracellularly. We assume that, among residues in membrane-spanning segments, only those lining the channel will be accessible to react with these hydrophilic reagents and that such a reaction would irreversibly alter conduction through the channel. Only the cysteines substituted for Gly-91, Lys-95, and Gln-98 were accessible to the reagents. We conclude that these residues are in the channel lining. The periodicity of these residues is consistent with an alpha-helical secondary structure.	COLUMBIA UNIV, DEPT PHYSIOL & CELLULAR BIOPHYS, NEW YORK, NY 10032 USA; COLUMBIA UNIV, DEPT MED, NEW YORK, NY 10032 USA	Columbia University; Columbia University	AKABAS, MH (corresponding author), COLUMBIA UNIV, CTR MOLEC RECOGNIT, 630 W 168TH ST, NEW YORK, NY 10032 USA.			Akabas, Myles/0000-0001-8781-7846	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK041146] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK41146] Funding Source: Medline; NIGMS NIH HHS [GM08224] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; BEAR CE, 1991, J BIOL CHEM, V266, P19142; CHALKLEY G, 1991, J MED GENET, V28, P875, DOI 10.1136/jmg.28.12.875; CHANG XB, 1993, J BIOL CHEM, V268, P11304; CUNNINGHAM SA, 1992, AM J PHYSIOL, V262, pC783, DOI 10.1152/ajpcell.1992.262.3.C783; DENNING GM, 1992, J CLIN INVEST, V89, P339, DOI 10.1172/JCI115582; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; EGAN M, 1992, NATURE, V358, P581, DOI 10.1038/358581a0; FALKE JJ, 1988, J BIOL CHEM, V263, P14850; FINKELSTEIN A, 1981, J MEMBRANE BIOL, V59, P155, DOI 10.1007/BF01875422; FLOTTE TR, 1993, J BIOL CHEM, V268, P3781; GUILLERMIT H, 1993, HUM GENET, V91, P233; HASEGAWA H, 1992, SCIENCE, V258, P1477, DOI 10.1126/science.1279809; JAKES KS, 1990, J BIOL CHEM, V265, P6984; Kenyon G L, 1977, Methods Enzymol, V47, P407; PAKULA AA, 1992, P NATL ACAD SCI USA, V89, P4144, DOI 10.1073/pnas.89.9.4144; QUINTON PM, 1992, NATURE, V360, P79, DOI 10.1038/360079a0; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RICH DP, 1993, J BIOL CHEM, V268, P20259; RIORDAN JR, 1989, SCIENCE, V245, P1066; RIORDAN JR, 1993, ANNU REV PHYSIOL, V55, P609, DOI 10.1146/annurev.ph.55.030193.003141; SHEPPARD DN, 1993, NATURE, V362, P160, DOI 10.1038/362160a0; TABCHARANI JA, 1993, NATURE, V366, P79, DOI 10.1038/366079a0; TODD AP, 1989, PROTEINS, V6, P294, DOI 10.1002/prot.340060312; Tsui L C, 1991, Adv Hum Genet, V20, P153; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; XU M, 1993, J BIOL CHEM, V268, P21505; ZIELENSKI J, 1991, GENOMICS, V10, P229, DOI 10.1016/0888-7543(91)90504-8	30	138	139	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					14865	14868						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	7515047				2022-12-27	WOS:A1994NP73800005
J	BARNEA, G; GRUMET, M; MILEV, P; SILVENNOINEN, O; LEVY, JB; SAP, J; SCHLESSINGER, J				BARNEA, G; GRUMET, M; MILEV, P; SILVENNOINEN, O; LEVY, JB; SAP, J; SCHLESSINGER, J			RECEPTOR TYROSINE PHOSPHATASE-BETA IS EXPRESSED IN THE FORM OF PROTEOGLYCAN AND BINDS TO THE EXTRACELLULAR-MATRIX PROTEIN TENASCIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CHONDROITIN SULFATE PROTEOGLYCANS; CELL-ADHESION MOLECULE; NEURITE OUTGROWTH; NERVOUS-SYSTEM; CYTOTACTIN; BRAIN; J1/TENASCIN; INHIBITION; BOUNDARIES; TISSUES	The extracellular domain of receptor type protein tyrosine phosphatase beta (RPTP beta) exhibits striking sequence similarity with a soluble, rat brain chondroitin sulfate proteoglycan (3F8 PG). Immunoprecipitation experiments of cells transfected with RPTP beta expression vector and metabolically labeled with [S-35]sulfate and [S-35]methionine indicate that the transmembrane form of RPTP beta is indeed a chondroitin sulfate proteoglycan. The 3F8 PG is therefore a variant form composed of the entire extracellular domain of RPTP beta probably generated by alternative RNA splicing. Previous immunohistochemical studies indicated that both RPTP beta and the extracellular matrix protein tenascin are localized in similar regions of the central nervous system. We have performed co-aggregation assays with red and green Covaspheres coated with tenascin and 3F8 PG, respectively, showing that the extracellular domain of RPTP beta (3F8 PG) binds specifically to tenascin. The interaction between a receptor tyrosine phosphatase and an extracellular matrix protein may have a role in development of the mammalian central nervous system.	NYU,MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016	New York University			grumet, martin/ABC-6462-2020		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021629, R01NS013876] Funding Source: NIH RePORTER; NIMH NIH HHS [MH-00129] Funding Source: Medline; NINDS NIH HHS [NS-21629, NS-13876] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARNEA G, 1993, MOL CELL BIOL, V13, P1497, DOI 10.1128/MCB.13.3.1497; BARNEA G, 1994, CELL, V76, P205, DOI 10.1016/0092-8674(94)90328-X; BRACKENBURY R, 1977, J BIOL CHEM, V252, P6835; BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; CANOLL PD, 1993, DEV BRAIN RES, V75, P293, DOI 10.1016/0165-3806(93)90035-9; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIQUET M, 1991, SEMIN NEUROSCI, V3, P341; CROSSIN KL, 1991, P NATL ACAD SCI USA, V88, P11403, DOI 10.1073/pnas.88.24.11403; CROSSIN KL, 1989, DEV BIOL, V136, P381, DOI 10.1016/0012-1606(89)90264-9; ERICKSON HP, 1989, ANNU REV CELL BIOL, V5, P71, DOI 10.1146/annurev.cb.05.110189.000443; FALTZ LL, 1979, J BIOL CHEM, V254, P1375; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GEBBINK MFBG, 1993, J BIOL CHEM, V268, P16101; GRUMET M, 1985, P NATL ACAD SCI USA, V82, P8075, DOI 10.1073/pnas.82.23.8075; GRUMET M, 1993, J CELL BIOL, V120, P815, DOI 10.1083/jcb.120.3.815; GRUMET M, 1984, J CELL BIOL, V98, P1746, DOI 10.1083/jcb.98.5.1746; GRUMET M, 1988, J CELL BIOL, V106, P487, DOI 10.1083/jcb.106.2.487; KAPLAN R, 1990, P NATL ACAD SCI USA, V87, P7000, DOI 10.1073/pnas.87.18.7000; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KRUEGER NX, 1992, P NATL ACAD SCI USA, V89, P7417, DOI 10.1073/pnas.89.16.7417; KUHN TB, 1991, J CELL BIOL, V115, P1113, DOI 10.1083/jcb.115.4.1113; LEVY JB, 1993, J BIOL CHEM, V268, P10573; LOCHTER A, 1991, J CELL BIOL, V113, P1159, DOI 10.1083/jcb.113.5.1159; MARGOLIS RK, 1993, EXPERIENTIA, V49, P429, DOI 10.1007/BF01923587; MAUREL P, 1994, P NATL ACAD SCI USA, V91, P2512, DOI 10.1073/pnas.91.7.2512; MILEV P, 1993, J NEUROCHEM, V61, pS110; NORENBERG U, 1992, NEURON, V8, P849, DOI 10.1016/0896-6273(92)90199-N; PERRIS R, 1990, DEV BIOL, V137, P1, DOI 10.1016/0012-1606(90)90002-Z; PRIETO AL, 1990, J CELL BIOL, V111, P685, DOI 10.1083/jcb.111.2.685; RAUCH U, 1991, J BIOL CHEM, V266, P14785; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; SAGA Y, 1992, GENE DEV, V6, P1821, DOI 10.1101/gad.6.10.1821; SAITO H, 1991, CELL GROWTH DIFFER, V2, P59; SAP J, 1994, MOL CELL BIOL, V14, P1; SNOW DM, 1990, DEV BIOL, V138, P359, DOI 10.1016/0012-1606(90)90203-U; STEINDLER DA, 1989, DEV BIOL, V131, P243, DOI 10.1016/S0012-1606(89)80056-9	36	176	178	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14349	14352						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	7514167				2022-12-27	WOS:A1994NM06500006
J	KO, YH; THOMAS, PJ; PEDERSEN, PL				KO, YH; THOMAS, PJ; PEDERSEN, PL			THE CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR - NUCLEOTIDE-BINDING TO A SYNTHETIC PEPTIDE SEGMENT FROM THE 2ND PREDICTED NUCLEOTIDE-BINDING FOLD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL ATP SYNTHASE; CFTR CHLORIDE CHANNEL; BETA-SUBUNIT PEPTIDE; 50-AMINO ACID; MUTATIONS; PROTEIN; PURIFICATION; SEQUENCES; TURNS; GENE	Previous studies from this laboratory with a 67-amino acid synthetic peptide (P-67) demonstrated directly that the first predicted nucleotide binding fold of the cystic fibrosis transmembrane conductance regulator (CFTR) binds ATP (Thomas, P. J., Shenbagamurthi, P, Ysern, S., and Pedersen, P L. (1991) Science 251, 555-557). Although mutational analysis within the predicted second nucleotide binding fold indicates that this domain may be functionally important also, direct evidence for nucleotide binding is lacking. Here, we report the design, chemical synthesis, and purification of a 51-amino acid segment (P-51) of the second predicted nucleotide binding fold of CFTR and demonstrate that this peptide binds ATP. P-51 consists of amino acid residues hom glutamic acid 1228 through threonine 1278 and contains a motif, GX(4)GKS, very similar or identical to that found in many nucleotide-binding proteins. The freshly dissolved peptide moves predominantly as a single species upon molecular sieve chromatography and readily binds ATP without eliciting its hydrolysis. P-51 also readily binds the fluorescent ATP analogs TNP-ATP (2'(3')-0-(2,4,6-trinitrophenyl)-adenosine-5'-triphosphate) and TNP-ADP but exhibits much less capacity to bind TNP-AMP. ATP displaces TNP-ATP with a K-d (ATP) of 0.46 mM. In the presence of the denaturant urea, P-51 loses most of its binding capacity indicating that structure is important for binding. Consistent with this conclusion, circular dichroism spectroscopy revealed that P-51 has significant secondary structure. Elements of such structure calculated from deconvolution of the circular dichroism spectra compare favorably with those predicted from the program of Chou, P.Y., and Fasman, G. D. (1977) J. Mol. Biol. 115, 135-175. These experiments provide the first direct evidence that the second predicted nucleotide binding fold of CFTR binds ATP and define a 51-amino acid segment within the similar to 150-amino acid fold critical for this function. They also indicate that the beta and gamma phosphate groups of ATP may be important for binding and that the 51-amino acid region studied is not sufficient to catalyze ATP hydrolysis. Finally, as seven different mutations within P-51 are known to cause cystic fibrosis, these studies will be important in future efforts to understand the molecular basis of the disease.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205	Johns Hopkins University			Thomas, Philip J/F-7115-2012		NIDDK NIH HHS [DK 43962] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043962] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ARORA KK, 1990, J BIOL CHEM, V265, P5324; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; CHOU PY, 1977, J MOL BIOL, V115, P135, DOI 10.1016/0022-2836(77)90094-8; DIXON M, 1979, ENZYYMES, P806; EDMAN P, 1950, ACTA CHEM SCAND, V4, P283, DOI 10.3891/acta.chem.scand.04-0283; FRY DC, 1985, BIOCHEMISTRY-US, V24, P4680, DOI 10.1021/bi00338a030; GARBOCZI DN, 1990, J BIOL CHEM, V265, P14632; GARBOCZI DN, 1988, J BIOL CHEM, V263, P812; HARTMAN J, 1992, J BIOL CHEM, V267, P6455; HUNKAPILLER MW, 1983, SCIENCE, V219, P650, DOI 10.1126/science.6687410; KO YH, 1993, J BIOL CHEM, V268, P24330; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; PEDERSEN PL, 1976, J BIOL CHEM, V251, P934; QUINTON PM, 1992, NATURE, V360, P79, DOI 10.1038/360079a0; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RIORDAN JR, 1989, SCIENCE, V245, P1066; SCHULTZ BD, 1993, PEDIATR PULMONO S212, V9; SENIOR AE, 1992, J BIOL CHEM, V267, P21471; STINSON RA, 1973, BIOCHEM J, V131, P719, DOI 10.1042/bj1310719; THOMAS PJ, 1992, J BIOL CHEM, V267, P5727; THOMAS PJ, 1991, SCIENCE, V251, P555, DOI 10.1126/science.1703660; THOMAS PJ, 1992, J BIOL CHEM, V267, P20331; TRAVIS SM, 1993, J BIOL CHEM, V268, P15336; TSUI LC, 1992, TRENDS GENET, V8, P392, DOI 10.1016/0168-9525(92)90301-J; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R	29	22	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14584	14588						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	7514174				2022-12-27	WOS:A1994NM06500044
J	LEE, KH; BAEK, MY; MOON, KY; SONG, WK; CHUNG, CH; HA, DB; KANG, MS				LEE, KH; BAEK, MY; MOON, KY; SONG, WK; CHUNG, CH; HA, DB; KANG, MS			NITRIC-OXIDE AS A MESSENGER MOLECULE FOR MYOBLAST FUSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CYCLIC-GMP; L-ARGININE; PROTEIN-KINASE; SYNTHASE; ENZYME; PHOSPHORYLATION; CALMODULIN; RADIOIMMUNOASSAY; RELAXATION; INHIBITION	Nitric oxide (NO) is a messenger molecule of vascular endothelial cells, macrophages, and neurons. Here, we demonstrate that the activity of NO synthase increases transiently but dramatically in chick embryonic myoblasts that are competent for fusion. This activity requires Ca2+, calmodulin, and NADPH. In addition, the increase in NO synthase activity coincides with an increase in cellular cGMP level. Furthermore, NO generated by treatment with sodium nitroprusside induces precocious myoblast fusion, while treatment with N-G-monomethyl-L-arginine, a competitive inhibitor of NO synthase, or methylene blue, an inhibitor of guanylate cyclase, delays fusion. These results provide the first evidence for a strong association of NO with myoblast fusion.	SEOUL NATL UNIV,COLL NAT SCI,DEPT MOLEC BIOL,SEOUL 151742,SOUTH KOREA; SEOUL NATL UNIV,COLL NAT SCI,SRC CELL DIFFERENTIAT,SEOUL 151742,SOUTH KOREA	Seoul National University (SNU); Seoul National University (SNU)								BREDT DS, 1992, J BIOL CHEM, V267, P10976; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BRUNE B, 1991, BIOCHEM BIOPH RES CO, V181, P921, DOI 10.1016/0006-291X(91)91279-L; BUSSE R, 1990, FEBS LETT, V265, P133, DOI 10.1016/0014-5793(90)80902-U; CHOI SW, 1992, EXP CELL RES, V199, P129, DOI 10.1016/0014-4827(92)90470-S; DAVID JD, 1981, DEV BIOL, V82, P297, DOI 10.1016/0012-1606(81)90453-X; ENTWISTLE A, 1988, J CELL BIOL, V106, P1693, DOI 10.1083/jcb.106.5.1693; EPPENBERGER HM, 1967, J BIOL CHEM, V242, P204; HARPER JF, 1975, J CYCLIC NUCL PROT, V1, P207; HERMANN H, 1970, CURRENT TOPICS DEVEL, V5, P181; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; IGNARRO LJ, 1985, ANNU REV PHARMACOL, V25, P171, DOI 10.1146/annurev.pharmtox.25.1.171; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; IZUMI Y, 1992, SCIENCE, V257, P1273, DOI 10.1126/science.1519065; KIM HS, 1992, DEV BIOL, V150, P223, DOI 10.1016/0012-1606(92)90237-B; KNOWLES RG, 1989, P NATL ACAD SCI USA, V86, P5159, DOI 10.1073/pnas.86.13.5159; KWON NS, 1990, J BIOL CHEM, V265, P13442; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; LEE LJ, 1969, TOXICOLOGY, V3, P281; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; MONCADA S, 1991, P NATL ACAD SCI USA, V88, P2166, DOI 10.1073/pnas.88.6.2166; MONCADA S, 1991, PHARMACOL REV, V43, P109; Murad F, 1978, Adv Cyclic Nucleotide Res, V9, P145; NAKANE M, 1993, FEBS LETT, V316, P175, DOI 10.1016/0014-5793(93)81210-Q; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; PALMER RMJ, 1989, BIOCHEM BIOPH RES CO, V158, P348, DOI 10.1016/S0006-291X(89)80219-0; PALMER RMJ, 1988, BIOCHEM BIOPH RES CO, V153, P1251, DOI 10.1016/S0006-291X(88)81362-7; PRZYBYLSKI RJ, 1989, IN VITRO CELL DEV B, V25, P830; SNYDER SH, 1992, SCIENCE, V257, P494, DOI 10.1126/science.1353273; STEINER AL, 1972, J BIOL CHEM, V247, P1106; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAKELAM MJO, 1985, BIOCHEM J, V228, P1	35	135	143	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14371	14374						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	7514168				2022-12-27	WOS:A1994NM06500012
J	KING, SL; LICHTLER, AC; ROWE, DW; XIE, RL; LONG, GL; ABSHER, MP; CUTRONEO, KR				KING, SL; LICHTLER, AC; ROWE, DW; XIE, RL; LONG, GL; ABSHER, MP; CUTRONEO, KR			BLEOMYCIN STIMULATES PRO-ALPHA-1(I) COLLAGEN PROMOTER THROUGH TRANSFORMING GROWTH-FACTOR-BETA RESPONSE ELEMENT BY INTRACELLULAR AND EXTRACELLULAR SIGNALING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED PULMONARY FIBROSIS; MESSENGER-RNA LEVELS; HUMAN DERMAL FIBROBLASTS; HUMAN-LUNG FIBROBLASTS; STEADY-STATE LEVELS; SHORT-PATCH REPAIR; I PROCOLLAGEN; CHLORAMPHENICOL ACETYLTRANSFERASE; GENE-EXPRESSION; MAMMALIAN-CELLS	The role of transforming growth factor beta as a mediator of the fibrogenic effect of bleomycin in lung has been investigated at the transcriptional level. Several constructs containing the rat pro-alpha 1(I) collagen promoter fused to the chloramphenicol acetyltransferase gene were transfected into rat lung fibroblasts. Both bleomycin and transforming growth factor beta 1 increased promoter activity in fibroblasts transfected with constructs containing the transforming growth factor beta response element. Fibroblasts transfected with a deletion construct that lacks this response element did not respond to either bleomycin or transforming growth factor beta 1. Anti-transforming growth factor beta 1-neutralizing antibodies did not block the increase in promoter activity induced by bleomycin, suggesting intracellular signaling. Mutation of the transforming growth factor beta response element greatly reduced the bleomycin effect, which also infers intracellular signaling. In addition, plasmin added to the media greatly enhanced bleomycin stimulation of promoter activity demonstrating that transforming growth factor beta mediates the bleomycin effect through extracellular signaling.	UNIV VERMONT,COLL MED,DEPT BIOCHEM,BURLINGTON,VT 05405; UNIV VERMONT,COLL MED,DEPT MED,BURLINGTON,VT 05405; UNIV CONNECTICUT,CTR HLTH,DEPT PEDIAT,FARMINGTON,CT 06032; UNIV CONNECTICUT,CTR HLTH,DEPT MED,FARMINGTON,CT 06032	University of Vermont; University of Vermont; University of Connecticut; University of Connecticut					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045138] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45138] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABSHER M, 1984, AM REV RESPIR DIS, V129, P125; ADAMSON IYR, 1976, ENVIRON HEALTH PERSP, V16, P119, DOI 10.2307/3428592; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BAGHOW R, 1989, J CLIN INVEST, V84, P1836; BARNARD JA, 1990, BIOCHIM BIOPHYS ACTA, V1032, P79, DOI 10.1016/0304-419X(90)90013-Q; BECKMANN RP, 1987, BIOCHEMISTRY-US, V26, P5409, DOI 10.1021/bi00391a029; BENNETT JM, 1979, ANN INTERN MED, V90, P945, DOI 10.7326/0003-4819-90-6-945; BLUM RH, 1973, CANCER, V31, P903, DOI 10.1002/1097-0142(197304)31:4<903::AID-CNCR2820310422>3.0.CO;2-N; BREEN E, 1992, AM J RESP CELL MOL, V6, P146, DOI 10.1165/ajrcmb/6.2.146; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CLARK JG, 1980, BIOCHIM BIOPHYS ACTA, V631, P359, DOI 10.1016/0304-4165(80)90309-8; DANDREA AD, 1978, P NATL ACAD SCI USA, V75, P3608, DOI 10.1073/pnas.75.8.3608; DIGIUSEPPE JA, 1989, BIOCHEMISTRY-US, V28, P9515, DOI 10.1021/bi00450a040; FINE A, 1990, CONNECT TISSUE RES, V24, P237, DOI 10.3109/03008209009152152; GIRI SN, 1980, EXP MOL PATHOL, V33, P1, DOI 10.1016/0014-4800(80)90002-7; GOLDSTEIN RH, 1990, J BIOL CHEM, V265, P13623; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HARRISON JH, 1989, MOL PHARMACOL, V36, P231; HOYT DG, 1988, J PHARMACOL EXP THER, V246, P765; HUSSAR DA, 1974, AM J PHARM, V146, P37; IGNOTZ RA, 1987, J BIOL CHEM, V262, P6443; KALTER VG, 1991, AM J RESP CELL MOL, V4, P397, DOI 10.1165/ajrcmb/4.5.397; KELLEY J, 1991, AM J PHYSIOL, V260, pL123, DOI 10.1152/ajplung.1991.260.2.L123; KELLEY J, 1985, BIOCHEM BIOPH RES CO, V131, P836, DOI 10.1016/0006-291X(85)91315-4; KESKIOJA J, 1988, J BIOL CHEM, V263, P3111; KROSS J, 1982, BIOCHEMISTRY-US, V21, P4310, DOI 10.1021/bi00261a021; LAURENT GJ, 1983, AM REV RESPIR DIS, V128, P82, DOI 10.1164/arrd.1983.128.1.82; LAZO JS, 1983, P NATL ACAD SCI-BIOL, V80, P3064, DOI 10.1073/pnas.80.10.3064; LICHTLER A, 1989, J BIOL CHEM, V264, P3072; LOPEZLARRAZA DM, 1993, ENVIRON MOL MUTAGEN, V21, P258, DOI 10.1002/em.2850210309; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYONS RM, 1988, J CELL BIOL, V106, P1659, DOI 10.1083/jcb.106.5.1659; MCANULTY RJ, 1991, BIOCHIM BIOPHYS ACTA, V1091, P231, DOI 10.1016/0167-4889(91)90066-7; MURRAY V, 1985, J BIOL CHEM, V260, P389; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NIGHTINGALE KP, 1993, NUCLEIC ACIDS RES, V21, P2549, DOI 10.1093/nar/21.11.2549; PAVLIN D, 1992, J CELL BIOL, V116, P227, DOI 10.1083/jcb.116.1.227; PENTTINEN RP, 1988, P NATL ACAD SCI USA, V85, P1105, DOI 10.1073/pnas.85.4.1105; PHAN SH, 1985, J CLIN INVEST, V76, P241, DOI 10.1172/JCI111953; PHAN SH, 1992, EXP LUNG RES, V18, P29, DOI 10.3109/01902149209020649; QUINONES F, 1986, AM REV RESPIR DIS, V134, P1163; RAGHOW R, 1985, J CLIN INVEST, V76, P1733, DOI 10.1172/JCI112163; RAGHOW R, 1987, J CLIN INVEST, V79, P1285, DOI 10.1172/JCI112950; RAGHU G, 1989, AM REV RESPIR DIS, V140, P95, DOI 10.1164/ajrccm/140.1.95; RITZENTHALER JD, 1993, J BIOL CHEM, V268, P13625; RITZENTHALER JD, 1991, BIOCHEM J, V280, P157, DOI 10.1042/bj2800157; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; SATO Y, 1989, J CELL BIOL, V109, P309, DOI 10.1083/jcb.109.1.309; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SIDIK K, 1990, BIOCHEMISTRY-US, V29, P7501, DOI 10.1021/bi00484a020; SNIDER GL, 1978, AM REV RESPIR DIS, V117, P1099; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPORN MB, 1987, J CELL BIOL, V105, P1039, DOI 10.1083/jcb.105.3.1039; STERLING KM, 1982, CANCER RES, V42, P3502; STERLING KM, 1983, J BIOL CHEM, V258, P4438; TOM WM, 1980, TOXICOL APPL PHARM, V53, P64, DOI 10.1016/0041-008X(80)90382-8; UMEZAWA H, 1984, TETRAHEDRON, V40, P501, DOI 10.1016/0040-4020(84)85055-3; VARGA J, 1987, BIOCHEM J, V247, P597, DOI 10.1042/bj2470597; VARGA J, 1986, BIOCHEM BIOPH RES CO, V138, P974, DOI 10.1016/S0006-291X(86)80591-5	62	42	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13156	13161						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	7513699				2022-12-27	WOS:A1994NK18400019
J	AOUBALA, M; DELAFOURNIERE, L; DOUCHET, I; ABOUSALHAM, A; DANIEL, C; HIRN, M; GARGOURI, Y; VERGER, R; DECARO, A				AOUBALA, M; DELAFOURNIERE, L; DOUCHET, I; ABOUSALHAM, A; DANIEL, C; HIRN, M; GARGOURI, Y; VERGER, R; DECARO, A			HUMAN PANCREATIC LIPASE - IMPORTANCE OF THE HINGE REGION BETWEEN THE 2 DOMAINS, AS REVEALED BY MONOCLONAL-ANTIBODIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GASTRIC LIPASE; LINKED IMMUNOSORBENT-ASSAY; LIMITED PROTEOLYSIS; PROCOLIPASE COMPLEX; COLIPASE; SPECIFICITY; ENZYME; LIPOLYSIS; PROTEINS; GEL	Several monoclonal antibodies (mAbs) were prepared against human pancreatic lipase (HPL). Two enzyme-linked immunosorbent assay (ELISA) procedures were set up for screening hybridomas producing specific antibodies. Four mAbs (81-23, 146-40, 315-25, and 320-24) of the IgG1 isotype were found to react with HPL in both simple sandwich and double sandwich ELISAs, while mAb 248-31, of the IgG2b isotype, reacted only with HPL in a double sandwich ELISA. The results of Western blot analysis carried out with native and SDS-denatured HPLs indicated that mAb 248 31 recognized only native HPL, while all the other mAbs recognized both forms of HPL. Since mAb 248-31 did not recognize SDS-denatured HPL, it was not possible to localize its epitope. To carry out epitope mapping along the primary sequence of HPL, four fragments (14, 26, 30, and 36 kDa) resulting hom a Limited chymotryptic cleavage of HPL were characterized by Western blotting as well as N-terminal amino acid sequence analysis. Of the above five anti-HPL mAbs, four (81-23, 248-31, 315-25, and 320-24) were found to inhibit the lipolytic activity of HPL (in both the presence and absence of bile salts and colipase), while mAb 146-40 had no inhibitory effects. The epitope recognized by mAb 146-40 was found to be located in the N-terminal domain (Lys(1)-Phe(335)). Combined immunoinactivation and epitope mapping studies showed that three inhibitory mAbs (81-23, 315-25, and 320-24) recognize overlapping epitopes from the hinge region between the N- and C-terminal domains of HPL, belonging to the 26-kDa fragment. In the presence of Lipids, a significant decrease has been observed in the bending angle between the N- and C-terminal domains of the HPL tertiary structure (van Tilbeurgh, H., Egloff, M. P., Martinet, C., Rugani, N., Verger, R. and Cambillau, C. (1993) Nature 362, 814-820). From the present immunochemical data, we further propose that locking the hinge movement with mAbs may induce lipase immunoinactivation.	CNRS,LIPOLYSE ENZYMAT LAB,GROUPEMENT RECH 1000,UNITE PROPRE RECH 9025,F-13402 MARSEILLE 20,FRANCE; IMMUNOTECH SA,F-13009 MARSEILLE,FRANCE	Centre National de la Recherche Scientifique (CNRS)			ABOUSALHAM, Abdelkarim/Q-4487-2019; abousalham, abdelkarim/A-4363-2018	abousalham, abdelkarim/0000-0002-8020-4294				ABOUSALHAM A, 1992, PROTEIN ENG, V5, P105, DOI 10.1093/protein/5.1.105; AOUBALA M, 1993, BIOCHIM BIOPHYS ACTA, V1169, P183, DOI 10.1016/0005-2760(93)90204-M; AOUBALA M, 1993, EUR J BIOCHEM, V211, P99, DOI 10.1111/j.1432-1033.1993.tb19874.x; BOSCBIERNE I, 1987, BIOCHIM BIOPHYS ACTA, V911, P326; BOUSSETRISSO M, 1985, FEBS LETT, V182, P323, DOI 10.1016/0014-5793(85)80325-2; CARRIERE F, 1993, GASTROENTEROLOGY, V105, P876, DOI 10.1016/0016-5085(93)90908-U; DECARO A, 1977, BIOCHIM BIOPHYS ACTA, V490, P411, DOI 10.1016/0005-2795(77)90016-2; DELAFOURNIERE L, 1989, BIOCHIM BIOPHYS ACTA, V998, P158, DOI 10.1016/0167-4838(89)90268-9; ERLANSONALBERTS.C, 1992, BIOCHIM BIOPHYS ACTA, V1125, P1; FOURNET B, 1987, EUR J BIOCHEM, V170, P369, DOI 10.1111/j.1432-1033.1987.tb13709.x; FRIGUET B, 1983, J IMMUNOL METHODS, V60, P351, DOI 10.1016/0022-1759(83)90292-2; FRIGUET B, 1985, J IMMUNOL METHODS, V77, P305, DOI 10.1016/0022-1759(85)90044-4; GARGOURI Y, 1983, J LIPID RES, V24, P1336; GARGOURI Y, 1989, BIOCHIM BIOPHYS ACTA, V1006, P255, DOI 10.1016/0005-2760(89)90012-X; GERSHONI JM, 1982, ANAL BIOCHEM, V124, P396, DOI 10.1016/0003-2697(82)90056-2; Hamosh M., 1990, LINGUAL GASTRIC LIPA, P179; IVANOVA MG, 1993, COLLOID SURFACE B, V1, P17, DOI 10.1016/0927-7765(93)80013-O; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; PARHAM P, 1983, J IMMUNOL, V131, P2895; RATHELOT J, 1975, BIOCHIMIE, V57, P1117; RUGANI N, 1991, BIOCHEM BIOPH RES CO, V177, P726, DOI 10.1016/0006-291X(91)91848-7; VANDEKERCKHOVE J, 1985, EUR J BIOCHEM, V152, P9, DOI 10.1111/j.1432-1033.1985.tb09157.x; VANTILBEURGH H, 1993, NATURE, V362, P814, DOI 10.1038/362814a0; VANTILBEURGH H, 1992, NATURE, V359, P159, DOI 10.1038/359159a0; Verger R, 1980, Methods Enzymol, V64, P340; WILSON JE, 1985, J BIOL CHEM, V260, P2838; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0	28	16	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3932	3937		10.1074/jbc.270.8.3932	http://dx.doi.org/10.1074/jbc.270.8.3932			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7533157	hybrid			2022-12-27	WOS:A1995QH68800071
J	ARMSTRONG, SK; MCINTOSH, MA				ARMSTRONG, SK; MCINTOSH, MA			EPITOPE INSERTIONS DEFINE FUNCTIONAL AND TOPOLOGICAL FEATURES OF THE ESCHERICHIA-COLI FERRIC ENTEROBACTIN RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE; NUCLEOTIDE-SEQUENCE; CYTOPLASMIC MEMBRANE; RESISTANT MUTANTS; PROTEIN; TRANSPORT; TONB; GENE; BACTERIA; K-12	The outer membrane protein FepA of Escherichia coli is the receptor for the ferric enterobactin siderophore complex and colicins B and D. A foreign antigenic determinant inserted into selected FepA sites allowed mutational analysis of receptor function and in situ immunological tracking of specific protein domain's with respect to the bacterial cell compartment, Immunoblot analysis of bacterial proteins using an epitope-specific antibody detected the peptide determinant in the receptor fusions. The impact of the insertions on FepA function was examined by ferric enterobactin-mediated iron uptake experiments and colicin sensitivity tests. In all cases, FepA retained biological activity despite introduction of the foreign sequence. To further develop the topological model of FepA, the peptide-specific antibody was used to localize epitope-carrying FepA domains in intact bacterial cells and their isolated membranes. One epitope resided in a region on the exterior of the cell, at the surface of the FepA protein, while other epitopes appeared to be localized to the periplasm or within the outer membrane.	E CAROLINA UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,GREENVILLE,NC 27858; UNIV MISSOURI,SCH MED,DEPT MOLEC MICROBIOL & IMMUNOL,COLUMBIA,MO 65212	University of North Carolina; East Carolina University; University of Missouri System; University of Missouri Columbia					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI007610] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040565] Funding Source: NIH RePORTER; NIAID NIH HHS [1 F32 AI 07610] Funding Source: Medline; NIGMS NIH HHS [1 R01 GM40565] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGTERBERG M, 1990, VACCINE, V8, P85, DOI 10.1016/0264-410X(90)90184-N; ARMSTRONG SK, 1990, J BIOL CHEM, V265, P14536; ARMSTRONG SK, 1989, MOL MICROBIOL, V3, P757, DOI 10.1111/j.1365-2958.1989.tb00224.x; CHARBIT A, 1991, J BACTERIOL, V173, P262, DOI 10.1128/jb.173.1.262-275.1991; CHARBIT A, 1987, J IMMUNOL, V139, P1658; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; GIBRAT JF, 1987, J MOL BIOL, V198, P425, DOI 10.1016/0022-2836(87)90292-0; HELLER K, 1985, J BACTERIOL, V161, P904, DOI 10.1128/JB.161.3.904-908.1985; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; KADNER RJ, 1990, MOL MICROBIOL, V4, P2027, DOI 10.1111/j.1365-2958.1990.tb00562.x; LANGMAN L, 1972, J BACTERIOL, V112, P1142, DOI 10.1128/JB.112.3.1142-1149.1972; LUCKEY M, 1980, P NATL ACAD SCI-BIOL, V77, P167, DOI 10.1073/pnas.77.1.167; LUNDRIGAN MD, 1986, J BIOL CHEM, V261, P797; Miller J. H., 1972, EXPT MOL GENETICS, P433; MURPHY CK, 1990, J BACTERIOL, V172, P2736, DOI 10.1128/jb.172.5.2736-2746.1990; NIKAIDO H, 1992, SCIENCE, V258, P936, DOI 10.1126/science.1279804; PIERCE JR, 1986, J BACTERIOL, V166, P930, DOI 10.1128/jb.166.3.930-936.1986; POSTLE K, 1990, MOL MICROBIOL, V4, P2019, DOI 10.1111/j.1365-2958.1990.tb00561.x; PUGSLEY AP, 1976, J BACTERIOL, V127, P218, DOI 10.1128/JB.127.1.218-228.1976; PUGSLEY AP, 1976, J BACTERIOL, V126, P1052, DOI 10.1128/JB.126.3.1052-1062.1976; PUGSLEY AP, 1977, J BACTERIOL, V130, P26, DOI 10.1128/JB.130.1.26-36.1977; RUTZ JM, 1992, SCIENCE, V258, P471, DOI 10.1126/science.1411544; RUTZ JM, 1991, J BACTERIOL, V173, P5964, DOI 10.1128/jb.173.19.5964-5974.1991; Sambrook J, 1989, MOL CLONING LABORATO; SAUER M, 1990, MOL MICROBIOL, V4, P427, DOI 10.1111/j.1365-2958.1990.tb00609.x; SCHOFFLER H, 1989, MOL GEN GENET, V217, P378, DOI 10.1007/BF02464907; SHEA CM, 1991, MOL MICROBIOL, V5, P1415, DOI 10.1111/j.1365-2958.1991.tb00788.x; SKARE JT, 1993, J BIOL CHEM, V268, P16302; VANDIE I, 1990, MOL GEN GENET, V222, P297, DOI 10.1007/BF00633832	29	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2483	2488		10.1074/jbc.270.6.2483	http://dx.doi.org/10.1074/jbc.270.6.2483			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7531690	hybrid			2022-12-27	WOS:A1995QF53500016
J	NAGY, E; RIGBY, WFC				NAGY, E; RIGBY, WFC			GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE SELECTIVELY BINDS AU-RICH RNA IN THE NAD(+)-BINDING REGION (ROSSMANN FOLD)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' UNTRANSLATED REGION; MYC MESSENGER-RNA; C-MYC; GROWTH-FACTOR; PROTEIN; SEQUENCE; IDENTIFICATION; ASSOCIATION; INVITRO; CELLS	A 36-kDa protein that binds AU-rich RNA was purified from human spleen and identified as glyceraldehyde-3-phosphate dehydrogenase (GAPDH). CARER has been previously demonstrated to bind tRNA with high affinity. Competition studies suggested that cytoplasmic GAPDH binds the AU-rich elements (AREs) of lymphokine mRNA 3'-untranslated regions with higher affinity than tRNA. The AUUUA-specific RNA binding activity of GAPDH was inhibited by NAD(+), NADH, and ATP in a concentration-dependent manner, suggesting that RNA binding of GAPDH might involve the NAD(+)-binding region, or dinucleotide-binding (Rossmann) fold. This hypothesis was supported by experiments that localized RNA binding to the predicted N-terminal 6.8-kDa peptide, known to be involved in the formation of the NAD(+)-binding domain. The direct demonstration of ARE-specific binding protein activity localized to the NAD(+)-binding region of GAPDH supports the general concept that enzymes containing this domain may exhibit specific RNA binding activity and play additional roles in nucleic acid metabolism. Finally, cytoplasmic GAPER was found in the polysomal fraction of T lymphocytes. Thus, the RNA binding specificity of GAPDH as well as its localization within the cell merit its strong consideration as a protein important in the regulation of ARE-dependent mRNA turnover and translation in addition to its well described role in glycolysis.	DARTMOUTH COLL SCH MED,DEPT MED,LEBANON,NH 03756; DARTMOUTH COLL SCH MED,DEPT MICROBIOL,LEBANON,NH 03756; VET ADM MED CTR,WHITE RIVER JCT,VT 05009	Dartmouth College; Dartmouth College; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K04AI000910] Funding Source: NIH RePORTER; NIAID NIH HHS [KO4 AI00910, R01 AI2434] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHARON T, 1993, MOL CELL BIOL, V13, P1971, DOI 10.1128/MCB.13.3.1971; ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; BICKEL M, 1990, J IMMUNOL, V145, P840; BICKEL M, 1992, P NATL ACAD SCI USA, V89, P10001, DOI 10.1073/pnas.89.21.10001; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; Brawerman G., 1993, CONTROL MESSENGER RN, P149; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; BREWER G, 1990, METHOD ENZYMOL, V181, P202; BURD CG, 1989, P NATL ACAD SCI USA, V86, P9788, DOI 10.1073/pnas.86.24.9788; CHU E, 1993, BIOCHEMISTRY-US, V32, P4756, DOI 10.1021/bi00069a009; CHU E, 1993, P NATL ACAD SCI USA, V90, P517, DOI 10.1073/pnas.90.2.517; CLERCH LB, 1993, FASEB J, V7, pA1233; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; ELZINGA SDJ, 1993, NUCLEIC ACIDS RES, V21, P5328, DOI 10.1093/nar/21.23.5328; FUKAMIKOBAYASHI K, 1993, FEBS LETT, V335, P289, DOI 10.1016/0014-5793(93)80749-K; FURFINE CS, 1965, J BIOL CHEM, V240, P844; GRAFI G, 1993, MOL CELL BIOL, V13, P3487, DOI 10.1128/MCB.13.6.3487; GRAY PW, 1982, NATURE, V295, P503, DOI 10.1038/295503a0; Greenberg ME, 1993, CONTROL MESSENGER RN, P199, DOI 10.1016/B978-0-08-091652-1.50013-X; GROSSE F, 1986, EUR J BIOCHEM, V160, P459, DOI 10.1111/j.1432-1033.1986.tb10062.x; HAMILTON BJ, 1993, J BIOL CHEM, V268, P8881; HARRIS JI, 1976, ENZYMES, V13, P1; HENICS T, 1994, J BIOL CHEM, V269, P5377; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; HENTZE MW, 1994, TRENDS BIOCHEM SCI, V19, P101, DOI 10.1016/0968-0004(94)90198-8; HOLBROOK NJ, 1984, P NATL ACAD SCI-BIOL, V81, P1634, DOI 10.1073/pnas.81.6.1634; HOUMARD J, 1972, P NATL ACAD SCI USA, V69, P3506, DOI 10.1073/pnas.69.12.3506; HUANG LY, 1993, J BIOL CHEM, V268, P25769; HUITOREL P, 1985, EUR J BIOCHEM, V150, P265, DOI 10.1111/j.1432-1033.1985.tb09016.x; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KAPTAIN S, 1991, P NATL ACAD SCI USA, V88, P10109, DOI 10.1073/pnas.88.22.10109; KARPEL RL, 1981, BIOCHIM BIOPHYS ACTA, V654, P256, DOI 10.1016/0005-2787(81)90180-5; KATZ DA, 1994, NUCLEIC ACIDS RES, V22, P238, DOI 10.1093/nar/22.2.238; KAWAMOTO RM, 1986, BIOCHEMISTRY-US, V25, P656, DOI 10.1021/bi00351a022; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KRUYS V, 1989, SCIENCE, V245, P852, DOI 10.1126/science.2672333; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE TD, 1993, MOL CELL BIOL, V13, P3494, DOI 10.1128/MCB.13.6.3494; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MALTER JS, 1991, J BIOL CHEM, V266, P3167; MATTAJ IW, 1993, CELL, V73, P837, DOI 10.1016/0092-8674(93)90265-R; MEHLIN H, 1992, CELL, V69, P605, DOI 10.1016/0092-8674(92)90224-Z; MEJEAN C, 1989, BIOCHEM J, V264, P671, DOI 10.1042/bj2640671; MEYERSIEGLER K, 1991, P NATL ACAD SCI USA, V88, P5460; MISETA A, 1991, J BIOL CHEM, V266, P19158; MORALES MJ, 1989, NUCLEIC ACIDS RES, V17, P6865, DOI 10.1093/nar/17.17.6865; MORGENEGG G, 1986, J NEUROCHEM, V47, P54; MULLER WEG, 1992, J MOL BIOL, V226, P721, DOI 10.1016/0022-2836(92)90628-W; NANBU R, 1993, J BIOCHEM-TOKYO, V114, P432, DOI 10.1093/oxfordjournals.jbchem.a124193; PERONA JJ, 1991, P NATL ACAD SCI USA, V88, P2903, DOI 10.1073/pnas.88.7.2903; PERUCHO M, 1977, EUR J BIOCHEM, V81, P557, DOI 10.1111/j.1432-1033.1977.tb11982.x; PINOLROMA S, 1992, NATURE, V335, P730; PONTIUS BW, 1990, P NATL ACAD SCI USA, V87, P8403, DOI 10.1073/pnas.87.21.8403; PREISS T, 1993, J BIOL CHEM, V268, P24523; ROSSMANN RG, 1975, ENZYMES, P62; RYAZANOV AG, 1985, FEBS LETT, V192, P131, DOI 10.1016/0014-5793(85)80058-2; SAVANTBHONSALE S, 1992, GENE DEV, V6, P1927, DOI 10.1101/gad.6.10.1927; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEAL G, 1988, P NATL ACAD SCI USA, V85, P2339, DOI 10.1073/pnas.85.7.2339; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHAW J, 1988, J IMMUNOL, V140, P2243; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; SINGH R, 1993, SCIENCE, V259, P365, DOI 10.1126/science.8420004; SULLIVAN NF, 1992, BIOESSAYS, V14, P333, DOI 10.1002/bies.950140508; TANIGUCHI T, 1988, ANNU REV IMMUNOL, V6, P439, DOI 10.1146/annurev.iy.06.040188.002255; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; YANG ST, 1969, BIOCHEMISTRY-US, V8, P2806, DOI 10.1021/bi00835a017; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	69	299	327	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2755	2763		10.1074/jbc.270.6.2755	http://dx.doi.org/10.1074/jbc.270.6.2755			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7531693	hybrid			2022-12-27	WOS:A1995QF53500056
J	TEDESCHI, G; CHEN, S; MASSEY, V				TEDESCHI, G; CHEN, S; MASSEY, V			ACTIVE-SITE STUDIES OF DT-DIAPHORASE EMPLOYING ARTIFICIAL FLAVINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER NAD(P)H-QUINONE OXIDOREDUCTASE; AMINO-ACID SEQUENCE; RAT-LIVER; NAD(P)H DEHYDROGENASE; 6-SUBSTITUTED FLAVINS; DIRECTED MUTAGENESIS; BINDING-SITE; ONE-ELECTRON; MECHANISM; REDUCTASE	NAD(P)H:quinone oxidoreductase (EC 1.6.99.2) (DT-diaphorase) is an FAD-containing enzyme that catalyzes the 2-electron reduction of quinones to hydroquinones using either NADH or NADPH as the electron donor. In this study, FAD was removed by dialyzing the holoprotein against 2 M KBr, and synthetic analogs of FAD were substituted in the flavin binding site as structural probes. Spectral analysis indicates that the benzoquinoid forms of 8-mercapto-FAD and 6-mercapto-FAD are stabilized on binding to the enzyme. This is consistent with the fact that the native flavoprotein forms the anion flavin radical upon photoreduction and suggests the presence of a positive charge near the N(1)C(2)O position of the isoalloxazine ring. Reactivity studies using 8-chloro- and 8-mercapto-flavins suggest that the 8 position of the FAD is accessible to the solvent. However, the rates of the reactions were dramatically decreased in the presence of the competitive inhibitor, dicumarol. 6-Mercapto-, 6-thiocyanato-, 6-azido-, and 6-amino-flavins were also used as structural probes. The results indicate that the 6 position is accessible to solvent. Dicumarol binding increases the pK(a) of the enzyme-bound 6-mercapto-flavin from below pH 5.0 to higher than pH 9.0. The results suggest that DT-diaphorase shows the same properties as the C-C transhydrogenases, and the binding of dicumarol elicits a conformational change or an adjustment in the polarity of the FAD pocket. The enzyme reconstituted with oxidized 5-deaza-FAD has significant catalytic activity, confirming that DT-diaphorase is an obligatory 2-electron transfer enzyme and plays a role in the detoxification of quinones and quinoid compounds by reducing them to the relatively stable hydroquinones.	UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109; BECKMAN RES INST CITY HOPE,DIV IMMUNOL,DUARTE,CA 91010	University of Michigan System; University of Michigan; City of Hope; Beckman Research Institute of City of Hope			Tedeschi, Gabriella/I-6247-2017	Tedeschi, Gabriella/0000-0003-2082-6443	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM011106, R01GM011106] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-11106] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMED SA, 1992, J BIOL CHEM, V267, P3832; BAYNEY RM, 1987, J BIOL CHEM, V262, P572; BLANKENHORN G, 1976, EUR J BIOCHEM, V67, P67, DOI 10.1111/j.1432-1033.1976.tb10634.x; CHEN HH, 1992, BIOCHEM J, V284, P855, DOI 10.1042/bj2840855; Clark W.M., 1960, OXIDATION REDUCTION, P184; DEFLORA S, 1985, CANCER RES, V45, P3188; DENG PSK, 1991, BIOCHEMISTRY-US, V30, P6942, DOI 10.1021/bi00242a019; ERNSTER L, 1962, BIOCHIM BIOPHYS ACTA, V58, P171, DOI 10.1016/0006-3002(62)90997-6; FITZPATRICK PF, 1983, J BIOL CHEM, V258, P9700; FORREST GL, 1990, BIOCHEM BIOPH RES CO, V169, P1087, DOI 10.1016/0006-291X(90)92006-L; GHISLA S, 1986, BIOCHEMISTRY-US, V25, P3282, DOI 10.1021/bi00359a030; GHISLA S, 1980, BIOCHEMISTRY-US, V19, P2537, DOI 10.1021/bi00553a001; GHISLA S, 1986, BIOCHEM J, V239, P1; HANIU M, 1988, BIOCHEMISTRY-US, V27, P6877, DOI 10.1021/bi00418a033; HOSODA S, 1974, J BIOL CHEM, V249, P6416; HUANG MT, 1979, J BIOL CHEM, V254, P1223; IYANAGI T, 1970, BIOCHIM BIOPHYS ACTA, V216, P282, DOI 10.1016/0005-2728(70)90220-3; LAURELL C, 1970, TETRAHEDRON LETT, V26, P2235; LIN AJ, 1972, J MED CHEM, V15, P1247, DOI 10.1021/jm00282a011; LIU XF, 1989, MOL PHARMACOL, V35, P818; MA Q, 1992, J BIOL CHEM, V267, P22298; MASSEY V, 1979, J BIOL CHEM, V254, P9640; MASSEY V, 1985, BIOCHEMISTRY-US, V25, P8103; Massey V, 1980, BIOCHEM SOC T, V8, P246, DOI 10.1042/bst0080246; MOORE EG, 1979, J BIOL CHEM, V254, P8173; MOORE EG, 1978, J BIOL CHEM, V253, P6413; MYSZKA DG, 1991, J BIOL CHEM, V266, P4789; NAGAO M, 1966, ADV CANCER RES, V23, P131; PROCHASKA HJ, 1991, OXIDATIVE STRESS OXI, P195; ROBERTSON JA, 1986, J BIOL CHEM, V261, P5794; SCHOPFER LM, 1981, J BIOL CHEM, V256, P7329; SHOPFER L, 1990, STUDY ENZYMES, V2, P247; SPENCER R, 1977, BIOCHEMISTRY-US, V16, P3594, DOI 10.1021/bi00635a015; SPENCER R, 1977, BIOCHEMISTRY-US, V16, P3586, DOI 10.1021/bi00635a014; TEDESCHI G, 1995, J BIOL CHEM, V270, P1198, DOI 10.1074/jbc.270.3.1198; TSUDA H, 1984, CARCINOGENESIS, V5, P331, DOI 10.1093/carcin/5.3.331; WALLIN R, 1978, BIOCHEM J, V169, P95, DOI 10.1042/bj1690095; WALSH C, 1978, BIOCHEMISTRY-US, V17, P1942, DOI 10.1021/bi00603a022; Williams C H Jr, 1979, Methods Enzymol, V62, P185	39	24	24	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2512	2516		10.1074/jbc.270.6.2512	http://dx.doi.org/10.1074/jbc.270.6.2512			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7531691	hybrid			2022-12-27	WOS:A1995QF53500020
J	MAYER, B; KLATT, P; WERNER, ER; SCHMIDT, K				MAYER, B; KLATT, P; WERNER, ER; SCHMIDT, K			KINETICS AND MECHANISM OF TETRAHYDROBIOPTERIN-INDUCED OXIDATION OF NITRIC-OXIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-ARGININE; SYNTHASE; BRAIN; SUPEROXIDE; PEROXYNITRITE; PURIFICATION; INHIBITION; COFACTOR; CELLS; HEMOPROTEIN	A Clark-type nitric oxide-sensitive electrode was used for electrochemical determination of NO oxidation kinetics. Reaction with molecular oxygen followed second-order rate law with respect to NO with an overall rate constant of 9.2 +/- 0.33 x 10(6) M(-2) s(-1). Tetrahydrobiopterin, an essential cofactor of NO syntheses, was found to induce rapid oxidation of NO in a 1:1 stoichiometry. The reaction required the presence of oxygen, was zero order with respect to NO and first order with respect to tetrahydrobiopterin, completely blocked by 5,000 units/ml superoxide dismutase, and mimicked by a superoxide-generating system, Purified brain NO synthase produced no detectable NO unless high amounts of superoxide dismutase were present. NO synthase catalyzed citrulline formation was inhibited by superoxide dismutase (5,000 units/ml) in an oxyhemoglobin-sensitive manner, indicating that NO induces feedback inhibition of NO synthase, NO-stimulated soluble guanylyl cyclase was inhibited by tetrahydrobiopterin at half-maximally active concentrations of 2 mu m. The present data suggest that NO is inactivated to peroxynitrite by superoxide generated in the course of tetrahydrobiopterin autoxidation.	UNIV INNSBRUCK, INST MED CHEM & BIOCHEM, A-6020 INNSBRUCK, AUSTRIA	University of Innsbruck	MAYER, B (corresponding author), KARL FRANZENS UNIV GRAZ, INST PHARMAKOL & TOXIKOL, UNIV PL 2, A-8010 GRAZ, AUSTRIA.		Mayer, Bernd/B-9391-2008	Werner, Ernst R./0000-0003-1948-3391; Mayer, Bernd/0000-0002-2921-3494				ASSREUY J, 1993, BRIT J PHARMACOL, V108, P833, DOI 10.1111/j.1476-5381.1993.tb12886.x; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BECKMAN JS, 1992, ARCH BIOCHEM BIOPHYS, V298, P438, DOI 10.1016/0003-9861(92)90432-V; BLAIR JA, 1974, J CHEM SOC PERK T 2, P80, DOI 10.1039/p29740000080; BUGA GM, 1993, CIRC RES, V73, P808, DOI 10.1161/01.RES.73.5.808; DAVIS MD, 1993, ARCH BIOCHEM BIOPHYS, V304, P9, DOI 10.1006/abbi.1993.1315; FORD PC, 1993, FEBS LETT, V326, P1, DOI 10.1016/0014-5793(93)81748-O; FUKUTO JM, 1993, J MED CHEM, V36, P2666, DOI 10.1021/jm00070a010; GIOVANELLI J, 1991, P NATL ACAD SCI USA, V88, P7091, DOI 10.1073/pnas.88.16.7091; GRISCAVAGE JM, 1994, J BIOL CHEM, V269, P21644; GRISCAVAGE JM, 1993, J IMMUNOL, V151, P6329; HEINZEL B, 1992, BIOCHEM J, V281, P627, DOI 10.1042/bj2810627; HENRY Y, 1993, FASEB J, V7, P1124, DOI 10.1096/fasebj.7.12.8397130; HUMBERT P, 1990, EUR J BIOCHEM, V190, P273, DOI 10.1111/j.1432-1033.1990.tb15572.x; IGNARRO LJ, 1993, P NATL ACAD SCI USA, V90, P8103, DOI 10.1073/pnas.90.17.8103; IGNARRO LJ, 1991, BLOOD VESSELS, V28, P67; KHARITONOV VG, 1994, J BIOL CHEM, V269, P5881; KLATT P, 1994, J BIOL CHEM, V269, P13861; KLATT P, 1993, J BIOL CHEM, V268, P14781; KLATT P, 1992, BIOCHEM J, V288, P15, DOI 10.1042/bj2880015; KUKOVETZ WR, 1989, J CARDIOVASC PHARM, V14, pS40, DOI 10.1097/00005344-198914110-00008; LIU S, 1994, J PHARMACOL EXP THER, V268, P1114; MARAGOS CM, 1991, J MED CHEM, V34, P3242, DOI 10.1021/jm00115a013; MAYER B, 1992, J NEUROCHEM, V59, P2024; MAYER B, 1990, FEBS LETT, V277, P215, DOI 10.1016/0014-5793(90)80848-D; MAYER B, 1993, BIOCHEM PHARMACOL, V45, P367, DOI 10.1016/0006-2952(93)90072-5; MAYER B, 1992, J CARDIOVASC PHARM, V20, pS54, DOI 10.1097/00005344-199204002-00016; MAYER B, 1994, IN PRESS BIOL NITRIC; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MORO MA, 1994, P NATL ACAD SCI USA, V91, P6702, DOI 10.1073/pnas.91.14.6702; NGUYEN T, 1992, P NATL ACAD SCI USA, V89, P3030, DOI 10.1073/pnas.89.7.3030; NICHOL CA, 1985, ANNU REV BIOCHEM, V54, P729, DOI 10.1146/annurev.biochem.54.1.729; POU S, 1992, J BIOL CHEM, V267, P24173; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; RENGASAMY A, 1993, MOL PHARMACOL, V44, P124; ROGERS NE, 1992, BIOCHEM BIOPH RES CO, V189, P242, DOI 10.1016/0006-291X(92)91550-A; SCHMIDT K, 1994, BIOCHEM J, V301, P645, DOI 10.1042/bj3010645; Schultz G., 1984, METHOD ENZYMAT AN, P379; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; TSUKAHARA H, 1993, BIOCHEM BIOPH RES CO, V193, P722, DOI 10.1006/bbrc.1993.1685; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001; WINK DA, 1993, CHEM RES TOXICOL, V6, P23, DOI 10.1021/tx00031a003; WINK DA, 1991, SCIENCE, V254, P1001, DOI 10.1126/science.1948068; WINK DA, 1993, ARCH BIOCHEM BIOPHYS, V300, P115, DOI 10.1006/abbi.1993.1016	45	145	145	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					655	659		10.1074/jbc.270.2.655	http://dx.doi.org/10.1074/jbc.270.2.655			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7529763	hybrid			2022-12-27	WOS:A1995QB81600025
J	PIRNER, MA; LINCK, RW				PIRNER, MA; LINCK, RW			TEKTINS ARE HETERODIMERIC POLYMERS IN FLAGELLAR MICROTUBULES WITH AXIAL PERIODICITIES MATCHING THE TUBULIN LATTICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEDIATE-FILAMENT PROTEINS; URCHIN SPERM FLAGELLA; DOUBLET MICROTUBULES; CHLAMYDOMONAS FLAGELLA; SURFACE LATTICE; COILED-COIL; COMPONENTS; SUBUNITS; CILIARY; PROTOFILAMENTS	Tektins are proteins that copartition with tubulin in a stable ribbon of three protofilaments from ciliary and flagellar microtubules. After purification, tektins A, B, and C from sea urchin sperm flagellar microtubules appear as extended relatively insoluble filaments, <5 nm in diameter. We used cross-linking reagents to investigate the associations and structural organization of subunits within tektin polymers isolated from stable protofilament ribbons of Strongylocentrotus purpuratus. We show by SDS-polyacrylamide gel electrophoresis, immunoblots, and transmission electron microscopy that tektins are continuous heteropolymers in the stable protofilament ribbons, and thus flagellar microtubules. Our results also provide evidence for the arrangement of different tektin polypeptides within ''core'' filaments containing equimolar tektins A and B, Treatment of these core filaments with bis(sulfosuccinimidyl)suberate and with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide yielded a predominant cross-linked similar to 106-kDa heterodimer of tektins A and B; similar results were obtained by glutaraldehyde cross-linking of tektins solubilized under mild conditions. Finally, cross-linking with 3,3'-dithiobis(sulfosuccinimidylpropionate revealed a 16 nn periodicity in isolated tektin AB filaments that can be related to the 8 nm tubulin dimer lattice and to periodically associated microtubule components.			PIRNER, MA (corresponding author), UNIV MINNESOTA, DEPT CELL BIOL & NEUROANAT, MINNEAPOLIS, MN 55455 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035648] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35648] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMOS LA, 1974, J CELL SCI, V14, P523; AMOS LA, 1976, CELL MOTILITY, P847; AMOS WB, 1986, J CELL SCI, P55; CHANG XJ, 1987, J CELL BIOL, V104, P1563, DOI 10.1083/jcb.104.6.1563; CHEN R, 1993, J CELL SCI, V106, P909; COULOMBE PA, 1990, J CELL BIOL, V111, P153, DOI 10.1083/jcb.111.1.153; ERICKSON HP, 1974, J CELL BIOL, V60, P153, DOI 10.1083/jcb.60.1.153; GEISLER N, 1992, EUR J BIOCHEM, V206, P841, DOI 10.1111/j.1432-1033.1992.tb16992.x; GIBBONS IR, 1972, J CELL BIOL, V54, P365, DOI 10.1083/jcb.54.2.365; GIBBONS IR, 1960, J BIOPHYS BIOCHEM CY, V7, P697, DOI 10.1083/jcb.7.4.697; GOODENOUGH UW, 1985, J CELL BIOL, V100, P2008, DOI 10.1083/jcb.100.6.2008; HARRISON BC, 1993, NATURE, V362, P73, DOI 10.1038/362073a0; HATZFELD M, 1990, J CELL BIOL, V110, P1199, DOI 10.1083/jcb.110.4.1199; JOHNSON KA, 1994, J CELL SCI, V107, P1551; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINCK RW, 1981, J CELL BIOL, V89, P309, DOI 10.1083/jcb.89.2.309; LINCK RW, 1985, J CELL BIOL, V100, P126, DOI 10.1083/jcb.100.1.126; LINCK RW, 1982, J CELL SCI, V58, P1; LINCK RW, 1987, J CELL BIOL, V104, P1069, DOI 10.1083/jcb.104.4.1069; LINCK RW, 1976, J CELL SCI, V20, P405; LINCK RW, 1987, J CELL SCI, V88, P453; LINCK RW, 1990, ADV CELL BIOL, V3, P35; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MEZA I, 1972, EXP CELL RES, V74, P535, DOI 10.1016/0014-4827(72)90413-2; MOEREMANS M, 1985, ANAL BIOCHEM, V145, P315, DOI 10.1016/0003-2697(85)90368-9; NORRANDER JM, 1992, P NATL ACAD SCI USA, V89, P8567, DOI 10.1073/pnas.89.18.8567; QUINLAN RA, 1986, J MOL BIOL, V192, P337, DOI 10.1016/0022-2836(86)90369-4; SONG YH, 1993, P NATL ACAD SCI USA, V90, P1671, DOI 10.1073/pnas.90.5.1671; STEFFEN W, 1988, P NATL ACAD SCI USA, V85, P2643, DOI 10.1073/pnas.85.8.2643; STEFFEN W, 1992, J CELL SCI, V101, P809; STEFFEN W, 1989, CELL MOTIL CYTOSKEL, V14, P359, DOI 10.1002/cm.970140306; STEFFEN W, 1994, J CELL SCI, V107, P2095; STEINERT PM, 1990, J BIOL CHEM, V265, P8766; STEPHENS RE, 1989, J CELL SCI, V92, P391; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAISSTEIDER C, 1987, J MOL BIOL, V197, P205, DOI 10.1016/0022-2836(87)90119-7; WITMAN GB, 1972, J CELL BIOL, V54, P540, DOI 10.1083/jcb.54.3.540; WITMAN GB, 1972, J CELL BIOL, V54, P507, DOI 10.1083/jcb.54.3.507; [No title captured]; [No title captured]	40	53	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31800	31806						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7527396				2022-12-27	WOS:A1994PX30300073
J	PETERSON, JE; JELINEK, T; KALEKO, M; SIDDLE, K; WEBER, MJ				PETERSON, JE; JELINEK, T; KALEKO, M; SIDDLE, K; WEBER, MJ			C-PHOSPHORYLATION AND ACTIVATION OF THE IGF-I RECEPTOR IN SRC-TRANSFORMED CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-I; ROUS-SARCOMA VIRUS; CHICKEN-EMBRYO FIBROBLASTS; PHOSPHOTYROSINE-CONTAINING PROTEINS; TYROSINE KINASE-ACTIVITY; HUMAN INSULIN-RECEPTOR; HUMAN-SKIN FIBROBLASTS; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL TRANSDUCTION; BETA-SUBUNIT	Using a panel of src mutants partially defective for malignant transformation, our laboratory has previously identified the insulin-like growth factor (IGF-I) receptor as a protein whose tyrosine phosphorylation correlates with transformation by src in embryonic chick cells (Kozma ct al., 1990; Kozma and Weber, 1990). It has not been clear, however, whether are-induced phosphorylation altered the enzymatic or signaling properties of the IGF-I receptor and thus whether the IGF-I receptor could be a functionally significant target for pp(60v.src). To examine the effect of src expression on the activity of the IGF-I receptor, the human IGF-I receptor was expressed in Rat-1 fibroblasts co-expressing the temperature-sensitive v-src mutant, tsLA29, The IGF-I receptor exhibited an elevated level of tyrosine phosphorylation in are transformed cells even in the absence of IGF-I treatment. Increased receptor phosphorylation occurred rapidly when cells expressing a temperature-conditional are mutant were shifted from the restrictive to the permissive temperature. Src-induced phosphorylation of the receptor was correlated with an increase in the in vitro tyrosine kinase activity of the receptor, both toward itself and exogenous substrates. The are-induced increase in receptor activity was shown to be dependent on tyrosine phosphorylation, as treatment with a tyrosine-specific phosphatase lowered receptor activity. A kinase-defective mutant of the IGF-I receptor also became constitutively phosphorylated in are-transformed cells, ruling out a possible autocrine mechanism for this phosphorylation. Collectively these data indicate that pp(60v.src) induces ligand-independent phosphorylation and activation of the IGF-I receptor by an intracellular mechanism, consistent with the possibility that receptor phosphorylation could contribute to the genesis of the transformed phenotype.	UNIV VIRGINIA,HLTH SCI CTR,DEPT MICROBIOL,CHARLOTTESVILLE,VA 22908; GENET THERAPY INC,GAITHERSBURG,MD 20878; UNIV CAMBRIDGE,DEPT CLIN BIOCHEM,CAMBRIDGE CB2 2QR,ENGLAND	University of Virginia; Novartis; University of Cambridge					NATIONAL CANCER INSTITUTE [R37CA039076, R01CA039076, P01CA040042] Funding Source: NIH RePORTER; NCI NIH HHS [CA 39076, CA 40042] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMO M, 1992, BIOFACTORS, V3, P151; BACKER JM, 1992, J BIOL CHEM, V267, P1367; BACKER JM, 1990, J BIOL CHEM, V265, P16450; BARON V, 1992, J BIOL CHEM, V267, P23290; BEGUM N, 1993, J BIOL CHEM, V268, P7917; BURGERING BMT, 1989, MOL CELL BIOL, V9, P4312, DOI 10.1128/MCB.9.10.4312; CHAIKEN RL, 1986, J CLIN ENDOCR METAB, V63, P1181, DOI 10.1210/jcem-63-5-1181; Chen E, 1986, Biochem Soc Symp, V52, P65; COOPER J, 1983, J VIROL, V46, P15, DOI 10.1128/JVI.46.1.15-28.1983; COOPER JA, 1981, MOL CELL BIOL, V1, P165, DOI 10.1128/MCB.1.2.165; CZECH MP, 1989, CELL, V59, P235, DOI 10.1016/0092-8674(89)90281-X; CZECH MP, 1982, CELL, V31, P8, DOI 10.1016/0092-8674(82)90399-3; FALCO JP, 1988, ONCOGENE, V2, P573; FLIER JS, 1986, P NATL ACAD SCI USA, V83, P664, DOI 10.1073/pnas.83.3.664; FORMISANO P, 1993, J BIOL CHEM, V268, P5241; FRATTALI AL, 1993, J BIOL CHEM, V268, P7393; GAMMELTOFT S, 1989, PEPTIDE HORMONES PRO, P176; GIORGETTI S, 1993, J BIOL CHEM, V268, P7358; JACOBS S, 1990, HDB EXPT PHARM, V92, P267; JANICOT M, 1991, J BIOL CHEM, V266, P9382; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; KATO H, 1993, J BIOL CHEM, V268, P2655; KOZMA LM, 1990, MOL CELL BIOL, V10, P837, DOI 10.1128/MCB.10.2.837; KOZMA LM, 1990, MOL CELL BIOL, V10, P3626, DOI 10.1128/MCB.10.7.3626; LAMMERS R, 1989, EMBO J, V8, P1369, DOI 10.1002/j.1460-2075.1989.tb03517.x; LAMPHERE L, 1994, AM J PHYSIOL, V266, P486; LAVAN BE, 1992, J BIOL CHEM, V267, P11631; LINDER ME, 1988, P NATL ACAD SCI USA, V85, P2608, DOI 10.1073/pnas.85.8.2608; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LIU DL, 1992, J VIROL, V66, P374, DOI 10.1128/JVI.66.1.374-385.1992; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; MARTINEZ R, 1982, MOL CELL BIOL, V2, P653, DOI 10.1128/MCB.2.6.653; MCCLAIN DA, 1990, J BIOL CHEM, V265, P1678; MOONEY RA, 1992, J BIOL CHEM, V267, P23443; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; PARSONS JT, 1989, CURR TOP MICROBIOL I, V147, P80; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; PENHOAT A, 1988, ENDOCRINOLOGY, V122, P2518, DOI 10.1210/endo-122-6-2518; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; REYNOLDS AB, 1992, ONCOGENE, V7, P2439; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; SASOAKA T, 1988, DIABETES, V37, P1515; SHOELSON SE, 1992, P NATL ACAD SCI USA, V89, P2027, DOI 10.1073/pnas.89.6.2027; SOOS MA, 1989, BIOCHEM J, V263, P553, DOI 10.1042/bj2630553; TREADWAY JL, 1991, P NATL ACAD SCI USA, V88, P214, DOI 10.1073/pnas.88.1.214; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WAGES DS, 1992, J VIROL, V66, P1866, DOI 10.1128/JVI.66.4.1866-1874.1992; WASILENKO WJ, 1991, MOL CELL BIOL, V11, P309, DOI 10.1128/MCB.11.1.309; WEBER MJ, 1979, CELL, V16, P25, DOI 10.1016/0092-8674(79)90184-3; WEBER MJ, 1984, ADV VIRAL ONCOL, V4, P249; WHITE MF, 1984, J CELL BIOCHEM, V26, P169, DOI 10.1002/jcb.240260305; WHITE MF, 1988, J BIOL CHEM, V263, P2969; YAMAMOTO K, 1992, J BIOL CHEM, V267, P11337; YAMASAKI H, 1992, J BIOL CHEM, V267, P20953; YONEZAWA K, 1992, J BIOL CHEM, V267, P25958; YU KT, 1985, J BIOL CHEM, V260, P5838; ZHAN X, 1986, MOL CELL BIOL, V6, P3541, DOI 10.1128/MCB.6.10.3541	59	66	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27315	27321						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7525552				2022-12-27	WOS:A1994PV77100029
J	CHIAVAROLI, C; BIRD, GS; PUTNEY, JW				CHIAVAROLI, C; BIRD, GS; PUTNEY, JW			DELAYED ALL-OR-NONE ACTIVATION OF INOSITOL 1,4,5-TRISPHOSPHATE-DEPENDENT CALCIUM SIGNALING IN SINGLE-RAT HEPATOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACRIMAL ACINAR-CELLS; PERMEABILIZED HEPATOCYTES; STIMULATED HEPATOCYTES; CA2+ MOBILIZATION; OSCILLATIONS; VASOPRESSIN; RELEASE; FURA-2; SEQUESTRATION; SECRETION	When single rat hepatocytes were stimulated with the phospholipase C-activating hormone, vasopressin (from 300 pM to 1 mu M), the [Ca2+](i) signals were always ''all-or-none'' responses. At low concentrations of vasopressin, Ca2+ release was maximal because liberation of additional inositol 1,4,5-trisphosphate (IP3) by photolysis of its caged precursor at the top of the [Ca2+](i) spike failed to increase [Ca2+](i) further. However, if IP3 was generated by photolysis of caged IP3 in previously unstimulated cells, [Ca2+](i) increased immediately, and the magnitude of the response was a graded function of the quantity of IP3 released. We also analyzed the kinetics of activation of intracellular IP3 receptor/Ca2+ channels by monitoring the quench of sequestered dye by the entry of cytoplasmic Mn2+ into fura-2-loaded intracellular IP3-sensitive organelles. This Mn2+-induced quench was precipitous and always preceded by a delay inversely related to the vasopressin concentration. In hepatocytes stimulated with 10 nM vasopressin, IP3 increased slowly, and the half-time of the IP3 rise was comparable with the latency for the release of intracellular calcium. The slow rise in IP3 would be predicted to produce accelerating Ca2+ release. This is consistent with the results of the Mn2+ quench experiments, which revealed accelerating activation of intracellular IP3-regulated calcium channels. We conclude that this accelerating release of Ca2+, which does not occur with instantaneous increases in IP3 due to flash photolysis, is likely to be important for generating the all-or-none Ca2+ mobilization that initiates the processes of intracellular [Ca2+](i) oscillations.			CHIAVAROLI, C (corresponding author), NIEHS,CELLULAR & MOLEC PHARMACOL LAB,RES TRIANGLE PK,NC 27709, USA.		Bird, Gary/AAI-8186-2021; Putney, James/F-7247-2019	Bird, Gary/0000-0003-1389-8748; Putney, James/0000-0002-3379-4789				Berridge Michael J., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P211; BIRD GS, 1992, J BIOL CHEM, V267, P18382; BIRD GS, 1992, J BIOL CHEM, V267, P17722; BIRD GSJ, 1993, J BIOL CHEM, V268, P8425; BLATTER LA, 1990, BIOPHYS J, V58, P1491, DOI 10.1016/S0006-3495(90)82494-2; BURGESS GM, 1991, J BIOL CHEM, V266, P4772; CANNY BJ, 1992, J BIOL CHEM, V267, P8325; DIVIRGILIO F, 1990, CELL CALCIUM, V11, P57, DOI 10.1016/0143-4160(90)90059-4; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; GLENNON MC, 1992, J BIOL CHEM, V267, P8230; GRAY PTA, 1988, J PHYSIOL-LONDON, V406, P35, DOI 10.1113/jphysiol.1988.sp017367; HAJNOCZKY G, 1994, J BIOL CHEM, V269, P10280; HAJNOCZKY G, 1993, BIOCHEM J, V293, P413, DOI 10.1042/bj2930413; HUGHES AR, 1988, J BIOL CHEM, V263, P10314; KWAN CY, 1990, J BIOL CHEM, V265, P678; MEYER T, 1988, P NATL ACAD SCI USA, V85, P5051, DOI 10.1073/pnas.85.14.5051; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.bb.20.060191.001101; MEYER T, 1988, SCIENCE, V240, P653, DOI 10.1126/science.2452482; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; MONCK JR, 1988, J BIOL CHEM, V263, P4569; PETERSEN CCH, 1991, EMBO J, V10, P527, DOI 10.1002/j.1460-2075.1991.tb07979.x; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; RENARDROONEY DC, 1993, J BIOL CHEM, V268, P23601; ROONEY TA, 1989, J BIOL CHEM, V264, P17131; WOODS NM, 1986, NATURE, V319, P600, DOI 10.1038/319600a0	25	41	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25570	25575						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7523388				2022-12-27	WOS:A1994PQ49100053
J	WEIL, R; VEILLETTE, A				WEIL, R; VEILLETTE, A			INTRAMOLECULAR AND EXTRAMOLECULAR MECHANISMS REPRESS THE CATALYTIC FUNCTION OF P56(LCK) IN RESTING T-LYMPHOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PROTEIN-KINASE; CELL ANTIGEN RECEPTOR; SH3 DOMAINS; ZETA-CHAIN; PHENYLARSINE OXIDE; PHOSPHATASE CD45; PHOSPHORYLATION; P56LCK; LCK; EXPRESSION	Accumulating data show that the catalytic function of the Src-related tyrosine protein kinase p56(lck) is repressed by phosphorylation of a conserved carboxyl-terminal tyrosine residue (tyrosine 505). However, previous findings (Abraham, N., Miceli, M. C., Parnes, J. R., and Veillette, A. (1991) Nature 350, 62-66) suggest that mechanisms unrelated to tyrosine 505 phosphorylation repress the catalytic function of p56(lck) in resting T-cells. In keeping with this view, we report herein that the Src homology 3 (SH3) and SH2 domains negatively regulate the catalytic activity of p56(lck), by a process independent of carboxyl-terminal tyrosine phosphorylation. While the exact mechanism of this inhibition are not established, its structural requirements in the SH2 domain are distinct hom those allowing recruitment of Lck in T-cell receptor signaling. In addition, we obtained evidence that the elevated tyrosine protein phosphatase activity present in T-cells also contributes to inhibit the enzymatic function of p56(lck). Such an effect is seemingly mediated by dephosphorylation of tyrosine 394, the site of positive regulation of p56(lck). Collectively these results indicate that the catalytic function of p56(lck) in resting T-cells is repressed by a complex set of processes, which involves both intramolecular and extramolecular mechanisms.	MCGILL UNIV,MCGILL CTR,MONTREAL H3G 1Y6,PQ,CANADA; MCGILL UNIV,DEPT BIOCHEM,MONTREAL H3G 1Y6,PQ,CANADA; MCGILL UNIV,DEPT MED,MONTREAL H3G 1Y6,PQ,CANADA; MCGILL UNIV,DEPT ONCOL,MONTREAL H3G 1Y6,PQ,CANADA; MONTREAL GEN HOSP,DEPT MED,MONTREAL H3G 1A4,PQ,CANADA; MONTREAL GEN HOSP,DEPT ONCOL,MONTREAL H3G 1A4,PQ,CANADA	McGill University; McGill University; McGill University; McGill University; McGill University; McGill University				Weil, Robert/0000-0001-5235-0932				ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BUDAY L, 1994, J BIOL CHEM, V269, P9019; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARON L, 1992, MOL CELL BIOL, V12, P2720, DOI 10.1128/MCB.12.6.2720; CASNELLIE JE, 1987, J BIOL CHEM, V262, P9858; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHOW LML, 1993, NATURE, V365, P156, DOI 10.1038/365156a0; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; DAVIDSON D, 1992, J EXP MED, V175, P1483, DOI 10.1084/jem.175.6.1483; ECK MJ, 1994, NATURE, V368, P764, DOI 10.1038/368764a0; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; FLETCHER MC, 1993, J BIOL CHEM, V268, P23697; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9255, DOI 10.1073/pnas.87.23.9255; HURLEY TR, 1993, MOL CELL BIOL, V13, P1651, DOI 10.1128/MCB.13.3.1651; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; LORENZ U, 1994, MOL CELL BIOL, V14, P1824, DOI 10.1128/MCB.14.3.1824; LUO K, 1990, ONCOGENE, V5, P803; LUO KX, 1990, MOL CELL BIOL, V10, P5305, DOI 10.1128/MCB.10.10.5305; LUO KX, 1992, MOL CELL BIOL, V12, P4724, DOI 10.1128/MCB.12.10.4724; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MCFARLAND EDC, 1993, P NATL ACAD SCI USA, V90, P1402, DOI 10.1073/pnas.90.4.1402; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OKADA M, 1991, J BIOL CHEM, V266, P24249; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PEI DH, 1993, P NATL ACAD SCI USA, V90, P1092, DOI 10.1073/pnas.90.3.1092; PERI KG, 1993, ONCOGENE, V8, P2765; PERLMUTTER RM, 1993, ANNU REV IMMUNOL, V11, P451, DOI 10.1146/annurev.iy.11.040193.002315; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; RESKEKUNZ AB, 1985, EUR J IMMUNOL, V15, P1048, DOI 10.1002/eji.1830151017; REYNOLDS PJ, 1992, ONCOGENE, V7, P1949; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SHENOYSCARIA AM, 1993, MOL CELL BIOL, V13, P6385, DOI 10.1128/MCB.13.10.6385; SIEH M, 1993, EMBO J, V12, P315, DOI 10.1002/j.1460-2075.1993.tb05659.x; SOULA M, 1993, J BIOL CHEM, V268, P27420; STANNERS CP, 1971, NATURE-NEW BIOL, V230, P52, DOI 10.1038/newbio230052a0; Veillette A, 1991, Semin Immunol, V3, P143; VEILLETTE A, 1992, ONCOGENE, V7, P971; VEILLETTE A, 1988, ONCOGENE RES, V2, P385; VEILLETTE A, 1987, ONCOGENE RES, V1, P357; VEILLETTE A, 1992, TRENDS GENET, V8, P61, DOI 10.1016/0168-9525(92)90045-6; WANGE RL, 1993, J BIOL CHEM, V268, P19797; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4	51	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 9	1994	269	36					22830	22838						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ163	7521333				2022-12-27	WOS:A1994PQ16300057
J	STANCATO, LF; CHOW, YH; OWENSGRILLO, JK; YEM, AW; DEIBEL, MR; JOVE, R; PRATT, WB				STANCATO, LF; CHOW, YH; OWENSGRILLO, JK; YEM, AW; DEIBEL, MR; JOVE, R; PRATT, WB			THE NATIVE V-RAF-CENTER-DOT-HSP90-CENTER-DOT-P50 HETEROCOMPLEX CONTAINS A NOVEL IMMUNOPHILIN OF THE FK506 BINDING CLASS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-RECEPTOR COMPLEXES; ROUS-SARCOMA VIRUS; HEAT-SHOCK PROTEINS; PEPTIDYL-PROLYL ISOMERASE; CELL-FREE SYSTEM; GLUCOCORTICOID RECEPTOR; PROGESTERONE-RECEPTOR; FK506-BINDING PROTEIN; IMMUNOSUPPRESSANT FK506; TRANSFORMING PROTEIN	We have recently reported that v-Raf forms a native heterocomplex with rat heat shock protein (hsp) 90 and a 50-kDa phosphoprotein (p50) in stably transfected 3Y1 fibroblasts (Stancato, L. F., Chow, Y-H., Hutchison, K. A., Perdew, G. H., Jove, R., and Pratt, W. B. (1993) J. Biol. Chem. 268, 21711-21716). Several members of the nuclear receptor family exist in heterocomplexes containing hsp90 and various members of the immunophilin protein family, including hsp56, an immunophilin of the FK506 binding class (Pratt, W E. (1993) J. Biol. Chem. 268, 21455-21458). In this work, we have asked if Raf is also associated with an immunophilin. We have immunoadsorbed v-Raf from stably transfected rat 3Y1 fibroblasts and show that the immunoadsorbed v-Raf.hsp90.p50 p50 heterocomplex binds the immunosuppressant drug [H-3]FK506. The binding is of high affinity (K-D 82 nM) and specific in the sense that it is competed by nonradioactive FK506 and rapamycin but not by cyclosporin A. The [H-3]FK506 binding activity is eliminated when the heterocomplex proteins are dissociated from v Raf. Using the 22W mutant of c-Raf in which the NH2-terminal half has been deleted, we show that the catalytic domain of the kinase is sufficient for the immunophilin association. We have shown that hsp90 and p50 do not bind FK506, and the v-Raf heterocomplex does not contain any of the established FK506-binding proteins. Thus, we propose that Raf is associated with a novel immunophilin.	UNIV MICHIGAN,SCH MED,DEPT PHARMACOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT MICROBIOL & IMMUNOL,ANN ARBOR,MI 48109; UPJOHN CO,DEPT BIOCHEM,KALAMAZOO,MI 49001	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Pfizer					NATIONAL CANCER INSTITUTE [R01CA028010, R01CA055652] Funding Source: NIH RePORTER; NCI NIH HHS [CA28010, CA55652] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRUGGE J, 1983, MOL CELL BIOL, V3, P9, DOI 10.1128/MCB.3.1.9; BRUGGE JS, 1981, CELL, V25, P363, DOI 10.1016/0092-8674(81)90055-6; BRUGGE JS, 1986, CURR TOP MICROBIOL, V123, P1; COURTNEIDGE SA, 1982, P NATL ACAD SCI-BIOL, V79, P7117, DOI 10.1073/pnas.79.23.7117; FRETZ H, 1991, J AM CHEM SOC, V113, P1409, DOI 10.1021/ja00004a051; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HUTCHISON KA, 1992, J BIOL CHEM, V267, P2902; HUTCHISON KA, 1993, BIOCHEMISTRY-US, V32, P3953, DOI 10.1021/bi00066a015; HUTCHISON KA, 1994, J BIOL CHEM, V269, P5043; JIN YJ, 1992, J BIOL CHEM, V267, P10942; KIEFFER LJ, 1992, J BIOL CHEM, V267, P5503; KIEFFER LJ, 1993, J BIOL CHEM, V268, P12303; LEBEAU MC, 1992, J BIOL CHEM, V267, P4281; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; PARK ST, 1992, J BIOL CHEM, V267, P3316; PEATTIE DA, 1992, P NATL ACAD SCI USA, V89, P10974, DOI 10.1073/pnas.89.22.10974; PRATT WB, 1993, J STEROID BIOCHEM, V46, P269, DOI 10.1016/0960-0760(93)90216-J; PRATT WB, 1993, J BIOL CHEM, V268, P21455; RATAJCZAK T, 1993, J BIOL CHEM, V268, P13187; RATAJCZAK T, 1990, J STEROID BIOCHEM, V35, P543, DOI 10.1016/0022-4731(90)90197-Z; RUFF VA, 1992, J BIOL CHEM, V267, P21285; RUFF VA, 1992, IMMUNOL INVEST, V21, P259, DOI 10.3109/08820139209072263; SANCHEZ ER, 1990, BIOCHEMISTRY-US, V29, P5145, DOI 10.1021/bi00473a021; SANCHEZ ER, 1990, J BIOL CHEM, V265, P22067; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; SMITH DF, 1990, MOL ENDOCRINOL, V4, P1704, DOI 10.1210/mend-4-11-1704; SMITH DF, 1990, J BIOL CHEM, V265, P3996; SMITH DF, 1993, J BIOL CHEM, V268, P24270; SMITH DF, 1993, J BIOL CHEM, V268, P18365; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; TAI PKK, 1993, BIOCHEMISTRY-US, V32, P8842, DOI 10.1021/bi00085a015; TAI PKK, 1986, BIOCHEMISTRY-US, V25, P5269, DOI 10.1021/bi00366a043; TAI PKK, 1992, SCIENCE, V256, P1315, DOI 10.1126/science.1376003; WALSH CT, 1992, J BIOL CHEM, V267, P13115; WHITELAW ML, 1991, J BIOL CHEM, V266, P16436; YEM AW, 1992, J BIOL CHEM, V267, P2868	39	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22157	22161						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	7520912				2022-12-27	WOS:A1994PE09800037
J	SHIMADA, M; INOUYE, S; INOUYE, M				SHIMADA, M; INOUYE, S; INOUYE, M			REQUIREMENTS OF THE SECONDARY STRUCTURES IN THE PRIMARY TRANSCRIPT FOR MULTICOPY SINGLE-STRANDED-DNA SYNTHESIS BY REVERSE-TRANSCRIPTASE FROM BACTERIAL RETRON-EC107	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-LINKED MSDNA; ESCHERICHIA-COLI; MYXOCOCCUS-XANTHUS; EXTRACTION	Multicopy single-stranded DNA (msDNA) is produced by bacterial retroelements called retrons. It consists of single-stranded DNA that is linked to an internal G residue of an RNA molecule by a 2',5'-phosphodiester linkage. It has been demonstrated that specific primary sequences, as well as the secondary structures immediately downstream of the G residue, are essential for the cDNA priming reaction (Shimamoto, T, Hsu, M.-Y., Inouye, S., and Inouye, M. (1993) J. Biol. Chem. 268, 2684-2692). We have now examined the requirement of the structures in the region corresponding to DNA for msDNA synthesis. The upper stem region consisting of 71 bases of msDNA-Ec107 was found not to be essential, and this region could be deleted to efficiently produce a truncated msDNA containing only a 36-base single-stranded DNA. Various mutations including base replacements, deletions, and insertions were constructed in the lower stem region. It was found that any mutations resulting in more stable secondary structures caused reduction in msDNA synthesis. The results indicated that reverse transcriptase requires a loose secondary structure in the template RNA near the cDNA priming site for cDNA elongation.			SHIMADA, M (corresponding author), ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854, USA.		Inouye, Sharon/R-7216-2019		NIGMS NIH HHS [GM44012] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044012] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIYAR A, 1994, J VIROL, V68, P611, DOI 10.1128/JVI.68.2.611-618.1994; BAUDIN F, 1993, J MOL BIOL, V229, P382, DOI 10.1006/jmbi.1993.1041; BERKHOUT B, 1993, NUCLEIC ACIDS RES, V21, P1171, DOI 10.1093/nar/21.5.1171; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; HERZER PJ, 1992, MOL MICROBIOL, V6, P345, DOI 10.1111/j.1365-2958.1992.tb01477.x; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HSU MY, 1989, J BIOL CHEM, V264, P6214; HSU MY, 1992, J BIOL CHEM, V267, P13823; INOUYE M, 1991, ANNU REV MICROBIOL, V45, P163; INOUYE M, 1992, J BACTERIOL, V174, P2412; INOUYE S, 1991, DIRECTED MUTAGENESIS, P71; LAMPSON BC, 1989, SCIENCE, V243, P1033, DOI 10.1126/science.2466332; LERNER CG, 1990, NUCLEIC ACIDS RES, V18, P4631, DOI 10.1093/nar/18.15.4631; LIM D, 1989, CELL, V56, P891, DOI 10.1016/0092-8674(89)90693-4; Miller J.H., 1992, SHORT COURSE BACTERI, P150; MIROCHNITCHENKO O, 1994, J BIOL CHEM, V269, P2380; MIYATA S, 1992, P NATL ACAD SCI USA, V89, P5735, DOI 10.1073/pnas.89.13.5735; MOUGEL M, 1993, NUCLEIC ACIDS RES, V21, P4677, DOI 10.1093/nar/21.20.4677; RICE SA, 1993, J BACTERIOL, V175, P4250, DOI 10.1128/JB.175.13.4250-4254.1993; SALSER W, 1977, COLD SPRING HARB SYM, V42, P985; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHARP PA, 1973, BIOCHEMISTRY-US, V12, P3055, DOI 10.1021/bi00740a018; SHIMAMOTO T, 1993, J BIOL CHEM, V268, P2684; SUN J, 1991, J BACTERIOL, V173, P4171, DOI 10.1128/jb.173.13.4171-4181.1991; WAKEFIELD JK, 1994, J VIROL, V68, P1605, DOI 10.1128/JVI.68.3.1605-1614.1994; YEE T, 1984, CELL, V38, P203, DOI 10.1016/0092-8674(84)90541-5	27	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14553	14558						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	7514172				2022-12-27	WOS:A1994NM06500040
J	SUGIMOTO, S; WANDLESS, TJ; SHOELSON, SE; NEEL, BG; WALSH, CT				SUGIMOTO, S; WANDLESS, TJ; SHOELSON, SE; NEEL, BG; WALSH, CT			ACTIVATION OF THE SH2-CONTAINING PROTEIN-TYROSINE-PHOSPHATASE, SH-PTP2, BY PHOSPHOTYROSINE-CONTAINING PEPTIDES DERIVED FROM INSULIN-RECEPTOR SUBSTRATE-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC HOMOLOGY-2 DOMAINS; SIGNAL TRANSDUCTION; SH2 DOMAIN; PHOSPHATIDYLINOSITOL 3'-KINASE; IRS-1; LOCALIZATION; INTERMEDIATE; ASSOCIATION; EXPRESSION; CORKSCREW	The cytoplasmic insulin receptor substrate-1 (IRS-1), which is multiply phosphorylated in vivo on tyrosine residues, is a known binding protein for the tandem src homology 2 (SH2) domain containing protein tyrosine phosphatase, SH-PTP2. Eleven phosphotyrosyl (pY) pep- tides from IRS-1 were screened for allosteric activation of SH-PTP2 phosphatase activity toward phosphorylated, reduced, carboxyamidomethylated, and maleylated-lysozyme. Peptides IRS-1pY895, IRS-1pY1172, and IRS-1pY1222 showed up to 50-fold acceleration of dephosphorylation. Analyses of Arg to Lys mutants in either or both SH2 domains indicate that both the N-terminal (N-SH2) and C-terminal (C-SH2) domains function in allosteric activation. Direct determination by surface plasmon resonance of the dissociation constants between pY peptides and glutathione S-transferase fusions to N-SH2 and C-SH2 domains reveals a 240-fold preference of the N-SH2 domain (compared with the C-SH2 domain) for IRS-1pY1172. The N-SH2 domain prefers IRS-1pY1172>IRS-1pY895> IRS 1pY1222, whereas C-SH2 domain prefers IRS-1pY1222>IRS-1pY895>IRS-1pY1172. These data suggest that each SH2 domain can bind to a distinct pY sequence of multiply phosphorylated protein substrates such as IRS-1, while activating hydrolysis at a third pY sequence bound in the SH-PTP2 active site. In addition, proteolysis and truncation studies reveal an autoregulatory function for the C-terminal region of SH-PTP2. Limited tryptic cleavage within the C terminus results in 27-fold activation of protein tyrosine phosphatase activity. The activated tryptic fragment cannot be further activated by pY peptide binding to the SH2 do mains indicating that autoregulatory functions of the SH2 domains are dependent on the C-terminal region. These data suggest that multiple levels for control of SH-PTP2 enzymatic activity may exist in vitro and in vivo.	HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, JOSLIN DIABET CTR, BOSTON, MA 02115 USA; BETH ISRAEL HOSP, MOLEC MED UNIT, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Beth Israel Deaconess Medical Center					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020011, R37GM020011] Funding Source: NIH RePORTER; NIDCR NIH HHS [DERC 36836] Funding Source: Medline; NIGMS NIH HHS [GM20011] Funding Source: Medline; PHS HHS [49152] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; ARAKI E, 1993, DIABETES, V42, P1041, DOI 10.2337/diabetes.42.7.1041; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CASE RD, 1994, J BIOL CHEM, V269, P10467; CHO HJ, 1992, J AM CHEM SOC, V114, P7296, DOI 10.1021/ja00044a052; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FELDER S, 1993, MOL CELL BIOL, V13, P1449, DOI 10.1128/MCB.13.3.1449; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; GRANZOW R, 1992, BIO-TECHNOL, V10, P390, DOI 10.1038/nbt0492-390; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KITAS EA, 1991, HELV CHIM ACTA, V74, P1314, DOI 10.1002/hlca.19910740621; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVAN BE, 1992, J BIOL CHEM, V267, P11631; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LORENZ U, 1994, MOL CELL BIOL, V14, P1824, DOI 10.1128/MCB.14.3.1824; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LU XY, 1993, GENE DEV, V7, P621, DOI 10.1101/gad.7.4.621; MARGOLIS B, 1992, CELL GROWTH DIFFER, V3, P73; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PAYNE G, 1993, P NATL ACAD SCI USA, V90, P4902, DOI 10.1073/pnas.90.11.4902; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PICCIONE E, 1993, BIOCHEMISTRY-US, V32, P3197, DOI 10.1021/bi00064a001; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; PLUTZKY J, 1992, GENOMICS, V13, P869, DOI 10.1016/0888-7543(92)90172-O; POT DA, 1992, J BIOL CHEM, V267, P140; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SUGIMOTO S, 1993, J BIOL CHEM, V268, P22771; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; TOBE K, 1993, J BIOL CHEM, V268, P11167; TONKS NK, 1988, J BIOL CHEM, V263, P6731; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VILLAMORUZZI E, 1993, J BIOL CHEM, V268, P18176; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WO YYP, 1992, BIOCHEMISTRY-US, V31, P1712, DOI 10.1021/bi00121a019; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; ZHAO ZZ, 1993, J BIOL CHEM, V268, P2816; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	55	190	192	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13614	13622						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	7513703				2022-12-27	WOS:A1994NK18400081
J	OKUTANI, T; OKABAYASHI, Y; KIDO, Y; SUGIMOTO, Y; SAKAGUCHI, K; MATUOKA, K; TAKENAWA, T; KASUGA, M				OKUTANI, T; OKABAYASHI, Y; KIDO, Y; SUGIMOTO, Y; SAKAGUCHI, K; MATUOKA, K; TAKENAWA, T; KASUGA, M			GRB2/ASH BINDS DIRECTLY TO TYROSINE-1068 AND TYROSINE-1086 AND INDIRECTLY TO TYROSINE-1148 OF ACTIVATED HUMAN EPIDERMAL GROWTH-FACTOR RECEPTORS IN INTACT-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY PHOSPHOTYROSYL PEPTIDE; GUANINE-NUCLEOTIDE EXCHANGE; SH3 DOMAINS; SIGNAL TRANSDUCTION; PHOSPHATIDYLINOSITOL 3-KINASE; AUTOPHOSPHORYLATION SITES; PHOSPHORYLATION SITES; MITOGENIC SIGNAL; ADAPTER PROTEIN; 85-KDA SUBUNIT	The activation of receptor tyrosine kinases generates tyrosine-phosphorylated recognition motifs for the binding of signaling proteins containing Src homology 2 domains. We determined the binding sites of Grb2/Ash, an Src homology 2 domain-containing adaptor protein, within epidermal growth factor (EGF) receptors, using Chinese hamster ovary cells overexpressing human EGF receptor mutants in which one of the autophosphorylation sites was retained. In intact cells, the amount of Grb2/Ash coimmunoprecipitated with mutant receptors retaining tyrosines 992, 1068, 1086, 1148, or 1173 was approximately 10, 85, 55, 50, or 20% of wild-type levels, respectively The association of Grb2/Ash with in vitro autophosphorylated EGF receptor mutants was detectable in those retaining either tyrosines 1068 or 1086 but not in other mutants including those retaining tyrosine 1148. In peptide inhibition assay phosphorylated peptides representing tyrosines 1068 and 1086 inhibited the binding of Grb2/Ash to in vitro autophosphorylated wild-type EGF receptors, whereas the other peptides representing tyrosines 992, 1148, and 1173 failed to inhibit the binding. Given that tyrosine 1148 of the activated EGF receptor is a major binding site of Shc (Okabayashi, Y., Kido, Y., Okutani, T., Sugimoto, Y., Sakaguchi, K., and Kasuga, M. (1994) J. Biol. Chem. 269, 18674-18678), these results indicate that tyrosines 1068 and 1086 of activated human EGF receptors are direct high affinity binding sites of Grb2/Ash and that tyrosine 1148 is an indirect binding site through Shc in intact cells.	KOBE UNIV, SCH MED, DEPT INTERNAL MED 2, CHUO KU, KOBE 650, JAPAN; TOKYO METROPOLITAN GERIATR HOSP & INST GERENTOL, DEPT BIOSIGNAL RES, TOKYO 173, JAPAN; UNIV TOKYO, INST MED SCI, DEPT MOLEC ONCOL, TOKYO 108, JAPAN	Kobe University; University of Tokyo								ANDO A, 1994, EMBO J, V13, P3033, DOI 10.1002/j.1460-2075.1994.tb06602.x; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BIRGE RB, 1993, SCIENCE, V262, P1522, DOI 10.1126/science.7504323; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DENHERTOG J, 1994, EMBO J, V13, P3020, DOI 10.1002/j.1460-2075.1994.tb06601.x; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HSUAN JJ, 1989, BIOCHEM J, V262, P659, DOI 10.1042/bj2620659; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS BL, 1989, J BIOL CHEM, V264, P10667; MATTHEWS RJ, 1990, P NATL ACAD SCI USA, V87, P4444, DOI 10.1073/pnas.87.12.4444; MATUOKA K, 1993, EMBO J, V12, P3467, DOI 10.1002/j.1460-2075.1993.tb06021.x; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MIKI H, 1994, J BIOL CHEM, V269, P5489; NAKAFUKU M, 1992, J BIOL CHEM, V267, P19448; OKABAYASHI Y, 1994, J BIOL CHEM, V269, P18674; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1992, J BIOL CHEM, V267, P24149; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SCAIFE R, 1994, EMBO J, V13, P2574, DOI 10.1002/j.1460-2075.1994.tb06547.x; SEEDORF K, 1994, J BIOL CHEM, V269, P16009; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SOLER C, 1994, J BIOL CHEM, V269, P12320; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WALTON GM, 1990, J BIOL CHEM, V265, P1750; YAMAZAKI H, 1990, JPN J CANCER RES, V81, P773, DOI 10.1111/j.1349-7006.1990.tb02644.x; YONEZAWA K, 1992, J BIOL CHEM, V267, P25958; YONEZAWA K, 1994, J BIOL CHEM, V269, P4634; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	54	86	87	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					31310	31314						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7527043				2022-12-27	WOS:A1994PV51000086
J	DANILOV, S; JASPARD, E; CHURAKOVA, T; TOWBIN, H; SAVOIE, F; WEI, L; ALHENCGELAS, F				DANILOV, S; JASPARD, E; CHURAKOVA, T; TOWBIN, H; SAVOIE, F; WEI, L; ALHENCGELAS, F			STRUCTURE-FUNCTION ANALYSIS OF ANGIOTENSIN I-CONVERTING ENZYME USING MONOCLONAL-ANTIBODIES - SELECTIVE-INHIBITION OF THE AMINO-TERMINAL ACTIVE-SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2 HOMOLOGOUS DOMAINS; MOLECULAR-CLONING; LUNG; LOCALIZATION; PLASMA; SPECIFICITIES; BRADYKININ; RECEPTOR; PROTEINS; ISOZYME	Angiotensin I-converting enzyme (ACE; kininase II) contains two very similar domains (the NH2- and COOH-terminal domains (N and C domains, respectively)), each bearing an active site. These active sites hydrolyze the same peptides, but do not have the same catalytic properties and substrate specificities. In an attempt to develop domain-specific immunological probes, two series of monoclonal antibodies (mAbs), 19 clones in all, were produced and tested against human ACE. These mAbs recognized at least nine different epitopes within three antigenic regions of the ACE molecule. Testing on wildtype recombinant ACE and several mutants with only one intact domain showed that these epitopes were all located in the N domain. None of the mAbs recognized the C domain. This particular specificity and analysis of results obtained with several polyclonal antibodies to human ACE suggest that ACE immunogenicity is determined mainly by the N domain. Two mAbs (3A5 and i2H5) recognizing epitopes from different antigenic regions of ACE inhibited the enzymatic activity of the N (but not of the C) domain. mAb 3A5 had the same inhibitory potency toward hippuryl-His-Leu, benzyloxycarbonyl-Phe-His-Leu, and angiotensin I hydrolysis, with 50% inhibition achieved at a mAb/ACE molar ratio of 6. mAb i2H5 was roughly three times more effective than mAb 3A5 in inhibiting the hydrolysis of benzyloxycarbonyl-Phe-His-Leu and the natural substrates angiotensin I and bradykinin (50% inhibition at a molar ratio of 1-2), but was less effective in inhibiting hippuryl-His-Leu cleavage (50% inhibition at a molar ratio of 22-25), indicating that this substrate interacts with a specific subsite. mAb i2H5 almost completely inhibited the hydrolysis of the luteinizing hormone-releasing hormone by the isolated N domain. Both the primary carboxyl- and amino-terminal cleavages of this peptide were suppressed. This antibody suppressed the primary amino-terminal cleavage of the luteinizing hormone-releasing hormone by wild-type ACE by >90%, indicating that this particular ACE function is mediated mainly by the N domain active site. These data provide evidence for structural differences between the two homologous domains of ACE despite their high degree of sequence homology and show that monoclonal antibodies are able to distinguish between the two active sites in ACE.	INSERM,U367,F-75005 PARIS,FRANCE; CARDIOL RES CTR,MOSCOW 121552,RUSSIA; CIBA GEIGY AG,DIV PHARMACOL,DEPT BIOL RES,CH-4002 BASEL,SWITZERLAND	Institut National de la Sante et de la Recherche Medicale (Inserm); National Medical Research Center of Cardiology; Novartis			Alhenc-Gelas, Francois/F-9511-2017					ALHENCGELAS F, 1983, J LAB CLIN MED, V101, P83; ALHENCGELAS F, 1981, BIOCHIM BIOPHYS ACTA, V677, P477, DOI 10.1016/0304-4165(81)90262-2; AUERBACH R, 1982, P NATL ACAD SCI-BIOL, V79, P7891, DOI 10.1073/pnas.79.24.7891; BELDENT V, 1993, J BIOL CHEM, V268, P26428; BENJAMIN DC, 1984, ANNU REV IMMUNOL, V2, P67, DOI 10.1146/annurev.iy.02.040184.000435; BERNSTEIN KE, 1989, J BIOL CHEM, V264, P11945; BRUNEVAL P, 1986, HISTOCHEMISTRY, V85, P73, DOI 10.1007/BF00508656; CALDWELL PRB, 1976, FEBS LETT, V63, P82, DOI 10.1016/0014-5793(76)80199-8; CAMUSSI G, 1990, EXP LUNG RES, V16, P423, DOI 10.3109/01902149009068818; CONROY JM, 1976, J BIOL CHEM, V251, P4828; CUSHMAN DW, 1971, BIOCHEM PHARMACOL, V20, P1637, DOI 10.1016/0006-2952(71)90292-9; DANILOV SM, 1987, BIOTECHNOL APPL BIOC, V9, P319; DANILOV SM, 1989, J NUCL MED, V30, P1686; DANILOV SM, 1991, LAB INVEST, V64, P118; DAS M, 1976, BIOCHEMISTRY-US, V15, P5088, DOI 10.1021/bi00668a022; Ehler MRW, 1990, HYPERTENSION PATHOPH, P1217; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P7118, DOI 10.1021/bi00243a012; EHLERS MRW, 1989, P NATL ACAD SCI USA, V86, P7741, DOI 10.1073/pnas.86.20.7741; EISENHN, 1980, IMMUNOLOGY, P363; ERDOS EG, 1987, LAB INVEST, V56, P345; FEIZI T, 1987, BIOCHEM J, V245, P1; FRIEDLAND J, 1976, AM J CLIN PATHOL, V66, P416; HOOPER NM, 1991, INT J BIOCHEM, V23, P641, DOI 10.1016/0020-711X(91)90032-I; HOWARD TE, 1990, MOL CELL BIOL, V10, P4294, DOI 10.1128/MCB.10.8.4294; HUANG H, 1989, CLIN EXP HYPERTENS A, V11, P1535, DOI 10.3109/10641968909038181; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; IWATA K, 1983, ARCH BIOCHEM BIOPHYS, V227, P186; JASPARD E, 1993, J BIOL CHEM, V268, P9496; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KUMAR RS, 1989, J BIOL CHEM, V264, P16754; LATTION AL, 1989, FEBS LETT, V252, P99, DOI 10.1016/0014-5793(89)80897-X; LO MMS, 1984, NATURE, V310, P792, DOI 10.1038/310792a0; MARKLE RA, 1978, P NATL ACAD SCI USA, V75, P5702, DOI 10.1073/pnas.75.11.5702; MCCORMICK JR, 1980, CLIN IMMUNOL IMMUNOP, V15, P444, DOI 10.1016/0090-1229(80)90056-2; MOORE MG, 1984, CLIN IMMUNOL IMMUNOP, V33, P301, DOI 10.1016/0090-1229(84)90301-5; MORGAN DO, 1986, BIOCHEMISTRY-US, V25, P1364, DOI 10.1021/bi00354a026; ONDETTI MA, 1982, ANNU REV BIOCHEM, V51, P283, DOI 10.1146/annurev.bi.51.070182.001435; PARKER JMR, 1986, BIOCHEMISTRY-US, V25, P5432; PIQUILLO.Y, 1970, BIOCHIM BIOPHYS ACTA, V206, P136, DOI 10.1016/0005-2744(70)90090-2; POLSKYCYNKIN R, 1979, INT J BIOCHEM, V10, P669, DOI 10.1016/0020-711X(79)90210-6; Safer R. L., 1981, BIOCH REGULATION BLO, P123; Sakharov I Iu, 1991, Biokhimiia, V56, P55; SKEGGS LT, 1956, J EXP MED, V103, P295, DOI 10.1084/jem.103.3.295; SKIDGEL RA, 1985, P NATL ACAD SCI USA, V82, P1025, DOI 10.1073/pnas.82.4.1025; SOFFER RL, 1983, FED PROC, V42, P2335; SOUBRIER F, 1988, P NATL ACAD SCI USA, V85, P9386, DOI 10.1073/pnas.85.24.9386; STOCKER JW, 1982, 21713 HOFFM LAR RES, P155; STRITTMATTER SM, 1984, ENDOCRINOLOGY, V115, P2332, DOI 10.1210/endo-115-6-2332; THEAN ET, 1990, ANAL BIOCHEM, V188, P330, DOI 10.1016/0003-2697(90)90615-G; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSARTOS SJ, 1981, J BIOL CHEM, V256, P8635; Waeber BNJ, 1990, HYPERTENSION PATHOPH, P2209; WEI L, 1992, J BIOL CHEM, V267, P13398; WEI L, 1991, J BIOL CHEM, V266, P9002; WEI L, 1991, J BIOL CHEM, V266, P5540; WILLIAMS TA, 1992, BIOCHEM J, V288, P875, DOI 10.1042/bj2880875; WISE JG, 1981, J BIOL CHEM, V256, P383; YANG HYT, 1970, BIOCHIM BIOPHYS ACTA, V214, P374, DOI 10.1016/0005-2795(70)90017-6; YOTSUMOTO H, 1983, BIOCHIM BIOPHYS ACTA, V749, P180, DOI 10.1016/0167-4838(83)90250-9	59	106	113	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26806	26814						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7523412				2022-12-27	WOS:A1994PQ93100037
J	FREY, C; NARAYANAN, K; MCMILLAN, K; SPACK, L; GROSS, SS; MASTERS, BS; GRIFFITH, OW				FREY, C; NARAYANAN, K; MCMILLAN, K; SPACK, L; GROSS, SS; MASTERS, BS; GRIFFITH, OW			L-THIOCITRULLINE - A STEREOSPECIFIC, HEME-BINDING INHIBITOR OF NITRIC-OXIDE SYNTHASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; METHYL-L-ARGININE; ENDOTHELIAL-CELLS; NG-METHYLARGININE; SELECTIVE-INHIBITION; CARBON-MONOXIDE; BLOOD-PRESSURE; L-CITRULLINE; MACROPHAGE; ENZYME	Nitric-oxide synthase (NOS) catalyzes the oxidation of L-arginine to citrulline and nitric oxide (NO). The enzyme is inhibited by a variety of N-omega-monosubstituted L-arginine analogs, and some of these compounds are useful in reversing pathologies associated with the overproduction of NO (e.g. the hypotension of septic shock). We report here that L-thiocitrulline (gamma-thioureido-L-norvaline) is a potent, stereospecific inhibitor of the constitutive brain and endothelial isoforms of NOS as well as the isoform induced in vascular smooth muscle cells by lipopolysaccharide and interferon-gamma. Steady state kinetic studies show L-thiocitrulline inhibition is competitive with L-arginine (K-i similar to 4-20% of K-m(Arg)), indicating that initial binding is as a substrate/product analog. In contrast to L-arginine and N-omega-methyl-L-arginine, the prototypic NOS inhibitor, L-thiocitrulline binding elicits a ''Type II'' difference spectrum, indicating a high spin to low spin transition of the iron in the heme cofactor. This finding suggests that L-thiocitrulline is contributing the sixth ligand to heme iron, probably through the thioureido sulfur. Such interaction with heme iron neither stimulates nor inhibits the direct flavin-mediated cytochrome c reduction activity of the enzyme, but it does inhibit heme-dependent superoxide formation. In vivo, L-thiocitrulline is a potent presser agent in both normal and endotoxemic rats, the latter finding suggesting utility in treating the hypotension of septic shock.	MED COLL WISCONSIN, DEPT BIOCHEM, MILWAUKEE, WI 53226 USA; MED COLL WISCONSIN, DEPT PEDIAT, MILWAUKEE, WI 53226 USA; UNIV TEXAS, HLTH SCI CTR, DEPT BIOCHEM, SAN ANTONIO, TX 78284 USA; CORNELL UNIV, MED CTR, DEPT PHARMACOL, NEW YORK, NY 10021 USA	Medical College of Wisconsin; Medical College of Wisconsin; University of Texas System; University of Texas Health San Antonio; Cornell University								ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; AISAKA K, 1989, BIOCHEM BIOPH RES CO, V163, P710, DOI 10.1016/0006-291X(89)92281-X; AISAKA K, 1989, BIOCHEM BIOPH RES CO, V160, P881, DOI 10.1016/0006-291X(89)92517-5; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BUSSE R, 1990, FEBS LETT, V275, P87, DOI 10.1016/0014-5793(90)81445-T; BUZZARD CJ, 1993, CIRC RES, V72, P1023, DOI 10.1161/01.RES.72.5.1023; CORBIN JL, 1974, ANAL BIOCHEM, V57, P310, DOI 10.1016/0003-2697(74)90080-3; DESAI KM, 1991, NATURE, V351, P477, DOI 10.1038/351477a0; DESAI VS, 1993, CHEST, V104, P1254, DOI 10.1378/chest.104.4.1254; FEELISCH M, 1987, EUR J PHARMACOL, V139, P19, DOI 10.1016/0014-2999(87)90493-6; FELDMAN PL, 1993, J MED CHEM, V36, P491, DOI 10.1021/jm00056a009; FELDMAN PL, 1993, CHEM ENG NEWS, V71, P26; FELDMAN PL, 1991, TETRAHEDRON LETT, V32, P875, DOI 10.1016/S0040-4039(00)92109-9; FORSTERMANN U, 1989, N-S ARCH PHARMACOL, V340, P771; FUKUTO JM, 1990, BIOCHEM BIOPH RES CO, V168, P458, DOI 10.1016/0006-291X(90)92343-X; FURFINE ES, 1993, BIOCHEMISTRY-US, V32, P8512, DOI 10.1021/bi00084a017; GRIFFITH OW, 1992, FASEB J, V6, pA1255; GROSS SS, 1990, BIOCHEM BIOPH RES CO, V170, P96, DOI 10.1016/0006-291X(90)91245-N; GROSS SS, 1992, J BIOL CHEM, V267, P25722; GUENGERICH FP, 1990, FASEB J, V4, P2453, DOI 10.1096/fasebj.4.8.2185971; HATTORI Y, 1994, J BIOL CHEM, V269, P9405; HECKER M, 1990, BIOCHEM BIOPH RES CO, V167, P1037, DOI 10.1016/0006-291X(90)90627-Y; HIBBS JB, 1987, SCIENCE, V235, P473, DOI 10.1126/science.2432665; JONES BN, 1983, J CHROMATOGR, V266, P471, DOI 10.1016/S0021-9673(01)90918-5; KILBOURN RG, 1992, J NATL CANCER I, V84, P827, DOI 10.1093/jnci/84.11.827; KILBOURN RG, 1990, BIOCHEM BIOPH RES CO, V172, P1132, DOI 10.1016/0006-291X(90)91565-A; KLATT P, 1994, J BIOL CHEM, V269, P1674; KLATT P, 1993, J BIOL CHEM, V268, P14781; KLATT P, 1992, J BIOL CHEM, V267, P11374; KWON NS, 1990, J BIOL CHEM, V265, P13442; LIEW FY, 1993, ANN TROP MED PARASIT, V87, P637, DOI 10.1080/00034983.1993.11812822; LOWENSTEIN CJ, 1992, CELL, V70, P705, DOI 10.1016/0092-8674(92)90301-R; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MAYER B, 1989, BIOCHEM BIOPH RES CO, V164, P678, DOI 10.1016/0006-291X(89)91513-1; MCCALL TB, 1991, BRIT J PHARMACOL, V102, P234, DOI 10.1111/j.1476-5381.1991.tb12159.x; MCCARTNEYFRANCIS N, 1993, J EXP MED, V178, P749, DOI 10.1084/jem.178.2.749; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MCMILLAN K, 1993, BIOCHEMISTRY-US, V32, P9875, DOI 10.1021/bi00089a001; MITCHELL JA, 1991, BIOCHEM BIOPH RES CO, V176, P1417, DOI 10.1016/0006-291X(91)90444-C; NARAYANAN K, 1994, J MED CHEM, V37, P885, DOI 10.1021/jm00033a004; NARAYANAN K, 1994, IN PRESS 3RD INT M B; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; NISHIKAWA T, 1993, STROKE, V24, P1717, DOI 10.1161/01.STR.24.11.1717; OLKEN NM, 1993, BIOCHEMISTRY-US, V32, P9677, DOI 10.1021/bi00088a020; RADOMSKI MW, 1990, P NATL ACAD SCI USA, V87, P5193, DOI 10.1073/pnas.87.13.5193; REES DD, 1989, P NATL ACAD SCI USA, V86, P3375, DOI 10.1073/pnas.86.9.3375; ROGERS NE, 1992, BIOCHEM BIOPH RES CO, V189, P242, DOI 10.1016/0006-291X(92)91550-A; ROTH M, 1971, ANAL CHEM, V43, P880, DOI 10.1021/ac60302a020; SCHENKMAN JB, 1967, MOL PHARMACOL, V3, P113; SCHMIDT K, 1993, MOL PHARMACOL, V44, P615; SESSA WC, 1992, J BIOL CHEM, V267, P15274; SHETA EA, 1994, J BIOL CHEM, V269, P15147; SONNTAG M, 1992, PFLUG ARCH EUR J PHY, V420, P194, DOI 10.1007/BF00374990; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; STUEHR DJ, 1992, ADV ENZYMOL RELAT AR, V65, P287; WEINBERG JB, 1994, J EXP MED, V179, P651, DOI 10.1084/jem.179.2.651; WOLFF DJ, 1993, J BIOL CHEM, V268, P9425; ZHUO M, 1993, SCIENCE, V260, P1946, DOI 10.1126/science.8100368	60	99	101	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26083	26091						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7523401				2022-12-27	WOS:A1994PQ93000025
J	CARTER, BZ; HABIB, GM; SEPULVEDA, AR; BARRIOS, R; WAN, DF; LEBOVITZ, RM; LIEBERMAN, MW				CARTER, BZ; HABIB, GM; SEPULVEDA, AR; BARRIOS, R; WAN, DF; LEBOVITZ, RM; LIEBERMAN, MW			TYPE-VI RNA IS THE MAJOR GAMMA-GLUTAMYL-TRANSPEPTIDASE RNA IN THE MOUSE SMALL-INTESTINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBRAL ENDOTHELIAL-CELLS; TRANSFERASE TRANSPEPTIDASE; MESSENGER-RNAS; RAT-KIDNEY; HEPATOCARCINOGENESIS; GLUTATHIONE; EXPRESSION; SEQUENCE; FETAL; LIVER	Mouse gamma-glutamyl transpeptidase (gamma GT) is encoded by a single copy gene with at least five and probably six different promoters directing the transcription of six types of gamma GT RNAs. In mouse small intestine, only Type I, V, and VI gamma GT RNAs are detected, and ribonuclease protection assays reveal that Type VI represents more than 90% of gamma GT RNA. To investigate the structure of intestinal gamma GT RNA in greater detail, we cloned and sequenced mouse intestinal gamma GT cDNAs. Seven of eight informative clones were Type VI and consisted of Type VI unique exons, VIa and VIb (as described previously by us) (Rajagopalan, S., Wan, D.-F., Habib, G. M., Sepulveda, A. R., McLeod, M. R., Lebovitz, R. M., and Lieberman, M. W. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 6179-6183) as well as common 3' sequences. Exon VIb contains two alternative splice accepters, one previously identified by us and the other 17 bases 5' of this site. Another clone contained a previously unidentified gamma GT mRNA designated as Type VII. Type VII consists of a unique 5' exon which is 315 base pairs upstream of the exon VIa splice donor site and is spliced to exon VIb. Regulation of gamma GT expression in the small intestine is complex and involves at least three previously described promoters, alternative splicing, and a previously undescribed exonic sequence (Type VII RNA) 5' of promoter VI.	BAYLOR COLL MED, DEPT PATHOL, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT CELL BIOL, HOUSTON, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine					NATIONAL CANCER INSTITUTE [R37CA039392, R01CA039392] Funding Source: NIH RePORTER; NCI NIH HHS [CA 39392] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAUER HC, 1990, BIOCHEM BIOPH RES CO, V168, P358, DOI 10.1016/0006-291X(90)91716-6; BEACHY PA, 1985, NATURE, V313, P545, DOI 10.1038/313545a0; BERK AJ, 1978, CELL, V14, P695, DOI 10.1016/0092-8674(78)90252-0; BOGGS RT, 1987, CELL, V50, P739, DOI 10.1016/0092-8674(87)90332-1; CHEVEZBARRIOS P, 1993, AM J PATHOL, V143, P20; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CURTHOYS NP, 1983, MINER ELECTROL METAB, V9, P236; DARBOUY M, 1991, AM J PHYSIOL, V261, pC1130, DOI 10.1152/ajpcell.1991.261.6.C1130; GE H, 1990, P NATL ACAD SCI USA, V87, P3338, DOI 10.1073/pnas.87.9.3338; HABIB GM, 1992, MOL CARCINOGEN, V5, P75; HANIGAN MH, 1985, CARCINOGENESIS, V6, P165, DOI 10.1093/carcin/6.2.165; IANNACCONE PM, 1983, J HISTOCHEM CYTOCHEM, V31, P1312, DOI 10.1177/31.11.6194205; JACOBSON A, 1987, METHOD ENZYMOL, V152, P254; JACQUEMIN E, 1990, J PEDIATR GASTR NUTR, V11, P89, DOI 10.1097/00005176-199007000-00018; LAPERCHE Y, 1986, P NATL ACAD SCI USA, V83, P937, DOI 10.1073/pnas.83.4.937; MARATHE GV, 1979, FEBS LETT, V107, P436, DOI 10.1016/0014-5793(79)80425-1; MAXWELL K, 1987, BRAIN RES, V410, P309, DOI 10.1016/0006-8993(87)90329-5; ORMSTAD K, 1983, GLUTATHIONE STORAGE, P107; RAJAGOPALAN S, 1993, P NATL ACAD SCI USA, V90, P6179, DOI 10.1073/pnas.90.13.6179; REED R, 1988, GENE DEV, V2, P1268, DOI 10.1101/gad.2.10.1268; ROSALKI SB, 1972, CLIN CHIM ACTA, V39, P41, DOI 10.1016/0009-8981(72)90297-5; SAWABU N, 1983, CANCER, V51, P327, DOI 10.1002/1097-0142(19830115)51:2<327::AID-CNCR2820510227>3.0.CO;2-C; SEPULVEDA AR, 1994, J BIOL CHEM, V269, P10699; TATE SS, 1981, MOL CELL BIOCHEM, V39, P357, DOI 10.1007/BF00232585; TATE SS, 1985, METHOD ENZYMOL, V113, P400; WINOKUR TS, 1990, CARCINOGENESIS, V11, P365, DOI 10.1093/carcin/11.3.365	26	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24581	24585						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7523374				2022-12-27	WOS:A1994PQ49000014
J	ENSLEN, H; SODERLING, TR				ENSLEN, H; SODERLING, TR			ROLES OF CALMODULIN-DEPENDENT PROTEIN-KINASES AND PHOSPHATASE IN CALCIUM-DEPENDENT TRANSCRIPTION OF IMMEDIATE-EARLY GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; AMP-RESPONSIVE ELEMENT; C-FOS GENE; MEMBRANE DEPOLARIZATION; CYCLOSPORINE-A; T-CELLS; PROTOONCOGENE EXPRESSION; SOMATOSTATIN GENE; BINDING PROTEINS; FACTORS ENCODES	Recent studies indicate multiple mechanisms are involved in Ca2+ stimulation of gene expression. We have used cell-permeable, specific inhibitors of calmodulin-dependent protein kinases (CaM kinases) and phosphatase (calcineurin) to investigate the involvement of these enzymes in transcriptional regulation of three immediate early genes in PC12 cells stimulated with A(23187) or KCl. Preincubation of PC12 cells with the CaM kinase inhibitor KN-62 blocked autophosphorylation of CaM kinase II in response to stimulation by the Ca2+ ionophore A(23187). KN-62 treatment also resulted in a 60-70% inhibition of Ca2+-dependent transcription of c-fos, NGFI-A (zif 268), and NGFI-B (nur77) as assessed by either Northern or nuclear run-on analyses. Preincubation with the calcineurin inhibitors FK-506 or cyclosporin A strongly enhanced expression of NGFI-A and blocked transcription of NGFI-B, but it had no significant effect on Ca2+-stimulated transcription of c-fos. Both FK-506 and KN-62 were specific for Ca2+-stimulated transcription as neither effected transcription in response to forskolin or phorbol ester (12-O-tetradecanoylphorbol-13-acetate) treatment. This is the first report of CaM kinase and calcineurin involvement in transcriptional regulation of NGFI-A and NGFI-B. Activation of CaM kinases and calcineurin, in response to elevated intracellular Ca2+, would exert antagonistic effects on transcription of NGFI-A. Since inhibition of either the kinase or phosphatase decreased transcription of NGFI-B by 60-90%, this suggests that each enzyme is necessary but not sufficient for Ca2+ stimulation. These results indicate that CaM kinases and calcineurin can mediate broad and complex regulation of Ca2+-stimulated gene expression.	OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT CELL BIOL & ANAT,PORTLAND,OR 97201	Oregon Health & Science University; Oregon Health & Science University			Enslen, Hervé/M-3400-2017	Enslen, Hervé/0000-0001-9741-5293	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK044239] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44239] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; BROWN AMC, 1984, P NATL ACAD SCI-BIOL, V81, P6344, DOI 10.1073/pnas.81.20.6344; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COLLART MA, 1991, MOL CELL BIOL, V11, P2826, DOI 10.1128/MCB.11.5.2826; CORBIN JD, 1973, J BIOL CHEM, V248, P1813; CRUZALEGUI FH, 1993, J BIOL CHEM, V268, P26171; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; DARCANGELO G, 1993, MOL CELL BIOL, V13, P3146, DOI 10.1128/MCB.13.6.3146; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; FARBER LH, 1987, J NEUROCHEM, V49, P404, DOI 10.1111/j.1471-4159.1987.tb02880.x; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; GARGLIO P, 1981, NUCLEIC ACIDS RES, V9, P2589; Ginty D D, 1992, Curr Opin Neurobiol, V2, P312, DOI 10.1016/0959-4388(92)90121-Z; GINTY DD, 1991, J BIOL CHEM, V266, P17454; GOELET P, 1986, NATURE, V322, P419, DOI 10.1038/322419a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GOODMAN RH, 1990, ANNU REV NEUROSCI, V13, P111, DOI 10.1146/annurev.neuro.13.1.111; GRANELLIPIPERNO A, 1986, J EXP MED, V163, P922, DOI 10.1084/jem.163.4.922; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JENSEN KF, 1991, P NATL ACAD SCI USA, V88, P2850, DOI 10.1073/pnas.88.7.2850; JONES DA, 1991, FEBS LETT, V289, P105, DOI 10.1016/0014-5793(91)80919-T; KAPILOFF MS, 1991, P NATL ACAD SCI USA, V88, P3710, DOI 10.1073/pnas.88.9.3710; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MACNICOL M, 1990, J BIOL CHEM, V265, P16055; MEANS AR, 1991, MOL CELL BIOL, V11, P3960, DOI 10.1128/MCB.11.8.3960; MECHTI N, 1991, MOL CELL BIOL, V11, P2832, DOI 10.1128/MCB.11.5.2832; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MIYANO O, 1992, J BIOL CHEM, V267, P1198; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MOSHIZUKI H, 1993, J BIOL CHEM, V268, P9143; NATAZUKA T, 1993, INT J CANCER, V54, P348, DOI 10.1002/ijc.2910540230; OHMSTEDE CA, 1989, J BIOL CHEM, V264, P5866; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; PUJOL MJ, 1993, J NEUROCHEM, V60, P1422, DOI 10.1111/j.1471-4159.1993.tb03304.x; SCHONTHAL A, 1991, P NATL ACAD SCI USA, V88, P7096, DOI 10.1073/pnas.88.16.7096; SCHWANINGER M, 1993, J BIOL CHEM, V268, P23111; SCHWANINGER M, 1993, J BIOL CHEM, V268, P5168; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SODERLING TR, 1972, J BIOL CHEM, V248, P1822; TANSEY MG, 1992, J BIOL CHEM, V267, P12511; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; VELCICH A, 1990, MOL CELL BIOL, V10, P6273, DOI 10.1128/MCB.10.12.6273; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WERLEN G, 1993, J BIOL CHEM, V268, P16596; YOON JK, 1993, J BIOL CHEM, V268, P9148	57	151	154	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					20872	20877						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	7520433				2022-12-27	WOS:A1994PC40300013
J	FANG, KS; SABE, H; SAITO, H; HANAFUSA, H				FANG, KS; SABE, H; SAITO, H; HANAFUSA, H			COMPARATIVE-STUDY OF 3 PROTEIN-TYROSINE PHOSPHATASES - CHICKEN PROTEIN-TYROSINE-PHOSPHATASE-LAMBDA DEPHOSPHORYLATES C-SRC TYROSINE-527	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RECEPTOR KINASE; CELL-TRANSFORMATION; ESCHERICHIA-COLI; V-SRC; ACTIVATION; P60C-SRC; DOMAIN; PHOSPHORYLATION; PURIFICATION; PP60(C-SRC)	To examine the substrate preference of protein tyrosine phosphatases (PTPs), we compared the activity of three transmembrane PTPs on dephosphorylation and regulation of c-Src and v-Src: chicken PTP lambda (ChPTP lambda), chicken PTP alpha (ChPTP alpha), and human leukocyte common antigen-related molecule (HLAR). In vitro, all three PTPs dephosphorylated v-Src, but only ChPTP lambda dephosphorylated c Src. Their activities were also compared in Cos cells coexpressing Src and the phosphatase domains of three PTPs. These domains were fused with peptides for myristylation, so they associated with the cellular membrane. When c-Src was coexpressed with myrPTP lambda, its kinase activity was elevated 3-4-folds. This activation was less obvious when c-Src was coexpressed with myrPTP alpha or myrLAR. Analysis by cyanogen bromide cleavage showed that ChPTP lambda and myrPTP lambda dephosphorylated Tyr-527 of c-Src. Our data demonstrated the different activities of three PTPs on phosphoproteins, suggesting that Src Tyr-527 may require more specific PTP(s) than Src Tyr-416 for dephosphorylation in vivo.	ROCKEFELLER UNIV, MOLEC ONCOL LAB, NEW YORK, NY 10021 USA; HARVARD UNIV, DANA FARBER CANC INST, BOSTON, MA 02115 USA	Rockefeller University; Harvard University; Dana-Farber Cancer Institute			Sabe, Hisataka/GPF-4385-2022; Sabe, Hisataka/A-4066-2012		NATIONAL CANCER INSTITUTE [R35CA044356] Funding Source: NIH RePORTER; NCI NIH HHS [CA44356] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARUFFO A, 1987, EUR J BIOCHEM, V107, P303; BABA TW, 1985, VIROLOGY, V144, P139, DOI 10.1016/0042-6822(85)90312-5; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BUXSER SE, 1983, J CELL BIOCHEM, V22, P219, DOI 10.1002/jcb.240220404; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHO HJ, 1991, BIOCHEMISTRY-US, V30, P6210, DOI 10.1021/bi00239a019; COOPER JA, 1990, SRC FAMILY PROTEIN T; DENHERTOG J, 1993, EMBO J, V12, P3789, DOI 10.1002/j.1460-2075.1993.tb06057.x; FANG KS, 1994, J BIOL CHEM, V269, P14056; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FUKUI Y, 1991, ONCOGENE, V6, P407; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; HANAFUSA H, 1969, P NATL ACAD SCI USA, V63, P318, DOI 10.1073/pnas.63.2.318; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARLOW E, 1988, ANTIBODIES LABORATOR; HASHIMOTO N, 1992, J BIOL CHEM, V267, P13811; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; ISHIBASHI T, 1992, P NATL ACAD SCI USA, V89, P12170, DOI 10.1073/pnas.89.24.12170; JOVE R, 1989, ONCOGENE RES, V5, P49; JOVE R, 1987, CELL, V50, P937, DOI 10.1016/0092-8674(87)90520-4; JOVE R, 1986, J VIROL, V60, P849, DOI 10.1128/JVI.60.3.849-857.1986; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; LEVINE BA, 1991, J BIOL CHEM, V266, P3565; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MILLAR JBA, 1992, CELL, V68, P407, DOI 10.1016/0092-8674(92)90177-E; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; OBRIEN MC, 1990, MOL CELL BIOL, V10, P2855, DOI 10.1128/MCB.10.6.2855; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PELLMAN D, 1985, P NATL ACAD SCI USA, V82, P1623, DOI 10.1073/pnas.82.6.1623; RAMACHANDRAN C, 1992, BIOCHEMISTRY-US, V31, P4232, DOI 10.1021/bi00132a012; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; SABE H, 1992, MOL CELL BIOL, V12, P4706, DOI 10.1128/MCB.12.10.4706; SHIROO M, 1992, EMBO J, V11, P4887, DOI 10.1002/j.1460-2075.1992.tb05595.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.immunol.7.1.339; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	45	46	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					20194	20200						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	7519604				2022-12-27	WOS:A1994PA12600079
J	LEMAS, MV; YU, HY; TAKEYASU, K; KONE, B; FAMBROUGH, DM				LEMAS, MV; YU, HY; TAKEYASU, K; KONE, B; FAMBROUGH, DM			ASSEMBLY OF NA,K-ATPASE ALPHA-SUBUNIT ISOFORMS WITH NA,K-ATPASE BETA-SUBUNIT ISOFORMS AND H,K-ATPASE BETA-SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+-K+-ATPASE; (NA+ + K+)-ATPASE; INTRACELLULAR-TRANSPORT; XENOPUS-OOCYTES; SODIUM-PUMP; FUNCTIONAL EXPRESSION; GASTRIC H+,K+-ATPASE; SKELETAL-MUSCLE; NA+,K+-ATPASE; SEQUENCE	cDNA encoding an epitope tag was joined to cDNAs encoding the chicken Na,K-ATPase beta 1 and beta 2 and H,K-ATPase beta-subunits to allow recognition of these beta-subunits with the same monoclonal antibody during assembly assays. cDNAs encoding chicken Na,K-ATPase alpha 1, alpha 2, or alpha 3 and Na,K-ATPase beta 1 or beta 2 or H,K-ATPase beta-subunits were transiently coexpressed in mammalian cells. Subunit assembly was assayed by immune precipitation of alpha-isoforms with a monoclonal antibody to the epitope-tagged beta-subunits. Each of the chicken alpha-isoforms assembled with each of the Na,K-ATPase beta-subunits and the H,K-ATPase beta-subunit. Each of the epitope-tagged beta-subunits also assembled with a Na,K-ATPase/Ca-ATPase chimera that retained only 26 amino acids of the Na,K-ATPase alpha-subunit, demonstrating that all three beta-subunits recognize this same alpha-subunit assembly site.	JOHNS HOPKINS UNIV, DEPT BIOL, BALTIMORE, MD 21218 USA; OHIO STATE UNIV, DEPT MED BIOCHEM, COLUMBUS, OH 43210 USA; OHIO STATE UNIV, CTR BIOTECHNOL, COLUMBUS, OH 43210 USA; UNIV FLORIDA, DIV NEPHROL HYPERTENS & TRANSPLANTAT, GAINESVILLE, FL 32610 USA	Johns Hopkins University; Ohio State University; Ohio State University; State University System of Florida; University of Florida					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R21GM044373, R01GM044373] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023241] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-44373] Funding Source: Medline; NINDS NIH HHS [NS-23241] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ACKERMANN U, 1990, FEBS LETT, V269, P105, DOI 10.1016/0014-5793(90)81130-G; CROWSON MS, 1992, J BIOL CHEM, V267, P13740; EAKLE KA, 1992, P NATL ACAD SCI USA, V89, P2834, DOI 10.1073/pnas.89.7.2834; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FAMBROUGH DM, 1988, TRENDS NEUROSCI, V11, P325, DOI 10.1016/0166-2236(88)90096-3; FAMBROUGH DM, 1983, COLD SPRING HARB SYM, V48, P297, DOI 10.1101/SQB.1983.048.01.032; FUERST TR, 1987, MOL CELL BIOL, V7, P2538, DOI 10.1128/MCB.7.7.2538; GEERING K, 1989, AM J PHYSIOL, V257, pC851, DOI 10.1152/ajpcell.1989.257.5.C851; GOTTARDI CJ, 1993, J CELL BIOL, V121, P283, DOI 10.1083/jcb.121.2.283; HAMRICK M, 1993, J BIOL CHEM, V268, P24367; HORISBERGER JD, 1991, ANNU REV PHYSIOL, V53, P565, DOI 10.1146/annurev.physiol.53.1.565; HORISBERGER JD, 1991, J BIOL CHEM, V266, P19131; HOROWITZ B, 1990, J BIOL CHEM, V265, P4189; JAISSER F, 1992, J BIOL CHEM, V267, P16895; JAUNIN P, 1992, J BIOL CHEM, V267, P577; KARIN NJ, 1989, MOL CELL BIOL, V9, P1978, DOI 10.1128/MCB.9.5.1978; Kone BC., 1991, SODIUM PUMP RECENT D, P265; LEMAS MV, 1994, J BIOL CHEM, V269, P8255; LEMAS MV, 1992, J BIOL CHEM, V267, P20987; LEMAS MV, 1993, BIOCHIM BIOPHYS ACTA, V1149, P339; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; NOGUCHI S, 1990, BIOCHIM BIOPHYS ACTA, V1023, P247, DOI 10.1016/0005-2736(90)90420-S; NOGUCHI S, 1987, FEBS LETT, V225, P27, DOI 10.1016/0014-5793(87)81125-0; RENAUD KJ, 1991, J BIOL CHEM, V266, P20491; REUBEN MA, 1990, P NATL ACAD SCI USA, V87, P6767, DOI 10.1073/pnas.87.17.6767; SCHMALZING G, 1992, J BIOL CHEM, V267, P20212; SHULL GE, 1990, J BIOL CHEM, V265, P12123; SHULL GE, 1986, J BIOL CHEM, V261, P6788; SHULL GE, 1986, BIOCHEMISTRY-US, V25, P8125, DOI 10.1021/bi00373a001; STULTS NL, 1989, ANAL BIOCHEM, V180, P114, DOI 10.1016/0003-2697(89)90097-3; TAKEYASU K, 1990, AM J PHYSIOL, V259, pC619, DOI 10.1152/ajpcell.1990.259.4.C619; TAKEYASU K, 1989, CURR TOP MEMBR TRANS, V34, P143; TAKEYASU K, 1988, J BIOL CHEM, V263, P4347; TAKEYASU K, 1987, J BIOL CHEM, V262, P10733; TAMKUN MM, 1986, J BIOL CHEM, V261, P1009; YU HY, 1994, BBA-BIOMEMBRANES, V1190, P189, DOI 10.1016/0005-2736(94)90052-3	36	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18651	18655						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	7518440				2022-12-27	WOS:A1994NW79800066
J	SHETA, EA; MCMILLAN, K; MASTERS, BSS				SHETA, EA; MCMILLAN, K; MASTERS, BSS			EVIDENCE FOR A BIDOMAIN STRUCTURE OF CONSTITUTIVE CEREBELLAR NITRIC-OXIDE SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING DOMAIN; HYDROXY-L-ARGININE; CYTOCHROME-C REDUCTASE; SMOOTH-MUSCLE CELLS; NITROGEN-OXIDES; LIMITED PROTEOLYSIS; ENDOTHELIAL-CELLS; RELAXING FACTOR; BRAIN; OXIDATION	Nitric oxide synthase (NOS) catalyzes the NADPH-dependent, Ca2+/calmodulin dependent formation of NO and citrulline from L-arginine and molecular oxygen. The localization of the heme-binding consensus sequence in the NH2-terminal half of NOS and of the bind sequences for nucleotides (FMN and FAD) in the COOH-terminal half suggests a bidomain structure. In addition, the presence of a putative calmodulin-binding sequence between the heme- and flavin-binding domains of the enzyme suggests a role for calmodulin in modulating a spatial orientation of these domains that is required for catalytic activity. First, to determine the effects of calmodulin and the functionality of the separated domains, Ca2+/calmodulin binding-induced conformational changes in NOS were measured by fluorescence quenching from which a binding constant of similar to 1 nM for calmodulin was calculated. Second, electron transport to various artificial accepters was measured. The addition of Ca2+/calmodulin increased cytochrome c reduction from 10-15-fold while stimulating the rate of 2,6-dichlorophenolindophenol and ferricyanide reduction only slightly, if at all. Calmodulin stimulation of NOS results in NADPH-mediated cytochrome c reduction, which is sensitive to superoxide dismutase, and the reduction of acetylated cytochrome c, which is only weakly reducible by unstimulated NOS. Thus, this stimulated activity is presumably superoxide anion-mediated. Third, limited proteolysis of NOS in the absence of calmodulin resulted in a time dependent increase in cytochrome c reductase activity, which was not inhibitable by superoxide dismutase, and a decrease in catalysis of NO formation, SDS-polyacrylamide gel electrophoresis analysis of the tryptic digest demonstrated the formation of similar to 89- and similar to 79-kDa fragments. Sequence analysis of the peptides confirmed that trypsin cleaves the enzyme in the putative calmodulin-binding region beginning with Ala(728). This region was protected from proteolysis by the addition of Ca2+/calmodulin, The separated NH2-terminal domain exhibited the characteristic spectrum of bound heme, while the COOH-terminal domain showed the characteristic spectrum of bound flavins. Other cleavage patterns were obtained in the presence of calmodulin. The data demonstrate that the heme- and flavin-binding domains of NOS can be isolated in functionally intact forms.	UNIV TEXAS, HLTH SCI CTR, DEPT BIOCHEM, SAN ANTONIO, TX 78284 USA	University of Texas System; University of Texas Health San Antonio					NHLBI NIH HHS [HL30050] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL130050, R37HL030050, R01HL030050] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDRONIKLION V, 1992, BIOCHEM BIOPH RES CO, V185, P452, DOI 10.1016/S0006-291X(05)81006-X; BEASLEY D, 1991, J CLIN INVEST, V87, P602, DOI 10.1172/JCI115036; BLUMENTHAL DK, 1987, METHOD ENZYMOL, V139, P115; BOUCHER JL, 1992, BIOCHEM BIOPH RES CO, V187, P880, DOI 10.1016/0006-291X(92)91279-Y; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDT DS, 1992, J BIOL CHEM, V267, P10976; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BUSSE R, 1990, FEBS LETT, V265, P133, DOI 10.1016/0014-5793(90)80902-U; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; DINERMAN JL, 1993, CIRC RES, V73, P217, DOI 10.1161/01.RES.73.2.217; FORSTERMANN U, 1991, BIOCHEM PHARMACOL, V42, P1849, DOI 10.1016/0006-2952(91)90581-O; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; GIOVANELLI J, 1991, P NATL ACAD SCI USA, V88, P7091, DOI 10.1073/pnas.88.16.7091; HUBBARD MJ, 1989, BIOCHEMISTRY-US, V28, P1868, DOI 10.1021/bi00430a066; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; KELM M, 1988, BIOCHEM BIOPH RES CO, V154, P236, DOI 10.1016/0006-291X(88)90675-4; KILBOURN RG, 1990, J NATL CANCER I, V82, P772, DOI 10.1093/jnci/82.9.772; KLATT P, 1992, J BIOL CHEM, V267, P11374; KWON NS, 1989, J BIOL CHEM, V264, P20496; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; Masters B, 1967, METHOD ENZYMOL, V10, P565; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MAYER B, 1991, FEBS LETT, V288, P187, DOI 10.1016/0014-5793(91)81031-3; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MCMILLAN K, 1993, BIOCHEMISTRY-US, V32, P9875, DOI 10.1021/bi00089a001; MONCADA S, 1991, PHARMACOL REV, V43, P109; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; POLLOCK JS, 1991, P NATL ACAD SCI USA, V88, P10480, DOI 10.1073/pnas.88.23.10480; POU S, 1992, J BIOL CHEM, V267, P24173; PROUGH RA, 1973, ANN NY ACAD SCI, V212, P89, DOI 10.1111/j.1749-6632.1973.tb47588.x; PUFAHL RA, 1993, BIOCHEM BIOPH RES CO, V193, P963, DOI 10.1006/bbrc.1993.1719; RENAUD JP, 1993, BIOCHEM BIOPH RES CO, V192, P53, DOI 10.1006/bbrc.1993.1380; SCHINI VB, 1991, BIOCHEM BIOPH RES CO, V176, P114, DOI 10.1016/0006-291X(91)90897-G; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; VORHERR T, 1990, BIOCHEMISTRY-US, V29, P355, DOI 10.1021/bi00454a008; VORHERR T, 1993, BIOCHEMISTRY-US, V32, P6081, DOI 10.1021/bi00074a020; WALSH C, 1979, ENZYMATIC REACTION M, P388; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001; WILSON JE, 1991, METHOD BIOCHEM ANAL, V35, P207; WOLFF DJ, 1993, J BIOL CHEM, V268, P9425	43	201	203	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15147	15153						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	7515050				2022-12-27	WOS:A1994NP73800046
J	BORCHELT, DR; KOLIATSOS, VE; GUARNIERI, M; PARDO, CA; SISODIA, SS; PRICE, DL				BORCHELT, DR; KOLIATSOS, VE; GUARNIERI, M; PARDO, CA; SISODIA, SS; PRICE, DL			RAPID ANTEROGRADE AXONAL-TRANSPORT OF THE CELLULAR PRION GLYCOPROTEIN IN THE PERIPHERAL AND CENTRAL NERVOUS SYSTEMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREUTZFELDT-JAKOB DISEASE; ASPARAGINE-LINKED GLYCOSYLATION; GERSTMANN-STRAUSSLER SYNDROME; SCRAPIE-ASSOCIATED FORM; MOUSE SCRAPIE; CULTURED-CELLS; ALZHEIMERS-DISEASE; AMYLOID PROTEIN; NEURAL SPREAD; PRP 27-30	In prion diseases, the cellular prion protein (PrPC), abundant in neurons, is converted posttranslationally into an amyloid-forming scrapie prion protein (PrPSc), which accumulates in white matter tracts and nerve terminals. The trafficking of PrPC in neurons was investigated in vivo by injecting [S-35]methionine into the L4 and L5 dorsal root ganglia and the entorhinal cortices of adult rats and by tracing the movement of radiolabeled PrPC. In both paradigms, labeled 33-55-kDa PrPC was transported, within 4 h, to distal axons and nerve terminals cofractionating with proteins in the fast component. Future studies using these methods may allow us to determine whether PrPC is converted into Prp(Sc) during axonal transport and whether PrPSc is transported in animals with prion diseases.	JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	BORCHELT, DR (corresponding author), JOHNS HOPKINS UNIV,SCH MED,NEUROPATHOL LAB,558 ROSS RES BLDG,720 RUTLAND AVE,BALTIMORE,MD 21205, USA.		Pardo, Carlos A./A-5192-2008	Pardo, Carlos A./0000-0002-4128-5335	NIA NIH HHS [AG 05146] Funding Source: Medline; NINDS NIH HHS [NS 20471, NS 10580] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS020471, P01NS020471] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P50AG005146] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BASLER K, 1986, CELL, V46, P417, DOI 10.1016/0092-8674(86)90662-8; BENDHEIM PE, 1984, NATURE, V310, P418, DOI 10.1038/310418a0; BENDHEIM PE, 1992, NEUROLOGY, V42, P149, DOI 10.1212/WNL.42.1.149; BOLTON DC, 1985, J VIROL, V53, P596, DOI 10.1128/JVI.53.2.596-606.1985; BORCHELT DR, 1990, J CELL BIOL, V110, P743, DOI 10.1083/jcb.110.3.743; BORCHELT DR, 1992, J BIOL CHEM, V267, P16188; BORCHELT DR, 1993, GLYCOBIOLOGY, V3, P319, DOI 10.1093/glycob/3.4.319; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; BUYUKMIHCI N, 1983, EXP NEUROL, V81, P396, DOI 10.1016/0014-4886(83)90271-6; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; CAUGHEY B, 1991, J VIROL, V65, P6597, DOI 10.1128/JVI.65.12.6597-6603.1991; CAUGHEY B, 1989, J VIROL, V63, P175, DOI 10.1128/JVI.63.1.175-181.1989; DEARMOND SJ, 1985, CELL, V41, P221, DOI 10.1016/0092-8674(85)90076-5; DOTTI CG, 1991, NATURE, V349, P158, DOI 10.1038/349158a0; ENDO T, 1989, BIOCHEMISTRY-US, V28, P8380, DOI 10.1021/bi00447a017; FRASER H, 1985, BRAIN RES, V346, P32, DOI 10.1016/0006-8993(85)91091-1; FRASER H, 1982, NATURE, V295, P149, DOI 10.1038/295149a0; GAJDUSEK DC, 1966, NATURE, V209, P794, DOI 10.1038/209794a0; GAJDUSEK DC, 1977, SCIENCE, V197, P943, DOI 10.1126/science.142303; GASSET M, 1993, P NATL ACAD SCI USA, V90, P1, DOI 10.1073/pnas.90.1.1; GIBBS CJ, 1968, SCIENCE, V161, P388, DOI 10.1126/science.161.3839.388; GOLDFARB LG, 1993, P NATL ACAD SCI USA, V90, P4451, DOI 10.1073/pnas.90.10.4451; GRAFSTEIN B, 1967, SCIENCE, V157, P196, DOI 10.1126/science.157.3785.196; HARAGUCHI T, 1989, ARCH BIOCHEM BIOPHYS, V274, P1, DOI 10.1016/0003-9861(89)90409-8; HARRIS DA, 1993, BIOCHEMISTRY-US, V32, P1009, DOI 10.1021/bi00055a003; HSIAO K, 1989, NATURE, V338, P342, DOI 10.1038/338342a0; JENDROSKA K, 1991, NEUROLOGY, V41, P1482, DOI 10.1212/WNL.41.9.1482; KIMBERLIN RH, 1982, J ROY SOC MED, V75, P618; KIMBERLIN RH, 1980, J GEN VIROL, V51, P183, DOI 10.1099/0022-1317-51-1-183; KIMBERLIN RH, 1983, J NEUROL SCI, V61, P315, DOI 10.1016/0022-510X(83)90165-X; KIMBERLIN RH, 1983, J GEN VIROL, V64, P713, DOI 10.1099/0022-1317-64-3-713; KITAMOTO T, 1986, ANN NEUROL, V20, P204, DOI 10.1002/ana.410200205; KITAMOTO T, 1992, AM J PATHOL, V140, P1285; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; KRETZSCHMAR HA, 1986, AM J PATHOL, V122, P1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASEK RAYMOND, 1968, BRAIN RES, V7, P360, DOI 10.1016/0006-8993(68)90003-6; LUBINSKA L, 1964, J NEUROCHEM, V11, P493, DOI 10.1111/j.1471-4159.1964.tb07498.x; MASTERS CL, 1981, BRAIN, V104, P535, DOI 10.1093/brain/104.3.535; MASTERS CL, 1981, BRAIN, V104, P559, DOI 10.1093/brain/104.3.559; MCKINLEY MP, 1991, J VIROL, V65, P1340, DOI 10.1128/JVI.65.3.1340-1351.1991; MEDORI R, 1992, NEW ENGL J MED, V326, P444, DOI 10.1056/NEJM199202133260704; OCHS S, 1967, J NEUROCHEM, V14, P317, DOI 10.1111/j.1471-4159.1967.tb09529.x; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; PRUSINER SB, 1992, ADV VIRUS RES, V41, P241, DOI 10.1016/S0065-3527(08)60038-X; ROBERTS GW, 1988, NEUROLOGY, V38, P1534, DOI 10.1212/WNL.38.10.1534; SARBAN D, 1990, NEUROLOGY, V40, P110; SISODIA SS, 1993, J NEUROSCI, V13, P3136; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; STAHL N, 1990, MOL CELL BIOL MEMBRA, P189; STEWARD O, 1976, J COMP NEUROL, V167, P285, DOI 10.1002/cne.901670303; STEWARD O, 1976, J COMP NEUROL, V169, P347, DOI 10.1002/cne.901690306; TARABOULOS A, 1990, J CELL BIOL, V110, P2117, DOI 10.1083/jcb.110.6.2117; TARABOULOS A, 1990, P NATL ACAD SCI USA, V87, P8262, DOI 10.1073/pnas.87.21.8262; TARABOULOS A, 1992, MOL BIOL CELL, V3, P851, DOI 10.1091/mbc.3.8.851; TARABOULOS A, 1992, P NATL ACAD SCI USA, V89, P7620, DOI 10.1073/pnas.89.16.7620; TARABOULOS A, 1991, Journal of Cell Biology, V115, p473A; VALLEE RB, 1991, ANNU REV NEUROSCI, V14, P59, DOI 10.1146/annurev.ne.14.030191.000423; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3	62	101	103	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14711	14714						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	7514179				2022-12-27	WOS:A1994NM06500064
J	NUTTLE, LC; DUBYAK, GR				NUTTLE, LC; DUBYAK, GR			DIFFERENTIAL ACTIVATION OF CATION CHANNELS AND NONSELECTIVE PORES BY MACROPHAGE P-2Z PURINERGIC RECEPTORS EXPRESSED IN XENOPUS-OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC RECEPTORS; EXTRACELLULAR ATP; MOUSE MACROPHAGES; PLASMA-MEMBRANE; AMILORIDE ANALOGS; HUMAN-LYMPHOCYTES; ION CHANNEL; MAST-CELLS; CA-2+; PERMEABILITY	In macrophages and certain other cell types, extracellular ATP(4-) can increase plasma membrane permeability through activation of the P-2z purinergic receptor. This permeability change involves the induction of non-selective pores which are permeable to molecules with M(r) less than or equal to 900. Electrophysiological studies indicate that agonist occupation of P-2z purinergic receptors can additionally activate cation channels which may be distinct from the non selective pores. We have observed that mammalian P-2z purinergic receptors can be expressed in Xenopus oocytes injected with mRNA from the BAC1.2F5 murine macrophage cell line. Under voltage-clamp analysis, these oocytes exhibit a multiphasic inward current in response to ATP or 3'-O-(4-benzoyl)benzoyl-ATP (BzATP), a selective agonist for the P-2z purinergic receptor. This ATP/BzATP-induced current is characterized by a rapidly activated phase which is followed by a delayed, but steady, increase in conductance. We have used two-electrode voltage-clamp analysis and ion substitution to further characterize these P-2z purinergic receptor-induced currents as expressed in mRNA-injected oocytes. N,N-Hexamethylene amiloride (HMA), a potent inhibitor of various exchangers and channels, selectively and reversibly inhibited the delayed component of the BzATP-induced inward current. This delayed HMA-sensitive current can be carried by large organic cations, such as N-methyl-D-glucamine (NMG(+)) and Tris(+), in addition to small inorganic cations including Na+, Li+, and K+. In contrast, the rapidly activated HMA-insensitive current is readily carried by Na+, Li+, and K+, but is poorly carried by NMG(+) and Tris(+). Additional studies characterized P-2z receptor regulation of Ca2+ influx, depolarization, ethidium uptake, and fura-2 loss in native BAC1.2F5 macrophages. Reduced temperature permitted discrimination of two distinct permeability pathways which could be activated by BzATP. At 20 degrees C, BzATP did not significantly increase membrane permeability to NMG(+) (M(r) 195), ethidium(+) (M(r) 314), or fura-2 (M(r) 831) but did stimulate an ion conducting pathway which could be competitively permeated by Na+ or Ca2+. At 37 degrees C, BzATP treatment increased membrane permeability to NMG(+), ethidium(+), and fura-2, in addition to Na+ and Ca2+. These data indicate that macrophage P-2z purinergic receptors can be differentially coupled to: 1) a rapidly gated cation channel, and 2) a time- and temperature-dependent formation of non selective pores. These two permeability pathways can be distinguished by their rates of activation, ion selectivities, sensitivities to amiloride analogs, and temperature dependence.			NUTTLE, LC (corresponding author), CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44106, USA.			Dubyak, George/0000-0001-9720-4226; Nuttle, Louise/0000-0003-0073-0743	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007653] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036387] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07653] Funding Source: Medline; NIGMS NIH HHS [GM-36387] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBUQUERQUE C, 1993, AM J PHYSIOL, V265, pC1663, DOI 10.1152/ajpcell.1993.265.6.C1663; ALONSOTORRE SR, 1993, J BIOL CHEM, V268, P18640; BEAN BP, 1992, TRENDS PHARMACOL SCI, V13, P87, DOI 10.1016/0165-6147(92)90032-2; BLANCHARD DK, 1991, J IMMUNOL, V147, P2579; BUISMAN HP, 1988, P NATL ACAD SCI USA, V85, P7988, DOI 10.1073/pnas.85.21.7988; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COCKCROFT S, 1979, NATURE, V279, P541, DOI 10.1038/279541a0; DAHLQUIST R, 1974, ACTA PHARMACOL TOX, V35, P11; DIVIRGILIO F, 1988, BIOCHEM J, V256, P959, DOI 10.1042/bj2560959; DIVIRGILIO F, 1989, J IMMUNOL, V143, P1955; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; DUBYAK GR, 1986, ARCH BIOCHEM BIOPHYS, V245, P84, DOI 10.1016/0003-9861(86)90192-X; ELMOATASSIM C, 1993, J BIOL CHEM, V268, P15571; ELMOATASSIM C, 1992, J BIOL CHEM, V267, P23664; ELMOATASSIM C, 1989, FEBS LETT, V242, P391, DOI 10.1016/0014-5793(89)80508-3; ELMOATASSIM C, 1990, EUR J PHARMACOL, V18, P111; GARRITSEN A, 1990, BIOCHEM PHARMACOL, V40, P827, DOI 10.1016/0006-2952(90)90323-D; GARRITSEN A, 1991, J RECEPTOR RES, V11, P891, DOI 10.3109/10799899109064686; GREENBERG S, 1988, J BIOL CHEM, V263, P10337; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HARA N, 1990, COMP BIOCHEM PHYS A, V97, P417, DOI 10.1016/0300-9629(90)90633-4; HOWARD MJ, 1987, MOL PHARMACOL, V32, P53; HOWARD MJ, 1987, AM J PHYSIOL, V253, pF21, DOI 10.1152/ajprenal.1987.253.1.F21; KLEYMAN TR, 1988, J MEMBRANE BIOL, V105, P1, DOI 10.1007/BF01871102; LUSTIG KD, 1993, P NATL ACAD SCI USA, V90, P5113, DOI 10.1073/pnas.90.11.5113; NAUMOV AP, 1992, FEBS LETT, V313, P285, DOI 10.1016/0014-5793(92)81210-D; NUTTLE LC, 1993, MOL PHARMACOL, V44, P93; PIZZO P, 1991, BIOCHEM J, V274, P139, DOI 10.1042/bj2740139; ROZENGURT E, 1975, BIOCHEM BIOPH RES CO, V67, P1581, DOI 10.1016/0006-291X(75)90207-7; ROZENGURT E, 1977, J BIOL CHEM, V252, P4584; SOLTOFF SP, 1992, AM J PHYSIOL, V262, pC934, DOI 10.1152/ajpcell.1992.262.4.C934; STEINBERG TH, 1987, J BIOL CHEM, V262, P8884; STEINBERG TH, 1991, CURR OPIN IMMUNOL, V3, P711; SUNG SSJ, 1985, J BIOL CHEM, V260, P3442; TATHAM PER, 1990, J GEN PHYSIOL, V95, P459, DOI 10.1085/jgp.95.3.459; WEBB TE, 1993, FEBS LETT, V324, P219, DOI 10.1016/0014-5793(93)81397-I; WHETTON AD, 1988, BIOCHEM BIOPH RES CO, V152, P1173, DOI 10.1016/S0006-291X(88)80408-X; WILEY JS, 1990, ARCH BIOCHEM BIOPHYS, V280, P263, DOI 10.1016/0003-9861(90)90328-V; WILEY JS, 1992, ARCH BIOCHEM BIOPHYS, V292, P411, DOI 10.1016/0003-9861(92)90010-T; WILEY JS, 1993, ARCH BIOCHEM BIOPHYS, V305, P54, DOI 10.1006/abbi.1993.1392	41	159	160	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13988	13996						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	7514597				2022-12-27	WOS:A1994NL60600042
J	SHANKAR, R; DELAMOTTE, CA; POPTIC, EJ; DICORLETO, PE				SHANKAR, R; DELAMOTTE, CA; POPTIC, EJ; DICORLETO, PE			THROMBIN RECEPTOR-ACTIVATING PEPTIDES DIFFERENTIALLY STIMULATE PLATELET-DERIVED GROWTH-FACTOR PRODUCTION, MONOCYTIC CELL-ADHESION, AND E-SELECTIN EXPRESSION IN HUMAN UMBILICAL VEIN ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE PLASMINOGEN-ACTIVATOR; PROSTACYCLIN PRODUCTION; TRANSCRIPTIONAL REGULATION; RELEASE; MECHANISM; PATHWAYS; PROTEIN; PDGF; REQUIREMENTS; FIBROBLASTS	Recent studies have shown that the synthetic peptides SFL LRN and SFL LRN PND KYEPF (thrombin receptor-activating peptides (TRAP)) derived from the deduced sequence of the new amino terminus of the cleaved thrombin receptor can mimic thrombin receptor activation, act as full agonists for platelet activation, and induce prostaglandin I-2 production as well as cytosolic Ca2+ increase in human umbilical vein endothelial cells (HUVEC). Here, we have compared the ability of these synthetic peptide ligands and thrombin to stimulate platelet-derived growth factor (PDGF) production by, and monocyte adhesion to, HUVEC. Thrombin (50 units/ ml) and TRAP (25 mu M) maximally stimulated monocyte adhesion. Furthermore, the stimulation of E-selectin cell surface expression and the steady-state E-selectin mRNA levels by thrombin and TRAP were comparable. Thrombin (50 units/ml) stimulated PDGF production 400% above the basal level in 24 h, whereas the 6-mer and 14-mer TRAP, even at 200 mu M, did not significantly stimulate PDGF production. Northern analysis, however, revealed that TRAP at 100 mu M stimulated PDGF-A and -B chain mRNA expression to a level similar to that induced by thrombin. These results suggest that activation of cell signaling by TRAP can mimic thrombin and is sufficient for the stimulation of monocyte adhesion to HUVEC; however, thrombin-stimulated PDGF production by HUVEC may require mechanisms in addition to the signaling events initiated by TRAP or may require the participation of a novel thrombin receptor.	LOYOLA UNIV, MED CTR, DEPT SURG, MAYWOOD, IL 60153 USA; CLEVELAND CLIN RES INST, DEPT CELL BIOL, CLEVELAND, OH 44196 USA	Loyola University Chicago; Cleveland Clinic Foundation	SHANKAR, R (corresponding author), LOYOLA UNIV, MED CTR, INST SHOCK TRAUMA, 2160 S 1ST AVE, MAYWOOD, IL 60153 USA.				NHLBI NIH HHS [HL 29582, HL 34727] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029582, R01HL034727] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARSHAVIT R, 1983, LAB INVEST, V49, P702; BARSHAVIT R, 1983, SCIENCE, V220, P728, DOI 10.1126/science.6836310; BARSHAVIT R, 1986, J CELL BIOCHEM, V32, P261, DOI 10.1002/jcb.240320403; BARTHA K, 1993, J BIOL CHEM, V268, P421; BOWENPOPE DF, 1989, J BIOL CHEM, V264, P2502; CARNEY DH, 1992, J CLIN INVEST, V89, P1469, DOI 10.1172/JCI115737; CARNEY DH, 1978, J CELL PHYSIOL, V95, P13, DOI 10.1002/jcp.1040950103; CHEN LB, 1976, EXP CELL RES, V101, P41, DOI 10.1016/0014-4827(76)90409-2; CHEN LB, 1975, P NATL ACAD SCI USA, V72, P131, DOI 10.1073/pnas.72.1.131; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DANIEL TO, 1987, J BIOL CHEM, V262, P11893; DANIEL TO, 1988, J BIOL CHEM, V263, P19815; DICORLETO PE, 1989, BIOCHEM J, V264, P71, DOI 10.1042/bj2640071; DICORLETO PE, 1983, P NATL ACAD SCI-BIOL, V80, P1919, DOI 10.1073/pnas.80.7.1919; DICORLETO PE, 1989, J IMMUNOL, V143, P3666; DICORLETO PE, 1985, J CLIN INVEST, V75, P1153, DOI 10.1172/JCI111810; EDIT JF, 1989, J CLIN INVEST, V84, P18; FENTON JW, 1988, SEMIN THROMB HEMOST, V14, P234, DOI 10.1055/s-2007-1002783; FITZGERALD DJ, 1989, P NATL ACAD SCI USA, V86, P7585, DOI 10.1073/pnas.86.19.7585; FUKUSHIMA M, 1989, INVEST OPHTH VIS SCI, V30, P1576; GELEHRTER TD, 1986, J CLIN INVEST, V77, P165, DOI 10.1172/JCI112271; HALLAM TJ, 1988, BIOCHEM J, V251, P243, DOI 10.1042/bj2510243; HARLAN JM, 1986, J CELL BIOL, V103, P1129, DOI 10.1083/jcb.103.3.1129; HELDIN CH, 1979, P NATL ACAD SCI USA, V76, P3722, DOI 10.1073/pnas.76.8.3722; JAFFE EA, 1987, HUM PATHOL, V18, P234, DOI 10.1016/S0046-8177(87)80005-9; KAVANAUGH WM, 1988, J BIOL CHEM, V263, P8470; LEVIN EG, 1984, J CLIN INVEST, V74, P1988, DOI 10.1172/JCI111620; MCNAMARA CA, 1993, J CLIN INVEST, V91, P94, DOI 10.1172/JCI116206; NGAIZA JR, 1991, BIOCHEM BIOPH RES CO, V179, P1656, DOI 10.1016/0006-291X(91)91765-5; PEREZRODRIGUEZ R, 1981, CELL BIOL INT REP, V5, P347, DOI 10.1016/0309-1651(81)90004-7; POHJANPELTO P, 1977, J CELL PHYSIOL, V91, P387, DOI 10.1002/jcp.1040910308; PRESCOTT SM, 1984, P NATL ACAD SCI-BIOL, V81, P3534, DOI 10.1073/pnas.81.11.3534; RAINES EW, 1992, J CELL BIOL, V116, P533, DOI 10.1083/jcb.116.2.533; RAINES EW, 1990, HDB EXPT PHARM 1, V95, P173; RASMUSSEN UB, 1991, FEBS LETT, V288, P123, DOI 10.1016/0014-5793(91)81017-3; SCARBOROUGH RM, 1992, J BIOL CHEM, V267, P13146; SCHINI VB, 1989, EUR J PHARMACOL, V165, P333, DOI 10.1016/0014-2999(89)90733-4; SHANKAR R, 1992, AM J PHYSIOL, V262, pC199, DOI 10.1152/ajpcell.1992.262.1.C199; SHANKAR R, 1992, J BIOL CHEM, V267, P9376; SHUMAN MA, 1986, ANN NY ACAD SCI, V485, P228, DOI 10.1111/j.1749-6632.1986.tb34585.x; SPORN LA, 1986, CELL, V46, P185, DOI 10.1016/0092-8674(86)90735-X; SUGAMA Y, 1992, J CELL BIOL, V119, P935, DOI 10.1083/jcb.119.4.935; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; VASSALLO RR, 1992, J BIOL CHEM, V267, P6081; VOURETCRAVIARI V, 1993, BIOCHEM J, V289, P209, DOI 10.1042/bj2890209; VOURETCRAVIARI V, 1992, MOL BIOL CELL, V3, P95, DOI 10.1091/mbc.3.1.95; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; WEKSLER BB, 1978, J CLIN INVEST, V62, P923, DOI 10.1172/JCI109220	49	100	102	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13936	13941						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	7514596				2022-12-27	WOS:A1994NL60600036
J	DAVIS, SJ; DAVIES, EA; BARCLAY, AN; DAENKE, S; BODIAN, DL; JONES, EY; STUART, DI; BUTTERS, TD; DWEK, RA; VANDERMERWE, PA				DAVIS, SJ; DAVIES, EA; BARCLAY, AN; DAENKE, S; BODIAN, DL; JONES, EY; STUART, DI; BUTTERS, TD; DWEK, RA; VANDERMERWE, PA			LIGAND-BINDING BY THE IMMUNOGLOBULIN SUPERFAMILY RECOGNITION MOLECULE CD2 IS GLYCOSYLATION-INDEPENDENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I HISTOCOMPATIBILITY ANTIGEN; CELL ERYTHROCYTE RECEPTOR; CRYSTAL-STRUCTURE; N-GLYCOSYLATION; 3-DIMENSIONAL STRUCTURE; GLYCOPROTEIN CD2; ADHESION DOMAIN; RIBONUCLEASE-B; SOLUBLE FORM; RAT CD2	The evolutionary success of the immunoglobulin superfamily (IgSF) is thought to reflect the ability of IgSF protein domains to form stable structural units. The role of glycosylation in stabilizing these domains is controversial, however. In this study a systematic analysis of the effect of glycosylation on the ligand-binding properties of the cell cell recognition molecule CD2, which consists of two IgSF domains, was undertaken. A form of human soluble CD2 (hsCD2) with single N-acetylglucosamine residues at each glycosylation site was produced by inhibiting glucosidase I with N-butyldeoxynojirimycin during expression in Chinese hamster ovary cells and digesting the expressed hsCD2 with endoglycosidase H. The ligand and antibody binding properties of this form of hsCD2 were indistinguishable from those of fully glycosylated hsCD2 as determined by surface plasmon resonance analyses. The protein also formed diffraction quality crystals and analysis of the 2.5-Angstrom resolution crystal structure indicated that the single N-acetylglucosamine residue present on domain 1 is unlikely to stabilize the ligand binding face of hsCD2. A second, fully deglycosylated form of hsCD2 also bound the ligand and antibodies although this form of the protein tended to aggregate. In contrast to the results of previous studies, the current data indicate that the structural integrity and ligand binding function of human CD2 are glycosylation-independent.	JOHN RADCLIFFE HOSP, NUFFIELD DEPT CLIN MED, DIV MOLEC SCI, OXFORD OX3 9DU, ENGLAND; UNIV OXFORD, OXFORD CTR MOLEC SCI, OXFORD OX1 3QU, ENGLAND; UNIV OXFORD, INST GLYCOBIOL, DEPT BIOCHEM, OXFORD OX1 3QU, ENGLAND	University of Oxford; University of Oxford; University of Oxford	DAVIS, SJ (corresponding author), UNIV OXFORD, SIR WILLIAM DUNN SCH PATHOL, MRC, CELLULAR IMMUNOL UNIT, S PARKS RD, OXFORD OX1 3RE, ENGLAND.		Jones, Yvonne/J-2293-2016; van der Merwe, P. Anton/F-8539-2011; Jones, Yvonne/N-8111-2019	Jones, Yvonne/0000-0002-3834-1893; Jones, Yvonne/0000-0002-3834-1893; Stuart, David/0000-0002-3426-4210; Daenke, Susan/0000-0003-3290-6627				ALLEN H, 1986, P NATL ACAD SCI USA, V83, P7447, DOI 10.1073/pnas.83.19.7447; AMZEL LM, 1979, ANNU REV BIOCHEM, V48, P961, DOI 10.1146/annurev.bi.48.070179.004525; ANDERSON MS, 1992, P NATL ACAD SCI USA, V89, P2282, DOI 10.1073/pnas.89.6.2282; ARULANANDAM ARN, 1993, P NATL ACAD SCI USA, V90, P11613, DOI 10.1073/pnas.90.24.11613; ARVIEUX J, 1988, ANTIBODIES PRACTICAL, P113; BARCLAY AN, 1992, LEUCOCYTE ANTIGEN FA, P13; BENJANNET S, 1993, BIOCHEM J, V294, P735, DOI 10.1042/bj2940735; BERMAN E, 1981, J BIOL CHEM, V256, P3853; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BODIAN DL, 1994, STRUCTURE, V2, P755, DOI 10.1016/S0969-2126(94)00076-X; BROCKBANK RL, 1990, BIOCHEMISTRY-US, V29, P5574, DOI 10.1021/bi00475a023; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BROWN MH, 1994, PROTEIN ENG, V7, P515, DOI 10.1093/protein/7.4.515; CICCARELLI E, 1993, EUR J BIOCHEM, V213, P271, DOI 10.1111/j.1432-1033.1993.tb17759.x; CYSTER JG, 1992, THESIS OXFORD U; DAVIS SJ, 1993, PROTEIN ENG, V6, P229, DOI 10.1093/protein/6.2.229; DAVIS SJ, 1993, BIOCHEM SOC T, V21, P952, DOI 10.1042/bst0210952; DRISCOLL PC, 1991, NATURE, V353, P762, DOI 10.1038/353762a0; DUSTIN ML, 1987, J EXP MED, V165, P677, DOI 10.1084/jem.165.3.677; JOAO HC, 1992, FEBS LETT, V307, P343, DOI 10.1016/0014-5793(92)80709-P; JONES EY, 1992, NATURE, V360, P232, DOI 10.1038/360232a0; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; KARLSSON GB, 1993, J BIOL CHEM, V268, P570; KATO K, 1992, J EXP MED, V176, P1241, DOI 10.1084/jem.176.5.1241; KILLEEN N, 1988, EMBO J, V7, P3087, DOI 10.1002/j.1460-2075.1988.tb03174.x; LAVER WG, 1990, CELL, V61, P553, DOI 10.1016/0092-8674(90)90464-P; LEAHY DJ, 1992, CELL, V68, P1145, DOI 10.1016/0092-8674(92)90085-Q; LOCH N, 1992, EUR J BIOCHEM, V210, P161, DOI 10.1111/j.1432-1033.1992.tb17404.x; MATHEW PA, 1993, J IMMUNOL, V151, P5328; PETERSON A, 1987, NATURE, V329, P842, DOI 10.1038/329842a0; RECNY MA, 1992, J BIOL CHEM, V267, P22428; RUDD PM, 1994, BIOCHEMISTRY-US, V33, P17, DOI 10.1021/bi00167a003; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SANDRIN MS, 1992, J IMMUNOL, V149, P1636; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SELVARAJ P, 1987, NATURE, V326, P400, DOI 10.1038/326400a0; SOMOZA C, 1993, J EXP MED, V178, P549, DOI 10.1084/jem.178.2.549; VANDERMERWE PA, 1993, EMBO J, V12, P4945, DOI 10.1002/j.1460-2075.1993.tb06188.x; VANDERMERWE PA, 1993, EUR J IMMUNOL, V23, P1373, DOI 10.1002/eji.1830230628; VANDERMERWE PA, 1994, BIOCHEMISTRY-US, V33, P10149, DOI 10.1021/bi00199a043; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WILLIAMS AF, 1987, IMMUNOL TODAY, V8, P298, DOI 10.1016/0167-5699(87)90016-8; WILLIAMS RL, 1987, J BIOL CHEM, V262, P16020; WITHKA JM, 1993, STRUCTURE, V1, P69, DOI 10.1016/0969-2126(93)90009-6; WOLFF HL, 1990, J IMMUNOL, V144, P1215; WONG YW, 1990, J EXP MED, V171, P2115, DOI 10.1084/jem.171.6.2115; WOODS RJ, 1994, NAT STRUCT BIOL, V1, P499, DOI 10.1038/nsb0894-499; WORMALD MR, 1991, EUR J BIOCHEM, V198, P131, DOI 10.1111/j.1432-1033.1991.tb15995.x; WYSS DF, 1993, BIOCHEMISTRY-US, V32, P10995, DOI 10.1021/bi00092a008; YANG B, 1993, J BIOL CHEM, V268, P7435	52	56	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					369	375		10.1074/jbc.270.1.369	http://dx.doi.org/10.1074/jbc.270.1.369			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7529232	hybrid			2022-12-27	WOS:A1995QA28700058
J	PYPE, S; SLEGERS, H; MOENS, L; MERLEVEDE, W; GORIS, J				PYPE, S; SLEGERS, H; MOENS, L; MERLEVEDE, W; GORIS, J			TYROSINE PHOSPHORYLATION OF A M(R) 38,000 A/B-TYPE HNRNP PROTEIN SELECTIVELY MODULATES ITS RNA-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; POLYSOMAL MESSENGER RIBONUCLEOPROTEINS; DROSOPHILA-MELANOGASTER; CRYPTOBIOTIC GASTRULAE; TERMINAL DOMAIN; XENOPUS-OOCYTES; CASEIN KINASE-2; ARTEMIA-SALINA; ACID; COMPLEXES	The M(r) 38,000 RNA-binding protein (P38) is the major component of translationally repressed messenger ribonucleoproteins in cryptobiotic gastrulae of the brine shrimp Artemia. Partial elucidation of the amino acid sequence of P38 reveals that it is homologous to A/B-type hnRNP proteins. This was confirmed by immunodetection with antibodies specific for A/B-type hnRNP proteins from Drosophila melanogaster. P38 can be phosphorylated in vitro by a src-related protein tyrosine kinase on multiple tyrosine residues located predominantly in the glycine-rich domain. Tyrosine phosphorylated P38 can be efficiently dephosphorylated by a specific protein tyrosine phosphatase (1B-like) and by protein phosphatase 2A activated by the phosphotyrosyl phosphatase activator. Tyrosine phosphorylation of P38 slightly influences its subsequent phosphorylation by casein kinase II. The latter phosphorylation site is located in the glycine-rich domain of P38. Two dimensional gel electrophoresis resolves P38 into multiple isoforms which shift to more acidic pi values after phosphorylation by protein tyrosine kinase or casein kinase II. From nitrocellulose filter binding and UV crosslinking analysis, evidence was obtained that tyrosine phosphorylation of P38 impairs its binding to poly(A) but not to poly(U). This demonstrates the involvement of tyrosine residues in polynucleotide-specific RNA binding that can be regulated by phosphorylation/dephosphorylation.	UNIV INSTELLING ANTWERPEN, DEPT BIOCHEM, B-2610 ANTWERP, BELGIUM; KATHOLIEKE UNIV LEUVEN, AFDELING BIOCHEM, B-3000 LOUVAIN, BELGIUM	University of Antwerp; KU Leuven								ALLEN G, 1989, LABORATORY TECHNIQUE, V9; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BARNETT SF, 1991, MOL CELL BIOL, V11, P864, DOI 10.1128/MCB.11.2.864; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURD CG, 1994, EMBO J, V13, P1197, DOI 10.1002/j.1460-2075.1994.tb06369.x; BURD CG, 1989, P NATL ACAD SCI USA, V86, P9788, DOI 10.1073/pnas.86.24.9788; BUVOLI M, 1990, NUCLEIC ACIDS RES, V18, P6595, DOI 10.1093/nar/18.22.6595; BUVOLI M, 1990, EMBO J, V9, P1229, DOI 10.1002/j.1460-2075.1990.tb08230.x; CASASFINET JR, 1991, J MOL BIOL, V221, P693, DOI 10.1016/0022-2836(91)80081-5; CAYLA X, 1990, BIOCHEMISTRY-US, V29, P658, DOI 10.1021/bi00455a010; CAYLA X, 1994, J BIOL CHEM, V269, P15668; CLEGG JS, 1980, BRINE SHRIMP ARTEMIA, V2, P12; COBIANCHI F, 1993, NUCLEIC ACIDS RES, V21, P949, DOI 10.1093/nar/21.4.949; CUMMINGS A, 1989, BIOCHIM BIOPHYS ACTA, V1014, P319, DOI 10.1016/0167-4889(89)90229-2; DEGROOT RP, 1993, EMBO J, V12, P3903, DOI 10.1002/j.1460-2075.1993.tb06068.x; DEHERDT E, 1984, EUR J BIOCHEM, V139, P155; DEHERDT E, 1983, EUR J BIOCHEM, V132, P623; DEHERDT E, 1982, EUR J BIOCHEM, V122, P453; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; GORG A, 1988, ELECTROPHORESIS, V9, P531, DOI 10.1002/elps.1150090913; HACCARD O, 1993, MOL REPROD DEV, V36, P96, DOI 10.1002/mrd.1080360114; HAMILTON BJ, 1993, J BIOL CHEM, V268, P8881; HAYNES SR, 1990, MOL CELL BIOL, V10, P316, DOI 10.1128/MCB.10.1.316; HENDRIX P, 1993, J BIOL CHEM, V268, P7330; HENDRIX P, 1989, ADV PROTEIN PHOSPHAT, V5, P593; HEUKESHOVEN J, 1988, ELECTROPHORESIS, V9, P28, DOI 10.1002/elps.1150090106; JESSUS C, 1991, DEVELOPMENT, V111, P813; KAY BK, 1990, P NATL ACAD SCI USA, V87, P1367, DOI 10.1073/pnas.87.4.1367; KELLEY RL, 1993, GENE DEV, V7, P948, DOI 10.1101/gad.7.6.948; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; KUMAR A, 1990, J BIOL CHEM, V265, P17094; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LITCHFIELD DW, 1993, MOL CELL BIOCHEM, V128, P187, DOI 10.1007/BF01076770; MARVIL DK, 1980, J BIOL CHEM, V255, P6466; MATUNIS EL, 1994, P NATL ACAD SCI USA, V91, P2781, DOI 10.1073/pnas.91.7.2781; MATUNIS EL, 1992, J CELL BIOL, V116, P257, DOI 10.1083/jcb.116.2.257; MATUNIS MJ, 1992, J CELL BIOL, V116, P245, DOI 10.1083/jcb.116.2.245; MAYRAND SH, 1993, P NATL ACAD SCI USA, V90, P7764, DOI 10.1073/pnas.90.16.7764; MEGGIO F, 1991, FEBS LETT, V279, P307, DOI 10.1016/0014-5793(91)80174-2; NAJBAUER J, 1993, J BIOL CHEM, V268, P10501; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; RAYCHAUDHURI G, 1992, MOL CELL BIOL, V12, P847, DOI 10.1128/MCB.12.2.847; Sambrook J, 1989, MOL CLONING LABORATO; Slegers H., 1989, P21; Smith K. C., 1976, PHOTOCHEM PHOTOBIOL, V2, P187; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; THOMAS JO, 1982, PROG NUCLEIC ACID RE, V27, P157, DOI 10.1016/S0079-6603(08)60600-5; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANFLETEREN JR, 1992, BIOTECHNIQUES, V12, P550; VANHOVE L, 1985, BIOCHEM BIOPH RES CO, V131, P1241, DOI 10.1016/0006-291X(85)90224-4; VANHOVE L, 1987, ARTEMIA RES ITS APPL, V2, P189	58	23	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31457	31465						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7527388				2022-12-27	WOS:A1994PX30300023
J	VITALE, N; DELOULME, JC; THIERSE, D; AUNIS, D; BADER, MF				VITALE, N; DELOULME, JC; THIERSE, D; AUNIS, D; BADER, MF			GAP-43 CONTROLS THE AVAILABILITY OF SECRETORY CHROMAFFIN GRANULES FOR REGULATED EXOCYTOSIS BY STIMULATING A GRANULE-ASSOCIATED G(O)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; GTP-BINDING PROTEINS; HETEROTRIMERIC G-PROTEIN; DYNAMIC FATTY ACYLATION; SUBSTRATE B-50 GAP-43; GROWTH CONE PROTEIN; SENSITIVE G-PROTEIN; GUANINE-NUCLEOTIDES; NORADRENALINE RELEASE; GOLGI MEMBRANES	Besides having a role in signal transduction, heterotrimeric G proteins may also be involved in membrane trafficking events as suggested by their presence in specific intracellular compartments. In chromaffin cells, G(alpha o) is associated with secretory organelles, and its activation inhibits exocytosis. Although plasma membrane-bound G proteins are activated by cell surface receptors, the intracellular proteins controlling organelle-associated G proteins are currently unknown. GAP-43, a neuronal protein enriched in axonal growth cones and presynaptic terminals, is one possible candidate since it can directly stimulate purified G(o). We have investigated the interaction of adrenal medullary GAP-43 with chromaffin granule-associated G(o) and its effect on catecholamine secretion. Cytosolic and depalmitoylated membrane-extracted GAP-43 were found to stimulate guanine nucleotide binding and exchange activity in chromaffin granule membranes. In permeabilized chromaffin cells, both forms of GAP-43 blocked calcium dependent exocytosis, and this effect was inhibited by specific antibodies against G(alpha o). A synthetic peptide corresponding to the GAP-43 domain that interacts with G(o) inhibited catecholamine secretion. This effect could be selectively reversed by the COOH-terminal peptide of G(alpha o). These results indicate that GAP-43 may be an endogenous pseudoreceptor for the secretory granule-bound form of G(o) and can thereby control calcium-regulated exocytosis in chromaffin cells.	INSERM,U338,F-67084 STRASBOURG,FRANCE; CNRS,UPR 417,NEUROBIOL ONTOGEN LAB,F-67084 STRASBOURG,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Deloulme, Jean Christophe/P-6858-2017; Bader, Marie-France/O-2098-2016; Dominique, Aunis/W-1419-2019; Vitale, Nicolas/G-5967-2014	Deloulme, Jean Christophe/0000-0002-2234-5865; Vitale, Nicolas/0000-0002-4752-4907				ALEXANDER KA, 1988, J BIOL CHEM, V263, P7544; ALI N, 1989, BIOCHEM J, V261, P905, DOI 10.1042/bj2610905; ARIDOR M, 1993, SCIENCE, V262, P1569, DOI 10.1126/science.7504324; AUDIGIER Y, 1988, J BIOL CHEM, V263, P16352; BADER MF, 1986, J BIOL CHEM, V261, P5777; Barr F A, 1992, Trends Cell Biol, V2, P91, DOI 10.1016/0962-8924(92)90001-4; BARR FA, 1991, FEBS LETT, V294, P239, DOI 10.1016/0014-5793(91)81438-E; BARROSO M, 1994, J CELL BIOL, V124, P83, DOI 10.1083/jcb.124.1.83; BARROWMAN MM, 1986, NATURE, V319, P504, DOI 10.1038/319504a0; BAUDIER J, 1989, J BIOL CHEM, V264, P1824; BENOWITZ LI, 1987, TRENDS NEUROSCI, V10, P527, DOI 10.1016/0166-2236(87)90135-4; BON S, 1990, EUR J BIOCHEM, V190, P221, DOI 10.1111/j.1432-1033.1990.tb15567.x; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CARTER LL, 1993, J CELL BIOL, V120, P37, DOI 10.1083/jcb.120.1.37; CIMLER BM, 1985, J BIOL CHEM, V260, P784; COLOMBO MI, 1992, SCIENCE, V255, P1695, DOI 10.1126/science.1348148; DEKKER LV, 1991, J NEUROCHEM, V56, P1146, DOI 10.1111/j.1471-4159.1991.tb11404.x; DEKKER LV, 1989, NATURE, V342, P74, DOI 10.1038/342074a0; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; ERCOLANI L, 1990, P NATL ACAD SCI USA, V87, P4635, DOI 10.1073/pnas.87.12.4635; FEDEROFF HJ, 1988, J BIOL CHEM, V263, P19290; FLODGAARD H, 1974, J BIOL CHEM, V249, P3465; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GOSLIN K, 1988, NATURE, V336, P672, DOI 10.1038/336672a0; GRANT NJ, 1992, EUR J NEUROSCI, V8, P1789; HASLAM RJ, 1984, FEBS LETT, V174, P90, DOI 10.1016/0014-5793(84)81084-4; HENS JJH, 1993, J NEUROCHEM, V61, P602; HENS JJH, 1993, J NEUROCHEM, V60, P1264, DOI 10.1111/j.1471-4159.1993.tb03286.x; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; HOWELL TW, 1987, J CELL BIOL, V105, P191, DOI 10.1083/jcb.105.1.191; HUANG EM, 1989, BIOCHIM BIOPHYS ACTA, V1011, P134, DOI 10.1016/0167-4889(89)90200-0; IRVINS KJ, 1993, J NEUROCHEM, V60, P626; JOCHEN A, 1991, BIOCHEM BIOPH RES CO, V177, P797, DOI 10.1016/0006-291X(91)91859-B; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KTISTAKIS NT, 1992, NATURE, V356, P344, DOI 10.1038/356344a0; LLEDO PM, 1992, NEURON, V8, P455, DOI 10.1016/0896-6273(92)90273-G; LOVINGER DM, 1985, BRAIN RES, V343, P137, DOI 10.1016/0006-8993(85)91167-9; LUINI A, 1990, J NEUROCHEM, V54, P30, DOI 10.1111/j.1471-4159.1990.tb13279.x; MAGEE AI, 1987, EMBO J, V6, P3353, DOI 10.1002/j.1460-2075.1987.tb02656.x; MILLIGAN G, 1988, BIOCHEM J, V255, P1; MONTMAYEUR JP, 1994, SCIENCE, V263, P95, DOI 10.1126/science.8272874; MUKAI H, 1992, J BIOL CHEM, V267, P16237; OHARAIMAIZUMI M, 1992, J NEUROCHEM, V58, P2275, DOI 10.1111/j.1471-4159.1992.tb10974.x; PIMPLIKAR SW, 1993, NATURE, V362, P456, DOI 10.1038/362456a0; ROUOT B, 1989, BIOCHEM J, V260, P307, DOI 10.1042/bj2600307; SCHULTZ AM, 1988, ANNU REV CELL BIOL, V4, P611, DOI 10.1146/annurev.cb.04.110188.003143; SCHWANINGER R, 1992, J CELL BIOL, V119, P1077, DOI 10.1083/jcb.119.5.1077; SILLEN LG, 1971, STABILITY CONSTANTS, V1; SKENE JHP, 1989, ANNU REV NEUROSCI, V12, P127, DOI 10.1146/annurev.ne.12.030189.001015; SKENE JHP, 1989, J CELL BIOL, V108, P613, DOI 10.1083/jcb.108.2.613; STAUFENBIEL M, 1986, P NATL ACAD SCI USA, V83, P318, DOI 10.1073/pnas.83.2.318; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; STRITTMATTER SM, 1991, J BIOL CHEM, V266, P22465; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; SUDO Y, 1992, EMBO J, V11, P2095, DOI 10.1002/j.1460-2075.1992.tb05268.x; TAYLOR CW, 1990, BIOCHEM J, V272, P1; TOUTANT M, 1987, FEBS LETT, V215, P339, DOI 10.1016/0014-5793(87)80174-6; VALLAR L, 1987, J BIOL CHEM, V262, P5049; VANHOOFF COM, 1988, J NEUROSCI, V8, P1789; VITALE N, 1993, J BIOL CHEM, V268, P14715; VITALE N, 1994, BIOCHEM J, V300, P217, DOI 10.1042/bj3000217; WEINGARTEN R, 1990, J BIOL CHEM, V265, P11044; ZUBER MX, 1989, NATURE, V341, P345, DOI 10.1038/341345a0	65	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30293	30298						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7527027				2022-12-27	WOS:A1994PU52500041
J	SMITH, M; HICKS, S; BAKER, K; MCCAULEY, R				SMITH, M; HICKS, S; BAKER, K; MCCAULEY, R			RUPTURE OF THE MITOCHONDRIAL OUTER-MEMBRANE IMPAIRS PORIN ASSEMBLY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN IMPORT; YEAST MITOCHONDRIA; INNER MEMBRANE; PRECURSOR PROTEINS; TRANSLOCATION; INSERTION; INVITRO; INTEGRATION; SITES	Outer membranes isolated from yeast mitochondria were capable mediating the in vitro insertion of porin. As with the outer membrane of intact mitochondria, the insertion was ATP-dependent, and the inserted porin was resistant to trypsin treatment after detergent solubilization. However, the extent of porin insertion into isolated outer membranes was much less per mg of outer membrane protein than with intact mitochondria. The greater efficiency of intact mitochondria was not due to contact site-mediated translocation as isolated contact sites were less able to insert porin than isolated outer membranes, and blockade of the contact site channel in intact mitochondria did not affect porin insertion. However, mitochondria that had been subjected to osmotic shock sufficient to rupture the outer membrane and deplete the contents of the intermembrane space (i.e. mitoplasts) lost most of their ability to insert porin. Since outer membranes are isolated from mitoplasts, the low insertion activity of mitoplasts explains the low efficiency of insertion into isolated outer membranes. These results also indicate that, unlike proteins that are imported to the inner membrane and matrix of the mitochondria, porin's assembly is severely reduced by breaching the outer membrane and depletion of the intermembrane space contents.	WAYNE STATE UNIV,DEPT PHARMACOL,DETROIT,MI 48201; GENENTECH INC,DEPT MOLEC BIOL,S SAN FRANCISCO,CA 94080	Wayne State University; Roche Holding; Genentech					FIC NIH HHS [1 FO6 TWO1363-01] Funding Source: Medline; NIMH NIH HHS [2 R24 MH47181-04] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [F06TW001363] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R24MH047181] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BAKER KP, 1990, NATURE, V348, P605, DOI 10.1038/348605a0; BOLLINGER L, EMBO J, V13, P2006; DAUM G, 1982, J BIOL CHEM, V257, P3028; DECKER GL, 1977, J ULTRA MOL STRUCT R, V59, P44, DOI 10.1016/S0022-5320(77)80027-0; FUJIKI M, 1991, J BIOL CHEM, V266, P6841; FUJIKI M, 1993, J BIOL CHEM, V268, P1914; GASSER SM, 1983, J BIOL CHEM, V258, P3427; HURT EC, 1985, EMBO J, V4, P3509, DOI 10.1002/j.1460-2075.1985.tb04110.x; HWANG ST, 1989, P NATL ACAD SCI USA, V86, P8432, DOI 10.1073/pnas.86.21.8432; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; LI JM, 1992, BIOCHIM BIOPHYS ACTA, V1106, P233, DOI 10.1016/0005-2736(92)90001-3; MAYER A, 1993, J CELL BIOL, V121, P1233, DOI 10.1083/jcb.121.6.1233; MIHARA K, 1982, P NATL ACAD SCI-BIOL, V79, P7102, DOI 10.1073/pnas.79.23.7102; NICCHITTA CV, 1993, CELL, V73, P989, DOI 10.1016/0092-8674(93)90276-V; OHBA M, 1987, EMBO J, V6, P2117, DOI 10.1002/j.1460-2075.1987.tb02478.x; ONO H, 1987, EUR J BIOCHEM, V168, P509, DOI 10.1111/j.1432-1033.1987.tb13447.x; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PON L, 1989, J CELL BIOL, V109, P2603, DOI 10.1083/jcb.109.6.2603; RIEZMAN H, 1983, EMBO J, V2, P1105, DOI 10.1002/j.1460-2075.1983.tb01553.x; ROWELY N, 1994, CELL, V77, P249; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; SCHLEYER M, 1985, CELL, V43, P339, DOI 10.1016/0092-8674(85)90039-X; SOLLNER T, 1992, NATURE, V355, P84, DOI 10.1038/355084a0; TIKHONOV VN, 1965, ZH ANAL KHIM, V20, P390; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0; VESTWEBER D, 1988, J CELL BIOL, V107, P2037, DOI 10.1083/jcb.107.6.2037; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; ZHUANG Z, 1989, J BIOL CHEM, V264, P14594; ZHUANG ZP, 1992, J BIOL CHEM, V267, P591	29	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28460	28464						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7525575				2022-12-27	WOS:A1994PV77200100
J	JARAMILLO, ML; AFAR, DEH; ALMAZAN, G; BELL, JC				JARAMILLO, ML; AFAR, DEH; ALMAZAN, G; BELL, JC			IDENTIFICATION OF TYROSINE-620 AS THE MAJOR PHOSPHORYLATION SITE OF MYELIN-ASSOCIATED GLYCOPROTEIN AND ITS IMPLICATION IN INTERACTING WITH SIGNALING MOLECULES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; PROTEIN-KINASE; DOMAINS; SH2; PHOSPHOTYROSINE; SUPERFAMILY; ISOFORMS; HOMOLOGY; RECEPTOR; BRAIN	Myelin-associated glycoprotein (MAG) is a myelin-specific cell adhesion molecule of the immunoglobulin supergene family and is tyrosine-phosphorylated in the developing brain. To define the role of MAG in signal transduction, the tyrosine phosphorylation sites were analyzed. The major tyrosine phosphorylation residue was identified as Tyr-620, which was found to interact specifically with the SH2 domains of phospholipase C (PLC gamma). This domain may represent a novel protein binding motif that can be regulated by tyrosine phosphorylation. MAG also specifically bound the Fyn tyrosine kinase, suggesting that MAG serves as a docking protein that allows the interaction between different signaling molecules.	UNIV OTTAWA, DEPT BIOCHEM, OTTAWA K1H 8M5, ON, CANADA; UNIV OTTAWA, DEPT MED, OTTAWA K1H 8M5, ON, CANADA; MCGILL UNIV, DEPT PHARMACOL & THERAPEUT, MONTREAL H3G 1Y6, PQ, CANADA	University of Ottawa; University of Ottawa; McGill University								AFAR DEH, 1990, J NEUROCHEM, V55, P1418, DOI 10.1111/j.1471-4159.1990.tb03155.x; AFAR DEH, 1991, J NEUROSCI RES, V29, P429, DOI 10.1002/jnr.490290403; ALMAZAN G, 1993, J NEUROSCI RES, V36, P163, DOI 10.1002/jnr.490360206; ARQUINT M, 1987, P NATL ACAD SCI USA, V84, P600, DOI 10.1073/pnas.84.2.600; BANIK NL, 1977, BIOCHEM J, V162, P247, DOI 10.1042/bj1620247; BROWN E, 1978, VIROLOGY, V89, P7, DOI 10.1016/0042-6822(78)90035-1; CLARK MR, 1994, EMBO J, V13, P1911, DOI 10.1002/j.1460-2075.1994.tb06460.x; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DEUSTACHIO P, 1988, J NEUROCHEM, V50, P589, DOI 10.1111/j.1471-4159.1988.tb02951.x; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; DULAC C, 1992, NEURON, V8, P323, DOI 10.1016/0896-6273(92)90298-R; EDWARDS AM, 1988, MOL CELL BIOL, V8, P2655, DOI 10.1128/MCB.8.6.2655; HIGGINS GA, 1989, P NATL ACAD SCI USA, V86, P2074, DOI 10.1073/pnas.86.6.2074; JOHNSON PW, 1989, NEURON, V3, P377, DOI 10.1016/0896-6273(89)90262-6; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAI C, 1987, P NATL ACAD SCI USA, V84, P4337, DOI 10.1073/pnas.84.12.4337; LUO K, 1990, ONCOGENE, V5, P921; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; PEDRAZA L, 1991, J NEUROSCI RES, V29, P141, DOI 10.1002/jnr.490290202; PERI KG, 1993, ONCOGENE, V8, P2765; PLEIMAN CM, 1994, P NATL ACAD SCI USA, V91, P4268, DOI 10.1073/pnas.91.10.4268; PLEIMAN CM, 1993, MOL CELL BIOL, V13, P5877, DOI 10.1128/MCB.13.9.5877; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; RUDD CE, 1993, BIOCHIM BIOPHYS ACTA, V1155, P239, DOI 10.1016/0304-419X(93)90007-Y; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SALZER JL, 1987, J CELL BIOL, V104, P957, DOI 10.1083/jcb.104.4.957; TROPAK MB, 1988, MOL BRAIN RES, V4, P143, DOI 10.1016/0169-328X(88)90006-X; UMEMORI H, 1994, NATURE, V367, P572, DOI 10.1038/367572a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	31	50	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27240	27245						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7525550				2022-12-27	WOS:A1994PV77100016
J	TATE, CG; BLAKELY, RD				TATE, CG; BLAKELY, RD			THE EFFECT OF N-LINKED GLYCOSYLATION ON ACTIVITY OF THE NA+-DEPENDENT AND CL--DEPENDENT SEROTONIN TRANSPORTER EXPRESSED USING RECOMBINANT BACULOVIRUS IN INSECT CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINOBUTYRIC-ACID TRANSPORTER; PLATELET PLASMA-MEMBRANE; HUMAN-BLOOD-PLATELETS; PARTIAL-PURIFICATION; 5-HYDROXYTRYPTAMINE TRANSPORTER; NEUROTRANSMITTER TRANSPORTERS; AFFINITY-CHROMATOGRAPHY; FUNCTIONAL EXPRESSION; PROJECTION STRUCTURE; GLUCOSE-TRANSPORTER	The rat Na+- and Cl--dependent serotonin transporter was expressed in Sf9 insect cells using the baculovirus system. Expression of the serotonin transporter caused the Sf9 cells to accumulate [H-3]serotonin (K-m 78 nM) and to bind the specific transport inhibitor [I-125]RTI55 (2 beta-carbomethoxy-3 beta-(4- [I-125]iodophenyl)tropane) (K-d 0.22 nM). Ligand binding assays on isolated membranes showed 500,000 copies of the serotonin transporter/cell (9 pmol/mg of membrane protein). Immunoreactive bands of apparent M(r) 54,000 (unglycosylated) and 60,000 (glycosylated) were observed in Western blots of membrane proteins from infected cells. The 54-kDa band was significantly smaller than the expected M(r) of 72,500 predicted from the cDNA sequence. The 54-kDa band was shown to represent the intact serotonin transporter by expressing a recombinant serotonin transporter that contained c-Myc and FLAG epitope tags engineered at the N and C termini, respectively. Both tags were present on a membrane protein that migrated slightly slower than the previously observed 54-kDa band, consistent with the extra mass added by the tags. The tags did not affect the K-d for [I-125]RTI55 binding. The effect of N-linked glycosylation on ligand binding and the level of expression were studied. The expression of the serotonin transporter in tunicamycin-treated Sf9 cells resulted in low levels of ligand binding activity (0.2 pmol/mg) but unchanged K-d. Similarly, mutated serotonin transporters that contained reduced numbers of N-linked glycosylation sites had unchanged K-d for [I-125]RTI55 binding whether there were 2, 1, or 0 N-linked glycosylation sites present on the serotonin transporter. In contrast, B-max was dramatically reduced; levels of expression of the unglycosylated serotonin transporter (0.4 pmol/mg) were 20-fold lower compared with levels of the fully glycosylated serotonin transporter. The K-m for [H-3]serotonin uptake was also unchanged. These data indicate that glycosylation is required for optimal stability of the serotonin transporter in the membrane but not for serotonin transport or ligand binding per se.	EMORY UNIV, SCH MED, DEPT ANAT & CELL BIOL, ATLANTA, GA 30322 USA	Emory University	TATE, CG (corresponding author), MRC, MOLEC BIOL LAB, HILLS RD, CAMBRIDGE CB2 2QH, ENGLAND.			Tate, Christopher/0000-0002-2008-9183	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA007390] Funding Source: NIH RePORTER; NIDA NIH HHS [DA 07390] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		BALKOVETZ DF, 1989, J BIOL CHEM, V264, P2195; BENDAHAN A, 1993, FEBS LETT, V318, P41, DOI 10.1016/0014-5793(93)81323-R; BIESSEN EAL, 1990, BIOCHEMISTRY-US, V29, P3349, DOI 10.1021/bi00465a029; BLAKELY RD, 1993, SOC GEN PHY, V48, P283; BLAKELY RD, 1991, ANAL BIOCHEM, V194, P302, DOI 10.1016/0003-2697(91)90233-J; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; CLARK JA, 1993, BIOESSAYS, V15, P323, DOI 10.1002/bies.950150506; CONSLER TG, 1993, P NATL ACAD SCI USA, V90, P6934, DOI 10.1073/pnas.90.15.6934; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FRASER MJ, 1992, CURR TOP MICROBIOL, V158, P131; GRAHAM D, 1992, BIOCHEM J, V286, P801, DOI 10.1042/bj2860801; GU H, 1994, J BIOL CHEM, V269, P7124; HAVELKA WA, 1993, J MOL BIOL, V234, P837, DOI 10.1006/jmbi.1993.1629; HOFFMAN BJ, 1991, SCIENCE, V254, P579, DOI 10.1126/science.1948036; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; JAP BK, 1992, ULTRAMICROSCOPY, V46, P45, DOI 10.1016/0304-3991(92)90007-7; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KANNER BI, 1989, BIOCHEMISTRY-US, V28, P3722, DOI 10.1021/bi00435a015; KEYNAN S, 1992, BIOCHEMISTRY-US, V31, P1974, DOI 10.1021/bi00122a011; KITAYAMA S, 1992, P NATL ACAD SCI USA, V89, P7782, DOI 10.1073/pnas.89.16.7782; KLAIBER K, 1990, NEURON, V5, P221, DOI 10.1016/0896-6273(90)90311-3; KLEINBERGERDORON N, 1994, J BIOL CHEM, V269, P3063; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KUHLBRANDT W, 1992, Q REV BIOPHYS, V25, P1; LAUNAY JM, 1992, J BIOL CHEM, V267, P11344; LODDENKOTTER B, 1993, P NATL ACAD SCI USA, V90, P2155, DOI 10.1073/pnas.90.6.2155; MARCUSSON JO, 1990, PSYCHOPHARMACOLOGY, V102, P145, DOI 10.1007/BF02245915; MATZUK MM, 1988, J CELL BIOL, V106, P1049, DOI 10.1083/jcb.106.4.1049; MCPHERSON GA, 1985, J PHARMACOL METHOD, V14, P213, DOI 10.1016/0160-5402(85)90034-8; MELIKIAN HE, 1994, J BIOL CHEM, V269, P12290; MELIKIAN HE, 1993, SOC NEUR ABSTR, V19; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; OMURA F, 1992, EUR J BIOCHEM, V210, P591, DOI 10.1111/j.1432-1033.1992.tb17459.x; PANTANOWITZ S, 1993, J BIOL CHEM, V268, P3222; RAMAMOORTHY S, 1993, P NATL ACAD SCI USA, V90, P2542, DOI 10.1073/pnas.90.6.2542; RAMAMOORTHY S, 1993, J BIOL CHEM, V268, P21626; RAMAMOORTHY S, 1992, BIOCHEM J, V286, P89, DOI 10.1042/bj2860089; RAMAMOORTHY S, 1993, PLACENTA, V14, P449, DOI 10.1016/S0143-4004(05)80465-5; RANDS E, 1990, J BIOL CHEM, V265, P10759; REHAVI M, 1982, FEBS LETT, V150, P514, DOI 10.1016/0014-5793(82)80802-8; RUDNICK G, 1977, J BIOL CHEM, V252, P2170; RUDNICK G, 1993, BIOCHIM BIOPHYS ACTA, V1144, P249, DOI 10.1016/0005-2728(93)90109-S; RUDNICK G, 1992, P NATL ACAD SCI USA, V89, P1817, DOI 10.1073/pnas.89.5.1817; Sambrook J, 1989, MOL CLONING LABORATO; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; Schertler G. F. X., 1992, CURR OPIN STRUC BIOL, V2, P534, DOI DOI 10.1016/0959-440X(92)90083-J; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; Summers MD, 1987, MANUAL METHODS BACUL; TALVENHEIMO J, 1980, J BIOL CHEM, V255, P8606; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TOYOSHIMA C, 1993, NATURE, V362, P469, DOI 10.1038/362469a0; UHL GR, 1992, TRENDS NEUROSCI, V15, P265, DOI 10.1016/0166-2236(92)90068-J; WAEBER U, 1993, FEBS LETT, V324, P109, DOI 10.1016/0014-5793(93)81542-8; WALL SC, 1993, MOL PHARMACOL, V43, P264; WOLF WA, 1992, J BIOL CHEM, V267, P20820; YI CK, 1992, BIOCHEM J, V283, P643, DOI 10.1042/bj2830643	57	157	160	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26303	26310						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7523405				2022-12-27	WOS:A1994PQ93000057
J	HENSLEY, P; MCDEVITT, PJ; BROOKS, I; TRILL, JJ; FEILD, JA; MCNULTY, DE; CONNOR, JR; GRISWOLD, DE; KUMAR, NV; KOPPLE, KD; CARR, SA; DALTON, BJ; JOHANSON, K				HENSLEY, P; MCDEVITT, PJ; BROOKS, I; TRILL, JJ; FEILD, JA; MCNULTY, DE; CONNOR, JR; GRISWOLD, DE; KUMAR, NV; KOPPLE, KD; CARR, SA; DALTON, BJ; JOHANSON, K			THE SOLUBLE FORM OF E-SELECTIN IS AN ASYMMETRIC MONOMER - EXPRESSION, PURIFICATION, AND CHARACTERIZATION OF THE RECOMBINANT PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE ADHESION MOLECULE-1; SIALYL LEWIS-X; ENDOTHELIAL-CELLS; POLYACRYLAMIDE GELS; T-CELLS; CUTANEOUS INFLAMMATION; ELAM-1; BINDING; NEUTROPHILS; LIGANDS	The gene coding for a soluble form of human E-selectin (sE-selectin) has been expressed in Chinese hamster ovary (CHO) cells. Cells seeded into a hollow fiber reactor secreted protein at a level of 160 mg/liter. The protein was purified to >95% pure and low endotoxin (<2 ng/mg), using physiological pH and buffers. The amino acid composition and N-terminal sequence were as predicted from the cDNA sequence. HL-60 cells bound to sE-selectin-coated plates in a dose dependent manner, and this binding could be blocked up to 100% by pretreatment of HL60 cells with sE-selectin. The concentration of sE-selectin required for 50% inhibition was 1 mu M. This value puts an upper limit for the affinity of E-selectin for its natural receptor. sE-selectin also inhibited inflammatory migration of neutrophils in a selective fashion. Purified sE-selectin exhibited a broad band of M(r) similar to 75,000 on nonreducing SDS-PAGE. sE-selectin eluted with M(r) similar to 310,000 from size exclusion chromatography at physiological pH and buffers, suggesting an oligomeric state. Matrix-assisted laser-desorption MS gave a molecular weight of 80,000, while the minimum monomer molecular weight from the gene sequence should be 58,571, demonstrating that the monomeric molecule thus expressed had 27% carbohydrate. Equilibrium analytical ultracentrifugation gave an average solution molecular weight of 81,600 (+/- 4,500). Velocity ultracentrifugation gave a sedimentation coefficient of 4.3 S and, from this, an apparent axial ratio of 10.5:1, assuming a prolate ellipsoid of revolution. An analysis of the NMR NOESY spectra of sE-selectin, sialyl-lewis X, and sE-selectin with sialyl-Lewis X demonstrates that the recombinant protein binds sialyl-Lewis X productively. Hence, in solution, sE-selectin is a functional elongated monomer.	SMITHKLINE BEECHAM PHARMACEUT,DEPT PROT BIOCHEM,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT GENE EXPRESS SCI,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT CELLULAR BIOCHEM,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT INFLAMMAT & RESP PHARMACOL,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT PHYS & STRUCT CHEM,KING OF PRUSSIA,PA 19406	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	HENSLEY, P (corresponding author), SMITHKLINE BEECHAM PHARMACEUT,DEPT MACROMOLEC SCI UE0447B,709 SWEDELAND RD,KING OF PRUSSIA,PA 19406, USA.		Brooks, Ian/AAI-2571-2021; Carr, Steven A./AAH-8366-2019; Brooks, Ian/E-7052-2010	Brooks, Ian/0000-0002-3793-3635				ANDREWS P, 1964, BIOCHEM J, V91, P222, DOI 10.1042/bj0910222; ATHERTON A, 1972, J PHYSIOL-LONDON, V222, P447, DOI 10.1113/jphysiol.1972.sp009808; BALL GE, 1992, J AM CHEM SOC, V114, P5449, DOI 10.1021/ja00039a080; BEVILACQUA M, 1991, CELL, V67, P233, DOI 10.1016/0092-8674(91)90174-W; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BOCHNER BS, 1991, J EXP MED, V173, P1553, DOI 10.1084/jem.173.6.1553; BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462; BROOKS I, 1994, IN PRESS METHODS ENZ, V240; BROOKS L, 1994, MODERN ANAL ULTRACEN, P15; CALTABIANO MM, 1989, GENE, V85, P479, DOI 10.1016/0378-1119(89)90442-3; CAMPBELL AP, 1991, J MAGN RESON, V93, P77, DOI 10.1016/0022-2364(91)90033-P; CAMPBELL AP, 1993, ANNU REV BIOPH BIOM, V22, P99, DOI 10.1146/annurev.bb.22.060193.000531; CANTOR CR, 1980, BIOPHYSICAL CHEM 2, P557; CARLOS T, 1991, BLOOD, V77, P2266; CLORE GM, 1982, J MAGN RESON, V48, P402, DOI 10.1016/0022-2364(82)90073-7; CRUMMEY A, 1987, AGENTS ACTIONS, V20, P69, DOI 10.1007/BF01965627; GIMBRONE MA, 1989, SCIENCE, V246, P1601, DOI 10.1126/science.2688092; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; GRABER N, 1990, J IMMUNOL, V145, P819; GRISWOLD DE, 1991, BIOCHEM PHARMACOL, V42, P825, DOI 10.1016/0006-2952(91)90042-4; GRISWOLD DE, 1993, INFLAMMATION, V17, P333, DOI 10.1007/BF00918994; HENSLEY P, 1986, J BIOL CHEM, V261, P1038; HESSION C, 1990, P NATL ACAD SCI USA, V87, P1673, DOI 10.1073/pnas.87.5.1673; JOHNSON ML, 1992, METHOD ENZYMOL, V210, P1; JOHNSON ML, 1985, METHOD ENZYMOL, V117, P301; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; Kuntz I D Jr, 1974, Adv Protein Chem, V28, P239, DOI 10.1016/S0065-3233(08)60232-6; KYANAUNG U, 1991, J IMMUNOL, V146, P521; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LIN YC, 1992, J AM CHEM SOC, V114, P5452, DOI 10.1021/ja00039a082; LOBB RR, 1991, J IMMUNOL, V147, P124; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MILLER KE, 1992, BIOCHEMISTRY-US, V31, P6703, DOI 10.1021/bi00144a009; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MUKHOPADHYAY C, 1994, BIOPOLYMERS, V34, P21, DOI 10.1002/bip.360340104; MURAMATSU N, 1988, ANAL BIOCHEM, V168, P345, DOI 10.1016/0003-2697(88)90328-4; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; PICKER LJ, 1991, NATURE, V349, P796, DOI 10.1038/349796a0; PLAMBLAD JEW, 1992, CLIN EXP IMMUNOL, V90, P300; SHIMIZU Y, 1991, NATURE, V349, P799, DOI 10.1038/349799a0; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; SKINNER MP, 1991, J BIOL CHEM, V266, P5371; STECK G, 1980, ANAL BIOCHEM, V107, P21, DOI 10.1016/0003-2697(80)90486-8; Teller D C, 1979, Methods Enzymol, V61, P103; TINOCO I, 1978, PHYSICAL CHEM, P212; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRILL JJ, 1990, FIBRINOLYSIS, V4, P131, DOI 10.1016/S0268-9499(05)80044-X; URLAUB G, 1983, CELL, V33, P405, DOI 10.1016/0092-8674(83)90422-1; USHIYAMA S, 1993, J BIOL CHEM, V268, P15229; VONANDRIAN UH, 1991, P NATL ACAD SCI USA, V88, P7538, DOI 10.1073/pnas.88.17.7538; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WELLICOME SM, 1990, J IMMUNOL, V144, P2558; WHITAKER JR, 1963, ANAL CHEM, V35, P1950, DOI 10.1021/ac60205a048; WORMALD MR, 1991, BIOCHEM BIOPH RES CO, V180, P1214, DOI 10.1016/S0006-291X(05)81325-7; Zamyatnin A A, 1972, Prog Biophys Mol Biol, V24, P107, DOI 10.1016/0079-6107(72)90005-3	59	60	60	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					23949	23958						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7523364				2022-12-27	WOS:A1994PQ34600018
J	MIZRAHI, V; BROOKSBANK, RL; NKABINDE, NC				MIZRAHI, V; BROOKSBANK, RL; NKABINDE, NC			MUTAGENESIS OF THE CONSERVED ASPARTIC-ACID-443, GLUTAMIC-ACID-478, ASPARAGINE-494, AND ASPARTIC-ACID-498 RESIDUES IN THE RIBONUCLEASE H-DOMAIN OF P66/P51 HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-I REVERSE-TRANSCRIPTASE - EXPRESSION AND BIOCHEMICAL-ANALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; DNA-POLYMERASE-I; ESCHERICHIA-COLI; RNASE-H; ACTIVE-SITE; AMINO-ACID; CRYSTAL-STRUCTURE; ANGSTROM RESOLUTION; 3'-5' EXONUCLEASE; MUTATIONS	The effects of point mutations of the conserved Asp(445), Glu(478), Asn(494) and Asp(498) residues in the RNase H domain of human immunodeficiency virus type I (HIV-1) reverse transcriptase (RT) have been analyzed. The mutants fell into two classes: (i) functional RT, but no detectable ribonuclease H activity, and (ii) uncharacterizable phenotype due to protein instability in the context of the RT/protease Escherichia coli co-expression system (Mizrahi, V., Lazarus, G;. M., Miles, L. M., Meyers, C. A., and Debouck, C. (1989) Arch. Biochem. Biophys. 273, 347-358). The only mutation in the former class was D443A, whereas those in the latter included D443E, E478D, E478Q, D498E, D443A/D498N, D443E/D498N, D443Q/ D498N, N494A, N494D, and N494Q. The results were interpreted in terms of the x-ray crystal structure of the HIV-1 RNase H domain (Davies, J.F., II, Hostomska, Z., Hostomsky, Z., Jordan, S.R., and Matthews, D.A. (1991) Science 252, 88-95) and a general acid general base hydrolysis mechanism (Katayanagi, K., Okumura, M., and Morikawa, K. (1993) Proteins Struct. Funct. Genet 17, 337-346). The data suggested that structural perturbations within the RNase H domain interfered with maturation of the pol precursor by HIV-1 protease. Analysis of selected D443/D498 double mutants suggested that the destabilization caused by the D498N mutation could be suppressed by the formation of a new hydrogen bond between Asn(498) and Asn(443).	UNIV WITWATERSRAND, SCH MED, DEPT HAEMATOL, JOHANNESBURG 2000, SOUTH AFRICA	University of Witwatersrand	MIZRAHI, V (corresponding author), UNIV WITWATERSRAND, SCH MED, S AFRICAN INST MED RES, MOLEC BIOL UNIT, POB 1038, JOHANNESBURG 2000, SOUTH AFRICA.							ARNOLD E, 1992, NATURE, V357, P85, DOI 10.1038/357085a0; BECERRA SP, 1990, FEBS LETT, V270, P76, DOI 10.1016/0014-5793(90)81238-J; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; DERBYSHIRE V, 1991, EMBO J, V10, P17, DOI 10.1002/j.1460-2075.1991.tb07916.x; DUDDING LR, 1990, BIOCHEM BIOPH RES CO, V167, P244, DOI 10.1016/0006-291X(90)91757-J; DUDDING LR, 1993, BIOCHEMISTRY-US, V32, P6116, DOI 10.1021/bi00074a025; DUDDING LR, 1991, BIOCHEMISTRY-US, V30, P10498, DOI 10.1021/bi00107a019; GRAVES MC, 1990, BIOCHEM BIOPH RES CO, V168, P30, DOI 10.1016/0006-291X(90)91670-N; HANSEN J, 1988, EMBO J, V7, P239, DOI 10.1002/j.1460-2075.1988.tb02805.x; HANSEN J, 1987, J BIOL CHEM, V262, P12393; HOSTOMSKY Z, 1991, P NATL ACAD SCI USA, V88, P1148, DOI 10.1073/pnas.88.4.1148; JACOBOMOLINA A, 1991, BIOCHEMISTRY-US, V30, P6351, DOI 10.1021/bi00240a001; KANAYA S, 1990, J BIOL CHEM, V265, P4615; KATAYANAGI K, 1993, PROTEINS, V17, P337, DOI 10.1002/prot.340170402; KATAYANAGI K, 1992, J MOL BIOL, V223, P1029, DOI 10.1016/0022-2836(92)90260-Q; KATAYANAGI K, 1990, NATURE, V347, P306, DOI 10.1038/347306a0; KATAYANAGI K, 1993, J BIOL CHEM, V268, P22092; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LEGRICE SFJ, 1989, J BIOL CHEM, V264, P14902; LIGHTFOOTE MM, 1986, J VIROL, V60, P771, DOI 10.1128/JVI.60.2.771-775.1986; MIZRAHI V, 1989, ARCH BIOCHEM BIOPHYS, V273, P347, DOI 10.1016/0003-9861(89)90493-1; MIZRAHI V, 1990, NUCLEIC ACIDS RES, V18, P5359, DOI 10.1093/nar/18.18.5359; PICCIRILLI JA, 1993, NATURE, V361, P85, DOI 10.1038/361085a0; POWERS R, 1992, BIOCHEMISTRY-US, V31, P9150, DOI 10.1021/bi00153a006; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; SCHATZ O, 1989, FEBS LETT, V257, P311, DOI 10.1016/0014-5793(89)81559-5; TANESE N, 1988, P NATL ACAD SCI USA, V85, P1777, DOI 10.1073/pnas.85.6.1777; TISDALE M, 1991, J GEN VIROL, V72, P59, DOI 10.1099/0022-1317-72-1-59; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504; VOLKMANN S, 1993, J BIOL CHEM, V268, P2674; WOHRL BM, 1991, J MOL BIOL, V220, P801, DOI 10.1016/0022-2836(91)90119-Q; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648	33	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19245	19249						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	7518454				2022-12-27	WOS:A1994NY33200010
J	RANDOLPH, CA; CHAMPOUX, JJ				RANDOLPH, CA; CHAMPOUX, JJ			THE USE OF DNA AND RNA OLIGONUCLEOTIDES IN HYBRID STRUCTURES WITH LONGER POLYNUCLEOTIDE CHAINS TO PROBE THE STRUCTURAL REQUIREMENTS FOR MOLONEY MURINE LEUKEMIA-VIRUS PLUS STRAND PRIMING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TYPE-1 REVERSE-TRANSCRIPTASE; SEQUENCE FEATURES IMPORTANT; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; RIBONUCLEASE H; INTEGRATION; INITIATION; TEMPLATE; PRIMER	Plus strand priming during retroviral reverse transcription requires specific cleavage within the polypurine tract of the viral genome by the reverse transcriptase-associated RNase H. Previously it has been shown that a 190-base RNA-DNA hybrid containing the Moloney murine leukemia virus polypurine tract can serve as a substrate for the priming reaction. To investigate the structural requirements for the reaction, a series of DNA oligonucleotides was hybridized to the 190-base single stranded RNA and tested as substrates for RNase H. At low enzyme concentrations, the sites of cleavage are located 17-23 nucleotides from the 3'-end of the DNA oligonucleotide, consistent with the observations of others that binding of the DNA polymerase at a primer terminus fixes the position of cleavage by RNase H. At higher enzyme concentrations, additional cleavages are observed in the RNA 3' of these sites, but there is no preference for cleavage at the plus strand origin. In contrast to the results with DNA oligonucleotides, hybridization of RNA oligonucleotides containing the polypurine tract to the 190-base single stranded DNA generates substrates that are cleaved at the origin and efficiently extended into DNA. An RNA oligonucleotide hybridized downstream of the polypurine tract is cleaved but not extended. These results support the view that RNase H cleavage to generate the plus strand primer is uncoupled from minus strand DNA synthesis.	UNIV WASHINGTON,SCH MED,DEPT MICROBIOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NCI NIH HHS [CA51605] Funding Source: Medline; NIGMS NIH HHS [T32 GM07270] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA051605, R01CA051605] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007270] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BEEN MD, 1983, METHOD ENZYMOL, V101, P90; BENARTZI H, 1993, J BIOL CHEM, V268, P16465; BROWN PO, 1989, P NATL ACAD SCI USA, V86, P2525, DOI 10.1073/pnas.86.8.2525; CHAMPOUX JJ, 1993, REVERSE TRANSCRIPTAS, P103; COLICELLI J, 1985, CELL, V42, P573, DOI 10.1016/0092-8674(85)90114-X; DESTEFANO JJ, 1991, J BIOL CHEM, V266, P7423; DESTEFANO JJ, 1993, NUCLEIC ACIDS RES, V21, P4330, DOI 10.1093/nar/21.18.4330; FINSTON WI, 1984, J VIROL, V51, P26, DOI 10.1128/JVI.51.1.26-33.1984; FU TB, 1992, J VIROL, V66, P4271, DOI 10.1128/JVI.66.7.4271-4278.1992; FURFINE ES, 1991, J BIOL CHEM, V266, P406; GILBOA E, 1979, CELL, V18, P93, DOI 10.1016/0092-8674(79)90357-X; GRANDGENETT DP, 1990, CELL, V60, P3, DOI 10.1016/0092-8674(90)90707-L; HUBER HE, 1990, J BIOL CHEM, V265, P10565; HUBER HE, 1989, J BIOL CHEM, V264, P4669; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LEHMAN IR, 1981, ENZYMES, V14, P51; LUO GX, 1990, J VIROL, V64, P592, DOI 10.1128/JVI.64.2.592-597.1990; METZGER W, 1993, P NATL ACAD SCI USA, V90, P5909, DOI 10.1073/pnas.90.13.5909; OYAMA F, 1989, J BIOL CHEM, V264, P18808; PANGANIBAN AT, 1983, NATURE, V306, P155, DOI 10.1038/306155a0; PULLEN KA, 1993, J BIOL CHEM, V268, P6221; PULLEN KA, 1990, J VIROL, V64, P6274, DOI 10.1128/JVI.64.12.6274-6277.1990; RATTRAY AJ, 1989, J MOL BIOL, V208, P445, DOI 10.1016/0022-2836(89)90508-1; RATTRAY AJ, 1987, J VIROL, V61, P2843, DOI 10.1128/JVI.61.9.2843-2851.1987; REARDON JE, 1991, J BIOL CHEM, V266, P14128; RESNICK R, 1984, J VIROL, V51, P813, DOI 10.1128/JVI.51.3.813-821.1984; RICCHETTI M, 1993, EMBO J, V12, P387, DOI 10.1002/j.1460-2075.1993.tb05670.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHATZ O, 1990, EMBO J, V9, P1171, DOI 10.1002/j.1460-2075.1990.tb08224.x; SHINNICK TM, 1981, NATURE, V293, P543, DOI 10.1038/293543a0; SKALKA A, 1993, REVERSE TRANSCRIPTAS; SMITH JK, 1984, J VIROL, V52, P314, DOI 10.1128/JVI.52.2.314-319.1984; TANESE N, 1991, J VIROL, V65, P4387, DOI 10.1128/JVI.65.8.4387-4397.1991; TELESNITSKY A, 1993, EMBO J, V12, P4433, DOI 10.1002/j.1460-2075.1993.tb06128.x; TELESNITSKY A, 1993, P NATL ACAD SCI USA, V90, P1276, DOI 10.1073/pnas.90.4.1276; VARMUS H, 1989, MOBILE DNA, P53; WILLIAMS KJ, 1990, J BIOL CHEM, V265, P18682; WOHRL BM, 1990, BIOCHEMISTRY-US, V29, P10141, DOI 10.1021/bi00496a001	40	28	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19207	19215						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	7518453				2022-12-27	WOS:A1994NY33200005
J	BU, GJ; MAKSYMOVITCH, EA; NERBONNE, JM; SCHWARTZ, AL				BU, GJ; MAKSYMOVITCH, EA; NERBONNE, JM; SCHWARTZ, AL			EXPRESSION AND FUNCTION OF THE LOW-DENSITY-LIPOPROTEIN RECEPTOR-RELATED PROTEIN (LRP) IN MAMMALIAN CENTRAL NEURONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATOR INHIBITOR TYPE-1; LONG-TERM POTENTIATION; PLASMINOGEN-ACTIVATOR; ALPHA-2-MACROGLOBULIN RECEPTOR; INSITU HYBRIDIZATION; APOLIPOPROTEIN-E; MEDIATED ENDOCYTOSIS; ALZHEIMERS-DISEASE; 39-KDA PROTEIN; NERVOUS-SYSTEM	The low density lipoprotein receptor-related protein (LRP) is a multifunctional cell surface receptor, expressed in liver, that binds with high affinity and endocytoses several structurally and functionally distinct ligands, including apolipoprotein E-activated beta-migrating very low density lipoprotein, tissue-type plasminogen activator, and alpha(2)-macroglobulin. Here using in situ hybridization and quantitative RNase protection assays, we show that LRP is also expressed throughout the brain. LRP message is particularly high in the cerebellum, cortex, hippocampus, and brain stem. In addition, we demonstrate that a 39-kDa protein which copurifies with LRP and regulates the binding of other ligands to LRP is also expressed throughout the brain. Interestingly, expression of the 39 kDa message is similar to 100-fold of that found in liver, suggesting that the activity of LRP is more tightly regulated in brain tissue than in liver. Using primary cultures of isolated postnatal cortical neurons, [S-35]methionine biosynthetic labeling and immunoprecipitation, we also demonstrate the de novo biosynthesis of LRP, the 39-kDa protein, as well as tissue-type plasminogen activator. Finally, using radioligand binding as well as fluorescent ligand binding and uptake studies, we show that LRP is functional in cortical neurons. These results taken together thus demonstrate expression of functional LRP in neuronal cells and suggest a potential role for LRP in brain protein and lipoprotein metabolism, development, and regeneration.	WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110	Washington University (WUSTL)	BU, GJ (corresponding author), WASHINGTON UNIV,SCH MED,CHILDRENS HOSP,EDWARD MALLINCKRODT DEPT PEDIAT,400 S KINGSHIGHWAY BLVD,ST LOUIS,MO 63110, USA.				NHLBI NIH HHS [T32HL07275, HL52040] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052040, T32HL007275] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAUER J, 1991, FEBS LETT, V285, P111, DOI 10.1016/0014-5793(91)80737-N; BENARI Y, 1990, TRENDS NEUROSCI, V13, P312, DOI 10.1016/0166-2236(90)90135-W; BROWN MS, 1991, CURR OPIN LIPIDOL, V2, P65; BU GJ, 1992, J BIOL CHEM, V267, P15595; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; BU GJ, 1993, J BIOL CHEM, V268, P13002; CAVAZOS JE, 1991, J NEUROSCI, V11, P2795; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; DZIEGIELEWSKA KM, 1986, DEV BIOL, V115, P93, DOI 10.1016/0012-1606(86)90231-9; GIFFIN K, 1991, NEURON, V6, P321, DOI 10.1016/0896-6273(91)90242-R; GROBMYER SR, 1993, J BIOL CHEM, V268, P13291; HANDELMANN GE, 1992, J LIPID RES, V33, P1677; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; HUETTNER JE, 1986, J NEUROSCI, V6, P3044; IGNATIUS MJ, 1987, SCIENCE, V236, P959, DOI 10.1126/science.3576212; KODELJA V, 1986, EMBO J, V5, P3151, DOI 10.1002/j.1460-2075.1986.tb04622.x; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; KRYSTOSEK A, 1981, SCIENCE, V213, P1532, DOI 10.1126/science.7197054; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MOESTRUP SK, 1992, CELL TISSUE RES, V269, P375, DOI 10.1007/BF00353892; MONARD D, 1988, TRENDS NEUROSCI, V11, P541, DOI 10.1016/0166-2236(88)90182-8; MORTON PA, 1989, J BIOL CHEM, V264, P7228; NIELSEN FC, 1991, J NEUROCHEM, V56, P12, DOI 10.1111/j.1471-4159.1991.tb02556.x; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; ORTH K, P NATL ACAD SCI USA, V8972, P92; OWENSBY DA, 1989, J BIOL CHEM, V264, P18180; PIETROMONACO S, 1990, P NATL ACAD SCI USA, V87, P1811, DOI 10.1073/pnas.87.5.1811; PITAS RE, 1987, J BIOL CHEM, V262, P14352; QIAN Z, 1993, NATURE, V361, P453, DOI 10.1038/361453a0; SCHMID SL, 1992, BIOESSAYS, V14, P589, DOI 10.1002/bies.950140903; SIMMONS DM, 1989, J HISTOTECHNOL, V12, P169; SINCLAIR GI, 1988, BRAIN RES, V450, P60, DOI 10.1016/0006-8993(88)91544-2; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; SWANSON LW, 1988, P NATL ACAD SCI USA, V85, P9821, DOI 10.1073/pnas.85.24.9821; WARSHAWSKY I, 1993, J BIOL CHEM, V268, P22046; WARSHAWSKY I, 1993, J CLIN INVEST, V92, P937, DOI 10.1172/JCI116669; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; WOLF BB, 1992, AM J PATHOL, V141, P37	45	201	204	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18521	18528						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	7518435				2022-12-27	WOS:A1994NW79800047
J	LAWRENCE, DA; BERKENPAS, MB; PALANIAPPAN, S; GINSBURG, D				LAWRENCE, DA; BERKENPAS, MB; PALANIAPPAN, S; GINSBURG, D			LOCALIZATION OF VITRONECTIN BINDING DOMAIN IN PLASMINOGEN-ACTIVATOR INHIBITOR-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE DEFICIENT MICE; EXTRACELLULAR-MATRIX; PROTEIN STABILITY; ENDOTHELIAL-CELLS; ESCHERICHIA-COLI; REACTIVE CENTER; TYPE-1; MUTANTS; HEPARIN; MUTAGENESIS	Plasminogen activator inhibitor type 1 (PAI-1) is the rapid physiologic inhibitor of tissue-type plasminogen activator and urokinase-type plasminogen activator (uPA). In plasma and the extracellular matrix, PAI-1 is associated with the adhesive glycoprotein vitronectin. In order to characterize the PAI-1 structural domain responsible for binding to vitronectin, the segment of the PAI-1 cDNA encoding amino acids 13-147 (nucleotides 248-650) was randomly mutagenized and subcloned into a bacterial expression vector containing the mature PAI-1 coding sequence. Recombinant PAI-1 mutants were expressed in Escherichia coli and bacterial lysates assayed in duplicate for uPA inhibitory activity and vitronectin binding. Of 190 clones screened, six consistently demonstrated decreased vitronectin binding relative to uPA inhibitory activity. DNA sequence analysis of four of these clones identified 10 unique missense mutations, all located between base pairs 298 and 641, with each clone containing between one and four substitutions. Each substitution was expressed independently by site-directed mutagenesis and again analyzed for uPA inhibitory activity and vitronectin binding. Five point mutations that selectively disrupt vitronectin binding were identified. All 5 residues are located on the exterior of the PAI-1 structure. These findings appear to define a complex binding surface that bridges alpha-helices C and E to beta-strand 1A and includes amino acids 55, 109, 110, 116, and 123. These results suggest that vitronectin binding may stabilize the active conformation of PAI-1 by restricting the movement of beta-sheet A and thereby preventing insertion of the reactive center loop.	UNIV MICHIGAN, DEPT INTERNAL MED, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, DEPT HUMAN GENET, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	LAWRENCE, DA (corresponding author), UNIV MICHIGAN, HOWARD HUGHES MED INST, RM 4520 MSRB I, ANN ARBOR, MI 48109 USA.			Lawrence, Daniel/0000-0003-3126-1935	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039137, F32HL008572] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 39137, HL 08572] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBER T, 1989, ANNU REV BIOCHEM, V58, P765, DOI 10.1146/annurev.biochem.58.1.765; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; CARMELIET P, 1993, J CLIN INVEST, V92, P2756, DOI 10.1172/JCI116893; CARMELIET P, 1993, J CLIN INVEST, V92, P2746, DOI 10.1172/JCI116892; Carrell R.W, 1986, PROTEINASE INHIBITOR, P403; CARRELL RW, 1991, NATURE, V353, P576, DOI 10.1038/353576a0; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DECLERCK PJ, 1988, J BIOL CHEM, V263, P15454; EDELBERG JM, 1991, J BIOL CHEM, V266, P7488; EHRLICH HJ, 1992, J BIOL CHEM, V267, P11606; EHRLICH HJ, 1990, J BIOL CHEM, V265, P13029; EVNIN LB, 1990, P NATL ACAD SCI USA, V87, P6659, DOI 10.1073/pnas.87.17.6659; FAY WP, 1992, NEW ENGL J MED, V327, P1729, DOI 10.1056/NEJM199212103272406; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; HUMPHREYS GO, 1976, MOL GEN GENET, V145, P101, DOI 10.1007/BF00331564; KEIJER J, 1991, BLOOD, V78, P1254; KOST C, 1992, J BIOL CHEM, V267, P12098; LAWRENCE D, 1989, EUR J BIOCHEM, V186, P523, DOI 10.1111/j.1432-1033.1989.tb15238.x; LAWRENCE DA, 1990, J BIOL CHEM, V265, P20293; LAWRENCE DA, 1994, BIOCHEMISTRY-US, V33, P3643, DOI 10.1021/bi00178a022; LOSKUTOFF DJ, 1989, PROG HEMOST THROMB, V9, P87; MATTHEWS BW, 1987, BIOCHEMISTRY-US, V26, P6885, DOI 10.1021/bi00396a001; MIMURO J, 1987, BLOOD, V70, P721; MIMURO J, 1989, J BIOL CHEM, V264, P5058; MIMURO J, 1993, BIOCHEMISTRY-US, V32, P2314, DOI 10.1021/bi00060a024; MISRA R, 1991, J BIOL CHEM, V266, P13592; MITRAKI A, 1991, SCIENCE, V253, P54, DOI 10.1126/science.1648264; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; MUNIR KM, 1993, P NATL ACAD SCI USA, V90, P4012, DOI 10.1073/pnas.90.9.4012; NASKI MC, 1993, J BIOL CHEM, V268, P12367; NY T, 1986, P NATL ACAD SCI USA, V83, P6776, DOI 10.1073/pnas.83.18.6776; SALONEN EM, 1989, J BIOL CHEM, V264, P6339; SANDKVIST M, 1993, MOL MICROBIOL, V10, P635, DOI 10.1111/j.1365-2958.1993.tb00935.x; SEIFFERT D, 1991, J BIOL CHEM, V266, P2824; SEIFFERT D, 1991, BIOCHIM BIOPHYS ACTA, V1078, P23, DOI 10.1016/0167-4838(91)90087-G; SHERMAN PM, 1992, J BIOL CHEM, V267, P7588; SIGURDARDOTTIR O, 1990, BIOCHIM BIOPHYS ACTA, V1035, P56, DOI 10.1016/0304-4165(90)90173-T; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Tomasini B R, 1991, Prog Hemost Thromb, V10, P269; VANOSTADE X, 1991, EMBO J, V10, P827, DOI 10.1002/j.1460-2075.1991.tb08015.x; VASSALLI JD, 1991, J CLIN INVEST, V88, P1067, DOI 10.1172/JCI115405	41	119	128	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15223	15228						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	7515053				2022-12-27	WOS:A1994NP73800056
J	WANG, QM; FIOL, CJ; DEPAOLIROACH, AA; ROACH, PJ				WANG, QM; FIOL, CJ; DEPAOLIROACH, AA; ROACH, PJ			GLYCOGEN-SYNTHASE KINASE-3-BETA IS A DUAL-SPECIFICITY KINASE DIFFERENTIALLY REGULATED BY TYROSINE AND SERINE/THREONINE PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN PHOSPHATASE; SERINE THREONINE KINASES; RABBIT SKELETAL-MUSCLE; GENE-PRODUCT; CONSERVED FEATURES; ACTIVATION; SEQUENCE; PURIFICATION; RECOGNITION; MULTISITE	The enzyme glycogen synthase kinase-3 (GSK-3) has been implicated in the control of several metabolic enzymes and transcription factors in response to extracellular signals. In the past, the enzyme has been considered to be a protein Ser/Thr kinase although it was recently reported to contain Tyr(P) (Hughes, K., Nikolakaki, E., Plyte, S. E., Totty, N. F., and Woodgett, J. R. (1993) EMBO J. 12, 803-808). A cDNA encoding rabbit skeletal muscle GSK-3 beta was cloned and expressed in Escherichia coli as an active protein kinase, with apparent M(r) 46,000, capable of phosphorylating several known GSK-3 substrates. Recombinant GSK-3 beta autophosphorylated on Ser, Thr, and Tyr residues although the enzyme already contained Tyr(P) as judged by its recognition by anti-Tyr(P) antibodies. The net result of the autophosphorylation was a 3-5-fold reduction in enzyme activity. GSK-3 alpha, purified from rabbit muscle, also underwent autophosphorylation but only on Ser and Thr residues. In this case, the autophosphorylation stabilized the enzyme activity compared with the control lacking ATP/Mg2+. Of several phosphatases tested, the lambda-phage phosphatase was the most effective in dephosphorylating at Ser and Thr residues but did not dephosphorylate at Tyr residues. The action of the lambda-phosphatase caused a reactivation of GSK-3 beta to similar to 80% of the starting activity. The protein tyrosine phosphatase PTP1B was able to dephosphorylate at Tyr residues leading to a reduction in enzyme activity. A truncated form of GSK-3 beta, apparent M(r) 40,000, had a significantly higher specific activity, was defective in autophosphorylation, and was not inactivated in the autophosphorylation reaction. We conclude that GSK-3 beta is a dual specificity protein kinase in the same sense as the mitogen-activated protein kinase/ERK family of enzymes. Phosphorylation at different residues differentially controls enzyme activity, Ser/Thr phosphorylation causing inactivation and Tyr phosphorylation resulting in increased activity.			WANG, QM (corresponding author), INDIANA UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOL, INDIANAPOLIS, IN 46202 USA.				NIDDK NIH HHS [DK36569, DK27221] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK027221, R01DK027221, R01DK036569] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHN NG, 1991, J BIOL CHEM, V266, P4220; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; Cohen P., 1986, ENZYMES, VXVII, P461; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; CREWS CM, 1991, P NATL ACAD SCI USA, V88, P8845, DOI 10.1073/pnas.88.19.8845; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAILEY D, 1990, MOL CELL BIOL, V10, P6244, DOI 10.1128/MCB.10.12.6244; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DEGROOT RP, 1993, EMBO J, V12, P3903, DOI 10.1002/j.1460-2075.1993.tb06068.x; DEGROOT RP, 1992, ONCOGENE, V7, P841; DENT P, 1989, FEBS LETT, V248, P67, DOI 10.1016/0014-5793(89)80433-8; DEPAOLIROACH AA, 1984, J BIOL CHEM, V259, P2144; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FIOL CJ, 1990, J BIOL CHEM, V265, P6061; FIOL CJ, 1988, ARCH BIOCHEM BIOPHYS, V267, P797, DOI 10.1016/0003-9861(88)90089-6; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOODE N, 1992, J BIOL CHEM, V267, P16878; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; GRAVES PR, 1993, J BIOL CHEM, V268, P6394; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HANGER DP, 1992, NEUROSCI LETT, V147, P58, DOI 10.1016/0304-3940(92)90774-2; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HEMMINGS BA, 1982, FEBS LETT, V150, P319, DOI 10.1016/0014-5793(82)80760-6; HEMMINGS BA, 1981, EUR J BIOCHEM, V119, P443, DOI 10.1111/j.1432-1033.1981.tb05628.x; HEMMINGS BA, 1982, EUR J BIOCHEM, V127, P473; HOWELL BW, 1991, MOL CELL BIOL, V11, P568, DOI 10.1128/MCB.11.1.568; HUGHES K, 1992, EUR J BIOCHEM, V203, P305, DOI 10.1111/j.1432-1033.1992.tb19860.x; HUGHES K, 1993, EMBO J, V12, P803, DOI 10.1002/j.1460-2075.1993.tb05715.x; HUGHES K, 1992, BIOCHEM J, V288, P309, DOI 10.1042/bj2880309; HUNTER T, 1991, METHOD ENZYMOL, V200, P3; ISHIGURO K, 1993, FEBS LETT, V325, P167, DOI 10.1016/0014-5793(93)81066-9; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; Krebs EG, 1986, ENZYMES, V17, P3, DOI 10.1016/S1874-6047(08)60426-6; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; LINDBERG RA, 1992, TRENDS BIOCHEM SCI, V17, P114, DOI 10.1016/0968-0004(92)90248-8; MANDELKOW EM, 1992, FEBS LETT, V314, P315, DOI 10.1016/0014-5793(92)81496-9; NEIGEBORN L, 1991, GENE DEV, V5, P533, DOI 10.1101/gad.5.4.533; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; PLYTE SE, 1992, BIOCHIM BIOPHYS ACTA, V1114, P147, DOI 10.1016/0304-419X(92)90012-N; POSADA J, 1992, MOL BIOL CELL, V3, P583, DOI 10.1091/mbc.3.6.583; PUZISS JW, 1994, MOL CELL BIOL, V14, P831, DOI 10.1128/MCB.14.1.831; RAMAKRISHNA S, 1988, J BIOL CHEM, V263, P12677; ROACH PJ, 1990, FASEB J, V4, P2961, DOI 10.1096/fasebj.4.12.2168324; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; RUEL L, 1993, NATURE, V362, P557, DOI 10.1038/362557a0; RUEL L, 1993, EMBO J, V12, P1657, DOI 10.1002/j.1460-2075.1993.tb05811.x; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; SHERO JH, 1991, GENE DEV, V5, P549, DOI 10.1101/gad.5.4.549; SIEGFRIED E, 1992, CELL, V71, P1167, DOI 10.1016/S0092-8674(05)80065-0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUTHERLAND C, 1994, FEBS LETT, V338, P37, DOI 10.1016/0014-5793(94)80112-6; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; TUNG HYL, 1989, J BIOL CHEM, V264, P2985; VILLAMORUZZI E, 1989, FEBS LETT, V258, P208, DOI 10.1016/0014-5793(89)81654-0; WANG QM, 1994, BIOCHEMISTRY-US, V33, P143, DOI 10.1021/bi00167a018; WELSH GI, 1993, BIOCHEM J, V294, P625, DOI 10.1042/bj2940625; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; WOODGETT JR, 1991, TRENDS BIOCHEM SCI, V16, P177, DOI 10.1016/0968-0004(91)90071-3; WU J, 1993, P NATL ACAD SCI USA, V90, P173, DOI 10.1073/pnas.90.1.173; WU J, 1991, P NATL ACAD SCI USA, V88, P9508, DOI 10.1073/pnas.88.21.9508; YANG SD, 1988, BIOCHEM BIOPH RES CO, V151, P61, DOI 10.1016/0006-291X(88)90559-1; ZHANG WM, 1989, FASEB J, V3, P2532, DOI 10.1096/fasebj.3.13.2509275; ZHANG WM, 1993, ARCH BIOCHEM BIOPHYS, V304, P219, DOI 10.1006/abbi.1993.1342; ZHENG CF, 1993, J BIOL CHEM, V268, P16116; ZHENG CF, 1993, J BIOL CHEM, V268, P11435; ZHHANG ZY, 1992, J BIOL CHEM, V267, P23759; ZHUO S, 1993, J BIOL CHEM, V268, P17754; ZIONCHECK TF, 1986, J BIOL CHEM, V261, P5637	78	259	263	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14566	14574						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	7514173				2022-12-27	WOS:A1994NM06500042
J	WANG, MH; COX, GW; YOSHIMURA, T; SHEFFLER, LA; SKEEL, A; LEONARD, EJ				WANG, MH; COX, GW; YOSHIMURA, T; SHEFFLER, LA; SKEEL, A; LEONARD, EJ			MACROPHAGE-STIMULATING PROTEIN INHIBITS INDUCTION OF NITRIC-OXIDE PRODUCTION BY ENDOTOXIN-STIMULATED OR CYTOKINE-STIMULATED MOUSE MACROPHAGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERITONEAL-MACROPHAGES; RELAXING FACTOR; L-ARGININE; IFN-GAMMA; MOLECULAR-CLONING; PLATELET-ADHESION; SUPEROXIDE ANION; ENDOTHELIUM; EXPRESSION; SYNTHASE	Human serum macrophage-stimulating protein (MSP) is a disulfide-linked heterodimer that induces motile and phagocytic activity of mouse resident peritoneal macrophages. In this work, we found that MSP blocked the increase in macrophage nitric oxide synthase mRNA, as well as the associated increase in nitric oxide production, that occurred in response to several stimuli. These included bacterial products and mammalian cytokines: endotoxin, and interferon-gamma plus endotoxin, interleukin-2, or tumor necrosis factor-alpha. The inhibition by MSP of induction of nitric oxide synthase mRNA and; nitric oxide secretion was concentration-dependent. The concentration of MSP that caused maximal inhibition of nitric oxide production was comparable with the optimum for stimulation of macrophage motile and phagocytic activity. Time course studies showed that nitrate was first detected in culture fluid about 8 h after endotoxin stimulation, and it accumulated at a linear rate during the ensuing 16 h. Inhibition by MSP occurred during the 8-h lipopolysaccharide (LPS) induction period; inhibition was maximal when MSP and LPS were added together and decreased progressively to no inhibition as the interval between LPS and MSP addition increased to 11 h.	NCI,FREDERICK CANC RES & DEV CTR,EXPTL IMMUNOL LAB,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	WANG, MH (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,IMMUNOBIOL LAB,BLDG 560,RM 12-71,FREDERICK,MD 21702, USA.							ARNDT H, 1993, HYPERTENSION, V21, P667, DOI 10.1161/01.HYP.21.5.667; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COX GW, 1992, J IMMUNOL, V149, P3290; CURRAN RD, 1991, FASEB J, V5, P2085, DOI 10.1096/fasebj.5.7.1707021; DEGRAAF JC, 1992, CIRCULATION, V85, P2284, DOI 10.1161/01.CIR.85.6.2284; DING A, 1990, J IMMUNOL, V145, P940; DING AH, 1988, J IMMUNOL, V141, P2407; GAUTAM S, 1992, J IMMUNOL, V148, P1725; GREEN SJ, 1990, J IMMUNOL, V144, P278; GRYGLEWSKI RJ, 1986, NATURE, V320, P454, DOI 10.1038/320454a0; HARBRECHT BG, 1992, J LEUKOCYTE BIOL, V52, P390, DOI 10.1002/jlb.52.4.390; HIBBS JB, 1987, SCIENCE, V235, P473, DOI 10.1126/science.2432665; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; JOHNSTON RB, 1978, J EXP MED, V148, P115; KRONCKE KD, 1992, IMMUNOL TODAY, V13, P157; KUBES P, 1991, P NATL ACAD SCI USA, V88, P4651, DOI 10.1073/pnas.88.11.4651; LEIJH PCJ, 1984, INFECT IMMUN, V46, P448, DOI 10.1128/IAI.46.2.448-452.1984; LEIJH PCJ, 1984, INFECT IMMUN, V46, P754, DOI 10.1128/IAI.46.3.754-758.1984; LEONARD EJ, 1976, EXP CELL RES, V102, P434, DOI 10.1016/0014-4827(76)90065-3; LEONARD EJ, 1978, EXP CELL RES, V114, P117, DOI 10.1016/0014-4827(78)90043-5; LEONARD EJ, 1980, J RETICULOENDOTH SOC, V28, P437; LIEW FY, 1990, J IMMUNOL, V144, P4794; LOWENSTEIN CJ, 1992, CELL, V70, P705, DOI 10.1016/0092-8674(92)90301-R; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; LUSCHER TF, 1987, LANCET, V2, P1057; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MURRAY HW, 1984, MACROPHAGE ACTIVATIO, P97; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; RADOMSKI MW, 1987, BIOCHEM BIOPH RES CO, V148, P1482, DOI 10.1016/S0006-291X(87)80299-1; RUBANYI GM, 1986, AM J PHYSIOL, V250, pH822, DOI 10.1152/ajpheart.1986.250.5.H822; SARIH M, 1993, BIOCHEM BIOPH RES CO, V191, P503, DOI 10.1006/bbrc.1993.1246; SASADA M, 1980, J EXP MED, V152, P85, DOI 10.1084/jem.152.1.85; SKEEL A, 1991, J EXP MED, V173, P1227, DOI 10.1084/jem.173.5.1227; SKEEL A, 1994, IN PRESS J IMMUNOL; STADLER J, 1991, ARCH SURG-CHICAGO, V126, P186; STUEHR DJ, 1989, J EXP MED, V169, P1543, DOI 10.1084/jem.169.5.1543; VODOVOTZ Y, 1993, J EXP MED, V178, P605, DOI 10.1084/jem.178.2.605; WANG MH, 1993, J LEUKOCYTE BIOL, V54, P289, DOI 10.1002/jlb.54.4.289; WANG MH, 1994, J BIOL CHEM, V269, P3436; WINK DA, 1993, P NATL ACAD SCI USA, V90, P9813, DOI 10.1073/pnas.90.21.9813; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; YOSHIMURA T, 1993, J BIOL CHEM, V268, P15461; YOSHIMURA T, 1991, BIOCHEM BIOPH RES CO, V174, P504, DOI 10.1016/0006-291X(91)91445-I; ZHU L, 1992, ARCH BIOCHEM BIOPHYS, V298, P452, DOI 10.1016/0003-9861(92)90434-X	46	92	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14027	14031						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	7514598				2022-12-27	WOS:A1994NL60600048
J	KIM, HH; YAMAGUCHI, Y; MASUDA, K; MATSUNAGA, C; YAMAMOTO, K; IRIMURA, T; TAKAHASHI, N; KATO, K; ARATA, Y				KIM, HH; YAMAGUCHI, Y; MASUDA, K; MATSUNAGA, C; YAMAMOTO, K; IRIMURA, T; TAKAHASHI, N; KATO, K; ARATA, Y			O-GLYCOSYLATION IN HINGE REGION OF MOUSE IMMUNOGLOBULIN G2B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIANT ANTIDANSYL ANTIBODIES; NUCLEAR MAGNETIC-RESONANCE; MONOCLONAL-ANTIBODY; SUGAR CHAINS; LINKED OLIGOSACCHARIDES; BIOLOGICAL SIGNIFICANCE; EFFECTOR FUNCTIONS; ANTIGEN-BINDING; IGG2B; CARBOHYDRATE	Mouse monoclonal immunoglobulin G2b (IgG2b) antibodies are known to contain two forms of the heavy chain that are different in susceptibility to the protease attack. In the present study, by use of an affinity column containing sialic acid-binding lectins from Maackia amurensis seeds, a mouse monoclonal IgG2b was successfully separated into three phenotypes, which are different in the degree of sialylation in the heavy chain. In the N-linked oligosaccharides from all of the IgG2b phenotypes, virtually no sialylation was detected. Elution profiles of the lysyl endopeptidase digestion products were compared for the three phenotypes. The peptides eluted at different retention times were subjected to fast atom bombardment-mass spectrometry and amino acid sequence analyses. It was revealed that approximately 40% of the heavy chain of the mouse IgG2b are O-glycosylated at Thr-221A in the hinge region, predominantly with a tetrasaccharide composed of GalNAc, Gal, and two N-glycolylneuraminic acid residues. We suggest that the O-glycosylation renders the hinge region resistant against the proteolyses of the heavy chain. A therapeutic significance of the O-glycosylation of IgG2b is briefly discussed.	UNIV TOKYO,FAC PHARMACEUT SCI,TOKYO 113,JAPAN; NAKANO VINEGAR CO LTD,GLYCOLAB,HANDA,AICHI 475,JAPAN; MEIJO UNIV,FAC PHARM,TEMPAKU KU,NAGOYA,AICHI 468,JAPAN	University of Tokyo; Meijo University			Yamaguchi, Yoshiki/N-5246-2015	Yamaguchi, Yoshiki/0000-0003-0100-5439; Kato, Koichi/0000-0001-7187-9612				CARRAWAY KL, 1989, BIOESSAYS, V10, P117, DOI 10.1002/bies.950100406; COCOMARTIN JM, 1992, J IMMUNOL METHODS, V155, P241, DOI 10.1016/0022-1759(92)90291-Z; DANGL JL, 1982, CYTOMETRY, V2, P395; DEMIGNOT S, 1990, CANCER RES, V50, P2936; DEMIGNOT S, 1989, J IMMUNOL METHODS, V121, P209, DOI 10.1016/0022-1759(89)90162-2; EDELMAN GM, 1969, P NATL ACAD SCI USA, V63, P78, DOI 10.1073/pnas.63.1.78; ENDO S, 1985, BIOCHEMISTRY-US, V24, P1561, DOI 10.1021/bi00327a041; FANGER MW, 1972, BIOCHEM J, V127, P767, DOI 10.1042/bj1270767; FERNANDEZ PA, 1989, MOL IMMUNOL, V26, P539, DOI 10.1016/0161-5890(89)90005-9; FUKUDA M, 1971, BIOCHEM J, V123, P407, DOI 10.1042/bj1230407; FURUKAWA K, 1991, MOL IMMUNOL, V28, P1333; GLENNIE MJ, 1982, NATURE, V295, P712, DOI 10.1038/295712a0; GOOCHEE CF, 1991, BIO-TECHNOL, V9, P1347, DOI 10.1038/nbt1291-1347; HARDY MR, 1988, ANAL BIOCHEM, V170, P54, DOI 10.1016/0003-2697(88)90089-9; Kabat EA, 1991, SEQUENCES PROTEINS I; KATO K, 1991, BIOCHEMISTRY-US, V30, P6604, DOI 10.1021/bi00240a033; KATO K, 1989, J BIOCHEM-TOKYO, V105, P867, DOI 10.1093/oxfordjournals.jbchem.a122769; KATO K, 1993, FEBS LETT, V328, P49, DOI 10.1016/0014-5793(93)80963-U; KATO K, 1991, BIOCHEMISTRY-US, V30, P270, DOI 10.1021/bi00215a037; KAWAGUCHI T, 1974, J BIOL CHEM, V249, P2786; KIM H, 1994, J MOL BIOL, V236, P300, DOI 10.1006/jmbi.1994.1136; KOHLER G, 1978, EUR J IMMUNOL, V8, P82, DOI 10.1002/eji.1830080203; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEATHERBARROW RJ, 1985, MOL IMMUNOL, V22, P407, DOI 10.1016/0161-5890(85)90125-7; MARQUART M, 1980, J MOL BIOL, V141, P369, DOI 10.1016/0022-2836(80)90252-1; MATSUNAGA C, 1991, Journal of Biomolecular NMR, V1, P379, DOI 10.1007/BF02192861; MAYFORTH RD, 1993, DESIGNING ANTIBODIES, P88; MIZUOCHI T, 1987, ARCH BIOCHEM BIOPHYS, V257, P387, DOI 10.1016/0003-9861(87)90581-9; MIZUOCHI T, 1980, J BIOL CHEM, V255, P3526; NOSE M, 1983, P NATL ACAD SCI-BIOL, V80, P6632, DOI 10.1073/pnas.80.21.6632; PARHAM P, 1983, J IMMUNOL, V131, P2895; PARHAM P, 1986, HDB EXPT IMMUNOLOGY; PAULSON JC, 1989, TRENDS BIOCHEM SCI, V14, P272, DOI 10.1016/0968-0004(89)90062-5; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; ROHRER JS, 1993, ANAL BIOCHEM, V212, P7, DOI 10.1006/abio.1993.1283; ROTHMAN RJ, 1989, BIOCHEMISTRY-US, V28, P1377, DOI 10.1021/bi00429a065; SUMII H, 1989, ACTA MED OKAYAMA, V43, P135; TAKAHASHI N, 1987, BIOCHEMISTRY-US, V26, P1137, DOI 10.1021/bi00378a023; TAO MH, 1989, J IMMUNOL, V143, P2595; WANG WC, 1988, J BIOL CHEM, V263, P4576; WILSON IBH, 1991, BIOCHEM J, V275, P529, DOI 10.1042/bj2750529; YABE N, 1986, IN VITRO CELL DEV B, V22, P363; YAMAMOTO S, 1989, J BIOCHEM-TOKYO, V105, P547, DOI 10.1093/oxfordjournals.jbchem.a122703	43	47	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12345	12350						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	7512967				2022-12-27	WOS:A1994NG37700101
J	UCHIDA, T; MATOZAKI, T; NOGUCHI, T; YAMAO, T; HORITA, K; SUZUKI, T; FUJIOKA, Y; SAKAMOTO, C; KASUGA, M				UCHIDA, T; MATOZAKI, T; NOGUCHI, T; YAMAO, T; HORITA, K; SUZUKI, T; FUJIOKA, Y; SAKAMOTO, C; KASUGA, M			INSULIN STIMULATES THE PHOSPHORYLATION OF TYR(538) AND THE CATALYTIC ACTIVITY OF PTP1C, A PROTEIN-TYROSINE-PHOSPHATASE WITH SRC HOMOLOGY-2 DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR KINASE-ACTIVITY; SIGNAL TRANSDUCTION; SH2 DOMAIN; CELLS; ANTIBODY; SEQUENCE	PTP1C is a non-transmembrane protein-tyrosine phosphatase and contains two Src homology-2 (SH2) domains. Insulin stimulated the tyrosine phosphorylation of PTP1C in human 1M-9 lymphoblast cells, in rat H35 hepatoma cells and in Chinese hamster ovary cells over-expressing both insulin receptors and PTP1C. Insulin also stimulated the tyrosine phosphorylation of a mutant PTP1C lacking SH2 domains in Chinese hamster ovary cells, suggesting that the SH2 domains are not required for insulin-stimulated tyrosine phosphorylation of PTP1C. The insulin receptor tyrosine kinase catalyzed the tyrosine phosphorylation of PTP1C in a cell-free system. Peptide mapping of phosphorylated PTP1C showed that Tyr(538) in the C-terminal region was phosphorylated in response to insulin. The tyrosine phosphorylation of PTP1C by the insulin receptor kinase increased phosphatase activity. Furthermore, PTP1C was shown to bind to autophosphorylated insulin receptors through its C-terminal region, but PTP1C did not bind to unphosphorylated receptors. These results suggest that PTP1C is a target protein for the insulin receptor tyrosine kinase and that the C-terminal region of PTP1C may function both in the regulation of phosphatase activity and in the association of PTP1C with autophosphorylated insulin receptors.	KOBE UNIV, SCH MED, DEPT INTERNAL MED 2, CHUO KU, KOBE 650, JAPAN	Kobe University								BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHOU CK, 1987, J BIOL CHEM, V262, P1842; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FISHER EH, 1991, SCIENCE, V253, P401; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; HASHIMOTO N, 1992, J BIOL CHEM, V267, P13811; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; HUNTER T, 1982, J BIOL CHEM, V257, P4843; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; IZUMI T, 1988, J BIOL CHEM, V263, P10386; KASUGA M, 1983, P NATL ACAD SCI-BIOL, V80, P2137, DOI 10.1073/pnas.80.8.2137; KASUGA M, 1990, DIABETES CARE, V13, P317, DOI 10.2337/diacare.13.3.317; KASUGA M, 1985, METHOD ENZYMOL, V109, P609; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; MATOZAKI T, 1992, BIOCHEM BIOPH RES CO, V182, P215, DOI 10.1016/S0006-291X(05)80133-0; MATOZAKI T, 1994, J BIOL CHEM, V269, P2075; MATOZAKI T, 1992, CANCER RES, V52, P1; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MORGAN DO, 1987, P NATL ACAD SCI USA, V84, P41, DOI 10.1073/pnas.84.1.41; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; RADHA V, 1993, BIOCHEMISTRY-US, V32, P2194, DOI 10.1021/bi00060a010; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; ROTH RA, 1983, SCIENCE, V219, P299, DOI 10.1126/science.6849137; SCHUH SM, 1988, MOL CELL BIOL, V8, P2465, DOI 10.1128/MCB.8.6.2465; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TOBE K, 1993, J BIOL CHEM, V268, P11167; TROWBRIDGE IS, 1991, J BIOL CHEM, V266, P23517; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; UCHIDA T, 1993, J BIOL CHEM, V268, P11845; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; YAMAMOTOHONDA R, 1990, J BIOL CHEM, V265, P23447; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YONEZAWA K, 1992, J BIOL CHEM, V267, P25958; ZHAO ZZ, 1993, J BIOL CHEM, V268, P2816	49	129	130	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12220	12228						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	7512963				2022-12-27	WOS:A1994NG37700083
J	SHEPPARD, AM; MCQUILLAN, JJ; IADEMARCO, MF; DEAN, DC				SHEPPARD, AM; MCQUILLAN, JJ; IADEMARCO, MF; DEAN, DC			CONTROL OF VASCULAR CELL-ADHESION MOLECULE-1 GENE PROMOTER ACTIVITY DURING NEURAL DIFFERENTIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; INTEGRIN VLA-4; TRANSCRIPTION FACTORS; EMBRYONIC-CELLS; VCAM-1; PROTEIN; SUBUNIT; DNA; LYMPHOCYTES; ACTIVATION	Here we demonstrate that vascular cell adhesion molecule-1 (VCAM-1) is expressed in the developing central nervous system on neuroepithelial cells, which are the precursors of neurons and glia. As these cells differentiate, VCAM-1 is restricted to a subset of the glial population. An understanding of mechanisms responsible for this restricted pattern could provide insights into how lineage-specific gene expression is maintained during neural differentiation. As a model of neural differentiation, we turned to the P19 embryonic carcinoma cell line, which in response to retinoic acid will differentiate along a neural pathway. We show that VCAM-1 expression on the differentiating P19 cells resembles that in the central nervous system. Transfection of VCAM-1 gene promoter constructs into P19 cells revealed that the VCAM-1 gene is controlled sequentially by negative and positive elements during differentiation. We present evidence that early during differentiation, POU proteins block VCAM-1 gene activity; however, later in differentiation coincident with the appearance of VCAM-1 the pattern of POU proteins changes and the VCAM-1 gene promoter is activated. This activation is mediated through the NF kappa B/rel complex p50/p65, which forms during P19 cell differentiation.	WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT CELL BIOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007317, R01HL043418] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041908] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL43418, HL07317] Funding Source: Medline; NIAMS NIH HHS [AR41908] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BAEUERLE PA, 1991, MOL ASPECTS CELL REG, V6, P409; Brindle PK, 1992, CURR OPIN GENET DEV, V2, P199, DOI 10.1016/S0959-437X(05)80274-6; COLLARINI EJ, 1992, DEVELOPMENT, V116, P193; DENT CL, 1991, MOL CELL BIOL, V11, P3925, DOI 10.1128/MCB.11.8.3925; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EASTER SS, 1993, J NEUROSCI, V13, P285; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; ENG LF, 1971, BRAIN RES, V28, P351, DOI 10.1016/0006-8993(71)90668-8; ERLE DJ, 1991, J BIOL CHEM, V266, P11009; FREEDMAN AS, 1991, SCIENCE, V249, P1030; GILBERT SF, 1988, DEV BIOL, P156; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; HE X, 1991, MOL CELL BIOL, V11, P1739, DOI 10.1128/MCB.11.3.1739; HIRANO M, 1988, J NEUROSCI RES, V21, P155, DOI 10.1002/jnr.490210208; HOCKFIELD S, 1985, J NEUROSCI, V5, P3310; HUETTNER JE, 1986, J NEUROSCI, V6, P3044; IADEMARCO MF, 1993, P NATL ACAD SCI USA, V90, P3943, DOI 10.1073/pnas.90.9.3943; IADEMARCO MF, 1992, J BIOL CHEM, V267, P16323; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; LERNBECHER T, 1993, NATURE, V365, P767, DOI 10.1038/365767a0; MEIJER D, 1990, NUCLEIC ACIDS RES, V18, P7357, DOI 10.1093/nar/18.24.7357; MISSON JP, 1987, DEV BRAIN RES, V38, P183; MIYAKE K, 1991, J EXP MED, V173, P599, DOI 10.1084/jem.173.3.599; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; RAKIC P, 1972, J COMP NEUROL, V145, P61, DOI 10.1002/cne.901450105; RICE GE, 1990, J EXP MED, V171, P1369, DOI 10.1084/jem.171.4.1369; ROSEN GD, 1992, CELL, V69, P1107, DOI 10.1016/0092-8674(92)90633-N; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; ROSNER MH, 1991, SCIENCE, V253, P144, DOI 10.1126/science.1853199; ROSNER MH, 1990, NATURE, V344, P686; RUEGG C, 1992, J CELL BIOL, V117, P179, DOI 10.1083/jcb.117.1.179; RUVKUN G, 1991, CELL, V64, P475, DOI 10.1016/0092-8674(91)90227-P; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHEEREN RA, 1991, EUR J IMMUNOL, V21, P1101, DOI 10.1002/eji.1830210503; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SHEPPARD AM, 1994, CELL ADHES COMMUN, V1, P27; SHIMAZAKI T, 1993, EMBO J, V12, P4489, DOI 10.1002/j.1460-2075.1993.tb06138.x; SHIMIZU Y, 1991, J CELL BIOL, V113, P1203, DOI 10.1083/jcb.113.5.1203; STOYKOVA AS, 1992, NEURON, V8, P541, DOI 10.1016/0896-6273(92)90282-I; URBAN MB, 1991, EMBO J, V10, P1817, DOI 10.1002/j.1460-2075.1991.tb07707.x; WASSERMAN SA, 1993, MOL BIOL CELL, V8, P767; Wegner M, 1993, CURR OPIN CELL BIOL, V5, P488, DOI 10.1016/0955-0674(93)90015-I	47	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3710	3719		10.1074/jbc.270.8.3710	http://dx.doi.org/10.1074/jbc.270.8.3710			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7533155	hybrid			2022-12-27	WOS:A1995QH68800040
J	CHANTRY, A				CHANTRY, A			THE KINASE DOMAIN AND MEMBRANE LOCALIZATION DETERMINE INTRACELLULAR INTERACTIONS BETWEEN EPIDERMAL GROWTH-FACTOR RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING DOMAIN; TYROSINE KINASES; TRANSMEMBRANE DOMAIN; INSULIN-RECEPTORS; EGF RECEPTOR; SH2 DOMAINS; PROTEIN; TRANSPHOSPHORYLATION; PHOSPHORYLATION; OLIGOMERIZATION	Receptor tyrosine kinases play a central role in cellular growth, differentiation, and oncogenesis. Ah of these responses are triggered by growth factors interacting with the extracellular domain of transmembrane-spanning receptors, leading to dimerization and activation of an intrinsic tyrosine specific kinase activity by an allosteric mechanism. Precise mechanisms of receptor dimerization remain poorly understood, and current models suggest that the ligand binding domain plays a major determining role. To examine the role of the in tracellular domain in the association of juxtaposing receptor molecules, the full-length epidermal growth factor receptor was transiently co-expressed in human 293 fibroblasts with a truncated receptor that lacks the extracellular domain. After metabolic labeling with [S-35]methionine, the association of these receptor constructs was monitored by co-immunoprecipitation with an extracellular domain-specific antibody. Specific interactions found between these receptors were independent of ligand binding or an intact ATP-binding site. Truncated receptors that had sequences necessary for membrane localization, and that were capable of interacting with full-length receptor tyrosine kinase, also displayed constitutive kinase activity as well as the capacity to transphosphorylate kinase-negative receptors. Receptor co-immunoprecipitation occurred between constructs that comprise the intracellular domains of the epidermal growth factor and beta-platelet-derived growth factor receptors, and HER-2. Subsequent deletion analysis has identified the major region of epidermal growth factor receptor intracellular interaction to be within the kinase domain.	CHARING CROSS & WESTMINSTER MED SCH,DEPT MED ONCOL,LONDON W6 8RP,ENGLAND	Imperial College London	CHANTRY, A (corresponding author), CHARING CROSS & WESTMINSTER MED SCH,DEPT BIOCHEM,FULHAM PALACE RD,LONDON W6 8RP,ENGLAND.							ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BALLOTTI R, 1989, EMBO J, V8, P3303, DOI 10.1002/j.1460-2075.1989.tb08491.x; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BASU A, 1989, MOL CELL BIOL, V9, P671, DOI 10.1128/MCB.9.2.671; BELLOT F, 1991, EMBO J, V10, P2849, DOI 10.1002/j.1460-2075.1991.tb07834.x; CARPENTER CD, 1991, J BIOL CHEM, V266, P5750; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FENDLY BM, 1990, CANCER RES, V50, P1550; GORMAN CM, 1989, VIROLOGY, V171, P377, DOI 10.1016/0042-6822(89)90605-3; GREENFIELD C, 1989, EMBO J, V8, P4115, DOI 10.1002/j.1460-2075.1989.tb08596.x; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HONEGGER AM, 1989, P NATL ACAD SCI USA, V86, P925, DOI 10.1073/pnas.86.3.925; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KRYLOV D, 1994, EMBO J, V13, P2849, DOI 10.1002/j.1460-2075.1994.tb06579.x; KWATRA MM, 1992, BIOCHIM BIOPHYS ACTA, V1134, P178, DOI 10.1016/0167-4889(92)90042-A; LAMMERS R, 1990, J BIOL CHEM, V265, P16886; LAX I, 1991, J BIOL CHEM, V266, P13828; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; REDEMANN N, 1992, MOL CELL BIOL, V12, P491, DOI 10.1128/MCB.12.2.491; RIEDEL H, 1989, EMBO J, V8, P2943, DOI 10.1002/j.1460-2075.1989.tb08444.x; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SEEDORF K, 1991, J BIOL CHEM, V266, P13828; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SOROKIN A, 1994, J BIOL CHEM, V269, P9752; TARTARE S, 1991, J BIOL CHEM, V266, P13828; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034	33	74	80	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 17	1995	270	7					3068	3073						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QG471	7531698				2022-12-27	WOS:A1995QG47100029
J	DIBRINO, M; PARKER, KC; MARGULIES, DH; SHILOACH, J; TURNER, RV; BIDDISON, WE; COLIGAN, JE				DIBRINO, M; PARKER, KC; MARGULIES, DH; SHILOACH, J; TURNER, RV; BIDDISON, WE; COLIGAN, JE			THE HLA-B14 PEPTIDE BINDING-SITE CAN ACCOMMODATE PEPTIDES WITH DIFFERENT COMBINATIONS OF ANCHOR RESIDUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; LYMPHOCYTE-T RECOGNITION; INFLUENZA-VIRUS PROTEINS; ENDOGENOUS PEPTIDES; MATRIX PEPTIDE; VIRAL PEPTIDES; CELL EPITOPES; MHC; MOLECULES; ANTIGEN	Most peptides that bind to a particular major histocompatibility complex class I molecule share amino acid residues important for binding at one or two positions. Sequence analyses of peptides bound to HLA-B14 revealed at least four candidates for these so-called anchor residues: Arg at P2, Tyr at P3, Arg at P5, and Leu at P9. Combinations of any three of these amino acids sufficed for binding to HLA-B14 in vitro. Using this information, we identified an antigenic peptide critical for cytotoxic T lymphocyte recognition of virus-infected cells. Molecular models of HLA-B14 peptide complexes were constructed to investigate how the potential anchor residues might function. By using binding data to calculate the contribution to binding of each amino acid at anchor positions and predicting the stability of all possible nonapeptide complexes that could be formed from antigenic proteins, we estimate that three known antigenic nonapeptides are in the highest affinity cohort of peptides, Thus, even when multiple combinations of anchor residues contribute to binding, antigenic peptides are routinely identifiable.	NIAID, MOLEC STRUCT LAB, BETHESDA, MD 20892 USA; NIAID, IMMUNOL LAB, MOLEC BIOL SECT, BETHESDA, MD 20892 USA; NIDDK, CELLULAR & DEV BIOL LAB, BETHESDA, MD 20892 USA; NINCDS, NEUROIMMUNOL BRANCH, MOLEC IMMUNOL SECT, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)				Margulies, David/0000-0001-8530-7375; Parker, Kenneth/0000-0002-6282-2478				BENNINK JR, 1988, J EXP MED, V168, P1935, DOI 10.1084/jem.168.5.1935; BJORKMAN PJ, 1990, ANNU REV BIOCHEM, V59, P253, DOI 10.1146/annurev.bi.59.070190.001345; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BOVIER M, 1994, SCIENCE, V265, P398; BRUNGER AT, 1990, XPLOR MANUAL VERSION; CORR M, 1992, J EXP MED, V176, P1681, DOI 10.1084/jem.176.6.1681; CORR M, 1993, J EXP MED, V178, P1877, DOI 10.1084/jem.178.6.1877; COX AL, 1994, SCIENCE, V264, P716, DOI 10.1126/science.7513441; DIBRINO M, 1994, J IMMUNOL, V152, P620; DIBRINO M, 1993, J IMMUNOL, V151, P5930; DIBRINO M, 1993, P NATL ACAD SCI USA, V90, P1508, DOI 10.1073/pnas.90.4.1508; FALK K, 1993, IMMUNOGENETICS, V38, P161, DOI 10.1007/BF00190906; FALK K, 1993, P NATL ACAD SCI USA, V90, P12005, DOI 10.1073/pnas.90.24.12005; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; GUO HC, 1992, NATURE, V360, P364, DOI 10.1038/360364a0; HARLOW E, 1988, ANTIBODIES LABORATOR; HOGAN KT, 1988, J EXP MED, V168, P725, DOI 10.1084/jem.168.2.725; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; JOHNSON RP, 1992, J EXP MED, V175, P961, DOI 10.1084/jem.175.4.961; JOHNSON RP, 1991, J IMMUNOL, V147, P1512; KENWRICK S, 1992, HUM MOL GENET, V1, P179, DOI 10.1093/hmg/1.3.179; KOENIG S, 1993, J IMMUNOL, V151, P3874; LI ML, 1991, GENE, V107, P329, DOI 10.1016/0378-1119(91)90335-9; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; PAMER EG, 1991, NATURE, V353, P852, DOI 10.1038/353852a0; PARHAM P, 1979, J IMMUNOL, V123, P342; PARKER KC, 1992, J BIOL CHEM, V267, P5451; PARKER KC, 1992, J IMMUNOL, V149, P1896; PARKER KC, 1994, J IMMUNOL, V152, P163; RAMMENSEE HG, 1993, ANNU REV IMMUNOL, V11, P213, DOI 10.1146/annurev.iy.11.040193.001241; ROTZSCHKE O, 1991, EUR J IMMUNOL, V21, P2891, DOI 10.1002/eji.1830211136; RUPPERT J, 1993, CELL, V74, P929, DOI 10.1016/0092-8674(93)90472-3; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; SCHWARTZ RH, 1985, ANNU REV IMMUNOL, V3, P237, DOI 10.1146/annurev.iy.03.040185.001321; SILVER ML, 1992, NATURE, V360, P367, DOI 10.1038/360367a0; STORKUS WJ, 1987, J IMMUNOL, V138, P1657; SUTTON J, 1993, EUR J IMMUNOL, V23, P447, DOI 10.1002/eji.1830230222; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; WINTER CC, 1991, J IMMUNOL, V146, P3508; ZEMMOUR J, 1992, J IMMUNOL, V148, P1941; ZEMMOUR J, 1991, HUM IMMUNOL, V31, P195, DOI 10.1016/0198-8859(91)90026-6; ZHANG QJ, 1993, P NATL ACAD SCI USA, V90, P2217, DOI 10.1073/pnas.90.6.2217	46	45	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32426	32434						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7528217				2022-12-27	WOS:A1994PX30400062
J	REICHSLOTKY, R; BONNEHBARKAY, D; SHAOUL, E; BLUMA, B; SVAHN, CM; RON, D				REICHSLOTKY, R; BONNEHBARKAY, D; SHAOUL, E; BLUMA, B; SVAHN, CM; RON, D			DIFFERENTIAL EFFECT OF CELL-ASSOCIATED HEPARAN SULFATES ON THE BINDING OF KERATINOCYTE GROWTH-FACTOR (KGF) AND ACIDIC FIBROBLAST GROWTH-FACTOR TO THE KGF RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY RECEPTOR; EXTRACELLULAR-MATRIX; MESSENGER-RNA; FACTOR FAMILY; FGF RECEPTOR; BASIC-FGF; SPECIFICITY; LIGAND; EXPRESSION; PROTEINS	The fibroblast growth factors (FGFs) act through high affinity tyrosine kinase receptors and, in addition, interact with lower affinity receptors that represent cellor matrix-associated heparan sulfate proteoglycans. These lower affinity receptors modulate the biological activities of FGFs, but the mechanism by which they exert these effects is rather controversial. We have previously shown (Ron, D., Bottaro, D. P., Finch, P. W., Morris, D., Rubin, J. S., and Aaronson, S. A. (1993) J. Biol. Chem, 268, 2984-2988) that heparin potentiates the mitogenic activity of acidic FGF (aFGF) but inhibits that of the keratinocyte growth factor (HGF) in cells that express the KGF receptor (KGFR). Both growth factors bind the KGFR with high affinity, To gain an insight into the mechanism by which heparin modulates the biological activity of aFGF and KGF, we studied the effect of heparin and cell-associated heparan sulfates on the binding of these two growth factors to the KGFR, To work in a well defined system, we expressed functional KGFR in L6E9 myoblasts that lack detectable high affinity binding sites for FGFs, Low concentrations of heparin inhibited the binding of KGF to the KGFR. By contrast, similar concentrations of heparin enhanced the binding of aFGF to this receptor, The effect of heparin was not unique to L6E9 cells expressing the KGFR; it was also observed in Balb/MK cells that naturally express KGFR. Treatment of cells with sodium chlorate, which blocks sulfation of proteoglycans, reduced the binding of aFGF to its low and high affinity binding sites by 95 and 80%, respectively. In contrast, the binding of KGF to its high affinity binding sites was enhanced about S-fold, Similar results were obtained after degradation of cell-associated heparan sulfates by heparinase and heparitinase. Heparin restored the high affinity binding of aFGF to chlorate-treated cells and completely abolished the high affinity binding of KGF, Binding competition experiments suggest that aFGF and KGF bind to the same population of cell-associated heparan sulfates, In addition, KGF is apparently interacting with an as yet unidentified type of low affinity binding site that is not affected by chlorate or heparan sulfate-degrading enzymes. An important property of the FGF high affinity receptors is their ability to bind more than one ligand with high affinity, Based on the differential effect of cell-associated heparan sulfates on the binding of KGF and aFGF to the KGFR, we propose a regulatory role for cell-associated heparan sulfates as coordinators of the interaction of aFGF and KGF with the KGFR, Such a regulatory mechanism may be important for the coordination of cellular responses to KGF and aFGF.	TECHNION ISRAEL INST TECHNOL, DEPT BIOL, IL-32000 HAIFA, ISRAEL; KABI PHARM, S-11287 STOCKHOLM, SWEDEN	Technion Israel Institute of Technology								ALARID ET, 1994, P NATL ACAD SCI USA, V91, P1074, DOI 10.1073/pnas.91.3.1074; BAIRD A, 1991, CANCER CELL-MON REV, V3, P239; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BOTTARO DP, 1993, J BIOL CHEM, V268, P9180; BOTTARO DP, 1990, J BIOL CHEM, V265, P12767; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHAMPIONARNAUD P, 1991, ONCOGENE, V6, P979; CHEON HG, 1994, P NATL ACAD SCI USA, V91, P989, DOI 10.1073/pnas.91.3.989; CORDONCARDO C, 1990, LAB INVEST, V63, P832; CRUMLEY G, 1991, ONCOGENE, V6, P2255; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; EISEMANN A, 1991, ONCOGENE, V6, P1195; FARLEY JR, 1978, ARCH BIOCHEM BIOPHYS, V185, P376, DOI 10.1016/0003-9861(78)90180-7; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; GOSPADAROWICZ D, 1990, J CLIN ORTHOPED RELA, V58, P231; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; ISHAIMICHAELI R, 1992, BIOCHEMISTRY-US, V31, P2080, DOI 10.1021/bi00122a027; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; Klagsbrun M, 1990, CURR OPIN CELL BIOL, V2, P857, DOI 10.1016/0955-0674(90)90084-R; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI M, 1992, P NATL ACAD SCI USA, V89, P3315, DOI 10.1073/pnas.89.8.3315; LINHARDT RJ, 1990, BIOCHEMISTRY-US, V29, P2611, DOI 10.1021/bi00462a026; MARICS I, 1989, ONCOGENE, V4, P335; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; ROGHANI M, 1994, J BIOL CHEM, V269, P3976; RON D, 1993, J BIOL CHEM, V268, P2984; RON D, 1993, J BIOL CHEM, V268, P5388; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; RUBIN JS, 1994, IN PRESS J ENDOCRINO; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; TURNBULL JE, 1990, BIOCHEM J, V265, P715, DOI 10.1042/bj2650715; TURNBULL JE, 1991, BIOCHEM J, V273, P553, DOI 10.1042/bj2730553; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; VLODAVSKY I, 1991, TRENDS BIOCHEM SCI, V16, P268, DOI 10.1016/0968-0004(91)90102-2; WEISSMAN BE, 1983, CELL, V32, P599, DOI 10.1016/0092-8674(83)90479-8; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; YUEN S, 1991, METHOD ENZYMOL, V198, P91	58	77	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32279	32285						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7528211				2022-12-27	WOS:A1994PX30400042
J	YEE, NS; HSIAU, CWM; SERVE, H; VOSSELLER, K; BESMER, P				YEE, NS; HSIAU, CWM; SERVE, H; VOSSELLER, K; BESMER, P			MECHANISM OF DOWN-REGULATION OF C-KIT RECEPTOR - ROLES OF RECEPTOR TYROSINE KINASE, PHOSPHATIDYLINOSITOL 3'-KINASE, AND PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; LIGAND-INDUCED INTERNALIZATION; FACTOR BETA-RECEPTOR; FACTOR-I RECEPTOR; STEM-CELL FACTOR; MAST-CELLS; SIGNAL-TRANSDUCTION; INSULIN-RECEPTOR; EGF RECEPTOR; W-LOCUS	The receptor tyrosine kinase Kit and Hit ligand (KL), encoded at the murine white spotting (W) and steel (SI) loci, respectively, function in hematopoiesis, melanogenesis, and gametogenesis. To understand the mechanism of turnover of Bit in mast cells, mutant receptors generated in vitro were heterologously expressed in W-sh/W-sh mast cells lacking endogenous c-kit expression, and the effects of mutations on KL-induced internalization and ubiquitination/degradation of Kit were studied. Upon binding of KL, KL-Kit receptor complexes were rapidly internalized, and the turnover was accelerated by ubiquitin-mediated degradation. Inactivation of the Kit kinase resulted in a reduced rate of internalization of KL-Kit complexes, degradation of kinase-inactive receptor complexes was relatively slow, and receptor ubiquitination was absent. But abolishment of Kt induced receptor association and activation of phosphatidylinositol 3'-kinase and of tyrosine 821 autophosphorylation did not affect KL-induced internalization and ubiquitination/degradation of Kit. Furthermore, Kit receptors can be down-regulated by proteolytic cleavage induced by either activation of protein kinase C or by isopropyl alcohol. In summary, KL-induced internalization of ICL Kit complexes and ubiquitination/degradation require an active kinase. By contrast, proteolytic cleavage of Kit mediated by protein kinase C activation is independent of kinase activity.	SLOAN KETTERING INST,PROGRAM MOLEC BIOL,NEW YORK,NY 10021; CORNELL UNIV,GRAD SCH MED SCI,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Cornell University					NCI NIH HHS [R37 CA 32926] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA032926] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BACKER JM, 1989, P NATL ACAD SCI USA, V86, P3209, DOI 10.1073/pnas.86.9.3209; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; BLUMEJENSEN P, 1993, EMBO J, V12, P4199, DOI 10.1002/j.1460-2075.1993.tb06104.x; CARLBERG K, 1991, EMBO J, V10, P877, DOI 10.1002/j.1460-2075.1991.tb08020.x; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; DASTYCH J, 1994, J IMMUNOL, V152, P213; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; DUTTLINGER R, 1993, DEVELOPMENT, V118, P705; ESCOBEDO JA, 1988, MOL CELL BIOL, V8, P5126, DOI 10.1128/MCB.8.12.5126; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARLOW E, 1988, ANTIBODIES LABORATOR, P354; HAYASHI SI, 1991, NUCLEIC ACIDS RES, V19, P1267, DOI 10.1093/nar/19.6.1267; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KOIKE T, 1993, J IMMUNOL, V151, P359; KONG SK, 1992, J BIOL CHEM, V267, P14189; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MORI S, 1992, J BIOL CHEM, V267, P6429; MORI S, 1993, J BIOL CHEM, V268, P577; MORI S, 1994, J BIOL CHEM, V269, P4917; NISHIKAWA S, 1991, EMBO J, V10, P2111, DOI 10.1002/j.1460-2075.1991.tb07744.x; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; NOCKA K, 1990, EMBO J, V9, P3287, DOI 10.1002/j.1460-2075.1990.tb07528.x; Panayotou George, 1992, Trends in Cell Biology, V2, P358, DOI 10.1016/0962-8924(92)90042-L; PRYWES R, 1986, EMBO J, V5, P2179, DOI 10.1002/j.1460-2075.1986.tb04482.x; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; RAY P, 1991, GENE DEV, V5, P2265, DOI 10.1101/gad.5.12a.2265; RECHSTEINER M, 1987, ANNU REV CELL BIOL, V3, P1, DOI 10.1146/annurev.cb.03.110187.000245; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; RUSSELL DS, 1987, J BIOL CHEM, V262, P11833; SERVE H, 1994, J BIOL CHEM, V269, P6026; SHIEH JH, 1991, J IMMUNOL, V146, P2648; SORKIN A, 1991, J CELL BIOL, V112, P469, DOI 10.1083/jcb.112.3.469; TAN JC, 1990, SCIENCE, V247, P209, DOI 10.1126/science.1688471; TONO T, 1992, BLOOD, V80, P1448; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YEE NS, 1993, J BIOL CHEM, V268, P14189; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	48	134	137	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31991	31998						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7527401				2022-12-27	WOS:A1994PX30300100
J	FORD, CE; FURLONG, MT; GEAHLEN, RL; HARRISON, ML				FORD, CE; FURLONG, MT; GEAHLEN, RL; HARRISON, ML			SIGNALING-INDUCED ASSOCIATION OF A TYROSINE-PHOSPHORYLATED 36-KDA PROTEIN WITH P50(CSK)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; SRC FAMILY KINASES; PHOSPHATASE INHIBITOR; LYMPHOCYTES-T; ACTIVATION; CSK; TRANSDUCTION; PERVANADATE; EXPRESSION; PLATELETS	The protein-tyrosine kinase, p50(csk), is thought to participate in the regulation of signal transduction pathways by catalyzing the phosphorylation of the Src-related protein-tyrosine kinases on a negative regulatory tyrosine residue located near the COOH terminus. To study possible mechanisms by which the activity of p50(csk) might be regulated, we searched for p50(csk)-interacting proteins in human erythroleukemia cells. We found that in response to the treatment of cells with pervanadate, a potent inhibitor of protein tyrosine phosphatases, or to the cross-linking of Fc gamma RIIA receptors, p50(csk) becomes tightly associated with a 36-kDa protein (p36). This association is dependent on the tyrosine phosphorylation of p36 and involves its interaction with the SH2 domain of p50(csk). p36 can be phosphorylated in vitro by p50(csk) or by a full-length GST-Csk fusion protein expressed in Escherichia coli. Tyrosine-phosphorylated p36 is found exclusively in the particulate membrane fraction of the cell. Conditions that induce the formation of the p50(csk) p36 complex promote the appearance of p50(csk) in the particulate fraction. These data suggest that the association between p50(csk) and p36 serves to translocate the normally cytosolic p50(csk) to the membrane, where it presumably interacts with its physiologically relevant substrates.	PURDUE UNIV, DEPT MED CHEM & PHARMACOGNOSY, W LAFAYETTE, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus				Geahlen, Robert/0000-0001-8400-2924	NIDCD NIH HHS [1F31DC00152] Funding Source: Medline; NIGMS NIH HHS [GM48099] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048099] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [F31DC000152] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		AGARWAL A, 1993, J BIOL CHEM, V268, P15900; AUTERO M, 1994, MOL CELL BIOL, V14, P1308, DOI 10.1128/MCB.14.2.1308; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BOLEN JB, 1991, ADV CANCER RES, V57, P103; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; BOUGERET C, 1993, ONCOGENE, V8, P1241; BOURGOIN S, 1992, J BIOL CHEM, V267, P11908; BUDAY L, 1994, J BIOL CHEM, V269, P9019; CAMBIER JC, 1994, ANNU REV IMMUNOL, V12, P457, DOI 10.1146/annurev.immunol.12.1.457; CARLSSON J, 1978, BIOCHEM J, V173, P723, DOI 10.1042/bj1730723; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; CHOW LML, 1993, NATURE, V365, P156, DOI 10.1038/365156a0; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; EISEMAN E, 1992, NATURE, V355, P78; GHAZIZADEH S, 1994, J BIOL CHEM, V269, P8878; GORDON JA, 1991, METHOD ENZYMOL, V201, P477; HAMADA F, 1993, P NATL ACAD SCI USA, V90, P6305, DOI 10.1073/pnas.90.13.6305; HARRISON ML, 1994, J BIOL CHEM, V269, P955; HUANG MM, 1992, J BIOL CHEM, V267, P5467; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KIENER PA, 1993, J BIOL CHEM, V268, P24442; KING M, 1992, EXP HEMATOL, V20, P576; KUENZEL EA, 1985, P NATL ACAD SCI USA, V82, P737, DOI 10.1073/pnas.82.3.737; MUSTELIN T, 1993, TRENDS BIOCHEM SCI, V18, P215, DOI 10.1016/0968-0004(93)90192-P; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; O'SHEA JJ, 1992, P NATL ACAD SCI USA, V89, P10306, DOI 10.1073/pnas.89.21.10306; OETKEN C, 1994, ONCOGENE, V9, P1625; OKADA M, 1991, J BIOL CHEM, V266, P24249; PAIGE LA, 1993, J BIOL CHEM, V268, P8669; PARTANEN J, 1991, ONCOGENE, V6, P2013; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PUMIGLIA KM, 1992, BIOCHEM J, V286, P441, DOI 10.1042/bj2860441; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RUZZENE M, 1994, J BIOL CHEM, V269, P15885; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; SEFTON BM, 1991, ONCOGENE, V6, P683; SIEH M, 1994, MOL CELL BIOL, V14, P4435, DOI 10.1128/MCB.14.7.4435; TAKEUCHI M, 1993, J BIOL CHEM, V268, P27413; TONKS NK, 1988, BIOCHEMISTRY-US, V27, P8696; TREVILLYAN JM, 1986, BIOCHIM BIOPHYS ACTA, V888, P286, DOI 10.1016/0167-4889(86)90228-4; WANG QM, 1991, BIOCHEM J, V279, P567, DOI 10.1042/bj2790567; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4	50	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30378	30385						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7527029				2022-12-27	WOS:A1994PU52500054
J	GUERIN, B; BUNOUST, O; ROUQUEYS, V; RIGOULET, M				GUERIN, B; BUNOUST, O; ROUQUEYS, V; RIGOULET, M			ATP-INDUCED UNSPECIFIC CHANNEL IN YEAST MITOCHONDRIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE ANION CHANNEL; PHOSPHATE-TRANSPORT PROTEIN; HEART-MITOCHONDRIA; SACCHAROMYCES-CEREVISIAE; K+/H+ ANTIPORT; CHLORIDE; ABSENCE	ATP induced swelling of isolated yeast mitochondria suspended in an isoosmotic solution of potassium gluconate. Valinomycin stimulated the swelling rate, indicating that K+ influx in the presence of ATP is rate-controlling. This swelling was inhibited by ADP, phosphate (probably acting on the external face of the inner membrane), and Mg2+, which forms a complex with ATP. ATP-induced swelling did not require working F-0-F-1-ATPase since it was not inhibited by oligomycin and uncoupler. CTP and GTP also induced a swelling. ATP also induced mitochondrial swelling in potassium glutamate, chlo ride, and acetate but not in phosphate solutions. Sodium, but not ammonium, can replace potassium ion. It is probable that the ATP-channel opening also necessitates an electrogenic cation influx. Respiration also induced swelling of mitochondria suspended in isoosmotic potassium gluconate solution. ATP- or respiration-induced swelling were inhibited equally by N,N'-dicyclohexylcarbodiimide, propanolol, and Zn2+ but not by quinine; all these drugs inhibit the H+/K+ exchange. It was concluded that this unspecific channel is not open un der conditions used to measure oxidative phosphorylation. Its physiological role remains unknown.			GUERIN, B (corresponding author), UNIV BORDEAUX 2,INST BIOCHEM & GENET CELLULAIRES,1 RUE CAMILLE ST SAENS,F-33077 BORDEAUX,FRANCE.							AZZI A, 1966, BIOCHIM BIOPHYS ACTA, V120, P466, DOI 10.1016/0926-6585(66)90316-5; AZZI A, 1967, BIOCHIM BIOPHYS ACTA, V131, P468, DOI 10.1016/0005-2728(67)90006-0; BEAVIS AD, 1987, J BIOL CHEM, V262, P15085; BEAVIS AD, 1992, J BIOL CHEM, V267, P3079; BEAVIS AD, 1992, J BIOENERG BIOMEMBR, V24, P77, DOI 10.1007/BF00769534; BEAVIS AD, 1983, FED PROC, V42, P1096; BRIERLEY GP, 1969, BIOCHEM BIOPH RES CO, V35, P396, DOI 10.1016/0006-291X(69)90512-9; BRIERLEY GP, 1984, J BIOL CHEM, V259, P4672; BRIERLEY GP, 1970, BIOCHEMISTRY-US, V9, P697, DOI 10.1021/bi00806a001; BRIERLEY GP, 1978, ARCH BIOCHEM BIOPHYS, V190, P181, DOI 10.1016/0003-9861(78)90266-7; DAWSON RMC, 1986, DATA BIOCH RES, P413; DECHATEAUBODEAU GA, 1976, BIOCHIMIE PARIS, V58, P601; GARLID KD, 1986, BIOCHIM BIOPHYS ACTA, V853, P187, DOI 10.1016/0304-4173(87)90001-2; GUERIN B, 1990, J BIOL CHEM, V265, P19736; Guerin B, 1979, Methods Enzymol, V55, P149; KINNALLY KW, 1989, J BIOENERG BIOMEMBR, V21, P497, DOI 10.1007/BF00762521; KINNALLY KW, 1992, J BIOENERG BIOMEMBR, V266, P3376; KLINGENBERG M, 1969, ENERGY LEVEL METABOL, P189; MANON S, 1993, J BIOENERG BIOMEMBR, V25, P671; MANON S, 1992, BIOCHIM BIOPHYS ACTA, V1108, P169, DOI 10.1016/0005-2736(92)90022-E; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; PHELPS A, 1991, BIOCHEMISTRY-US, V30, P248, DOI 10.1021/bi00215a035; PRETRONILLI V, 1989, FEBS LETT, V259, P137; PRIETO S, 1992, EUR J BIOCHEM, V208, P487, DOI 10.1111/j.1432-1033.1992.tb17212.x; RIGOULET M, 1987, EUR J BIOCHEM, V168, P275, DOI 10.1111/j.1432-1033.1987.tb13417.x; SORGATO MC, 1987, NATURE, V330, P498, DOI 10.1038/330498a0; SZABO I, 1991, J BIOL CHEM, V266, P3376; Vignais P. V., 1985, STRUCTURE PROPERTIES, V2, P139; WELIHINDA AA, 1993, BIOCHIM BIOPHYS ACTA, V1144, P367, DOI 10.1016/0005-2728(93)90122-V	29	43	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25406	25410						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7523386				2022-12-27	WOS:A1994PQ49100030
J	LIU, CY; ZHU, G; CONVERSE, R; KAO, CWC; NAKAMURA, H; TSENG, SCG; MUI, MM; SEYER, J; JUSTICE, MJ; STECH, ME; HANSEN, GM; KAO, WWY				LIU, CY; ZHU, G; CONVERSE, R; KAO, CWC; NAKAMURA, H; TSENG, SCG; MUI, MM; SEYER, J; JUSTICE, MJ; STECH, ME; HANSEN, GM; KAO, WWY			CHARACTERIZATION AND CHROMOSOMAL LOCALIZATION OF THE CORNEA-SPECIFIC MURINE KERATIN GENE KRT1.12	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICKEN PROLYL 4-HYDROXYLASE; EPITHELIAL DIFFERENTIATION; INTERMEDIATE FILAMENTS; CONJUNCTIVAL EPITHELIUM; MONOCLONAL-ANTIBODY; ENHANCER ELEMENTS; BETA-SUBUNIT; LINKAGE MAP; I KERATIN; EXPRESSION	Keratins are a group of water-insoluble proteins constituting paired acidic and basic keratin molecules that form 10-nm intermediate filaments in epithelial cells. Expression of the K3/K12 keratin pair characterizes the cornea-type differentiation. However, the mechanism that regulates this cornea-specific K12 expression remains unknown. To provide a better understanding of the cornea-specific expression, we have cloned the K12 cDNA (Liu, C.-Y., Zhu, G., Westerhausen-Larson, A., Converse, R., Kao, C. W.-C., Sun, T.-T., and Kao, W. W.-Y. (1993) Curr. Eye Res. 12, 963-974). In present studies, the murine K12 keratin gene (Krt1.12) was isolated and characterized. The murine Krt1.12 gene spans 6,567 base pairs of genomic DNA, and the mRNA encoding K12 keratin is distributed into eight exons. Chromosome mapping reveals that murine Krt1.12 is located within the Krt1 complex of mouse chromosome 11. In addition to the production of authentic K12 mRNA, the Krt1.12 gene gives rise to several alternate poly(A)(+) RNAs by the use of alternative splicing in intron 2, an alternative pro meter in intron 1, and/or both. Sequence analysis indicates that the transcripts derived from alternative splicing and/or the alternative promoter do not have a long open reading frame for keratin or keratin-like molecules. It is not known whether these alternate K12 poly(A)(+) RNAs have any biological functions, e.g. regulation of K12 gene expression.	UNIV CINCINNATI,DEPT OPHTHALMOL,CINCINNATI,OH 45267; UNIV MIAMI,DEPT OPHTHALMOL,MIAMI,FL 33101; UNIV TENNESSEE,DEPT BIOCHEM,MEMPHIS,TN 38104; KANSAS STATE UNIV AGR & APPL SCI,DIV BIOL,MANHATTAN,KS 66506	University System of Ohio; University of Cincinnati; University of Miami; University of Tennessee System; University of Tennessee Health Science Center; Kansas State University				Liu, Chia-yang/0000-0002-8398-5516	NATIONAL EYE INSTITUTE [R01EY006819] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041496] Funding Source: NIH RePORTER; NEI NIH HHS [EY 06819, EY 05629] Funding Source: Medline; NHLBI NIH HHS [HL 41496] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BADER BL, 1986, EMBO J, V5, P1865, DOI 10.1002/j.1460-2075.1986.tb04438.x; BARLETTA C, 1990, CYTOGENET CELL GENET, V54, P158; BASSAM BJ, 1991, ANAL BIOCHEM, V196, P80, DOI 10.1016/0003-2697(91)90120-I; BENNETT VD, 1990, J BIOL CHEM, V265, P2223; BLESSING M, 1989, EMBO J, V8, P117, DOI 10.1002/j.1460-2075.1989.tb03355.x; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; BUCHBERG AM, 1993, MAMM GENOME, V4, P5164; CHALOINDUFAU C, 1990, CELL DIFFER DEV, V32, P97, DOI 10.1016/0922-3371(90)90103-4; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COOPER D, 1985, LAB INVEST, V52, P243; COOPER D, 1986, J BIOL CHEM, V261, P4646; COPELAND NG, 1993, SCIENCE, V262, P57, DOI 10.1126/science.8211130; COULOMBE PA, 1990, J CELL BIOL, V111, P153, DOI 10.1083/jcb.111.1.153; DIETRICH W, 1992, GENETICS, V131, P423; DIETRICH W, 1993, SSLP GENETIC MAP MOU; EICHNER R, 1986, J CELL BIOL, V102, P1767, DOI 10.1083/jcb.102.5.1767; Galvin S, 1989, Adv Dermatol, V4, P277; GREEN MC, 1989, CATALOGUE MUTANT GEN, P12; GUO LF, 1993, EMBO J, V12, P973, DOI 10.1002/j.1460-2075.1993.tb05738.x; ISHIZAKI M, 1993, INVEST OPHTH VIS SCI, V34, P2680; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; JUSTICE MJ, 1990, GENOMICS, V6, P341, DOI 10.1016/0888-7543(90)90575-F; KAO WWY, 1988, CONNECT TISSUE RES, V18, P157, DOI 10.3109/03008208809016805; KINOSHIT S, 1992, INVEST OPHTH VIS SCI, V33, P1176; KIRITOSHI A, 1992, INVEST OPHTH VIS SCI, V33, P1241; KREIG TM, 1988, J BIOL CHEM, V260, P5867; KULESH D, 1988, MOL CELL BIOL, V4, P1540; KURPAKUS MA, 1990, INVEST OPHTH VIS SCI, V31, P448; LEUBE RE, 1988, J CELL BIOL, V106, P1249, DOI 10.1083/jcb.106.4.1249; LIU CY, 1993, CURR EYE RES, V12, P963, DOI 10.3109/02713689309029222; LIU CY, 1993, DEV DYNAM, V198, P150, DOI 10.1002/aja.1001980208; Lyon ME, 1986, MOUSE NEWS LETT, V74, P96; MARCHUK D, 1985, P NATL ACAD SCI USA, V82, P1609, DOI 10.1073/pnas.82.6.1609; Maxam A M, 1980, Methods Enzymol, V65, P499; MCGUIRE J, 1984, BRIT J DERMATOL, V111, P27, DOI 10.1111/j.1365-2133.1984.tb15579.x; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MUI MM, 1993, INVEST OPHTH VIS SCI, V34, P1470; NADEAU JH, 1989, GENOMICS, V5, P454, DOI 10.1016/0888-7543(89)90009-8; NAKAZAWA M, 1988, GENE, V71, P451, DOI 10.1016/0378-1119(88)90062-5; QUINLAN RA, 1985, ANN NY ACAD SCI, V455, P282, DOI 10.1111/j.1749-6632.1985.tb50418.x; RAYCHAUDHURY A, 1986, MOL CELL BIOL, V6, P539, DOI 10.1128/MCB.6.2.539; RIEGER M, 1988, J MOL BIOL, V204, P841, DOI 10.1016/0022-2836(88)90045-9; SCHERMER A, 1989, DIFFERENTIATION, V42, P103, DOI 10.1111/j.1432-0436.1989.tb00611.x; SCHERMER A, 1986, J CELL BIOL, V103, P49, DOI 10.1083/jcb.103.1.49; SCHWEIZER J, 1984, CELL, V37, P159, DOI 10.1016/0092-8674(84)90311-8; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; STOLER A, 1988, J CELL BIOL, V107, P427, DOI 10.1083/jcb.107.2.427; TSENG SCG, 1982, CELL, V30, P361, DOI 10.1016/0092-8674(82)90234-3; YEN MT, 1992, INVEST OPHTH VIS SCI, V33, P3235; ZHU G, 1992, CURR EYE RES, V11, P875, DOI 10.3109/02713689209033485	52	97	100	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24627	24636						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7523376				2022-12-27	WOS:A1994PQ49000021
J	LIN, Q; LUO, X; SAWADOGO, M				LIN, Q; LUO, X; SAWADOGO, M			ARCHAIC STRUCTURE OF THE GENE ENCODING TRANSCRIPTION FACTOR USF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIX-LOOP-HELIX; MAJOR LATE PROMOTER; RNA POLYMERASE-II; UPSTREAM STIMULATORY FACTOR; DNA-BINDING; ENHANCER-BINDING; PROTEIN; MYC; SEQUENCE; ELEMENT	The upstream stimulatory factor (USF) is a helix-loop-helix transcription factor that interacts with specific sites on the DNA that are also recognized by the MYC oncoproteins. We isolated genomic clones to the murine 44-kDa form of USF (USF2 gene). This unique gene spans 13 kilobases of DNA and is composed of 10 exons. The gene seems to have maintained its archaic structure, since many of the exons encode discrete functional domains of the transcription factor originally identified by protein sequence comparisons. A particularly striking HpaII tiny fragment island, extending over nearly 2,000 base pairs, surrounds the USF2 translation initiation site. This region, which includes the USF2 promoter and the first four exons, is characterized by an overall GC content greater than 74%. Analysis by S1 mapping and transient transfection assays revealed that the USF2 transcripts originate from an initiator element located within a highly GC-rich region that is surrounded by two long polyadenylate stretches and functions as a bidirectional promoter. Different forms of USF2 messages result from the presence or absence of the fourth exon in the processed USF2 mRNA. Alternative splicing correlates with the lack of a consensus lariat branch point in the third intron. Transient cotransfection assays revealed that the presence or absence of the amino acid sequences encoded by exon 4 affects considerably the transcription activation properties of the USF2 protein.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT MOLEC GENET, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center					NIGMS NIH HHS [GM38212] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038212] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIRD WC, 1994, J BIOL CHEM, V269, P883; ANDERS DG, 1992, J VIROL, V66, P3373, DOI 10.1128/JVI.66.6.3373-3384.1992; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CARTHEW RW, 1987, GENE DEV, V1, P973, DOI 10.1101/gad.1.9.973; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHODOSH LA, 1987, SCIENCE, V238, P684, DOI 10.1126/science.3672119; DREW HR, 1984, J MOL BIOL, V176, P535, DOI 10.1016/0022-2836(84)90176-1; DURET L, 1993, NUCLEIC ACIDS RES, V21, P2315, DOI 10.1093/nar/21.10.2315; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FERREDAMARE AR, 1994, EMBO J, V13, P180, DOI 10.1002/j.1460-2075.1994.tb06247.x; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GREENE JJ, 1988, CURRENT PROTOCOLS MO; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; GUO LH, 1983, METHOD ENZYMOL, V100, P60; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; HOLLAND SK, 1987, BIOSYSTEMS, V20, P181, DOI 10.1016/0303-2647(87)90044-X; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; JONES PA, 1990, P NATL ACAD SCI USA, V87, P6117, DOI 10.1073/pnas.87.16.6117; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; KAULEN H, 1991, MOL CELL BIOL, V11, P412, DOI 10.1128/MCB.11.1.412; KIRSCHBAUM BJ, 1992, MOL CELL BIOL, V12, P5094, DOI 10.1128/MCB.12.11.5094; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZLOWSKI MT, 1991, DEV BIOL, V148, P625, DOI 10.1016/0012-1606(91)90280-G; KUHL DPA, 1993, CURR OPIN GENET DEV, V3, P404, DOI 10.1016/0959-437X(93)90112-3; LAVIA P, 1987, EMBO J, V6, P2773, DOI 10.1002/j.1460-2075.1987.tb02572.x; LEBEDENKO EN, 1991, NUCLEIC ACIDS RES, V19, P6757, DOI 10.1093/nar/19.24.6757; LEGRAVEREND C, 1993, NUCLEIC ACIDS RES, V21, P1735, DOI 10.1093/nar/21.8.1735; LEMAIGRE FP, 1989, EUR J BIOCHEM, V181, P555, DOI 10.1111/j.1432-1033.1989.tb14760.x; LENNARD AC, 1991, MOL CELL BIOL, V11, P1281, DOI 10.1128/MCB.11.3.1281; LUE NF, 1989, P NATL ACAD SCI USA, V86, P486, DOI 10.1073/pnas.86.2.486; Maxam A M, 1980, Methods Enzymol, V65, P499; MICHAEL NL, 1994, J VIROL, V68, P979, DOI 10.1128/JVI.68.2.979-987.1994; MIYAMOTO NG, 1985, EMBO J, V4, P3563, DOI 10.1002/j.1460-2075.1985.tb04118.x; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; POTTER JJ, 1991, J BIOL CHEM, V266, P15457; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; REACH M, 1991, EMBO J, V10, P3439, DOI 10.1002/j.1460-2075.1991.tb04908.x; READ ML, 1993, BIOCHEM J, V295, P233, DOI 10.1042/bj2950233; REISMAN D, 1993, NUCLEIC ACIDS RES, V21, P345, DOI 10.1093/nar/21.2.345; RICCIO A, 1992, MOL CELL BIOL, V12, P1846, DOI 10.1128/MCB.12.4.1846; RUNKEL L, 1991, MOL CELL BIOL, V11, P1270, DOI 10.1128/MCB.11.3.1270; RYON JJ, 1993, J VIROL, V67, P4006, DOI 10.1128/JVI.67.7.4006-4016.1993; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO M, 1989, J BIOL CHEM, V264, P10251; SAWADOGO M, 1988, J BIOL CHEM, V263, P11985; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; SERFLING E, 1989, TRENDS GENET, V5, P131, DOI 10.1016/0168-9525(89)90049-8; SHRADER TE, 1990, J MOL BIOL, V216, P69, DOI 10.1016/S0022-2836(05)80061-0; SIMPSON RT, 1991, PROG NUCLEIC ACID RE, V40, P143; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; Sirito Mario, 1992, Gene Expression, V2, P231; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; STRUHL K, 1985, P NATL ACAD SCI USA, V82, P8419, DOI 10.1073/pnas.82.24.8419; THORN JT, 1991, ONCOGENE, V6, P1843; VANDYKE MW, 1992, GENE, V111, P99, DOI 10.1016/0378-1119(92)90608-R; VAULONT S, 1989, J MOL BIOL, V209, P205, DOI 10.1016/0022-2836(89)90273-8; VERRIJZER CP, 1994, SCIENCE, V264, P933, DOI 10.1126/science.8178153; WANG JC, 1993, BIOCHIM BIOPHYS ACTA, V1216, P73, DOI 10.1016/0167-4781(93)90039-G; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZIMMERMAN K, 1990, Critical Reviews in Oncogenesis, V2, P75	72	40	44	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					23894	23903						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7523363				2022-12-27	WOS:A1994PQ34600011
J	WELHAM, MJ; DECHERT, U; LESLIE, KB; JIRIK, F; SCHRADER, JW				WELHAM, MJ; DECHERT, U; LESLIE, KB; JIRIK, F; SCHRADER, JW			INTERLEUKIN (IL)-3 AND GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR, BUT NOT IL-4, INDUCE TYROSINE PHOSPHORYLATION, ACTIVATION, AND ASSOCIATION OF SHPTP2 WITH GRB2 AND PHOSPHATIDYLINOSITOL 3'-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; SIGNAL-TRANSDUCTION PATHWAYS; FACTOR RECEPTOR-BETA; SH2 DOMAIN; MOTH-EATEN; CELL LINES; PROTEIN; KINASE; EXPRESSION; MUTATIONS	Binding of interleukin (IL)-3 and granulocyte/macrophage colony stimulating factor (GM-CSF) to their high affinity cell surface receptors induces tyrosine phosphorylation of a similar set of protein substrates. We have identified one of these common substrates (p70) as the protein-tyrosine phosphatase SHPTP2. The Src homology 2 (SH2) domain of the adaptor protein Grb2 bound with high affinity to tyrosinephosphorylated SHPTP2 following treatment of cells with IL-3 or GM-CSF, but not IL-4. This interaction was inhibited by two phosphotyrosine peptides, based on sequences within SHPTP2, which conform to the postulated consensus sequence for Grb2 SH2 recognition. Following treatment with IL-3 or GM-CSF, but not IL-4, SHPTP2 co-immunoprecipitated with antibodies directed against the p85 subunit of PI 3'-kinase. This was partially blocked by the same phosphopeptides that blocked Grb2-SH2 binding to SRPTP2. Importantly treatment with IL-3 resulted in a 2-3-fold increase in SHPTP2 phosphatase activity. These results suggest that SHPTP2 may play an important role in integrating signals from the IL-3 and GM-CSF receptors to both Ras and PI 3'-kinase.	UNIV BRITISH COLUMBIA,DEPT MED,VANCOUVER V6T 1Z3,BC,CANADA	University of British Columbia	WELHAM, MJ (corresponding author), UNIV BRITISH COLUMBIA,BIOMED RES CTR,2222 HLTH SCI MALL,VANCOUVER V6T 1Z3,BC,CANADA.							BOULTON TG, 1994, J BIOL CHEM, V269, P11649; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; COSMAN D, 1993, CYTOKINE, V5, P95, DOI 10.1016/1043-4666(93)90047-9; DAUM G, 1993, ANAL BIOCHEM, V211, P50, DOI 10.1006/abio.1993.1231; DECHERT U, 1994, J BIOL CHEM, V269, P5602; DURONIO V, 1992, J BIOL CHEM, V267, P21856; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; GOLD MR, 1994, J BIOL CHEM, V269, P5403; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; HARDER KW, 1994, BIOCHEM J, V298, P395, DOI 10.1042/bj2980395; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LORENZ U, 1994, MOL CELL BIOL, V14, P1824, DOI 10.1128/MCB.14.3.1824; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; OKUDA K, 1992, BLOOD, V79, P2880; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; Sambrook J, 1989, MOL CLONING LABORATO; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; TAUCHI T, 1994, J BIOL CHEM, V269, P15381; TORIGOE T, 1992, BLOOD, V80, P617; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WELHAM MJ, 1994, J BIOL CHEM, V269, P21165; WELHAM MJ, 1994, J BIOL CHEM, V269, P5865; WELHAM MJ, 1992, J IMMUNOL, V149, P1683; WELHAM MJ, 1992, J IMMUNOL, V149, P2772; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577	44	132	133	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23764	23768						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	7522233				2022-12-27	WOS:A1994PQ34500058
J	CHEN, SRW; MACLENNAN, DH				CHEN, SRW; MACLENNAN, DH			IDENTIFICATION OF CALMODULIN, CA2+, AND RUTHENIUM RED-BINDING DOMAINS IN THE CA2+ RELEASE CHANNEL (RYANODINE RECEPTOR) OF RABBIT SKELETAL-MUSCLE SARCOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE; FUNCTIONAL EXPRESSION; ADENINE-NUCLEOTIDE; MOLECULAR-CLONING; PROTEINS; CA-2+; CDNA; PURIFICATION; SITE; ANTIBODIES	cDNAs encoding trpE fusion proteins containing fragments of the skeletal muscle Ca2+ release channel (ryanodine receptor) were expressed in bacteria. The fusion proteins, which covered about 90% of the linear sequence of the ryanodine receptor, were used to identify calmodulin- (CaM), Ca2+, and ruthenium red-binding regions in the ryanodine receptor through the use of I-125-CaM, Ca-45(2+), and ruthenium red overlay procedures. Six Ca2+-dependent CaM-binding domains were detected in the skeletal muscle ryanodine receptor. Strong CaM-binding domains were localized in regions 6, 11, 12, and 13, in subregions 6b, 11b, and 13b, and in short sequences 6b3, 11b1, and 13b2, lying between amino acid residues 2063 and 2091, 3611 and 3642, and 4303 and 4328. Weaker CaM-binding domains were localized in regions 4, 9, and 10 and in subregions 4b, 9b, and 10a, lying between residues 921 and 1173, 2804 and 2930, and 2961 and 3084. Most of these CaM-binding domains encompassed all or part of previously predicted CaM-binding sites. Strong Ca-45(2+)- and ruthenium red-binding domains were localized in the NH2- and COOH-terminal regions of the ryanodine receptor and in regions 6, 12, and 13. The Ca-45(2+)- and ruthenium red-binding sites in regions 6 and 12 were localized in subregions 6b and 12b, lying between residues 1861-2094 and 3657-3776. These data together with earlier studies (Chen, S.R W., Zhang, L., and MacLennan, D. H. (1992) J. Biol. Chem. 267, 23318-23326), show that strong CaM-, Ca2+-, and ruthenium red-binding domains are colocalized in the skeletal muscle ryanodine receptor.	UNIV TORONTO,CHARLES H BEST INST,BANTING & BEST DEPT MED RES,TORONTO M5G 1L6,ON,CANADA	University of Toronto								BRANDT NR, 1992, J MEMBRANE BIOL, V127, P35; CAMPBELL KP, 1981, J BIOL CHEM, V256, P4626; CAMPBELL KP, 1987, J BIOL CHEM, V262, P6460; CARLIN RK, 1981, J CELL BIOL, V89, P449, DOI 10.1083/jcb.89.3.449; CHAPMAN ER, 1991, J BIOL CHEM, V266, P207; CHARUK JHM, 1990, ANAL BIOCHEM, V188, P123, DOI 10.1016/0003-2697(90)90539-L; CHEN SRW, 1993, BIOCHEMISTRY-US, V32, P3743, DOI 10.1021/bi00065a029; CHEN SRW, 1993, J BIOL CHEM, V268, P13414; CHEN SRW, 1992, J BIOL CHEM, V267, P23318; CHEN SRW, 1993, J BIOL CHEM, V268, P22642; DIECKMANN CL, 1985, J BIOL CHEM, V260, P1513; ENDO M, 1985, CURR TOP MEMBR TRANS, V25, P181; FLANAGAN SD, 1984, ANAL BIOCHEM, V140, P510, DOI 10.1016/0003-2697(84)90202-1; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; HOFMANN F, 1993, J BIOL CHEM, V268, P10252; HYMEL L, 1988, P NATL ACAD SCI USA, V85, P441, DOI 10.1073/pnas.85.2.441; INUI M, 1987, J BIOL CHEM, V262, P1740; KELLY GM, 1991, J BIOL CHEM, V266, P12469; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI FA, 1987, BIOCHEM BIOPH RES CO, V143, P704, DOI 10.1016/0006-291X(87)91411-2; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; MARKS AR, 1990, J BIOL CHEM, V265, P13143; MCPHERSON PS, 1993, J BIOL CHEM, V268, P13765; MEISSNER G, 1986, BIOCHEMISTRY-US, V25, P244, DOI 10.1021/bi00349a034; MEISSNER G, 1987, J BIOL CHEM, V262, P3065; NAKAI J, 1990, FEBS LETT, V271, P169, DOI 10.1016/0014-5793(90)80399-4; OTSU K, 1990, J BIOL CHEM, V265, P13472; PENNER R, 1989, FEBS LETT, V259, P217, DOI 10.1016/0014-5793(89)81532-7; Sambrook J, 1989, MOL CLONING LABORATO; SEILER S, 1984, J BIOL CHEM, V259, P8550; SMITH JS, 1989, CIRC RES, V64, P352, DOI 10.1161/01.RES.64.2.352; SMITH JS, 1988, J GEN PHYSIOL, V92, P1, DOI 10.1085/jgp.92.1.1; SMITH JS, 1985, NATURE, V316, P446, DOI 10.1038/316446a0; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TREVES S, 1993, BIOCHEM J, V291, P757, DOI 10.1042/bj2910757; TUANA BS, 1988, FEBS LETT, V235, P219, DOI 10.1016/0014-5793(88)81266-3; VALE MGP, 1988, J BIOL CHEM, V263, P12872; VORHERR T, 1993, BIOCHEMISTRY-US, V32, P6081, DOI 10.1021/bi00074a020; WITCHER DR, 1991, J BIOL CHEM, V266, P11144; YANG HC, 1994, BIOCHEMISTRY-US, V33, P518, DOI 10.1021/bi00168a017; ZARKA A, 1993, EUR J BIOCHEM, V213, P147, DOI 10.1111/j.1432-1033.1993.tb17744.x; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	43	123	123	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 9	1994	269	36					22698	22704						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ163	7521330				2022-12-27	WOS:A1994PQ16300039
J	REISIN, IL; PRAT, AG; ABRAHAM, EH; AMARA, JF; GREGORY, RJ; AUSIELLO, DA; CANTIELLO, HF				REISIN, IL; PRAT, AG; ABRAHAM, EH; AMARA, JF; GREGORY, RJ; AUSIELLO, DA; CANTIELLO, HF			THE CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR IS A DUAL ATP AND CHLORIDE CHANNEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE; CL CHANNEL; CFTR; CELLS; GENE; EXPRESSION; BINDING; IDENTIFICATION; NUCLEOTIDES; ACTIVATION	The cystic fibrosis transmembrane conductance regulator (CFTR) belongs to a superfamily of proteins implicated in the transport of ions, proteins, and hydrophobic substances. Recent studies have demonstrated that CFTR is a protein kinase A-sensitive anion channel regulated by ATP. In the present study, patch-clamp techniques were used to assess the role of CFTR in the transport of Cl- and ATP. The stable transfection of mouse mammary carcinoma cells, C127i, with the cDNA for human CFTR resulted in the appearance of a diphenylamine-2-carboxylate-inhibitable Cl- channel, which was activated by cAMP under whole-cell and cell-attached conditions and by protein kinase A plus ATP under excised, inside-out conditions. CFTR expression was also associated with the electrodiffusional movement of ATP as indicated by the cAMP activation of ATP currents measured under whole-cell conditions. In excised, inside-out patches, it was demonstrated that ATP currents were mediated by ATP-conductive channels, which were also activated by protein kinase A and blocked by the Cl- channel blocker diphenylamine-2-carboxylate under excised, inside-out conditions. Single-channel currents observed in the presence of asymmetrical Cl-/ATP concentrations indicated that the same conductive pathway was responsible for both ATP and Cl- movement. Thus, CFTR is a multifunctional protein with more than one anion transport capability and may modify signal transduction pathways for Cl- or other secretory processes by the selective delivery of nucleotides to the extracellular domain.	HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02129 USA; GENZYME CORP, FRAMINGHAM, MA 01701 USA; MASSACHUSETTS GEN HOSP, RENAL UNIT, BOSTON, MA 02129 USA; MASSACHUSETTS GEN HOSP, DEPT RADIAT ONCOL, BOSTON, MA 02129 USA	Harvard University; Harvard Medical School; Sanofi-Aventis; Genzyme Corporation; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital								ABRAHAM EH, 1993, P NATL ACAD SCI USA, V90, P312, DOI 10.1073/pnas.90.1.312; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; ARISPE N, 1992, P NATL ACAD SCI USA, V89, P1539, DOI 10.1073/pnas.89.5.1539; BANDERALI U, 1992, AM J PHYSIOL, V263, pC1200, DOI 10.1152/ajpcell.1992.263.6.C1200; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BOUCHER RC, 1988, J PHYSIOL-LONDON, V405, P77, DOI 10.1113/jphysiol.1988.sp017322; BOUCHER RC, 1984, CYSTIC FIBROSIS HORI, P167; BULL HB, 1964, INTRO PHYSICAL BIOCH; CANTIELLO HF, 1994, J BIOL CHEM, V269, P11224; CANTIELLO HF, 1990, J BIOL CHEM, V265, P21624; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DISTEFANO A, 1985, PFLUG ARCH EUR J PHY, V405, pS95, DOI 10.1007/BF00581787; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; DUBYAK GR, 1990, BIOL ACTIONS EXTRACE; EGAN M, 1992, NATURE, V358, P581, DOI 10.1038/358581a0; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HSIUNG N, 1984, Journal of Molecular and Applied Genetics, V2, P497; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KNOWLES MR, 1991, NEW ENGL J MED, V325, P533, DOI 10.1056/NEJM199108223250802; LIN PY, 1987, J BIOL CHEM, V262, P15345; MEYERS KM, 1982, AM J PHYSIOL, V243, pR454, DOI 10.1152/ajpregu.1982.243.3.R454; Pullman B., 1963, QUANTUM BIOCH; QUINTON PM, 1992, NATURE, V360, P79, DOI 10.1038/360079a0; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; Ryan J W, 1971, Trans Assoc Am Physicians, V84, P297; SIGWORTH FJ, 1984, SINGLE CHANNEL RECOR, P3; SLAKEY LL, 1990, ANN NY ACAD SCI, V603, P366; Szent-Gyorgyi A., 1960, INTRO SUBMOLECULAR B; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; TRAMS EG, 1980, J THEOR BIOL, V87, P609, DOI 10.1016/0022-5193(80)90239-8; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; WELSH MJ, 1989, ANN NY ACAD SCI, V574, P44	39	300	304	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20584	20591						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	7519611				2022-12-27	WOS:A1994PB31700059
J	BOUCHARD, P; ZHAO, ZZ; BANVILLE, D; DUMAS, F; FISCHER, EH; SHEN, SH				BOUCHARD, P; ZHAO, ZZ; BANVILLE, D; DUMAS, F; FISCHER, EH; SHEN, SH			PHOSPHORYLATION AND IDENTIFICATION OF A MAJOR TYROSINE PHOSPHORYLATION SITE IN PROTEIN-TYROSINE-PHOSPHATASE 1C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; FACTOR-RECEPTOR; SIGNAL TRANSDUCTION; SH3 DOMAINS; EXPRESSION; CORKSCREW; ASSOCIATION; ACTIVATION; SEQUENCES; KINASES	Protein tyrosine phosphatase 1C (PTP1C) was the first member of the protein tyrosine phosphatase family demonstrated to contain the src homology 2 (SH2) domain. This enzyme is believed to play a role in regulating downstream signaling in hematopoietic cells since it was predominantly expressed in these cells. However, recent studies have revealed that the protein is expressed in other tissues as well. This report describes both the phosphorylation of PTP1C in non-hematopoietic cells treated with growth factors (in vivo) and incubation of purified PTP1C with a variety of protein kinases (in vitro). PTP1C was transiently phosphorylated in A431 and 293 cells and also when the purified enzyme was incubated with receptor protein tyrosine kinases. In vitro, the tyrosine-phosphorylated PTP1C underwent rapid auto-dephosphorylation, an effect which could be blocked by the addition of sodium vanadate. On the other hand, cells containing a PTP1C in which the catalytic site had been inactivated through mutagenesis, stably phosphorylated the phosphatase. These results suggested that PTP1C was responsible for its own auto-dephosphorylation. The sites of tyrosine phosphorylation were characterized from purified enzyme following treatment with insulin receptor kinase and from PTP1C expressed in 293 cells which had been stimulated with platelet-derived growth factor. Through the techniques of peptide mapping and microsequencing, Tyr(538) was determined to be the major phosphorylation site. This result was confirmed in vivo through site-specific mutagenesis of PTP1C expressed in 293 cells; changing Tyr(538) to Phe(538) completely abolished tyrosine phosphorylation of the molecule. In addition, Tyr(538) lies within the sequence ESEYGNI which can be correlated with the consensus sequence pYXNX associated with GRB2 binding. These results suggest that PTP1C plays a prominent role in growth factor receptor-mediated signal transduction within both hematopoietic cells and tissues of non-lymphoid origin.	NATL RES COUNCIL CANADA, BIOTECHNOL RES INST, MOLEC PHARMACEUT SECTOR, MONTREAL H4P 2R2, PQ, CANADA; UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA	National Research Council Canada; University of Washington; University of Washington Seattle					NIDDK NIH HHS [DK07902] Funding Source: Medline; NIGMS NIH HHS [GM42508] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK007902] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM042508] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; Gros E., 1967, METHOD ENZYMOL, V11, P238; HSU CYJ, 1990, CELL GROWTH DIFFER, V1, P191; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; SHEN SH, 1991, J BIOL CHEM, V266, P1058; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; TURCK C W, 1991, Peptide Research, V4, P36; UCHIDA T, 1993, J BIOL CHEM, V268, P11845; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VILLAMORUZZI E, 1993, J BIOL CHEM, V268, P18176; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; YEUNG YG, 1992, J BIOL CHEM, V267, P23447; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; ZHAO ZZ, 1991, BIOCHEM BIOPH RES CO, V176, P1454, DOI 10.1016/0006-291X(91)90450-L; ZHAO ZZ, 1993, J BIOL CHEM, V268, P2816; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	31	69	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19585	19589						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	7518460				2022-12-27	WOS:A1994NY33200060
J	ABRAMS, C; DENG, YJ; STEINER, B; OTOOLE, T; SHATTIL, SJ				ABRAMS, C; DENG, YJ; STEINER, B; OTOOLE, T; SHATTIL, SJ			DETERMINANTS OF SPECIFICITY OF A BACULOVIRUS-EXPRESSED ANTIBODY FAB FRAGMENT THAT BINDS SELECTIVELY TO THE ACTIVATED FORM OF INTEGRIN ALPHA(IIB)BETA(3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; ARG-GLY-ASP; SITE-DIRECTED MUTAGENESIS; GPIIB-IIIA; PLATELET RECEPTOR; TYROSINE PHOSPHORYLATION; MONOCLONAL-ANTIBODY; LIGAND-BINDING; CELL-ADHESION; ALPHA-CHAIN	PAC1 is an IgM kappa murine monoclonal antibody that, like the Arg-Gly-Asp-containing ligand fibrinogen, binds to integrin alpha(IIb)beta(3) only on activated platelets. The unique binding properties of PAC1 may be determined by its large size, its multivalency, and by variable region sequences, including an Arg-Tyr-Asp at residues 100A-C in H-CDR3. To study the molecular determinants of PAC1 function, baculoviruses containing cloned cDNA for the Fd heavy and kappa light chains of PAC1 were used to coinfect Sf9 insect cells. Infected cells secreted a soluble, monovalent, 50-kDa Fab fragment that bound saturably to agonist-stimulated platelets but not to resting cells. Fab binding was inhibited >85% by 10 mM EDTA, 1 mM RGDS, 1 mM fibrinogen gamma(397-411), or 12 mu M fibrinogen, but not by 1 mM RGES. Compared to PAC1 IgM, a 60-fold higher molar concentration of PAC1 Fab was required for half-maximal binding to platelets or for half-maximal inhibition of fibrinogen binding. PAC1 Fab bound to an activated form of alpha(IIb)beta(3) expressed in Chinese hamster ovary cells, but not to the resting form of the receptor in these cells or to alpha(V) beta(3) in human endothelial cells. Conversion of Asp(100C) to Glu by site-directed mutagenesis rendered the antibody inactive, indicating that the Arg-Tyr-Asp sequence in H-CDR3 is essential for PAC1 recognition of alpha(IIb)beta(3). Binding of fibrinogen or PAC1 IgM to platelets induced tyrosine phosphorylation of a 140-kDa platelet protein, but binding of PAC1 Fab did not. These studies demonstrate that the specificity of PAC1 for activated alpha(IIb)beta(3) is determined by an integrin recognition sequence within H-CDR3. However, the strength of this binding interaction and the ability of PAC1 to trigger signaling in platelets also depend on antibody valency.	UNIV PENN, SCH MED, DEPT MED, DIV HEMATOL ONCOL, PHILADELPHIA, PA 19104 USA; F HOFFMANN LA ROCHE & CO LTD, CH-4002 BASEL, SWITZERLAND; Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA	University of Pennsylvania; Roche Holding; Scripps Research Institute					NHLBI NIH HHS [HL-40387, HL-49845] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL040387, R01HL049845] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAMS CS, 1992, J BIOL CHEM, V267, P2775; ADLER M, 1991, SCIENCE, V253, P445, DOI 10.1126/science.1862345; ALIG L, 1992, J MED CHEM, V35, P4393, DOI 10.1021/jm00101a017; AUMAILLEY M, 1991, FEBS LETT, V291, P50, DOI 10.1016/0014-5793(91)81101-D; BARBAS CF, 1993, P NATL ACAD SCI USA, V90, P10003, DOI 10.1073/pnas.90.21.10003; BEACHAM DA, 1992, J BIOL CHEM, V267, P3409; BENNETT JS, 1988, J BIOL CHEM, V263, P12948; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; CARRELL NA, 1985, J BIOL CHEM, V260, P1743; CHERESH DA, 1989, CELL, V58, P945, DOI 10.1016/0092-8674(89)90946-X; CHERNY RC, 1993, J BIOL CHEM, V268, P9725; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLLER BS, 1986, J CELL BIOL, V103, P451, DOI 10.1083/jcb.103.2.451; COLLER BS, 1991, BLOOD, V77, P75; COLLER BS, 1985, J CLIN INVEST, V76, P101, DOI 10.1172/JCI111931; COLLER BS, 1992, ANNU REV MED, V43, P171; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; DU XP, 1993, J BIOL CHEM, V268, P23087; FARRELL DH, 1992, P NATL ACAD SCI USA, V89, P10729, DOI 10.1073/pnas.89.22.10729; FAUCHERE JL, 1993, INT J PEPT PROT RES, V42, P440; GARTNER TK, 1985, J BIOL CHEM, V260, P1891; Ginsberg Mark H., 1992, Current Opinion in Cell Biology, V4, P766, DOI 10.1016/0955-0674(92)90099-X; GOLDEN A, 1990, J CELL BIOL, V111, P3117, DOI 10.1083/jcb.111.6.3117; GOULD RJ, 1990, P SOC EXP BIOL MED, V195, P168, DOI 10.3181/00379727-195-43129B; GRABER SG, 1992, J BIOL CHEM, V267, P13123; Habermann BF, 1993, CURR OPIN CELL BIOL, V5, P864, DOI 10.1016/0955-0674(93)90036-P; HAIMOVICH B, 1993, J BIOL CHEM, V268, P15868; HASEMANN CA, 1990, P NATL ACAD SCI USA, V87, P3942, DOI 10.1073/pnas.87.10.3942; HAWIGER J, 1989, BIOCHEMISTRY-US, V28, P2909, DOI 10.1021/bi00433a024; HUANG MM, 1993, J CELL BIOL, V122, P473, DOI 10.1083/jcb.122.2.473; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JORDAN R, 1991, THROMB HAEMOSTASIS, V65, P828; Juliano RL, 1993, CURR OPIN CELL BIOL, V5, P812, DOI 10.1016/0955-0674(93)90030-T; Kabat E. A., 1987, SEQUENCES PROTEINS I, DOI 10.1016/0003-2697(84)90805-4; KOUNS WC, 1992, J BIOL CHEM, V267, P18844; KOUNS WC, 1992, BLOOD, V80, P2539; KUIPERS OP, 1991, NUCLEIC ACIDS RES, V19, P4558, DOI 10.1093/nar/19.16.4558; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE G, 1993, PROTEIN ENG, V6, P745, DOI 10.1093/protein/6.7.745; MCLANE M, 1993, THROMB HAEMOSTASIS, V69, P925; MULLER CE, 1983, J IMMUNOL, V131, P877; NESBIT M, 1992, J IMMUNOL METHODS, V151, P201, DOI 10.1016/0022-1759(92)90118-D; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PLOW EF, 1992, SEMIN THROMB HEMOST, V18, P324, DOI 10.1055/s-2007-1002571; PLOW EF, 1989, PROG HEMOST THROMB, V9, P117; PLOW EF, 1985, P NATL ACAD SCI USA, V82, P8057, DOI 10.1073/pnas.82.23.8057; PUTLITZ JZ, 1990, BIO-TECHNOL, V8, P651, DOI 10.1038/nbt0790-651; RANDEN I, 1993, EUR J IMMUNOL, V23, P2682, DOI 10.1002/eji.1830231044; RAO SN, 1992, PEPTIDE RES, V5, P148; REMOLDODONNELL E, 1992, BLOOD, V79, P1754; SCARBOROUGH RM, 1993, J BIOL CHEM, V268, P1066; SHATTIL SJ, 1993, THROMB HAEMOSTASIS, V70, P224; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SHATTIL SJ, 1987, BLOOD, V70, P307; SHATTIL SJ, 1986, BLOOD, V68, P1224; SHATTIL SJ, 1992, IMMUNOMETHODS, V1, P53; SISK WP, 1992, BIOTECHNIQUES, V13, P186; SMITH JW, 1990, J BIOL CHEM, V265, P12267; TAUB R, 1989, J BIOL CHEM, V264, P259; TESSIER DC, 1991, GENE, V98, P177, DOI 10.1016/0378-1119(91)90171-7; TOMIYAMA Y, 1992, J BIOL CHEM, V267, P18085; UDAKA K, 1990, MOL IMMUNOL, V27, P25, DOI 10.1016/0161-5890(90)90057-7; WEBB N R, 1990, Technique (Philadelphia), V2, P173; WEISEL JW, 1992, J BIOL CHEM, V267, P16637; WEISS HJ, 1991, THROMB HAEMOSTASIS, V65, P202; WILSON IA, 1993, CURR OPIN STRUC BIOL, V3, P113, DOI 10.1016/0959-440X(93)90210-C	69	49	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					18781	18788						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	7518445				2022-12-27	WOS:A1994NX32700017
J	VONZASTROW, M; KOBILKA, BK				VONZASTROW, M; KOBILKA, BK			ANTAGONIST-DEPENDENT AND ANTAGONIST-INDEPENDENT STEPS IN THE MECHANISM OF ADRENERGIC-RECEPTOR INTERNALIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DESENSITIZATION; ENDOCYTOSIS; MEMBRANE; SIGNAL; CELLS	Epitope tagging and immunocytochemical techniques were used to examine the agonist regulated internalization of human beta(2)-adrenergic receptors in 293 cells. In the absence of agonist, receptors tagged with monoclonal antibody remain in the plasma membrane for >1 h. In the presence of agonist, tagged receptors are endocytosed within 10 min. Endocytosed receptors are located in endosomes and can be recycled to the plasma membrane. In the prolonged presence of agonist, receptor endocytosis continues even after maximum sequestration of surface receptors (measured by radioligand binding to intact cells) has occurred. The process of receptor endocytosis requires cellular ATP and is temperature-dependent. At 4 degrees C, no agonist-induced redistribution of receptors located in the plasma membrane is observed. At 16 degrees C, agonist causes receptors to cluster in and around coated invaginations of the plasma membrane, but receptor endocytosis does not occur. Agonist treatment of cells at 16 degrees C, but not 4 degrees C, predisposes receptors to agonist independent endocytosis upon warming to 37 degrees C. These studies suggest that: 1) beta(2)-adrenerse receptors reside stably in the plasma membrane of untreated cells, while they continuously cycle between the plasma membrane and endosomes in the presence of agonist; 2) agonist regulates an early step in the endocytosis mechanism, which is associated with the redistribution of adrenergic receptors between distinct microdomains of the plasma membrane; and 3) later steps in the endocytosis mechanism do not require agonist and may utilize the same endocytic machinery that mediates the endocytosis of constitutively recycling receptors.	STANFORD UNIV, SCH MED, HOWARD HUGHES MED INST, DEPT CARDIOVASC MED, STANFORD, CA 94305 USA; STANFORD UNIV, SCH MED, HOWARD HUGHES MED INST, DEPT MOLEC & CELLULAR PHYSIOL, STANFORD, CA 94305 USA	Howard Hughes Medical Institute; Stanford University; Howard Hughes Medical Institute; Stanford University				Kobilka, Brian/0000-0001-5958-3990				BARAK LS, 1994, J BIOL CHEM, V269, P2790; CARON MG, 1993, RECENT PROG HORM RES, V48, P277; CLARK RB, 1986, ADV CYCLIC NUCL PROT, V20, P151; COLLAWN JF, 1993, J BIOL CHEM, V268, P21686; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; HAUSDORFF WP, 1990, SYM SOC EXP BIOL, V44, P225; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HERTEL C, 1990, J BIOL CHEM, V265, P17988; HOPKINS CR, 1992, TRENDS BIOCHEM SCI, V17, P27, DOI 10.1016/0968-0004(92)90423-7; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KURZ JB, 1992, MOL PHARMACOL, V41, P375; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PERKINS JP, 1991, BETA ADRENERGIC RECE, P73; RAPOSO G, 1989, EUR J CELL BIOL, V50, P340; ROHRER J, 1993, MOL BIOL CELL, V4, P511, DOI 10.1091/mbc.4.5.511; SCHMID SL, 1990, J CELL BIOL, V111, P2307, DOI 10.1083/jcb.111.6.2307; STAEHELIN M, 1982, EMBO J, V1, P187, DOI 10.1002/j.1460-2075.1982.tb01145.x; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; VONZASTROW M, 1993, J BIOL CHEM, V268, P763; YU SS, 1993, J BIOL CHEM, V268, P337	21	161	163	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18448	18452						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	7518433				2022-12-27	WOS:A1994NW79800036
J	CLEGHON, V; MORRISON, DK				CLEGHON, V; MORRISON, DK			RAF-1 INTERACTS WITH FYN AND SRC IN A NON-PHOSPHOTYROSINE-DEPENDENT MANNER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE-THREONINE KINASE; PROTEIN-TYROSINE KINASES; GROWTH-FACTOR RECEPTORS; SIGNAL TRANSDUCTION; SH2 DOMAINS; PHOSPHATIDYLINOSITOL 3-KINASE; REGULATORY DOMAIN; PHOSPHORYLATION; BINDING; ASSOCIATION	To identify novel proteins capable of associating with the Raf-1 serine/threonine kinase, we investigated whether Raf-1 could interact with the Src homology 2 (SH2) domains of various signal-transducing molecules. In this report, we demonstrate that Raf-1 associated with the SH2 domain of Fyn (a member of the Src tyrosine kinase family) but not with the SH2 domains of phospholipase C-gamma 1, the p85 alpha subunit of phosphatidylinositol 3-kinase, and SH2 containing protein tyrosine phosphatase 2. Unlike most SH2 domain interactions that require tyrosine-phosphorylated residues, the Raf-1/Fyn SH2 domain association was dependent on the serine phosphorylation of Raf-1. Our results also demonstrate that Raf-1 interacted with the SH2 domain of Src and that this interaction was destabilized by mutation of Arg(175) found within the conserved SH2 domain FLVRES sequence. In addition, we show that inclusion of additional Src sequences containing the SH3 domain increased the association of Raf-1 with the Src SH2 domain. Finally, using the baculovirus/Sf9 cell system, we show that coexpression of Raf-1 with full-length Fyn/Src resulted in the coimmunoprecipitation of Raf-1 with Fyn/Src, the tyrosine phosphorylation of Raf-1, and the stimulation of Raf-1 kinase activity. These results suggest that Raf-1 may form a functional complex with Fyn/Src mediated in part by SH2 domains and the serine phosphorylation of Raf-1.			CLEGHON, V (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,MOLEC MECHANISMS CAREINOGENESIS LAB,FREDERICK,MD 21702, USA.				OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BIBBINS KB, 1993, MOL CELL BIOL, V13, P7278, DOI 10.1128/MCB.13.12.7278; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARROLL MP, 1990, J BIOL CHEM, V265, P812; COOPER JA, 1993, MOL CELL BIOL, V13, P1737, DOI 10.1128/MCB.13.3.1737; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; FABIAN JR, 1993, J CELL BIOL, V122, P645, DOI 10.1083/jcb.122.3.645; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FINNEY RE, 1993, CURR BIOL, V3, P805, DOI 10.1016/0960-9822(93)90214-9; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; GILLIS S, 1977, NATURE, V268, P154, DOI 10.1038/268154a0; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; HAN M, 1993, NATURE, V363, P137; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; KOBAYASHI N, 1993, P NATL ACAD SCI USA, V90, P4201, DOI 10.1073/pnas.90.9.4201; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; KYRIAKIS JM, 1993, J BIOL CHEM, V268, P16009; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MEISENHELDER J, 1992, MOL CELL BIOL, V12, P5843, DOI 10.1128/MCB.12.12.5843; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; MORRISON DK, 1990, CANCER CELL-MON REV, V2, P377; MULLER AJ, 1992, MOL CELL BIOL, V12, P5087, DOI 10.1128/MCB.12.11.5087; PARK D, 1992, MOL CELL BIOL, V12, P5816, DOI 10.1128/MCB.12.12.5816; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; ROBERTS TM, 1992, NATURE, V360, P534, DOI 10.1038/360534a0; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; TSUDA L, 1993, CELL, V72, P407, DOI 10.1016/0092-8674(93)90117-9; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	51	89	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17749	17755						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	7517401				2022-12-27	WOS:A1994NU12800063
J	LIU, L; CUTLER, RL; MUI, ALF; KRYSTAL, G				LIU, L; CUTLER, RL; MUI, ALF; KRYSTAL, G			STEEL FACTOR STIMULATES THE SERINE/THREONINE PHOSPHORYLATION OF THE INTERLEUKIN-3 RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL GROWTH-FACTOR; PROTEIN-KINASE-C; HEMATOPOIETIC PROGENITOR CELLS; TYROSINE PHOSPHORYLATION; COLONY FORMATION; KIT-LIGAND; SIGNAL-TRANSDUCTION; PHORBOL ESTER; GENE-PRODUCT; MAST-CELLS	The murine interleukin-3 (IL-3) dependent cell line, B6SUtA(1), which expresses high IL-3 receptor (IL-3R) numbers, was found to proliferate in a greater than additive fashion when grown in the presence of IL-3 and steel factor (SF). However, pretreatment of these cells with SF had no effect on the number of IL-3Rs expressed at the cell surface nor their affinity for IL-3. Interestingly, although, SF did induce the rapid and transient serine- and threonine-specific phosphorylation of the beta(IL-3) subunit of the IL-3R. This serine/threonine phosphorylation was also observed with the phorbol ester, 12-O-tetradecanoylphorbol-13-acetate, and both the 12-O-tetradecanoylphorbol-13-acetate- and SF-induced phosphorylation of the IL-3R could be inhibited with the highly specific protein kinase C inhibitor, bisindolyl-maleimide (Compound 3), suggesting that SF might be stimulating this phosphorylation via protein kinase C. This SF-induced phosphorylation also occurred within 10 min of incubation at 4 degrees C, indicating that this might be a relatively early event in the c-kit signaling pathway. Last, this SF-induced phosphorylation of the IL-3R occurred in the presence of the tyrosine kinase inhibitor, genistein, at levels which blocked the autophosphorylation of c-kit. This suggests that c-kit might be capable of mediating this cross-talk phenomenon in the absence of its endogenous tyrosine kinase activity.	BRITISH COLUMBIA CANC AGCY,TERRY FOX LAB,VANCOUVER V5Z 1L3,BC,CANADA; UNIV BRITISH COLUMBIA,VANCOUVER V5Z 1L3,BC,CANADA	British Columbia Cancer Agency; University of British Columbia				Krystal, Gerald/0000-0002-1961-6281				ALAI M, 1992, J BIOL CHEM, V267, P18021; ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; BAXTER GT, 1992, BIOCHEMISTRY-US, V31, P10950, DOI 10.1021/bi00160a002; BERNSTEIN ID, 1991, BLOOD, V77, P2316; BLUMEJENSEN P, 1993, EMBO J, V12, P4199, DOI 10.1002/j.1460-2075.1993.tb06104.x; BOSWELL HS, 1990, EXP HEMATOL, V18, P794; BRANDT J, 1992, BLOOD, V79, P634; BROOKS G, 1989, CARCINOGENESIS, V10, P283, DOI 10.1093/carcin/10.2.283; BROXMEYER HE, 1991, CANCER CELL-MON REV, V3, P480; BROXMEYER HE, 1991, EXP HEMATOL, V19, P143; BROXMEYER HE, 1991, BLOOD, V77, P2142; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; CATLETT JP, 1991, BLOOD, V78, P3186; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DAMEN J, 1992, BLOOD, V80, P1923; DAVIS PD, 1989, FEBS LETT, V259, P61, DOI 10.1016/0014-5793(89)81494-2; DEVRIES P, 1991, J EXP MED, V173, P1205, DOI 10.1084/jem.173.5.1205; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; DURONIO V, 1992, J BIOL CHEM, V267, P21856; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; GRUNBERGER G, 1982, AM J PHYSIOL, V243, pE319, DOI 10.1152/ajpendo.1982.243.4.E319; GUILBERT LJ, 1983, J CELL PHYSIOL, V115, P276, DOI 10.1002/jcp.1041150310; HENDRIE PC, 1991, EXP HEMATOL, V19, P1031; HERMINE O, 1993, BLOOD, V82, pA231; HEYWORTH CM, 1993, BLOOD, V81, P894; HIRAYAMA F, 1992, P NATL ACAD SCI USA, V89, P5907, DOI 10.1073/pnas.89.13.5907; HIRAYAMA F, 1993, J CELL BIOCH B, V17, P225; HORIE M, 1993, J BIOL CHEM, V268, P968; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; ISFORT RJ, 1988, P NATL ACAD SCI USA, V85, P7982, DOI 10.1073/pnas.85.21.7982; JACOBSEN SEW, 1992, BLOOD, V80, P678; KANAKURA Y, 1991, J BIOL CHEM, V266, P490; LEE LS, 1978, SCIENCE, V202, P313, DOI 10.1126/science.308698; Lehtola L, 1989, GROWTH FACTORS, V1, DOI 10.3109/08977198909000256; LEV S, 1991, EMBO J, V10, P647, DOI 10.1002/j.1460-2075.1991.tb07993.x; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MCNIECE IK, 1991, EXP HEMATOL, V19, P226; METCALF D, 1991, P NATL ACAD SCI USA, V88, P6239, DOI 10.1073/pnas.88.14.6239; MIGLIACCIO G, 1991, P NATL ACAD SCI USA, V88, P7420, DOI 10.1073/pnas.88.16.7420; MIYAZAWA K, 1994, BLOOD, V83, P137; MIYAZAWA K, 1991, EXP HEMATOL, V19, P1110; MUI ALF, 1992, P NATL ACAD SCI USA, V89, P10812, DOI 10.1073/pnas.89.22.10812; MUI ALF, 1992, EXP HEMATOL, V20, P753; MURTHY SC, 1990, EXP HEMATOL, V18, P11; MURTHY SC, 1989, BLOOD, V73, P1180; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; NOCKA K, 1990, EMBO J, V9, P3287, DOI 10.1002/j.1460-2075.1990.tb07528.x; OEZ S, 1993, EXP HEMATOL, V21, P1144; OKUDA K, 1991, BLOOD, V78, P1928; OKUDA K, 1992, BLOOD, V79, P2880; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SORENSEN P, 1989, J BIOL CHEM, V264, P19253; TESTA U, 1993, BLOOD, V81, P1442; THOMOPOULOS P, 1982, EUR J BIOCHEM, V129, P389, DOI 10.1111/j.1432-1033.1982.tb07062.x; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TSUJI K, 1991, J CELL PHYSIOL, V148, P362, DOI 10.1002/jcp.1041480306; TSUJI K, 1991, BLOOD, V78, P1223; TSUJI K, 1992, BLOOD, V79, P2855; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WALKER F, 1985, CELL, V43, P269, DOI 10.1016/0092-8674(85)90032-7; WELHAM MJ, 1991, MOL CELL BIOL, V11, P2901, DOI 10.1128/MCB.11.5.2901; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YEE NS, 1993, J BIOL CHEM, V268, P14189; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	69	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16774	16779						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	7515884				2022-12-27	WOS:A1994NR29600042
J	GROBLEWSKI, GE; WAGNER, ACC; WILLIAMS, JA				GROBLEWSKI, GE; WAGNER, ACC; WILLIAMS, JA			CYCLOSPORINE-A INHIBITS CA2+/CALMODULIN-DEPENDENT PROTEIN PHOSPHATASE AND SECRETION IN PANCREATIC ACINAR-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXOCRINE PANCREAS; SIGNAL TRANSDUCTION; MEDIATOR RELEASE; HUMAN BASOPHILS; OKADAIC ACID; CALCINEURIN; CYCLOPHILIN; FK-506; FK506; EXOCYTOSIS	The immunosuppressant cyclosporin A (CsA) was utilized as a highly specific inhibitor of the Ca2+/calmodulin-dependent protein phosphatase, PP2B in rat pancreatic acinar cells. Treatment of cells with CsA for 20 min resulted in a concentration-dependent inhibition of PP2B that was maximal (>90%) at 1 mu M and exhibited an IC50 of 65 nM. CsA also inhibited cholecystokinin-, 100 pM, or carbamylcholine-, 10 mu M, induced amylase release in a concentration-dependent manner. A maximal inhibition to 55% of stimulated control cells occurred at 1 mu M CsA with half-maximal inhibition occurring at approximately 200 nM. Secretion in response to 1 mu M 12-O-tetradecanoylphorbol-13-acetate (TPA) was uneffected by CsA treatment. Conversely, amylase release stimulated by the Ca2+ mobilizing agent, thapsigargin, when added alone at 2 mu M or in combination with TPA, was inhibited by CsA to 66 and 61% of control cells, respectively. These data indicate that CsA-mediated inhibition occurs only when stimulation involves an increase in intracellular Ca2+. In addition, analogues of CsA, 6-methyl-alanine-CsA, and 11-methyl-leucine-CsA had no effect on PP2B activity or amylase secretion. The chemically distinct immunosuppressant, FK506, produced only partial inhibition of PP2B activity and did not significantly inhibit amylase secretion at concentrations up to 1 mu M. Two-dimensional gel electrophoresis of proteins from P-32-labeled acinar cells revealed that CsA specifically blocked the cholecystokinin stimulated dephosphorylation of a 24-kDa protein in a concentration range similar to that seen for inhibition of secretion. Using P-32-labeled cytosol and purified calcineurin, a Ca2+- and calmodulin-dependent dephosphorylation of the 24-kDa protein was also demonstrated in vitro. Collectively, these data indicate that the Ca2+/calmodulin-dependent protein phosphatase, PP2B, plays a significant role in stimulus-secretion coupling in pancreatic acinar cells.	UNIV MICHIGAN,DEPT INTERNAL MED,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan	GROBLEWSKI, GE (corresponding author), UNIV MICHIGAN,DEPT PHYSIOL,7737 MED SCI 2,ANN ARBOR,MI 48109, USA.			Williams, John/0000-0002-6063-7615	NIDDK NIH HHS [NRSA DK08819, NIDDK DK-41122] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK008819, R01DK041122] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANTONI FA, 1993, BIOCHEM BIOPH RES CO, V194, P226, DOI 10.1006/bbrc.1993.1808; ASWAD DW, 1981, J BIOL CHEM, V256, P3487; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BLUMENTHAL DK, 1986, J BIOL CHEM, V261, P8140; BURNHAM DB, 1985, BIOCHEM J, V231, P335, DOI 10.1042/bj2310335; BURNHAM DB, 1982, J BIOL CHEM, V257, P523; BURNHAM DB, 1986, BIOCHEM J, V235, P125, DOI 10.1042/bj2350125; CHANTLER PD, 1985, J CELL BIOL, V101, P207, DOI 10.1083/jcb.101.1.207; CIRILLO R, 1990, J IMMUNOL, V144, P3891; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; DEPAULIS A, 1991, J IMMUNOL, V146, P2374; DOI R, 1993, GASTROENTEROLOGY, V104, P1153, DOI 10.1016/0016-5085(93)90287-M; DOI R, 1993, PANCREAS, V7, P197; DOI RH, 1993, J PHARMACOL EXP THER, V264, P873; DURETTE PL, 1988, TRANSPLANT P, V20, P51; FORREST MJ, 1991, BIOCHEM PHARMACOL, V42, P1221, DOI 10.1016/0006-2952(91)90257-6; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; HEMMINGS HC, 1992, J NEUROCHEM, V59, P1053, DOI 10.1111/j.1471-4159.1992.tb08347.x; HULTSCH T, 1990, J IMMUNOL, V144, P2659; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P255, DOI 10.1111/j.1432-1033.1983.tb07357.x; JUNG DH, 1980, CLIN CHIM ACTA, V100, P7, DOI 10.1016/0009-8981(80)90179-5; KAYE RE, 1992, P NATL ACAD SCI USA, V89, P8542, DOI 10.1073/pnas.89.18.8542; Kincaid Randall, 1993, V27, P1; KINCAID RL, 1987, P NATL ACAD SCI USA, V84, P1118, DOI 10.1073/pnas.84.4.1118; KING MM, 1984, J BIOL CHEM, V259, P8080; LANCKI DW, 1989, J IMMUNOL, V142, P416; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; MCKEON F, 1991, CELL, V66, P823, DOI 10.1016/0092-8674(91)90426-Y; METZ DC, 1992, J BIOL CHEM, V267, P20620; MOMAYEZI M, 1987, J CELL BIOL, V105, P181, DOI 10.1083/jcb.105.1.181; RYFFEL B, 1991, IMMUNOLOGY, V72, P399; WAGNER ACC, 1992, BIOCHEM BIOPH RES CO, V189, P1606, DOI 10.1016/0006-291X(92)90260-R; WAGNER ACC, 1992, AM J PHYSIOL, V263, pC1172, DOI 10.1152/ajpcell.1992.263.6.C1172; WALSH CT, 1992, J BIOL CHEM, V267, P13115; WASCHULEWSKI IH, 1993, BRIT J PHARMACOL, V108, P892, DOI 10.1111/j.1476-5381.1993.tb13483.x; Williams John A., 1993, P167; WISHART MJ, 1993, GASTROENTEROLOGY, V104, pA343; YULE DI, 1993, AM J PHYSIOL, V264, pG786, DOI 10.1152/ajpgi.1993.264.4.G786	40	78	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15111	15117						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	7515049				2022-12-27	WOS:A1994NP73800041
J	GUMUCIO, DL; SHELTON, DA; BLANCHARDMCQUATE, K; GRAY, T; TARLE, S; HEILSTEDTWILLIAMSON, H; SLIGHTOM, JL; COLLINS, F; GOODMAN, M				GUMUCIO, DL; SHELTON, DA; BLANCHARDMCQUATE, K; GRAY, T; TARLE, S; HEILSTEDTWILLIAMSON, H; SLIGHTOM, JL; COLLINS, F; GOODMAN, M			DIFFERENTIAL PHYLOGENETIC FOOTPRINTING AS A MEANS TO IDENTIFY BASE CHANGES RESPONSIBLE FOR RECRUITMENT OF THE ANTHROPOID GAMMA-GENE TO A FETAL EXPRESSION PATTERN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPSILON-GLOBIN GENE; STAGE SELECTOR ELEMENT; AMINO-ACID SEQUENCES; LOCUS-CONTROL REGION; HEREDITARY PERSISTENCE; 5'-FLANKING REGION; NUCLEAR-PROTEIN; FACTOR-BINDING; PROMOTER; HPFH	Expression of the anthropoid (simian) gamma gene in fetal life contrasts with the exclusively embryonic expression pattern of the gamma-like genes of other eutherian mammals. To elucidate the factors responsible for this change in expression pattern, we utilized a strategy called differential phylogenetic footprinting (DPF). This strategy entails the following: (a) identification, within regulatory regions, of the gamma promoter, of individual nucleotides that differ between human (fetal expression), and galago (embryonic expression) gamma genes, (b) analysis of the effect of these nucleotide differences on the binding of nuclear proteins to human and galago sequences, and (c) assessment of the functional consequences of these binding changes in expression assays. The DPF analysis revealed several proteins that bind upstream from the CCAAT motif in the galago gamma promoter but do not bind to the corresponding region of the human gamma promoter. In transfection assays, binding of these proteins is associated with erythroid-specific repression of promoter strength. Binding sites for these proteins also occur near the CCAAT box of other embryonically expressed genes, including rabbit, mouse, and dwarf lemur gamma genes and the human epsilon globin gene. These data are consistent with the hypothesis that sequence changes near the proximal CCAAT box in the ancestral simian gamma gene may have facilitated a novel expression pattern by reducing the binding of repressors that act in the fetal stage.	UNIV MICHIGAN, HOWARD HUGHES MED INST, ANN ARBOR, MI 48109 USA; WAYNE STATE UNIV, SCH MED, DEPT ANAT & CELL BIOL, DETROIT, MI 48201 USA; UPJOHN CO, MOLEC BIOL UNIT 7242, KALAMAZOO, MI 49007 USA; NIH, NATL CTR HUMAN GENOME RES, BETHESDA, MD 20892 USA	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; Wayne State University; Pfizer; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	GUMUCIO, DL (corresponding author), UNIV MICHIGAN, SCH MED, DEPT ANAT & CELL BIOL, 5793A MED SCI 2, ANN ARBOR, MI 48109 USA.				NCRR NIH HHS [MO1-RR00042] Funding Source: Medline; NHLBI NIH HHS [HL-33940] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000042] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033940] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bailey WJ, 1992, MOL PHYLOGENET EVOL, V1, P97, DOI 10.1016/1055-7903(92)90024-B; CAO SX, 1989, P NATL ACAD SCI USA, V86, P5306, DOI 10.1073/pnas.86.14.5306; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; FITCH DHA, 1991, P NATL ACAD SCI USA, V88, P7396, DOI 10.1073/pnas.88.16.7396; FITCH DHA, 1990, J BIOL CHEM, V265, P781; FRASER P, 1993, GENE DEV, V7, P106, DOI 10.1101/gad.7.1.106; GOODMAN M, 1979, SYST ZOOL, V28, P132, DOI 10.2307/2412519; GOODMAN M, 1984, J MOL BIOL, V180, P803, DOI 10.1016/0022-2836(84)90258-4; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; GUMUCIO DL, 1991, BLOOD, V78, P1853; GUMUCIO DL, 1992, MOL CELL BIOL, V12, P4919, DOI 10.1128/MCB.12.11.4919; GUMUCIO DL, 1988, MOL CELL BIOL, V8, P5310, DOI 10.1128/MCB.8.12.5310; GUMUCIO DL, 1993, P NATL ACAD SCI USA, V90, P6018, DOI 10.1073/pnas.90.13.6018; GUMUCIO DL, 1991, 7TH P C HEM SWITCH, P277; HARDIES SC, 1984, J BIOL CHEM, V259, P3748; HARDISON R, 1993, NUCLEIC ACIDS RES, V21, P1265, DOI 10.1093/nar/21.5.1265; HARDISON RC, 1984, MOL BIOL EVOL, V1, P390; HAYASAKA K, 1992, J MOL BIOL, V224, P875, DOI 10.1016/0022-2836(92)90568-5; HILL A, 1984, J BIOL CHEM, V259, P3739; JANE SM, 1992, EMBO J, V11, P2961, DOI 10.1002/j.1460-2075.1992.tb05366.x; JANE SM, 1993, MOL CELL BIOL, V13, P3272, DOI 10.1128/MCB.13.6.3272; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; KOOP BF, 1989, MOL BIOL EVOL, V6, P580; LLOYD JA, 1989, NUCLEIC ACIDS RES, V17, P4339, DOI 10.1093/nar/17.11.4339; MANTOVANI R, 1988, NUCLEIC ACIDS RES, V16, P7783, DOI 10.1093/nar/16.16.7783; MANTOVANI R, 1989, NUCLEIC ACIDS RES, V17, P6681, DOI 10.1093/nar/17.16.6681; MANTOVANI R, 1987, NUCLEIC ACIDS RES, V15, P9349, DOI 10.1093/nar/15.22.9349; MARTIN DIK, 1989, NATURE, V338, P435, DOI 10.1038/338435a0; MOORE GW, 1973, J THEOR BIOL, V38, P459, DOI 10.1016/0022-5193(73)90252-X; MORGAN DA, 1991, BLOOD, V78, P2860; OTTOLENGHI S, 1988, BLOOD, V71, P815; PEREZSTABLE C, 1990, MOL CELL BIOL, V10, P1116, DOI 10.1128/MCB.10.3.1116; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; STOMING TA, 1989, BLOOD, V73, P329; SUPERTIFURGA G, 1988, EMBO J, V7, P3099, DOI 10.1002/j.1460-2075.1988.tb03176.x; SURREY S, 1988, BLOOD, V71, P807; TAGLE DA, 1988, J MOL BIOL, V203, P439, DOI 10.1016/0022-2836(88)90011-3; [No title captured]; [No title captured]	42	39	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15371	15380						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	7515056				2022-12-27	WOS:A1994NP73800077
J	SMITH, PL; LOWE, JB				SMITH, PL; LOWE, JB			MOLECULAR-CLONING OF A MURINE N-ACETYLGALACTOSAMINE TRANSFERASE CDNA THAT DETERMINES EXPRESSION OF THE T-LYMPHOCYTE-SPECIFIC CT OLIGOSACCHARIDE DIFFERENTIATION ANTIGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GALACTOSE BETA-1,4-N-ACETYLGALACTOSAMINYLTRANSFERASE; ASPARAGINE-LINKED OLIGOSACCHARIDES; TAMM-HORSFALL GLYCOPROTEIN; LEUKOCYTE-COMMON ANTIGEN; VICIA-VILLOSA LECTIN; MONOCLONAL-ANTIBODIES; SDA ANTIGEN; GUINEA-PIG; INTRAEPITHELIAL LYMPHOCYTES; SIALYLATED OLIGOSACCHARIDES	Two monoclonal antibodies termed CT1 and CT2 define a cell surface oligosaccharide molecule expressed on restricted populations of murine lymphocytes. This oligosaccharide structure is largely associated with the extracellular domain of the CD45 family of tyrosine phosphatases, molecules required for lymphocytes to proliferate in response to antigen stimulation. Previous work has shown that the oligosaccharide structure recognized by the CT antibodies is identical, at least in part, to that of the human Sd(a) blood group, a structure formed through enzymatic addition of N-acetylgalactosamine in beta 1,4-linkage to a sub-terminal galactose substituted with an alpha 2,3-linked N-acetylneuraminic acid residue. We have used a mammalian transient expression cloning approach to isolate a murine cDNA that determines expression of an oligosaccharide structure recognized by the CT antibodies as well as human anti-Sd(a) serum. The nucleotide sequence predicts a 510-amino acid type II transmembrane protein characteristic of other mammalian glycosyltransferases. Enzymatic characterization of the protein expressed by this cDNA demonstrates that it encodes a beta 1,4-N-acetylgalactosamine transferase activity that can add to the low molecular weight acceptor 3'-sialyl-N-acetyllactosamine, to form the nonreducing terminal tetrasaccharide Sd(a) blood group structure. This cDNA shares 51% nucleotide sequence identity with a cDNA encoding the human G(M2)/G(D2) synthase, particularly throughout the regions encoding their putative catalytic domains. Southern blot analysis demonstrates that these two cDNA's represent distinct loci in the murine genome. The CT-GalNAc transferase cDNA isolated here represents a tool with which to define the role(s) of lymphocyte cell surface CT determinants, and may facilitate the isolation of the human Sd(a) blood group locus through cross-hybridization approaches.	UNIV MICHIGAN,DEPT PATHOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan	SMITH, PL (corresponding author), UNIV MICHIGAN,HOWARD HUGHES MED INST,RM 3500 MSRB I,1150 W MED CTR DR,ANN ARBOR,MI 48109, USA.							ANDREW ME, 1984, J IMMUNOL, V132, P839; ARUFFO A, 1987, NATURE, V329, P840; BAENZIGER JU, 1981, ANAL BIOCHEM, V112, P357, DOI 10.1016/0003-2697(81)90305-5; BIERHUIZEN MFA, 1993, GENE DEV, V7, P468, DOI 10.1101/gad.7.3.468; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; BRACIALE TJ, 1981, J EXP MED, V153, P910, DOI 10.1084/jem.153.4.910; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CONZELMANN A, 1987, BIOCHEM J, V242, P817, DOI 10.1042/bj2420817; CONZELMANN A, 1988, J EXP MED, V167, P119, DOI 10.1084/jem.167.1.119; CONZELMANN A, 1984, J BIOL CHEM, V259, P2536; CONZELMANN A, 1984, J BIOL CHEM, V259, P2528; DALLOLIO F, 1987, BIOSCIENCE REP, V7, P925, DOI 10.1007/BF01122125; DESAI DM, 1993, CELL, V73, P541, DOI 10.1016/0092-8674(93)90141-C; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DILWORTH SM, 1982, P NATL ACAD SCI-BIOL, V79, P1059, DOI 10.1073/pnas.79.4.1059; DONALD ASR, 1983, BIOCHEM BIOPH RES CO, V115, P625, DOI 10.1016/S0006-291X(83)80190-9; DONALD ASR, 1987, BIOCHEM SOC T, V15, P606, DOI 10.1042/bst0150606; ERNST LK, 1989, J BIOL CHEM, V264, P3436; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUKUSHIMA K, 1984, CANCER RES, V44, P5279; GILLARD BK, 1988, BIOCHEMISTRY-US, V27, P4601, DOI 10.1021/bi00413a003; Goldstein I., 1986, LECTINS, DOI DOI 10.1016/B978-0-12-449945-4.50007-5; GOODMAN T, 1988, NATURE, V333, P855, DOI 10.1038/333855a0; GOODMAN TG, 1990, J IMMUNOL, V145, P2959; GREEN ED, 1985, J BIOL CHEM, V260, P5623; GREEN ED, 1988, J BIOL CHEM, V263, P25; GREEN ED, 1988, J BIOL CHEM, V263, P18253; HEFFERNAN M, 1991, NUCLEIC ACIDS RES, V19, P85, DOI 10.1093/nar/19.1.85; HIRAIWA N, 1990, CANCER RES, V50, P5497; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; ITOH T, 1981, J BIOL CHEM, V256, P165; KIMURA A, 1979, J EXP MED, V149, P473, DOI 10.1084/jem.149.2.473; KINGSLEY DM, 1986, CELL, V44, P749, DOI 10.1016/0092-8674(86)90841-X; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LARSEN RD, 1989, P NATL ACAD SCI USA, V86, P8227, DOI 10.1073/pnas.86.21.8227; LEFRANCOIS L, 1985, J IMMUNOL, V135, P374; LEFRANCOIS L, 1986, J IMMUNOL, V136, P1171; LEFRANCOIS L, 1985, NATURE, V314, P449, DOI 10.1038/314449a0; LEFRANCOIS L, 1985, J EXP MED, V162, P1275, DOI 10.1084/jem.162.4.1275; LEFRANCOIS L, 1987, J IMMUNOL, V138, P3375; Lowe J B, 1991, Semin Cell Biol, V2, P289; MACKVIE SI, 1967, VOX SANG, V13, P485; MALAGOLINI N, 1989, CANCER RES, V49, P6466; Maniatis T., 1982, MOL CLONING; MORTON JA, 1988, IMMUNOL INVEST, V17, P217, DOI 10.3109/08820138809052961; MUELLER BM, 1990, P NATL ACAD SCI USA, V87, P5702, DOI 10.1073/pnas.87.15.5702; MULLER WJ, 1984, MOL CELL BIOL, V4, P2406, DOI 10.1128/MCB.4.11.2406; NAGATA Y, 1992, J BIOL CHEM, V267, P12082; ORR GA, 1981, J BIOL CHEM, V256, P761; PAULSON JC, 1977, J BIOL CHEM, V252, P2363; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PILLER F, 1986, CARBOHYD RES, V149, P171, DOI 10.1016/S0008-6215(00)90376-8; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; RENTON PH, 1967, VOX SANG, V13, P493, DOI 10.1111/j.1423-0410.1967.tb03796.x; SANCHEZLOPEZ R, 1988, J BIOL CHEM, V263, P11892; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SERAFINICESSI F, 1988, ARCH BIOCHEM BIOPHYS, V266, P573, DOI 10.1016/0003-9861(88)90290-1; SERAFINICESSI F, 1986, CARBOHYD RES, V151, P65, DOI 10.1016/S0008-6215(00)90330-6; SERAFINICESSI F, 1983, BIOCHEM J, V215, P483, DOI 10.1042/bj2150483; SMITH PL, 1990, J BIOL CHEM, V265, P874; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SVENNERHOLM L, 1973, J BIOL CHEM, V248, P740; TAKEYA A, 1987, J BIOCHEM-TOKYO, V101, P251, DOI 10.1093/oxfordjournals.jbchem.a121898; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.immunol.7.1.339; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938; Wiegandt H, 1985, GLYCOLIPIDS, V10, P199, DOI DOI 10.1016/S0167-7306(08)60022-8	70	100	112	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15162	15171						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	7515051				2022-12-27	WOS:A1994NP73800048
J	ARTS, EJ; LI, XG; GU, ZX; KLEIMAN, L; PARNIAK, MA; WAINBERG, MA				ARTS, EJ; LI, XG; GU, ZX; KLEIMAN, L; PARNIAK, MA; WAINBERG, MA			COMPARISON OF DEOXYOLIGONUCLEOTIDE AND TRNA(LYS-3) AS PRIMERS IN AN ENDOGENOUS HUMAN IMMUNODEFICIENCY VIRUS-1 IN-VITRO REVERSE TRANSCRIPTION TEMPLATE-SWITCHING REACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT DNA POLYMERASE; RNASE-H ACTIVITIES; TRANSFER RNA(LYS-3); SEQUENCE; INVITRO; POLYMERIZATION; TERMINATION; INITIATION; VIRIONS; REGIONS	We developed an endogenous in vitro reverse transcription assay to study the properties of priming and template switching during human immunodeficiency virus (HIV) replication. Reactions were primed with HIV reverse transcriptase (RT) and either a deoxyoligonucleotide primer (dPR) or tRNA(Lys-3), the natural primer for reverse transcription. The RNA templates utilized were the actual HN sequences involved in the first template switch, namely a primer binding sequence (PBS)/ U5/R RNA donor template and a R/U3 RNA acceptor template. Reverse transcription reactions using the latter templates and dPR or tRNA(Lys-3) as primers yielded four major products: (-)-strong-stop DNA, a partial template-switched DNA, full template-switched DNA, and a pseudo-PBS-primed product. Use of dPR resulted in three times less template switching than was obtained with tRNA(Lys-3). When reactions were primed with either dPR or tRNA(Lys-3), increases in acceptor:donor template ratios resulted in augmented template switching. Increasing the concentration of RT resulted in increased priming from the PBS but had no effect on the efficiency of template switching. Decreasing the extent of R region overlap resulted in a drop in efficiency of template switching. Decreases in the R region on the donor template also caused a drop in initiation of transcription that was primed by tRNA(Lys-3) from the PBS. In contrast, a corresponding reduction of the R region on the acceptor template had no effect on priming. We conclude that a transcriptional complex of tRNA(Lys-3) and RT may be associated not only with the PBS but also with other cis RNA sequences and secondary structures in a manner essential for efficient priming and template switching.	MCGILL UNIV,JEWISH GEN HOSP,LADY DAVIS INST MED RES,MCGILL AIDS CTR,MONTREAL H3T 1E2,PQ,CANADA; MCGILL UNIV,DEPT MICROBIOL & IMMUNOL,MONTREAL H3T 1E2,PQ,CANADA; MCGILL UNIV,DEPT MED,MONTREAL H3T 1E2,PQ,CANADA	Lady Davis Institute; McGill University; McGill University; McGill University				Arts, Eric/0000-0002-4880-7968				ABBOTTS J, 1993, J BIOL CHEM, V268, P10312; BALTIMORE D, 1970, NATURE, V226, P1209, DOI 10.1038/2261209a0; BARAT C, 1989, EMBO J, V8, P3279, DOI 10.1002/j.1460-2075.1989.tb08488.x; BEBENEK K, 1993, J BIOL CHEM, V268, P10324; COBRINIK D, 1988, J VIROL, V62, P3622, DOI 10.1128/JVI.62.10.3622-3630.1988; COBRINIK D, 1991, J VIROL, V65, P3864, DOI 10.1128/JVI.65.7.3864-3872.1991; DESTEFANO JJ, 1992, J VIROL, V66, P6370, DOI 10.1128/JVI.66.11.6370-6378.1992; FERRIS AL, 1990, VIROLOGY, V175, P456, DOI 10.1016/0042-6822(90)90430-Y; FURFINE ES, 1991, J BIOL CHEM, V266, P406; GOPALAKRISHNAN V, 1992, P NATL ACAD SCI USA, V89, P10763, DOI 10.1073/pnas.89.22.10763; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JACOBOMOLINA A, 1991, BIOCHEMISTRY-US, V30, P6351, DOI 10.1021/bi00240a001; JIANG M, 1992, BIOCHEM BIOPH RES CO, V185, P1005, DOI 10.1016/0006-291X(92)91727-8; KHAN R, 1992, J BIOL CHEM, V267, P6689; KLARMANN GJ, 1993, J BIOL CHEM, V268, P9793; KOHLSTAEDT LA, 1992, P NATL ACAD SCI USA, V89, P9652, DOI 10.1073/pnas.89.20.9652; LACEY SF, 1992, J BIOL CHEM, V267, P15789; LOWE DM, 1988, BIOCHEMISTRY-US, V27, P8884, DOI 10.1021/bi00425a002; LUO G, 1990, J VIROL, V64, P4321, DOI 10.1128/JVI.64.9.4321-4328.1990; MUESING MA, 1987, CELL, V48, P691, DOI 10.1016/0092-8674(87)90247-9; OMER CA, 1984, J VIROL, V50, P465, DOI 10.1128/JVI.50.2.465-470.1984; PANGANIBAN AT, 1988, SCIENCE, V241, P1064, DOI 10.1126/science.2457948; PELISKA JA, 1992, SCIENCE, V258, P1112, DOI 10.1126/science.1279806; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; PULLEN KA, 1993, J BIOL CHEM, V268, P6221; RESTLE T, 1990, J BIOL CHEM, V265, P8986; RICHTERCOOK NJ, 1992, J BIOL CHEM, V267, P15952; Sambrook J, 1989, MOL CLONING LABORATO; SARIHCOTTIN L, 1992, J MOL BIOL, V226, P1, DOI 10.1016/0022-2836(92)90117-3; TEMIN HM, 1970, NATURE, V226, P1211, DOI 10.1038/2261211a0; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504; WATSON KF, 1979, BIOCHEMISTRY-US, V18, P3210, DOI 10.1021/bi00582a004; Weiss R, 1985, RNA TUMOR VIRUSES; WOHRL BM, 1993, J BIOL CHEM, V268, P13617	34	128	129	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14672	14680						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	7514178				2022-12-27	WOS:A1994NM06500059
J	BORJIGIN, J; NATHANS, J				BORJIGIN, J; NATHANS, J			INSERTIONAL MUTAGENESIS AS A PROBE OF RHODOPSINS TOPOGRAPHY, STABILITY, AND ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEIN TOPOLOGY; SCHIFF-BASE COUNTERION; COENZYME-A REDUCTASE; BOVINE RHODOPSIN; ENDOPLASMIC-RETICULUM; CELL-SURFACE; ROD CELL; ANTIBODIES; TRANSDUCIN; EPITOPE	This paper reports a study of rhodopsin's structure and function using insertional mutagenesis with a flexible epitope. Sixteen rhodopsin derivatives were constructed, each of which carried a la-amino acid epitope derived from the c-Myc protein flanked by penta-glycine linkers. For eight of the insertion mutants, the membrane sidedness of the epitope insert was determined by immunostaining of intact or permeabilized cells. The results confirm the sidedness of each of the six helix connecting loops and the amino and carboxyl termini as postulated by the current seven-helix models of G-protein coupled receptors and provide the first experimental evidence for the existence of the third extracellular loop. In general, inserts that were either closer to the amino terminus or on the extracellular face were more likely to disrupt folding and/or stability than were inserts near the carboxyl terminus or on the cytosolic face. Epitope insertion at positions 139 or 239, in the second and third cytosolic loops, respectively, failed to activate transducin, whereas an insertion at position 333 in the carboxyl-terminal tail was fully functional. The experimental approach described here should prove generally useful for elucidating structural and functional properties of both membrane and globular proteins.	JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROSCI, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT MOLEC BIOL & GENET, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT OPHTHALMOL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, HOWARD HUGHES MED INST, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University			Borjigin, Jimo/GXA-3484-2022	Nathans, Jeremy/0000-0001-8106-5460				ADAMUS G, 1988, Peptide Research, V1, P42; ANAND R, 1993, BIOCHEMISTRY-US, V32, P9975, DOI 10.1021/bi00089a013; BARCLAY PL, 1984, BIOCHEM J, V220, P75, DOI 10.1042/bj2200075; BORJIGIN J, 1993, P NATL ACAD SCI USA, V90, P337, DOI 10.1073/pnas.90.1.337; BOWNDS D, 1967, NATURE, V216, P1178, DOI 10.1038/2161178a0; CAMPBELL AM, 1992, J BIOL CHEM, V267, P9321; CHAN T, 1992, J BIOL CHEM, V267, P9478; CHARBIT A, 1986, EMBO J, V5, P3029, DOI 10.1002/j.1460-2075.1986.tb04602.x; DOI T, 1990, P NATL ACAD SCI USA, V87, P4991, DOI 10.1073/pnas.87.13.4991; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; FRANKE RR, 1992, J BIOL CHEM, V267, P14767; FREUDL R, 1986, J MOL BIOL, V188, P491, DOI 10.1016/0022-2836(86)90171-3; FREUDL R, 1989, GENE, V82, P229, DOI 10.1016/0378-1119(89)90048-6; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; HARGRAVE PA, 1983, BIOPHYS STRUCT MECH, V9, P235, DOI 10.1007/BF00535659; HODGES RS, 1988, J BIOL CHEM, V263, P11768; IMAJOHOHMI S, 1992, J BIOL CHEM, V267, P180; JENNINGS ML, 1989, ANNU REV BIOCHEM, V58, P999; KARNIK SS, 1990, J BIOL CHEM, V265, P17520; KHORANA HG, 1992, J BIOL CHEM, V267, P1; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KUHN H, 1982, METHOD ENZYMOL, V81, P556; LEI SJ, 1993, BIOCHEMISTRY-US, V32, P91, DOI 10.1021/bi00052a013; MANOIL C, 1986, SCIENCE, V233, P1403, DOI 10.1126/science.3529391; MARTYNOV VI, 1983, BIOORG KHIM, V9, P735; MERBS SL, 1993, PHOTOCHEM PHOTOBIOL, V58, P706, DOI 10.1111/j.1751-1097.1993.tb04956.x; NATHANS J, 1983, CELL, V34, P807, DOI 10.1016/0092-8674(83)90537-8; NATHANS J, 1990, BIOCHEMISTRY-US, V29, P9746, DOI 10.1021/bi00493a034; NATHANS J, 1992, BIOCHEMISTRY-US, V31, P4923, DOI 10.1021/bi00136a001; NEITZ M, 1991, SCIENCE, V252, P971, DOI 10.1126/science.1903559; OLENDER EH, 1992, J BIOL CHEM, V267, P4223; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; OVCHINNIKOV YA, 1983, BIOORG KHIM+, V9, P1331; PEDERSEN SE, 1990, J BIOL CHEM, V265, P569; ROHLICH P, 1976, NATURE, V263, P789, DOI 10.1038/263789a0; ROITELMAN J, 1992, J CELL BIOL, V117, P959, DOI 10.1083/jcb.117.5.959; SAKMAR TP, 1989, P NATL ACAD SCI USA, V86, P8309, DOI 10.1073/pnas.86.21.8309; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; SENGSTAG C, 1990, MOL CELL BIOL, V10, P672, DOI 10.1128/MCB.10.2.672; SHICHI H, 1978, J BIOL CHEM, V253, P7040; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P8840, DOI 10.1073/pnas.88.19.8840; SUNG CH, 1993, J BIOL CHEM, V268, P26645; TEUFEL M, 1993, EMBO J, V12, P3399, DOI 10.1002/j.1460-2075.1993.tb06014.x; WANG JK, 1980, BIOCHEMISTRY-US, V19, P5111, DOI 10.1021/bi00563a027; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WONG PC, 1990, J CELL BIOL, V111, P1987, DOI 10.1083/jcb.111.5.1987; ZHUKOVSKY EA, 1989, SCIENCE, V246, P928, DOI 10.1126/science.2573154	50	66	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14715	14722						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	7514180				2022-12-27	WOS:A1994NM06500065
J	ALLEN, LAH; HOPE, L; RAETZ, CRH; THIERINGER, R				ALLEN, LAH; HOPE, L; RAETZ, CRH; THIERINGER, R			GENETIC-EVIDENCE SUPPORTING THE ROLE OF PEROXISOME ASSEMBLY FACTOR (PAF)-1 IN PEROXISOME BIOGENESIS - POLYMERASE CHAIN-REACTION DETECTION OF A MISSENSE MUTATION IN PAF-1 OF CHINESE-HAMSTER OVARY CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COA OXIDASE; ZELLWEGER SYNDROME; 3-KETOACYL-COA THIOLASE; HANSENULA-POLYMORPHA; DEFICIENT MUTANTS; SOMATIC-CELLS; ANIMAL-CELLS; PROTEIN; BIOSYNTHESIS; PLASMALOGENS	The peroxisome/plasmalogen-deficient Chinese hamster ovary (CHO) mutant cell line ZR-78.1 contains a mis-sense mutation in its cDNA-encoding peroxisome assembly factor-1 (PAF-1). Using a rapid polymerase chain reaction assay, we now demonstrate that the genome of ZR-78.1 contains only the mutant allele. When mutant ZR-78.1 is fused with wild-type karyoplasts, occasional ''negative nuclear hybrids'' are observed that lack peroxisomes (Allen, L.-A. H., Morand, O. H., and Raetz, C. R. H. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 7012-7016). Despite the fact that negative nuclear hybrids are tetraploid, they do not contain the wild-type PAF-1 gene, suggesting that a chromosome fragment bearing the wild-type copy of PAF-1 was lost. Negative nuclear hybrids reconstituted with wild-type cytoplasts do contain a wild-type PAF-1 gene, indicating that the cytoplasts somehow reintroduced the wild-type PAF-1 allele without increasing ploidy. These findings support the role of PAF-1 and exclude the hypothesis of an additional cytoplasmic requirement for reinitiation of peroxisome biogenesis in peroxisome-deficient CHO cells. The plasmalogen deficiency and some other biochemical properties of ZR-78.1 are partially corrected in 5-azacytidine-treated subclones. However, such pseudorevertants do not contain peroxisomes, consistent with the fact that there is no wild-type PAF-1 gene to reactivate by demethylation.	MERCK RES LABS,DEPT BIOCHEM,RAHWAY,NJ 07065; UNIV WISCONSIN,COLL AGR & LIFE SCI,DEPT BIOCHEM,MADISON,WI 53706	Merck & Company; University of Wisconsin System; University of Wisconsin Madison				Allen, Lee-Ann/0000-0001-8929-6968				ALLEN LAH, 1992, J BIOL CHEM, V267, P13191; ALLEN LAH, 1989, P NATL ACAD SCI USA, V86, P7012, DOI 10.1073/pnas.86.18.7012; BALFE A, 1990, PEDIATR RES, V27, P304, DOI 10.1203/00006450-199003000-00023; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BORST P, 1989, BIOCHIM BIOPHYS ACTA, V1008, P1, DOI 10.1016/0167-4781(89)90163-2; BORST P, 1986, BIOCHIM BIOPHYS ACTA, V866, P179, DOI 10.1016/0167-4781(86)90044-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; CREGG JM, 1990, YEAST, V6, P87, DOI 10.1002/yea.320060202; DEDUVE C, 1966, PHYSIOL REV, V46, P323, DOI 10.1152/physrev.1966.46.2.323; DEMARS R, 1974, MUTAT RES, V24, P335, DOI 10.1016/0165-1218(74)90189-X; DIDION T, 1990, CURR GENET, V17, P113, DOI 10.1007/BF00312854; ELGERSMA Y, 1993, GENETICS, V135, P731; ERDMANN R, 1991, CELL, V64, P499, DOI 10.1016/0092-8674(91)90234-P; ERDMANN R, 1989, P NATL ACAD SCI USA, V86, P5419, DOI 10.1073/pnas.86.14.5419; Fournier R. E. K., 1982, TECHNIQUES SOMATIC C, P309; FOURNIER REK, 1977, P NATL ACAD SCI USA, V74, P319, DOI 10.1073/pnas.74.1.319; GOLDFISCHER S, 1973, SCIENCE, V182, P62, DOI 10.1126/science.182.4107.62; GOULD SJ, 1992, YEAST, V8, P613, DOI 10.1002/yea.320080805; HAJRA AK, 1982, ANN NY ACAD SCI, V386, P170, DOI 10.1111/j.1749-6632.1982.tb21415.x; HALIASSOS A, 1989, NUCLEIC ACIDS RES, V17, P8093, DOI 10.1093/nar/17.20.8093; HARRIS M, 1984, SOMAT CELL MOLEC GEN, V10, P615, DOI 10.1007/BF01535227; HARRIS M, 1982, CELL, V29, P483, DOI 10.1016/0092-8674(82)90165-9; HOHFELD J, 1991, J CELL BIOL, V114, P1167, DOI 10.1083/jcb.114.6.1167; IMANAKA T, 1987, J CELL BIOL, V105, P2915, DOI 10.1083/jcb.105.6.2915; Jones PA, 1984, DNA METHYLATION BIOC, P165; KUNAU WH, 1993, BIOCHIMIE, V75, P209, DOI 10.1016/0300-9084(93)90079-8; Lazarow P. B., 1989, METABOLIC BASIS INHE, P1479; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; LITTLEFIELD JW, 1964, SCIENCE, V145, P709, DOI 10.1126/science.145.3633.709; LUNGU O, 1993, BIOTECHNIQUES, V14, P62; MCCOLLUM D, 1993, J CELL BIOL, V121, P761, DOI 10.1083/jcb.121.4.761; MORAND OH, 1988, J BIOL CHEM, V263, P11597; PETERS TJ, 1972, J EXP MED, V136, P1117, DOI 10.1084/jem.136.5.1117; RAETZ CRH, 1982, P NATL ACAD SCI-BIOL, V79, P3223, DOI 10.1073/pnas.79.10.3223; RAPP S, 1993, EXP CELL RES, V205, P59, DOI 10.1006/excr.1993.1058; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTOS MJ, 1988, SCIENCE, V239, P1536, DOI 10.1126/science.3281254; SCHLOSSMAN DM, 1976, J BIOL CHEM, V251, P5738; SHIMOZAWA N, 1992, J CLIN INVEST, V90, P1864, DOI 10.1172/JCI116063; SHIMOZAWA N, 1993, AM J HUM GENET, V52, P843; SHIMOZAWA N, 1992, SCIENCE, V255, P1132, DOI 10.1126/science.1546315; SIMINOVITCH L, 1976, CELL, V7, P1, DOI 10.1016/0092-8674(76)90249-X; SINGH I, 1983, J LIPID RES, V24, P662; SMALL GM, 1988, EMBO J, V7, P1167, DOI 10.1002/j.1460-2075.1988.tb02927.x; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SPONG AP, 1993, J CELL BIOL, V123, P535, DOI 10.1083/jcb.123.3.535; STEGLICH C, 1985, SOMAT CELL MOLEC GEN, V11, P11, DOI 10.1007/BF01534730; SUBRAMANI S, 1993, ANNU REV CELL BIOL, V9, P445, DOI 10.1146/annurev.cb.09.110193.002305; SWINKELS BW, 1991, EMBO J, V10, P3255, DOI 10.1002/j.1460-2075.1991.tb04889.x; TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G; THIERINGER R, 1993, J BIOL CHEM, V268, P12631; TSUKAMOTO T, 1990, J CELL BIOL, V110, P651, DOI 10.1083/jcb.110.3.651; TSUKAMOTO T, 1991, NATURE, V350, P77, DOI 10.1038/350077a0; VANDENBOSCH H, 1992, ANNU REV BIOCHEM, V61, P157, DOI 10.1146/annurev.bi.61.070192.001105; VANDERLEIJ I, 1992, J CELL BIOL, V119, P153, DOI 10.1083/jcb.119.1.153; VANHEUSDEN GPH, 1992, BIOCHIM BIOPHYS ACTA, V1126, P81, DOI 10.1016/0005-2760(92)90220-P; VOORNBROUWER T, 1993, BIOCHIM BIOPHYS ACTA, V1216, P325, DOI 10.1016/0167-4781(93)90166-B; WANDERS RJA, 1986, CLIN CHIM ACTA, V159, P1, DOI 10.1016/0009-8981(86)90160-9; WATERHAM HR, 1993, EMBO J, V12, P4785, DOI 10.1002/j.1460-2075.1993.tb06167.x; WENDLAND M, 1993, J CELL BIOL, V120, P675, DOI 10.1083/jcb.120.3.675; WIEBEL FF, 1992, NATURE, V359, P73, DOI 10.1038/359073a0; ZHANG JW, 1993, J CELL BIOL, V123, P1133, DOI 10.1083/jcb.123.5.1133; ZOELLER RA, 1986, P NATL ACAD SCI USA, V83, P5170, DOI 10.1073/pnas.83.14.5170; ZOELLER RA, 1989, J BIOL CHEM, V264, P21872; ZOELLER RA, 1988, J BIOL CHEM, V263, P11590	66	3	3	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11734	11742						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	7512952				2022-12-27	WOS:A1994NG37700013
J	FALKENBERG, C; ALLHORN, M; THOGERSEN, IB; VALNICKOVA, Z; PIZZO, SV; SALVESEN, G; AKERSTROM, B; ENGHILD, JJ				FALKENBERG, C; ALLHORN, M; THOGERSEN, IB; VALNICKOVA, Z; PIZZO, SV; SALVESEN, G; AKERSTROM, B; ENGHILD, JJ			ALPHA(1)-MICROGLOBULIN DESTROYS THE PROTEINASE INHIBITORY ACTIVITY OF ALPHA(1)-INHIBITOR-3 BY COMPLEX-FORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-TRYPSIN INHIBITOR; IMMUNE-RESPONSE; FAST FORMS; RAT; ALPHA-1-MICROGLOBULIN; ALPHA-2-MACROGLOBULIN; BINDING; RECEPTOR; ALPHA2-MACROGLOBULIN; ALPHA-1-INHIBITOR-3	The immunoregulatory plasma protein alpha(1)-microglobulin (alpha(1)-m) and the proteinase inhibitor alpha(1)-inhibitor-3 (alpha(1)I(3)) form a complex in rat plasma. In the present work, it was demonstrated that the alpha(1)I(3).alpha(1)-m complex has no inhibitory activity, the bait region was not cleaved by low amounts of proteinases, and it was unable to covalently incorporate proteinases. The results also indicated that the thiolester bond of the alpha(1)I(3).alpha(1)-m complex was broken. The alpha(1)I(3).alpha(1)-m complex was cleared from the circulation much faster than native alpha(1)I(3), with a half-life of approximately 7 min. Structurally, however, the alpha(1)I(3).alpha(1)-m complex was similar to native alpha(1)I(3) rather than alpha(1)I(3) cleaved by proteinases. It is speculated that the role of alpha(1)-m is to destroy the function of alpha(1)I(3) by blocking the bait region and breaking the thiolester and causing its physical elimination by rapid clearing from the blood circulation. It is also possible that the formation of complexes between alpha(1)-m and alpha(1)I(3) may serve as a mean to regulate the function of alpha(1)-m since its complex with alpha(1)I(3) is taken up rapidly by cellular receptors for alpha-macroglobulins.	DUKE UNIV, MED CTR, DEPT PATHOL, DURHAM, NC 27710 USA	Duke University	FALKENBERG, C (corresponding author), LUND UNIV, DEPT MED & PHYSIOL CHEM, POB 94, S-22100 LUND, SWEDEN.			Enghild, Jan Johannes/0000-0001-9292-9172	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL024066, R01HL049542, R01HL024066] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL24066, HL49542] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKERSTROM B, 1990, TRENDS BIOCHEM SCI, V15, P240, DOI 10.1016/0968-0004(90)90037-C; AKERSTROM B, 1992, FOLIA HISTOCHEM CYTO, V30, P183; BABIKERMOHAMED H, 1991, SCAND J IMMUNOL, V34, P655, DOI 10.1111/j.1365-3083.1991.tb01589.x; BARRETT AJ, 1979, BIOCHEM J, V181, P401, DOI 10.1042/bj1810401; BARRETT AJ, 1973, BIOCHEM J, V133, P709, DOI 10.1042/bj1330709; BRATT T, 1993, BIOCHIM BIOPHYS ACTA, V1157, P147, DOI 10.1016/0304-4165(93)90058-G; BURY AF, 1981, J CHROMATOGR, V213, P491, DOI 10.1016/S0021-9673(00)80500-2; CALERO M, 1994, J BIOL CHEM, V269, P384; CHASE T, 1967, BIOCHEM BIOPH RES CO, V29, P508, DOI 10.1016/0006-291X(67)90513-X; CHU CT, 1993, J IMMUNOL, V150, P48; CHU CT, 1994, J IMMUNOL, V152, P1538; DAVID GS, 1974, BIOCHEMISTRY-US, V13, P1014, DOI 10.1021/bi00702a028; DEBANNE MT, 1976, BIOCHIM BIOPHYS ACTA, V428, P466; ENGHILD JJ, 1989, J BIOL CHEM, V264, P11428; ENGHILD JJ, 1989, BIOCHEMISTRY-US, V28, P1406, DOI 10.1021/bi00429a069; FALKENBERG C, 1994, BIOCHEM J, V301, P745, DOI 10.1042/bj3010745; FALKENBERG C, 1990, J BIOL CHEM, V265, P16150; FOWLER WE, 1979, J MOL BIOL, V134, P241, DOI 10.1016/0022-2836(79)90034-2; GAUTHIER F, 1979, BIOCHIM BIOPHYS ACTA, V566, P200, DOI 10.1016/0005-2744(79)90262-6; GLIEMANN J, 1987, FEBS LETT, V221, P55, DOI 10.1016/0014-5793(87)80351-4; Goldenberg D.P, 1989, PROTEIN STRUCTURE PR, P225; GRUBB A, 1986, J BIOL CHEM, V261, P14313; IMBER MJ, 1981, J BIOL CHEM, V256, P8134; KAUMEYER JF, 1986, NUCLEIC ACIDS RES, V14, P7839, DOI 10.1093/nar/14.20.7839; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAST AE, 1991, BIOCHEMISTRY-US, V30, P1723, DOI 10.1021/bi00220a039; MESTECKY J, 1987, ADV IMMUNOL, V40, P153, DOI 10.1016/S0065-2776(08)60240-0; NILSON B, 1986, J IMMUNOL METHODS, V91, P275, DOI 10.1016/0022-1759(86)90490-4; PIERZCHALSKI P, 1992, FEBS LETT, V298, P165, DOI 10.1016/0014-5793(92)80047-K; SALIER JP, 1990, TRENDS BIOCHEM SCI, V15, P435, DOI 10.1016/0968-0004(90)90282-G; SALVESEN G, 1993, METHOD ENZYMOL, V223, P121; Sottrup-Jensen L., 1987, PLASMA PROTEINS, V5, P191; VANLEUVEN F, 1979, J BIOL CHEM, V254, P5155	33	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4478	4483		10.1074/jbc.270.9.4478	http://dx.doi.org/10.1074/jbc.270.9.4478			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7533162	hybrid			2022-12-27	WOS:A1995QK08400047
J	FISCHER, D; CHIQUETEHRISMANN, R; BERNASCONI, C; CHIQUET, M				FISCHER, D; CHIQUETEHRISMANN, R; BERNASCONI, C; CHIQUET, M			A SINGLE HEPARIN-BINDING REGION WITHIN THE FIBRINOGEN-LIKE DOMAIN IS FUNCTIONAL IN CHICK TENASCIN-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONIC TOOTH MESENCHYME; NEURITE OUTGROWTH; LEECH NEURONS; CELL-ADHESION; FIBRONECTIN; EXPRESSION; CYTOTACTIN; MATRIX; PROTEOGLYCAN; FRAGMENTS	Tenascin-C binds to cell surface and matrix proteoglycans and to heparin. Two heparin binding regions have recently been localized per tenascin-C monomer, one in the C-terminal fibrinogen-like domain and the other in fibronectin type III repeats 3-5. Here we show that a single region in each subunit is necessary and sufficient for heparin binding by whole tenascin-C at physiological ionic strength. First, native tenascin-C was bound to heparin-agarose and digested with Pronase. A 29-kDa fragment retained on the heparin column was recognized by a monoclonal antibody against the fibrinogen-like domain. In contrast, small fragments labeled by an antibody against fibronectin type III repeats 2-5 were released. Second, mild tryptic digestion of tenascin-C yielded two related fragments of 180 and 170 kDa. The latter missed part of the fibrinogen domain and had lost affinity for heparin, in contrast to the former. Finally, chick tenascin-C constructs were recombinantly expressed in human cells. Whereas the complete protein and a mutant lacking fibronectin type III repeats 1-5 bound to heparin-agarose, recombinant tenascin-C missing the C-terminal fibrinogen-like globe did not. Thus, whole chick tenascin-C contains one essential heparin binding region per subunit, located in the fibrinogen-like domain within 10 kDa from the C terminus.	FRIEDRICH MIESCHER INST, CH-4002 BASEL, SWITZERLAND; UNIV BASEL, BIOCTR, DEPT BIOPHYS CHEM, CH-4056 BASEL, SWITZERLAND	Friedrich Miescher Institute for Biomedical Research; University of Basel				Chiquet, Matthias/0000-0001-7812-4853				ARECHIGA H, 1986, J EXP BIOL, V126, P15; AUKHIL I, 1993, J BIOL CHEM, V268, P2542; BARKALOW FJB, 1991, J BIOL CHEM, V266, P7812; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CHIQUET M, 1984, J CELL BIOL, V98, P1937, DOI 10.1083/jcb.98.6.1937; CHIQUET M, 1994, PERSPECT DEV NEUROBI, V2, P67; CHIQUET M, 1988, J CELL BIOL, V107, P1189, DOI 10.1083/jcb.107.3.1189; CHIQUET M, 1991, EUR J BIOCHEM, V199, P379, DOI 10.1111/j.1432-1033.1991.tb16134.x; Chiquet-Ehrismann R, 1991, CURR OPIN CELL BIOL, V3, P800, DOI 10.1016/0955-0674(91)90053-2; CHIQUETEHRISMANN R, 1991, CELL REGUL, V2, P927, DOI 10.1091/mbc.2.11.927; CHIQUETEHRISMANN R, 1994, PERSPECT DEV NEUROBI, V2, P3; CHIQUETEHRISMANN R, 1988, CELL, V53, P383, DOI 10.1016/0092-8674(88)90158-4; ERICKSON HP, 1989, ANNU REV CELL BIOL, V5, P71, DOI 10.1146/annurev.cb.05.110189.000443; ERICKSON HP, 1993, CURR OPIN BIOL, V5, P865; FAISSNER A, 1990, J NEUROCHEM, V54, P1004, DOI 10.1111/j.1471-4159.1990.tb02350.x; FRIEDLANDER DR, 1988, J CELL BIOL, V107, P2329, DOI 10.1083/jcb.107.6.2329; GRUMET M, 1994, J BIOL CHEM, V269, P12142; HALFTER W, 1989, DEV BIOL, V132, P14, DOI 10.1016/0012-1606(89)90200-5; HOFFMAN S, 1988, J CELL BIOL, V106, P519, DOI 10.1083/jcb.106.2.519; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HUMPHRIES DE, 1989, METHOD ENZYMOL, V179, P428; HUSMANN K, 1992, J CELL BIOL, V116, P1475, DOI 10.1083/jcb.116.6.1475; JENNES L, 1983, METHOD ENZYMOL, V103, P448; JONES FS, 1989, P NATL ACAD SCI USA, V86, P1905, DOI 10.1073/pnas.86.6.1905; JOSHI P, 1993, J CELL SCI, V106, P389; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; LOCHTER A, 1991, J CELL BIOL, V113, P1159, DOI 10.1083/jcb.113.5.1159; LOTZ MM, 1989, J CELL BIOL, V109, P1795, DOI 10.1083/jcb.109.4.1795; MARTON LS, 1989, J BIOL CHEM, V264, P13145; NOONAN DM, 1991, J BIOL CHEM, V266, P22939; PEARSON CA, 1988, EMBO J, V7, P2977, DOI 10.1002/j.1460-2075.1988.tb03160.x; PRIETO AL, 1992, J CELL BIOL, V119, P663, DOI 10.1083/jcb.119.3.663; SALMIVIRTA M, 1991, J BIOL CHEM, V266, P7733; SAUNDERS S, 1988, J CELL BIOL, V106, P423, DOI 10.1083/jcb.106.2.423; SCHENK S, IN PRESS INT J CANCE; SIRI A, 1991, NUCLEIC ACIDS RES, V19, P525, DOI 10.1093/nar/19.3.525; SPRING J, 1989, CELL, V59, P325, DOI 10.1016/0092-8674(89)90294-8; SRIRAMARAO P, 1993, J CELL SCI, V105, P1001; THESLEFF I, 1987, DEVELOPMENT, V101, P289; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VAINIO S, 1989, J CELL BIOL, V108, P1945, DOI 10.1083/jcb.108.5.1945; WEHRLE B, 1990, DEVELOPMENT, V110, P401; WEHRLEHALLER B, 1993, J CELL SCI, V106, P597; WELLER A, 1991, J CELL BIOL, V112, P355, DOI 10.1083/jcb.112.2.355; YURCHENCO PD, 1993, J BIOL CHEM, V268, P8356	46	45	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	1995	270	7					3378	3384		10.1074/jbc.270.7.3378	http://dx.doi.org/10.1074/jbc.270.7.3378			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QG471	7531705	hybrid			2022-12-27	WOS:A1995QG47100073
J	JUAN, TSC; KELLEY, MJ; JOHNSON, DA; BUSSE, LA; HAILMAN, E; WRIGHT, SD; LICHENSTEIN, HS				JUAN, TSC; KELLEY, MJ; JOHNSON, DA; BUSSE, LA; HAILMAN, E; WRIGHT, SD; LICHENSTEIN, HS			SOLUBLE CD14 TRUNCATED AT AMINO-ACID-152 BINDS LIPOPOLYSACCHARIDE (LPS) AND ENABLES CELLULAR-RESPONSE TO LPS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; ENDOTOXIN; PROTEIN; ACTIVATION; MEMBRANE; LEUCINE; ANTIGEN; CELLS; RECEPTOR; CAPACITY	CD14 is a 55-kDa glycoprotein which binds lipopolysaccharide (LPS) and enables LPS-dependent responses in a variety of cells. In order to identify the domains in CD14 required for function, we deleted increasing amounts of CD14 from the C terminus. Truncated CD14 cDNA sequences were transfected into COS-7 cells and serum-free conditioned medium was analyzed for mutant CD14 expression and bioactivity, Mutant CD14s containing as few as 152 amino acids were found to have activity equivalent to full-length sCD14, To further characterize the mutant CD14, we constructed a stable Chinese hamster ovary cell line expressing sCD14(1-152) and purified the protein to homogeneity. sCD14(1-152) bound radioactive LPS, enabled U373 cells to synthesize interleukin 6 in response to LPS, and enabled human neutrophils to respond to smooth LPS. In all of these assays, the behavior of sCD14(1-152) was quantitatively similar to full-length sCD14. We also found that two neutralizing anti-CD14 antibodies (3C10 and MEM-18) bound and neutralized sCD14(1-152). We conclude from these experiments that the N-terminal 152 amino acids of CD14 are sufficient to bind LPS and confer essentially wild-type bioactivity in vitro.	AMGEN INC,THOUSAND OAKS,CA 91320; ROCKEFELLER UNIV,CELLULAR PHYSIOL & IMMUNOL LAB,NEW YORK,NY 10021	Amgen; Rockefeller University								ARDITI M, 1993, INFECT IMMUN, V61, P3149, DOI 10.1128/IAI.61.8.3149-3156.1993; BAZIL V, 1989, MOL IMMUNOL, V26, P657, DOI 10.1016/0161-5890(89)90048-5; BAZIL V, 1986, EUR J IMMUNOL, V16, P1583, DOI 10.1002/eji.1830161218; DENTENER MA, 1993, J IMMUNOL, V150, P2885; DETMERS PA, 1994, J IMMUNOL, V152, P2137; FERRERO E, 1990, J IMMUNOL, V145, P331; FREY EA, 1992, J EXP MED, V176, P1665, DOI 10.1084/jem.176.6.1665; GAZZANOSANTORO H, 1992, INFECT IMMUN, V60, P4754, DOI 10.1128/IAI.60.11.4754-4761.1992; GRUNWALD U, 1993, CIRC SHOCK, V39, P220; HAILMAN E, 1994, J EXP MED, V179, P269, DOI 10.1084/jem.179.1.269; HAZIOT A, 1988, J IMMUNOL, V141, P547; HAZIOT A, 1993, J IMMUNOL, V150, P5556; HAZIOT A, 1993, J IMMUNOL, V151, P1500; HOESS A, 1993, EMBO J, V12, P3351, DOI 10.1002/j.1460-2075.1993.tb06008.x; KRANTZ DD, 1991, J BIOL CHEM, V266, P16801; LEE FS, 1988, BIOCHEMISTRY-US, V27, P8545, DOI 10.1021/bi00423a007; LEE JD, 1993, P NATL ACAD SCI USA, V90, P9930, DOI 10.1073/pnas.90.21.9930; MATA T, 1991, J BIOL CHEM, V266, P6554; PUGIN J, 1993, P NATL ACAD SCI USA, V90, P2744, DOI 10.1073/pnas.90.7.2744; REINKE R, 1988, CELL, V52, P291, DOI 10.1016/0092-8674(88)90518-1; SETOGUCHI M, 1989, BIOCHIM BIOPHYS ACTA, V1008, P213, DOI 10.1016/0167-4781(80)90012-3; SIMMONS DL, 1989, BLOOD, V73, P284; TAKAHASHI N, 1985, P NATL ACAD SCI USA, V82, P1906, DOI 10.1073/pnas.82.7.1906; TAN FL, 1990, J BIOL CHEM, V265, P13; TOBIAS PS, 1986, J EXP MED, V164, P777, DOI 10.1084/jem.164.3.777; VANKESSEL KPM, 1994, J IMMUNOL METHODS, V172, P25; WARREN HS, 1992, INFECT IMMUN, V60, P2506, DOI 10.1128/IAI.60.6.2506-2513.1992; WRIGHT SD, 1991, J EXP MED, V173, P1281, DOI 10.1084/jem.173.5.1281; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311	29	73	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1382	1387		10.1074/jbc.270.3.1382	http://dx.doi.org/10.1074/jbc.270.3.1382			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7530712	hybrid			2022-12-27	WOS:A1995QB15600061
J	LIAO, J; LOWTHERT, LA; GHORI, N; OMARY, MB				LIAO, J; LOWTHERT, LA; GHORI, N; OMARY, MB			THE 70-KDA HEAT-SHOCK PROTEINS ASSOCIATE WITH GLANDULAR INTERMEDIATE FILAMENTS IN AN ATP-DEPENDENT MANNER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR LAMIN-B; COGNATE PROTEIN; UNCOATING ATPASE; EPITHELIAL-CELLS; KINASE-C; BETA-INTERNEXIN; COATED VESICLES; VIMENTIN; CLATHRIN; BINDING	Keratin polypeptides 8 and 18 (K8/18) are intermediate filament proteins expressed preferentially in glandular epithelia. We describe the identification, by coimmunoprecipitation from normal human colonic tissues and cultured cell lines, of the 70-kDa heat shock protein (hsp) and its related heat shock cognate protein as K8/18-associated proteins (hsp/c). The association is significant but sub-stoichiometric and occurs preferentially with the soluble rather than the cytoskeletal K8/18 fractions. Heat stress increases the level of soluble K8/18 in association with an increase in hsp70 levels and an increase in the stoichiometry of K8/18-hsp70 association. Identity of the associated proteins was confirmed by microsequencing of a tryptic digest of the purified associated protein and by using anti-hsp/c70-specific antibodies. The K8/18-hsp/c70 complex can be dissociated in a Mg-ATP-dependent manner that requires ATP hydrolysis. finding of hsp to K8/18 can be reconstituted using purified bovine hsp70 and human K8/18 immunoprecipitates that have been depleted of bound hsp/c70 and increases slightly in the presence of ATP. The reconstituted H8/18-hsp70 complex can be again released in the presence of Mg-ATP. In addition, hsp70 binds to K8/18 without having a significant effect on in vitro filament assembly when added during or after assembly. Using an overlay assay, hsp70 binds exclusively to K8 in the presence of ATP. Our results show direct association of the hsp/c70 proteins with K8/18, This interaction may serve, at least in part, to regulate the function of these two abundant protein groups.	VET AFFAIRS MED CTR, PALO ALTO, CA 94304 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA)	LIAO, J (corresponding author), STANFORD UNIV, SCH MED, CTR DIGEST DIS, LAB SURGE BLDG, RM P304, STANFORD, CA 94305 USA.			Omary, Bishr/0000-0002-8624-2347	NIAAA NIH HHS [AA0947A-01] Funding Source: Medline; NIDDK NIH HHS [DK380707] Funding Source: Medline	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACHTSTAETTER T, 1986, METHOD ENZYMOL, V134, P355; BECKER J, 1994, EUR J BIOCHEM, V219, P11, DOI 10.1111/j.1432-1033.1994.tb19910.x; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BROWN KD, 1992, J CELL SCI, V102, P19; CARTAUD A, 1990, J CELL BIOL, V111, P581, DOI 10.1083/jcb.111.2.581; CHAPPELL TG, 1986, CELL, V45, P3, DOI 10.1016/0092-8674(86)90532-5; CHOU CF, 1994, BIOCHEM J, V298, P457, DOI 10.1042/bj2980457; CHOU CF, 1992, J BIOL CHEM, V267, P3901; CHOU CF, 1993, J CELL SCI, V105, P433; CHOU CF, 1991, FEBS LETT, V282, P200, DOI 10.1016/0014-5793(91)80477-K; CHOU CF, 1994, J CELL SCI, V107, P1833; CIAVARRA RP, 1994, P NATL ACAD SCI USA, V91, P1751, DOI 10.1073/pnas.91.5.1751; CLARK BD, 1986, BIOCHEM BIOPH RES CO, V139, P974, DOI 10.1016/S0006-291X(86)80273-X; CLARKE CF, 1988, MOL CELL BIOL, V8, P1206, DOI 10.1128/MCB.8.3.1206; CYR DM, 1992, J BIOL CHEM, V267, P20927; DICE JF, 1990, TRENDS BIOCHEM SCI, V15, P305, DOI 10.1016/0968-0004(90)90019-8; DJABALI K, 1991, CELL, V64, P109, DOI 10.1016/0092-8674(91)90213-I; DWORNICZAK B, 1987, NUCLEIC ACIDS RES, V15, P5181, DOI 10.1093/nar/15.13.5181; FOISNER R, 1991, P NATL ACAD SCI USA, V88, P3812, DOI 10.1073/pnas.88.9.3812; Foisner R, 1991, CURR OPIN CELL BIOL, V3, P75, DOI 10.1016/0955-0674(91)90168-X; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; GAO Y, 1983, MOL CELL BIOL, V13, P2478; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; GEORGATOS SD, 1987, P NATL ACAD SCI USA, V84, P6780, DOI 10.1073/pnas.84.19.6780; GEORGATOS SD, 1989, J CELL BIOL, V109, P257; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GREEN LAD, 1989, J BIOL CHEM, V264, P15210; GUPTA RS, 1990, TRENDS BIOCHEM SCI, V15, P415, DOI 10.1016/0968-0004(90)90276-H; HAUS U, 1993, EMBO J, V12, P3763, DOI 10.1002/j.1460-2075.1993.tb06054.x; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; IMAMOTO N, 1992, J CELL BIOL, V119, P1047, DOI 10.1083/jcb.119.5.1047; KLYMKOWSKY MW, 1989, CELL MOTIL CYTOSKEL, V14, P309, DOI 10.1002/cm.970140302; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE WC, 1993, J CELL BIOCHEM, V52, P253, DOI 10.1002/jcb.240520302; LITVINOV SV, 1994, J CELL BIOL, V125, P437, DOI 10.1083/jcb.125.2.437; MACMILLANCROW LA, 1994, BIOCHEMISTRY-US, V33, P8035, DOI 10.1021/bi00192a007; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MOLL R, 1990, J CELL BIOL, V111, P567, DOI 10.1083/jcb.111.2.567; MURTI KG, 1992, EXP CELL RES, V202, P36, DOI 10.1016/0014-4827(92)90401-S; NAPOLITANO EW, 1985, J CELL BIOL, V101, P1323, DOI 10.1083/jcb.101.4.1323; NICHOLL ID, 1994, EMBO J, V13, P945, DOI 10.1002/j.1460-2075.1994.tb06339.x; OHTSUKA K, 1986, RADIAT RES, V108, P34, DOI 10.2307/3576967; OMARY MB, 1992, J CELL BIOL, V117, P583, DOI 10.1083/jcb.117.3.583; OMARY MB, 1992, J CELL BIOCHEM, V48, P316, DOI 10.1002/jcb.240480312; OMARY MB, 1992, MOL IMMUNOL, V29, P9, DOI 10.1016/0161-5890(92)90151-M; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; ROTHMAN JE, 1986, CELL, V46, P5, DOI 10.1016/0092-8674(86)90852-4; SCHLESINGER MJ, 1990, J BIOL CHEM, V265, P12111; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; SHI YG, 1992, MOL CELL BIOL, V12, P2186, DOI 10.1128/MCB.12.5.2186; SKALLI O, 1994, J CELL BIOL, V125, P159, DOI 10.1083/jcb.125.1.159; SKALLI O, 1991, CELL MOTIL CYTOSKEL, V19, P67, DOI 10.1002/cm.970190202; SPUDICH A, 1992, CELL MOTIL CYTOSKEL, V22, P250, DOI 10.1002/cm.970220405; STAPPENBECK TS, 1993, J CELL BIOL, V123, P691, DOI 10.1083/jcb.123.3.691; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; SUN TT, 1979, P NATL ACAD SCI USA, V76, P2813, DOI 10.1073/pnas.76.6.2813; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UNGEWICKELL E, 1985, EMBO J, V4, P3385, DOI 10.1002/j.1460-2075.1985.tb04094.x; WALTON PA, 1994, J CELL BIOL, V125, P1037, DOI 10.1083/jcb.125.5.1037; WYATT TA, 1991, J BIOL CHEM, V266, P21274	64	90	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					915	922		10.1074/jbc.270.2.915	http://dx.doi.org/10.1074/jbc.270.2.915			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7529764	hybrid			2022-12-27	WOS:A1995QB81600065
J	ABRAMS, CS; ZHAO, W				ABRAMS, CS; ZHAO, W			SH3 DOMAINS SPECIFICALLY REGULATE KINASE-ACTIVITY OF EXPRESSED SRC FAMILY PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICKEN-EMBRYO FIBROBLASTS; SITE-DIRECTED MUTAGENESIS; ROUS-SARCOMA VIRUS; C-SRC; TYROSINE KINASE; V-SRC; SIGNAL TRANSDUCTION; BINDING SITE; GENE-PRODUCT; 3T3 CELLS	The Src homology 2 (SH2) and Src homology 3 (SH3) domain are approximately 50% conserved in various Src family kinase members. Several lines of evidence suggest that in Src these domains are sequence motifs that direct substrate recognition, regulate kinase activity, or control subcellular localization, We sought to investigate the function of the homology domains in human Lyn, and to determine whether the differences between various SH3 domains affect function. To do this, we generated variant forms of Lyn lacking SH2 and SH3 domains, and created chimeras in which the SH3 domains in human c-Src and Lyn were replaced with SH3 domains from other family members. In contrast to similar deletions in Src, forms of Lyn lacking SH2 or SH3 had decreased kinase activity. The SH3 chimeras all had individual characteristics. Insertion of the Blk SH3 domain into Lyn restored kinase activity, while insertion of the Fyn or Src SH3 into Lyn enhanced the kinase activity 2-3-fold. Insertion of the Lyn SH3 into Src also doubled kinase activity, Expression of the Lyn-Src SH3 chimera in mammalian cells induced cell transformation, This study 1) demonstrates that the regulation of Lyn is different than Src, and 2) provides new evidence that despite their homology, there are important functional differences between the SH3 domains of the various Src family members.			ABRAMS, CS (corresponding author), UNIV PENN, SCH MED,DEPT MED,DIV HEMATOL ONCOL,415 CURIE BLVD, RM 678, PHILADELPHIA, PA 19104 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K11HL002464] Funding Source: NIH RePORTER; NHLBI NIH HHS [5-K11-HL02464] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARFOD ET, 1993, J BIOL CHEM, V268, P26059; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BOLEN JB, 1991, CELL GROWTH DIFFER, V2, P409; BOOKER GW, 1993, CELL, V73, P813, DOI 10.1016/0092-8674(93)90259-S; BRUGGE JS, 1984, J BIOL CHEM, V259, P4550; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; DUCHESNE M, 1993, SCIENCE, V259, P525, DOI 10.1126/science.7678707; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; GRANDORI C, 1989, NATURE, V338, P467, DOI 10.1038/338467a0; HIRAI H, 1990, P NATL ACAD SCI USA, V87, P8592, DOI 10.1073/pnas.87.21.8592; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; IBA H, 1984, P NATL ACAD SCI-BIOL, V81, P4424, DOI 10.1073/pnas.81.14.4424; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; JOVE R, 1987, CELL, V50, P937, DOI 10.1016/0092-8674(87)90520-4; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KAPLAN JM, 1988, MOL CELL BIOL, V8, P2435, DOI 10.1128/MCB.8.6.2435; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LEVINSON AD, 1991, P NATL ACAD SCI USA, V78, P1624; LEVY JB, 1989, MOL CELL BIOL, V9, P3332, DOI 10.1128/MCB.9.8.3332; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; MORRIS JF, 1991, ONCOGENE, V6, P2339; MURPHY SM, 1993, MOL CELL BIOL, V13, P5290, DOI 10.1128/MCB.13.9.5290; NEMETH SP, 1989, MOL CELL BIOL, V9, P1109, DOI 10.1128/MCB.9.3.1109; OKADA M, 1993, J BIOL CHEM, V268, P18070; PARKER RC, 1984, CELL, V37, P131, DOI 10.1016/0092-8674(84)90308-8; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; PLEIMAN CM, 1994, P NATL ACAD SCI USA, V91, P4268, DOI 10.1073/pnas.91.10.4268; Potts W M, 1988, Oncogene Res, V3, P343; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RODAWAY ARF, 1989, NATURE, V342, P624, DOI 10.1038/342624a0; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; Sambrook J, 1989, MOL CLONING LABORATO; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHUH SM, 1988, MOL CELL BIOL, V8, P2465, DOI 10.1128/MCB.8.6.2465; SEFTON BM, 1980, CELL, V20, P807, DOI 10.1016/0092-8674(80)90327-X; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SUDOL M, 1993, ONCOGENE, V8, P823; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; VEILLETTE A, 1992, ONCOGENE, V7, P971; WENG ZG, 1993, J BIOL CHEM, V268, P14956; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	54	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					333	339		10.1074/jbc.270.1.333	http://dx.doi.org/10.1074/jbc.270.1.333			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7529230	hybrid			2022-12-27	WOS:A1995QA28700053
J	HAQUE, NS; BUCHBERG, AM; KHALILI, K				HAQUE, NS; BUCHBERG, AM; KHALILI, K			ISOLATION AND CHARACTERIZATION OF MRF-1, A BRAIN-DERIVED DNA-BINDING PROTEIN WITH A CAPACITY TO REGULATE EXPRESSION OF MYELIN BASIC-PROTEIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPLICING FACTOR SC35; MOUSE-BRAIN; MOLECULAR-BIOLOGY; MUTANT MICE; TRANSCRIPTION; ELEMENTS; CELLS; PROMOTER; IDENTIFICATION; CLONING	The 5'-flanking region of the myelin basic protein (MBP) contains several regulatory elements that differentially contribute to the cell type specific transcription of MBP in cells derived from the central nervous system. The distal regulatory element, termed MB3, had previously been shown to have characteristics of a cell type-specific enhancer element and bind to multiple brain-derived nuclear proteins in vitro. We now report the isolation of a recombinant cDNA clone, named myelin regulatory factor-1 (MRF-1) from a mouse brain expression library that encodes a novel protein which interacts with the MB3 domain. Computer-assisted analysis of MRF-1 revealed substantial sequence homology in the central and the COOH-terminal regions of this protein with the previously identified splicing factor SC35. Co transfection studies indicated that MRF-1 increases transcription of the MBP promoter in glial cells and that this activation requires an intact MRF-1-binding site within the MB3 region. MRF-1 cDNA hybridized to three RNA species 1.8, 2.5, and 3.0 kilobases which are expressed in all tissues analyzed. The gene encoding MRF-1 is located on the distal half of mouse chromosome 11 in a region where the human homolog would be predicted to reside on human chromosome 17.	THOMAS JEFFERSON UNIV, JEFFERSON INST MOLEC MED, DEPT BIOCHEM & MOLEC BIOL, MOLEC NEUROVIROL SECT, PHILADELPHIA, PA 19107 USA; THOMAS JEFFERSON UNIV, JEFFERSON CANC INST, DEPT MICROBIOL & IMMUNOL, PHILADELPHIA, PA 19107 USA	Jefferson University; Jefferson University				Buchberg, Arthur/0000-0002-0543-5631				Ausubel FM, 1988, MOL REPROD DEV; BARBARESE E, 1978, J NEUROCHEM, V31, P779, DOI 10.1111/j.1471-4159.1978.tb00110.x; BERNDT JA, 1992, J BIOL CHEM, V267, P14730; BRUNEL F, 1991, NUCLEIC ACIDS RES, V19, P5237, DOI 10.1093/nar/19.19.5237; BUCHBERG AM, 1989, GENETICS, V122, P153; BUCHBERG AM, 1993, MAMM GENOME, V4, pS164, DOI 10.1007/BF00360837; CAMPAGNONI AT, 1988, J NEUROCHEM, V51, P1, DOI 10.1111/j.1471-4159.1988.tb04827.x; CAMPAGNONI CW, 1978, ARCH BIOCHEM BIOPHYS, V190, P118, DOI 10.1016/0003-9861(78)90258-8; CARSON JH, 1983, DEV BIOL, V96, P485, DOI 10.1016/0012-1606(83)90185-9; DEVINEBEACH K, 1990, J BIOL CHEM, V265, P13830; DEVINEBEACH K, 1992, NUCLEIC ACIDS RES, V20, P545, DOI 10.1093/nar/20.3.545; Dickie M.M., 1967, MOUSE NEWS LETT, V36, P39; DIETRICH W, 1992, GENETICS, V131, P423; DUBOISDALCQ M, 1986, J CELL BIOL, V102, P384, DOI 10.1083/jcb.102.2.384; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; FU XD, 1992, P NATL ACAD SCI USA, V89, P1725, DOI 10.1073/pnas.89.5.1725; FU XD, 1992, SCIENCE, V256, P535, DOI 10.1126/science.1373910; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; GONG QH, 1988, NUCLEIC ACIDS RES, V16, P1203, DOI 10.1093/nar/16.3.1203; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Green MC., 1989, GENETIC VARIANTS STR, P12; HAAS S, 1993, MOL CELL BIOL, V13, P3103, DOI 10.1128/MCB.13.5.3103; INOUE T, 1990, J BIOL CHEM, V265, P19065; JACKSON I, 1990, MOUSE GENOME, V86, P226; JANSENDURR P, 1992, NUCLEIC ACIDS RES, V20, P1243, DOI 10.1093/nar/20.6.1243; KAMADA S, 1992, GENE, V119, P229, DOI 10.1016/0378-1119(92)90276-U; KAMHOLZ J, 1988, J NEUROSCI RES, V21, P62, DOI 10.1002/jnr.490210110; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KRAINER AR, 1990, GENE DEV, V4, P1158, DOI 10.1101/gad.4.7.1158; KRONQUIST KE, 1987, J NEUROSCI RES, V18, P395, DOI 10.1002/jnr.490180303; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LASHGARI MS, 1990, J CLIN INVEST, V86, P1671, DOI 10.1172/JCI114890; MA Q, 1993, P NATL ACAD SCI USA, V90, P6350, DOI 10.1073/pnas.90.13.6350; MACKLIN WB, 1991, J NEUROCHEM, V56, P163, DOI 10.1111/j.1471-4159.1991.tb02576.x; MAJOR EO, 1992, CLIN MICROBIOL REV, V5, P49, DOI 10.1128/CMR.5.1.49-73.1992; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MARINI JC, 1993, GENOMICS, V15, P200, DOI 10.1006/geno.1993.1034; MEIER H, 1967, ARCH NEUROL-CHICAGO, V16, P59, DOI 10.1001/archneur.1967.00470190063008; MIURA M, 1989, GENE, V75, P31; MORGAN WC, 1950, J HERED, V41, P208, DOI 10.1093/oxfordjournals.jhered.a106131; SHIOTA C, 1991, J NEUROCHEM, V56, P818, DOI 10.1111/j.1471-4159.1991.tb01997.x; SIDMAN RL, 1980, MOUSE NEWS LETT, V63, P13; STRUM R, 1987, GENE DEV, V1, P1147; TAMURA T, 1991, NUCLEIC ACIDS RES, V19, P3861, DOI 10.1093/nar/19.14.3861; TAMURA T, 1988, NUCLEIC ACIDS RES, V16, P11441, DOI 10.1093/nar/16.24.11441; TAMURA TA, 1989, MOL CELL BIOL, V9, P3122, DOI 10.1128/MCB.9.7.3122; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WIKTOROWICZ M, 1991, DEV NEUROSCI-BASEL, V13, P143, DOI 10.1159/000112152; YOKOYAMA T, 1993, SCIENCE, V260, P679, DOI 10.1126/science.8480178; ZELLER NK, 1984, P NATL ACAD SCI-BIOL, V81, P18, DOI 10.1073/pnas.81.1.18	52	8	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					31149	31156						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7527040				2022-12-27	WOS:A1994PV51000064
J	YOKOSAKI, Y; PALMER, EL; PRIETO, AL; CROSSIN, KL; BOURDON, MA; PYTELA, R; SHEPPARD, D				YOKOSAKI, Y; PALMER, EL; PRIETO, AL; CROSSIN, KL; BOURDON, MA; PYTELA, R; SHEPPARD, D			THE INTEGRIN-ALPHA-9-BETA-1 MEDIATES CELL ATTACHMENT TO A NON-RGD SITE IN THE 3RD FIBRONECTIN TYPE-III REPEAT OF TENASCIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOTACTIN-BINDING; PROTEIN; ADHESION; DISTINCT; VITRONECTIN; EXPRESSION; RECEPTORS; MOLECULES; FAMILY; TUMORS	We have previously reported the sequence of the integrin alpha 9 subunit, a partner of the beta 1 subunit that is expressed in basal keratinocytes, hepatocytes, airway epithelial cells, and smooth and skeletal muscle. In the present study, we have stably expressed alpha 9 beta 1 on the surface of the human embryonic kidney cell line 293 and the human colon carcinoma cell line SW480 and used these transfected cell lines to identify ligand(s) for this integrin. Transfected cells did not appear to utilize alpha 9 beta 1 for attachment to the extracellular matrix proteins fibronectin, laminin, vitronectin, fibrinogen, thrombospondin, or type I or IV collagen. However, in contrast to mock transfectants, both 293 cells and SW480 cells expressing alpha 9 beta 1 adhered to intact chicken tenascin. By utilizing a variety of recombinant fragments of tenascin, we were able to localize the binding site for alpha 9 beta 1 to the third type III repeat. This repeat contains the arginine-glycine-aspartic acid (RGD) tripeptide that has been shown to serve as a binding site in tenascin for alpha v-integrins. However, the RGD site does not appear to be the binding site for alpha 9 beta 1, as the attachment of alpha 9 transfectants to this fragment was not inhibited by RGD peptide, nor by changing the RGD site to RAD or RAA.	UNIV CALIF SAN FRANCISCO, CTR LUNG BIOL,CTR ENVIRONM & OCCUPAT HLTH, INST CARDIOVASC RES,DEPT MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CTR LUNG BIOL, CTR ENVIRONM & OCCUPAT HLTH, INST CARDIOVASC RES, SAN FRANCISCO, CA 94143 USA; SCRIPPS RES INST, DEPT NEUROL, LA JOLLA, CA 92037 USA; LA JOLLA INST EXPTL MED, LA JOLLA, CA 92037 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Scripps Research Institute					NHLBI NIH HHS [HL25816, HLA133259, HL47412] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047412, P01HL025816] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; BERLIN C, 1993, CELL, V74, P185, DOI 10.1016/0092-8674(93)90305-A; BUSK M, 1992, J BIOL CHEM, V267, P5790; CHERESH DA, 1989, CELL, V57, P59, DOI 10.1016/0092-8674(89)90172-4; CROSSIN KL, 1991, P NATL ACAD SCI USA, V88, P11403, DOI 10.1073/pnas.88.24.11403; DITTEL BN, 1993, BLOOD, V81, P2272; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; ERICKSON HP, 1989, ANNU REV CELL BIOL, V5, P71, DOI 10.1146/annurev.cb.05.110189.000443; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HOFFMAN S, 1988, J CELL BIOL, V106, P519, DOI 10.1083/jcb.106.2.519; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JOSHI P, 1993, J CELL SCI, V106, P389; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; LIGHTNER VA, 1994, J INVEST DERMATOL, V102, P273, DOI 10.1111/1523-1747.ep12371780; PALMER EL, 1993, J CELL BIOL, V123, P1289, DOI 10.1083/jcb.123.5.1289; PRIETO AL, 1992, J CELL BIOL, V119, P663, DOI 10.1083/jcb.119.3.663; PRIETO AL, 1993, P NATL ACAD SCI USA, V90, P10154, DOI 10.1073/pnas.90.21.10154; PULIDO R, 1991, J BIOL CHEM, V266, P10241; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SAMBROOK J, 1989, TRANSFECTION COPRECI; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Shattil SJ, 1991, CURR OPIN CELL BIOL, V3, P869, DOI 10.1016/0955-0674(91)90062-4; SOINI Y, 1993, AM J CLIN PATHOL, V100, P145, DOI 10.1093/ajcp/100.2.145; SRIRAMARAO P, 1993, J CELL SCI, V105, P1001; TERVO T, 1990, OPHTHALMIC RES, V22, P128, DOI 10.1159/000267012; TUCKER RP, 1994, DEVELOPMENT, V120, P637; VANEYKEN P, 1992, HEPATOLOGY, V15, P909, DOI 10.1002/hep.1840150526; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; WEINACKER A, 1994, J BIOL CHEM, V269, P6940; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281	32	184	191	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26691	26696						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7523411				2022-12-27	WOS:A1994PQ93100020
J	KAMATA, T; TAKADA, Y				KAMATA, T; TAKADA, Y			DIRECT BINDING OF COLLAGEN TO THE I-DOMAIN OF INTEGRIN ALPHA-2-BETA-1 (VLA-2, CD49B/CD29) IN A DIVALENT CATION-INDEPENDENT MANNER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE ADHESION GLYCOPROTEIN; COMPLEMENT RECEPTOR TYPE-3; AMINO-ACID SEQUENCE; VONWILLEBRAND-FACTOR; ALPHA-SUBUNIT; MONOCLONAL-ANTIBODY; CELL-ADHESION; VI COLLAGEN; FACTOR-B; FIBRONECTIN	Integrin alpha 2 beta 1 is a major divalent cation dependent receptor for collagen. Here, we show that the recombinant inserted/interactive domain (I domain) of alpha 2 specifically interacts with collagen, indicating the I domain contains all the components necessary for collagen binding. Evidence was obtained that divalent cations are not required for collagen binding to the I domain fragment, indicating that divalent cations are not involved in the actual binding to collagen but probably in the regulation of the binding. We identified Thr-221 within the previously identified putative ligand binding region as a residue critical for collagen binding to both alpha beta 1 and the I domain fragment. Thr-221 may be involved in the actual collagen binding and recognition.	Scripps Res Inst, DEPT VASC BIOL, VB-4, LA JOLLA, CA 92037 USA	Scripps Research Institute				takada, yoshikazu/0000-0001-5481-9589	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047157] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47157] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARGRAVES WS, 1987, P NATL ACAD SCI USA, V84, P464, DOI 10.1073/pnas.84.2.464; ARNAOUT MA, 1988, J CELL BIOL, V106, P2153, DOI 10.1083/jcb.106.6.2153; BENTLEY DR, 1986, BIOCHEM J, V239, P339, DOI 10.1042/bj2390339; BERGELSON JM, 1992, SCIENCE, V255, P1718, DOI 10.1126/science.1553561; BERGELSON JM, 1993, J CLIN INVEST, V92, P232, DOI 10.1172/JCI116555; BOCKENSTEDT P, 1986, J CLIN INVEST, V78, P551, DOI 10.1172/JCI112608; BONALDO P, 1989, J BIOL CHEM, V264, P5575; BRIESEWITZ R, 1993, J BIOL CHEM, V268, P2989; CARTER WG, 1990, J CELL BIOL, V110, P1387, DOI 10.1083/jcb.110.4.1387; CHEN FA, 1991, J EXP MED, V173, P1111, DOI 10.1084/jem.173.5.1111; CHU ML, 1990, EMBO J, V9, P385, DOI 10.1002/j.1460-2075.1990.tb08122.x; COLLER BS, 1989, BLOOD, V74, P182; CORBI AL, 1987, EMBO J, V6, P4023, DOI 10.1002/j.1460-2075.1987.tb02746.x; CORBI AL, 1988, J BIOL CHEM, V263, P12403; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; GINSBERG MH, 1983, J CLIN INVEST, V71, P619, DOI 10.1172/JCI110808; GOLDMAN R, 1992, EUR J IMMUNOL, V22, P1109, DOI 10.1002/eji.1830220502; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IGNATIUS MJ, 1990, J CELL BIOL, V111, P709, DOI 10.1083/jcb.111.2.709; KAMATA T, 1994, J BIOL CHEM, V269, P9659; KLEIN CE, 1991, J CELL BIOL, V115, P1427, DOI 10.1083/jcb.115.5.1427; KUNICKI TJ, 1988, J BIOL CHEM, V263, P4516; LARJAVA H, 1990, J CELL BIOL, V110, P803, DOI 10.1083/jcb.110.3.803; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; MOLE JE, 1984, J BIOL CHEM, V259, P3407; NIEUWENHUIS HK, 1985, NATURE, V318, P470, DOI 10.1038/318470a0; OCONNELL PJ, 1991, IMMUNOL CELL BIOL, V69, P103, DOI 10.1038/icb.1991.16; PISCHEL KD, 1987, J IMMUNOL, V138, P226; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; PYTELA R, 1988, EMBO J, V7, P1371, DOI 10.1002/j.1460-2075.1988.tb02953.x; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SANTORO SA, 1988, BIOCHEM BIOPH RES CO, V153, P217, DOI 10.1016/S0006-291X(88)81211-7; SCHIRO JA, 1991, CELL, V67, P403, DOI 10.1016/0092-8674(91)90191-Z; SHAW SK, 1994, J BIOL CHEM, V269, P6016; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; SYMINGTON BE, 1993, J CELL BIOL, V120, P523, DOI 10.1083/jcb.120.2.523; TAKADA Y, 1988, J CELL BIOCHEM, V37, P385, DOI 10.1002/jcb.240370406; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; TENCHINI ML, 1993, CELL ADHES COMMUN, V1, P55, DOI 10.3109/15419069309095681; VERWEIJ CL, 1986, EMBO J, V5, P1839, DOI 10.1002/j.1460-2075.1986.tb04435.x; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873; YAMADA KM, 1990, CANCER RES, V50, P4485; YAMADA KM, 1991, J BIOL CHEM, V266, P12809; YAMADA KM, 1988, FIBRONECTIN, P47	48	151	157	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26006	26010						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7523399				2022-12-27	WOS:A1994PQ93000014
J	CHEN, PF; TSAI, AL; WU, KK				CHEN, PF; TSAI, AL; WU, KK			CYSTEINE-184 OF ENDOTHELIAL NITRIC-OXIDE SYNTHASE IS INVOLVED IN HEME COORDINATION AND CATALYTIC ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; EXPRESSION; CELLS; ENZYME; BRAIN; IDENTIFICATION; PURIFICATION; HEMOPROTEIN; CALMODULIN	Nitric oxide synthase catalyzes the formation of an important messenger molecule, nitric oxide (NO). It is a P450-type hemoprotein, containing a cysteine thiolate as its proximal heme ligand, but the exact cysteine residue involved in heme coordination has not been identified. To locate this specific cysteine, we altered three potential cysteine residues (Cys-99, Cys-184, and Cys-441) to alanine residues in human endothelial nitric oxide synthase (eNOS) by oligonucleotide directed mutagenesis and expressed the wild-type and mutant eNOSs in COS-1 and the baculovirus expression system. Mutation of Cys-235 to alanine was included to serve as a control. Mutation of Cys-184 resulted in a complete loss of NOS catalytic activity and abrogation of the formation of carbon monoxide (CO)-heme ferrous complex, which was detected on CO difference spectra as a distinct peak centered on 444-446 nm, without reduction in the quantity of eNOS protein. Mutation of Cys-99 also resulted in a loss of catalytic activity but did not eliminate the 444-446 nn peak, C441A and C235A mutants displayed considerable NOS activity and retained the CO-heme peak on CO-ferrous difference spectra. These results indicate that the cysteine 184 of human eNOS is most likely the proximal heme ligand.	UNIV TEXAS,HLTH SCI CTR,DEPT INTERNAL MED,DIV HEMATOL,HOUSTON,TX 77030; UNIV TEXAS,HLTH SCI CTR,VASC BIOL RES CTR,HOUSTON,TX 77030	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston			Wu, Kenneth Kun-Yu/B-1070-2010		NHLBI NIH HHS [HL-50675, HL-35387] Funding Source: Medline; NINDS NIH HHS [NS-23327] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035387, R01HL050675] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS023327] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; ASSEFFA A, 1989, ARCH BIOCHEM BIOPHYS, V274, P481, DOI 10.1016/0003-9861(89)90461-X; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CULLEN BR, 1987, METHOD ENZYMOL, V152, P8125; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; Griffin B. W., 1979, PORPHYRINS, V7, P333; HEVEL JM, 1991, J BIOL CHEM, V266, P22789; JANSSENS SP, 1992, J BIOL CHEM, V267, P14519; KLATT P, 1992, BIOCHEM J, V288, P15, DOI 10.1042/bj2880015; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MONCADA S, 1991, PHARMACOL REV, V43, P109; NATHAN C, 1994, J BIOL CHEM, V269, P13725; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; PENG C, 1991, J VIROL, V65, P2751, DOI 10.1128/JVI.65.5.2751-2756.1991; POLLOCK JS, 1991, P NATL ACAD SCI USA, V88, P10480, DOI 10.1073/pnas.88.23.10480; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SESSA WC, 1992, J BIOL CHEM, V267, P15274; SHETA EA, 1994, J BIOL CHEM, V269, P15147; STUEHR DJ, 1989, J EXP MED, V169, P1543, DOI 10.1084/jem.169.5.1543; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; WANG JL, 1993, J BIOL CHEM, V268, P22255; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001; WU KK, 1988, J BIOL CHEM, V263, P19043; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522	32	111	112	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					25062	25066						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7523378				2022-12-27	WOS:A1994PQ49000081
J	TAUCHI, T; FENG, GS; MARSHALL, MS; SHEN, R; MANTEL, C; PAWSON, T; BROXMEYER, HE				TAUCHI, T; FENG, GS; MARSHALL, MS; SHEN, R; MANTEL, C; PAWSON, T; BROXMEYER, HE			THE UBIQUITOUSLY EXPRESSED SYP PHOSPHATASE INTERACTS WITH C-KIT AND GRB2 IN HEMATOPOIETIC-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; SIGNAL TRANSDUCTION; SH3 DOMAINS; NUCLEOTIDE EXCHANGE; KINASE-ACTIVITY; RAS; RECEPTOR; PHOSPHORYLATION; ASSOCIATION	The c-kit proto oncogene encodes a transmembrane tyrosine kinase receptor, which is important for the normal development of hematopoietic cells, melanoblasts, and germ cells. Autophosphorylation of c-kit receptor on tyrosine creates binding sites for cellular src homology 2 (SH2)-containing signaling molecules. The discovery of phosphotyrosine phosphatases that contain SH2 domains suggests roles for these molecules in growth factor signaling pathways. We found that Syp, a phosphotyrosine phosphatase widely expressed in all the tissues in mammals, associates with c-kit receptor after activation with its ligand, steel factor, in the factor-dependent cell line, M07e. Both NH2-terminal and COOH-terminal SH2 domains of Syp, made as glutathione S-transferase fusion proteins, were able to bind to the activated c-kit receptor in vitro. Furthermore, Syp became marginally phosphorylated on tyrosine upon c-Kit receptor activation, and tyrosine-phosphorylated Syp was found to be complexed with Grb2 in steel factor-stimulated M07e cells. Direct binding between Syp and Grb2 was also observed in vitro. Last, Ras and Raf interacts in vitro as a result of steel factor-stimulated Ras activation. These results suggest that Syp may be an important signaling component downstream of the c-kit receptor and involved in activation of the Ras signaling pathway in hematopoietic cells.	INDIANA UNIV, SCH MED, WALTHER ONCOL CTR, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, SCH MED, DEPT MED HEMATOL ONCOL, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOL, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, SCH MED, DEPT MICROBIOL & IMMUNOL, INDIANAPOLIS, IN 46202 USA; MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, TORONTO M5G 1X5, ON, CANADA	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute			Pawson, Tony J/E-4578-2013		NCI NIH HHS [R37 CA36464] Funding Source: Medline; NHLBI NIH HHS [R01 HL49202, R01 HL46549] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA036464] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049202, R01HL046549] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; AVANZI GC, 1988, BRIT J HAEMATOL, V69, P359, DOI 10.1111/j.1365-2141.1988.tb02374.x; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; CULTER RL, 1993, J BIOL CHEM, V268, P21463; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FENG GS, 1994, ONCOGENE, V9, P1545; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; HENDRIE PC, 1991, EXP HEMATOL, V19, P1031; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LENER NB, 1991, BLOOD, V77, P1876; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; PAWSON T, 1992, NATURE, V356, P285, DOI 10.1038/356285a0; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; TAUCHI T, 1994, J BIOL CHEM, V269, P15381; TAUCHI T, 1994, J EXP MED, V179, P167, DOI 10.1084/jem.179.1.167; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	43	144	146	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					25206	25211						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7523381				2022-12-27	WOS:A1994PQ49000101
J	NAM, KB; HUDSON, RHE; CHAPMAN, KB; GANESHAN, K; DAMHA, MJ; BOEKE, JD				NAM, KB; HUDSON, RHE; CHAPMAN, KB; GANESHAN, K; DAMHA, MJ; BOEKE, JD			YEAST LARIAT DEBRANCHING ENZYME - SUBSTRATE AND SEQUENCE SPECIFICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER RNA; SINGLE-STRANDED-DNA; GROUP-II INTRON; BRANCHED RNA; STIGMATELLA-AURANTIACA; MYXOCOCCUS-XANTHUS; ESCHERICHIA-COLI; 5' END; PURIFICATION; MSDNA	Yeast RNA lariat debranching enzyme has been purified to near homogeneity using a bacterial overproducer of the enzyme. The enzyme is capable of digesting a variety of branched nucleic acid substrates, including group II intron lariats, multicopy single-stranded DNAs (msDNAs), and a variety of synthetic branched RNAs. A trinucleotide release assay using radiolabeled msDNA substrates was developed and used to determine the basic biochemical parameters for the enzyme. The debranching enzyme shows a strong preference for purines at the 2'-position in both msDNA and synthetic branched RNA substrates, in accord with the structure of its native substrate, which always has a 2'-G residue. The use of small synthetic branched RNA substrates will allow systematic mechanistic and structural studies of this unique enzyme.	MCGILL UNIV,DEPT CHEM,MONTREAL H3A 2B2,PQ,CANADA; JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205; UNIV TORONTO,DEPT CHEM,TORONTO M5S 1A4,ON,CANADA	McGill University; Johns Hopkins University; University of Toronto			Hudson, Robert/L-6325-2015; Damha, Masad J/B-5522-2013		NCI NIH HHS [ET32 CA 09139] Funding Source: Medline; NIGMS NIH HHS [GM36481] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009139] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036481] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARENAS J, 1987, J BIOL CHEM, V262, P4274; BOEKE JD, 1991, MOL CELLULAR BIOL YE, P193; CHAPMAN KB, 1991, CELL, V65, P483, DOI 10.1016/0092-8674(91)90466-C; DAMHA MJ, 1992, NUCLEIC ACIDS RES, V20, P6565, DOI 10.1093/nar/20.24.6565; DAMHA MJ, 1988, J ORG CHEM, V53, P3710, DOI 10.1021/jo00251a010; DHUNDALE A, 1987, CELL, V51, P1105, DOI 10.1016/0092-8674(87)90596-4; DOMDEY H, 1984, CELL, V39, P611, DOI 10.1016/0092-8674(84)90468-9; FURUICHI T, 1987, CELL, V48, P55, DOI 10.1016/0092-8674(87)90355-2; FURUICHI T, 1987, CELL, V48, P47, DOI 10.1016/0092-8674(87)90354-0; GREEN MR, 1986, ANNU REV GENET, V20, P671, DOI 10.1146/annurev.ge.20.120186.003323; HARTMUTH K, 1988, MOL CELL BIOL, V8, P2011, DOI 10.1128/MCB.8.5.2011; HSU MY, 1992, J BIOL CHEM, V267, P13823; JACQUIER A, 1991, J MOL BIOL, V219, P415, DOI 10.1016/0022-2836(91)90183-7; JACQUIER A, 1987, CELL, V50, P17, DOI 10.1016/0092-8674(87)90658-1; JACQUIER A, 1986, P NATL ACAD SCI USA, V83, P5835, DOI 10.1073/pnas.83.16.5835; KRAMER A, 1985, EMBO J, V4, P3571, DOI 10.1002/j.1460-2075.1985.tb04119.x; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamond AI, 1991, CURR OPIN CELL BIOL, V3, P493, DOI 10.1016/0955-0674(91)90078-D; LIM D, 1989, CELL, V56, P891, DOI 10.1016/0092-8674(89)90693-4; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MURPHY WJ, 1986, CELL, V47, P517, DOI 10.1016/0092-8674(86)90616-1; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PARKER R, 1985, CELL, V41, P107, DOI 10.1016/0092-8674(85)90065-0; PEEBLES CL, 1993, J BIOL CHEM, V268, P11929; RUSKIN B, 1990, METHOD ENZYMOL, V181, P180; RUSKIN B, 1984, CELL, V38, P317, DOI 10.1016/0092-8674(84)90553-1; RUSKIN B, 1985, SCIENCE, V229, P135, DOI 10.1126/science.2990042; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUTTON RE, 1988, EMBO J, V7, P1431, DOI 10.1002/j.1460-2075.1988.tb02960.x; WALLACE JC, 1983, P NATL ACAD SCI-BIOL, V80, P950, DOI 10.1073/pnas.80.4.950; YEE T, 1984, CELL, V38, P203, DOI 10.1016/0092-8674(84)90541-5	33	62	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20613	20621						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	7519612				2022-12-27	WOS:A1994PB31700063
J	LUKASHEV, ME; SHEPPARD, D; PYTELA, R				LUKASHEV, ME; SHEPPARD, D; PYTELA, R			DISRUPTION OF INTEGRIN FUNCTION AND INDUCTION OF TYROSINE PHOSPHORYLATION BY THE AUTONOMOUSLY EXPRESSED BETA(1) INTEGRIN CYTOPLASMIC DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							FIBRONECTIN RECEPTOR; CELL-ADHESION; EXTRACELLULAR-MATRIX; SIGNAL TRANSDUCTION; PROTEIN; KINASE; SUBUNIT; DIFFERENTIATION; INVITRO; GENE	The cytoplasmic domains of integrin beta subunits are essential for the function of integrins in cell adhesion and signaling. A chimera combining the transmembrane and cytoplasmic domains of the beta(1) integrin subunit with an irrelevant extracellular domain derived from L3T4 (murine CD4) was tested for its ability to interfere with integrin function. Expression of this construct in cultured human embryonic kidney cells under the control of the inducible metallothionein promoter resulted in cell rounding and detachment, and blocked cell adhesion mediated by the beta(1) and alpha(v) beta(5) integrins. Expression of the beta(1) chimera at basal levels interfered with the tyrosine phosphorylation of a 125-kDa protein induced by antibody-induced clustering of integrins. Induced expression of the chimera resulted in sustained tyrosine phosphorylation of this protein, which could be enhanced by clustering of the chimera but was insensitive to clustering of integrins. These results demonstrate that the autonomously expressed beta(1) integrin cytoplasmic domain can act as a trans-dominant inhibitor of integrin function, presumably via competitive interactions with cytoplasmic components that are required for integrin-mediated cell adhesion and tyrosine phosphorylation.	UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	LUKASHEV, ME (corresponding author), UNIV CALIF SAN FRANCISCO,CTR LUNG BIOL,DEPT MED,BOX 0854,SAN FRANCISCO,CA 94143, USA.				NCI NIH HHS [CA53259] Funding Source: Medline; NHLBI NIH HHS [HL191551, HL/A133259] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; BAUER JS, 1993, J CELL BIOL, V122, P209, DOI 10.1083/jcb.122.1.209; BAUER JS, 1992, J CELL BIOL, V116, P477, DOI 10.1083/jcb.116.2.477; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CLEGG CH, 1987, J BIOL CHEM, V262, P13111; DITTEL BN, 1993, BLOOD, V81, P919; GEIGER B, 1992, J CELL SCI, V103, P943; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HOUGHTON AN, 1982, J EXP MED, V156, P1755, DOI 10.1084/jem.156.6.1755; HUBBARD BD, 1979, J CELL BIOL, V80, P166, DOI 10.1083/jcb.80.1.166; HYNES RO, 1992, VRLL, V69, P11; KINTNER C, 1992, CELL, V69, P225, DOI 10.1016/0092-8674(92)90404-Z; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KORNBERG L, 1992, TRENDS PHARMACOL SCI, V13, P93, DOI 10.1016/0165-6147(92)90034-4; LAFLAMME SE, 1992, J CELL BIOL, V117, P437, DOI 10.1083/jcb.117.2.437; LITTMAN DR, 1987, NATURE, V325, P453, DOI 10.1038/325453a0; Otey C. A., 1993, Molecular Biology of the Cell, V4, p347A; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; PELLETIER AJ, 1992, MOL BIOL CELL, V3, P989, DOI 10.1091/mbc.3.9.989; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; STEPHENS LE, 1993, J CELL BIOL, V123, P1607, DOI 10.1083/jcb.123.6.1607; TOMASELLI KJ, 1988, J CELL BIOL, V107, P1241, DOI 10.1083/jcb.107.3.1241; WEINACKER A, 1994, J BIOL CHEM, V269, P6940	26	147	150	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18311	18314						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	7518428				2022-12-27	WOS:A1994NW79800014
J	RIVEROLEZCANO, OM; SAMESHIMA, JH; MARCILLA, A; ROBBINS, KC				RIVEROLEZCANO, OM; SAMESHIMA, JH; MARCILLA, A; ROBBINS, KC			PHYSICAL ASSOCIATION BETWEEN SRC HOMOLOGY-3 ELEMENTS AND THE PROTEIN PRODUCT OF THE C-CBL PROTOONCOGENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							V-CBL; CYTOPLASMIC PROTEIN; TYROSINE KINASES; SH3 DOMAIN; CELLS; BINDING; GROWTH; RAS; NCK; SIMILARITY	To investigate the nature of proteins recognized by Src homology 3 (SH3) domains, a cDNA expression library was prepared from macrophages and screened with a probe representing the three SH3 domains of p47(nck). Two clones were isolated, and one, designated SAKAP I (for Src A box Nck-associated protein I), contained the carboxyl-terminal half of the cbl proto-oncogene product. Studies in vitro demonstrated reactivity between SAKAP I and SH3 domains derived from a variety of molecules. Wide variations in this assay suggested a high degree of specificity inherent in SAKAP I binding. Moreover, it was possible to demonstrate an in vivo association between p47(nck) and p120(c-cbl) in HL60 cells. These findings suggest that proteins containing SH3 elements regulate Cbl function.	NIDR, CELLULAR DEV & ONCOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)			marcilla, antonio/F-9996-2010; Rivero-Lezcano, Octavio Miguel/J-9089-2015	marcilla, antonio/0000-0003-0004-0531; Rivero-Lezcano, Octavio Miguel/0000-0002-8793-0731				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; KATAMINE S, 1988, MOL CELL BIOL, V8, P259, DOI 10.1128/MCB.8.1.259; LANGDON WY, 1989, J VIROL, V63, P5420, DOI 10.1128/JVI.63.12.5420-5424.1989; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; RASCHKE WC, 1978, CELL, V15, P261, DOI 10.1016/0092-8674(78)90101-0; RIVEROLEZCANO OM, 1994, FEBS LETT, V338, P183, DOI 10.1016/0014-5793(94)80361-7; RODAWAY ARF, 1989, NATURE, V342, P624, DOI 10.1038/342624a0; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; WASENIUS VM, 1989, J CELL BIOL, V108, P79, DOI 10.1083/jcb.108.1.79; WENG ZG, 1993, J BIOL CHEM, V268, P14956; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	27	167	168	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17363	17366						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	7517397				2022-12-27	WOS:A1994NU12800002
J	THOMAS, SR; MOHR, D; STOCKER, R				THOMAS, SR; MOHR, D; STOCKER, R			NITRIC-OXIDE INHIBITS INDOLEAMINE 2,3-DIOXYGENASE ACTIVITY IN INTERFERON-GAMMA PRIMED MONONUCLEAR PHAGOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI LIPOPOLYSACCHARIDE; TRYPTOPHAN DEGRADATION; L-ARGININE; ANTIMICROBIAL ACTIVITY; GLYCERYL TRINITRATE; TOXOPLASMA-GONDII; RESPIRATORY BURST; HUMAN MACROPHAGES; SUPEROXIDE ANION; QUINOLINIC ACID	Indoleamine 2,3-dioxygenase (IDO) and nitric oxide synthase are part of the anti-tumor and antimicrobial activities of mononuclear phagocytes induced by interferon-gamma (IFN gamma). As IDO is a heme containing enzyme and NO, the product of nitric oxide synthase initiated arginine degradation, is a regulator of heme enzymes, we investigated whether NO is capable of modulating IDO activity in IFN gamma-primed mononuclear phagocytes. Authentic NO gas or the NO generating compound, diethylamine dinitric oxide adduct, dose dependently inhibited IDO activity in cell lysates prepared from IFN gamma-primed human peripheral blood mononuclear cells, as assessed by the ascorbate/methylene blue assay for IDO. In contrast, neither nitrite nor nitrate affected IDO activity. Exposure of intact IFN gamma-primed human peripheral blood mononuclear cells or monocyte-derived macrophages to any of the NO-generating compounds, sodium nitroprusside, glyceryl trinitrate, S-nitroso-N-acetylpenicillamine, or diethylamine dinitric oxide adduct, resulted in inhibition of both the consumption of tryptophan from and formation of its metabolite, kynurenine, in the culture medium. The observed inhibition of IDO activity was not due to toxicity of the NO generators and was abrogated by the co-addition of oxyhemoglobin, an antagonist of NO function. Comparable concentrations of nitrite or nitrate did not inhibit IDO activity in intact cells. In contrast to human cells, addition of IFN gamma to murine macrophages, cultured in complete RPMI 1640 medium, readily induced nitric oxide synthase. Others have reported that such treatment does not induce HDO activity in these cells. However, induction of IDO activity was observed in murine macrophages when the synthesis of reactive nitrogen species was inhibited, by using arginine-free medium and/or the nitric oxide synthesis inhibitor, N-G-monomethyl-L-arginine. Together, these results demonstrate that both exogenous and endogenous NO inhibit IDO activity and that oxidative arginine and tryptophan metabolism in IFN gamma-primed mononuclear phagocytes are functionally related. Our study thereby provides an insight into how these cells may regulate some of their antimicrobial and anti-tumor activities.	HEART RES INST,BIOCHEM GRP,SYDNEY,NSW 2050,AUSTRALIA	University of Sydney; Heart Research Institute			Stocker, Roland/AAV-4489-2021					ADAMS LB, 1990, J IMMUNOL, V144, P2725; AUNE TM, 1989, J CLIN INVEST, V84, P863, DOI 10.1172/JCI114247; BYRNE GI, 1989, INFECT IMMUN, V57, P1318, DOI 10.1128/IAI.57.4.1318-1320.1989; CARLIN JM, 1989, J LEUKOCYTE BIOL, V45, P29, DOI 10.1002/jlb.45.1.29; CARLIN JM, 1989, EXPERIENTIA, V45, P535, DOI 10.1007/BF01990503; CHRISTEN S, 1990, P NATL ACAD SCI USA, V87, P2506, DOI 10.1073/pnas.87.7.2506; CHRISTEN S, 1994, IN PRESS J CLIN INVE; CLANCY RM, 1992, J CLIN INVEST, V90, P1116, DOI 10.1172/JCI115929; CRAVEN PA, 1983, BIOCHIM BIOPHYS ACTA, V745, P310, DOI 10.1016/0167-4838(83)90063-8; DING AH, 1988, J IMMUNOL, V141, P2407; DRAGO RS, 1960, J AM CHEM SOC, V82, P96, DOI 10.1021/ja01486a021; DRAGO RS, 1961, J AM CHEM SOC, V83, P1819, DOI 10.1021/ja01469a012; DRAPIER JC, 1988, EUR J IMMUNOL, V18, P1587, DOI 10.1002/eji.1830181018; FIELD L, 1978, J CHEM SOC CHEM COMM, P249, DOI 10.1039/c39780000249; FOGELMAN AM, 1979, J LIPID RES, V20, P379; HABARAOHKUBO A, 1993, INFECT IMMUN, V61, P1810, DOI 10.1128/IAI.61.5.1810-1813.1993; HAYAISHI O, 1977, J BIOL CHEM, V252, P3548; HAYAISHI O, 1985, BIKEN J, V28, P39; HEYES MP, 1992, BRAIN, V115, P1249, DOI 10.1093/brain/115.5.1249; HEYES MP, 1992, BIOCHEM J, V283, P633, DOI 10.1042/bj2830633; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; IGNARRO LJ, 1981, J PHARMACOL EXP THER, V218, P739; IYENGAR R, 1987, P NATL ACAD SCI USA, V84, P6369, DOI 10.1073/pnas.84.18.6369; JESSUP W, 1991, BIOCHEM J, V278, P163, DOI 10.1042/bj2780163; LEPOIVRE M, 1989, CANCER RES, V49, P1970; LOWENSTEIN CJ, 1992, CELL, V70, P705, DOI 10.1016/0092-8674(92)90301-R; MARAGOS CM, 1991, J MED CHEM, V34, P3242, DOI 10.1021/jm00115a013; MELILLO G, 1993, J IMMUNOL, V150, P4031; MURRAY HW, 1989, INFECT IMMUN, V57, P845, DOI 10.1128/IAI.57.3.845-849.1989; MURRAY HW, 1988, SEMIN HEMATOL, V25, P101; NATHAN C, 1988, INFLAMMATION BASIC P, P229; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; OHNISHI T, 1977, J BIOL CHEM, V252, P4643; PADGETT EL, 1992, BIOCHEM BIOPH RES CO, V186, P775, DOI 10.1016/0006-291X(92)90813-Z; PFEFFERKORN ER, 1984, P NATL ACAD SCI-BIOL, V81, P908, DOI 10.1073/pnas.81.3.908; RENGASAMY A, 1993, MOL PHARMACOL, V44, P124; SALVEMINI D, 1992, BIOCHEM PHARMACOL, V44, P17, DOI 10.1016/0006-2952(92)90032-E; SALVEMINI D, 1989, P NATL ACAD SCI USA, V86, P6328, DOI 10.1073/pnas.86.16.6328; SALVEMINI D, 1992, P NATL ACAD SCI USA, V89, P982, DOI 10.1073/pnas.89.3.982; SALVEMINI D, 1993, P NATL ACAD SCI USA, V90, P7240, DOI 10.1073/pnas.90.15.7240; SONO M, 1989, J BIOL CHEM, V264, P1616; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; TAKIKAWA O, 1988, J BIOL CHEM, V263, P2041; TAYLOR MW, 1991, FASEB J, V5, P2516, DOI 10.1096/fasebj.5.11.1907934; THOMAS SM, 1993, J IMMUNOL, V150, P5529; VEDIA LM, 1992, J BIOL CHEM, V267, P24929; WERNERFELMAYER G, 1989, BIOCHIM BIOPHYS ACTA, V1012, P140, DOI 10.1016/0167-4889(89)90087-6; YOSHIDA R, 1979, P NATL ACAD SCI USA, V76, P4084, DOI 10.1073/pnas.76.8.4084; ZHU L, 1992, ARCH BIOCHEM BIOPHYS, V298, P452, DOI 10.1016/0003-9861(92)90434-X	50	178	191	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14457	14464						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	7514170				2022-12-27	WOS:A1994NM06500026
J	SAWASDIKOSOL, S; RAVICHANDRAN, KS; LEE, KK; CHANG, JH; BURAKOFF, SJ				SAWASDIKOSOL, S; RAVICHANDRAN, KS; LEE, KK; CHANG, JH; BURAKOFF, SJ			CRK INTERACTS WITH TYROSINE-PHOSPHORYLATED P116 UPON T-CELL ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SIGNAL TRANSDUCTION; SH3 DOMAINS; PROTEIN; ONCOGENE; RECEPTOR; FIBROBLASTS; KINASES	Products of the crk oncogene are expressed in all tissues. Crk proteins are composed exclusively of Src homology 2 (SH2) and Src homology 3 (SH3) domains, and they have been implicated in intracellular signaling. For example, they participate as mediators of Ras activation during nerve growth factor stimulation of PC12 pheochromocytoma cells. We examined the role of Crk proteins during T cell receptor-mediated signaling and observed that Crk proteins specifically interact, via their SH2 domains, with a tyrosine-phosphorylated 116-kDa protein upon T cell activation. p116 may be related to the recently cloned fibroblast p130(cus) and/or p120-Cbl. In addition, we observed that GST-Crk fusion proteins and Crk-L bind, most likely via their SH3 domain, to C3G, a has guanine nucleotide exchange factor. Thus, the interaction of Crk with p116 and C3G strongly implicates Crk as a mediator of T cell receptor signaling, possibly involved in Ras activation.	HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	SAWASDIKOSOL, S (corresponding author), HARVARD UNIV, DANA FARBER CANC INST, DIV PEDIAT ONCOL, BOSTON, MA 02115 USA.		Ravichandran, Kattur Soundarapandian/AAG-7319-2019	Ravichandran, Kattur Soundarapandian/0000-0003-2397-461X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017258] Funding Source: NIH RePORTER; NIAID NIH HHS [AI17258] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BLAKE TJ, 1991, ONCOGENE, V6, P653; BUDAY L, 1994, J BIOL CHEM, V269, P9019; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; DASILVA AJ, 1993, J EXP MED, V178, P2107, DOI 10.1084/jem.178.6.2107; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; HEMPSTEAD BL, 1994, MOL CELL BIOL, V14, P1964, DOI 10.1128/MCB.14.3.1964; Hoeve J.T., 1993, ONCOGENE, V8, P2469; HOEVE JT, 1994, BLOOD, V84, P1731; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MATSUDA M, 1994, MOL CELL BIOL, V11, P1697; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; RAVICHANDRAN KS, 1994, J EXP MED, V179, P727, DOI 10.1084/jem.179.2.727; REEDQUIST KA, 1994, P NATL ACAD SCI USA, V91, P4135, DOI 10.1073/pnas.91.10.4135; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TSUCHIE H, 1989, ONCOGENE, V4, P1281; TSYGANKOV AY, 1994, J BIOL CHEM, V269, P7792; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	36	79	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	1995	270	7					2893	2896		10.1074/jbc.270.7.2893	http://dx.doi.org/10.1074/jbc.270.7.2893			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QG471	7531694	hybrid			2022-12-27	WOS:A1995QG47100004
J	SMITH, BL; BAUER, GB; POVIRK, LF				SMITH, BL; BAUER, GB; POVIRK, LF			DNA-DAMAGE INDUCED BY BLEOMYCIN, NEOCARZINOSTATIN, AND MELPHALAN IN A PRECISELY POSITIONED NUCLEOSOME - ASYMMETRY IN PROTECTION AT THE PERIPHERY OF NUCLEOSOME-BOUND DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORE PARTICLE; ANTIBIOTICS BLEOMYCIN; DEOXYRIBONUCLEIC-ACID; CLEAVAGE; BINDING; LESIONS; STRAND; INTERCALATION; CHROMOPHORE; MECHANISMS	The antitumor drugs bleomycin, neocarzinostatin, and melphalan all damage DNA by mechanisms which involve binding in the minor groove. In order to examine at high resolution the modulating effects of chromatin structure on the action of these drugs, an end-labeled DNA fragment from the Xenopus laevis 5 S rRNA gene was reconstituted with histone octamers to form a precisely positioned nucleosome. For each drug, DNA damage at specific sequence positions in the fragment was then compared for nucleosome-bound versus naked DNA. Reconstitution into nucleosomes resulted in a marked inhibition of the DNA cleavage induced by bleomycin (5-fold) and neocarzinostatin (2.4 fold) in the central region of nucleosomal DNA. However, at the periphery of nucleosome bound DNA a distinct asymmetry was apparent, with marked inhibition of cleavage toward the upstream side, but little if any inhibition to ward the downstream side, which overlaps the binding site of the transcription factor TFIIIA. In the case of melphalan, alkylation at adenine N-3 was inhibited by nearly 2-fold throughout the nucleosome, whereas alky lation at guanine N-7 was either slightly inhibited or slightly enhanced, depending on sequence position. None of the drugs showed the 10-base pair periodicity characteristic of hydroxyl radical-induced cleavage of nucleosomal DNA. The results are consistent with a model in which minor groove sites in nucleosome-bound DNA remain relatively accessible to small molecules, even where the minor groove faces the histone core, and in which drug-induced DNA damage is inhibited by conformational constraints imposed on DNA by nucleosome structure. Furthermore, the degree of such constraints appears to be sequence dependent, at least near the periphery of nucleosome-bound DNA.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PHARMACOL & TOXICOL,RICHMOND,VA 23298	Virginia Commonwealth University			Maddux, Bettye/D-1269-2009	Maddux, Bettye/0000-0001-5890-5249	NATIONAL CANCER INSTITUTE [R01CA040615, T32CA009564] Funding Source: NIH RePORTER; NCI NIH HHS [CA09564, CA40615] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUSTIN M J F, 1991, Proceedings of the American Association for Cancer Research Annual Meeting, V32, P101; Bauer G. B., 1993, Proceedings of the American Association for Cancer Research Annual Meeting, V34, P136; BENNETT R A O, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P175; BENNETT RAO, 1993, BIOCHEMISTRY-US, V32, P3188, DOI 10.1021/bi00063a034; DEDON PC, 1992, CHEM RES TOXICOL, V5, P311, DOI 10.1021/tx00027a001; DEDON PC, 1990, J BIOL CHEM, V265, P14713; DREW HR, 1987, J MOL BIOL, V195, P143, DOI 10.1016/0022-2836(87)90333-0; DREW HR, 1985, J MOL BIOL, V186, P773, DOI 10.1016/0022-2836(85)90396-1; FOX KR, 1988, NUCLEIC ACIDS RES, V16, P2063, DOI 10.1093/nar/16.5.2063; GALAT A, 1990, NUCLEIC ACIDS RES, V18, P2093, DOI 10.1093/nar/18.8.2093; HAYES JJ, 1992, BIOESSAYS, V14, P597, DOI 10.1002/bies.950140905; HAYES JJ, 1990, P NATL ACAD SCI USA, V87, P7405, DOI 10.1073/pnas.87.19.7405; HAYES JJ, 1992, P NATL ACAD SCI USA, V89, P1229, DOI 10.1073/pnas.89.4.1229; HENNE T, 1985, CANCER TREAT REV, V12, P77, DOI 10.1016/0305-7372(85)90001-5; KAPPEN LS, 1983, BIOCHEMISTRY-US, V22, P4872, DOI 10.1021/bi00290a002; KUO MT, 1981, CANCER RES, V41, P2439; KUO MT, 1978, CHROMOSOMA, V68, P229, DOI 10.1007/BF00335418; KUWAHARA J, 1988, P NATL ACAD SCI USA, V85, P2459, DOI 10.1073/pnas.85.8.2459; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LONN U, 1990, BIOCHEM PHARMACOL, V39, P101, DOI 10.1016/0006-2952(90)90653-3; Maxam A M, 1980, Methods Enzymol, V65, P499; MCHUGH MM, 1982, BIOCHIM BIOPHYS ACTA, V696, P7, DOI 10.1016/0167-4781(82)90003-3; MCMURRAY CT, 1991, BIOCHEMISTRY-US, V30, P5631, DOI 10.1021/bi00237a001; MCMURRAY CT, 1991, BIOCHEMISTRY-US, V30, P5644, DOI 10.1021/bi00237a002; MOYER R, 1989, J BIOL CHEM, V264, P12226; NIETO MA, 1988, BIOCHEMISTRY-US, V27, P5635, DOI 10.1021/bi00415a036; OSBORNE MR, 1993, CHEM-BIOL INTERACT, V89, P49, DOI 10.1016/0009-2797(93)03197-3; POVIRK LF, 1988, J BIOL CHEM, V263, P19263; POVIRK LF, 1979, BIOCHEMISTRY-US, V18, P96, DOI 10.1021/bi00568a015; POVIRK LF, 1988, BIOCHEMISTRY-US, V27, P3850, DOI 10.1021/bi00410a049; POVIRK LF, 1981, BIOCHEMISTRY-US, V20, P4007, DOI 10.1021/bi00517a009; POVIRK LF, 1989, BIOCHEMISTRY-US, V28, P8508; PRATT WB, 1994, ANTICANCER DRUGS; RAMSAY N, 1986, J MOL BIOL, V189, P178; RHODES D, 1985, EMBO J, V4, P3473, DOI 10.1002/j.1460-2075.1985.tb04106.x; SIMPSON RT, 1983, P NATL ACAD SCI-BIOL, V80, P51, DOI 10.1073/pnas.80.1.51; SMITH BL, 1993, J BIOL CHEM, V268, P20620; STEIGHNER RJ, 1990, P NATL ACAD SCI USA, V87, P8350, DOI 10.1073/pnas.87.21.8350; THOMA F, 1992, BIOCHIM BIOPHYS ACTA, V1130, P1, DOI 10.1016/0167-4781(92)90455-9; van Holde KE., 1989, SPRINGER SERIES MOL; WANG P, 1990, CANCER RES, V50, P7527; WANG P, 1991, BIOCHEMISTRY-US, V30, P11515, DOI 10.1021/bi00113a005	42	52	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30587	30594						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7527033				2022-12-27	WOS:A1994PU52500084
J	OGAWA, W; HOSOMI, Y; SHII, K; ROTH, RA				OGAWA, W; HOSOMI, Y; SHII, K; ROTH, RA			EVIDENCE FOR 2 DISTINCT 60-KILODALTON SUBSTRATES OF THE SRC TYROSINE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; GROWTH FACTOR-I; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL TRANSDUCTION; CELL-TRANSFORMATION; MOLECULAR-CLONING; SH2 DOMAINS; INSULIN; RECEPTOR; RAS	A monoclonal antibody to a 60-kDa substrate of the insulin receptor tyrosine kinase is utilized in the present studies to examine this molecule in 3T3 cells expressing either the transforming chicken c-Src (mutant Phe-527), the wild type molecule, or the parental cells. The tyrosine phosphorylation of this 60-kDa protein was greatly increased in cells expressing transforming Src and partially increased in cells expressing wild type enzyme. This tyrosine phosphorylation correlated with an increased association with the GTPase-activating protein of p21(ras) (GAP). However, this 60-kDa protein did not react with antibodies to another 62-kDa tyrosine-phosphorylated protein previously isolated from Src-transformed cells (Wong, G., Muller, O., Clark, R., Conroy, L., Moran, M. F., Polakis, P., and McCormick, F. (1992) Cell 69, 551-558), although this latter antibody did react with a 62-kDa protein in anti-phosphotyrosine precipitates from cells expressing transforming c-Src but not the parental cells. These two proteins could also be distinguished by their subcellular location, the ability of the latter but not the former protein to bind RNA, and their migration in SDS gels. Moreover, the 62-kDa RNA-binding phosphoprotein could be almost completely depleted from cell lysates with poly(U)-Sepharose without affecting the amount of either the GAP-associated 60-kDa tyrosine-phosphorylated protein or the protein precipitated with the monoclonal antibody. when the two proteins were phosphorylated in vitro with purified c-Src, they were both found to bind directly to the aminoterminal SH2 domain of GAP, although the RNA-binding protein was found to have a weaker affinity. These results indicate that two distinct 60-kDa proteins are substrates for the Src tyrosine kinase, one which binds RNA and the other which constitutes the major GAP-associated 60-kDa phosphoprotein.	STANFORD UNIV,MED CTR,SCH MED,DEPT MOLEC PHARMACOL,STANFORD,CA 94305; HYOGO INST CLIN RES,AKASHI 673,HYOGO,JAPAN	Stanford University			OGAWA, Wataru/AAQ-9586-2020		NIDDK NIH HHS [DK 41765, DK 34926] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041765, R01DK034926, R37DK034926] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIRGE RB, 1993, SCIENCE, V262, P1522, DOI 10.1126/science.7504323; BOUTON AH, 1991, MOL CELL BIOL, V11, P945, DOI 10.1128/MCB.11.2.945; BRICKELL P M, 1992, Critical Reviews in Oncogenesis, V3, P401; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; DECLUE JE, 1993, MOL CELL BIOL, V13, P6799, DOI 10.1128/MCB.13.11.6799; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; HOSOMI Y, 1994, J BIOL CHEM, V269, P11498; KELLY KL, 1993, J BIOL CHEM, V268, P4391; KOZMA LM, 1990, MOL CELL BIOL, V10, P3626, DOI 10.1128/MCB.10.7.3626; KUHNE MR, 1994, J BIOL CHEM, V269, P15833; LAVAN BE, 1993, J BIOL CHEM, V268, P5921; MARENGERE LEM, 1992, J BIOL CHEM, V267, P22779; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MOLLOY CJ, 1992, MOL CELL BIOL, V12, P3903, DOI 10.1128/MCB.12.9.3903; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MYERS MG, 1993, DIABETES, V42, P643, DOI 10.2337/diabetes.42.5.643; OHMICHI M, 1993, ENDOCRINOLOGY, V133, P46, DOI 10.1210/en.133.1.46; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PORRAS A, 1992, J BIOL CHEM, V267, P21124; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SATOH T, 1992, J BIOL CHEM, V267, P24149; SCHALLER MD, 1993, PROG NUCLEIC ACID RE, V44, P205, DOI 10.1016/S0079-6603(08)60221-4; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SUNG CK, 1994, J BIOL CHEM, V269, P12503; SUNG CK, 1992, BIOCHEM BIOPH RES CO, V189, P1024, DOI 10.1016/0006-291X(92)92306-I; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; YAMAMOTO K, 1992, J BIOL CHEM, V267, P11337; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZHANG B, 1992, J BIOL CHEM, V267, P18320	39	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29602	29608						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7525585				2022-12-27	WOS:A1994PU28400047
J	FURFINE, ES; HARMON, MF; PAITH, JE; KNOWLES, RG; SALTER, M; KIFF, RJ; DUFFY, C; HAZELWOOD, R; OPLINGER, JA; GARVEY, EP				FURFINE, ES; HARMON, MF; PAITH, JE; KNOWLES, RG; SALTER, M; KIFF, RJ; DUFFY, C; HAZELWOOD, R; OPLINGER, JA; GARVEY, EP			POTENT AND SELECTIVE-INHIBITION OF HUMAN NITRIC-OXIDE SYNTHASES - SELECTIVE-INHIBITION OF NEURONAL NITRIC-OXIDE SYNTHASE BY S-METHYL-L-THIOCITRULLINE AND S-ETHYL-L-THIOCITRULLINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRAIN; PURIFICATION; BINDING	Potent and selective inhibition of neuronal nitric oxide synthase (nNOS) compared to endothelial NOS (eNOS) and inducible NOS (iNOS) may be useful to treat cerebral ischemia (stroke) and other neurodegenerative diseases. S-Methyl-L-thiocitrulline (Me-TC) and S-ethyll-thiocitrulline (Et-TC) inhibited the oxidation of L-arginine and the L-arginine-independent oxidation of NADPH by nNOS from human brain. Me-TC and Et-TC were slow, tight binding inhibitors of nNOS with second-order association rate constants (k(on)) of 2.6 x 10(5) M(-1) s(-1) and 1.3 x 10(5) M(-1) s(-1), respectively. The respective dissociation rate constants (k(off)) were 3 x 10(-4) s(-1) and 0.7 x 10(-4) s(-1). Thus, the K-d values calculated from k(off)/k(on) were 1.2 and 0.5 nM, respectively. L-Arginine was a competitive inhibitor of Me-TC and Et-TC binding with competition constant (K-s) values of 2.2 and 2.7 mu M respectively. The K-m of nNOS for L-arginine was 1.6 mu M. The active site concentration of nNOS was estimated by titration with Et-TC. Based on this active site concentration, a k(cat) of 0.4 s(-1) for the oxidation of L-arginine, was calculated. Me-TC and Et-TC were less potent inhibitors of human iNOS (K-i values of 34 and 17 nM, respectively) and human eNOS (K-i values of 11 and 24 nM). Thus, Me-TC and Et-TC were 10- and 50-fold, respectively, more potent inhibitors of nNOS than eNOS. Furthermore, Me-TC was also 17-fold selective for rat nNOS in neuronal tissue compared to rat eNOS in vascular endothelium, suggesting that Me-TC may be selective for nNOS in vivo and therefore, may be therapeutically useful to treat neurodegenerative diseases.	BURROUGHS WELLCOME CO,WELLCOME RES LABS,DIV ORGAN CHEM,RES TRIANGLE PK,NC 27709; WELLCOME RES LABS,BECKENHAM BR3 3BS,KENT,ENGLAND	Burroughs Wellcome Fund; Wellcome Research Laboratories; GlaxoSmithKline; Wellcome Research Laboratories	FURFINE, ES (corresponding author), BURROUGHS WELLCOME CO,WELLCOME RES LABS,DIV EXPTL THERAPY,RES TRIANGLE PK,NC 27709, USA.							Bevington P. R., 1969, DATA REDUCTION ERROR, P56; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOI DW, 1993, P NATL ACAD SCI USA, V90, P9741, DOI 10.1073/pnas.90.21.9741; DAWSON TM, 1992, ANN NEUROL, V32, P297, DOI 10.1002/ana.410320302; FELDMAN PL, 1991, TETRAHEDRON LETT, V32, P875, DOI 10.1016/S0040-4039(00)92109-9; FERSHT A, 1985, ENZYME STRUCTURE MEC, P150; FORSTERMANN U, 1991, BIOCHEM PHARMACOL, V42, P1849, DOI 10.1016/0006-2952(91)90581-O; FURFINE ES, 1993, BIOCHEMISTRY-US, V32, P8512, DOI 10.1021/bi00084a017; GARVEY EP, 1994, ARCH BIOCHEM BIOPHYS, V311, P235, DOI 10.1006/abbi.1994.1232; GARVEY EP, 1994, J BIOL CHEM, V269, P26669; KRISHNASWAMY K, 1994, J MED CHEM, V37, P885; MAYER B, 1991, FEBS LETT, V288, P187, DOI 10.1016/0014-5793(91)81031-3; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; MONCADA S, 1991, PHARMACOL REV, V43, P109; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; OLKEN NM, 1993, BIOCHEMISTRY-US, V32, P9677, DOI 10.1021/bi00088a020; POU S, 1992, J BIOL CHEM, V267, P24173; REES DD, 1989, BRIT J PHARMACOL, V96, P418, DOI 10.1111/j.1476-5381.1989.tb11833.x; SCHMIDT HHHW, 1991, P NATL ACAD SCI USA, V88, P365, DOI 10.1073/pnas.88.2.365; SCHMIDT HHHW, 1992, BIOCHEMISTRY-US, V31, P3243, DOI 10.1021/bi00127a028; SHERMAN PA, 1993, BIOCHEMISTRY-US, V32, P11600, DOI 10.1021/bi00094a017; STEUHR DJ, 1992, ADV ENZYMOL RELAT AR, V65, P287	24	203	206	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26677	26683						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7523410				2022-12-27	WOS:A1994PQ93100018
J	CHOWRIRA, BM; PAVCO, PA; MCSWIGGEN, JA				CHOWRIRA, BM; PAVCO, PA; MCSWIGGEN, JA			IN-VITRO AND IN-VIVO COMPARISON OF HAMMERHEAD, HAIRPIN, AND HEPATITIS-DELTA VIRUS SELF-PROCESSING RIBOZYME CASSETTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; DIVALENT METAL-IONS; MESSENGER-RNA; 3' END; SEQUENCE REQUIREMENTS; SECONDARY STRUCTURE; INVITRO SELECTION; CLEAVAGE REACTION; TRIMMING PLASMID; EXPRESSION	Ribozyme expression cassettes were constructed which generate trimmed, trans-acting ribozymes from longer transcripts through the action of a downstream cis-acting ribozyme. This self-processing system produces small, well-defined trans-acting ribozymes with minimal, nonproductive, intramolecular structure. These cassettes also permit direct comparison of different ribozyme expression vectors without the need to compensate for different transcription initiation and termination sequences. Expression cassettes were created that contain a T7 promoter and that encode a single trans-acting ribozyme followed by either a hammerhead, hairpin, or hepatitis delta virus cis-acting ribozyme. Ah three ribozyme motifs function efficiently when transcribed in vitro, although slight differences are observed in the efficiency of self-processing for the different motifs. When transiently expressed in cultured mouse cells, the same specific cleavage products are observed. In addition, the relative efficiencies of in vitro self-processing between the three ribozyme constructs was maintained in vivo. Thus, the cellular milieu does not differentially alter the activity of the three ribozyme motifs. Detection of ribozyme-catalyzed RNA cleavage products from cultured cells is direct proof of ribozyme action in vivo.			CHOWRIRA, BM (corresponding author), RIBOZYME PHARMACEUT INC, BOULDER, CO 80301 USA.				NIAID NIH HHS [5UO1-AI25959-06] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI025959] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTSCHULER M, 1992, GENE, V122, P85, DOI 10.1016/0378-1119(92)90035-N; ANTAO VP, 1991, NUCLEIC ACIDS RES, V19, P5901, DOI 10.1093/nar/19.21.5901; BALL LA, 1992, J VIROL, V66, P2335, DOI 10.1128/JVI.66.4.2335-2345.1992; BEEN MD, 1992, BIOCHEMISTRY-US, V31, P11843, DOI 10.1021/bi00162a024; BERTRAND E, 1994, NUCLEIC ACIDS RES, V22, P293, DOI 10.1093/nar/22.3.293; BERZALHERRANZ A, 1992, GENE DEV, V6, P129, DOI 10.1101/gad.6.1.129; BERZALHERRANZ A, 1993, EMBO J, V12, P2567, DOI 10.1002/j.1460-2075.1993.tb05912.x; CAMERON FH, 1989, P NATL ACAD SCI USA, V86, P9139, DOI 10.1073/pnas.86.23.9139; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOWRIRA BM, 1991, BIOCHEMISTRY-US, V30, P8518, DOI 10.1021/bi00099a003; CHOWRIRA BM, 1993, BIOCHEMISTRY-US, V32, P1088, DOI 10.1021/bi00055a014; COTTEN M, 1989, EMBO J, V8, P3861, DOI 10.1002/j.1460-2075.1989.tb08564.x; CRISELL P, 1993, NUCLEIC ACIDS RES, V21, P5251, DOI 10.1093/nar/21.22.5251; DAHM SC, 1991, BIOCHEMISTRY-US, V30, P9464, DOI 10.1021/bi00103a011; ECKNER R, 1991, EMBO J, V10, P3513, DOI 10.1002/j.1460-2075.1991.tb04915.x; ELROYSTEIN O, 1990, P NATL ACAD SCI USA, V87, P6743, DOI 10.1073/pnas.87.17.6743; FEDOR MJ, 1990, P NATL ACAD SCI USA, V87, P1668, DOI 10.1073/pnas.87.5.1668; FELDSTEIN PA, 1993, NUCLEIC ACIDS RES, V21, P1991, DOI 10.1093/nar/21.8.1991; GROSSHANS CA, 1991, NUCLEIC ACIDS RES, V19, P3875, DOI 10.1093/nar/19.14.3875; HAMPEL A, 1990, NUCLEIC ACIDS RES, V18, P299, DOI 10.1093/nar/18.2.299; HAMPEL A, 1989, BIOCHEMISTRY-US, V28, P4929, DOI 10.1021/bi00438a002; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; HERTEL KJ, 1992, NUCLEIC ACIDS RES, V20, P3252, DOI 10.1093/nar/20.12.3252; JOSEPH S, 1993, GENE DEV, V7, P130, DOI 10.1101/gad.7.1.130; KIM SH, 1987, P NATL ACAD SCI USA, V84, P8788, DOI 10.1073/pnas.84.24.8788; LATHAM JA, 1989, SCIENCE, V245, P276, DOI 10.1126/science.2501870; LONG DM, 1994, P NATL ACAD SCI USA, V91, P6977, DOI 10.1073/pnas.91.15.6977; LUND E, 1992, SCIENCE, V255, P327, DOI 10.1126/science.1549778; Maniatis T., 1982, MOL CLONING; MARTIN CT, 1988, BIOCHEMISTRY-US, V27, P3966, DOI 10.1021/bi00411a012; MICHEL F, 1992, GENE DEV, V6, P1373, DOI 10.1101/gad.6.8.1373; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; MURPHY E, 1991, ANNU REV PHYSIOL, V53, P273, DOI 10.1146/annurev.physiol.53.1.273; OHKAWA J, 1993, P NATL ACAD SCI USA, V90, P11302, DOI 10.1073/pnas.90.23.11302; OJWANG JO, 1992, P NATL ACAD SCI USA, V89, P10802, DOI 10.1073/pnas.89.22.10802; PATTNAIK AK, 1992, CELL, V69, P1011, DOI 10.1016/0092-8674(92)90619-N; PERROTTA AT, 1991, NATURE, V350, P434, DOI 10.1038/350434a0; PERROTTA AT, 1990, NUCLEIC ACIDS RES, V18, P6821, DOI 10.1093/nar/18.23.6821; ROMANI A, 1992, ARCH BIOCHEM BIOPHYS, V298, P1, DOI 10.1016/0003-9861(92)90086-C; RUFFNER DE, 1990, BIOCHEMISTRY-US, V29, P10695, DOI 10.1021/bi00499a018; SARVER N, 1990, SCIENCE, V247, P1222, DOI 10.1126/science.2107573; SAXENA SK, 1990, J BIOL CHEM, V265, P17106; SIOUD M, 1992, J MOL BIOL, V223, P831, DOI 10.1016/0022-2836(92)90244-E; SIOUD M, 1991, P NATL ACAD SCI USA, V88, P7303, DOI 10.1073/pnas.88.16.7303; STEINECKE P, 1992, EMBO J, V11, P1525, DOI 10.1002/j.1460-2075.1992.tb05197.x; SUH YA, 1993, NUCLEIC ACIDS RES, V21, P3277, DOI 10.1093/nar/21.14.3277; SULLENGER BA, 1993, SCIENCE, V262, P1566, DOI 10.1126/science.8248806; SYMONS RH, 1992, ANNU REV BIOCHEM, V61, P641; TAIRA K, 1990, PROTEIN ENG, V3, P733, DOI 10.1093/protein/3.8.733; TAIRA K, 1991, NUCLEIC ACIDS RES, V19, P5125, DOI 10.1093/nar/19.19.5125; TAYLOR NR, 1991, ANTISENSE RES DEV, V8, P3861; TSUCHIHASHI Z, 1993, SCIENCE, V262, P99, DOI 10.1126/science.7692597; VELOSO D, 1973, J BIOL CHEM, V248, P4811; VENTURA M, 1993, NUCLEIC ACIDS RES, V21, P3249, DOI 10.1093/nar/21.14.3249; YU M, 1993, P NATL ACAD SCI USA, V90, P6340, DOI 10.1073/pnas.90.13.6340; YUYAMA N, 1992, BIOCHEM BIOPH RES CO, V186, P1271, DOI 10.1016/S0006-291X(05)81543-8; ZHAO JJG, 1993, NATURE, V365, P448, DOI 10.1038/365448a0	58	57	120	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25856	25864						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7523395				2022-12-27	WOS:A1994PQ49100091
J	DU, EZ; KURTH, J; WANG, SL; HUMISTON, P; DAVIS, RA				DU, EZ; KURTH, J; WANG, SL; HUMISTON, P; DAVIS, RA			PROTEOLYSIS COUPLED SECRETION OF THE N-TERMINUS OF APOLIPOPROTEIN-B - CHARACTERIZATION OF A TRANSIENT, TRANSLOCATION ARRESTED INTERMEDIATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEIN; ENDOPLASMIC-RETICULUM MEMBRANE; HEP G2 CELLS; MESSENGER-RNA; INTRACELLULAR-DISTRIBUTION; TRANSFER SEQUENCE; RAT HEPATOCYTES; PAUSE TRANSFER; APO-B; DEGRADATION	We have shown that non-hepatic Chinese hamster ovary cells (CHO) have a specific inability to translocate and secrete apolipoprotein B (apoB), leading to its complete degradation in the endoplasmic reticulum (Thrift, It. N., Drisko, J., Dueland, S., Trawick, J. D., and Davis, R. A. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 9161-9165). To gain an understanding why a protein having no predictable trans-membrane sequences can be stably integrated into the endoplasmic reticulum, we determined the topography and metabolic fate of apoB in both CHO cells and human hepatoma cells (HepG2). Using epitope-specific antibodies, we show that in microsomes from both cell types, apoB assumes a trans-membrane orientation having 69 kDa of its N terminus in the lumen and the remaining portion of the C terminus residing on the cytoplasmic surface. In both cell types, proteolytic cleavage of the translocation arrested apoB by a process that can be blocked by acetyl-leucine, leucine, norleucal, produces an 85-kDa N-terminal fragment that resumes translocation and is secreted. This same N-terminal 85-kDa fragment is also found in human plasma. These results show that sequences residing outside of the membrane spanning domain can block translocation. Moreover, our data provide compelling evidence showing that apoB undergoes an unusual transient, translocation arrest, that serves as an entrance into the intracellular degradative pathway regulating its secretion.	SAN DIEGO STATE UNIV,DEPT BIOL,MAMMALIAN CELL & MOLEC BIOL LAB,SAN DIEGO,CA 92182	California State University System; San Diego State University					NHLBI NIH HHS [HL51643] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADELI K, 1994, J BIOL CHEM, V269, P9166; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BOOGAERTS JR, 1984, AM J PHYSIOL, V246, pE77, DOI 10.1152/ajpendo.1984.246.1.E77; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; BOREN J, 1993, ARTERIOSCLER THROMB, V13, P1743, DOI 10.1161/01.ATV.13.12.1743; BOREN J, 1990, J BIOL CHEM, V265, P10556; CARTWRIGHT IJ, 1993, J BIOL CHEM, V268, P20937; CHEN GC, 1989, BIOCHEMISTRY-US, V28, P2477, DOI 10.1021/bi00432a019; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; CHUCK SL, 1993, J BIOL CHEM, V268, P22794; CHUCK SL, 1992, CELL, V68, P9, DOI 10.1016/0092-8674(92)90202-N; CHUCK SL, 1990, NATURE, V346, P382, DOI 10.1038/346382a0; CLADARAS C, 1986, EMBO J, V5, P3495, DOI 10.1002/j.1460-2075.1986.tb04675.x; COLEMAN RA, 1988, J LIPID RES, V29, P33; CURTISS LK, 1982, J BIOL CHEM, V257, P5213; DAVIDSON NO, 1988, J LIPID RES, V29, P1511; Davis R A, 1986, Methods Enzymol, V129, P272; Davis R.A., 1991, BIOCH LIPIDS LIPOPRO, P403; DAVIS RA, 1989, J LIPID RES, V30, P1185; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; Davis Roger A., 1993, V21, P169; DIXON JL, 1992, J CELL BIOL, V117, P1161, DOI 10.1083/jcb.117.6.1161; DIXON JL, 1993, J LIPID RES, V34, P167; FURUKAWA S, 1992, J BIOL CHEM, V267, P22630; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; HARDMAN DA, 1986, BIOCHEM BIOPH RES CO, V137, P821, DOI 10.1016/0006-291X(86)91153-8; HOSPATTANKAR AV, 1987, BIOCHEM BIOPH RES CO, V148, P279, DOI 10.1016/0006-291X(87)91107-7; INNERARITY TL, 1987, J CLIN INVEST, V80, P1794, DOI 10.1172/JCI113273; INOUE S, 1991, J BIOL CHEM, V266, P13311; KANE JP, 1983, ANNU REV PHYSIOL, V45, P637, DOI 10.1146/annurev.ph.45.030183.003225; KNOTT TJ, 1986, NATURE, V323, P734, DOI 10.1038/323734a0; KRISHNAIAH KV, 1980, P NATL ACAD SCI-BIOL, V77, P3806, DOI 10.1073/pnas.77.7.3806; LEIGHTON JK, 1990, J LIPID RES, V31, P1663; MIZE NK, 1986, CELL, V47, P711, DOI 10.1016/0092-8674(86)90514-3; PEASE RJ, 1991, NATURE, V353, P448, DOI 10.1038/353448a0; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; PULLINGER CR, 1989, J LIPID RES, V30, P1065; ROITELMAN J, 1991, J BIOL CHEM, V266, P16085; RUSINOL AE, 1993, J BIOL CHEM, V268, P25168; SATO R, 1990, J BIOL CHEM, V265, P11880; SHELNESS GS, 1994, J BIOL CHEM, V269, P9310; SIVARAM P, 1994, J BIOL CHEM, V269, P9409; SPRING DJ, 1992, J BIOL CHEM, V267, P14839; STEINBERG D, 1989, CIRCULATION, V80, P719, DOI 10.1161/01.CIR.80.3.719; SWINKELS DW, 1989, ARTERIOSCLEROSIS, V9, P604, DOI 10.1161/01.ATV.9.5.604; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; THEOLIS R, 1984, ARTERIOSCLEROSIS, V4, P498, DOI 10.1161/01.ATV.4.5.498; THRIFT RN, 1986, J LIPID RES, V27, P236; THRIFT RN, 1992, P NATL ACAD SCI USA, V89, P9161, DOI 10.1073/pnas.89.19.9161; VERKADE HJ, 1993, J BIOL CHEM, V268, P24990; WETTERAU JR, 1992, SCIENCE, V258, P999; WILKINSON J, 1992, BIOCHEM J, V288, P413, DOI 10.1042/bj2880413; WILKINSON J, 1992, FEBS LETT, V304, P24, DOI 10.1016/0014-5793(92)80581-Z; YANG CY, 1986, NATURE, V323, P738, DOI 10.1038/323738a0; YANG CY, 1989, ARTERIOSCLEROSIS, V9, P96, DOI 10.1161/01.ATV.9.1.96; YAO ZM, 1991, J BIOL CHEM, V266, P3300; YOUNG SG, 1990, CIRCULATION, V82, P1574, DOI 10.1161/01.CIR.82.5.1574	57	87	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24169	24176						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7523367				2022-12-27	WOS:A1994PQ34600052
J	BODDEN, MK; HARBER, GJ; BIRKEDALHANSEN, B; WINDSOR, LJ; CATERINA, NCM; ENGLER, JA; BIRKEDALHANSEN, H				BODDEN, MK; HARBER, GJ; BIRKEDALHANSEN, B; WINDSOR, LJ; CATERINA, NCM; ENGLER, JA; BIRKEDALHANSEN, H			FUNCTIONAL DOMAINS OF HUMAN TIMP-1 (TISSUE INHIBITOR OF METALLOPROTEINASES)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROID-POTENTIATING ACTIVITY; HUMAN FIBROBLAST COLLAGENASE; MAMMALIAN ALPHA-MACROGLOBULINS; IV COLLAGENASE; MATRIX METALLOPROTEINASES; 72-KDA PROGELATINASE; MONOCLONAL-ANTIBODY; CLEAVAGE SITES; CDNA CLONING; CELL-LINE	To define domains of tissue inhibitor of metalloproteinases (TIMP-1) that are important to its ability to inhibit fibroblast-type collagenase (FIB-CL), two different approaches were used: (i) competition with synthetic peptides modeled after the human TIMP-1 sequence and (ii) localization of epitopes of blocking antibodies. TIMP-1 consists of six loops, held in place by six disulfide bonds arranged in three knotlike structures. Several long peptides (n = 20-34), together covering three-fourths of the human TIMP-1 sequence, were able to block inhibition of human FIB-CL by TIMP-1. While most of these peptides were modeled after sequences in the NH2-terminal domain of the molecule (loops 1, 2, and 3), they also included two thirds of the residues of the COOH-terminal domain including loops 4 and 5 and the COOH-terminal tail but not loop 6. Refinement by competition with shorter peptides (7-10 residues) showed that the region surrounding the second ''disulfide knot'' (Cys(13)-Cys(124), Cys(127)-Cys(174)) plays a major role in the inhibition of FIB-CL. This region consists of two strands, residues 10-25 and 121-129, connected through Cys(13)-Cys(124). Peptides from this region also directly inhibited FIB-CL in the absence of TIMP-1. Additional competing peptides included T2-11 ofthe NH2-terminal domain and T34-42, a highly conserved region in the middle of loop 1. Among a series of monoclonal and polyclonal antibodies (mAbs and pAbs) to TIMP-1, we identified two, one mAb and one pAb, that neutralized the activity of TIMP-1 against FIB-CL. Both recognized epitopes in loop 3. The epitope for the mAb was located in the sequence that marks the transition between loops 3 and 4, GCEEC(127), a region also identified as important by peptide competition experiments. By contrast, the epitope for a nonblocking mAb was located in a short 9-residue segment of loop 4, and a nonblocking pAb recognized epitopes in loop 1, loop 6, and the COOH-terminal tail. Our findings suggest that the FIB-CL.TIMP-1 complex possesses multiple contact sites that involve several different subdomains of the inhibitor.	UNIV ALABAMA,ORAL BIOL RES CTR,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT PATHOL,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT DIAGNOST SCI,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT BIOCHEM,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	BODDEN, MK (corresponding author), UNIV ALABAMA,SCH DENT,DEPT ORAL BIOL,SDB BOX 54,BIRMINGHAM,AL 35294, USA.							ALTSCHUH D, 1992, BIOCHEMISTRY-US, V31, P6298, DOI 10.1021/bi00142a019; AVALOS BR, 1988, BLOOD, V71, P1720; Birkedal-Hansen B, 1992, Matrix Suppl, V1, P328; BIRKEDALHANSEN H, 1987, METHOD ENZYMOL, V144, P140; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BIRKEDALHANSEN H, 1992, MATRIX METALLOPROTEI, P368; BOONE TC, 1990, P NATL ACAD SCI USA, V87, P2800, DOI 10.1073/pnas.87.7.2800; CARMICHAEL DF, 1986, P NATL ACAD SCI USA, V83, P2407, DOI 10.1073/pnas.83.8.2407; CARRELL RW, 1986, RES MONOGRAPHS CELL, V12, P403; CAWSTON TE, 1983, BIOCHEM J, V211, P313, DOI 10.1042/bj2110313; CAWSTON TE, 1986, FEBS LETT, V209, P9, DOI 10.1016/0014-5793(86)81074-2; CLARK SD, 1987, J CLIN INVEST, V80, P1280, DOI 10.1172/JCI113203; COULOMBE B, 1988, J BIOL CHEM, V263, P1439; DECLERCK YA, 1991, J BIOL CHEM, V266, P3893; DECLERCK YA, 1989, J BIOL CHEM, V264, P17445; DECLERCK YA, 1992, CANCER RES, V52, P701; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; FREUDENSTEIN J, 1990, BIOCHEM BIOPH RES CO, V171, P250, DOI 10.1016/0006-291X(90)91384-5; GASSON JC, 1985, NATURE, V315, P768, DOI 10.1038/315768a0; GAVRILOVIC J, 1985, CELL BIOL INT REP, V9, P1097, DOI 10.1016/S0309-1651(85)80007-2; GEWERT DR, 1987, EMBO J, V6, P651, DOI 10.1002/j.1460-2075.1987.tb04804.x; GOLDE DW, 1980, P NATL ACAD SCI-BIOL, V77, P593, DOI 10.1073/pnas.77.1.593; HAYAKAWA T, 1991, BIOMED RES-TOKYO, V12, P169, DOI 10.2220/biomedres.12.169; HAYAKAWA T, 1990, FEBS LETT, V268, P125, DOI 10.1016/0014-5793(90)80989-V; HAYAKAWA T, 1992, FEBS LETT, V298, P29, DOI 10.1016/0014-5793(92)80015-9; HE CS, 1989, P NATL ACAD SCI USA, V86, P2632, DOI 10.1073/pnas.86.8.2632; HOWARD EW, 1991, J BIOL CHEM, V266, P13070; HOWARD EW, 1991, J BIOL CHEM, V266, P13064; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; KLEINER DE, 1992, BIOCHEMISTRY-US, V31, P1665, DOI 10.1021/bi00121a013; KODAMA S, 1987, COLLAGEN REL RES, V7, P341; KOLKENBROCK H, 1991, EUR J BIOCHEM, V198, P775, DOI 10.1111/j.1432-1033.1991.tb16080.x; MACNAUL KL, 1990, J BIOL CHEM, V265, P17238; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MURPHY G, 1991, BIOCHEMISTRY-US, V30, P8097, DOI 10.1021/bi00247a001; NAGASE H, 1990, BIOCHEMISTRY-US, V29, P5783, DOI 10.1021/bi00476a020; OSHEA M, 1992, BIOCHEMISTRY-US, V31, P10146, DOI 10.1021/bi00157a002; PAVLOFF N, 1992, J BIOL CHEM, V267, P17321; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; ROSWIT WT, 1992, ARCH BIOCHEM BIOPHYS, V292, P402, DOI 10.1016/0003-9861(92)90009-L; SCHULTZ RM, 1988, CANCER RES, V48, P5539; SCHULZ GE, 1988, SPRINGER ADV TEXTS C, P36; SHIMIZU S, 1992, GENE, V114, P291, DOI 10.1016/0378-1119(92)90591-C; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P15781; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P393; STASKUS PW, 1991, J BIOL CHEM, V266, P449; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P1353; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; STRICKLIN GP, 1983, BIOCHEMISTRY-US, V22, P61, DOI 10.1021/bi00270a009; STRICKLIN GP, 1986, COLLAGEN REL RES, V6, P219; STRICKLIN GP, 1983, J BIOL CHEM, V258, P2252; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; WELGUS HG, 1980, J BIOL CHEM, V255, P6806; WESTBROOK CA, 1984, J BIOL CHEM, V259, P9992; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WINDSOR LJ, 1991, BIOCHEMISTRY-US, V30, P641, DOI 10.1021/bi00217a008; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705	59	59	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					18943	18952						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	7518446				2022-12-27	WOS:A1994NX32700039
J	PATEL, RC; STANTON, P; SEN, GC				PATEL, RC; STANTON, P; SEN, GC			ROLE OF THE AMINO-TERMINAL RESIDUES OF THE INTERFERON-INDUCED PROTEIN-KINASE IN ITS ACTIVATION BY DOUBLE-STRANDED-RNA AND HEPARIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING DOMAIN; P68 KINASE; TRANSLATIONAL REGULATION; MESSENGER-RNA; EXPRESSION; CELLS; VIRUS; IDENTIFICATION; 2-AMINOPURINE; INFECTION	We have previously reported that the amino-terminal residues 1-34 of the interferon-induced protein kinase (RNA-activated) (PKR) are necessary for its binding to and activation by double-stranded RNA (dsRNA) (Patel, R. C., and Sen, G. C. (1992) J. Biol. Chen. 267, 7671-7676). Here, we report that the amino-terminal 24 residues are indispensable for these properties of the enzyme. The replacement of these residues with 14 unrelated residues fully restored the protein's dsRNA binding activity, but only partially restored the enzyme activity. Mutation of residues 18 and 19 revealed their importance in determining the affinity of PKR for dsRNA and its ability to phosphorylate eukaryotic initiation factor 2 alpha. These mutations, however, did not affect PKR's autophosphorylation activity. Deletion mutants that failed to bind to and be activated by dsRNA could be fully activated by the alternative activator, heparin. Thus, activation of PKR by dsRNA and heparin is mediated through different mechanisms that require different domains of the protein.	CLEVELAND CLIN FDN,RES INST,DEPT MOLEC BIOL,CLEVELAND,OH 44195	Cleveland Clinic Foundation			Patel, Rekha/M-7123-2015	Patel, Rekha/0000-0001-9434-4880	NIAID NIH HHS [AI-22510] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022510] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARBER GN, 1993, P NATL ACAD SCI USA, V90, P4621, DOI 10.1073/pnas.90.10.4621; BARBER GN, 1992, VIROLOGY, V191, P670, DOI 10.1016/0042-6822(92)90242-H; BISCHOFF JR, 1989, VIROLOGY, V172, P106, DOI 10.1016/0042-6822(89)90112-8; BLACK TL, 1989, J VIROL, V63, P2244, DOI 10.1128/JVI.63.5.2244-2251.1989; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; COLTHURST DR, 1987, EUR J BIOCHEM, V166, P357, DOI 10.1111/j.1432-1033.1987.tb13523.x; EDERY I, 1989, CELL, V56, P303, DOI 10.1016/0092-8674(89)90904-5; FENG GS, 1992, P NATL ACAD SCI USA, V89, P5447, DOI 10.1073/pnas.89.12.5447; GHOSH SK, 1991, J BIOL CHEM, V266, P15293; GREEN SR, 1992, GENE DEV, V6, P2478, DOI 10.1101/gad.6.12b.2478; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HOVANESSIAN AG, 1987, EUR J BIOCHEM, V167, P467, DOI 10.1111/j.1432-1033.1987.tb13360.x; HOVANESSIAN AG, 1989, J INTERFERON RES, V9, P641, DOI 10.1089/jir.1989.9.641; JUDAWARE R, 1991, MOL CELL BIOL, V11, P3259; KATZE MG, 1988, J VIROL, V62, P3710, DOI 10.1128/JVI.62.10.3710-3717.1988; KATZE MG, 1991, MOL CELL BIOL, V11, P5497, DOI 10.1128/MCB.11.11.5497; KATZE MG, 1992, J INTERFERON RES, V12, P241, DOI 10.1089/jir.1992.12.241; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; KOSTURA M, 1989, MOL CELL BIOL, V9, P1576, DOI 10.1128/MCB.9.4.1576; LEE SB, 1993, VIROLOGY, V193, P1037, DOI 10.1006/viro.1993.1223; LENGYEL P, 1982, ANNU REV BIOCHEM, V51, P251, DOI 10.1146/annurev.bi.51.070182.001343; MANCHE L, 1992, MOL CELL BIOL, V12, P5238, DOI 10.1128/MCB.12.11.5238; MARAN A, 1988, VIROLOGY, V164, P106, DOI 10.1016/0042-6822(88)90625-3; MARCUS PI, 1988, J GEN VIROL, V69, P1637, DOI 10.1099/0022-1317-69-7-1637; MCCORMACK SJ, 1994, VIROLOGY, V198, P92, DOI 10.1006/viro.1994.1011; MCCORMACK SJ, 1992, VIROLOGY, V188, P47, DOI 10.1016/0042-6822(92)90733-6; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MEURS EF, 1992, J VIROL, V66, P5805, DOI 10.1128/JVI.66.10.5805-5814.1992; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MINKS MA, 1979, J BIOL CHEM, V254, P180; PATEL RC, 1992, J BIOL CHEM, V267, P7671; PETRYSHYN R, 1984, J BIOL CHEM, V259, P4736; SAMUEL CE, 1991, VIROLOGY, V183, P1, DOI 10.1016/0042-6822(91)90112-O; SCHNEIDER RJ, 1987, ANNU REV BIOCHEM, V56, P317, DOI 10.1146/annurev.biochem.56.1.317; SENGUPTA DN, 1989, NUCLEIC ACIDS RES, V17, P969, DOI 10.1093/nar/17.3.969; SONENBERG N, 1990, New Biologist, V2, P402; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TIWARI RK, 1988, MOL CELL BIOL, V8, P4289, DOI 10.1128/MCB.8.10.4289; ZINN K, 1988, SCIENCE, V240, P210, DOI 10.1126/science.3281258	40	55	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18593	18598						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	7518438				2022-12-27	WOS:A1994NW79800058
J	VASSILIOU, G; STANLEY, KK				VASSILIOU, G; STANLEY, KK			EXOGENOUS RECEPTOR-ASSOCIATED PROTEIN BINDS TO 2 DISTINCT SITES ON HUMAN FIBROBLASTS BUT DOES NOT BIND TO THE GLYCOSAMINOGLYCAN RESIDUES OF HEPARAN-SULFATE PROTEOGLYCANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN-RECEPTOR; ACTIVATOR INHIBITOR TYPE-1; ALPHA-2-MACROGLOBULIN RECEPTOR; PLASMINOGEN-ACTIVATOR; LDL-RECEPTOR; APOLIPOPROTEIN-E; PROTEOHEPARAN SULFATE; HEYMANN NEPHRITIS; ENDOTHELIAL-CELLS; HIGH-AFFINITY	We have investigated the proposal that the receptor-associated protein (RAP) of the low density lipoprotein receptor-related protein/alpha(2)-macroglobulin receptor binds to heparan sulfate proteoglycans (HSP). I-125-RAP binds to two sites on the surface of fibroblasts as follows: a high affinity site with a K-d of 1.4 nM and a low affinity site (K-d = 188 nM) with a capacity of more than 1000-fold the maximum amount of lipoprotein receptor-related protein/alpha(2)-macroglobulin receptor on the cell surface. I-125-RAP binding to the low affinity site was abolished by heparin or Suramin. However, maximal digestion of the glycosaminoglycan chains of HSP with heparinase or culturing the cells in chlorate, an inhibitor of proteoglycan sulfation, did not affect the binding of I-125-RAP or of I-125-labeled, methylamine-activated alpha(2)-macroglobulin. Comparison of I-125-RAp degradation at two different concentrations suggests that the low affinity, high capacity site on the surface of human fibroblasts participates in the endocytosis of I-125-RAp. The nature of the low affinity site remains to be elucidated, but we can exclude the glycosaminoglycan chains of HSP.			VASSILIOU, G (corresponding author), HEART RES INST,145 MISSENDEN RD,SYDNEY,NSW 2050,AUSTRALIA.							ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BAEUERLE PA, 1986, BIOCHEM BIOPH RES CO, V141, P870, DOI 10.1016/S0006-291X(86)80253-4; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; CHAPPELL DA, 1993, J BIOL CHEM, V268, P14168; CHENG CF, 1981, J BIOL CHEM, V256, P2893; DICKSON RB, 1981, J BIOL CHEM, V256, P3454; FRANSSON LA, 1984, P NATL ACAD SCI-BIOL, V81, P5657, DOI 10.1073/pnas.81.18.5657; FRANSSON LA, 1987, TRENDS BIOCHEM SCI, V12, P406, DOI 10.1016/0968-0004(87)90197-6; FURUKAWA T, 1990, J BIOCHEM-TOKYO, V108, P297, DOI 10.1093/oxfordjournals.jbchem.a123197; GREVE H, 1988, J BIOL CHEM, V263, P12886; HASSELL JR, 1992, INVEST OPHTH VIS SCI, V33, P547; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; IADONATO SP, 1993, BIOCHEM J, V296, P867, DOI 10.1042/bj2960867; IMBER MJ, 1981, J BIOL CHEM, V256, P8134; JI ZS, 1993, J BIOL CHEM, V268, P10160; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P21162; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P14176; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; Mahley R. W., 1991, CURR OPIN LIPIDOL, V2, P170; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; MOESTRUP SK, 1993, J BIOL CHEM, V268, P13691; MULDER M, 1993, J BIOL CHEM, V268, P9369; MUNSON PJ, 1983, METHOD ENZYMOL, V92, P543; MURDOCH AD, 1992, J BIOL CHEM, V267, P8544; NOONAN DM, 1991, J BIOL CHEM, V266, P22939; NYKJAER A, 1993, J BIOL CHEM, V268, P15048; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; PORATH J, 1975, NATURE, V258, P598, DOI 10.1038/258598a0; RAYCHOWDHURY R, 1989, SCIENCE, V244, P1163, DOI 10.1126/science.2786251; RUSSELL DW, 1989, J BIOL CHEM, V264, P21682; SAXENA U, 1990, J BIOL CHEM, V265, P12880; SCHMIDT G, 1987, J CELL BIOL, V104, P1683, DOI 10.1083/jcb.104.6.1683; SCHON P, 1992, EUR J CELL BIOL, V59, P329; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; VANLEUVEN F, 1979, J BIOL CHEM, V254, P5155; WANG D, 1981, ARCH BIOCHEM BIOPHYS, V211, P500, DOI 10.1016/0003-9861(81)90483-5; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172	48	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15172	15178						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	7515052				2022-12-27	WOS:A1994NP73800049
J	MANOLSON, MF; WU, BG; PROTEAU, D; TAILLON, BE; ROBERTS, BT; HOYT, MA; JONES, EW				MANOLSON, MF; WU, BG; PROTEAU, D; TAILLON, BE; ROBERTS, BT; HOYT, MA; JONES, EW			STV1 GENE ENCODES FUNCTIONAL HOMOLOG OF 95-KDA YEAST VACUOLAR H+-ATPASE SUBUNIT VPH1P	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICLE PROTON PUMP; SACCHAROMYCES-CEREVISIAE; ADENOSINE-TRIPHOSPHATASE; SHUTTLE VECTORS; EXPRESSED GENES; MEMBRANE; ACIDIFICATION; POLYPEPTIDE; PRODUCT; MUTANTS	The Saccharomyces cerevisiae gene, VPH1 (Vacuolar pH 1), encodes a 95-kDa integral membrane subunit of the vacuolar-type H+-ATPase (V-ATPase) that is required for enzyme assembly; disruption of the VPH1 gene impairs vacuolar acidification (Manolson, M. F., Proteau, D., Preston, R. A, Stenbit, A, Roberts, B. T., Hoyt, M. A., Preuss, D., Mulholland, J., Botstein, D., and Jones, E. W. (1992) J. Biol. Chem. 267, 14294-14303). Here we show that STV1 (Similar To VPH1) encodes an integral membrane polypeptide of 102 kDa with 54% identity with the peptide sequence of Vph1p. High copy expression of STV1 partially restores vacuolar acidification in a Delta vph1 mutant strain; solubilization and fractionation of membrane proteins from these vacuoles show that Stv1p co-purifies with bafilomycin A(1)-sensitive ATPase activity and with the 60- and 69-kDa V-ATPase subunits. Immunofluorescence microscopy of strains bearing a single copy of epitope tagged STV1 reveals punctate staining of the cytoplasm; overexpression of epitopetagged Stv1p reveals both punctate cytoplasmic staining and vacuolar membrane staining. Northern analysis shows that disruption of STV1 does not affect the level of transcription of VPH1 and that disruption of VPH1 does not affect the level of transcription of STV1. Strains bearing disruption of genes encoding other V-ATPase subunits (VMA1, VMA2, VMA3, and VMA4) fail to grow on media supplemented with 100 mM CaCl2 or 4 mM ZnCl2, media buffered to pH 7.5, or media with a glycerol carbon source. On the same types of media only a Delta vph1 Delta stv1 double disruption mutant has growth phenotypes equivalent to strains bearing a single disruption of the VMA1, VMA2, VMA3, and VMA4 genes; a Delta vph1 strain has only moderate growth inhibition while a Delta stv1 strain has wild type growth on the conditions listed above. We conclude that Stv1p is a functional homologue of Vph1p and suggest that Stv1p and Vph1p may be equivalent subunits for V-ATPases located on different organelles. The function of these 100-kDa homologues may be to target or regulate other common V-ATPase subunits for two distinct cellular locations.	CARNEGIE MELLON UNIV, DEPT BIOL SCI, PITTSBURGH, PA 15213 USA; CARNEGIE MELLON UNIV, CTR SCI & TECHNOL, PITTSBURGH, PA 15213 USA; JOHNS HOPKINS UNIV, DEPT BIOL, BALTIMORE, MD 21218 USA	Carnegie Mellon University; Carnegie Mellon University; Johns Hopkins University	MANOLSON, MF (corresponding author), HOSP SICK CHILDREN, DIV CELL BIOL, 555 UNIV AVE, TORONTO M5G 1X8, ON, CANADA.			Manolson, Morris/0000-0001-8755-5460	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018090, R37DK018090] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049363, R01GM029713] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK18090] Funding Source: Medline; NIGMS NIH HHS [GM49363, GM29713] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI I, 1990, J BIOL CHEM, V265, P960; ADAMS MD, 1993, NAT GENET, V4, P256, DOI 10.1038/ng0793-256; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANRAKU Y, 1989, J BIOENERG BIOMEMBR, V21, P589, DOI 10.1007/BF00808115; Ausubel FM, 1992, CURRENT PROTOCOLS MO; BACHHAWAT AK, 1993, YEAST, V9, P175, DOI 10.1002/yea.320090208; BARNES DA, 1986, MOL CELL BIOL, V6, P2828, DOI 10.1128/MCB.6.8.2828; BAUERLE C, 1993, J BIOL CHEM, V268, P12749; BELTRAN C, 1992, J BIOL CHEM, V267, P774; BOGUSKI MS, 1993, NAT GENET, V4, P332, DOI 10.1038/ng0893-332; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; EIDA DJ, 1993, MOL GEN GENET, V241, P447; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; FORGAC M, 1990, PHYSL REV, V265; FOURY F, 1990, J BIOL CHEM, V265, P18554; GILLESPIE J, 1991, FEBS LETT, V282, P9; HERSKOWITZ I, 1991, METHOD ENZYMOL, V194, P132; HIRATA R, 1993, J BIOL CHEM, V268, P961; HIRATA R, 1990, J BIOL CHEM, V265, P6726; HO MN, 1993, J BIOL CHEM, V268, P18286; HO MN, 1993, J BIOL CHEM, V268, P221; KANE PM, 1990, SCIENCE, V250, P651, DOI 10.1126/science.2146742; KANE PM, 1989, J BIOL CHEM, V264, P19236; KANE PM, 1992, J BIOL CHEM, V267, P447; LEE CK, 1990, MOL IMMUNOL, V27, P1137; MANOLSON MF, 1985, J BIOL CHEM, V260, P2273; MANOLSON MF, 1992, J EXP BIOL, V172, P105; MANOLSON MF, 1988, J BIOL CHEM, V263, P17987; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; NELSON H, 1989, FEBS LETT, V247, P147, DOI 10.1016/0014-5793(89)81259-1; NELSON H, 1989, J BIOL CHEM, V264, P1775; NOTHWEHR SF, 1993, J CELL BIOL, V121, P1197, DOI 10.1083/jcb.121.6.1197; OHSUMI Y, 1983, J BIOL CHEM, V258, P5614; OHYA Y, 1986, J GEN MICROBIOL, V132, P979; PAULOVICH AG, 1993, GENETICS, V135, P719; PERIN MS, 1991, J BIOL CHEM, V266, P3877; PRESTON RA, 1991, MOL CELL BIOL, V11, P5801, DOI 10.1128/MCB.11.12.5801; PRESTON RA, 1989, P NATL ACAD SCI USA, V86, P7027, DOI 10.1073/pnas.86.18.7027; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; ROBERTS CJ, 1992, J CELL BIOL, V119, P69, DOI 10.1083/jcb.119.1.69; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SHARP PM, 1986, NUCLEIC ACIDS RES, V14, P5125, DOI 10.1093/nar/14.13.5125; SHIH CK, 1988, MOL CELL BIOL, V8, P3094, DOI 10.1128/MCB.8.8.3094; SIKORSKI RS, 1989, GENETICS, V122, P19; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; TYERS M, 1993, EMBO J, V12, P1955, DOI 10.1002/j.1460-2075.1993.tb05845.x; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; UMEMOTO N, 1991, J BIOL CHEM, V266, P24526; UMEMOTO N, 1990, J BIOL CHEM, V265, P18447; WATERSTON R, 1992, NAT GENET, V1, P114, DOI 10.1038/ng0592-114; WELCH J, 1989, EMBO J, V8, P255, DOI 10.1002/j.1460-2075.1989.tb03371.x; WOOLFORD CA, 1990, GENETICS, V125, P739; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737	57	269	273	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14064	14074						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	7514599				2022-12-27	WOS:A1994NL60600053
J	CHIO, CL; DRONG, RF; RILEY, DT; GILL, GS; SLIGHTOM, JL; HUFF, RM				CHIO, CL; DRONG, RF; RILEY, DT; GILL, GS; SLIGHTOM, JL; HUFF, RM			D4 DOPAMINE RECEPTOR-MEDIATED SIGNALING EVENTS DETERMINED IN TRANSFECTED CHINESE-HAMSTER OVARY CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID RELEASE; ADENYLATE-CYCLASE; STIMULATION; FIBROBLASTS; MECHANISMS; CLOZAPINE; EXCHANGE; GENE	A Chinese hamster ovary (CHO) cell line stably expressing a recombinant human D4 dopamine receptor made from a synthetic gene has been used to determine potential D4-mediated signaling events. We designed and synthesized a modified gene coding for a human D4 receptor with reduced G + C content but unaltered encoded amino acids. Stable expression of this gene was obtained in two cell lines, inducible expression in CHO locI cells and constitutive expression in HEK293 cells. In CHO lacI cells induced to express D4 receptors but not in uninduced cells, dopamine and quinpirole inhibit forskolin-stimulated cAMP accumulation and potentiate ATP-stimulated [H-3]arachidonic acid release through a mechanism that requires protein kinase C but is unaffected by membrane-soluble cAMP analogs. In addition, D4 receptor activation causes an increase in the rate of extracellular acidification measured by microphysiometry. This response is unaffected by protein kinase C down-regulation but is inhibited by removal of extracellular sodium and inhibitors of NaH-1 exchange, suggesting the involvement of a Na+/H+ exchanger. All responses are blocked by clozapine and are sensitive to pertussis toxin. D4 receptors, like other G(i)/G(o)-linked receptors, mediate multiple signaling events, and the pathways activated are similar to those used by D2 and D3 receptors expressed in similar cells.	UPJOHN CO,CELL BIOL RES,KALAMAZOO,MI 49001; UPJOHN CO,MOLEC BIOL RES,KALAMAZOO,MI 49001; UPJOHN CO,MED CHEM RES,KALAMAZOO,MI 49001	Pfizer; Pfizer; Pfizer								Angst J., 1971, PHARMACOPSYCHIATRY, V4, P201; BARBER DL, 1991, CELL SIGNAL, V3, P387, DOI 10.1016/0898-6568(91)90069-7; BOUVIER C, 1993, J RECEPTOR RES, V13, P559, DOI 10.3109/10799899309073679; CHENG Y, 1978, BIOCHEM PHARMACOL, V22, P3099; CHIO CL, 1994, MOL PHARMACOL, V45, P51; COHEN AI, 1992, P NATL ACAD SCI USA, V89, P12093, DOI 10.1073/pnas.89.24.12093; FELDER CC, 1991, P NATL ACAD SCI USA, V88, P6477, DOI 10.1073/pnas.88.15.6477; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; KANTERMAN RY, 1991, MOL PHARMACOL, V39, P364; KEBABIAN JW, 1979, NATURE, V277, P93, DOI 10.1038/277093a0; LAHTI RA, 1992, MOL PHARMACOL, V42, P432; LALLEMAIN G, 1984, J BIOL CHEM, V259, P4313; LIMBIRD LE, 1988, FASEB J, V2, P2686, DOI 10.1096/fasebj.2.11.2840317; MILLS A, 1993, FEBS LETT, V320, P130, DOI 10.1016/0014-5793(93)80077-8; NEVE KA, 1992, J BIOL CHEM, V267, P25748; OWICKI JC, 1990, P NATL ACAD SCI USA, V87, P4007, DOI 10.1073/pnas.87.10.4007; PARCE JW, 1989, SCIENCE, V246, P243, DOI 10.1126/science.2799384; PIOMELLI D, 1993, J LIPID MEDIATOR, V6, P433; PIOMELLI D, 1991, NATURE, V353, P164, DOI 10.1038/353164a0; SAWADOGO M, 1991, NUCLEIC ACIDS RES, V19, P674, DOI 10.1093/nar/19.3.674; SEEMAN P, 1980, PHARMACOL REV, V32, P229; SEEMAN P, 1992, NEUROPSYCHOPHARMACOL, V7, P261; SIEMIENIAK DR, 1991, ANAL BIOCHEM, V192, P441, DOI 10.1016/0003-2697(91)90562-8; SLIGHTOM JL, 1991, PHYLOGENETIC ANALYSIS OF DNA SEQUENCES, P18; Stille G., 1971, PHARMACOPSYCHIATRY, V4, P182; VALLAR L, 1990, J BIOL CHEM, V265, P10320; VANTOL HHM, 1991, NATURE, V350, P610, DOI 10.1038/350610a0	27	112	119	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11813	11819						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	7512953				2022-12-27	WOS:A1994NG37700024
J	FUKASAWA, M; HIROTA, K; ADACHI, H; MIMURA, K; MURAKAMIMUROFUSHI, K; TSUJIMOTO, M; ARAI, H; INOUE, K				FUKASAWA, M; HIROTA, K; ADACHI, H; MIMURA, K; MURAKAMIMUROFUSHI, K; TSUJIMOTO, M; ARAI, H; INOUE, K			CHINESE-HAMSTER OVARY CELLS EXPRESSING A NOVEL TYPE OF ACETYLATED LOW-DENSITY-LIPOPROTEIN RECEPTOR - ISOLATION AND CHARACTERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROPHAGE SCAVENGER RECEPTORS; HUMAN MONOCYTE-MACROPHAGES; HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; SMOOTH-MUSCLE CELLS; ENDOTHELIAL-CELLS; MEDIATED ENDOCYTOSIS; BINDING-PROPERTIES; LIGAND-BINDING; CULTURED-CELLS; DEGRADATION	Macrophage scavenger receptors mediate the recognition of a wide range of negatively charged macromolecules including acetylated low density lipoproteins (AcLDL). Chinese hamster ovary (CHO) cells were cultured in the presence of increasing concentrations of simvastatin, a cholesterol biosynthesis inhibitor, and AcLDL as the sole source of exogenous Lipoproteins. The cells surviving under these conditions specifically bound I-125-labeled AcLDL with high affinity and degraded them via an endocytic pathway, Unexpectedly, the association and degradation of I-125-labeled AcLDL by these CHO cells were not inhibited by dextran sulfate, fucoidan, and polyinosinic acid, competitors of macrophage scavenger receptors, but were completely inhibited by maleylated bovine serum albumin. Furthermore, these cells effectively took up negatively charged liposomes containing acidic phospholipids such as phosphatidylserine and phosphatidic acid, whereas CHO cells expressing macrophage scavenger receptors did not. AcLDL and negatively charged liposomes were cross-competed with each other. Northern blot analysis using the cDNA for the macrophage scavenger receptor revealed that these CHO cells did not express this receptor. From these observations, we conclude that the isolated CHO cells express a novel type of AcLDL receptor, which is distinct from macrophage scavenger receptors with respect to ligand specificity and competitor sensitivity.	UNIV TOKYO,FAC PHARMACEUT SCI,DEPT HLTH CHEM,BUNKYO KU,TOKYO 113,JAPAN; SUNTORY INST BIOMED RES,MISHIMA 618,SHIZUOKA,JAPAN; OCHANOMIZU UNIV,FAC SCI,DEPT BIOL,BUNKYO KU,TOKYO 112,JAPAN	University of Tokyo; Suntory Holdings Ltd; Ochanomizu University								ACTON SL, 1994, J BIOL CHEM, V269, P21003; ASHKENAS J, 1993, J LIPID RES, V34, P983; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; BICKEL PE, 1992, J CLIN INVEST, V90, P1450, DOI 10.1172/JCI116012; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; CHEN Z, 1993, BIOCHIM BIOPHYS ACTA, V1150, P79, DOI 10.1016/0005-2736(93)90124-I; DANIEL TO, 1983, J BIOL CHEM, V258, P4606; DEDUVE C, 1974, BIOCHEM PHARMACOL, V23, P2495, DOI 10.1016/0006-2952(74)90174-9; DEVRIES HE, 1993, J NEUROCHEM, V61, P1813; EMI M, 1993, J BIOL CHEM, V268, P2120; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; FOGELMAN AM, 1980, P NATL ACAD SCI-BIOL, V77, P2214, DOI 10.1073/pnas.77.4.2214; FREEMAN M, 1990, P NATL ACAD SCI USA, V87, P8810, DOI 10.1073/pnas.87.22.8810; FREEMAN M, 1991, P NATL ACAD SCI USA, V88, P4931, DOI 10.1073/pnas.88.11.4931; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1974, J BIOL CHEM, V249, P5153; GOLDSTEIN JL, 1976, P NATL ACAD SCI USA, V76, P333; HABERLAND ME, 1985, P NATL ACAD SCI USA, V82, P2693, DOI 10.1073/pnas.82.9.2693; HENRIKSEN T, 1981, P NATL ACAD SCI-BIOL, V78, P6499, DOI 10.1073/pnas.78.10.6499; INABA T, 1992, J BIOL CHEM, V267, P13107; KATO Y, 1994, HEPATOLOGY, V20, P417; KINGSLEY DM, 1984, P NATL ACAD SCI-BIOL, V81, P5454, DOI 10.1073/pnas.81.17.5454; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KODAMA T, 1988, P NATL ACAD SCI USA, V85, P9238, DOI 10.1073/pnas.85.23.9238; KRIEGER M, 1993, J BIOL CHEM, V268, P4569; KUME N, 1991, BIOCHIM BIOPHYS ACTA, V1091, P63, DOI 10.1016/0167-4889(91)90223-K; LEE KD, 1992, BIOCHIM BIOPHYS ACTA, V1111, P1, DOI 10.1016/0005-2736(92)90267-P; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUMOTO A, 1990, P NATL ACAD SCI USA, V87, P9133, DOI 10.1073/pnas.87.23.9133; NAGELKERKE JF, 1983, J BIOL CHEM, V258, P2221; NAITO M, 1991, AM J PATHOL, V139, P1411; NISHIKAWA K, 1990, J BIOL CHEM, V265, P5226; PITAS RE, 1985, J CELL BIOL, V100, P103, DOI 10.1083/jcb.100.1.103; ROHRER L, 1990, NATURE, V343, P570, DOI 10.1038/343570a0; SHECHTER I, 1981, J LIPID RES, V22, P63; STANTON LW, 1992, J BIOL CHEM, V267, P22446; STEIN O, 1980, BIOCHIM BIOPHYS ACTA, V620, P631, DOI 10.1016/0005-2760(80)90155-1; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; SWERLICK RA, 1992, J IMMUNOL, V148, P78; TALLE MA, 1983, CELL IMMUNOL, V78, P83, DOI 10.1016/0008-8749(83)90262-9; VANBERKEL TJC, 1991, J BIOL CHEM, V266, P2282; WIBO M, 1974, J CELL BIOL, V63, P430, DOI 10.1083/jcb.63.2.430	42	19	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 27	1995	270	4					1921	1927		10.1074/jbc.270.4.1921	http://dx.doi.org/10.1074/jbc.270.4.1921			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QD204	7530251				2022-12-27	WOS:A1995QD20400066
J	ROBINSON, LJ; BUSCONI, L; MICHEL, T				ROBINSON, LJ; BUSCONI, L; MICHEL, T			AGONIST-MODULATED PALMITOYLATION OF ENDOTHELIAL NITRIC-OXIDE SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							KINASE-C SUBSTRATE; PLASMA-MEMBRANE; PHOSPHORYLATION; TRANSLOCATION; ACYLATION; PROTEINS; RECEPTOR; MARCKS	The nitric oxide synthases (NOS) comprise a family of enzymes which differ in primary structure, biological roles, subcellular distribution, and post-translational modifications. The endothelial nitric oxide synthase (ecNOS) is unique among the NOS isoforms in being modified by N-terminal myristoylation, which is necessary for its targeting to the endothelial cell membrane. The subcellular localization of the ecNOS, but not enzyme myristoylation, is dynamically regulated by agonists such as bradykinin, which promote ecNOS translocation from membrane to cytosol, as well as enhancing enzyme phosphorylation. Using transiently transfected endothelial cells, we now show that a myristoylation-deficient mutant ecNOS undergoes phosphorylation despite restriction to the cytosol, suggesting that phosphorylation may be a consequence rather than a cause of ecNOS translocation. We therefore explored whether other post-translational modifications might regulate ecNOS targeting and now report that ecNOS is reversibly palmitoylated. Biosynthetic labeling of endothelial cells with [H-3]palmitic acid followed by immunoprecipitation of ecNOS revealed that the enzyme is palmitoylated; the label is released by hydroxylamine, consistent with formation of a fatty acyl thioester, and authentic palmitate can be recovered from labeled ecNOS following acid hydrolysis. Importantly, pulse-chase experiments in endothelial cells biosynthetically labeled with [H-3]palmitate show that bradykinin treatment promotes ecNOS depalmitoylation. We conclude that ecNOS palmitoylation is dynamically regulated by bradykinin and propose that depalmitoylation of the enzyme may result in its cytosolic translocation and subsequent phosphorylation.	HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DIV CARDIOVASC, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL046457, R01HL046457] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL46457] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLAND L, 1994, J BIOL CHEM, V269, P16701; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BUSCONI L, 1994, J BIOL CHEM, V269, P25016; BUSCONI L, 1993, J BIOL CHEM, V268, P8410; CAMP LA, 1993, J BIOL CHEM, V268, P22566; CAMP LA, 1994, J BIOL CHEM, V269, P23212; CASEY PJ, 1994, CURR OPIN CELL BIOL, V6, P219, DOI 10.1016/0955-0674(94)90139-2; DEGTYAREV MY, 1993, J BIOL CHEM, V268, P23769; HALLAK H, 1994, J BIOL CHEM, V269, P4571; HESS DT, 1993, NATURE, V366, P562, DOI 10.1038/366562a0; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; LIU JW, 1994, J BIOL CHEM, V269, P11691; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MICHEL T, 1993, P NATL ACAD SCI USA, V90, P6252, DOI 10.1073/pnas.90.13.6252; MONCADA S, 1991, PHARMACOL REV, V43, P109; MOUILLAC B, 1992, J BIOL CHEM, V267, P21733; MUMBY SM, 1994, P NATL ACAD SCI USA, V91, P2800, DOI 10.1073/pnas.91.7.2800; NATHAN C, 1994, J BIOL CHEM, V269, P13725; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PAIGE LA, 1993, J BIOL CHEM, V268, P8669; PEITZSCH RM, 1993, BIOCHEMISTRY-US, V32, P10436, DOI 10.1021/bi00090a020; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; SEFTON BM, 1987, J CELL BIOL, V104, P1449, DOI 10.1083/jcb.104.6.1449; STUEHR DJ, 1992, ADV ENZYMOL RELAT AR, V65, P287; TANIGUCHI H, 1993, J BIOL CHEM, V268, P9960; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; WALKER F, 1993, J BIOL CHEM, V268, P19552; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6	29	203	210	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					995	998		10.1074/jbc.270.3.995	http://dx.doi.org/10.1074/jbc.270.3.995			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7530714	hybrid			2022-12-27	WOS:A1995QB15600003
J	ALI, N; HALFTER, U; CHUA, NH				ALI, N; HALFTER, U; CHUA, NH			CLONING AND BIOCHEMICAL-CHARACTERIZATION OF A PLANT PROTEIN-KINASE THAT PHOSPHORYLATES SERINE, THREONINE, AND TYROSINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; GENE; RECEPTOR; HOMOLOG; ARABIDOPSIS; ENCODES; P34CDC2; REGULATOR; BRASSICA; DOMAIN	Phosphorylation of proteins on serine, threonine, or tyrosine residues represents an important biochemical mechanism to regulate the activity of enzymes and is used in many cellular processes. In animals, protein serine/threonine and protein tyrosine kinases are known to perform essential roles in many pathways that transmit external stimuli from the cell surface to the cell inferior and the nucleus, In plants, although an increasing number of protein serine/threonine kinases have been cloned, the existence of protein tyrosine kinases remains yet to be demonstrated, Here, we report the cloning and biochemical characterization of a plant protein kinase, Arabidopsis dual specificity kinase 1 (ADK1), using a functional screening method, namely by screening an Arabidopsis expression Library with antiphosphotyrosine antibodies. Four independent cDNA clones that define a polypeptide of 319 amino acids length with homology to protein kinases were identified in this screen, Phosphoamino acid analysis of the autophosphorylated kinase shows that ADK1 phosphorylates serine, threonine, and tyrosine, Using poly(GIu/Tyr) as a substrate, we confirm that ADK1 is capable of phosphorylating tyrosine residues.	ROCKEFELLER UNIV,PLANT MOLEC BIOL LAB,NEW YORK,NY 10021	Rockefeller University								BARRETT CB, 1992, J BIOL CHEM, V267, P4408; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHANG C, 1992, PLANT CELL, V4, P1263, DOI 10.1105/tpc.4.10.1263; COLASANTI J, 1991, P NATL ACAD SCI USA, V88, P3377, DOI 10.1073/pnas.88.8.3377; DAILEY D, 1990, MOL CELL BIOL, V10, P6244, DOI 10.1128/MCB.10.12.6244; DUERR B, 1993, PLANT CELL, V5, P87, DOI 10.1105/tpc.5.1.87; FERREIRA PCG, 1991, PLANT CELL, V3, P531, DOI 10.1105/tpc.3.5.531; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; HALFTER U, 1994, EMBO J, V13, P1443, DOI 10.1002/j.1460-2075.1994.tb06398.x; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARPER JF, 1991, SCIENCE, V252, P951, DOI 10.1126/science.1852075; HIRT H, 1991, P NATL ACAD SCI USA, V88, P1636, DOI 10.1073/pnas.88.5.1636; HOWELL BW, 1991, MOL CELL BIOL, V11, P568, DOI 10.1128/MCB.11.1.568; HUNTER T, 1986, ENZYMES, V17, P191; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; LETWIN K, 1992, EMBO J, V11, P3521, DOI 10.1002/j.1460-2075.1992.tb05435.x; LINDBERG RA, 1992, TRENDS BIOCHEM SCI, V17, P114, DOI 10.1016/0968-0004(92)90248-8; MARTIN GB, 1993, SCIENCE, V262, P1432, DOI 10.1126/science.7902614; MU JH, 1994, PLANT CELL, V6, P709, DOI 10.1105/tpc.6.5.709; ROBINSON LC, 1992, P NATL ACAD SCI USA, V89, P28, DOI 10.1073/pnas.89.1.28; ROE JL, 1993, CELL, V75, P939, DOI 10.1016/0092-8674(93)90537-Z; ROWLES J, 1991, P NATL ACAD SCI USA, V88, P9548, DOI 10.1073/pnas.88.21.9548; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; STAFSTROM JP, 1993, PLANT MOL BIOL, V22, P83, DOI 10.1007/BF00038997; STEIN JC, 1991, P NATL ACAD SCI USA, V88, P8816, DOI 10.1073/pnas.88.19.8816; STERN DF, 1991, MOL CELL BIOL, V11, P987, DOI 10.1128/MCB.11.2.987; TAN JL, 1990, MOL CELL BIOL, V10, P3578, DOI 10.1128/MCB.10.7.3578; TORRUELLA M, 1986, J BIOL CHEM, V261, P6651; WALKER JC, 1990, NATURE, V345, P743, DOI 10.1038/345743a0	30	54	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31626	31629						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7527390				2022-12-27	WOS:A1994PX30300047
J	BHAT, GJ; THEKKUMKARA, TJ; THOMAS, WG; CONRAD, KM; BAKER, KM				BHAT, GJ; THEKKUMKARA, TJ; THOMAS, WG; CONRAD, KM; BAKER, KM			ANGIOTENSIN-II STIMULATES SIS-INDUCING FACTOR-LIKE DNA-BINDING ACTIVITY - EVIDENCE THAT THE AT(1A) RECEPTOR ACTIVATES TRANSCRIPTION FACTOR-STAT91 AND/OR A RELATED PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; CARDIAC FIBROBLASTS; INTERFERON-GAMMA; GENE-EXPRESSION; MESSENGER-RNA; KINASE; INDUCTION	Recent studies on cytokine and growth factor stimulated signal transduction have defined a direct pathway (Stat91) linking cell surface receptors to target genes in the nucleus. The Stat91 pathway regulated c-fos gene transcription involves activation by tyrosine phosphorylation of the DNA binding factor SIF (sis-inducing factor) in the cytoplasm, its nuclear translocation, and interaction with the regulatory element SIE (sis-inducing element). SIF is a complex of proteins containing members of the STAT family of transcription factors. We determined whether angiotensin II (ATI), which acts as a growth factor in many cell types, could activate the Stat91 pathway. We used neonatal rat cardiac fibroblasts expressing G-protein linked AII receptors and CHO-gl cells expressing stably transfected angiotensin type 1A (AT,) receptors to address this question. Angiotensin II induced SIF-like activity in both cell types, with initial induction at 15-30 min, maximal around 2-3 h, and undetectable at 6 h. Cytoplasmic and nuclear fractions from cells exposed to AII contained DNA binding activity to SIE. The SIF activity was insensitive to protein synthesis inhibitors and sensitive to the tyrosine kinase inhibitor genistein. Stat91 or a related protein was identified as a component of the AII-induced SIF complex and increased levels of this tyrosine phosphorylated protein were found in nuclear extracts of cells treated with AII. This is the first evidence that a seven transmembrane, G-protein-coupled receptor, namely AT(1A), activates the Stat91-nuclear signaling pathway.			BHAT, GJ (corresponding author), GEISINGER MED CLIN, WEIS CTR RES, 100 N ACAD AVE, DANVILLE, PA 17822 USA.		Thomas, Walter/I-2208-2015	Thomas, Walter/0000-0003-0685-2952	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044379, R01HL044883] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL44379, HL44883] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; BOCZ GW, 1994, AM J PHYTL, V267, pC1308; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; CRABOS M, 1994, J CLIN INVEST, V93, P2372, DOI 10.1172/JCI117243; CRAWFORD DC, 1994, CIRC RES, V74, P727, DOI 10.1161/01.RES.74.4.727; DALY C, 1994, TRENDS ENDOCRIN MET, V5, P159, DOI 10.1016/1043-2760(94)90013-2; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUBEY RK, 1992, CIRC RES, V71, P1143, DOI 10.1161/01.RES.71.5.1143; EDWARDS DR, 1994, TRENDS PHARMACOL SCI, V15, P239, DOI 10.1016/0165-6147(94)90318-2; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; HAYES TE, 1987, P NATL ACAD SCI USA, V84, P1272, DOI 10.1073/pnas.84.5.1272; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; IHLE JN, 1994, TRENDS ENDOCRIN MET, V5, P137, DOI 10.1016/1043-2760(94)90096-5; IHLE JN, 1994, TRENDS BIOCHEM SCI, V18, P338; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KAWAMURA M, 1994, P NATL ACAD SCI USA, V91, P6374, DOI 10.1073/pnas.91.14.6374; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LINDPAINTNER K, 1994, CARDIAC RENIN ANGIOT; MARRERO MB, 1994, J BIOL CHEM, V269, P10935; MEEK DW, 1992, BIOCHEM J, V287, P1; MOLLOY CJ, 1993, J BIOL CHEM, V268, P7338; NAFTILAN AJ, 1990, MOL CELL BIOL, V10, P5536, DOI 10.1128/MCB.10.10.5536; NAFTILAN AJ, 1989, J CLIN INVEST, V83, P1419, DOI 10.1172/JCI114032; NAFTILAN AJ, 1989, HYPERTENSION, V13, P706, DOI 10.1161/01.HYP.13.6.706; OWENS GK, 1989, AM J PHYSIOL, V257, pH1755, DOI 10.1152/ajpheart.1989.257.6.H1755; PEACH MJ, 1981, BIOCHEM PHARMACOL, V30, P2745, DOI 10.1016/0006-2952(81)90410-X; PEACH MJ, 1980, RENIN ANGIOTENSIN SY; Raizada M.K., 1993, CELLULAR MOL BIOL RE; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SADOSHIMA J, 1993, CIRC RES, V73, P424, DOI 10.1161/01.RES.73.3.424; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHORB W, 1993, CIRC RES, V72, P1245, DOI 10.1161/01.RES.72.6.1245; SECHI LA, 1992, CIRC RES, V71, P1482, DOI 10.1161/01.RES.71.6.1482; SHARIFI BG, 1992, J BIOL CHEM, V267, P23910; SHCORB W, 1994, J BIOL CHEM, V269, P19626; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SUZUKI J, 1993, CIRC RES, V73, P439, DOI 10.1161/01.RES.73.3.439; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526; THEKKUMKARA TJ, 1993, FASEB J, V7, pA491; TSUDA T, 1991, FEBS LETT, V285, P44, DOI 10.1016/0014-5793(91)80721-E; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WEBER H, 1994, J CLIN INVEST, V93, P788, DOI 10.1172/JCI117033; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	52	168	173	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31443	31449						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7527386				2022-12-27	WOS:A1994PX30300021
J	JONCKHEERE, H; TAYMANS, JM; BALZARINI, J; VELAZQUEZ, S; CAMARASA, MJ; DESMYTER, J; DECLERCQ, E; ANNE, J				JONCKHEERE, H; TAYMANS, JM; BALZARINI, J; VELAZQUEZ, S; CAMARASA, MJ; DESMYTER, J; DECLERCQ, E; ANNE, J			RESISTANCE OF HIV-1 REVERSE-TRANSCRIPTASE AGAINST [2',5'-BIS-O-(TERT-BUTYLDIMETHYLSILYL)-3'-SPIRO-5''-(4''-AMINO-1'',2''-OXATHIOLE-2'',2''-DIOXIDE)] (TSAO) DERIVATIVES IS DETERMINED BY THE MUTATION GLU(138)-]LYS ON THE P51 SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN-IMMUNODEFICIENCY-VIRUS; RIBONUCLEASE-H; ANGSTROM RESOLUTION; NUCLEOSIDE ANALOGS; CRYSTAL-STRUCTURE; TYPE-1; INHIBITORS; DNA; INVITRO; REPLICATION	Determination of the three-dimensional structure of the human immunodeficiency virus type-1 (HIV-1) reverse transcriptase (RT) has indicated a totally different folding for the 51-kDa subunit (p51) than for the 66-kDa subunit (p66). The polymerase catalytic site is located on the p66 subunit. Moreover, the HIV-1-specific RT inhibitors, also designated as the non-nucleoside RT inhibitors (NNRTIs), select for amino acid mutations that afford resistance to these compounds and are clustered in the palm domain of the HIV-1 RT p66 subunit. This pocket is located in the vicinity of, but clearly distinct from, the polymerase active site. However, for the NNRTIs that belong to the class of the [2',5'-bis-O-(tert-butyldimethylsilyl)-3 '-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)] (TSAO) derivatives, the resistance mutation is located at position Glu(138). On the p66 subunit, this amino acid is distant from the binding site of the HIV-1-specific RT inhibitors. When the TSAO-specific resistance mutation Glu(138) --> Lys was introduced solely in the p51 subunit of the RT p66/p51 heterodimer, the enzyme proved completely resistant to TSAO-m(3)T but retained full sensitivity to TIBO R82150 and ddGTP. On the other hand, when the mutation was introduced only in the p66 subunit the enzyme remained equally sensitive to the inhibitory effects of TSAO-m(3)T, TIBO R82150, and ddGTP. Our data provide compelling evidence for a structural and functional role of the p51 subunit in the sensitivity and/or resistance of the enzyme to the NNRTIs.	CSIC,INST QUIM MED,E-28006 MADRID,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Medica (IQM); CSIC - Instituto de Quimica Organica General (IQOG)	JONCKHEERE, H (corresponding author), CATHOLIC UNIV LEUVEN,REGA INST MED RES,MINDERBROEDERSSTR 10,B-3000 LOUVAIN,BELGIUM.		Velázquez, sonsoles/B-6339-2015; Taymans, Jean-Marc/M-9175-2018; Camarasa, María-José/N-8845-2019; ANNE, Jozef/H-7983-2019; Velazquez, Sonsoles/N-7777-2019; Camarasa, María-José/B-6340-2015	Velázquez, sonsoles/0000-0003-2209-1751; Taymans, Jean-Marc/0000-0001-5503-5524; Camarasa, María-José/0000-0002-4978-6468; ANNE, Jozef/0000-0002-0493-2644; Velazquez, Sonsoles/0000-0003-2209-1751; Camarasa, María-José/0000-0002-4978-6468; De Clercq, Erik/0000-0002-2985-8890				ARNOLD E, 1992, NATURE, V357, P85, DOI 10.1038/357085a0; BALZARINI J, 1992, P NATL ACAD SCI USA, V89, P4392, DOI 10.1073/pnas.89.10.4392; BALZARINI J, 1993, P NATL ACAD SCI USA, V90, P6952, DOI 10.1073/pnas.90.15.6952; BALZARINI J, 1994, BIOCHEM BIOPH RES CO, V201, P1305, DOI 10.1006/bbrc.1994.1846; BALZARINI J, 1993, VIROLOGY, V192, P246, DOI 10.1006/viro.1993.1027; BATHURST IC, 1990, BIOCHEM BIOPH RES CO, V171, P589, DOI 10.1016/0006-291X(90)91187-W; BAVAND MR, 1993, BIOCHEMISTRY-US, V32, P10543, DOI 10.1021/bi00091a003; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; DAQUILA RT, 1989, J ACQ IMMUN DEF SYND, V2, P579; DEBYSER Z, 1993, MOL PHARMACOL, V43, P521; DEBYSER Z, 1992, MOL PHARMACOL, V41, P963; DECLERCQ E, 1994, BIOCHEM PHARMACOL, V47, P155, DOI 10.1016/0006-2952(94)90001-9; EVANS DB, 1993, BIOTECHNOL APPL BIOC, V17, P91; GOLDMAN ME, 1991, P NATL ACAD SCI USA, V88, P6863, DOI 10.1073/pnas.88.15.6863; HOSTOMSKY Z, 1991, P NATL ACAD SCI USA, V88, P1148, DOI 10.1073/pnas.88.4.1148; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JACQUES PS, 1994, J BIOL CHEM, V269, P1388; JONCKHEERE H, 1993, THESIS KATHOLIEKE U; KNOPSGERRITS PP, 1992, THESIS KATHOLIEKE U; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LEGRICE SFJ, 1991, EMBO J, V10, P3905, DOI 10.1002/j.1460-2075.1991.tb04960.x; LEGRICE SFJ, 1989, J BIOL CHEM, V264, P14902; LIGHTFOOTE MM, 1986, J VIROL, V60, P771, DOI 10.1128/JVI.60.2.771-775.1986; LORI F, 1988, AIDS RES HUM RETROV, V4, P393, DOI 10.1089/aid.1988.4.393; MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568; MITSUYA H, 1986, P NATL ACAD SCI USA, V83, P1911, DOI 10.1073/pnas.83.6.1911; MITSUYA H, 1985, P NATL ACAD SCI USA, V82, P7096, DOI 10.1073/pnas.82.20.7096; MIZRAHI V, 1989, ARCH BIOCHEM BIOPHYS, V273, P347, DOI 10.1016/0003-9861(89)90493-1; Nanni Raymond G., 1993, Perspectives in Drug Discovery and Design, V1, P129, DOI 10.1007/BF02171659; PAUWELS R, 1993, P NATL ACAD SCI USA, V90, P1711, DOI 10.1073/pnas.90.5.1711; PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0; PRASAD VR, 1989, P NATL ACAD SCI USA, V86, P3104, DOI 10.1073/pnas.86.9.3104; RESTLE T, 1990, J BIOL CHEM, V265, P8986; ROMERO DL, 1991, P NATL ACAD SCI USA, V88, P8806, DOI 10.1073/pnas.88.19.8806; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMERDON SJ, 1994, P NATL ACAD SCI USA, V91, P3911, DOI 10.1073/pnas.91.9.3911; TISDALE M, 1988, J VIROL, V62, P3662, DOI 10.1128/JVI.62.10.3662-3667.1988; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504; WEST AB, 1992, P NATL ACAD SCI USA, V89, P9720, DOI 10.1073/pnas.89.20.9720; WOHRL BM, 1994, J BIOL CHEM, V269, P8541; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	41	85	87	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25255	25258						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7523383				2022-12-27	WOS:A1994PQ49100006
J	SLUNGAARD, A; KEY, NS				SLUNGAARD, A; KEY, NS			PLATELET FACTOR-4 STIMULATES THROMBOMODULIN PROTEIN-C ACTIVATING COFACTOR ACTIVITY - A STRUCTURE-FUNCTION ANALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT HUMAN THROMBOMODULIN; GAMMA-CARBOXYGLUTAMIC ACID; FACTOR-IV; GRANULE PROTEINS; ANTICOAGULANT ACTIVITIES; PROTEOLYTIC FORMATION; BASIC-PROTEIN; BINDING; HEPARIN; INHIBITION	Thrombomodulin (TM) is an anionic (pI approximate to 4) protein cofactor that promotes thrombin (THR) cleavage of protein C to generate activated protein C (APC), a potent anticoagulant. We find that the cationic platelet alpha-granule protein platelet factor 4 (PF4) stimulates 4-25-fold the cofactor activity of rabbit TM and two differentially glycanated versions of an extracellular domain human TM polypeptide in which the glycosaminoglycan (GAG) is either present (GAG+ TM) or absent (GAG- TM) with an ED(50) of 3.3-10 mu g/ml. No such stimulation occurs in response to beta-thromboglobulin or thrombospondin, or when protein C lacking its gamma-carboxyglutamic acid (Gla) domain is the substrate. Heparin and chondroitin sulfates A and E reverse PF4 stimulation. PF4 minimally affects the K-d for THR but decreases 30-fold (from 8.3 to 0.3 mu M) the K-m for protein C of APC generation by GAG+ TM. PF4 also strikingly transforms the [Ca2+] dependence profile of rabbit and GAG+ TM to resemble that of GAG- TM. A potential explanation for this is that PF4, like Ca2+, induces heparin-reversible alterations in native (but not Gla-domainless) protein C conformation as assessed by autofluorescence emission analysis. We conclude that PF4 stimulates TM APC generation by interacting electrostatically with both the TM GAG and the protein C Gla domain to enhance markedly the affinity of the THR.TM complex for protein C. By this mechanism, PF4 may play a previously unsuspected role in the physiologic regulation of clotting.			SLUNGAARD, A (corresponding author), UNIV MINNESOTA, DEPT MED, BOX 480 UMHC, MINNEAPOLIS, MN 55455 USA.				NHLBI NIH HHS [R01 HL48915] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048915] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLEN DH, 1993, THROMB HAEMOSTASIS, V69, P753; BOURIN MC, 1988, J BIOL CHEM, V263, P8044; BOURIN MC, 1990, J BIOL CHEM, V265, P15424; CAPITANIO AM, 1985, BIOCHIM BIOPHYS ACTA, V839, P161, DOI 10.1016/0304-4165(85)90033-9; CLARKE JH, 1993, J BIOL CHEM, V268, P6309; COOK JJ, 1992, CIRCULATION, V85, P1102, DOI 10.1161/01.CIR.85.3.1102; DEUEL TF, 1977, P NATL ACAD SCI USA, V74, P2256, DOI 10.1073/pnas.74.6.2256; DEUEL TF, 1981, P NATL ACAD SCI-BIOL, V78, P4584, DOI 10.1073/pnas.78.7.4584; DITTMAN WA, 1990, BLOOD, V75, P329; DUMENCO LL, 1988, J LAB CLIN MED, V112, P394; ESMON CT, 1993, THROMB HAEMOSTASIS, V70, P29; ESMON CT, 1989, J BIOL CHEM, V264, P4743; ESMON NL, 1983, J BIOL CHEM, V258, P5548; FAUCI AS, 1982, ANN INTERN MED, V97, P78, DOI 10.7326/0003-4819-97-1-78; GLASER CB, 1992, J CLIN INVEST, V90, P2565, DOI 10.1172/JCI116151; GOLDBERG ID, 1980, SCIENCE, V209, P611, DOI 10.1126/science.6994228; GRIFFIN JH, 1981, J CLIN INVEST, V68, P1370, DOI 10.1172/JCI110385; HANDIN RI, 1976, J BIOL CHEM, V251, P4273; HAYASHI T, 1990, J BIOL CHEM, V265, P20156; HOLT JC, 1989, METHOD ENZYMOL, V169, P224; HOLT JC, 1985, SEMIN HEMATOL, V22, P151; ISHII H, 1985, J CLIN INVEST, V76, P2178, DOI 10.1172/JCI112225; JOHNSON AE, 1983, J BIOL CHEM, V258, P5554; KATZ IR, 1991, PROGR LEUKOCYTE BIOL, P11117; KUROSAWA S, 1985, THROMB RES, V37, P353, DOI 10.1016/0049-3848(85)90064-7; KUROSAWA S, 1987, J BIOL CHEM, V262, P2206; LANE DA, 1984, BIOCHEM J, V218, P725, DOI 10.1042/bj2180725; LAWLER JW, 1981, THROMB RES, V22, P267, DOI 10.1016/0049-3848(81)90119-5; LAWLER JW, 1978, J BIOL CHEM, V253, P8609; LEATHERBARROW RJ, 1990, TRENDS BIOCHEM SCI, V15, P455, DOI 10.1016/0968-0004(90)90295-M; LONKY SA, 1981, J CLIN INVEST, V67, P817, DOI 10.1172/JCI110099; LONKY SA, 1978, BIOCHEM BIOPH RES CO, V85, P1113, DOI 10.1016/0006-291X(78)90657-5; MAIONE TE, 1991, CANCER RES, V51, P2077; MAIONE TE, 1990, SCIENCE, V247, P77, DOI 10.1126/science.1688470; NAGASHIMA M, 1993, J BIOL CHEM, V268, P2888; NAWA K, 1990, BIOCHEM BIOPH RES CO, V171, P729, DOI 10.1016/0006-291X(90)91207-9; PARKINSON JF, 1992, BIOCHEM J, V283, P151, DOI 10.1042/bj2830151; PARKINSON JF, 1990, J BIOL CHEM, V265, P12602; PREISSNER KT, 1987, BIOCHEMISTRY-US, V26, P2521, DOI 10.1021/bi00383a018; PREISSNER KT, 1990, J BIOL CHEM, V265, P4915; SCULLY MF, 1980, THROMB RES, V20, P461, DOI 10.1016/0049-3848(80)90284-4; SELIGSOHN U, 1984, NEW ENGL J MED, V310, P559, DOI 10.1056/NEJM198403013100904; SLUNGAARD A, 1993, J CLIN INVEST, V91, P1721, DOI 10.1172/JCI116382; TAI PC, 1987, LANCET, V1, P643; TAKANO S, 1990, BLOOD, V76, P2024; WASSOM DL, 1981, J CLIN INVEST, V67, P651, DOI 10.1172/JCI110080; YE J, 1991, J BIOL CHEM, V266, P23016; ZUCKER MB, 1991, P SOC EXP BIOL MED, V198, P693; ZUSHI M, 1991, J BIOL CHEM, V266, P19886	49	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25549	25556						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7523387				2022-12-27	WOS:A1994PQ49100050
J	KUDO, S; FUKUDA, M				KUDO, S; FUKUDA, M			CONTRIBUTION OF GENE CONVERSION TO THE RETENTION OF THE SEQUENCE FOR M-BLOOD-GROUP TYPE DETERMINANT IN GLYCOPHORIN-E GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE-MEMBRANE; SOMATIC-CELL MUTATIONS; MONOCLONAL-ANTIBODIES; HOMINOID PRIMATES; CDNA CLONES; DNA; RECOMBINATION; EVOLUTION; FAMILY; IDENTIFICATION	M and N blood group antigens are presented by glycophorins A (GPA) and B (GPB) of the erythrocyte membrane. GPA expresses M or N blood group antigen depending on the allelic gene (GPA(M) gene or GPA(N) gene), while GPB expresses only the N antigen. M or N blood group antigen is specified by the first and fifth NH,terminal amino acid residues in the mature proteins, encoded by the second exon of these genes. Glycophorin E (GPE) gene, another member of this gene family, has a genomic structure very similar to that of GPB. However, a predicted product of GPE gene carries M blood group antigen. To delineate evolutionary events leading to the formation of the sequences for M or N blood group type determinant in the members of human glycophorin gene family, the nucleotide sequences of a 1.45-kilobase pair region including the 3' part of intron 1, exon 2, and the entire intron 2 were compared for GPA(M), GPA(N), GPB, and GPE genes. Encompassing exon 2, there were identical sequence stretches of 139 and 138 base pairs between GPA(M) and GPE genes and between GPA(N) and GPB genes, respectively. The data of the entire sequences in this region revealed that the divergence of the sequence between GPE and GPA genes (2.14-2.49%) is less than that of the sequence between GPE and GPB genes (3.10%). The higher rate of divergence in this region was observed between GPA and GPB genes (3.79-3.86%). These results strongly suggest that GPE gene acquired the sequence for M blood group type determinant from GPA(M) gene through gene conversion after duplication of a progenitor gene common to GPB and GPE genes.			KUDO, S (corresponding author), LA JOLLA CANC RES FDN,CANC RES CTR,10901 N TORREY PINES RD,LA JOLLA,CA 92037, USA.				NATIONAL CANCER INSTITUTE [R01CA033000, R37CA033000] Funding Source: NIH RePORTER; NCI NIH HHS [NCI CA33000] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIGBEE WL, 1989, AM J HUM GENET, V44, P402; BIGBEE WL, 1990, MUTAT RES, V240, P165, DOI 10.1016/0165-1218(90)90056-8; BLUMENFELD OO, 1978, P NATL ACAD SCI USA, V75, P2727, DOI 10.1073/pnas.75.6.2727; DENDUNNEN JT, 1986, J MOL BIOL, V189, P37, DOI 10.1016/0022-2836(86)90379-7; FUKUDA M, 1993, SEMIN HEMATOL, V30, P188; HOLLIDAY R, 1964, GENET RES, V5, P282, DOI 10.1017/S0016672300001233; Huang C H, 1991, Baillieres Clin Haematol, V4, P821, DOI 10.1016/S0950-3536(06)80032-6; HUANG CH, 1991, BLOOD, V77, P381; HUANG CH, 1993, J BIOL CHEM, V268, P4945; KOMATSU N, 1991, CANCER RES, V51, P341; KUDO S, 1990, J BIOL CHEM, V265, P13825; KUDO S, 1990, J BIOL CHEM, V265, P1102; KUDO S, 1989, P NATL ACAD SCI USA, V86, P4619, DOI 10.1073/pnas.86.12.4619; KUNKEL LM, 1977, P NATL ACAD SCI USA, V74, P1245, DOI 10.1073/pnas.74.3.1245; LANGLOIS RG, 1985, J IMMUNOL, V134, P4009; LANGLOIS RG, 1989, P NATL ACAD SCI USA, V86, P670, DOI 10.1073/pnas.86.2.670; LANGLOIS RG, 1987, SCIENCE, V236, P445, DOI 10.1126/science.3563520; MAIZELS N, 1989, TRENDS GENET, V5, P4, DOI 10.1016/0168-9525(89)90004-8; Maniatis T., 1982, MOL CLONING; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MCINTYRE KR, 1984, NATURE, V308, P551, DOI 10.1038/308551a0; MESELSON MS, 1975, P NATL ACAD SCI USA, V72, P358, DOI 10.1073/pnas.72.1.358; MOORE LA, 1992, J MOL BIOL, V223, P383, DOI 10.1016/0022-2836(92)90741-2; Nei M., 1987, MOL EVOLUTIONARY GEN; ONDA M, 1993, P NATL ACAD SCI USA, V90, P7220, DOI 10.1073/pnas.90.15.7220; ONDA M, 1994, J BIOL CHEM, V269, P13013; RADDING CM, 1982, ANNU REV GENET, V16, P405, DOI 10.1146/annurev.ge.16.120182.002201; RAHUEL C, 1988, EUR J BIOCHEM, V172, P147, DOI 10.1111/j.1432-1033.1988.tb13866.x; RAYNAUD CA, 1987, CELL, V48, P379; REARDEN A, 1990, BIOCHEM GENET, V28, P209, DOI 10.1007/BF00561338; REARDEN A, 1993, J BIOL CHEM, V268, P2260; REARDEN A, 1986, J IMMUNOL, V136, P2504; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SLIGHTOM JL, 1980, CELL, V21, P627, DOI 10.1016/0092-8674(80)90426-2; SOCHA WW, 1983, BLOOD GROUPS PRIMATE, V3; TATE CG, 1988, BIOCHEM J, V254, P743, DOI 10.1042/bj2540743; VIGAL A, 1990, EUR J BIOCHEM, V191, P619	38	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					22969	22974						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	7521873				2022-12-27	WOS:A1994PQ16400013
J	ZHENG, XM; PALLEN, CJ				ZHENG, XM; PALLEN, CJ			EXPRESSION OF RECEPTOR-LIKE PROTEIN-TYROSINE-PHOSPHATASE-ALPHA IN RAT EMBRYO FIBROBLASTS ACTIVATES MITOGEN-ACTIVATED PROTEIN-KINASE AND C-JUN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE THREONINE KINASES; TRANSCRIPTION FACTOR; MAP KINASE; NEURONAL DIFFERENTIATION; NUCLEAR TRANSLOCATION; SIGNAL TRANSDUCTION; TRANSFORMING GENE; MAMMALIAN-CELLS; TRANS-ACTIVATOR; DNA-BINDING	Anti-c-Src and anti-phosphotyrosine immunoprecipitates from receptor-like protein tyrosine phosphatase a (PTP alpha)-transfected and control rat embryo fibroblasts contain a 39-kDa phosphoprotein (p39) whose phosphorylation is enhanced by PTP alpha expression. The p39 that co-immunoprecipitates with c-Src has been identified as c-Jun by immunological and functional criteria; it is recognized by several different anti-c-Jun antibodies and binds to a c-Jun recognition element-containing oligonucleotide. Whereas the association of c-Src and c-Jun is unexpected, it may be of significance in PTP alpha signaling since we have previously demonstrated that c-Src is activated by PTP alpha (Zheng, X. M., Wang, Y., and Fallen, C. J. (1992) Nature 359, 336-339. Examination of c-Jun activity in these fibroblasts demonstrates that c-Jun DNA binding activity and c-Jun-mediated transcription of a chloramphenicol acetyltransferase reporter gene are elevated in PTP alpha-expressing cells. In addition to c-Jun activation, mitogen activated protein kinase is activated in PTP alpha-expressing cells and translocated to the nuclei of these cells. The nuclear localization of activated mitogen activated protein kinase and c-Jun suggests that their activation represents downstream events in the receptor-like PTP alpha-initiated signaling pathway(s).	NATL UNIV SINGAPORE, INST MOLEC & CELL BIOL, CELL REGULAT LAB, SINGAPORE 0511, SINGAPORE	Agency for Science Technology & Research (ASTAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore				Pallen, Catherine/0000-0002-3576-5295				ADLER V, 1992, J BIOL CHEM, V267, P17001; AHN NG, 1990, J BIOL CHEM, V265, P11487; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BAICHWAL VR, 1991, NATURE, V352, P165, DOI 10.1038/352165a0; BAKER SJ, 1992, MOL CELL BIOL, V12, P4694, DOI 10.1128/MCB.12.10.4694; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BROWNSHIMER S, 1992, CANCER RES, V52, P478; CATLING AD, 1993, ONCOGENE, V8, P1875; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHIDA K, 1992, P NATL ACAD SCI USA, V89, P4290, DOI 10.1073/pnas.89.10.4290; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHOU SY, 1992, MOL BIOL CELL, V3, P1117, DOI 10.1091/mbc.3.10.1117; COURTNEIDGE SA, 1980, P NATL ACAD SCI-BIOL, V77, P3783, DOI 10.1073/pnas.77.7.3783; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DAUM G, 1991, J BIOL CHEM, V266, P12211; DENHERTOG J, 1993, EMBO J, V12, P3789, DOI 10.1002/j.1460-2075.1993.tb06057.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ERICKSON AK, 1990, J BIOL CHEM, V265, P19728; FRANKLIN CC, 1992, P NATL ACAD SCI USA, V89, P7247, DOI 10.1073/pnas.89.15.7247; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HEASLEY LE, 1992, MOL BIOL CELL, V3, P545, DOI 10.1091/mbc.3.5.545; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; KAPLAN KB, 1992, J CELL BIOL, V118, P321, DOI 10.1083/jcb.118.2.321; KNUTSON JC, 1987, ANAL BIOCHEM, V164, P44, DOI 10.1016/0003-2697(87)90365-4; LEE H, 1993, J BIOL CHEM, V268, P8181; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; MATTHEWS RJ, 1990, P NATL ACAD SCI USA, V87, P4444, DOI 10.1073/pnas.87.12.4444; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; PULVERER BJ, 1993, ONCOGENE, V8, P407; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RESH MD, 1985, J CELL BIOL, V100, P409, DOI 10.1083/jcb.100.2.409; SAP J, 1990, P NATL ACAD SCI USA, V87, P6112, DOI 10.1073/pnas.87.16.6112; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; STRAUSS F, 1984, CELL, V37, P889, DOI 10.1016/0092-8674(84)90424-0; TAYLOR SJ, 1993, CURR OPIN GENET DEV, V3, P26, DOI 10.1016/S0959-437X(05)80337-5; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; WANG HCR, 1992, MOL BIOL CELL, V3, P1329, DOI 10.1091/mbc.3.12.1329; WANG Y, 1991, EMBO J, V10, P3231, DOI 10.1002/j.1460-2075.1991.tb04886.x; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; WEBSTER N, 1988, CELL, V52, P169, DOI 10.1016/0092-8674(88)90505-3; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZANDER NF, 1993, ONCOGENE, V8, P1175; ZHAO YH, 1992, P NATL ACAD SCI USA, V89, P8298, DOI 10.1073/pnas.89.17.8298; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	58	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					23302	23309						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	7521877				2022-12-27	WOS:A1994PQ16400062
J	OSTERMEIER, M; GEORGIOU, G				OSTERMEIER, M; GEORGIOU, G			THE FOLDING OF BOVINE PANCREATIC TRYPSIN-INHIBITOR IN THE ESCHERICHIA-COLI PERIPLASM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-DISULFIDE-ISOMERASE; BOND FORMATION INVIVO; ENDOPLASMIC-RETICULUM; IN-VITRO; EFFICIENT CATALYSIS; DSBA; PATHWAY; VIVO; BPTI; INTERMEDIATE	PreOmpA-bovine pancreatic trypsin inhibitor (BPTI) (Goldenberg, D. P. (1988) Biochemistry 27, 2481-2489) was expressed in Escherichia coli, and the folding pathway of the mature protein in the periplasmic space was analyzed by pulse-chase experiments. Folding intermediates were trapped with iodoacetamide, immunoprecipitated with antisera specific for either the reduced or the native protein, and resolved by electrophoresis. In vivo, native BPTI formed with a half-life of 7 min which is 3-fold faster than the optimal in vitro folding rate in growth media supplemented with low molecular weight disulfides. The measured in vivo half-life includes the time required for translocation and processing by leader peptidase and therefore represents the lower limit for the actual folding rate in the cell. In addition to the native species, two-disulfide intermediates accumulated in the cell at appreciable levels and did not chase to the native species for at least 20 min. We found that the folding of BPTI in E. coli was absolutely dependent on DsbA, a protein which accelerates the formation of disulfide bonds in the periplasm. In a dsbA mutant strain, trace amounts of oxidized BPTI could be detected only in cultures grown under strongly oxidizing conditions. In wild-type cells, the addition of different concentrations of GSH/GSSG or oxidized dithiothreitol did not affect the kinetics of BPTI oxidation by DsbA. Finally, even though the folding of BPTI in vitro decreases by almost 10-fold/unit pH decrease, folding in cells grown at pH 6.0 was only marginally slower than folding in cells grown at neutral pH, despite the fact that the pH of the periplasmic space varies in response to the extracellular fluid.	UNIV TEXAS, DEPT CHEM ENGN, AUSTIN, TX 78712 USA	University of Texas System; University of Texas Austin			Ostermeier, Marc/A-2697-2010	Ostermeier, Marc/0000-0003-0900-3665	NIGMS NIH HHS [1R01 GM 47520-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047520] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANEYX F, 1992, STABILITY PROTEIN PH, P69; BARDWELL JCA, 1993, CELL, V74, P769, DOI 10.1016/0092-8674(93)90455-Y; BARDWELL JCA, 1993, P NATL ACAD SCI USA, V90, P1038, DOI 10.1073/pnas.90.3.1038; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BEDOWS E, 1992, J BIOL CHEM, V267, P8880; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; CHUN SY, 1993, J BIOL CHEM, V268, P20855; CREIGHTON TE, 1980, J MOL BIOL, V142, P43, DOI 10.1016/0022-2836(80)90205-3; CREIGHTON TE, 1978, PROG BIOPHYS MOL BIO, V33, P231; CREIGHTON TE, 1984, J MOL BIOL, V179, P497, DOI 10.1016/0022-2836(84)90077-9; CREIGHTON TE, 1978, J MOL BIOL, V123, P129, DOI 10.1016/0022-2836(78)90317-0; CREIGHTON TE, 1993, J MOL BIOL, V232, P1176, DOI 10.1006/jmbi.1993.1470; CREIGHTON TE, 1980, J MOL BIOL, V144, P521, DOI 10.1016/0022-2836(80)90335-6; DERMAN AI, 1991, J BACTERIOL, V173, P7719, DOI 10.1128/jb.173.23.7719-7722.1991; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; GEORGIOU G, 1988, BIOTECHNOL LETT, V10, P377, DOI 10.1007/BF01087432; GOLDENBERG D, 1982, P NATL ACAD SCI-BIOL, V79, P3403, DOI 10.1073/pnas.79.11.3403; GOLDENBERG DP, 1992, TRENDS BIOCHEM SCI, V17, P257, DOI 10.1016/0968-0004(92)90405-X; GOLDENBERG DP, 1988, BIOCHEMISTRY-US, V27, P2481, DOI 10.1021/bi00407a034; HUTH JR, 1993, J BIOL CHEM, V268, P16472; MARKS CB, 1986, J BIOL CHEM, V261, P7115; MARTIN JL, 1993, NATURE, V365, P464, DOI 10.1038/365464a0; MITRAKI A, 1991, SCIENCE, V253, P54, DOI 10.1126/science.1648264; NILSSON B, 1991, J BIOL CHEM, V266, P2970; NOIVA R, 1991, J BIOL CHEM, V266, P19645; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; REISFELD RA, 1962, NATURE, V195, P281, DOI 10.1038/195281a0; STOCK JB, 1977, J BIOL CHEM, V252, P7850; VANMIERLO CPM, 1993, J MOL BIOL, V229, P1125, DOI 10.1006/jmbi.1993.1108; WEISSMAN JS, 1993, NATURE, V365, P185, DOI 10.1038/365185a0; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783; WUNDERLICH M, 1993, PROTEIN SCI, V2, P717, DOI 10.1002/pro.5560020503; WUNDERLICH M, 1993, J BIOL CHEM, V268, P24547; WUNDERLICH M, 1993, BIOCHEMISTRY-US, V32, P12251, DOI 10.1021/bi00096a039; ZAPUN A, 1993, BIOCHEMISTRY-US, V32, P5083, DOI 10.1021/bi00070a016; ZAPUN A, 1992, PROTEINS, V14, P10, DOI 10.1002/prot.340140104	36	34	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					21072	21077						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	7520437				2022-12-27	WOS:A1994PC40300041
J	ARAI, T; PARKER, A; BUSBY, W; CLEMMONS, DR				ARAI, T; PARKER, A; BUSBY, W; CLEMMONS, DR			HEPARIN, HEPARAN-SULFATE, AND DERMATAN SULFATE REGULATE FORMATION OF THE INSULIN-LIKE GROWTH-FACTOR-I AND INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR IGF BINDING; SOMATOMEDIN-C; HUMAN FIBROBLASTS; 2 FORMS; CELLS; GLYCOSAMINOGLYCANS; IDENTIFICATION; PROTEOGLYCANS; MECHANISMS; SEQUENCE	The mechanisms by which insulin-like growth factor-I (IGF-I) is released from insulin-like growth factor binding proteins (IGFBPs) and then binds to its receptor have not been defined. This study was designed to determine the role of glycosaminoglycans in altering the formation of the IGF-I.IGFBP complexes. Heparin inhibited formation of the IGF-I.IGFBP-5 complex and also separated preformed IGF-I.IGFBP-5 complexes. Heparin also inhibited formation of the IGF-I.IGFBP-3 complex; however, it did not inhibit formation of complexes between IGF-I and IGFBP-1, -2, or -4. Heparin exposure was associated with a 17-fold decrease in the affinity of IGFBP-5 for IGF-I. A synthetic peptide that contains residues from Arg(221) to Arg(238) of IGFBP-5, and a heparin binding domain prevented the inhibitory effects of heparin on formation of the IGF-I.IGFBP-5 complex. It did not directly compete with IGF-I for binding to IGFBP-5, suggesting that heparin binding to this region of IGFBP-5 resulted in a conformational change in IGFBP-5 which lowered its affinity for IGF-I. Other glycosaminoglycans that contained O-linked sulfates in the 2 or 3 carbon positions of iduronic acid, e.g. heparan sulfate and dermatan sulfate, also inhibited the IGF-I.IGFBP-5 complex formation, whereas those that did not, such as keratan sulfate or hyaluronic acid, had minimal effects. Anionic polysaccharides that contained O-sulfate groups in the 2 or 3 positions, such as dextran sulfate, pentosan polysulfate, and fucoidan, also had inhibitory activity. The findings suggest a role for these compounds in inhibiting IGF-I.IGFBP interactions, thus making IGF-I available to bind to its receptor.	UNIV N CAROLINA,SCH MED,DEPT MED,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL026309] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG002331, R37AG002331] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-26309] Funding Source: Medline; NIA NIH HHS [AG02331] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDRESS DL, 1992, J BIOL CHEM, V267, P22467; BAXTER RC, 1990, BIOCHEM J, V271, P773, DOI 10.1042/bj2710773; BAXTER RC, 1989, P NATL ACAD SCI USA, V86, P6898, DOI 10.1073/pnas.86.18.6898; BOURNER MJ, 1992, J CELL BIOCHEM, V48, P215; BUSBY WH, 1988, J BIOL CHEM, V263, P14203; BUSBY WH, 1988, J CLIN ENDOCR METAB, V67, P1225, DOI 10.1210/jcem-67-6-1225; CAMACHOHUBNER C, 1992, J BIOL CHEM, V267, P11949; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CLEMMONS DR, 1983, J CLIN ENDOCR METAB, V56, P384, DOI 10.1210/jcem-56-2-384; CLEMMONS DR, 1986, J CLIN INVEST, V77, P1548, DOI 10.1172/JCI112470; COHICK WS, 1993, J CELL PHYSIOL, V157, P52, DOI 10.1002/jcp.1041570107; CONOVER CA, 1990, ENDOCRINOLOGY, V127, P2795, DOI 10.1210/endo-127-6-2795; DAMON DH, 1989, J CELL PHYSIOL, V138, P221, DOI 10.1002/jcp.1041380202; ELGIN RG, 1987, P NATL ACAD SCI USA, V84, P3254, DOI 10.1073/pnas.84.10.3254; Esko JD, 1991, CURR OPIN CELL BIOL, V3, P805, DOI 10.1016/0955-0674(91)90054-3; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JONES JI, 1993, J CELL BIOL, V121, P679, DOI 10.1083/jcb.121.3.679; JONES JI, 1993, P NATL ACAD SCI USA, V90, P10553, DOI 10.1073/pnas.90.22.10553; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTIN JL, 1992, ENDOCRINOLOGY, V131, P1703, DOI 10.1210/en.131.4.1703; MCCUSKER RH, 1990, J CELL PHYSIOL, V144, P244, DOI 10.1002/jcp.1041440210; MERRIFIELD RB, 1964, J AM CHEM SOC, V86, P304, DOI 10.1021/ja01056a056; MOSCATELLI D, 1988, J CELL BIOL, V107, P753, DOI 10.1083/jcb.107.2.753; OLSON JT, 1989, J BIOL CHEM, V264, P3111; RECHLER MM, 1985, ANNU REV PHYSIOL, V47, P425; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; SHIMASAKI S, 1991, J BIOL CHEM, V266, P10646; WILKINS JR, 1985, J CLIN INVEST, V75, P1350, DOI 10.1172/JCI111836; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0	30	145	151	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20388	20393						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	7519608				2022-12-27	WOS:A1994PB31700030
J	MURO, Y; TSAI, WM; HOUGHTEN, R; TAN, EM				MURO, Y; TSAI, WM; HOUGHTEN, R; TAN, EM			SYNTHETIC COMPOUND PEPTIDE SIMULATING ANTIGENICITY OF CONFORMATION-DEPENDENT AUTOEPITOPE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; DNA-POLYMERASE-DELTA; MONOCLONAL-ANTIBODIES; PCNA CYCLIN; AUXILIARY PROTEIN; AMINO-ACIDS; REPLICATION; EPITOPES; AUTOANTIBODY; REPAIR	Proliferating cell nuclear antigen (PCNA), also known as auxiliary protein of DNA polymerase delta, is involved in DNA replication and repair. Certain patients with systemic lupus erythematosus (lupus) produce autoantibodies to PCNA and the autoantibody-defined epitopes of PCNA have been inferred to be conformation-dependent. Based on antigenic properties of continuous primary structure peptides, compound peptides composed of covalently linked discontinuous sequences were synthesized and used as immunogens in rabbits. One compound peptide induced an antibody response to a nuclear antigen which demonstrated a cell cycle-related pattern of nuclear immunofluorescence with maximum expression in the DNA synthesis phase of the cell cycle associated with other features which simulated the conformation -dependent properties of lupus defined autoepitopes. Other rabbit antibodies raised against different compound peptides did not show such properties and recognized epitopes which were continuous primary sequence regions. These results show that from analysis of antigenic sites on a protein, it might be possible to construct synthetic compound peptides which can mimic conformation-dependent epitopes recognized by spontaneously occurring autoantibodies.	SCRIPPS RES INST, WM KECK AUTOIMMUNE DIS CTR, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA; TORREY PINES INST MOLEC STUDIES, SAN DIEGO, CA 92121 USA	Scripps Research Institute; Torrey Pines Institute for Molecular Studies, California			MURO, Yoshinao/M-8883-2014	Muro, Yoshinao/0000-0003-2329-8375	NIAID NIH HHS [AI32834] Funding Source: Medline; NIAMS NIH HHS [AR32063] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI032834] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR032063, R37AR032063] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALTMAN JD, 1991, PROTEIN ENG, V4, P593, DOI 10.1093/protein/4.5.593; APPEL JR, 1990, J IMMUNOL, V144, P976; BIDART JM, 1990, SCIENCE, V248, P736, DOI 10.1126/science.1692160; BRAVO R, 1986, EXP CELL RES, V163, P287, DOI 10.1016/0014-4827(86)90059-5; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; CELIS JE, 1986, FEBS LETT, V209, P277, DOI 10.1016/0014-5793(86)81127-9; GARCIA RL, 1989, AM J PATHOL, V134, P733; HOPP TP, 1986, J IMMUNOL METHODS, V88, P1, DOI 10.1016/0022-1759(86)90045-1; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; HUFF JP, 1990, J EXP MED, V172, P419, DOI 10.1084/jem.172.2.419; HUMBERT C, 1992, J CELL SCI, V103, P97; JASKULSKI D, 1988, SCIENCE, V240, P1544, DOI 10.1126/science.2897717; KAMEL OW, 1991, AM J PATHOL, V138, P1471; KILL IR, 1991, J CELL SCI, V100, P869; KITAGAWA T, 1976, J BIOCHEM-TOKYO, V79, P233, DOI 10.1093/oxfordjournals.jbchem.a131053; LANDBERG G, 1991, CANCER RES, V51, P4570; LANDBERG G, 1991, ACTA ONCOL, V30, P917, DOI 10.3109/02841869109088244; LAVER WG, 1990, CELL, V61, P553, DOI 10.1016/0092-8674(90)90464-P; LEE SH, 1988, P NATL ACAD SCI USA, V85, P9469, DOI 10.1073/pnas.85.24.9469; LERNER RA, 1981, P NATL ACAD SCI-BIOL, V78, P3403, DOI 10.1073/pnas.78.6.3403; LIU FT, 1979, BIOCHEMISTRY-US, V18, P690, DOI 10.1021/bi00571a022; MIYACHI K, 1978, J IMMUNOL, V121, P2228; OGATA K, 1987, J IMMUNOL, V139, P2942; OGATA K, 1987, EXP CELL RES, V168, P475, DOI 10.1016/0014-4827(87)90020-6; PARRY NR, 1989, J GEN VIROL, V70, P1493, DOI 10.1099/0022-1317-70-6-1493; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; REIMER G, 1988, ARTHRITIS RHEUM, V31, P525, DOI 10.1002/art.1780310409; ROOS G, 1993, LAB INVEST, V68, P204; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; TAKASAKI Y, 1984, J EXP MED, V159, P981, DOI 10.1084/jem.159.4.981; TAKASAKI Y, 1990, J IMMUNOL METHODS, V132, P227, DOI 10.1016/0022-1759(90)90034-S; TAN CK, 1987, NUCLEIC ACIDS RES, V15, P9299, DOI 10.1093/nar/15.22.9299; TAN CK, 1986, J BIOL CHEM, V261, P2310; Tan E.M., 1989, ADV IMMUNOL, V44, P151, DOI [10.1016/S0065-2776(08)60641-0, DOI 10.1016/S0065-2776(08)60641-0]; TOSCHI L, 1988, J CELL BIOL, V107, P1623, DOI 10.1083/jcb.107.5.1623; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAI WM, 1992, J IMMUNOL, V149, P2227; VANDIERENDONCK JH, 1991, AM J PATHOL, V138, P1165; WASEEM NH, 1990, J CELL SCI, V96, P121; ZUBER M, 1989, MOL CELL BIOL, V9, P57, DOI 10.1128/MCB.9.1.57	41	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18529	18534						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	7518436				2022-12-27	WOS:A1994NW79800048
J	JENKINS, AL; BOOTMAN, MD; BERRIDGE, MJ; STONE, SR				JENKINS, AL; BOOTMAN, MD; BERRIDGE, MJ; STONE, SR			DIFFERENCES IN INTRACELLULAR CALCIUM SIGNALING AFTER ACTIVATION OF THE THROMBIN RECEPTOR BY THROMBIN AND AGONIST PEPTIDE IN OSTEOBLAST-LIKE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE INHIBITORS; PHOSPHOLIPASE-C; HUMAN-PLATELETS; ALPHA-THROMBIN; PHORBOL ESTERS; OKADAIC ACID; PROTEOLYTIC MECHANISM; INOSITOL PHOSPHATES; MOLECULAR-CLONING; CA2+ MOBILIZATION	Thrombin and the thrombin receptor agonist peptide (TRAP) caused a rise in intracellular calcium concentration ([Ca2+](i)) in the human osteoblast like cell line Saos-2. Striking differences in the [Ca2+](i) signals elicited by these agonists were revealed. In cell populations, thrombin induced a transient increase in [Ca2+](i) while TRAP caused a biphasic [Ca2+](i) response consisting of an initial peak and a sustained plateau phase. In individual cells, thrombin mainly caused a single [Ca2+](i) transient while TRAP induced repetitive [Ca2+](i) spikes. Neither tyrosine phosphorylation, cAMP-dependent phospho rylation, nor pertussis toxin-sensitive G proteins appeared to be involved in thrombin receptor [Ca2+](i) signaling in this cell line. However, the sustained [Ca2+](i) response caused by TRAP was converted into a transient, thrombin-like response by pretreatment with serine/threonine phosphatase inhibitors. Pretreatment with the phorbol ester phorbol 12-myristate 13-acetate (PMA) abrogated thrombin receptor [Ca2+](i) signaling, and TRAP-induced Ca2+ entry was inhibited by the acute treatment with PMA In contrast, Ca2+ entry stimulated by thapsigargin was not sensitive to agents affecting serine/threonine phosphorylation. The observation that thrombin and TRAP, despite being agonists for a common receptor, induce dissimilar [Ca2+](i) responses indicates that binding of TRAP alone is insufficient to fully regulate the thrombin receptor in Saos-2 cells.	UNIV CAMBRIDGE,CTR MRC,DEPT HEMATOL,CAMBRIDGE CB2 2QH,ENGLAND; UNIV CAMBRIDGE,DEPT ZOOL,BABRAHAM INST,MOLEC SIGNALLING LAB,CAMBRIDGE CB2 3EJ,ENGLAND	University of Cambridge; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; University of Cambridge			Bootman, Martin/AAB-3330-2019	Bootman, Martin/0000-0002-6447-3451	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BOOTMAN MD, 1992, J PHYSIOL-LONDON, V450, P163, DOI 10.1113/jphysiol.1992.sp019121; BOOTMAN MD, 1992, J BIOL CHEM, V267, P25113; BRASS LF, 1992, J BIOL CHEM, V267, P6044; BRASS LF, 1994, J BIOL CHEM, V269, P2943; CARLSON KE, 1989, J BIOL CHEM, V264, P13298; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; FUKAYAMA S, 1993, AM J PHYSIOL, V264, pC464, DOI 10.1152/ajpcell.1993.264.2.C464; GARCIA JGN, 1993, J CELL PHYSL, V150, P4876; GRYNKIEWICZ G, 1985, J BIOL CHEM, V264, P17665; Hescheler J, 1993, Curr Opin Neurobiol, V3, P360, DOI 10.1016/0959-4388(93)90129-M; HOWELLS GL, 1993, BRIT J HAEMATOL, V84, P156, DOI 10.1111/j.1365-2141.1993.tb03039.x; HOXIE JA, 1993, J BIOL CHEM, V268, P13756; HUANG RS, 1991, J BIOL CHEM, V266, P18435; HUNG DT, 1992, J CELL BIOL, V116, P827, DOI 10.1083/jcb.116.3.827; IRVINE RF, 1992, FASEB J, V6, P3085, DOI 10.1096/fasebj.6.12.1325932; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; ISHII K, 1994, J BIOL CHEM, V269, P1125; ISHII K, 1993, J BIOL CHEM, V268, P9780; JACKSON TR, 1988, BIOCHEM J, V253, P81, DOI 10.1042/bj2530081; Jenkins Alison L., 1993, Journal of Biological Chemistry, V268, P21432; KELLEHER DJ, 1986, J BIOL CHEM, V261, P4749; LEE KM, 1993, J BIOL CHEM, V268, P9945; OFORIDARKO E, 1992, AM J PHYSIOL, pC1266; OSULLIVAN AJ, 1989, EMBO J, V8, P401, DOI 10.1002/j.1460-2075.1989.tb03391.x; PARK DJ, 1992, J BIOL CHEM, V267, P1496; Penner R, 1993, Curr Opin Neurobiol, V3, P368, DOI 10.1016/0959-4388(93)90130-Q; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RASMUSSEN UB, 1991, FEBS LETT, V288, P123, DOI 10.1016/0014-5793(91)81017-3; RAYMOND JR, 1991, J BIOL CHEM, V266, P14747; SARGEANT P, 1993, FEBS LETT, V315, P242, DOI 10.1016/0014-5793(93)81172-V; SARGEANT P, 1993, J BIOL CHEM, V268, P18151; SMITH CD, 1987, J BIOL CHEM, V262, P6121; STONE SR, 1986, BIOCHEMISTRY-US, V25, P4622, DOI 10.1021/bi00364a025; SUIDAN HS, 1992, NEURON, V8, P363, DOI 10.1016/0896-6273(92)90302-T; TATAKIS DN, 1989, BIOCHEM BIOPH RES CO, V164, P119, DOI 10.1016/0006-291X(89)91691-4; TBRDAI A, 1993, J IMMUNOL, V150, P4876; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; VALONE FH, 1987, BIOCHEM J, V247, P669, DOI 10.1042/bj2470669; VOURETCRAVIARI V, 1993, BIOCHEM J, V289, P209, DOI 10.1042/bj2890209; VOURETCRAVIARI V, 1992, MOL BIOL CELL, V3, P95, DOI 10.1091/mbc.3.1.95; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; YAMAGUCHI DT, 1989, J BIOL CHEM, V264, P197; ZHONG CZ, 1992, J BIOL CHEM, V267, P16975	45	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 24	1994	269	25					17104	17110						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NT846	7516333				2022-12-27	WOS:A1994NT84600021
J	MOKUNO, H; BRADY, S; KOTITE, L; HERZ, J; HAVEL, RJ				MOKUNO, H; BRADY, S; KOTITE, L; HERZ, J; HAVEL, RJ			EFFECT OF THE 39-KDA RECEPTOR-ASSOCIATED PROTEIN ON THE HEPATIC-UPTAKE AND ENDOCYTOSIS OF CHYLOMICRON REMNANTS AND LOW-DENSITY LIPOPROTEINS IN THE RAT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARENCHYMAL LIVER-CELLS; TRIGLYCERIDE-RICH LIPOPROTEINS; ACTIVATOR INHIBITOR TYPE-1; 3 ENDOSOMAL FRACTIONS; ALPHA-2-MACROGLOBULIN RECEPTOR; LDL-RECEPTOR; PLASMINOGEN-ACTIVATOR; APOLIPOPROTEIN-E; ARGININE-RICH; BINDING	The low density lipoprotein (LDL) receptor-related protein, which serves as the cell surface receptor for several proteins including alpha(2)-macroglobulin-protease complexes, has been proposed to be a candidate hepatocytic receptor for chylomicron remnants through its recognition of apolipoprotein E. We have studied the effect of two ligands for this receptor, activated alpha(2)-macroglobulin and the recently described 39-kDa protein that copurifies with the LDL receptor-related protein (receptor-associated protein), on the uptake and endocytosis of chylomicrons in intact rats and in isolated, perfused rat livers. Both of these ligands were rapidly taken up and endocytosed into the liver of rats. Chylomicrons from normal rats were injected in vivo and chylomicrons from estradiol-treated rats that were enriched in apolipoprotein E were added to liver perfusates. Prior administration of amounts of activated alpha(2)-macroglobulin that saturated hepatic uptake mechanisms did not inhibit hepatic uptake or endocytosis of endogenously labeled cholesteryl esters of chylomicron particles in vivo or in perfused livers over a period of 15 min. By contrast, prior administration of saturating amounts of the receptor-associated protein (expressed in bacteria as a fusion protein with glutathione S-transferase) reduced hepatic uptake by about 30% and virtually abolished endocytosis. The receptor-associated protein inhibited hepatic uptake of human LDL in vivo by 70% and endocytosis by 81%. Our results show that receptor-associated protein-sensitive processes predominate in the overall pathways by which chylomicron remnants are endocytosed by rat liver. Furthermore, they show that the receptor-associated protein binds to and inhibits the function of the LDL receptor as well as the LDL receptor-related protein.	UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; UNIV TEXAS,SW MED SCH,DEPT MOLEC GENET,DALLAS,TX 75235	University of California System; University of California San Francisco; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NHLBI NIH HHS [HL-14237, HL-20948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014237, P01HL020948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARRETT AJ, 1981, METHOD ENZYMOL, V80, P737; BEISIEGEL U, 1982, J BIOL CHEM, V257, P3150; BELCHER JD, 1987, P NATL ACAD SCI USA, V84, P6785, DOI 10.1073/pnas.84.19.6785; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; CHAO Y, 1979, J BIOL CHEM, V254, P1360; CHOI SSY, 1991, J CLIN INVEST, V88, P1173, DOI 10.1172/JCI115419; CHOI SY, 1993, J BIOL CHEM, V268, P15804; DANIEL TO, 1983, J BIOL CHEM, V258, P4606; FAINARU M, 1977, BIOCHIM BIOPHYS ACTA, V490, P144, DOI 10.1016/0005-2795(77)90114-3; FELKER TE, 1977, J LIPID RES, V18, P465; FIELDING CJ, 1979, BIOCHIM BIOPHYS ACTA, V573, P255, DOI 10.1016/0005-2760(79)90059-6; FOLCH J, 1957, J BIOL CHEM, V226, P497; HARKES L, 1984, BIOCHIM BIOPHYS ACTA, V794, P340, DOI 10.1016/0005-2760(84)90165-6; HARKES L, 1984, BIOCHEM J, V224, P21, DOI 10.1042/bj2240021; HAVEL RJ, 1988, HEPATOLOGY, V8, P1689, DOI 10.1002/hep.1840080637; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; HERZ J, 1990, J BIOL CHEM, V265, P21355; HOUSSAIN MM, 1991, J BIOL CHEM, V266, P13936; HUSSAINI IM, 1990, J BIOL CHEM, V265, P19441; IMAIZUMI K, 1978, J LIPID RES, V19, P712; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; JACKLE S, 1991, J LIPID RES, V32, P485; JACKLE S, 1993, J LIPID RES, V34, P309; JAECKLE S, 1989, P NATL ACAD SCI USA, V86, P1880, DOI 10.1073/pnas.86.6.1880; JONES AL, 1984, J LIPID RES, V25, P1151; KITA T, 1982, P NATL ACAD SCI-BIOL, V79, P3623, DOI 10.1073/pnas.79.11.3623; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P21862; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUND H, 1989, P NATL ACAD SCI USA, V86, P9318, DOI 10.1073/pnas.86.23.9318; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; NAGATA Y, 1988, J BIOL CHEM, V263, P15151; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; PORATH J, 1975, NATURE, V258, P598, DOI 10.1038/258598a0; RUBINSZTEIN DC, 1990, J CLIN INVEST, V86, P1306, DOI 10.1172/JCI114839; RUNQUIST EA, 1991, J BIOL CHEM, V266, P22557; SHAFI S, 1994, J LIPID RES, V35, P709; SIGURDSSON G, 1978, J LIPID RES, V19, P628; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; VANDIJK MCM, 1991, BIOCHEM J, V279, P863, DOI 10.1042/bj2790863; WARSHAWSKY I, 1993, J CLIN INVEST, V92, P937, DOI 10.1172/JCI116669; WINDLER E, 1980, J BIOL CHEM, V255, P8303; WINDLER E, 1980, J BIOL CHEM, V255, P5475; WINDLER EET, 1988, BIOCHEM J, V252, P553, DOI 10.1042/bj2520553	51	77	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13238	13243						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	7513700				2022-12-27	WOS:A1994NK18400031
J	JOVOV, B; ISMAILOV, II; BENOS, DJ				JOVOV, B; ISMAILOV, II; BENOS, DJ			CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR IS REQUIRED FOR PROTEIN-KINASE-A ACTIVATION OF AN OUTWARDLY RECTIFIED ANION CHANNEL PURIFIED FROM BOVINE TRACHEAL EPITHELIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECTIFYING CHLORIDE CHANNELS; CL CHANNELS; FUNCTIONAL RECONSTITUTION; SECRETORY EPITHELIA; CFTR; AIRWAY; CELLS; CAMP; TEMPERATURE; MEMBRANES	Our laboratory has developed a protocol for the isolation of a 140-kDa protein that forms an anion-selective channel when reconstituted into planar lipid bilayers. Polyclonal antibodies have been raised against the 38-kDa component of this purified protein, This channel has a linear current-voltage relationship and is not activated by protein kinase A (PKA) plus ATP. Using the same antibody and a modified purification protocol (eliminating the ion exchange chromatography steps), we isolated and reconstituted two other anion channels from tracheal membrane vesicles. In vitro phosphorylation of these isolated proteins by PKA and ATP revealed four bands migrating at 52, 85, 120, and 174 kDa. Immunoprecipitation experiments with anti-CFTR antibodies indicate that the 174-kDa phosphoprotein was CFTR. Upon incorporation of these isolated proteins into planar bilayers, an anion channel that exhibited a marked outward rectification in symmetrical Cl- solutions with a slope conductance of 82 pS at depolarizing voltages was observed, PKA and ATP increased channel activity but only from one side of the bilayer. However, channel activity was unaffected by addition of ATP alone from either side of the membrane, DIDS (100 mu M) applied to the opposite side of the bilayer to which PKA and ATP act, blocked channel activity. A linear anion-selective channel with a conductance of 16 pS could be also resolved after inhibition of the outwardly rectified anion channel by DIDS in the presence of PKA and ATP. This small conductance channel was inhibited by 300 mu M diphenylamine 2-carboxylic acid. Immunodepletion of the 174-kDa phosphoprotein from the preparation prevented activation of the 82-pS outwardly rectified anion channel by PKA and ATP. However, the PKA-dependent in vitro phosphorylation of the 52-, 85-, and 120-kDa phosphoproteins was unaffected by the absence of CFTR. Our results suggest a direct regulatory relationship between an outwardly rectified anion channel and CFTR.			JOVOV, B (corresponding author), UNIV ALABAMA,DEPT PHYSIOL & BIOPHYS,UAB STN,BIRMINGHAM,AL 35294, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK042017] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK42017] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALVAREZ O, 1985, J ELECTROPHYSIOL TEC, V12, P159; ANDERSON MP, 1992, AM J PHYSIOL, V263, pL1, DOI 10.1152/ajplung.1992.263.1.L1; ANDERSON MP, 1991, SCIENCE, V251, P269; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; CLIFF WH, 1992, AM J PHYSIOL, V262, pC1154, DOI 10.1152/ajpcell.1992.262.5.C1154; CLIFF WH, 1990, P NATL ACAD SCI USA, V87, P4956, DOI 10.1073/pnas.87.13.4956; DENNING GM, 1992, J CLIN INVEST, V89, P339, DOI 10.1172/JCI115582; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DHO S, 1992, AM J PHYSIOL, V262, pC67, DOI 10.1152/ajpcell.1992.262.1.C67; EGAN M, 1992, NATURE, V358, P581, DOI 10.1038/358581a0; FRIZZELL RA, 1986, FASEB J, V45, P2727; FULLER CM, 1992, AM J PHYSIOL, V262, pC396, DOI 10.1152/ajpcell.1992.262.2.C396; FULLER CM, 1992, AM J PHYSIOL, V263, pC267, DOI 10.1152/ajpcell.1992.263.2.C267; FULLER CM, 1994, J BIOL CHEM, V269, P26642; GABRIEL SE, 1993, NATURE, V363, P263, DOI 10.1038/363263a0; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; GUGGINO WB, 1993, J BIOENERG BIOMEMBR, V25, P27, DOI 10.1007/BF00768065; HALM DR, 1989, AM J PHYSIOL, V245, pC505; HWANG TC, 1989, SCIENCE, V244, P1351, DOI 10.1126/science.2472005; ISMAILOV II, 1994, J BIOL CHEM, V269, P10235; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGRIDGESMITH JE, 1983, BIOCHIM BIOPHYS ACTA, V731, P318, DOI 10.1016/0005-2736(83)90024-X; LI M, 1988, NATURE, V331, P358, DOI 10.1038/331358a0; MADERA JL, 1993, J CLIN INVEST, V91, P2320; QUINTON PM, 1983, NATURE, V301, P421, DOI 10.1038/301421a0; RAN S, 1992, J BIOL CHEM, V267, P20630; RAN S, 1991, J BIOL CHEM, V266, P4782; RAN S, 1992, J BIOL CHEM, V267, P3618; SCHUMACHER RA, 1987, NATURE, V330, P752; SCHWIEBERT EM, 1994, AM J PHYSIOL, V266, pC1464, DOI 10.1152/ajpcell.1994.266.5.C1464; SCHWIEBERT EM, 1994, BIOPHYS J, V66, pA2; STUTTS MJ, 1992, P NATL ACAD SCI USA, V89, P1621, DOI 10.1073/pnas.89.5.1621; TILLY BC, 1992, J BIOL CHEM, V267, P9470; WELSH MJ, 1989, J CLIN INVEST, V84, P2002, DOI 10.1172/JCI114391	34	55	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 27	1995	270	4					1521	1528		10.1074/jbc.270.4.1521	http://dx.doi.org/10.1074/jbc.270.4.1521			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QD204	7530244	hybrid			2022-12-27	WOS:A1995QD20400009
J	MCCOURT, PAG; EK, B; FORSBERG, N; GUSTAFSON, S				MCCOURT, PAG; EK, B; FORSBERG, N; GUSTAFSON, S			INTERCELLULAR-ADHESION MOLECULE-1 IS A CELL-SURFACE RECEPTOR FOR HYALURONAN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							LIVER ENDOTHELIAL-CELLS; RAT-LIVER; BINDING; ICAM-1; CD44; IDENTIFICATION; DEGRADATION; EXPRESSION; MEMBRANES; SEQUENCE	Our laboratory has previously characterized and purified the hyaluronan receptor by hyaluronan affinity chromatography of rat liver endothelial cells. We have now isolated the receptor from whole rat liver and have obtained sufficient quantities for amino acid sequence analysis. Four peptides of various lengths were obtained from affinity-purified receptor and found to have identity with rat intercellular adhesion molecule-1. This glycoprotein is normally expressed in low amounts on the endothelial cells, but is up-regulated in inflamed and malignant tissues, and mediates cell-cell adhesion as a ligand for lymphocyte function-associated antigen-1 and the macrophage associated Mac-1. The affinity of intercellular adhesion molecule-1 for hyaluronan is likely to have important implications for cell adhesion in normal and in disease states such as inflammation, atherosclerosis, and cancer.	UNIV UPPSALA, CTR BIOMED, DEPT MED & PHYSIOL CHEM, S-75123 UPPSALA, SWEDEN; SWEDISH UNIV AGR SCI, UPPSALA GENET CTR, DEPT CELL RES, S-75007 UPPSALA, SWEDEN	Uppsala University; Swedish University of Agricultural Sciences			McCourt, Peter/B-3043-2009	McCourt, Peter/0000-0001-5072-4590				ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BRACIAK TA, 1988, J BIOL CHEM, V263, P3999; CULTY M, 1992, J CELL BIOL, V116, P1055, DOI 10.1083/jcb.116.4.1055; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; DUSTIN ML, 1988, IMMUNOL TODAY, V9, P213, DOI 10.1016/0167-5699(88)91216-9; DUSTIN ML, 1986, J IMMUNOL, V137, P245; ENGSTROMLAURENT A, 1989, CIBA F SYMP, V143, P233; FOETS BJJ, 1992, BRIT J OPHTHALMOL, V76, P205, DOI 10.1136/bjo.76.4.205; FORSBERG N, 1991, BIOCHIM BIOPHYS ACTA, V1078, P12, DOI 10.1016/0167-4838(91)90085-E; FORSBERG N, 1994, IN PRESS EXP EYE RES; FRASER JRE, 1989, CIBA F SYMP, V143, P41; FRASER JRE, 1985, CELL TISSUE RES, V242, P505; GUSTAFSON S, 1991, BIOCHIM BIOPHYS ACTA, V1091, P36, DOI 10.1016/0167-4889(91)90218-M; GUSTAFSON S, 1994, 1ST INT WORKSH HYAL, V33, P43; HARDWICK C, 1992, J CELL BIOL, V117, P1343, DOI 10.1083/jcb.117.6.1343; HYODO I, 1993, INT J CANCER, V55, P775, DOI 10.1002/ijc.2910550514; KING SR, 1991, SURGERY, V109, P76; KITA Y, 1992, BIOCHIM BIOPHYS ACTA, V1131, P108, DOI 10.1016/0167-4781(92)90107-B; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; LAURENT TC, 1986, BIOCHEM J, V234, P653, DOI 10.1042/bj2340653; LEVESQUE H, 1994, ATHEROSCLEROSIS, V105, P51, DOI 10.1016/0021-9150(94)90007-8; MADSEN K, 1989, INVEST OPHTH VIS SCI, V30, P2132; MAKGOBA MW, 1988, NATURE, V331, P86, DOI 10.1038/331086a0; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; POSTON RN, 1992, AM J PATHOL, V140, P665; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; SANCHEZMADRID F, 1983, J EXP MED, V158, P1785, DOI 10.1084/jem.158.6.1785; SMEDSROD B, 1984, BIOCHEM J, V223, P617, DOI 10.1042/bj2230617; SMEDSROD B, 1990, BIOCHEM J, V266, P313, DOI 10.1042/bj2660313; TOOLE BP, 1984, ROLE EXTRACELLULAR M, P43; UNDERHILL C, 1992, J CELL SCI, V103, P293; UNDERHILL CB, 1985, J BIOL CHEM, V260, P8128; YANG BH, 1994, EMBO J, V13, P286, DOI 10.1002/j.1460-2075.1994.tb06261.x; YANNARIELLOBROWN J, 1992, J BIOL CHEM, V267, P20451	35	175	177	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30081	30084						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7527024				2022-12-27	WOS:A1994PU52500005
J	SOUZA, SC; FRICK, GP; YIP, R; LOBO, RB; TAI, LR; GOODMAN, HM				SOUZA, SC; FRICK, GP; YIP, R; LOBO, RB; TAI, LR; GOODMAN, HM			GROWTH-HORMONE STIMULATES TYROSINE PHOSPHORYLATION OF INSULIN-RECEPTOR SUBSTRATE-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN-KINASE ACTIVITY; RAT ADIPOCYTES; ADIPOSE-TISSUE; HEMATOPOIETIC-CELLS; BINDING; RESPONSES; INDUCTION; IRS-1	Growth hormone (GH) produces insulin-like effects in rat adipocytes that have been deprived of GH for at least 3 h. The effect of a saturating concentration of GH is qualitatively and quantitatively similar to that produced by 2-4 ng/ml insulin but differs from that of insulin in the respect that adipocytes become refractory to prolonged or repeated stimulation with GH. Since activation of tyrosine kinase is an early event in the action of both hormones, we investigated the possibility that GH stimulation of tyrosine phosphorylation of some protein in the insulin transduction cascade might result in the similar effect of the two hormones. Adipocytes were preincubated for 3 h in the absence of hormones and then reincubated without or with 500 ng/ml GH or 4-400 ng/ml insulin for 10 min. The cells were lysed with an equal volume of buffer containing 1% SDS and preheated to 100 degrees C. Proteins were separated by electrophoresis on 7.5% polyacrylamide gels and transferred to nitrocellulose membranes, and tyrosine-phosphorylated proteins were detected using anti-phosphotyrosine antiserum coupled to horseradish peroxidase and reagents to produce chemiluminescence. The faint band seen at 185 kDa in control lanes was increased by GH treatment in five independent experiments. Insulin produced a similar effect at a concentration of 4 ng/ml, and phosphorylation increased in a dose-related manner in cells treated with higher concentrations of insulin. A prominent similar to 95-kDa band that is probably not the beta subunit of the insulin receptor was also seen in GH-treated cells. The beta subunit of the insulin receptor has similar electrophoretic mobility to the 95-kDa protein, but was not phosphorylated to an extent that allowed detection when insulin was added at concentrations below 400 ng/ml. Phosphorylation of the 185- and 95-kDa bands was evident within 1 min after addition of GH, persisted for at least 30 min, and was equally prominent in sensitive and refractory cells. Antiserum to IRS-1 immunoprecipitated the tyrosine-phosphorylated 185-kDa protein. The data suggest that IRS-1 is a substrate for a GH-activated tyrosine kinase, possibly JAK-2, which may account for the insulin-like effects of GH. The data further suggest that refractoriness to insulin-like stimulation by GH may result from an additional GH-dependent action that is distinct from phosphorylation of IRS-1.	UNIV MASSACHUSETTS,SCH MED,DEPT PHYSIOL,WORCESTER,MA 01655; UNIV SAO PAULO,FAC MED RIBEIRAO PRETO,BR-14049 RIBEIRAO PRET,SP,BRAZIL	University of Massachusetts System; University of Massachusetts Worcester; Universidade de Sao Paulo					NIDDK NIH HHS [DK 14392] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BIRNBAUM RS, 1976, ENDOCRINOLOGY, V99, P1336, DOI 10.1210/endo-99-5-1336; CAMPBELL GS, 1993, J BIOL CHEM, V268, P7427; COIRO V, 1981, ENDOCRINOLOGY, V109, P2213, DOI 10.1210/endo-109-6-2213; EDEN S, 1982, ENDOCRINOLOGY, V111, P1505, DOI 10.1210/endo-111-5-1505; GOODMAN HM, 1987, ENDOCRINOL JAPON, V34, P59; GOODMAN HM, 1990, ENDOCRINOLOGY, V126, P441, DOI 10.1210/endo-126-1-441; GOODMAN HM, 1978, ENDOCRINOLOGY, V102, P210, DOI 10.1210/endo-102-1-210; GOODMAN HM, 1981, ENDOCRINOLOGY, V108, P113, DOI 10.1210/endo-108-1-113; GOODMAN HM, 1981, ENDOCRINOLOGY, V109, P120, DOI 10.1210/endo-109-1-120; GOODMAN HM, 1968, ANN NY ACAD SCI, V148, P419, DOI 10.1111/j.1749-6632.1968.tb20367.x; GOODMAN HM, 1981, HORM METAB RES, V13, P351, DOI 10.1055/s-2007-1019264; GOODMAN HM, 1988, HUMAN GROWTH HORMONE, P75; GRICHTING G, 1983, ENDOCRINOLOGY, V113, P1111, DOI 10.1210/endo-113-3-1111; HONEYMAN TW, 1980, AM J PHYSIOL, V238, P389; KAHN CR, 1993, RECENT PROG HORM RES, V48, P291; KASUGA M, 1983, P NATL ACAD SCI-BIOL, V80, P2137, DOI 10.1073/pnas.80.8.2137; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVAN BE, 1993, J BIOL CHEM, V268, P5921; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; MEYER DJ, 1994, J BIOL CHEM, V269, P4701; MOODY AJ, 1974, HORM METAB RES, V6, P12, DOI 10.1055/s-0028-1093895; PETRUZZELLI L, 1984, P NATL ACAD SCI-BIOL, V81, P3327, DOI 10.1073/pnas.81.11.3327; RODBELL M, 1964, J BIOL CHEM, V239, P375; SCHWARTZ Y, 1991, P NATL ACAD SCI USA, V88, P6790, DOI 10.1073/pnas.88.15.6790; SCHWARTZ Y, 1990, ENDOCRINOLOGY, V126, P170; SILVA CM, 1993, ENDOCRINOLOGY, V132, P101, DOI 10.1210/en.132.1.101; SMAL J, 1987, J BIOL CHEM, V262, P11071; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; VANDERKUUR JA, 1994, 76TH M END SOC AN, P456; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; WANG XZ, 1994, P NATL ACAD SCI USA, V91, P1391, DOI 10.1073/pnas.91.4.1391; WHITE MF, 1987, J BIOL CHEM, V262, P9769; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITE MF, 1994, J BIOL CHEM, V269, P1; WHITE MF, 1994, J BIOL CHEM, V269, P28	37	112	112	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30085	30088						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7527025				2022-12-27	WOS:A1994PU52500006
J	NOGUCHI, M; MIYAMOTO, S; SILVERMAN, TA; SAFER, B				NOGUCHI, M; MIYAMOTO, S; SILVERMAN, TA; SAFER, B			CHARACTERIZATION OF AN ANTISENSE INR ELEMENT IN THE EIF-2-ALPHA GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR LATE PROMOTER; RNA POLYMERASE-II; EUKARYOTIC INITIATION FACTOR-2-ALPHA; HUMAN SQUAMOUS CARCINOMA; TRANSCRIPTION FACTOR; MAMMALIAN-CELLS; PROTEIN-SYNTHESIS; S-POMBE; EXPRESSION; BINDING	We recently discovered an opposing initiator prometer (Inr) downstream of the sense promoter region of the eIF-2 alpha gene (Silverman, T., Noguchi, M., and Safer, B. (1992) J. Biol. Chem. 267, 9738-9742). By reverse transcriptase/polymerase chain reaction analysis of G(0) and activated (G(1)) T-lymphocyte RNAs, overlapping sense and antisense transcripts are now identified. Sense transcription of the eIF-2 alpha gene proceeds from left to right to generate alpha-mRNA; antisense transcription proceeds from right to left to generate RNA, having a sequence complementary to eIF-2 alpha mRNA. Upstream indicates a position 5' relative to the transcription start site. Using DNase I footprint analysis and EMSA, we have found a potential cis-regulatory sequence immediately upstream of the Inr which binds a 43-kDa protein. In addition to conferring protection against DNase I (+457 to +474), the factor also generates hypersensitive sites directly over the Inr (+447 to +457). Insertion of the Inr footprint region into a luciferase reporter gene construct increases expression 150-fold. While mutation of the Inr conserved sequence decreases luciferase activity by 50%, mutation of the 43-kDa factor binding site inhibits luciferase activity by 20%. Sense orientation of the Inr footprint region decreases activity by 80%. The 43-kDa Inr-associated binding protein may be involved in allowing access of RNA polymerase II transcription complexes to the initiation site of this TATA-less gene A model for the regulation of eIF-2 alpha expression involving the rapid degradation of dsRNA generated by the relative activities of the two overlapping and opposing promoters is proposed.	NHLBI,MOLEC HEMATOL BRANCH,PROT & RNA BIOSYNTH SECT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								BASS BL, 1988, CELL, V55, P1089, DOI 10.1016/0092-8674(88)90253-X; BEAUPAIN D, 1990, NUCLEIC ACIDS RES, V18, P6509, DOI 10.1093/nar/18.22.6509; BOAL TR, 1993, BIOCHIM BIOPHYS ACTA, V1176, P257, DOI 10.1016/0167-4889(93)90053-R; CARCAMO J, 1991, P NATL ACAD SCI USA, V88, P8052, DOI 10.1073/pnas.88.18.8052; CARCAMO J, 1990, GENE DEV, V4, P1611, DOI 10.1101/gad.4.9.1611; CASTLE V, 1991, J CLIN INVEST, V87, P1883, DOI 10.1172/JCI115212; CHIORINI JA, 1993, J BIOL CHEM, V268, P13748; COHEN RB, 1990, EMBO J, V9, P3831, DOI 10.1002/j.1460-2075.1990.tb07601.x; CROWLEY TE, 1985, CELL, V43, P633, DOI 10.1016/0092-8674(85)90235-1; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUIN M, 1989, MOL CELL BIOL, V9, P1794; FREID M, 1981, NUCLEIC ACIDS RES, V9, P6505; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GARFINKEL S, 1990, J BIOL CHEM, V265, P10309; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREEN PJ, 1986, ANNU REV BIOCHEM, V55, P569, DOI 10.1146/annurev.bi.55.070186.003033; HELENE C, 1990, BIOCHIM BIOPHYS ACTA, V1049, P99, DOI 10.1016/0167-4781(90)90031-V; HOVANESSIAN AG, 1993, TRANSLATIONAL REGULA, V2, P163; HUMBELIN M, 1989, GENE, V81, P315, DOI 10.1016/0378-1119(89)90192-3; IINO Y, 1991, EMBO J, V10, P221, DOI 10.1002/j.1460-2075.1991.tb07939.x; JACOB WF, 1989, J BIOL CHEM, V264, P20372; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KASID U, 1989, SCIENCE, V243, P1354, DOI 10.1126/science.2466340; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KRINKE L, 1987, GENE DEV, V1, P1005, DOI 10.1101/gad.1.9.1005; KRYSTAL GW, 1990, MOL CELL BIOL, V10, P4180, DOI 10.1128/MCB.10.8.4180; LAZAR MA, 1989, MOL CELL BIOL, V9, P1128, DOI 10.1128/MCB.9.3.1128; LIU JM, 1991, VIROLOGY, V185, P39, DOI 10.1016/0042-6822(91)90751-V; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; MEEGAN JM, 1989, SCIENCE, V244, P1089, DOI 10.1126/science.2471268; MELTON DA, 1985, P NATL ACAD SCI USA, V82, P144, DOI 10.1073/pnas.82.1.144; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; NELLEN W, 1993, TRENDS BIOCHEM SCI, V18, P419, DOI 10.1016/0968-0004(93)90137-C; OKAMOTO K, 1986, P NATL ACAD SCI USA, V83, P5000, DOI 10.1073/pnas.83.14.5000; PAIN VM, 1986, BIOCHEM J, V235, P625, DOI 10.1042/bj2350625; Rhoads RE, 1991, CURR OPIN CELL BIOL, V3, P1019, DOI 10.1016/0955-0674(91)90123-G; SAFER B, 1991, J BIOL CHEM, V266, P10989; SAFER B, 1988, MOL CELL BIOL, V8, P105, DOI 10.1128/MCB.8.1.105; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SILVERMAN TA, 1992, J BIOL CHEM, V267, P9738; SKEIKY YAW, 1990, J MOL BIOL, V213, P53, DOI 10.1016/S0022-2836(05)80121-4; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SPENCER CA, 1986, NATURE, V322, P279, DOI 10.1038/322279a0; VOLK R, 1989, EMBO J, V8, P2983, DOI 10.1002/j.1460-2075.1989.tb08448.x; WAGNER RW, 1990, MOL CELL BIOL, V10, P5586, DOI 10.1128/MCB.10.10.5586; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; XU HP, 1990, NUCLEIC ACIDS RES, V18, P5304, DOI 10.1093/nar/18.17.5304; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2	52	33	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					29161	29167						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7525581				2022-12-27	WOS:A1994PU16800094
J	CHANG, CP; HUSLER, T; ZHAO, J; WIEDMER, T; SIMS, PJ				CHANG, CP; HUSLER, T; ZHAO, J; WIEDMER, T; SIMS, PJ			IDENTITY OF A PEPTIDE DOMAIN OF HUMAN C9 THAT IS BOUND BY THE CELL-SURFACE COMPLEMENT INHIBITOR, CD59	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-PLATELETS; PROTEINS C5B-9; 9TH COMPONENT; MEMBRANE; C8; INSERTION; LYSIS; CHAIN	The CD59 antigen is a plasma membrane glycoprotein that serves as an inhibitor of the C5b-9 complex of complement. This inhibitory activity appears related to the capacity of CD59 to bind with high affinity to sites that are nascently exposed in the cy-chain subunit of human C8, as well as within the C9b domain (amino acid residues 245-538) of human C9, during assembly of the C5b-9 complex on the target membrane (Ninomiya, H., and Sims, P. J. (1992) J. Biol. Chem. 267, 13675-13680). The CD59 binding site in C9 was first investigated by N-terminal sequencing of CD59-binding peptides generated by limited digest of the isolated C9b domain. These experiments revealed a 17-kDa fragment (starting at C9 residue Thr-320) that retained affinity for CD59, suggesting the possibility for localizing the CD59 binding site by mapping with small C9-derived peptides. Peptides spanning the entire C9b sequence were expressed in Escherichia coli and then probed with CD59. CD59 bound specifically to all peptides starting N-terminal to C9 residue 359 with C termini extending beyond residue 411. Little to no CD59 binding was observed for various CS derived peptides that started C-terminal to residue 359 or that were truncated N-terminal to residue 411. Affinity-purified antibody against C9 residues 320-411 inhibited CD59 binding to C9 by >50% and completely inhibited its binding to the isolated C9b domain. Little to no specific binding of CD59 was detected for peptides restricted to the putative hinge domain within C9b (residues 245-271). These results indicate that a CD59 binding site is located between residues 320 and 411 of the C9 polypeptide and suggest that the affinity of this site is principally determined by residues 359-411.	BLOOD CTR SE WISCONSIN INC,BLOOD RES INST,MILWAUKEE,WI 53233	Versiti Blood Center of Wisconsin					NHLBI NIH HHS [HL36061] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL036061, R01HL036061] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BIESECKER G, 1982, J BIOL CHEM, V257, P2584; BIESECKER G, 1993, MOL IMMUNOL, V30, P1369, DOI 10.1016/0161-5890(93)90098-V; DANKERT JR, 1985, P NATL ACAD SCI USA, V82, P2128, DOI 10.1073/pnas.82.7.2128; DAVIES A, 1993, IMMUNOL RES, V12, P258, DOI 10.1007/BF02918257; DISCIPIO RG, 1993, MOL IMMUNOL, V30, P1097, DOI 10.1016/0161-5890(93)90156-6; DUPUIS M, 1993, MOL IMMUNOL, V30, P95, DOI 10.1016/0161-5890(93)90430-J; HNATOWICH DJ, 1987, J NUCL MED, V28, P1294; LEHTO T, 1993, J IMMUNOL, V151, P4941; MERI S, 1990, IMMUNOLOGY, V71, P1; NINOMIYA H, 1992, J BIOL CHEM, V267, P13675; Okada N, 1989, Int Immunol, V1, P205, DOI 10.1093/intimm/1.2.205; PEITSCH M C, 1991, Current Opinion in Cell Biology, V3, P710, DOI 10.1016/0955-0674(91)90045-Z; ROLLINS SA, 1990, J IMMUNOL, V144, P3478; ROLLINS SA, 1991, J IMMUNOL, V146, P2345; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIVER JW, 1986, J BIOL CHEM, V261, P9629; SIMS PJ, 1989, J BIOL CHEM, V264, P19228; STANLEY KK, 1987, EMBO J, V6, P1951, DOI 10.1002/j.1460-2075.1987.tb02457.x; TAKIZAWA H, 1992, EUR J IMMUNOL, V22, P1943, DOI 10.1002/eji.1830220741; TOMLINSON S, 1994, J IMMUNOL, P1927; WHITE RV, 1994, J IMMUNOL, V152, P2501; WIEDMER T, 1985, J MEMBRANE BIOL, V84, P249, DOI 10.1007/BF01871388; WIEDMER T, 1985, J BIOL CHEM, V260, P8014; ZHAO J, 1991, J BIOL CHEM, V266, P13418	24	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26424	26430						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7523406				2022-12-27	WOS:A1994PQ93000074
J	NINOMIYA, N; HAZEKI, K; FUKUI, Y; SEYA, T; OKADA, T; HAZEKI, O; UI, M				NINOMIYA, N; HAZEKI, K; FUKUI, Y; SEYA, T; OKADA, T; HAZEKI, O; UI, M			INVOLVEMENT OF PHOSPHATIDYLINOSITOL 3-KINASE IN FC-GAMMA RECEPTOR SIGNALING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; MYELOID DERIVED CELLS; NATURAL-KILLER-CELLS; CROSS-LINKING; PHOSPHOINOSITIDE 3-KINASE; HEMATOPOIETIC-CELLS; HUMAN PLATELETS; RBL-2H3 CELLS; HIGH-AFFINITY; PHOSPHORYLATION	Wortmannin, a potent and selective inhibitor of phosphatidylinositol (PI) 3-kinase (Okada, T., Sakuma, L., Fukui, Y., Hazeki, 0., and Ui, M. (1994) J. Biol. Chem. 269, 3563-3567), prevented Fc receptor for IgG (Fc gamma R)-dependent phagocytosis of the human monocytic cell line U937 or guinea pig neutrophils. Cross-linking of Fc gamma R on the surface of U937 cells increased PI 3-kinase activity that was immunoprecipitated with antibody against phosphotyrosine or antibody against the 85-kDa regulatory subunit of PI 3-kinase. Specific cross-linking of Fc gamma R subclass Fc gamma RI or Fc gamma RII, using monoclonal antibodies against each receptor subclass and the F(ab')(2) fragment of goat antibody against mouse IgG, increased anti-phosphotyrosine-precipitable PI 3-kinase activity. Treatment of cells with anti-Fc gamma RIII antibody plus the same F(ab')(2) did not affect the activity, reflecting the lack of Fc gamma RIII in U937 cells. Fc gamma R stimulation triggered prominent tyrosine phosphorylation of several proteins, among which the 115-kDa peptide showed strong association with PI 3-kinase. Thus, Fc gamma R appears to be coupled functionally, via a tyrosine kinase, to PI 3-kinase, which may regulate the phagocytotic activity of the cells.	INST PHYS & CHEM RES,UI LAB,WAKO,SAITAMA 35101,JAPAN; UNIV TOKYO,FAC AGR,DEPT AGR CHEM,TOKYO 113,JAPAN; CTR ADULT DIS,DEPT IMMUNOL,HIGASHINARI KU,OSAKA 537,JAPAN; UNIV TOKYO,FAC PHARMACEUT SCI,DEPT PHYSIOL CHEM,BUNKYO KU,TOKYO 113,JAPAN	RIKEN; University of Tokyo; University of Tokyo			Fukui, Yasuhisa/E-8806-2010; Seya, Tsukasa/A-4336-2012					AGARWAL A, 1993, J BIOL CHEM, V268, P15900; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BACKER JM, 1992, J BIOL CHEM, V267, P1367; BENHAMOU M, 1992, J BIOL CHEM, V267, P7310; BJORGE JD, 1990, P NATL ACAD SCI USA, V87, P3816, DOI 10.1073/pnas.87.10.3816; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CONE JC, 1993, EUR J IMMUNOL, V23, P2488; COREY S, 1993, EMBO J, V12, P2681, DOI 10.1002/j.1460-2075.1993.tb05929.x; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; FLEIT HB, 1982, P NATL ACAD SCI-BIOL, V79, P3275, DOI 10.1073/pnas.79.10.3275; GHAZIZADEH S, 1994, J IMMUNOL, V152, P30; GOLD MR, 1994, J IMMUNOL, V152, P42; GREENBERG S, 1993, J EXP MED, V177, P529, DOI 10.1084/jem.177.2.529; GUTKIND JS, 1990, MOL CELL BIOL, V10, P3806, DOI 10.1128/MCB.10.7.3806; HAMADA F, 1993, P NATL ACAD SCI USA, V90, P6305, DOI 10.1073/pnas.90.13.6305; HUANG MM, 1992, J BIOL CHEM, V267, P5467; KELLY KL, 1993, J BIOL CHEM, V268, P4391; KIENER PA, 1993, J BIOL CHEM, V268, P24442; KOJIMA A, 1991, SCAND J IMMUNOL, V33, P707, DOI 10.1111/j.1365-3083.1991.tb02544.x; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; LAVAN BE, 1993, J BIOL CHEM, V268, P5921; LIAO F, 1992, P NATL ACAD SCI USA, V89, P3659, DOI 10.1073/pnas.89.8.3659; LIAO F, 1993, J IMMUNOL, V150, P2668; OKADA T, 1994, J BIOL CHEM, V269, P3563; OKADA T, 1994, J BIOL CHEM, V269, P3568; OKAJIMA F, 1984, J BIOL CHEM, V259, P3863; OSHEA JJ, 1991, P NATL ACAD SCI USA, V88, P350, DOI 10.1073/pnas.88.2.350; RANKIN BM, 1993, J IMMUNOL, V150, P605; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; REMILLARD B, 1991, J BIOL CHEM, V266, P14167; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SCHOLL PR, 1992, J IMMUNOL, V149, P1751; STEPHENS L, 1993, EMBO J, V12, P2265, DOI 10.1002/j.1460-2075.1993.tb05880.x; STEPHENS L, 1993, J BIOL CHEM, V268, P17162; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TANAKA S, 1993, JPN J CANCER RES, V84, P279, DOI 10.1111/j.1349-7006.1993.tb02868.x; TING AT, 1992, J EXP MED, V176, P1751, DOI 10.1084/jem.176.6.1751; TRAYNORKAPLAN AE, 1988, NATURE, V334, P353, DOI 10.1038/334353a0; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; UNKELESS JC, 1988, ANNU REV IMMUNOL, V6, P251, DOI 10.1146/annurev.iy.06.040188.001343; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; VENKITARAMAN AR, 1992, P NATL ACAD SCI USA, V89, P12083, DOI 10.1073/pnas.89.24.12083; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; WARD SG, 1992, EUR J IMMUNOL, V22, P45, DOI 10.1002/eji.1830220108; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118; YANO H, 1993, J BIOL CHEM, V268, P25846; ZHANG J, 1992, J BIOL CHEM, V267, P4686	51	179	180	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 9	1994	269	36					22732	22737						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ163	7521331				2022-12-27	WOS:A1994PQ16300044
J	BLUMEJENSEN, P; RONNSTRAND, L; GOUT, I; WATERFIELD, MD; HELDIN, CH				BLUMEJENSEN, P; RONNSTRAND, L; GOUT, I; WATERFIELD, MD; HELDIN, CH			MODULATION OF KIT STEM-CELL FACTOR RECEPTOR-INDUCED SIGNALING BY PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BETA-RECEPTOR; COLONY-STIMULATING FACTOR; GROWTH-FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE KINASE; KIT RECEPTOR; MITOGENIC SIGNAL; SH2 DOMAIN; PHOSPHOINOSITIDE 3-KINASE; AUTOPHOSPHORYLATION SITES	The Kit/stem cell factor receptor (Kit/SCF-R) is a transmembrane tyrosine kinase receptor of importance for the normal development of hemopoietic cells, melanoblasts, and germ cells. We recently reported that protein kinase C (PRC) is involved in a negative feedback loop regulating the Kit/SCF-R by direct phosphorylation on serine residues in the receptor. Inhibition of Pf(C led to increased SCF-induced tyrosine kinase activity and mitogenicity, but PKC was necessary for SCF-induced motility. In this report we have further examined the modulatory role of PKC on SCF-induced signaling. The ligand-activated Kit/SCF-R associated weakly with GRB2 and induced only little tyrosine phosphorylation of phospholipase C-gamma in porcine aortic endothelial cells transfected with Kit/SCF-R. In contrast, the SCF-stimulated Kit/SCF-R associated efficiently with, and induced tyrosine phosphorylation of, the p85 alpha regulatory subunit of phosphatidyl inositide-3'-kinase (PI-3'-kinase). Both receptor association and tyrosine phosphorylation of p85 alpha were increased after inhibition of PKC, while its serine phosphorylation was decreased. Concomitantly, the specific activity of receptor-associated PI-3'-kinase activity was increased, Inhibition of PI-3'-kinase with wortmannin inhibited SCF-induced mitogenicity. SCF-induced phosphorylation of Raf-1 and activation of ERK2 still occurred after PKC inhibition but was not increased. In conclusion, SCF-induced PI-3'-kinase activation paralleled the increased SCF-induced mitogenicity after inhibition of PKC.	LUDWIG INST CANC RES,LONDON W1P 8BT,ENGLAND	Ludwig Institute for Cancer Research	BLUMEJENSEN, P (corresponding author), LUDWIG INST CANC RES,CTR BIOMED,UPPSALA BRANCH,BOX 595,S-75124 UPPSALA,SWEDEN.		Ronnstrand, Lars/A-2429-2011	Ronnstrand, Lars/0000-0003-1275-5809				ALAI M, 1992, J BIOL CHEM, V267, P18021; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; ARTEAGA CL, 1991, P NATL ACAD SCI USA, V88, P10435, DOI 10.1073/pnas.88.23.10435; AZZI A, 1992, EUR J BIOCHEM, V208, P547, DOI 10.1111/j.1432-1033.1992.tb17219.x; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; Besmer P, 1991, CURR OPIN CELL BIOL, V3, P939, DOI 10.1016/0955-0674(91)90111-B; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BLUMEJENSEN P, 1991, EMBO J, V10, P4121, DOI 10.1002/j.1460-2075.1991.tb04989.x; BLUMEJENSEN P, 1993, EMBO J, V12, P4199, DOI 10.1002/j.1460-2075.1993.tb06104.x; CAI H, 1992, MOL CELL BIOL, V12, P5329, DOI 10.1128/MCB.12.12.5329; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1993, MOL CELL BIOL, V13, P1657, DOI 10.1128/MCB.13.3.1657; CLAESSONWELSH L, 1989, J BIOL CHEM, V264, P1742; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; DOWNES CP, 1991, CELL SIGNAL, V3, P501, DOI 10.1016/0898-6568(91)90027-R; FLEISCHMAN RA, 1993, TRENDS GENET, V9, P285, DOI 10.1016/0168-9525(93)90015-A; HERBST R, 1991, J BIOL CHEM, V266, P19908; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HOLT KH, 1994, MOL CELL BIOL, V14, P42, DOI 10.1128/MCB.14.1.42; HU P, 1993, MOL CELL BIOL, V13, P7677, DOI 10.1128/MCB.13.12.7677; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KAPELLER R, 1993, MOL CELL BIOL, V13, P6052, DOI 10.1128/MCB.13.10.6052; KAVANAUGH WM, 1992, MOL CELL BIOL, V12, P3415, DOI 10.1128/MCB.12.8.3415; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KOIKE T, 1993, J IMMUNOL, V151, P359; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LEV S, 1991, EMBO J, V10, P647, DOI 10.1002/j.1460-2075.1991.tb07993.x; LEV S, 1992, P NATL ACAD SCI USA, V89, P678, DOI 10.1073/pnas.89.2.678; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MIYAZAWA K, 1991, EXP HEMATOL, V19, P1110; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PANAYOTOU G, 1993, MOL CELL BIOL, V13, P3567, DOI 10.1128/MCB.13.6.3567; PANAYOTOU G, 1992, EMBO J, V11, P4261, DOI 10.1002/j.1460-2075.1992.tb05524.x; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; RONNSTRAND L, 1987, J BIOL CHEM, V262, P2929; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; ROSALES OR, 1992, BIOCHEM BIOPH RES CO, V189, P40, DOI 10.1016/0006-291X(92)91522-R; SATOH T, 1993, MOL CELL BIOL, V13, P3706, DOI 10.1128/MCB.13.6.3706; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SCHULTZ AM, 1985, VIROLOGY, V146, P78, DOI 10.1016/0042-6822(85)90054-6; SHEARMAN MS, 1993, EMBO J, V12, P3817, DOI 10.1002/j.1460-2075.1993.tb06060.x; SHOELSON SE, 1993, EMBO J, V12, P795, DOI 10.1002/j.1460-2075.1993.tb05714.x; SJOLANDER A, 1991, P NATL ACAD SCI USA, V88, P7908, DOI 10.1073/pnas.88.18.7908; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOZERI O, 1992, ONCOGENE, V7, P2259; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WENNSTROM S, 1992, J BIOL CHEM, V267, P13749; WENNSTROM S, 1994, ONCOGENE, V9, P651; WITTE ON, 1990, CELL, V63, P5, DOI 10.1016/0092-8674(90)90280-R; XU XX, 1993, MOL CELL BIOL, V13, P1522, DOI 10.1128/MCB.13.3.1522; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; YONEZAWA K, 1992, J BIOL CHEM, V267, P25958	66	81	84	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 26	1994	269	34					21793	21802						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PK973	7520444				2022-12-27	WOS:A1994PK97300062
J	WESTON, SA; HULMES, DJS; MOULD, AP; WATSON, RB; HUMPHRIES, MJ				WESTON, SA; HULMES, DJS; MOULD, AP; WATSON, RB; HUMPHRIES, MJ			IDENTIFICATION OF INTEGRIN ALPHA-2-BETA-1 AS CELL-SURFACE RECEPTOR FOR THE CARBOXYL-TERMINAL PROPEPTIDE OF TYPE PROCOLLAGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBRONECTIN RECEPTOR; LAMININ RECEPTOR; I PROCOLLAGEN; C-PROPEPTIDE; COLLAGEN; ADHESION; CHONDROCALCIN; PURIFICATION; BINDING; PROTEIN	The carboxyl-terminal propeptide of procollagen type I (CPP-I) plays a key role in the regulation of collagen fibrillogenesis. In addition, it has been reported that, after cleavage from procollagen, CPP-I exerts feedback control of collagen biosynthesis. To further elucidate the mechanisms involved in each of these processes, we have investigated the nature of cell surface receptors for CPP-I. CPP-I affinity chromatography, using detergent extracts of iodinated HT1080 cells and EDTA elution, resulted in the isolation of two polypeptides of molecular mass 160 and 110 kDa. Since the migratory behavior of these polypeptides under nonreducing and reducing conditions was characteristic of a subset of integrin receptors, their reactivity with anti-integrin monoclonal antibodies was tested. Antibodies directed against the alpha 2 and beta 1 subunits specifically immunoprecipitated both CPP-I-binding polypeptides, indicating that the CPP-I receptor is the integrin alpha 2 beta 1. CPP-I was found to support the attachment and spreading of HT1080 cells, demonstrating that it can function as an adhesion protein. Two other approaches supported the identification of alpha 2 beta 1 as the CPP-I receptor. First, antifunctional anti-integrin monoclonal antibodies directed against the alpha 2 and beta 1 subunits completely abrogated the adhesive activity of CPP-I and, second, highly purified CPP-I bound specifically to alpha 2 beta 1-containing integrin preparations in a solid-phase receptor-ligand binding assay. These findings have important implications for the function of fibrillar collagen carboxyl-terminal propeptides and for the role played by integrins in the regulation of cellular phenotype.	UNIV EDINBURGH,DEPT BIOCHEM,EDINBURGH EH8 9XD,SCOTLAND	University of Edinburgh	WESTON, SA (corresponding author), UNIV MANCHESTER,SCH BIOL SCI,2205 STOPFORD BLDG,MANCHESTER M13 9PT,ENGLAND.			Hulmes, David/0000-0002-0651-1317; Humphries, Martin/0000-0002-4331-6967	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; AYCOCK RS, 1986, J BIOL CHEM, V261, P14355; BARD JBL, 1993, J CELL SCI, V105, P1045; CHARO IF, 1990, J CELL BIOL, V111, P2795, DOI 10.1083/jcb.111.6.2795; CHEN FA, 1991, J EXP MED, V173, P1111, DOI 10.1084/jem.173.5.1111; CHOGLAY AA, 1993, J BIOL CHEM, V268, P6107; ELICES MJ, 1989, P NATL ACAD SCI USA, V86, P9906, DOI 10.1073/pnas.86.24.9906; ENGEL J, 1991, ANNU REV BIOPHYS BIO, V20, P137, DOI 10.1146/annurev.biophys.20.1.137; FESSLER LI, 1981, J BIOL CHEM, V256, P9640; FLEISCHMAJER R, 1983, P NATL ACAD SCI-BIOL, V80, P3354, DOI 10.1073/pnas.80.11.3354; FLEISCHMAJER R, 1981, P NATL ACAD SCI-BIOL, V78, P7360, DOI 10.1073/pnas.78.12.7360; GERGE BR, 1992, J BONE MINER RES, V7, P807; HOJIMA Y, 1985, J BIOL CHEM, V260, P5996; HORLEIN D, 1981, P NATL ACAD SCI-BIOL, V78, P6163, DOI 10.1073/pnas.78.10.6163; HUMPHRIES MJ, 1986, J CELL BIOL, V103, P2637, DOI 10.1083/jcb.103.6.2637; KADLER KE, 1987, J BIOL CHEM, V262, P15696; KATAYAMA K, 1991, BIOCHEMISTRY-US, V30, P7097, DOI 10.1021/bi00243a009; Kielty Cay M., 1993, P103; KIRSCH T, 1992, FEBS LETT, V310, P143, DOI 10.1016/0014-5793(92)81316-E; KUNICKI TJ, 1988, J BIOL CHEM, V263, P4516; LANGUINO LR, 1989, J CELL BIOL, V109, P2455, DOI 10.1083/jcb.109.5.2455; LEBIEN TW, 1982, J IMMUNOL, V129, P2287; LEUNG MKK, 1979, J BIOL CHEM, V254, P224; MAKAREM R, 1994, J BIOL CHEM, V269, P4005; MORRIS NP, 1979, J BIOL CHEM, V254, P1024; MOULD AP, 1990, J MOL BIOL, V211, P581, DOI 10.1016/0022-2836(90)90267-P; OLSEN BR, 1977, BIOCHEMISTRY-US, V16, P3030, DOI 10.1021/bi00632a034; Olsen BR, 1991, CELL BIOL EXTRACELLU, P177; PAGLIA L, 1979, BIOCHEMISTRY-US, V18, P5030, DOI 10.1021/bi00589a034; POOLE AR, 1984, J CELL BIOL, V98, P54, DOI 10.1083/jcb.98.1.54; ROBERTS CJ, 1988, J BIOL CHEM, V263, P4586; SANTORO SA, 1986, CELL, V46, P913, DOI 10.1016/0092-8674(86)90073-5; SANTORO SA, 1988, BIOCHEM BIOPH RES CO, V153, P217, DOI 10.1016/S0006-291X(88)81211-7; TAKADA Y, 1988, J CELL BIOCHEM, V37, P385, DOI 10.1002/jcb.240370406; TENCHINI ML, 1993, CELL ADHES COMMUN, V1, P55, DOI 10.3109/15419069309095681; TUDERMAN L, 1978, BIOCHEMISTRY-US, V17, P2948, DOI 10.1021/bi00608a002; UITTO J, 1977, ARCH BIOCHEM BIOPHYS, V179, P654, DOI 10.1016/0003-9861(77)90154-0; VANDERREST M, 1986, BIOCHEM J, V237, P923, DOI 10.1042/bj2370923; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873; WIESTNER M, 1979, J BIOL CHEM, V254, P7016; WU CH, 1986, J BIOL CHEM, V261, P482; WU CH, 1991, J BIOL CHEM, V266, P2983	42	38	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					20982	20986						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	7520435				2022-12-27	WOS:A1994PC40300028
J	ENGHILD, JJ; VALNICKOVA, Z; THOGERSEN, IB; PIZZO, SV				ENGHILD, JJ; VALNICKOVA, Z; THOGERSEN, IB; PIZZO, SV			COMPLEXES BETWEEN SERPINS AND INACTIVE PROTEINASES ARE NOT THERMODYNAMICALLY STABLE BUT ARE RECOGNIZED BY SERPIN RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE PROTEASE INHIBITOR; REACTIVE-BOND LOOP; ALPHA-1-PROTEINASE INHIBITOR; ANTITHROMBIN-III; PLASMA ELIMINATION; BETA-SHEET; SITE LOOP; ALPHA-1-ANTITRYPSIN; ALPHA-2-ANTIPLASMIN; SUBSTRATE	The serpin mechanism of action may resemble the ''standard mechanism'' described for small protein inhibitors of serine proteinases. Since these inhibitors are able to bind active site-modified target proteinases, we have investigated the interactions between two serpins and their 3,4 -dichloroisocoumarin (DCI)-inactivated target proteinases. alpha(2)-Antiplasmin and alpha(1)-proteinase inhibitor bound stoichiometrically to DCI-inactivated chymotrypsin (EC 3.4.21.1) and DCI-inactivated human neutrophil elastase, respectively. Similar to active proteinases, the DCI-inactivated proteinases failed to bind complexes between serpins and synthetic reactive site loop peptides. Thus, the abilities of active and inactive proteinases to bind the serpins probably depend on the same structural characteristics. The thermodynamic stability of the alpha(2)-antiplasmin-DCI/chymotrypsin and alpha(1)-proteinase inhibitor-DCI/human neutrophil elastase complexes was similar to that of virgin serpins. However, in mouse plasma elimination studies the two complexes were removed rapidly from the circulation, suggesting that they have adopted the receptor recognized conformation. Consequently, cleavage of the reactive center peptide bond and formation of an inhibitor-acyl enzyme complex is neither obligatory to serpin-proteinase complex formation nor essential for the conformational change responsible for receptor mediated endocytosis.			ENGHILD, JJ (corresponding author), DUKE UNIV,MED CTR,DEPT PATHOL,POB 3712,DURHAM,NC 27710, USA.			Enghild, Jan Johannes/0000-0001-9292-9172	NHLBI NIH HHS [HL24066, HL31932, HL49542] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024066, R37HL024066, R01HL031932, R01HL049542] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agostini A.D., 1988, J CLIN INVEST, V82, P700; AKO H, 1974, BIOCHEMISTRY-US, V13, P132, DOI 10.1021/bi00698a021; BJORK I, 1992, J BIOL CHEM, V267, P1976; BJORK I, 1993, BIOCHEMISTRY-US, V32, P6501; BOCK SC, 1990, PROTEIN ENG, V4, P107, DOI 10.1093/protein/4.2.107; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; Bode W, 1991, CURR OPIN STRUC BIOL, V1, P45, DOI 10.1016/0959-440X(91)90010-Q; BURY A, 1981, J CHROMATOGR, V213, P490; CARRELL R, 1985, TRENDS BIOCHEM SCI, V10, P20, DOI 10.1016/0968-0004(85)90011-8; CARRELL RW, 1991, NATURE, V353, P576, DOI 10.1038/353576a0; CHASE T, 1967, BIOCHEM BIOPH RES CO, V29, P508, DOI 10.1016/0006-291X(67)90513-X; COHEN AB, 1978, BIOCHEMISTRY-US, V17, P392, DOI 10.1021/bi00596a002; DRECHSEL D, 1984, ANAL BIOCHEM, V143, P141, DOI 10.1016/0003-2697(84)90568-2; ENGHILD JJ, 1993, BIOCHEM J, V291, P933, DOI 10.1042/bj2910933; Goldenberg D.P, 1989, PROTEIN STRUCTURE PR, P225; GONIAS SL, 1982, THROMB HAEMOSTASIS, V48, P208; HARIS PI, 1990, BIOCHEMISTRY-US, V29, P1377, DOI 10.1021/bi00458a005; HARPER JW, 1985, BIOCHEMISTRY-US, V24, P1831, DOI 10.1021/bi00329a005; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; HUBER R, 1975, BIOPHYS STRUCT MECH, V3, P189; IMBER MJ, 1981, J BIOL CHEM, V256, P8134; LASKOWSKI M, 1987, COLD SPRING HARB SYM, V52, P545, DOI 10.1101/SQB.1987.052.01.062; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; LAWRENCE DA, 1990, J BIOL CHEM, V265, P20293; LOBERMANN H, 1984, J MOL BIOL, V177, P531; MAST AE, 1992, BIOCHEMISTRY-US, V31, P2720, DOI 10.1021/bi00125a012; MAST AE, 1991, BIOCHEMISTRY-US, V30, P1723, DOI 10.1021/bi00220a039; MATHESON NR, 1991, J BIOL CHEM, V266, P13489; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MOROI M, 1977, BIOCHIM BIOPHYS ACTA, V482, P412, DOI 10.1016/0005-2744(77)90255-8; PANNELL R, 1974, BIOCHEMISTRY-US, V13, P5439, DOI 10.1021/bi00723a031; PATSTON PA, 1991, BIOCHEMISTRY-US, V30, P8876, DOI 10.1021/bi00100a022; PERLMUTTER DH, 1990, P NATL ACAD SCI USA, V87, P3753, DOI 10.1073/pnas.87.10.3753; PIZZO SV, 1988, BIOCHIM BIOPHYS ACTA, V967, P158, DOI 10.1016/0304-4165(88)90005-0; READ RJ, 1986, PROTEINASE INHIBITOR, P301; RICHARZ R, 1980, BIOCHEMISTRY-US, V19, P5711, DOI 10.1021/bi00566a007; Salvesen G, 1989, PROTEOLYTIC ENZYMES, P83; SCHREUDER HA, 1994, STRUCT BIOL, V1, P48; SCHULZE AJ, 1990, EUR J BIOCHEM, V194, P51, DOI 10.1111/j.1432-1033.1990.tb19425.x; SCHULZE AJ, 1992, BIOCHEMISTRY-US, V31, P7560, DOI 10.1021/bi00148a017; SHIEH BH, 1989, J BIOL CHEM, V264, P13420; SKRIVER K, 1991, J BIOL CHEM, V266, P9216; STEIN PE, 1989, BIOCHEM J, V262, P102; TOMONO T, 1986, ACTA HAEMATOL JAPON, V49, P969; VINCENT JP, 1974, BIOCHEMISTRY-US, V13, P4205, DOI 10.1021/bi00717a023; WIMAN B, 1980, BIOCHEM J, V191, P229, DOI 10.1042/bj1910229	46	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					20159	20166						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	7519603				2022-12-27	WOS:A1994PA12600074
J	PARSONS, JN; WIEDERRECHT, GJ; SALOWE, S; BURBAUM, JJ; ROKOSZ, LL; KINCAID, RL; OKEEFE, SJ				PARSONS, JN; WIEDERRECHT, GJ; SALOWE, S; BURBAUM, JJ; ROKOSZ, LL; KINCAID, RL; OKEEFE, SJ			REGULATION OF CALCINEURIN PHOSPHATASE-ACTIVITY AND INTERACTION WITH THE FK-506-CENTER-DOT-FK-506 BINDING-PROTEIN COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLOSPORINE-A; CALMODULIN-BINDING; ACTIVATION; SUBUNIT; INHIBITION; ISOFORMS; FK-506; DOMAIN; IDENTIFICATION; EXPRESSION	The immunosuppressant FK-506 (tacrolimus) forms a complex with a ubiquitous intracellular receptor, FK-506 binding protein (FKBP12), and this complex inhibits the heterodimeric Ca2+/calmodulin dependent phosphatase, calcineurin, an essential component of the T-cell receptor signal transduction pathway. Using a series of truncated calcineurin catalytic subunits, we show here that a region within the catalytic subunit that regulates phosphatase activity, the autoinhibitory domain, also regulates the Ca2+-dependent interaction of calcineurin with the FK-506 FKBP12 complex. Deletion of this domain produces constitutive activation of the phosphatase as demonstrated by transient transfection experiments in which expression of the truncated protein permitted Ca2+-independent induction of interleukin-2 transcription. Thus, deletion of the autoinhibitory domain is necessary and sufficient to constitutively activate calcineurin (CaN). Furthermore, CaN A467-492, an inhibitory peptide based on the autoinhibitory domain from calcineurin (ITSFEEAKGLDRINERMPPRRDAMP), inhibited dephosphorylation of the RII peptide substrate competitively with a K-i = 4 mu M, consistent with binding of the autoinhibitory domain at the active site of the enzyme. To assess the role of the autoinhibitory domain in regulating the interaction of CaN with the FK-506 FKBP12 complex, we reconstituted wild type and mutant phosphatase heterodimers using in vitro transcribed and translated subunits. Association of the reconstituted calcineurin heterodimers with FKBP12 was dependent on FK-506. In the case of the wild type heterodimer, association with the FK-506 FKBP12 complex was also dependent upon Ca2+; however, mutant catalytic subunits, in which the autoinhibitory domains were deleted, associated with the drug-binding protein complex in the presence of 10 mM EGTA. These results indicate that the conserved autoinhibitory domain regulates both Ca2+-dependent phosphatase activity and association with the FK-506 FKBP12 complex.	MERCK SHARP & DOHME LTD,RES LABS,DEPT MOLEC IMMUNOL,RAHWAY,NJ 07065; MERCK SHARP & DOHME LTD,RES LABS,DEPT CELLULAR IMMUNOL,RAHWAY,NJ 07065; MERCK SHARP & DOHME LTD,RES LABS,DEPT BIOPHYS CHEM,RAHWAY,NJ 07065; HUMAN GENOME SCI,DEPT CELL BIOL,ROCKVILLE,MD 20850	Merck & Company; Merck & Company; Merck & Company; GlaxoSmithKline; Human Genome Sciences Inc								APERIA A, 1992, P NATL ACAD SCI USA, V89, P7394, DOI 10.1073/pnas.89.16.7394; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; DENICOLA L, 1993, J CLIN INVEST, V92, P1859, DOI 10.1172/JCI116777; DUMONT FJ, 1992, J EXP MED, V176, P751, DOI 10.1084/jem.176.3.751; FOOR F, 1992, NATURE, V360, P682; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HADDY A, 1992, FEBS LETT, V314, P37, DOI 10.1016/0014-5793(92)81456-V; HASHIMOTO Y, 1990, J BIOL CHEM, V265, P1924; HOLLON T, 1989, ANAL BIOCHEM, V182, P411, DOI 10.1016/0003-2697(89)90616-7; HUBBARD MJ, 1987, J BIOL CHEM, V262, P15062; HUBBARD MJ, 1989, BIOCHEMISTRY-US, V28, P1868, DOI 10.1021/bi00430a066; KEMP BE, 1991, BIOCHIM BIOPHYS ACTA, V1094, P67, DOI 10.1016/0167-4889(91)90027-U; KINCAID R, 1993, ADV SEC MESS PHOSPH, V27, P1; KINCAID RL, 1990, J BIOL CHEM, V265, P11312; KINCAID RL, 1988, P NATL ACAD SCI USA, V85, P8983, DOI 10.1073/pnas.85.23.8983; LI W, 1993, J BIOL CHEM, V268, P14040; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; LYSON T, 1993, CIRC RES, V73, P596, DOI 10.1161/01.RES.73.3.596; MERAT DL, 1985, J BIOL CHEM, V260, P1053; MUKAI H, 1993, J BIOCHEM, V113, P292, DOI 10.1093/oxfordjournals.jbchem.a124041; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; PERRINO BA, 1992, J BIOL CHEM, V267, P15965; RYFFEL B, 1993, BIOCHEM BIOPH RES CO, V194, P1074, DOI 10.1006/bbrc.1993.1931; SHAPIRO R, 1990, TRANSPLANT P, V22, P35; SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511; TALLANT EA, 1984, BIOCHEMISTRY-US, V23, P973, DOI 10.1021/bi00300a027; UEKI K, 1992, BIOCHEM BIOPH RES CO, V187, P537, DOI 10.1016/S0006-291X(05)81527-X; UEKI K, 1993, J BIOL CHEM, V268, P6554; WEIDERRECHT G, 1992, J BIOL CHEM, V267, P21753; YOKOYAMA N, 1994, FEBS LETT, V337, P128, DOI 10.1016/0014-5793(94)80258-0	32	54	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19610	19616						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	7518461				2022-12-27	WOS:A1994NY33200064
J	KAYANOKI, Y; FUJII, J; SUZUKI, K; KAWATA, S; MATSUZAWA, Y; TANIGUCHI, N				KAYANOKI, Y; FUJII, J; SUZUKI, K; KAWATA, S; MATSUZAWA, Y; TANIGUCHI, N			SUPPRESSION OF ANTIOXIDATIVE ENZYME EXPRESSION BY TRANSFORMING GROWTH-FACTOR-BETA-1 IN RAT HEPATOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANGANESE SUPEROXIDE-DISMUTASE; TUMOR NECROSIS FACTOR; BETA MESSENGER-RNA; SERUM-FREE MEDIUM; REACTIVE OXYGEN; DNA-SYNTHESIS; FACTOR-ALPHA; CELL-LINES; LIVER; INDUCTION	We have investigated the effect of transforming growth factor-beta 1 (TGF-beta 1) and three cytokines on expression of antioxidative enzymes, manganese-superoxide dismutase, copper, zinc-superoxide dismutase, and catalase in cultured hepatocytes of rat, While interleukin-1 beta and interleukin-6 induced manganese-superoxide dismutase gene expression, they slightly suppressed catalase gene expression in rat hepatocytes. TGF-beta 1 suppressed expression of all these antioxidative enzymes in time- and cell density-dependent manners. Furthermore, we examined the effect of TGF-beta 1 on expression of glutathione peroxidase and glutathione-S-transferase, which exhibit glutathione-dependent peroxidase activity in rat hepatocytes. Expression of two major classes of the rat glutathione-S-transferase subunits 1 and 2 was also reduced by TGF-beta 1, although expression of glutathione peroxidase was not affected. Flow cytometric analysis indicated that production of peroxides was increased in hepatocytes treated with TGF-beta 1. These data suggest that augmented production of hydrogen peroxide and its intermediate through suppression of antioxidative enzyme expression may participate in cellular injury or growth inhibition promoted by TGF-beta 1.	OSAKA UNIV, SCH MED, DEPT BIOCHEM, SUITA, OSAKA 565, JAPAN; OSAKA UNIV, SCH MED, DEPT INTERNAL MED 2, SUITA, OSAKA 565, JAPAN	Osaka University; Osaka University			Taniguchi, Naoyuki/I-4182-2014; Taniguchi, Naoyuki/A-7086-2016	Taniguchi, Naoyuki/0000-0001-5889-5968; 				BASS DA, 1983, J IMMUNOL, V130, P1910; BRAUN L, 1988, P NATL ACAD SCI USA, V85, P1539, DOI 10.1073/pnas.85.5.1539; BRAUN L, 1990, CELL GROWTH DIFFER, V1, P103; CARR BI, 1986, CANCER RES, V46, P2330; CASTILLA A, 1991, NEW ENGL J MED, V324, P933, DOI 10.1056/NEJM199104043241401; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTENSEN MJ, 1992, J NUTR, V122, P1620, DOI 10.1093/jn/122.8.1620; DELABAR JM, 1987, EUR J BIOCHEM, V166, P181, DOI 10.1111/j.1432-1033.1987.tb13500.x; DOUGALL WC, 1991, ENDOCRINOLOGY, V129, P2376, DOI 10.1210/endo-129-5-2376; EMERIT I, 1981, NATURE, V293, P144, DOI 10.1038/293144a0; FRATERSCHRODER M, 1986, BIOCHEM BIOPH RES CO, V137, P295, DOI 10.1016/0006-291X(86)91209-X; FURUTA S, 1986, P NATL ACAD SCI USA, V83, P313, DOI 10.1073/pnas.83.2.313; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HEINE UI, 1987, J CELL BIOL, V105, P2861, DOI 10.1083/jcb.105.6.2861; HO YS, 1987, NUCLEIC ACIDS RES, V15, P10070, DOI 10.1093/nar/15.23.10070; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; ISHIKAWA M, 1990, CANCER RES, V50, P2538; ITO N, 1991, CANCER RES, V51, P4080; KAWAGUCHI T, 1990, BIOCHEM BIOPH RES CO, V171, P1378, DOI 10.1016/0006-291X(90)90838-E; KAWAMURA N, 1992, FREE RADICAL BIO MED, V12, P281, DOI 10.1016/0891-5849(92)90115-W; KEHRL JH, 1986, J EXP MED, V163, P1037, DOI 10.1084/jem.163.5.1037; KILBERG MS, 1989, METHOD ENZYMOL, V173, P564; KINSELLA AR, 1978, P NATL ACAD SCI USA, V75, P6149, DOI 10.1073/pnas.75.12.6149; LENNON SV, 1991, CELL PROLIFERAT, V24, P203, DOI 10.1111/j.1365-2184.1991.tb01150.x; MALIK S, 1991, BRIT J CANCER, V64, P612; Maniatis T., 1982, MOL CLONING; MASUDA A, 1988, FASEB J, V2, P3087, DOI 10.1096/fasebj.2.15.3263930; MASUI T, 1986, P NATL ACAD SCI USA, V83, P2438, DOI 10.1073/pnas.83.8.2438; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MEYER DJ, 1985, FEBS LETT, V184, P139, DOI 10.1016/0014-5793(85)80670-0; NAKAMURA Y, 1985, CARCINOGENESIS, V6, P229, DOI 10.1093/carcin/6.2.229; NAKATA T, 1992, CARCINOGENESIS, V13, P1941, DOI 10.1093/carcin/13.10.1941; NAKATSUKASA H, 1990, J CLIN INVEST, V85, P1833, DOI 10.1172/JCI114643; NISHIURA T, 1992, CANCER LETT, V62, P211, DOI 10.1016/0304-3835(92)90098-G; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; OBERLEY LW, 1978, J NATL CANCER I, V61, P375; OOKAWARA T, 1992, J BIOL CHEM, V267, P18505; RAGHOW R, 1987, J CLIN INVEST, V79, P1285, DOI 10.1172/JCI112950; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; RUSSELL WE, 1988, P NATL ACAD SCI USA, V85, P5126, DOI 10.1073/pnas.85.14.5126; SANDSTROM PA, 1993, P NATL ACAD SCI USA, V90, P4708, DOI 10.1073/pnas.90.10.4708; SATO K, 1992, MOL CELL BIOL, V12, P2525, DOI 10.1128/MCB.12.6.2525; SHIBANUMA M, 1991, CELL GROWTH DIFFER, V2, P583; SHIPLEY GD, 1986, CANCER RES, V46, P2068; SIMON RH, 1981, J BIOL CHEM, V256, P7181; STCLAIR DK, 1991, CANCER RES, V51, P939; TANIGUCHI N, 1992, ADV CLIN CHEM, V29, P1, DOI 10.1016/S0065-2423(08)60221-8; TU CPD, 1984, J BIOL CHEM, V259, P9434; VISNER GA, 1990, J BIOL CHEM, V265, P2856; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703	50	164	164	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15488	15492						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	7515058				2022-12-27	WOS:A1994NP51300017
J	DONG, BH; XU, LL; ZHOU, AM; HASSEL, BA; LEE, X; TORRENCE, PF; SILVERMAN, RH				DONG, BH; XU, LL; ZHOU, AM; HASSEL, BA; LEE, X; TORRENCE, PF; SILVERMAN, RH			INTRINSIC MOLECULAR ACTIVITIES OF THE INTERFERON-INDUCED 2-5A-DEPENDENT RNASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; FREE PROTEIN-SYNTHESIS; TREATED CELLS; PPP(A2'P)NA-DEPENDENT RNASE; JLS-V9R CELLS; 2-5A; ACTIVATION; BINDING; 2',5'-OLIGOADENYLATES; ENDORIBONUCLEASE	2-5A-dependent RNase (RNase L), a unique endoribonuclease that requires 5'-phosphorylated 2',5'-linked oligoadenylates (2-5A), functions in the molecular mechanism of interferon action. Because this enzyme is present at very low levels in nature, characterization and analysis have been limited. The molecular cloning of human, 2-5A-dependent RNase cDNA has facilitated its expression to high levels in insect cells by infecting with recombinant baculovirus. To determine the properties of the enzyme in the absence of other proteins, the recombinant 2-5A-dependent RNase was purified to homogeneity. The purified enzyme migrated as a monomer upon gel filtration in the absence of activator and showed highly specific, 2-5A-dependent RNase activity. The precise activator requirements were determined by stimulating the purified enzyme with a variety of 2',5'-linked oligonucleotides. The activated enzyme was capable of cleaving poly(rU) and, to a lesser extent, poly(rA), to sets of discrete products ranging from between 4 and 22 nucleotides in length. Reduced rates of 2-5A-dependent RNA cleavage were observed even after removal of ATP and chelation of divalent cations. However, optimal RNA cleavage rates required the presence of either manganese or magnesium and ATP.	CLEVELAND CLIN FDN,RES INST,DEPT CANC BIOL,CLEVELAND,OH 44195; NIDDK,MED CHEM LAB,BIOMED CHEM SECT,BETHESDA,MD 20892	Cleveland Clinic Foundation; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)					NATIONAL CANCER INSTITUTE [R01CA044059] Funding Source: NIH RePORTER; NCI NIH HHS [5R01 CA44059] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ball L A, 1980, Ann N Y Acad Sci, V350, P486, DOI 10.1111/j.1749-6632.1980.tb20651.x; Belasco J.G., 2012, CONTROL MESSENGER RN; BISBAL C, 1989, EUR J BIOCHEM, V179, P595, DOI 10.1111/j.1432-1033.1989.tb14588.x; BROWN GE, 1976, BIOCHEM BIOPH RES CO, V69, P114, DOI 10.1016/S0006-291X(76)80280-X; CAYLEY PJ, 1982, EUR J BIOCHEM, V122, P601; CAYLEY PJ, 1982, BIOCHEM BIOPH RES CO, V108, P1243, DOI 10.1016/0006-291X(82)92133-7; CLEMENS MJ, 1978, CELL, V13, P565, DOI 10.1016/0092-8674(78)90329-X; DEUTSCHER MP, 1993, J BIOL CHEM, V268, P13011; FERBUS D, 1981, BIOCHEM BIOPH RES CO, V100, P847, DOI 10.1016/S0006-291X(81)80251-3; FLOYDSMITH G, 1981, SCIENCE, V212, P1020; HASSEL BA, 1993, EMBO J, V12, P3297, DOI 10.1002/j.1460-2075.1993.tb05999.x; HOVANESSIAN AG, 1977, NATURE, V268, P537, DOI 10.1038/268537a0; IMAI J, 1984, BIOCHEMISTRY-US, V23, P766, DOI 10.1021/bi00299a028; IMAI J, 1985, J ORG CHEM, V50, P1418, DOI 10.1021/jo00209a014; IMAI J, 1985, J BIOL CHEM, V260, P1390; Imai J, 1981, Methods Enzymol, V79, P233; JACOBSEN H, 1983, P NATL ACAD SCI-BIOL, V80, P4954, DOI 10.1073/pnas.80.16.4954; JACOBSEN H, 1983, VIROLOGY, V125, P496, DOI 10.1016/0042-6822(83)90222-2; KERR IM, 1976, EUR J BIOCHEM, V69, P551, DOI 10.1111/j.1432-1033.1976.tb10940.x; KERR IM, 1974, NATURE, V250, P57, DOI 10.1038/250057a0; KERR IM, 1978, P NATL ACAD SCI USA, V75, P256, DOI 10.1073/pnas.75.1.256; KITADE Y, 1991, BIOORG CHEM, V19, P283, DOI 10.1016/0045-2068(91)90054-S; KNIGHT M, 1980, NATURE, V288, P189, DOI 10.1038/288189a0; KOVACS T, 1993, BIOORG CHEM, V21, P192, DOI 10.1006/bioo.1993.1017; KRAUSE D, 1986, J BIOL CHEM, V261, P6836; KRAUSE D, 1985, EUR J BIOCHEM, V146, P611, DOI 10.1111/j.1432-1033.1985.tb08695.x; LENGYEL P, 1993, P NATL ACAD SCI USA, V90, P5893, DOI 10.1073/pnas.90.13.5893; LESIAK K, 1993, BIOCONJUGATE CHEM, V4, P467, DOI 10.1021/bc00024a008; LESIAK K, 1987, J BIOL CHEM, V262, P1961; LESIAK K, 1983, J BIOL CHEM, V258, P3082; NILSEN TW, 1979, P NATL ACAD SCI USA, V76, P2600, DOI 10.1073/pnas.76.6.2600; NOLANSORDEN NL, 1990, ANAL BIOCHEM, V184, P298, DOI 10.1016/0003-2697(90)90684-2; SALEHZADA T, 1993, J BIOL CHEM, V268, P7733; SILVERMAN RH, 1985, ANAL BIOCHEM, V144, P450, DOI 10.1016/0003-2697(85)90141-1; SILVERMAN RH, 1988, J BIOL CHEM, V263, P7336; SILVERMAN RH, 1987, LYMPHOKINES INTERFER, P149; SLATTERY E, 1979, P NATL ACAD SCI USA, V76, P4778, DOI 10.1073/pnas.76.10.4778; SQUIRE J, 1994, GENOMICS, V19, P174, DOI 10.1006/geno.1994.1033; TORRENCE PF, 1984, J MED CHEM, V27, P726, DOI 10.1021/jm00372a004; TORRENCE PF, 1993, P NATL ACAD SCI USA, V90, P1300, DOI 10.1073/pnas.90.4.1300; TORRENCE PF, 1992, ANTIVIR RES, V18, P275, DOI 10.1016/0166-3542(92)90061-9; TORRENCE PF, 1988, J BIOL CHEM, V263, P1131; WRESCHNER DH, 1982, EUR J BIOCHEM, V124, P261; WRESCHNER DH, 1981, NATURE, V289, P414, DOI 10.1038/289414a0; ZHOU AM, 1993, CELL, V72, P753, DOI 10.1016/0092-8674(93)90403-D	45	130	132	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14153	14158						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	7514601				2022-12-27	WOS:A1994NL60600065
J	FUJIHARA, M; ITO, N; PACE, JL; WATANABE, Y; RUSSELL, SW; SUZUKI, T				FUJIHARA, M; ITO, N; PACE, JL; WATANABE, Y; RUSSELL, SW; SUZUKI, T			ROLE OF ENDOGENOUS INTERFERON-BETA IN LIPOPOLYSACCHARIDE-TRIGGERED ACTIVATION OF THE INDUCIBLE NITRIC-OXIDE SYNTHASE GENE IN A MOUSE MACROPHAGE CELL-LINE, J774	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								The role of endogenous tumor necrosis factor alpha (TNF-alpha) and interferon-beta (IFN-beta) in lipopolysaccharide (LPS)-induced activation of the inducible nitric-oxide synthase (i-NOS) gene was investigated. By Northern analysis or reverse-transcription polymerase chain reaction, the mouse macrophage cell line (J774) was found to respond to LPS treatment by increased expression of mRNAs specific for TNF-alpha, IFN-beta, and i-NOS with the kinetics unique for each gene. Bioassay of the culture supernatants showed that TNF-alpha and IFN-beta secreted by J774 cells increased from an undetectable level to about 300 and 340 units/ml, respectively, 3-6 h after LPS stimulation. Nitrite concentration was found to increase from 0 to 7.8 and 28.5 mu M by 12 and 24 h, respectively, in the culture supernatant of LPS-treated J774 cells. The presence of a neutralizing dose of antibodies against IFN-beta, but not against TNF-alpha, during treatment with either 10 ng or 1 mu g of LPS/ml significantly, but not completely, decreased the level of i-NOS specific mRNA expression and NO production. The incubation of J774 cells with mouse natural IFN-beta itself (up to the level of 1,200 units/ ml) did not induce i-NOS-specific mRNA and therefore did not stimulate J774 cells to produce NO, However, natural IFN-beta synergistically augmented the expression of i-NOS mRNA and the production of NO by J774 cells triggered by suboptimal concentrations of LPS (1 to 5 ng/ml). These data thus suggest that endogenous IFN-beta, but not TNF-alpha, produced by LPS-stimulated J774 cells specifically contributes, probably in an auto/paracrine fashion, to the activation of the i-NOS gene expression by LPS.	UNIV KANSAS, MED CTR, DEPT MICROBIOL MOLEC GENET & IMMUNOL, KANSAS CITY, KS 66160 USA; UNIV KANSAS, MED CTR, DEPT PATHOL & LAB MED, KANSAS CITY, KS 66160 USA; UNIV KANSAS, MED CTR, CTR CANC, KANSAS CITY, KS 66160 USA; KYOTO UNIV, FAC PHARMACEUT SCI, DEPT MOLEC MICROBIOL, SAKYO KU, KYOTO 606, JAPAN	University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; Kyoto University					NATIONAL CANCER INSTITUTE [P01CA054474, R01CA035977] Funding Source: NIH RePORTER; NCI NIH HHS [1 PO1 CA54474, 5 RO1 CA 35977] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS DO, 1989, IMMUNOL TODAY, V10, P33, DOI 10.1016/0167-5699(89)90298-3; ASSREUY J, 1993, BRIT J PHARMACOL, V108, P833, DOI 10.1111/j.1476-5381.1993.tb12886.x; BLALOCK JE, 1975, J GEN VIROL, V29, P315, DOI 10.1099/0022-1317-29-3-315; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DING A, 1990, J IMMUNOL, V145, P940; DING AH, 1988, J IMMUNOL, V141, P2407; DIRKS W, 1989, J INTERFERON RES, V9, P125, DOI 10.1089/jir.1989.9.125; EIZIRIK DL, 1993, FEBS LETT, V317, P62, DOI 10.1016/0014-5793(93)81492-I; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUJIHARA M, 1994, J IMMUNOL, V152, P1898; FUJIHARA M, 1993, J BIOL CHEM, V268, P14898; GESSANI S, 1989, J VIROL, V63, P2785, DOI 10.1128/JVI.63.6.2785-2789.1989; GREEN SJ, 1992, J IMMUNOL, V149, P2069; HENRICSON BE, 1993, INFECT IMMUN, V61, P2325, DOI 10.1128/IAI.61.6.2325-2333.1993; INABA K, 1986, J EXP MED, V163, P1030, DOI 10.1084/jem.163.4.1030; IYENGAR R, 1987, P NATL ACAD SCI USA, V84, P6369, DOI 10.1073/pnas.84.18.6369; JAATTELA M, 1991, LAB INVEST, V64, P724; KAWASAKI ES, 1988, P NATL ACAD SCI USA, V85, P5698, DOI 10.1073/pnas.85.15.5698; KHALILI K, 1984, J BIOL CHEM, V258, P6701; KILBOURN RG, 1990, J NATL CANCER I, V82, P772, DOI 10.1093/jnci/82.9.772; LEONE AM, 1991, J BIOL CHEM, V266, P23790; LORSBACH RB, 1993, J BIOL CHEM, V268, P1908; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MAROTTA P, 1992, BRIT J PHARMACOL, V107, P640, DOI 10.1111/j.1476-5381.1992.tb14499.x; MULLER JM, 1993, IMMUNOBIOLOGY, V187, P233; MUNOZFERNANDEZ MA, 1992, EUR J IMMUNOL, V22, P301, DOI 10.1002/eji.1830220203; MUROI M, 1993, CELL SIGNAL, V5, P289, DOI 10.1016/0898-6568(93)90019-I; MUROI M, 1993, J BIOL CHEM, V268, P19534; MYERS MJ, 1989, J IMMUNOL, V142, P153; NOVOTNEY M, 1991, BIOCHEMISTRY-US, V30, P5597, DOI 10.1021/bi00236a037; NUSSLER A, 1991, EUR J IMMUNOL, V21, P227, DOI 10.1002/eji.1830210134; OHMORI Y, 1993, J BIOL CHEM, V268, P6677; RALPH P, 1975, J IMMUNOL, V114, P898; RICHES DWH, 1991, J BIOL CHEM, V266, P24785; SEVERN A, 1992, BIOCHEM BIOPH RES CO, V188, P997, DOI 10.1016/0006-291X(92)91330-S; STUEHR DJ, 1985, P NATL ACAD SCI USA, V82, P7738, DOI 10.1073/pnas.82.22.7738; STUEHR DJ, 1987, CANCER RES, V47, P5590; STUEHR DJ, 1989, J EXP MED, V169, P1543, DOI 10.1084/jem.169.5.1543; WERNERFELMAYER G, 1990, J EXP MED, V172, P1599, DOI 10.1084/jem.172.6.1599; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779	42	102	104	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12773	12778						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	7513694				2022-12-27	WOS:A1994NH71600062
J	KIM, SJ; KAHN, CR				KIM, SJ; KAHN, CR			INSULIN STIMULATES PHOSPHORYLATION OF C-JUN, C-FOS, AND FOS-RELATED PROTEINS IN CULTURED ADIPOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; KINASE-C; NUCLEAR PROTEINS; GENE-EXPRESSION; TRANSCRIPTION; ACTIVATION; CELLS; COMPLEXES; GROWTH; SITES	In differentiated 3T3-F442A adipocytes, insulin stimulated rapid and transient phosphorylation of c-Jun. Insulin also stimulated phosphorylation of c-Fos and several Fos-related proteins (pp72, pp45, and pp39) as indicated by precipitation with anti-c-Fos antibody following exposure to denaturating conditions. Phosphorylation of c Fos was stimulated by 7-fold by 60 min, while phosphorylation of Fos-related proteins reached maxima of 3.5-5.5-fold at 15 to 60 min. The increase in phosphorylated c-Fos was due to an increase in both c-Fos protein and the stoichiometry of c-Fos phosphorylation, and was not observed in c-fos (-/-) cells. Additionally, insulin stimulated phosphorylation of a protein with molecular mass of similar to 82 kDa on tyrosine residues by 2.5-fold within 30 min; this protein appeared to be immunologically related to c-Fos. These increases in the phosphorylation of AP-1 transcription factors correlated with a >5-fold stimulation of expression of a 12-O-tetradecanoylphorbol-13-acetate-responsive element-chloramphenicol acetyltransferase reporter gene transiently transfected into 3T3-F442A cells. These results indicate that insulin stimulates the phosphorylation of AP-1 transcription factors and several Fos-related proteins on serine and tyrosine residues. This is associated with changes in AP-1-mediated gene expression in vivo, suggesting that AP-1 phosphorylation by insulin plays a role in insulin regulated gene expression.	BRIGHAM & WOMENS HOSP,JOSLIN DIABET CTR,DEPT MED,DIV RES,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA 02215	Harvard University; Brigham & Women's Hospital; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School			Kahn, Ronald/AAY-2435-2021	Kahn, Ronald/0000-0002-7583-9228	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033201, P30DK036836] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 33201, DK 36836] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABATE C, 1991, ONCOGENE, V6, P2179; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BAKER SJ, 1992, MOL CELL BIOL, V12, P4694, DOI 10.1128/MCB.12.10.4694; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CSERMELY P, 1993, J BIOL CHEM, V268, P9747; CSERMELY P, 1992, BIOCHEMISTRY-US, V31, P9940, DOI 10.1021/bi00156a012; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; ERIKSON E, 1989, J BIOL CHEM, V264, P13711; FEUERSTEIN N, 1991, EXP CELL RES, V194, P289, DOI 10.1016/0014-4827(91)90367-4; FIELD SJ, 1992, P NATL ACAD SCI USA, V89, P9306, DOI 10.1073/pnas.89.19.9306; FRANZA BR, 1987, ONCOGENE, V1, P213; GURNEY AL, 1992, J BIOL CHEM, V267, P18133; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HONEYMAN MC, 1993, DIABETES, V42, P626, DOI 10.2337/diabetes.42.4.626; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KASUGA M, 1982, J BIOL CHEM, V257, P392; KIM SJ, 1993, J CELL PHYSIOL, V157, P217, DOI 10.1002/jcp.1041570203; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; OBRIEN RM, 1991, BIOCHEM J, V278, P609, DOI 10.1042/bj2780609; OEMAR BS, 1991, J BIOL CHEM, V266, P24241; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAY LB, 1988, J BIOL CHEM, V263, P12721; REUSCH JEB, 1993, CLIN RES, V41, pA210; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; STUMPO DJ, 1986, P NATL ACAD SCI USA, V83, P9453, DOI 10.1073/pnas.83.24.9453; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUTHERLAND JA, 1992, GENE DEV, V6, P1810, DOI 10.1101/gad.6.9.1810; TAYLOR LK, 1993, P NATL ACAD SCI USA, V90, P368, DOI 10.1073/pnas.90.2.368; ZAFARULLAH M, 1992, FEBS LETT, V306, P169, DOI 10.1016/0014-5793(92)80992-P	37	51	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11887	11892						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	7512956				2022-12-27	WOS:A1994NG37700035
J	RIIKONEN, T; KOIVISTO, L; VIHINEN, P; HEINO, J				RIIKONEN, T; KOIVISTO, L; VIHINEN, P; HEINO, J			TRANSFORMING GROWTH-FACTOR-BETA REGULATES COLLAGEN GEL CONTRACTION BY INCREASING ALPHA-2-BETA-1 INTEGRIN EXPRESSION IN OSTEOGENIC CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADHESION RECEPTORS; SARCOMA CELLS; FIBRONECTIN; FIBROBLASTS; SUBUNIT; MATRIX; BONE; IDENTIFICATION; LAMININ; FAMILY	The contraction of floating collagen gels is suggested to mimic the reorganization of collagenous matrix during development and tissue healing. Here, we have studied two osteogenic cell lines, namely MG-63 and HOS, and a chemically transformed subclone of HOS cells, HOS-MNNG. Transforming growth factor-beta (TGF-beta), a putative regulator of bone fracture healing, increased collagen gel contraction by MG-63 and HOS-MNNG, but not by HOS cells. Our data show that TGF-beta-induced fibronectin synthesis is not sufficient for the process. Instead, anti-beta 1 integrin antibodies could prevent the contraction. There are three different integrin heterodimers that are known to mediate the cell collagen interaction, namely alpha 1 beta 1, alpha 2 beta 1, and alpha 3 beta 1. In MG-63 cells TGF-beta increased the expression of alpha 2 beta 1 integrin and decreased the expression of alpha 3 beta 1 integrin, whereas alpha 1 beta 1 integrin is not expressed. HOS cells had no alpha 2 beta 1 integrin, neither did TGF-beta induce its expression. However, HOS-MNNG cells expressed more alpha 2 beta 1 integrin when treated with TGF-beta. Thus, we suggest that the mechanism of the enhanced collagen gel contraction by TGF-beta is the increased expression of alpha 2 beta 1 integrin heterodimer. To further test this hypothesis, we expressed a full-length alpha 2 integrin cDNA in HOS cells and in MG-63 cells. We obtained HOS cell clones that expressed alpha 2 beta 1 heterodimer, and the ability of these cells to contract collagen gels was greatly enhanced. Furthermore, the contraction by MG-63 cells transfected with alpha 2 integrin cDNA was enhanced, and the contraction by cells transfected with antisense oriented alpha 2 integrin cDNA was decreased. Thus, both in MG-63 and HOS cells the increased alpha 2 integrin expression alone was sufficient for the enhanced contraction of collagen gels. Furthermore, the amount of alpha 2 integrin is critical for the process, and its decrease leads to diminished ability to contract gels.	UNIV TURKU, DEPT MED BIOCHEM, SF-20520 TURKU, FINLAND; UNIV TURKU, MEDICITY RES LAB, SF-20520 TURKU, FINLAND	University of Turku; University of Turku			Vihinen, Pia/AAQ-5574-2021	Vihinen, Pia/0000-0003-1763-5363				AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; ASAGA H, 1991, EXP CELL RES, V193, P167, DOI 10.1016/0014-4827(91)90552-6; BELLOWS CG, 1981, J ULTRASTRUCT RES, V78, P178; BRIGHTON CT, 1992, J ORTHOP RES, V10, P766, DOI 10.1002/jor.1100100604; CHEN WT, 1986, J CELL BIOL, V103, P1649, DOI 10.1083/jcb.103.5.1649; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5291; CLARK RAF, 1989, J CLIN INVEST, V84, P1036, DOI 10.1172/JCI114227; CLOVER J, 1992, J CELL SCI, V103, P267; DANS MJ, 1994, J INVEST DERMATOL, V102, P118, DOI 10.1111/1523-1747.ep12371743; DEDHAR S, 1990, J CELL BIOL, V110, P481, DOI 10.1083/jcb.110.2.481; DEFILIPPI P, 1991, J BIOL CHEM, V266, P7638; ELSDALE T, 1972, J CELL BIOL, V54, P626, DOI 10.1083/jcb.54.3.626; GRINNELL F, 1994, J CELL BIOL, V124, P401, DOI 10.1083/jcb.124.4.401; GULLBERG D, 1990, EXP CELL RES, V186, P264, DOI 10.1016/0014-4827(90)90305-T; HEINO J, 1989, J BIOL CHEM, V264, P21806; HEINO J, 1990, J BIOL CHEM, V265, P10181; HEINO J, 1989, J BIOL CHEM, V264, P380; HUGHES DE, 1993, J BONE MINER RES, V8, P527; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; IGNOTZ RA, 1987, CELL, V51, P189, DOI 10.1016/0092-8674(87)90146-2; JOYCE ME, 1990, J CELL BIOL, V110, P2195, DOI 10.1083/jcb.110.6.2195; KLEIN CE, 1991, J CELL BIOL, V115, P1427, DOI 10.1083/jcb.115.5.1427; LARJAVA H, 1993, J CELL PHYSIOL, V157, P190, DOI 10.1002/jcp.1041570125; LARJAVA H, 1993, J CLIN INVEST, V92, P1425, DOI 10.1172/JCI116719; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MONTESANO R, 1988, P NATL ACAD SCI USA, V85, P4894, DOI 10.1073/pnas.85.13.4894; NIKKARI L, 1993, AM J PATHOL, V142, P1019; NODA M, 1989, ENDOCRINOLOGY, V124, P2991, DOI 10.1210/endo-124-6-2991; NUGENT MA, 1989, J BIOL CHEM, V264, P18060; OHASHI PS, 1985, NATURE, V316, P606, DOI 10.1038/316606a0; Reddi A. Hari, 1992, Current Opinion in Cell Biology, V4, P850; RETTIG WJ, 1984, P NATL ACAD SCI-BIOL, V81, P6437, DOI 10.1073/pnas.81.20.6437; ROBERTS CJ, 1988, J BIOL CHEM, V263, P4586; ROBEY PG, 1993, J BONE MINER RES, V8, P483; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SAITO T, 1994, J ORTHOP RES, V12, P384, DOI 10.1002/jor.1100120311; SANTALA P, 1994, J BIOL CHEM, V269, P1276; SANTALA P, 1991, J BIOL CHEM, V266, P23505; SHIRO JA, 1991, CELL, V67, P403; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; TAKADA Y, 1987, NATURE, V326, P607, DOI 10.1038/326607a0; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873	43	100	104	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					376	382		10.1074/jbc.270.1.376	http://dx.doi.org/10.1074/jbc.270.1.376			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7529233	hybrid			2022-12-27	WOS:A1995QA28700059
J	PRUDOVSKY, I; SAVION, N; ZHAN, X; FRIESEL, R; XU, JM; HOU, JZ; MCKEEHAN, WL; MACIAG, T				PRUDOVSKY, I; SAVION, N; ZHAN, X; FRIESEL, R; XU, JM; HOU, JZ; MCKEEHAN, WL; MACIAG, T			INTACT AND FUNCTIONAL FIBROBLAST GROWTH-FACTOR (FGF) RECEPTOR-1 TRAFFICKS NEAR THE NUCLEUS IN RESPONSE TO FGF-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; KINASE-ACTIVITY; CELL-CYCLE; FACTOR-I; TRANSLOCATION; ASSOCIATION; EXPRESSION; PROTEINS; PHASE	Exogenous fibroblast growth factor-1 (FGF-1) associates with the nucleus in a receptor-dependent manner during the entire G(1) period of the BALB/c 3T3 cell cycle (Zhan, X., Hu, X., Friesel, R., and Maciag, T. (1993) J. Biol, Chem, 268, 9611-9620). To further study the role of the FGF receptor (FGFR) during this translocation, the intracellular fate of FGFR-1 protein and enzymatic activity was examined, Immunoprecipitation using multiple FGFR-1 antibodies followed by an in vitro tyrosine kinase activity assay enabled us to identify FGFR-1 as a 130-kDa phosphotyrosine-containing protein associated with the nuclear fraction of NIH 3T3 cells exposed to FGF-1. While FGFR-1 tyrosine kinase activity could be detected as a nuclear-associated protein after a 2-h exposure of the NIH 3T3 cells to FGF-1, this activity appeared to be maximal in the nuclear fraction between 4 and 12 h after FGF-1 treatment, In addition, analysis by confocal immunofluorescence microscopy of quiescent and FGF-1-stimulated NIH 3T3 cells reveal a prominent perinuclear FGFR-1 staining pattern in the cells exposed to FGF-1 but not in the quiescent population, We also observed FGFR-1 associated with the nuclear fraction in FGFR-1-transfected L6 rat myoblasts, which are known to be refractive to exogenous FGF-1 and express relatively low levels of endogenous FGFR-1, In addition, these cells also exhibited the presence of a 145-kDa phosphoprotein in the nuclear fraction that was recognized by FGFR-1 antibodies, These results suggest that the FGFR-1 may be translocated near the nucleus upon interaction with its ligand during the entire G(1) period of the NIH 3T3 cell cycle as a structurally intact and functional tyrosine kinase that may be accessible to perinuclear polypeptides as a regulatory enzyme.	AMER RED CROSS,DEPT MOLEC BIOL,HOLLAND LAB,ROCKVILLE,MD 20855; TEXAS A&M UNIV,INST BIOSCI & TECHNOL,HOUSTON,TX 77030	American Red Cross; Texas A&M University System			Savion, Naphtali/K-1013-2019; Prudovsky, Igor/GVU-1521-2022	Savion, Naphtali/0000-0001-8899-0624	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD029561] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL044336, R01HL032348] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL44336, HL32348] Funding Source: Medline; NICHD NIH HHS [HD29561] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ACKLAND P, 1990, NATURE, V343, P662; BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FRIEDMAN S, 1992, BIOCHEM BIOPH RES CO, V198, P1203; FRIESEL R, 1989, MOL CELL BIOL, V9, P1857, DOI 10.1128/MCB.9.5.1857; FRIESEL R, 1991, MOL CELL BIOL, V11, P2481, DOI 10.1128/MCB.11.5.2481; HUANG SS, 1986, J BIOL CHEM, V261, P9568; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; OLWIN BB, 1989, J CELL BIOCHEM, V39, P443, DOI 10.1002/jcb.240390410; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; WONG S, 1992, ONCOGENE, V7, P2407; XIE YM, 1994, BIOCHEM BIOPH RES CO, V203, P1589, DOI 10.1006/bbrc.1994.2368; XU JM, 1992, J BIOL CHEM, V267, P17792; ZHAN X, 1993, J BIOL CHEM, V268, P24427; ZHAN X, 1993, J BIOL CHEM, V268, P9611; ZHAN X, 1994, J BIOL CHEM, V269, P20221	22	78	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31720	31724						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7527394				2022-12-27	WOS:A1994PX30300062
J	YOON, KL; GUIDOTTI, G				YOON, KL; GUIDOTTI, G			STUDIES ON THE MEMBRANE TOPOLOGY OF THE (NA,K)-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA,K-ATPASE BETA-SUBUNIT; AMINO-ACID-SEQUENCE; TISSUE-SPECIFIC EXPRESSION; SITE-DIRECTED MUTAGENESIS; ALPHA-SUBUNIT; MOLECULAR-CLONING; H+-ATPASE; EXTRACELLULAR DOMAIN; CATALYTIC SUBUNIT; RAT-BRAIN	The topology of the alpha 1 and beta 1 subunits of the rat (Na,K)-ATPase has been studied by insertion of epitope(s): at the NH2 terminus and COOH terminus and between Glu-117 and Glu-118, Lys-828 and Arg-829, Gln-900 and Trp-901, and Val-939 and Phe-940 of the a subunit; and at the NH2 terminus and COOH terminus and between Glu-228 and Tyr-229 of the beta subunit. The epitope-tagged alpha 1 constructs were expressed in HeLa cells to select for stable cell lines expressing a functional (Na,K)-ATPase. The epitope-tagged beta constructs were transiently expressed in Cos-7 cells. The membrane arrangement of the epitopes was revealed by indirect immunofluorescence with cells expressing the (Na,K)-ATPase chains. The results indicate that the alpha subunit has 4 transmembrane segments in the COOH-terminal membrane-bound domain between residues 760 and 938, and that both the NH2 terminus and the COOH terminus are in the cytosol; it was not determined whether there are more transmembrane segments between residue 938 and the COOH terminus. The beta subunit has only one transmembrane spanning region with the NH2 terminus in the cytosol and the COOH terminus on the extracytoplasmic surface of the plasma membrane.			YOON, KL (corresponding author), HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,7 DIVIN AVE,CAMBRIDGE,MA 02138, USA.				NHLBI NIH HHS [HL08893] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADDISON R, 1986, J BIOL CHEM, V261, P4896; ANTOLOVIC R, 1991, EUR J BIOCHEM, V199, P195, DOI 10.1111/j.1432-1033.1991.tb16109.x; BALL WJ, 1987, BIOCHIM BIOPHYS ACTA, V916, P100, DOI 10.1016/0167-4838(87)90216-0; BAYER R, 1990, BIOCHEMISTRY-US, V29, P2251, DOI 10.1021/bi00461a007; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; BROWN TA, 1987, BIOCHIM BIOPHYS ACTA, V912, P244, DOI 10.1016/0167-4838(87)90095-1; CAPASSO JM, 1992, J BIOL CHEM, V267, P1150; CHERTOVA EN, 1989, FEBS LETT, V254, P13, DOI 10.1016/0014-5793(89)80999-8; CHIN G, 1983, BIOCHEMISTRY-US, V22, P3405, DOI 10.1021/bi00283a016; CHIN GJ, 1985, BIOCHEMISTRY-US, V24, P5943, DOI 10.1021/bi00342a038; CLARKE DM, 1990, J BIOL CHEM, V265, P17405; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; EMERICK MC, 1993, J BIOL CHEM, V268, P23455; FARLEY RA, 1986, BIOCHIM BIOPHYS ACTA, V873, P136, DOI 10.1016/0167-4838(86)90199-8; FELSENFELD DP, 1988, J BIOL CHEM, V263, P10932; FISCHBARG J, 1993, P NATL ACAD SCI USA, V90, P11658, DOI 10.1073/pnas.90.24.11658; FISONE G, 1994, J BIOL CHEM, V269, P9368; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HAGER KM, 1986, P NATL ACAD SCI USA, V83, P7693, DOI 10.1073/pnas.83.20.7693; HAMRICK M, 1993, J BIOL CHEM, V268, P24367; HARA Y, 1987, J BIOCHEM-TOKYO, V102, P43, DOI 10.1093/oxfordjournals.jbchem.a122039; JORGENSEN PL, 1983, BIOCHIM BIOPHYS ACTA, V735, P291, DOI 10.1016/0005-2736(83)90304-8; JORGENSEN PL, 1982, J BIOL CHEM, V257, P7435; JORGENSEN PL, 1988, J MEMBRANE BIOL, V103, P95, DOI 10.1007/BF01870942; KAPLAN JG, 1978, ANNU REV PHYSIOL, V40, P19, DOI 10.1146/annurev.ph.40.030178.000315; KARLISH SJD, 1993, J BIOL CHEM, V268, P3471; KAWAKAMI K, 1986, NUCLEIC ACIDS RES, V14, P2833, DOI 10.1093/nar/14.7.2833; LEMAS MV, 1994, J BIOL CHEM, V269, P8255; LEMAS MV, 1992, J BIOL CHEM, V267, P20987; LUTSENKO S, 1993, BIOCHEMISTRY-US, V32, P6737, DOI 10.1021/bi00077a029; LUTSENKO S, 1994, J BIOL CHEM, V269, P4555; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MANDALA SM, 1989, J BIOL CHEM, V264, P16276; MARTINVASALLO P, 1989, J BIOL CHEM, V264, P4613; MATTHEWS I, 1990, J BIOL CHEM, V265, P18737; MCDONOUGH AA, 1990, FASEB J, V4, P1598, DOI 10.1096/fasebj.4.6.2156741; MERCER RW, 1986, MOL CELL BIOL, V6, P3884, DOI 10.1128/MCB.6.11.3884; MODYANOV N, 1992, ACTA PHYSIOL SCAND, V146, P49; MOHRAZ M, 1994, J BIOL CHEM, V269, P2929; MONK BC, 1991, J BIOL CHEM, V266, P18097; NELSON WJ, 1989, J CELL BIOL, V108, P893, DOI 10.1083/jcb.108.3.893; NOGUCHI S, 1986, FEBS LETT, V196, P315, DOI 10.1016/0014-5793(86)80270-8; OHTA T, 1986, FEBS LETT, V204, P297, DOI 10.1016/0014-5793(86)80832-8; OVCHINNIKOV YA, 1986, FEBS LETT, V201, P237, DOI 10.1016/0014-5793(86)80616-0; OVCHINNIKOV YA, 1987, FEBS LETT, V217, P269, DOI 10.1016/0014-5793(87)80676-2; OVCHINNIKOV YA, 1988, FEBS LETT, V227, P230, DOI 10.1016/0014-5793(88)80904-9; PELMAN HRB, 1986, CELL, V46, P959; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; PRICE EM, 1990, J BIOL CHEM, V265, P6638; RAO US, 1991, J BIOL CHEM, V266, P14740; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; SHULL GE, 1988, J BIOL CHEM, V263, P8646; SHULL GE, 1986, NATURE, V321, P429, DOI 10.1038/321429a0; SHULL GE, 1986, J BIOL CHEM, V261, P6788; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; SHULL MM, 1989, J BIOL CHEM, V264, P17532; SMILEY JK, 1990, J VIROL, V64, P4558, DOI 10.1128/JVI.64.9.4558-4564.1990; SMITH DL, 1993, J BIOL CHEM, V268, P22469; TAKEYASU K, 1987, J BIOL CHEM, V262, P10733; THIBAULT D, 1993, BIOCHEMISTRY-US, V32, P2813, DOI 10.1021/bi00062a012; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107; VERMA AK, 1988, J BIOL CHEM, V263, P14152; YOUNG RM, 1987, J BIOL CHEM, V262, P4905	64	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28249	28258						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7525571				2022-12-27	WOS:A1994PV77200072
J	LIU, X; GUY, HI; EVANS, DR				LIU, X; GUY, HI; EVANS, DR			IDENTIFICATION OF THE REGULATORY DOMAIN OF THE MAMMALIAN MULTIFUNCTIONAL PROTEIN CAD BY THE CONSTRUCTION OF AN ESCHERICHIA-COLI HAMSTER HYBRID CARBAMYL-PHOSPHATE SYNTHETASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATES PYRIMIDINE BIOSYNTHESIS; CARBONIC-PHOSPHORIC ANHYDRIDE; EHRLICH ASCITES-CARCINOMA; RAT-LIVER MITOCHONDRIA; COOH-TERMINAL DOMAIN; ASPARTATE-TRANSCARBAMYLASE; NUCLEOTIDE-SEQUENCE; LARGE SUBUNIT; URA2 GENE; SACCHAROMYCES-CEREVISIAE	Carbamyl-phosphate synthetases from different organisms have similar catalytic mechanisms and amino acid sequences, but their structural organization, subunit structure, and mode of regulation can be very different. Escherichia coli carbamyl-phosphate synthetase (CPSase), a monofunctional protein consisting of amidotransferase and synthetase subunits, is allosterically inhibited by UMP and activated by NH3, IMP, and ornithine. In contrast, mammalian CPSase II, part of the large multifunctional polypeptide, CAD, is inhibited by UTP and activated by 5-phosphoribosyl-1-pyrophosphate (PRPP). Previous photoaffinity labeling studies of E. coli CPSase showed that allosteric effecters bind near the carboxyl-terminal end of the synthetase subunit. This region of the molecule may be a regulatory subdomain common to ah CPSases. An E. coli mammalian hybrid CPSase gene has been constructed and expressed in E. coli. The hybrid consists of the E. coli CPSase synthetase catalytic subdomains, residues 1-900 of the 1073 residue polypeptide, fused to the amino-terminal end of the putative 190-residue regulatory subdomain of the mammalian protein. The hybrid CPSase had normal activity, but was no longer regulated by the prokaryotic allosteric effecters. Instead, the glutamine- and ammonia-dependent CPSase activities and both ATP-dependent partial reactions were activated by PRPP and inhibited by UTP, indicating that the binding sites of both of these ligands are located in a regulatory region at the carboxyl-terminal end of the CPSase domain of CAD. The apparent ligand dissociation constants and extent of inhibition by UTP are similar in the hybrid and the wild type mammalian protein, but PRPP binds 4-fold more weakly to the hybrid. The allosteric ligands affected the steady state kinetic parameters of the hybrid differently suggesting that while the linkage between the catalytic and regulatory subdomains has been preserved, there may be qualitative differences in interdomain signal transmission. Nevertheless, switching prokaryotic and eukaryotic allosteric controls argues for remarkable conservation of structure and regulatory mechanisms in this family of proteins.	WAYNE STATE UNIV, SCH MED, DEPT BIOCHEM, DETROIT, MI 48201 USA	Wayne State University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047399] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 47399] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AITKEN DM, 1975, CAN J BIOCHEM CELL B, V53, P721, DOI 10.1139/o75-099; ANDERSON PM, 1965, BIOCHEMISTRY-US, V4, P2803, DOI 10.1021/bi00888a034; ANDERSON PM, 1966, BIOCHEMISTRY-US, V5, P3157, DOI 10.1021/bi00874a012; ANDERSON PM, 1966, BIOCHEMISTRY-US, V5, P3164, DOI 10.1021/bi00874a013; BEIN K, 1991, J BIOL CHEM, V266, P3791; BELKAID M, 1988, ARCH BIOCHEM BIOPHYS, V262, P171, DOI 10.1016/0003-9861(88)90179-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARREY EA, 1986, BIOCHEM J, V236, P327, DOI 10.1042/bj2360327; CARREY EA, 1985, EMBO J, V4, P3735, DOI 10.1002/j.1460-2075.1985.tb04142.x; CERVERA J, 1993, J BIOL CHEM, V268, P12504; CLARKE S, 1976, J BIOL CHEM, V251, P950; COLEMAN PF, 1977, J BIOL CHEM, V252, P6379; DAVIDSON JN, 1981, J BIOL CHEM, V256, P5220; EVANS DR, 1988, BIOCHIM BIOPHYS ACTA, V953, P185, DOI 10.1016/0167-4838(88)90023-4; Evans DR, 1986, MULTIDOMAIN PROTEINS; FAURE M, 1989, EUR J BIOCHEM, V179, P345, DOI 10.1111/j.1432-1033.1989.tb14560.x; FREUND JN, 1987, J MOL BIOL, V193, P1, DOI 10.1016/0022-2836(87)90621-8; GRAYSON DR, 1985, J BIOL CHEM, V260, P5840; GRAYSON DR, 1983, J BIOL CHEM, V258, P4123; GRISOLIA S, 1951, J BIOL CHEM, V191, P189; GUADALAJARA AM, 1987, THESIS U VALENCIA VA; GUY HI, 1994, J BIOL CHEM, V269, P7702; HAGER SE, 1967, J BIOL CHEM, V242, P5674; HAGER SE, 1967, J BIOL CHEM, V242, P5667; HALL LM, 1958, J BIOL CHEM, V230, P1013; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; HARAGUCHI Y, 1991, GENE, V107, P335; HAWKES R, 1982, ANAL BIOCHEM, V119, P142, DOI 10.1016/0003-2697(82)90677-7; HOOGENRAAD NJ, 1971, BIOCHEM BIOPH RES CO, V44, P981, DOI 10.1016/0006-291X(71)90808-4; KELLY RE, 1986, J BIOL CHEM, V261, P6073; KILSTRUP M, 1988, EUR J BIOCHEM, V176, P421, DOI 10.1111/j.1432-1033.1988.tb14299.x; KIM H, 1991, BIOCHEMISTRY-US, V30, P10322, DOI 10.1021/bi00106a033; KIM HS, 1992, J BIOL CHEM, V267, P7177; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE L, 1985, P NATL ACAD SCI USA, V82, P6802, DOI 10.1073/pnas.82.20.6802; LEVINE RL, 1971, BIOCHEMISTRY-US, V10, P3694; LUSTY CJ, 1978, EUR J BIOCHEM, V85, P373, DOI 10.1111/j.1432-1033.1978.tb12249.x; LUSTY CJ, 1983, J BIOL CHEM, V258, P4466; MALLY MI, 1980, J BIOL CHEM, V255, P1372; MALLY MI, 1981, P NATL ACAD SCI-BIOL, V78, P6647, DOI 10.1073/pnas.78.11.6647; Maniatis T., 1982, MOL CLONING; MARSHALL M, 1961, J BIOL CHEM, V236, P2229; MARSHALL M, 1988, ARCH BIOCHEM BIOPHYS, V262, P455, DOI 10.1016/0003-9861(88)90397-9; MEISTER A, 1989, ADV ENZYMOL RAMB, V62, P315; METZENBERG RL, 1957, J BIOL CHEM, V229, P1019; MORI M, 1975, BIOCHEMISTRY-US, V14, P2622, DOI 10.1021/bi00683a010; MORI M, 1975, J BIOCHEM, V78, P239; NAGY M, 1989, J BIOL CHEM, V264, P8366; NYUNOYA H, 1983, P NATL ACAD SCI-BIOL, V80, P4629, DOI 10.1073/pnas.80.15.4629; NYUNOYA H, 1985, J BIOL CHEM, V260, P9346; NYUNOYA H, 1984, J BIOL CHEM, V259, P9790; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PERBAL B, 1988, PRACTICAL GUIDE MOL, P305; PIERARD A, 1978, J BACTERIOL, V134, P167; PIERARD A, 1966, SCIENCE, V154, P1572, DOI 10.1126/science.154.3756.1572; PIETTE J, 1984, P NATL ACAD SCI-BIOL, V81, P4134, DOI 10.1073/pnas.81.13.4134; POST LE, 1990, J BIOL CHEM, V265, P7742; POWERS SG, 1976, P NATL ACAD SCI USA, V73, P3020, DOI 10.1073/pnas.73.9.3020; POWERS SG, 1978, J BIOL CHEM, V253, P1258; POWERS SG, 1978, J BIOL CHEM, V253, P800; POWERSLEE SG, 1987, J BIOL CHEM, V262, P9052; QUINN CL, 1991, J BIOL CHEM, V266, P9113; RODRIGUEZAPARICIO LB, 1989, BIOCHEMISTRY-US, V28, P3070, DOI 10.1021/bi00433a050; RUBINO SD, 1987, J BIOL CHEM, V262, P4382; RUBIO V, 1991, BIOCHEMISTRY-US, V30, P1068, DOI 10.1021/bi00218a027; SCHOFIELD JP, 1993, CLIN SCI, V84, P119, DOI 10.1042/cs0840119; Segel I.H., 1975, ENZYME KINETICS BEHA, P161; SHOAF WT, 1973, BIOCHEMISTRY-US, V12, P4039, DOI 10.1021/bi00745a004; SHOAF WT, 1971, BIOCHEM BIOPH RES CO, V45, P796; SIMMER JP, 1990, J BIOL CHEM, V265, P10395; SIMMER JP, 1990, P NATL ACAD SCI USA, V87, P174, DOI 10.1073/pnas.87.1.174; SIMMER JP, 1989, P NATL ACAD SCI USA, V86, P4382, DOI 10.1073/pnas.86.12.4382; SOUCIET JL, 1987, MOL GEN GENET, V207, P314, DOI 10.1007/BF00331595; SOUCIET JL, 1989, GENE, V79, P59, DOI 10.1016/0378-1119(89)90092-9; TATIBANA M, 1969, J BIOL CHEM, V244, P5403; TEKKANAT KK, 1988, CLIN CHEM, V34, P925; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TROTTA PP, 1971, P NATL ACAD SCI USA, V68, P2599, DOI 10.1073/pnas.68.10.2599; TROTTA PP, 1974, J BIOL CHEM, V249, P492; WERNER M, 1985, EUR J BIOCHEM, V146, P371, DOI 10.1111/j.1432-1033.1985.tb08663.x	80	45	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27747	27755						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7525561				2022-12-27	WOS:A1994PV77100091
J	JACKSON, SP; SCHOENWAELDER, SM; YUAN, YP; RABINOWITZ, I; SALEM, HH; MITCHELL, CA				JACKSON, SP; SCHOENWAELDER, SM; YUAN, YP; RABINOWITZ, I; SALEM, HH; MITCHELL, CA			ADHESION RECEPTOR ACTIVATION OF PHOSPHATIDYLINOSITOL 3-KINASE - VON-WILLEBRAND-FACTOR STIMULATES THE CYTOSKELETAL ASSOCIATION AND ACTIVATION OF PHOSPHATIDYLINOSITOL 3-KINASE AND PP60(C-SRC) IN HUMAN PLATELETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IIB-IIIA; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; MEMBRANE SKELETON; PHOSPHOINOSITIDE 3-KINASE; VONWILLEBRAND DISEASE; ACTIN POLYMERIZATION; GLYCOPROTEIN-IB; CELL-ADHESION; THROMBIN	The cytoskeleton participates in the coordinated regulation of intracellular signaling molecules, following agonist stimulation of cells. We have demonstrated that von Willebrand factor (vWF) induced the cytoskeletal association and activation of phosphatidylinositol 3-kinase (PtdIns 3-kinase) in human platelets. The activation of PtdIns 3-kinase coincided with the tyrosine phosphorylation of multiple platelet proteins, as assessed by anti-phosphotyrosine immunoblotting. One of these tyrosine-phosphorylated proteins, pp60(c-src), became specifically enriched in the cytoskeletal fraction of vWF-stimulated platelets. The vWF-stimulated cytoskeletal association of PtdIns 3-kinase and pp60(c-src) required platelet stirring and aggregation, was specifically blocked by an anti-GPIb monoclonal antibody, and was not observed in platelets lacking the glycoprotein Ib/IX complex (Bernard-Soulier syndrome). Pretreatment of normal platelets with 5 mM EDTA (37 degrees C for 90 min) or RODS (2 mM), which disrupts the binding of various adhesive proteins to platelet integrins and inhibits fibrinogen-mediated platelet aggregation, did not alter the vWF-stimulated activation and cytoskeletal association of PtdIns 3-kinase and pp60(c-src). Pretreatment of platelets with acetylsalicylic acid (1 mM) completely abolished vWF-stimulated production of thromboxane A(2), dense granule release, and the activation of protein kinase C, without altering the activation and cytoskeletal translocation of PtdIns 3-kinase and pp60(c-src). Our results suggest that vWF binding to the platelet adhesion receptor glycoprotein Ib/IX can mediate activation and translocation of both tyrosine and lipid kinase(s) independent of other agonists.			JACKSON, SP (corresponding author), MONASH UNIV,BOX HILL HOSP,SCH MED,DEPT MED,NELSON RD,BOX HILL,VIC 3128,AUSTRALIA.		Schoenwaelder, Simone/E-9506-2011; Jackson, Shaun P/E-9633-2011	Jackson, Shaun/0000-0002-4750-1991; Mitchell, Christina A/0000-0001-9372-3192; Schoenwaelder, Simone/0000-0003-0465-5840				AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; AUGER KR, 1992, J BIOL CHEM, V267, P5408; Baenziger N L, 1974, Methods Enzymol, V31, P149; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; DIVECHA N, 1991, EMBO J, V10, P3207, DOI 10.1002/j.1460-2075.1991.tb04883.x; EBERLE M, 1990, J BIOL CHEM, V265, P16725; FERRELL JE, 1988, MOL CELL BIOL, V8, P3603, DOI 10.1128/MCB.8.9.3603; FOX JEB, 1985, J CLIN INVEST, V76, P1673, DOI 10.1172/JCI112153; FOX JEB, 1993, J BIOL CHEM, V268, P25973; GEORGE JN, 1991, NEW ENGL J MED, V324, P27, DOI 10.1056/NEJM199101033240106; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GRONDIN P, 1991, J BIOL CHEM, V266, P15705; GUTKIND JS, 1990, MOL CELL BIOL, V10, P3806, DOI 10.1128/MCB.10.7.3806; HORVATH AR, 1992, EMBO J, V11, P855, DOI 10.1002/j.1460-2075.1992.tb05123.x; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JAKOBSEN E, 1973, Thrombosis Research, V3, P145, DOI 10.1016/0049-3848(73)90065-0; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KROLL MH, 1991, J CLIN INVEST, V88, P1568, DOI 10.1172/JCI115468; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAJERUS PW, 1990, CELL, V63, P459, DOI 10.1016/0092-8674(90)90442-H; MONTGOMERY RR, 1978, J CLIN INVEST, V61, P1498, DOI 10.1172/JCI109070; ODA A, 1992, J BIOL CHEM, V267, P20075; PUMIGLIA KM, 1993, BIOCHEM J, V294, P253, DOI 10.1042/bj2940253; ROTH GJ, 1991, BLOOD, V77, P5; RUGGERI ZM, 1987, BLOOD, V70, P895; SAVAGE B, 1992, J BIOL CHEM, V267, P11300; Shattil SJ, 1991, CURR OPIN CELL BIOL, V3, P869, DOI 10.1016/0955-0674(91)90062-4; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SMYTH SS, 1993, BLOOD, V81, P2827; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; SULTAN C, 1991, J BIOL CHEM, V266, P23554; SUSA M, 1992, J BIOL CHEM, V267, P22951; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAYNORKAPLAN AE, 1988, NATURE, V334, P353, DOI 10.1038/334353a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; WYMANN M, 1994, BIOCHEM J, V298, P517, DOI 10.1042/bj2980517; ZHANG J, 1992, J BIOL CHEM, V267, P4686	43	114	117	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					27093	27099						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7523416				2022-12-27	WOS:A1994PQ93100076
J	KIM, JP; ZHANG, K; CHEN, JD; KRAMER, RH; WOODLEY, DT				KIM, JP; ZHANG, K; CHEN, JD; KRAMER, RH; WOODLEY, DT			VITRONECTIN-DRIVEN HUMAN KERATINOCYTE LOCOMOTION IS MEDIATED BY THE ALPHA-V-BETA-5 INTEGRIN RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM SPREADING FACTOR; MICROVASCULAR ENDOTHELIAL-CELLS; FIBRONECTIN RECEPTOR; ALPHA-V; EXTRACELLULAR-MATRIX; GROWTH-FACTOR; BETA-SUBUNIT; HUMAN-PLASMA; ADHESION; MIGRATION	Vitronectin is a soluble serum factor that is known to promote epiboly of keratinocytes in explant cultures and enhance cell spreading and attachment to matrix. Recently, vitronectin was demonstrated to promote human keratinocyte locomotion. The mechanism(s) by which vitronectin enhances keratinocyte migration is unknown. In this study, we quantitated the vitronectin-driven migration of human keratinocytes in the presence of antibodies to vitronectin receptors. We found that vitronectin's effect of promoting human keratinocyte migration was inhibited by antibody-directed against the alpha v beta 5 receptor. In addition, we surface-labeled human keratinocytes, chromatographed extracts of the cell membranes on a vitronectin column, and then immunoprecipitated the bound and eluted proteins with antibodies to specific vitronectin receptors. We identified the vitronectin receptors on human keratinocytes as bands of 150,000 and 100,000 daltons without reduction and as 125,000 and 110,000 daltons under reducing conditions. Immunoprecipitation with specific antibodies identified the major receptor to be the alpha v beta 5 integrin. In addition, we quantitated vitronectin-driven migration of human keratinocytes in the presence of Arg-Gly-Asp (RGD) and control peptides. We found that the presence of RGD, but not control peptide, inhibited vitronectin-driven migration of human keratinocytes. These studies demonstrate that human keratinocytes express vitronectin receptors and use the alpha v beta 5 receptor for cellular locomotion.	STANFORD UNIV,SCH MED,DEPT DERMATOL,STANFORD,CA 94305; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT ANAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH DENT,DEPT STOMATOL,SAN FRANCISCO,CA 94143	Stanford University; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR041045, T32AR007422, R01AR033625] Funding Source: NIH RePORTER; NIAMS NIH HHS [T32-AR07422, AR41045, AR33625] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; ALBRECHTBUEHLER G, 1977, CELL, V11, P395, DOI 10.1016/0092-8674(77)90057-5; BARNES DW, 1983, J BIOL CHEM, V258, P2548; BASARA ML, 1985, CANCER RES, V45, P2487; BAUER JS, 1992, J CELL BIOL, V116, P477, DOI 10.1083/jcb.116.2.477; BODARY SC, 1990, J BIOL CHEM, V265, P5938; BOWDITCH RD, 1991, J BIOL CHEM, V266, P23323; Boyce S.T., 1983, J INVEST DERMATOL S, V81, P33; BROWN C, 1991, J INVEST DERMATOL, V96, P724, DOI 10.1111/1523-1747.ep12470960; BUSK M, 1992, J BIOL CHEM, V267, P5790; CHEN JD, 1994, DERMATOLOGY, V188, P6, DOI 10.1159/000247076; CHEN WT, 1986, J CELL BIOL, V103, P1649, DOI 10.1083/jcb.103.5.1649; CHENG YF, 1991, EXP CELL RES, V194, P69, DOI 10.1016/0014-4827(91)90131-D; CHENG YF, 1989, J CELL PHYSIOL, V139, P275, DOI 10.1002/jcp.1041390209; CHERESH DA, 1987, J BIOL CHEM, V262, P1434; CHERESH DA, 1989, CELL, V57, P59, DOI 10.1016/0092-8674(89)90172-4; CLARK RAF, 1985, J AM ACAD DERMATOL, V13, P701, DOI 10.1016/S0190-9622(85)70213-7; COUCHMAN JR, 1979, J CELL SCI, V39, P149; DUBAND JL, 1988, J CELL BIOL, V107, P1385, DOI 10.1083/jcb.107.4.1385; DUBAND JL, 1986, J CELL BIOL, V102, P160, DOI 10.1083/jcb.102.1.160; FREED E, 1989, EMBO J, V8, P2955, DOI 10.1002/j.1460-2075.1989.tb08445.x; GARTNER TK, 1993, THROMB RES, V71, P47; HAYMAN EG, 1985, J CELL BIOL, V100, P1948, DOI 10.1083/jcb.100.6.1948; HAYMAN EG, 1985, EXP CELL RES, V160, P245, DOI 10.1016/0014-4827(85)90173-9; HAYMAN EG, 1983, P NATL ACAD SCI-BIOL, V80, P4003, DOI 10.1073/pnas.80.13.4003; HERTLE MD, 1991, DEVELOPMENT, V112, P193; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; JULIANO RL, 1987, BIOCHIM BIOPHYS ACTA, V907, P261, DOI 10.1016/0304-419X(87)90009-6; KIM JP, 1992, J INVEST DERMATOL, V98, P764, DOI 10.1111/1523-1747.ep12499947; KIM JP, 1992, J CELL PHYSIOL, V151, P443, DOI 10.1002/jcp.1041510303; KRAMER RH, 1989, CANCER RES, V49, P393; KRISSANSEN GW, 1990, J BIOL CHEM, V265, P823; LEAVESLEY DI, 1992, J CELL BIOL, V117, P1101, DOI 10.1083/jcb.117.5.1101; MARKS R, 1978, BRIT J DERMATOL, V98, P631; OKEEFE EJ, 1985, J INVEST DERMATOL, V85, P125, DOI 10.1111/1523-1747.ep12276531; OKEEFE EJ, 1988, J INVEST DERMATOL, V90, P2, DOI 10.1111/1523-1747.ep12462409; PETERSEN MJ, 1987, J BIOL CHEM, V262, P835; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SARRET Y, 1992, J INVEST DERMATOL, V98, P12, DOI 10.1111/1523-1747.ep12493517; SHEPPARD D, 1992, J BIOL CHEM, V267, P17409; SMITH JW, 1990, J BIOL CHEM, V265, P12267; Stenn K.S., 1988, MOL CELLULAR BIOL WO, P321; STENN KS, 1979, NATURE, V277, P229, DOI 10.1038/277229a0; STENN KS, 1981, P NATL ACAD SCI-BIOL, V78, P6907, DOI 10.1073/pnas.78.11.6907; Stuiver I., 1993, Molecular Biology of the Cell, V4, p285A; VANDIJK S, 1993, J BONE MINER RES, V8, P1499; VANSTRIJP JAG, 1993, J IMMUNOL, V151, P3324; VOGEL BE, 1990, J BIOL CHEM, V265, P5934; WAYNER EA, 1991, J CELL BIOL, V113, P919, DOI 10.1083/jcb.113.4.919; WHATELEY JG, 1980, BIOCHEM J, V185, P349, DOI 10.1042/bj1850349; WOODLEY D, 1980, J INVEST DERMATOL, V75, P148, DOI 10.1111/1523-1747.ep12522536; WOODLEY DT, 1988, J CELL PHYSIOL, V136, P140, DOI 10.1002/jcp.1041360118; WOODLEY DT, 1967, J CLIN INVEST, V179, P1826; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281	55	72	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26926	26932						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7523414				2022-12-27	WOS:A1994PQ93100054
J	RABEN, N; NICHOLS, R; DOHLMAN, J; MCPHIE, P; SRIDHAR, V; HYDE, C; LEFF, R; PLOTZ, P				RABEN, N; NICHOLS, R; DOHLMAN, J; MCPHIE, P; SRIDHAR, V; HYDE, C; LEFF, R; PLOTZ, P			A MOTIF IN HUMAN HISTIDYL-TRANSFER-RNA SYNTHETASE WHICH IS SHARED AMONG SEVERAL AMINOACYL-TRANSFER-RNA SYNTHETASES IS A COILED-COIL THAT IS ESSENTIAL FOR ENZYMATIC-ACTIVITY AND CONTAINS THE MAJOR AUTOANTIGENIC EPITOPE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; CHAIN-RELEASE FACTOR; ESCHERICHIA-COLI; DIADENOSINE 5',5'''-P1,P4-TETRAPHOSPHATE; SACCHAROMYCES-CEREVISIAE; SECONDARY-STRUCTURE; CIRCULAR-DICHROISM; ANTI-JO-1 ANTIBODY; TERMINAL EXTENSION; MYOSITIS	In myositis, disease-specific autoantibodies may be directed against an aminoacyl-tRNA synthetase, usually histidyl-tRNA synthetase. To explore the basis for this phenomenon, we have made recombinant histidyl-tRNA synthetase in the baculovirus system. It was enzymatically active and recognized by human autoantibodies. A truncated protein lacking the first 60 amino acids was inactive as an antigen and as an enzyme. This region is within the first two exons, is predicted to have a coiled-coil configuration, and is found in some other synthetases but not in Escherichia coli or yeast histidyl-tRNA synthetase. Circular dichroism showed that the peptides from this region (amino acids 1-60 and 1-47) have the predicted high alpha-helical content, but smaller fragments (1-30, 14-45, and 31-60) do not. The peptides with a high alpha-helical content could inhibit autoantibodies almost completely, whereas the smaller peptides were unable to do so. The amino acid sequence of this coiled-coil domain in human histidyl-tRNA synthetase resembles the sequence of the extended this coiled-coil arm near the NH2 terminus of bacterial seryl-tRNA synthetase as well as similar regions in some eukaryotic aminoaayl-tRNA synthetases, raising the possibility that this domain serves a similar tRNA-stabilizing role and has been preserved from a common ancestor.	NIDDK,BETHESDA,MD 20892; NIAMSD,STRUCT BIOL RES LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	RABEN, N (corresponding author), NIAMSD,CTR CLIN 9N244,ARTHRIT & RHEUMATISM BRANCH,CONNECT TISSUE DIS SECT,BETHESDA,MD 20892, USA.							BERNSTEIN RM, 1985, EXCERPTA MED INT C S, V675, P273; BIERZYNSKI A, 1982, P NATL ACAD SCI-BIOL, V79, P2470, DOI 10.1073/pnas.79.8.2470; BIOU V, 1994, SCIENCE, V263, P1404, DOI 10.1126/science.8128220; BISWAS T, 1987, J IMMUNOL METHODS, V98, P235, DOI 10.1016/0022-1759(87)90010-X; BISWAS T, 1987, J IMMUNOL METHODS, V98, P243, DOI 10.1016/0022-1759(87)90011-1; BUNN CC, 1986, J EXP MED, V163, P1281, DOI 10.1084/jem.163.5.1281; CERINI C, 1991, EMBO J, V10, P4267, DOI 10.1002/j.1460-2075.1991.tb05005.x; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; DOHLMAN JG, 1993, BIOCHEM BIOPH RES CO, V195, P686, DOI 10.1006/bbrc.1993.2100; ESCALANTE C, 1993, J BIOL CHEM, V268, P6014; FAHOUM SK, 1987, BIOCHEMISTRY-US, V26, P5871, DOI 10.1021/bi00392a044; FERBER S, 1987, NATURE, V326, P808, DOI 10.1038/326808a0; FETT R, 1991, J BIOL CHEM, V266, P1448; FROLOVA LY, 1991, GENE, V109, P291, DOI 10.1016/0378-1119(91)90624-K; FROLOVA LY, 1993, EUR J BIOCHEM, V212, P457, DOI 10.1111/j.1432-1033.1993.tb17682.x; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GARRET M, 1991, BIOCHEMISTRY-US, V30, P7809, DOI 10.1021/bi00245a021; GUO QB, 1992, GENE DEV, V6, P1357, DOI 10.1101/gad.6.8.1357; ISOM LL, 1984, MACROMOLECULES, V17, P2445, DOI 10.1021/ma00141a042; JAHN M, 1991, NATURE, V352, P258, DOI 10.1038/352258a0; JAHN MJ, 1991, NUCLEIC ACIDS RES, V19, P2786, DOI 10.1093/nar/19.10.2786; KANE SM, 1978, BIOCHEMISTRY-US, V17, P1509, DOI 10.1021/bi00601a024; KAUMAYA PTP, 1990, BIOCHEMISTRY-US, V29, P13, DOI 10.1021/bi00453a002; KERJAN P, 1992, BIOCHIMIE, V74, P195, DOI 10.1016/0300-9084(92)90046-H; LORBER B, 1988, EUR J BIOCHEM, V174, P155, DOI 10.1111/j.1432-1033.1988.tb14076.x; LOVE LA, 1991, MEDICINE, V70, P360, DOI 10.1097/00005792-199111000-00002; LUDMERER SW, 1987, J BIOL CHEM, V262, P10807; LUPUS A, 1991, SCIENCE, V252, P1162; MATHEWS MB, 1984, J EXP MED, V160, P420, DOI 10.1084/jem.160.2.420; MATHEWS MB, 1983, NATURE, V304, P177, DOI 10.1038/304177a0; MCPHIE P, 1992, ARCH BIOCHEM BIOPHYS, V293, P46, DOI 10.1016/0003-9861(92)90363-2; Merrifield RB, 1976, SCIENCE, V232, P341, DOI DOI 10.1126/SCIENCE.3961484; MILLER FW, 1990, J CLIN INVEST, V85, P468, DOI 10.1172/JCI114461; MILLER FW, 1990, P NATL ACAD SCI USA, V87, P9933, DOI 10.1073/pnas.87.24.9933; MIRANDE M, 1988, J BIOL CHEM, V263, P18443; MISETA A, 1991, J BIOL CHEM, V266, P19158; MOHR G, 1991, NATURE, V354, P164, DOI 10.1038/354164a0; MULLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; MYSZKA DG, 1994, BIOCHEMISTRY-US, V33, P2363, DOI 10.1021/bi00175a003; NADA S, 1993, J BIOL CHEM, V268, P7660; RABEN N, 1992, NUCLEIC ACIDS RES, V20, P1075, DOI 10.1093/nar/20.5.1075; RAMSDEN DA, 1989, J IMMUNOL, V143, P2267; SMITH MW, 1992, TRENDS BIOCHEM SCI, V17, P489, DOI 10.1016/0968-0004(92)90335-7; Summers MD, 1987, MANUAL METHODS BACUL; TAKAHASHI R, 1987, ARCH GERONTOL GERIAT, V6, P73, DOI 10.1016/0167-4943(87)90040-9; TARGOFF IN, 1993, J CLIN INVEST, V91, P2556, DOI 10.1172/JCI116493; TARGOFF IN, 1987, J IMMUNOL, V138, P2874; TARGOFF IN, 1990, J IMMUNOL, V144, P1737; TING SM, 1992, J BIOL CHEM, V267, P17701; TSUI FWL, 1987, NUCLEIC ACIDS RES, V15, P3349, DOI 10.1093/nar/15.8.3349; VARSHAVSKY A, 1983, CELL, V34, P711, DOI 10.1016/0092-8674(83)90526-3; WALKER EJ, 1987, J IMMUNOL METHODS, V96, P149, DOI 10.1016/0022-1759(87)90308-5; WALTER P, 1989, J BIOL CHEM, V264, P17126; WEBB AC, 1991, BIOTECHNIQUES, V11, P512; WEBB N R, 1990, Technique (Philadelphia), V2, P173; ZAMECNIK P, 1983, ANAL BIOCHEM, V134, P1, DOI 10.1016/0003-2697(83)90255-5; ZAWADZKI V, 1991, NUCLEIC ACIDS RES, V19, P1948, DOI 10.1093/nar/19.8.1948; ZHOU NE, 1992, J BIOL CHEM, V267, P2664	62	71	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24277	24283						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7523371				2022-12-27	WOS:A1994PQ34600066
J	RAZ, R; DURBIN, JE; LEVY, DE				RAZ, R; DURBIN, JE; LEVY, DE			ACUTE-PHASE RESPONSE FACTOR AND ADDITIONAL MEMBERS OF THE INTERFERON-STIMULATED GENE FACTOR-3 FAMILY INTEGRATE DIVERSE SIGNALS FROM CYTOKINES, INTERFERONS, AND GROWTH-FACTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; DNA-BINDING PROTEINS; MUTANT-CELL LINE; TRANSCRIPTION FACTOR; ERYTHROPOIETIN RECEPTOR; TRANSDUCTION PATHWAY; GAMMA; PHOSPHORYLATION; ALPHA; JAK2	Cytokines and growth factors elicit responses in target cells through induction of gene expression. Signaling mechanisms leading to gene transcription from cell surface receptors often require tyrosine phosphorylation. A family of transcription factors comprising the interferon (IFN)-stimulated gene factor 3 (ISGF3) multimeric complex are phosphorylated and activated in response to interferon. We describe a protein 50% identical to the 91-kDa subunit ofISGF3 that constitutes the acute phase response factor (APRF). This protein was rapidly activated by interleukin-6 to bind an enhancer element common to genes activated in liver cells during the acute phase response to inflammation. Remarkably, APRF was also activated by IFN alpha, IFN gamma, epidermal growth factor, platelet-derived growth factor, colony stimulating factor-1, and the cytokines leukemia inhibitory factor and oncostatin M. The growth factors also activated a third, distinct but related, DNA-binding protein in addition to APRF and p91. This novel factor or a closely related one, but neither APRF nor p91, was also activated in lymphoid cells by interleukin-2, erythropoietin, and interleukin-3. Activation of APRF, p91, and additional members of the ISGF3 family is thus a general feature of a wide variety of signaling pathways, integrating diverse signals through common transcriptional regulators.	NYU,SCH MED,DEPT PATHOL,NEW YORK,NY 10016; NYU,SCH MED,KAPLAN COMPREHENS CANC CTR,NEW YORK,NY 10016	New York University; New York University			Levy, David/GPS-4945-2022; Levy, David/AAG-6202-2019	Levy, David/0000-0002-7320-7788	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028900] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI28900] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BONNI A, 1993, SCIENCE, V262, P1575, DOI 10.1126/science.7504325; DANDREA AD, 1991, MOL CELL BIOL, V11, P1980, DOI 10.1128/MCB.11.4.1980; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EILERS A, 1994, MOL CELL BIOL, V14, P1364, DOI 10.1128/MCB.14.2.1364; FINBLOOM DS, 1994, MOL CELL BIOL, V14, P2113, DOI 10.1128/MCB.14.3.2113; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; GILLIS S, 1977, NATURE, V268, P154, DOI 10.1038/268154a0; HAYES TE, 1987, P NATL ACAD SCI USA, V84, P1272, DOI 10.1073/pnas.84.5.1272; HUNTER T, 1993, NATURE, V366, P114, DOI 10.1038/366114a0; LAMB P, 1994, BLOOD, V83, P2063; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LEVY D, 1990, New Biologist, V2, P923; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MEYER DJ, 1994, J BIOL CHEM, V269, P4701; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YUAN JP, 1994, MOL CELL BIOL, V14, P1657, DOI 10.1128/MCB.14.3.1657; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806	42	143	146	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24391	24395						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7523373				2022-12-27	WOS:A1994PQ34600084
J	ZHONG, GM; SMITH, GP; BERRY, J; BRUNHAM, RC				ZHONG, GM; SMITH, GP; BERRY, J; BRUNHAM, RC			CONFORMATIONAL MIMICRY OF A CHLAMYDIAL NEUTRALIZATION EPITOPE ON FILAMENTOUS PHAGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE PROTEIN; INFLUENZA-VIRUS HEMAGGLUTININ; TRACHOMATIS; PEPTIDES; IMMUNOGENICITY; LIBRARY; GENES; BACTERIOPHAGE; DETERMINANTS; MIMICKING	Conformational constraints were imposed on a peptide epitope from Chlamydia trachomatis to improve its ability to elicit antibodies that cross-react with native antigen. Appropriate constraints were discovered by a strategy that required no prior knowledge of the epitope's native conformation. First, we constructed a library of 3.2 x 10(5) peptides in which the epitope's contact residues were subject to random conformational constraints, each constrained peptide being fused genetically to the surface of a filamentous phage vector. Next, we selected phage displaying the most native-like peptides in the library by affinity purification with antibodies that bind the epitope only in its native conformation. Finally, we immunized mice with the selected phage and titered the resulting antisera against both whole cells and unconstrained peptide. The ratio of anti-cell titer to anti-peptide titer, which reflects the channeling of the antibody response to the native epitope, was up to five times higher for affinity-selected phage than for unselected peptide phage. In this case, therefore, ''antigenic fitness,'' the ability of a peptide to bind antibodies specific for native epitope, correlated with ''immunogenic fitness,'' its ability to elicit antibodies that are effective against the native antigen on an invading pathogen. If the correlation is general, surveying thousands or millions of peptides for antigenic fitness with phage display technology may be a simple but effective pre-screen for immunogenic fitness, which is costly to assess directly.	UNIV MISSOURI,DIV BIOL SCI,COLUMBIA,MO 65211; UNIV MANITOBA,DEPT MED MICROBIOL,WINNIPEG R3E 0W3,MB,CANADA	University of Missouri System; University of Missouri Columbia; University of Manitoba					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041478] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41478] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAEHR W, 1988, P NATL ACAD SCI USA, V85, P4000, DOI 10.1073/pnas.85.11.4000; BIDART JM, 1990, SCIENCE, V248, P736, DOI 10.1126/science.1692160; GEYSEN HM, 1987, J IMMUNOL METHODS, V102, P259, DOI 10.1016/0022-1759(87)90085-8; GRAYSTON JT, 1975, J INFECT DIS, V132, P87, DOI 10.1093/infdis/132.1.87; GREENWOOD J, 1991, J MOL BIOL, V220, P821, DOI 10.1016/0022-2836(91)90354-9; HAAS SJ, 1993, BIOTECHNIQUES, V15, P422; KAUMAYA PTP, 1992, J BIOL CHEM, V267, P6338; LUZZAGO A, 1993, GENE, V128, P51, DOI 10.1016/0378-1119(93)90152-S; MCLAFFERTY MA, 1993, GENE, V128, P29, DOI 10.1016/0378-1119(93)90149-W; MULLER S, 1990, VACCINE, V8, P308, DOI 10.1016/0264-410X(90)90086-2; ONEIL KT, 1992, PROTEINS, V14, P509, DOI 10.1002/prot.340140411; PARMLEY SF, 1988, GENE, V73, P305, DOI 10.1016/0378-1119(88)90495-7; Sambrook J, 1989, MOL CLONING LABORATO; SCHULZEGAHMEN U, 1986, EUR J BIOCHEM, V159, P283, DOI 10.1111/j.1432-1033.1986.tb09865.x; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SMITH GP, 1988, VIROLOGY, V167, P156, DOI 10.1016/0042-6822(88)90065-7; SMITH GP, 1993, METHOD ENZYMOL, V217, P228; STEPHENS RS, 1987, J BACTERIOL, V169, P3879, DOI 10.1128/jb.169.9.3879-3885.1987; SU H, 1992, J EXP MED, V175, P227, DOI 10.1084/jem.175.1.227; WILLIAMS WV, 1991, J BIOL CHEM, V266, P5182; ZHONG GM, 1992, INFECT IMMUN, V60, P3143, DOI 10.1128/IAI.60.8.3143-3149.1992; ZHONG GM, 1991, INFECT IMMUN, V59, P1141, DOI 10.1128/IAI.59.3.1141-1147.1991; ZHONG GM, 1990, INFECT IMMUN, V58, P3438, DOI 10.1128/IAI.58.10.3438-3441.1990; ZHONG GM, 1994, INFECT IMMUN, V62, P1576, DOI 10.1128/IAI.62.5.1576-1583.1994; ZHONG GM, 1993, J IMMUNOL, V151, P3728	26	84	95	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24183	24188						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7523368				2022-12-27	WOS:A1994PQ34600054
J	DO, KY; FREGIEN, N; PIERCE, M; CUMMINGS, RD				DO, KY; FREGIEN, N; PIERCE, M; CUMMINGS, RD			MODIFICATION OF GLYCOPROTEINS BY N-ACETYLGLUCOSAMINYLTRANSFERASE-V IS GREATLY INFLUENCED BY ACCESSIBILITY OF THE ENZYME TO OLIGOSACCHARIDE ACCEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; LYSOSOMAL MEMBRANE-GLYCOPROTEINS; HAMSTER-KIDNEY CELLS; HUMAN-SERUM TRANSFERRIN; AMINO-ACID-SEQUENCE; SUGAR CHAINS; OVARY CELLS; ACETYLGALACTOSAMINE-TRANSFERASE; ACETYLLACTOSAMINE CHAINS; ONCOGENIC TRANSFORMATION	The formation of tri- and tetraantennary complex-type N-linked oligosaccharides in animal glycoproteins is partly regulated by UDP-N-acetylglucosamine:beta-6-D-mannoside beta-1,6-N-acetylglucosaminyltransferase (EC 2.4.1.155) (GlcNAc-T V), which generates 2,6-branched mannose. In Chinese hamster ovary (CHO) cells we found that 2,6-branched mannosyl structures are preferentially contained on lysosome-associated membrane proteins (LAMPs) and are generally low or absent in other cellular glycoproteins (Do, K.-P. and Cummings, R.D. (1993) J. Biol. Chem. 268, 22028-22035). To determine the mechanism by which GlcNAc-T V appears to preferentially recognize glycoproteins, we examined the activity of purified GlcNAc-T V toward a variety of glycoprotein accepters. Because GlcNAc-T V requires as accepters oligosaccharides lacking outer galactosyl and sialyl residues, we utilized two classes of acceptor preparations. The first class of acceptor was enzymatically desialylated (DS) and degalactosylated (DG) preparations of bovine fetuin, human transferrin, and human fibrinogen. The second class was glycoproteins in extracts of the mutant CHO cell line, Lec8 CHO, which cannot add galactose or sialic acid to N-linked oligosaccharides. GlcNAc-T V was highly active toward DSDG-fetuin, -transferrin, and -fibrinogen (K-m values ranged between 30 and 74 mu M), and the catalytic efficiencies (V-max/K-m) of the enzyme toward different accepters were comparable. In the case of fetuin, each of its three sites for attachment of N-linked oligosaccharides were shown to be utilized equally well by GlcNAc-T V. Notably, the enzyme exhibited a 2-3-fold higher rate of transfer toward DSDG-transferrin when it was further denatured by reduction and S-carboxymethylation. When extracts of Lec8 CHO cells were used as accepters, GlcNAc-T V preferentially transferred to LAMPs, and only low level transfer was observed to other cell-derived glycoproteins, thus demonstrating specificity of GlcNAc-T V to ward native glycoprotein accepters. When the cell-derived glycoproteins were denatured by reduction and S-carboxymethylation prior to use as accepters for GlcNAc-T V, significant transfer occurred to other glycoproteins. These results demonstrate that the mechanism of glycoprotein-specific branching by GlcNAc-T V is determined primarily by its accessibility to available bi/triantennary oligosaccharides on glycoproteins and not by its recognition of peptide determinants or conformation-specific determinants.	UNIV OKLAHOMA, HLTH SCI CTR, DEPT BIOCHEM & MOLEC BIOL, OKLAHOMA CITY, OK 73190 USA; UNIV MIAMI, SCH MED, DEPT CELL BIOL & ANAT, MIAMI, FL 33101 USA; UNIV GEORGIA, DEPT BIOCHEM, ATHENS, GA 30605 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Miami; University System of Georgia; University of Georgia					NCI NIH HHS [CA-37626] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037626] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMOS B, 1990, J BIOL CHEM, V265, P19192; BAENZIGER JU, 1979, J BIOL CHEM, V254, P9795; BRILES EB, 1977, J BIOL CHEM, V252, P1107; CARLSSON SR, 1988, J BIOL CHEM, V263, P18911; CARLSSON Sr, 1990, J BIOL CHEM, V265, P20488; CUMMINGS RD, 1982, J BIOL CHEM, V257, P13421; CUMMINGS RD, 1984, J BIOL CHEM, V259, P6253; CUMMINGS RD, 1982, J BIOL CHEM, V257, P1230; CUMMINGS RD, 1992, GLYCOCONJUGATES COMP, P333; DENNIS JW, 1989, ONCOGENE, V4, P853; Dennis JW, 1992, CELL SURFACE CARBOHY, P161; DEUTSCHER SL, 1986, J BIOL CHEM, V261, P96; DHARMESH SM, 1993, J BIOL CHEM, V268, P17096; DO KY, 1993, J BIOL CHEM, V268, P22028; DO KY, 1990, BIOCHEM BIOPH RES CO, V173, P1123, DOI 10.1016/S0006-291X(05)80902-7; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; DZIEGIELEWSKA KM, 1990, J BIOL CHEM, V265, P4354; Fukuda M., 1992, CELL SURFACE CARBOHY, P127; GREEN ED, 1988, J BIOL CHEM, V263, P18253; HEFFERNAN M, 1989, CANCER RES, V49, P6077; HUBBARD SC, 1987, J BIOL CHEM, V262, P16403; KNIBBS RN, 1989, BIOCHEMISTRY-US, V28, P6379, DOI 10.1021/bi00441a034; KOBATA A, 1992, CELL SURFACE CARBOHY, P1; KORNFELD K, 1981, J BIOL CHEM, V256, P6633; KORNFELD S, 1986, J CLIN INVEST, V77, P1, DOI 10.1172/JCI112262; LAFERTE S, 1989, BIOCHEM J, V259, P569, DOI 10.1042/bj2590569; LEE N, 1990, J BIOL CHEM, V265, P20476; LEMAIRE S, 1994, J BIOL CHEM, V269, P8069; MACGILLIVRAY RTA, 1982, P NATL ACAD SCI-BIOL, V79, P2504, DOI 10.1073/pnas.79.8.2504; MACGILLIVRAY RTA, 1983, J BIOL CHEM, V258, P3543; MERKLE RK, 1988, J BIOL CHEM, V263, P16143; MERKLE RK, 1987, METHOD ENZYMOL, V138, P232; ORBERGER G, 1992, EUR J BIOCHEM, V205, P257, DOI 10.1111/j.1432-1033.1992.tb16776.x; PALCIC MM, 1990, J BIOL CHEM, V265, P6759; PALCIC MM, 1988, GLYCOCONJUGATE J, V5, P49, DOI 10.1007/BF01048331; PAREKH RB, 1985, NATURE, V316, P452, DOI 10.1038/316452a0; PIERCE M, 1986, J BIOL CHEM, V261, P772; QUN Z, 1993, ARCH BIOCHEM BIOPHYS, V300, P6, DOI 10.1006/abbi.1993.1002; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; REITMAN ML, 1981, J BIOL CHEM, V256, P1977; SANTER UV, 1979, BIOCHEMISTRY-US, V18, P2533, DOI 10.1021/bi00579a016; SANTER UV, 1989, EUR J BIOCHEM, V181, P249, DOI 10.1111/j.1432-1033.1989.tb14719.x; Schachter H, 1991, CURR OPIN STRUC BIOL, V1, P755, DOI 10.1016/0959-440X(91)90175-S; SHOREIBAH M, 1993, J BIOL CHEM, V268, P15381; SHOREIBAH MG, 1992, J BIOL CHEM, V267, P2920; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SMITH PL, 1988, SCIENCE, V242, P930, DOI 10.1126/science.2460923; SMITH PL, 1992, P NATL ACAD SCI USA, V89, P329, DOI 10.1073/pnas.89.1.329; SMITH PL, 1990, P NATL ACAD SCI USA, V87, P7275, DOI 10.1073/pnas.87.18.7275; SPIRO RG, 1973, ADV PROTEIN CHEM, V27, P379; STANLEY P, 1984, ANNU REV GENET, V18, P525, DOI 10.1146/annurev.ge.18.120184.002521; SUTTON BJ, 1983, BIOCHEM SOC T, V11, P130, DOI 10.1042/bst0110130; TAKEUCHI M, 1988, J BIOL CHEM, V263, P3657; TOWNSEND RR, 1982, J BIOL CHEM, V257, P9704; VANDENEIJNDEN DH, 1993, CURR OPIN STRUC BIOL, V3, P711, DOI 10.1016/0959-440X(93)90054-O; VONFIGURA K, 1986, ANNU REV BIOCHEM, V256, P11977; YAMASHITA K, 1989, J BIOL CHEM, V264, P2415; YAMASHITA K, 1985, J BIOL CHEM, V260, P3963; YAMASHITA K, 1984, J BIOL CHEM, V259, P834; YAMASHITA K, 1982, J BIOL CHEM, V257, P2809; YET MG, 1988, J BIOL CHEM, V263, P111; YOSHIMA H, 1981, J BIOL CHEM, V256, P8476; YOUSEFI S, 1991, J BIOL CHEM, V266, P1772; ZHOU Q, 1992, CELL SURFACE CARBOHY, P99	64	37	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23456	23464						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	7522229				2022-12-27	WOS:A1994PQ34500015
J	SILVERMAN, JA; MINDELL, JA; FINKELSTEIN, A; SHEN, WH; COLLIER, RJ				SILVERMAN, JA; MINDELL, JA; FINKELSTEIN, A; SHEN, WH; COLLIER, RJ			MUTATIONAL ANALYSIS OF THE HELICAL HAIRPIN REGION OF DIPHTHERIA-TOXIN TRANSMEMBRANE DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLANAR LIPID BILAYERS; HIGH-LEVEL EXPRESSION; MEMBRANE TRANSLOCATION; ESCHERICHIA-COLI; LOW PH; MODEL MEMBRANES; FULL-LENGTH; FRAGMENT-B; CHANNELS; INSERTION	Entry of the catalytic domain of diphtheria toxin into the cytoplasm of eukaryotic cells depends on insertion of the T (transmembrane) domain into the endosomal membrane, a process triggered by low pH. To probe the mechanism of insertion, we mutated ionizable residues within the helical hairpin region of the T domain. Only three mutations caused significant effects on cytotoxicity, D295K, E349K, and D352K. Each of these represents a substitution of a basic for an acidic residue at the tip of a helical hairpin. Substitution of Lys for Glu(349) or Asp(352), in the TH8/9 hairpin, reduced toxicity for Vero cells >100-fold, whereas a Lys substitution for Asp(295), one of 3 acidic residues in the TH5/6/7 hairpin, caused a less marked reduction. Ah three mutations also altered the pH-dependent formation, and/or ion conductance, of channels formed by the toxin in artificial bilayers or the plasma membrane. E349K or D352K did not alter the pH dependence of conformational changes in the toxin occurring near pH 5. Our findings support the hypothesis that the TH8/9 hairpin inserts into the endosomal membrane after low pH-mediated partial unfolding of the T domain. A positive residue at the tip of this hairpin apparently inhibits insertion and blocks toxin action. The ion-conducting properties of channels formed by selected mutants, described elsewhere, are consistent with this model. The status of the TH5/6/7 hairpin in the integral membrane form of the T domain remains uncertain.	HARVARD UNIV, SCH MED, SHIPLEY INST MED, DEPT MICROBIOL & MOLEC GENET, BOSTON, MA 02115 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT PHYSIOL & BIOPHYS, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT NEUROSCI, BRONX, NY 10461 USA	Harvard University; Harvard Medical School; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine			; Mindell, Joseph/P-4461-2017	Collier, R John/0000-0002-2427-4239; Mindell, Joseph/0000-0002-6952-8247	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022848, R01AI022021, R37AI022021] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288] Funding Source: NIH RePORTER; NIAID NIH HHS [AI22848, AI22021] Funding Source: Medline; NIGMS NIH HHS [T32 GM07288] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BARBIERI JT, 1987, INFECT IMMUN, V55, P1647, DOI 10.1128/IAI.55.7.1647-1651.1987; BISHAI WR, 1987, J BACTERIOL, V169, P5140, DOI 10.1128/jb.169.11.5140-5151.1987; BLEWITT MG, 1985, BIOCHEMISTRY-US, V24, P5458, DOI 10.1021/bi00341a027; BOQUET P, 1976, P NATL ACAD SCI USA, V73, P4449, DOI 10.1073/pnas.73.12.4449; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; CABIAUX V, 1989, J BIOL CHEM, V264, P4928; CABIAUX V, 1993, INFECT IMMUN, V61, P2200, DOI 10.1128/IAI.61.5.2200-2202.1993; CABIAUX V, 1990, J PHYSIOL-PARIS, V84, P273; CARROLL SF, 1988, METHOD ENZYMOL, V165, P218; CARROLL SF, 1988, METHOD ENZYMOL, V165, P68; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; CHUNG LA, 1988, BIOCHEMISTRY-US, V27, P1245, DOI 10.1021/bi00404a026; COLLIER RJ, 1990, ADP RIBOSYLATING TOX, P3, DOI DOI 10.1126/SCIENCE.250.4982.841-A; DELEERS M, 1983, FEBS LETT, V160, P82, DOI 10.1016/0014-5793(83)80941-7; DONOVAN JJ, 1981, P NATL ACAD SCI-BIOL, V78, P172, DOI 10.1073/pnas.78.1.172; DRAPER RK, 1980, J CELL BIOL, V87, P849, DOI 10.1083/jcb.87.3.849; DUMONT ME, 1988, J BIOL CHEM, V263, P2087; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FALNES PO, 1992, J BIOL CHEM, V267, P12284; FARAHBAKHSH ZT, 1992, PHOTOCHEM PHOTOBIOL, V56, P1019, DOI 10.1111/j.1751-1097.1992.tb09725.x; HOCH DH, 1985, P NATL ACAD SCI USA, V82, P1692, DOI 10.1073/pnas.82.6.1692; HOVDE CJ, 1988, P NATL ACAD SCI USA, V85, P2568, DOI 10.1073/pnas.85.8.2568; HU VW, 1984, J BIOL CHEM, V259, P2226; JIANG JX, 1991, BIOCHEMISTRY-US, V30, P3857, DOI 10.1021/bi00230a008; KAGAN BL, 1981, P NATL ACAD SCI-BIOL, V78, P4950, DOI 10.1073/pnas.78.8.4950; KIM K, 1965, J BACTERIOL, V90, P1552, DOI 10.1128/JB.90.6.1552-1556.1965; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWE DM, 1985, BIOCHEMISTRY-US, V24, P5106, DOI 10.1021/bi00340a022; MERION M, 1983, P NATL ACAD SCI-BIOL, V80, P5315, DOI 10.1073/pnas.80.17.5315; MIDDLEBROOK JL, 1984, MICROBIOL REV, V48, P199, DOI 10.1128/MMBR.48.3.199-221.1984; MINDELL JA, 1994, J MEMBRANE BIOL, V137, P45; MINDELL JA, 1994, J MEMBRANE BIOL, V137, P29; MINDELL JA, 1992, BIOPHYS J, V62, P41, DOI 10.1016/S0006-3495(92)81772-1; Montal M, 1974, Methods Enzymol, V32, P545; OKEEFE DO, 1989, P NATL ACAD SCI USA, V86, P343, DOI 10.1073/pnas.86.1.343; OKEEFE DO, 1992, P NATL ACAD SCI USA, V89, P6202, DOI 10.1073/pnas.89.13.6202; OKEEFE DO, 1992, ARCH BIOCHEM BIOPHYS, V296, P678, DOI 10.1016/0003-9861(92)90626-8; Olsnes S, 1988, Cancer Treat Res, V37, P39; PAPINI E, 1988, EMBO J, V7, P3353, DOI 10.1002/j.1460-2075.1988.tb03207.x; PAPINI E, 1993, J BIOL CHEM, V268, P1567; SANDVIG K, 1988, J BIOL CHEM, V263, P12352; SANDVIG K, 1980, J CELL BIOL, V87, P828, DOI 10.1083/jcb.87.3.828; SHIN YK, 1993, SCIENCE, V259, P960, DOI 10.1126/science.8382373; SILVERMAN JA, 1994, J MEMBRANE BIOL, V137, P17; STENMARK H, 1991, J CELL BIOL, V113, P1025, DOI 10.1083/jcb.113.5.1025; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; THELESTAM M, 1988, METHOD ENZYMOL, V165, P278; TWETEN RK, 1983, J BACTERIOL, V156, P680, DOI 10.1128/JB.156.2.680-685.1983; UCHIDA T, 1971, NATURE-NEW BIOL, V233, P8, DOI 10.1038/newbio233008a0; WILSON BA, 1992, CURR TOP MICROBIOL, V175, P27; WONDERLIN WF, 1990, BIOPHYS J, V58, P289, DOI 10.1016/S0006-3495(90)82376-6; ZALMAN LS, 1984, P NATL ACAD SCI-BIOL, V81, P3341, DOI 10.1073/pnas.81.11.3341	53	73	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	1994	269	36					22524	22532						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ163	7521329				2022-12-27	WOS:A1994PQ16300015
J	SZCZYPKA, MS; WEMMIE, JA; MOYEROWLEY, WS; THIELE, DJ				SZCZYPKA, MS; WEMMIE, JA; MOYEROWLEY, WS; THIELE, DJ			A YEAST METAL RESISTANCE PROTEIN SIMILAR TO HUMAN CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) AND MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR TRANSPORTER STE6; SACCHAROMYCES-CEREVISIAE; GENE-REGULATION; METALLOTHIONEIN; IDENTIFICATION; EXPRESSION; SELECTION; MEMBRANE; BACTERIA; CADMIUM	Members of the ATP binding cassette (ABC) protein superfamify transport a variety of substances across biological membranes, including drugs, ions, and peptides. The yeast cadmium factor (YCF1) gene from Saccharomyces cerevisiae is required for cadmium resistance and encodes a 1,515 amino acid protein with extensive homology to both the human multidrug resistance-associated protein (MRP1) and the cystic fibrosis transmembrane conductance regulator (hCFTR). S. cerevisiae cells harboring a deletion of the YCF1 gene are hypersensitive to cadmium compared with wild type cells. Mutagenesis experiments demonstrate that conserved amino acid residues, functionally critical in hCFTR, play a vital role in YCF1-mediated cadmium resistance. Mutagenesis of phenylalanine 713 in the YCF1 nucleotide binding fold 1, which correlates with the Delta F508 mutation found in the most common form of cystic fibrosis, completely abolished YCF1 function in cadmium detoxification. Furthermore, substitution of a serine to alanine residue in a potential protein kinase A phosphorylation site in a central region of YCF1, which displays sequence similarity to the central regulatory domain of hCFTR, also rendered YCF1 nonfunctional. These results suggest that YCF1 is composed of modular domains found in human proteins which function in drug and ion transport.	UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109; UNIV IOWA,COLL MED,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	University of Michigan System; University of Michigan; University of Iowa			Moye-Rowley, Scott/AFL-7135-2022	Moye-Rowley, Scott/0000-0002-7163-1120; Wemmie, John/0000-0001-7531-9065	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041840] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR00042] Funding Source: Medline; NIDDK NIH HHS [DK25295] Funding Source: Medline; NIGMS NIH HHS [GM41840] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGUILERA A, 1990, NUCLEIC ACIDS RES, V18, P1064, DOI 10.1093/nar/18.4.1064; ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; ANDERSON MP, 1991, P NATL ACAD SCI USA, V88, P6003, DOI 10.1073/pnas.88.14.6003; Ausubel FM, 1988, MOL REPROD DEV; BERKOWER C, 1991, EMBO J, V10, P3777, DOI 10.1002/j.1460-2075.1991.tb04947.x; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; COLLINS FS, 1992, SCIENCE, V256, P774, DOI 10.1126/science.1375392; COTTON FA, 1988, ADV INORG CHEM, V5, P1385; DENTE L, 1983, NUCLEIC ACIDS RES, V11, P1645, DOI 10.1093/nar/11.6.1645; DOIGE CA, 1993, ANNU REV MICROBIOL, V47, P291, DOI 10.1146/annurev.micro.47.1.291; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; HAMER DH, 1985, SCIENCE, V228, P685, DOI 10.1126/science.3887570; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; Kagi J H, 1987, Experientia Suppl, V52, P25; KUCHLER K, 1993, J CELL BIOL, V120, P1203, DOI 10.1083/jcb.120.5.1203; KUGE S, 1994, EMBO J, V13, P655, DOI 10.1002/j.1460-2075.1994.tb06304.x; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LILLIE SH, 1987, YEAST, V3, P1; MASTERS BA, 1994, P NATL ACAD SCI USA, V91, P584, DOI 10.1073/pnas.91.2.584; MEHRA RK, 1991, J CELL BIOCHEM, V45, P30, DOI 10.1002/jcb.240450109; MICHALSKI AE, 1993, P NATL ACAD SCI USA, V90, P8099; ORR GA, 1993, J BIOL CHEM, V268, P25054; ORTIZ DF, 1992, EMBO J, V11, P3491, DOI 10.1002/j.1460-2075.1992.tb05431.x; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROSEN BP, 1992, ANN NY ACAD SCI, V671, P257, DOI 10.1111/j.1749-6632.1992.tb43801.x; Sherman F., 1983, METHODS YEAST GENETI; SILVER S, 1992, MICROBIOL REV, V56, P195, DOI 10.1128/MMBR.56.1.195-228.1992; SINGHAL RK, 1987, FASEB J, V1, P220, DOI 10.1096/fasebj.1.3.2887478; THIELE DJ, 1992, NUCLEIC ACIDS RES, V20, P1183, DOI 10.1093/nar/20.6.1183; TSUI LC, 1994, CYSTIC FIBROSIS GENE, V7; WAALKES MP, 1992, CRIT REV TOXICOL, V22, P175, DOI 10.3109/10408449209145323; WELSH MJ, 1992, NEURON, V8, P821, DOI 10.1016/0896-6273(92)90196-K; WU AL, 1993, J BIOL CHEM, V268, P18850; ZHOU PB, 1993, BIOFACTORS, V4, P105; ZHOU PB, 1992, MOL CELL BIOL, V12, P3766, DOI 10.1128/MCB.12.9.3766; 1992, ENV HLTH CRITER, V134, P1	41	322	333	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 9	1994	269	36					22853	22857						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ163	7521334				2022-12-27	WOS:A1994PQ16300060
J	GRABAREK, J; GROOPMAN, JE; LYLES, YR; JIANG, SX; BENNETT, L; ZSEBO, K; AVRAHAM, H				GRABAREK, J; GROOPMAN, JE; LYLES, YR; JIANG, SX; BENNETT, L; ZSEBO, K; AVRAHAM, H			HUMAN KIT-LIGAND (STEM-CELL FACTOR) MODULATES PLATELET ACTIVATION IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; RECEPTOR TYROSINE KINASE; C-KIT; SIGNAL TRANSDUCTION; GROWTH-FACTOR; BLOOD-PLATELETS; PHOSPHATIDYLINOSITOL-3 KINASE; PDGF RECEPTOR; SI-LOCUS; THROMBIN	The human stem cell factor (SCF), also termed c-Kit ligand (KL), is a hematopoietic growth factor produced by mesenchymal cells that induces proliferation of bone marrow progenitor cells, megakaryocytes, and mast cells via interaction with c-kit, its cognate receptor Expression of the c-kit gene was identified in human platelets by the polymerase chain reaction technique. The presence of the c-Kit receptor was demonstrated by the specific binding of I-125-KL/SCF to ADP-stimulated platelets. The identity of the c-Kit protein was cofirmed by immunoreactivity with an anti-c-Kit-specific antibody and by its characterization as a phosphotyrosine containing protein. Under constitutive conditions, was found to be tyrosine-phosphorylated and was associated with a 85-kDa phosphoprotein that could be a fragment of phosphatidylinositol 3-kinase. These data indicate the presence of a new platelet surface molecule that could function in platelet activation. We demonstrate that the secondary wave of platelet aggregation and serotonin secretion induced by epinephrine and ADP, but not by the thromboxane analog U46619, was augmented by KL/SCF. The effect of KL/SCF on epinephrine/ADP-induced platelet activation appeared to be mediated in part through the thromboxane pathway. These data suggest that KL/SCF could modulate hemostasis via interaction pith platelets, particularly in conditions where mesenchymal cells are exposed to circulating blood elements, such as in wound healing or atherosclerosis.	AMGEN INC, THOUSAND OAKS, CA 91320 USA	Amgen	GRABAREK, J (corresponding author), HARVARD UNIV, NEW ENGLAND DEACONESS HOSP,SCH MED,DEPT MED, DIV HEMATOL ONCOL, 185 PILGRIM RD, BOSTON, MA 02215 USA.			Avraham, Hava/0000-0002-7545-3640	NHLBI NIH HHS [HL50562, HL46668] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046668, R29HL050562] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMBLER J, 1985, ADV EXP MED BIOL, V192, P293; ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; ANDREWS RG, 1990, BLOOD, V76, P10; AVRAHAM H, 1992, BLOOD, V79, P365; AVRAHAM H, 1992, BLOOD, V80, P1679; BORN GVR, 1962, NATURE, V194, P927, DOI 10.1038/194927b0; BRIDDELL RA, 1991, BLOOD, V78, P2854; COUGHLIN SR, 1989, SCIENCE, V243, P1191; CUNNINGHAM TW, 1990, J BIOL CHEM, V265, P21676; FIGS WR, 1986, J BIOL CHEM, V261, P5981; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; GERRARD JM, 1987, PLATELETS BIOL PATHO, V3, P317; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GOLDEN A, 1986, P NATL ACAD SCI USA, V83, P852, DOI 10.1073/pnas.83.4.852; GRABAREK J, 1992, J BIOL CHEM, V267, P10011; GRABAREK J, 1993, J BIOL CHEM, V268, P5543; GRANT JA, 1980, BRIT J HAEMATOL, V44, P109, DOI 10.1111/j.1365-2141.1980.tb01189.x; GUTKIND JS, 1990, MOL CELL BIOL, V10, P3806, DOI 10.1128/MCB.10.7.3806; HOLMSEN H, 1977, BIOCHIM BIOPHYS ACTA, V497, P46, DOI 10.1016/0304-4165(77)90138-6; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KATAYAMA N, 1993, BLOOD, V82, P2353; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KERALY CL, 1988, THROMB HAEMOSTASIS, V60, P209; KINLOUGHRATHBON.RL, 1987, PLATELETS BIOL PATHO, V3, P239; KINLOUGHRATHBON.RL, 1986, PLATELET RESPONSES M, P193; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEV S, 1990, MOL CELL BIOL, V10, P6064, DOI 10.1128/MCB.10.11.6064; LEV S, 1992, J BIOL CHEM, V267, P15970; LEV S, 1991, EMBO J, V10, P647, DOI 10.1002/j.1460-2075.1991.tb07993.x; LEV S, 1992, P NATL ACAD SCI USA, V89, P678, DOI 10.1073/pnas.89.2.678; MANIATIS T, 1982, MOL CLONING LABORATO, P185; MITCHELL CA, 1990, P NATL ACAD SCI USA, V87, P9396, DOI 10.1073/pnas.87.23.9396; NEWMAN PJ, 1988, J CLIN INVEST, V82, P739, DOI 10.1172/JCI113656; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; SHIMODA K, 1993, J CLIN INVEST, V91, P1310, DOI 10.1172/JCI116330; SIESS W, 1989, PHYSIOL REV, V69, P58, DOI 10.1152/physrev.1989.69.1.58; TANAKA H, 1989, BRIT J HAEMATOL, V73, P18, DOI 10.1111/j.1365-2141.1989.tb00212.x; ULICH TR, 1991, BLOOD, V78, P1954; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; Wang J. -X., 1992, RECEPTOR LIGAND INTE, P213; WARE JA, 1987, J CLIN INVEST, V80, P267, DOI 10.1172/JCI113058; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; ZHANG J, 1992, J BIOL CHEM, V267, P4686; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U; ZUCKER MB, 1989, METHOD ENZYMOL, V169, P117	50	40	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	1994	269	34					21718	21724						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PK973	7520441				2022-12-27	WOS:A1994PK97300052
J	DELUCA, LG; JOHNSON, DR; WHITLEY, MZ; COLLINS, T; POBER, JS				DELUCA, LG; JOHNSON, DR; WHITLEY, MZ; COLLINS, T; POBER, JS			CAMP AND TUMOR-NECROSIS-FACTOR COMPETITIVELY REGULATE TRANSCRIPTIONAL ACTIVATION THROUGH AND NUCLEAR FACTOR-BINDING TO THE CAMP-RESPONSIVE ELEMENT ACTIVATING TRANSCRIPTION FACTOR ELEMENT OF THE ENDOTHELIAL-LEUKOCYTE ADHESION MOLECULE-1 (E-SELECTIN) PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							NF-KAPPA-B; ELAM-1 GENE-TRANSCRIPTION; CYTOKINE INDUCTION; CELLS; FAMILY; RECEPTOR; INTERFERON; MEMBERS; PROTEIN	The cAMP-responsive element/activating transcription factor (CRE/ATF) element (also known as NF-ELAM1) of the endothelial leukocyte adhesion molecule-1 (ELAM-1) promoter is necessary for full cytokine responsiveness. It differs from a consensus cAMP-responsive element (CRE) by 1 nucleotide (G --> A conversion) and does not mediate transcriptional activation in response to cAMP. We reported previously that cAMP actually decreases ELAM-1 synthesis induced by tumor necrosis factor (TNF). We now show that cAMP decreases the ELAM-1 promoter response to TNF in transient transfection assays in bovine aortic endothelial cells and that cAMP-mediated inhibition maps to the CRE/ATF element. Electrophoretic mobility shift assays using the ELAM-1 CRE/ATF DNA sequence reveal three complexes. Antibody supershift assays suggest the slowest migrating form (complex 1) contains ATF2, the middle form (complex 2) contains ATF2 and c-Jun, and the fastest migrating form (complex 3) contains a CRE-binding protein. TNF increases c-Jun-containing complex 2 while diminishing complex 1, whereas cAMP decreases complex 2 and increases complex 1. Complex 3 is unchanged by either treatment, and the CRE-binding protein is not phosphorylated, Our data suggest that a change in the composition of the proteins binding to the CRE/ATF promoter element contributes to the competing effects of TNF and cAMP on ELAM-1 gene expression.	YALE UNIV,SCH MED,BOYER CTR MOLEC MED,NEW HAVEN,CT 06536; BRIGHAM & WOMENS HOSP,DEPT PATHOL,DIV VASC RES,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Yale University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035716, R01HL045462, R37HL036003] Funding Source: NIH RePORTER; NHLBI NIH HHS [R37-HL-36003, R01-HL-45462, R01-HL-35716] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; COLLINS T, 1991, J BIOL CHEM, V266, P2466; COWELL IG, 1992, MOL CELL BIOL, V12, P3070, DOI 10.1128/MCB.12.7.3070; DU W, 1992, P NATL ACAD SCI USA, V89, P2150, DOI 10.1073/pnas.89.6.2150; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; JAMIESON C, 1991, J IMMUNOL, V147, P416; KARPINSKI BA, 1992, P NATL ACAD SCI USA, V89, P4820, DOI 10.1073/pnas.89.11.4820; KASZUBSKA W, 1993, MOL CELL BIOL, V13, P7180, DOI 10.1128/MCB.13.11.7180; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; MADRI JA, 1980, LAB INVEST, V43, P303; MONTGOMERY KF, 1991, P NATL ACAD SCI USA, V88, P6523, DOI 10.1073/pnas.88.15.6523; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; PARHAMI F, 1993, J CLIN INVEST, V92, P471, DOI 10.1172/JCI116590; POBER JS, 1993, J IMMUNOL, V150, P5114; POBER JS, 1986, J IMMUNOL, V137, P1893; POBER JS, 1990, PHYSIOL REV, V70, P427, DOI 10.1152/physrev.1990.70.2.427; READ MA, 1994, J EXP MED, V179, P503, DOI 10.1084/jem.179.2.503; SCHWANINGER M, 1993, J BIOL CHEM, V268, P5168; VANHUIJSDUIJNEN RH, 1992, J BIOL CHEM, V267, P22385; WHELAN J, 1991, NUCLEIC ACIDS RES, V19, P2645, DOI 10.1093/nar/19.10.2645	23	82	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19193	19196						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	7518452				2022-12-27	WOS:A1994NY33200001
J	ARMESILLA, AL; VEGA, MA				ARMESILLA, AL; VEGA, MA			STRUCTURAL ORGANIZATION OF THE GENE FOR HUMAN CD36 GLYCOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET MEMBRANE GLYCOPROTEIN; IV CD36; THROMBOSPONDIN RECEPTOR; SIGNAL TRANSDUCTION; MONOCLONAL-ANTIBODY; INFECTED ERYTHROCYTES; TRANSCRIPTION FACTORS; PROMOTER SEQUENCES; ENDOTHELIAL-CELLS; HUMAN MONOCYTES	The cell-surface glycoprotein CD36 interacts with a large variety of ligands, including collagen types I and IV, thrombospondin, erythrocytes parasitized with Plasmodium falciparum, platelet-agglutinating protein p37, oxidized low density lipoprotein, and long-chain fatty acids. Its expression is restricted to platelets, monocytes, adipocytes, and some endothelial and epithelial cells and is regulated during cell activation, differentiation, and development. CD36 belongs to a novel gene family of structurally related glycoproteins that includes CLA-1 and the lysosomal membrane glycoprotein LIMPII. To advance our knowledge on the genomic organization and the regulation of the cellular expression of the genes of this family, we have investigated the structural organization of the human CD36 gene and of its 5'-proximal flanking region. The CD36 gene is encoded by 15 exons that extend more than 32 kilobases on the human genome. Interestingly, the CD36 mRNA 5'-untranslated region is encoded by three exons. The 3'-untranslated region is contained in two exons, whose expression pattern can originate two mRNA forms. The cytoplasmic and transmembrane regions predicted at both terminal ends of the polypeptide chain are encoded by single exons, while the extracellular domain is encoded by 11 exons. The transcription initiation site of the CD36 gene is located 289 nucleotides upstream from the translational start codon. Sequence analysis of the proximal 5'-flanking region of the gene reveals the existence of a TATA box appropriately located with respect to the transcription initiation site and several potential cis-regulatory elements that might contribute to the transcriptional regulation of the CD36 gene. Delineation of the structural organization of the CD36 gene may help in defining the boundaries of relevant structural and/or functional domains in CD36 and, by extension, in the other members of the family.	HOSP PRINCESA,E-28006 MADRID,SPAIN; CSIC,E-28006 MADRID,SPAIN	Hospital de La Princesa; Consejo Superior de Investigaciones Cientificas (CSIC)			Vega, Miguel A/M-1367-2016	Vega, Miguel A/0000-0001-6151-4193; Armesilla, Angel/0000-0003-3546-5580				ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; AIKEN ML, 1990, BLOOD, V76, P2501; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ALBERTSEN HM, 1990, P NATL ACAD SCI USA, V88, P4123; ASCH AS, 1987, J CLIN INVEST, V79, P1054, DOI 10.1172/JCI112918; ASCH AS, 1993, SCIENCE, V262, P1436, DOI 10.1126/science.7504322; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BARNWELL JW, 1985, J IMMUNOL, V135, P3494; BUCHER P, 1986, NUCLEIC ACIDS RES, V14, P10009, DOI 10.1093/nar/14.24.10009; CALVO D, 1993, J BIOL CHEM, V268, P18929; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; CLEZARDIN P, 1985, BRIT J HAEMATOL, V60, P331, DOI 10.1111/j.1365-2141.1985.tb07419.x; COURTOIS SJ, 1990, NUCLEIC ACIDS RES, V18, P57, DOI 10.1093/nar/18.1.57; EDELMAN P, 1986, BLOOD, V67, P56; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FERNANDEZRUIZ E, 1993, GENOMICS, V17, P759, DOI 10.1006/geno.1993.1401; FITZGERALD M, 1981, CELL, V24, P251, DOI 10.1016/0092-8674(81)90521-3; GHOSH D, 1991, TRENDS BIOCHEM SCI, V16, P445, DOI 10.1016/0968-0004(91)90173-S; GREENWALT DE, 1990, BIOCHEMISTRY-US, V29, P7054, DOI 10.1021/bi00482a015; GREENWALT DE, 1992, BLOOD, V80, P1105; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; JUHLIN L, 1989, ACTA DERM-VENEREOL, V69, P403; KIEFFER N, 1989, BIOCHEM J, V262, P835, DOI 10.1042/bj2620835; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KNOWLES DM, 1984, J IMMUNOL, V132, P2170; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEUNG LLK, 1992, J BIOL CHEM, V267, P18244; LIAN ECY, 1991, THROMB HAEMOSTASIS, V65, P102; LIPSKY RH, 1991, THROMB HAEMOSTASIS, V65, P456; MARTH JD, 1988, NATURE, V332, P171, DOI 10.1038/332171a0; MCGREGOR JL, 1989, J BIOL CHEM, V264, P501; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NOGUCHI K, 1993, BIOCHEM BIOPH RES CO, V192, P88, DOI 10.1006/bbrc.1993.1385; OCKENHOUSE CF, 1989, SCIENCE, V243, P1469, DOI 10.1126/science.2467377; OCKENHOUSE CF, 1989, J CLIN INVEST, V84, P468, DOI 10.1172/JCI114188; OQUENDO P, 1989, CELL, V58, P95, DOI 10.1016/0092-8674(89)90406-6; PARTHASARATHY S, 1992, ANNU REV MED, V43, P219, DOI 10.1146/annurev.me.43.020192.001251; POSTEL EH, 1989, MOL CELL BIOL, V9, P5123, DOI 10.1128/MCB.9.11.5123; RENKAWITZ R, 1984, CELL, V37, P503, DOI 10.1016/0092-8674(84)90380-5; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sambrook J, 1989, MOL CLONING LABORATO; SAVILL J, 1992, J CLIN INVEST, V90, P1513, DOI 10.1172/JCI116019; SCHUEPP BJ, 1991, BIOCHEM BIOPH RES CO, V175, P263, DOI 10.1016/S0006-291X(05)81229-X; SCOTT LM, 1992, BLOOD, V80, P1725; SHANNON MF, 1988, P NATL ACAD SCI USA, V85, P674, DOI 10.1073/pnas.85.3.674; SIDDIQUI FA, 1992, BIOCHEM INT, V27, P485; SILVERSTEIN RL, 1989, J CLIN INVEST, V84, P546, DOI 10.1172/JCI114197; SILVERSTEIN RL, 1992, J BIOL CHEM, V267, P16607; SMITH MW, 1988, J MOL EVOL, V27, P45, DOI 10.1007/BF02099729; SWERLICK RA, 1992, J IMMUNOL, V148, P78; TANDON NN, 1989, J BIOL CHEM, V264, P7576; TANDON NN, 1991, BLOOD, V78, P2809; TREZZINI C, 1990, IMMUNOLOGY, V71, P29; VANSCHRAVENDIJK MR, 1992, BLOOD, V80, P2105; VASSEURCOGNET M, 1993, CURR OPIN GENET DEV, V3, P238, DOI 10.1016/0959-437X(93)90029-O; VEGA MA, 1991, J BIOL CHEM, V266, P16818; WELLS RD, 1988, J BIOL CHEM, V263, P1095; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; YANG Z, 1990, P NATL ACAD SCI USA, V87, P9226, DOI 10.1073/pnas.87.23.9226	61	105	112	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					18985	18991						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	7518447				2022-12-27	WOS:A1994NX32700044
J	AKIYAMA, SK; YAMADA, SS; YAMADA, KM; LAFLAMME, SE				AKIYAMA, SK; YAMADA, SS; YAMADA, KM; LAFLAMME, SE			TRANSMEMBRANE SIGNAL-TRANSDUCTION BY INTEGRIN CYTOPLASMIC DOMAINS EXPRESSED IN SINGLE-SUBUNIT CHIMERAS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN-TYROSINE KINASE; HUMAN INTERLEUKIN-2 RECEPTOR; CELL-SURFACE RECEPTORS; EXTRACELLULAR-MATRIX; FIBRONECTIN RECEPTOR; BETA-SUBUNIT; MONOCLONAL-ANTIBODIES; BOMBESIN STIMULATION; MOLECULAR-CLONING; FOCAL ADHESIONS	Integrins are heterodimeric, transmembrane cell adhesion receptors that have recently been shown to function in transmembrane signal transduction. To examine the specific role of integrin intracellular domains in signal transduction, chimeric receptors containing various integrin intracellular domains coupled to a reporter consisting of the transmembrane and extracellular domains of the small, non-signaling subunit of the interleukin-2 receptor were expressed in cultured human fibroblasts and assayed for their ability to trigger tyrosine phosphorylation of the 125-kDa cytoplasmic tyrosine kinase, pp125(FAK). Tyrosine phosphorylation of pp125(FAK) was induced in cultured fibroblasts that transiently expressed chimeric receptors containing either the beta(1), beta(3), beta(5) integrin intracellular domain and were selected by magnetic bead sorting. However, expression of chimeric receptors containing either the alpha(5) or an alternatively spliced form of the beta(3) intracellular domain (beta(3B)), as well as those lacking an intracellular domain, failed to induce tyrosine phosphorylation of pp125(FAK). These results indicate that information contained in the beta(1), beta(3), or beta(5) integrin intracellular domain is sufficient to stimulate integrin-mediated tyrosine phosphorylation of specific intracellular proteins and that integrin extracellular and transmembrane domains are not required for inducing tyrosine phosphorylation. Our results also indicate that alternative splicing can regulate the ability of beta integrin intracellular domains to participate in signal transduction, and they further suggest that the carboxyl-terminal region of specific beta integrins may play a role in the signal transduction pathway involving extracellular matrix molecules.			AKIYAMA, SK (corresponding author), NIDR, DEV BIOL LAB, BLDG 30, BETHESDA, MD 20892 USA.			Yamada, Kenneth/0000-0003-1512-6805				AKIYAMA SK, 1990, BIOCHIM BIOPHYS ACTA, V1031, P91, DOI 10.1016/0304-4157(90)90004-V; AKIYAMA SK, 1985, J BIOL CHEM, V260, P3256; AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; BAUER JS, 1993, J CELL BIOL, V122, P209, DOI 10.1083/jcb.122.1.209; BOCKHOLT SM, 1993, J BIOL CHEM, V268, P14565; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CHAN BM, 1992, CELL, V68, P1051, DOI 10.1016/0092-8674(92)90077-P; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; FITZGERALD LA, 1987, J BIOL CHEM, V262, P3936; GEIGER B, 1992, J CELL SCI, V103, P943; Ginsberg Mark H., 1992, Current Opinion in Cell Biology, V4, P766, DOI 10.1016/0955-0674(92)90099-X; GIORDANO T, 1991, EXP CELL RES, V192, P193, DOI 10.1016/0014-4827(91)90175-T; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HAIMOVICH B, 1993, J BIOL CHEM, V268, P15868; HAMAWY MM, 1993, J BIOL CHEM, V268, P6851; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HAYASHI Y, 1990, J CELL BIOL, V110, P175, DOI 10.1083/jcb.110.1.175; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HIBBS ML, 1991, J EXP MED, V174, P1227, DOI 10.1084/jem.174.5.1227; HOGERVORST F, 1993, J BIOL CHEM, V268, P18427; HUANG MM, 1993, J CELL BIOL, V122, P473, DOI 10.1083/jcb.122.2.473; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KASSNER PD, 1993, J EXP MED, V178, P649, DOI 10.1084/jem.178.2.649; KAWAGUCHI S, 1993, J BIOL CHEM, V268, P16279; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; LAFLAMME SE, 1992, J CELL BIOL, V117, P437, DOI 10.1083/jcb.117.2.437; LEEBLUNDBERG LMF, 1993, J BIOL CHEM, V268, P8151; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MARCANTONIO EE, 1990, CELL REGUL, V1, P597, DOI 10.1091/mbc.1.8.597; MCLEAN JW, 1990, J BIOL CHEM, V265, P17126; MIEKKA SI, 1982, THROMB RES, V27, P1, DOI 10.1016/0049-3848(82)90272-9; NIKAIDO T, 1984, NATURE, V311, P631, DOI 10.1038/311631a0; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; PADMANABHAN R, 1988, ANAL BIOCHEM, V170, P341, DOI 10.1016/0003-2697(88)90640-9; RAMASWAMY H, 1990, EMBO J, V9, P1561, DOI 10.1002/j.1460-2075.1990.tb08275.x; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; Sambrook J, 1989, MOL CLONING LABORATO; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHWARTZ M A, 1992, Trends in Cell Biology, V2, P304, DOI 10.1016/0962-8924(92)90120-C; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; SOLOWSKA J, 1989, J CELL BIOL, V109, P853, DOI 10.1083/jcb.109.2.853; SUZUKI S, 1990, P NATL ACAD SCI USA, V87, P5354, DOI 10.1073/pnas.87.14.5354; TURNER CE, 1993, J CELL SCI, V105, P637; VANKUPPEVELT THMSM, 1989, P NATL ACAD SCI USA, V86, P5415; YAMADA KM, 1992, COLD SPRING HARB SYM, V57, P203, DOI 10.1101/SQB.1992.057.01.025; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P	57	155	157	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					15961	15964						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	7515874				2022-12-27	WOS:A1994NQ72900002
J	MAUREL, C; REIZER, J; SCHROEDER, JI; CHRISPEELS, MJ; SAIER, MH				MAUREL, C; REIZER, J; SCHROEDER, JI; CHRISPEELS, MJ; SAIER, MH			FUNCTIONAL-CHARACTERIZATION OF THE ESCHERICHIA-COLI GLYCEROL FACILITATOR, GLPF, IN XENOPUS-OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR INTRINSIC PROTEIN; CHANNELS; OPERON; KINASE; CHIP28; CELL	The glycerol facilitator of Escherichia coli, GlpF, is a putative nonselective transport channel in the inner membrane of this Gram-negative bacterium. It is a member of the major intrinsic protein (MIP) family of transmembrane channel proteins. Its characterization has been hampered by the lack of a heterologous test system in which its activity can be examined in the absence of other bacterial proteins. Transport of glycerol mediated by this protein was characterized following injection of glpF mRNA into Xenopus laevis oocytes. The properties of GlpF were compared with those of the homologous plant water channel protein, gamma tonoplast intrinsic protein (gamma TIP), as well as the nonhomologous Xenopus K+ channel, Xsha. GlpF selectively transported glycerol but not water or ions, while gamma TIP and Xsha were specific for water and K+, respectively. Voltage clamp experiments showed that GlpF was not voltage-activated for ion transport. Glycerol transport via GlpF proved to be nonsaturable up to 200 mM and exhibited a low temperature of activation (Ea = 4.5 kcal/mol), consistent with the conclusion of Heller ct al. (Heller, K. B., Lin, E. C. C., and Wilson, T. H. (1980) J. Bacteriol. 144, 274-278) that GlpF mediates glycerol diffusion via a pore type mechanism. GlpF-mediated transport of glycerol was blocked by mercuric ions (Hg2+) but not N-ethylmaleimide. The inhibitory effect of Hg2+ was partially prevented by inclusion of a high concentration of glycerol and reversed by mercaptoethanol. The results serve to characterize the transport properties of the E. coli glycerol facilitator.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI014176, R01AI021702] Funding Source: NIH RePORTER; NIAID NIH HHS [2RO1AI 14176, 5RO1AI 21702] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALEMOHAMMAD MM, 1974, J GEN MICROBIOL, V82, P125, DOI 10.1099/00221287-82-1-125; BAKER ME, 1990, CELL, V60, P185, DOI 10.1016/0092-8674(90)90731-S; BENAZILLA F, 1977, J GEN PHYSIOL, V70, P549; BERMANKU.M, 1971, J BACTERIOL, V106, P724, DOI 10.1128/JB.106.3.724-731.1971; BISSON LF, 1983, P NATL ACAD SCI-BIOL, V80, P1730, DOI 10.1073/pnas.80.6.1730; COZZARELLI NR, 1968, J MOL BIOL, V31, P371, DOI 10.1016/0022-2836(68)90415-4; EHRING GR, 1990, J GEN PHYSIOL, V96, P631, DOI 10.1085/jgp.96.3.631; HAYASHI SI, 1965, J MOL BIOL, V14, P515, DOI 10.1016/S0022-2836(65)80200-5; HELLER KB, 1980, J BACTERIOL, V144, P274, DOI 10.1128/JB.144.1.274-278.1980; JASPERS HTA, 1975, BIOCHIM BIOPHYS ACTA, V406, P370, DOI 10.1016/0005-2736(75)90017-6; LIN ECC, 1976, ANNU REV MICROBIOL, V30, P535, DOI 10.1146/annurev.mi.30.100176.002535; LIN ECC, 1977, ANNU REV BIOCHEM, V46, P765, DOI 10.1146/annurev.bi.46.070177.004001; MAUREL C, 1993, EMBO J, V12, P2241, DOI 10.1002/j.1460-2075.1993.tb05877.x; MURAMATSU S, 1989, NUCLEIC ACIDS RES, V17, P4378; NOVOTNY MJ, 1985, J BACTERIOL, V162, P810, DOI 10.1128/JB.162.2.810-816.1985; PAO GM, 1991, MOL MICROBIOL, V5, P33, DOI 10.1111/j.1365-2958.1991.tb01823.x; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1993, J BIOL CHEM, V268, P17; REIZER J, 1993, CRIT REV BIOCHEM MOL, V28, P235, DOI 10.3109/10409239309086796; SAIER MH, 1985, MECHANISMS REGULATIO; SIEGEL E, 1990, J MEMBRANE BIOL, V117, P201; SWEET G, 1990, J BACTERIOL, V172, P424, DOI 10.1128/JB.172.1.424-430.1990; TRUNIGER V, 1992, J BACTERIOL, V174, P6981, DOI 10.1128/JB.174.21.6981-6991.1992; VANCE DE, 1993, BIOCHEMISTRY-US, V3, P163; VANHOEK AN, 1992, J BIOL CHEM, V267, P18267; VOEGELE RT, 1993, J BACTERIOL, V175, P1087, DOI 10.1128/JB.175.4.1087-1094.1993; WEISSENBORN DL, 1992, J BIOL CHEM, V267, P6122	27	156	158	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11869	11872						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	7512955				2022-12-27	WOS:A1994NG37700032
J	CONOVER, CA; DURHAM, SK; ZAPF, J; MASIARZ, FR; KIEFER, MC				CONOVER, CA; DURHAM, SK; ZAPF, J; MASIARZ, FR; KIEFER, MC			CLEAVAGE ANALYSIS OF INSULIN-LIKE GROWTH-FACTOR (IGF)-DEPENDENT IGF-BINDING PROTEIN-4 PROTEOLYSIS AND EXPRESSION OF PROTEASE-RESISTANT IGF-BINDING PROTEIN-4 MUTANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RIBONUCLEIC-ACID; CELL-CONDITIONED MEDIUM; MOLECULAR-CLONING; HORMONAL-REGULATION; HUMAN-FIBROBLASTS; RAT; SEQUENCE	Cultured human fibroblasts and osteoblast-like cells secrete an insulin-like growth factor (IGF)-dependent protease that cleaves IGF-binding protein-4 (IGFBP-4) into two fragments of similar to 18 and 14 kDa. Edman degradation of the isolated proteins established the amino ter mini of the reaction products, Sequence analysis of the 14-kDa carboxyl terminal half of IGFBP-4 suggested cleavage after methionine at position 135 of the mature protein, Four variant IGPBP-4 molecules with single amino acid substitutions around this cleavage site were constructed and expressed, Wild-type and mutant IGFBPs-4 bound IGF-I and IGF-II with equivalent affinities and, in the intact state, were equally effective inhibitors of IGF-I action, However, the IGFEP-4 mutants were relatively resistant to IGF-dependent proteolysis, A 5-6-h incubation in human fibroblast conditioned medium in the presence of IGF-II was sufficient for near total hydrolysis of wild-type IGFBP-4, whereas the mutant IGFBPs-4 were only minimally affected at this time, After a 24-h incubation with IGF-II, all mutant IGFBPs-4 showed extensive proteolysis, generating 18- and 14-kDa fragments, Pre-exposure of human fibroblasts in serum-free conditioned medium to IGF-II for 5 h potentiated subsequent IGF-I stimulation of DNA synthesis, When added with IGF-II, the protease-resistant mutant IGFBPs-4, but not wild-type IGFBP-4, suppressed IGF-II enhancement of IGF-I-stimulated DNA synthesis, These biological studies suggest that the IGFBP-4/IGFBP-4 protease system may play a role modulating local cellular response to IGF-I.	UNIV ZURICH HOSP,DEPT MED,METAB UNIT,CH-8091 ZURICH,SWITZERLAND; CHIRON CORP,EMERYVILLE,CA 94608; LXR BIOTECHNOL INC,RICHMOND,CA 94804	University of Zurich; University Zurich Hospital; Novartis	CONOVER, CA (corresponding author), MAYO CLIN & MAYO FDN,DIV ENDOCRINOL & METAB,ENDOCRINE RES UNIT,5-164 W JOSEPH,ROCHESTER,MN 55905, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK043258, T32DK007352, R01DK043258] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-43258, DK-07352] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDRESS DL, 1992, J BIOL CHEM, V267, P22467; BALE LK, 1992, ENDOCRINOLOGY, V131, P608, DOI 10.1210/en.131.2.608; CHERNAUSEK SD, 1994, 3RD INT S INS LIK GR; CHEUNG PT, 1991, ENDOCRINOLOGY, V129, P1005; CLEMENTS JA, 1989, ENDOCR REV, V10, P393, DOI 10.1210/edrv-10-4-393; CONOVER CA, 1993, J CLIN INVEST, V91, P1129, DOI 10.1172/JCI116272; CONOVER CA, 1989, J CLIN INVEST, V83, P852, DOI 10.1172/JCI113968; CONOVER CA, 1992, ENDOCRINOLOGY, V130, P3191, DOI 10.1210/en.130.6.3191; CONOVER CA, 1994, ENDOCRINOLOGY, V135, P76, DOI 10.1210/en.135.1.76; CONOVER CA, 1993, ENDOCRINOLOGY, V133, P1347, DOI 10.1210/en.133.3.1347; CULOUSCOU JM, 1991, CANCER RES, V51, P2813; DURHAM SK, 1994, J BONE MINER RES, V9, P111; ERICKSON GF, 1992, ENDOCRINOLOGY, V130, P625, DOI 10.1210/en.130.2.625; FOWLKES J, 1992, ENDOCRINOLOGY, V131, P2071, DOI 10.1210/en.131.5.2071; HANCOCK K, 1983, ANAL BIOCHEM, V133, P157, DOI 10.1016/0003-2697(83)90237-3; HOSSENLOPP P, 1986, ANAL BIOCHEM, V154, P138, DOI 10.1016/0003-2697(86)90507-5; HUHTALA ML, 1986, BIOCHEM BIOPH RES CO, V141, P263, DOI 10.1016/S0006-291X(86)80363-1; KANZAKI S, 1994, ENDOCRINOLOGY, V134, P383, DOI 10.1210/en.134.1.383; KIEFER MC, 1992, J BIOL CHEM, V267, P12692; KIEFER MC, 1991, BIOCHEM BIOPH RES CO, V176, P219, DOI 10.1016/0006-291X(91)90912-Q; LATOUR D, 1990, MOL ENDOCRINOL, V4, P1806, DOI 10.1210/mend-4-12-1806; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOHAN S, 1989, P NATL ACAD SCI USA, V86, P8338, DOI 10.1073/pnas.86.21.8338; PERKEL VS, 1990, J CLIN ENDOCR METAB, V71, P533, DOI 10.1210/jcem-71-2-533; SCHMID C, 1991, BIOCHEM BIOPH RES CO, V179, P579, DOI 10.1016/0006-291X(91)91410-E; SHIMASAKI S, 1991, MOL ENDOCRINOL, V5, P938, DOI 10.1210/mend-5-7-938; SHIMASAKI S, 1990, MOL ENDOCRINOL, V4, P1451, DOI 10.1210/mend-4-10-1451; WANG JF, 1988, BIOCHEM BIOPH RES CO, V157, P718, DOI 10.1016/S0006-291X(88)80309-7	28	88	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4395	4400		10.1074/jbc.270.9.4395	http://dx.doi.org/10.1074/jbc.270.9.4395			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7533161	hybrid			2022-12-27	WOS:A1995QK08400035
J	LUSTINARASIMHAN, M; POWER, CA; ALLET, B; ALOUANI, S; BACON, KB; MERMOD, JJ; PROUDFOOT, AEI; WELLS, TNC				LUSTINARASIMHAN, M; POWER, CA; ALLET, B; ALOUANI, S; BACON, KB; MERMOD, JJ; PROUDFOOT, AEI; WELLS, TNC			MUTATION OF LEU(25) AND VAL(27) INTRODUCES CC CHEMOKINE ACTIVITY INTO INTERLEUKIN-8	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE CHEMOATTRACTANT PROTEIN-1; FUNCTIONAL EXPRESSION; ACTIVATING FACTOR; RECEPTOR; FAMILY; RANTES; PURIFICATION; CYTOKINE; GENE; LYMPHOCYTES	Interleukin-8 (IL-8) is a member of the CXC branch of the chemokine superfamily and activates neutrophils but not monocytes. The related CC chemokine branch, which includes monocyte chemoattractant protein-1 (MCP-1) and RANTES are potent chemoattractants for monocytes but not neutrophils. Examination of the sequences of the CXC chemokines reveals that the highly conserved leucine, corresponding to Leu(25) in IL-8, is always replaced by tyrosine in CC chemokines, There is also a high degree of conservation among the CXC chemokines of the adjacent Val(27) residue, which points out from the same side of the beta-sheet as Leu(25). In RANTES, Val(27) is also replaced by a tyrosine. In order to investigate the role of these residues in controlling cell specificity, we have made the single mutants Leu(25) --> Tyr, Val(27) --> Tyr and the double mutant Leu(25) --> Tyr, Val(27) --> Tyr of IL-8. These proteins have been expressed in Escherichia colt and purified to homogeneity from inclusion body material, Ah three mutants have lower potency and efficacy in chemotaxis and calcium mobilization assays using neutrophils. The mutants also show lowered affinity to both IL-8 receptors A and B expressed recombinantly in HL-60 cells and to neutrophils in [(125)]IL-8 com petition assays. Additionally, the Leu(25) --> Tyr mutation introduces a novel monocyte chemoattractant activity into IL-8, We therefore studied the displacement of [I-125]MIP-1 alpha by IL-8 Leu(25) --> Tyr from the CC-CKR-1 receptor. The mutant displaces MIP-1 alpha ligand with an affinity only 12-fold less than MIP-1 alpha itself. This suggests that mutations in this region of IL-S are involved in receptor binding and activation and in the control of specificity between CC and CXC chemokines.	GLAXO INST MOLEC BIOL SA,CH-1228 PLAN LES OUATES,SWITZERLAND	GlaxoSmithKline				Wells, Timothy/0000-0001-9796-847X; Narasimhan, Manjulaa/0000-0003-0598-6887				ALAM R, 1993, J IMMUNOL, V150, P3442; ANISOWICZ A, 1987, P NATL ACAD SCI USA, V84, P7188, DOI 10.1073/pnas.84.20.7188; BAGGIOLINI M, 1992, FEBS LETT, V307, P97, DOI 10.1016/0014-5793(92)80909-Z; BALDWIN ET, 1991, P NATL ACAD SCI USA, V88, P502, DOI 10.1073/pnas.88.2.502; BEALL CJ, 1992, J BIOL CHEM, V267, P3455; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; CARTER PJ, 1984, CELL, V38, P835, DOI 10.1016/0092-8674(84)90278-2; CLARKLEWIS I, 1991, BIOCHEMISTRY-US, V30, P3128, DOI 10.1021/bi00226a021; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P1689, DOI 10.1021/bi00459a004; CLORE GM, 1991, PROTEIN ENG, V4, P263; FINCHAM NJ, 1988, J IMMUNOL, V140, P4294; FUHLBRIGGE RC, 1988, P NATL ACAD SCI USA, V85, P5649, DOI 10.1073/pnas.85.15.5649; GAO JL, 1993, J EXP MED, V199, P1421; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HARVATH L, 1980, J IMMUNOL METHODS, V37, P39, DOI 10.1016/0022-1759(80)90179-9; HEBERT CA, 1991, J BIOL CHEM, V266, P18989; HERMODSON M, 1977, J BIOL CHEM, V252, P6276; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; LEATHERBARROW RJ, 1993, GRAFIT VERSION 3 01; LODI PJ, 1994, SCIENCE, V263, P1762, DOI 10.1126/science.8134838; LUSTER AD, 1985, NATURE, V315, P672, DOI 10.1038/315672a0; MATSUSHIMA K, 1989, J EXP MED, V169, P1485, DOI 10.1084/jem.169.4.1485; MILLER MD, 1992, CRIT REV IMMUNOL, V12, P17; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; NIEWIAROWSKI S, 1981, PLATELETS BIOL PATHO, V2, P91; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PAOLINI JF, 1994, J IMMUNOL, V153, P2704; ROT A, 1992, J EXP MED, V176, P1489, DOI 10.1084/jem.176.6.1489; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; SCHALL TJ, 1988, J IMMUNOL, V141, P1018; SCHMID J, 1987, J IMMUNOL, V139, P250; SCHRODER JM, 1987, J IMMUNOL, V139, P3474; SHAW JP, 1994, J MOL BIOL, V237, P349; TSIEN RY, 1982, J CELL BIOL, V94, P325, DOI 10.1083/jcb.94.2.325; VANDAMME J, 1992, J EXP MED, V176, P59, DOI 10.1084/jem.176.1.59; VANRIPER G, 1993, J EXP MED, V177, P851, DOI 10.1084/jem.177.3.851; WALZ A, 1991, J EXP MED, V174, P1355, DOI 10.1084/jem.174.6.1355; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001; WELLS TNC, 1985, NATURE, V316, P656, DOI 10.1038/316656a0; WOLPE SD, 1988, J EXP MED, V167, P570, DOI 10.1084/jem.167.2.570; ZHANG YJ, 1994, J BIOL CHEM, V269, P15918	42	46	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2716	2721		10.1074/jbc.270.6.2716	http://dx.doi.org/10.1074/jbc.270.6.2716			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7531692	hybrid			2022-12-27	WOS:A1995QF53500050
J	ARIMILLI, S; CARDOSO, C; MUKKU, P; BAICHWAL, V; NAG, B				ARIMILLI, S; CARDOSO, C; MUKKU, P; BAICHWAL, V; NAG, B			REFOLDING AND RECONSTITUTION OF FUNCTIONALLY ACTIVE COMPLEXES OF HUMAN-LEUKOCYTE ANTIGEN-DR2 AND MYELIN BASIC-PROTEIN PEPTIDE FROM RECOMBINANT-ALPHA AND RECOMBINANT-BETA POLYPEPTIDE-CHAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-II MOLECULES; B-CELL LINE; ESCHERICHIA-COLI; T-CELLS; 3-DIMENSIONAL STRUCTURE; SCALE PURIFICATION; SURFACE EXPRESSION; HEAVY-CHAIN; MHC; BINDING	Major histocompatibility complex (MHC) class II molecules are cell surface heterodimeric glycoproteins consisting of one alpha and one beta polypeptide chain of similar size. These molecules play a critical role in immune recognition by displaying processed antigens to CD4-positive T helper cells. Several attempts to express the MHC class II molecules by recombinant methods in various systems resulted in either failure or poor recovery of the intact heterodimer. The present study describes our successful effort to refold and reconstitute HLA DR2 heterodimer from individually expressed alpha and beta polypeptide chains lacking the transmembrane hydrophobic regions in Escherichia coli, in the presence of an immunodominant epitope analog from human myelin basic protein (b-MBP(83-102)Y-83). The reconstituted DR2 heterodimer complex was selectively purified from unfolded alpha and beta chains using heterodimer-specific monoclonal antibody (L243) coupled to a solid support. The detection of two polypeptide chains in the purified refolded DR2-peptide complex preparations was accomplished by Western blot analysis and enzyme-linked immunosorbent assay using heterodimer- and chain-specific polyclonal antibodies, and the presence of equimolar amounts of both alpha chain and beta chain in the reconstituted complex preparation was confirmed by a double label experiment. The quantitation of the bound peptide in complex preparation was measured by incubating two chains in the presence of I-125-labeled peptide. An increase in the yield of refolded and reconstituted DR2-peptide complexes was observed with increasing peptide concentration in the reaction mixture. Finally, the functional activity of the reconstituted DR2 complexes was measured by their ability to stimulate gamma-interferon production by SS8T cloned T cells in an antigen-specific and dose-dependent manner. These results demonstrate that biologically active complexes of human DR2-b-MBP(83-102)Y-83 can be prepared by proper folding of human leukocyte antigen DR2 alpha and beta chains in the presence of antigenic peptide, The yield of such DR2 heterodimers with bound peptide is several thousand-fold higher over native DR2 purified from transformed B cells. Since purified MHC class II-peptide complexes have been shown to prevent autoimmune diseases in various animal models, reconstituted heterodimer complexes may have significant clinical relevance in antigen-specific treatment of various autoimmune diseases. In addition, such complexes with increased yield will provide better understanding of the trimolecular interactions between MHC-peptide and T cell receptor.	ANERGEN INC, REDWOOD CITY, CA 94063 USA									AGRAWAL B, 1994, J IMMUNOL, V152, P965; ALLEN PM, 1987, IMMUNOL REV, V98, P171, DOI 10.1111/j.1600-065X.1987.tb00524.x; ALTMAN JD, 1993, P NATL ACAD SCI USA, V90, P10330, DOI 10.1073/pnas.90.21.10330; BABITT BP, 1985, NATURE, V317, P359; BJORKMAN PJ, 1990, ANNU REV BIOCHEM, V59, P253, DOI 10.1146/annurev.bi.59.070190.001345; BRACIALE TJ, 1987, IMMUNOL REV, V98, P95, DOI 10.1111/j.1600-065X.1987.tb00521.x; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BUCHNER J, 1991, BIO-TECHNOL, V9, P157, DOI 10.1038/nbt0291-157; BUELOW R, 1993, EUR J IMMUNOL, V23, P69, DOI 10.1002/eji.1830230112; BUSS S, 1987, IMMUNOL REV, V98, P115; FAHENSTOCK ML, 1992, SCIENCE, V258, P1658; GARBOCZI DN, 1992, P NATL ACAD SCI USA, V89, P3429, DOI 10.1073/pnas.89.8.3429; GERMAIN RN, 1991, NATURE, V353, P134, DOI 10.1038/353134a0; GORGA JC, 1987, J BIOL CHEM, V262, P16087; HUNT DF, 1992, SCIENCE, V256, P1817, DOI 10.1126/science.1319610; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; JARDETZKY TS, 1990, EMBO J, V9, P1797, DOI 10.1002/j.1460-2075.1990.tb08304.x; LAMPSON LA, 1980, J IMMUNOL, V125, P293; LANZAVECCHIA A, 1988, NATURE, V334, P530, DOI 10.1038/334530a0; LIE WR, 1990, NATURE, V344, P439, DOI 10.1038/344439a0; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; NAG B, 1993, J BIOL CHEM, V268, P14360; NAG B, 1993, P NATL ACAD SCI USA, V90, P1604, DOI 10.1073/pnas.90.4.1604; NAG B, 1993, J IMMUNOL, V150, P1358; NAG B, 1994, J BIOL CHEM, V269, P10061; NAG B, 1994, MOL IMMUNOL, V31, P1161, DOI 10.1016/0161-5890(94)90030-2; NAG B, 1992, J IMMUNOL, V148, P369; PARHAM P, 1979, J BIOL CHEM, V254, P8709; PARKER KC, 1992, J BIOL CHEM, V267, P5451; PASSMORE D, 1992, J IMMUNOL METHODS, V155, P193, DOI 10.1016/0022-1759(92)90285-2; PICHLER WJ, 1994, IMMUNOL TODAY, V15, P312, DOI 10.1016/0167-5699(94)90078-7; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SADEGYNASSERI S, 1991, NATURE, V13, P43; SCHEIRLE A, 1992, J IMMUNOL, V149, P1994; SCHWARTZ RH, 1985, ANNU REV IMMUNOL, V3, P237, DOI 10.1146/annurev.iy.03.040185.001321; SHARMA SD, 1991, P NATL ACAD SCI USA, V88, P11465, DOI 10.1073/pnas.88.24.11465; SILVER ML, 1991, NATURE, V350, P619, DOI 10.1038/350619a0; SQUIRES CH, 1988, J BIOL CHEM, V263, P16297; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; STERN LJ, 1992, CELL, V68, P465, DOI 10.1016/0092-8674(92)90184-E; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TURKEWITZ AP, 1983, MOL IMMUNOL, V20, P1139, DOI 10.1016/0161-5890(83)90137-2; WEBER F, 1993, P NATL ACAD SCI USA, V90, P11049, DOI 10.1073/pnas.90.23.11049; WETTSTEIN DA, 1991, J EXP MED, V174, P219, DOI 10.1084/jem.174.1.219; WITT SN, 1992, J AM CHEM SOC, V114, P3506, DOI 10.1021/ja00035a052; YEWDELL JW, 1990, CELL, V62, P203, DOI 10.1016/0092-8674(90)90356-J	48	28	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					971	977		10.1074/jbc.270.2.971	http://dx.doi.org/10.1074/jbc.270.2.971			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7529765	hybrid			2022-12-27	WOS:A1995QB81600073
J	HANDLEYGEARHART, PM; STEPHEN, AG; TRAUSCHAZAR, JS; CIECHANOVER, A; SCHWARTZ, AL				HANDLEYGEARHART, PM; STEPHEN, AG; TRAUSCHAZAR, JS; CIECHANOVER, A; SCHWARTZ, AL			HUMAN UBIQUITIN-ACTIVATING ENZYME, E1 - INDICATION OF POTENTIAL NUCLEAR AND CYTOPLASMIC SUBPOPULATIONS USING EPITOPE-TAGGED CDNA CONSTRUCTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE Y-CHROMOSOME; MESSENGER-RNA; TRANSCRIPTIONAL ACTIVATOR; MOLECULAR-CLONING; CELL-NUCLEUS; PROTEIN; GENE; LOCALIZATION; EXPRESSION; MUTANT	The ubiquitin-activating enzyme E1 catalyzes the first step in the ubiquitin conjugation pathway, Previously, we have cloned and sequenced the cDNA for human E1. Expression of the E1 cDNA in the ts20 cell line, which harbors a thermolabile E1, abrogated the phenotypic defects associated with this line. However, little is known of the cell biology of the E1 protein or the nature of the E1 doublet. Thus, we constructed epitope-tagged E1 cDNAs in which the HA monoclonal antibody epitope tag sequence (from influenza hemagglutinin and recognized by the 12CA5 monoclonal antibody) was fused to the amino terminus of E1. Because the amino-terminal amino acid sequence of E1 is unknown, three constructs were made in which the HA tag was placed at each of the first three ATGs in the open reading frame (HA-1E1, HA-2E1, and HA-3E1). Western analysis of HeLa cells transfected with the constructs revealed that HA-1E1 closely comigrated with the upper band of the E1 doublet, and HA-2E1 comigrated with the lower band of the E1 doublet; HA-3E1 appeared smaller than either of the E1 bands, Metabolic labeling with P-32 and immunoprecipitation with anti-HA antibody revealed that only the HA-1E1 protein product is phosphorylated; polyclonal anti-E1 antibody showed that only the upper band of the endogenous E1 doublet is phosphorylated, Each of the constructs was able to rescue the mutant phenotype of the ts20 cell line. Immunofluorescence studies showed that HA-2E1 and HA-3E1 were distributed in the cytoplasm with both negative and positive nuclei. This pattern of distribution has also been observed when immunostaining with a monoclonal antibody to E1 (1C5). However, the staining pattern associated with a polyclonal anti-E1 antibody (JJJ) is characterized by positive staining cytoplasm and nuclei in all cells. The HA-1E1 construct exhibited apparently exclusive nuclear distribution in HeLa cells. The difference between the staining patterns of the polyclonal and monoclonal anti-E1 antibodies can be explained by the existence of two subpopulations of E1: one cytoplasmic and partially nuclear, and one that is nuclear. Deletion of a small region at the amino terminus of the HA-1E1, including the basic sequence KKRR, transformed its immunostaining pattern to that observed with HA-2E1.	WASHINGTON UNIV,SCH MED,EDWARD MALLINCKRODT DEPT PEDIAT,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,EDWARD MALLINCRODT DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110; TECHNION ISRAEL INST TECHNOL,FAC MED,RAPPAPORT FAMILY INST RES MED SCI,IL-31096 HAIFA,ISRAEL; TECHNION ISRAEL INST TECHNOL,FAC MED,BIOCHEM UNIT,IL-31096 HAIFA,ISRAEL	Washington University (WUSTL); Washington University (WUSTL); Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	HANDLEYGEARHART, PM (corresponding author), ST LOUIS CHILDRENS HOSP,DEPT PEDIAT,DIV PEDIAT HEMATOL ONCOL,1 CHILDRENS PL,ST LOUIS,MO 63110, USA.		Stephen, Andrew/W-2636-2019; Ciechanover, Aaron J/C-9166-2017	Stephen, Andrew/0000-0002-8259-621X; 				ARNOLD JE, 1990, BIOCHEM J, V267, P751, DOI 10.1042/bj2670751; AYUSAWA D, 1992, CELL STRUCT FUNCT, V17, P113, DOI 10.1247/csf.17.113; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CIECHANOVER A, 1982, J BIOL CHEM, V257, P2537; COOK JC, 1991, BIOCHEM BIOPH RES CO, V174, P564, DOI 10.1016/0006-291X(91)91454-K; COOK JC, 1992, J BIOL CHEM, V267, P24315; CROSBY SD, 1991, MOL CELL BIOL, V11, P3835, DOI 10.1128/MCB.11.8.3835; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DINGWALL C, 1986, ANNU REV CELL BIOL, V2, P367, DOI 10.1146/annurev.cellbio.2.1.367; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GRENFELL SJ, 1994, BIOCHEM J, V300, P701, DOI 10.1042/bj3000701; HANDLEY PM, 1991, P NATL ACAD SCI USA, V88, P258, DOI 10.1073/pnas.88.1.258; HANDLEYGEARHART PM, 1994, BIOCHEM J, V304, P1015, DOI 10.1042/bj3041015; HATFIELD PM, 1990, J BIOL CHEM, V265, P15813; HATFIELD PM, 1989, BIOCHEMISTRY-US, V28, P735, DOI 10.1021/bi00428a048; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; KAY GF, 1991, NATURE, V354, P486, DOI 10.1038/354486a0; KOK K, 1993, P NATL ACAD SCI USA, V90, P6071, DOI 10.1073/pnas.90.13.6071; KOLODZIEJ P, 1989, MOL CELL BIOL, V9, P5387, DOI 10.1128/MCB.9.12.5387; KONG SK, 1992, J BIOL CHEM, V267, P14189; KOZAK M, 1992, CRIT REV BIOCHEM MOL, V27, P385, DOI 10.3109/10409239209082567; KOZAK M, 1986, CELL, V47, P481, DOI 10.1016/0092-8674(86)90609-4; KUDO M, 1991, EXP CELL RES, V192, P110, DOI 10.1016/0014-4827(91)90164-P; KULKA RG, 1988, J BIOL CHEM, V263, P15726; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENK SE, 1992, J CELL BIOL, V118, P301, DOI 10.1083/jcb.118.2.301; LEYSER HMO, 1993, NATURE, V364, P161, DOI 10.1038/364161a0; MAYER A, 1989, J BIOL CHEM, V264, P2060; MCGRATH JP, 1991, EMBO J, V10, P227, DOI 10.1002/j.1460-2075.1991.tb07940.x; MITCHELL MJ, 1991, NATURE, V354, P483, DOI 10.1038/354483a0; NISHITANI H, 1992, BIOCHEM BIOPH RES CO, V184, P1015, DOI 10.1016/0006-291X(92)90692-E; OSSIPOW V, 1993, P NATL ACAD SCI USA, V90, P8219, DOI 10.1073/pnas.90.17.8219; PAOLINI R, 1993, EMBO J, V12, P779, DOI 10.1002/j.1460-2075.1993.tb05712.x; SCHWARTZ AL, 1992, P NATL ACAD SCI USA, V89, P5542, DOI 10.1073/pnas.89.12.5542; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAUSCH JS, 1993, AM J PHYSIOL, pC93; ZACKSENHAUS E, 1990, EMBO J, V9, P2923, DOI 10.1002/j.1460-2075.1990.tb07483.x	38	59	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					33171	33178						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7528747				2022-12-27	WOS:A1994QA63800067
J	HAYNES, PA; OKA, JA; WEIGEL, PH				HAYNES, PA; OKA, JA; WEIGEL, PH			THE RAT HEPATIC LECTIN-1 SUBUNIT OF THE RAT ASIALOGLYCOPROTEIN RECEPTOR IS A PHOSPHOPROTEIN AND CONTAINS PHOSPHOTYROSINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN TRANSFERRIN RECEPTOR; CYTOPLASMIC DOMAIN; SIGNAL SEQUENCE; COATED PITS; TYROSINE PHOSPHORYLATION; GALACTOSYL RECEPTORS; ISOLATED HEPATOCYTES; RAPID ENDOCYTOSIS; PROTEIN-KINASE; CELL-MEMBRANES	The rat asialoglycoprotein receptor (ASGPR) is an integral transmembrane glycoprotein composed of three polypeptide subunits, designated rat hepatic lectins (RHL) 1, 2, and 3. Each subunit contains one or more Ser and Thr residues in its cytoplasmic domain that are potential sites of phosphorylation; in addition, RHL1 also contains one cytoplasmic Tyr. Based on [P-32]PO4 metabolic radiolabeling experiments, Takahashi et al. (Takahashi, T., Nakada, H., Okumura, T., Sawamura, T., and Tashiro, Y. (1985) Biochem. Biophys. Res. Commun. 126, 1054-1060) concluded that RHL2 and RHL3 are phosphoproteins but that RHL1 is not. We report here that RHL1 in active ASGPR is, in fact, a phosphoprotein. Western blot analysis using anti-Tyr(P) antibody identified Tyr(P) in RHL1 of affinity-purified ASGPRs. RHL2 and RHL3, which do not contain Tyr in their cytoplasmic domains, did not react with this antibody. When isolated hepatocytes were radiolabeled metabolically with [P-32]PO4, RHL1, RHL2, and RHL3 became radiolabeled. Each ASGPR subunit was radiolabeled to a similar extent in the presence or absence of the ligand asialo-orosomucoid, indicating that functioning of the ASGPR does not change its steady-state P-23-radiolabeling. Phosphoamino acid analysis of radiolabeled ASGPR subunits identified Ser(P) as the predominant (similar to 95%) and Thr(P) as a minor (similar to 5%) phosphoamino acid in each polypeptide and confirmed the presence of Tyr(P) (similar to 1%) in RHL1. Furthermore, treatment of hepatocytes with 3 mM vandate at 37 degrees C for 30 min doubled the steady-state level of Tyr(P) in RHL1.	UNIV TEXAS, MED BRANCH, DEPT HUMAN BIOL CHEM & GENET, GALVESTON, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049695, R01GM030218] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 49695, GM 30218] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALVAREZ E, 1990, BIOCHEM J, V267, P31, DOI 10.1042/bj2670031; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BREITFELD PP, 1990, J BIOL CHEM, V265, P13750; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; CLARKE BL, 1987, J BIOL CHEM, V262, P17384; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DAVIS CG, 1986, CELL, V45, P15, DOI 10.1016/0092-8674(86)90533-7; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; DRICKAMER K, 1984, J BIOL CHEM, V259, P770; EARP HS, 1983, FEBS LETT, V161, P180; FALLON RJ, 1994, J BIOL CHEM, V269, P11011; FALLON RJ, 1992, EXP CELL RES, V203, P420, DOI 10.1016/0014-4827(92)90016-2; FALLON RJ, 1990, J BIOL CHEM, V265, P3401; FALLON RJ, 1990, BIOCHEM BIOPH RES CO, V170, P1191, DOI 10.1016/0006-291X(90)90519-S; FUHRER C, 1991, J CELL BIOL, V114, P423, DOI 10.1083/jcb.114.3.423; GEFFEN I, 1991, P NATL ACAD SCI USA, V88, P8425, DOI 10.1073/pnas.88.19.8425; GEFFEN I, 1993, J BIOL CHEM, V268, P20772; GIRONES N, 1991, J BIOL CHEM, V266, P19006; GORDON JA, 1991, METHOD ENZYMOL, V201, P477; HALBERG DF, 1987, J BIOL CHEM, V262, P9828; HAYNES PA, 1994, IN PRESS J BIOL CHEM, V269, P33152; HERZIG MCS, 1990, BIOCHEMISTRY-US, V29, P6437, DOI 10.1021/bi00479a015; HOLLAND EC, 1984, P NATL ACAD SCI-BIOL, V81, P7338, DOI 10.1073/pnas.81.23.7338; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; KAMPS MP, 1991, METHOD ENZYMOL, V201, P21; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZAROVITS J, 1988, CELL, V53, P743, DOI 10.1016/0092-8674(88)90092-X; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; MCABEE DD, 1988, BIOCHEMISTRY-US, V27, P2061, DOI 10.1021/bi00406a037; MCPHAUL M, 1987, MOL CELL BIOL, V7, P1841, DOI 10.1128/MCB.7.5.1841; MEDH JD, 1991, J BIOL CHEM, V266, P8771; OKA JA, 1991, ARCH BIOCHEM BIOPHYS, V289, P362, DOI 10.1016/0003-9861(91)90424-H; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; PETERS C, 1990, EMBO J, V9, P3497, DOI 10.1002/j.1460-2075.1990.tb07558.x; POLSON A, 1980, IMMUNOL COMMUN, V9, P475, DOI 10.3109/08820138009066010; SANFORD JP, 1990, BIOCHIM BIOPHYS ACTA, V1087, P259, DOI 10.1016/0167-4781(90)90216-O; SCHWARTZ AL, 1984, BIOCHEM J, V223, P481, DOI 10.1042/bj2230481; SEGLEN PO, 1973, EXP CELL RES, V82, P391, DOI 10.1016/0014-4827(73)90357-1; SPIESS M, 1985, P NATL ACAD SCI USA, V82, P6465, DOI 10.1073/pnas.82.19.6465; SPIESS M, 1985, J BIOL CHEM, V260, P1979; TAKAHASHI T, 1985, BIOCHEM BIOPH RES CO, V126, P1054, DOI 10.1016/0006-291X(85)90292-X; TAKEZAWA R, 1993, BIOCHIM BIOPHYS ACTA, V1172, P220, DOI 10.1016/0167-4781(93)90300-3; TAMURA S, 1984, J BIOL CHEM, V259, P6650; WEIGEL PH, 1982, J BIOL CHEM, V257, P1201; WEIGEL PH, 1983, J BIOL CHEM, V258, P5089; WEIGEL PH, 1992, GLYCOCONJUGATES COMP, P421; WILLIAMS GM, 1974, EXP CELL RES, V89, P139, DOI 10.1016/0014-4827(74)90196-7; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955	50	8	8	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					33146	33151						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7528746				2022-12-27	WOS:A1994QA63800063
J	CARROLL, SS; STAHLHUT, M; GEIB, J; OLSEN, DB				CARROLL, SS; STAHLHUT, M; GEIB, J; OLSEN, DB			INHIBITION OF HIV-1 REVERSE-TRANSCRIPTASE BY A QUINAZOLINONE AND COMPARISON WITH INHIBITION BY PYRIDINONES - DIFFERENCES IN THE RATES OF INHIBITOR BINDING AND IN SYNERGISTIC INHIBITION WITH NUCLEOSIDE ANALOGS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; REPLICATION; DERIVATIVES; RESISTANCE; BI-RG-587; SEQUENCE; INVITRO	6-Chloro-(4S)-cyclopropyl-3,4-dihydro 4-((2-pyridyl)-ethynyl)quinazolin-2(1H)-one (L-738,372) is representative of a novel structural class of nonnucleoside inhibitors of human immunodeficiency virus, strain 1 (HIV-1), reverse transcriptase (RT), the quinazolinones. L-738,372 is a reversible inhibitor of HIV-1 RT and is noncompetitive against dTTP with a K-i of 140 nM with poly(rA).oligo(dT) as primer-template. Mixed noncompetitive inhibition by L-738,372 was observed against poly(rC).oligo(dG) as primer-template. This quinazolinone binds to RT at a site that overlaps the binding site of other nonnucleoside inhibitors as evidenced by the ability of L-738,372 to displace bound radiolabeled L-696,229, a member of the pyridinone class of inhibitors of HIV-I RT, from complexes of RT and primer-template. Inhibition by L-738,372 shows slow binding characteristics in reactions with all of the primer-templates employed. Synergistic inhibition of RT activity was evident in combinations of L-738,372 and any of the nucleoside analogs, azidothymidine triphosphate, dideoxyinosine triphosphate, or dideoxycytosine triphosphate. The azidothymidine-resistant form of RT (D67N, K70R, T215Y, K219Q) is inhibited by L-738,372 with 2-3-fold more potency than is the wild-type RT. Comparison of inhibition by L-738,372 with inhibition by pyridinone inhibitors reveals differences in synergistic inhibition with nucleoside analogs and in the rates of binding of the inhibitors.			CARROLL, SS (corresponding author), MERCK SHARP & DOHME LTD,RES LABS,DEPT BIOL CHEM,WP26-331,W POINT,PA 19486, USA.			olsen, david/0000-0001-5521-0206				ACKERMANN WW, 1949, P SOC EXP BIOL MED, V72, P1; ALIZON M, 1986, CELL, V46, P63, DOI 10.1016/0092-8674(86)90860-3; ALTHAUS IW, 1993, BIOCHEMISTRY-US, V32, P6548, DOI 10.1021/bi00077a008; BABA M, 1991, ANTIMICROB AGENTS CH, V35, P1430, DOI 10.1128/AAC.35.7.1430; BRYANT FR, 1983, BIOCHEMISTRY-US, V22, P3537, DOI 10.1021/bi00284a001; CARROLL SS, 1993, J BIOL CHEM, V268, P276; DEBYSER Z, 1991, P NATL ACAD SCI USA, V88, P1451, DOI 10.1073/pnas.88.4.1451; DECLERCQ E, 1993, MED RES REV, V13, P229, DOI 10.1002/med.2610130303; ELION GB, 1954, J BIOL CHEM, V208, P477; GOLDMAN ME, 1991, P NATL ACAD SCI USA, V88, P6863, DOI 10.1073/pnas.88.15.6863; GOPALAKRISHNAN V, 1994, J BIOL CHEM, V269, P4110; HEIDENREICH O, 1990, EUR J BIOCHEM, V192, P621, DOI 10.1111/j.1432-1033.1990.tb19268.x; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568; MORRISON JF, 1982, TRENDS BIOCHEM SCI, V7, P102, DOI 10.1016/0968-0004(82)90157-8; NUNBERG JH, 1991, J VIROL, V65, P4887, DOI 10.1128/JVI.65.9.4887-4892.1991; PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0; REARDON JE, 1990, J BIOL CHEM, V265, P20302; RICHMAN D, 1991, ANTIMICROB AGENTS CH, V35, P305, DOI 10.1128/AAC.35.2.305; ROMERO DL, 1991, P NATL ACAD SCI USA, V88, P8806, DOI 10.1073/pnas.88.19.8806; SAAG MS, 1993, NEW ENGL J MED, V329, P1065, DOI 10.1056/NEJM199310073291502; SAARI WS, 1991, J MED CHEM, V34, P2925; SARDANA VV, 1992, J BIOL CHEM, V267, P17526; SEGEL LH, 1975, ENZYME KINETICS BEHA, P481; TRAMONTANO E, 1992, BIOCHEM PHARMACOL, V43, P1371; TUCKER TJ, 1994, J MED CHEM, V37, P2437, DOI 10.1021/jm00041a023; WU JC, 1991, BIOCHEMISTRY-US, V30, P2022, DOI 10.1021/bi00222a003; YONETANI T, 1964, ARCH BIOCHEM BIOPHYS, V106, P243, DOI 10.1016/0003-9861(64)90184-5	28	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32351	32357						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7528214				2022-12-27	WOS:A1994PX30400052
J	GILMER, T; RODRIQUEZ, M; JORDAN, S; CROSBY, R; ALLIGOOD, K; GREEN, M; KIMERY, M; WAGNER, C; KINDER, D; CHARIFSON, P; HASSELL, AM; WILLARD, D; LUTHER, M; RUSNAK, D; STERNBACH, DD; MEHROTRA, M; PEEL, M; SHAMPINE, L; DAVIS, R; ROBBINS, J; PATEL, IR; KASSEL, D; BURKHART, W; MOYER, M; BRADSHAW, T; BERMAN, J				GILMER, T; RODRIQUEZ, M; JORDAN, S; CROSBY, R; ALLIGOOD, K; GREEN, M; KIMERY, M; WAGNER, C; KINDER, D; CHARIFSON, P; HASSELL, AM; WILLARD, D; LUTHER, M; RUSNAK, D; STERNBACH, DD; MEHROTRA, M; PEEL, M; SHAMPINE, L; DAVIS, R; ROBBINS, J; PATEL, IR; KASSEL, D; BURKHART, W; MOYER, M; BRADSHAW, T; BERMAN, J			PEPTIDE INHIBITORS OF SRC SH3-SH2-PHOSPHOPROTEIN INTERACTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY PHOSPHOTYROSYL PEPTIDE; GROWTH-FACTOR RECEPTOR; SH3 DOMAINS; PHOSPHORYLATED PEPTIDES; TYROSINE KINASES; BINDING; PROTEINS; IDENTIFICATION; ASSOCIATION; RECOGNITION	Activated pp60(c-src) has been implicated in a number of human malignancies including colon carcinoma and breast adenocarcinoma. Association of the src SH2 do main with tyrosine-phosphorylated proteins plays a role in src-mediated signal transduction, Inhibitors of src SH2 domain-phosphoprotein interactions are, thus, of great interest in defining the role(s) of src in signal transduction pathways, To facilitate such studies, an enzyme-linked immunosorbent assay (ELISA) was developed to detect inhibitors of src SH2-phosphoprotein interactions, This assay measures inhibition of binding of a fusion construct (glutathione S-transferase src SH3-SH2) with autophosphorylated epidermal growth factor receptor tyrosine kinase domain, Activities of phosphopeptide segments derived from potential src SH2 cognate phosphoprotein partners were determined, with the focal adhesion kinase-derived segment VSETDDY*AEIIDE yielding the highest inhibitory activity, Structure activity studies starting from acetyl (Ac)-Y*EEIE have identified Ac-Y*Y*Y*IE as the most active compound screened ill the ELISA. This compound is at least all-fold more active than the parent peptide Ac-Y*EEIE. A high resolution (2 Angstrom) crystal structure of human src SH2 complexed with Ac-Y*EEIE was obtained and provided a useful framework for understanding the structure-activity relationships, Additionally, Ac-Y*EEIE was able to block interactions between src and its cellular phosphoprotein partners in vanadate-treated cell lysates from MDA-MB-468 breast carcinoma cells, However, it is unable to abrogate proliferation of MDA-MB-468 cells in culture, presumably because of poor cell penetration and/or lability of the phosphate group on tyrosine.	GLAXO INC, RES INST, RES TRIANGLE PK, NC 27709 USA	GlaxoSmithKline								ALLEY MC, 1988, CANCER RES, V48, P589; ANDREWS DM, 1991, INT J PEPT PROT RES, V38, P469; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; BIRKETT AJ, 1991, ANAL BIOCHEM, V196, P137, DOI 10.1016/0003-2697(91)90129-H; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; DIXON WJ, 1953, BIOMETRICS, V9, P74, DOI 10.2307/3001634; DOMCHEK SM, 1992, BIOCHEMISTRY-US, V31, P9865, DOI 10.1021/bi00156a002; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FIELDS GG, 1990, INT J PAPT PROT RES, V35, P151; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KURIYAN J, 1993, CURR OPIN STRUC BIOL, V3, P828, DOI 10.1016/0959-440X(93)90145-B; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; MARGOLIS B, 1992, CELL GROWTH DIFFER, V3, P73; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; RIORDAN JF, 1979, MOL CELL BIOCHEM, V26, P71; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	35	166	179	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31711	31719						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7527393				2022-12-27	WOS:A1994PX30300061
J	BALLIGAND, JL; UNGUREANULONGROIS, D; SIMMONS, WW; PIMENTAL, D; MALINSKI, TA; KAPTURCZAK, M; TAHA, Z; LOWENSTEIN, CJ; DAVIDOFF, AJ; KELLY, RA; SMITH, TW; MICHEL, T				BALLIGAND, JL; UNGUREANULONGROIS, D; SIMMONS, WW; PIMENTAL, D; MALINSKI, TA; KAPTURCZAK, M; TAHA, Z; LOWENSTEIN, CJ; DAVIDOFF, AJ; KELLY, RA; SMITH, TW; MICHEL, T			CYTOKINE-INDUCIBLE NITRIC-OXIDE SYNTHASE (INOS) EXPRESSION IN CARDIAC MYOCYTES - CHARACTERIZATION AND REGULATION OF INOS EXPRESSION AND DETECTION OF INOS ACTIVITY IN SINGLE CARDIAC MYOCYTES IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT VENTRICULAR MYOCYTES; VASCULAR SMOOTH-MUSCLE; GROWTH-FACTOR-BETA; MOUSE MACROPHAGES; INTERFERON-GAMMA; ENDOTHELIAL-CELLS; CLONING; BIOSYNTHESIS; HEPATOCYTES; PATHWAY	Cellular constituents of heart muscle contain both constitutive and inducible nitric oxide (NO) signaling pathways that modulate the contractile properties of cardiac myocytes. The identities of the inducible NO synthase (iNOS) isoform(s) expressed in cardiac muscle, and of the specific cell types expressing iNOS activity, remain poorly characterized. We amplified a 217-base pair cDNA by reverse transcriptase-polymerase chain reaction from primary cultures of inflammatory cytokine pretreated adult rat ventricular myocytes (ARVM) that was nearly identical to other NOS cDNA sequences. Using this 217-base pair cDNA as a probe in Northern blots, we found no evidence of iNOS mRNA in control myocytes, but both interleukin-1 beta and interferon-gamma individually increased MOS mRNA abundance in primary cultures of ARVM, with maximal expression at 12 h. The half life of iNOS mRNA in actinomycin C1-treated cells was 4 h. Both dexamethasone and transforming growth factor-beta attenuated the induction of iNOS mRNA abundance and enzyme activity by IL-1 beta and INF gamma. Pretreatment with dexamethasone also abolished the induction of iNOS mRNA, but not the increase in GTP cyclohydrolase mRNA in purified cardiac myocytes from lipopolysaccharide-injected rats, In order to further characterize the specific cell type producing NO, we used a NO-specific porphyrinic/Nafion-coated microsensor to record NO release from a single, isolated ARVM pretreated with IL-1 beta and IFN gamma in L-arginine-depleted medium. NO release could be detected following microinjection of L-arginine in the vicinity of the cell juxtaposed to the NO microsensor, but not following microinjection of D-arginine, and not from ARVM pretreated with L-N-monomethylarginine. Cytokine-pretreated ARVM that had been maintained in L-arginine-depleted medium also exhibited a depressed contractile response to isoproterenol after addition of L-arginine, but not D-arginine. These results indicate that altered contractile function of cardiac myocytes following exposure to specific inflammatory cytokines is due to induction of myocyte iNOS.	BRIGHAM & WOMENS HOSP,DIV CARDIOVASC,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115; JOHNS HOPKINS UNIV,DEPT MED,BALTIMORE,MD 21205; OAKLAND UNIV,DEPT CHEM,ROCHESTER,MI 48309; OAKLAND UNIV,INST BIOTECHNOL,ROCHESTER,MI 48309; WAYNE STATE UNIV,SCH MED,DETROIT,MI 48201	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Johns Hopkins University; Oakland University; Oakland University; Wayne State University			Balligand, Jean-Luc J/D-7543-2012	BALLIGAND, Jean-Luc/0000-0002-0522-4156; Lowenstein, Charles/0000-0003-0485-7514	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL046457, R01HL046457, R01HL036141, R37HL036141] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL46457, HL36141] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BALLIGAND JL, 1993, J CLIN INVEST, V91, P2314, DOI 10.1172/JCI116461; BALLIGAND JL, 1993, P NATL ACAD SCI USA, V90, P347, DOI 10.1073/pnas.90.1.347; BALLIGAND JL, 1994, IN PRESS AM J PHYSL; BERGER HJ, 1994, AM J PHYSIOL, V266, pH341, DOI 10.1152/ajpheart.1994.266.1.H341; BOGDAN C, 1993, J IMMUNOL, V151, P301; BRADY AJB, 1992, AM J PHYSIOL, V263, pH193; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CHARLES IG, 1993, P NATL ACAD SCI USA, V90, P11419, DOI 10.1073/pnas.90.23.11419; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CUNHA FQ, 1994, IMMUNOLOGY, V81, P211; DRAPIER JC, 1993, EMBO J, V12, P3643, DOI 10.1002/j.1460-2075.1993.tb06038.x; ELLINGSEN O, 1993, AM J PHYSIOL, V265, pH747, DOI 10.1152/ajpheart.1993.265.2.H747; FINKEL MS, 1992, SCIENCE, V257, P387, DOI 10.1126/science.1631560; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P522, DOI 10.1073/pnas.90.2.522; GENG Y, 1992, CIRC RES, V71, P1268, DOI 10.1161/01.RES.71.5.1268; GROSS SS, 1992, J BIOL CHEM, V267, P25722; HAN X, 1994, IN PRESS J PHYSL; HATAKEYAMA K, 1991, J BIOL CHEM, V266, P765; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; KARUPIAH G, 1993, SCIENCE, V261, P1445, DOI 10.1126/science.7690156; KELLY RA, 1990, J CLIN INVEST, V86, P1164, DOI 10.1172/JCI114822; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; LORSBACH RB, 1993, J BIOL CHEM, V268, P1908; LOWENSTEIN C, 1991, P NATL ACAD SCI USA, V89, P6711; MALINSKI T, 1992, NATURE, V358, P676, DOI 10.1038/358676a0; MALINSKI T, 1993, BIOCHEM BIOPH RES CO, V193, P1076, DOI 10.1006/bbrc.1993.1735; MCDONALD LJ, 1993, P NATL ACAD SCI USA, V90, P6238, DOI 10.1073/pnas.90.13.6238; NATHAN C, 1994, J BIOL CHEM, V269, P13725; NATHAN C, 1994, J CLIN INVEST, V93, P1875, DOI 10.1172/JCI117176; NISHIDA M, 1993, J CLIN INVEST, V91, P1934, DOI 10.1172/JCI116412; NUNOKAWA Y, 1993, BIOCHEM BIOPH RES CO, V191, P89, DOI 10.1006/bbrc.1993.1188; RAETZ CRH, 1991, FASEB J, V5, P2652, DOI 10.1096/fasebj.5.12.1916089; ROBERTS AB, 1992, MOL ENDOCRINOL, V6, P1921, DOI 10.1210/me.6.11.1921; ROBERTS AB, 1992, J CLIN INVEST, V90, P2056, DOI 10.1172/JCI116087; SCHOEDON G, 1993, EUR J BIOCHEM, V213, P833, DOI 10.1111/j.1432-1033.1993.tb17826.x; SCHULZ R, 1992, BRIT J PHARMACOL, V105, P575, DOI 10.1111/j.1476-5381.1992.tb09021.x; SCOTTBURDEN T, 1993, BIOCHEM BIOPH RES CO, V196, P1261, DOI 10.1006/bbrc.1993.2388; SHERMAN PA, 1993, BIOCHEMISTRY-US, V32, P11600, DOI 10.1021/bi00094a017; VODOVOTZ Y, 1993, J EXP MED, V178, P605, DOI 10.1084/jem.178.2.605; VOLZ A, 1991, J MOL CELL CARDIOL, V23, P1206; WEISS G, 1993, EMBO J, V12, P3651, DOI 10.1002/j.1460-2075.1993.tb06039.x; WERNERFELMAYER G, 1993, J BIOL CHEM, V268, P1842; WERNERFELMAYER G, 1993, FEBS LETT, V322, P232; WOOD ER, 1993, BIOCHEM BIOPH RES CO, V191, P767, DOI 10.1006/bbrc.1993.1283; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522	47	399	405	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27580	27588						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7525557				2022-12-27	WOS:A1994PV77100066
J	SEUFFERLEIN, T; ROZENGURT, E				SEUFFERLEIN, T; ROZENGURT, E			SPHINGOSINE INDUCES P125(FAK) AND PAXILLIN TYROSINE PHOSPHORYLATION, ACTIN STRESS FIBER FORMATION, AND FOCAL CONTACT ASSEMBLY IN SWISS 3T3 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHOSPHATIDIC-ACID LEVELS; ADHESION KINASE; BOMBESIN STIMULATION; CELLULAR PROLIFERATION; EXTRACELLULAR-MATRIX; GROWTH-FACTORS; EARLY SIGNALS; DNA-SYNTHESIS; VASOPRESSIN	Treatment of Swiss 3T3 cells with sphingosine, a potential breakdown product of all sphingolipids, induced tyrosine phosphorylation of multiple substrates including bands of M(r) 110,000-130,000 and M(r) 70,000-80,000. Tyrosine phosphorylation in response to sphingosine occurred in a concentration dependent manner (EC(50) = 10 mu M) and developed gradually reaching half maximum and maximum effects at 20 and 60 min, respectively. The dihydroenantiomere of sphingosine, DL-threo-dihydrosphingosine, neither induced tyrosine phosphorylation nor interfered with sphingosine-stimulated tyrosine phosphorylation. Focal adhesion kinase (p125(FAK)) and paxillin were identified as prominent substrates for sphingosine stimulated tyrosine phosphorylation. Cell permeable ceramides also stimulated tyrosine phosphorylation of the M(r) 110,000-130,000 band as well as p125(FAK), but the effect was less pronounced than that of sphingosine. Tyrosine phosphorylation by sphingosine could be dissociated from both protein kinase C activation and Ca2+ mobilization from intracellular stores. Sphingosine stimulated striking actin stress fiber formation and focal adhesion assembly in Swiss 3T3 cells. The kinetics of actin stress fiber formation and tyrosine phosphorylation in response to sphingosine closely paralleled. Cytochalasin D, which disrupts the network of actin microfilaments, completely inhibited sphingosine induced tyrosine phosphorylation. In addition, tyrosine phosphorylation of p125(FAK) and paxillin in response to sphingosine was completely prevented when cells were stimulated in the presence of platelet-derived growth factor at a concentration (30 ng/ml) that caused disruption of the actin cytoskeleton. Our results demonstrate, for the first time, that sphingosine induces p125(FAK) and paxillin tyrosine phosphorylation, actin stress fiber formation and focal adhesion assembly in Swiss 3T3 cells.	IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND	Cancer Research UK			Seufferlein, Thomas TW/P-7147-2018					BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; COLLINS MKL, 1984, J CELL PHYSIOL, V118, P133, DOI 10.1002/jcp.1041180205; DESAI NN, 1992, J BIOL CHEM, V267, P23122; ERUSALIMSKY JD, 1991, J BIOL CHEM, V266, P7073; EXTON JH, 1994, CURR OPIN CELL BIOL, V6, P226, DOI 10.1016/0955-0674(94)90140-6; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HANNUN YA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P223, DOI 10.1016/0304-4157(93)90001-5; HAUSER JML, 1994, J BIOL CHEM, V269, P6803; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KUMAGAI N, 1993, FEBS LETT, V329, P273, DOI 10.1016/0014-5793(93)80236-N; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; NANBERG E, 1988, EMBO J, V7, P2741, DOI 10.1002/j.1460-2075.1988.tb03128.x; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; PELLETIER AJ, 1992, MOL BIOL CELL, V3, P989, DOI 10.1091/mbc.3.9.989; RANKIN S, 1994, J BIOL CHEM, V269, P704; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; ROZENGURT E, 1988, PROG NUCLEIC ACID RE, V35, P261, DOI 10.1016/S0079-6603(08)60616-9; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; ROZENGURT E, 1983, P NATL ACAD SCI USA, V80, P7224; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SECKL M, 1993, J BIOL CHEM, V268, P9548; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; THASTRUP O, 1987, BIOCHIM BIOPHYS ACTA, V927, P65, DOI 10.1016/0167-4889(87)90066-8; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TURNER CE, 1991, EXP CELL RES, V192, P651, DOI 10.1016/0014-4827(91)90090-H; TURNER CE, 1993, J CELL SCI, V105, P637; TURNER CE, 1991, J CELL BIOL, V115, P201, DOI 10.1083/jcb.115.1.201; VUORI K, 1993, J BIOL CHEM, V268, P21459; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZACHARY I, 1993, J BIOL CHEM, V268, P22060; ZACHARY I, 1992, J BIOL CHEM, V267, P19031; ZHANG H, 1990, J BIOL CHEM, V265, P76; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155; ZHANG H, 1990, J BIOL CHEM, V265, P21309	46	113	113	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27610	27617						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7525558				2022-12-27	WOS:A1994PV77100070
J	PEI, DQ; MAJMUDAR, G; WEISS, SJ				PEI, DQ; MAJMUDAR, G; WEISS, SJ			HYDROLYTIC INACTIVATION OF A BREAST-CARCINOMA CELL-DERIVED SERPIN BY HUMAN STROMELYSIN-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-1-PROTEINASE INHIBITOR; MATRIX METALLOPROTEINASES; PROTEOLYTIC INACTIVATION; FIBROBLASTIC CELLS; TERMINAL DOMAIN; GENE; COLLAGENASE; ALPHA-1-ANTICHYMOTRYPSIN; SPECIFICITY; PROTEINS	To elucidate structure-function relationships of stromelysin-3, a putative matrix metalloproteinase originally identified at the tumor-stromal cell interface in breast carcinomas, the human cDNA was expressed in mammalian cells, and its products were isolated and characterized. In stably transfected cells, stromelysin-3 was recovered as a complex mixture of species ranging in size from similar to 20 to 65 kDa. Among these products, a major 45-kDa species with an N terminus of Phe(98) and an intact C-terminal domain was identified as a true endopeptidase on the basis of its ability to cleave the bait region of alpha(2)-macroglobulin between Phe(684) and Tyr(685), a site identical to that recognized by stromelysin-1. However, unlike stromelysin-1 or other members of the matrix metalloproteinase family, the mature form of stromelysin 3 was unable to hydrolyze a range of extracellular matrix molecules associated with either the basement membrane or interstitium. To probe for alternate substrates among tumor cell-derived products, purified stromelysin-3 was incubated with [S-35]methionine-labeled medium conditioned by the breast cancer cell line, MCF-7. Under these conditions, a single, tumor cell-derived protein was hydrolyzed as assessed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and autoradiography. Following anion-exchange chromatography and preparative gel electrophoresis, the stromelysin-3 substrate was identified by N-terminal sequencing as the serine proteinase inhibitor, alpha(1)-proteinase inhibitor. Further studies demonstrated that stromelysin-3 rapidly destroyed the antiproteolytic function of alpha(1)-proteinase inhibitor by cleaving the antiproteinase at a distinct site between Ala(350) and Met(351) within the reactive-site loop. Together, these data not only demonstrate that human stromelysin-3 acts as a powerful endopeptidase with a restricted substrate specificity distinct from all other matrix metalloproteinases, but also serve to identify serine proteinase inhibitors as potential physiologic targets at sites of extracellular matrix remodeling.	UNIV MICHIGAN,CTR COMPREHENS CANC,DEPT INTERNAL MED,ANN ARBOR,MI 48109; UNIV MICHIGAN,CTR COMPREHENS CANC,DEPT DERMATOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NIAID NIH HHS [AI-23876] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023876] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BASSET P, 1993, BREAST CANCER RES TR, V24, P185, DOI 10.1007/BF01833259; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; DAVIES B, 1993, CANCER RES, V53, P2087; DESROCHERS PE, 1991, J CLIN INVEST, V87, P2258, DOI 10.1172/JCI115262; DESROCHERS PE, 1992, J BIOL CHEM, V267, P5005; FINLAY TH, 1993, ENDOCRINOLOGY, V133, P996, DOI 10.1210/en.133.3.996; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAZIADEI I, 1994, BLOOD, V83, P260; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HARLOW E, 1988, ANTIBODIES LABORATOR; LEFEBVRE O, 1992, J CELL BIOL, V119, P997, DOI 10.1083/jcb.119.4.997; MAST AE, 1991, J BIOL CHEM, V266, P15810; MURPHY G, 1993, J BIOL CHEM, V268, P15435; MURPHY G, 1992, J BIOL CHEM, V267, P9612; MURPHY GJP, 1991, FEBS LETT, V289, P4, DOI 10.1016/0014-5793(91)80895-A; NAKAMURA T, 1984, EXP CELL RES, V154, P81; PEI DO, 1993, FASEB J, V7, pA1209; PERLMUTTER DH, 1989, J BIOL CHEM, V264, P9485; POTEMPA J, 1988, SCIENCE, V241, P699, DOI 10.1126/science.2456616; REDDY VY, 1994, J BIOL CHEM, V269, P4683; RHINEHART AR, 1993, AM J RESPIR CELL MOL, V9, P666; SANCHEZLOPEZ R, 1993, J BIOL CHEM, V268, P7238; SCOTT GK, 1989, BIOCHIM BIOPHYS ACTA, V1010, P160, DOI 10.1016/0167-4889(89)90156-0; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P11539; TORRESROSADO A, 1993, P NATL ACAD SCI USA, V90, P7191; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WINYARD PG, 1991, FEBS LETT, V279, P91, DOI 10.1016/0014-5793(91)80258-5; WOLF C, 1992, J INVEST DERMATOL, V99, P870, DOI 10.1111/1523-1747.ep12614846; WOLF C, 1993, P NATL ACAD SCI USA, V90, P1843, DOI 10.1073/pnas.90.5.1843; YAMASHITA JI, 1994, BRIT J CANCER, V69, P72, DOI 10.1038/bjc.1994.11; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	32	194	199	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25849	25855						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7523394				2022-12-27	WOS:A1994PQ49100090
J	NICHOLS, RA; SUPLICK, GR; BROWN, JM				NICHOLS, RA; SUPLICK, GR; BROWN, JM			CALCINEURIN-MEDIATED PROTEIN DEPHOSPHORYLATION IN BRAIN NERVE-TERMINALS REGULATES THE RELEASE OF GLUTAMATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT CORTICAL SYNAPTOSOMES; OKADAIC ACID; NEUROTRANSMITTER RELEASE; DROSOPHILA-MELANOGASTER; DYNAMIN GTPASE; CYCLIC-AMP; KINASE-C; PHOSPHORYLATION; CALCIUM; DEPOLARIZATION	In response to Ca2+ entry, several prominent brain nerve terminal phosphoproteins undergo dephosphorylation, but the relation between dephosphorylation and neurotransmitter release is unknown. Using the immunosuppressants cyclosporin A (CsA) and L-683,590 (FK-520) to inhibit specifically the Ca2+/calmodulin-dependent protein phosphatase calcineurin, we demonstrate here that Ca2+-dependent dephosphorylation in isolated rat brain nerve terminals (synaptosomes) is mediated by calcineurin. Pretreatment with micromolar CsA resulted in a 76-95% inhibition of stimulation-induced decreases in P-32-labeled dynamin (previously referred to as dephosphin), a phosphoprotein of M(r) = 145,000 (145-kDa protein), and a phosphoprotein of M(r) = 170,000 (170-kDa protein). Pretreatment with FH-520 also inhibited Ca2+ dependent dephosphorylation. Using hypotonic lysates of P-32-labeled synaptosomes, the addition of Ca2+ plus calmodulin, but not either agent alone, induced dynamin dephosphorylation. CsA and FK-520 had little to no effect on the release of glutamate induced by either K+-depolarization or the Ca2+ ionophore ionomycin. In contrast, calcineurin inhibition led to a substantial enhancement of glutamate release evoked by the K+-channel blocker 4-aminopyridine, an agent whose action most closely mimics physiological stimulation. Calcineurin inhibition had no effect on stimulation-induced changes in synaptosomal Ca2+ levels. Based on our findings, we hypothesize that Ca2+-dependent protein dephosphorylation resulting from calcineurin activation during physiological stimulation limits neu rotransmitter release from brain nerve terminal, perhaps being dependent upon cyclic repolarization of the membrane during stimulation.			NICHOLS, RA (corresponding author), MED COLL PENN,DEPT PHARMACOL,3200 HENRY AVE,PHILADELPHIA,PA 19129, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS030577] Funding Source: NIH RePORTER; NINDS NIH HHS [NS30577] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANTHONY FA, 1988, J NEUROSCI, V8, P1245; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COOPER NGF, 1985, J CELL BIOL, V101, P1212, DOI 10.1083/jcb.101.4.1212; DUMONT FJ, 1992, J EXP MED, V176, P751, DOI 10.1084/jem.176.3.751; DUNKLEY PR, 1986, J NEUROCHEM, V46, P1692; DUNKLEY PR, 1986, BRAIN RES, V372, P115, DOI 10.1016/0006-8993(86)91464-2; GOMEZPUERTAS P, 1991, J NEUROCHEM, V56, P2039, DOI 10.1111/j.1471-4159.1991.tb03464.x; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HALPAIN S, 1990, NATURE, V343, P369, DOI 10.1038/343369a0; HALPAIN S, 1990, NEURON, V5, P237, DOI 10.1016/0896-6273(90)90161-8; HASHIMOTO Y, 1990, J BIOL CHEM, V265, P1924; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; HULTSCH T, 1990, J IMMUNOL, V144, P1000; HUTTNER WB, 1981, J BIOL CHEM, V256, P1482; HUTTNER WB, 1979, P NATL ACAD SCI USA, V76, P5402, DOI 10.1073/pnas.76.10.5402; IKEDA K, 1976, NATURE, V259, P489, DOI 10.1038/259489a0; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; KOENIG JH, 1983, J CELL BIOL, V96, P1517, DOI 10.1083/jcb.96.6.1517; KOENIG JH, 1989, J NEUROSCI, V9, P1937; KOMULAINEN H, 1987, NEUROCHEM INT, V10, P55, DOI 10.1016/0197-0186(87)90172-0; KOSAKA T, 1983, J CELL BIOL, V97, P499, DOI 10.1083/jcb.97.2.499; KREUGER BK, 1977, J BIOL CHEM, V252, P2764; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU CM, 1978, J BIOL CHEM, V253, P5892; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MCMAHON HT, 1991, J NEUROCHEM, V56, P86, DOI 10.1111/j.1471-4159.1991.tb02566.x; NICHOLLS DG, 1987, J NEUROCHEM, V49, P50, DOI 10.1111/j.1471-4159.1987.tb03393.x; NICHOLS RA, 1989, J NEUROCHEM, V52, P521, DOI 10.1111/j.1471-4159.1989.tb09151.x; NISHIWAKI S, 1990, CARCINOGENESIS, V11, P1837, DOI 10.1093/carcin/11.10.1837; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; OHARA K, 1990, TRANSPLANT P, V22, P83; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; POODRY CA, 1979, J CELL BIOL, V81, P520, DOI 10.1083/jcb.81.3.520; ROBINSON PJ, 1985, J NEUROCHEM, V44, P338, DOI 10.1111/j.1471-4159.1985.tb05422.x; ROBINSON PJ, 1987, J NEUROCHEM, V48, P187, DOI 10.1111/j.1471-4159.1987.tb13146.x; ROBINSON PJ, 1983, J NEUROCHEM, V41, P909, DOI 10.1111/j.1471-4159.1983.tb09034.x; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; ROBINSON PJ, 1991, MOL NEUROBIOL, V5, P87, DOI 10.1007/BF02935541; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; SIHRA TS, 1993, NEUROCHEM RES, V18, P47, DOI 10.1007/BF00966922; SIHRA TS, 1992, J BIOL CHEM, V267, P1983; SIHRA TS, 1993, J NEUROCHEM, V61, P1220, DOI 10.1111/j.1471-4159.1993.tb13612.x; SIM ATR, 1991, NEUROSCI LETT, V126, P203, DOI 10.1016/0304-3940(91)90554-7; STAMNES M A, 1992, Trends in Cell Biology, V2, P272, DOI 10.1016/0962-8924(92)90200-7; STEINER JP, 1992, NATURE, V358, P584, DOI 10.1038/358584a0; TIBBS GR, 1989, J NEUROCHEM, V53, P1693, DOI 10.1111/j.1471-4159.1989.tb09232.x; TUMA PL, 1993, J BIOL CHEM, V268, P17240; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; WALKER RW, 1988, NEUROL CLIN, V6, P261, DOI 10.1016/S0733-8619(18)30869-7; WANG JKT, 1988, J NEUROSCI, V8, P281; ZUCKER RS, 1988, NATURE, V335, P360, DOI 10.1038/335360a0	59	115	116	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23817	23823						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	7522234				2022-12-27	WOS:A1994PQ34500065
J	TAKUMA, T; ICHIDA, T				TAKUMA, T; ICHIDA, T			CATALYTIC SUBUNIT OF PROTEIN-KINASE-A INDUCES AMYLASE RELEASE FROM STREPTOLYSIN O-PERMEABILIZED PAROTID ACINI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE PHOSPHOPROTEINS; RAT PANCREATIC ACINI; GTP-GAMMA-S; CYCLIC-AMP; MEDIATED EXOCYTOSIS; MICROSOMAL PROTEIN; EXOCRINE PANCREAS; MICROMOLAR RANGE; CELLULAR ATP; CELLS	Amylase release from parotid acinar cells is a typical model of cAMP-mediated exocytosis. To obtain unequivocal data concerning the role of cAMP-dependent protein kinase (PKA) in amylase exocytosis, we undertook the direct introduction of the PKA catalytic subunit into the parotid acini by permeabilization with streptolysin O (SLO). In the presence of 100 hemolytic units/ml SLO, cAMP increased amylase release in a time- and dose-dependent manner. PKI-(5-24)-peptide, a specific PKA inhibitor, markedly inhibited amylase release, but the extent of inhibition was approximately 50%. On the other hand, the PKA catalytic subunit highly purified from bovine hearts significantly induced amylase release. The release was strictly dependent on the presence of SLO and the catalytic activity of PKA added. The catalytic subunit dose dependently induced amylase release, but the heat-inactivated subunit had no stimulatory effect. PKI-(5-24)-peptide completely blocked amylase release evoked by the subunit. These results clearly demonstrate that the catalytic subunit of PKA regulates cAMP-mediated amylase release through phosphorylation of unidentified protein(s) directly or indirectly involved in the process of exocytosis.			TAKUMA, T (corresponding author), HLTH SCI UNIV HOKKAIDO, SCH DENT, DEPT ORAL BIOCHEM, TOBETSU, HOKKAIDO 06102, JAPAN.							AHNERTHILGER G, 1985, J BIOL CHEM, V260, P2730; BALDYSWALIGORSKA A, 1987, BIOCHIM BIOPHYS ACTA, V929, P190, DOI 10.1016/0167-4889(87)90175-3; BAUM BJ, 1981, J BIOL CHEM, V256, P9731; BERNFELD P, 1955, METHOD ENZYMOL, V1, P149, DOI 10.1016/0076-6879(55)01021-5; BHAKDI S, 1985, INFECT IMMUN, V47, P52; BUCKINGHAM L, 1983, BIOCHIM BIOPHYS ACTA, V729, P115, DOI 10.1016/0005-2736(83)90462-5; BURGESS GM, 1983, J BIOL CHEM, V258, P5336; BURNHAM DB, 1982, J BIOL CHEM, V257, P523; BURNHAM DB, 1986, BIOCHEM J, V235, P125, DOI 10.1042/bj2350125; Butcher F R, 1980, Adv Cyclic Nucleotide Res, V13, P215; DOWD FJ, 1981, BIOCHEM BIOPH RES CO, V101, P281, DOI 10.1016/S0006-291X(81)80042-3; EDWARDSON JM, 1990, BIOCHIM BIOPHYS ACTA, V1053, P32, DOI 10.1016/0167-4889(90)90022-6; FREEDMAN SD, 1982, J CELL BIOL, V95, P909, DOI 10.1083/jcb.95.3.909; FREEDMAN SD, 1982, J CELL BIOL, V95, P903, DOI 10.1083/jcb.95.3.903; GOMPERTS BD, 1990, ANNU REV PHYSIOL, V52, P591; HARPER JF, 1988, ADV SEC MESS PHOSPH, V22, P193; HINCKE MT, 1988, BIOCHIM BIOPHYS ACTA, V967, P204, DOI 10.1016/0304-4165(88)90010-4; HINCKE MT, 1992, ARCH ORAL BIOL, V37, P85, DOI 10.1016/0003-9969(92)90002-P; HOOTMAN SR, 1987, PHYSL GASTROINTESTIN, P1129; HOWELL TW, 1987, BIOCHIM BIOPHYS ACTA, V927, P177, DOI 10.1016/0167-4889(87)90132-7; JAHN R, 1980, EUR J BIOCHEM, V112, P345, DOI 10.1111/j.1432-1033.1980.tb07211.x; JAHN R, 1983, FEBS LETT, V153, P71, DOI 10.1016/0014-5793(83)80121-5; KANAMORI T, 1980, BIOCHEM INT, V1, P395; KITAGAWA M, 1990, AM J PHYSIOL, V259, pG157, DOI 10.1152/ajpgi.1990.259.2.G157; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; NAKAMURA T, 1987, NATURE, V325, P442, DOI 10.1038/325442a0; OSULLIVAN AJ, 1992, BIOCHEM J, V287, P403, DOI 10.1042/bj2870403; QUISSELL DO, 1992, ARCH ORAL BIOL, V37, P289, DOI 10.1016/0003-9969(92)90051-9; QUISSELL DO, 1985, P NATL ACAD SCI USA, V82, P3237, DOI 10.1073/pnas.82.10.3237; RAFFANIELLO RD, 1993, J BIOL CHEM, V268, P8491; SIESS W, 1989, PHYSIOL REV, V69, P58, DOI 10.1152/physrev.1989.69.1.58; SPEARMAN TN, 1984, J CELL BIOL, V99, P1354, DOI 10.1083/jcb.99.4.1354; STECHER B, 1992, BIOCHEM J, V283, P899, DOI 10.1042/bj2830899; TAKUMA T, 1988, J BIOCHEM-TOKYO, V103, P95, DOI 10.1093/oxfordjournals.jbchem.a122247; TAKUMA T, 1991, J BIOCHEM-TOKYO, V110, P292, DOI 10.1093/oxfordjournals.jbchem.a123573; TAKUMA T, 1991, FEBS LETT, V285, P124, DOI 10.1016/0014-5793(91)80740-T; TAKUMA T, 1988, BIOCHEM J, V256, P867, DOI 10.1042/bj2560867; TAKUMA T, 1994, FEBS LETT, V340, P29, DOI 10.1016/0014-5793(94)80167-3; TAKUMA T, 1993, FEBS LETT, V323, P145, DOI 10.1016/0014-5793(93)81467-E; TAKUMA T, 1990, J BIOCHEM, V108, P99, DOI 10.1093/oxfordjournals.jbchem.a123171; TAYLOR SS, 1989, J BIOL CHEM, V264, P8443; THIEL G, 1988, EUR J BIOCHEM, V174, P601, DOI 10.1111/j.1432-1033.1988.tb14141.x; THIEL G, 1988, EUR J BIOCHEM, V170, P643, DOI 10.1111/j.1432-1033.1988.tb13746.x; TOJYO Y, 1990, BIOCHEM PHARMACOL, V39, P1775	44	40	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22124	22128						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	7520911				2022-12-27	WOS:A1994PE09800032
J	BEERS, MF; KIM, CY; DODIA, C; FISHER, AB				BEERS, MF; KIM, CY; DODIA, C; FISHER, AB			LOCALIZATION, SYNTHESIS, AND PROCESSING OF SURFACTANT PROTEIN SP-C IN RAT LUNG ANALYZED BY EPITOPE-SPECIFIC ANTIPEPTIDE ANTIBODIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; PULMONARY SURFACTANT; II CELLS; HYDROPHOBIC PROTEINS; INSITU HYBRIDIZATION; LAMELLAR BODIES; BREFELDIN-A; SP-B; PRECURSOR; BOVINE	Surfactant protein C (SP-C), a 3.7-kDa hydrophobic lung-specific protein, is synthesized and secreted by pulmonary type II cells through proteolytic processing of a 21-kDa propeptide (SP-C-21) by currently undefined pathways. Previously, we reported the production of a polyclonal antibody against rat SP-C-21 (anti-CPROSP-C) using a synthetic peptide as the immunizing antigen (Beers, M. F., Wali, A., Eckenhoff, M. E. F., Feinstein, S., Fisher, J. H., and Fisher, A. B. (1992) Am. J. Respir. Cell. Mol. Biol. 7, 368-378). In this study, two additional epitope-specific proSP-C antibodies produced using synthetic peptide sequences were utilized to examine synthetic processing of SP-C. Anti-NPROSP-C (Met(10)-Gln(23)) and anti-CTERMSP-C (Ser(149)-Ser(166)) recognized native proSP-C-21 produced from in vitro translation of SP-C cDNA. Immunocytochemistry using anti-NPROSP-C confirmed the localization of proSP-C peptides exclusively in type II cells. Western analysis of subcellular fractions identified a single 21-kDa band in microsomes and a 16-kDa form in lamellar bodies each recognized by all three antisera, while anti-NPROSP-C also uniquely identified a prominent 5-6-kDa form in lamellar bodies. In a perfused rat lung model labeled with [S-35]cysteine/methionine, immunoprecipitation of lung homogenate and lamellar body fractions identified early appearances of S-35-labeled 21-, 18-, and 16-kDa SP-C forms in homogenate and a 16-kDa intermediate form in lamellar bodies. Anti-NPROSP-C also exclusively detected time-dependent appearances of 5-10-kDa proSP-C forms in lamellar bodies and homogenates. Processing of proSP-C-21 was completely blocked by inclusion of brefeldin A (15 mu g/ml) in the perfusate. These results demonstrate that synthetic peptides can be used to produce epitope specific antisera which recognize more hydrophilic domains of proSP-C and show that proSP-C processing occurs intracellularly in subcellular compartments of type II cells which are distal to the trans-Golgi network.	HOSP UNIV PENN,DEPT MED,DIV PULM & CRIT CARE,PHILADELPHIA,PA 19104	University of Pennsylvania; Pennsylvania Medicine	BEERS, MF (corresponding author), UNIV PENN,SCH MED,INST ENVIRONM MED,1 JOHN MORGAN BLDG,36TH & HAMILTON WALK,PHILADELPHIA,PA 19104, USA.				NHLBI NIH HHS [HL-02869] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002869] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEERS MF, 1992, AM J PHYSIOL, V263, pL151, DOI 10.1152/ajplung.1992.263.2.L151; BEERS MF, 1992, AM J PHYSIOL, V262, pL773, DOI 10.1152/ajplung.1992.262.6.L773; BEERS MF, 1992, AM J RESP CELL MOL, V7, P368, DOI 10.1165/ajrcmb/7.4.368; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANDER A, 1983, BIOCHIM BIOPHYS ACTA, V753, P119, DOI 10.1016/0005-2760(83)90105-4; CURSTEDT T, 1987, EUR J BIOCHEM, V168, P255, DOI 10.1111/j.1432-1033.1987.tb13414.x; CURSTEDT T, 1990, P NATL ACAD SCI USA, V87, P2985, DOI 10.1073/pnas.87.8.2985; DOBBS LG, 1982, BIOCHIM BIOPHYS ACTA, V713, P118, DOI 10.1016/0005-2760(82)90174-6; DODIA C, 1991, FASEB J, V5, P1490; EMRIE PA, 1989, BIOCHIM BIOPHYS ACTA, V994, P215, DOI 10.1016/0167-4838(89)90296-3; FISHER AB, 1991, AM J PHYSIOL, V261, pL334, DOI 10.1152/ajplung.1991.261.4.L334; FISHER JH, 1991, AM J RESP CELL MOL, V5, P63, DOI 10.1165/ajrcmb/5.1.63; FISHER JH, 1989, BIOCHIM BIOPHYS ACTA, V995, P225, DOI 10.1016/0167-4838(89)90040-X; GLASSER SW, 1990, J BIOL CHEM, V265, P9; GLASSER SW, 1988, J BIOL CHEM, V257, P13135; GORDON RD, 1987, P NATL ACAD SCI USA, V84, P308, DOI 10.1073/pnas.84.1.308; HAWGOOD S, 1989, AM J PHYSIOL, V257, pL13, DOI 10.1152/ajplung.1989.257.2.L13; IMAJOHOHMI S, 1992, J BIOL CHEM, V267, P180; JOBE A, 1977, BIOCHIM BIOPHYS ACTA, V489, P440, DOI 10.1016/0005-2760(77)90165-5; JOHANNSEN J, 1990, METHODS PROTEIN SEQU, P197; KALINA M, 1992, AM J RESP CELL MOL, V6, P594, DOI 10.1165/ajrcmb/6.6.594; KATYAL SL, 1977, LAB INVEST, V36, P585; KELLER A, 1992, AM J RESP CELL MOL, V6, P601, DOI 10.1165/ajrcmb/6.6.601; KELLER A, 1991, BIOCHEM J, V277, P493, DOI 10.1042/bj2770493; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KOZAK M, 1992, CRIT REV BIOCHEM MOL, V27, P385, DOI 10.3109/10409239209082567; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; MATHIALAGAN N, 1990, BIOCHIM BIOPHYS ACTA, V1045, P121, DOI 10.1016/0005-2760(90)90140-S; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MILLER EJ, 1991, AM J PHYSIOL, V260, pL1, DOI 10.1152/ajplung.1991.260.2.L1; OOSTERLAKENDIJKSTERHUIS MA, 1991, BIOCHEM J, V274, P115, DOI 10.1042/bj2740115; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; PHELPS DS, 1988, AM REV RESPIR DIS, V137, P939, DOI 10.1164/ajrccm/137.4.939; PHELPS DS, 1991, EXP LUNG RES, V17, P985, DOI 10.3109/01902149109064330; PHIZACKERLEY PJR, 1979, BIOCHEM J, V183, P731, DOI 10.1042/bj1830731; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHANNON JM, 1990, AM J RESP CELL MOL, V2, P183, DOI 10.1165/ajrcmb/2.2.183; SHINNICK TM, 1983, ANNU REV MICROBIOL, V37, P425, DOI 10.1146/annurev.mi.37.100183.002233; STULTS JT, 1991, AM J PHYSIOL, V261, pL118, DOI 10.1152/ajplung.1991.261.2.L118; VOORHOUT WF, 1993, MICROSC RES TECHNIQ, V26, P366, DOI 10.1002/jemt.1070260504; VORBROKER DK, 1992, BIOCHIM BIOPHYS ACTA, V1105, P161, DOI 10.1016/0005-2736(92)90175-L; WALI A, 1993, AM J PHYSIOL, V264, pL431, DOI 10.1152/ajplung.1993.264.5.L431; WEAVER TE, 1989, AM J PHYSIOL, V257, pL100, DOI 10.1152/ajplung.1989.257.2.L100; WEAVER TE, 1991, BIOCHEM J, V273, P249, DOI 10.1042/bj2730249; WEAVER TE, 1992, AM J PHYSIOL, V263, pL95, DOI 10.1152/ajplung.1992.263.1.L95; WILLIAMS MC, 1988, AM REV RESPIR DIS, V137, P399, DOI 10.1164/ajrccm/137.2.399; WOHLFORDLENANE CL, 1992, AM J RESP CELL MOL, V6, P225, DOI 10.1165/ajrcmb/6.2.225	47	104	106	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20318	20328						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	7519606				2022-12-27	WOS:A1994PB31700020
J	ZHOU, LB; LEE, DHS; PLESCIA, J; LAU, CY; ALTIERI, DC				ZHOU, LB; LEE, DHS; PLESCIA, J; LAU, CY; ALTIERI, DC			DIFFERENTIAL LIGAND-BINDING SPECIFICITIES OF RECOMBINANT CD11B/CD18 INTEGRIN I-DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENT RECEPTOR; LEUKOCYTE ADHESION; MONOCLONAL-ANTIBODIES; GLYCOPROTEIN FAMILY; CELLULAR ADHESION; RECOGNITION SITE; MAC-1 CD11B/CD18; ESCHERICHIA-COLI; GAMMA-CHAIN; FIBRINOGEN	The alpha subunits of leukocyte CD11/CD18 integrins contain an similar to 200-amino acid ''inserted'' domain (I-domain) that may be important for multivalent adhesive recognitions. A recombinant form of the I-domain of CD11b/CD18 was generated and analyzed directly for interaction with complementary integrin ligands. CD11b I-domain bound the activation-dependent monoclonal antibody 7E3, and the functionally blocking anti-CD11b monoclonal antibodies OKM9, 60.1, and LM2/1, but not OKM1 or M1/70. Fibrinogen or soluble intercellular adhesion molecule-1 associated with CD11b I-domain in a concentration-dependent manner. Binding of I-125-fibrinogen to recombinant CD11b I-domain was saturable, governed by a K-d of similar to 0.22 +/- 0.06 mu M, and fully inhibited by molar excess of unlabeled fibrinogen, or by the P1 peptide (KY)GWTVFQKRLDGSV (IC50 similar to 2.5-5 mu M), duplicating the fibrinogen gamma chain sequence Gly(190)-Val(202). In contrast, I-125-factor X binding to CD11b I-domain was only partially inhibited (50-60%) by a molar excess of unlabeled factor X, and entirely unaffected by functionally blocking anti-CD11b monoclonal antibodies or by factor X-derived synthetic peptidyl antagonists. We conclude that the I-domain of CD11b participates in qualitative mechanisms of receptor activation and contains the binding site(s) for the CD11b/CD18 ligands fibrinogen and intercellular adhesion molecule-1, while it is only minimally implicated in the recognition of factor X.	Scripps Res Inst, RES INST, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; RW JOHNSON PHARMACEUT RES INST, DON MILLS M3C 1L9, ON, CANADA	Scripps Research Institute					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043773] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-43773] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTIERI DC, 1988, J IMMUNOL, V141, P2656; ALTIERI DC, 1991, SCIENCE, V254, P1200, DOI 10.1126/science.1957171; ALTIERI DC, 1993, J BIOL CHEM, V268, P1847; ALTIERI DC, 1988, J CELL BIOL, V107, P1893, DOI 10.1083/jcb.107.5.1893; ALTIERI DC, 1988, J BIOL CHEM, V263, P7007; ANDERSON DC, 1986, J IMMUNOL, V137, P15; ARNAOUT MA, 1990, BLOOD, V75, P1037; ARNAOUT MA, 1988, J CELL BIOL, V106, P2153, DOI 10.1083/jcb.106.6.2153; BELLER DI, 1982, J EXP MED, V156, P1000, DOI 10.1084/jem.156.4.1000; BRIESEWITZ R, 1993, J BIOL CHEM, V268, P2989; BROWN EJ, 1988, J CLIN INVEST, V81, P365, DOI 10.1172/JCI113328; COLLER BS, 1985, J CLIN INVEST, V76, P101, DOI 10.1172/JCI111931; COLOMBATTI A, 1991, BLOOD, V77, P2305; CORBI AL, 1988, J BIOL CHEM, V263, P12403; DIAMOND MS, 1993, J CELL BIOL, V120, P545, DOI 10.1083/jcb.120.2.545; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; DIAMOND MS, 1990, J CELL BIOL, V107, P321; GUSTAFSON EJ, 1989, J CELL BIOL, V109, P377, DOI 10.1083/jcb.109.1.377; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KLOCZEWIAK M, 1984, BIOCHEMISTRY-US, V23, P1767, DOI 10.1021/bi00303a028; LANDIS RC, 1993, J CELL BIOL, V120, P1519, DOI 10.1083/jcb.120.6.1519; MARTIN S, 1993, ANTIMICROB AGENTS CH, V37, P1278, DOI 10.1128/AAC.37.6.1278; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; MILLER LJ, 1986, J IMMUNOL, V137, P2891; PANG J, 1993, J IMMUNOL, V151, P6166; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SANCHEZMADRID F, 1983, J EXP MED, V158, P1785, DOI 10.1084/jem.158.6.1785; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHIFFENBAUM B, 1989, J IMMUNOL, V142, P3537; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; TREZZINI C, 1988, BIOCHEM BIOPH RES CO, V156, P477, DOI 10.1016/S0006-291X(88)80866-0; WALLIS WJ, 1986, BLOOD, V67, P1007; WIGHT SD, 1988, P NATL ACAD SCI USA, V85, P7734	34	133	139	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 24	1994	269	25					17075	17079						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NT846	7516332				2022-12-27	WOS:A1994NT84600017
J	FRIGUET, B; DJAVADIOHANIANCE, L; KING, J; GOLDBERG, ME				FRIGUET, B; DJAVADIOHANIANCE, L; KING, J; GOLDBERG, ME			IN-VITRO AND RIBOSOME-BOUND FOLDING INTERMEDIATES OF P22 TAILSPIKE PROTEIN DETECTED WITH MONOCLONAL-ANTIBODIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI TRYPTOPHAN SYNTHASE; RIBULOSE BISPHOSPHATE CARBOXYLASE; TAIL SPIKE ENDORHAMNOSIDASE; ESCHERICHIA-COLI; PHAGE-P22 TAILSPIKE; POLYPEPTIDE-CHAINS; RAMAN-SPECTROSCOPY; BETA-2 SUBUNIT; HEAT-SHOCK; WILD-TYPE	It remains unclear whether polypeptide chains renaturing in vitro from strong denaturants proceed through the same folding pathway as chains released from ribosomes within cells. Folding intermediates formed both in vivo and in vitro have been examined using three monoclonal antibodies shown previously to recognize different epitopes of the native P22 tailspike protein (Friguet, B., Djavadi-Ohaniance, L., Haase-Pettingell, C, A, King, J., and Goldberg, M. E. (1990) J. Biol. Chem. 265, 10347-10351). The tailspike protein was reconstituted from polypeptide chains unfolded by urea as described by Fuchs ct al. (Fuchs, A., Seiderer, C., and Seckler, R. (1991) Biochemistry 30, 6598-6604), and the appearance of immunoreactive forms during the refolding was monitored. The three antibodies discriminated intermediates at different stages in the folding pathway. On the basis of the reconstitution pathway determined from spectroscopic and hydrodynamic measurements by Fuchs ct al. (1991), monoclonal antibody (mAb) 236-3 recognized partially folded monomers, mAb 155-3 recognized folded protomers in a protrimer species, and mAb 33-2 recognized the native trimer. The kinetics of appearance of the immunoreactive forms during the in vitro refolding of the protein in crude extracts of phage-infected cells was similar to that observed with the pure tailspike. Thus, the antibodies provided probes for the chain folding and association pathway in vivo. The conformation of the ribosome-bound tailspike polypeptide chains of the infected cells was analyzed with the three antibodies. The antibodies recognizing native trimer and the protrimer did not bind chains associated with the ribosomes. Antibody 236-3, which recognized structured monomers in vitro, bound to the polypeptide chains still associated with ribosomes. This result suggests that steps that take place in solution during in vitro refolding may occur in a ribosome-bound state in vivo.	INST PASTEUR,UNITE BIOCHIM CELLULAIRE,CNRS,URA 1129,F-75724 PARIS 15,FRANCE; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Massachusetts Institute of Technology (MIT)				Friguet, Bertrand/0000-0001-8085-1961				BAUM J, 1989, BIOCHEMISTRY-US, V28, P7, DOI 10.1021/bi00427a002; BERGET PB, 1980, J VIROL, V34, P234, DOI 10.1128/JVI.34.1.234-243.1980; BLOND S, 1987, P NATL ACAD SCI USA, V84, P1147, DOI 10.1073/pnas.84.5.1147; BLONDELGUINDI S, 1990, BIOCHEMISTRY-US, V29, P2409, DOI 10.1021/bi00461a026; BYCROFT M, 1990, NATURE, V346, P488, DOI 10.1038/346488a0; CHEN BL, 1991, BIOCHEMISTRY-US, V30, P6260, DOI 10.1021/bi00239a026; CREIGHTON TE, 1978, PROG BIOPHYS MOL BIO, V33, P231; DJAVADIOHANIANCE L, 1986, BIOCHEMISTRY-US, V25, P2502, DOI 10.1021/bi00357a033; DJAVADIOHANIANCE L, 1984, BIOCHEMISTRY-US, V23, P97, DOI 10.1021/bi00296a016; ENGEL J, 1991, ANNU REV BIOPHYS BIO, V20, P137, DOI 10.1146/annurev.biophys.20.1.137; FEDOROV AN, 1992, J MOL BIOL, V228, P351, DOI 10.1016/0022-2836(92)90825-5; FRIGUET B, 1986, EUR J BIOCHEM, V160, P593, DOI 10.1111/j.1432-1033.1986.tb10079.x; FRIGUET B, 1990, J BIOL CHEM, V265, P10347; FRIGUET B, 1984, MOL IMMUNOL, V21, P673, DOI 10.1016/0161-5890(84)90053-1; FUCHS A, 1991, BIOCHEMISTRY-US, V30, P6598, DOI 10.1021/bi00240a032; GOLDBERG ME, 1985, TRENDS BIOCHEM SCI, V10, P388, DOI 10.1016/0968-0004(85)90066-0; GOLDENBERG D, 1982, P NATL ACAD SCI-BIOL, V79, P3403, DOI 10.1073/pnas.79.11.3403; GOLDENBERG DP, 1983, P NATL ACAD SCI-BIOL, V80, P7060, DOI 10.1073/pnas.80.23.7060; GOLDENBERG DP, 1982, J BIOL CHEM, V257, P7864; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; HAASEPETTINGELL CA, 1988, J BIOL CHEM, V263, P4977; HAMLIN J, 1972, P NATL ACAD SCI USA, V69, P412, DOI 10.1073/pnas.69.2.412; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; KIM PS, 1982, ANNU REV BIOCHEM, V51, P459, DOI 10.1146/annurev.bi.51.070182.002331; King J, 1986, Methods Enzymol, V131, P250; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARSTON FAO, 1986, BIOCHEM J, V240, P1, DOI 10.1042/bj2400001; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MITRAKI A, 1989, BIO-TECHNOL, V7, P690, DOI 10.1038/nbt0789-690; MURRYBRELIER A, 1988, BIOCHEMISTRY-US, V27, P7633, DOI 10.1021/bi00420a010; OAS TG, 1988, NATURE, V336, P42, DOI 10.1038/336042a0; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PURVIS IJ, 1987, J MOL BIOL, V14, P1238; RODER H, 1988, NATURE, V335, P700, DOI 10.1038/335700a0; SARGENT D, 1988, J MOL BIOL, V199, P491, DOI 10.1016/0022-2836(88)90620-1; SAUER RT, 1982, BIOCHEMISTRY-US, V21, P5811, DOI 10.1021/bi00266a014; SCHEIN CH, 1989, BIO-TECHNOL, V7, P1141; SCHONER RG, 1985, BIO-TECHNOL, V3, P151, DOI 10.1038/nbt0285-151; SCHWARZ JJ, 1989, J BIOL CHEM, V264, P20112; SECKLER R, 1989, J BIOL CHEM, V264, P11750; SMITH DH, 1981, J MOL BIOL, V145, P653, DOI 10.1016/0022-2836(81)90308-9; STURTEVANT JM, 1989, J BIOL CHEM, V264, P10693; THOMAS GJ, 1990, BIOCHEMISTRY-US, V29, P4181, DOI 10.1021/bi00469a022; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UDGAONKAR JB, 1988, NATURE, V335, P694, DOI 10.1038/335694a0; VILLAFANE R, 1988, J MOL BIOL, V204, P607, DOI 10.1016/0022-2836(88)90359-2; YU MH, 1988, J BIOL CHEM, V263, P1424	48	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15945	15949						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	7515066				2022-12-27	WOS:A1994NP51300084
J	SMITH, WC; MILAM, AH; DUGGER, D; ARENDT, A; HARGRAVE, PA; PALCZEWSKI, K				SMITH, WC; MILAM, AH; DUGGER, D; ARENDT, A; HARGRAVE, PA; PALCZEWSKI, K			A SPLICE VARIANT OF ARRESTIN - MOLECULAR-CLONING AND LOCALIZATION IN BOVINE RETINA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							COUPLED RECEPTOR KINASES; 48-KDA PROTEIN; S-ANTIGEN; PHOTOEXCITED RHODOPSIN; PHOTORECEPTORS; IDENTIFICATION; INACTIVATION; EXPRESSION; RODS; DNA	Inactivation of photolyzed rhodopsin requires phosphorylation of the receptor and binding of the 48-kDa regulatory protein arrestin. We recently isolated a novel form of arrestin, termed p(44), that is truncated at the COOH terminus (Palczewski, K., Buczylko, J., Ohguro, H., Annan, R. S., Carr, S. A., Crabb, J. W., Kaplan, M. W, Johnson, R. S., and Walsh, K. A. (1994) Protein Sci. 3, 319-329) and strongly inhibits G(t) activation by non-phosphorylated rhodopsin. p(44) is identical to arrestin except at the COOH terminus, where the 35 amino acids of arrestin are replaced by a single alanine residue. p(44) is identified as a splice variant of arrestin based on the identical cDNA sequence of p(44) with arrestin (except the 3' non-coding regions), the presence of an exon/intron junction at the Ser(369) codon, and identical Southern hybridization patterns generated by the 3' non-coding portion of arrestin and p(44). Immunocytochemistry reveals that p(44) is localized in the photoreceptor outer segment, whereas arrestin is present throughout the cell. This specificity of localization to the outer segment is persistent with a role of p(44) in the phototransduction cascade.	UNIV WASHINGTON,DEPT OPHTHALMOL,SEATTLE,WA 98195; UNIV FLORIDA,DEPT OPHTHALMOL,GAINESVILLE,FL 32610; UNIV FLORIDA,DEPT BIOCHEM & MOLEC BIOL,GAINESVILLE,FL 32610; UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; State University System of Florida; University of Florida; State University System of Florida; University of Florida; University of Washington; University of Washington Seattle			Smith, W. Clay/AAQ-1589-2021		NATIONAL EYE INSTITUTE [R01EY001311, R01EY009339] Funding Source: NIH RePORTER; NEI NIH HHS [EY06225, EY01311, EY09339] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ADAMUS G, 1988, Peptide Research, V1, P42; BENNETT N, 1988, BIOCHEMISTRY-US, V27, P1710, DOI 10.1021/bi00405a049; BREITMAN ML, 1991, J BIOL CHEM, V266, P15505; BUCZYLKO J, 1993, METH NEUROSCI, V15, P226; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DOLPH PJ, 1993, SCIENCE, V260, P1910, DOI 10.1126/science.8316831; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; HOFMANN KP, 1992, J BIOL CHEM, V267, P15701; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LEREA CL, 1989, NEURON, V3, P367, DOI 10.1016/0896-6273(89)90261-4; MANGINI NJ, 1988, INVEST OPHTH VIS SCI, V29, P1221; NIR I, 1992, J HISTOCHEM CYTOCHEM, V40, P343, DOI 10.1177/40.3.1372630; PALCZEWSKI K, 1989, J BIOL CHEM, V264, P15770; PALCZEWSKI K, 1993, J BIOL CHEM, V268, P6004; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; PALCZEWSKI K, 1994, PROTEIN SCI, V3, P319; PALCZEWSKI K, 1992, NEURON, V8, P177; PARRUTI G, 1993, J BIOL CHEM, V268, P9753; SAMBROOK J, 1989, MOL CLONING LABORATO, V1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHINOHARA T, 1987, P NATL ACAD SCI USA, V84, P6975, DOI 10.1073/pnas.84.20.6975; STERNEMARR R, 1993, J BIOL CHEM, V268, P15640; WACKER WB, 1977, J IMMUNOL, V119, P1949; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174	24	91	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15407	15410						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	7515057				2022-12-27	WOS:A1994NP51300003
J	PERRELLA, MA; YOSHIZUMI, M; FEN, Z; TSAI, JC; HSIEH, CM; KOUREMBANAS, S; LEE, ME				PERRELLA, MA; YOSHIZUMI, M; FEN, Z; TSAI, JC; HSIEH, CM; KOUREMBANAS, S; LEE, ME			TRANSFORMING GROWTH-FACTOR-BETA-1, BUT NOT DEXAMETHASONE, DOWN-REGULATES NITRIC-OXIDE SYNTHASE MESSENGER-RNA AFTER ITS INDUCTION BY INTERLEUKIN-1-BETA IN RAT SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR NECROSIS FACTOR; ENDOTHELIAL-CELLS; SEPTIC SHOCK; ANGIOTENSIN-II; EXPRESSION; CLONING; HYPOTENSION; INHIBITION; GENE	Nitric oxide (NO), which accounts for the biologic properties of endothelium-derived relaxing factor, is synthesized from L-arginine by nitric-oxide synthase (NOS). Two classes of NOS have been identified: a constitutive, calcium-dependent isozyme (cNOS) and an inducible, calcium-independent isozyme (iNOS). NO is generated after the induction of iNOS by cytokines such as interleukin-1 beta (IL-1 beta) and tumor necrosis factor-alpha. As a potent vasodilator, NO may have an important role in the severe hypotension of septic shock. We investigated whether dexamethasone and transforming growth factor-beta 1 (TGF-beta 1) suppress iNOS mRNA after its induction by IL-1 beta. We found that IL-1 beta induced NOS mRNA in rat aortic smooth muscle cells (RASMC) in a dose- and time-dependent fashion. IL-1 beta promoted a dramatic and pro longed induction of RASMC iNOS mRNA that peaked at 48 h. Dexamethasone prevented this induction of iNOS mRNA only when given before the addition of IL-1 beta. In contrast, TGF-beta 1 inhibited the induction of iNOS mRNA and NO production in RASMC both before and after the addition of IL-1 beta. After 24 h of IL-1 beta stimulation, TGF-beta 1 down-regulated the iNOS mRNA that had been induced during this initial time period. In nuclear run-on experiments, we found that the down-regulation of MOS mRNA by TGF-beta 1 in RASMC occurred at the transcriptional level. Our observation that TGF-beta 1 mediates inhibition of RASMC iNOS mRNA after its induction by cytokines may be an important insight into the treatment of septic shock.	HARVARD UNIV,SCH PUBL HLTH,CARDIOVASC BIOL LAB,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,JOINT PROGRAM NEONATOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DIV CARDIOVASC,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital					NHLBI NIH HHS [HL-02394, 1P05HL46491] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL046491, K08HL002394] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BONE RC, 1987, NEW ENGL J MED, V317, P653, DOI 10.1056/NEJM198709103171101; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; CHANTRY D, 1989, J IMMUNOL, V142, P4295; EIZIRIK DL, 1993, FEBS LETT, V317, P62, DOI 10.1016/0014-5793(93)81492-I; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P533; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; GUNTHER S, 1982, J CELL BIOL, V92, P289, DOI 10.1083/jcb.92.2.289; IGNARRO JJ, 1990, ANN REV PHARM TOXICO, V30, P535; JANSSENS SP, 1992, J BIOL CHEM, V267, P14519; KILBOURN RG, 1990, P NATL ACAD SCI USA, V87, P3629, DOI 10.1073/pnas.87.9.3629; KOIDE M, 1993, FEBS LETT, V318, P213, DOI 10.1016/0014-5793(93)80514-U; KOUREMBANAS S, 1990, J CLIN INVEST, V86, P670, DOI 10.1172/JCI114759; LEE ME, 1991, J BIOL CHEM, V266, P16188; LI LM, 1991, CANCER RES, V51, P2531; LORSBACH RB, 1993, J BIOL CHEM, V268, P1908; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; MONCADA S, 1991, PHARMACOL REV, V43, P109; NAVA E, 1992, J CARDIOVASC PHARM, V20, pS132, DOI 10.1097/00005344-199204002-00037; NAVA E, 1991, LANCET, V338, P1555, DOI 10.1016/0140-6736(91)92375-C; NUNOKAWA Y, 1993, BIOCHEM BIOPH RES CO, V191, P89, DOI 10.1006/bbrc.1993.1188; OKUSAWA S, 1988, J CLIN INVEST, V81, P1162, DOI 10.1172/JCI113431; Palmer R M, 1993, Curr Opin Nephrol Hypertens, V2, P122, DOI 10.1097/00041552-199301000-00018; PARRILLO JE, 1993, NEW ENGL J MED, V328, P1471, DOI 10.1056/nejm199305203282008; PETROS A, 1991, LANCET, V338, P1557, DOI 10.1016/0140-6736(91)92376-D; RADOMSKI MW, 1990, P NATL ACAD SCI USA, V87, P10043, DOI 10.1073/pnas.87.24.10043; REDINI F, 1993, ARTHRITIS RHEUM, V36, P44; Sambrook J, 1989, MOL CLONING LABORATO; SCHINI VB, 1992, EUR J PHARMACOL, V216, P379, DOI 10.1016/0014-2999(92)90434-6; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; TEMIZER DH, 1992, J BIOL CHEM, V267, P24892; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2483; VODOVOTZ Y, 1993, J EXP MED, V178, P605, DOI 10.1084/jem.178.2.605; WAHL SM, 1993, J IMMUNOL, V150, P3553; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522	35	147	147	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14595	14600						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	7514175				2022-12-27	WOS:A1994NM06500046
J	KITAZAWA, S; ROSS, FP; MCHUGH, K; TEITELBAUM, SL				KITAZAWA, S; ROSS, FP; MCHUGH, K; TEITELBAUM, SL			INTERLEUKIN-4 INDUCES EXPRESSION OF THE INTEGRIN ALPHA(V)BETA(3) VIA TRANSACTIVATION OF THE BETA(3) GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOCLASTIC BONE-RESORPTION; VITRONECTIN RECEPTOR; MULTINUCLEATED CELLS; CHICKEN OSTEOCLASTS; MANNOSE RECEPTOR; INVITRO; ALPHA-V-BETA-3; MACROPHAGES; MICE; OSTEOPONTIN	Osteoclastic bone resorption is dependent upon cell-matrix recognition. This process is mediated by the integrin alpha(v) beta(3), whose expression is enhanced, in avian osteoclast precursors, by bone-seeking steroids. The purpose of this study was to determine if bone-modulating cytokines impact on gp, expression by mouse marrow macrophages (BMMs), known to differentiate into osteoclasts. Of the cytokines tested. Interleukin-4 (IL-4) is most effective in increasing beta(3) mRNA levels by a mechanism involving transactivation of the beta(3), gene. Moreover, IL-4 augmented beta(3) mRNA is mirrored by plasma membrane appearance of alpha(v) beta(3). As IL-4 induces beta(3) and not alpha(v) mRNA, the beta(3) chain appears to regulate surface expression of the heterodimer. The functional significance of IL-4-induced alpha v beta 3, is underscored by the fact that, while attachment to fibronectin is unaltered, treatment of EMMs with the cytokine enhances alpha(v) beta(3)- mediated binding to vitronectin 5-fold, Expression of this heterodimer by BMMs driven along a non-osteoclastic lineage suggests alpha(v) beta(3), may play a role in the inflammatory response of macrophages.	WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110	Washington University (WUSTL)			Kitazawa, Sohei/E-5602-2010	Kitazawa, Sohei/0000-0002-7466-7356; Teitelbaum, Steven/0000-0002-4054-6679	NIAMS NIH HHS [AR42404] Funding Source: Medline; NIDCR NIH HHS [DE05413] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042404] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AKASHI K, 1991, J CLIN INVEST, V88, P223, DOI 10.1172/JCI115281; AKATSU T, 1991, J BONE MINER RES, V6, P183; ALVAREZ JI, 1991, ENDOCRINOLOGY, V128, P2324, DOI 10.1210/endo-128-5-2324; ASANO Y, 1988, J IMMUNOL, V140, P419; BISKOBING DM, 1993, ENDOCRINOLOGY, V132, P862, DOI 10.1210/en.132.2.862; BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207; BLAIR HC, 1988, J CELL PHYSIOL, V137, P476, DOI 10.1002/jcp.1041370312; BOSSY B, 1990, BIOCHEMISTRY-US, V29, P10191, DOI 10.1021/bi00496a006; CHERESH DA, 1989, CELL, V58, P945, DOI 10.1016/0092-8674(89)90946-X; CHIBA M, 1993, J BONE MINER RES, V8, P8144; CIEUTAT AM, 1993, BIOCHEM BIOPH RES CO, V193, P771, DOI 10.1006/bbrc.1993.1692; CLOHISY DR, 1987, J BIOL CHEM, V262, P15922; FISHER JE, 1993, ENDOCRINOLOGY, V132, P1411, DOI 10.1210/en.132.3.1411; HORTON MA, 1993, J BONE MINER RES, V8, P239; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100; LAKKAKORPI PT, 1993, J CELL SCI, V104, P663; LARSON RS, 1990, IMMUNOL REV, V114, P181, DOI 10.1111/j.1600-065X.1990.tb00565.x; LEWIS DB, 1993, P NATL ACAD SCI USA, V90, P11618, DOI 10.1073/pnas.90.24.11618; LORENZO JA, 1987, J CLIN INVEST, V80, P160, DOI 10.1172/JCI113042; MCINNES A, 1988, J EXP MED, V167, P598, DOI 10.1084/jem.167.2.598; MIMURA H, 1994, ENDOCRINOLOGY, V134, P1061, DOI 10.1210/en.134.3.1061; MIYAUCHI A, 1991, J BIOL CHEM, V266, P20369; PAUL WE, 1991, BLOOD, V77, P1859; PFEILSCHIFTER J, 1989, J BONE MINER RES, V4, P113, DOI 10.1002/jbmr.5650040116; RIANCHO JA, 1993, J BONE MINER RES, V8, P1337; ROSS FP, 1993, J BIOL CHEM, V268, P9901; SATO M, 1992, FASEB J, V6, P2966, DOI 10.1096/fasebj.6.11.1644260; SHIOI A, 1991, J CELL BIOCHEM, V47, P272, DOI 10.1002/jcb.240470313; STANLEY ER, 1985, METHOD ENZYMOL, V116, P564; STEIN M, 1992, J EXP MED, V176, P287, DOI 10.1084/jem.176.1.287; TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P1504, DOI 10.1210/endo-123-3-1504; TAMURA T, 1993, P NATL ACAD SCI USA, V90, P11924, DOI 10.1073/pnas.90.24.11924; TEPPER RI, 1990, CELL, V62, P457, DOI 10.1016/0092-8674(90)90011-3; UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260; ZAMBONINZALLONE A, 1989, EXP CELL RES, V182, P645, DOI 10.1016/0014-4827(89)90266-8	36	55	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					4115	4120		10.1074/jbc.270.8.4115	http://dx.doi.org/10.1074/jbc.270.8.4115			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7533159	hybrid			2022-12-27	WOS:A1995QH68800095
J	DESAI, SY; PATEL, RC; SEN, GC; MALHOTRA, P; GHADGE, GD; THIMMAPAYA, B				DESAI, SY; PATEL, RC; SEN, GC; MALHOTRA, P; GHADGE, GD; THIMMAPAYA, B			ACTIVATION OF INTERFERON-INDUCIBLE 2'-5'-OLIGOADENYLATE SYNTHETASE BY ADENOVIRAL VAI RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; TREATED HELA-CELLS; PROTEIN-KINASE; BINDING DOMAIN; TRANSLATION; POLYMERASE; VIRUS; DAI	2'-5' oligoadenylate (2-5(A)) synthetase and protein kinase, RNA activated (PKR) are the only two known enzymes that bind double-stranded RNA (dsRNA) and get activated by it. We have previously identified their dsRNA binding domains, which do not have any sequence homology. Here, we report a profound difference between the two enzymes with respect to the structural features of the dsRNA that are required for their activation. The adenoviral virus-associated type I (VAI) RNA cannot activate PKR, although it binds to the protein and thereby prevents its activation by authentic dsRNA. In contrast, we observed that VAI RNA can both bind and activate 2-5(A) synthetase. Mutations in VAI RNA, which removed occasional mismatches present in its double-stranded stems, markedly enhanced its 2-5(A) synthetase-activating capacity. These mutants, however, are incapable of activating PKR. Other mutations, which disrupted the structure of the central stem-loop region of the VAI RNA, reduced its ability to activate 2-5(A) synthetase. These debilitated mutants could bind to the synthetase protein, although they fail to bind to PKR.	CLEVELAND CLIN FDN,RES INST,DEPT MOLEC BIOL,CLEVELAND,OH 44195; NORTHWESTERN UNIV,SCH MED,ROBERT H LURIE CANC CTR,CHICAGO,IL 60611; NORTHWESTERN UNIV,SCH MED,DEPT MICROBIOL IMMUNOL,CHICAGO,IL 60611	Cleveland Clinic Foundation; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Northwestern University			Patel, Rekha/M-7123-2015	Patel, Rekha/0000-0001-9434-4880	NCI NIH HHS [CA-62220] Funding Source: Medline; NIAID NIH HHS [AI-22510, AI-18029] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA062220] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018029] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAGLIONI C, 1981, NUCLEIC ACIDS RES, V9, P4939, DOI 10.1093/nar/9.19.4939; CHEBATH J, 1987, J BIOL CHEM, V262, P3852; DOUGHERTY JP, 1980, J BIOL CHEM, V255, P3813; FURTADO MR, 1989, J VIROL, V63, P3423, DOI 10.1128/JVI.63.8.3423-3434.1989; GHADGE GD, 1994, J VIROL, V68, P4137, DOI 10.1128/JVI.68.7.4137-4151.1994; GHADGE GD, 1991, P NATL ACAD SCI USA, V88, P7140, DOI 10.1073/pnas.88.16.7140; GHOSH SK, 1991, J BIOL CHEM, V266, P15293; GREEN SR, 1992, GENE DEV, V6, P2478, DOI 10.1101/gad.6.12b.2478; GRIBAUDO G, 1991, J VIROL, V65, P1748, DOI 10.1128/JVI.65.4.1748-1757.1991; HASSEL BA, 1993, EMBO J, V12, P3297, DOI 10.1002/j.1460-2075.1993.tb05999.x; HOVANESSIAN AG, 1989, J INTERFERON RES, V9, P641, DOI 10.1089/jir.1989.9.641; KATZE MG, 1987, EMBO J, V6, P689, DOI 10.1002/j.1460-2075.1987.tb04809.x; KITAJEWSKI J, 1986, CELL, V45, P195, DOI 10.1016/0092-8674(86)90383-1; MATHEWS MB, 1991, J VIROL, V65, P5657, DOI 10.1128/JVI.65.11.5657-5662.1991; MELLITS KH, 1988, EMBO J, V7, P2849, DOI 10.1002/j.1460-2075.1988.tb03141.x; MELLITS KH, 1990, CELL, V61, P843, DOI 10.1016/0092-8674(90)90194-J; MINKS MA, 1980, J BIOL CHEM, V255, P6403; MORY Y, 1989, J INTERFERON RES, V9, P295, DOI 10.1089/jir.1989.9.295; PATEL RC, 1992, J BIOL CHEM, V267, P7671; PATEL RC, 1994, J BIOL CHEM, V269, P18593; SAMUEL CE, 1991, VIROLOGY, V183, P1, DOI 10.1016/0042-6822(91)90112-O; SAMUEL CE, 1993, J BIOL CHEM, V268, P7603; SEN GC, 1993, ADV VIRUS RES, V42, P57, DOI 10.1016/S0065-3527(08)60083-4; SEN GC, 1992, J BIOL CHEM, V267, P5017; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; THIMMAPAYA B, 1993, TRANSLATIONAL REGULA, P203; WILLIAMS BRG, 1985, 2 5 A SYSTEM CLIN MO	27	54	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 17	1995	270	7					3454	3461		10.1074/jbc.270.7.3454	http://dx.doi.org/10.1074/jbc.270.7.3454			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QG471	7531709	hybrid			2022-12-27	WOS:A1995QG47100084
J	SHIMAMOTO, T; INOUYE, M; INOUYE, S				SHIMAMOTO, T; INOUYE, M; INOUYE, S			THE FORMATION OF THE 2',5'-PHOSPHODIESTER LINKAGE IN THE CDNA PRIMING REACTION BY BACTERIAL REVERSE-TRANSCRIPTASE IN A CELL-FREE SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; RNA-LINKED MSDNA; ESCHERICHIA-COLI; MYXOCOCCUS-XANTHUS; CLONED GENES; NUCLEOTIDE-SEQUENCE; LEVEL EXPRESSION; POLYMERASE; RETROELEMENT; BIOSYNTHESIS	Bacterial reverse transcriptase (RT) is responsible for synthesis of multicopy single-stranded DNA (msDNA) consisting of single-stranded DNA linked to an internal guanosine residue of RNA by an unusual 2',5'-phosphodiester linkage. Here we purified a bacterial RT to homogeneity from Escherichia coli harboring the RT gene from retron-Ec73. The purified RT-Ec73 was able to synthesize msDNA in a cell-free system using an RNA template produced in vitro by T7 RNA polymerase. The in vitro synthesized msDNA was released from the template RNA only when treated with yeast debranching enzyme DBR1, a specific nuclease for a 2',5'-phosphodiester linkage. The position of the branching G residue in the template RNA and the DNA sequence of the cell-free product were identical to those of msDNA-Ec73 synthesized in vivo. These results clearly demonstrate that the formation of the 2',5'-phosphodiester Linkage in msDNA synthesis is carried out by RT itself.	UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, DEPT BIOCHEM, PISCATAWAY, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center			Shimamoto, Tadashi/A-7109-2018; Inouye, Sharon/R-7216-2019	Shimamoto, Tadashi/0000-0002-5538-0595; 	NIGMS NIH HHS [GM44012] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044012] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIYAR A, 1994, J VIROL, V68, P611, DOI 10.1128/JVI.68.2.611-618.1994; BECK E, 1982, GENE, V19, P327, DOI 10.1016/0378-1119(82)90023-3; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; CHAPMAN KB, 1991, CELL, V65, P483, DOI 10.1016/0092-8674(91)90466-C; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; FURUICHI T, 1987, CELL, V48, P47, DOI 10.1016/0092-8674(87)90354-0; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; HSU MY, 1989, J BIOL CHEM, V264, P6214; INOUYE M, 1992, J BACTERIOL, V174, P2419, DOI 10.1128/jb.174.8.2419-2424.1992; INOUYE S, 1993, CURR OPIN GENET DEV, V3, P713, DOI 10.1016/S0959-437X(05)80088-7; INOUYE S, 1989, CELL, V56, P709, DOI 10.1016/0092-8674(89)90593-X; INOUYE S, 1993, REVERSE TRANSCRIPTAS, P391; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPSON BC, 1989, SCIENCE, V243, P1033, DOI 10.1126/science.2466332; LAMPSON BC, 1989, CELL, V56, P701, DOI 10.1016/0092-8674(89)90592-8; Leis J, 1993, REVERSE TRANSCRIPTAS, P33; LERNER CG, 1990, NUCLEIC ACIDS RES, V18, P4631, DOI 10.1093/nar/18.15.4631; LIGHTFOOTE MM, 1986, J VIROL, V60, P771, DOI 10.1128/JVI.60.2.771-775.1986; LIM D, 1989, CELL, V56, P891, DOI 10.1016/0092-8674(89)90693-4; LUAN DD, 1993, CELL, V72, P595, DOI 10.1016/0092-8674(93)90078-5; Maxam A M, 1980, Methods Enzymol, V65, P499; RICE SA, 1993, J BACTERIOL, V175, P4250, DOI 10.1128/JB.175.13.4250-4254.1993; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIMADA M, 1994, J BIOL CHEM, V269, P14553; SHIMADA M, 1994, J BIOL CHEM, V269, P3925; SHIMAMOTO T, 1993, J BIOL CHEM, V268, P2684; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUN J, 1991, J BACTERIOL, V173, P4171, DOI 10.1128/jb.173.13.4171-4181.1991; VARMUS H, 1984, RNA TUMOR VIRUSES, P369; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504; WAKEFIELD JK, 1994, J VIROL, V68, P1605, DOI 10.1128/JVI.68.3.1605-1614.1994; WANG GH, 1992, CELL, V71, P663, DOI 10.1016/0092-8674(92)90599-8; WANG H, 1993, CELL, V75, P1071, DOI 10.1016/0092-8674(93)90317-J; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	37	27	28	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					581	588		10.1074/jbc.270.2.581	http://dx.doi.org/10.1074/jbc.270.2.581			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7529762	hybrid			2022-12-27	WOS:A1995QB81600015
J	CLIPSTONE, NA; FIORENTINO, DF; CRABTREE, GR				CLIPSTONE, NA; FIORENTINO, DF; CRABTREE, GR			MOLECULAR ANALYSIS OF THE INTERACTION OF CALCINEURIN WITH DRUG-IMMUNOPHILIN COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN PHOSPHATASE; CYCLOSPORINE-A; CATALYTIC SUBUNIT; NEUROSPORA-CRASSA; LYMPHOCYTES-T; CYCLOPHILIN; EXPRESSION; FK506; ACTIVATION; CLONING	The calcium/calmodulin-regulated phosphatase calcineurin (CN) is the site of action of the immunosuppressive drugs cyclosporin A (CsA) and FK506. CN has recently been established as a key signaling enzyme in the T cell signal transduction cascade and an important regulator of transcription factors such as MF-AT and GAP/Oct-1, which are involved in the expression of a number of important T cell early genes. CsA and FK506 act by forming complexes with their respective intracellular receptors cyclophilin and FKBP (immunophilins), which can then bind to CN, inhibiting its enzymatic activity and thereby preventing early gene expression. CN is comprised of two subunits: a 59-kDa catalytic subunit (CNA), which contains a calmodulin binding domain and autoinhibitory region, and a 19-kDa intrinsic calcium binding regulatory subunit (CNB). In this study, we have utilized a series of deletion mutants of the CNA subunit to investigate the subunit and molecular requirements that govern the interaction of CN with drug-immunophilin complexes. The calmodulin binding and autoinhibitory domains of the CNA subunit were found to be dispensable for the binding of CN to drug immunophilin complexes. In contrast, we found that the regulatory CNB subunit appears to play an obligatory role in this interaction and have defined an amino acid sequence of the CNA subunit which forms the binding site for CNB. Although necessary, the CNB subunit per se is not sufficient to mediate an interaction with drug-immunophilin complexes; amino acid residues of the the CNA subunit, specifically a region located within the putative catalytic domain, are rise required for the interaction of CN with both FKBP.FK506 and cyclophilin A.CsA.			CLIPSTONE, NA (corresponding author), STANFORD UNIV, SCH MED, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA.			Fiorentino, David/0000-0001-7951-3674				ALDAPE RA, 1992, J BIOL CHEM, V267, P16029; BICKEL M, 1987, P NATL ACAD SCI USA, V84, P3274, DOI 10.1073/pnas.84.10.3274; BIERER BE, 1990, SCIENCE, V250, P556, DOI 10.1126/science.1700475; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BRAM RJ, 1993, MOL CELL BIOL, V13, P4670; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; CLIPSTONE NA, 1993, ANN NY ACAD SCI, V696, P20; CYERT MS, 1992, MOL CELL BIOL, V12, P3460, DOI 10.1128/MCB.12.8.3460; CYERT MS, 1991, P NATL ACAD SCI USA, V88, P7376, DOI 10.1073/pnas.88.16.7376; DAVIES AA, 1987, LYMPHOCYTES PRACTICA, P229; DUMONT FJ, 1990, J IMMUNOL, V144, P1418; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FOOR F, 1992, NATURE, V360, P682; FRIEDMAN J, 1991, CELL, V66, P799, DOI 10.1016/0092-8674(91)90123-G; GRANELLIPIPERNO A, 1986, J EXP MED, V163, P922, DOI 10.1084/jem.163.4.922; GUERINI D, 1992, J BIOL CHEM, V267, P22542; GUERINI D, 1989, P NATL ACAD SCI USA, V86, P9183, DOI 10.1073/pnas.86.23.9183; HADDY A, 1992, FEBS LETT, V314, P37, DOI 10.1016/0014-5793(92)81456-V; HIGUCHI S, 1991, J BIOL CHEM, V266, P18104; HUSI H, 1994, J BIOL CHEM, V269, P14199; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KAHAN BD, 1989, NEW ENGL J MED, V321, P1725; KINCAID R, 1993, ADV SEC MESS PHOSPH, V27, P1; KINCAID RL, 1990, J BIOL CHEM, V265, P11312; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KRONKE M, 1984, P NATL ACAD SCI-BIOL, V81, P5214, DOI 10.1073/pnas.81.16.5214; LI W, 1993, J BIOL CHEM, V268, P14040; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; RYFFEL B, 1993, BIOCHEM BIOPH RES CO, V194, P1074, DOI 10.1006/bbrc.1993.1931; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; THOMSON AW, 1989, IMMUNOL TODAY, V10, P6, DOI 10.1016/0167-5699(89)90057-1; TOCCI MJ, 1989, J IMMUNOL, V143, P718; TROPSCHUG M, 1989, NATURE, V342, P953, DOI 10.1038/342953a0; UEKI K, 1992, BIOCHEM BIOPH RES CO, V187, P537, DOI 10.1016/S0006-291X(05)81527-X; YOKOYAMA N, 1990, J BIOL CHEM, V265, P8170	44	100	108	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26431	26437						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7523407				2022-12-27	WOS:A1994PQ93000075
J	HENDERSON, SA; LEE, PH; AEBERHARD, EE; ADAMS, JW; IGNARRO, LJ; MURPHY, WJ; SHERMAN, MP				HENDERSON, SA; LEE, PH; AEBERHARD, EE; ADAMS, JW; IGNARRO, LJ; MURPHY, WJ; SHERMAN, MP			NITRIC-OXIDE REDUCES EARLY GROWTH RESPONSE-1 GENE-EXPRESSION IN RAT LUNG MACROPHAGES TREATED WITH INTERFERON-GAMMA AND LIPOPOLYSACCHARIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN-IMMUNODEFICIENCY-VIRUS; ALVEOLAR MACROPHAGES; MOUSE MACROPHAGES; MOLECULAR-BASIS; SYNTHASE GENE; DIFFERENTIATION; ACTIVATION; INDUCTION; EGR-1; PROTEIN	Since early growth response-1 (Egr-1) is required for macrophage differentiation and nitric oxide (NO) is immunosuppressive, we hypothesized that NO would reduce Egr-1 expression in rat lung macrophages. The inflammatory stimuli interferon-gamma and lipopolysaccharide induced an early, transient increase in Egr-1 mRNA (>5-fold at 2 h) and a sustained, high level of inducible NO synthase mRNA (>100-fold from 4 to 24 h). The NO metabolites nitrite and nitrate rose >10-fold in medium from stimulated versus unstimulated cells over 24 h. Concomitant with elevated nitrogen oxides, Egr-1 mRNA levels declined to 80% below unstimulated cells at 24 h. This decline was blocked by an inhibitor of NO production, N-G-monomethyl-L-arginine. Further, the NO donor S-nitroso-N-acetylpenicillamine inhibited Egr-1 expression in a dose dependent manner, producing complete inhibition at 0.5 mM. The effect of S-nitroso-N-acetylpenicillamine was not due to reduced macrophage viability. We conclude that Egr-1 induction precedes inducible NO synthase induction in stimulated rat macrophages and that subsequent NO production reduces macrophage expression of Egr-1. We propose that this mechanism is used to regulate macrophage differentiation in human immunodeficiency virus infection and other inflammatory states.	UNIV CALIF LOS ANGELES, DEPT PHARMACOL, LOS ANGELES, CA 90024 USA; UNIV KANSAS, DEPT MICROBIOL MOLEC GENET & IMMUNOL, KANSAS CITY, KS 66160 USA; UNIV KANSAS, DEPT PEDIAT, KANSAS CITY, KS 66160 USA; UNIV CALIF LOS ANGELES, DEPT PEDIAT, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of Kansas; University of California System; University of California Los Angeles	HENDERSON, SA (corresponding author), UNIV CALIF LOS ANGELES, DEPT PHYSIOL SCI, LIFE SCI BLDG, RM 2322, 405 HILGARD AVE, LOS ANGELES, CA 90024 USA.				NHLBI NIH HHS [HL50706, HL40922, HL35014] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035014, R01HL040922, R29HL050706] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABEL PM, 1992, FEMS MICROBIOL IMMUN, V105, P317; BARUCHEL S, 1992, J LEUKOCYTE BIOL, V52, P111, DOI 10.1002/jlb.52.1.111; CAO XM, 1993, J BIOL CHEM, V268, P16949; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLEMAN DL, 1992, J IMMUNOL, V149, P3045; DATTA R, 1993, P NATL ACAD SCI USA, V90, P2419, DOI 10.1073/pnas.90.6.2419; DENHAM S, 1992, CLIN EXP IMMUNOL, V87, P157; FAUCI AS, 1993, SCIENCE, V262, P1011, DOI 10.1126/science.8235617; FU ZF, 1993, J VIROL, V67, P6674; GILLIAM MB, 1993, ANAL BIOCHEM, V212, P359, DOI 10.1006/abio.1993.1341; GRAZIOSI C, 1993, AIDS, V7, pS53, DOI 10.1097/00002030-199311002-00012; GRIFFIN GE, 1991, RES VIROLOGY, V142, P233, DOI 10.1016/0923-2516(91)90062-8; HAYMAN M, 1993, NEUROSCIENCE, V53, P1, DOI 10.1016/0306-4522(93)90278-N; HELMKE RJ, 1989, IN VITRO CELL DEV B, V25, P44; HERRIN DL, 1988, BIOTECHNIQUES, V6, P196; IGNARRO LJ, 1981, J PHARMACOL EXP THER, V218, P739; IGNARRO LJ, 1987, CIRC RES, V61, P866, DOI 10.1161/01.RES.61.6.866; JAMIESON GA, 1989, J CELL PHYSIOL, V139, P262, DOI 10.1002/jcp.1041390207; KALTER DC, 1991, J IMMUNOL, V146, P298; KHARBANDA S, 1991, J CLIN INVEST, V88, P571, DOI 10.1172/JCI115341; LORSBACH RB, 1993, J BIOL CHEM, V268, P1908; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; MACE K, 1993, RES VIROLOGY, V144, P27, DOI 10.1016/S0923-2516(06)80008-7; MAGRINAT G, 1992, BLOOD, V80, P1880; MERRYMAN PF, 1993, ARTHRITIS RHEUM, V36, P1414, DOI 10.1002/art.1780361014; MIESEL R, 1993, RHEUMATOL INT, V13, P95, DOI 10.1007/BF00290295; MILLS CD, 1991, J IMMUNOL, V146, P2719; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; NUSSLER AK, 1993, J LEUKOCYTE BIOL, V54, P171, DOI 10.1002/jlb.54.2.171; PIETRAFORTE D, 1994, J LEUKOCYTE BIOL, V55, P175, DOI 10.1002/jlb.55.2.175; SAKAMOTO KM, 1992, ONCOGENE, V7, P2125; Sambrook J, 1989, MOL CLONING LABORATO; SHERMAN MP, 1993, BIOCHEM BIOPH RES CO, V191, P1301, DOI 10.1006/bbrc.1993.1359; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; VAGO L, 1989, Applied Pathology, V7, P298; VAIRO G, 1992, J CELL PHYSIOL, V151, P630, DOI 10.1002/jcp.1041510324; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522	37	41	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25239	25242						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7523382				2022-12-27	WOS:A1994PQ49100002
J	HUANG, L; KIM, Y; TURCHI, JJ; BAMBARA, RA				HUANG, L; KIM, Y; TURCHI, JJ; BAMBARA, RA			STRUCTURE-SPECIFIC CLEAVAGE OF THE RNA PRIMER FROM OKAZAKI FRAGMENTS BY CALF THYMUS RNASE HI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS REVERSE-TRANSCRIPTASE; RIBONUCLEASE-H; SEROLOGICAL ANALYSIS; DNA-SYNTHESIS; PURIFICATION; REPLICATION; PRIMASE; PROTEINS; ORIGIN; CELLS	Cleavage specificity of RNase HI was examined on model Okazaki fragments, to determine the likely role of this nuclease in lagging strand DNA replication. Each substrate was prepared by annealing a short RNA primer, made by transcription in vitro, to a single-stranded synthetic DNA template, and subsequently extending the primer by DNA polymerization. The calf thymus RNase HI makes a structure-specific endonucleolytic cleavage in the RNA primer, releasing it intact, and leaving a mono-ribonucleotide at the 5' terminus of the RNA-RNA junction. This specific cleavage, one nucleotide upstream of the RNA-DNA junction, is RNA primer sequence- and length-independent. Cleavage specificity is lost if the RNA primer is not extended with DNA, or if the substrate has a nick at the RNA-DNA junction. In addition, the cleavage at a single site requires Mg2+. Cleavage in the presence of Mn2+ is less specific. Neither human immunodeficiency virus reverse transcriptase nor Escherichia coli RNases H perform such a structure specific cleavage before an RNA-DNA junction. Our work indicates that calf RNase HI is designed to recognize Okazaki fragments. It has the specificity to remove their initiator RNA segments, except for one ribonucleotide, by a single endonucleolytic cleavage in vivo.	UNIV ROCHESTER, SCH MED & DENT, DEPT BIOCHEM, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, SCH MED & DENT, CTR CANC, ROCHESTER, NY 14642 USA; WRIGHT STATE UNIV, DEPT BIOCHEM, DAYTON, OH 45435 USA	University of Rochester; University of Rochester; University System of Ohio; Wright State University Dayton			Turchi, John J/B-5807-2015	Turchi, John J/0000-0001-5375-2992	NATIONAL CANCER INSTITUTE [P30CA011198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024441] Funding Source: NIH RePORTER; NCI NIH HHS [CA11198] Funding Source: Medline; NIGMS NIH HHS [GM24441] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUSEN W, 1977, EUR J BIOCHEM, V74, P203, DOI 10.1111/j.1432-1033.1977.tb11382.x; BUSEN W, 1980, J BIOL CHEM, V255, P9434; CATHALA G, 1979, J BIOL CHEM, V254, P7353; DESTEFANO JJ, 1993, NUCLEIC ACIDS RES, V21, P4330, DOI 10.1093/nar/21.18.4330; DIFRANCESCO RA, 1985, J BIOL CHEM, V260, P4764; EDER PS, 1991, J BIOL CHEM, V266, P6472; FUNNELL BE, 1986, J BIOL CHEM, V261, P5616; FURFINE ES, 1991, BIOCHEMISTRY-US, V30, P7041, DOI 10.1021/bi00243a001; GOULIAN M, 1990, J BIOL CHEM, V265, P18461; HAGEMEIER A, 1989, EUR J BIOCHEM, V185, P621, DOI 10.1111/j.1432-1033.1989.tb15158.x; HOLLINGSWORTH HC, 1991, J BIOL CHEM, V266, P1888; HUBER HE, 1990, J BIOL CHEM, V265, P10565; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; KARWAN R, 1983, BIOCHEMISTRY-US, V22, P5500, DOI 10.1021/bi00293a008; KELLER W, 1972, P NATL ACAD SCI USA, V81, P3993; KITAHARA N, 1982, J BIOCHEM, V92, P855, DOI 10.1093/oxfordjournals.jbchem.a133999; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; Kornberg A., 1992, DNA REPLICATION; Linder M. C., 1991, NUTRITIONAL BIOCH ME; MASUTANI C, 1990, J BIOL CHEM, V265, P10210; MURANTE RS, 1994, J BIOL CHEM, V269, P1191; NAKAMURA H, 1991, P NATL ACAD SCI USA, V88, P11535, DOI 10.1073/pnas.88.24.11535; OGAWA T, 1984, MOL GEN GENET, V193, P321; PULLEN KA, 1992, J VIROL, V66, P367, DOI 10.1128/JVI.66.1.367-373.1992; ROEWEKAMP W, 1974, EUR J BIOCHEM, V43, P405, DOI 10.1111/j.1432-1033.1974.tb03426.x; RONG YW, 1990, BIOCHEMISTRY-US, V29, P383, DOI 10.1021/bi00454a012; Sambrook J, 1989, MOL CLONING LABORATO; SKALKA A, 1993, REVERSE TRANSCRIPTAS; STEIN H, 1969, SCIENCE, V166, P393, DOI 10.1126/science.166.3903.393; TURCHI JJ, 1993, J BIOL CHEM, V268, P15136; TURCHI JJ, 1994, IN PRESS P NATL ACAD; VONWIRTH H, 1989, EUR J BIOCHEM, V184, P321, DOI 10.1111/j.1432-1033.1989.tb15022.x; WAGA S, 1994, J BIOL CHEM, V269, P10923; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0	34	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25922	25927						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7523396				2022-12-27	WOS:A1994PQ49100100
J	BURKHARDT, AL; STEALEY, B; ROWLEY, RB; MAHAJAN, S; PRENDERGAST, M; FARGNOLI, J; BOLEN, JB				BURKHARDT, AL; STEALEY, B; ROWLEY, RB; MAHAJAN, S; PRENDERGAST, M; FARGNOLI, J; BOLEN, JB			TEMPORAL REGULATION OF NONTRANSMEMBRANE PROTEIN-TYROSINE KINASE ENZYME-ACTIVITY FOLLOWING T-CELL ANTIGEN RECEPTOR ENGAGEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; ZETA-CHAIN; CROSS-LINKING; SRC FAMILY; ACTIVATION; P56LCK; ZAP-70; RESPONSIVENESS; ASSOCIATION; P59FYN	We evaluated in Jurkat T cells the time-dependent re sponses of Fyn, Lck, Syk, and Zap following antibody-mediated cross-linking of the T cell antigen receptor. Our results show that the protein kinase activities of Fyn and Lck were activated within seconds of receptor cross-linking. Fyn activity, as measured by autophosphorylation and tyrosine phosphorylation of an exogenous substrate, was maximal 5 s to 1 min following receptor cross-linking. Lck was also found to be activated within 5 s of antigen receptor cross-linking but differed from Fyn in that Lck activity was elevated for at least 30 min. Syk and Zap protein kinase activities were found to peak between 5 and 10 min following receptor crosslinking, returning to approximately basal activity levels by 60 min. The protein kinase activities of both Syk and Zap were found to parallel their reactivity in immunoblotting experiments with anti-phosphotyrosine antibodies. Both Syk and Zap were found to associate with the tyrosine-phosphorylated zeta subunit of the T cell antigen receptor. These observations imply that T cell antigen receptor signal transduction involves the activation of multiple members of at least two different families of non-transmembrane protein tyrosine kinases.			BURKHARDT, AL (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST, DEPT MOLEC BIOL, SIGNAL TRANSDUCT LAB, POB 4000, PRINCETON, NJ 08543 USA.							ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; ADAM D, 1993, J BIOL CHEM, V268, P19882; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; BOLEN JB, 1993, ONCOGENE, V8, P2025; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; BURKHARDT AL, 1994, MOL CELL BIOL, V14, P1095, DOI 10.1128/MCB.14.2.1095; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; BURKHARDT AL, 1993, CURRENT PROTOCOLS IM, P1; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHOW LML, 1993, NATURE, V365, P156, DOI 10.1038/365156a0; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; DAVIDSON D, 1992, J EXP MED, V175, P1483, DOI 10.1084/jem.175.6.1483; EISEMAN E, 1992, NATURE, V355, P78; GREENBERG S, 1994, J BIOL CHEM, V269, P3897; HUTCHCROFT JE, 1991, J BIOL CHEM, V266, P14846; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; KARNITZ L, 1992, MOL CELL BIOL, V12, P4521, DOI 10.1128/MCB.12.10.4521; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; LEVIN SD, 1993, EMBO J, V12, P1671, DOI 10.1002/j.1460-2075.1993.tb05812.x; LI ZH, 1992, BIOCHEM BIOPH RES CO, V187, P1536, DOI 10.1016/0006-291X(92)90477-3; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; RUDD CE, 1990, IMMUNOL TODAY, V11, P400, DOI 10.1016/0167-5699(90)90159-7; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SAROSI GA, 1992, INT IMMUNOL, V4, P1211, DOI 10.1093/intimm/4.11.1211; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; TSYGANKOV AY, 1992, J BIOL CHEM, V267, P18259; TSYGANKOV AY, 1994, J BIOL CHEM, V269, P7792; VEILLETTE A, 1988, MOL CELL BIOL, V8, P4353, DOI 10.1128/MCB.8.10.4353; WANGE RL, 1992, J BIOL CHEM, V267, P11685; WANGE RL, 1993, J BIOL CHEM, V268, P19797; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; XU H, 1993, CELL, V74, P633, DOI 10.1016/0092-8674(93)90511-N	40	106	106	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23642	23647						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	7522230				2022-12-27	WOS:A1994PQ34500040
J	MULLHAUPT, B; FEREN, A; FODOR, E; JONES, A				MULLHAUPT, B; FEREN, A; FODOR, E; JONES, A			LIVER EXPRESSION OF EPIDERMAL GROWTH-FACTOR RNA - RAPID INCREASES IN IMMEDIATE-EARLY PHASE OF LIVER-REGENERATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							FACTOR PRECURSOR; FACTOR RECEPTOR; RAT-LIVER; NUCLEOTIDE-SEQUENCE; SIGNAL TRANSDUCTION; PARTIAL-HEPATECTOMY; MESSENGER-RNA; FACTOR-ALPHA; FACTOR CDNA; MOUSE	The liver exhibits a remarkable capacity to regenerate its mass following partial removal or after injury. Transmembrane receptors for epidermal growth factor (EGF) are highly expressed in liver cells, which quickly respond to this polypeptide mitogen by activating an intrinsically low rate of cell division. Although EGF appears to regulate liver growth, its significance has remained unclear, and only a small change in serum levels can be detected during hepatocellular proliferation. Using a reverse transcription-polymerase chain reaction assay, we report here the novel finding that EGF RNA transcripts are synthesized in a hepatic cell-specific pat tern, appearing in hepatocyte and lipocyte cell types. Our data reveal that within 15 min following a 70% liver removal, EGF RNA levels increase >10-fold and then diminish below basal levels prior to the first wave of regenerative cell division. Immunoanalysis of metabolically labeled hepatocytes shows that EGF accumulates as a large 60-kDa peptide. These results demonstrate that EGF transcription is a previously unrecognized component of hepatic gene expression, and rapid increases in EGF RNA levels in the immediate-early phase of liver regeneration point to EGF as an autocrine factor in the prereplicative hepatic growth program.	VET ADM MED CTR,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CTR ANAT & LIVER,SAN FRANCISCO,CA 94143	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; University of California System; University of California San Francisco			Mullhaupt, Beat/O-3744-2016	Mullhaupt, Beat/0000-0002-9020-8192				AVIVI A, 1991, ONCOGENE, V6, P673; BELL GI, 1986, NUCLEIC ACIDS RES, V14, P8427, DOI 10.1093/nar/14.21.8427; BISSELL DM, 1973, J CELL BIOL, V59, P722; BREYER JA, 1990, J BIOL CHEM, V265, P16564; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CARPENTER G, 1992, FASEB J, V6, P3283, DOI 10.1096/fasebj.6.14.1385243; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; EVARTS RP, 1992, MOL CARCINOGEN, V5, P25, DOI 10.1002/mc.2940050107; FAUSTO N, 1989, LAB INVEST, V60, P4; Fausto Nelson, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P117; FRIEDMAN SL, 1987, ANAL BIOCHEM, V161, P207, DOI 10.1016/0003-2697(87)90673-7; GRAY A, 1983, NATURE, V303, P722, DOI 10.1038/303722a0; HABER BA, 1993, J CLIN INVEST, V91, P1319, DOI 10.1172/JCI116332; KINOSHITA T, 1991, BIOCHEM BIOPH RES CO, V177, P330, DOI 10.1016/0006-291X(91)91987-N; KOCH KS, 1990, IN VITRO CELL DEV B, V26, P1011; KRUIJER W, 1986, J BIOL CHEM, V261, P7929; LAKSHMANAN J, 1990, BIOCHEM BIOPH RES CO, V173, P902, DOI 10.1016/S0006-291X(05)80871-X; MARTI U, 1989, HEPATOLOGY, V9, P126, DOI 10.1002/hep.1840090122; MARTI U, 1991, HEPATOLOGY, V13, P15, DOI 10.1016/0270-9139(91)90210-M; MEAD JE, 1989, P NATL ACAD SCI USA, V86, P1558, DOI 10.1073/pnas.86.5.1558; MICHALOPOULOS GK, 1990, FASEB J, V4, P176, DOI 10.1096/fasebj.4.2.2404819; MROCZKOWSKI B, 1989, MOL CELL BIOL, V9, P2771, DOI 10.1128/MCB.9.7.2771; MURPHY LD, 1990, BIOCHEMISTRY-US, V29, P10351, DOI 10.1021/bi00497a009; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; PESONEN K, 1989, J CLIN ENDOCR METAB, V68, P486, DOI 10.1210/jcem-68-2-486; PETCH LA, 1990, MOL CELL BIOL, V10, P2973, DOI 10.1128/MCB.10.6.2973; RALL LB, 1985, NATURE, V313, P228, DOI 10.1038/313228a0; RAPER SE, 1987, GASTROENTEROLOGY, V92, P1243, DOI 10.1016/S0016-5085(87)91084-5; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SAGGI SJ, 1992, DNA CELL BIOL, V11, P481, DOI 10.1089/dna.1992.11.481; SCHAUDIES RP, 1993, AM J PHYSIOL, V264, pF523, DOI 10.1152/ajprenal.1993.264.3.F523; SCOTT J, 1983, SCIENCE, V221, P236, DOI 10.1126/science.6602382; THOMPSON NL, 1986, CANCER RES, V46, P3111; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZARNEGAR R, 1991, BIOCHEM BIOPH RES CO, V177, P559, DOI 10.1016/0006-291X(91)92020-K	38	92	95	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					19667	19670						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	7519599				2022-12-27	WOS:A1994PA12600003
J	ARECES, LB; KAZANIETZ, MG; BLUMBERG, PM				ARECES, LB; KAZANIETZ, MG; BLUMBERG, PM			CLOSE SIMILARITY OF BACULOVIRUS-EXPRESSED N-CHIMAERIN AND PROTEIN-KINASE C-ALPHA AS PHORBOL ESTER RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; CD-1 MOUSE SKIN; NONPROMOTING 12-DEOXYPHORBOL 13-ESTERS; POTENT TUMOR PROMOTERS; 12,13-DIBUTYRATE BINDING; 12-MYRISTATE 13-ACETATE; CAENORHABDITIS-ELEGANS; CALPHOSTIN-C; UNC-13 GENE; INHIBITORS	n-Chimaerin is a recently described phorbol ester receptor that shares homology in its N-terminal region with the cysteine-rich zinc finger domain of protein kinase C. We have expressed n-chimaerin in insect cells using the baculovirus system and have used the isolated, recombinant n-chimaerin to characterize phorbol ester binding and structure-activity relations, lipid requirements, and inhibitor sensitivity. We find that n-chimaerin expressed in the baculovirus system bound [H-3]phorbol 12,13-dibutyrate with high affinity (0.17 +/- 0.01 nM). Although having only a single cysteine-rich zinc finger region compared to two for protein kinase C, n-chimaerin thus closely resembled protein kinase C alpha. n-chimaerin was likewise virtually indistinguishable from protein kinase C alpha in phorbol ester structure activity relations, in phospholipid requirements, and in inhibition of binding by sphingosine and calphostin C, protein kinase C inhibitors acting on the regulatory domain. We conclude that a number of typical approaches used to implicate protein kinase C in biological function in cells do not discriminate between the n-chimaerin and protein kinase C classes of phorbol ester receptors.	NCI, MOLEC MECHANISMS TUMOR PROMOT SECT, CELLULAR CARCINOGENESIS & TUMOR PROMOT LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								AHMED S, 1992, BIOCHEM J, V287, P995, DOI 10.1042/bj2870995; AHMED S, 1990, BIOCHEM J, V272, P767, DOI 10.1042/bj2720767; AKINAGA S, 1992, CANCER CHEMOTH PHARM, V29, P266, DOI 10.1007/BF00685943; BELL RM, 1991, J BIOL CHEM, V266, P4661; BLUMBERG PM, 1980, CRC CR REV TOXICOL, V8, P153, DOI 10.3109/10408448009037493; BLUMBERG PM, 1988, CANCER RES, V48, P1; BLUMBERG PM, 1981, CRC CR REV TOXICOL, V8, P199, DOI 10.3109/10408448109109658; BLUMBERG PM, 1992, ALFRED BENZON SYMP S, V33, P273; BRADSHAW D, 1993, AGENTS ACTIONS, V38, P135, DOI 10.1007/BF02027225; BRUNS RF, 1991, BIOCHEM BIOPH RES CO, V176, P288, DOI 10.1016/0006-291X(91)90922-T; BURNS DJ, 1991, J BIOL CHEM, V266, P18330; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; DUNN JA, 1985, CANCER RES, V45, P5540; DUNN JA, 1983, CANCER RES, V43, P4632; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HALL C, 1993, MOL CELL BIOL, V13, P4986, DOI 10.1128/MCB.13.8.4986; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; Hecker E., 1978, CARCINOGENESIS, P11; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; KAZANIETZ MG, 1994, J BIOL CHEM, V269, P11590; KAZANIETZ MG, 1992, J BIOL CHEM, V267, P20878; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; KAZANIETZ MG, 1994, J CELL BIOCHEM, P90; LEUNG T, 1993, J BIOL CHEM, V268, P3813; LIM HH, 1992, BIOCHEM J, V287, P415, DOI 10.1042/bj2870415; LUCKOW VA, 1988, VIROLOGY, V167, P56, DOI 10.1016/0042-6822(88)90054-2; MARUYAMA IN, 1991, P NATL ACAD SCI USA, V88, P5729, DOI 10.1073/pnas.88.13.5729; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; PALANIAPPAN K, 1993, J AM CHEM SOC, V115, P6452; PRENDIVILLE J, 1993, BRIT J CANCER, V68, P418, DOI 10.1038/bjc.1993.352; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHARKEY NA, 1985, CANCER RES, V45, P19; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; SZALLASI Z, 1994, J BIOL CHEM, V269, P2118; SZALLASI Z, 1991, CANCER RES, V51, P5355; SZALLASI Z, 1993, CANCER RES, V53, P2507; SZALLASI Z, 1992, CARCINOGENESIS, V13, P2161, DOI 10.1093/carcin/13.11.2161; TAMAOKI T, 1991, METHOD ENZYMOL, V201, P340	41	79	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19553	19558						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	7518459				2022-12-27	WOS:A1994NY33200055
J	ARREAZA, G; MELKONIAN, KA; LAFEVREBERNT, M; BROWN, DA				ARREAZA, G; MELKONIAN, KA; LAFEVREBERNT, M; BROWN, DA			TRITON X-100-RESISTANT MEMBRANE COMPLEXES FROM CULTURED KIDNEY EPITHELIAL-CELLS CONTAIN THE SRC FAMILY PROTEIN-TYROSINE KINASE P62(YES)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL-ANCHORED PROTEINS; MDCK CELLS; T-CELLS; EXPRESSION; ACTIVATION; SIGNAL; MOLECULES; RECEPTOR; SURFACE; PRODUCT	We have previously isolated detergent-resistant membrane complexes from lysates of cultured kidney epithelial cells. These structures are enriched in proteins anchored by glycosylphosphatidylinositol, which are localized to the apical plasma membrane of epithelial cells, and have a distinctive lipid composition. We now report that the membranes contain p62(yes), a non-receptor tyrosine kinase of the Src family. p62(yes) is the only major tyrosine-phosphorylated protein in the membrane complexes when they are isolated. Several proteins in the complexes can serve as substrates for phosphorylation by p62(yes) in vitro. The kinase is enriched at least 10-fold in the insoluble membranes compared to cellular membranes. p60(c-src) and p60(v-src), which are highly homologous to p62(yes), are not present in the complexes, even when the membranes are isolated from cells that overexpress the proteins. As p62(yes) is located near the apical plasma membrane of epithelial cells in several tissues in vivo, interaction of the kinase with other components of a detergent-resistant membrane microdomain may play an important role in transmembrane signal transduction.	SUNY STONY BROOK, DEPT BIOCHEM & CELL BIOL, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NIGMS NIH HHS [GM47897] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047897] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AZUMA K, 1991, J BIOL CHEM, V266, P4831; BOHUSLAV J, 1993, EUR J IMMUNOL, V23, P825, DOI 10.1002/eji.1830230409; BOLEN JB, 1991, ADV CANCER RES, V57, P103; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CINEK T, 1992, J IMMUNOL, V149, P2262; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; HSI ED, 1989, J BIOL CHEM, V264, P10836; JANEWAY CA, 1992, ANNU REV IMMUNOL, V10, P645, DOI 10.1146/annurev.immunol.10.1.645; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; ROBINSON PJ, 1991, IMMUNOL TODAY, V12, P35, DOI 10.1016/0167-5699(91)90110-F; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SHENOYSCARIA AM, 1993, MOL CELL BIOL, V13, P6385, DOI 10.1128/MCB.13.10.6385; SHENOYSCARIA AM, 1992, J IMMUNOL, V149, P3535; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; SUDOL M, 1986, MOL CELL BIOL, V6, P2839, DOI 10.1128/MCB.6.8.2839; THOMAS PM, 1992, J BIOL CHEM, V267, P12317; WARREN SL, 1987, MOL CELL BIOL, V7, P1326, DOI 10.1128/MCB.7.4.1326; WARREN SL, 1988, MOL CELL BIOL, V8, P632, DOI 10.1128/MCB.8.2.632; ZHAO YH, 1990, ONCOGENE, V5, P1629	25	79	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					19123	19127						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	7518450				2022-12-27	WOS:A1994NX32700064
J	RAJENDRA, S; LYNCH, JW; PIERCE, KD; FRENCH, CR; BARRY, PH; SCHOFIELD, PR				RAJENDRA, S; LYNCH, JW; PIERCE, KD; FRENCH, CR; BARRY, PH; SCHOFIELD, PR			STARTLE DISEASE MUTATIONS REDUCE THE AGONIST SENSITIVITY OF THE HUMAN INHIBITORY GLYCINE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GATED ION CHANNEL; FUNCTIONAL EXPRESSION; BINDING SUBUNIT; HYPEREKPLEXIA; SITE; GABA; DOMAINS; SHOWS; GENES; CELLS	The receptor for the inhibitory neurotransmitter glycine is a member of the ligand gated ion channel recep tor superfamily. Point mutations in the gene encoding the alpha 1 subunit of the glycine receptor channel complex (GlyR) have recently been identified in pedigrees with the autosomal dominant neurological disorder, startle disease (hyperekplexia). These mutations result in the substitution of leucine or glutamine for arginine 271. This charged residue is located near the ion channel region and is predicted to affect chloride permeation through the GlyR. We found little evidence for this role from the anion/cation selectivity and lack of pronounced rectification of currents flowing through recombinant human alpha 1 subunit GlyRs containing the startle disease mutations. We reveal, however, that the startle disease mutations profoundly disrupt GlyR func tion by causing 230-410-fold decreases in the sensitivity of receptor currents activated by the agonist glycine. Additionally, we report corresponding 56- and 120-fold reductions in the apparent binding affinity (K-i) of glycine to the mutant GlyRs, but no change in the binding affinity of the competitive antagonist, strychnine. Thus, startle disease reduces the efficacy of glycinergic inhibitory neurotransmission by producing GlyRs with diminished agonist responsiveness. Our results show that startle disease mutations define a novel receptor activation site.	ST VINCENTS HOSP,GARVAN INST MED RES,DARLINGHURST,NSW 2010,AUSTRALIA; UNIV NEW S WALES,SCH PHYSIOL & PHARMACOL,SYDNEY,NSW 2052,AUSTRALIA	Garvan Institute of Medical Research; St Vincents Hospital Sydney; University of New South Wales Sydney			French, Chris/AHA-1801-2022; Pierce, Kerrie D/O-7300-2018; Lynch, Joseph/C-8636-2009; Schofield, Peter/C-9669-2011	Pierce, Kerrie D/0000-0003-0636-4836; Schofield, Peter/0000-0003-2967-9662; French, Christopher/0000-0002-1445-8704				AMIN J, 1993, NATURE, V366, P565, DOI 10.1038/366565a0; ANDERMANN F, 1988, BRAIN DEV, V10, P313; BAKER E, 1994, IN PRESS GENOMICS; BARRY PH, 1994, J NEUROSCI METH, V57, P107; BECKER CM, 1992, NEURON, V8, P283, DOI 10.1016/0896-6273(92)90295-O; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DEVILLERSTHIERY A, 1994, J MEMBRANE BIOL, V136, P97; GOODMANGILMAN A, 1980, GOODMAN GILMANS PHAR, P587; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; GRENNINGLOH G, 1987, NATURE, V328, P215, DOI 10.1038/328215a0; GRENNINGLOH G, 1990, EMBO J, V9, P771, DOI 10.1002/j.1460-2075.1990.tb08172.x; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; KIRSTEIN L, 1958, ACTA PSYCH NEUROL, V33, P471, DOI 10.1111/j.1600-0447.1958.tb03533.x; KUHSE J, 1990, NEURON, V5, P867, DOI 10.1016/0896-6273(90)90346-H; KUHSE J, 1990, J BIOL CHEM, V265, P22317; LANGOSCH D, 1993, FEBS LETT, V336, P540, DOI 10.1016/0014-5793(93)80872-R; LANGOSCH D, 1991, BIOCHIM BIOPHYS ACTA, V1063, P36, DOI 10.1016/0005-2736(91)90350-H; MARICQ AV, 1991, SCIENCE, V254, P432, DOI 10.1126/science.1718042; RYAN SG, 1992, ANN NEUROL, V31, P663, DOI 10.1002/ana.410310615; RYAN SG, 1992, AM J HUM GENET, V51, P1334; RYAN SG, 1994, NAT GENET, V7, P131, DOI 10.1038/ng0694-131; SCHMIEDEN V, 1993, SCIENCE, V262, P256, DOI 10.1126/science.8211147; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; SHIANG R, 1993, NAT GENET, V5, P351, DOI 10.1038/ng1293-351; SIGEL E, 1992, EMBO J, V11, P2017, DOI 10.1002/j.1460-2075.1992.tb05258.x; SONTHEIMER H, 1989, NEURON, V2, P1491, DOI 10.1016/0896-6273(89)90195-5; SUHREN O, 1966, J NEUROL SCI, V3, P577, DOI 10.1016/0022-510X(66)90047-5; VANDENBERG RJ, 1992, P NATL ACAD SCI USA, V89, P1765, DOI 10.1073/pnas.89.5.1765; VANDENBERG RJ, 1992, NEURON, V9, P491, DOI 10.1016/0896-6273(92)90186-H; VANDENBERG RJ, 1993, MOL PHARMACOL, V44, P198; WHITE WF, 1982, NATURE, V298, P655, DOI 10.1038/298655a0	34	105	106	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					18739	18742						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	7518444				2022-12-27	WOS:A1994NX32700010
J	CHAPPELL, DA; INOUE, I; FRY, GL; PLADET, MW; BOWEN, SL; IVERIUS, PH; LALOUEL, JM; STRICKLAND, DK				CHAPPELL, DA; INOUE, I; FRY, GL; PLADET, MW; BOWEN, SL; IVERIUS, PH; LALOUEL, JM; STRICKLAND, DK			CELLULAR CATABOLISM OF NORMAL VERY-LOW-DENSITY LIPOPROTEINS VIA THE LOW-DENSITY-LIPOPROTEIN RECEPTOR-RELATED PROTEIN ALPHA(2)-MACROGLOBULIN RECEPTOR IS INDUCED BY THE C-TERMINAL DOMAIN OF LIPOPROTEIN-LIPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-2-MACROGLOBULIN RECEPTOR; HEPARAN-SULFATE; LDL-RECEPTOR; IN-VITRO; CHYLOMICRON REMNANTS; PROTEIN BINDS; METABOLISM; HYPERCHOLESTEROLEMIA; INTERNALIZATION; PROTEOGLYCANS	Lipoprotein lipase (LPL) binds to the low density lipoprotein receptor related protein (LRP)/alpha(2)-macroglobulin receptor and induces catabolism of normal human very low density lipoproteins (VLDL) via LRP in vitro. Recent studies showed that the C-terminal domain of LPL can bind LRP in solid phase assays and inhibit cellular catabolism of two LRP ligands, activated alpha(2)-macroglobulin and the 39-kDa receptor-associated protein (Williams, S. E., Inoue, I., Tran, H., Fry, G. L., Pladet, M. W., Iverius, P.-H., Lalouel, J.-M., Chappell, D. A., and Strickland, D. K. (1994) J. Biol. Chem. 269, 8653-8658). The current study investigated the potential for this region of LPL to promote cellular catabolism of VLDL via LRP. A fragment comprising the C-terminal domain of LPL (designated LPLC) was expressed in bacteria and found to promote cellular binding, uptake, and degradation of normal human VLDL in a dose dependent man ner. These effects were present whether LPLC was added simultaneously with I-125-VLDL or was prebound to cell surfaces prior to the assay. Mutations involving Lys(407), Trp(393), Trp(394), or deletion of the C terminal 14 residues reduced the effects of LPLC. Three LRP-binding proteins, the receptor-associated protein, lactoferrin, and a polyclonal antibody against LRP, competed for I-125-VLDL degradation induced by LPLC. Heparin or heparinase treatment of cells prevented LPLC-induced I-125-VLDL catabolism. Thus, cell-surface proteoglycans play an important role in this pathway. Interestingly, either LPLC or LPL when added in excess could block LPL-induced I-125-VLDL degradation presumably by interacting directly with LRP. However, unlabeled VLDL could not prevent catabolism of I-125-labeled LPLC or LPL. These data show that cellular fates for VLDL versus LPLC or LPL are divergent. This is probably due to independent catabolism of the latter via cell-surface proteoglycans. In summary, these in vitro studies indicate that a fragment of LPL corresponding to the C-terminal domain mimics the native enzyme with respect to induction of VLDL catabolism via LRP. Because LPLC lacks the catalytic site of native LPL, these studies establish that lipase activity is not required for LRP mediated lipoprotein catabolism.	AMER RED CROSS,BIOCHEM LAB,ROCKVILLE,MD 20855; VET AFFAIRS MED CTR,SALT LAKE CITY,UT 84148; UNIV UTAH,DEPT MED,SALT LAKE CITY,UT 84148; UNIV UTAH,HOWARD HUGHES MED INST,SALT LAKE CITY,UT 84148; UNIV UTAH,DEPT HUMAN GENET,SALT LAKE CITY,UT 84148	American Red Cross; US Department of Veterans Affairs; Veterans Health Administration (VHA); Utah System of Higher Education; University of Utah; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	CHAPPELL, DA (corresponding author), UNIV IOWA,COLL MED,DEPT INTERNAL MED,E318 GH,IOWA CITY,IA 52242, USA.				NHLBI NIH HHS [HL30200, HL49264] Funding Source: Medline; NIGMS NIH HHS [GM42581] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030200, P01HL049264] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042581] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; CHAPPELL DA, 1991, J BIOL CHEM, V266, P19296; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; CHAPPELL DA, 1993, J BIOL CHEM, V268, P14168; CHAPPELL DA, 1993, J BIOL CHEM, V268, P25487; CHAPPELL DA, 1992, J BIOL CHEM, V267, P270; CHENG CF, 1981, J BIOL CHEM, V256, P2893; CHOI SSY, 1991, J CLIN INVEST, V88, P1173, DOI 10.1172/JCI115419; DAVIS RC, 1992, J BIOL CHEM, V267, P21499; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; DEREWENDA ZS, 1991, J BIOL CHEM, V266, P23112; DICKSON RB, 1981, J BIOL CHEM, V256, P3454; EISENBERG S, 1992, J CLIN INVEST, V90, P2013, DOI 10.1172/JCI116081; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HOBBS HH, 1987, NEW ENGL J MED, V317, P734, DOI 10.1056/NEJM198709173171204; Iverius P H, 1986, Methods Enzymol, V129, P691; JACKLE S, 1992, J LIPID RES, V33, P419; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; LINDGREN FT, 1972, BLOOD LIPIDS LIPOPRO, P181; MAMO JCL, 1991, BIOCHIM BIOPHYS ACTA, V1081, P241, DOI 10.1016/0005-2760(91)90277-O; NYKJAER A, 1993, J BIOL CHEM, V268, P15048; RUMSEY SC, 1992, J CLIN INVEST, V90, P1504, DOI 10.1172/JCI116018; SAXENA U, 1990, J BIOL CHEM, V265, P12880; SHIMADA M, 1993, J BIOL CHEM, V268, P17924; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; VANTILBEURGH H, 1994, J BIOL CHEM, V269, P4626; VOYTA JC, 1985, J BIOL CHEM, V260, P893; WILLIAMS KJ, 1992, J BIOL CHEM, V267, P13284; WILLIAMS SE, 1994, J BIOL CHEM, V269, P8653; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; ZOU S, 1992, COMP BIOCHEM PHYS B, V103, P889, DOI 10.1016/0305-0491(92)90210-I	35	58	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					18001	18006						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	7517936				2022-12-27	WOS:A1994NV42200040
J	COMBETTES, L; HANNAERTMERAH, Z; COQUIL, JF; ROUSSEAU, C; CLARET, M; SWILLENS, S; CHAMPEIL, P				COMBETTES, L; HANNAERTMERAH, Z; COQUIL, JF; ROUSSEAU, C; CLARET, M; SWILLENS, S; CHAMPEIL, P			RAPID FILTRATION STUDIES OF THE EFFECT OF CYTOSOLIC CA2+ ON INOSITOL 1,4,5-TRISPHOSPHATE-INDUCED CA-45(2+) RELEASE FROM CEREBELLAR MICROSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM VESICLES; LIMULUS VENTRAL PHOTORECEPTORS; CARDIAC SARCOLEMMAL VESICLES; FROG SKELETAL-MUSCLE; ONE-POOL MODEL; CALCIUM-RELEASE; ADENINE-NUCLEOTIDES; CA-2+ RELEASE; TRISPHOSPHATE RECEPTOR; SMOOTH-MUSCLE	Using microsomal membrane vesicles derived from sheep cerebellum, we measured the rate of inositol 1,4,5-trisphosphate (InsP(3))-dependent Ca-45(2+) afflux from Ca-45(2+)-loaded compartments during rapid perfusion with a medium containing InsP(3) and various concentrations of free Ca-40(2+) on the cytosolic side (pH 7.1, 5 mM Mg2+, in the absence of ATP at 20 degrees C). At 0.15 mu M InsP(3) and pCa 6.5, half-Ca-45(2+) release was attained within less than 200 ms. At low Ca2+ concentrations, the initial rate of Ca-45(2+) release depended smoothly on InsP(3) concentration, and InsP(3) activated release with moderate positive cooperativity. Preliminary experiments performed at various free Ca-40(2+) concentrations were consistent with a bell-shaped Ca-40(2+) dependence of Ca-45(2+) release. In the range of micromolar or higher free Ca-40(2+) concentrations, the apparent inhibition of Ca-45(2+) release was dependent on InsP(3) concentration, and Ca-45(2+) release for intermediate InsP(3) concentrations was transient; under selected conditions, a second perfusion period, identical to the first one but separated from it by a short recovery period, was found to allow renewed Ca-45(2+) efflux. At high Ca2+ concentration, fast reversible Ca2+-dependent desensitization of the channel, and not heterogeneity, was therefore responsible for the termination of InsP(3)-triggered Ca-45(2+) afflux at submaximal concentrations of InsP(3). At lower Ca2+ concentrations, a large fraction of the apparent activating effect of submicromolar Ca-40(2+) concentrations on Ca-45(2+) efflux that we had observed in the preliminary experiments proved to be the artifactual consequence of an inhibitory effect exerted by metal-free Ca2+ chelators on InsP(3)-dependent afflux at nanomolar Ca-40(2+) concentrations. 1,2-Bis(2-aminophenoxy)ethane-N,N,N'-N'-tetraacetic acid, EGTA, and fluo-3 were all effective inhibitors. When this inhibition was taken into account, a rise in free Ca-40(2+) concentration from 30 to 300 nM only weakly enhanced Ca-45(2+) fluxes in the presence of a low concentration of InsP(3+). As a result, submicromolar free Ca-40(2+) appears to be only a poor activator of InsP(3)-induced Ca2+ release under these experimental conditions.	CENS, CEA, CNRS, URA 1290, F-91191 GIF SUR YVETTE, FRANCE; CENS, CEA, DEPT BIOL CELLULAIRE & MOLEC, BIOPHYS PROT & MEMBRANES SECT, F-91191 GIF SUR YVETTE, FRANCE; ECOLE CENT PARIS, BIOL LAB, F-92295 CHATENAY MALABRY, FRANCE; FREE UNIV BRUSSELS, FAC MED, INST RECH INTERDISCIPLINAIRE, B-1070 BRUSSELS, BELGIUM	CEA; Centre National de la Recherche Scientifique (CNRS); CEA; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay; Universite Libre de Bruxelles; Vrije Universiteit Brussel	COMBETTES, L (corresponding author), UNIV PARIS 11, INSERM, U274, UNITE RECH, F-91405 ORSAY, FRANCE.		Combettes, Laurent/L-1842-2013	Combettes, Laurent/0000-0002-1376-4574				ATRI A, 1993, BIOPHYS J, V65, P1727, DOI 10.1016/S0006-3495(93)81191-3; BEELER T, 1983, J MEMBRANE BIOL, V76, P165, DOI 10.1007/BF02000616; BERMAN MC, 1982, J BIOL CHEM, V257, P1953; BERMAN MC, 1990, BIOCHIM BIOPHYS ACTA, V1029, P235, DOI 10.1016/0005-2736(90)90159-L; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BIRCHMACHIN MA, 1986, BIOCHIM BIOPHYS ACTA, V855, P277, DOI 10.1016/0005-2736(86)90175-6; BROWN GR, 1992, BIOCHEM J, V282, P309, DOI 10.1042/bj2820309; BULL R, 1993, FEBS LETT, V331, P223, DOI 10.1016/0014-5793(93)80341-Q; CALLAMARAS N, 1994, CELL CALCIUM, V15, P66, DOI 10.1016/0143-4160(94)90105-8; CALVIELLO G, 1989, BIOCHEMISTRY-US, V28, P1301, DOI 10.1021/bi00429a053; CHAD JE, 1984, BIOPHYS J, V45, P993, DOI 10.1016/S0006-3495(84)84244-7; CHAMPEIL P, 1986, BIOCHEMISTRY-US, V25, P7623, DOI 10.1021/bi00371a053; CHAMPEIL P, 1989, J BIOL CHEM, V264, P17665; COMBETTES L, 1993, CELL CALCIUM, V14, P279, DOI 10.1016/0143-4160(93)90049-C; COMBETTES L, 1992, FEBS LETT, V301, P287, DOI 10.1016/0014-5793(92)80258-I; DEYOUNG GW, 1992, P NATL ACAD SCI USA, V89, P9895, DOI 10.1073/pnas.89.20.9895; DONOSO P, 1993, J BIOL CHEM, V268, P25432; DUPONT G, 1993, CELL CALCIUM, V14, P311, DOI 10.1016/0143-4160(93)90052-8; DUPONT Y, 1984, ANAL BIOCHEM, V142, P504, DOI 10.1016/0003-2697(84)90496-2; DUPONT Y, 1987, METHOD ENZYMOL, V148, P675; EBERHARD M, 1991, EUR J BIOCHEM, V202, P1333, DOI 10.1111/j.1432-1033.1991.tb16508.x; EHRLICH BE, 1988, NATURE, V336, P583, DOI 10.1038/336583a0; FERRIS CD, 1990, P NATL ACAD SCI USA, V87, P2147, DOI 10.1073/pnas.87.6.2147; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; GIRARD S, 1992, BIOPHYS J, V61, P509, DOI 10.1016/S0006-3495(92)81855-6; GUIMARAESMOTTA H, 1984, J BIOL CHEM, V259, P8699; GYORKE S, 1993, SCIENCE, V260, P807, DOI 10.1126/science.8387229; HAIN J, 1994, BIOPHYS J, V66, pA225; HILLY M, 1993, J BIOL CHEM, V268, P16488; IINO M, 1991, J GEN PHYSIOL, V98, P681, DOI 10.1085/jgp.98.4.681; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; JOSEPH SK, 1989, BIOCHEM J, V258, P261, DOI 10.1042/bj2580261; JOSEPH SK, 1989, MOL PHARMACOL, V36, P391; JOSEPH SK, 1993, J BIOL CHEM, V268, P23059; KATZ AM, 1980, BIOCHIM BIOPHYS ACTA, V596, P94, DOI 10.1016/0005-2736(80)90173-X; KHODAKHAH K, 1993, P NATL ACAD SCI USA, V90, P4976, DOI 10.1073/pnas.90.11.4976; KINDMAN LA, 1993, BIOCHEMISTRY-US, V32, P1270, DOI 10.1021/bi00056a011; LEVY S, 1993, J GEN PHYSIOL, V101, P67, DOI 10.1085/jgp.101.1.67; MAEDA N, 1991, J BIOL CHEM, V266, P1109; MAGNUSSON A, 1993, FEBS LETT, V323, P229, DOI 10.1016/0014-5793(93)81345-Z; MARSHALL ICB, 1993, J BIOL CHEM, V268, P13214; Martell A.E., 1974, CRITICAL STABILITY C, V1, P204; MATHEW J, 1991, NEUROTOXICOLOGY, V12, P245; MAYRLEITNER M, 1994, BIOPHYS J, V66, pA147; MEISSNER G, 1986, BIOCHEMISTRY-US, V25, P236, DOI 10.1021/bi00349a033; MEYER T, 1990, BIOCHEMISTRY-US, V29, P32, DOI 10.1021/bi00453a004; MEYER T, 1990, P NATL ACAD SCI USA, V87, P3841, DOI 10.1073/pnas.87.10.3841; MIGNERY GA, 1992, J BIOL CHEM, V267, P7450; MIKOSHIBA K, 1993, TRENDS PHARMACOL SCI, V14, P86, DOI 10.1016/0165-6147(93)90069-V; MINTA A, 1989, J BIOL CHEM, V264, P8171; MISSIAEN L, 1992, J BIOL CHEM, V267, P22961; MOUTIN MJ, 1988, J BIOL CHEM, V263, P4228; MUALLEM S, 1989, J BIOL CHEM, V264, P205; NAKAGAWA T, 1991, P NATL ACAD SCI USA, V88, P6244, DOI 10.1073/pnas.88.14.6244; OGDEN D, 1994, BIOPHYS J, V66, pA49; OGDEN DC, 1990, J PHYSIOL-LONDON, V422, P585, DOI 10.1113/jphysiol.1990.sp018002; OGDEN DC, 1993, J EXP BIOL, V184, P105; OLDERSHAW KA, 1991, BIOCHEM J, V278, P705, DOI 10.1042/bj2780705; ORLOWSKI S, 1991, BIOCHEMISTRY-US, V30, P352, DOI 10.1021/bi00216a007; PARKER I, 1990, P NATL ACAD SCI USA, V87, P260, DOI 10.1073/pnas.87.1.260; PARKER I, 1993, J PHYSIOL-LONDON, V461, P133, DOI 10.1113/jphysiol.1993.sp019506; PARYS JB, 1992, J BIOL CHEM, V267, P18776; PAYNE R, 1990, NEURON, V4, P547, DOI 10.1016/0896-6273(90)90112-S; PIERCE GN, 1987, MOL CELL BIOCHEM, V78, P89; PIETRI F, 1990, J BIOL CHEM, V265, P17478; RICHARDSON A, 1993, J BIOL CHEM, V268, P11528; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; ROSS CA, 1992, P NATL ACAD SCI USA, V89, P4265, DOI 10.1073/pnas.89.10.4265; SEGEL GB, 1981, J BIOL CHEM, V256, P6629; SMITH JA, 1993, FEBS LETT, V327, P137, DOI 10.1016/0014-5793(93)80157-P; SOMLYO AV, 1992, J BIOL CHEM, V267, P22316; SOMOGYI R, 1991, J BIOL CHEM, V266, P11068; SORENSON MM, 1977, BIOCHIM BIOPHYS ACTA, V465, P210, DOI 10.1016/0005-2736(77)90075-X; SPAT A, 1992, BIOCHEM J, V287, P335; STAUDERMAN KA, 1988, BIOCHEM J, V255, P677; STERN MD, 1992, CELL CALCIUM, V13, P183, DOI 10.1016/0143-4160(92)90046-U; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; Taylor Colin W., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P109; TAYLOR CW, 1990, BIOCHEM J, V266, P189, DOI 10.1042/bj2660189; TAYLOR CW, 1992, TRENDS BIOCHEM SCI, V17, P403, DOI 10.1016/0968-0004(92)90009-X; TROSPER TL, 1984, CELL CALCIUM, V5, P211, DOI 10.1016/0143-4160(84)90037-X; TSHIPAMBA M, 1993, J CELL PHYSIOL, V155, P96, DOI 10.1002/jcp.1041550113; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; VOLPE P, 1990, AM J PHYSIOL, V258, pC1077, DOI 10.1152/ajpcell.1990.258.6.C1077; WAKUI M, 1990, FEBS LETT, V263, P206, DOI 10.1016/0014-5793(90)81374-W; WATRAS J, 1991, J NEUROSCI, V11, P3239; WILLIAMSON JR, 1985, INOSITOL PHOSPHOINOS, P423; WOLFF HU, 1983, EXPERIENTIA, V29, P241; WORLEY PF, 1987, NATURE, V325, P159, DOI 10.1038/325159a0; WORLEY PF, 1987, J BIOL CHEM, V262, P12132; YAO Y, 1992, J PHYSIOL-LONDON, V458, P319, DOI 10.1113/jphysiol.1992.sp019420; YOO SH, 1994, BIOPHYS J, V66, pA384; ZHANG BX, 1993, J BIOL CHEM, V268, P10997; ZHAO H, 1990, J BIOL CHEM, V265, P21419	97	52	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17561	17571						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	7517399				2022-12-27	WOS:A1994NU12800037
J	SCHMID, A; BENZ, R; JUST, I; AKTORIES, K				SCHMID, A; BENZ, R; JUST, I; AKTORIES, K			INTERACTION OF CLOSTRIDIUM-BOTULINUM C2 TOXIN WITH LIPID BILAYER-MEMBRANES - FORMATION OF CATION-SELECTIVE CHANNELS AND INHIBITION OF CHANNEL FUNCTION BY CHLOROQUINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFRINGENS IOTA TOXIN; ADP-RIBOSYLATES ACTIN; TISSUE-CULTURE CELLS; MATRIX PROTEIN PORIN; DIPHTHERIA-TOXIN; ESCHERICHIA-COLI; ELECTRICAL-PROPERTIES; SKELETAL-MUSCLE; FORMS CHANNELS; C-2 TOXIN	Lipid bilayer experiments were performed with the C2-II binding component of the ADP-ribosylating C2 toxin from Clostridium botulinum. The trypsin-activated but not the nonactivated form of the protein was able to increase the specific conductance of artificial lipid bilayer membranes by the formation of ion-permeable channels. The channels had on average a single-channel conductance of 55 pS in 0.1 M KCl and were found to be cation-selective and voltage-dependent. The single-channel conductance was only moderately dependent on the bulk aqueous KCl concentration, which indicated point charge effects on the channel properties. Incubation of the activated C2-II binding component with antibodies against C2-II or with C2-I toxin inhibited channel formation to a large extent. Addition of chloroquine, a known inhibitor of endocytosis in cells, led to a dose-dependent decrease of the Ca-II-induced membrane conductance. This result suggested that the activated CS-II component contains a binding site for chloroquine inside the channel. It is discussed that the channels formed by C2-II component are involved in the translocation of C2-I toxin across the target cell membrane.	UNIV WURZBURG,BIOZENTRUM,THEODOR BOVERI INST,LEHRSTUHL BIOTECHNOL,D-97074 WURZBURG,GERMANY; UNIV SAARLAND,INST PHARMAKOL & TOXIKOL,D-66421 HOMBURG,GERMANY	University of Wurzburg; Saarland University			Aktories, Klaus/CAJ-5682-2022	Aktories, Klaus/0000-0002-5397-0436; Benz, Roland/0000-0002-9510-9265				AKTORIES K, 1986, NATURE, V322, P390, DOI 10.1038/322390a0; AKTORIES K, 1992, CURR TOP MICROBIOL, V175, P97; BENZ R, 1979, BIOCHIM BIOPHYS ACTA, V551, P238, DOI 10.1016/0005-2736(89)90002-3; BENZ R, 1978, BIOCHIM BIOPHYS ACTA, V511, P305, DOI 10.1016/0005-2736(78)90269-9; BENZ R, 1988, ANNU REV MICROBIOL, V42, P359, DOI 10.1146/annurev.mi.42.100188.002043; BENZ R, 1989, INFECT IMMUN, V57, P887, DOI 10.1128/IAI.57.3.887-895.1989; BLAUSTEIN RO, 1989, P NATL ACAD SCI USA, V86, P2209, DOI 10.1073/pnas.86.7.2209; BOQUET P, 1982, P NATL ACAD SCI-BIOL, V79, P7614, DOI 10.1073/pnas.79.24.7614; BOROCHOVNEORI H, 1984, BIOPHYS J, V45, P83, DOI 10.1016/S0006-3495(84)84117-X; CABIAUX V, 1993, INFECT IMMUN, V61, P2200, DOI 10.1128/IAI.61.5.2200-2202.1993; CONSIDINE RV, 1991, TOXICON, V29, P913, DOI 10.1016/0041-0101(91)90076-4; DONOVAN JJ, 1985, J BIOL CHEM, V260, P8817; DONOVAN JJ, 1982, NATURE, V298, P669, DOI 10.1038/298669a0; DONOVAN JJ, 1981, P NATL ACAD SCI-BIOL, V78, P172, DOI 10.1073/pnas.78.1.172; DONOVAN JJ, 1986, BIOCHEMISTRY-US, V25, P2872, DOI 10.1021/bi00358a020; GAMBALE F, 1983, BIOPHYS J, V53, P771; GEIPEL U, 1989, EUR J BIOCHEM, V179, P229, DOI 10.1111/j.1432-1033.1989.tb14545.x; GEIPEL U, 1990, BIOCHEM J, V266, P335, DOI 10.1042/bj2660335; HOCH DH, 1985, P NATL ACAD SCI USA, V82, P1692, DOI 10.1073/pnas.82.6.1692; KAGAN BL, 1981, P NATL ACAD SCI-BIOL, V78, P4950, DOI 10.1073/pnas.78.8.4950; LEPPLA SH, 1980, J BIOL CHEM, V255, P2247; NELSON AP, 1975, J THEOR BIOL, V55, P13, DOI 10.1016/S0022-5193(75)80106-8; OHISHI I, 1987, INFECT IMMUN, V55, P1461, DOI 10.1128/IAI.55.6.1461-1465.1987; OHISHI I, 1980, INFECT IMMUN, V30, P668; OHISHI I, 1992, INFECT IMMUN, V60, P4648, DOI 10.1128/IAI.60.11.4648-4655.1992; OHISHI I, 1984, FEMS MICROBIOL LETT, V23, P281; PAPINI E, 1988, EMBO J, V7, P3353, DOI 10.1002/j.1460-2075.1988.tb03207.x; POPOFF MR, 1988, BIOCHEM BIOPH RES CO, V152, P1361, DOI 10.1016/S0006-291X(88)80435-2; RAUCH G, 1984, EUR BIOPHYS J, V18, P79; REUNER KH, 1987, EUR J CELL BIOL, V43, P134; ROPELE M, 1989, BIOCHIM BIOPHYS ACTA, V985, P9, DOI 10.1016/0005-2736(89)90096-5; SANDVIG K, 1988, J BIOL CHEM, V263, P12352; SCHERING B, 1988, EUR J BIOCHEM, V171, P225, DOI 10.1111/j.1432-1033.1988.tb13780.x; SCHMID A, 1991, J BACTERIOL, V173, P4909, DOI 10.1128/jb.173.16.4909-4913.1991; SCHMID MF, 1993, NATURE, V364, P827, DOI 10.1038/364827a0; SIMPSON LI, 1989, J PHARMACOL EXP THER, V251, P1223; SIMPSON LL, 1987, INFECT IMMUN, V55, P118, DOI 10.1128/IAI.55.1.118-122.1987; SIMPSON LL, 1982, J PHARMACOL EXP THER, V222, P43; VANDEKERCKHOVE J, 1987, FEBS LETT, V225, P48, DOI 10.1016/0014-5793(87)81129-8; VANDEKERCKHOVE J, 1988, J BIOL CHEM, V263, P696; WEGNER A, 1988, J BIOL CHEM, V263, P13739; WEIGT C, 1989, FEBS LETT, V246, P181, DOI 10.1016/0014-5793(89)80279-0; WIEGERS W, 1991, EUR J CELL BIOL, V54, P237; WILLE M, 1992, J BIOL CHEM, V267, P50	44	99	100	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16706	16711						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	7515883				2022-12-27	WOS:A1994NR29600032
J	TCHOU, J; BODEPUDI, V; SHIBUTANI, S; ANTOSHECHKIN, I; MILLER, J; GROLLMAN, AP; JOHNSON, F				TCHOU, J; BODEPUDI, V; SHIBUTANI, S; ANTOSHECHKIN, I; MILLER, J; GROLLMAN, AP; JOHNSON, F			SUBSTRATE-SPECIFICITY OF FPG PROTEIN - RECOGNITION AND CLEAVAGE OF OXIDATIVELY DAMAGED DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APURINIC APYRIMIDINIC SITES; ESCHERICHIA-COLI; IONIZING-RADIATION; ENDONUCLEASE-V; ABASIC SITES; AQUEOUS-SOLUTION; IMIDAZOLE RINGS; GLYCOSYLASE; REPAIR; 8-HYDROXYGUANINE	The 8-oxoguanine-DNA glycosylase of Escherichia coli, also known as formamidopyrimidine-DNA glycosylase (Fpg protein), has N-glycosylase and AP-lyase activities. This enzyme repairs oxidative DNA damage by efficiently removing formamidopyrimidine lesions and 8-oxoguanine residues from DNA. Defined oligodeoxynucleotides containing various 8-oxopurines were used to examine the substrate specificity of Fpg protein and to establish the role of functional groups in DNA on damage recognition and catalysis. Binding affinities of Fpg protein were established for duplex oligodeoxynucleotides containing 8-oxo-2'-deoxyguanine, 8-oxo-2'-deoxyadenine, 8-oxo-2'-deoxynebularine, 8-oxo-2'-deoxyinosine, abasic sites, and a ring-opened adduct of C8-aminofluorene guanine. The C8 keto group of 8-oxodG:dC presents in the major groove and is correlated with tight binding (K-d = 8.9 nM). Binding is much weaker when the C8 keto functional group is in the minor groove, as in 8-oxodG:dA (K-d = 340 nM). K-m and V-max were determined for the cleavage reaction. Specificity constants (K-cat/K-m) are consistently higher for oligodeoxynucleotide duplexes containing 8-oxopurines with C6 and C8 keto groups, as in 8-oxodG:dC and 8-oxodI:dC, where K-cat/K-m are 9.3 and 18 min(-1) nM x 10(-3), respectively. 8-oxodN:dC lacks the C6 keto group; the specificity constant is 0.024 min(-1) nM x 10(-3). Taken together, our data suggest that the C8 keto group of 8-oxodeoxyguanine and the carbonyl moiety of formamidopyrimidine enable Fpg protein to recognize and bind duplex DNA containing these modified bases. An enzyme-catalyzed reaction involving the C6 keto group of the substrate leads to removal of these lesions. A mechanism involving protonation at O-6 of 8-oxoguanine is proposed to account for the N-glycosylase activity of this enzyme.	SUNY STONY BROOK,DEPT PHARMACOL SCI,STONY BROOK,NY 11794; UNIV CALIF LOS ANGELES,DEPT MICROBIOL & MOLEC GENET,LOS ANGELES,CA 90024	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of California System; University of California Los Angeles				Shibutani, Shinya/0000-0003-4190-9512	NATIONAL CANCER INSTITUTE [R01CA017395, R37CA017395] Funding Source: NIH RePORTER; NCI NIH HHS [CA17395] Funding Source: Medline; NIGMS NIH HHS [GM07518] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMES BN, 1989, MUTAT RES, V214, P41, DOI 10.1016/0027-5107(89)90196-6; BODEPUDI V, 1992, CHEM RES TOXICOL, V5, P608, DOI 10.1021/tx00029a004; BOITEUX S, 1992, BIOCHEMISTRY-US, V31, P106, DOI 10.1021/bi00116a016; BOITEUX S, 1984, NUCLEIC ACIDS RES, V12, P5429, DOI 10.1093/nar/12.13.5429; BOITEUX S, 1990, J BIOL CHEM, V265, P3916; BOITEUX S, 1990, DNA REPAIR MECHANISM, P37; BOITEUX S, 1989, CARCINOGENESIS, V10, P1095; BREIMER LH, 1984, NUCLEIC ACIDS RES, V12, P6359, DOI 10.1093/nar/12.16.6359; CASTAING B, 1992, NUCLEIC ACIDS RES, V20, P389, DOI 10.1093/nar/20.3.389; CHENG KC, 1992, J BIOL CHEM, V267, P166; CHETSANGA CJ, 1983, CARCINOGENESIS, V4, P997, DOI 10.1093/carcin/4.8.997; CHETSANGA CJ, 1979, NUCLEIC ACIDS RES, V6, P3673, DOI 10.1093/nar/6.11.3673; CHETSANGA CJ, 1981, BIOCHEMISTRY-US, V20, P5201, DOI 10.1021/bi00521a016; CHO BP, 1990, CHEM RES TOXICOL, V3, P445, DOI 10.1021/tx00017a010; DODSON ML, 1993, BIOCHEMISTRY-US, V32, P8284, DOI 10.1021/bi00083a032; FRAGA CG, 1990, P NATL ACAD SCI USA, V87, P4533, DOI 10.1073/pnas.87.12.4533; GROLLMAN AP, 1992, 7TH P CONV BIOM STER, P165; GUSCHLBAUER W, 1991, NUCLEIC ACIDS RES, V19, P1753, DOI 10.1093/nar/19.8.1753; JETTER MC, 1993, BIOCHEMISTRY-US, V32, P3249, DOI 10.1021/bi00064a006; KOUCHAKDJIAN M, 1991, BIOCHEMISTRY-US, V30, P3262, DOI 10.1021/bi00227a014; KOUCHAKDJIAN M, 1991, BIOCHEMISTRY-US, V30, P1403, DOI 10.1021/bi00219a034; KOW YW, 1987, BIOCHEMISTRY-US, V26, P8200, DOI 10.1021/bi00399a027; KRIEK E, 1980, CARCINOGENESIS, V1, P459, DOI 10.1093/carcin/1.6.459; KRIEK E, 1969, Chemico-Biological Interactions, V1, P3, DOI 10.1016/0009-2797(69)90015-5; LAVAL J, 1990, MUTAT RES, V233, P73, DOI 10.1016/0027-5107(90)90152-T; LEATHERBARROW RJ, 1987, ENZFITTER VERSION 1; MANOHARAN M, 1988, J AM CHEM SOC, V110, P2690, DOI 10.1021/ja00216a074; MAZUMDER A, 1991, BIOCHEMISTRY-US, V30, P1119, DOI 10.1021/bi00218a033; MICHAELS ML, 1992, BIOCHEMISTRY-US, V31, P10964, DOI 10.1021/bi00160a004; MICHAELS ML, 1992, P NATL ACAD SCI USA, V89, P7022, DOI 10.1073/pnas.89.15.7022; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; MICHAELS ML, 1991, NUCLEIC ACIDS RES, V19, P3629, DOI 10.1093/nar/19.13.3629; MORIKAWA K, 1992, SCIENCE, V256, P523, DOI 10.1126/science.1575827; MORIYA M, 1993, P NATL ACAD SCI USA, V90, P1122, DOI 10.1073/pnas.90.3.1122; MORIYA M, 1991, MUTAT RES, V254, P281, DOI 10.1016/0921-8777(91)90067-Y; OCONNOR TR, 1989, P NATL ACAD SCI USA, V86, P5222, DOI 10.1073/pnas.86.14.5222; ODA Y, 1991, NUCLEIC ACIDS RES, V19, P1407, DOI 10.1093/nar/19.7.1407; OLEYKOWSKI CA, 1993, J BIOL CHEM, V268, P7990; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PLUM GE, 1994, IN PRESS BIOCHEMISTR; SCHROCK RD, 1991, J BIOL CHEM, V266, P17631; SCHROCK RD, 1993, J BIOL CHEM, V268, P880; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; SHIBUTANI S, 1990, J AM CHEM SOC, V112, P5667, DOI 10.1021/ja00170a056; SHIBUTANI S, 1993, BIOCHEMISTRY-US, V32, P4615, DOI 10.1021/bi00068a019; STEENKEN S, 1989, CHEM REV, V89, P503, DOI 10.1021/cr00093a003; TAKESHITA M, 1987, J BIOL CHEM, V262, P10171; TCHOU J, 1993, MUTAT RES, V299, P277, DOI 10.1016/0165-1218(93)90104-L; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; TCHOU J, 1993, J BIOL CHEM, V268, P26738; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011	51	302	305	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15318	15324						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	7515054				2022-12-27	WOS:A1994NP73800069
J	NATHAN, C; XIE, QW				NATHAN, C; XIE, QW			REGULATION OF BIOSYNTHESIS OF NITRIC-OXIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							DEPENDENT PROTEIN-KINASE; VASCULAR SMOOTH-MUSCLE; L-ARGININE; MOLECULAR-CLONING; SYNTHASE ACTIVITY; NITROGEN-OXIDES; MACROPHAGES; CALMODULIN; CELLS; PHOSPHORYLATION		CORNELL UNIV,COLL MED,DEPT MED,BEATRICE & SAMUEL A SEAVER LAB,NEW YORK,NY 10021	Cornell University					NATIONAL CANCER INSTITUTE [R01CA043610] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051967] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034543, R21AI034543] Funding Source: NIH RePORTER; NCI NIH HHS [CA43610] Funding Source: Medline; NHLBI NIH HHS [HL51967] Funding Source: Medline; NIAID NIH HHS [AI/CA 34543] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; ALBINA JE, 1988, AM J PHYSIOL, V254, pE459, DOI 10.1152/ajpendo.1988.254.4.E459; ANDRONIKLION V, 1992, BIOCHEM BIOPH RES CO, V185, P452, DOI 10.1016/S0006-291X(05)81006-X; ASSREUY J, 1993, BRIT J PHARMACOL, V108, P833, DOI 10.1111/j.1476-5381.1993.tb12886.x; AWOLESI M, 1993, FASEB J, V7, P4360; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BOGDAN C, 1994, J LEUKOCYTE BIOL, V55, P227, DOI 10.1002/jlb.55.2.227; BOGDAN C, 1993, J IMMUNOL, V151, P301; BREDT DS, 1992, J BIOL CHEM, V267, P10976; BREDT DS, 1994, IN PRESS ANN REV BIO, V63; BRUNE B, 1991, BIOCHEM BIOPH RES CO, V181, P921, DOI 10.1016/0006-291X(91)91279-L; BUSCONI L, 1993, J BIOL CHEM, V268, P8410; CETKOVICCVRLJE M, 1993, ENDOCRINOLOGY, V133, P1739, DOI 10.1210/en.133.4.1739; CHARLES IG, 1993, P NATL ACAD SCI USA, V90, P11419, DOI 10.1073/pnas.90.23.11419; CHARTRAIN NA, 1994, J BIOL CHEM, V269, P6765; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; DAWSON TM, 1993, P NATL ACAD SCI USA, V90, P9808, DOI 10.1073/pnas.90.21.9808; DRAPIER JC, 1993, EMBO J, V12, P3643, DOI 10.1002/j.1460-2075.1993.tb06038.x; EVANS T, 1992, P NATL ACAD SCI USA, V89, P5361, DOI 10.1073/pnas.89.12.5361; FUJISAWA H, 1994, IN PRESS J NEUROCHEM; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; GRISCAVAGE JM, 1993, J IMMUNOL, V151, P6329; GROSS SS, 1992, J BIOL CHEM, V267, P25722; HANSSON GK, 1993, CIRCULATION, V88, P383; HARADA N, 1993, P NATL ACAD SCI USA, V90, P11312, DOI 10.1073/pnas.90.23.11312; HATTORI Y, 1994, J BIOL CHEM, V269, P9405; HECKER M, 1994, J NEUROCHEM, V62, P1524; HORTELANO S, 1992, J BIOL CHEM, V267, P24937; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; IIDA S, 1992, J BIOL CHEM, V267, P25385; IMAI T, 1994, J CLIN INVEST, V93, P543, DOI 10.1172/JCI117005; JANSSENS SP, 1992, J BIOL CHEM, V267, P14519; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; KARUPIAH G, 1993, SCIENCE, V261, P1445, DOI 10.1126/science.7690156; KIM N, 1993, J CLIN INVEST, V91, P437, DOI 10.1172/JCI116220; KLATT P, 1993, J BIOL CHEM, V268, P14781; KOBZIK L, 1993, AM J RESP CELL MOL, V9, P371, DOI 10.1165/ajrcmb/9.4.371; KOIDE M, 1993, J BIOL CHEM, V268, P24959; KURTZMAN J, 1993, ENDOTHELIUM S, V1, pS75; KWON NS, 1989, J BIOL CHEM, V264, P20496; KWON NS, 1990, J BIOL CHEM, V265, P13442; LANDER HM, 1993, J IMMUNOL, V150, P1509; LIU JW, 1994, J BIOL CHEM, V269, P11691; LORSBACH RB, 1993, J BIOL CHEM, V268, P1908; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; MALINSKI T, 1992, NATURE, V358, P676, DOI 10.1038/358676a0; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MARSDEN PA, 1992, FEBS LETT, V307, P287, DOI 10.1016/0014-5793(92)80697-F; MARSDEN PA, 1993, J BIOL CHEM, V268, P17478; MARSDEN PA, 1994, GENOMICS, V19, P182; MCCARTNEYFRANCIS N, 1993, J EXP MED, V178, P749, DOI 10.1084/jem.178.2.749; MELILLO G, 1993, J IMMUNOL, V150, P4031; MICHEL T, 1993, P NATL ACAD SCI USA, V90, P6252, DOI 10.1073/pnas.90.13.6252; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; NAKANE M, 1993, FEBS LETT, V316, P175, DOI 10.1016/0014-5793(93)81210-Q; NAKANE M, 1991, BIOCHEM BIOPH RES CO, V180, P1396, DOI 10.1016/S0006-291X(05)81351-8; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NISHIDA K, 1992, J CLIN INVEST, V90, P2092, DOI 10.1172/JCI116092; NUNOSHIBA T, 1993, P NATL ACAD SCI USA, V90, P9993, DOI 10.1073/pnas.90.21.9993; NUSSLER AK, 1994, J BIOL CHEM, V269, P1257; OGURA T, 1993, BIOCHEM BIOPH RES CO, V193, P1014, DOI 10.1006/bbrc.1993.1726; OGURA T, 1994, IN PRESS 3RD P INT M; PARK KH, 1992, CIRC RES, V71, P992, DOI 10.1161/01.RES.71.4.992; PENDINO KJ, 1993, J IMMUNOL, V151, P7196; PEUNOVA N, 1993, NATURE, V364, P450, DOI 10.1038/364450a0; PFEILSCHIFTER J, 1991, BIOCHEM BIOPH RES CO, V175, P372, DOI 10.1016/0006-291X(91)91574-V; POLLOCK JS, 1991, P NATL ACAD SCI USA, V88, P10480, DOI 10.1073/pnas.88.23.10480; RADOMSKI MW, 1991, PHILOS T ROY SOC B, V334, P129, DOI 10.1098/rstb.1991.0102; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; RIBEIRO JMC, 1993, SCIENCE, V260, P539, DOI 10.1126/science.8386393; ROBINSON LJ, 1994, GENOMICS, V19, P350, DOI 10.1006/geno.1994.1068; ROGERS NE, 1992, BIOCHEM BIOPH RES CO, V189, P242, DOI 10.1016/0006-291X(92)91550-A; ROSENKRANZWEISS P, 1994, IN PRESS J CLIN INVE; SCHINI VB, 1992, EUR J PHARMACOL, V216, P379, DOI 10.1016/0014-2999(92)90434-6; SCHINI VB, 1994, CIRC RES, V74, P24, DOI 10.1161/01.RES.74.1.24; SCHMIDT HHHW, 1992, J HISTOCHEM CYTOCHEM, V40, P1439, DOI 10.1177/40.10.1382087; SESSA WC, 1993, CIRC RES, V72, P921, DOI 10.1161/01.RES.72.4.921; SESSA WC, 1994, CIRC RES, V74, P349, DOI 10.1161/01.RES.74.2.349; SHERMAN PA, 1993, BIOCHEMISTRY-US, V32, P11600, DOI 10.1021/bi00094a017; SPARROW JR, 1994, IN PRESS EXP EYE RES; STUEHR DJ, 1989, BIOCHEM BIOPH RES CO, V161, P420, DOI 10.1016/0006-291X(89)92615-6; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; SUSCHEK C, 1993, J IMMUNOL, V151, P3283; TALMA B, 1994, IN PRESS BRAIN RES; THOMSEN LL, 1992, BIOCHEM PHARMACOL, V43, P2401, DOI 10.1016/0006-2952(92)90319-E; TOJO A, 1994, IN PRESS J AM SOC NE; VALLANCE P, 1992, LANCET, V339, P572; VODOVOTZ Y, 1993, J EXP MED, V178, P605, DOI 10.1084/jem.178.2.605; VODOVOTZ Y, 1994, J IMMUNOL, V152, P4110; VODOVOTZ Y, 1993, THESIS CORNELL U GRA, P88; WARREN JB, 1994, FASEB J, V8, P247, DOI 10.1096/fasebj.8.2.7509761; WEINBERG JB, 1994, J EXP MED, V179, P651, DOI 10.1084/jem.179.2.651; WEISS G, 1993, EMBO J, V12, P3651, DOI 10.1002/j.1460-2075.1993.tb06039.x; WERNERFELMAYER G, 1990, J EXP MED, V172, P1599, DOI 10.1084/jem.172.6.1599; WERNERFELMAYER G, 1993, J BIOL CHEM, V268, P1842; WU GY, 1992, BIOCHEM J, V281, P45, DOI 10.1042/bj2810045; XIE QW, 1994, J BIOL CHEM, V269, P4705; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; YOSHIZUMI M, 1993, CIRC RES, V73, P205, DOI 10.1161/01.RES.73.1.205	103	1506	1564	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13725	13728						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	7514592				2022-12-27	WOS:A1994NL60600001
J	AKIMOTO, K; MIZUNO, K; OSADA, S; HIRAI, S; TANUMA, S; SUZUKI, K; OHNO, S				AKIMOTO, K; MIZUNO, K; OSADA, S; HIRAI, S; TANUMA, S; SUZUKI, K; OHNO, S			A NEW MEMBER OF THE 3RD CLASS IN THE PROTEIN-KINASE-C FAMILY, PKC-LAMBDA, EXPRESSED DOMINANTLY IN AN UNDIFFERENTIATED MOUSE EMBRYONAL CARCINOMA CELL-LINE AND ALSO IN MANY TISSUES AND CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								Protein kinase C (PHC)-related cDNA clones isolated from cDNA libraries of mouse P19 embryonal carcinoma cells and mouse brain encoded a 67-kDa protein, PKC lambda. PKC lambda shows the highest amino acid sequence identity with PKC zeta (72%), the third class of the PKC family. Northern blot analysis showed that the mRNA for PKC lambda is expressed in a wide variety of cells and tissues, including P19 and MH 3T3 cells, as well as brain, kidney, testis, and ovary. In undifferentiated P19 cells, the mRNA for PKC lambda is the most abundant among all the PKC family members. The differentiation of P19 cells results in an increase in PKC alpha and epsilon, and a decrease in PKC lambda. Antiserum raised against a peptide of PKC lambda identified a 74-kDa protein in P19 cell extracts as well as in extracts from COS cells transfected with the PKC lambda expression plasmid. Autophosphorylation of the PKC lambda that immunoprecipitated with the specific antiserum was observed, indicating that PKC lambda possesses protein kinase activity. A phorbol ester binding assay using intact COS cells expressing PKC lambda failed to detect binding activity specific to PKC lambda at phorbol dibutylate concentrations up to 300 nM, suggesting that PKC lambda does not possess phorbol ester binding activity. These results, in conjunction with the results obtained in parallel experiments with PKC zeta and other PKC members, suggest a biochemical similarity between PKC lambda and zeta and their clear difference from other PKC members.	YOKOHAMA CITY UNIV, SCH MED, DEPT MOLEC BIOL, KANAZAWA KU, YOKOHAMA 236, JAPAN; UNIV TOKYO, INST MOLEC & CELLULAR BIOSCI, BUNKYO KU, TOKYO 113, JAPAN; SCI UNIV TOKYO, INST PHARMACOL SCI, DEPT BIOCHEM, SHINJUKU KU, TOKYO 162, JAPAN	Yokohama City University; University of Tokyo; Tokyo University of Science			Ohno, Shigeo/B-1768-2010	Ohno, Shigeo/0000-0002-1294-5269; Osada, Shin-Ichi/0000-0001-5387-085X				BACHER N, 1991, MOL CELL BIOL, V11, P126, DOI 10.1128/MCB.11.1.126; BENNER SA, 1991, ADV ENZYME REGUL, V31, P121, DOI 10.1016/0065-2571(91)90012-B; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; DOMINGUEZ I, 1992, MOL CELL BIOL, V12, P3776, DOI 10.1128/MCB.12.9.3776; HATA A, 1993, J BIOL CHEM, V268, P9122; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; Maniatis T, 1989, MOL CLONING; MIZUNO K, 1991, EUR J BIOCHEM, V202, P931, DOI 10.1111/j.1432-1033.1991.tb16453.x; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OHNO S, 1987, NATURE, V325, P161, DOI 10.1038/325161a0; OHNO S, 1991, ADV ENZYME REGUL, V31, P287, DOI 10.1016/0065-2571(91)90018-H; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; OHNO S, 1988, BIOCHEMISTRY-US, V27, P2083, DOI 10.1021/bi00406a040; ONO Y, 1987, SCIENCE, V236, P1116, DOI 10.1126/science.3576226; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; ONO Y, 1988, J BIOL CHEM, V263, P6927; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; OSADA S, 1992, MOL CELL BIOL, V12, P3930, DOI 10.1128/MCB.12.9.3930; OSADA S, 1990, J BIOL CHEM, V265, P22434; ROBERTSON EJ, 1987, TERATOCARCINOMAS EMB, P33; SCHEIBE RJ, 1991, J BIOL CHEM, V266, P21300; SNOEK GT, 1986, DEV BIOL, V115, P282, DOI 10.1016/0012-1606(86)90249-6; WAYS DK, 1992, J BIOL CHEM, V267, P4799	29	226	230	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12677	12683						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	7513693				2022-12-27	WOS:A1994NH71600049
J	KANG, I; WANG, JH				KANG, I; WANG, JH			DESIGN OF STRUCTURE-BASED REVERSE-TRANSCRIPTASE INHIBITORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; CALF THYMUS; HIV-1; RESOLUTION; PROTEINS; SITE	Based on the crystallographic structure of the active site in the reverse transcriptase (RT) of human immunodeficiency virus (HIV), a group of hydrophobic polyadenylic acid (5') derivatives were designed and synthesized as inhibitors of the enzyme. These compounds were found to inhibit all six of the RTs tested, with IC50 = 10(-11)-10(-8) M, but did not inhibit either RNA polymerase II (even at 10(-5) M) or DNA polymerase I up to 10(-6) M inhibitor concentration. The underivatized poly(A) did not inhibit any of the RTs tested under the same conditions. In aqueous solutions of purified HIV-1 RT, poly-2'-O-(2,4-dinitrophenyl)-oligo(A) was found to inhibit the enzyme reversibly and compete with the primer-template poly(A)-(dT)(12), whereas poly-2'-O-(3-fluoro-4,6-dinitrophenyl)-poly(A) was found to inactivate HIV-1 RT irreversibly by covalent labeling. A comparison of physicochemical properties of the hybrids poly(A)-poly(dT) and dinitrophenyl-poly(A)-poly(dT) shows that the hydrophobic dinitrophenyl groups stabilize double helical structures. These inhibitors were also found to be effective in keeping susceptible lymphocytes viable in the presence of H1V-1 (wild type). The effective inhibitor concentrations (EC(50)) were found to be 0.2-2.6 mu g/ml. No toxic effect on the host cells was found even at 100-1000-fold higher inhibitor concentrations.	SUNY BUFFALO,DEPT CHEM,BUFFALO,NY 14214	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					NIGMS NIH HHS [GM 41610] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041610] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNOLD E, 1992, NATURE, V357, P85, DOI 10.1038/357085a0; CHUAN H, 1989, J BIOL CHEM, V264, P7981; CHUAN H, 1988, J BIOL CHEM, V263, P13003; FREUND E, 1986, BIOCHEMISTRY-US, V25, P276, DOI 10.1021/bi00349a038; HARWOOD SJ, 1970, J BIOL CHEM, V245, P5614; HODO HG, 1977, BIOCHEMISTRY-US, V16, P2334, DOI 10.1021/bi00630a005; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; SHIH CK, 1991, P NATL ACAD SCI USA, V88, P9878, DOI 10.1073/pnas.88.21.9878; SOPTA M, 1985, J BIOL CHEM, V260, P353; WEISLOW OS, 1989, JNCI-J NATL CANCER I, V81, P577, DOI 10.1093/jnci/81.8.577; WU JC, 1991, BIOCHEMISTRY-US, V30, P1011	13	14	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12024	12031						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	7512957				2022-12-27	WOS:A1994NG37700055
J	LIU, JW; SESSA, WC				LIU, JW; SESSA, WC			IDENTIFICATION OF COVALENTLY BOUND AMINO-TERMINAL MYRISTIC ACID IN ENDOTHELIAL NITRIC-OXIDE SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MOLECULAR-CLONING; PROTEINS; MYRISTOYLATION; EXPRESSION; ACYLATION; ENZYME; P60SRC; CELLS	Endothelial nitric oxide synthase (eNOS) is unique among the nitric oxide synthase family of proteins due to the presence of an N-myristoylation consensus se sequence elucidated from the cloning of its cDNA. Although eNOS was metabolically labeled with [H-3]myristic acid and mutation of glycine 2 in the N-myristoylation consensus sequence changed the particulate localization of the enzyme to a cytosolic form, the definitive characterization of eNOS as an N-myristoylprotein has not been demonstrated. Therefore, the purpose of the present study was to determine the nature of the fatty acid incorporated into eNOS. Wild-type or G2A mutant (mutation of glycine 2, the myristic acid acceptor site, to alanine) eNOS-transfected COS cells and bovine aortic endothelial cells (BAEC) were metabolically labeled with [H-3]myristic acid for 5 h. The radiolabel was primarily incorporated into membrane-associated eNOS from wild-type transfected COS cells and cultured BAEC but not into the mutant eNOS from G2A-transfected COS cells. Qualitatively similar amounts of immunoreactive protein were found in wild-type and G2A-transfected cells. In addition, linkage of the radiolabel to eNOS was insensitive to hydroxylamine treatment, and incorporation of the radiolabel into eNOS was abolished by cycloheximide. Chemical analysis of the fatty acid released by acid methanolysis of labeled eNOS verified the H-3-labeled fatty acid as protein-bound myristic acid. These results unequivocally demonstrate that eNOS incorporates myristic acid via an amide linkage with the aminoterminal glycine of the enzyme as a co-translational modification.	YALE UNIV,SCH MED,BOYER CTR MOLEC MED,DEPT PHARMACOL,NEW HAVEN,CT 06536; YALE UNIV,SCH MED,BOYER CTR MOLEC MED,MOLEC CARDIOBIOL PROGRAM,NEW HAVEN,CT 06536	Yale University; Yale University			Sessa, William C/B-6844-2011	Sessa, William C/0000-0001-5759-1938				AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BUSCONI L, 1993, J BIOL CHEM, V268, P8410; BUSS JE, 1988, MOL CELL BIOL, V8, P3960, DOI 10.1128/MCB.8.9.3960; CHARLES IG, 1993, P NATL ACAD SCI USA, V90, P11419, DOI 10.1073/pnas.90.23.11419; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P522, DOI 10.1073/pnas.90.2.522; GORDON JI, 1991, J BIOL CHEM, V266, P8647; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; JANSSENS SP, 1992, J BIOL CHEM, V267, P14519; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MARSDEN PA, 1992, FEBS LETT, V307, P287, DOI 10.1016/0014-5793(92)80697-F; MUSZBEK L, 1993, J BIOL CHEM, V268, P8251; NAKANE M, 1993, FEBS LETT, V316, P175, DOI 10.1016/0014-5793(93)81210-Q; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NISHIDA K, 1992, J CLIN INVEST, V90, P2092, DOI 10.1172/JCI116092; NUNOKAWA Y, 1993, BIOCHEM BIOPH RES CO, V191, P89, DOI 10.1006/bbrc.1993.1188; OLSON EN, 1985, J BIOL CHEM, V260, P3784; POLLOCK JS, 1991, P NATL ACAD SCI USA, V88, P10480, DOI 10.1073/pnas.88.23.10480; POLLOCK JS, 1993, AM J PHYSIOL, V265, pC1379, DOI 10.1152/ajpcell.1993.265.5.C1379; RANDERATH K, 1963, LAYER CHROMATOGRAPHY, P133; RUDNICK DA, 1991, J BIOL CHEM, V266, P9732; SESSA WC, 1993, HYPERTENSION, V21, P934, DOI 10.1161/01.HYP.21.6.934; SESSA WC, 1993, CIRC RES, V72, P921, DOI 10.1161/01.RES.72.4.921; SESSA WC, 1992, J BIOL CHEM, V267, P15274; SIMON SM, 1992, J BIOL CHEM, V267, P3922; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; WILCOX C, 1987, SCIENCE, V238, P1275, DOI 10.1126/science.3685978; WOOD ER, 1993, BIOCHEM BIOPH RES CO, V191, P767, DOI 10.1006/bbrc.1993.1283; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522	34	84	86	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11691	11694						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	7512951				2022-12-27	WOS:A1994NG37700005
J	GHERZI, R; CARNEMOLLA, B; SIRI, A; PONASSI, M; BALZA, E; ZARDI, L				GHERZI, R; CARNEMOLLA, B; SIRI, A; PONASSI, M; BALZA, E; ZARDI, L			HUMAN TENASCIN GENE - STRUCTURE OF THE 5'-REGION, IDENTIFICATION, AND CHARACTERIZATION OF THE TRANSCRIPTION REGULATORY SEQUENCES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN HEXABRACHION TENASCIN; EXPRESSION; PROTEINS; INTRON; LOCALIZATION; HOMEODOMAIN; MOLECULE; HOMEOBOX; PROMOTER; BINDING	This report describes the genomic organization of the 5'-region of the human tenascin-C (TN) gene and the functional characterization of its promoter. Approximately 2300 base pairs of the TN gene 5'-flanking region have been cloned and sequenced. This genomic region contains several potential binding sites for transcription factors. By primer extension and S1 nuclease analysis we have localized the transcription start site. The first exon of the TN gene (179 base pairs long) is present in the two major TN transcripts, showing that the expression of these two mRNAs is regulated by a single promoter. The 220 bases upstream to the transcription start site are equally active in directing the expression of chloramphenicol acetyltransferase (CAT) reporter gene in TN producer and nonproducer cells. Using deletion fragments of the human 5'-flanking region we have shown the presence of putative ''silencer'' elements in the -220 to -2300 region active in both TN producer and nonproducer cell lines. Furthermore, we have demonstrated that the selective transcription in TN producing cells requires the presence of a 1.3-kilobase portion of the TN gene intron 1 in the CAT expression vectors. These findings indicate that complex mechanisms control the transcriptional regulation of TN gene.	IST NAZL RIC CANC, CELL BIOL LAB, I-16132 GENOA, ITALY	University of Genoa; IRCCS AOU San Martino IST			Gherzi, Roberto/AAA-7256-2020; Ponassi, Marco/K-8000-2016	Gherzi, Roberto/0000-0001-8654-0611; Ponassi, Marco/0000-0002-5418-2458				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Ausubel FA, 1990, CURRENT PROTOCOLS MO; BAUMGARTNER S, 1994, EMBO J, V13, P3728, DOI 10.1002/j.1460-2075.1994.tb06682.x; BORSI L, 1994, CELL ADHES COMMUN, V1, P307, DOI 10.3109/15419069409097262; BORSI L, 1990, FEBS LETT, V261, P175, DOI 10.1016/0014-5793(90)80664-5; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P4395, DOI 10.1128/MCB.8.10.4395; CHALEPAKIS G, 1991, CELL, V66, P873, DOI 10.1016/0092-8674(91)90434-Z; CHIQUET M, 1991, SEMIN NEUROSCI, V3, P341; CHIQUETEHRISMANN R, 1993, SEMIN CANCER BIOL, V4, P301; CHIQUETEHRISMANN R, 1994, PERSPECT DEV NEUROBI, V2, P3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COWELL IG, 1994, TRENDS BIOCHEM SCI, V19, P38, DOI 10.1016/0968-0004(94)90172-4; EDELMAN GM, 1993, J BIOL CHEM, V268, P20683; EDELMAN GM, 1992, TRENDS BIOCHEM SCI, V17, P228, DOI 10.1016/0968-0004(92)90383-K; EKBLOM P, 1989, International Journal of Developmental Biology, V33, P71; Erickson HP, 1993, CURR OPIN CELL BIOL, V5, P869, DOI 10.1016/0955-0674(93)90037-Q; ERICKSON HP, 1993, J CELL BIOL, V120, P1079, DOI 10.1083/jcb.120.5.1079; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FLORENCE B, 1991, MOL CELL BIOL, V11, P3613, DOI 10.1128/MCB.11.7.3613; FUSS B, 1993, J CELL BIOL, V120, P1237, DOI 10.1083/jcb.120.5.1237; GHERZI R, 1994, EXP CELL RES, V213, P20, DOI 10.1006/excr.1994.1168; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GULCHER JR, 1991, P NATL ACAD SCI USA, V88, P9438, DOI 10.1073/pnas.88.21.9438; GULCHER JR, 1989, P NATL ACAD SCI USA, V86, P1588, DOI 10.1073/pnas.86.5.1588; HOLST BD, 1994, J BIOL CHEM, V269, P22245; JONES FS, 1990, P NATL ACAD SCI USA, V87, P6497, DOI 10.1073/pnas.87.17.6497; JONES FS, 1992, P NATL ACAD SCI USA, V89, P2091, DOI 10.1073/pnas.89.6.2091; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; LEVINE A, 1994, CELL, V77, P587, DOI 10.1016/0092-8674(94)90220-8; LISKA DJ, 1994, J CELL BIOL, V125, P695, DOI 10.1083/jcb.125.3.695; MARCK C, 1988, NUCLEIC ACIDS RES, V16, P1829, DOI 10.1093/nar/16.5.1829; MATSUMOTO K, 1992, GENOMICS, V12, P485, DOI 10.1016/0888-7543(92)90438-X; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NEUBERGER MS, 1988, NUCLEIC ACIDS RES, V16, P6713, DOI 10.1093/nar/16.14.6713; NIES DE, 1991, J BIOL CHEM, V266, P2818; NORENBERG U, 1992, NEURON, V8, P849, DOI 10.1016/0896-6273(92)90199-N; POTHIER F, 1992, DNA CELL BIOL, V11, P83, DOI 10.1089/dna.1992.11.83; RENKAWITZ R, 1990, TRENDS GENET, V6, P192, DOI 10.1016/0168-9525(90)90176-7; SAGA Y, 1992, GENE DEV, V6, P1821, DOI 10.1101/gad.6.10.1821; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDERMAUNOURY S, 1993, CELL, V75, P1199, DOI 10.1016/0092-8674(93)90329-O; SIRI A, 1991, NUCLEIC ACIDS RES, V19, P525, DOI 10.1093/nar/19.3.525; SLATER EP, 1985, MOL CELL BIOL, V5, P2984, DOI 10.1128/MCB.5.11.2984; ZANNINI M, 1992, MOL CELL BIOL, V12, P4230, DOI 10.1128/MCB.12.9.4230	47	51	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	1995	270	7					3429	3434		10.1074/jbc.270.7.3429	http://dx.doi.org/10.1074/jbc.270.7.3429			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QG471	7531707	hybrid			2022-12-27	WOS:A1995QG47100080
J	REEVE, JG; GUADANO, A; XIONG, JY; MORGAN, J; BLEEHEN, NM				REEVE, JG; GUADANO, A; XIONG, JY; MORGAN, J; BLEEHEN, NM			DIMINISHED EXPRESSION OF INSULIN-LIKE GROWTH-FACTOR (IGF) BINDING PROTEIN-5 AND ACTIVATION OF IGF-I-MEDIATED AUTOCRINE GROWTH IN SIMIAN-VIRUS 40-TRANSFORMED HUMAN FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOMATOMEDIN-C; FACTOR RECEPTORS; TUMOR-ANTIGEN; CELLS; TRANSFORMATION; IDENTIFICATION; NOMENCLATURE; VARIABLES; SECRETION; GENE	The reduced growth factor requirements of murine fibroblasts transformed by simian virus 40 (SV 40) have been attributed to insulin-like growth factor (IGF)-I induction by T antigen and consequent activation of IGF-I receptor signaling. The present study shows that the autonomous growth of SV 40-transformed human fibroblasts also requires type-I IGF-I receptor activation but that this is not due to de novo induction of IGF-I gene expression since untransformed human fibroblasts, which fail to proliferate in the absence of serum, also showed IGF-I gene expression under serum-free conditions. DNA synthesis assays confirmed that untransformed cells were responsive to exogenous IGF and indicated that transformed cells were already maximally stimulated, In untransformed fibroblasts. IGF binding was principally to abundant membrane-associated IG FBP-5, whereas in transformed fibroblasts this protein was minimally expressed, and IGF binding was to IGF receptors. Loss of detectable membrane-associated IGFBP-5 in transformed cells was associated with diminished IGFBP-5 gene expression and with loss of IGF-II gene expression. Exogenous IGFBP-5 associated with the membranes of transformed cells and inhibited the autocrine growth of these cells. These findings suggest that loss of IGFBP-5 in SV 40 transformed fibroblasts facilitates interaction of endogenously produced IGF-I with the IGF-I receptor and increases their sensitivity to autocrine stimulation.			REEVE, JG (corresponding author), MRC, MRC CTR, CLIN ONCOL & RADIOTHERAPEUT UNIT, CAMBRIDGE CB2 2QH, ENGLAND.							BACH LA, 1994, GROWTH REGUL S1, V4, pI169; BACKELJAUW PF, 1993, ENDOCRINOLOGY, V132, P1677, DOI 10.1210/en.132.4.1677; BALLARD J, 1989, ACTA ENDOCRINOL-COP, V121, P751, DOI 10.1530/acta.0.1210751; Baxter R C, 1989, Prog Growth Factor Res, V1, P49, DOI 10.1016/0955-2235(89)90041-0; BELL GI, 1984, NATURE, V310, P775, DOI 10.1038/310775a0; Blat C, 1992, GROWTH FACTORS, V6, DOI 10.3109/08977199209008872; BOWENPOPE DF, 1984, P NATL ACAD SCI-BIOL, V81, P2396, DOI 10.1073/pnas.81.8.2396; BUSBY WH, 1988, J CLIN ENDOCR METAB, V67, P1225, DOI 10.1210/jcem-67-6-1225; CAMACHOHUBNER C, 1992, J BIOL CHEM, V267, P11949; CHEN JC, 1994, J CELL PHYSIOL, V158, P69, DOI 10.1002/jcp.1041580110; CLEMMONS DR, 1992, ENDOCRINOLOGY, V131, P890, DOI 10.1210/en.131.2.890; CLEMMONS DR, 1987, MOL ENDOCRINOL, V1, P339, DOI 10.1210/mend-1-5-339; CLEMMONS DR, 1991, J CLIN ENDOCR METAB, V73, P727, DOI 10.1210/jcem-73-4-727; CLEMMONS DR, 1986, J CLIN INVEST, V77, P1548, DOI 10.1172/JCI112470; COHEN P, 1991, ACTA ENDOCRINOL-COP, V124, P74; COHEN P, 1993, MOL ENDOCRINOL, V7, P380, DOI 10.1210/me.7.3.380; CONOVER CA, 1989, J CLIN INVEST, V83, P852, DOI 10.1172/JCI113968; DEFENDI V, 1982, J CELL PHYSIOL, P131; DICKER P, 1981, EXP CELL RES, V135, P221, DOI 10.1016/0014-4827(81)90314-1; DROP SLS, 1992, ENDOCRINOLOGY, V130, P1736; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; GOOLSBY CL, 1990, CANCER GENET CYTOGEN, V50, P231, DOI 10.1016/0165-4608(90)90183-B; Hill DJ, 1992, GROWTH FACTORS, V6, P315, DOI 10.3109/08977199209021543; HUSCHTSCHA LI, 1983, J CELL SCI, V63, P77; IRMINGER JC, 1989, EUR J PEDIATR, V148, P620, DOI 10.1007/BF00441514; JANSEN M, 1985, FEBS LETT, V179, P243, DOI 10.1016/0014-5793(85)80527-5; JONES JI, 1993, J CELL BIOL, V121, P679, DOI 10.1083/jcb.121.3.679; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; KAPLAN PL, 1981, VIROLOGY, V108, P484, DOI 10.1016/0042-6822(81)90455-4; KIEFER MC, 1992, J BIOL CHEM, V267, P12692; KIEFER MC, 1993, GROWTH REGULAT, V3, P56; KULL FC, 1983, J BIOL CHEM, V258, P6561; Lamson G, 1991, Growth Factors, V5, P19, DOI 10.3109/08977199109000268; MARTIN JL, 1990, J BIOL CHEM, V265, P4124; MCCUSKER RH, 1990, J CELL PHYSIOL, V144, P244, DOI 10.1002/jcp.1041440210; PIETRZKOWSKI Z, 1992, CELL GROWTH DIFFER, V3, P199; PORCU P, 1992, MOL CELL BIOL, V12, P5069, DOI 10.1128/MCB.12.11.5069; REEVE JG, 1993, CANCER RES, V53, P4680; REEVE JG, 1992, J NATL CANCER I, V84, P628, DOI 10.1093/jnci/84.8.628; RISSER R, 1974, VIROLOGY, V59, P477, DOI 10.1016/0042-6822(74)90457-7; SACH GH, 1981, IN VITRO, V17, P1; SCHOFIELD PN, 1991, BRIT J CANCER, V63, P687, DOI 10.1038/bjc.1991.156; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SHIMASAKI S, 1991, J BIOL CHEM, V266, P10646; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; SOOS MA, 1993, BIOCHEM J, V290, P419, DOI 10.1042/bj2900419; STURM MA, 1989, ENDOCRINOLOGY, V124, P388, DOI 10.1210/endo-124-1-388; TRAVALI S, 1991, MOL CELL BIOL, V11, P731, DOI 10.1128/MCB.11.2.731	48	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					135	142		10.1074/jbc.270.1.135	http://dx.doi.org/10.1074/jbc.270.1.135			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7529226	hybrid			2022-12-27	WOS:A1995QA28700025
J	VIRIYAKOSOL, S; KIRKLAND, TN				VIRIYAKOSOL, S; KIRKLAND, TN			A REGION OF HUMAN CD14 REQUIRED FOR LIPOPOLYSACCHARIDE-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; LPS-BINDING; 70Z/3 CELLS; PROTEIN; ENDOTOXIN; RESPONSES; RECEPTOR; ACTIVATION; EXPRESSION; CACHECTIN	CD14, a glycosylphosphatidylinositol-anchored protein on the surface of monocytes, macrophages, and polymorphonuclear leukocytes, is a receptor for lipopolysaccharide (LPS), CD14 binding of LPS is enhanced by serum proteins, especially lipopolysaccharide binding protein. The serum dependent binding of LPS to CD14 stimulates macrophages to make cytokines, which can cause septic shock in humans and animals. Here, we identify a region in human CD14 which is important in serum-dependent LPS binding and LPS-induced cellular activation. Four small regions (4-5 amino acids long) within the N-terminal 65 amino acids of CD14 were deleted singly or in combination. The deletion mutants were stably expressed in Chinese hamster ovary (CHO) cells. The mutants were characterized in three assays: reactivity with anti-CD14 monoclonal antibody, serum-dependent LPS binding, and LPS induced activation of NF-KB, Some of the mutants selectively lost reactivity with the anti-CD14 monoclonal antibody that inhibited serum-dependent LPS binding and cellular activation, All of the mutants bound much less LPS than wild type CD14 in the presence of serum, None of the mutants bound more LPS than control CD14-CHO cells in the absence of serum, CD14-CHO cells respond to LPS by activation of NP-kappa B. All of the deletion mutants were less active LPS receptors than wild type CD14-CHO cells. The Delta AVEVE mutant, the Delta DDED and Delta PQPD double mutant, and the Delta DDED, Delta PQPD, Delta AVEVE, and Delta DPRQY quadruple deletion mutants were essentially inactive LPS receptors in CHO cells. These studies suggest that the 65 N-terminal amino acids of CD14 are critical for serum-dependent binding of LPS to CD14 and subsequent signal transduction in CHO cells.	UNIV CALIF SAN DIEGO,VET AFFAIRS MED CTR,DEPT PATHOL,SAN DIEGO,CA 92161; UNIV CALIF SAN DIEGO,VET AFFAIRS MED CTR,DEPT MED,SAN DIEGO,CA 92161	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA)			Kirkland, Theo/ADK-9674-2022		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007036] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM037696] Funding Source: NIH RePORTER; NIAID NIH HHS [T32 AI07036] Funding Source: Medline; NIGMS NIH HHS [GM-37696] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEUTLER B, 1987, NEW ENGL J MED, V316, P379; BEUTLER B, 1986, SCIENCE, V232, P977, DOI 10.1126/science.3754653; BOMSZTYK K, 1990, J BIOL CHEM, V265, P9413; COUTURIER C, 1991, J IMMUNOL, V147, P1899; FERRERO E, 1990, J IMMUNOL, V145, P331; GOLENBOCK DT, 1993, J BIOL CHEM, V268, P22055; HAILMAN E, 1994, J EXP MED, V179, P269, DOI 10.1084/jem.179.1.269; HEUMANN D, 1992, J IMMUNOL, V148, P3505; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOESS A, 1993, EMBO J, V12, P3351, DOI 10.1002/j.1460-2075.1993.tb06008.x; KIRKLAND TN, 1993, J BIOL CHEM, V268, P24818; KIRKLAND TN, 1988, J IMMUNOL, V141, P3208; KITCHENS RL, 1992, J EXP MED, V176, P485, DOI 10.1084/jem.176.2.485; LEE JD, 1993, P NATL ACAD SCI USA, V90, P9930, DOI 10.1073/pnas.90.21.9930; LEE JD, 1992, J EXP MED, V175, P1697, DOI 10.1084/jem.175.6.1697; PUGIN J, 1993, P NATL ACAD SCI USA, V90, P2744, DOI 10.1073/pnas.90.7.2744; SKELLY RR, 1979, INFECT IMMUN, V23, P287, DOI 10.1128/IAI.23.2.287-293.1979; TOBIAS PS, 1993, J IMMUNOL, V150, P3011; ULEVITCH RJ, 1993, ADV IMMUNOL, V53, P267, DOI 10.1016/S0065-2776(08)60502-7; WAKABAYASHI GO, 1991, FASEB J, V5, P338, DOI 10.1096/fasebj.5.3.1825816; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311	21	92	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					361	368		10.1074/jbc.270.1.361	http://dx.doi.org/10.1074/jbc.270.1.361			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7529231	hybrid			2022-12-27	WOS:A1995QA28700057
J	HEMPEL, SL; MONICK, MM; HE, B; YANO, T; HUNNINGHAKE, GW				HEMPEL, SL; MONICK, MM; HE, B; YANO, T; HUNNINGHAKE, GW			SYNTHESIS OF PROSTAGLANDIN-H SYNTHASE-2 BY HUMAN ALVEOLAR MACROPHAGES IN RESPONSE TO LIPOPOLYSACCHARIDE IS INHIBITED BY DECREASED CELL OXIDANT TONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; INDUCIBLE CYCLOOXYGENASE; HYDROGEN-PEROXIDE; BINDING-ACTIVITY; HUMAN MONOCYTES; G/H SYNTHASE; INTACT-CELLS; C-JUN; ACTIVATION; EXPRESSION	We previously demonstrated that lipopolysaccharide (LPS) increases expression of the prostaglandin H synthase-2 (PGHS-2) gene (Hempel, S. L,, Monick, M. M., and Hunninghake, G. W. (1994) J. Clin. Invest. 93, 391-396). In this study, the expression of the PGHS-2 gene in response to changes in cell oxidant tone was studied. During LPS exposure, inhibition of synthesis of the free radical, NO, resulted in a small decrease in prostaglandin E(2) synthesis that did not reach statistical significance. There was no effect on enzyme mass or mRNA. In contrast, incubation of alveolar macrophages in the presence of LPS plus the antioxidant pyrrolidine dithiocarbamate, the spin trap 5,5-dimethyl-1-pyrroline-N-oxide, or hypoxia, resulted in near complete inhibition of prostaglandin E(2) synthesis, PGHS-2 enzyme synthesis, and gene transcription of PGHS-2 mRNA. There was no evidence of cytotoxicity. These results demonstrate that synthesis of PGHS-2 in response to LPS is inhibited by agents that decrease cell oxidant tone.	UNIV IOWA, DEPT MED, IOWA CITY, IA 52242 USA; UNIV IOWA, DEPT VET AFFAIRS MED CTR, IOWA CITY, IA 52242 USA	University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System					NHLBI NIH HHS [HL-37121] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL037121] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; AMSTAD PA, 1992, CANCER RES, V52, P3952; BARCHOWSKY A, 1987, BIOCHIM BIOPHYS ACTA, V927, P372, DOI 10.1016/0167-4889(87)90102-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DEFORGE LE, 1993, J BIOL CHEM, V268, P25568; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DOKTER WHA, 1993, BLOOD, V81, P337; HABIB A, 1993, J BIOL CHEM, V268, P23448; HEMLER ME, 1980, J BIOL CHEM, V255, P6253; HEMPEL SL, 1993, AM J PHYSIOL, V264, pC1448, DOI 10.1152/ajpcell.1993.264.6.C1448; HEMPEL SL, 1994, J CLIN INVEST, V93, P391, DOI 10.1172/JCI116971; HSUANYU YC, 1992, J BIOL CHEM, V267, P17649; IVANOV V, 1993, J IMMUNOL, V151, P4694; JONES DA, 1993, J BIOL CHEM, V268, P9049; KOSAKA T, 1994, EUR J BIOCHEM, V221, P889, DOI 10.1111/j.1432-1033.1994.tb18804.x; KRAEMER SA, 1992, ARCH BIOCHEM BIOPHYS, V293, P391, DOI 10.1016/0003-9861(92)90411-O; LEE SH, 1992, J BIOL CHEM, V267, P25934; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LI Y, 1992, J BIOL CHEM, V267, P15097; LOWENSTEIN CJ, 1994, ANN INTERN MED, V120, P227, DOI 10.7326/0003-4819-120-3-199402010-00009; MARSHALL PJ, 1987, J BIOL CHEM, V262, P3510; MENON SD, 1993, J BIOL CHEM, V268, P26805; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693; NILSSON UA, 1989, J BIOL CHEM, V264, P11131; NOSE K, 1991, EUR J BIOCHEM, V201, P99, DOI 10.1111/j.1432-1033.1991.tb16261.x; POU S, 1989, BIOCHIM BIOPHYS ACTA, V991, P459, DOI 10.1016/0304-4165(89)90073-1; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; SALVEMINI D, 1994, J CLIN INVEST, V93, P1940, DOI 10.1172/JCI117185; SALVEMINI D, 1993, P NATL ACAD SCI USA, V90, P7240, DOI 10.1073/pnas.90.15.7240; SAMUNI A, 1986, P NATL ACAD SCI USA, V83, P7593, DOI 10.1073/pnas.83.20.7593; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; STINSKI MF, 1983, J VIROL, V46, P1; TAYLOR L, 1983, J BIOL CHEM, V258, P6855; XIE WL, 1993, ARCH BIOCHEM BIOPHYS, V300, P247, DOI 10.1006/abbi.1993.1034; XIE WL, 1992, DRUG DEVELOP RES, V25, P249, DOI 10.1002/ddr.430250402; ZAVALA DC, 1983, RECENT ADV RESPIRATO, V3; ZIEGLERHEITBROCK HWL, 1993, J IMMUNOL, V151, P6986; [No title captured]	40	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32979	32984						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7528741				2022-12-27	WOS:A1994QA63800041
J	ABUSOUD, HM; YOHO, LL; STUEHR, DJ				ABUSOUD, HM; YOHO, LL; STUEHR, DJ			CALMODULIN CONTROLS NEURONAL NITRIC-OXIDE SYNTHASE BY A DUAL MECHANISM - ACTIVATION OF INTRADOMAIN AND INTERDOMAIN ELECTRON-TRANSFER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CYTOCHROME P-450 REDUCTASE; BRAIN; PURIFICATION; CALCIUM; IDENTIFICATION; HYDROGEN; SULFITE; ENZYME; FLAVIN; LIVER	In neuronal nitric-oxide synthase (NOS), electron transfer proceeds across domains in a linear sequence from NADPH to flavins to heme, with calmodulin (CaM) triggering the interdomain electron transfer to the heme (Abu-Soud, H. M., and Stuehr, D. J. (1993) Proc. Natl. Acad. Sci. U.S.A. 90, 10769-10772). Here, we utilized a neuronal NOS devoid of its bound heme and tetrahydrobiopterin (apo NOS) to examine whether interdomain electron transfer is responsible for CaM's activation of NO synthesis, substrate-independent NADPH oxidation, and cytochrome c and ferricyanide reduction, Of the four activities, two (cytochrome c and ferricyanide reduction) were similarly stimulated by CaM in ape-NOS when compared with native NOS, indicating that activation occurs by a mechanism not involving flavin-to-heme electron transfer, Further analysis showed that CaM increased the rate of electron transfer from NADPH into the flavin centers by a factor of 20, revealing a direct activation of the NOS reductase domain by CaM. In contrast, CaM's activation of NO synthesis and substrate-independent NADPH oxidation appeared to involve flavin-to-heme electron transfer because these reactions were not activated in ape-NOS and were blocked in native NOS by agents that prevent heme iron reduction, Thus, CaM activates neuronal NOS at two points in the electron transfer sequence: electron transfer into the flavins and interdomain electron transfer between the flavins and heme. Activation at each point is associated with an up-regulation of domain-specific catalytic functions, The dual regulation by CaM is unique and represents a new means by which electron transfer can be controlled in a metalloflavoprotein.	CLEVELAND CLIN,DEPT IMMUNOL,CLEVELAND,OH 44195; CASE WESTERN RESERVE UNIV,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44106	Cleveland Clinic Foundation; Case Western Reserve University					NCI NIH HHS [CA53914] Funding Source: Medline; NIGMS NIH HHS [GM51491] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA053914, R01CA053914] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051491] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABUSOUD HM, 1994, J BIOL CHEM, V269, P32318; ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; BREDT DS, 1992, J BIOL CHEM, V267, P10976; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CHEN L, 1991, BIOCHEM BIOPH RES CO, V180, P238, DOI 10.1016/S0006-291X(05)81282-3; DIGNAM JD, 1977, BIOCHEMISTRY-US, V16, P1116, DOI 10.1021/bi00625a014; HEINZEL B, 1992, BIOCHEM J, V281, P627, DOI 10.1042/bj2810627; KLATT P, 1994, J BIOL CHEM, V269, P1674; KLATT P, 1993, J BIOL CHEM, V268, P14781; MAYER B, 1990, FEBS LETT, V277, P215, DOI 10.1016/0014-5793(90)80848-D; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; OSTROWSKI J, 1989, J BIOL CHEM, V264, P15796; POU S, 1992, J BIOL CHEM, V267, P24173; SANE PV, 1987, PHYTOCHEMISTRY, V26, P1289, DOI 10.1016/S0031-9422(00)81796-3; SCHMIDT HHHW, 1992, BIOCHEMISTRY-US, V31, P3243, DOI 10.1021/bi00127a028; SHETA EA, 1994, J BIOL CHEM, V269, P15147; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; VERMILION JL, 1978, J BIOL CHEM, V253, P8812; WANG JL, 1993, J BIOL CHEM, V268, P22255; Williams C H Jr, 1979, Methods Enzymol, V62, P185; WOLFF DJ, 1993, J BIOL CHEM, V268, P9425	24	252	254	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32047	32050						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7528206				2022-12-27	WOS:A1994PX30400007
J	HJORTH, SA; ADELHORST, K; PEDERSEN, BB; KIRK, O; SCHWARTZ, TW				HJORTH, SA; ADELHORST, K; PEDERSEN, BB; KIRK, O; SCHWARTZ, TW			GLUCAGON AND GLUCAGON-LIKE PEPTIDE-1 - SELECTIVE RECEPTOR RECOGNITION VIA DISTINCT PEPTIDE EPITOPES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PIG SMALL-INTESTINE; EXPRESSION CLONING; PANCREAS; HORMONE; ANALOGS; BINDING; GENE	Glucagon and glucagon-like peptide 1 (GLP-1) are homologous peptide hormones that are recognized by likewise homologous, but highly selective receptors. Analogs of glucagon and GLP-1, in which the divergent residues were systematically exchanged, were employed to identify the structural requirements for their selective receptor recognition. Substitutions in the NH2-terminal part of the glucagon molecule with the corresponding GLP-1 residues, as for example in [Ala(2),Glu(3)]glucagon and [Val(10),Ser(12)]glucagon, reduced the binding affinity for the glucagon receptor several hundred-fold without increasing the affinity for the GLP-1 receptor. In contrast, introduction of GLP-1 residues into the far COOH-terminal part of the glucagon molecule, e.g. [Val(27),Lys(28),Gly(29),Arg(30)]glucagon, had a minimal effect on recognition of the glucagon receptor, but improved the affinity of the analog for the GLP-1 receptor up to 200-fold. Similarly, substitutions in especially the far COOH-terminal part of the GLP-1 molecule with the corresponding glucagon residues, e.g. des-Arg(30)-[Met(27)Asn(28), Thr(29)]GLP-1, decreased the affinity for the GLP-1 receptor several hundred-fold (IC50 = 0.4-190 nM) without increasing the affinity for the glucagon receptor. Conversely, substitutions in the NH2-terminal part of the GLP-1 molecule impaired the affinity for the GLP-1 receptor only moderately. We conclude that the selective recognition of the glucagon and GLP-1 receptors is determined by residues located at opposite ends of the homologous peptide ligands. This conclusion is supported by the observation that a ''chimeric'' peptide consisting of the NH2-terminal part of the glucagon molecule joined to the COOH-terminal part of the GLP-1 molecule was recognized with high affinity by both receptors.	RIGSHOSP 6321,MOLEC ENDOCRINOL LAB,DK-2100 COPENHAGEN,DENMARK; NOVO NORDISK AS,DIABET RES,DK-2880 BAGSVAERD,DENMARK	Rigshospitalet; Novo Nordisk				Hjorth, Siv Annegrethe/0000-0002-6470-650X; Schwartz, Thue W./0000-0002-0261-6904				ADELHORST K, 1994, J BIOL CHEM, V269, P6275; BRAND C, 1994, DIABETOLOGIA, V37; BRAND CL, 1994, DIABETES, V43, pA172; CASCIERI MA, 1992, MOL PHARMACOL, V41, P1096; GALLWITZ B, 1990, J MOL ENDOCRINOL, V5, P33, DOI 10.1677/jme.0.0050033; GEFEL D, 1990, ENDOCRINOLOGY, V126, P2164, DOI 10.1210/endo-126-4-2164; GOKE B, 1993, DIGESTION, V54, P339, DOI 10.1159/000201054; HOLST JJ, 1987, FEBS LETT, V211, P169, DOI 10.1016/0014-5793(87)81430-8; HOLST JJ, 1975, DIABETOLOGIA, V11, P211, DOI 10.1007/BF00422324; HRUBY VJ, 1986, BIOPOLYMERS, V25, P135; JACOBSEN CR, 1990, NEUROPEPTIDES THEIR, P403; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; JORGENSEN JC, 1990, EUR J PHARMACOL, V186, P105, DOI 10.1016/0014-2999(90)94065-6; KAWAI K, 1991, DIABETES, V40, pA71; KOFOD H, 1988, AM J PHYSIOL, V254, pE454, DOI 10.1152/ajpendo.1988.254.4.E454; LIN MC, 1975, BIOCHEMISTRY-US, V14, P1559, DOI 10.1021/bi00679a002; MOJSOV S, 1986, J BIOL CHEM, V261, P1880; NAUCK MA, 1993, DIABETOLOGIA, V36, P741, DOI 10.1007/BF00401145; NEVILLE DM, 1968, BIOCHIM BIOPHYS ACTA, V154, P540, DOI 10.1016/0005-2795(68)90014-7; ORSKOV C, 1987, DIABETOLOGIA, V30, P874; ORSKOV C, 1989, J BIOL CHEM, V264, P12826; ORSKOV C, 1992, DIABETOLOGIA, V35, P701; ORSKOV C, 1986, ENDOCRINOLOGY, V119, P1467, DOI 10.1210/endo-119-4-1467; Schwartz TW, 1990, MOL BIOL ISLETS LANG, P153; SEGRE GV, 1993, TRENDS ENDOCRIN MET, V4, P309, DOI 10.1016/1043-2760(93)90071-L; THORELL JI, 1971, BIOCHIM BIOPHYS ACTA, V251, P363, DOI 10.1016/0005-2795(71)90123-1; THORENS B, 1992, P NATL ACAD SCI USA, V89, P8641, DOI 10.1073/pnas.89.18.8641; UNSON CG, 1994, BIOCHEMISTRY-US, V33, P6884, DOI 10.1021/bi00188a018; UNSON CG, 1994, J BIOL CHEM, V269, P12548; UNSON CG, 1993, ARCH BIOCHEM BIOPHYS, V300, P747, DOI 10.1006/abbi.1993.1103; UNSON CG, 1991, J BIOL CHEM, V266, P2763	31	77	131	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30121	30124						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7527026				2022-12-27	WOS:A1994PU52500015
J	MAURO, LJ; OLMSTED, EA; SKROBACZ, BM; MOUREY, RJ; DAVIS, AR; DIXON, JE				MAURO, LJ; OLMSTED, EA; SKROBACZ, BM; MOUREY, RJ; DAVIS, AR; DIXON, JE			IDENTIFICATION OF A HORMONALLY REGULATED PROTEIN-TYROSINE-PHOSPHATASE ASSOCIATED WITH BONE AND TESTICULAR-DIFFERENTIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOBLAST-LIKE CELLS; RAT CALVARIA CELLS; PARATHYROID-HORMONE; PHOSPHOTYROSINE PHOSPHATASE; PROGRESSIVE DEVELOPMENT; GROWTH-FACTOR; TUMOR-CELLS; MOTH-EATEN; RECEPTOR; EXPRESSION	Absence of the tyrosine kinase activity of c-src and c-fms results in impairment of bone remodeling. Such dysfunction underscores the importance of tyrosine phosphorylation, yet the role of protein tyrosine phosphatases in bone metabolism remains unexamined. We have isolated the cDNA for a novel receptor-like tyrosine phosphatase expressed in bone and testis named osteotesticular protein tyrosine phosphatase (OST-PTP). The deduced 1711-residue protein possesses an extracellular domain with 10 fibronectin type III repeats and a cytoplasmic region with two catalytic domains. In primary rat osteoblasts, the 5.8-kilobase OST-PTP transcript is up-regulated in differentiating cultures and down-regulated in late stage mineralizing cultures. In addition, a presumed alternate transcript of 4.8-5.0 kilobases, which may lack PTP domains, is present in pro liferating osteoblasts, but not detectable at other stages. Parathyroid hormone, a modulator of bone function, as well as cyclic AMP analogues, increase OST-PTP mRNA 5-8-fold in UMR 106 cells. In situ hybridization of adult rat testis revealed stage-specific expression of OST-PTP. OST-PTP may function in signaling pathways during bone remodeling, as well as serve a broader role in cell interactions associated with differentiation in bone and testis.	UNIV MICHIGAN, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA; WYETH AYERST RES, DIV BONE METAB & OSTEOPOROSIS RES, RADNOR, PA 19087 USA	University of Michigan System; University of Michigan; Pfizer				Olmsted-Davis, Elizabeth/0000-0001-9457-1848	PHS HHS [18024] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; ANTOSZ ME, 1987, J BONE MINER RES, V2, P385; ARONOW MA, 1990, J CELL PHYSIOL, V143, P213, DOI 10.1002/jcp.1041430203; BOYCE BF, 1992, J CLIN INVEST, V90, P1622, DOI 10.1172/JCI116032; BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; CANALIS E, 1989, J CLIN INVEST, V83, P60, DOI 10.1172/JCI113885; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CIVITELLI R, 1988, AM J PHYSIOL, V255, pE660, DOI 10.1152/ajpendo.1988.255.5.E660; DEMPSTER DW, 1993, ENDOCR REV, V14, P690, DOI 10.1210/er.14.6.690; FLORIO T, 1992, J BIOL CHEM, V267, P24169; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; GEBBINK MFBG, 1993, J BIOL CHEM, V268, P16101; GUAN KL, 1990, P NATL ACAD SCI USA, V87, P1501, DOI 10.1073/pnas.87.4.1501; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; KIERSZENBAUM AL, 1994, ENDOCR REV, V15, P116, DOI 10.1210/er.15.1.116; KISHIHARA K, 1993, CELL, V74, P143, DOI 10.1016/0092-8674(93)90302-7; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; KRUEGER NX, 1992, P NATL ACAD SCI USA, V89, P7417, DOI 10.1073/pnas.89.16.7417; LAU KHW, 1988, ENDOCRINOLOGY, V123, P2858, DOI 10.1210/endo-123-6-2858; LAU KHW, 1987, J BIOL CHEM, V262, P1389; LEVY JB, 1993, J BIOL CHEM, V268, P10573; MAUREL P, 1994, P NATL ACAD SCI USA, V91, P2512, DOI 10.1073/pnas.91.7.2512; MAURO LJ, 1994, TRENDS BIOCHEM SCI, V19, P151, DOI 10.1016/0968-0004(94)90274-7; MCPARTLIN J, 1978, ENDOCRINOLOGY, V103, P1573, DOI 10.1210/endo-103-5-1573; MURAMATSU T, 1992, P NATL ACAD SCI USA, V89, P529, DOI 10.1073/pnas.89.2.529; NIJWEIDE PJ, 1986, PHYSIOL REV, V66, P855, DOI 10.1152/physrev.1986.66.4.855; NODA M, 1988, J BIOL CHEM, V263, P18574; OWEN TA, 1990, J CELL PHYSIOL, V143, P420, DOI 10.1002/jcp.1041430304; PAN MG, 1992, SCIENCE, V256, P1215, DOI 10.1126/science.256.5060.1215; PATTHY L, 1990, CELL, V61, P13, DOI 10.1016/0092-8674(90)90208-V; POT DA, 1991, J BIOL CHEM, V266, P19688; PUZAS JE, 1985, ENDOCRINOLOGY, V116, P2463, DOI 10.1210/endo-116-6-2463; RAISZ LG, 1963, NATURE, V197, P1015, DOI 10.1038/1971015a0; RUSSELL L, 1977, AM J ANAT, V148, P313, DOI 10.1002/aja.1001480303; Sambrook J, 1989, MOL CLONING LABORATO; SCOTT DK, 1992, MOL ENDOCRINOL, V6, P2153, DOI 10.1210/me.6.12.2153; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; TITUS L, 1993, BONE MINER, V23, P267, DOI 10.1016/S0169-6009(08)80103-1; TONKS N K, 1988, Biochemistry, V27, P8695, DOI 10.1021/bi00424a001; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; WALTON KM, 1993, NEURON, V11, P387, DOI 10.1016/0896-6273(93)90193-U; WIKTORJEDRZEJCZAK W, 1990, P NATL ACAD SCI USA, V87, P4828, DOI 10.1073/pnas.87.12.4828; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0; YOSHINAGA K, 1991, DEVELOPMENT, V113, P689; ZHANG ZY, 1994, ADV ENZYMOL RAMB, V68, P1	53	69	78	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30659	30667						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7527035				2022-12-27	WOS:A1994PU52500094
J	ROSENKILDE, MM; CAHIR, M; GETHER, U; HJORTH, SA; SCHWARTZ, TW				ROSENKILDE, MM; CAHIR, M; GETHER, U; HJORTH, SA; SCHWARTZ, TW			MUTATIONS ALONG TRANSMEMBRANE SEGMENT-II OF THE NK-1 RECEPTOR AFFECT SUBSTANCE-P COMPETITION WITH NONPEPTIDE ANTAGONISTS BUT NOT SUBSTANCE-P BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; NEUROKININ-1 RECEPTOR; NONPEPTIDE ANTAGONIST; SPECIES SELECTIVITY; MOLECULAR-BASIS; NK1 RECEPTOR; DOMAINS; SPECIFICITY; IDENTIFICATION; DELINEATION	Mutational analysis of the NK-1 receptor indicates that residues involved in non-peptide antagonist binding cluster around the outer portion of transmembrane segments (TM) V and VI. In contrast mutations affecting the binding of the natural peptide agonist, substance P, are scattered in the exterior part of the receptor. Recently it was reported that a number of mutations in TM-II also seriously impair substance P binding. Here we confirm that Ala substitutions for these residues located on a hydrophilic helical face of TM-II basically eliminate substance P binding to the NK-1 receptor, provided that a radiolabeled non-peptide antagonist is used as radioligand. Surprisingly, radiolabeled substance P bound well to all these mutant receptors and was displaced with only slightly reduced affinity by the unlabeled peptide and by the non-peptide antagonists. The wild-type homologous NK-2 receptor displayed properties similar to those observed in the mutated NK-1 receptors, i.e. concomitant high affinity binding of radiolabeled agonist peptide (in this case neurokinin A), yet low affinity, G-protein independent competition of unlabeled peptide with radiolabeled non-peptide antagonist. It is concluded that substitutions in TM-II of the NK-1 receptor do not affect the high affinity binding of substance P but instead block the ability of the peptides to compete for non-peptide antagonist binding. It is suggested that certain mutations can impair interchange between receptor conformations that each bind different ligands with high affinity.	UNIV COPENHAGEN,RIGSHOSP,DEPT CLIN BIOCHEM,MOLEC ENDOCRINOL LAB,DK-2100 COPENHAGEN,DENMARK	Rigshospitalet; University of Copenhagen				Hjorth, Siv Annegrethe/0000-0002-6470-650X; Schwartz, Thue W./0000-0002-0261-6904; Rosenkilde, Mette Marie/0000-0001-9600-3254; Gether, Ulrik/0000-0002-0020-3807				BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BARKER EL, 1994, J BIOL CHEM, V269, P11687; BOYD ND, 1991, ANN NY ACAD SCI, V632, P79, DOI 10.1111/j.1749-6632.1991.tb33096.x; CASCIERI MA, 1994, J BIOL CHEM, V269, P6587; EMONDSALT X, 1992, LIFE SCI, V50, P101; FONG TM, 1994, J BIOL CHEM, V269, P2728; FONG TM, 1992, J BIOL CHEM, V267, P25668; FONG TM, 1992, J BIOL CHEM, V267, P25664; FONG TM, 1993, NATURE, V362, P350; FUJII T, 1992, BRIT J PHARMACOL, V107, P785, DOI 10.1111/j.1476-5381.1992.tb14524.x; GETHER U, 1993, NATURE, V362, P345, DOI 10.1038/362345a0; GETHER U, 1993, J BIOL CHEM, V268, P7893; GETHER U, 1993, P NATL ACAD SCI USA, V90, P6194, DOI 10.1073/pnas.90.13.6194; GETHER U, 1994, J BIOL CHEM, V269, P23959; GETHER U, 1994, MOL PHARMACOL, V45, P500; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUANG RRC, 1994, BIOCHEMISTRY-US, V33, P3007, DOI 10.1021/bi00176a033; JENSEN CJ, 1994, MOL PHARMACOL, V45, P294; JOHANSEN TE, 1990, FEBS LETT, V267, P289, DOI 10.1016/0014-5793(90)80947-H; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KRYSTEK SR, 1994, J BIOL CHEM, V269, P12383; LEE JA, 1994, P NATL ACAD SCI USA, V91, P7164, DOI 10.1073/pnas.91.15.7164; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; LOWE JA, 1992, J MED CHEM, V35, P2591, DOI 10.1021/jm00092a009; MIYAYASU K, 1993, MOL PHARMACOL, V44, P539; OLIVEIRA L, 1994, TRENDS PHARMACOL SCI, V15, P170, DOI 10.1016/0165-6147(94)90137-6; SACHAIS BS, 1993, J BIOL CHEM, V268, P2319; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SAMAMA P, 1994, MOL PHARMACOL, V45, P390; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; SNIDER RM, 1991, SCIENCE, V251, P435, DOI 10.1126/science.1703323; STRADER CD, 1991, J BIOL CHEM, V266, P5; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; STRADER CD, 1989, J BIOL CHEM, V264, P13572; YOKOTA Y, 1992, EMBO J, V11, P3585, DOI 10.1002/j.1460-2075.1992.tb05442.x; YOKOTA Y, 1989, J BIOL CHEM, V264, P17649; ZOFFMANN S, 1993, FEBS LETT, V336, P506, DOI 10.1016/0014-5793(93)80865-R	38	108	111	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28160	28164						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7525569				2022-12-27	WOS:A1994PV77200059
J	CONNOR, A; WIERSMA, E; SHULMAN, MJ				CONNOR, A; WIERSMA, E; SHULMAN, MJ			ON THE LINKAGE BETWEEN RNA PROCESSING AND RNA TRANSLATABILITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN-MU-CHAIN; S MESSENGER-RNA; NONSENSE MUTATIONS; PREMESSENGER RNA; TRANSLATION; STABILITY; MEMBRANE; LOCUS; GENE; EXPRESSION	The immunoglobulin mu heavy chain gene of mouse hybridoma cells is expressed in two forms, mu s and mu m, differing in their use of 3' exons. As for many other mammalian genes, mutations in the mu gene which prematurely terminate translation often have the effect of reducing the amount of these mu RNAs. To test the generality of this relationship, we selected mutant hybridoma cell lines defective in IgM production and searched both for translation termination mutations which do not reduce the amount of mu RNA as well as for mutants which show the more commonly observed reduction in mu RNA. As observed previously, the amount of us RNA is normal in mutants terminating in the C mu 4 exon; by contrast the amount of um RNA is reduced in these mutants, indicating that the effect of the mutation is influenced by some feature near the 3' end of the RNA. Mutations terminating translation in other C region exons have a graded effect on RNA content, ranging from 10% the normal level for termination in the C mu 3 exon down to 1% for termination in the C mu 2 exon. By contrast, a mutant cell line terminating in the leader exon contained 25% the normal amount of mu RNA, suggesting that translation past some point might be required to fully engage the RNA degradation process.	UNIV TORONTO,DEPT IMMUNOL,TORONTO M5S 1A8,ON,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A8,ON,CANADA	University of Toronto; University of Toronto								BARKER GF, 1991, MOL CELL BIOL, V11, P2760, DOI 10.1128/MCB.11.5.2760; BASERGA SJ, 1992, P NATL ACAD SCI USA, V89, P2935, DOI 10.1073/pnas.89.7.2935; BAUMANN B, 1985, EMBO J, V4, P351, DOI 10.1002/j.1460-2075.1985.tb03636.x; BELGRADER P, 1993, P NATL ACAD SCI USA, V90, P482, DOI 10.1073/pnas.90.2.482; CATTANEO R, 1991, ANNU REV GENET, V25, P71, DOI 10.1146/annurev.ge.25.120191.000443; CHENG J, 1990, Molecular and Cellular Biology, V10, P5215; CHENG J, 1993, MOL CELL BIOL, V13, P1892, DOI 10.1128/MCB.13.3.1892; CONNOR A, 1993, SOMAT CELL MOLEC GEN, V19, P313, DOI 10.1007/BF01232744; DAAR IO, 1988, MOL CELL BIOL, V8, P802, DOI 10.1128/MCB.8.2.802; DANNER D, 1985, P NATL ACAD SCI USA, V82, P8658, DOI 10.1073/pnas.82.24.8658; DAVIS AC, 1989, J IMMUNOL, V43, P1352; DAVIS LG, 1986, BASIC METHODS MOL BI, P130; DIETZ HC, 1993, SCIENCE, V259, P680, DOI 10.1126/science.8430317; ENSSLE J, 1993, P NATL ACAD SCI USA, V90, P10091, DOI 10.1073/pnas.90.21.10091; FISHER CW, 1993, AM J HUM GENET, V52, P414; GALLI G, 1987, GENE DEV, V1, P471, DOI 10.1101/gad.1.5.471; GREENBLATT J, 1993, NATURE, V364, P401, DOI 10.1038/364401a0; HAM KKY, 1985, IMMUNOL LETT, V10, P303, DOI 10.1016/0165-2478(85)90106-3; HOLTON TA, 1991, NUCLEIC ACIDS RES, V19, P1156, DOI 10.1093/nar/19.5.1156; JACK HM, 1989, EUR J IMMUNOL, V19, P843, DOI 10.1002/eji.1830190510; KESSLER O, 1993, MOL CELL BIOL, V13, P6211, DOI 10.1128/MCB.13.10.6211; KOHLER G, 1982, EMBO J, V1, P555, DOI 10.1002/j.1460-2075.1982.tb01208.x; KOWALSKI J, 1989, MOL CELL BIOL, V9, P1946, DOI 10.1128/MCB.9.5.1946; KOZAK M, 1991, J BIOL CHEM, V266, P19867; MATHER EL, 1984, CELL, V36, P329, DOI 10.1016/0092-8674(84)90226-5; NAEGER LK, 1992, GENE DEV, V6, P1107, DOI 10.1101/gad.6.6.1107; NELSON KJ, 1983, MOL CELL BIOL, V3, P1317, DOI 10.1128/MCB.3.7.1317; PETERSON ML, 1986, P NATL ACAD SCI USA, V83, P8883, DOI 10.1073/pnas.83.23.8883; QIAN L, 1993, J IMMUNOL, V152, P6801; ROGERS J, 1980, CELL, V20, P303, DOI 10.1016/0092-8674(80)90616-9; SIMPSON SB, 1994, MOL CELL BIOL, V14, P1835, DOI 10.1128/MCB.14.3.1835; TRIMBLE WS, 1986, SOMAT CELL MOLEC GEN, V12, P467, DOI 10.1007/BF01539918; URLAUB G, 1989, MOL CELL BIOL, V9, P2868, DOI 10.1128/MCB.9.7.2868	33	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					25178	25184						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7523380				2022-12-27	WOS:A1994PQ49000097
J	HAYASHI, JI; OHTA, S; KAGAWA, Y; TAKAI, D; MIYABAYASHI, S; TADA, K; FUKUSHIMA, H; INUI, K; OKADA, S; GOTO, Y; NONAKA, I				HAYASHI, JI; OHTA, S; KAGAWA, Y; TAKAI, D; MIYABAYASHI, S; TADA, K; FUKUSHIMA, H; INUI, K; OKADA, S; GOTO, Y; NONAKA, I			FUNCTIONAL AND MORPHOLOGICAL ABNORMALITIES OF MITOCHONDRIA IN HUMAN-CELLS CONTAINING MITOCHONDRIAL-DNA WITH PATHOGENIC POINT MUTATIONS IN TRANSFER-RNA GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STROKE-LIKE EPISODES; TRANSFER RNA(LEU(UUR)) GENE; TRANSFER RNALEU(UUR) GENE; TRANSFER-RNA GENES; LACTIC-ACIDOSIS; PROTEIN-SYNTHESIS; MYOCLONIC EPILEPSY; DIABETES-MELLITUS; MTDNA MUTATION; HELA-CELLS	mtDNA with a point mutation in the tRN(Ile) gene at nucleotide position 4269 found in a patient with fatal cardiomyopathy and mtDNA with a point mutation in the tRNA(Arg) gene at 10410 found in a patient with Alpers disease were transferred cytoplasmically to rho degrees HeLa cells (HeLa cells lacking mtDNA) to determine whether these novel mtDNA mutations in the tRNA genes are responsible for the defects in mitochondrial respiration function observed in these diseases. Cybrid clones (clones of rho degrees HeLa cells with mtDNA from the patients) were isolated, and respiratory function and morphology of the mitochondria of the cybrid clones containing wild-type mtDNA and mutant mtDNA predominantly were compared. The results showed that accumulation of mutant mtDNA at 4269 alone without defects in the nuclear genome was sufficient to produce a disease phenotype, while mutant mtDNA at 10410 was not related to pathogenesis and reflected one of the rare polymorphic sites of human mtDNA. Moreover, we found that mitochondria in living cells were significantly swollen only when they contained predominantly the pathogenic mutant mtDNA, suggesting that the functional abnormality of mitochondria induced by pathogenic mtDNA mutations in tRNA genes is always associated with their swollen structure.	JICHI MED SCH,DEPT BIOCHEM,MINAMI KAWACHI,TOCHIGI 32904,JAPAN; TOHOKU UNIV,SCH MED,DEPT PEDIAT,SENDAI,MIYAGI 980,JAPAN; OSAKA UNIV,SCH MED,DEPT PEDIAT,SUITA,OSAKA 565,JAPAN; NATL CTR NEUROL & PSYCHIAT,NATL INST NEUROSCI,DIV ULTRASTRUCT RES,KODAIRA,TOKYO 187,JAPAN	Jichi Medical University; Tohoku University; Osaka University; National Center for Neurology & Psychiatry - Japan	HAYASHI, JI (corresponding author), UNIV TSUKUBA,INST BIOL SCI,TSUKUBA,IBARAKI 305,JAPAN.							BALLINGER SW, 1992, NAT GENET, V1, P11, DOI 10.1038/ng0492-11; BINDOFF LA, 1993, J BIOL CHEM, V268, P19559; BIRKY CW, 1983, SCIENCE, V222, P468, DOI 10.1126/science.6353578; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOMYN A, 1991, MOL CELL BIOL, V11, P2236, DOI 10.1128/MCB.11.4.2236; CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221; CLAYTON DA, 1991, ANNU REV CELL BIOL, V7, P453, DOI 10.1146/annurev.cb.07.110191.002321; DIMAURO S, 1985, ANN NEUROL, V17, P521, DOI 10.1002/ana.410170602; GOTO Y, 1991, BIOCHIM BIOPHYS ACTA, V1097, P238, DOI 10.1016/0925-4439(91)90042-8; GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0; HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614; HAYASHI JI, 1983, EXP CELL RES, V147, P51, DOI 10.1016/0014-4827(83)90270-7; HAYASHI JI, 1994, J BIOL CHEM, V269, P6878; HAYASHI JI, 1993, BIOCHEM BIOPH RES CO, V197, P1049, DOI 10.1006/bbrc.1993.2584; HAYASHI JI, 1991, PROG NEUROPATH, V7, P93; HAYASHI JI, 1992, SOMAT CELL MOLEC GEN, V18, P123, DOI 10.1007/BF01233159; HAYASHI JI, 1994, J CELL BIOL, V125, P43, DOI 10.1083/jcb.125.1.43; HAYASHI JI, 1984, CANCER RES, V44, P3957; HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0; KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480; KOBAYASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P816, DOI 10.1016/S0006-291X(05)80860-5; LAUBER J, 1991, NUCLEIC ACIDS RES, V19, P1393, DOI 10.1093/nar/19.7.1393; LERTRIT P, 1992, AM J HUM GENET, V51, P457; LINNANE AW, 1989, LANCET, V1, P642, DOI 10.1016/S0140-6736(89)92145-4; MIYABAYASHI S, 1989, J INHERIT METAB DIS, V12, P373, DOI 10.1007/BF01799245; MORAES CT, 1993, NAT GENET, V4, P284, DOI 10.1038/ng0793-284; MORAES CT, 1993, J CLIN INVEST, V92, P2906, DOI 10.1172/JCI116913; MUNSCHER C, 1993, FEBS LETT, V317, P27, DOI 10.1016/0014-5793(93)81484-H; NONAKA I, 1989, J NEUROL SCI, V9, P193; REARDON W, 1992, LANCET, V340, P1376, DOI 10.1016/0140-6736(92)92560-3; SAKUTA R, 1993, AM J HUM GENET, V53, P964; SELIGMAN AM, 1968, J CELL BIOL, V38, P1, DOI 10.1083/jcb.38.1.1; SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N; SILVESTRI G, 1992, AM J HUM GENET, V51, P1213; TANAKA M, 1990, LANCET, V336, P1452, DOI 10.1016/0140-6736(90)93162-I; TANAKA M, 1991, BIOCHEM BIOPH RES CO, V174, P861, DOI 10.1016/0006-291X(91)91497-Z; TANIIKE M, 1992, BIOCHEM BIOPH RES CO, V186, P47, DOI 10.1016/S0006-291X(05)80773-9; VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368; VANDENOUWELAND JMW, 1992, NUCLEIC ACIDS RES, V20, P679, DOI 10.1093/nar/20.4.679; WALLACE DC, 1986, SOMAT CELL MOLEC GEN, V12, P41, DOI 10.1007/BF01560726; WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953; YOON KL, 1991, BIOCHEM BIOPH RES CO, V176, P1112, DOI 10.1016/0006-291X(91)90399-R; ZEVIANI M, 1991, LANCET, V338, P143, DOI 10.1016/0140-6736(91)90136-D; ZHANG CF, 1993, BIOCHEM BIOPH RES CO, V195, P1104, DOI 10.1006/bbrc.1993.2158	44	74	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					19060	19066						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	7518448				2022-12-27	WOS:A1994NX32700055
J	VAINIKKA, S; JOUKOV, V; WENNSTROM, S; BERGMAN, M; PELICCI, PG; ALITALO, K				VAINIKKA, S; JOUKOV, V; WENNSTROM, S; BERGMAN, M; PELICCI, PG; ALITALO, K			SIGNAL-TRANSDUCTION BY FIBROBLAST GROWTH-FACTOR RECEPTOR-4 (FGFR-4) - COMPARISON WITH FGFR-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE PHOSPHATASE; TYROSINE PHOSPHORYLATION; NUCLEOTIDE-SEQUENCE; XENOPUS EMBRYOS; POINT MUTATION; BETA-RECEPTOR; KINASE KINASE; FACTOR FAMILY; CDNA CLONING; CELL-GROWTH	We have studied the signal transduction pathways of fibroblast growth factor receptor-4 (FGFR-4) and FGFR-1, which showed virtually identical acidic fibroblast growth factor binding profiles as well as tyrosine autophosphorylation upon activation in transfected L6 rat myoblasts and NIH3T3 mouse fibroblasts. A prominently tyrosyl-phosphorylated doublet of polypeptides of 85 kDa coprecipitated with activated FGFR-4 from both cell lines studied, but these polypeptides were not detected upon immunoprecipitation of activated FGFR-1. Furthermore, FGFR-4 induced only a weak tyrosyl phosphorylation of phospholipase C-gamma and no detectable tyrosyl phosphorylation of the SHC adaptor proteins in contrast to FGFR-1. No phosphorylation of Ras GTPase-activating protein, p64 Syp/PTP1D tyrosine phosphatase, or association of the GRB2 adaptor protein SH2 domain with these receptors was detected. Unlike FGFR-1, FGFR-4 induced only a barely detectable phosphorylation of the cellular serine/threonine kinase Raf-1 and a weaker tyrosyl phosphorylation of mitogen-activated protein kinases than FGFR-1. Despite these differences, stimulation of both receptors resulted in increased DNA synthesis.	UNIV HELSINKI,DEPT PATHOL,MOLEC CANC BIOL LAB,SF-00290 HELSINKI 29,FINLAND; LUDWIG INST CANC RES,S-75124 UPPSALA,SWEDEN; UNIV PERUGIA,MONTELUCE POLICLIN,IST CLIN MED,I-06100 PERUGIA,ITALY	University of Helsinki; Ludwig Institute for Cancer Research; University of Perugia			Pelicci, Pier Giuseppe/AAL-6572-2020; Joukov, Vladimir/K-3525-2019; Alitalo, Kari K/J-5013-2014	Alitalo, Kari K/0000-0002-7331-0902				ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BELLOT F, 1991, EMBO J, V10, P2849, DOI 10.1002/j.1460-2075.1991.tb07834.x; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BURGESS WH, 1990, MOL CELL BIOL, V10, P4770, DOI 10.1128/MCB.10.9.4770; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CAO Y, 1990, GROWTH FACTORS, V13, P1; CHOU MM, 1992, MOL CELL BIOL, V12, P5834, DOI 10.1128/MCB.12.12.5834; DICKSON C, 1987, NATURE, V326, P833, DOI 10.1038/326833a0; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FUKUI Y, 1989, ONCOGENE RES, V5, P13; HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; HOUSSAINT E, 1990, P NATL ACAD SCI USA, V87, P8180, DOI 10.1073/pnas.87.20.8180; HUGHES DA, 1993, NATURE, V364, P349, DOI 10.1038/364349a0; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KRYPTA RM, 1990, CELL, V62, P481; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; LOWNSTEIN EJ, 1992, CELL, V70, P431; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MARICS I, 1989, ONCOGENE, V4, P335; MCNICOL AM, 1993, CELL, V73, P571; MEISENHELDER J, 1992, MOL CELL BIOL, V12, P5846; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MUSCI TJ, 1990, P NATL ACAD SCI USA, V87, P8452; ORNIZ DM, 1992, J BIOL CHEM, V276, P16305; PARK D, 1992, MOL CELL BIOL, V12, P5816, DOI 10.1128/MCB.12.12.5816; PARTANEN J, 1993, PHILOS T R SOC B, V340, P297, DOI 10.1098/rstb.1993.0071; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; RAFFIONI S, 1992, P NATL ACAD SCI USA, V89, P9121, DOI 10.1073/pnas.89.19.9121; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; RON D, 1993, J BIOL CHEM, V268, P5388; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; RUTA M, 1988, ONCOGENE, V3, P9; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; STARK KL, 1991, DEVELOPMENT, V113, P641; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; VAINIKKA S, 1992, EMBO J, V11, P4273, DOI 10.1002/j.1460-2075.1992.tb05526.x; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WENNSTROM S, 1992, J BIOL CHEM, V267, P13749; Wennstrom S, 1991, GROWTH FACTORS, V4, DOI 10.3109/08977199109104816; YOSHIDA T, 1987, P NATL ACAD SCI USA, V84, P7305, DOI 10.1073/pnas.84.20.7305; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487; ZHANG XF, 1993, NATURE, V364, P303	64	133	142	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18320	18326						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	7518429				2022-12-27	WOS:A1994NW79800016
J	FISCHER, TH; GATLING, MN; MCCORMICK, F; DUFFY, CM; WHITE, GC				FISCHER, TH; GATLING, MN; MCCORMICK, F; DUFFY, CM; WHITE, GC			INCORPORATION OF RAP-1B INTO THE PLATELET CYTOSKELETON IS DEPENDENT ON THROMBIN ACTIVATION AND EXTRACELLULAR CALCIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; GTP-BINDING PROTEINS; PUTATIVE EFFECTOR DOMAIN; INTACT HUMAN-PLATELETS; HUMAN-BLOOD-PLATELETS; SMG P21; MEMBRANE-PROTEINS; MOLECULAR-CLONING; KINASE SUBSTRATE; RAS-P21 GTPASE	Rap 1b is a 22-kDa low molecular mass GTP-binding protein which is both a member of the Ras superfamily and a substrate for cAMP-dependent protein kinase. Recently, evidence has been presented to show that Rap 1b is incorporated into the detergent-extracted cytoskeleton of platelets during thrombin-induced activation. The aims of this study were to compare the incorporation of Rap 1b into the detergent-extracted cytoskeleton after activation with different agonists, to examine the role of extracellular calcium on the incorporation of Rap 1b into the cytoskeleton, to investigate the relationship between the association of Rap 1b and other proteins with the cytoskeleton, and to determine the effect of phosphorylation of Rap 1b incorporation into the cytoskeleton. Platelets were activated with thrombin, A23187, phorbol myristate acetate, ADP, epinephrine, and collagen in the presence and absence of calcium. The time dependence of Rap 1b incorporation into the detergent-extracted cytoskeleton was then measured. When platelets were activated by thrombin in the presence of extracellular calcium, conditions which permit aggregation, incorporation of Rap 1b into the detergent-extracted cytoskeleton was biphasic. Approximately 20% of the total cellular Rap 1b incorporated into the cytoskeleton within seconds and was followed by a slower second phase of incorporation. In contrast, when platelets were activated by thrombin in the absence of calcium, conditions which inhibit aggregation, or by the other agents in the presence or absence of calcium, only the initial phase of Rap 1b incorporation into the cytoskeleton was measured. The incorporation of Rap 1b paralleled the incorporation of membrane glycoproteins (GP) IIb/IIIa and PECAM-1, but not the incorporation of pp60(c-src). The GTPase-activating protein for Ras (Ras-GAP) did not associate with the detergent-extracted cytoskeleton. Two-dimensional isoelectric focusing SDS-polyacrylamide gel electrophoresis of the total cellular and cytoskeletal Rap 1b showed that unphosphorylated as well as phosphorylated isoforms of Rap 1b were incorporated into the cytoskeleton in the same molar ratio as was present in the intact cell. Furthermore, the rates of incorporation of phosphorylated and unphosphorylated Rap 1b into the cytoskeleton were similar. These experiments show that Rap 1b can regulate events that take place within seconds after activation, such as the initial formation of the cytoskeleton, as well as longer term changes in the cytoskeleton that occur in response to thrombin-induced aggregation. Furthermore, phosphorylation could modulate the (unknown) functions of Rap 1b as a component of the cytoskeleton.	UNIV N CAROLINA,CTR THROMBOSIS & HEMOSTASIS,DEPT MED,CHAPEL HILL,NC 27599; UNIV N CAROLINA,CTR THROMBOSIS & HEMOSTASIS,DEPT PHARMACOL,CHAPEL HILL,NC 27599; ONYX PHARMACEUT,RICHMOND,CA 94806	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NHLBI NIH HHS [HL26309, K01-HL02521] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL026309, K04HL002521] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADUNYAH SE, 1987, BIOCHIM BIOPHYS ACTA, V930, P401, DOI 10.1016/0167-4889(87)90013-9; ADUNYAH SE, 1988, BIOCHIM BIOPHYS ACTA, V941, P63, DOI 10.1016/0005-2736(88)90214-3; CHURCH FC, 1986, ANAL BIOCHEM, V157, P77, DOI 10.1016/0003-2697(86)90198-3; CICHOWSKI K, 1992, J BIOL CHEM, V267, P5025; COX AC, 1984, J CELL BIOL, V98, P8, DOI 10.1083/jcb.98.1.8; ENOUF J, 1987, BIOCHIM BIOPHYS ACTA, V928, P76, DOI 10.1016/0167-4889(87)90087-5; EVANS T, 1986, J BIOL CHEM, V261, P7052; FISCHER TH, 1987, BIOCHEM BIOPH RES CO, V149, P700, DOI 10.1016/0006-291X(87)90424-4; FISCHER TH, 1990, J BIOL CHEM, V265, P19405; FISCHER TH, 1991, FEBS LETT, V282, P173; FITZGERALD LA, 1985, ANAL BIOCHEM, V151, P169, DOI 10.1016/0003-2697(85)90067-3; FOX JEB, 1993, THROMB HAEMOSTASIS, V70, P884; FOX JEB, 1993, J BIOL CHEM, V268, P25973; FOX JEB, 1987, J BIOL CHEM, V262, P12627; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GRONDIN P, 1991, J BIOL CHEM, V266, P15705; HASLAM RJ, 1979, BIOCHEM J, V178, P397, DOI 10.1042/bj1780397; HASLAM RJ, 1980, PLATELETS CELLULAR R, P213; HATA Y, 1991, J BIOL CHEM, V266, P6571; HATA Y, 1990, J BIOL CHEM, V265, P7104; HETTASCH JM, 1987, BIOCHIM BIOPHYS ACTA, V931, P49, DOI 10.1016/0167-4889(87)90049-8; HOSHIJIMA M, 1988, BIOCHEM BIOPH RES CO, V157, P851, DOI 10.1016/S0006-291X(88)80953-7; JENNINGS LK, 1981, J BIOL CHEM, V256, P6927; KASERGLANZMANN R, 1979, BIOCHIM BIOPHYS ACTA, V558, P344, DOI 10.1016/0005-2736(79)90271-2; KAWATA M, 1990, P NATL ACAD SCI USA, V87, P8960, DOI 10.1073/pnas.87.22.8960; KAWATA M, 1989, J BIOL CHEM, V264, P15688; LACAL JC, 1986, P NATL ACAD SCI USA, V83, P5400, DOI 10.1073/pnas.83.15.5400; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPETINA EG, 1989, P NATL ACAD SCI USA, V86, P3131, DOI 10.1073/pnas.86.9.3131; LEPEUCH CJ, 1983, BIOCHIM BIOPHYS ACTA, V731, P456, DOI 10.1016/0005-2736(83)90041-X; MATSUI Y, 1990, BIOCHEM BIOPH RES CO, V166, P1010, DOI 10.1016/0006-291X(90)90911-6; NAGATA K, 1989, BIOCHEM BIOPH RES CO, V160, P235, DOI 10.1016/0006-291X(89)91646-X; NEWMAN PJ, 1992, J CELL BIOL, V119, P239, DOI 10.1083/jcb.119.1.239; ODA A, 1992, J BIOL CHEM, V267, P20075; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PARK S, 1992, J BIOL CHEM, V267, P11612; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PHILLIPS DR, 1980, J CELL BIOL, V86, P77, DOI 10.1083/jcb.86.1.77; REINHARD M, 1992, EMBO J, V11, P2063, DOI 10.1002/j.1460-2075.1992.tb05264.x; SIESS W, 1990, BIOCHEM BIOPH RES CO, V170, P944, DOI 10.1016/0006-291X(90)92182-Y; THIEL G, 1988, EUR J BIOCHEM, V174, P601, DOI 10.1111/j.1432-1033.1988.tb14141.x; TORTI M, 1991, BIOCHIM BIOPHYS ACTA, V1070, P20, DOI 10.1016/0005-2736(91)90141-T; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; WHEELER ME, 1984, J CLIN INVEST, V74, P1080, DOI 10.1172/JCI111475; WHITE GC, 1989, THROMB RES, V56, P575, DOI 10.1016/0049-3848(89)90265-X; WHITE TE, 1990, P NATL ACAD SCI USA, V87, P758, DOI 10.1073/pnas.87.2.758; ZHANG K, 1990, SCIENCE, V249, P162, DOI 10.1126/science.2115210	47	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 24	1994	269	25					17257	17261						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NT846	7516336				2022-12-27	WOS:A1994NT84600043
J	SOROKIN, A; MOHAMMADI, M; HUANG, JT; SCHLESSINGER, J				SOROKIN, A; MOHAMMADI, M; HUANG, JT; SCHLESSINGER, J			INTERNALIZATION OF FIBROBLAST GROWTH-FACTOR RECEPTOR IS INHIBITED BY A POINT MUTATION AT TYROSINE-766	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-INDUCED INTERNALIZATION; KINASE-ACTIVITY; BINDING SPECIFICITY; ENDOTHELIAL-CELLS; FGF RECEPTORS; FACTOR FAMILY; EGF RECEPTOR; SH3 DOMAINS; DYNAMIN; ENDOCYTOSIS	Binding of fibroblast growth factor (FGF) to the fibroblast growth factor receptor leads to autophosphorylation of the receptor on several tyrosine residues. Wild-type FGF receptor 1 (flg) and a mutated receptor (Y766F), in which an autophosphorylation site (Tyr-766) was mutated to phenylalanine, were expressed in rat myoblasts and in hematopoietic Ba/F3 cells. It was found that the point mutation at Tyr-766 resulted in a decrease in FGF receptor internalization, as well as a reduction in both ligand-induced FGF receptor down-regulation and degradation. It has been shown previously that phosphorylation of Tyr-766 is essential for interaction with phospholipase C gamma and that the Y766F FGF receptor mutant is unable to stimulate phosphatidylinositol hydrolysis and Ca2+ release from internal stores. The results presented in this report indicate that Tyr-766 is also essential for cellular trafficking of FGF receptor.	NYU, MED CTR, DEPT PHARMACOL, NEW YORK, NY 10016 USA	New York University			Mohammadi, Moosa/ABA-6745-2020; kasaei, fahime/T-7197-2018	Mohammadi, Moosa/0000-0003-2434-9437; Sorokin, Andrey/0000-0002-5660-0190				AARONSON SA, 1991, ANN NY ACAD SCI, V638, P62, DOI 10.1111/j.1749-6632.1991.tb49018.x; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BELLOT F, 1991, EMBO J, V10, P2849, DOI 10.1002/j.1460-2075.1991.tb07834.x; BELTZER JP, 1991, EMBO J, V10, P3735, DOI 10.1002/j.1460-2075.1991.tb04942.x; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BIKFALVI A, 1989, EXP CELL RES, V181, P75, DOI 10.1016/0014-4827(89)90183-3; BRIOZZO P, 1991, EXP CELL RES, V194, P252, DOI 10.1016/0014-4827(91)90362-X; BRODSKY FM, 1988, SCIENCE, V242, P1396, DOI 10.1126/science.2904698; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHANG CP, 1993, J BIOL CHEM, V268, P19312; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; COUGHLIN SR, 1988, J BIOL CHEM, V263, P988; DELL KR, 1992, J BIOL CHEM, V267, P21225; DIONNE CA, 1991, ANN NY ACAD SCI, V638, P161, DOI 10.1111/j.1749-6632.1991.tb49026.x; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GANNOUNZAKI L, 1991, EXP CELL RES, V197, P272, DOI 10.1016/0014-4827(91)90433-U; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; Gospodarowicz D, 1990, CLIN ORTHOP RELAT R, V257, P231; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HUANG SS, 1986, J BIOL CHEM, V261, P9568; JAYE M, 1988, EMBO J, V7, P963, DOI 10.1002/j.1460-2075.1988.tb02902.x; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; KUROKAWA M, 1989, J BIOL CHEM, V264, P7686; Ledoux Dominique, 1992, Progress in Growth Factor Research, V4, P107, DOI 10.1016/0955-2235(92)90026-E; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; Moenner M, 1989, GROWTH FACTORS, V1, P115, DOI 10.3109/08977198909029121; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; Moscatelli D, 1990, GROWTH FACTORS, V3, DOI 10.3109/08977199009037499; PEARSE BMF, 1989, METHOD CELL BIOL, V31, P229; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; PLEY U, 1993, CRIT REV BIOCHEM MOL, V28, P431, DOI 10.3109/10409239309078441; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; ROBINSON M S, 1992, Trends in Cell Biology, V2, P293, DOI 10.1016/0962-8924(92)90118-7; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; ROGHANI M, 1992, J BIOL CHEM, V267, P22156; RUTA M, 1989, P NATL ACAD SCI USA, V86, P8722, DOI 10.1073/pnas.86.22.8722; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SORKIN A, 1993, ONCOGENE, V8, P3021; SORKIN A, 1991, J BIOL CHEM, V266, P8355; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; SORKIN A, 1991, J CELL BIOL, V112, P469, DOI 10.1083/jcb.112.3.469; Trowbridge IS, 1991, CURR OPIN CELL BIOL, V3, P1062, DOI 10.1016/0955-0674(91)90130-Q; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALLEE RB, 1992, J MUSCLE RES CELL M, V13, P493, DOI 10.1007/BF01737991; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; WALICKE PA, 1991, J NEUROSCI, V11, P2249; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; WILEY HS, 1991, J BIOL CHEM, V266, P11083; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; 1992, CATALOG PROTOCOLS	65	101	103	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	1994	269	25					17056	17061						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NT846	7516330				2022-12-27	WOS:A1994NT84600014
J	ZIEGLERHEITBROCK, HWL; WEDEL, A; SCHRAUT, W; STROBEL, M; WENDELGASS, P; STERNSDORF, T; BAUERLE, PA; HAAS, JG; RIETHMULLER, G				ZIEGLERHEITBROCK, HWL; WEDEL, A; SCHRAUT, W; STROBEL, M; WENDELGASS, P; STERNSDORF, T; BAUERLE, PA; HAAS, JG; RIETHMULLER, G			TOLERANCE TO LIPOPOLYSACCHARIDE INVOLVES MOBILIZATION OF NUCLEAR FACTOR KAPPA-B WITH PREDOMINANCE OF P50 HOMODIMERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TUMOR-NECROSIS-FACTOR; TRANSCRIPTIONAL ACTIVATION; MOLECULAR MECHANISMS; FACTOR EXPRESSION; HUMAN MONOCYTES; DOWN-REGULATION; CELL-LINE; GENE; SUBUNIT; MACROPHAGES	Stimulation of the human monocytic cell line Mono Mac 6 with lipopolysaccharide (LPS) leads to rapid and transient expression of cytokines like tumor necrosis factor (TNF). When such cells are precultured for 2 days with a low dose of LPS (20 ng/ml) followed by stimulation with a high dose of LPS (1 mu g/ml), expression of the TNF gene is minimal, i.e. the cells are tolerant. In nuclear run-on analysis, such tolerant cells show only a low degree of transcription, indicating that tolerance operates at or upstream of the transcription level, The CD14 LPS receptor is, however, up-regulated (not down-regulated) in tolerant cells, and LPS can, in fact, still lead to activation of tolerant cells as evidenced by mobilization of the transcription factor nuclear factor kappa B (NF-kappa B). Resolution of the NF-kappa B complex in gel shift analysis shows that the binding protein, mobilized in naive Mono Mac 6 cells, consists mainly of p50-p65 heterodimers, while in tolerant cells, the p50 homodimer is predominant. This increase in p50 homodimers coincides with an increase in p105 mRNA, suggestive of a transcriptional up-regulation of p50. Reporter gene analysis reveals that the NF-kappa B complex mobilized in tolerant cells is functionally inactive in that NF-kappa B dependent luciferase constructs containing the human immunodeficiency virus long terminal repeat or the TNF 5'-region show only minimal transactivation after LPS stimulation. Similar to Mono Mac 6 cells, primary blood monocytes, when precultured with a low dose of LPS, also become tolerant and produce little TNF after LPS stimulation. The tolerant blood monocytes also up regulate CD14, and they mobilize NF-kappa B with a predominance of p50 homodimers. Taken together, these results demonstrate that tolerance to LPS is determined by post-receptor mechanisms that involve an altered composition of the NF-kappa B complex.	UNIV FREIBURG,INST BIOCHEM,D-79104 FREIBURG,GERMANY	University of Freiburg	ZIEGLERHEITBROCK, HWL (corresponding author), INST IMMUNOL,GOETHESTR 31,D-80336 MUNICH,GERMANY.							BACHELERIE F, 1991, NATURE, V350, P709, DOI 10.1038/350709a0; BEESON PB, 1947, J EXP MED, V86, P29, DOI 10.1084/jem.86.1.29; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COGSWELL PC, 1993, J IMMUNOL, V150, P2794; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; FREUDENBERG MA, 1988, INFECT IMMUN, V56, P1352, DOI 10.1128/IAI.56.5.1352-1357.1988; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAAS JG, 1989, J LEUKOCYTE BIOL, V46, P11, DOI 10.1002/jlb.46.1.11; HAAS JG, 1990, P NATL ACAD SCI USA, V87, P9563, DOI 10.1073/pnas.87.24.9563; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; ISRAEL A, 1987, P NATL ACAD SCI USA, V84, P2653, DOI 10.1073/pnas.84.9.2653; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; KAUFMAN PA, 1992, J CLIN INVEST, V90, P121, DOI 10.1172/JCI115824; LABETA MO, 1993, IMMUNOLOGY, V80, P415; MATHISON JC, 1990, J CLIN INVEST, V85, P1108, DOI 10.1172/JCI114542; MESSER G, 1991, J EXP MED, V173, P209, DOI 10.1084/jem.173.1.209; MULLER JM, 1993, IMMUNOBIOLOGY, V187, P233; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OMALLEY WE, 1962, J NATL CANCER I, V29, P1169; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; SIBLEY DR, 1985, NATURE, V317, P124, DOI 10.1038/317124a0; TEN RM, 1992, EMBO J, V11, P195, DOI 10.1002/j.1460-2075.1992.tb05042.x; UEBERLA K, 1993, J ACQ IMMUN DEF SYND, V6, P227; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; ZIEGLERHEITBROCK HWL, 1992, IMMUNOLOGY, V75, P264; ZIEGLERHEITBROCK HWL, 1994, J LEUKOCYTE BIOL, V55, P73, DOI 10.1002/jlb.55.1.73; ZIEGLERHEITBROCK HWL, 1993, IMMUNOL TODAY, V14, P121, DOI 10.1016/0167-5699(93)90212-4; ZIEGLERHEITBROCK HWL, 1992, J IMMUNOL, V148, P1753; ZIEGLERHEITBROCK HWL, 1993, J IMMUNOL, V151, P6986; ZIEGLERHEITBROCK HWL, 1988, INT J CANCER, V41, P456, DOI 10.1002/ijc.2910410324	35	264	271	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 24	1994	269	25					17001	17004						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NT846	7516328				2022-12-27	WOS:A1994NT84600005
J	BALLA, T; NAKANISHI, S; CATT, KJ				BALLA, T; NAKANISHI, S; CATT, KJ			CATION SENSITIVITY OF INOSITOL 1,4,5-TRISPHOSPHATE PRODUCTION AND METABOLISM IN AGONIST-STIMULATED ADRENAL GLOMERULOSA CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C; ANGIOTENSIN-II; POLYPHOSPHATE METABOLISM; SARCOPLASMIC-RETICULUM; ENDOTHELIAL-CELLS; TUMOR PROMOTER; CALCIUM ENTRY; ACINAR-CELLS; FREE CA-2+; THAPSIGARGIN	Angiotensin II (AII) evokes a biphasic increase in inositol 1, 4, 5-trisphosphate (Ins(1,4,5)P-3) levels in adrenal glomerulosa cells, with an extracellular Ca2+-independent early peak followed by a secondary sustained elevation that is highly dependent on the presence of extracellular Ca2+. The Ca2+ dependent sustained phase of agonist-induced Ins(1,4,5)P-3 production was closely correlated with Ca2+ influx and was inhibited by inorganic Ca2+ channel blockers with the potency ratio: La3+ >> Cd2+ > Mn2+ > Co2+ > Ni2+. Of the two Ca2+ surrogates, Sr2+ and Ba2+, Sr2+ was partially active compared with Ca2+, and Ba2+ was inactive in restoring Ins(1,4,5)P-3 formation in cells stimulated with AII in Ca2+-free medium. However, unlike Ca2+, Sr2+ only weakly supported and Ba2+ failed to affect the calmodulin activation of Ins(1,4,5)P-3 3-kinase. Also, there was an accumulation of Ins(1,4,5)P-3 and diminished formation of Ins(1,3,4,5)P-4 and Ins(1,3,4)P-3 when intact glomerulosa cells were stimulated by AII in the presence of Sr2+. This difference between the Sr2+ sensitivity of phospholipase C and Ins(1,4,5)P-3 3-kinase provides a means for the potentiation of agonist-induced elevations of Ins(1,4,5)P-3 in the intact cell and for direct analysis of the role of the inositol tris-/tetrakisphosphate pathway in cellular signaling.			BALLA, T (corresponding author), NIH,ENDOCRINOL & REPROD RES BRANCH,BLDG 49,RM 6A36,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.			Balla, Tamas/0000-0002-9077-3335				AKHTAR RA, 1978, J PHARMACOL EXP THER, V204, P655; BALLA T, 1991, J BIOL CHEM, V266, P24719; BALLA T, 1988, J BIOL CHEM, V263, P4083; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1982, BIOCHEM J, V206, P587, DOI 10.1042/bj2060587; BEZPROZVANNY I, 1993, NEURON, V10, P1175, DOI 10.1016/0896-6273(93)90065-Y; CAPPONI AM, 1984, J BIOL CHEM, V259, P8863; Catt KJ, 1993, CELLULAR MOL BIOL RE, P307; COCKCROFT S, 1986, BIOCHEM J, V240, P503, DOI 10.1042/bj2400503; COCKCROFT S, 1981, TRENDS PHARMACOL SCI, V2, P340, DOI 10.1016/0165-6147(81)90360-6; DECKMYN H, 1986, J BIOL CHEM, V261, P6553; ECKERT R, 1981, J PHYSIOL-LONDON, V314, P265, DOI 10.1113/jphysiol.1981.sp013706; ELY JA, 1991, J BIOL CHEM, V266, P18635; FOX AP, 1987, J PHYSIOL-LONDON, V394, P149, DOI 10.1113/jphysiol.1987.sp016864; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUILLEMETTE G, 1987, BIOCHEM BIOPH RES CO, V142, P15, DOI 10.1016/0006-291X(87)90445-1; GUILLEMETTE G, 1989, AM J HYPERTENS, V2, P387, DOI 10.1093/ajh/2.5.387; HAGIWARA S, 1975, J GEN PHYSIOL, V65, P617, DOI 10.1085/jgp.65.5.617; HAWTHORNE JN, 1981, NATURE, V295, P281; HELDMAN E, 1989, J BIOL CHEM, V264, P7914; HUNYADY L, 1990, ENDOCRINOLOGY, V126, P1001, DOI 10.1210/endo-126-2-1001; HUNYADY L, 1991, J BIOL CHEM, V266, P2783; IRVINE RF, 1984, BIOCHEM J, V223, P237, DOI 10.1042/bj2230237; JACKSON TR, 1988, BIOCHEM J, V253, P81, DOI 10.1042/bj2530081; JACOB R, 1990, J PHYSIOL-LONDON, V421, P55, DOI 10.1113/jphysiol.1990.sp017933; KWAN CY, 1990, J BIOL CHEM, V265, P678; LEE SY, 1990, J BIOL CHEM, V265, P9434; MORGAN RO, 1987, J BIOL CHEM, V262, P1166; PATEL J, 1991, J MOL NEUROSCI, V3, P19, DOI 10.1007/BF02896845; REBECCHI MJ, 1983, BIOCHEM J, V216, P287, DOI 10.1042/bj2160287; RENARD D, 1987, BIOCHEM J, V243, P391, DOI 10.1042/bj2430391; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; SCHILLING WP, 1989, J BIOL CHEM, V264, P12838; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; TINKER A, 1992, J GEN PHYSIOL, V100, P479, DOI 10.1085/jgp.100.3.479; VANDERKOOI JM, 1971, ARCH BIOCHEM BIOPHYS, V144, P99, DOI 10.1016/0003-9861(71)90458-9; WOODCOCK EA, 1988, ENDOCRINOLOGY, V122, P1053, DOI 10.1210/endo-122-3-1053; 1989, BIOCHEM J, V258, P1	38	16	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16101	16107						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	7515876				2022-12-27	WOS:A1994NQ72900025
J	DEMEIS, L; SUZANO, VA				DEMEIS, L; SUZANO, VA			UNCOUPLING OF MUSCLE AND BLOOD-PLATELETS CA2+ TRANSPORT ATPASES BY HEPARIN - REGULATION BY K+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA2+-ATPASE; INOSITOL 1,4,5-TRISPHOSPHATE; SKELETAL-MUSCLE; CALCIUM RELEASE; TRANSMEMBRANE CHANNEL; ATP SYNTHESIS; CELL-SURFACE; RAT-LIVER; BINDING; TRISPHOSPHATE	Heparin (1-10 mu g/ml) inhibits the Ca2+ transport ATPases found in the sarcoplasmic reticulum of skeletal muscle, the plasma membrane of red cells, and the dense tubular system of blood platelets, but not the (Na+ + K+)ATPase or the mitochondrial F-1-ATPase. In the reversal of the Ca2+ pump, heparin uncouples the synthesis of ATP from Ca2+ efflux and inhibits the phosphorylation of the sarcoplasmic reticulum Ca2+-ATPase by P-i, but has no effect the phosphorylation by ATP. The effect of heparin on the muscle Ca2+-ATPase is abolished by KCl and NaCl (100 mM) and to a lesser extent by LiCl. These monovalent cations are not effective as antagonists of heparin on the platelet Ca2+-ATPase. The effects of heparin are antagonized by the polyamines spermine, spermidine, and ruthenium red. Unlike KCl, polyamines are equally effective in counteracting the effects of heparin in both muscle and platelet Ca2+-ATPases. In addition to heparin, the Ca2+-ATPases of muscle and blood platelets are also inhibited by dextran sulfate and fucose-branched chondroitin sulfate. The inhibition promoted by these glycosaminoglycans is antagonized by monovalent cations and polyamines in the same manner as heparin. Heparan sulfate, chondroitin sulfate, and hyaluronic acid have no effect on the Ca2+-ATPases studied.			DEMEIS, L (corresponding author), FED UNIV RIO DE JANEIRO, ILHA FDN, INST CIENCIAS BIOL, DEPT BIOQUIM, CIDADE UNIV, BR-21941590 RIO DE JANEIRO, BRAZIL.							ALVES EW, 1986, J BIOL CHEM, V261, P6854; BARLOGIE B, 1971, FEBS LETT, V12, P267, DOI 10.1016/0014-5793(71)80194-1; BELL WR, 1980, NEW ENGL J MED, V303, P902, DOI 10.1056/NEJM198010163031602; CHALOUB RM, 1980, J BIOL CHEM, V255, P6168; CHIESI M, 1979, J BIOL CHEM, V254, P370; DEMEIS L, 1989, BIOCHIM BIOPHYS ACTA, V973, P333, DOI 10.1016/S0005-2728(89)80440-2; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; DEMEIS L, 1992, FEBS LETT, V299, P33, DOI 10.1016/0014-5793(92)80093-V; DEMEIS L, 1990, J BIOL CHEM, V265, P18848; DEMEIS L, 1991, J BIOL CHEM, V266, P5736; DEMEIS L, 1988, METHOD ENZYMOL, V157, P190; DEMEIS L, 1981, SARCOPLASMIC RETICUL, V2; DIETRICH CP, 1974, BIOCHIM BIOPHYS ACTA, V343, P34, DOI 10.1016/0304-4165(74)90237-2; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V282, P174, DOI 10.1016/0005-2736(72)90321-5; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; GUILLEMETTE G, 1989, MOL PHARMACOL, V35, P339; HASSELBACH W, 1978, BIOCHIM BIOPHYS ACTA, V515, P23, DOI 10.1016/0304-4157(78)90007-2; HIDALGO C, 1989, J BIOENERG BIOMEMBR, V21, P267, DOI 10.1007/BF00812072; HILL TD, 1987, BIOCHEM BIOPH RES CO, V149, P897, DOI 10.1016/0006-291X(87)90492-X; INESI G, 1989, J BIOL CHEM, V264, P5929; JORGENSEN PL, 1974, BIOCHIM BIOPHYS ACTA, V356, P53, DOI 10.1016/0005-2736(74)90293-4; LEA TJ, 1986, FEBS LETT, V207, P153, DOI 10.1016/0014-5793(86)80031-X; LEPEUCH CJ, 1983, BIOCHIM BIOPHYS ACTA, V731, P456, DOI 10.1016/0005-2736(83)90041-X; LINDAHL U, 1978, ANNU REV BIOCHEM, V47, P385, DOI 10.1146/annurev.bi.47.070178.002125; MAKINOSE M, 1971, FEBS LETT, V12, P271, DOI 10.1016/0014-5793(71)80196-5; MAUGER JP, 1989, J BIOL CHEM, V264, P8821; MCCAFFREY TA, 1992, J CELL PHYSIOL, V152, P430, DOI 10.1002/jcp.1041520226; NAGASAWA K, 1980, METHODS CARBOHYDRATE, P291; PAPE PC, 1988, FEBS LETT, V235, P57, DOI 10.1016/0014-5793(88)81233-X; PRATT CW, 1992, J BIOL CHEM, V267, P8795; PRATT CW, 1992, J BIOL CHEM, V267, P8789; Rega A., 1979, CATION FLUX BIOMEMBR, P67; RITOV VB, 1985, FEBS LETT, V188, P77, DOI 10.1016/0014-5793(85)80878-4; ROJAS C, 1990, PFLUG ARCH EUR J PHY, V416, P296, DOI 10.1007/BF00392066; SCHERER NM, 1985, BIOCHEM BIOPH RES CO, V128, P1064, DOI 10.1016/0006-291X(85)91048-4; SHERIDAN D, 1986, BLOOD, V67, P27; SULLIVAN KMC, 1993, CELL, V73, P1411, DOI 10.1016/0092-8674(93)90366-X; TANFORD C, 1984, CRC CR REV BIOCH MOL, V17, P123, DOI 10.3109/10409238409113603; TOLEDO OMS, 1977, BIOCHIM BIOPHYS ACTA, V498, P114, DOI 10.1016/0304-4165(77)90092-7; TUENADEGOMEZPUYOU M, 1977, ARCH BIOCHEM BIOPHYS, V182, P82; VERGARA J, 1985, P NATL ACAD SCI USA, V82, P6352, DOI 10.1073/pnas.82.18.6352; VIEIRA RP, 1991, J BIOL CHEM, V266, P13530; VOLPE P, 1985, NATURE, V316, P347, DOI 10.1038/316347a0; VOLPE P, 1986, FEBS LETT, V197, P1, DOI 10.1016/0014-5793(86)80285-X; WALKER JW, 1987, NATURE, V327, P249, DOI 10.1038/327249a0; WOLOSKER H, 1992, J BIOL CHEM, V267, P5785; WORLEY PF, 1987, J BIOL CHEM, V262, P12132; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	49	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14525	14529						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	7514171				2022-12-27	WOS:A1994NM06500035
J	XU, X; STAR, RA; TORTORICI, G; MUALLEM, S				XU, X; STAR, RA; TORTORICI, G; MUALLEM, S			DEPLETION OF INTRACELLULAR CA2+ STORES ACTIVATES NITRIC-OXIDE SYNTHASE TO GENERATE CGMP AND REGULATE CA2+ INFLUX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC ACINAR CELL; CAPACITATIVE CALCIUM ENTRY; FREE CYTOSOLIC CALCIUM; ENDOPLASMIC-RETICULUM; AMYLASE RELEASE; RELAXING FACTOR; CA-2+ RELEASE; AR42J CELLS; POOL; STIMULATION	The mechanism of activation of the agonist-stimulated Ca2+ entry pathway in the plasma membrane is not known. To determine the role of nitric-oxide synthase (NOS) and cGMP in the regulation of this pathway, we used intact and streptolysin O (SLO)-permeable pancre atic acini and measured the relationship between Ca2+ release from internal stores, the NO metabolic pathway, generation of cGMP, and activation of Ca2+ entry. We found that agonist- or thapsigargin (Tg)-activated Ca2+ entry is inhibited by L-NA, a specific inhibitor of NOS, and by LY83583, an inhibitor of guanylyl cyclase. Inhibition of Ca2+ entry by inhibition of NOS was reversed by the NO releasing molecules NO, and sodium nitroprusside (SNP) and by Bt(2)cGMP. Inhibition of Ca2+ entry by inhibition of guanylyl cyclase was reversed by Bt(2)cGMF, but not by the NO releasing agents. The use of L-NA-treated cells and different concentrations of SNP revealed that cGMP has a dual effect on Ca2+ entry. Increasing cGMP up to 10-fold above control activated Ca2+ entry. Further increase in cGMP up to 80-fold above control inhibited Ca2+ entry in a concentration-dependent manner. Measurement of cellular cGMP in intact cells showed that carbachol, Tg, and NO, increased cGMP to similar levels. The effects of carbachol and Tg were inhibited by L-NA and LY83588, whereas the effect of NO, was inhibited only by LY83583. SLO-permeabilized cells were shown to be agonist competent in that the agonist induced Ca2+ release from the inositol 1,4,5-trisphosphate (IP3) pool and activated a NO-dependent generation of cGMP. These cells were used to study the regulation of NOS by Ca2+ and by Ca2+ content of the internal stores. When internal stores were maintained loaded with Ca2+, increasing medium [Ca2+] up to 2.5 mu M only modestly in creased NOS activity. In contrast, the depletion of Ca2+ from internal stores markedly increased NOS activity independent of medium [Ca2+]. Thus, NOS senses both cytosolic [Ca2+], and internal store Ca2+ load. We propose that activation of Ca2+ entry involves an agonist-mediated Ca2+ release from internal stores which activates a cellular pool of NOS to generate cGMP, which then modulates Ca2+ entry pathway in the plasma membrane. This mechanism can explain the capacitative nature of Ca2+ entry. The biphasic effect of cGMF provides the cells with a negative feedback mechanism which inhibits Ca2+ entry during periods of high cell [Ca2+](i). This could allow oscillatory behavior of Ca2+ entry.	UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	XU, X (corresponding author), UNIV TEXAS,SW MED CTR,DEPT PHYSIOL,DALLAS,TX 75235, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038938, R01DK046591] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38938, DK45929, DK46591] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAHNSON TD, 1993, J BIOL CHEM, V268, P10808; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BIRD GS, 1993, J BIOL CHEM, V268, P21486; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BRUZZONE R, 1985, BIOCHEM J, V226, P621, DOI 10.1042/bj2260621; FASALATO C, 1993, J BIOL CHEM, V268, P20737; FASOLATO C, 1993, P NATL ACAD SCI USA, V90, P3068, DOI 10.1073/pnas.90.7.3068; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FURCHGOTT R F, 1988, P401; HALLAM TJ, 1989, BIOCHEM J, V259, P125, DOI 10.1042/bj2590125; HIRAMATSU Y, 1992, J MEMBRANE BIOL, V129, P277; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; LOESSBERG PA, 1991, J BIOL CHEM, V266, P1363; LUMME P, 1965, ACTA CHEM SCAND, V19, P2175, DOI 10.3891/acta.chem.scand.19-2175; MONCADA S, 1991, PHARMACOL REV, V43, P109; MUALLEM S, 1988, AM J PHYSIOL, V255, pG229, DOI 10.1152/ajpgi.1988.255.2.G229; MUALLEM S, 1990, J BIOL CHEM, V265, P2011; MUALLEM S, 1987, BIOCHEM BIOPH RES CO, V149, P213, DOI 10.1016/0006-291X(87)91626-3; MUALLEM S, 1989, ANNU REV PHYSIOL, V51, P83; Muallem Shmuel, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P351; MULSCH A, 1991, FEBS LETT, V294, P252, DOI 10.1016/0014-5793(91)81441-A; MYERS PR, 1990, NATURE, V345, P161, DOI 10.1038/345161a0; OSULLIVAN AJ, 1992, BIOCHEM J, V285, P597, DOI 10.1042/bj2850597; PANDOL SJ, 1987, J BIOL CHEM, V262, P16963; PANDOL SJ, 1985, J BIOL CHEM, V260, P81; PANDOL SJ, 1990, CELL CALCIUM, V11, P477, DOI 10.1016/0143-4160(90)90080-E; PANDOL SJ, 1990, J BIOL CHEM, V265, P12846; PANDOL SJ, 1989, CELL CALCIUM, V10, P255, DOI 10.1016/0143-4160(89)90008-0; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; PETERSEN OH, 1990, J MEMBRANE BIOL, V118, P93, DOI 10.1007/BF01868467; PETERSEN OH, 1992, J PHYSIOL-LONDON, V448, P1; POWIS G, 1990, J BIOL CHEM, V265, P10266; Putney James W. Jr, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P143; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; SAGE SO, 1987, J BIOL CHEM, V262, P16364; SALUJA AK, 1992, J BIOL CHEM, V267, P11202; SNYDER SH, 1992, SCIENCE, V257, P494, DOI 10.1126/science.1353273; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STAUFFER PL, 1993, J BIOL CHEM, V268, P19769; TAKEMURA H, 1989, BIOCHEM J, V258, P409, DOI 10.1042/bj2580409; TSUNODA Y, 1990, AM J PHYSIOL, V259, pG792, DOI 10.1152/ajpgi.1990.259.5.G792; VANIN AF, 1991, FEBS LETT, V289, P1, DOI 10.1016/0014-5793(91)80894-9; ZHANG BX, 1993, J BIOL CHEM, V268, P10997; ZHANG BX, 1992, J BIOL CHEM, V267, P15419; ZHAO H, 1990, J BIOL CHEM, V265, P20856	48	190	193	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12645	12653						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	7513692				2022-12-27	WOS:A1994NH71600045
J	HU, HM; OROURKE, K; BOGUSKI, MS; DIXIT, VM				HU, HM; OROURKE, K; BOGUSKI, MS; DIXIT, VM			NOVEL RING FINGER PROTEIN INTERACTS WITH THE CYTOPLASMIC DOMAIN OF CD40	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ZINC-FINGER; DEFECTIVE EXPRESSION; ACTIVATION MOLECULE; HYPER-IGM; LIGAND; SYSTEM; IDENTIFICATION; MOTIFS	CD40 is a member of the tumor necrosis factor receptor family and, like other members, it appears to possess no intrinsic signaling capacity (e.g. kinase activity), suggesting that signal transduction is likely mediated by associating molecules. To identify such molecules, we have utilized the yeast two-hybrid system to clone cDNAs encoding proteins that bind the CD40 cytoplasmic domain. One such interacting protein, designated CD40-binding protein, has a N-terminal RING finger motif that is found in a number of DNA-binding proteins, including the V(D)J recombination activating gene RAG1. In addition, it contains a prominent central coiled-coil segment that may allow homo- or hetero-oligomerization. The C terminus possesses substantial homology to the tumor necrosis factor receptor-associated factor (TRAF) domain that is found in two proteins (TRAF1 and TRAFS) that associate with the cytoplasmic domain of the related 75 kDa tumor necrosis factor receptor. This is the first identification of a molecule that interacts with CD40 and whose sequence suggests a potential role in signaling.	UNIV MICHIGAN, SCH MED, DEPT PATHOL, ANN ARBOR, MI 48109 USA; NIH, NATL LIB MED, NATL CTR BIOTECHNOL INFORMAT, BETHESDA, MD 20894 USA	University of Michigan System; University of Michigan; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM)			dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326; Hu, Hong-Ming/0000-0002-2206-3470	NCI NIH HHS [CA61348] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061348] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEN RC, 1993, SCIENCE, V259, P990, DOI 10.1126/science.7679801; ALTSCHUL SF, 1994, NAT GENET, V6, P119, DOI 10.1038/ng0294-119; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; BANCHEREAU J, 1991, SCIENCE, V251, P70, DOI 10.1126/science.1702555; CHAN EKL, 1991, J CLIN INVEST, V87, P68, DOI 10.1172/JCI115003; DRISCOLL DM, 1987, MOL CELL BIOL, V7, P4482, DOI 10.1128/MCB.7.12.4482; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; FULEIHAN R, 1993, P NATL ACAD SCI USA, V90, P2170, DOI 10.1073/pnas.90.6.2170; HARPER JW, 1993, CELL, V75, P805; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; INUI S, 1990, EUR J IMMUNOL, V20, P1747, DOI 10.1002/eji.1830200819; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI DOI 10.1083/JCB.108.2.229; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; OETTINGER MA, 1992, TRENDS GENET, V8, P413, DOI 10.1016/0168-9525(92)90323-V; OROURKE KM, 1992, J BIOL CHEM, V267, P24921; REDDY BA, 1992, TRENDS BIOCHEM SCI, V17, P344, DOI 10.1016/0968-0004(92)90308-V; RON D, 1992, BIOTECHNIQUES, V13, P866; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; STAUDINGER J, 1993, J BIOL CHEM, V268, P4608; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; TOMITA H, 1993, MOL GEN GENET, V238, P225, DOI 10.1007/BF00279551; YANG XO, 1992, SCIENCE, V257, P680, DOI 10.1126/science.1496382; ZHANG K, 1991, J IMMUNOL, V146, P1836	28	345	363	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30069	30072						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7527023				2022-12-27	WOS:A1994PU52500002
J	LATHAM, GJ; LLOYD, RS				LATHAM, GJ; LLOYD, RS			DEOXYNUCLEOTIDE POLYMERIZATION BY HIV-1 REVERSE-TRANSCRIPTASE IS TERMINATED BY SITE-SPECIFIC STYRENE OXIDE ADDUCTS AFTER TRANSLESION SYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							STEADY-STATE KINETICS; DNA-POLYMERASE-I; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; ZIDOVUDINE AZT; MECHANISM; TEMPLATE; VIRUS; SEQUENCE; REPLICATION	In an effort to integrate an understanding of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) structure with its function, the action of HIV-1 RT was examined in vitro on DNA templates modified with a model bulky DNA adduct. Styrene oxide was site-specifically and stereospecifically coupled to the N-6 position of adenine to form six different adducted templates. Primer extension assays were conducted under conditions defining both single and multiple encounters between the polymerase and the damaged template-primer. The extent of polymerization observed for each adduct was found to depend on both the chirality of the damage and the lesion sequence context. When HIV-1 RT polymerization was limited by single encounters with damaged DNA, the SO lesions were readily bypassed as evidenced by minimal pausing at the adducted base. However, RT replication of all SO-modified templates was significantly terminated 3-5 nucleotides after translesion synthesis but before reaching the end of the template. These truncated products could be readily extended when additional encounters between enzyme and template primer were permitted. A model is presented to explain these results in the context of HIV-1 RT structure during DNA replication.	UNIV TEXAS,MED BRANCH,SEALY CTR MOLEC SCI,GALVESTON,TX 77555; VANDERBILT UNIV,CTR MOLEC TOXICOL,NASHVILLE,TN 37235; VANDERBILT UNIV,DEPT BIOCHEM,NASHVILLE,TN 37235	University of Texas System; University of Texas Medical Branch Galveston; Vanderbilt University; Vanderbilt University				Lloyd, R. Stephen/0000-0001-7273-372X	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267, R01ES005509, P01ES005355] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES05509, ES00267, ES05355] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABBOTTS J, 1993, J BIOL CHEM, V268, P10312; ABBOTTS J, 1988, J BIOL CHEM, V263, P15094; ARNOLD E, 1992, NATURE, V357, P85, DOI 10.1038/357085a0; BASU AK, 1993, BIOCHEMISTRY-US, V32, P4708, DOI 10.1021/bi00069a004; BEARD WA, 1994, J BIOL CHEM, V269, P28091; BEBENEK K, 1989, J BIOL CHEM, V264, P16948; BELGUISEVALLADI.P, 1994, J MOL BIOL, V268, P10312; CAI H, 1993, J BIOL CHEM, V268, P23567; GOFF SP, 1990, J ACQ IMMUN DEF SYND, V3, P817; HARRIS CM, 1991, J AM CHEM SOC, V113, P4328, DOI 10.1021/ja00011a044; HOFFMAN AD, 1985, VIROLOGY, V147, P326, DOI 10.1016/0042-6822(85)90135-7; HRUSZKEWYCZ A, 1992, CARCINOGENESIS, V13, P2347, DOI 10.1093/carcin/13.12.2347; HRUSZKEWYCZ AM, 1991, CARCINOGENESIS, V12, P2185, DOI 10.1093/carcin/12.11.2185; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; LATHAM GJ, 1993, J BIOL CHEM, V268, P23427; MAJUMDAR C, 1988, J BIOL CHEM, V263, P15657; Nanni Raymond G., 1993, Perspectives in Drug Discovery and Design, V1, P129, DOI 10.1007/BF02171659; ODAY CL, 1992, NUCLEIC ACIDS RES, V20, P5403, DOI 10.1093/nar/20.20.5403; PATEL PH, 1994, P NATL ACAD SCI USA, V91, P549, DOI 10.1073/pnas.91.2.549; PELISKA JA, 1992, SCIENCE, V258, P1112, DOI 10.1126/science.1279806; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; RANDALL SK, 1987, J BIOL CHEM, V262, P6864; REARDON JE, 1992, BIOCHEMISTRY-US, V31, P4473, DOI 10.1021/bi00133a013; REARDON JE, 1993, J BIOL CHEM, V268, P8743; REY MA, 1984, BIOCHEM BIOPH RES CO, V121, P126, DOI 10.1016/0006-291X(84)90696-X; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; SHIBUTANI S, 1993, BIOCHEMISTRY-US, V32, P7531, DOI 10.1021/bi00080a027; SINGER B, 1989, P NATL ACAD SCI USA, V86, P8271, DOI 10.1073/pnas.86.21.8271; WANG CI, 1992, BIOCHEMISTRY-US, V31, P3671, DOI 10.1021/bi00129a016	32	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28527	28530						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7525577				2022-12-27	WOS:A1994PU16800002
J	CHEN, L; MAO, SJT; MCLEAN, LR; POWERS, RW; LARSEN, WJ				CHEN, L; MAO, SJT; MCLEAN, LR; POWERS, RW; LARSEN, WJ			PROTEINS OF THE INTER-ALPHA-TRYPSIN INHIBITOR FAMILY STABILIZE THE CUMULUS EXTRACELLULAR-MATRIX THROUGH THEIR DIRECT BINDING WITH HYALURONIC-ACID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-OOCYTE COMPLEX; MOUSE; SERUM; IDENTIFICATION; EXPANSION; DOMAINS; MASS; LINK; CD44	We have previously identified a glycoprotein of the inter-alpha-trypsin inhibitor family of proteins as a serum factor responsible for the stabilization of the expanding cumulus mass. In this study, the mechanism of interaction of this cumulus extracellular matrix stabilizing factor (cESF) with hyaluronic acid (HA) has been explored. It was found that the pH optimum for binding of cESF and HA is 7 and that binding is sensitive to ionic strength. The dissociation constant is about 1.9 x 10(-8) ar in 10 mM sodium phosphate buffer (pH 7.2). Circular dichroism studies show that cESF contains about 24% alpha-helical and 42% beta-sheet structure. Gross conformational changes in cESF, however, are not detected in the presence of HA. me also found that modification of lysine residues of cESF with citraconic anhydride greatly reduced its binding with HA and completely abolished its cumulus stabilizing activity, and deblocking lysine residues restored its capacity to bind with HA and its cumulus matrix stabilizing activity. This evidence supports the hypotheses that cESF stabilizes the expanding cumulus extracellular matrix by directly binding with HA and that cESF may serve as a structural protein to organize the formation of the cumulus extracellular matrix. Our evidence also supports the view that binding of cESF and HA is through a stereo-specific charge interaction. Putative binding sites of cESF that interact with HA are postulated.	UNIV CINCINNATI, COLL MED, DEPT ANAT & CELL BIOL, CINCINNATI, OH 45267 USA; MARION MERRELL DOW RES INST, CINCINNATI, OH 45267 USA	University System of Ohio; University of Cincinnati; Dow Chemical Company					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD029894] Funding Source: NIH RePORTER; NICHD NIH HHS [HD29894] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ASHER R, 1992, EXP CELL RES, V203, P80, DOI 10.1016/0014-4827(92)90042-7; Atassi M Z, 1972, Methods Enzymol, V25, P546, DOI 10.1016/S0076-6879(72)25053-4; BARTA E, 1993, BIOCHEM J, V292, P947, DOI 10.1042/bj2920947; CAMAIONI A, 1993, J BIOL CHEM, V268, P20473; CASTILLO GM, 1993, FEBS LETT, V318, P292, DOI 10.1016/0014-5793(93)80531-X; CHEN L, 1993, MOL REPROD DEV, V34, P87, DOI 10.1002/mrd.1080340114; CHEN L, 1992, J BIOL CHEM, V267, P12380; CHEN L, 1990, MOL REPROD DEV, V26, P236, DOI 10.1002/mrd.1080260307; DEKEL N, 1979, BIOL REPROD, V21, P9, DOI 10.1095/biolreprod21.1.9; DOWNS SM, 1986, GAMETE RES, V15, P115, DOI 10.1002/mrd.1120150203; ENGHILD JJ, 1991, J BIOL CHEM, V266, P747; ENGHILD JJ, 1993, J BIOL CHEM, V268, P8711; EPPIG JJ, 1979, NATURE, V281, P483, DOI 10.1038/281483a0; FRANCK C, 1983, SCAND J CLIN LAB INV, V43, P151; HABEEB AFS, 1966, ANAL BIOCHEM, V14, P328, DOI 10.1016/0003-2697(66)90275-2; HUANG L, 1993, J BIOL CHEM, V268, P26725; HUTADILOK N, 1988, ANN RHEUM DIS, V47, P377, DOI 10.1136/ard.47.5.377; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; MAFORTHING KG, 1992, RECEPTOR LIGAND INTE; MAHIBROWN CA, 1983, GAMETE RES, V8, P1, DOI 10.1002/mrd.1120080102; MCKEEHAN WL, 1986, J BIOL CHEM, V261, P5378; PEACH RJ, 1993, J CELL BIOL, V122, P257, DOI 10.1083/jcb.122.1.257; PERIDES G, 1989, J BIOL CHEM, V264, P5981; PERIDES G, 1991, BIOCHIM BIOPHYS ACTA, V1075, P248, DOI 10.1016/0304-4165(91)90273-J; POTEMPA J, 1989, J BIOL CHEM, V264, P15109; PRATT CW, 1987, BIOCHEMISTRY-US, V26, P2855, DOI 10.1021/bi00384a029; REISINGER P, 1985, BIOL CHEM H-S, V366, P479, DOI 10.1515/bchm3.1985.366.1.479; SALUSTRI A, 1989, J BIOL CHEM, V264, P13840; Sandson J, 1965, Trans Assoc Am Physicians, V78, P304; TENGBLAD A, 1979, BIOCHIM BIOPHYS ACTA, V578, P281, DOI 10.1016/0005-2795(79)90158-2; UNDERHILL CB, 1980, J BIOL CHEM, V255, P4544; YANG BH, 1993, J BIOL CHEM, V268, P8617; YANG JT, 1986, METHOD ENZYMOL, V130, P208	33	146	152	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28282	28287						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7525572				2022-12-27	WOS:A1994PV77200076
J	NAIM, HY; JACOB, R; NAIM, H; SAMBROOK, JF; GETHING, MJH				NAIM, HY; JACOB, R; NAIM, H; SAMBROOK, JF; GETHING, MJH			THE PRO REGION OF HUMAN INTESTINAL LACTASE-PHLORHIZIN HYDROLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOTENSIN-CONVERTING ENZYME; N-LINKED GLYCOSYLATION; BRUSH-BORDER MEMBRANE; CELL-FREE SYNTHESIS; PHLORHIZIN HYDROLASE; INTRAMOLECULAR CHAPERONE; INTRACELLULAR-TRANSPORT; SUCRASE-ISOMALTASE; EPITHELIAL-CELLS; O-GLYCOSYLATION	Human small intestinal lactase-phlorizin hydrolase (LPH) is synthesized as a single-chain polypeptide precursor, prepro-LPH, that undergoes two sequential cleavage steps: the first in the endoplasmic reticulum to pro-LPH (215-kDa) and the second, following terminal glycosylation in the Golgi apparatus, to mature 180-kDa LPH (denoted LPH beta). The LPH beta molecule is subsequently targetted to the brush-border membrane. Characterization of the N-terminal profragment (denoted LPH alpha) of pro-LPH using an epitope-specific, anti-peptide polyclonal antibody reveals that LPH alpha (i) has an apparent molecular weight of similar to 100,000, (ii) is not associated with LPH beta after cleavage of pro-LPH has occurred, and (iii) is not transported to the cell surface or secreted into the extracellular medium. In biosynthetic labeling experiments, a clear precursor/product relationship could be demonstrated between pro-LPH and the LPH alpha and LPH beta polypeptides. Further, LPH alpha has a significantly shorter half-life than LPH beta. LPH alpha is neither N- nor O-glycosylated, despite the presence of 5 potential N-glycosylation sites. LPH alpha, which is rich in cysteine and hydrophobic amino acid residues, may fold rapidly into a tight and rigid globular domain in which carbohydrate attachment sites are no longer accessible to glycosyltransferases. When expressed independently in COS-1 cells, the LPH beta polypeptide forms a misfolded, transport-incompetent molecule. We propose a role for the LPH alpha domain within the pro-LPH molecule as an intramolecular chaperone during folding in the ER.	UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	NAIM, HY (corresponding author), UNIV DUSSELDORF, INST MICROBIOL, PROT SECRET GRP, UNIV STR 1, D-40225 DUSSELDORF, GERMANY.				NIGMS NIH HHS [GM 37547] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037547] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER D, 1992, PROTEINS, V12, P339, DOI 10.1002/prot.340120406; BAKER D, 1992, NATURE, V356, P263, DOI 10.1038/356263a0; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BIRD P, 1987, J CELL BIOL, V105, P2905, DOI 10.1083/jcb.105.6.2905; BROWNING TH, 1969, J CLIN INVEST, V48, P1423, DOI 10.1172/JCI106108; BULLEID NJ, 1992, BIOCHEM J, V286, P275, DOI 10.1042/bj2860275; BULLER HA, 1987, J BIOL CHEM, V262, P17206; DANIELSEN EM, 1984, BIOCHEM BIOPH RES CO, V122, P82; EHLERS MRW, 1989, BIOCHEMISTRY-US, V28, P5311, DOI 10.1021/bi00439a001; ENDO Y, 1976, J BIOCHEM-TOKYO, V80, P1; FRANSEN JAM, 1985, EUR J CELL BIOL, V38, P6; HAURI HP, 1985, J CELL BIOL, V101, P838, DOI 10.1083/jcb.101.3.838; HENNING SJ, 1981, AM J PHYSIOL, V241, pG199, DOI 10.1152/ajpgi.1981.241.3.G199; HENNING SJ, 1985, ANNU REV PHYSIOL, V47, P231; HOOPER NM, 1987, BIOCHEM J, V247, P85, DOI 10.1042/bj2470085; INOUYE M, 1991, ENZYME, V45, P314, DOI 10.1159/000468904; JASCUR T, 1991, BIOCHEMISTRY-US, V30, P1908, DOI 10.1021/bi00221a025; JOHN DCA, 1993, EMBO J, V12, P1587, DOI 10.1002/j.1460-2075.1993.tb05803.x; KRETCHMER N, 1971, GASTROENTEROLOGY, V61, P805; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAIURI L, 1991, GASTROENTEROLOGY, V100, P359, DOI 10.1016/0016-5085(91)90203-W; MANTEI N, 1988, EMBO J, V7, P2705, DOI 10.1002/j.1460-2075.1988.tb03124.x; MONTGOMERY RK, 1991, FASEB J, V5, P2824, DOI 10.1096/fasebj.5.13.1916106; NAIM HY, 1992, BIOCHEM J, V286, P451, DOI 10.1042/bj2860451; NAIM HY, 1988, J BIOL CHEM, V263, P19709; NAIM HY, 1988, J BIOL CHEM, V263, P7242; NAIM HY, 1987, BIOCHEM J, V241, P427, DOI 10.1042/bj2410427; NAIM HY, 1992, J BIOL CHEM, V267, P25494; NAIM HY, 1991, J BIOL CHEM, V266, P12313; NAIM HY, 1992, BIOCHEM J, V285, P13, DOI 10.1042/bj2850013; NAIM HY, 1993, DYN NUTR R, V3, P102; Patchett A A, 1985, Adv Enzymol Relat Areas Mol Biol, V57, P1; QUAN R, 1990, J BIOL CHEM, V265, P15882; SEMENZA G, 1986, ANNU REV CELL BIOL, V2, P255, DOI 10.1146/annurev.cellbio.2.1.255; SHAKINESHLEMAN SH, 1992, J BIOL CHEM, V267, P10690; SHINDE U, 1993, P NATL ACAD SCI USA, V90, P6924, DOI 10.1073/pnas.90.15.6924; SILEN JL, 1989, NATURE, V341, P462, DOI 10.1038/341462a0; STERCHI EE, 1980, CLIN CHIM ACTA, V102, P49, DOI 10.1016/0009-8981(80)90432-5; STERCHI EE, 1990, J CLIN INVEST, V86, P1329, DOI 10.1172/JCI114842; THOMSEN DR, 1984, P NATL ACAD SCI-BIOL, V81, P659, DOI 10.1073/pnas.81.3.659; UMEMOTO J, 1977, J BIOL CHEM, V252, P8609; WACKER H, 1992, J BIOL CHEM, V267, P18744; WEISSMAN JS, 1992, CELL, V71, P841, DOI 10.1016/0092-8674(92)90559-U; WINTHER JR, 1991, P NATL ACAD SCI USA, V88, P9330, DOI 10.1073/pnas.88.20.9330; YEH KY, 1991, GASTROENTEROLOGY, V101, P312, DOI 10.1016/0016-5085(91)90005-6; ZHU XL, 1989, NATURE, V339, P483, DOI 10.1038/339483a0; [No title captured]	47	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26933	26943						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7523415				2022-12-27	WOS:A1994PQ93100055
J	JACQUES, PS; WOHRL, BM; OTTMANN, M; DARLIX, JL; LEGRICE, SFJ				JACQUES, PS; WOHRL, BM; OTTMANN, M; DARLIX, JL; LEGRICE, SFJ			MUTATING THE PRIMER GRIP OF P66 HIV-1 REVERSE-TRANSCRIPTASE IMPLICATES TRYPTOPHAN-229 IN TEMPLATE-PRIMER UTILIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; ANGSTROM RESOLUTION; TRANSFER RNA(LYS-3); CRYSTAL-STRUCTURE; DNA; HETERODIMER; POLYMERASE; CELLS; MUTAGENESIS; RETROVIRUS	''BcgI cassette'' mutagenesis was used to prepare variants of p66 human immunodeficiency virus (HIV)-1 reverse transcriptase with amino acid substitutions between residues Glu(224) and Trp(229). Mutant polypeptides were reconstituted in vitro with wild type p51 to generate the ''selectively mutated'' heterodimer series p66(224A)/p51-p66(229A)/p51. Purified enzymes were characterized with respect to dimerization, DNA polymerase, RNase H, and tRNA(Lys-3) binding. The combined analyses indicate that while alteration of p66 residues Glu(224)-Leu(228) has minimal consequences, the DNA polymerase activities of mutant p66(229A)/p51 are impaired. DNase I footprinting illustrates that this mutant does not form a stable replication complex with a model template-primer. In vivo studies indicate that the equivalent mutation eliminates viral infectivity, suggesting a contribution of Trp(229) toward architecture of the p66 primer grip.	CASE WESTERN RESERVE UNIV,SCH MED,DIV INFECT DIS,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DEPT BIOCHEM,CLEVELAND,OH 44106; ECOLE NORMALE SUPER LYON,INSERM,LABORETRO,F-69364 LYON,FRANCE	Case Western Reserve University; Case Western Reserve University; Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm)			LUC, DARLIX JEAN/AAE-9268-2020	ottmann, michele/0000-0002-6911-0705	NIAID NIH HHS [AI 31147] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031147] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; ARNOLD E, 1992, NATURE, V357, P85, DOI 10.1038/357085a0; BARAT C, 1991, NUCLEIC ACIDS RES, V19, P751, DOI 10.1093/nar/19.4.751; BENARTZI H, 1992, NUCLEIC ACIDS RES, V20, P5115, DOI 10.1093/nar/20.19.5115; BOYER PL, 1992, J VIROL, V66, P1031, DOI 10.1128/JVI.66.2.1031-1039.1992; BOYER PL, 1994, P NATL ACAD SCI USA, V91, P4882, DOI 10.1073/pnas.91.11.4882; CARTER P, 1988, NATURE, V332, P564, DOI 10.1038/332564a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; GOFF S, 1981, J VIROL, V38, P239, DOI 10.1128/JVI.38.1.239-248.1981; GOPALAKRISHNAN V, 1992, P NATL ACAD SCI USA, V89, P10763, DOI 10.1073/pnas.89.22.10763; GUYADER M, 1987, NATURE, V326, P662, DOI 10.1038/326662a0; HIZI A, 1992, J BIOL CHEM, V267, P18255; HOSTOMSKY Z, 1992, J VIROL, V66, P3179, DOI 10.1128/JVI.66.5.3179-3182.1992; HOSTOMSKY Z, 1994, J VIROL, V68, P1970, DOI 10.1128/JVI.68.3.1970-1971.1994; HOTTIGER M, 1994, J BIOL CHEM, V269, P986; HOWARD KJ, 1991, J BIOL CHEM, V266, P23003; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JACQUES PS, 1994, J BIOL CHEM, V269, P1388; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KONG H, 1994, J BIOL CHEM, V269, P683; LEDERER H, 1992, EMBO J, V11, P1131, DOI 10.1002/j.1460-2075.1992.tb05153.x; LEGRICE SFJ, 1991, EMBO J, V10, P3905, DOI 10.1002/j.1460-2075.1991.tb04960.x; LEGRICE SFJ, 1990, EUR J BIOCHEM, V187, P307, DOI 10.1111/j.1432-1033.1990.tb15306.x; METZGER W, 1993, P NATL ACAD SCI USA, V90, P5909, DOI 10.1073/pnas.90.13.5909; MSERDON SJ, 1994, P NATL ACAD SCI USA, V91, P3911; MULLER B, 1991, J BIOL CHEM, V266, P14709; MURPHEYCORB M, 1986, NATURE, V321, P435, DOI 10.1038/321435a0; Nanni Raymond G., 1993, Perspectives in Drug Discovery and Design, V1, P129, DOI 10.1007/BF02171659; OLMSTED RA, 1989, P NATL ACAD SCI USA, V86, P2448, DOI 10.1073/pnas.86.7.2448; PRASAD VR, 1993, REVERSE TRANSCRIPTAS, P135; RESTLE T, 1990, J BIOL CHEM, V265, P8986; RESTLE T, 1992, FEBS LETT, V300, P97, DOI 10.1016/0014-5793(92)80172-D; RICHTERCOOK NJ, 1992, J BIOL CHEM, V267, P15952; SCHATZ O, 1990, EMBO J, V9, P1171, DOI 10.1002/j.1460-2075.1990.tb08224.x; SCHMITZ A, 1979, NUCLEIC ACIDS RES, V6, P111, DOI 10.1093/nar/6.1.111; SMITH SD, 1984, CANCER RES, V44, P5657; SOBOL RW, 1991, BIOCHEMISTRY-US, V30, P10623, DOI 10.1021/bi00108a004; STEPHENS RM, 1986, SCIENCE, V231, P589, DOI 10.1126/science.3003905; TELESNITSKY A, 1993, P NATL ACAD SCI USA, V90, P1276, DOI 10.1073/pnas.90.4.1276; WOHRL BM, 1993, J BIOL CHEM, V268, P13617; WOHRL BM, 1994, J BIOL CHEM, V269, P8541; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x	42	71	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26472	26478						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7523408				2022-12-27	WOS:A1994PQ93000081
J	SEWELL, TJ; LAM, E; MARTIN, MM; LESZYK, J; WEIDNER, J; CALAYCAY, J; GRIFFIN, P; WILLIAMS, H; HUNG, S; CRYAN, J; SIGAL, NH; WIEDERRECHT, GJ				SEWELL, TJ; LAM, E; MARTIN, MM; LESZYK, J; WEIDNER, J; CALAYCAY, J; GRIFFIN, P; WILLIAMS, H; HUNG, S; CRYAN, J; SIGAL, NH; WIEDERRECHT, GJ			INHIBITION OF CALCINEURIN BY A NOVEL FK-506-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIS-TRANS ISOMERASE; CYTOSOLIC-BINDING-PROTEIN; AMINO-ACID-SEQUENCE; PEPTIDYL-PROLYL ISOMERASE; LYMPHOCYTE-T ACTIVATION; CALCIUM-RELEASE CHANNEL; CYCLOSPORINE-A; IMMUNOSUPPRESSANT FK506; RYANODINE RECEPTOR; FK506-BINDING PROTEIN	FK-506, a potent immunosuppressive drug, acts during the commitment phase of T-lymphocyte activation to block a subset of calcium-associated events necessary for transcription of certain early lymphokine genes. The drug binds to an abundant, cytosolic 11.8-kDa protein termed the FK-506-binding protein (FKBP12). The FKBP12.FK-506 complex inhibits calcineurin, a calcium-dependent phosphatase that is a component of the signal transduction pathway leading to early lymphokine gene transcription. FKBP12 is one member of a growing gene family. Prior to this report, all other FKBP family members had been irrelevant to the mechanism of action of FK-506 because no other FKBP.FK-506 complexes were able to bind and inhibit calcineurin. Here, we report the purification and characterization of a novel FK-506-binding protein, FKBP12.6. Having 85% amino acid sequence identity to FKBP12, FKBP12.6 is, among the FKBPs, most closely related to FKBP12. When complexed with FK-506, FKBP12.6 binds to and inhibits calcineurin, making it only the second FKBP discovered thus far to do so. The ability to inhibit calcineurin establishes the potential relevance of FKBP12.6 to the immunosuppressive or toxic side effects of FK-506.	MERCK SHARP & DOHME LTD,RES LABS,DEPT IMMUNOL RES,RAHWAY,NJ 07065; MERCK SHARP & DOHME LTD,RES LABS,DEPT ANALYT BIOCHEM,RAHWAY,NJ 07065; WORCESTER FDN EXPTL BIOL INC,SHREWSBURY,MA 01545	Merck & Company; Merck & Company; Worcester Foundation for Biomedical Research								APERIA A, 1992, P NATL ACAD SCI USA, V89, P7394, DOI 10.1073/pnas.89.16.7394; BIERER BE, 1990, SCIENCE, V250, P556, DOI 10.1126/science.1700475; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAM RJ, 1993, MOL CELL BIOL, V13, P4760, DOI 10.1128/MCB.13.8.4760; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COLLINS JH, 1991, BIOCHEM BIOPH RES CO, V178, P1288, DOI 10.1016/0006-291X(91)91033-9; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DAWSON TM, 1993, P NATL ACAD SCI USA, V90, P9808, DOI 10.1073/pnas.90.21.9808; DUMONT FJ, 1992, J EXP MED, V176, P751, DOI 10.1084/jem.176.3.751; DUMONT FJ, 1990, J IMMUNOL, V144, P1418; DUMONT FJ, 1990, J IMMUNOL, V144, P251; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FLIRI H, 1993, ANN NY ACAD SCI, V696, P47; FRIEDMAN J, 1991, CELL, V66, P799, DOI 10.1016/0092-8674(91)90123-G; GALAT A, 1993, FEBS LETT, V216, P689; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING MW, 1988, TRANSPLANTATION, V46, pS29; HARDING MW, 1986, J BIOL CHEM, V261, P8547; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HARRISON RK, 1990, BIOCHEMISTRY-US, V29, P3813, DOI 10.1021/bi00468a001; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; KIEFFER LJ, 1992, J BIOL CHEM, V267, P5503; KIEFFER LJ, 1993, J BIOL CHEM, V268, P12303; KOPRAK S, 1994, FASEB J, V8, pA567; KUMANO K, 1991, TRANSPL P, V23, P512; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; LYSON T, 1993, CIRC RES, V73, P596, DOI 10.1161/01.RES.73.3.596; MAKI N, 1990, P NATL ACAD SCI USA, V87, P5440, DOI 10.1073/pnas.87.14.5440; MANALAN AS, 1983, P NATL ACAD SCI-BIOL, V80, P4291, DOI 10.1073/pnas.80.14.4291; MCPHERSON PS, 1993, J BIOL CHEM, V268, P19785; MOZIER NM, 1990, EUR J BIOCHEM, V194, P19, DOI 10.1111/j.1432-1033.1990.tb19421.x; OHARA K, 1990, TRANSPLANT P, V22, P83; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; PEATTIE DA, 1992, P NATL ACAD SCI USA, V89, P10974, DOI 10.1073/pnas.89.22.10974; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SHIVELY JE, 1987, ANAL BIOCHEM, V163, P517, DOI 10.1016/0003-2697(87)90257-0; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; SIEKIERKA JJ, 1990, J BIOL CHEM, V265, P21011; SIEKIERKA JJ, 1989, J IMMUNOL, V143, P1580; SIGAL NH, 1991, J EXP MED, V173, P619, DOI 10.1084/jem.173.3.619; SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0; STEINER J, 1992, P NATL ACAD SCI USA, V358, P584; SWANSON SKH, 1992, P NATL ACAD SCI USA, V89, P3741, DOI 10.1073/pnas.89.9.3741; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; TIMERMAN AP, 1994, BIOCHEM BIOPH RES CO, V198, P701, DOI 10.1006/bbrc.1994.1101; TIMERMAN AP, 1993, J BIOL CHEM, V268, P22992; TOCCI MJ, 1989, J IMMUNOL, V143, P718; TRANDINH CC, 1992, FASEB J, V6, P3410, DOI 10.1096/fasebj.6.15.1464374; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; WIEDERRECHT G, 1992, J BIOL CHEM, V267, P21753; Williams J W, 1979, Methods Enzymol, V63, P437	57	75	79	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					21094	21102						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	7520438				2022-12-27	WOS:A1994PC40300044
